<SEC-DOCUMENT>0001682852-26-000033.txt : 20260220
<SEC-HEADER>0001682852-26-000033.hdr.sgml : 20260220
<ACCEPTANCE-DATETIME>20260220160204
ACCESSION NUMBER:		0001682852-26-000033
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260220
DATE AS OF CHANGE:		20260220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		26659719

	BUSINESS ADDRESS:	
		STREET 1:		325 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		325 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrna-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:2100a978-c810-4eca-85d9-7a3f37c08d9d,g:e414d930-d10b-4c86-a1cd-8d87f72aa21b,d:151f4968467f44d985f22077f4372877-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:mrna="http://www.modernatx.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrna-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001682852</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-496">one</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-497">one</ix:nonFraction><ix:nonNumeric contextRef="c-222" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-813">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-246" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-844">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-250" name="mrna:InventoryShelfLife" id="f-874">P9M</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1024">http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1025">http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1030">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1031">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1034">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1035">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-379" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1524">255</ix:nonNumeric><ix:nonNumeric contextRef="c-383" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1525">270</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrna-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="product"><xbrli:measure>mrna:product</xbrli:measure></xbrli:unit><xbrli:unit id="candidate"><xbrli:measure>mrna:candidate</xbrli:measure></xbrli:unit><xbrli:unit id="developmentprogram"><xbrli:measure>mrna:developmentProgram</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>mrna:segment</xbrli:measure></xbrli:unit><xbrli:unit id="participant"><xbrli:measure>mrna:participant</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>mrna:security</xbrli:measure></xbrli:unit><xbrli:unit id="campus"><xbrli:measure>mrna:campus</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="numberofextensionperiod"><xbrli:measure>mrna:numberOfExtensionPeriod</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>mrna:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="claim"><xbrli:measure>mrna:claim</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>mrna:installment</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>mrna:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:FFFEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:FFFEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:PublicWorksAndGovernmentServicesCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:PublicWorksAndGovernmentServicesCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:UKHealthSecurityAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:UKHealthSecurityAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MexicoMedistikMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BoryungBiopharmaKoreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TaiwanFoodAndDrugAdministrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MinistryOfHealthLaborAndWelfareOfJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:RSVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:RSVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:RSVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:StandReadyManufacturingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:StandReadyManufacturingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:StandReadyManufacturingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2025-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:ImmaticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:COVIDVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:COVIDVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:MNEXSPIKEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:RSVVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrna:ModernaTechnologyCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrna:ModernaTechnologyCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:InitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:DelayedDrawTermLoanFacility1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:DelayedDrawTermLoanFacility2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">mrna:TermSecuredOvernightFinancingRatePlusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrna:DebtInstrumentCovenantComplianceScenarioAxis">mrna:CovenantComplianceScenario1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrna:DebtInstrumentCovenantComplianceScenarioAxis">mrna:CovenantComplianceScenario2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:InitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrna:GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrna:GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrna:GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndGrantPlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionExchangeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-13</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionExchangeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">mrna:MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:TerminationOfTradingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:TerminationOfTradingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i151f4968467f44d985f22077f4372877_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:0.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:0.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-top:0.35pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.968%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3.5pt;margin-top:1.55pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:0.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from _ to _ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38753</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="mrna-20251231_g1.jpg" alt="modernalogo.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:212px" id="i-1"/></div><div style="margin-top:1.35pt;text-align:center"><span><br/></span></div><div style="margin-top:1.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Moderna, Inc.</ix:nonNumeric></span></div><div style="margin-top:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:0.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.831%"><tr><td style="width:1.0%"/><td style="width:32.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">81-3467528</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">325 Binney Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">02142</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">714-6500</ix:nonNumeric></span></div><div style="margin-top:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:0.8pt;text-align:center"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:10.12pt;padding-right:10.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:34.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.679%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">MRNA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">None</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.      </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>  &#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Yes  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>  &#9745;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>  &#9745;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>  &#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:1.2pt;padding-left:9pt;padding-right:33.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric> &#9745;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.5pt;padding-left:9pt;padding-right:33.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Yes <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric>   No  &#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Yes  &#9744; No  <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9745;</ix:nonNumeric><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-29">9.9</ix:nonFraction>&#160;billion. This excludes shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes. The registrant has no non-voting common stock.</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;13, 2026, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">394,939,424</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding. </span></div><div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" continuedAt="f-31-1" escape="true"><div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div></ix:nonNumeric><div style="margin-top:1.5pt;padding-left:9pt;padding-right:27pt;text-indent:11.25pt"><ix:continuation id="f-31-1"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span></ix:continuation><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1.5pt;padding-left:9pt;padding-right:27pt;text-indent:11.25pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i151f4968467f44d985f22077f4372877_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.15pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_73">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_82">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cybersecurity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_85">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_88">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_91">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_94">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART II</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_100">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">[Reserved]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_106">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_109">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures about Market Risk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_121">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_124">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_238">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_241">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_244">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_247">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART III</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 10.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_253">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Executive Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_256">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_259">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_262">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Principal Accountant Fees and Services</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_265">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART IV</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 15.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Exhibits, Financial Statement Schedules</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_271">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Form 10-K Summary</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_274">147</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_277">148</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i151f4968467f44d985f22077f4372877_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled &#8220;Risk Factors.&#8221; These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory and market uncertainty have and may continue to impact our business and the markets for our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience difficulties executing our near-term strategy and prioritized pipeline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The vaccine market, and pharmaceutical market more generally, is intensely competitive, and we may be unable to compete effectively in the market for existing or new products, treatment methods or technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have experienced commercial challenges and may experience additional challenges in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of our products depends on the degree of market acceptance by physicians, patients, third-party payors and others in the medical community;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and we may be adversely impacted by changes to such reimbursement policies or rules;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market opportunities for our products and product candidates may be smaller than we believe, or we may be unable to successfully identify clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot obtain, or are delayed in obtaining, regulatory approvals and advisory committee recommendations, we will be unable to commercialize, or will be delayed in commercializing, our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development is lengthy and uncertain, and our clinical programs may be delayed or terminated, or may be more costly to conduct than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products are, and any future products will be, subject to regulatory scrutiny;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping for any of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As we grow as a commercial company and our drug development pipeline matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to operational risks associated with the physical and digital infrastructure at our manufacturing facilities and those of our external service providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our intismeran autogene product candidates are uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in production;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on single-source suppliers for some of the components and materials used in, and the manufacturing processes required to develop and commercialize, our products and product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into strategic alliances with third parties for product development and commercialization. If these alliances are unsuccessful, our business could be adversely affected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may seek to establish additional strategic alliances and, if we are unable to do so on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain and enforce patent protection for our discoveries and the intellectual property rights therein, or protect the confidentiality of our trade secrets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable and can have adverse financial and freedom-to-operate consequences;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We incurred net losses in 2025 and 2024, and expect to incur additional losses in the future; we have a limited history of recognizing revenue from product sales and may not achieve long-term sustainable profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results may fluctuate. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing changes to the size, structure and scope of our company;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to the risks of doing business outside of the United States;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our internal computer systems and physical premises, or those of third parties with which we share sensitive data or information, may fail or suffer security breaches, including from cybersecurity incidents, which could materially disrupt our product development programs and manufacturing operations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock has been volatile, which could result in substantial losses for shareholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, in the section entitled &#8220;Risk Factors&#8221; and the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, before you decide whether to purchase our common stock. The risks described above are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to drive sales growth through geographic expansion and new product launches;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding revenue growth in 2026;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to deliver cost efficiency across our business and to achieve targeted cash breakeven;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the size and durability of the respiratory vaccine market and future demand for and sales of our products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and timing for future data readouts, regulatory filings, regulatory approvals and commercial launches;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of initiation, progress, completion, results (including interim data) and cost of our clinical trials, as well as those of our collaborators;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully contract with third-party suppliers, distributors and manufacturers;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the ability of third parties with whom we contract to successfully manufacture, supply and distribute our products, at scale, as well as drug substances, delivery vehicles and product candidates;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products, product candidates and technology, including our ability to enter into license agreements, and our expectations regarding pending legal proceedings related to our intellectual property;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">participant enrollment in our clinical trials, including enrollment demographics and timing; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages of mRNA as compared to traditional medicine;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize our products, if approved, including in light of the size and growth potential of the markets for our products and the degree of market acceptance of our products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our medicines, if approved;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the buildout of our global manufacturing and commercial operations, and our ability to leverage our global manufacturing network;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance and estimates of our future expenses, revenues and capital requirements;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic collaboration agreements and our ability to enter into strategic collaborations or other agreements with collaborators with development, regulatory and commercialization expertise;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal and regulatory developments in the United States and foreign countries;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to produce our products or product candidates with advantages in turnaround times and manufacturing cost;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific, manufacturing, regulatory, commercial and management personnel; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on forward-looking statements. Factors that may cause actual results or events to differ materially from current expectations include, among other things, those listed under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a guarantee of future performance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, the terms &#8220;Moderna,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this Annual Report on Form 10-K refer to Moderna, Inc. and its consolidated subsidiaries. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TRADEMARKS</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i151f4968467f44d985f22077f4372877_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_19"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 1. Business</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_22"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">With a global team and a unique culture, driven by our values and mindsets, our mission is to deliver the greatest possible impact to people through mRNA medicines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We currently have three commercial products&#8212;Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory syncytial virus (RSV)). mNEXSPIKE, which we launched commercially in the third quarter of 2025, is now our leading product in the U.S. retail channel. In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Beyond our commercial products, we continue to demonstrate the potential of our platform technology and are advancing a pipeline of development candidates across oncology, rare disease and infectious disease. In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157), our mRNA-based individualized neoantigen therapy, in combination with Merck&#8217;s pembrolizumab (KEYTRUDA&#174;), which demonstrated sustained improvement in recurrence-free survival in patients with high-risk melanoma (stage III/IV) following complete resection. We are advancing intismeran in collaboration with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types. In oncology, we are also advancing mRNA-4359, a cancer antigen therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In infectious disease, we have regulatory filings under review for our seasonal flu+COVID combination vaccine candidate (mRNA-1083) in Europe and Canada, and for our seasonal flu vaccine candidate (mRNA-1010) in the United States, Europe, Canada and Australia. For mRNA-1010, in response to a prior Refusal-to-File letter, we engaged with the U.S. Food and Drug Administration (FDA) in a Type A meeting and submitted an amended biologics license application (BLA) outlining a revised regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults. Following the meeting and submission of the amended application, the FDA accepted our BLA for review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026. In addition, we recently completed enrollment of a second Northern Hemisphere season (2025-2026) cohort in our ongoing Phase 3 study for our norovirus candidate (mRNA-1403).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In rare disease, our propionic acidemia therapeutic (mRNA-3927) has reached target enrollment in a registrational study. In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization. In addition, we expect the registrational study for our methylmalonic acidemia therapeutic (mRNA-3705) to begin in 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Since 2022, we have streamlined our production sites into a global manufacturing network to support new product launches and deliver products for multi-year collaborations. In 2025, we announced new drug product capabilities in the U.S. and we have added three Moderna-built and managed facilities in the UK, Canada and Australia to enable local access to mRNA vaccines. Additionally, our Marlborough, Massachusetts facility was purpose-built for intismeran and began clinical batch supply in September 2025.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_25"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">THE mRNA OPPORTUNITY</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">mRNA, the software of life</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">mRNA transfers the information stored in our genes to the cellular machinery that makes all the proteins required for life. Our genes are stored as sequences of DNA which contain the instructions to make specific proteins. DNA serves as a hard drive, safely storing these instructions in the cell&#8217;s nucleus until they are needed by the cell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">When a cell needs to produce a protein, the instructions to make that protein are copied from the DNA to mRNA, which serves as the template for protein production. Each mRNA molecule contains the instructions to produce a specific protein with a distinct function in the body. mRNA transmits those instructions to cellular machinery, called ribosomes, that make copies of the required protein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We see mRNA functioning as the &#8220;software of life.&#8221; Every cell uses mRNA to provide real time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. This was codified as the central dogma of molecular biology over 60 years ago, and is exemplified in the schematic below.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:9pt;text-align:center"><img src="mrna-20251231_g2.jpg" alt="image (26).jpg" style="height:227px;margin-bottom:5pt;vertical-align:text-bottom;width:720px" id="i-2"/></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The structure of mRNA </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA is a linear polymer comprising four monomers called nucleotides: adenosine (A), guanosine (G), cytosine (C) and uridine (U). Within the region of the molecule that codes for a protein (the coding region), the sequence of these four nucleotides forms a language made up of three-letter words called codons. The first codon, or start codon (AUG), signals where the ribosome should start protein synthesis. To know what protein to make, the ribosome then progresses along the mRNA one codon at a time, appending the appropriate amino acid to the growing protein. To end protein synthesis, three different codons (UAA, UAG, and UGA) serve as stop signals, telling the ribosome where to terminate protein synthesis. In total, there are 64 potential codons, but only 20 amino acids that are used to build proteins; therefore, multiple codons can encode for the same amino acid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of protein production is called translation because the ribosome is reading in one language (a sequence of codons) and outputting in another language (a sequence of amino acids). The coding region is analogous to a sentence in English. Much like a start codon, a capitalized word can indicate the start of a sentence. Codons within the coding region resemble groups of letters representing words. The end of the sentence is signaled by a period in English, or a stop codon for mRNA.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><img src="mrna-20251231_g3.jpg" alt="Image_1.jpg" style="height:296px;margin-bottom:5pt;vertical-align:text-bottom;width:720px" id="i-3"/></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In every cell, hundreds of thousands of mRNAs make hundreds of millions of proteins every day. A typical protein contains 200-600 amino acids; therefore, a typical mRNA coding region ranges from 600-1,800 nucleotides. In addition to the coding region, mRNAs contain four other key features: (1) the 5&#8217; untranslated region (5&#8217;-UTR); (2) the 3&#8217; untranslated region (3&#8217;-UTR); (3) the 5&#8217; cap; and (4) a 3&#8217; polyadenosine (poly-A) tail. The sequence of nucleotides in the 5&#8217;-UTR influences how efficiently the ribosome initiates protein synthesis, whereas the sequence of nucleotides in the 3&#8217;-UTR contains information about which cell types should translate that mRNA and how long the mRNA should last. The 5&#8217; cap and 3&#8217; poly-A tail enhance ribosome engagement and protect the mRNA from attack by intracellular enzymes that digest mRNA from its ends.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The intrinsic advantages of using mRNA as a medicine</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA possesses inherent characteristics that we believe position it to have a profound impact on human health:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA is used by every cell to produce all proteins:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA is used to make every type of protein, including secreted, membrane and intracellular proteins, in varying quantities over time, in different locations and in various combinations. Given the universal role of mRNA in protein production, we believe that mRNA medicines could have broad applicability across human disease.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Making proteins inside one&#8217;s own cells mimics human biology: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Tailored mRNA can be sent into cells to instruct them to produce specific protein therapeutics or vaccine antigens and provides certain advantages over traditional approaches to medicine, where a protein or chemical is introduced to the body.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA has a simple and flexible chemical structure:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Each mRNA molecule comprises four chemically similar nucleotides to encode proteins made</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from up to 20 chemically different amino acids. To make the full diversity of possible proteins, only simple sequence changes are required in mRNA, instead of starting from scratch for each new vaccine or therapy.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA has classic pharmacologic features: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA possesses many of the attractive pharmacologic features of most modern medicines, including reproducible activity, predictable potency and well-behaved dose dependency; mRNA also provides the ability to adjust dosing based on an individual patient&#8217;s needs, including stopping or lowering the dose, to seek to promote safety and tolerability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success in developing, manufacturing and commercializing mRNA medicines demonstrates the potential of our platform to help people and patients in far-reaching ways that could exceed the impact of traditional approaches to medicine.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the main advantages of mRNA as compared to traditional medicine are: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">mRNA could create an unprecedented abundance and diversity of medicines.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA&#8217;s breadth of applicability has the potential to create an extraordinary number of new mRNA medicines that are currently beyond the reach of recombinant protein technology.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Advances in the development of our mRNA medicines reduce risks across our portfolio. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA medicines share fundamental features that can</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be leveraged across our portfolio. We believe that once safety and proof of protein production has been established in one program, the technology and biology risks of related programs that use similar mRNA technologies, delivery technologies and manufacturing processes will decrease significantly.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">mRNA technology can accelerate discovery and development. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The software-like features of mRNA enable rapid</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">design and the use of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">automated high-throughput synthesis processes that permit discovery to proceed in parallel rather than sequentially. We believe these mRNA features can also accelerate drug development by allowing the use of shared manufacturing processes and infrastructure.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">The ability to leverage shared processes and infrastructure can drive significant capital efficiency over time. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe the manufacturing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">requirements of different mRNA medicines are similar and that at commercial scale, a portfolio of mRNA medicines will benefit from shared capital expenditures.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_28"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OUR STRATEGY</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the development of mRNA medicines represents a significant breakthrough for patients, our industry and human health globally. We are currently focused on four strategic priorities: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Deliver sales growth.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Our commercial growth drivers include geographic expansion and new product launches. In 2026, we expect to drive revenue growth from the annualized impact of our long-term partnerships in the UK, Canada and Australia, as well as continued strong uptake of mNEXSPIKE in the U.S. In addition, we expect multiple growth opportunities in 2027 and 2028.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Deliver cost efficiency across the business.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Throughout 2025, we maintained disciplined cost management, improving productivity across manufacturing, R&amp;D and SG&amp;A. We expect to further reduce costs in 2026 and 2027. We plan to leverage our global production network, artificial intelligence (AI) and digital tools to improve cost efficiency.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Execute on our prioritized pipeline.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> We anticipate pivotal trial data readouts in 2026 across our oncology, rare disease and infectious disease portfolios. We expect to launch several new infectious disease products over the next few years (flu, flu+COVID combination and Norovirus), which would expand our infectious disease vaccine franchise to as many as six approved products. We expect to invest the cash generated from these products into oncology and rare disease therapeutics.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Continue to advance our early pipeline and platform technology.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> We continue to advance our early-stage pipeline. This includes our early-stage oncology programs, which expand our oncology portfolio across cancer antigen therapies, T-cell engagers and cell-therapy enhancers, as well as multiple early-stage vaccine programs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_31"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OUR PLATFORM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview of our platform</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA &#8220;platform&#8221; refers to our accumulated knowledge and capabilities in basic and applied sciences. Our platform incorporates advances across three key components&#8212;mRNA, delivery and the manufacturing process&#8212; to advance our medicines. We integrate these components and combine different versions of mRNA delivery and process into each of our medicines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our platform: mRNA science advancements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in both basic and applied research, seeking to advance both the state of our technology and the state of the scientific community&#8217;s understanding of mRNA. Examples of advances in mRNA science that combine nucleotide chemistry, sequence engineering and targeting elements are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">mRNA chemistry: Modified nucleotides to mitigate immune system activation: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The innate immune system has evolved to protect cells from foreign RNA, such as viral RNA, by inducing inflammation and suppressing mRNA translation once detected. Many cells surveil their environment through sensors called toll-like-receptors (TLRs). These include types that are activated by the presence of double-stranded RNA (TLR3) or uridine containing RNA fragments (TLR7, TLR8). Additionally, all cells have cytosolic double-stranded RNA, sensors, including retinoic acid inducible gene-I (RIG-I) that are sensitive to foreign RNA inside the cell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The immune and cellular response to mRNA is complex, context specific, and often linked to the sensing of uridine. To minimize undesired immune responses to our potential mRNA medicines, our platform employs chemically-modified uridine nucleotides to minimize recognition by both immune cell sensors such as TLR3/7/8, and broadly-distributed cytosolic receptors such as RIG-I. </span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">mRNA sequence engineering: Maximizing protein expression: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA exists transiently in the cytoplasm, during which time it can be translated into thousands of proteins before eventually being degraded. Our platform applies bioinformatic, biochemical, and biological screening capabilities, most of which have been invented internally that aim to optimize the amount of protein produced per mRNA. We have identified proprietary sequences for the 5&#8217;-UTR that have been observed to increase the likelihood that a ribosome bound to the 5&#8217;-end of the mRNA transcript will find the desired start codon and reliably initiate translation of the coding region.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We additionally design the nucleotide sequence of the coding region to maximize its successful translation into protein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Targeting elements: Enabling tissue-targeted translation: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All nucleated cells in the body are capable of translating mRNA, resulting in pharmacologic activity in any cell in which mRNA is delivered and translated. To minimize or prevent potential off-target effects, our platform employs technologies that regulate mRNA translation in select cell types. Cells often contain short RNA sequences, called microRNAs or miRNAs, that bind to mRNA to regulate protein translation at the mRNA level. Different cell types have different concentrations of specific microRNAs, in effect giving cells a microRNA signature. microRNA binding directly to mRNA effectively silences or reduces mRNA translation and promotes mRNA degradation. We design microRNA binding sites into the 3&#8217;-UTR of our potential mRNA medicines so that if our mRNA is delivered to cells with such microRNAs, it will be minimally translated and rapidly degraded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our platform: Delivery science</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA can, in specific instances, be delivered by direct injection to a tissue in a simple saline formulation without lipid nanoparticles (LNPs) to locally produce small amounts of pharmacologically active protein. However, the blood and interstitial fluids in humans contain significant RNA degrading enzymes that rapidly degrade any extracellular mRNA and prevent broader distribution without LNPs. Additionally, cell membranes tend to act as a significant barrier to entry of large, negatively-charged molecules such as mRNA. We have therefore invested heavily in delivery science and have developed LNP technologies to enable delivery of larger quantities of mRNA to target tissues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">LNPs are generally composed of four components: an amino lipid, a phospholipid, cholesterol, and a pegylated-lipid (PEG-lipid). Each component, as well as the overall composition, or mix of components, contributes to the properties of each LNP system. LNPs containing mRNA injected into the body rapidly bind proteins that can drive uptake of LNPs into cells. Once internalized in endosomes within cells, the LNPs are designed to escape the endosome and release their mRNA cargo into the cell cytoplasm, where the mRNA can be translated to make a protein and have the desired therapeutic effect. Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chemistry: Novel lipid chemistry to potentially improve safety and tolerability: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary LNP systems are designed to be highly tolerated and minimize any LNP vehicle-related toxicities with repeat administration </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. To overcome limitations of previous LNP formulations, we have engineered amino lipids to avoid the immune system and to be rapidly biodegradable relative to prior lipids. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Composition: Proprietary LNPs enhance delivery efficiency: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our platform includes extensive in-house expertise in medicinal chemistry, which we have applied to design large libraries of novel lipids. Using these libraries in combination with our discovery biology capabilities, we have conducted high throughput screens for desired LNP properties and believe that we have made fundamental discoveries in preclinical studies about the relationships between structural motifs of lipids and LNP performance for protein expression. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Surface properties: Novel LNP design to avoid immune recognition: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have designed our proprietary LNP systems for sustained pharmacology upon repeat dosing by eliminating or altering features that activate the immune system. These are based on insights into the surface properties of LNPs. Upon repeated dosing, surface features on traditional LNPs such as amino lipids, phospholipids, and PEG-lipids, can be recognized by the immune system, leading to rapid clearance from the bloodstream, a decrease in potency upon repeat dosing, and an increase in inflammation.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on our insights into these mechanisms, we have engineered our LNP systems to reduce or eliminate undesirable surface features. In clinical studies for our systemic therapeutic product candidates that use our novel LNP systems, we have been able to repeat dose with negligible or undetectable loss in potency, liver damage, and immune system activation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our platform: Manufacturing process science</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We invest significantly in manufacturing process science to impart more potent features to our mRNA and LNPs, and to invent the technological capabilities necessary to manufacture our mRNA medicines at scales ranging from micrograms to kilograms, as well as achieve pharmaceutical properties such as solubility and shelf life. We view developing these goals of manufacturing and pharmaceutical properties as appropriate for each program, based on its stage of development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">mRNA manufacturing process: Improving pharmacology: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our platform creates mRNA using a cell-free approach called </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> transcription in which an RNA polymerase enzyme binds to and transcribes a DNA template, adding the nucleotides encoded by the DNA to the growing RNA strand. Following transcription, we employ proprietary purification techniques to ensure that our mRNA is free from undesired synthesis components and impurities that could activate the immune system in an indiscriminate manner. Applying our understanding of the basic science underlying each step in the manufacturing process, we have designed proprietary manufacturing processes to impart desirable pharmacologic features, for example increasing potency in a vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LNP manufacturing process: Improving pharmacology:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform technology includes synthetic processes to produce LNPs. Traditionally LNPs are assembled by dissolving the four molecular components, amino lipid, phospholipid, cholesterol, and PEG-lipid, in ethanol and then mixing this with mRNA in an aqueous buffer. The resulting mixture is then purified to isolate LNPs from impurities. Such impurities include molecular components that have not been incorporated into particles, un-encapsulated mRNA that could activate the immune system, and particles outside of the desired size range.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Going beyond optimization of traditional manufacturing processes, we have invested in understanding and measuring the various biochemical and physical interactions during LNP assembly and purification. We have additionally developed state-of-the-art analytical techniques necessary to characterize our LNPs and biological systems to analyze their </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> performance. With these insights, we have identified manufacturing process parameters that drive LNP performance, for example, the potency in a secreted therapeutic setting. These insights have allowed us to make significant improvements in the efficiency of our processing and the potency of our LNPs. </span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_34"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Harnessing the power of mRNA through modalities </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Within our platform, we invest in science to invent novel ways to deliver mRNA into various cell types. Each novel delivery system is a new application, called a &#8220;modality.&#8221; While the programs within a modality may target diverse diseases, they share similar mRNA characteristics and manufacturing processes to achieve shared product features.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the high technological correlation within a modality allows us to rapidly accelerate the expansion of programs within that modality based on learnings from the earlier programs, while the lower technology correlation between modalities allows us to compartmentalize the technology risks. Additionally, because programs within a modality pursue diverse diseases, they often have uncorrelated biology risk. New modalities and product candidates can create a network effect by helping us gain additional insight into the other programs in our pipeline. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although developing a new modality is difficult, time-consuming and expensive, we believe our experience and technology provide us with unique advantages in the development of mRNA medicines. Over the last decade, we have developed a number of modalities, each with one or many product candidates in the clinic. We believe that our ongoing investments in our platform will lead to the identification of additional modalities and expand the utility of our existing modalities and the diversity of our pipeline. </span></div><div style="padding-left:45pt"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_37"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OUR PIPELINE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Over the last decade, we have advanced in parallel a diverse development pipeline that currently consists of 35 therapeutic and vaccine programs, 6 of which are in late-stage development. The scope of our pipeline reflects the breadth of biology addressable using mRNA technology, and spans three franchises: infectious disease vaccines, oncology therapeutics, and rare disease therapeutics. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our selection process for advancing new product candidates reflects both program-specific and portfolio-wide considerations. Program-specific criteria include, among other relevant factors, the severity of the unmet medical need, the biology risk of our chosen target or disease, the feasibility of clinical development, the costs of development and the commercial opportunity. Portfolio-wide considerations include the ability to demonstrate technical success for our platform components within a modality, thereby increasing the probability of success and learnings for subsequent programs.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our full pipeline is shown in the figure below: </span></div><div style="text-align:center"><img src="mrna-20251231_g4.jpg" alt="Moderna pipeline_021726.jpg" style="height:883px;margin-bottom:5pt;vertical-align:text-bottom;width:720px" id="i-4"/></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_40"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFECTIOUS DISEASE FRANCHISE </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Respiratory Vaccines </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have three commercial respiratory vaccines&#8212;Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our RSV vaccine for older adults and high-risk adults ages 18-59). Additionally, we have regulatory filings under review for our seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for our seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Our current respiratory programs are summarized below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COVID vaccines (Spikevax/mRNA-1273, mNEXSPIKE/mRNA-1283) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 is caused by the SARS-CoV-2 virus that was first identified in humans in 2019, driving a global pandemic resulting in millions of deaths. The risk of mortality increases with age, and the risk of severe disease and mortality is higher among individuals with certain pre-existing conditions, including cardiovascular disease, diabetes, chronic lung disease and obesity. As the SARS-CoV-2 virus continues to evolve, our COVID vaccines continue to be key tools in fighting COVID-19. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We currently have two approved COVID vaccines: Spikevax (our original COVID vaccine) and mNEXSPIKE. mNEXSPIKE was approved by the FDA in May 2025 for individuals 65 years of age and older, and individuals 12 through 64 years of age who are at high risk for severe COVID-19. mNEXSPIKE focuses immune responses to the domains of the SARS-CoV-2 spike protein that are critical for neutralizing antibody and T cell responses. mNEXSPIKE&#8217;s mRNA dose is one-fifth that of Spikevax. In April 2025, we shared Phase 3 data showing non-inferior vaccine efficacy relative to Spikevax, and a 13.5% relative vaccine efficacy (rVE) compared to Spikevax in participants 65 years of age and older.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As part of our strategy to continue to combat COVID-19, we develop and assess variant-specific versions of our COVID vaccines. We pursue updated vaccine compositions based on guidance from the FDA, and other regulatory bodies including European Medicines Agency (EMA) and the World Health Organization (WHO), with the goal of broadening vaccine-induced immunity and providing protection against circulating SARS-CoV-2 variants. Our 2025-2026 formulas for Spikevax and mNEXSPIKE target the LP.8.1 variant of SARS-CoV-2. The FDA has approved our 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years and all adults 65 years of age and older. We have received approval of our 2025-2026 Spikevax formula in 40 countries. The FDA has approved our 2025-2026 mNEXSPIKE formula for high-risk individuals 12 through 64 years of age and all adults 65 years of age and older. We have also received approvals of mNEXSPIKE in Europe, Canada and Australia. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RSV vaccine (mRESVIA/mRNA-1345)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RSV is one of the most common causes of lower respiratory disease in children under the age of five and in older adults. Populations that are especially vulnerable to developing severe RSV infections include infants, young children, children and adults with chronic medical conditions and older adults. Most children are infected at least once by age two. In the United States, it is estimated that up to 80,000 children are hospitalized due to RSV infection annually. RSV infection causes up to 160,000 hospitalizations and up to 10,000 deaths per year in adults aged 65 years or older in the United States. Adults 18 to 59 years of age with certain comorbidities also face a significant disease burden that is similar to that of older adults.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an RSV vaccine (mRNA-1345 or mRESVIA) for adults. mRESVIA encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP. In May 2024, we announced the FDA approved mRNA-1345, brand name mRESVIA, for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults 60 years or older. Subsequently, the Advisory Committee on Immunization Practices (ACIP) issued a recommendation for all unvaccinated people aged 75 years and older and unvaccinated people aged 60 to 74 who are at increased risk for RSV. In June 2025, we received FDA approval for use of mRESVIA in adults ages 18-59 who are at increased risk for RSV-LRTD. In April 2025, the ACIP expanded its RSV vaccination recommendation to include high-risk individuals ages 50-59. mRESVIA was approved in the EU in August 2024 and in Canada in November 2024. In Canada, mRESVIA is recommended for individuals 75 and over and high-risk individuals ages 50-74, while in Europe, the vaccine is recommended for individuals 60 and over as well as high-risk individuals ages 18-59. mRESVIA has been approved in 40 countries for all adults 60 years and older and also approved in 31 of those countries for high-risk adults aged 18-59.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have completed additional Phase 3 studies in adults that have shown that mRNA-1345 restores immune response when revaccinated at 12 or 24 months, can be co-administered with a COVID mRNA vaccine, and is immunogenic in the solid organ transplant population.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Seasonal influenza vaccine (mRNA-1010) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The WHO estimates that seasonal influenza viruses cause three to five million cases of severe illness and 290,000 to 650,000 deaths each year, resulting in a severe challenge to public health. Currently licensed seasonal influenza vaccines rarely exceed 60% overall effectiveness and can provide low effectiveness during years when the circulating viruses do not match the strains selected for the vaccine antigens. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our seasonal influenza vaccine candidate (mRNA-1010) encodes for the hemagglutinin (HA) proteins of the strains recommended by the WHO. We aim to work with the WHO, regulators and public health authorities to enable strain selection closer to the influenza season to provide a better match to the circulating viruses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced interim results from the P301 study of mRNA-1010. The results indicated that mRNA-1010 achieved higher seroconversion rates for A/H3N2 and A/H1N1, as well as superiority on geometric mean titer ratios for A/H3N2 and non-inferiority on geometric mean titer rations for A/H1N1. Non-inferiority was not met for either endpoints for the influenza B/Victoria- or B/Yamagata-lineage strains. mRNA-1010 showed an acceptable safety and tolerability profile. In April 2023, we announced the P302 study of mRNA-1010 did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial. In September 2023, we announced the P303 immunogenicity and safety study of mRNA-1010 met all eight co-primary endpoints with an updated composition that was able to generate an improved immune response to influenza B strains. mRNA-1010 also elicited higher titers than the licensed comparator against all strains in this study. In September 2024, we shared results in an older adult extension study of P303, where mRNA-1010 met all primary immunogenicity endpoints, including superiority for all strains, compared to a licensed enhanced flu vaccine and showed an acceptable reactogenicity profile. Consequently, we announced that we were planning to start a confirmatory vaccine efficacy study, P304, funded by project financing through Blackstone Life Sciences, a collaboration we announced in 2024. In October 2025, we presented the results of this study showing a 26.6% relative vaccine efficacy versus the standard dose comparator in adults 50 year of age and older.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1010 has been filed for approval in the United States, Europe, Canada and Australia. In February 2026, in response to a prior Refusal-to-File letter, we engaged with the FDA in a Type A meeting and submitted an amended BLA outlining a revised regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults. Following the meeting and submission of the amended application, the FDA accepted our BLA for review and assigned a PDUFA goal date of August 5, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have paused development of mRNA-1011, mRNA-1012, mRNA-1020, and mRNA-1030, which were flu vaccines that included additional antigens relative to what is included in mRNA-1010.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Combination vaccines (mRNA-1083 and mRNA-1365)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are developing combination vaccine candidates to simplify and facilitate protection against a range of respiratory diseases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID and seasonal influenza combination vaccine (mRNA-1083), encodes the same antigens as our seasonal influenza vaccine (mRNA-1010) and mNEXSPIKE. In June 2024, we announced that our Phase 3 clinical trial of mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older. We filed for FDA approval for mRNA-1083 in November 2024 and also submitted regulatory applications in other geographies, including the EU, Canada, Australia and the UK. Demonstration of vaccine efficacy in our ongoing Phase 3 mRNA-1010 flu study was required by regulatory authorities in certain jurisdictions to support approval of mRNA-1083. As a result, we withdrew our application for mRNA-1083 in certain geographies until the mRNA-1010 Phase 3 study was completed. In October 2025, we reported full results of our mRNA-1010 vaccine efficacy study. mRNA-1083 is under regulatory review in Europe and Canada, and we are awaiting further guidance from the FDA for re-filing in the U.S. In addition, we plan to pursue regulatory submissions for mRNA-1083 in selected additional international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate the clinical development strategy for mRNA-1083, including the appropriate age populations and indications for future studies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, safety follow-up continues in our Phase 1 study for mRNA-1365, our RSV and human metapneumovirus (hMPV) combination vaccine, in children five to 23 months of age. We are also evaluating an updated version of mRNA-1365 in older adults.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pandemic influenza vaccine (mRNA-1018) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An influenza pandemic is a global outbreak of a new influenza A virus that is very different from recently circulating human seasonal influenza A viruses. Historically, pandemic strains have arisen by antigenic shift, which is a major change in an influenza A virus caused by the exchange of genetic segments between a non-human influenza virus with another influenza virus; this can occur through a simultaneous infection of an animal (e.g., swine) or humans with multiple influenza viruses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a pandemic influenza vaccine candidate that encodes for hemagglutinin (HA) glycoproteins. In 2023, we initiated a Phase 1/2 study to generate safety and immunogenicity data of our investigational pandemic influenza vaccine (mRNA-1018) in healthy adults 18 years of age and older. The study included vaccine candidates against H5 and H7 avian influenza viruses. In October 2025, we presented results of this study showing that mRNA-1018 demonstrated a rapid, potent and durable immune response. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved hemagglutination inhibition (HAI) antibody titers &#8805;1:40, an HAI titer considered to correlate with protection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase 3 clinical trial that aims to help advance our investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure. The Phase 3 trial is expected to begin in early 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Latent and Other Vaccines</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current latent and other vaccines programs are summarized below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaccines against latent viruses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CMV vaccine (mRNA-1647)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Cytomegalovirus (CMV) is member of the herpes virus family and a common human pathogen that causes complications for people who are immunosuppressed or can be passed to babies during pregnancy and result in congenital malformation. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our CMV vaccine candidate, mRNA-1647, combines six mRNAs in one vaccine. These six mRNAs encode proteins located on the surface of CMV: five mRNAs encode the subunits that form the membrane-bound pentamer complex and one mRNA encodes the full-length membrane-bound glycoprotein B (gB). Both pentamer and gB are essential for CMV to infect barrier epithelial surfaces and gain access to the body, which is the first step in CMV infection. mRNA-1647 is designed to produce an immune response against both pentamer and gB for the prevention of CMV infection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Congenital CMV (cCMV) results when infected mothers transmit the virus to their unborn child and it is the leading infectious cause of birth defects in the United States. We conducted a cCMV Phase 3 study of mRNA-1647 in women of childbearing age and announced in October 2025 that the study failed to reach its primary clinical endpoint. The program in women of childbearing age was discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the health burden of cCMV infection, CMV is a major health risk in the transplant population. There are approximately 47,000 solid organ transplants and 23,000 hematopoietic stem cell transplants in the U.S. annually. Each recipient faces a significant risk of CMV infection post-transplant, and this could result in graft rejection or end-organ CMV disease. mRNA-1647 has the potential to prevent CMV viral replication and/or disease in transplant populations. A Phase 2 proof-of-concept study for mRNA-1647 in allogeneic hematopoietic cell transplant (HCT) patients is ongoing. In interim data from our Phase 2 study, we reported robust CMV-specific T-Cell responses, and we expect to present full Phase 2 data after the study&#8217;s conclusion.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EBV vaccines (mRNA-1189 and mRNA-1195)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Epstein-Barr virus (EBV) is a member of the herpesvirus family that infects approximately 90% of people in the U.S. by adulthood, with primary infection typically occurring during childhood or late adolescence (approximately 50% and 89% seropositivity, respectively). EBV is the major cause of infectious mononucleosis, accounting for over 90% of the cases in the U.S. each year. Infectious mononucleosis can debilitate patients for weeks to months and, in some cases, can lead to hospitalization due to complications such as splenic rupture. EBV infection is also associated with the development and progression of certain lymphoproliferative disorders, cancers and autoimmune diseases. In particular, EBV infection and infectious mononucleosis are associated with increased risk of developing multiple sclerosis (MS), an autoimmune disease of the central nervous system. MS is the most common neurodegenerative disorder of the central nervous system, affecting approximately 2.8 million individuals worldwide of which approximately 1 million live in the U.S. MS leads to progressive disability, with profound socioeconomic impact on the patients, caregivers and the healthcare system.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are developing two mRNA candidates against EBV &#8212;a prophylactic vaccine to prevent infectious mononucleosis (mRNA-1189) and a therapeutic to treat multiple sclerosis (mRNA-1195). We believe that an effective EBV vaccine must generate an immune response against antigens that are required for viral entry and reactivation in susceptible cell types. mRNA-1189 is designed to elicit an immune response to EBV envelope glycoproteins, which are required for infection of both epithelial and B cells. mRNA-1195 encodes for entry glycoproteins and latent antigens aimed at inducing an antibody and T cell response, and will be investigated in the context of multiple sclerosis and post-transplant lymphoproliferative disorder.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting Phase 2, randomized, observer-blind, placebo-controlled studies of mRNA-1189 and mRNA-1195. The primary purpose of these studies is to assess the safety, tolerability and immunogenicity of these candidates, and to enable dose selection for further clinical development. In March 2024, we shared Phase 1 data for mRNA-1189, where the randomized, observer-blind, placebo-controlled study showed mRNA-1189 was immunogenic and generally well tolerated across all dose levels. We have since fully enrolled a dose finding Phase 2 study for mRNA-1189. Our Phase 1 study for mRNA-1195 is fully enrolled, and in November 2025 we shared data that showed mRNA-1195 was immunogenic and generally well tolerated across all dose levels. Our mRNA-1195 Phase 2 proof of concept trial in MS is ongoing, with an initial sentinel cohort fully enrolled as of December 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">HIV vaccine (mRNA-1645)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Human immunodeficiency virus (HIV) is responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Approximately 38 million people worldwide are currently living with HIV, with 1.2 million in the U.S. Approximately 1.5 million new infections of HIV are acquired worldwide every year and approximately 680,000 people die annually due to complications from HIV/AIDS. The primary routes of transmission are sexual intercourse and IV drug use, putting young adults at the highest risk of infection. From 2000 to 2015, a total of $562.6 billion globally was spent on care, treatment and prevention of HIV, representing a significant economic burden.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our HIV vaccine candidate (mRNA-1645) is being studied in Phase 1 clinical trials, sponsored by IAVI, to determine the optimal design to induce broadly neutralizing antibodies capable of addressing the genetic diversity of HIV that is necessary in future proof of concept studies. In collaboration with the Gates Foundation, International AIDS Vaccine Initiative (IAVI), The Scripps Research Institute and the National Institutes of Health (NIH), Phase 1 studies of previous versions of our HIV vaccine have been completed. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaccines against enteric viruses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Norovirus vaccines (mRNA-1403 and mRNA-1405) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Norovirus is a leading cause of acute gastroenteritis (AGE), responsible for approximately 18% of all AGE cases worldwide and imposing a substantial global health care burden. Annually, norovirus causes an estimated 685 million illnesses and 200,000 deaths, including more than 50,000 deaths in children under the age of five. While the incidence of norovirus AGE is highest among children under five years of age, disease severity is most pronounced in infants, older adults, and individuals with underlying medical conditions. In high-income countries such as the United States, approximately 90% of norovirus-associated deaths occur among older adults. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Norovirus is highly infectious and difficult to control due to its environmental stability and persistence on contaminated surfaces, frequently leading to large, disruptive, and costly outbreaks in closed or semi-closed settings such as daycare centers, schools, cruise ships, long term care facilities and healthcare institutions. Globally, the economic impact of norovirus is estimated at $60 billion per year. In the United States alone, norovirus causes an estimated 20 million infections, 100,000 hospitalizations and 900 deaths each year, with associated costs of approximately $2 billion. As populations age and reliance on institutionalized care increases, the burden of norovirus disease among older adults is expected to rise further.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Norovirus exhibits broad genetic diversity, with 10 genogroups and 49 genotypes identified to date, 30 of which infect humans. Vaccine development has been challenging to date for many reasons, including the lack of a robust cell culture system, no reliable immune markers of norovirus protection and the broad and shifting diversity of genotypes. A multivalent vaccine with broad genotype coverage is needed to maximize protection against the genotypes most frequently associated with AGE in older adults and young children. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing pentavalent (mRNA-1405) and trivalent (mRNA-1403) vaccine candidates for norovirus. Both candidates were reviewed in a Phase 1 study to evaluate safety, reactogenicity and immunogenicity in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. In March 2024, we presented data demonstrating that a single dose of trivalent vaccine candidate mRNA-1403 was well-tolerated across all dose levels evaluated and elicited robust antibody responses against vaccine-matched norovirus genogroup I &amp; II selected genotypes, including functional histo-blood group antigen (HBGA) blocking antibodies. In September 2024, we presented additional data that mRNA-1403 elicited robust HBGA blocking antibody titers against a second GII genotype in older and younger adults.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, we began dosing participants in a Phase 3 study of mRNA-1403. This Phase 3 trial is a randomized, observer-blind, placebo-controlled trial evaluating the efficacy, safety and immunogenicity of mRNA-1403. The trial has enrolled approximately 38,000 participants 18 years of age and older globally, across countries in the Northern Hemisphere (U.S., Canada, UK and Japan), and Panama and Australia. Approximately 33,000 participants 60 years of age and older and approximately 5,000 participants between 18 and 59 years of age have been enrolled to assess the ability of mRNA-1403 to protect against vaccine genotype-matched moderate to severe norovirus AGE, with a focus on the older adult age group that is at greatest risk of severe outcomes including hospitalization and death.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 study of mRNA-1403 completed its first seasons in the Northern and Southern Hemispheres. A second Northern Hemisphere season cohort is fully enrolled and the study is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bacterial vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Lyme vaccines (mRNA-1975 and mRNA-1982)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lyme disease is an illness caused by Borrelia bacteria transmitted by the bite of infected ticks. Lyme disease affects approximately 675,000 people annually in the U.S. and Europe, with incidence increasing due to expanding tick territories driven by rising temperatures. The disease burden follows a bimodal age distribution, predominantly impacting children under 15 and older adults. Symptoms include rash, fever, headaches, fatigue, joint pain, swelling, stiffness, and headaches. While no vaccines are currently approved, prior Phase 3 trials of outer surface protein A (OspA) antigen-based vaccines achieved efficacy up to 92%, with protection linked to high levels of antigen-specific antibodies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a randomized, observer-blind, placebo-controlled, dose-ranging Phase 1/2 trial in healthy participants aged 18 to 70. This trial evaluates the safety and immunogenicity of a heptavalent (mRNA-1975) and monovalent (mRNA-1982) approach in parallel. mRNA-1982 targets Borrelia burgdorferi, responsible for nearly all Lyme cases in North America, while mRNA-1975 targets the four major Borrelia species causing disease in North America and Europe.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No safety concerns have been identified across the evaluated dose levels for three injections of mRNA-1975/1982. Furthermore, three injections of mRNA-1975/1982 elicit robust anti-OspA IgG antibody responses, with titers up to ~1,300 times above baseline for OspA serotype 1 of Borrelia burgdorferi. The program will progress to a Phase 2 dose ranging study of mRNA-1982.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health vaccines</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nipah vaccine (mRNA-1215) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nipah virus (NiV) is a zoonotic virus transmitted to humans from animals, contaminated food or through direct human-to-human transmission and causes a range of illnesses including fatal encephalitis. Severe respiratory and neurologic complications from NiV have no treatment other than intensive supportive care. The case fatality rate among those infected is estimated at 40-75%. NiV outbreaks cause significant economic burden to impacted regions due to loss of human life and interventions to prevent further spread, such as the slaughter of infected animals. NiV has been identified as the cause of isolated outbreaks in India, </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Bangladesh, Malaysia and Singapore since 2000 and is included on the WHO R&amp;D Blueprint list of epidemic threats needing urgent research and development action.  </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with the NIH-Vaccine Research Center (VRC), we conducted a Phase 1 clinical trial of mRNA-1215, our vaccine candidate against NiV, and testing was focused on pandemic preparedness. This Phase 1 dose-escalation, open-label clinical trial was the first study of mRNA-1215 in healthy adults to evaluate the safety, tolerability and immunogenicity of a NiV mRNA vaccine candidate. The trial was sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Mpox vaccine (mRNA-1769)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Mpox (formerly known as monkeypox) is an infectious disease caused by the mpox virus, a member of the Orthopoxvirus genus, which also includes Variola virus, the virus that caused smallpox. Although smallpox was eradicated in 1980, continued protection from smallpox is of great importance given the lethality of the infection and potential for use as an agent of bioterrorism. Other viruses associated with the Orthopoxvirus genus include cowpox, rabbitpox and camelpox. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are two main types of the mpox virus, Clade I and Clade II, each with subtypes (a and b). Prior to 2022, mpox outbreaks were primarily sporadic, driven by zoonotic spillover in endemic regions. Mpox can infect humans and other animals and is spread mainly through close physical contact with an infected person or contaminated materials, as well as through contact with infected animals. Respiratory transmission via face-to-face interaction is also possible. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clade II (subclade IIb) was responsible for the 2022 global mpox outbreak which led the WHO to declare a Public Health Emergency of International Concern (PHEIC). Transmission during the outbreak occurred primarily through sexual contact. In 2024, a second PHEIC was declared due to Clade I outbreak expansion in the Democratic Republic of the Congo and neighboring countries. Current epidemiology reports indicate that both Clade I and Clade II viruses continue to circulate globally, with recent expansions of Clade Ib transmission in some regions outside Africa, sometimes without direct travel links to endemic areas.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The incubation period for mpox typically ranges from 3 to 17 days. Initial symptoms include fever, headache, muscle aches, fatigue, and swollen lymph nodes, followed by a characteristic rash or skin lesions that may last 2-4 weeks. Most individuals recover fully, although severe disease can occur, particularly in people with weakened immune systems.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The current standard of care for mpox prevention is JYNNEOS, which is approved by the FDA for prevention of mpox and smallpox.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our mpox vaccine candidate, mRNA-1769, is designed to express four antigens from the mpox virus. In preclinical studies using a stringent non-human primate model, vaccination with mRNA-1769 resulted in fewer lesions, reduced viral replication, and stronger neutralizing and functional antibody responses compared with existing treatments. The immune responses induced by mRNA-1769 also showed broad activity against several orthopoxviruses. These results were published in 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a randomized, placebo-controlled, dose-ranging Phase 1/2 study to evaluate the safety, tolerability, and immune response of three dose levels of mRNA-1769 in healthy adult participants. Interim analysis showed that mRNA-1769 demonstrated a favorable safety profile and strong immunogenicity. These interim results were presented as an oral presentation at the 2025 ESCMID Global conference. The full study results are currently expected in 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLOGY THERAPEUTICS FRANCHISE </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Within our oncology therapeutics franchise, we are developing intismeran autogene (mRNA-4157) in collaboration with Merck. We and Merck are targeting a variety of tumor types, with eight Phase 2 and Phase 3 trials ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Separate from the collaboration with Merck, our Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. We have also expanded our oncology portfolio with early-stage programs, including mRNA-4106 (a cancer antigen therapy), mRNA-2808 (a T-cell engager), and mRNA-4203 (a cell-therapy enhancer). mRNA-4203 is being developed in collaboration with Immatics.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intismeran autogene (mRNA-4157) </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As tumors grow, they acquire mutations which may lead to the creation of new protein segments (neoantigens) that can be presented on human leukocyte antigen (HLA) molecules in the tumor and recognized as non-self by T cells. While some neoantigens are shared across tumors, the majority are completely unique to an individual patient&#8217;s tumor and their presentation is dependent on a patient&#8217;s specific HLA type.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intismeran autogene, mRNA-4157, uses next generation sequencing and a machine-learning based algorithm to design an mRNA that encodes up to 34 neoantigens against each individual patient&#8217;s tumor mutations with specificity to their HLA type, and is predicted to elicit both class I (CD8+ T cells) and class II (CD4+ T cells) responses. The neoantigens are encoded in a single mRNA sequence and formulated in our proprietary LNPs designed for intramuscular injection. Intismeran autogene is manufactured using an automated workflow to enable a rapid turnaround time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are developing mRNA-4157 in collaboration with Merck. In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement). Pursuant to the PCV Agreement, we and Merck will collaborate on further development and commercialization of mRNA-4157, and we will share costs and any profits and losses worldwide related to mRNA-4157 equally.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we announced that the randomized Phase 2 trial of mRNA-4157 had met its primary endpoint. The open-label Phase 2 study is investigating a 1 mg dose of mRNA-4157 in combination with Merck&#8217;s KEYTRUDA, compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma. The study showed that mRNA-4157 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.02]; one-sided p value=0.0266) compared with KEYTRUDA alone. The results were the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial in melanoma. Adverse events observed were consistent with those previously reported in a Phase 1 clinical trial, which showed mRNA-4157 to be well-tolerated at all dose levels. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, mRNA-4157 received a Breakthrough Therapy Designation from the FDA, and in April 2023, mRNA-4157 received PRIME Scheme Designation from the EMA.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we announced that at a planned median follow-up of approximately three years, mRNA-4157 in combination with KEYTRUDA showed sustained benefit, reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection. These data were presented at the American Society of Clinical Oncology (ASCO) in June 2024, as well as translational biomarker data that suggests mRNA-4157 may benefit a broad patient population, irrespective of the status of PD-L1, TMB, ctDNA, and HLA heterozygosity. Three-year exploratory endpoint data also showed an encouraging trend in overall survival (OS) with the combination versus pembrolizumab monotherapy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, we announced that at a planned median follow-up of approximately five years, mRNA-4157 in combination with KEYTRUDA showed continued sustained benefit, reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.294-0.887]; one-sided nominal p=0.0075) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and Merck have expanded the intismeran autogene program, initiating Phase 3 studies in adjuvant melanoma, adjuvant non-small cell lung cancer (NSCLC), and adjuvant NSCLC post neoadjuvant treatment. We also have Phase 2 trials ongoing in adjuvant renal cell carcinoma (RCC), muscle-invasive bladder cancer (MIBC), non-muscle-invasive bladder cancer (NMIBC), metastatic melanoma, and first-line metastatic squamous NSCLC. In addition, we have an ongoing Phase 1 study in early and advanced solid tumors. Enrollment of the Phase 3 adjuvant melanoma study was completed in 2024 and enrollment of the Phase 2 RCC study was completed in 2025.  </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cancer antigen therapy (mRNA-4359)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a cancer antigen therapy (mRNA-4359) that encodes Indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1) antigens. We designed mRNA-4359 with the goal of stimulating effector T cells that target and kill suppressive immune and tumor cells that express the target antigens. Our initial indications for mRNA-4359 are advanced or metastatic cutaneous melanoma and NSCLC. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We presented data from the Phase 1a study of mRNA-4359 at the European Society for Medical Oncology (ESMO) Congress in 2024, where in a population of patients with heavily pre-treated, advanced stage cancers, eight of 16 response-evaluable patients achieved a best overall response (BOR) of stable disease. Translational data showed antigen-specific T-cell responses were elicited by mRNA-4359 treatment; a proportion of activated, cytotoxic, and memory T cells were elevated and a proportion of regulatory T cells and myeloid-derived suppressor cells (MDSCs) were diminished on treatment. mRNA-4359 monotherapy was tolerable at all dose levels tested with most adverse events of low grade (grade 1&#8211;2) and manageable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We presented data from the Phase 1b study at ESMO in 2025, where in a population of 29 checkpoint inhibitor resistant/refractory melanoma patients, across all evaluable patients, mRNA-4359 in combination with pembrolizumab, the objective response rate (ORR) was 24%, and the disease control rate, or the combination of patients achieving tumor response and stable disease, was 60%. mRNA also demonstrated a consistently manageable safety profile. Responses were enriched in patients with PD-L1 &#8805;1% tumor proportion score (TPS), with an ORR of 67%, indicating encouraging activity in this difficult to treat patient population. Translational analyses demonstrated biological activity of mRNA-4359, including induction of PD-L1&#8211; and IDO1-specific T-cell responses and novel clonal T-cell expansion in the periphery, consistent with the proposed mechanism of action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional translational analyses presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting further demonstrated that the magnitude of immune activation, including T-cell clonal expansion, correlated with clinical outcomes and was accompanied by early and substantial reductions in circulating tumor DNA. Tumor-based analyses showed that responders had higher baseline gene expression of PD-L1 and IDO1 and exhibited on-treatment increases in immune-inflamed gene expression signatures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1/2 study of mRNA-4349 is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cancer antigen therapy (mRNA-4106)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-4106 is a cancer antigen therapy offering broad coverage across tumor types. It encodes for multiple tumor targets and is designed to broaden coverage across and within patients. Our Phase 1 study commenced in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">T-cell engager (mRNA-2808)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-2808 is a T-cell engager targeting surface antigens in multiple myeloma and is currently dosing in a Phase 1 / 2 clinical study.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cell therapy enhancer (mRNA-4203 and Anzu-cel (IMA203))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-4203 is a cell therapy enhancer that encodes for the target of an ex-vivo cell therapy to enhance the persistence and efficacy of the cell therapy. mRNA-4203 is being developed in collaboration with Immatics and is dosed in combination with Immatics&#8217; IMA203. The Phase 1 study commenced in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RARE DISEASE FRANCHISE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current rare disease programs are summarized below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Propionic acidemia (mRNA-3927)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Propionic acidemia (PA) is a rare, inherited metabolic disorder with significant morbidity and mortality, affecting one in 100,000-150,000 individuals worldwide. PA is caused by pathogenic variants in the propionyl-coenzyme A carboxylase (PCC) &#945; or &#946; subunits (PCCA and PCCB genes, respectively), leading to PCC deficiency and subsequent accumulation of toxic metabolites. PA is characterized by recurrent life-threatening metabolic decompensation events (MDEs) and multisystemic complications. Multisystemic complications include neurological manifestations, cardiomyopathy, arrythmias, growth retardation, recurrent pancreatitis, bone marrow suppression and predisposition to infection. Long-term, insults by toxic metabolites cause complications in various organs, and cognitive outcome is negatively correlated with the number of MDEs. Currently, there is no approved therapy for PA that targets the underlying root cause of the disease. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our PA therapy candidate, mRNA-3927, is a novel, IV-administered, LNP-encapsulated dual mRNA therapy that encodes for PCCA and PCCB subunit proteins to restore functional PCC enzyme activity in the liver. By encoding for intracellular proteins, mRNA therapy has a potential role in preventing and treating acute metabolic decompensations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have received Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Designation from the FDA and Orphan Designation from the European Commission for the PA program. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025, we reported data from the ongoing global Phase 1 / 2 clinical trial for mRNA-3927 in patients one year and older with PA. In part one, 22 patients were dosed and mRNA-3927 was well tolerated in all doses administered. Treatment continued to demonstrate sustained reduction in MDEs, with benefit highest for patients receiving doses of 0.6 mg/kg or greater. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-3927 is in a registrational study and target enrollment has been reached. An infant dose-finding study is also ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Methylmalonic acidemia (mRNA-3705)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Methylmalonic acidemia (MMA) is a rare, inherited metabolic disorder with significant morbidity and mortality caused by a deficiency in an enzyme called methylmalonyl-CoA mutase (MUT). There are an estimated 500-2,000 people with MMA MUT deficiency in the United States based on estimated birth prevalence (0.3-1.2:100,000 newborns) and mortality rates. Mortality is significant, with rates of 50% for those with complete MUT deficiency (mut 0) (median age of death 2 years) and 40% for MMA patients with partial MUT deficiency (mut -) (median age of death 4.5 years) reported in a large European study. MMA mainly affects the pediatric population and usually presents in the first few days or weeks of life. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of acute metabolic decompensations is the hallmark of the disorder, and decompensations are typically more frequent in the first few years of life. Each decompensation is life-threatening and often requires hospitalization and management at an intensive care unit. Survivors often suffer from numerous complications including chronic renal failure and neurologic complications such as movement disorders, developmental delays, and seizures. Consequently, the health-related quality of life for MMA patients and their families is significantly impaired. There are currently no approved therapies that address the underlying defect for MMA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our MMA therapy candidate, mRNA-3705, is an investigational, lipid nanoparticle-encapsulated therapy administered intravenously that codes for the human MUT (hMUT) enzyme and is hypothesized to restore normal MUT production.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the FDA announced that it had selected our MMA therapy candidate, mRNA-3705, for the Support for Clinical trials Advancing Rare Disease Therapeutics (START) program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, we reported MMA data at the International Congress for Inborn Errors of Metabolism (ICIEM). In an ongoing Phase 1/2 study, eighteen participants have been dosed. All eligible participants opted to participate in the Open-Label Extension study. mRNA-3705 was generally well-tolerated. Initial data are encouraging, with reductions in methylmalonic acid and other pathway biomarkers. The registrational study is expected to begin in 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cystic Fibrosis (mRNA-3692/VX-522)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cystic Fibrosis (CF) is a rare genetic disease, which is progressive from birth and leads to multi-organ damage and early death due to lung dysfunction. It is caused by the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in the loss of CFTR chloride ion channel function. This decreased function of CFTR at the cell surface leads to thick, sticky mucus in multiple organ systems but most pathologically the lungs. There are approximately 92,000 patients living with cystic fibrosis in the United States, Europe, Australia and Canada, with over 5,000 of these patients not being able to benefit from the approved CFTR modulators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Vertex on our CF candidate, mRNA-3692/VX-522, which is designed to treat the underlying cause of CF by enabling cells in the lungs to produce functional CFTR protein for the treatment of the over 5,000 patients who do not produce any modulator-responsive CFTR protein. This would be our first demonstration of a nebulized mRNA therapy. The FDA has granted VX-522 Fast Track designation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The multiple ascending dose portion of the Phase 1/2 study of VX-522 is underway, with data expected in the second half of 2026.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PROGRAMS DISCONTINUED IN 2025</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of portfolio prioritization and emerging clinical data, we discontinued a number of programs in 2025 as we focus our research and development efforts. We do not have current plans for future development of the following programs:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-1647: CMV in congenital CMV (we plan to continue to evaluate mRNA-1647 in an ongoing Phase 2 trial of bone marrow transplant patients)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-1608: Herpes simplex virus (HSV) vaccine</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-1468: Varicella-Zoster virus (VZV) vaccine</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-3745: Glycogen Storage Disease Type 1a (GSD1a) therapeutic</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-3210: Phenylketonuria (PKU) therapeutic</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_43"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our m</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">anufacturing </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capabilities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">play a critical role in our value chain and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> support every stage of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development of our products, from discovery to commercialization. During the research stage of product development, manufacturing provides mRNA drug substance and drug product for platform research and therapeutic area drug discovery. During early development of our product candidates, we manufacture drug substance and drug product for IND-enabling GLP toxicology studies and initial human clinical studies. For late clinical development, we produce mRNA and drug product for Phase 3 trials. At the commercial stage, we manufacture drug substance </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and drug product in collaboration with our contract manufacturing organizations (CMOs), both in the United States and internationally.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview of our manufacturing operating model </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing activities generally focus on: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Commercial Production:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;Our manufacturing capabilities include state-of-the-art technologies for mRNA and drug product manufacturing, as well as quality control testing to attain a robust and consistent supply that matches target product profiles. Our manufacturing technology is built to scale-up and support production of products for commercial approval. Our platform allows for efficient manufacturing at scale. </span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Research and Development Support:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8239;The product supply enables platform research and drug discovery in our therapeutic and vaccine areas, in addition to activities related to clinical studies of our product candidates. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have built a dedicated in-house, multi-building manufacturing campus in Norwood, Massachusetts, the Moderna Technology Center (MTC). In December 2024, we purchased the MTC campus to provide greater operational flexibility and long-term stability in supporting our manufacturing and development capabilities. The MTC provides supply for our preclinical research, IND-enabling GLP toxicology study supplies, our Phase 1 and Phase 2 pipeline activities, later-stage clinical development activities, as well as drug substance commercial production for vaccines. The MTC campus has been designed with a high level of automation and state-of-the-art digital integration to handle manufacturing execution, product testing and release, and regulatory filings. In 2025, we began construction at the MTC campus for new commercial drug product manufacturing and packaging capability to enable full end-to-end manufacturing for our mRNA medicines in the U.S. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we acquired a biomanufacturing facility in Marlborough, Massachusetts. In 2025, we completed construction of the facility, which was purpose-built for intismeran autogene. Designed for speed and scalability with advanced automation and robotics, the site was approved for clinical supply and began shipping patient batches in September 2025. We are on track for potential commercial launch, pending regulatory approvals.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, we </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have built and manage</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA manufacturing facilities in the United Kingdom, Canada and Australia. The</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">se facilities were fully licensed in 2025, and the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hese local manufacturing facilities will provide direct access to rapid pandemic response capabilities and our respiratory vaccine candidates. We may seek to enter into future agreements with other governments to provide similar manufacturing capabilities in other geographies. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our internal manufacturing facilities, we also maintain relationships with CMOs in the United States and abroad, providing critical raw material production and fill-finish capacity for our vaccines. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing technology development </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To support our broad pipeline of products, which spans multiple therapeutic areas and routes of administration, our platform research and technical development teams closely collaborate to facilitate rapid and seamless clinical translation of scientific breakthroughs. This enables us to develop potential medicines to serve a broad patient population. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Technical development encompasses the design and optimization of robust and consistent manufacturing processes, product characterization, fit-for-purpose formulations and product presentations. For instance, our novel hardware platforms&#8217; automation and robotics, coupled with the flexibility of our in-house digital development systems, allows for thousands of experiments and process parameters across our projects, thus supporting our drug product pharmaceutical readiness. Moreover, our technical manufacturing advances have enabled internalization of new key capabilities, including DNA plasmids and small molecules. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In parallel, we continue to refine existing processes, resulting in increased manufacturing capabilities. These improvements may allow us better control over our supply chain, resulting in larger production yields and longer shelf life of our products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our substantial investments in recent years in technical development have enabled the breadth and depth of our pipeline, and laid the foundation to help meet the needs and requirements associated with late-stage development and the commercialization of our products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply of mRNA for All Stages of Product Development and Commercialization </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply for Research </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">High-throughput automation and custom engineered equipment allow us to produce and deliver high quality mRNA and formulated constructs in a short period of time: our proprietary platform is capable of producing up to&#8239;1,000 lots of mRNA sequences and formulations per month with a turnaround time of a few weeks from sequence to final product. The typical scale of mRNA manufactured by this team is 1-1,000 mg. This has been possible, in part, due to the ability of researchers in the Moderna ecosystem to order constructs through an integrated digital portal that tracks materials end-to-end in less than 45 days. In addition, multiple integrated algorithms that leverage artificial intelligence and machine learning optimize manufacturability, reduce failures and increase quality of mRNA sequences. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply for Clinical Development </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have established manufacturing capabilities that support the early development stage of product development in three key areas: GLP Tox, Clinical Studies and intismeran. We supply formulated product to conduct IND-enabling GLP toxicology studies. In addition, human clinical studies rely on supply to meet required cGMP standards. This is achieved via internal manufacturing at the MTC campus. Our MTC campus is also suited to enable rapid technology development and scale-up for future needs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing also produces cGMP intismeran. Due to the specialized nature of personalized medicine (i.e., where a batch is specifically designed and manufactured for a single patient), the manufacturing process for intismeran has unique requirements. We digitally integrate patient-specific data from sequencing tumor samples to automatically design intismeran for patients. We have developed proprietary bioinformatics designed algorithms linked to an automated manufacturing process for rapid production of formulated mRNA, with a typical turnaround time of a few weeks.&#8239;We have operationalized intismeran manufacturing to meet our Phase 1 and 2 pipeline supply needs by using single-use systems with fast &#8220;needle-to-needle&#8221; turnaround times.&#8239;Unlike traditional process development, each intismeran batch is manufactured for a single patient and thus scaled-out (in parallel) with extensive use of automation and robotics to account for the larger number of patients involved in later phases of development and commercialization. We have shown consistent quality in our production of many patient batches, each with unique mRNA sequences. Our new Marlborough facility has state-of-the-art mRNA manufacturing areas, including a full manufacturing clean room, quality control laboratories, and a just-in-time satellite warehouse.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing capabilities have allowed us to build our broad pipeline of&#8239;development programs, including the output required to supply related toxicological and human clinical studies. While the technology that underpins these programs is the same, each program typically requires customization based on target product profiles. These custom features range from varying molecular architecture to different routes of administration, often requiring multivalent products. All programs, except for intismeran, require that we progressively scale up supply to meet clinical demand requirements across development phases, in addition to the necessary preparation for regulatory approval and commercial production, which demand larger batch sizes. In contrast, the intismeran program seeks to develop a cancer therapeutic that is designed and manufactured for a specific patient, thus increasing the number of unique batches. As we scale manufacturing output for each program, we plan to continuously improve yield, purity and the pharmaceutical properties of our product candidates. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply for Late-Stage Development and Commercialization </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our development pipeline continues to advance to later-stage development and towards commercialization. Our platform approach allows us to continue to evolve our manufacturing suites and other capabilities at our manufacturing facilities. mRNA manufacturing is flexible and one plant can manufacture multiple vaccines and therapeutics. Our manufacturing facilities also permit us to manufacture products in parallel. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quality Unit </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Quality is core to the way we operate. We seek to ensure quality at Moderna through a combination of a robust Quality Management System (QMS), our quality culture and our people. In accordance with applicable regulations, we have established, documented and implemented a QMS to assure continued compliance with the requirements therein. The QMS facilitates cGMP compliance by implementing practices that identify the various required processes, their application throughout the organization and the sequence of interaction of these processes. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The primary mode of documenting these key practices is through policies, standard operating procedures (SOPs), forms and other quality records, which include an overarching Quality Policy and Quality Manual. We have implemented tools and metrics to monitor, measure, and analyze these practices to support cGMP operations, achieve planned results, and support continuous improvement. We monitor these quality metrics through formal governance processes, including Quality Management Review (QMR), to enable continuous improvement. We have also established an independent Quality Unit that fulfills quality assurance and quality control responsibilities. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environment, Health, and Safety </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have established a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and compliance. Our approach integrates environmentally responsible practices with health and safety measures focused on risk reduction to promote long-term workplace well-being and environmental stewardship. We achieve this through a combination of training, procedures, digital data collection and reporting tools, and corporate programs that drive towards continuous improvement. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain Unit </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have established a global supply chain to enable supply of the raw materials and components used to produce our products, consistent with clinical and preclinical demands. We have worked with our external vendors to characterize critical raw materials and to understand their impact on the quality of drug substance and formulated drug product. We also assess the quality system and performance of our external vendors and work with them to comply with regulatory requirements. In addition, we have established an infrastructure to enable direct-to-customer shipments for our commercial products. We leverage third-party wholesalers and integrate with artificial intelligence-driven data analytics to ensure successful ordering and delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engineering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our global engineering organization is structured to deliver exceptional facilities and services. We partner closely with external and internal service providers to incorporate robotics, automation and predictive analysis for equipment operation. Engineering plays a critical role in the design, build, operation and maintenance of our facilities.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_46"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DIGITAL AND AI STRATEGY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding, we have been a digital-first company, seeking to use the power of digital information to maximize our impact on patients. mRNA is an information molecule, and our company was built on the premise that the natural flow of information in life can be used to develop medicines. Leveraging over a decade of experience developing mRNA medicines, we have built a large library of data that, combined with our platform approach and cloud-native infrastructure, positions us well to scale a digital operating model using artificial intelligence (AI).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Led by our Chief People and Digital Technology Officer, our digital organization partners across all Moderna functions to perpetuate and grow Moderna's AI-native culture. To that end, we have implemented cross-organization AI training initiatives to support our employees in transforming the way we work. Through these initiatives, our employees learn how to leverage AI in their specific job functions to augment their capacity and capabilities, and to maximize our impact on patients. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">AI helps optimize each aspect of our value chain, from drug design to commercial manufacturing and beyond. At the research stage, our digital and AI infrastructure allows our scientists to design novel mRNA constructs, use AI algorithms to optimize them and order them from our high throughput preclinical scale production line. Our capabilities allow us to design mRNA, protein and LNP components with desired properties, such as reduced toxicity or increased stability. At the product development stage, AI helps to improve the efficiency of our clinical trial operations by, for example, forecasting participant enrollment and automating clinical trial data processing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing processes likewise utilize the power of AI. For example, we leverage a series of fully autonomous, integrated AI algorithms in connection with manufacturing intismeran autogene (mRNA-4157). Our machine-learning based algorithms design the specific therapy for each individual patient and optimize the timely manufacture and delivery of intismeran to each patient. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the commercial stage, our digital and commercial organizations partner to drive performance and prepare for product launches. Digital and AI are key components of our commercialization strategy and are vital to our ability to increase our speed to market, enhance our commercial capabilities and continuously improve the quality of our products. We believe that our ability to move with both scale and speed positions us well to pursue our goals related to future product launches.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In early 2023, we began a collaboration with OpenAI to co-innovate with a shared vision of AI&#8217;s transformative potential in the future of business and healthcare. In 2024, our AI culture led to the deployment across the company of ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs. These GPTs are now embedded across our business functions, including legal, research, manufacturing and commercial, helping to drive productivity. For example, our Dose ID GPT uses ChatGPT Enterprise&#8217;s Advanced Data Analytics feature to further evaluate the optimal vaccine dose selected by the clinical study team. By applying standard dose selection criteria and principles, Dose ID provides a rationale, references its sources, and generates informative charts illustrating the key findings. This allows for a detailed review, led by humans and augmented with AI input, while prioritizing safety and optimizing the vaccine dose profile prior to further development in late-stage clinical trials. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we continued to scale our use of generative AI across the enterprise while further strengthening governance, security and responsible AI controls to support safe and compliant adoption. We also expanded the use of customized GPTs and advanced analytics in additional workflows, with a continued emphasis on human oversight, data integrity and alignment with our scientific, regulatory and ethical standards.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the integrated AI ecosystem we are building at Moderna will accelerate our mission to deliver the greatest possible impact to people through mRNA medicines. </span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_49"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continue to build our differentiated commercial model, with active commercial subsidiaries in key markets across North America, Europe and the Asia-Pacific region. Our commercial footprint provides us with local commercial teams in major markets where respiratory vaccines have high utilization rates and sales. To support the build out of our commercial activities in markets worldwide, we have hired talent with extensive pharmaceutical company experience. Our commercial teams also work with third-party distributors and other commercial alliances in countries where we do not have a direct presence. Our commercial activities are dependent on regulatory approvals and on agreements that we have made or may make in the future with strategic collaborators. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently have three commercial products&#8212;Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our RSV vaccine). The commercial markets for these vaccines are seasonal and characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries. The private vaccine market is also characterized by market practices regarding rebates, discounts and returns. The respiratory vaccine market, and markets for COVID and RSV vaccines in particular, depends on many factors such as medical need, viral evolution, public health authority recommendations and consumer motivation to vaccinate.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us. See &#8220;&#8212;Manufacturing&#8221; above for further detail.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_52"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">THIRD-PARTY STRATEGIC ALLIANCES</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Strategic alliances</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are party to strategic alliances with a diverse group of collaborators, including pharmaceutical and biotechnology companies, government agencies, academic laboratories, foundations and research institutes with therapeutic area expertise and resources. Through our collaborations, we seek to advance our discovery and development programs, while leveraging our platform and our research and early development capabilities. From time to time, we also partner with and invest in companies developing other types of therapeutics where we believe we can leverage our core mRNA and LNP capabilities to expand the reach of our technology.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through certain of our strategic alliances, we share the benefits and risks of developing a new mRNA modality or program, where we may have early research data and desire a strategic collaborator to join us in advancing early development candidates within such modality into the clinic. Representative relationships and associated programs include those with Merck, for our intismeran programs (mRNA-4157), and Vertex, for our CF program (mRNA-3692).</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To maintain the integrity of our platform, our strategic collaboration agreements generally grant either us the rights to develop and commercialize potential mRNA medicines we design and manufacture, or grant our collaborators those rights. These agreements do not allow collaborators to use our platform to generate new mRNA technologies, and we generally retain ownership of intellectual property related to our platform arising from research conducted under the alliance. We may continue to identify potential strategic collaborators who can contribute meaningful technology and insights to our programs and allow us to expand our impact more rapidly to broader patient populations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Below are brief descriptions of certain of our ongoing collaborations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Merck&#8212;Strategic Alliance for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Personalized mRNA Cancer Vaccines</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intismeran Autogene)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a Collaboration and License Agreement, which was subsequently amended in 2018, with Merck (the PCV Agreement) for the development and commercialization of personalized mRNA cancer vaccines (PCV), also known as Individualized Neoantigen Therapy (INT), which has been assigned the generic name intismeran autogene.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Under the strategic alliance, we identify genetic mutations present in a particular patient&#8217;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique intismeran designed to specifically activate the patient&#8217;s immune system against her or his own cancer cells.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PCV Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching intismeran, providing manufacturing capacity and manufacturing intismeran and conducting Phase 1 and Phase 2 clinical trials for intismeran, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option for intismeran, including mRNA-4157, pursuant to the terms of the PCV Agreement and in October 2022 paid us an option exercise fee of $250 million. Pursuant to the PCV Agreement, we and Merck have agreed to collaborate on further development and potential commercialization of intismeran, with costs and any profits or losses generally shared equally on a worldwide basis, subject to certain exceptions as outlined in the agreement. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Vertex&#8212;2016 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex). The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of CF by enabling cells in the lungs of people with CF to produce functional CFTR proteins.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology, such as our collaboration with Immatics N.V. to pioneer novel and transformative therapies for cancer patients with high unmet medical need. We have also entered into agreements with other parties under which we have received licenses of certain technology.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, in January 2026, we entered into a collaboration with Recordati, an international pharmaceutical group, to advance our investigational PA therapeutic (mRNA-3927) through the final stages of clinical development and, if approved, global commercialization. We will continue to lead the clinical development of mRNA-3927 through approval and Recordati will lead commercialization.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Strategic alliances with government organizations and foundations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Biomedical Advanced Research and Development Authority (BARDA)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with BARDA for an award of up to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$483&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to accelerate development of mRNA-1273, our original COVID vaccine. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of mRNA-1273, including a 30,000 participant Phase 3 study,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$1.8&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. All contract options have been exercised. The BARDA contract concluded on June 15, 2025, upon completion of all contractual deliverables. As of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the remaining available funding, net of revenue earned, was approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$62&#160;million, and we do not expect to utilize a material portion of this amount following the conclusion of the contract.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Coalition for Epidemic Preparedness Innovations (CEPI)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, CEPI agreed to invest up to $54.3 million to support a pivotal Phase 3 clinical trial that aims to help advance our investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Institute for Life Changing Medicines (ILCM)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a collaboration agreement with the ILCM to develop a new mRNA therapeutic (mRNA-3351) for type 1 Crigler-Najjar syndrome (CN-1). Under the terms of the agreement, we agreed to license mRNA-3351 to ILCM with no upfront fees, and without any downstream payments. ILCM will be responsible for the clinical development of mRNA-3351.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The Gates Foundation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill &amp; Melinda Gates Foundation (n/k/a the Gates Foundation) to advance mRNA development projects for various infectious diseases. Under the framework agreement, the Gates Foundation committed funding to support certain preclinical and clinical development activities, including a program evaluating mRNA-based approaches for the prevention of HIV infection. The funded activities under the framework agreement concluded during 2025, following completion of the agreed-upon program scope. The collaboration supported multiple preclinical and early-stage clinical studies; results from these efforts were published in peer-reviewed scientific journals in 2022-2025 and additional publications are in preparation. As of December 31, 2025, there were no remaining funding commitments under the framework agreement. We continue to engage in scientific dialogue with the Gates Foundation regarding potential future areas of collaboration.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_55"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/>We rely on a combination of intellectual property laws, including patent, trademark, copyright and trade secret, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Protecting our platform, modality and program investments: Building an expansive, multi-layered IP estate</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have built a substantial IP estate that includes numerous patents and patent applications related to the development and commercialization of mRNA vaccine and therapeutic development candidates, including related platform technologies. Our platform IP protects advances in mRNA design and engineering, proprietary LNP components, delivery systems, processes for the manufacture and purification of drug substances and products and analytical methods. A significant portion of our platform IP estate further provides multi-layered protection for our modalities and programs.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our IP estate, our solely-owned patent portfolio consists of more than 260 issued or allowed U.S. patents or patent applications and more than 140 granted or allowed patents in jurisdictions outside of the U.S. (including granted European patents that have been validated in numerous European countries) covering certain of our proprietary platform technology, inventions and improvements, and covering key aspects of our clinical and most advanced development candidates. We have 485 additional pending patent applications that, in many cases, are counterparts to the foregoing U.S. and foreign patents.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Most of the patents and applications (if issued) in our portfolio will not expire until 2033 at the earliest. Any patent that may issue from our most recently filed patent applications is projected to expire between 2044 and 2045, at the earliest. We file additional U.S. and foreign patent applications in key markets as necessary to protect our evolving intellectual property positions.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks, copyright, trade secrets and know-how relating to our proprietary technology and programs, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of mRNA therapeutic and vaccine technologies. We take additional steps, such as entering into confidentiality and license agreements, to protect our intellectually property and proprietary rights. We additionally plan to rely on data exclusivity, market exclusivity and patent term extensions when and where available, and plan to seek and rely on regulatory protection afforded through orphan drug designations. We also possess substantial proprietary know-how associated with related manufacturing processes and expertise.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IP protecting our platform</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have a broad IP estate covering key aspects of our platform. This estate provides multiple layers of protection covering the making and use of the mRNA drug substance and delivery technologies.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our platform, we have a portfolio that includes U.S. and foreign patents or patent applications covering platform innovations that are related to the design, manufacturing and formulating of mRNA medicines. For example, these patents and patent applications include claims directed to:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA chemistry imparting improved properties for vaccine and therapeutic uses;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods for mRNA sequence optimization to enhance the levels and fidelity of proteins expressed from our mRNA medicines;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods for identifying epitopes having superior suitability in cancer vaccine contexts;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engineering elements tailored to enhance stability and the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;performance of mRNA medicines;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LNP delivery systems, including novel lipid components designed for optimal delivery and expression of both therapeutic and vaccine nucleic acids, in particular, prophylactic infectious disease and cancer therapy nucleic acids, intratumoral immuno-oncology therapeutics, local regenerative therapeutics, systemic therapeutics, and inhaled pulmonary therapeutics; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IP protection</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our IP estate provides protection for the multiple programs both at the product-specific level and at various broader levels. For example, we have patent coverage for LNP-encapsulated mRNAs having specific chemical modification suited for vaccine and therapeutic mRNA use. Our estate also includes IP covering certain LNP-encapsulated mRNAs coding for infectious disease antigens for use in preventing or treating infectious diseases, including those caused by respiratory and latent viruses, as well as bacterial diseases known to threaten public health. Our mRNA chemistry, formulation and manufacturing patent applications and related know-how, along with trade secrets, may also provide us with additional IP protection relating to our development candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Respiratory vaccines</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For our respiratory vaccines programs, we have pursued patent protection featuring composition of matter and method of use claims. Where we may pursue patent protection may vary based on the unique geographic prevalence of various infectious diseases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Approved products</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have filed several patent applications covering our betacoronavirus vaccine program. We are pursuing patent protection for both our existing and new betacoronavirus vaccines. We have also filed several patent applications covering our RSV vaccine. Our RSV patent portfolio includes multiple families of differing patent breadth. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The table below sets forth the year of projected expiration for the latest to expire, currently granted patents covering each of our approved products or a component thereof. Patent term extensions, supplementary protection certificates, and pediatric exclusivity periods (if any) are not reflected in the expiration dates listed in the table below. We also have additional patents covering each product. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:150%">Product</span></div></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:150%">Projected Expiration of U.S. Patents</span></div></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:150%">Projected Expiration of European Patents</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Spikevax</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">2041</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">mNEXSPIKE</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">2041</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">2036</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">mRESVIA</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">2041</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">2036</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Influenza</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple patent families spanning different levels of breadth, design and antigen valency pending in the U.S., </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Europe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and around the world, including several granted patents.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">hMPV</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Human metapneumovirus (hMPV) is a single-stranded RNA virus that is used in a combination program. We have patent applications covering our hMPV vaccine pending in the U.S. and Europe, with a granted patent in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latent vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have vaccine programs and patent applications directed to diseases caused by various latent viruses, in some cases, using both preventative vaccines targeting the acute phase and therapeutic vaccines for treating the latent diseases in those who do become infected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMV</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The patent coverage for our human CMV vaccine candidate is extensive and is based on a vaccine with six mRNAs encoding a pentamer surface glycoprotein complex and the gB surface glycoprotein. Both pentamer and gB facilitate entry of the virus into different cell types and therefore immune responses targeting these proteins can block virus entry, spread and reactivation. The current patent portfolio contains both compositions of matter and methods of treating subjects using the vaccine. In the U.S., our CMV vaccine is covered by multiple issued U.S. patents of differing breadth. Each family has counterparts consisting of pending applications and issued patents in non-U.S. jurisdictions, including, in some cases, Europe and Japan. A separate family of CMV patents, which includes mRNA-1647 for use in CMV vaccines for transplant indications, is also yielding patents and applications in foreign jurisdictions are pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EBV, HSV and VZV</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similar to CMV, we have filed patent applications, and in some cases multiple patent families, for each of EBV, HSV and VZV, e.g., covering prophylactic and/or therapeutic indications. In addition to patent applications filed in the United States, certain of these patent families have foreign counterparts, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in Europe.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public health vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a multi-program effort at developing vaccines for potential future pandemics and for use in parts of the world with less well-established health care systems. This group of programs include infectious diseases such as flaviviruses such as Zika and dengue viruses, HIV, Nipah virus, and the Mpox virus. In addition, programs are ongoing in many bacterial diseases. While patent applications are filed on some potential public health targets, in some scenarios, platform patents rather than target specific patents may be used to provide patent protection for public health target vaccines.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For our oncology programs, we are pursuing patent protection in numerous jurisdictions. The scope and geographic extent of patent protection may vary based on factors such as differences in regulatory regimes, competitive landscapes, and market considerations across these jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intismeran</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter and method claims are being pursued to protect intismeran. Proprietary methods around the making and therapeutic use of our intismeran and resulting vaccine compositions are described and claimed in one granted and one allowed U.S. patent, eight pending U.S. patent applications, five pending European patent applications, two granted patent and five pending patent applications in Japan, three pending patent applications and one granted patent in China, and several pending patent applications in New Zealand, South Africa, Asian and South American countries, as well as two PCT applications. These applications also relate to various vaccine design formats, in particular, polyepitopic vaccine formats, and methods of treating cancer with intismeran. We also possess substantial know-how and trade secrets relating to the development and commercialization of our cancer therapy programs, including related manufacturing process and technology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cancer antigen therapy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For our checkpoint cancer antigen therapy program (mRNA-4359), we are pursuing patent protection in various jurisdictions. Any U.S. and foreign patents that may issue from these patent applications would be expected to expire in 2043, excluding any patent term adjustments, any patent term extensions and/or any terminal disclaimers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rare diseases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have programs featuring expression of therapeutic proteins, e.g., intracellular enzymes for the treatment of rare diseases. For our rare disease programs, we generally pursue patent protection featuring composition of matter and method of use claims, for example, pharmaceutical composition and method of treatment claims. We have patent applications granted, pending and/or published for our most advanced rare disease development candidates targeting PA and MMA. In addition, we have patent applications granted, pending and/or published for our other rare disease candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any U.S. and foreign patents that may issue from these patent families would be expected to expire in 2036 for the earliest of the MMA patents and 2038 to 2042 for the remaining MMA and PA patents, excluding any patent term adjustments, any patent term extensions and any terminal disclaimers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As further described below, as we continue the development of our intended products, we continue to identify additional means of protecting our assets that would potentially enhance commercial success, including possible patent protection for additional methods of use, formulation, or manufacture.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our CF development candidate is covered by pending U.S., European and PCT patent applications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark portfolio currently contains at least 1,400 trademark registrations, including at least 29 registrations in the United States and the remaining in Canada, the European Union, the United Kingdom, Israel, China, Japan, Australia, and elsewhere. In addition, we have at least 180 pending trademark applications in more than 55 jurisdictions, including in the aforementioned locations and additional countries throughout Africa, Asia, and South America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">In-licensed intellectual property</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we develop and manufacture our potential mRNA medicines using our internally created mRNA technology platform, we also seek out and evaluate third party technologies and IP that may be complementary to our platform.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent sublicense agreements with Cellscript and mRNA RiboTherapeutics</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Trustees of the University of Pennsylvania owns several issued U.S. patents, granted European patents and pending U.S. patent applications directed, in part, to nucleoside-modified mRNAs and their uses (the Penn Modified mRNA Patents). mRNA RiboTherapeutics, Inc. (MRT) obtained an exclusive license to the Penn Modified mRNA Patents and granted its affiliate, Cellscript, LLC (Cellscript), a sublicense to the Penn Modified mRNA Patents in certain fields of use.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we entered into two sublicense agreements, one with Cellscript, and one with MRT, which agreements we collectively refer to as the Cellscript-MRT Agreements. Together, the Cellscript-MRT Agreements grant us a worldwide, sublicensable sublicense to the Penn Modified mRNA Patents to research, develop, make, and commercialize products covered by the Penn Modified mRNA Patents (licensed products), for all</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;uses in humans and animals, including therapeutic, prophylactic, and diagnostic applications. The Cellscript-MRT Agreements are non-exclusive, although Cellscript and MRT are subject to certain time restrictions on granting additional sublicenses for</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;uses in humans under the Penn Modified mRNA Patents. The Cellscript-MRT Agreements require us to pay royalties based on annual net sales of licensed products at rates in the low single digits for therapeutic, prophylactic, and diagnostic uses, and royalties based on annual net sales of licensed products sold for research uses at rates in the mid-single digits, subject to certain reductions, with an aggregate minimum floor.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Cellscript-MRT Agreements will terminate upon the expiration or abandonment of the last to expire or become abandoned of the Penn Modified mRNA Patents. Cellscript or MRT, as applicable, may terminate its respective Cellscript-MRT Agreement if we fail to make required payments or otherwise materially breach the applicable agreement, subject to specified notice and cure provisions. Cellscript or MRT, as applicable, may also terminate the applicable Cellscript-MRT Agreement upon written notice in the event of our bankruptcy or insolvency or if we challenge the validity or enforceability of the Penn Modified mRNA Patents. We have the right to terminate each Cellscript-MRT Agreement at will upon 60 days&#8217; prior notice to Cellscript or MRT, as applicable, provided that we cease all development and commercialization of licensed products upon such termination. If rights to MRT or Cellscript under the Penn Modified mRNA Patents are terminated (e.g., due to bankruptcy of MRT or Cellscript), the terminated party will assign its interest in the respective Cellscript-MRT Agreement to the licensor from which it received rights under the Penn Modified mRNA Patents and our rights will continue under the new licensor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent license agreements with NIAID</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH), to license certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we entered into a non-exclusive patent license agreement with NIAID to license certain patent rights concerning prefusion RSV F proteins and their use. Pursuant to the agreement, we have agreed to pay tiered, low-to-mid single-digit royalties on net sales of our RSV vaccine, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Formulation technology in-licenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our development candidates use internally developed formulation technology that we own. We do, however, have rights to use and exploit multiple issued and pending patents covering formulation technologies under licenses from other entities.&#160;If in the future we elect to use or to grant our strategic collaborators sublicenses to use these in-licensed formulation technologies, we or our strategic collaborators may be liable for milestone and royalty payment obligations arising from such use. We consider the commercial terms of these licenses and their provisions regarding diligence, insurance, indemnification and other similar matters, to be reasonable and customary for our industry.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_58"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,700</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> full-time employees in 18 countries as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment for talent, particularly as we seek to attract and retain talent with experience in the biotechnology and pharmaceutical sectors. Our workforce is highly educated, and as of December 31, 2025, 46% of our employees hold Ph.D., Doctorate, M.D., J.D. or Master&#8217;s degrees. Among our employees, as of December 31, 2025, 49% are female. Among our leadership (which we define as employees at the vice president level and above), as of December 31, 2025, approximately 39% are female. 44% of our U.S. employees identify as racially or ethnically diverse as of December 31, 2025. In 2025, for the fourth year in a row, an outside statistical pay equity analysis confirmed zero statistically significant differences in pay across gender globally and across gender, race and ethnicity in the United States.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our approach to attracting and retaining talent </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ensuring that our employees find that their careers at Moderna are filled with purpose, growth and fulfillment. We believe that a career at Moderna provides opportunity for:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Impact</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Our people have the opportunity to do work that is unparalleled in terms of its innovation and scope of impact on people&#8217;s lives.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Growth</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We provide incredible opportunities for growth and we obsess over learning (as demonstrated, in part, by our Mindsets (see below). We invest substantially in the development of our people. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Well-being</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We are deeply invested in the health and wellness of our employees and provide benefits and resources that support each person at work, at home and in their communities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Belonging</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: We believe that innovation happens through bringing together a broad set of perspectives and backgrounds, and creating an environment where differences are celebrated.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Compelling rewards</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: To attract and retain the best talent, we provide competitive rewards that help to drive groundbreaking work and allow employees to share in the value we will create together, including through our equity programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Giving and volunteering: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our people have the opportunity to give back to their communities and directly support causes that they are passionate about through volunteer and employee matching donation programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To help promote alignment between our employees and our shareholders, all employees participate in our corporate equity programs through the receipt of equity awards, and the percentage of equity as a component of overall pay mix increases with seniority. We also allow our employees to select how they want the value of their award to be split between stock options and restricted stock units (RSUs). We believe that in addition to incentivizing growth that leads to shareholder value, broad eligibility for our equity programs further embeds our "We behave like owners" mindset and helps promote employee retention as these awards generally vest over a four-year period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None of our employees have entered into a collective bargaining agreement with us. A small number of employees in France, Italy and Spain are covered by statutory collective bargaining agreements governing certain benefits and working conditions. Employees in our Madrid work center are represented by a works council. None of our other employees are represented by a labor union or a works council. We consider our employee relations to be good.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our employees are highly engaged, and our company and team have been publicly recognized for our leadership, innovation and good corporate citizenship. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Science</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> magazine ranked us as a top employer for each of the last eleven years. Additionally, in 2025, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biospace</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> ranked us a top large employer in its 2026 Best Places to Work in Biopharma report for the fifth consecutive year. We measure employee engagement through a vendor-supplied engagement software, using validated external benchmarks to track employee engagement factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continually monitor employee turnover rates, as our success depends upon retaining our highly trained personnel. We believe that the competitive compensation we offer, along with the combination of the factors listed above, among other factors, have helped reduce voluntary turnover. In 2025, our voluntary turnover rate was approximately 11%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our approach to training our employees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To further invest in our teams, we have established a structured training curriculum for our employees so that every employee becomes deeply familiar with our core technology and technologies that might further enable our innovation. In addition, we are focused on creating strong leaders through various management and leadership trainings. We have also built an online library of videos of a variety of scientific material that our employees can access flexibly. This content includes presentations by external speakers at in-house scientific seminars, scientific courses at external universities and peer-to-peer video series in which in-house experts provide an introductory view of complex topics they tackle within their teams.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">New employees participate in our Moderna ONE onboarding program, which is an interactive learning experience designed to immerse our people in our culture and Mindsets from day one. Following onboarding, our employees continue to learn throughout their careers at Moderna and we deploy a digital learning management system to track and administer training programs for each employee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we launched our AI Academy. The AI Academy is intended to educate and empower our employees to identify and integrate AI and machine learning solutions into every Moderna system and process to bring mRNA medicines to patients. In 2025, we delivered a targeted learning portfolio focused on practical AI skills designed to build durable habits and fundamentally change how employees work.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our culture</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As an organization, we are bold, collaborative, curious and relentless. These values are underpinned by a core set of what we call &#8220;basecamp&#8221; values&#8212; integrity, quality, respect. Additionally, with the continued rapid growth of our company, we articulated the Moderna Mindsets, which define how we behave, lead and make decisions. We believe our Mindsets will be integral to our future success, and we integrate them into every facet of how we identify, onboard, grow and manage our talent.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To further develop and retain our workforce, we conduct periodic talent reviews that identify key talent within the organization. We use that data to inform specific development opportunities for key current and potential future leaders, and to support our periodic succession planning activities for key roles. These steps together ensure we have a robust understanding of our workforce and a talent pipeline to grow future leaders, and provide our employees an opportunity to continuously grow and advance in a way that meets their aspirations and talents.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_61"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE SOCIAL RESPONSIBILITY </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As we pursue our mission to deliver the greatest possible impact to people through mRNA medicines, we have developed a corporate social responsibility (CSR) program that demonstrates our commitment to patients, employees, the environment and local communities. Our CSR framework consists of five key focus areas: medicines for patients, community, governance and ethics, employees and environment. Please refer to our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Impacting Human Health Report under the &#8220;Responsibility&#8212;Corporate policies &amp; reporting&#8221; section of our website, which can be found at www.modernatx.com/responsibility/corporate-policies, as well as our proxy statement related to our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting of Stockholders that we will file with the SEC, for a description of some of the measures we have taken to progress our commitment to corporate social responsibility.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_64"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. There is also a strong emphasis on defense of intellectual property and proprietary products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage. However, we face competition from others developing mRNA medicines, as well as other medicines that compete or could compete with our products. We face competition from various sources, including large pharmaceutical companies, biotechnology companies, academic institutions, government agencies and public and private research institutions. The continued growth of the mRNA field is leading to increased competitive pressure, including from large and more established pharmaceutical companies. We also face competition when entering into strategic alliances to advance and grow our pipeline.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Seasonal vaccines</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax&#8217;s. Additionally, some competitors have developed COVID treatments, including Pfizer&#8217;s antiviral pill, which may reduce demand for vaccines. With respect to our RSV vaccine, we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date. We will also face competition for other seasonal vaccines we expect to launch in the future; for example, we are developing a seasonal flu vaccine for which there is a well-developed market.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Competition for the sale of our products is impacted by many factors, including, among others, actual and perceived vaccine efficacy, safety and tolerability, perceptions of mRNA technology, storage and handling conditions and the relative ease of distribution and administration, the timing and scope of regulatory approvals, reimbursement coverage and production and distribution costs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In markets that we enter after competitors have already introduced a competing product, we may have difficulty achieving market share, as was the case in connection with the launch of our RSV vaccine. See &#8220;Risk Factors&#8212;The vaccine market, and pharmaceutical market more generally, is intensely competitive, and we may be unable compete effectively in the market for existing or new products, treatment methods or technologies.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Oncology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We face intense competition in the oncology space, including from large pharmaceutical and biotechnology companies developing a broad range of oncology products and platforms. Oncology markets evolve rapidly and are subject to significant clinical and regulatory uncertainty; competitors may generate superior data, advance more quickly, and establish new standards of care. As a result, competition could reduce the commercial opportunity and adversely affect development timelines. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and our strategic collaborators also face competition in therapeutic areas beyond seasonal vaccines and oncology. These competitors include a number of pharmaceutical and biotechnology companies and academic and research institutions developing a broad range of therapeutic approaches and platforms that may compete with our current or future programs.   </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_67"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States and in other countries and regions, such as in the EU, regulate the research, development, manufacture and marketing of our products. Before a new medicine is marketed, data demonstrating its quality, safety and efficacy must be generated, submitted for review, and approved by the competent regulatory authority.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">U.S. drug and biologic development and approval</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs and biologics under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, together with their implementing regulations and other applicable federal, state, and local laws. Failure to comply with these requirements at any stage of development, approval, or post-approval may result in administrative or judicial sanctions, including the FDA&#8217;s refusal to approve pending applications, license revocation, clinical holds, untitled or warning letters, product recalls, market withdrawals, product seizures, suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, and civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved through a biologics license application (BLA) or new drug application (NDA), or a supplement, before they may be marketed in the United States.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical studies</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Before testing in humans, our development candidates undergo preclinical studies that include laboratory evaluation of product chemistry and formulation, as well as </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and animal studies designed to assess safety and, in some cases, establish a rationale for therapeutic use. Preclinical safety and toxicology studies are subject to GLP requirements.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To begin human clinical trials, a sponsor must submit an IND to the FDA containing, among other things, the results of preclinical studies, manufacturing and analytical information, any available clinical data or literature, and proposed clinical trial protocols. An IND must become effective before human clinical trials may begin. Unless the FDA raises concerns, an IND generally becomes effective 30 days after receipt. If the FDA identifies deficiencies, the sponsor and the FDA must resolve those issues before clinical trials may proceed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Clinical trials</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of an investigational product to volunteers or patients under the supervision of qualified investigators and in accordance with Good Clinical Practice ( GCP) requirements. Clinical trials are conducted pursuant to protocols that specify, among other things, trial objectives, dosing, subject eligibility criteria, and safety and efficacy assessments. Each protocol and any amendments must be submitted to the FDA under the IND.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each clinical trial must also be reviewed and approved by an Institutional Review Board (IRB) at each participating institution to ensure that risks to subjects are minimized and reasonable in relation to anticipated benefits. IRBs approve informed consent documents and provide ongoing oversight of the trial. Sponsors must submit periodic reports to the FDA, including safety reports and annual progress reports, and must report serious adverse events on an expedited basis. Information regarding certain clinical trials must be submitted for posting on the clinicaltrials.gov website within required timeframes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain gene-based clinical trials are subject to oversight under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, including review by an institutional biosafety committee. Although the NIH Guidelines are mandatory only for institutions receiving NIH funding, many sponsors voluntarily follow these guidelines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign clinical studies conducted under an IND must comply with the same requirements applicable to U.S. studies. Data from foreign studies not conducted under an IND may be submitted in support of a BLA if the studies were conducted in accordance with GCP and the FDA is able to validate the data.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development generally proceeds in three sequential phases, which may overlap. Phase 1 clinical trials typically assess safety, tolerability, and pharmacology of the investigational product in a small number of healthy volunteers or disease-affected patients.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 clinical trials generally evaluate dosing and preliminary efficacy of an investigational product in disease-affected patients while continuing to assess safety.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 clinical trials are designed to generate the pivotal evidence of safety and efficacy of an investigational product for its intended use in a large number of disease-affected patients at multiple sites to support regulatory approval and labeling.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require post-approval Phase 4 non-registrational studies to further characterize safety, efficacy, or other scientific questions during commercial use.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, an IRB, or a clinical trial site may suspend or terminate a clinical trial at any time for safety, protocol compliance, or other reasons. In addition, certain trials are overseen by an independent data safety monitoring board or committee that periodically reviews accumulating data and may recommend continuation, modification, or termination of the trial. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FDA review process</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following completion of the clinical trials, data are analyzed to determine whether the investigational product is safe and effective for its proposed indication. The results of preclinical and clinical studies, together with proposed labeling, chemistry, manufacturing, and controls information, and other required data, are submitted to the FDA as part of a BLA or NDA.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A BLA seeks approval to market a biologic and must demonstrate the product&#8217;s safety, purity, and potency. An NDA seeks approval to market a drug and must demonstrate safety and efficacy. In all cases, the submission must contain sufficient evidence to satisfy the FDA&#8217;s standards for approval. FDA approval must be obtained before a product may be marketed in the United States. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of its review, the FDA conducts pre-approval inspections of manufacturing facilities to assess compliance with cGMP requirements and may audit clinical trial data to confirm compliance with GCP. The FDA may also convene an advisory committee to review applications that present novel scientific or regulatory issues. Advisory committee recommendations are not binding but are often considered by the FDA in its decision-making. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following review, the FDA may approve the application, request additional information, or issue a complete response letter identifying deficiencies that must be addressed before approval can be granted. A complete response letter may require additional preclinical or clinical studies or other data, and submission of such information does not guarantee eventual approval. If approved, the FDA issues an approval letter authorizing commercial marketing for specified indications and with approved labeling.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expedited development and review programs</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has several programs to facilitate and expedite the development and review of medicines intended to treat serious or life-threatening conditions, including fast track designation, breakthrough therapy designation, accelerated approval, and priority review. Fast track designation is designed to facilitate the development and review of medicines that address unmet medical needs. Breakthrough therapy designation is designed to expedite the development and review of medicines for which preliminary clinical evidence demonstrates substantial improvement over available therapies. Priority review designation establishes a goal of FDA action on an application within six months of filing and may be granted for medicines that offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based on an effect on a surrogate endpoint or an intermediate clinical endpoint reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require post-marketing confirmatory clinical trials and may impose additional post-approval requirements or restrictions on distribution or use to assure safe use of the product. Pursuant to the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that confirmatory trials be underway prior to approval or completed within specified timelines and has enhanced authority to expedite withdrawal of accelerated approval if clinical benefit is not verified or trials are not conducted with due diligence.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the applicable criteria or that review timelines will not be shortened. Participation in these programs does not change the statutory standards for approval.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Use Authorization and PREP Act </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Secretary of Health and Human Services (HHS) may authorize unapproved medical products , or unapproved uses of approved medical products, during a declared public health emergency. Following such a declaration, the FDA may issue Emergency Use Authorizations (EUA) for specific products if statutory criteria are met, including a determination that the product may be effective in diagnosing, treating, or preventing serious or life-threatening disease and that no adequate, approved, and available alternatives exist. An Emergency Use Authorization terminates when the underlying emergency declaration ends and is not a long-term substitute for FDA approval or licensure. The FDA may revoke an EUA at any time, including if the public health emergency no longer warrants such authorization. In August 2025, the FDA revoked the EUA for emergency use of our COVID vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Public Readiness and Emergency Preparedness Act (PREP Act) provides liability immunity for manufacturers and other covered persons against certain claims arising from the administration or use of covered countermeasures during a declared public health emergency, subject to a limited exception for willful misconduct. Covered countermeasures include qualified pandemic or epidemic products, such as vaccines intended to diagnose, prevent, or treat pandemic or epidemic diseases. To qualify for immunity, the Secretary of HHS must issue a declaration identifying the applicable emergency or credible risk of a future emergency. The Secretary issued a PREP Act declaration in March 2020 relating to COVID-19 and has issued subsequent amendments. While we believe our products sold to the U.S. Government continue to fall within the scope of applicable PREP Act declarations, this cannot be assured</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, all marketing applications for new active ingredients, indications, dosage forms, dosing regimens or routes of administration must contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred or inapplicable.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, a product may be eligible for pediatric exclusivity, which adds six months to existing exclusivity periods and patent terms. This exclusivity may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued written request for such a study.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rare Pediatric Disease Designation and Priority Review Vouchers</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug, and Cosmetic Act, as amended, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the FDA incentivizes the development of product candidates that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug or biologic for such disease or condition will be received from sales in the United States of such drug or biologic. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent marketing application after the date of approval of the rare pediatric disease drug product. A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a priority review voucher (&#8220;PRV&#8221;) upon approval of its BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Under current law, after September 30, 2029, the FDA may not award any rare pediatric disease priority review vouchers, although the FDA&#8217;s authority to do so could be extended by Congress in the future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Post-approval requirements</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, manufacturers and approved products remain subject to ongoing FDA regulation. These requirements include, among other things, adverse event reporting, recordkeeping, pharmacovigilance, compliance with promotional and advertising restrictions, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe approved products for off-label uses, manufacturers are prohibited from marketing or promoting products for unapproved indications. Certain prescription drug and biologic promotional materials must be submitted to the FDA in connection with their initial use.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes to an approved product, including changes to indications, labeling, manufacturing processes, or manufacturing facilities, may require the submission and approval of a new application or a supplemental BLA or NDA and may necessitate the generation of additional preclinical or clinical data.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose post-approval conditions to ensure that a product&#8217;s benefits outweigh its risks, including the requirement to implement a Risk Evaluation and Mitigation Strategy (REMS). A REMS may include medication guides, communication plans, restricted distribution systems, patient registries, or other measures designed to mitigate specific risks. Newly identified safety or effectiveness information may require labeling updates, additional risk management measures, or post-marketing studies. Failure to comply with regulatory requirements or the emergence of post-marketing safety issues may result in enforcement actions, including withdrawal of approval.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Approved drugs and biologics must be manufactured in registered facilities in compliance with current good manufacturing practice requirements. Manufacturers and third-party contractors involved in manufacturing or distribution must maintain quality systems, documentation, and procedures to investigate and correct deviations. Facilities are subject to periodic, unannounced FDA inspections. Identified violations or post-approval product issues may result in enforcement actions, including manufacturing restrictions or product recalls.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">U.S. patent term restoration and regulatory data exclusivity</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, some U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Amendments. Patent term restoration is intended to compensate for patent life lost during product development and the FDA review process and may extend a patent term by up to five years, subject to a maximum remaining patent term of 14 years from the product&#8217;s approval date. Only one patent per approved product may be eligible for such restoration, and any application for patent term restoration must be submitted prior to patent expiration. The U.S. Patent and Trademark Office, in consultation with the FDA, determines eligibility for patent term restoration.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain drug products may also qualify for periods of non-patent regulatory data exclusivity. A drug product containing an active ingredient not previously approved by the FDA is generally entitled to five years of regulatory data exclusivity. Products approved based on the FDA&#8217;s reliance on new clinical investigations essential to approval may receive three years of regulatory data exclusivity. If pediatric studies are conducted in response to an FDA request, pediatric exclusivity may be granted, which for drugs extends existing patent and regulatory exclusivities by six months and for biologics extends existing regulatory exclusivities by six months. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 established an abbreviated licensure pathway for biological products demonstrated to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. A biosimilar product must be shown to be highly similar to the reference product and to have no clinically meaningful differences in safety, purity, or potency. An interchangeable product must additionally be shown to produce the same clinical result in any given patient and, for products administered more than once, to be capable of alternating or switching with the reference product without increased risk. A reference biological product is entitled to 12 years of regulatory data exclusivity from the date of first licensure, and the FDA may not accept an application for a biosimilar or interchangeable product until four years after that date. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Orphan Drug Act, certain product candidates may also receive orphan drug designation for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product's marketing approval if granted by the FDA. A sponsor may apply for orphan designation at any time prior to submitting a marketing application. Designation is granted by the FDA&#8217;s Office of Orphan Products Development (OOPD) based on a confidential request, after which the product must undergo the standard review and approval process for commercial distribution.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A sponsor may seek orphan designation for an unapproved product, a new orphan indication for an approved product, or, in limited circumstances, for a product that is the same as an already approved orphan drug if they can demonstrate a plausible hypothesis of clinical superiority. Multiple sponsors may receive orphan designation for the same product and indication, provided each submits a complete request.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Orphan drug exclusivity begins on the date of FDA approval and applies only to the designated indication. During the exclusivity period, the FDA generally may not approve the same product by another manufacturer for the same indication unless the original sponsor consents, cannot supply sufficient quantities, or the subsequent product is clinically superior. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Drug development in the European Economic Area</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medicinal products can be marketed in the European Economic Area (EEA), which is comprised of the 27 Member States of the EU and Norway, Iceland and Liechtenstein, only if a marketing authorization from the competent regulatory authority has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the EU/EEA are subject to significant regulatory controls. Effective since January 2022, the Clinical Trials Regulation (EC) No. 536/2014 aims to streamline and harmonize the procedures for assessment and governance of clinical trials throughout the EU and to require that information on the authorization, conduct and results of each clinical trial conducted in the EU be publicly available.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric investigation plan</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An application for marketing authorization of a medicinal product for human use that is not yet authorized in the EU must include a Pediatric Investigational Plan (PIP) pursuant to the Regulation No. 1901/2006 on medicinal products for pediatric use (known as the Paediatric Regulation), unless a waiver applies. A scientific committee established at the European Medicines Agency (EMA), the Paediatric Committee (PDCO) assesses the content of any PIP, waivers, and deferrals for a medicinal product submitted to it and formulates an opinion thereon.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Review and approval process</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU/EEA, in order to obtain a marketing authorization from the applicable regulatory authority, a company may submit marketing authorization applications either under a centralized or national procedure. The centralized procedure is mandatory for certain categories of medicinal products, including those developed using specified biotechnological processes, advanced therapy medicinal products, orphan medicinal products, and certain innovative medicinal products, and is optional for other medicinal products that are considered highly innovative or contain a new active substance. The centralized procedure results in a single marketing authorization that is valid throughout the EU and EEA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a marketing authorization may be obtained through a national procedure, which requires separate applications to and approvals by individual Member States, through a decentralized procedure under which applications are submitted simultaneously to multiple Member States, or through a mutual recognition procedure, under which a marketing authorization granted in one Member State may be recognized by others.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A conditional marketing authorization may be granted in the EU when comprehensive clinical data for the safety and efficacy of the medicinal product have not been supplied but all the following requirements are met: (i) the risk-benefit balance of the medicine is positive; (ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data post-authorization; (iii) the medicine fulfills an unmet medical need; and (iv) the benefit to public health of the immediate availability on the market of the medicine outweighs the risk that additional data is still required. Conditional marketing authorizations are valid for one year, on a renewable basis. The marketing authorization holder will be required to fulfil specific obligations within certain timeframes, which may include completing ongoing trials or conducting new trials to confirm that the benefit-risk balance is positive. Once such obligations are fulfilled, provided the benefit-risk balance is still positive, a conditional marketing authorization can be converted into a standard marketing authorization.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">European regulatory data protection</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, innovative medicinal products authorized for marketing qualify for regulatory data protection consisting of eight years of data exclusivity and an additional two years of market protection upon the grant of a marketing authorization. Data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#8217;s data when applying for a generic or biosimilar marketing authorization. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the additional two-year period of market protection, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market protection period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be an innovative medicinal product, and products may not qualify for regulatory data protection.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">European orphan designation and exclusivity</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Orphan medicinal product designation is available in the EU to promote the development of products that are intended for the diagnosis, prevention, or treatment of life threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU community, or where it is unlikely that the development of the medicine would generate sufficient return to justify the necessary investment in its development, and in each case for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or, if a method exists, the product would be a significant benefit to those affected). Medicinal products that receive and maintain orphan drug designation following approval are entitled to 10 years of market exclusivity, which protects against applications for and the grant of marketing authorizations for similar medicinal products in the same therapeutic indication. This period may be reduced to six years if, at the end of the fifth year, it is established that the orphan drug designation criteria are no longer met. During the period of market exclusivity, a marketing authorization for a similar medicinal product for the same therapeutic indication may only be granted if the subsequent product is demonstrated to be clinically superior, the marketing authorization holder consents, or the holder of the authorized orphan medicinal product is unable to supply sufficient quantities of the product to meet patient needs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned EU rules are generally applicable in the EEA.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Reform of the Regulatory Framework in the European Union</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). In April 2024, the European Parliament adopted its position on the legislative proposals and, in June 2025, the Council of the European Union adopted its position. A common position on the text has been agreed upon on December 11, 2025, in the context of subsequent inter-institutional trilogue negotiations. The proposed revisions remain to be adopted, and are not expected to become applicable before 2028.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">European data protection regulations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The EU General Data Protection Regulation (EU GDPR) governs the collection and use of personal data in the EU. The EU GDPR imposes strict requirements relating to the consent of the individuals to whom the personal data relates, the collection and processing of sensitive data (such as health data), the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of the personal data. The EU GDPR also imposes strict rules on the transfer of personal data out of the EU, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4% of the annual global revenues of the infringer, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with competent national data protection authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Non-compliance could also result in the imposition of orders to stop data processing activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The UK has incorporated the GDPR into UK law (the UK GDPR). The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Marketing of medicines in the EU</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the Anti-Kickback Statute prohibition in the United States discussed below, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. Infringement of relevant EU laws could result in substantial fines and imprisonment. Payments may be made to physicians in limited circumstances, and in certain EU Member States such payments must be publicly disclosed. Moreover, agreements with physicians for the provision of services often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rest of the world regulation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States and the EU, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. If we fail to comply with such requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, or criminal prosecution.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and reimbursement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there is no uniform policy for coverage and reimbursement among third-party payors. As a result, obtaining coverage and reimbursement approvals can be time-consuming and costly and may require submission of scientific, clinical, and economic data to individual payors on a case-by-case basis, with no assurance of favorable outcomes. Coverage and reimbursement decisions for new medicines are often influenced by determinations made by the Centers for Medicare and Medicaid Services, and private payors frequently follow CMS policies. Even if coverage is obtained, reimbursement rates may be inadequate to achieve or sustain profitability or may require patient cost sharing that limits access or utilization. In addition, third-party payors may limit or exclude coverage for follow-up care or monitoring associated with the use of approved products. For vaccines, coverage decisions may be influenced by recommendations of the Advisory Committee on Immunization Practices, although such recommendations do not guarantee coverage or reimbursement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is therefore difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2026, the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act of 2022 requires CMS to implement negotiated prices for certain high-expenditure Medicare Part D drugs. CMS has issued guidance for multiple cycles of the negotiation program, and additional negotiated pricing rounds are expected in future years. The scope, timing, and impact of this program, including its potential application to additional drugs or coverage categories, remain subject to change and could affect pricing benchmarks, reimbursement levels, and net realized prices for our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net prices for drugs may also be reduced by mandatory discounts or rebates required by government healthcare programs or negotiated by private payors. Manufacturers are subject to complex price reporting obligations, including reporting of metrics such as average sales price and best price, and may be subject to penalties for failure to report accurately or timely. Changes in laws or policies affecting drug importation or pricing methodologies could further pressure pricing in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current and future healthcare reform initiatives may result in more restrictive coverage criteria, additional pricing pressure, expanded post-approval requirements, or further limitations on sales and promotional activities for pharmaceutical products. The impact of these measures on coverage, reimbursement, and pricing for our products remains uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in certain foreign jurisdictions, proposed pricing for a drug must be approved before the product may be marketed. Pricing and reimbursement requirements vary widely by country. In the EU, Member States may limit the medicinal products eligible for reimbursement under national health insurance systems and may impose direct or indirect controls on pricing or profitability. To obtain reimbursement or pricing approval, some Member States may require clinical or health economic data, including comparative cost effectiveness analyses, relative to existing therapies. A Member State may approve a specific price for a medicinal product or instead apply other pricing or profitability controls.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that any country with price controls or reimbursement limitations will permit favorable pricing or reimbursement for any of our products or product candidates. Prices for pharmaceutical products in the EU are generally lower than prices in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For further information on risks associated with pricing and reimbursement, see &#8220;Risk Factors&#8212;Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and we may be adversely impacted by changes to such reimbursement policies or rules.&#8221;</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other healthcare laws</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians, and third-party payors, including governmental payors such as Medicare and Medicaid in the United States, play a significant role in the recommendation, prescription, and reimbursement of pharmaceutical products. Our arrangements with these parties are subject to extensive federal, state, and foreign healthcare laws and regulations. In the United States, these laws include, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals or the purchase, recommendation, or prescription of products reimbursable under federal healthcare programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal False Claims Act, which imposes civil liability, including through whistleblower actions, for knowingly submitting or causing the submission of false or fraudulent claims for payment to federal healthcare programs or for avoiding or decreasing an obligation to pay the federal government.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal criminal healthcare fraud provisions, including those under the Health Insurance Portability and Accountability Act (HIPAA), which impose criminal and civil penalties for schemes to defraud healthcare benefit programs or for making false statements in connection with healthcare benefits, items, or services.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose obligations relating to the privacy and security of individually identifiable health information.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act (ACA), which requires certain manufacturers to disclose annually payments and other transfers of value made to physicians, teaching hospitals, and certain other healthcare professionals.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal government price reporting laws, which require manufacturers to calculate and report pricing metrics accurately and timely to government programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal consumer protection and unfair competition laws that regulate marketing and business practices.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state fraud and abuse laws, including state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain state and foreign data privacy and security laws govern the processing and protection of personal information and may impose requirements that differ from, and are not preempted by, HIPAA. For example, the California Consumer Privacy Act and the California Privacy Rights Act establish comprehensive privacy obligations and enforcement mechanisms, including expanded consumer rights and potential statutory damages. While certain clinical trial data governed by HIPAA are exempt, other personal information we process may be subject to these laws. Similar privacy laws have been enacted or proposed in other U.S. states and foreign jurisdictions. The scope and enforcement of these laws continue to evolve, increasing compliance complexity and risk.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Current and future healthcare reform legislation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and internationally, legislative and regulatory changes affecting the healthcare system may prevent or delay marketing approval, restrict post-approval activities, or affect our ability to commercialize products profitably. Existing healthcare reform laws and future reforms may result in more restrictive coverage criteria, increased pricing pressure, or expanded compliance obligations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the ACA introduced measures intended to increase competition and reduce healthcare costs, including provisions affecting biosimilar competition, Medicaid rebate obligations, Medicare discounts, and industry fees. Other federal laws have further affected reimbursement dynamics. The Budget Control Act of 2011 resulted in reductions to Medicare payments that are currently scheduled to remain in effect through 2031 absent further legislative action. The American Rescue Plan Act eliminated the statutory Medicaid drug rebate cap beginning in 2024, which may increase rebate liabilities for certain drugs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act was enacted and includes provisions that are being implemented over time and are expected to affect pharmaceutical pricing and reimbursement. These provisions include a cap on Medicare Part D beneficiary out-of-pocket spending, increased manufacturer financial liability under Medicare Part D, inflation-based rebates, and a program allowing the federal government to negotiate prices for certain high-expenditure drugs and biologics without generic or biosimilar competition, with negotiated prices taking effect beginning in 2026. The scope and impact of these measures, including future negotiation cycles, remain subject to change and uncertainty.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pharmaceutical pricing practices continue to be subject to heightened scrutiny by federal and state governments, including legislative proposals and investigations focused on pricing transparency, patient assistance programs, and reimbursement methodologies. Governments in the United States and abroad have also implemented or proposed cost-containment measures, such as price controls, reference pricing, reimbursement restrictions, upper-payment limits, drug price transparency reporting and substitution requirements, which could further affect pricing, coverage, and utilization of pharmaceutical products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment, breach of our regulatory obligations or expose individuals to harm, we could be liable for damages and governmental fines. Equivalent laws have been adopted in foreign countries that impose similar obligations.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_70"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE INFORMATION</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware on July 22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Moderna LLC was the successor in interest to Moderna Therapeutics, Inc., a Delaware corporation incorporated in 2009 as Newco LS18, Inc. by Flagship Pioneering. In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. Our principal corporate office is located at 325 Binney Street, Cambridge, MA 02142, and our telephone number is (617) 714-6500.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our&#160;website, www.modernatx.com, including the Investor Relations section, www.investors.modernatx.com; corporate blog www.modernatx.com/moderna-blog, and our Statements and Perspectives webpage, https://investors.modernatx.com/Statements--Perspectives/default.aspx; as well as our social media channels: Facebook, www.facebook.com/modernatx; X, www.x.com/moderna_tx; and LinkedIn, www.linkedin.com/company/modernatx; contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. The information on our website and that we disclose through social media channels is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the Securities and Exchange Commission (the SEC).</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, and amendments to those reports.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The SEC also maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding us and other issuers that file electronically with the SEC.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_73"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K. Any of the risk factors we describe </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">below </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">could adversely affect our business, financial condition or results of operations and the market price of our common stock.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to commercialization and our products </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory and market uncertainty have and may continue to impact our business and the markets for our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize our approved vaccines and any future products depends in part on evolving regulatory requirements, public health recommendations and market acceptance. In 2025, changes at U.S. regulatory agencies impacted policies and priorities related to our industry. For example, changes in FDA regulatory policies, post-marketing safety monitoring, and evidentiary expectations, as well as CDC and Advisory Committee on Immunization Practices (ACIP) recommendations regarding eligibility, target populations, and vaccination practices, may have affected and may continue to affect demand for our vaccines. Some of these changes, including new post-marketing commitments, have impacted and may in the future impact our costs. Ongoing regulatory uncertainty and evolving regulatory and public health guidance could impact future approvals, advisory committee recommendations, acceptance and demand for our existing or future products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vaccination rates in the future may also be lower than our expectations due to other factors, including viral evolution, medical need and consumer motivation to vaccinate. These and other factors may make it difficult to accurately forecast vaccination rates for our products. If demand for COVID vaccines continues to decline, we lose significant market share, or our products are subject to significant competitive pricing pressure, our product sales may not materialize consistent with our projections. Beyond COVID, we have experienced challenges in the RSV market, in part due to advisory committee recommendations that were more limited than anticipated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our decisions regarding seasonal vaccine development, including for COVID-19, will be informed by annual guidance from the FDA and foreign regulators, which may impact the timing of development for our COVID vaccines. Different regulators have in the past and may in the future issue varying guidance regarding vaccine composition or populations who should receive a vaccine. Additionally, if our efforts to develop variant-specific vaccines are delayed or not as successful as our competitors&#8217;, we could suffer reputational harm, loss of market share and adverse financial results. We may expend significant resources adapting our vaccines or conducting clinical trials to protect against variants, but a market for our adapted vaccines may fail to develop or demand may not align with our projections or cost expenditures.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties executing our near-term strategy and prioritized pipeline.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we expect to launch multiple new products over the next several years, our ability to commercialize our pipeline is subject to many risks, including those described elsewhere in these </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> under &#8220;Risks related to our pipeline, product development and regulatory review&#8221; and &#8220;Risks related to the manufacturing of our commercial products and product candidates.&#8221; If we do not successfully execute our near-term plan for growing our infectious disease vaccine franchise, our ability to invest in our pipeline, including our oncology and rare disease programs, may suffer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our broad clinical success and post-pandemic commercial challenges have necessitated a more selective and paced approach to our research and development investment. If we do not successfully implement our cost efficiency and prioritization programs, we may fail to meet our cash breakeven goal. Additionally, as we pursue development of our prioritized programs, we may forego or delay pursuit of other opportunities that could prove to have greater commercial potential. If our prioritized programs are unsuccessful, or not as successful as others could have been, we may be unable to realize a sustainable return on our investments and or achieve long-term growth. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The vaccine market, and pharmaceutical market more generally, is intensely competitive, and we may be unable to compete effectively in the market for existing or new products, treatment methods or technologies.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We compete with larger, well-established and experienced pharmaceutical companies for sales of our products, including against Pfizer and Sanofi for sales of our COVID vaccines and Pfizer and GSK for our RSV vaccine. Additionally, we have been excluded from selling our COVID vaccines in many European markets due to a competitor&#8217;s contract with the European Commission, which does not lapse until year-end 2026. For RSV vaccines, we entered a market already occupied by two larger competitors and may continue to face difficulties achieving market share. These competitors have exploited and may in the future exploit their greater size, infrastructure, resources and experience to gain advantages in contracting with customers by, among other things, bundling their products, leveraging larger supply chains and greater purchasing power and utilizing their global networks.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices. We may also be adversely affected by similar market practices outside of the United States. In some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">More generally, the pharmaceutical market is highly competitive and certain of the disease areas we are targeting present particularly high competitive risk. For example, the oncology market is intensely competitive, innovative and fast-moving. Other companies, academic institutions, governmental agencies and public and private research organizations are developing products that may compete with programs in our development pipeline. These competitors may have products that have already been approved and accepted by the medical community or are in later stages of development. For example, we are developing a seasonal flu vaccine, for which there is a well-developed market</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and we may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability. Additionally, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our products. In oncology, standards of care often evolve rapidly, and changes during the development or commercialization of our product candidates could reduce their clinical relevance, complicate clinical trial design, increase development costs or timelines, or limit commercial adoption, even for programs that show promising early results.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our products may struggle to compete against competitors&#8217; products for a variety of reasons, including relative safety and effectiveness, degree of any side effects, shelf-life, ease of administration and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals, the availability and cost of manufacturing, distribution, marketing and sales capabilities, price, reimbursement coverage and patent protection. Even if our products demonstrate superiority to competitors&#8217; products, consumers and retailers may fail to appreciate that benefit, or existing purchase commitments with competitors may discourage them from purchasing from us. These factors, or the perception of these factors, could lead to a competitor&#8217;s product being more successfully commercialized. Further, the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies. The actual or perceived success or failure of others may adversely impact our ability to commercialize our products. See &#8220;Business&#8212;Government Regulation&#8212;Coverage and reimbursement.&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced commercial challenges and may experience additional challenges in the future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to successfully commercializing our products. In the past, commercial challenges have led to lower-than-expected sales and required us to adapt our business strategy. Moving forward, we may need to dedicate greater resources to our commercial efforts than we anticipate, and we may not realize a return on this investment. Additionally, we may be unsuccessful in accurately anticipating future rates of return for our products, which may adversely impact our accounting estimates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may seek to enter into agreements with others to utilize their marketing and distribution capabilities, but may be unable to enter into agreements on favorable terms, if at all. If we rely on others to commercialize our products, our revenues may be lower than if we commercialized these products ourselves. In addition, we may have little or no control over such third parties&#8217; sales efforts. If our partners commit insufficient resources to commercialize our products, and we cannot independently develop necessary marketing capabilities, we may be unable to generate sufficient product revenue to sustain our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our products depends on the degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of our products will depend on numerous factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efficacy and potential advantages over alternative treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of protection provided by our products compared to those of our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of mRNA products generally and the availability of competing non-mRNA medicines that may be preferred by the medical community or the public;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and the prevalence and severity of any side effects, including any limitations, restrictions (including for use together with other medicines) or warnings contained in a product&#8217;s approved labeling;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects resulting from checkpoint inhibitors or other products or therapies with which our products are co-administered;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try, and physicians to prescribe, new therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">presentation meets customer demand</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity and health authority communications concerning our products or competing products and treatments; and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product cost and sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product candidate shows a favorable efficacy and safety profile in clinical trials, market acceptance will be unknown until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of pharmaceutical products depend on the availability and extent of reimbursement from third-party payors, and we may be adversely impacted by changes to such reimbursement policies or rules.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products depend on adequate coverage, pricing and reimbursement from third-party payors. When a new product is approved, the availability and extent of government and private reimbursement, and the pricing, for that product may be uncertain. Additionally, pricing and reimbursement for any product we develop may be adversely affected by various factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pressure by employers on private health insurance plans to reduce costs; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for any product we develop will vary significantly by country. Our inability to obtain and maintain adequate prices in a particular country may limit the revenues from our products within that country and adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision whether to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> use of commercial manufacturer co-pay payment assistance programs. Significant consolidation in the health insurance industry </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products, particularly our therapeutic products or those that are individualized for a particular patient. Coverage and reimbursement by a third-party payor may depend on various factors, including the third-party payor&#8217;s determination that use of a product is a covered benefit under its health plan, safe, effective and medically necessary, appropriate for the specific patient, cost-effective and neither experimental nor investigational.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, target patient populations for some of our product candidates may be small (e.g., for rare diseases) or require individual customization (e.g., for intismeran autogene). The pricing and reimbursement of our medicines, if approved, must be adequate to support commercial infrastructure. If we cannot obtain adequate levels of reimbursement, we may be unable to successfully market and sell our products. Further, inadequate reimbursement for services related to our products (e.g., for administration to patients) may discourage physicians from prescribing or recommending our products, adversely affecting our ability to market or sell those products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models and other, similar regulatory actions could impact our product revenues and materially harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2025, President Trump issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. and directing the Secretary of Health and Human Services (HHS) to communicate price targets to pharmaceutical manufacturers to align prices with those in comparably developed nations, an approach commonly referred to as "most-favored-nation" (MFN) pricing and, in the event significant progress towards MFN pricing is not delivered, to propose rulemaking to impose MFN pricing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MFN pricing models in the U.S. could also affect our international pricing strategy and future decisions on reimbursement and commercialization in certain jurisdictions. If our U.S. pricing becomes tied to international reference prices, we may face decisions regarding pricing in foreign markets that could result in reduced patient access internationally, affect our relationships with foreign regulatory authorities and payers, or impact our ability to obtain or maintain reimbursement approvals in ex-U.S. markets. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These reforms remain subject to change, potential legal challenges, or expansion through additional rulemaking or sub&#8209;regulatory guidance, creating uncertainty for our overall pricing strategy. It remains to be seen whether and how these drug pricing initiatives will apply to our products, how they will affect the broader pharmaceutical industry, and whether similar reform measures may be adopted in the future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our products and product candidates may be smaller than we believe, or we may be unable to successfully identify clinical trial participants.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We focus certain of our research and development activities on treatments for severe rare genetic diseases, where patient populations are small and difficult to ascertain. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our products may only be approved for certain populations or lines of treatment.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of addressable patient populations are based on our beliefs and are derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may be lower than expected and potential clinical trial participants or patients may not be otherwise amenable to treatment with our product candidates or products, or new clinical trial participants or patients may become increasingly difficult to identify or gain access to. Even if we obtain significant market share for our products, if approved, because the potential target populations are small, these medicines may never be profitable.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Furthermore, the size of markets that we target may be impacted by health authority recommendations regarding who should receive our products, which may be impacted by the new U.S. federal government administration.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our pipeline, product development and regulatory review</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot obtain, or are delayed in obtaining, regulatory approvals and advisory committee recommendations, we will be unable to effectively commercialize, or will be delayed in commercializing, our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any products we may develop are subject to comprehensive regulation by the FDA and comparable foreign regulators. To obtain required regulatory approvals to commercialize any product candidate, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective for their intended use.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, regulators conduct pre-approval inspections and negative findings may lead to delay in approval and failure to commercialize a product candidate. Even once approved, products may be subject to recommendations from advisory committees, such as the ACIP, before or after they can be brought to market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have only received regulatory approvals for our COVID and RSV vaccines, and our current or future product candidates may never obtain regulatory approval or advisory committee recommendations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. We may need to rely on third parties to assist us in making applications for marketing approvals. Preclinical studies and clinical trials conducted in one country may not be accepted by regulators elsewhere, and regulatory approval in one country does not guarantee approval in another. Regulators may require that we conduct additional clinical trials to support our applications for approval beyond our clinical development plans, which may result in increased expense and delays in bringing our products to market.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the process of obtaining marketing approvals is expensive, time-consuming and uncertain, and can vary substantially based on many factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in law or changes in regulatory review may delay the review of a submitted product application. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For example, recent FDA policy updates regarding COVID vaccine approvals and the evidence expected for certain populations could require additional clinical data or trials to support broader indications, delay approvals or supplemental applications, or result in more limited labeled populations, which could adversely affect the timing and scope of commercialization for our COVID vaccines, including updated or variant-adapted formulations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulators have substantial discretion in the approval process and may refuse to accept any marketing approval application or may decide that our data are insufficient for marketing approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Additional delays or non-approval may result if an FDA advisory committee or other regulator recommends non-approval or restrictions on approval. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development is lengthy and uncertain, and our clinical programs may be delayed or terminated, or may be more costly to conduct than we anticipate.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, complex and lengthy, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved as products. Although we have demonstrated historical success with our platform technology, we may not continue to realize the same levels of success with clinical trials in the future.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and our strategic collaborators also may experience unforeseen events during, or as a result of, clinical trials that could delay or prevent us or them from successfully developing our product candidates and gaining approval from regulators. Such events could include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, Institutional Review Boards (IRBs) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective contract research organizations (CROs);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to the scale or site of our manufacturing could cause significant delays or changes in our clinical trial designs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish or achieve clinically meaningful endpoints for our studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we make changes to our product candidates after clinical trials have commenced (which we have done in the past), we may be required to repeat earlier stages or delay later stages of clinical testing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates, or other medicines in the same class as ours, may cause significant adverse events or other undesirable side effects, such as the immunogenicity of the LNPs or their components, the immunogenicity of the protein made by the mRNA or degradation products, any of which could lead to serious adverse events, or other effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the applicable clinical trial protocol or withdraw from the applicable clinical trial, which may require that we add new clinical trial sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may impose a complete or partial clinical hold on a clinical trial (or a trial of another company working on mRNA medicines), or we or our investigators, IRBs or ethics committees may suspend or terminate clinical research or trials for various reasons, including quality events, noncompliance with regulatory requirements or a finding that participants are being exposed to an unacceptable benefit-risk ratio;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy concerns regarding our product candidates will be considered by us and by the FDA and other regulators as we pursue clinical trials of new product candidates, develop effective informed consent documentation and work with IRBs and scientific review committees (SRCs);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or efficacy concerns could arise from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse side effects could be observed in future clinical trials where our product candidates are administered in combination with other therapies (such as the co-administration of intismeran autogene</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in developing assays acceptable to the FDA or other regulators; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a lack of adequate funding to continue a particular clinical trial, including due to higher-than-anticipated costs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have conducted and may conduct in the future &#8220;open-label&#8221; clinical trials, where both the patient and investigator know whether the patient is receiving the investigational product candidate, an approved drug or a placebo. The results from an open-label clinical trial may not be predictive of future clinical trial results from a controlled environment with a placebo or active control. Further, the FDA or other regulators may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Significant preclinical or nonclinical testing and studies or clinical trial delays for our product candidates could allow our competitors to bring products to market before we do and could harm our business.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are risks unique to each of our programs and modalities and risks applicable across programs and modalities, which may delay or prevent our ability to advance one or more of our programs in clinical development, obtain regulatory approval or commercialize our products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain features in our product candidates, including those related to mRNA, chemical modifications, surface chemistries, LNPs and their components, may result in risks that apply to some or all of our programs and modalities. As our product candidates progress, we or others may determine that certain of our risk allocation decisions were incorrect or insufficient, we made platform-level technology mistakes, individual programs or our mRNA science in general has technology or biology risks that were unknown or under-appreciated, our choices on how to develop our infrastructure to support our scale will result in an inability to manufacture our product candidates for clinical trials or otherwise impair our manufacturing or we have allocated resources in such a way that we cannot recover large investments or rapidly re-direct capital.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We utilize earlier programs in a modality to understand the technology risks within the modality, including the program&#8217;s manufacturing and pharmaceutical properties. Even if our earlier programs in a modality are successful in any phase of development, other programs may fail at that stage, and any program may fail at a later phase of development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This may be a result of technical challenges or biology risk unique to that program. The biology risk across much of our pipeline represents targets and pathways not clinically validated by one or more approved drugs, and the risk that the targets or pathways that we have selected may not be effective will continue to apply across our current and future programs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As we progress our programs through clinical development, new technical challenges may arise that cause an entire modality to fail. Additionally, any portfolio-spanning risks, whether known or unknown, such as an increased risk of a particular type of side effect, if realized in any one of our programs, would have a material and adverse effect on our other programs and on our overall business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are also specific additional risks to certain of our modalities and programs. For example, prophylactic vaccines typically require clinical testing in up to tens of thousands of healthy volunteers to define an approvable benefit-risk profile. The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious safety findings, negatively impacting a program prior to or after commercial launch. Even if we observe positive safety, tolerability and levels of immunogenicity in early clinical trials, we may not observe acceptable safety or efficacy profiles in later-stage trials required for approval of these programs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are many clinical and manufacturing challenges specific to intismeran autogene and any other neoantigen therapies we may develop. These include a rapid production turn-around time measured in weeks in order to supply patients before further progression and mutation of their tumors, the significant costs incurred in making individualized medicines and potential lack of immune responses due to the biology of the tumor or patient&#8217;s immune status. These risks apply to intismeran and other neoepitope investigational medicine programs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the translatability of target selection from preclinical animal models to successful clinical trial results is uncertain and may fail, particularly for systemic therapies and cancer antigen therapies. In general, several biological steps are required for delivery of mRNA to translate into therapeutically active medicines. These processing steps may differ between individuals or tissues, potentially leading to variable levels of therapeutic protein, activity, immunogenicity or distribution to tissues for a therapeutic effect. mRNA medicines may elicit innate or adaptive immune responses to the mRNA, delivery vehicle (such as an LNP) or the encoded protein, which could result in adverse events or reduced tolerability. In certain settings, immune responses to the encoded protein limit the effectiveness or durability of treatment, including upon repeat administration, or require changes to dosing, formulation or clinical development plans.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience delays in enrolling participants in our clinical trials.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Enrolling participants in our clinical trials is critical to our success. Difficulties or delays in enrolling a sufficient number of participants could increase costs or impact the timing or outcome of our planned clinical trials, which could prevent trial completion and adversely affect our ability to advance the development of and obtain regulatory approval for our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Participant enrollment is affected by many factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexity and design of the clinical trial protocol;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the patient population and eligibility criteria for the clinical trial in question, including age-based eligibility criteria limiting subject enrollment to adolescent or pediatric populations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of competing therapies and clinical trials, and clinicians&#8217; and participants&#8217; perceptions of the relative advantages, risks and side effects of our product candidates compared to other available therapies, including any new drugs or treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to monitor trial participants adequately during and after treatment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to recruit qualified clinical trial investigators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or other safety signals in our trials or related to other product candidates, and any resulting negative publicity, which could discourage potential participants and their physicians from participating in our trials; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain participant informed consent.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may have limited or no ability to influence enrollment in clinical trials where our collaborators control clinical development. Even if we or our collaborators successfully enroll participants, some may not be dosed or complete the trial.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA drug development involves substantial clinical and regulatory risks, and negative perceptions of our platform, products and product candidates could adversely affect our business and ability to obtain regulatory approvals. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Few mRNA medicines have been approved to date by the FDA or other regulators, and efficacy, safety, tolerability and immunogenicity data and real-world evidence with respect to mRNA medicines continue to accumulate. We may observe new, more frequent or more severe adverse events in clinical trial participants or among vaccinated individuals. For example, some studies have suggested that Spikevax may be associated with higher rates of myocarditis and pericarditis in young males compared to other COVID vaccines. Myocarditis and pericarditis have also been reported following vaccination with other COVID vaccines, including mNEXSPIKE. If similar observations are made in recipients of our other products or product candidates, or if other unexpected safety issues arise, we could suffer significant damage to our reputation and that of our mRNA platform. Such events </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> lead to other issues, including delays in our other programs, the need to re-design our clinical trials and the need for significant additional financial resources. In addition, the FDA and other regulators may interpret data from our clinical trials differently than we do and such agencies may require us to conduct additional studies or analyses, which could delay or prevent us from obtaining full regulatory approvals</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in certain jurisdictions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> or for certain demographics. Further, local legislatures may attempt to regulate or restrict the use of mRNA medicines in their jurisdictions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Successful discovery and development of mRNA medicines by us or our strategic collaborators is highly uncertain and depends on many factors beyond our or their control, and our business decisions and development efforts relating to mRNA technology, delivery systems and manufacturing processes may ultimately be unsuccessful. Promising early-phase product candidates may fail to advance, be delayed in the clinic, be subject to clinical holds or fail to reach the market for many reasons, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonclinical, preclinical or clinical trial results may show potential mRNA medicines to be less effective than desired or to have harmful or problematic side effects or toxicities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results in our clinical trials, or in those of others developing similar products, or adverse effects relating to mRNA, or our LNPs, may lead to negative publicity or delays in or termination of our programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy or safety of a combination vaccine product candidate could be less than that seen with the administration of the vaccine</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s separately, which could prevent the combination product from obtaining regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse events related to products that are perceived to be similar to mRNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our product candidates and less demand for any product that we may develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the insufficient ability of our translational models to reduce risk or predict outcomes in humans, particularly given that each component of our product candidates may have a dependent or independent effect on safety, tolerability and efficacy, which may be species-dependent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing failures or insufficient supply of current Good Manufacturing Practice (cGMP)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make mRNA medicines commercially unattractive;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes that we make to optimize our manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability and efficacy profile of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement issues or other factors that delay clinical trials or make any mRNA medicine uneconomical or noncompetitive with other therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our large pipeline of product candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to timely advance our programs or a failure or delay in receiving necessary regulatory approvals due to, among other factors, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, preparation of a BLA or the equivalent application, discussions with the FDA or EMA, a regulatory request for additional nonclinical or clinical data or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new legislation or regulations passed by U.S., state or foreign governments in response to negative public perception of mRNA medicines; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proprietary rights of others and their competing products and technologies that may prevent our mRNA medicines from being commercialized.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulators may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we are currently attempting to address or may address in the future. For many rare diseases,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">few clinical trials have been attempted. As a result, the design and conduct of clinical trials of product candidates for the treatment of these disorders may take longer, be more costly or be less effective.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA finds our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in our pivotal or other clinical trials, or our results may be inconsistent or unpredictable compared to traditional efficacy endpoints. Further, the FDA may give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of licensure. Regulators in other countries may make similar findings with respect to these endpoints.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain mRNA therapies are classified as gene therapies by the FDA and the EMA. The association of our products with gene therapies could result in increased regulatory burdens, impair the reputation of our products or negatively impact our platform or our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are only a few approved gene therapy products in the United States and other jurisdictions, and significant adverse events associated with their testing and use have been reported. Regulatory requirements governing these products have evolved and may continue to change in the future, and the implications for mRNA therapies are unknown. For example, the FDA has established the Office of Therapeutics Products within its Center for Biologics Evaluation and Research (CBER) to consolidate review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER. In the EU, certain mRNA therapies have been characterized as gene therapy medicinal products, which are subject to additional regulatory requirements. In certain other countries, such as Japan, mRNA therapies have not yet been classified. Notwithstanding the differences between mRNA medicines and gene therapies, the classification of some of our mRNA product candidates as gene therapies could adversely impact our ability to develop our product candidates, including if a clinical hold applicable to gene therapy products were applied to our mRNA product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events reported with respect to gene therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapies caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result may delay one or more of our clinical trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory agencies may negatively affect our business by lengthening the regulatory review process, requiring us to perform additional or larger studies or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates, or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our work in genomic editing is subject to all risks associated with gene therapies. Genome editing technologies are relatively new and their therapeutic utility is largely unproven. Public perception and related media coverage of potential therapy-related efficacy or safety issues, as well as ethical concerns related specifically to genome editing, may adversely influence the willingness of subjects to participate in clinical trials. In addition, any review conducted by an institutional biosafety committee may result in delay or prevent initiation of a gene therapy clinical trial.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any such therapeutic is approved, physicians, health care providers, third-party payors and patients may be slow or fail to accept these novel and personalized treatments. Physicians may be unwilling to undergo necessary training, view a particular therapy as too complex or potentially risky to adopt without appropriate training and choose not to administer the therapy. Further, certain patients may not be candidates for the therapies, for many reasons, including due to health conditions or genetic profile. In addition, responses by federal and state agencies, congressional committees and foreign governments to negative public perception, ethical concerns or financial considerations may result in new legislation, regulations or medical standards that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are, and any future products will be, subject to regulatory scrutiny.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval in a jurisdiction, we may remain subject to significant restrictions on the indicated uses or marketing of our product and ongoing requirements for potentially costly post-approval studies, such as those required under an accelerated approval by the FDA or other similar type of approval, or post-market surveillance. For example, a BLA holder must monitor and report adverse events and any failure of a product to meet applicable specifications, as well as submit and obtain FDA approval for certain new or supplemental applications relating to the approved product, labeling or manufacturing process. Additionally, pharmacovigilance obligations under the regulatory regimes of the jurisdictions where our products are distributed require us to collect, process, analyze and monitor safety </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">data and to identify</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and evaluate adverse reactions to our products</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as they are administered in those </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">jurisdic</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> we or any of our partners assisting us in meeting these obligations cannot comply with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> relevant regulations, we may be subject to sanctions, increased costs and reputational harm, or our re</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gulatory authorizations to distribute our vaccines in the relevant jurisdiction</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> may be revoked or curtailed. In addition, regulators may increasingly rely on post-approval studies or real-world evidence to determine whether to maintain, modify or expand approved indications or population eligibility, which could increase costs, delay commercialization or limit the scope of approved use of our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, advertising and promotional materials must comply with FDA rules and regulations and are subject to FDA review, in addition to other applicable federal and state laws. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are required by the FDA to conduct post-marketing studies for mRNA-1273, including to assess the risk of myocarditis and pericarditis and to evaluate outcomes in pregnant women and infants post-vaccination. We or others could identify previously unknown side effects, or known side effects could be observed as being more frequent or severe than in clinical trials or earlier post-marketing periods. If we, our contract manufacturers or other collaborators fail to comply with any post-approval regulatory requirements, a regulator may issue a warning letter asserting that we are in violation of the law, seek an injunction or impose civil or criminal penalties or monetary fines, suspend or withdraw regulatory approval or revoke a license, suspend any ongoing clinical trials, refuse to approve a pending BLA or supplements to a BLA submitted by us, seize or recall products or product candidates, or require field alerts to physicians, pharmacists and hospitals or refuse to allow us to enter into supply contracts. We could also be required to conduct additional nonclinical studies or clinical trials or implement changes in labeling or to our manufacturing processes, specifications or facilities. Initiation of any government investigation or lawsuit, including class-action lawsuits, would require us to expend significant time and resources in response and would likely generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our COVID vaccine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or any future approved products, and generate revenues.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA or other regulators could require us to adopt Risk Evaluation and Mitigation Strategies (REMS) for any product to ensure that the benefits of treatment outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including the suspension or withdrawal of approvals and licenses, the addition of warning labels, changes to the way a product is administered, the requirement to conduct further clinical trials, lawsuits or increased liability for harm to patients and their children and reputational harm to us. Any of these events could prevent us from achieving or maintaining market acceptance of any products we develop.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court&#8217;s June 2024 decision in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> overturned the longstanding </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decision could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, on which we rely. Additionally, the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decision may result in increased regulatory uncertainty, inconsistent judicial interpretations and other impacts to the agency rule-making process. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical development is lengthy and uncertain, especially for mRNA medicines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Much of our pipeline is in preclinical development, and these programs could be delayed or not advanced into the clinic. Before initiating clinical trials for a product candidate, we must complete extensive preclinical studies, including IND-enabling good laboratory practice (GLP) toxicology testing, as well as significant Chemistry, Manufacturing, and Controls (CMC) activities for inclusion in an IND submission. CMC activities for mRNA medicines involve complex manufacturing processes and analytical development, which are uncertain and lengthy. We have had and may in the future have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our product candidates. If we must produce new batches, our preclinical studies could be delayed. We cannot be certain of the timely completion of our preclinical testing and studies, whether the FDA or other regulators will accept the results or if the outcome of our preclinical testing, studies and CMC activities will ultimately support further development of our programs. As a result, we may be unable to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and such applications may not result in the FDA or other regulators allowing clinical trials to begin.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Although we have obtained rare pediatric disease designation for mRNA-3927, we may not be eligible to receive a priority review voucher in the event the FDA determines we no longer meet the criteria for designation, revokes the designation or FDA approval does not occur by September 30, 2029.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The sponsor of an application for a rare pediatric disease drug product may be eligible for a voucher that can be used or sold to obtain a priority review for a subsequent application submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act. We received rare pediatric disease designation from the FDA for mRNA-3927. We may, in the future, apply for rare pediatric disease designation from the FDA for future product candidates that may qualify for designation. Vouchers for rare pediatric disease drugs are awarded for qualifying applications when the drug receives approval. Under current law, after September 30, 2029, the FDA may not award any rare pediatric disease priority review vouchers, although the FDA's authority to do so could be extended by Congress in the future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to the manufacturing of our commercial products and product candidates</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping for any of our products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing processes for our mRNA medicines are novel and complex. We and our collaborators have experienced and may continue to encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping, including delays as our supply chain expands and grows more complex. We may experience difficulties effectively managing and executing the complexities of a larger and multi-product supply plan, including those resulting from complexities of producing batches at larger scale, equipment failure, human error, choice and quality of raw materials and excipients, analytical testing technology and product instability. Further, mRNA medicines encapsulated in LNPs must be developed and manufactured under well-controlled conditions, or pharmacological activity can be adversely impacted.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to optimize product features, we have in the past and may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This has in the past and may in the future result in our having to resupply batches for preclinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our product candidates could materially delay our ability to continue clinical trials or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical or clinical supply. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our high rate of innovation may result in a high degree of technology change that could negatively impact product comparability during and after clinical development. These technology changes may necessitate changes to, or the sourcing of, new manufacturing infrastructure or may adversely affect third-party relationships.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we may need to utilize multiple batches of drug substance and drug product to meet the supply requirement of a single preclinical study or clinical trial. Failure in our ability to scale up batch size or failure in any batch, which we have experienced in the past, may lead to a substantial delay in our clinical trials or in the commercialization of any approved product. For example, the changes we make as we continue developing new manufacturing processes for our drug substance and drug product may impact specification and stability of the drug product, and may lead to failure of batches, resulting in a substantial delay in delivery of commercial product or conduct of our clinical trials. Our mRNA product candidates may prove to have a stability profile that leads to a lower than desired shelf life of the final approved medicine. This poses risk in supply requirements, wasted stock and higher cost of goods. We may also experience wasted stock from other factors such as volatile demand forecasts or our inability to scale down for products that have low demand.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our medicines. If we encounter unexpected performance issues with such equipment, we could encounter delays or interruptions to clinical and commercial supply. Due to the number of different programs, we may have cross contamination of product candidates inside of our factories, CROs, suppliers or in the clinic that affect the integrity of our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As we scale the manufacturing output for commercial production and particular programs, we plan to continuously improve yield, purity and the pharmaceutical properties of our products and product candidates from</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">IND-enabling studies through commercial launch, including shelf-life stability, and solubility properties of drug product and drug substance. Because of continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after a change in process, more time will be required for pharmaceutical property testing, such as 6 or 12 month stability testing. That may require resupplying clinical material or making additional cGMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We utilize a number of raw materials and excipients that may have a single source of supply, are new to the pharmaceutical industry and are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our products or product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have established several analytical assays and may have to establish several more to assess the quality of our mRNA product candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy or stability. This may lead to an inability to release mRNA product candidates until the manufacturing or testing process is rectified.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As we grow as a commercial company and our drug development pipeline matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Completion of our trials and commercialization of our products depend on the availability of facilities capable of manufacturing our vaccines at sufficient yields and at commercial scale. We expect to continue to make significant investments in our manufacturing network as we expand our commercial launch efforts. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our new manufacturing plants in Australia, Canada and the United Kingdom are subject to risks associated with operating these facilities, and we may encounter difficulties in optimizing our global manufacturing network</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal manufacturing infrastructure, we may rely on third parties for product manufacturing, packaging, testing, warehousing, distribution and other logistical services, and the manufacture and testing of raw materials, components, parts and consumables, and we may need to engage additional third parties in the future to meet capacity needs. If we cannot enter into or maintain such arrangements on favorable terms, or at all, our ability to develop, manufacture and distribute our products could be adversely affected. Further, efforts to establish and scale these capabilities may not meet expectations regarding scheduling, scale-up, reproducibility, yield, purity, cost, potency or quality. If we are unable to institute necessary controls related to product development, manufacturing and quality, we may encounter difficulties producing our products on the timelines and in the quantities required to meet demand or supply obligations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past, and may in the future, seek to resize our manufacturing infrastructure to reflect anticipated demand for our products. This resizing may result in our incurring costs associated with exiting commitments, such as with suppliers for raw materials and contract manufacturing organizations (CMOs). Additionally, as a result of lower demand for our products, we have experienced, and may in the future experience, increased costs with respect to raw material suppliers as we seek to exit or modify our purchase commitments. Further, we have entered, and may in the future enter, into non-cancellable or take-or-pay purchase commitments for raw materials that require a long lead time to procure, increasing our commitment exposure.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Demand for third-party manufacturing, raw materials or testing facilities may grow faster than available capacity, which could disrupt our ability to secure sufficient quantities of materials and services. The use of service providers and suppliers could expose us to risks, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or non-renewal of supply and service agreements in a manner or at a time that is costly or damaging to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of these suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the supplier or service provider; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of third-party facilities by regulators that could have a negative outcome and result in delays to or termination of their ability to supply our requirements.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers may also result in unforeseen delays or operational problems beyond our control. Because of contractual restrictions and the limited number of manufacturers with the expertise, required regulatory approvals and facilities to manufacture our bulk vaccines on a commercial scale, replacing a third-party manufacturer may be expensive, time-consuming or disruptive. Regulators may require us to register our facilities or those of another supplier if we terminate an existing third-party manufacturer relationship, which could delay or limit our ability to supply a particular market. In addition, third-party manufacturers may experience production interruptions due to factors such as production cost pressures, scale-up challenges, shortages of qualified personnel, availability of raw materials and supplies, quality control failures, compliance with regulatory requirements or lack of capital funding.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to operational risks associated with the physical and digital infrastructure at our manufacturing facilities and those of our external service providers.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities incorporate a significant level of automation of equipment with integration of several digital systems, including those that may utilize artificial intelligence (AI), to improve efficiency of operations. The digitization of our facilities exposes us to the risk of process equipment malfunctions. These risks include potential system failures or shutdowns due to internal or external factors including design issues, system compatibility or potential cybersecurity compromises, incidents or breaches. Upgrades or changes to our systems, infrastructure or the software that we implement, use, or upon which our business relies, may result in the introduction of new cybersecurity vulnerabilities and risks.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and infrastructure or those of our contract manufacturers or other third-parties may also be subject to attacks or acts of sabotage by outside actors, contractors or employees. Any disruption in these manufacturing capabilities could delay scaling up production capacity for our drug substances or products or shut down facilities, add costs, cause us to fail to meet certain product volume or delivery timing obligations, or may require us to identify, qualify and establish an alternative manufacturing site, which could adversely affect our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our development and commercial capacities, we have and expect that we will continue to establish additional manufacturing capabilities in our global network. This expansion may lead to regulatory delays or prove more costly than anticipated. If we fail to select suitable locations, complete construction in an efficient manner, engage effectively with local regulators, recruit the required personnel or manage our growth effectively, the development and production of products or our product candidates could be delayed or curtailed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products and product candidates are sensitive to shipping and storage conditions, which, in some cases, requires cold-chain logistics and subjects them to risk of loss or damage.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our products and product candidates are sensitive to temperature, storage and handling conditions, and we could lose medicines if the product or product intermediates are not stored or handled properly. Shelf life for our products and product candidates is variable, and they may expire prior to use. Further, if we or third-party distributors do not maintain effective cold-chain supply logistics required for certain of our products and product candidates, products may be returned, become out-of-date or be rendered unusable. This has led and could lead to added manufacturing costs and delays in our ability to supply required quantities for clinical trials or commercial sale. In addition, the cost associated with such transportation services and the limited pool of vendors could cause supply disruptions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities or those of third-party manufacturers or suppliers may fail to meet regulatory requirements, which could delay approval of or increase production costs for our products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of medicines for clinical trials or commercial sale is subject to extensive regulation, and components of such products must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping and the implementation and operation of quality systems to control and assure the quality of products and materials used in clinical trials and for commercial supply. Poor control of cGMP manufacturing processes can lead to product quality failures that may impact our ability to supply product, resulting in cost overruns and cause significant delays to clinical development timelines. Such manufacturing process issues may include:</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">critical deviations in the manufacturing process;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective corrective or preventative actions taken to address such deviations as processes scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility and equipment failures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product or facility contamination, including due to ineffective quality control strategies or failures identified through environmental monitoring programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failures of raw materials, components or consumables, including due to ineffective supplier qualification or regulatory compliance issues at critical suppliers; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective product stability; </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulators typically require representative manufacturing site inspections to assess compliance with cGMP and manufacturing controls. Such inspections may occur at any time during product</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development or commercialization, may be unannounced, and may be product- or facility-specific or conducted in response to issues identified by regulators. If one of our, or a third-party manufacturer&#8217;s, sites fails to maintain sufficient quality assurance or control, or receives a deficient inspection outcome, a product may not receive or maintain regulatory approval, and our manufacturers or suppliers may be unable to meet their supply obligations, impacting or delaying supply or programs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing processes for our products are subject to regulatory approval, and if we or our third-party manufacturers are unable to reliably produce products or product candidates to specifications acceptable to regulators, we or our strategic collaborators may not obtain or maintain the approvals needed to commercialize such products. Even after regulatory approval is obtained, there is no assurance that we or our CMOs will be able to manufacture the approved medicine to specifications acceptable to the FDA or other regulators. Any of these challenges could delay or prevent completion of clinical trials, require bridging or repeat clinical trials, increase trial costs, delay regulatory approval, impair commercialization efforts or increase our cost of goods, any of which could have an adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not have direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Our contract manufacturers supply or manufacture materials or products for other companies and their failure to meet applicable </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements may affect the regulatory status of their facilities. In addition, to the extent that we rely on foreign contract manufacturers, we are subject to additional risks, including the need to comply with import and export regulations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the EMA and other regulators may require us to submit product samples of any lot of any approved product, together with the protocols showing the results of applicable tests, at any time. In some cases, regulators may prohibit us from distributing a lot until it authorizes release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may cause unacceptable changes in the product, resulting in lot failures or product recalls. In the past, our third-party contract manufacturers experienced lot failures resulting in product recalls of our COVID vaccine. Lot failures have caused, and lot failures or product recalls in the future with respect to product produced by either our own or our third-party manufacturers&#8217; facilities could cause, us and strategic collaborators to delay clinical trials or product launches.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and our manufacturing partners also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Additionally, we may not be able to control for or detect intentional sabotage or negligence by any employee or contractor.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intismeran autogene product candidates are uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in production.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We custom design and manufacture intismeran tailored for each patient. As a result, manufacturing is susceptible to product loss or failure due to issues with:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics associated with the collection and shipping of a patient&#8217;s tumor, blood or other tissue sample;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next-generation sequencing of the tumor mRNA and identification of appropriate tumor-specific mutations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our product candidate, to assist with the design of the patient-specific mRNA, which software must be maintained and secured;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effective design of the patient-specific mRNA that encodes for the required neoantigens;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">batch specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control testing failures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected failures of batches placed on stability;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs associated with individualized manufacturing that may adversely affect our ability to continue development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely manufacture and release of the patient-specific batch;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shipment issues encountered during transport of the batch to the patient site of care; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to define a consistent safety profile at a given dose when each participant receives a unique therapy.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have purpose-built our facility in Marlborough, Massachusetts for intismeran, and it may encounter difficulties or it take longer than anticipated to scale up the facility to meet future commercial demand, if intismeran is approved. Manufacturing demand for intismeran may also increase as we continue our current late-stage trials and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> expand to additional tumor types</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we may encounter difficulties executing our plans to improve turnaround time and reduce costs. The addition of new facilities could also lead to product comparability issues, which could further delay introduction of new capacity. In addition, if our equipment does not function as designed, we could experience deviations in the drug product produced, which could lead to increased batch failure and the inability to supply patients enrolled in a clinical trial. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because intismeran is manufactured for each individual patient, we are required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, sequence data derived from such tissue sample, results of analysis of such patient&#8217;s genomic analysis and the custom manufactured product for each patient. Maintaining such a chain of identity is difficult and complex, and failure to do so has resulted and may in the future result in product mix up, adverse patient outcomes, loss of product or regulatory action, including withdrawal of any approved products from the market. Further, as intismeran is developed through clinical trials towards approval and commercialization, multiple aspects of the complicated collection, analysis, manufacture and delivery process may be modified to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause intismeran to perform differently than we expect, potentially affecting the results of clinical trials.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our reliance on third parties</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on single-source suppliers for some of the components and materials used in, and the manufacturing processes required to develop and commercialize, our products and product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot ensure that the suppliers we rely on will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that will cease working with us. Our use of single-source suppliers exposes us to several risks, including disruptions in supply, price increases, late deliveries or business interruptions. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are, in general, few alternative sources of supply for substitute components. If we must switch suppliers, the manufacture and delivery of our products or product candidates could be interrupted for an extended period. Establishing additional or replacement suppliers for any of the components or processes used in our products or product candidates may not be accomplished quickly, if at all. Any replacement supplier (or us, if we produced directly) would need to be qualified and may require additional regulatory approval, resulting in further delay. Any such interruption or delay, or our inability to obtain components or materials from alternate sources on acceptable terms, could impair our ability to meet demand for our products or product candidates. Additionally, as part of the FDA&#8217;s approval of our product candidates, the FDA will review the manufacturing processes and facilities of our single-source suppliers.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into strategic alliances with third parties for product development and commercialization. If these alliances are unsuccessful, our business could be adversely affected.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic alliances with collaborators that have provided funding, intellectual property licenses and other resources for developing, manufacturing and commercializing our product candidates. Additionally, we have entered into strategic alliances where we agree to provide funding, intellectual property licenses and other resources to third parties. Our strategic alliances may pose a number of risks, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not perform their obligations as expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may cease or deprioritize development or commercialization of our products due to unfavorable clinical trial results, changes in their focus or funding, or other factors that divert their resources or create competing priorities, such as potential competition with their own products or candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may delay, stop or provide insufficient funding or resources for clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(whether as a result of a business decision or necessitated</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> by financial difficulties of such collaborator);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a strategic collaborator with marketing and distribution rights to one or more of our products may commit insufficient resources to the marketing and distribution of any such product;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with strategic collaborators, including over proprietary rights, contract interpretation or the course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, lead to additional responsibilities for us with respect to such product candidates or result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our IP or proprietary information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of IP developed pursuant to our strategic alliances;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may infringe the IP rights of third parties, exposing us to potential litigation and liability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any equity investments we make in collaborators could decrease in value or become worthless; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in the United States.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic collaborators generally may materially amend or terminate their agreements with us in accordance with the terms of those agreements, which has happened in the past. If any collaboration agreement is terminated, we may not receive anticipated future research or development funding or milestone, earn-out royalty, profit share or other contingent payments and the research or development of our product candidates may be delayed or discontinued. It may also be difficult to attract new strategic collaborators to continue development or commercialization of the applicable product candidate, and our reputation could be adversely affected. All the risks relating to product development, regulatory approval and commercialization described elsewhere in these </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> apply to our strategic </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">collaboration </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional strategic alliances and, if we are unable to do so on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our development programs and the potential commercialization of our product candidates will require substantial cash to fund expenses. We may collaborate with other companies to develop and potentially commercialize some of our product candidates, and we face significant competition in seeking collaborators. Our ability to establish additional strategic alliances will depend, among other things, on our assessment of the collaborator&#8217;s resources and expertise, proposed terms and conditions and the collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of regulatory approval, potential market sizes and competition, the costs and complexities of manufacturing and delivering a product candidate to trial participants, uncertainty with respect to our or the proposed collaborator&#8217;s ownership of technology (regardless of the merits of the challenge)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and industry and market conditions generally.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also restricted under some of our existing strategic alliance agreements from entering into agreements on certain terms with potential strategic collaborators to pursue other targets on our own. These restrictions on working with targets, polypeptides, routes of administration and fields could limit our ability to enter into strategic collaborations with other collaborators or to pursue certain potentially valuable product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Strategic alliances are complex and time-consuming to negotiate and document. If we cannot enter alliances on a timely basis, on favorable terms or at all, we may need to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">undertake development or commercialization activities at our own expense.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to rely on third parties to conduct aspects of our research, preclinical studies, protocol development and clinical trials. If these third parties do not perform satisfactorily or comply with regulatory requirements, we may be unable to obtain regulatory approval for or commercialize our product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties such as CROs to help manage certain preclinical work, and on medical institutions, clinical investigators and CROs to assist in the design, review and conduct of our clinical trials, including enrolling qualified patients. In addition, we engage third-party contractors and collaborators to support other research, commercial and administrative activities, which reduces our control over these activities but does not relieve us of our responsibilities, such as ensuring that each clinical trial is conducted in accordance with its general investigational plan and protocols. Moreover, the FDA requires us to comply with GLPs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and good clinical practices for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that in the case of clinical trials the rights, integrity and confidentiality of trial participants are protected. Such standards will evolve and subject us and third parties to new or changing requirements.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If third parties do not successfully carry out their contractual duties or meet expected deadlines, we may need to replace them, which could delay clinical trials, drug development or other activity. If clinical trials are not conducted in accordance with our contractual expectations or regulatory requirements, action by regulators may significantly and adversely affect the conduct or progress of such trials or require a clinical trial to be redone. Accordingly, our efforts to obtain regulatory approvals and commercialize our drug candidates could be delayed. In addition, failure of any third-party contractor to timely provide access to our data in a format acceptable to us may result in delays or impediments to our regulatory submissions or other development activities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain and enforce patent protection for our discoveries and the intellectual property rights therein, or protect the confidentiality of our trade secrets.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to protect proprietary methods and technologies that we develop under the patent and other IP laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. Because certain U.S. patent applications are confidential until the patents issue, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, if at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications or that we were the first to file for patent protection of such inventions. We therefore may be unable to secure desired patent rights, thereby losing exclusivity. In the past, we have obtained licenses under third-party patents to market our products or conduct our research and development or other activities, and we may do so in the future if necessary. If licenses are not available to us on favorable terms, we may not be able to market the affected products or conduct the desired activities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining and enforcing patent protection is expensive and time-consuming and our pending patent applications may not result in issued patents. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent applications may fail to result in valid enforceable patents, or our patent protection could be reduced or eliminated, for non-compliance with these requirements. If we or our strategic collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Despite our and our strategic collaborators&#8217; efforts to protect our proprietary rights, unauthorized parties may obtain and use information that we regard as proprietary. While issued patents are presumed valid, they may not survive a validity challenge and could be held unenforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties seeking to design around our IP. Also, third parties through the USPTO or European Patent Office (EPO) may commence patent office proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation, or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third-party licensors and could have a material adverse impact on our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. One major provision of the America Invents Act changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer can provide proof that we were in possession of the invention prior to the competitor&#8217;s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. We also rely on non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and maintain all available regulatory exclusivities and broad patent scope and to maximize patent term restoration or extension on patents covering our products may lead to loss of exclusivity and early biosimilar entry resulting in a loss of market share or revenue.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may choose not to enforce our IP rights in certain circumstances or for certain periods of time. For example, in March 2022, we announced that we will not enforce our patents for COVID vaccines against companies manufacturing in or for the Gavi COVAX Advance Market Commitment (AMC) countries, provided that the manufactured vaccines are solely for use in the AMC 92 countries. In addition, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we are willing to license our IP for COVID vaccines to manufacturers, but licensing of our IP may be limited, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and our business may be otherwise adversely impacted if we are unable to enforce our IP.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty over IP in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable and can have adverse financial and freedom-to-operate consequences.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mRNA medicines are a relatively new scientific field and, as the field continues to mature, patent applications are being processed by national patent offices globally. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. Litigation is ongoing over the underlying technology to mRNA medicines between many mRNA market participants. It is likely that there will continue to be significant litigation and patent office proceedings in various patent offices relating to patent rights in the mRNA field.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have issued patents and pending patent applications in the United States and in key markets globally that claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of mRNA medicines and our delivery technology, including LNPs. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Oppositions and inter partes review petitions have been filed against some of our patents, and we expect that further proceedings will be filed in the EPO, USPTO and elsewhere relating to patents and patent applications in our portfolio.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In many cases, the possibility of appeal exists for any party, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. We cannot be certain that any patent will survive or that the claims will remain in the current form. Even if our rights are not directly challenged, disputes could lead to the weakening of our IP rights.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties in the field of mRNA medicines. We have a number of these proceedings ongoing against third-party patents. If </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we are unsuccessful in narrowing or invalidating such third-party patents, those third parties may attempt to assert those patents against our products. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products or product candidates may be subject to claims</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of infringement of the patent rights of third parties.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have invested billions of dollars in creating our patented mRNA platform, which is integral to the development of our mRNA medicines, and we are involved in various intellectual property litigation as described under Part I, Item 3, &#8220;Legal Proceedings.&#8221; We expect to expend substantial financial and managerial resources in connection with these legal proceedings, and the ultimate outcome of each proceeding is uncertain.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are, and may in the future become, involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products and product candidates, and third parties may assert that we are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our products or product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to commercialize such product unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product or product candidate unless we obtained a license or until such patent expires.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Defense of infringement and other claims, regardless of their merit, involves substantial litigation expense and diverts employee resources from our business. In the event of a successful infringement claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability, which could jeopardize our ability to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our IP may be offset by amounts paid by our collaborators to third parties who have competing or superior IP positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with certain license and strategic alliance agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to IP rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to IP rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research, development and commercialization efforts and limit our ability to continue our operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party owners of any patent rights that we license do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may become party to licenses that give us rights to third-party IP necessary or useful for our business and our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed IP. Our licensors may fail to successfully prosecute the patent applications we license, fail to maintain these patents, determine not to pursue litigation against other companies that are infringing these patents or pursue such litigation less aggressively than we would. Without protection for the IP we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our strategic collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our strategic alliance agreements or result in termination of an agreement by one or more of our strategic collaborators.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license IP rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We license IP, which involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. We are a party to certain IP license agreements and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license and may be subject to additional liabilities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our strategic collaborators. Disputes may arise regarding IP subject to a licensing agreement, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our technology and processes that are not subject to the licensing agreement infringe on IP of the licensor;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of IP by our licensors and us and our strategic collaborators; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over IP that we have licensed prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to the same risks with respect to protection of IP that we license as we are for IP that we own. If we or our licensors fail to adequately protect this IP, our ability to commercialize products could suffer.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. From time to time, we are subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed IP, including trade secrets or other proprietary information, of third parties, including our employees&#8217; former employers. Litigation may be necessary to defend against these claims. If we fail to defend such claims, in addition to paying monetary damages, we may lose valuable IP rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other IP.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and have been </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other IP. Ownership disputes may arise, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights, including exclusive ownership of, or right to use, valuable IP. Such an outcome could have a material adverse impact on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract management and other employees, and could impact or patenting strategy.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent and regulatory law could impair our ability to protect our products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. patent law continues to evolve, and certain</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. These rulings have increased uncertainty regarding our ability to obtain patents in the future, as well as with respect to the value of patents, once obtained.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Depending on actions or decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to protect our IP rights throughout the world.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents in every country would be prohibitively expensive, and our foreign IP rights can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect IP rights to the same extent as U.S. federal and state laws. Consequently, we may be unable to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies to develop their own products in jurisdictions where we have not obtained patent protection or may export infringing products to territories where we have patent protection, but enforcement is not as strong as in the United States.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending IP rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other IP protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our IP rights around the world may be inadequate to obtain a significant commercial advantage from the IP that we develop or license.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the relevant patent rights. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on government funding and collaboration from governmental and quasi-governmental entities for certain of our programs adds uncertainty to our research and development efforts with respect to those programs and may impose requirements related to IP rights and requirements that increase the costs of development, commercialization and production of any programs developed under those government-funded programs.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants funded by the U.S. government and its agencies, including our agreements funded by BARDA and DARPA and our collaboration with NIAID, and with foreign governments and agencies, including in the United Kingdom, Canada and Australia, may include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate agreements, in whole or in part, for any or no reason;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce or modify the government&#8217;s obligations under such agreements without our consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claim rights, including IP rights, in products and data developed under such agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">audit contract-related costs and fees, including allocated indirect costs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or debar the contractor or grantee from doing future business with the government;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">control and potentially prohibit the export of products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue criminal or civil remedies under the False Claims Act, False Statements Act and similar remedy provisions specific to government agreements; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the government&#8217;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the right to prohibit the U.S. government from using certain technologies developed by us and we may be unable to prohibit other companies, including our competitors, from using those technologies in providing products and services to the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specialized accounting systems unique to government contracts and grants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public disclosures of certain contract and grant information, which may enable competitors to gain insights into our research program; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs and environmental compliance requirements.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, under these agreements we are subject to the obligations to and the rights of the U.S. government set forth in the Bayh-Dole Act of 1980 (Bayh-Dole Act). As a result, the U.S. government may have rights in certain inventions developed under these government-funded programs, including a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive or nonexclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as &#8220;march-in rights.&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations and prospects. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Biden administration released a proposed framework specifying for the first time that price can be a factor in considering whether an invention is sufficiently available to the public. The proposed framework could potentially enable march-in rights to be used as a tool to regulate drug pricing. The potential inclusion of price as a factor in a march-in determination is expected to draw extensive criticism and challenge, and the ultimate impact is currently unknown.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> If the U.S. government exercises such march-in rights, we may receive compensation deemed reasonable by the U.S. government, which may be less than what we might be able to obtain in the open market. IP generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have significant contracts with the U.S. and other governments, and as such are subject to related regulatory compliance obligations. If we fail to maintain compliance with those obligations, we may be subject to potential liability and to termination of our contracts.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial condition and results of operations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incurred net losses in 2025 and 2024, and expect to incur additional losses in the future; we may not achieve long-term sustainable profitability.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We incurred net losses of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.8 billion and $3.6 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, and other than in 2022 and 2021, we have incurred net losses in each year since our inception. Currently, our COVID and RSV vaccines are our only commercial products and our RSV sales have been minimal. Although we anticipate near-term product launches, their occurrence and timing is uncertain. Our ability to achieve profitability depends on our ability to successfully develop and obtain the regulatory approvals necessary to commercialize our products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred, and expect to continue to incur, significant costs associated with commercializing our products and our clinical development activities. Although we continue to implement cost reduction and prioritization measures, these efforts may fail to reduce our costs in line with expectations, which could require us to seek additional funding to continue operations. Our expenses could increase for many reasons, including if and as we:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional clinical trials, particularly large pivotal trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to build out our manufacturing capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">build out a sales, marketing and distribution infrastructure to commercialize any products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with any of the above.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results may fluctuate. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline and negatively impact our financing or funding ability, as well as our ability to exist as a standalone company.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results may fluctuate from quarter-to-quarter and year-to-year due to many factors, many of which are beyond our control. As such, a period-to-period comparison of our operating results may not be predictive of our future performance. In any quarter, our operating results could be below market expectations, which could cause our stock price to decline. Our stock price could be affected by events not necessarily tied to our actual operating results, including recommendations by securities analysts, the timing of certain public disclosures by us, our collaborators or our competitors and our ability to accurately report our financial results in a timely manner. Other factors relating to our business that may contribute to these fluctuations include those described in these </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and elsewhere in this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents and investments is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we had approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$8.1 billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in cash, cash equivalents and investments, which includes a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$600 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> draw down from our term loan facility, which is subject to general credit, liquidity, market, inflation and interest rate risks. We may realize losses in the fair value of these investments. In addition, if our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. These and other market risks associated with our investment portfolio may adversely affect our results of operations, liquidity and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with the covenants in our credit agreement could adversely affect our business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A failure to comply with the covenants in our credit agreement with lenders led by Ares Capital Corporation, as administrative agent, could result in an event of default, which, if not cured or waived, could have a material, adverse effect on our business, financial condition, and results of operations. In the event of any such default, the holders of our indebtedness (i) would not be required to lend any additional amounts to us; and (ii) could elect to declare all then outstanding indebtedness, including accrued interest and unpaid fees, to be due and payable and terminate all commitments to extend further credit, if applicable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to repay those amounts, the holders of our secured indebtedness could proceed against their secured collateral to seek repayment from the proceeds of the sale or liquidation of our assets. If our indebtedness were to be accelerated, there can be no assurance that our assets would be sufficient to repay such indebtedness in full.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business and operations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing changes to the size, structure and scope of our company.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant growth in our operations and workforce in recent years and, more recently, have undertaken initiatives to reduce costs, prioritize our portfolio and adjust the size and structure of our organization. As a result, we must continue to adapt and improve our managerial, operational, and financial systems to effectively support our evolving business, including potential future growth and expansion initiatives. These efforts may require our management to devote substantial time and attention away from day-to-day operations and strategic execution.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Successfully developing, manufacturing and commercializing products across the many therapeutic areas and diseases we seek to address requires significant depth of talent, resources and robust corporate processes to support simultaneous execution. Organizational changes, including workforce reductions, restructuring, and shifts in strategic priorities, may make it more difficult to retain personnel, recruit and train qualified employees, maintain institutional knowledge, and preserve employee morale and productivity. If we are unable to effectively manage these challenges, we may experience weaknesses in our infrastructure, operational mistakes or inefficiencies, loss of business opportunities and reduced productivity. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to operate and expand a global manufacturing and operational footprint, including our Norwood and Marlborough campuses in Massachusetts and manufacturing facilities outside the United States. Managing the costs, operational complexity, regulatory requirements, and execution risks associated with these facilities may require significant financial and managerial resources and could divert capital from other priorities, including the development of our product candidates. If we are unable to effectively manage organizational change, operational scale, and resource allocation, our financial performance and ability to commercialize our products may be affected negatively.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the risks of doing business outside of the United States.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to risks associated with doing business globally. We are not permitted to market or promote any of our product candidates before receiving regulatory approval or other authorization from applicable authorities, which we may never obtain. To obtain regulatory approval in various jurisdictions, we must comply with numerous regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, manufacturing, commercial sales, pricing and distribution of our product candidates, and we may fail to obtain approval. We have rapidly expanded our global operations, establishing commercial subsidiaries and entering into arrangements to support the worldwide manufacture and distribution of our products, which is a complex task. For example, we are building regional manufacturing facilities and investing in research and development in several countries. Our business may be adversely affected by many factors associated with our expanding global business, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to develop an international commercial sales, marketing and supply chain and distribution organization, including efforts to mitigate longer accounts receivable collection times, longer lead times for shipping and potential language barriers; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our customers&#8217; ability to obtain reimbursement for our products in foreign markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to directly control commercial activities because we rely on third parties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increased legal and compliance burden to establish, maintain and operate legal entities in foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden of complying with complex and changing foreign regulatory, tax, accounting, reporting and legal requirements, including the European General Data Protection Regulation 2016/679 (GDPR);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute, and the difficulty of effective enforcement of contractual provisions in local jurisdictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate IP protection in foreign countries and the existence of potentially relevant third-party IP rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade-protection measures including trade restrictions, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties, or suspension or revocation of export privileges, the imposition of government controls and changes in tariffs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of applicable foreign tax structures and potentially adverse tax consequences; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant adverse changes in foreign currency exchange rates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to extensive federal, state and foreign anti-bribery regulations, including the U.S. Foreign Corrupt Practices Act (FCPA), the UK Bribery Act and similar laws in other countries. Compliance with the FCPA is expensive and difficult, particularly in countries where corruption is a recognized problem. Additionally, the FCPA presents particular challenges to the pharmaceutical industry because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations and executive orders also restrict the use and dissemination outside the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. As we expand our presence outside the United States, we will need to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in many jurisdictions outside the United States, we have or may become subject to additional industry-specific codes of conduct that impose additional compliance responsibilities on us.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these codes particularly as we enter new markets has, and could in the future, result in findings against us, which could result in financial sanctions or reputational harm.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that we, or our employees, consultants or third-party contractors are or will be in compliance with all federal, state and foreign regulations regarding bribery and corruption. Moreover, our strategic collaborators and third-party contractors outside the United States may have inadequate compliance programs or fail to respect the laws and guidance of the territories where they operate, which may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Even if we are not determined to have violated these laws, government investigations typically require the expenditure of significant resources and generate negative publicity.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to maintain our enterprise resource planning (ERP) system could adversely impact our business and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ny disruptions or difficulties using our global ERP system could adversely affect our controls, resulting in harm to our business, including our ability to forecast or make sales and collect our receivables. S</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ignificant delays in documenting, reviewing and testing our internal controls could cause our non-compliance with our SEC reporting obligations related to our management</span><span style="color:#008080;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s assessment of our internal control over financial reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, resulting in unanticipated costs and the diversion of management&#8217;s attention.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends on our ability to attract and retain highly qualified managerial, scientific, technical, quality-control, manufacturing, medical, regulatory and commercial personnel. The turnover rate in our industry is high and we compete with other companies, as well as academic institutions, for individuals with certain skill sets. Failure to attract and retain personnel, or to maintain relationships with key consultants, contractors and advisors, could result in delays in production or difficulties in maintaining compliance with regulatory requirements. In addition, negative business developments and changes in immigration laws, policies or enforcement patterns, or announcements thereof, that make it more difficult or less desirable for immigrants to work in the U.S. or introduce greater uncertainty into the immigration system may make it difficult to recruit and retain qualified personnel.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on members of our management and scientific teams. Each of our executive officers and key employees are employed &#8220;at will,&#8221; and the loss of any of their services may adversely impact the achievement of our business objectives. We do not have &#8220;key person&#8221; insurance on any of our employees. Several of our executives have valuable, fully vested stock options or other long-term equity awards. Additionally, significant declines in our stock price have in the past reduced, and may in the future reduce, the retentive power of equity awards for our executives or other key personnel. We may not be able to retain these employees due to the competitive environment in the biotechnology industry, particularly in Cambridge, Massachusetts.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain our corporate culture, we could lose the innovation, teamwork and passion that we believe contribute to our success.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It may be increasingly difficult to maintain our culture, which we have invested substantial resources in building. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The evolution of our workforce and shifts in workplace and workstyle increase this risk. Failure to preserve our culture could negatively affect our future success.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems and physical premises, or those of third parties with which we share sensitive data or information, may fail or suffer security breaches, including from cybersecurity incidents, which could materially disrupt our product development programs and manufacturing operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our internal computer systems and infrastructure and those of our strategic collaborators, vendors, contractors, consultants or regulators with whom we share confidential, protected or sensitive data or information, or upon which our business relies, are vulnerable to damage from computer viruses, unauthorized access, misuse, natural disasters, terrorism, cybersecurity threats, war and telecommunication and electrical failures, as well as security compromises or data breaches, which may compromise our systems, infrastructure, data or that of those with whom we share such data or information or upon which our business relies, or lead to data compromise, misuse, misappropriation or leakage. We have experienced, and may experience additional, cyber-attacks on our information technology systems and infrastructure by threat actors of all types (including nation states, criminal enterprises, individual actors or advanced persistent threat groups). Bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">and intellectual property. In addition, the use of generative AI models in our internal or third-party systems may create new attack surfaces or methods for adversaries, which could impact us and our vendors. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. In addition, we may experience intrusions on our physical premises by these threat actors. In addition to extracting sensitive information, such attacks could include the deployment of harmful malware, ransomware, digital extortion, business email compromises and denial-of-service attacks, social engineering (including phishing attacks) and other means to affect server reliability and threaten the confidentiality, integrity and availability of information, systems or infrastructure. If any such cyber-attack or physical intrusion against us or those with whom we share confidential, protected or sensitive data or information, or upon which our business relies, were to result in a loss of or damage to our data, systems or infrastructure, or interrupt our operations, such as a material disruption of our development programs or our manufacturing operations, or due to a loss of any of our proprietary or confidential information, it would have a material adverse effect on us. For example, the loss of clinical trial data could delay our regulatory approval efforts and increase our costs to recover or reproduce the data. In addition, because we run multiple clinical trials in parallel, any breach or compromise of our computer systems or infrastructure or physical premises may result in a loss of data or compromised data integrity across multiple programs in many stages of development. While we seek to take steps to address cybersecurity risks, our efforts may not wholly mitigate such risks. Further, our</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any data breach, security incident or compromise of confidential, protected or personal information, including any clinical trial participant personal data, may also result in notification requirements or other disclosure obligations and may subject us to civil fines and penalties, litigation, regulatory investigations or enforcement actions, or claims for damages under the GDPR and UK GDPR and relevant member state law in the EU, other foreign laws, and the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), and other relevant state and federal privacy laws in the United States including the California Consumer Privacy Act, as amended by the California Privacy Rights Act (the CCPA). We have from time to time received information that companies working on vaccine research and development may be a particular focus for those planning cyberattacks, including by nation states and affiliated cyber actors. To the extent that any disruption or security compromise incident or breach were to result in a loss of, or damage to, our data, systems, infrastructure or applications, or inappropriate use or disclosure of confidential or proprietary information, including information related to the research and manufacturing of our products, we could incur liability, our competitive and reputational position could be harmed and the further development and commercialization of our product candidates could be delayed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human capital to pursue a particular research program or product candidate and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We pursue and fund the development of selected research programs or product candidates and may choose to forego or delay pursuit of other opportunities that could later prove to have greater commercial potential. For example, we are currently focusing our efforts on certain prioritized programs that we expect to file for approval over the next several years. Our resource allocation decisions, or our contractual commitments to provide resources to our strategic collaborators, may cause us to fail to capitalize on other commercial products or market opportunities. Additionally, spending on research and development programs may not yield commercially viable products. We may also seek to enter into strategic collaborations or financing arrangements pursuant to which we may relinquish valuable rights to product candidates, including the rights to a portion of future revenues, through a strategic alliance, licensing or other royalty arrangements in cases where it would have been more advantageous for us to retain sole development and commercialization rights. Additionally, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a strategic alliance.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional products, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our longer-term strategy is to discover, develop and commercialize products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our drug discovery efforts, exploring potential strategic alliances for the development of new products and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources. We may fail to identify promising candidates or to successfully develop and commercialize products for many reasons, which would impair our potential for growth.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be harmed if we suffer damage to our reputation, including as a result of a product recall.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or foreign regulators could require the recall of our products. The FDA has authority to recall a biologic product if it finds that a batch, lot or other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, foreign governmental bodies may require the recall of any products in the event of material deficiencies or defects in design or manufacture. Manufacturers may independently recall a product if a material deficiency in a product is found. A government-mandated or voluntary recall by us or our strategic collaborators could occur because of manufacturing errors, design or labeling defects or other deficiencies and issues, as occurred with the recall in 2021 of certain batches of our COVID vaccine shipped to Japan that were found to contain foreign particulate. Recalls of any of our products would divert managerial and financial resources and adversely affect our financial condition and results of operations. A recall announcement could harm our reputation and negatively affect our sales. Our reputation could be further impacted by public discourse regarding our business and perception of our business strategy.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to product liability risk related to the development, testing, manufacturing and marketing of our products and product candidates in clinical trials. Product liability claims and related cross-claims and claims for indemnification may be brought against us by patients, healthcare providers or others using, prescribing, selling or otherwise coming into contact with our products or product candidates. For example, we may be sued if any product or product candidate allegedly causes injury or is found to be otherwise unsuitable during clinical trials, manufacturing or, if approved, marketing, sale or commercial use. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We could also face product liability claims relating to the worsening of a patient&#8217;s condition, injury or death alleged to have been caused by our products or product candidates. Any such claims may include allegations of defects in manufacturing or design, a failure to warn of dangers inherent in the product, including due to interactions with alcohol or other drugs, knowledge of risks, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. Such claims might not be fully covered by product liability insurance. For any marketed products, product liability claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, suspension or withdrawal of approvals or license revocation. Regardless of the merits or eventual outcome, liability claims may cause decreased demand for our products, injury to our reputation and significant negative media attention, costs to defend the related litigation, withdrawal of clinical trial participants, loss of revenue, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants, patients or their family members, payments to indemnify clinical trial sites and other clinical trial partners and a decline in our stock price. On occasion, large judgments have been awarded in individual, mass tort and class-action lawsuits based on drugs or medical treatments that had unanticipated adverse effects.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our COVID vaccine, although the U.S. and certain foreign governments contractually agreed to indemnify us or make statutory immunity available to us for sales during the pandemic public health emergency, which has since ended, such indemnification or statutory immunity may be unavailable to cover potential claims or liabilities resulting from the research, development, manufacture, distribution or commercialization of the vaccine. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our COVID vaccine currently benefits from liability protections under the Public Readiness and Emergency Preparedness (PREP) Act. However, if the Secretary of the U.S. Department of Health and Human Services were to revoke or materially modify the declaration underlying such PREP Act coverage, or if our COVID vaccine is not successfully transitioned to the National Vaccine Injury Compensation Program (VICP), our COVID vaccine could become subject to significantly greater product liability exposure in the United States. In addition, any significant changes to, or overhaul of, the VICP could increase our potential liability exposure.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, other foreign governments that we contract with have not provided us with similar contractual indemnity or statutory immunity, and we generally no longer have the benefit of such indemnities or immunities for future sales of our commercial products. Substantial claims arising from the vaccine outside the scope of or in excess of U.S. or foreign government indemnity or statutory immunity could harm our financial condition and operating results. Moreover, any adverse event or injury for which we are liable, even if fully covered under an indemnity or immunity, could negatively affect our reputation.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to maintain our product liability insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If the costs of maintaining adequate insurance coverage increase significantly in the future, our operating results could be materially adversely affected. Likewise, if insurance coverage became unavailable to us or economically impractical, we would be required to operate our business without indemnity from commercial insurance providers. Additionally, even if we maintain insurance coverage for a type of liability, a particular claim may not be covered if it is subject to a coverage exclusion or we do not otherwise meet the conditions for coverage. If we operate our business with inadequate insurance, we could be responsible for paying claims or judgments against us, which could adversely affect our results of operations or financial condition.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal legislation and actions by federal, state and local governments may permit reimportation into the United States of drugs from foreign countries where the drugs are sold at lower prices.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States from medicines sourced from foreign countries with price controls on pharmaceutical products. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For example, in October 2020, the FDA published a final rule that would allow for the importation of certain prescription drugs from Canada, where there are government price controls. In January 2024, the FDA approved Florida&#8217;s request to import certain lower-priced medications from Canada. While the full implications of the final rule are unknown, legislation or regulations allowing the reimportation of drugs could decrease the price we receive for our products and adversely affect our future revenues and potential profitability.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence how our products are prescribed and purchased. For example, provisions of the ACA resulted in changes in the way health care is paid for by governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. Additionally, the Inflation Reduction Act of 2022 includes provisions, such as drug pricing controls and Medicare redesign, that have begun to be implemented and are likely to impact our business, but its ultimate effect on our business and the healthcare industry in general is not yet known. See &#8220;Business&#8212;Government Regulation-Current and future healthcare reform legislation.&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties due to efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. There is no assurance that the ACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing, which could have significant effects on our business. These actions and the uncertainty about the future of the ACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government is pursuing measures intended to reduce the cost of drugs in the United States. For example, in May 2025, the President issued an executive order directing the U.S. Department of Health and Human Services and other federal agencies to take certain steps intended to, among other things, reduce the prices of drugs sold in the United States to match the lowest price available for the same drugs in comparably developed nations. It is currently unclear how and to what extent these measures may be implemented and what impact any such implementation would have on us.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for drugs or that would allow for importation of pharmaceutical products from lower cost jurisdictions outside the United States. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. In addition, changes to federal Medicaid rebate requirements may increase manufacturer rebate liabilities. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products, if approved.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures may adversely affect our revenues and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws and false claims laws. If we cannot comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as a wide range of pricing, discounting, structuring and commissions, certain customer incentive programs and other business arrangements, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices, which may restrict or prohibit such activities and arrangements. Activities subject to these laws also involve the improper use of information obtained during patient recruitment for clinical trials. Se</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e &#8220;Business&#8212;Government Regulation&#8212;Other healthcare laws.&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible government investigations, is time- and resource-consuming and can divert a company&#8217;s attention from the business. If our operations are found to violate any of these laws or any other regulations, we may be subject to significant sanctions, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance. Furthermore, if any physician or other healthcare provider or entity with whom we do business is found to be not in compliance with applicable laws, they may be subject to similar penalties. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. In addition, the approval and commercialization of any product candidate we develop outside the United States will subject us to foreign healthcare laws.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU and the UK. The provision of benefits or advantages to induce or reward improper performance generally is also governed by the national anti-bribery laws of EU Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. The EU Directive </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2001/83/EC, as amended)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> governing medicinal products for human use provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been retained in UK law despite the UK's departure from the EU.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed, and agreements with physicians often are the subject of prior notification and approval by the physician&#8217;s employer, competent professional organization or applicable regulatory authorities. Failure to comply with these requirements could result in reputational harm, public reprimands, administrative penalties, fines or imprisonment.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could result in fines or criminal penalties and damage our reputation.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to data privacy and security laws and regulations in the United States, Europe and other jurisdictions where we operate or collect personal information. These laws and regulations apply to the collection, storage, use, sharing and security of personal data, including health information, and impose significant compliance obligations. In addition, numerous other federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection and privacy laws, impose additional requirements with respect to personal information.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR and UK GDPR are wide-ranging in scope and impose </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">numerous requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party service providers. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Different EEA Member States have interpreted the EU GDPR differently and many have imposed additional requirements, adding to the complexity of processing personal data in the EEA. The EU GDPR and UK GDPR also impose strict rules on the transfer of personal data to countries outside the EEA that are not considered to provide </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;adequate&#8221; protection to personal data</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including the United States, and permits data protection authorities to impose large penalties for violations. Compliance with the EU GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices. We could be subject to fines and penalties, litigation and reputational harm in connection with any activities falling within the scope of the EU GDPR or UK GDPR.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, at the federal level, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. In addition, numerous states have introduced comprehensive laws which govern the privacy and security of personal information. For example, California has passed the CCPA and more than a dozen other states have passed their own similar comprehensive consumer privacy laws. Other states </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">proposed or passed laws that target particular aspects of privacy, including health, genetic and biometric information, which could have particular impact for our business. For example, Washington passed a law that protects the privacy of consumer health-related information that is not covered by HIPAA and includes a private right of action. In addition, state laws such as the Texas Genomic Privacy Act and others focus specifically on genetic information and could materially impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulators and legislators are also increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries. For example, the Department of Justice&#8217;s January 8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; prohibits data brokerage transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements, employment agreements and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls. Actual or alleged violations of these rules may be punishable by criminal and/or civil sanctions, result in exclusion from participation in federal and state programs or restrict our ability to use certain vendors, sites, investigators, or service providers in global clinical trials.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, many foreign jurisdictions have passed or are considering various proposals for data privacy and protection laws, and data privacy remains an evolving landscape at the domestic and international levels, subject to continued legal challenges. We must devote significant resources to understanding and complying with the changing landscape in this area. Each law is also subject to various interpretations by courts and regulatory agencies, creating additional uncertainty, and any failure or perceived failure to comply with the evolving data protection laws could expose us to risk of enforcement actions taken by authorities, private rights of action in some jurisdictions and potential significant penalties, including criminal sanctions, if we are found to be non-compliant. For example, we could be subject to penalties, including criminal penalties, if we knowingly obtain or disclose individually identifiable health information from a HIPAA-covered health care provider or research institution that has not complied with HIPAA&#8217;s requirements for disclosing such information. Furthermore, the number of government investigations related to data security incidents and privacy violations continues to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and our reputation.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Clinical Trials Regulation (EU) No. 536/2014 (the Clinical Trials Regulation) and the EMA policy on publication of clinical data for medicinal products for human use provide for the publication of certain clinical information submitted in marketing authorization applications (MAAs). The ability of third parties to review or analyze data from our clinical trials may increase the risk of commercial confidentiality breaches and result in enhanced scrutiny of our clinical trial results. Such scrutiny could result in public misconceptions regarding our drugs and drug candidates. These publications could also result in the disclosure of information to our competitors that we might otherwise deem confidential, which could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of generative AI ("GenAI") and other AI technologies presents certain risks and challenges given the emerging nature of AI technologies.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The development and use of GenAI and other AI technologies (collectively, AI Technologies), together with an uncertain and rapidly evolving global regulatory landscape, pose risks that could harm our reputation, expose us to liability, increase compliance costs, or otherwise adversely affect our business. In particular, new and emerging regulations, such as the European Union Artificial Intelligence Act (the EU AI Act), impose or are expected to impose enhanced obligations related to the development, deployment, transparency, governance, risk management, and use of certain AI systems, including those classified as high-risk, and may subject us to significant fines, penalties, operational restrictions, or changes to our business practices if we fail to comply. These requirements may apply extraterritorially, including to AI systems developed or deployed outside the European Union if their outputs are used in the EU.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI and GenAI governance and regulation, including on deployment of AI Technologies in healthcare settings. At the same time, the Trump Administration has endorsed a federal moratorium on the enforcement of state AI laws, including through an executive order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. Moreover, the FDA has advanced guidance and proposed frameworks for regulating AI Technologies in drug discovery, marketing submissions, and medical device development.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The integration of AI Technologies into our and our vendors&#8217; systems (potentially without the vendor disclosing such use to us) subjects us to the risk that the providers of AI Technologies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> may not meet existing or evolving legal, regulatory or industry standards relating to privacy, data protection, cybersecurity, intellectual property, product safety, human oversight, or algorithmic accountability. Compliance with these requirements may require substantial investments in governance, documentation, monitoring, testing, or operational controls, and may limit our ability to deploy or scale certain AI-enabled tools or features.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, bad actors globally use increasingly sophisticated methods, including AI Technologies, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. The use of GenAI models in our internal or third-party systems may create new attack surfaces or methods for adversaries, which could impact us and our vendors. </span><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These factors may lead to breaches of security or privacy, reduced system performance or availability, loss of intellectual property, unauthorized disclosure of confidential or proprietary information. Sophisticated cyber-attacks, including those leveraging AI, could exacerbate these risks. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, GenAI&#8217;s potential for producing false, misleading or biased outputs, or to generate content that may not be subject to IP protection or that may infringe the proprietary rights of third parties, poses additional risks to our business. Regulatory changes or reinterpretations could introduce new compliance risks, including potential government enforcement actions or civil lawsuits. Our competitors&#8217; faster or more effective adoption of AI could also disadvantage us.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be adversely affected by outbreaks of epidemic, pandemic or other contagious diseases. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n the event of a future epidemic or pandemic,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> our clinical trials could be paused or delayed due to restrictions (such as quarantines or travel limitations) or re</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">prioritization of resources</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ravel limitations could also create challenges and potential delays in our development and production activities, increasing the expense and timelines for producing our products and product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We utilize third parties to, among other things, manufacture raw materials, components, parts and consumables, perform quality testing and ship our products. If these third parties were to experience delays or disruptions in providing their services in response to an epidemic or pandemic, our supply chain could be disrupted, limiting our ability to manufacture and sell our products and manufacture product candidates for our clinical trials, as well as negatively impacting our research and development operations. Such delays or disruptions could adversely impact our strategic collaborators&#8217; ability to fulfill their obligations, which could affect the clinical development or regulatory approvals of product candidates under joint development.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during a global health crisis, one or more government entities could take actions (such as via the Defense Production Act in the U.S.) that diminish our rights or economic opportunities with respect to our products. Our third-party service providers could be impacted by government-imposed restrictions on services they might otherwise offer. Any such action could cause us to experience delays in the development, production, distribution or export of our products and product candidates and increased expenses. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engaging in acquisitions, joint ventures or strategic collaborations may increase our capital requirements, dilute our shareholders and cause us to incur debt or assume contingent liabilities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may engage in acquisitions, joint ventures and collaborations, including licensing or acquiring complementary products, IP rights, technologies or businesses. Such transactions and relationships may entail numerous risks, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased operating expenses and cash requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, IP and products, including difficulties associated with integrating new personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from our existing product programs and initiatives;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we undertake acquisitions in the future, we may utilize cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, if we cannot locate suitable acquisition or strategic collaboration opportunities, our ability to grow or obtain access to technology or products that may be important to the development of our business may be impaired.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or stolen versions of mRNA products could negatively impact our financial performance or reputation.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third parties could illegally distribute and sell, especially online, counterfeit versions of mRNA products that do not meet the rigorous cGMP manufacturing and testing standards. Counterfeit medicines may contain harmful substances or the wrong dose, are frequently unsafe or ineffective and could be life-threatening. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reports of adverse reactions to counterfeit products, increased levels of counterfeiting or unsafe mRNA products could materially affect patient confidence in our mRNA products. Adverse events caused by unsafe counterfeit or other non-mRNA products could mistakenly be attributed to our mRNA products. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business. The public could lose confidence in the integrity of mRNA products because of counterfeiting, theft or improper manufacturing processes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to physical risks (such as rising temperatures, flooding and severe storms), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in customer behavior and cost and availability of raw materials) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term). Climate-related physical risks to our facilities and those of our suppliers could disrupt our operations and supply chain, which may result in increased costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">New legal or regulatory requirements may be enacted to prevent, mitigate or adapt to the implications of climate change and its effects on the environment. These regulations, which may differ across jurisdictions, could subject us to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, investments in data gathering and reporting systems, upgrades of facilities to meet new building codes and the redesign of utility systems, which could increase our operating costs, including the cost of electricity and energy. Our supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to us, which may affect our procurement of raw materials or other supplies required to operate our business at the quantities and levels we require.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evolving environmental, social and governance (ESG) standards and expectations may expose us to numerous risks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many investors use ESG screening criteria to determine whether we qualify for inclusion in their investment portfolios, and such investors and other stakeholders expect us to set ESG goals and provide robust disclosure regarding such goals, progress toward goals and other ESG matters of interest. Potential changes in voting practices and the fragmented influence of proxy advisors may impact investor expectations. In addition, we also face ESG-related expectations from certain customers outside the U.S. that can impact our competitiveness in commercial tenders. In response, we have established ESG goals and adapted our tracking and reporting to various ESG frameworks; however, these goals reflect our current plans and aspirations and may not be achieved.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ESG reporting standards are relatively new, have not been harmonized and continue to evolve, and differing interpretations, changing frameworks and evolving regulatory expectations could make compliance more complex and result in inconsistent or revised disclosures over time. If our ESG practices, disclosures or progress do not meet evolving stakeholder or regulatory expectations, or if we fail or are perceived to fail to achieve or accurately report progress toward our goals, our reputation, ability to attract and retain employees and attractiveness as an investment or business partner could be adversely affected, and we could be subject to enforcement actions or litigation. Additionally, the increased focus on ESG matters by policymakers, regulators and investors has in some instances resulted in diverging expectations and standards, which could make it more difficult to comply with ESG-related regulations across our global business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous and flammable materials and wastes, including chemicals and biological materials. We generally contract with third parties for the disposal of these materials and waste products, and we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines, penalties or other sanctions for failure to comply with such laws and regulations. We may also incur substantial costs to comply with such laws and regulations, and these laws and regulations could impair our research, development or production efforts.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our workers&#8217; compensation insurance may not provide adequate coverage against potential liabilities due to injuries to our employees resulting from the use of hazardous materials. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to ownership of our common stock</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been volatile, which could result in substantial losses for shareholders.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is expected to continue to be, subject to substantial volatility. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our IPO in December 2018, o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ur stock price has ranged from a high of $497.49 to a low of $11.54 per share. Over the last several years, our stock has experienced pronounced and extended periods of volatility, which could cause our shareholders to incur substantial losses. Public statements by us, government agencies, the media, competitors, financial analysts or others have resulted, and may result, in significant fluctuations in our stock price. Public information, regardless of accuracy, has had and will likely continue to have an outsized impact on our stock price. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The stock market generally, and the biopharmaceutical sector in particular, has experienced significant volatility that may be unrelated to company operating performance, and you may be unable to sell your shares at or above your initial purchase price. Our stock price may be influenced by many factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product sales and anticipated product revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively reduce costs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial launch of any additional products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing and results of clinical trials or progress of our product candidates or those of our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusion or removal of our stock from market indices; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence or decline of new or existing variants of the SARS-CoV-2 virus;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments regarding our manufacturing, regulatory and commercialization efforts, or information regarding such efforts by competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to any of our products or clinical development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates of financial results, development timelines or recommendations by securities analysts;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, industry and market conditions generally, and in the biopharmaceutical sector specifically; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement by us or our competitors of the commencement or termination of significant acquisitions, strategic collaborations, joint ventures or capital commitments.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities class-action litigation often has been instituted against companies following periods of volatility in their stock price. In 2024, class action and derivative litigations were filed against us related to statements made about our RSV vaccine. See Item 3. &#8220;Legal Proceedings.&#8221; We could incur substantial costs in defense of such litigation or any future lawsuits that may be filed against us, and management&#8217;s attention and resources could be diverted.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal shareholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to shareholder approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of February 13, 2026, our executive officers, directors and affiliated shareholders owned, directly or indirectly, approximately 8% of our outstanding common stock. In addition, non-affiliated five percent or greater shareholders owned approximately 32% of our outstanding common stock. These shareholders have the ability to influence us through their ownership positions. For example, if t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hey were to act together, they could exert significant influence over matters such as elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our shareholders may believe to be in their best interests.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our organizational documents and Delaware law could make it more difficult or costly for a third party to acquire us or remove our current management, even if doing so would benefit our shareholders.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation (charter), second amended and restated by-laws (by-laws) and Delaware law contain provisions that could delay or prevent a hostile takeover or change in control of us or changes in our management. Our charter and by-laws include provisions that:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be authorized for issuance by our board of directors without shareholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create a classified board of directors whose members serve staggered three-year terms;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit shareholders&#8217; ability to call a special meeting of shareholders to shareholders representing at least 20% of our outstanding shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit shareholder action by written consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for shareholder approvals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed only for cause;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that no shareholder is permitted to cumulate votes at any election of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expressly authorize our board of directors to modify, alter or repeal our by-laws; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our charter and by-laws.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of shareholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Any provision of our charter, by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our shareholders to receive a premium for their shares, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay cash dividends for the foreseeable future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to declare or pay cash dividends on our capital stock and instead intend to retain any future earnings to finance the growth and development of our business or to return cash to shareholders through share repurchases. In addition, our existing credit agreement contains restrictions on our ability to pay dividends, and any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our by-laws designate the Court of Chancery of the State of Delaware or the U.S. District Court for the District of Massachusetts as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to by-laws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our shareholders, (3) any action asserting a claim against us or any of our current or former directors, officers, employees or shareholders arising pursuant to any provision of the Delaware General Corporation Law or our by-laws or (4) any action asserting a claim governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our by-laws further provide that the U.S. District Court for the District of Massachusetts is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the Federal Forum Provision). Our by-laws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on shareholders in pursuing any such claims, particularly if the shareholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clauses in our by-laws may limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. The Federal Forum Provision may also impose additional litigation costs on shareholders who assert that the provision is unenforceable or invalid, and if the Federal Forum Provision is found to be unenforceable, we may incur additional costs in resolving such matters. The Court of Chancery of the State of Delaware and the U.S. District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General risk factors</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators leading our clinical trials and consultants. Such misconduct could include failures to comply with FDA regulations or similar regulations in other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, comply with industry codes of conduct, report financial information or data accurately, or disclose unauthorized activities to us. Such misconduct also could involve improper use of information obtained during clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and we may fail to control unknown or unmanaged risks or losses or take steps that protect us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including through the imposition of significant fines or other sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face unfavorable U.S. or global economic conditions, including as a result of disease outbreak, war, conflict or other political instability, or geopolitical risks</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and financial markets, including disruptions caused by pandemic, war, conflict or other political instability. Adverse macroeconomic conditions, and perceptions or expectations about current or future conditions, such as inflation, slowing growth, rising interest rates, the imposition of tariffs (either on imports or exports, which may impact us directly or indirectly through increased costs in our supply chain), rising unemployment and recession, could negatively affect our business and financial condition. Additionally, global events, including war, conflict, political instability or other adverse economic conditions have and may in the future cause governments to divert spending away from healthcare, negatively impacting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> the market for our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any severe or prolonged economic downturn could create a variety of risks to our business, including weakened demand for our medicines, and negatively impact our ability to raise additional capital or financing if needed on favorable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, geopolitical tensions could adversely impact our business and our commercial plans. For instance, restrictions by the U.S. government on the export of mRNA technology or our products to certain markets, or restrictions on the establishment of manufacturing in certain foreign jurisdictions, may prevent us from seeking commercial growth opportunities in a manner that harms our competitive position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in tariffs and other governmental trade policies could negatively affect our business and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Recent governmental actions and proposals relating to tariffs and other trade policies have created uncertainty about future trading arrangements and the possibility of imposing or increasing tariffs on certain goods. For example, certain governments (including the U.S.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other countries where we do business) have imposed or may impose tariffs on a wide range of products, raw materials, and intermediate goods. Additional tariffs, or retaliatory measures by other countries in response, may be implemented at any time. Should these or similar tariffs remain in place (or be re-imposed or increased), or if additional tariffs or trade restrictions are enacted in the future, they could cause us or our customers to face higher supply costs, delays or a need to switch suppliers. These actions could adversely affect our margins, profitability, financial condition, and results of operations. While we have not experienced adverse impacts of tariffs to date, we cannot predict future changes in trade policy or the terms of any renegotiated trade agreements, nor can we determine the impact they may have on our business. Any such changes could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile workplace, discrimination, wage and hour disputes, sexual harassment or other employment issues. Recently, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ineffective internal controls could adversely impact our business and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, failure or interruption of information technology systems, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and operating results could be harmed and we could fail to meet our financial reporting obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, CDC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s ability to review and approve new products can be affected by a variety of factors, including government priorities, budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average FDA review times have fluctuated in recent years as a result. In addition, funding of other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA, CDC and other agencies may delay the review or approval of new product candidates, or the development of usage recommendations. If a prolonged government shutdown occurred, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to evolving and complex tax laws in the jurisdictions in which we operate. The rules dealing with U.S. federal, state, local and non-U.S. income taxation are constantly under review by legislative and tax authorities. Changes to tax laws (which could apply retroactively) could adversely affect us and our shareholders. In recent years, such changes have been made and changes are likely to occur in the future, which could have a material adverse effect on our business, cash flow, financial condition and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents risks and challenges.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, product candidates, commercial products and the diseases our products and product candidates are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This uncertainty creates risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations or we may be unable to defend our business in the face of political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cyber Risk Management and Strategy                                 </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-36" continuedAt="f-36-1" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity organization&#8217;s mission is to provide a targeted set of services, support and capabilities to reduce the risk of cyberattacks, rapidly detect and contain threats, and mitigate risks to critical data.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-37" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">Recognizing the threat of security breaches and cyberattacks globally, we have developed a cybersecurity program, overseen by our Chief Technology and Information Security Officer (CISO), that is designed to protect patient trust, defend the Moderna brand, and reduce the risk and impact of cyber-attacks.</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-39">Our cybersecurity program is informed by industry standards and includes periodic risk assessments and security testing supported by cybersecurity technologies, including third-party security solutions, vulnerability management, and monitoring tools, designed to monitor, identify, and manage risks from cyber threats. In addition, we have implemented employee security and awareness training.</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-40">Management has established a cyber incident response plan (CIRP) designed to assess, identify and manage risks from cybersecurity threats and enable prompt response in the event that a cybersecurity incident is detected. We have a process in place for notification to our leadership response team in the event of a significant cyber incident, and for escalation of these events to our Audit Committee and Board, as appropriate</ix:nonNumeric>. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-41">To date, we have not experienced a cybersecurity incident that has had a material impact on our business strategy, results of operations, or financial condition</ix:nonNumeric>.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-36-1">We undergo several annual internal compliance audits and external reviews to evaluate our controls, including cybersecurity controls. In an effort to minimize third-party risk, we have established a process to assess the security practices of third-party suppliers and related risks, including through review of relevant supplier certifications and security and responses to standardized information gathering (SIG) questionnaires, as applicable and appropriate.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance Related to Cybersecurity Risks</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-44" continuedAt="f-44-1" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-42" escape="true">Our Board of Directors oversees Moderna&#8217;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff.</ix:nonNumeric> </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-44-1">The Audit Committee receives cyber-related updates from management, including our CISO at committee meetings. During meetings, our CISO updates the committee on Moderna&#8217;s cybersecurity posture, potential threats and risk mitigation strategies, and the progress of the Company&#8217;s cybersecurity initiatives, as appropriate. The Chair of the Audit Committee and management provide regular briefings on such matters to the full <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-45">Board of Directors</ix:nonNumeric>, as appropriate.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-48" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-47" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-46" escape="true">At the management level, our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-49">CISO</ix:nonNumeric> is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-50" escape="true">Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies.</ix:nonNumeric> Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have two main campuses in Massachusetts. During the third quarter of 2023, we commenced a lease for a property in Cambridge, Massachusetts. This building, spanning approximately 462,000 square feet, is designated as our Moderna Science Center (MSC). The MSC accommodates a combination of scientific and office spaces, including our principal executive offices, and is the location of our corporate headquarters and platform, drug discovery, and clinical development activities. The lease has a term of 15 years, with options for us to extend the lease for up to two additional seven-year terms. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Moderna Technology Center (MTC) is located in Norwood, Massachusetts and is primarily comprised of three buildings (MTC South, MTC North and MTC East). The MTC campus is approximately 722,000 square feet and includes lab and office space, directly supporting our manufacturing capabilities and commercial and clinical activities. In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings. This acquisition transitioned the facilities from leased to owned properties, providing greater operational flexibility and long-term stability in supporting our manufacturing and development capabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we acquired a newly constructed biomanufacturing facility, encompassing 140,000 square feet, in Marlborough, Massachusetts. This facility underwent enhancements, including the addition of 60,000 square feet to the existing structure. The facility includes state-of-the-art mRNA manufacturing areas, including a full manufacturing clean room, quality control laboratories, and a just-in-time satellite warehouse. The Marlborough facility became operational in August 2025 and is intended to support our intismeran autogene program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, we completed construction of our mRNA manufacturing facility in Laval, Quebec, Canada, which we own, and the facility received a Drug Establishment License from Health Canada authorizing the production of mRNA vaccine drug substance. The facility encompasses approximately 100,000 square feet of manufacturing space and has the capacity to produce up to 100 million doses annually. In 2025, the facility began manufacturing drug substance for our Spikevax, supporting domestic mRNA vaccine production for Canada. In December 2025, Health Canada approved the addition of the Laval drug substance site for mRESVIA production, representing the second product approval for the Canadian supply chain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We own a large-scale mRNA manufacturing facility, the Moderna Technology Centre &#8211; Melbourne (MTC-M), located in Clayton, Victoria, Australia, within Monash University&#8217;s Technology Precinct. The facility encompasses approximately 130,000 square feet of manufacturing space and is designed to support end-to-end mRNA vaccine manufacturing, with the capacity to produce up to 100 million doses annually. In August 2025, the facility received full Good Manufacturing Practice (GMP) licensing, authorizing the manufacture of mRNA vaccine drug substance and finished drug product in compliance with applicable regulatory standards.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We own the Moderna Innovation and Technology Centre (MITC), a manufacturing and research facility located at the Harwell Science and Innovation Campus in Oxfordshire, United Kingdom. The facility, which officially opened in September 2025, encompasses approximately 100,000 square feet and is designed to support mRNA vaccine manufacturing and related research activities. The MITC has the capacity to produce up to 100 million doses annually and up to approximately 250 million doses in the event of a pandemic. The facility is intended to produce British-made mRNA respiratory vaccines to support the National Health Service (NHS) seasonal vaccination programs and also supports research into the application of mRNA technology in additional disease areas.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also own and lease various parcels of land, office and lab spaces across the globe for our business operations.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_91"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various claims and legal proceedings of a nature considered ordinary course in our business, including the intellectual property litigation described below. Most of the issues raised by these claims are highly complex and subject to substantial uncertainties. For a description of risks relating to these and other legal proceedings we face, see Part I, Item 1A, &#8220;Risk Factors,&#8221; including the discussion under the headings entitled &#8220;Risks related to our intellectual property&#8221; and &#8220;Risks related to the manufacturing of our commercial products and product candidates.&#8221; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. We describe below those legal matters for which a material loss is either (i) possible but not probable, and/or (ii) not reasonably estimable at this time.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer/BioNTech Patent Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Proceedings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we filed a lawsuit in the U.S. District Court for the District of Massachusetts against Pfizer Inc. (Pfizer) and BioNTech SE, BioNTech Manufacturing GmbH and BioNTech US Inc. (collectively, BioNTech), asserting infringement of certain U.S. patents concerning our mRNA platform technology and disease-specific vaccine designs in Pfizer and BioNTech&#8217;s manufacture and sale of their mRNA COVID vaccines. The complaint seeks a judgment of infringement of the asserted patents and monetary damages. The case has been stayed pending the outcome of two Inter Partes Review proceedings (IPRs) before the U.S. Patent and Trademark Office&#8217;s Patent Trial and Appeal Board (PTAB) regarding the validity of two of the three asserted patents. In March 2025, the PTAB found the patents invalid and we appealed to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">European Proceedings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also in August 2022, we initiated patent infringement proceedings in the UK (in the High Court of Justice of England &amp; Wales), the Netherlands (in the District Court of The Hague) and Germany (in the Dusseldorf Regional Court), against Pfizer, BioNTech and related entities with respect to certain European patents that also concern our mRNA platform technology and disease-specific vaccine designs, including coronaviruses. In May 2023, we initiated patent infringement proceedings in Ireland (in the High Court) and Belgium (in the Brussels Business Court) against Pfizer, BioNTech and related entities with respect to the same European patents. As in the U.S. action, we seek a judgment of infringement of the asserted patents and monetary damages.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the High Court of Justice of England &amp; Wales ruled that EP3590949 (the &#8216;949 patent), which relates to chemically-modified mRNA, was valid and infringed by Pfizer and BioNTech. The court further ruled that EP3718565 (the &#8216;565 patent), which relates to coronavirus mRNA vaccines, was invalid. In August 2025, the UK Court of Appeal upheld the High Court&#8217;s decision that the &#8216;949 patent is valid and infringed by Pfizer and BioNTech. In December 2025, the UK Supreme Court denied permission for appeal by Pfizer and BioNTech. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the District Court of The Hague ruled that the &#8216;949 patent was invalid. We appealed to the Court of Appeal of The Hague, which held a hearing on September 22, 2025, and is expected to issue its decision on March 31, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Dusseldorf Regional Court in Germany ruled that Pfizer and BioNTech infringed the &#8216;949 patent. Pfizer and BioNTech have appealed to the Higher Regional Court of Dusseldorf, which will hold a hearing November 26, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer Inc. and BioNTech SE have filed oppositions seeking revocation of the &#8216;949 and &#8216;565 patents at the European Patent Office. In May 2024, the Opposition Division (OD) ruled that the &#8216;949 patent was valid, and Pfizer and BioNTech appealed to the Technical Appeal Board (TBA), which will hold a hearing on September 8-10, 2026. In November 2023, the OD ruled that the &#8216;565 patent was invalid and we appealed to the TBA, which confirmed the invalidity on January 27, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arbutus Patent Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of our COVID vaccine willfully infringes certain U.S. patents concerning lipid nanoparticles but does not seek to prevent or stop the marketing or sales of our COVID vaccines. The complaint seeks a judgment of infringement of the asserted patents and monetary damages. The Court has set trial to begin March 9, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, Arbutus and Genevant filed five international lawsuits asserting that our manufacture and sale of Spikevax and/or mRESVIA infringes certain patents concerning lipid nanoparticles. The companies filed lawsuits in the Canadian Federal Court, the Tokyo District Court in Japan and the Swiss Federal Patent Court and submitted two lawsuits to the Unified Patent Court (UPC). The UPC actions seek relief in all UPC member states and in ten additional European Patent Convention contracting states. Each proceeding identifies Spikevax and mRESVIA as accused products except for the Canadian proceeding, which only identifies Spikevax. The complaints seek monetary relief and injunctive relief after a trial decision and before any appeals are decided. Hearings for the UPC actions are set for May 19 and 20, 2026. The Canadian lawsuit is scheduled for trial beginning in September 2027. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GSK Patent Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, GlaxoSmithKline Biologicals SA (GSK) filed two separate complaints against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of our COVID and RSV vaccines willfully infringe certain U.S. patents directed to lipid-mRNA vaccine formulation technology. Each complaint seeks a judgment of infringement of the asserted patents and unspecified damages, and injunctive relief related to RSV after any appeals are decided. The Court has set trial to begin on July 19, 2027 with respect to our COVID vaccines, and on August 23, 2027 with respect to our RSV vaccine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, GSK submitted two lawsuits to the UPC asserting that our manufacture and sale of our COVID and RSV vaccines infringe three European patents related to liposomes with specified characteristics for RNA delivery. The complaints seek monetary and injunctive relief after appeal. Hearings are set for September 2026. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, GSK served us with two separate complaints in the Barcelona Commercial Court and the Madrid Commercial Court (the Spanish Courts) asserting that our manufacture and sale of our COVID and RSV vaccines infringe the same patents asserted in the UPC actions. The complaints seek monetary and injunctive relief after an appeal decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Northwestern University Patent Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, Northwestern University filed a complaint against us in the U.S. District Court for the District of Delaware asserting that our COVID and RSV vaccines infringe several U.S. patents concerning lipid nanoparticle technology. The complaint seeks a judgment of infringement of the asserted patents and unspecified damages. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Patent Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 and July 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed two complaints against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of our COVID vaccine infringed certain U.S. patents concerning cationic lipids. On August 25, 2023, the Court entered a Final Judgment of non-infringement of all asserted patents in these lawsuits. In the first case, Alnylam appealed and the Federal Circuit decided the appeal in our favor in June 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Relatedly, in May 2023, Alnylam filed a third complaint against us in the U.S. District Court for the District of Delaware asserting three additional U.S. patents concerning cationic lipids. The complaint sought judgments of infringement of the asserted patents and monetary damages. In November 2023, the District Court entered an order of partial dismissal with respect to two of the patents at issue. Subsequently, in October 2024, the District Court entered a final judgment of non-infringement in our favor with respect to the third patent at issue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the June 2025 Federal Circuit decision in our favor, we and Alnylam entered into an agreement in September 2025 to settle all disputes between the parties, including filing a stipulated dismissal of Alnylam&#8217;s claims with prejudice. The settlement did not include payments of any kind by us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer CropSciences Patent Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, Bayer CropScience LLC, Monsanto Company and Monsanto Technology, LLC (collectively, Bayer) filed a complaint against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of our COVID vaccines infringe a U.S. patent directed to methods of modifying gene sequences. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mNG Bio Patent Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, mNG Bio, LLC (mNG) filed a complaint against us in the U.S. District Court for the District of Massachusetts asserting that certain tests of our COVID vaccines willfully infringe a U.S. patent directed to a yellow-green fluorescent protein. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTech Patent Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2026, BioNTech SE filed a complaint against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of mNEXSPIKE willfully infringes a U.S. patent directed to modified mRNA compositions encoding a spike protein fragment. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, a putative shareholder class action complaint was filed against us and certain officers in the U.S. District Court for the District of Massachusetts. The action was purportedly brought on behalf of a class of shareholders who purchased Moderna common stock between January 18, 2023 and June 25, 2024. The complaint asserts claims under the Securities Exchange Act of 1934 regarding statements about our RSV vaccine (mRNA-1345) and seeks unspecified damages. On August 25, 2025, plaintiff filed an amended complaint, which, among other things, narrowed the asserted class period to February 15, 2024 to May 31, 2024. On October 24, 2025, the Company filed a motion to dismiss, which remains pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Litigation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Between September and November 2024, purported shareholder derivative complaints were filed in the U.S. District Court for the District of Massachusetts against certain of our officers and directors and against us as a nominal defendant. The complaints allege breaches of fiduciary duty and claims under the Securities Exchange Act of 1934 regarding statements about mRNA-1345 and seek declaratory and injunctive relief and unspecified damages payable to us. The cases were stayed pending a decision on defendants&#8217; motion to dismiss the putative securities class action described above.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_97"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;MRNA&#8221;. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Performance Graph </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of the Exchange Act or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of Moderna, Inc. under the Securities Act or the Exchange Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following graph illustrates a comparison for the five years ended December 31, 2025 of the cumulative total return for our common stock, the Nasdaq Biotechnology Index, and the Standard &amp; Poor&#8217;s 500 Stock Index (the S&amp;P 500) each of which assumes an initial investment of $100 and reinvestment of all dividends. Such returns are based on historical results and are not intended to suggest future performance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock. </span></div><div><span><br/></span></div><div style="text-align:center"><img src="mrna-20251231_g5.jpg" alt="1256" style="height:401px;margin-bottom:5pt;vertical-align:text-bottom;width:700px" id="i-5"/></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately 62 stockholders of record as of February&#160;13, 2026. Because many of our outstanding shares are held in accounts with brokers and other institutions, the number of beneficial owners is significantly greater than the number of record holders. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. In addition, our Credit Agreement with lenders led by Ares Capital Corporation includes covenants that, subject to certain exceptions, restrict our ability and the ability of our subsidiaries to pay dividends or distributions. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans in Item 12 of Part III of this Annual Report on Form 10-K is incorporated herein by reference. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, our Board of Directors authorized a share repurchase program for our common stock of up to $3.0 billion, with no expiration date. During the three months ended December 31, 2025, there were no shares repurchased. As of December 31, 2025, $1.7&#160;billion of our Board of Directors&#8217; authorization for repurchases of our common stock remained outstanding, with no expiration date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_199">Note </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_199">13</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to consolidated financial statements for information regarding our share repurchase programs.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_109"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in &#8220;Part I, Item 1A - Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We currently have three commercial products&#8212;Spikevax&#174; and mNEXSPIKE&#174;, our COVID vaccines, and mRESVIA&#174;, our vaccine against respiratory syncytial virus (RSV). We also have a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025 Business Highlights</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Manufacturing Capabilities Expansion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we announced the expansion of our U.S. manufacturing capabilities through the onshoring of drug product manufacturing to our existing Moderna Technology Center in Norwood, Massachusetts. Upon completion, this expansion will enable end-to-end mRNA manufacturing in the United States, supporting both commercial and clinical supply needs. This expansion is part of our continued investment in U.S.-based manufacturing infrastructure to support our mRNA vaccine and therapeutic pipeline. Construction for the new drug product manufacturing capability has commenced, with completion targeted in the first half of 2027.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">$1.5 Billion Five-Year Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we entered into a five-year term loan facility providing for up to $1.5 billion of capital to enhance our balance sheet and provide increased financial flexibility. The facility includes a $600 million initial term loan funded at closing, a $400 million delayed draw term loan facility available through November 2027, and an additional $500 million delayed draw term loan facility available through November 2028, subject to the achievement of specified regulatory milestones. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Revenue and Loss Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2025, we recognized total revenue of $1.9&#160;billion compared to $3.2&#160;billion and $6.8&#160;billion for the years ended December 31, 2024 and 2023, respectively. Loss per share was $(7.26) for the year ended December 31, 2025, compared to loss per share of $(9.28) and $(12.33) for the years ended December 31, 2024 and 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Program Developments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infectious Disease Vaccines</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">COVID vaccines: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have received approval in 40 countries for our 2025-2026 formula for Spikevax. We have also received U.S. Food and Drug Administration (FDA) approval of our 2025-2026 formula for mNEXSPIKE, our second COVID vaccine, in all adults aged 65 and older, as well as individuals aged 12 to 64 years with at least one underlying risk factor. mNEXSPIKE is also approved in Europe, Canada and Australia and we have filed and are targeting 2026 approvals in Japan and Taiwan.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">mRESVIA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Our RSV vaccine has been approved for adults aged 60 years and older in 40 countries. It is also approved in 31 of those countries for individuals 18 to 59 years of age who are at increased risk for disease.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Seasonal flu vaccine:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Our mRNA-1010 regulatory filings are under review in the United States, Europe, Canada and Australia. In February 2026, in response to a prior Refusal-to-File letter, we engaged with the FDA in a Type A meeting and submitted an amended biologics license application (BLA) outlining a revised regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults. Following the meeting and submission of the amended application, the FDA accepted our BLA for review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Seasonal flu + COVID vaccine:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Our mRNA-1083 regulatory filing is under review in Europe and Canada. We are awaiting further guidance from the FDA on refiling. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Norovirus vaccine: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recently completed enrollment of a second Northern Hemisphere season (2025-2026) cohort in our ongoing Phase 3 study for our norovirus vaccine candidate (mRNA-1403).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology Therapeutics </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Intismeran autogene:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> We are advancing intismeran (mRNA-4157), our mRNA-based individualized neoantigen therapy, in collaboration with Merck, with eight total Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran in combination with KEYTRUDA, which demonstrated sustained improvement in recurrence-free survival in patients with high-risk melanoma (stage III/IV) following complete resection.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA-4359: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC, and we expect a potential Phase 2 data readout in 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rare Disease Therapeutics</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Propionic acidemia (PA) therapeutic:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA-3927 is in a registrational study and target enrollment has been reached. In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Methylmalonic acidemia (MMA) therapeutic:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA-3705 has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, with a registrational study expected to begin in 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other Business Updates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2025, our mRNA manufacturing facilities in Australia and the United Kingdom were licensed and became operational. These facilities were established under long-term strategic agreements with the respective governments to support domestic mRNA manufacturing and pandemic preparedness. The facilities will enable local supply of our mRNA vaccines and provide rapid response capabilities in the event of future public health emergencies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, we delivered the first mRNA vaccines fully manufactured in Canada from our facility in Laval, Quebec, marking a significant milestone in our collaboration with the Government of Canada. The site, which received its Drug Establishment License from Health Canada in 2024, now produces the drug substance for our updated Spikevax targeting the LP.8.1 variant. Fill-and-finish of the vaccine, including the new single-use pre-filled syringes, is completed by Novocol Pharma in Cambridge, Ontario. This milestone demonstrates the execution of our end-to-end manufacturing strategy and our ability to provide timely access to locally manufactured mRNA vaccines through collaboration with government and industry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we entered into an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) under which CEPI will provide up to $54 million in funding to support a pivotal Phase 3 clinical trial for our investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, which is expected to begin in early 2026. If licensure is granted and in the event of an influenza pandemic, Moderna is committed to working to provide people around the world with rapid, equitable access to the resulting H5 vaccine, including, as part of this agreement, allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net product sales </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:52.242%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.663%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.663%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain agreements may include upfront payments for our vaccine supply, initially recorded as deferred revenue. As of December 31, 2025, we had deferred revenue of $107&#160;million related to product sales, of which $42 million is expected to be realized in less than one year. </span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue comprises grant revenue, collaboration revenue, licensing and royalty revenue and stand-ready manufacturing revenue. Grant and collaboration revenues have been primarily derived from government-sponsored and private organizations including the Biomedical Advanced Research and Development Authority (BARDA), the Defense Advanced Research Projects Agency (DARPA) and the Gates Foundation and from strategic alliances with Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex) and others to discover, develop, and commercialize potential mRNA medicines. Licensing and royalty revenue is related to our out-licensing agreement for mRNA COVID related intellectual property in Japan, executed in 2024. Stand-ready manufacturing revenue relates to long-term strategic agreements with certain government entities to maintain manufacturing readiness, while the remaining consideration under these agreements is related to product sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes raw materials, personnel, facility and other indirect overhead costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and final formulation and packaging costs. Cost of sales also includes shipping costs, third-party royalties on net sales of our products, and charges for inventory valuation, excess and obsolete inventory and losses on firm purchase commitments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities generate a significant amount of research and development costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses represent costs incurred by us for the following:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cost to develop our platform;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">discovery efforts leading to development candidates;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preclinical, nonclinical, and clinical development costs for our programs;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cost to develop our manufacturing technology and infrastructure; and</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">digital infrastructure costs related to our drug discovery efforts and clinical trials.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The costs above comprise the following categories:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">personnel-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations (CROs), that conduct our preclinical studies and clinical trials, and in-licensing arrangements;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses associated with developing manufacturing, modification of formulation or design of a product or process, advancing the design to meet specific functional and economic requirements for manufacture and obtaining materials for preclinical studies, clinical trials and pre-launch inventory from internal and third-party contract manufacturing organizations (CMOs);</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process; </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">upfront fees and milestones paid to third-parties for licenses and technologies that had not reached technological feasibility and did not have an alternative future use; and</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are generally not recorded or maintained on a program- or therapeutic area-specific basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our research and development expenses, including direct program specific expenses summarized by therapeutic area and indirect or shared operating costs summarized under other research and development expenses during the years ended December 31, 2025, 2024, and 2023 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:60.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.280%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Program-specific expenses by therapeutic area:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease vaccines</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rare disease therapeutics</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total program-specific expenses by therapeutic area</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Other research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discovery and platform research</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Technical development and manufacturing expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shared discovery and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes a total of 25 development candidates at December 31, 2025, 34 development candidates at December 31, 2024, and 42 development candidates at December 31, 2023. Program-specific expenses are reflected as of the beginning of the period in which the program was internally advanced to development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The program-specific expenses by therapeutic area summarized in the table above include external development costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials. We generally do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by therapeutic area. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Discovery and platform research expenses include costs associated with early-stage research activities for preclinical programs and the development of technical advances in mRNA science, delivery science, and manufacturing process design. These costs include external CRO and lab services, personnel-related costs, technology and digital, facilities, and other directly attributable research support costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Technology development and manufacturing expenses are primarily related to manufacturing process development and manufacturing costs, including expenses for acquiring and manufacturing pre-launch inventory, mRNA supply for preclinical studies and clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, such as the purchase of priority review vouchers. These expenses are not otherwise included in development programs, discovery and platform research, technical development, manufacturing expenses, or stock-based compensation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have made substantial investments in research and development activities, including development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development, such as our intismeran autogene, norovirus, and flu+COVID combination vaccine candidates, and development of any new COVID vaccines against variants of SARS-CoV-2, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-</span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stage clinical trials. In addition, we may incur research and development costs related to postmarketing commitments, though the timing and scope of such commitments remain uncertain. We expect our research and development costs to be substantial in the near term as our investigational medicines advance through development phases and as we identify and develop additional programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of many of our investigational medicines. Moreover, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development, commercial, marketing, and other administrative and operational functions, professional fees, accounting and legal services, technology and digital and facility-related costs, and expenses associated with obtaining, maintaining, and defending intellectual property (IP). These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2024, selling, general and administrative expenses increased annually as we expanded our commercial infrastructure to support the global commercialization of our COVID vaccine. These increases were driven by investments in building regulatory, sales, and marketing teams, establishing subsidiaries in multiple countries, and supporting operational growth. In 2025 and 2024, selling, general and administrative expenses decreased significantly year over year by $156 million and $375 million, or 13% and 24%, respectively. This decline reflects our focus on productivity improvements, cost-saving initiatives, and targeted investments that strengthen our overall efficiency.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of interest expense, gains or losses related to the sale of investments in marketable securities, changes in fair value of investments in equity securities, foreign currency transactions, remeasurements and hedges, and other income and expense unrelated to our core operations. Interest expense is primarily derived from our finance leases related to our Moderna Technology Center prior to its acquisition in December 2024, certain contract manufacturing service agreements, and, beginning in November 2025, interest associated with our long-term debt (see</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190"> </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190">Note 1</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190">0</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">Note 1</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">1</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the consolidated financial statements prospectively from the date of change in estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policy used in the preparation of our </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements requires the most significant judgments and estimates.</span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net product sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter of 2023, we sold our COVID vaccine to the U.S. Government, foreign governments and organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. In the third quarter of 2023, we commenced sales of Spikevax to the U.S. commercial market, in addition to continuing sales to foreign governments and organizations, and subsequently expanded our commercial COVID vaccine portfolio with the launch of mNEXSPIKE in the third quarter of 2025. We also commenced sales of our RSV vaccine in the third quarter of 2024. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, government rebates, and other related deductions. These provisions are recorded based on contractual terms, our estimate of returns for product sold, and other relevant considerations, during the period, using the expected value method or the most likely amount method. Estimates are assessed each period and adjusted as required to revise information or actual experience. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_151">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements for further discussion and analysis of each significant category of product sales provisions and the accounting policy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The application of our critical accounting policies necessitates substantial management judgment and estimation, particularly when determining the amount of variable consideration to recognize. The subjectivity of this process is heightened when assessing factors outside our direct control such as the limited historical data, constrained third-party information, and evolving market dynamics. Among all variables, estimating returns presents the most significant judgment due to the broad range of potential outcomes and the current lack of established return trends. While we now have two years of data on our product returns, this remains limited and subject significant variability given current market conditions. We will continue to refine our projections as additional information becomes available. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_151">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Summary of Significant Accounting Policies, to the consolidated financial statements, under the caption &#8220;Recently Issued Accounting Standards&#8221;.</span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A discussion regarding our results of operations for the year ended December 31, 2025 compared to 2024 is presented below. A discussion regarding our results of operations for the year ended December 31, 2024 compared to 2023 can be found under Part II -Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (SEC) on February 21, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated statements of operations for the periods presented (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change 2025 vs. 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,292)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,163)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,074)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,945)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by $1.3 billion, or 40%, in 2025, primarily driven by a decline in net product sales. Net product sales decreased by $1.3 billion, or 42%, in 2025, largely due to lower sales volumes of our COVID vaccine across all regions. In the U.S., net product sales declined compared to 2024, reflecting a year-over-year decline in overall COVID vaccine demand. This decrease was partially offset by increased market share in the retail channel, supported by the successful launch and performance of mNEXSPIKE during the 2025/2026 respiratory vaccination season. In Europe and the rest of the world, net product sales declined compared to 2024, driven largely by the completion of advance purchase agreements related to COVID vaccines with government customers that contributed to revenue in the prior year, as well as lower overall demand in these markets. These impacts were partially offset by product sales generated under long-term strategic partnerships with government entities through our in-country manufacturing arrangements. Other revenue was relatively consistent compared to 2024, as lower grant revenue, collaboration revenue, and licensing and royalty revenue were largely offset by higher stand-ready manufacturing revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are expected to return to growth in 2026, supported by the full-year impact of long-term strategic partnerships with government entities, as well as continued uptake of mNEXSPIKE in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of sales was $868&#160;million, or 48% of our net product sales, in 2025, including third-party royalties of $88&#160;million, inventory write-downs of $291 million, primarily for raw materials and our finished and semi-finished COVID vaccine inventory, and unutilized manufacturing capacity and wind-down costs of $93 million. Our cost of sales was $1.5&#160;billion, or 47% of our net product sales, in 2024, including third-party royalties of $155&#160;million, inventory write-downs of $495 million, unutilized manufacturing capacity and wind down costs of $368 million, and losses on firm purchase commitments and cancellation fees of $60&#160;million. These charges in both 2025 and 2024, other than royalties, were largely driven by customer demand forecast adjustments related to the seasonal nature of the COVID vaccine market, termination of third-party contract manufacturing service agreements, and commitments for </span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing capacity and raw material purchase agreements. Forecasting demand for COVID vaccines requires advance production planning ahead of each season, including production of multiple COVID vaccine products, which resulted in excess inventory and capacity as actual demand differed from forecasted demand. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_175">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements for further details on inventory related charges and this initiative.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales for 2025 decreased by $596&#160;million, or 41%, compared to 2024. As a percentage of net product sales, cost of sales was 48% in 2025 compared to 47% in 2024, remaining relatively consistent year over year. The decrease in cost of sales was primarily driven by reduced inventory write-downs, reduced unutilized manufacturing capacity and wind-down costs, lower losses on purchase commitments, and lower sales volume. In 2024, cost of sales included $238&#160;million of wind-down costs related to the termination of a contract manufacturing agreement, whereas wind-down costs incurred in 2025 were significantly lower. As a result, the cost of sales as a percentage of net product sales remained relatively consistent year over year, as the benefit of a more efficient manufacturing cost structure was largely offset by lower product sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2026, we anticipate that cost of sales will remain at a relatively consistent level compared to 2025, reflecting continued manufacturing productivity improvements and operational efficiencies. To the extent net product sales increase, cost of sales as a percentage of net product sales may decrease modestly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $1.4 billion, or 31%, in 2025. The decrease was primarily attributable to lower clinical trial expenses of&#160;$578 million and lower clinical manufacturing expenses of $239 million, reflecting the wind-down of large Phase 3 respiratory programs and the timing of certain clinical trial activities shifting into 2026, partially offset by increased investment in our norovirus vaccine and oncology program. In addition, preclinical research expenses decreased by $107 million due to continued portfolio prioritization across the organization, and consulting and outside service costs declined by $175 million, consistent with the lower level of clinical and manufacturing activities. Separately, the prior-year period included an expense related to the purchase of two priority review vouchers, which did not recur in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate a modest reduction in research and development expenses in 2026 compared to 2025, driven by continued portfolio prioritization, disciplined cost management, and a focused approach to pipeline execution. These reductions are expected to be partially offset by certain clinical trial activities shifting into 2026 and additional costs related to post-marketing commitments. We remain committed to advancing our pipeline and late-stage programs, including intismeran autogene and norovirus vaccine programs, while continuing to manage research and development investment levels in line with our long-term objectives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased by $156 million, or 13%, in 2025. The decrease was mainly due to a $57 million broad-based reduction in consulting and outside services, along with a $59 million reduction in commercial, marketing and distribution costs. These decreases were attributable to continued cost discipline and ongoing efforts to streamline operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect selling, general and administrative expenses in 2026 to remain at a level relatively consistent with 2025, reflecting an efficient and scalable operating structure. While we will continue to make selective investments to support our key priorities, including our global commercial and regulatory activities, we expect these investments to be largely offset by ongoing efficiency initiatives and disciplined resource allocation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income generated from our investments in marketable securities decreased by&#160;$111 million in 2025, mainly due to lower average investment balances.</span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other expense, net for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:58.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change 2025 vs. 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on investments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net decreased by $79 million, or 91%, in 2025. The decrease was primarily driven by lower equity investment losses and lower interest expense. Interest expense is primarily related to our finance leases related to our Moderna Technology Center prior to its acquisition in December 2024, certain contract manufacturing service agreements, and, beginning in November 2025, interest associated with our long-term debt. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">N</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">ote</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066"> 11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Provision for income taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for 2025 remained immaterial and consistent with 2024 and 2023, reflecting the valuation allowance established on deferred tax assets in 2023, which has been applied consistently since its initial recognition. Provision for income taxes increased by $100&#160;million, or 217%, in 2025, mainly driven by the absence of a discrete tax benefit related to research and development credits that was recognized in 2024, as well as taxable income in certain of our foreign subsidiaries, while we incurred a consolidated pre-tax loss. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_205">Note 1</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_205">4</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, investments and working capital for each period presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Our investments, consisting primarily of government and corporate debt securities, are stated at fair value. Cash, cash equivalents and investments as of December 31, 2025 decreased by $1.4 billion, or 15%, compared to December 31, 2024. For the year ended December 31, 2025, we had a net cash outflow from operations of $1.9 billion, and purchases of property, plant and equipment of $192 million, partially offset by $578 million of net proceeds from our credit facility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Working capital, defined as current assets less current liabilities, as of December 31, 2025 decreased by $1.3 billion, or 23%, compared to December 31, 2024. This was primarily due to a $1.2 billion decrease in cash, cash equivalents and short-term investments, mainly used to fund our operating activities, a $191 million decrease in prepaid expenses and other current assets driven by reduced manufacturing and capital spend, and a $174 million decrease in accounts receivable, primarily driven by lower revenue and invoice volumes as well as timing of collections. These decreases were partially offset by a $129 million reduction in accounts payable and accrued liabilities, reflecting an overall reduction in operating expenses, and a $54 million reduction in short-term deferred revenue, mainly resulting from revenue recognized from deferred revenue in excess of customer advance payments received.</span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flow</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for the periods presented (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We derive cash flows from operations primarily from cash collected from customer advance payments and accounts receivable related to our product sales, as well as other revenue and funding arrangements. Our cash flows from operating activities are significantly affected by our use of cash for operating expenses and working capital to support the business. We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. Certain supply agreements include upfront payments, which are initially recorded as deferred revenue. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers, which typically do not make upfront payments. In addition, we receive customer advance payments related to certain other revenue arrangements. As of December 31, 2025, we had $252 million in deferred revenue related to customer advance payments received or billable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used by operating activities in 2025 was $1.9 billion and consisted of net loss of $2.8 billion and non-cash adjustments of $716 million, plus a net change in assets and liabilities of $233 million. Non-cash items primarily included stock-based compensation of $483 million and depreciation and amortization of $215 million. The net change in assets and liabilities was primarily due to a decrease in accounts receivable of $156 million, mainly due to lower invoice volumes and timing of collections, a $153 million decrease in prepaid expenses and other current assets, primarily due to reduced manufacturing and capital spend, and a $41 million decrease in deferred revenue due to revenue recognized from deferred revenue in excess of customer advance payments received. This was partially offset by a decrease in accounts payable and accrued liabilities of $94 million resulting from overall lower operating expenses in the period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used by operating activities decreased by $1.1 billion, or 38%, in 2025 compared to 2024. This decrease was primarily driven by a decrease in net loss of $739 million, a change in deferred revenue of $480 million, reflecting less revenue recognized from deferred revenue in excess of customer advance payments received in 2025, and a change in accounts payable and accrued liabilities of $360 million, driven by decreased clinical and manufacturing spend. This was partially offset by a change in accounts receivable of $378 million, driven by lower invoice volumes and timing of collections, and a change in inventory of $117 million, driven by a smaller reduction in inventory write-downs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our primary investing activities consist of purchases, sales, and maturities of our investments, capital expenditures for land, building, leasehold improvements, manufacturing, laboratory, computer equipment and software, and business development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities in 2025 was $1.9 billion, which primarily included proceeds from maturities of marketable securities of $5.6 billion and proceeds from sales of marketable securities of $2.4 billion, partially offset by purchases of marketable securities of $5.8 billion, and purchases of property, plant and equipment of $192 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash flows provided by investing activities were relatively consistent in 2025 compared to 2024, primarily due to a decrease in proceeds from sale of marketable securities of $1.6 billion, which was partially offset by a decrease of $859 million in purchases of property, plant, and equipment, and a $761 million decrease in purchases of marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our primary financing activities consist of issuance of common stock related to our equity plans, repurchases of common stock, borrowings under our credit facility, and finance leases. </span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities in 2025 was $593 million, consisting of $578 million of net proceeds from our credit facility and net proceeds from the issuance of common stock in connection with the exercise of stock options and employee stock purchases under our equity plans of $35 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities increased by $537 million, or 959%, in 2025 compared to 2024, mainly due to the net proceeds from our credit facility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operation and funding requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of funding as of December 31, 2025 consisted of cash and cash equivalents, investments, and cash we may generate from operations. We reported a net loss of $2.8 billion, $3.6 billion and $4.7 billion for the years ended December 31, 2025, 2024 and 2023, respectively. In contrast, we generated net income of $8.4 billion and $12.2 billion for the years ended December 31, 2022 and 2021, respectively, following the authorization of our first commercial product in December 2020. From our inception to the end of 2020, we incurred significant losses from operations due to our significant research and development expenses. We have retained earnings of $7.2 billion as of December 31, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have significant future capital requirements including expected operating expenses to conduct research and development activities, operate our organization, and meet capital expenditure needs. We anticipate maintaining substantial expenses across all areas of our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. This also extends to our manufacturing costs, including our arrangements with our manufacturers and suppliers. Our ongoing work on our intismeran autogene, norovirus, and flu+COVID combination vaccine candidates, development of any new COVID vaccines against variants of SARS-CoV-2, late-stage clinical development, investments in digital capabilities and artificial intelligence technologies, and buildout of global commercial, regulatory, sales and marketing infrastructure and manufacturing facilities will require significant cash outflows in future periods, most of which may not be reimbursed or otherwise paid for by our collaborators or alliances. We may also incur additional costs related to postmarketing commitments, though the timing and scope of such commitments remain uncertain. In addition, we have substantial facility, lease and purchase obligations. We have also entered into various collaboration and licensing agreements, as well as a research and development funding arrangement with a third party. These arrangements collectively encompass the funding of specific research and development activities, with the distinction that under the research and development funding arrangements, we receive funding. However, for all these arrangements, we may be obligated to make potential future milestone and royalty payments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we entered into a Credit Agreement providing for a term loan facility with aggregate commitments of $1.5 billion. As of December 31, 2025, we had drawn $600 million under the initial term loan. The Credit Agreement also provides for $900 million of delayed draw term loan commitments, consisting of $400 million available, subject to applicable conditions, through November 2027 and $500 million available, subject to applicable conditions and specified regulatory approval milestones, through November 2028. Borrowings under the Credit Agreement bear interest at a variable rate based on Term SOFR or a base rate, at our option, plus an applicable margin, with interest payable periodically and the principal amount due in full at maturity in November 2030. The Credit Agreement includes customary affirmative and negative covenants, with which we were in compliance as of December 31, 2025. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of December 31, 2025, together with cash expected to be generated from product sales and available borrowings under our credit facility, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months from the issuance of the financial statements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">included in this Annual Report on Form 10-K. We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors, which may adversely affect our business. For example, we experienced a decline in customer demand for our COVID vaccine in 2023 and 2024, and this trend has continued into 2025 as the market transitions to a more competitive and commercially driven environment. We foresee that our commitment to investing in our business for future product launches may lead to continued negative cash flows from operations in upcoming periods. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. </span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contractual obligations and commitments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December 31, 2025, and the effects that such obligations are expected to have on our liquidity and cash flows in future periods (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less&#160;than&#160;1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">year</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;-&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;-&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">More&#160;than&#160;5</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financing leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual cash obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The amounts represent non-cancelable fixed payment obligations related to purchases of raw materials, contract manufacturing services, research and development and other goods or services in the normal course of business. As of December 31, 2025, $5 million of the purchase commitments related to raw materials was recorded as an accrued liability for loss on future firm purchase commitments and is included in the purchase obligations line above.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">In November 2025, we entered into the Credit Agreement providing for a senior secured term loan facility with aggregate commitments of $1.5 billion, consisting of a $600 million initial term loan and $900 million of delayed draw term loan commitments. As of December 31, 2025, the $600 million initial term loan was outstanding and matures on November 24, 2030. Borrowings under the Credit Agreement bear interest at a variable rate. Interest amounts preset in the table are based on the applicable interest rate in effect as of December 31, 2025. The principal amount of $600 million is due in full at maturity, and no principal payments are required prior to that date. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with certain vendors for various services, including services related to clinical operations and support and contract manufacturing, which we are not contractually able to terminate for convenience. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly to reimburse them for their unrecoverable outlays incurred prior to cancellation. The exact amounts of such obligations are dependent on the timing of termination, and the exact terms of the relevant agreement and cannot be reasonably estimated. At December 31, 2025, we had cancelable open purchase orders of approximately $1.8 billion, reflecting amounts associated with our significant vendor arrangements, under such agreements for our clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2025, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally allow us the option to cancel, reschedule, and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. It is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we did not have any off-balance sheet arrangements, other than those obligations and commitments disclosed herein, that were material or reasonably likely to become material to our financial condition or results of operations. </span></div><div><span><br/></span></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and 2024, we had cash, cash equivalents, restricted cash, and investments in marketable securities of $8.1 billion and $9.5 billion, respectively. Our investment portfolio comprises money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper), which are classified as available-for-sale securities. Our primary investment objectives are the preservation of capital and the maintenance of liquidity, and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by one percentage point from levels at December 31, 2025, the net fair value of our marketable securities would decrease by approximately $47&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we entered into a variable-rate Credit Agreement providing for borrowings of up to $1.5 billion, under which outstanding amounts bear interest at rates based on Term SOFR plus a margin of 5.50% or a base rate plus a margin of 4.50%, at our option. As a result, our interest expense is exposed to changes in market interest rates. As of December 31, 2025, we had $600&#160;million outstanding under this facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. As a result, we are exposed to risks arising from changes in foreign currency exchange rates driven by both our business operations and economic conditions. For the year ended December 31, 2025, approximately 27% of our revenue was denominated in foreign currencies, although our revenue generating activities and operations continued to be primarily denominated in U.S. dollars. Our foreign currency revenue exposure in 2025 was primarily associated with the Canadian dollar, Euro, Korean won, and Mexican peso markets.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As our business evolves, we have transitioned to receiving payments in local currencies rather than U.S. dollars. In addition, during 2025 we established and expanded manufacturing operations in the United Kingdom, Canada and Australia, where we also transact in foreign currencies. These developments are expected to result in higher levels of foreign currency denominated revenues and expenses on an annualized basis in the future, which may increase our exposure to fluctuations in foreign currency exchange rates and could impact our results of operations and cash flows. To manage this exposure, we have focused on balance sheet hedging activities as part of our strategy to address foreign currency fluctuations. While cash flow hedging programs are in place, there were no foreign currency cash flow hedging activities during 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, receivables, payables and lease liabilities in the Australian dollar, British pound, Canadian dollar, and Euro that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as prepaid expenses and other current assets or other current liabilities in our consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other income (expense), net, in our consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other income (expense), net, in our consolidated statements of operations. As of December 31, 2025, our outstanding balance sheet hedging derivatives, carried at fair value, had maturities of less than three months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into these foreign exchange contracts to hedge our monetary assets and liabilities denominated in foreign currency in the normal course of business and accordingly, they are not speculative in nature. We believe the counterparties to our foreign currency forward contracts are creditworthy multinational commercial banks. While we believe the risk of counterparty nonperformance is not material, a sustained decline in the financial stability of financial institutions as a result of disruption in the financial markets could affect our ability to secure creditworthy counterparties for our foreign currency hedging programs.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our efforts to mitigate some foreign currency exchange risks, there can be no assurance that our hedging activities will adequately protect us against the risks associated with foreign currency fluctuations. As of December 31, 2025, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in balance sheet hedging of approximately $58&#160;million. We expect that any increase or decrease in the fair value of the portfolio would be substantially offset by increases or decreases in the underlying exposures being hedged.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_124"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_127">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_127">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_130">Consolidated Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_130">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_130"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_130">24</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_130">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">Consolidated Statements of Operations for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_133">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">, and 2</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_136">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_139">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">Consolidated Statements of Cash Flows for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_142">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_145">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_145">108</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_127"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Moderna, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Moderna, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;20, 2026 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:12.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provisions for returns on product sales</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company&#8217;s net product sales were $1.8 billion. As explained in Note 2 of the consolidated financial statements, revenue from product sales includes estimates of variable consideration for which provisions are established, including provisions for product sales returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s measurement of provisions for returns on product sales under its contracts with customers was especially challenging because (1) the estimate relies on management&#8217;s assumptions regarding inventory remaining in the distribution channel as of the balance sheet date that may be subject to return in future periods, as well as projected market demand, and (2) the Company has limited historical returns on which to base its assumptions. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company&#8217;s process to determine provisions for returns on product sales. For example, we tested controls over management&#8217;s review of the completeness and accuracy of the data used in the process and the assumptions about the amount of inventory in the distribution channel that could be subject to return in future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company&#8217;s provisions for returns on product sales, our audit procedures included, among other procedures, testing the accuracy and completeness of the underlying data used in the calculations and evaluating the assumptions applied by management in estimating the provisions. To test management&#8217;s assumptions, we inspected agreements with significant customers to validate the rights of return, made inquiries of members of the commercial function regarding any changes to the terms and conditions of commercial contracts, and assessed the historical accuracy of management&#8217;s estimates. We also examined credit memos issued during and after year end to identify any unusual items or trends inconsistent with the Company&#8217;s analysis of product returns and performed revenue cutoff testing at period end to evaluate whether any unusual trends should have been considered in the Company&#8217;s analysis of product returns.  In addition, we reviewed inventory on hand-reporting from significant customers around the balance sheet date and subsequent to the balance sheet date and inspected vaccination data from third-party sources after the balance sheet date. We also performed sensitivity analyses on the Company&#8217;s return rate to assess the impact of changes in assumptions.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-51">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-52">Boston, Massachusetts</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;20, 2026</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_130"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-53">2,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-54">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-55">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-56">5,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-57">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-58">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="f-59">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="f-60">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-61">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-62">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-63">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-64">8,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-65">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-66">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-67">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-68">2,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-69">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-70">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-71">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-72">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-73">12,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-74">14,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-75">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-76">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-77">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-78">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-79">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-80">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-81">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-82">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-83">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-84">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-85">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-86">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-87">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-88">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-89">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-90">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-91">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-93">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-94">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-95">3,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-96">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_193">Note </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_193">12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-97"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-98"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-99"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-100">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-102">162</ix:nonFraction></ix:nonFraction>&#160;shares authorized as of December 31, 2025 and 2024; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-106">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2025 and 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-109"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-110">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-112">1,600</ix:nonFraction></ix:nonFraction> shares authorized as of December 31, 2025 and 2024; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-114">394</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-116">386</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2025 and 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="f-117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-119">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-120">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-121">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-122">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-123">7,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-124">10,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-125">8,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-126">10,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-127">12,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-128">14,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_133"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-129">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-130">3,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-131">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-132">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-133">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-134">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-135">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-136">3,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-137">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-138">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-139">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-140">4,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-141">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-142">4,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-143">4,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-144">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-145">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-146">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-147">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-148">7,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-149">11,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-150">3,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-151">3,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-152">4,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-153">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-154">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-155">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-156">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-157">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-158">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-159">2,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-160">3,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-161">3,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-162">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-163">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-164">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-165">2,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-166">3,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-167">4,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-168"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-169">7.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-170"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">9.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-173">12.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of loss per share:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-174"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-175">389</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-176"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-177">384</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-178"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-179">382</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_136"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"/><td style="width:61.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-180">2,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-181">3,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-182">4,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax:&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-183">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-184">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-185">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: net realized (gains) losses on available-for-sale securities reclassified in net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-186">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-187">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-188">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net increase from available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-189">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-190">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-191">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses on derivative instruments reclassified in net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-194">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net increase from derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:fixed-zero" scale="6" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:fixed-zero" scale="6" id="f-196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="f-197">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-198">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-199">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement obligation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" scale="6" id="f-201">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" scale="6" id="f-202">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" scale="6" id="f-203">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-204">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-205">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-206">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-207">2,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-208">3,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-209">4,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_139"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.095%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-210">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-212">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-213">370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-214">18,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-215">19,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="6" id="f-216">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-217">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-218">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-219">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-220">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-221">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-222">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-223">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-224">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-225">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock, including excise tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-226">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-227">1,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-228">1,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-229">4,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-230">4,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-231">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-233">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-234">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-235">13,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-236">13,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.095%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-237">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-239">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-240">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-241">13,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-242">13,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="6" id="f-243">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-244">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-245">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-246">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-247">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-248">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-249">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-250">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-251">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-252">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-253">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-254">3,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-255">3,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-256">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-258">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-259">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-260">10,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-261">10,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.886%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-262">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-264">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-265">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-266">10,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-267">10,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="6" id="f-268">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-269">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-270">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-271">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax payments related to net share settlements on equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-272">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-273">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-274">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-275">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-276">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-277">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-278">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-279">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-280">2,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-281">2,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-282">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-284">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-285">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-286">7,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-287">8,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.715%"><tr><td style="width:1.0%"/><td style="width:60.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-288">2,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-289">3,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-290">4,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-291">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-292">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-293">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="f-294">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="f-295">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherDepreciationAndAmortization" scale="6" id="f-296">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amortization/accretion of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="f-297">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="f-298">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="f-299">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Loss on equity investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="f-300">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="f-301">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="f-302">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-303">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-304">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-305">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-306">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-307">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-308">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-309">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-310">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="f-311">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-312">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-313">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-314">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="f-315">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="f-316">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="f-317">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-318">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-319">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-320">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-321">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-322">385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-323">340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-324">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-325">439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-326">2,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-327">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-328">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-329">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-330">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-331">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-332">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-333">1,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-334">3,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-335">3,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-336">5,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-337">6,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-338">3,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-339">5,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-340">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-341">5,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-342">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-343">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-344">3,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-345">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-346">1,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-347">707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-350">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-351">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Investment in convertible notes and equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="6" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="6" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="6" id="f-356">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-357">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-358">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-359">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="f-360">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Payment of credit facility issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="f-363">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock through equity plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="f-366">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="f-367">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="f-368">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax payments related to net share settlements on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-369">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-371">1,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments" scale="6" id="f-372">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments" scale="6" id="f-373">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments" scale="6" id="f-374">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-375">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-376">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-377">1,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effect of changes in exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-378">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-381">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-382">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-383">289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-384">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-385">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-386">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-387">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-388">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-389">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid (received) for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-390">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-391">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-392">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-393">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-394">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-395">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-396">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-397">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-398">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_148"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-399" continuedAt="f-399-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-399-1">Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We currently have <ix:nonFraction unitRef="product" contextRef="c-1" decimals="INF" name="mrna:NumberOfCommercialProducts" format="ixt-sec:numwordsen" scale="0" id="f-400">three</ix:nonFraction> commercial products&#8212;Spikevax&#174; and mNEXSPIKE&#174;, our COVID vaccines, and mRESVIA&#174;, our vaccine against respiratory syncytial virus (RSV). Additionally, we also have a diverse development pipeline of <ix:nonFraction unitRef="candidate" contextRef="c-4" decimals="INF" name="mrna:NumberOfDevelopmentCandidates" scale="0" id="f-401">25</ix:nonFraction> development candidates across our <ix:nonFraction unitRef="developmentprogram" contextRef="c-4" decimals="INF" name="mrna:NumberOfDevelopmentPrograms" scale="0" id="f-402">35</ix:nonFraction> development programs currently in clinical studies.</ix:continuation> </span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_151"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-403" continuedAt="f-403-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-404" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-405" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-406" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-407" escape="true">The Company operates as a single operating and reportable segment, reflecting the integrated nature of our business focused on the research, development, and commercialization of mRNA-based medicines. Our Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), responsible for assessing the Company's performance and making resource allocation decisions. The CODM evaluates financial information on a consolidated basis, focusing on key metrics such as total revenue, operating expenses, and net income or loss, which is our reported measure of segment profit or loss. The CODM allocates resources based on the Company's available cash resources, forecasted cash flow, and expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities. Resource allocation decisions are informed by budgeted and forecasted expense information, along with actual expenses incurred to date. Disaggregated profit or loss information at the program or functional level is not regularly provided to or relied upon by the CODM, as our integrated operating model emphasizes shared resources and centralized decision-making. The interdependent nature of our research, development, and commercialization activities, supported by common infrastructure such as our mRNA platform, makes further disaggregation of expenses less meaningful for assessing performance. Additionally, there are no segment managers accountable for operations, operating results, and planning for levels or components below the consolidated unit level.</ix:nonNumeric> </span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-403-1" continuedAt="f-403-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-408" continuedAt="f-408-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net <span id="ice4d497822074fb680bb6adb64870e63_40370"></span>Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations.  In the U.S., our COVID vaccine and RSV vaccine are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net product sales when control of the product transfers to the customer, typically upon delivery. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="f-409">Payment terms generally range from 30 to 60 days</ix:nonNumeric>, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, government rebates, and other related deductions. These provisions are recorded based on contractual terms, our estimate of returns for product sold during the period, and other relevant considerations, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wholesaler chargebacks, discounts and fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our vaccines are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, projected market demand, and our historical experience with returns. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates and other fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets. In 2024, we began recognizing Medicare rebates associated with our RSV product. The estimation of Medicare rebates requires judgment and is based on historical utilization trends, and the mix of customers and payers. The estimated liability for unpaid or unbilled rebates is presented as accrued liabilities on our consolidated balance sheets. For 2024 and 2025, the product sales subject to Medicare rebates were immaterial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control, such as the limited historical data, constrained third-party information, and evolving market dynamics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now have two years of data on our product returns, this remains limited and subject to significant variability given current market conditions. We will continue to refine our projections as additional information becomes available. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="padding-right:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-403-2" continuedAt="f-403-3"><ix:continuation id="f-408-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue consists primarily of grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing and Royalty Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License revenue is recognized when the license is granted to the licensee, provided no significant performance obligations remain. Royalty revenue is recognized based on sales by licensees when the underlying sales occur, in accordance with the terms of the licensing agreement and when collectibility is reasonably assured.</span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stand-Ready Manufacturing Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into long-term strategic agreements with government entities to establish domestic mRNA manufacturing capabilities and support pandemic readiness. Under these agreements, we are required to build and maintain manufacturing facilities and to supply vaccines in accordance with minimum spend commitments or annual demand forecasts established by the respective governments. A portion of the total consideration under each agreement is allocated to a stand-ready obligation to maintain manufacturing readiness and is recognized as other revenue on a straight-line basis over the contractual period. The remaining consideration is related to our obligation to supply vaccines and will be recognized as product sales when control of the vaccines transfers upon delivery.</span></div></ix:continuation><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-410" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-403-3" continuedAt="f-403-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-412" continuedAt="f-412-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-411" continuedAt="f-411-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-413">2,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-414">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-415">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-416">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-417">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-418">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-419">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-420">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-421">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-422">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-423">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-424">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric><div><ix:continuation id="f-412-1" continuedAt="f-412-2"><ix:continuation id="f-411-1" continuedAt="f-411-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-412-2"><ix:continuation id="f-411-2">Included in other non-current assets in the consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-425" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific-identification method, and are included in other income (expense), net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument&#8217;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Available-for-sale securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other income (expense), net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other income (expense), net, in our consolidated statements of operations.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-426" continuedAt="f-426-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (see our &#8220;Revenue Recognition&#8221; policy within </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_151">Note 2</a></span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-426-1"> for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors.</ix:continuation> The allowance for doubtful accounts was <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-427"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-428">immaterial</ix:nonFraction></ix:nonFraction> at December 31, 2025 and 2024. Additionally, bad debt expenses were <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="f-429"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="f-430"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="f-431">immaterial</ix:nonFraction></ix:nonFraction></ix:nonFraction> for the years ended December 31, 2025, 2024 and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-432" continuedAt="f-432-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution.  </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-403-4" continuedAt="f-403-5"><ix:continuation id="f-432-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable, net related to our net product sales and other revenue. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="f-433" escape="true">Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, stand-ready manufacturing revenue from international government entities, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances.</ix:nonNumeric> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-434" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:50.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.933%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;<br/>Accounts&#160;Receivable<br/>December&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">FFF Enterprises</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-44" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-435">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-45" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-436">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Public Works and Government Services Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-46" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-437">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-47" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-438">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-48" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-439">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom Health Security Agency</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-49" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-440">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-50" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-441">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mexico Medistik</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-442">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Boryung Biopharma Korea</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-52" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-443">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan Food and Drug Administration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-444">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ministry of Health, Labor, and Welfare of Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-54" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-445">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-446" continuedAt="f-446-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div></ix:nonNumeric><div><span><br/></span></div><div><ix:continuation id="f-446-1" continuedAt="f-446-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable debt securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_169">Note&#160;6</a></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-446-2">). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk.</ix:continuation> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-403-5" continuedAt="f-403-6"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-447" continuedAt="f-447-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value, with cost determined principally using first-in, first-out method. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-launch Inventory </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-447-1">Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2025 and 2024, we did not have any capitalized pre-launch inventory on our consolidated balance sheets.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-448" continuedAt="f-448-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-449" continuedAt="f-449-1" escape="true">The estimated useful lives of property, plant and equipment are described below:</ix:nonNumeric></span></div><ix:continuation id="f-449-1" continuedAt="f-449-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:48.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and permanent land improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Limited-life land improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Determined on a project-by-project basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-450">40</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-56" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-451">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c-57" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-452">12</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-58" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-453">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-59" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-454">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-60" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-455">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-448-1">Construction in progress includes direct costs related to the construction of various property, plant and equipment, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-456" continuedAt="f-456-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-456-1">Finite-lived intangible assets primarily consist of acquired intellectual property and regulatory approval and commercial sales milestone payments. These assets are recorded at cost, net of accumulated amortization, and amortized on a straight-line basis over their estimated useful lives.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-403-6" continuedAt="f-403-7"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-457" escape="true">We evaluate our long-lived assets, which consist of property, plant and equipment, finite-lived intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.</ix:nonNumeric> Impairment expenses for the years ended December 31, 2025, 2024 and 2023 were <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-458"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-459"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-460">immaterial</ix:nonFraction></ix:nonFraction></ix:nonFraction>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-461" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are initially measured as the lease liability plus direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-462" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaborator are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). See our "Revenue Recognition" policy within </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_151">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaborator, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Funding Arrangements </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mrna:ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" id="f-463" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into research and development funding arrangements to support a targeted programs, under which a third party has committed to fund us up to a specified amount. Contingent upon the regulatory approval of the program, we are obligated to pay certain milestones and royalties as outlined in the respective agreements. We account for funding received under research and development arrangements as a reduction to expenses when substantive financial risk is transferred to the funding party. These arrangements are accounted for as an obligation to conduct research and development activities. The funding is recognized proportionally as the related costs are incurred, using an input method. Contingent payments, such as milestones or royalties, will be recognized separately upon achievement of the related conditions.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-403-7" continuedAt="f-403-8"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-464" continuedAt="f-464-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-464-1">Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-465" escape="true">Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations</ix:nonNumeric>. Advertising expenses were </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdvertisingExpense" scale="6" id="f-466">133</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in 2025, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AdvertisingExpense" scale="6" id="f-467">146</ix:nonFraction>&#160;million in 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AdvertisingExpense" scale="6" id="f-468">204</ix:nonFraction> million in 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-469" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation&#8212;Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2025, we estimated the expected term of our stock options using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. During 2025, we used historical exercise data in estimating the expected term of stock options, utilizing a methodology that combines historical settlement data with a hypothetical settlement pattern for outstanding options, based on estimated time to arrival at-the-money and adjusted for employee departure rates. The change in methodology used during 2025 did not have a material impact on stock-based compensation and our financial statements. However, during the fourth quarter of 2025, in connection with our stock option exchange program (see </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_199">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), which resulted in changes to our stock option population, we determined that we no longer have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, as such data is no longer indicative of future exercise patterns. Accordingly, beginning in 2026, we will estimate the expected term of stock options using the simplified method. We will continue to apply this process until a sufficient amount of historical information regarding the expected term becomes available and we believe that historical experience is relevant to our expectations for current grants. The expected volatility is based on our stock price volatility and incorporates both historical volatility of our stock price and implied volatility derived from the price of exchange traded options on our stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-470" continuedAt="f-470-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-403-8" continuedAt="f-403-9"><ix:continuation id="f-470-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-471" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted stock units, performance stock units, stock options, and shares under the employee stock purchase plan that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-472" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments, derivatives designated as hedging instruments, and foreign currency translation, as well as, pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-473" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive loss for the years ended December 31, 2025 and 2024 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.071%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gains on Available-for-Sale Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Postretirement Obligation Adjustments</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses (gains) on Foreign Currency Translation </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-474">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-475">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-477">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-478">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-479">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-480">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-481">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-482">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-483">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-484">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-485">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-486">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-487">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-488">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-489">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-490">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-491">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-492">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-493">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-494" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-495" continuedAt="f-495-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early adoption is permitted. We adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_205">Note 14</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Income Taxes.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-495-1"><ix:continuation id="f-403-9"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires entities to disclose, on an annual and interim basis, disaggregated information in the footnotes related to certain expense categories included in income statement line items. Specifically, entities are expected to provide tabular disclosures for prescribed categories such as inventory purchases, employee compensation, depreciation, and intangible asset amortization for each relevant expense caption. The standard also requires disclosure of total selling expenses and a definition of those expenses in annual filings. Any remaining amounts not quantitatively disclosed are expected to be described qualitatively. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption permitted, and the standard may be applied on a prospective or retrospective basis. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU No. 2025-06, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU makes targeted amendments to the accounting for and disclosure of software costs under ASC 350-40. The amendments modernize the guidance to reflect current software development practices, including nonlinear development approaches, and remove references to &#8220;development stages.&#8221; Under the ASU, the following two criteria must be met for entities to begin capitalizing software costs: (1) management, with the relevant authority, implicitly or explicitly authorizes and commits to funding a computer software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition threshold&#8221;). The ASU clarifies that this threshold would not be met when there is &#8220;significant uncertainty associated with the development activities of the software (referred to as &#8216;significant development uncertainty&#8217;).&#8221; The ASU is effective for all entities for annual reporting periods beginning after December 15, 2027, and for interim reporting periods within those fiscal years. Early adoption is permitted, and entities may apply the amendments prospectively, retrospectively, or using a modified prospective transition approach. We are currently evaluating the impact that this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU No. 2025-07,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration From a Customer in a Revenue Contract</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU expands the scope exceptions in the derivatives guidance to exclude certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties to the contract, including the occurrence or nonoccurrence of an event specific to those operations or activities. The ASU also clarifies that share-based noncash consideration received from a customer in exchange for goods or services should be accounted for as noncash consideration under ASC 606 unless and until the entity&#8217;s right to receive or retain such consideration becomes unconditional. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact that adoption of this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU No. 2025-10,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU establishes guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The guidance defines a government grant as a transfer of a monetary asset or a tangible nonmonetary asset from a government to a business entity other than in an exchange transaction and excludes transactions within the scope of other U.S. GAAP. Under the ASU, government grants are classified as either grants related to an asset or grants related to income, and recognition is permitted only when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The ASU permits alternative presentation approaches depending on the nature of the grant and requires disclosures regarding the nature of the grant, affected financial statement line items, and significant terms and conditions. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, including interim periods within those annual reporting periods. Early adoption is permitted, and the standard may be applied on a modified prospective, modified retrospective, or full retrospective basis. We are currently evaluating the impact of this new accounting standard and do not expect its adoption to have a material impact on our consolidated financial statements and disclosures.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_154"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-498" continuedAt="f-498-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Net Product Sales</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-499" continuedAt="f-499-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-500">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-501">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-502">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-503">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-504">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-505">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-506">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-507">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-508">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-509">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-510">3,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-511">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-512" continuedAt="f-512-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-513">1,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-514">3,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-515">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-516">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-517">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-519">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-520">3,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-521">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2025, we have <ix:nonFraction unitRef="product" contextRef="c-6" decimals="INF" name="mrna:NumberOfCommercialProducts" format="ixt-sec:numwordsen" scale="0" id="f-522">three</ix:nonFraction> commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-498-1" continuedAt="f-498-2"><ix:continuation id="f-512-1" continuedAt="f-512-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross" format="ixt:num-dot-decimal" scale="6" id="f-523">3,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross" format="ixt:num-dot-decimal" scale="6" id="f-524">4,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross" format="ixt:num-dot-decimal" scale="6" id="f-525">8,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" format="ixt:num-dot-decimal" scale="6" id="f-526">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" format="ixt:num-dot-decimal" scale="6" id="f-527">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" scale="6" id="f-528">976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" scale="6" id="f-529">449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" scale="6" id="f-530">267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" scale="6" id="f-531">556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvision" format="ixt:num-dot-decimal" scale="6" id="f-532">1,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvision" format="ixt:num-dot-decimal" scale="6" id="f-533">1,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvision" format="ixt:num-dot-decimal" scale="6" id="f-534">1,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-535">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-536">3,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-537">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">_______</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Includes an adjustment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mrna:ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" scale="6" id="f-538">216</ix:nonFraction>&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div></ix:continuation><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-539" continuedAt="f-539-1" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Returns, rebates and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="f-540">370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" scale="6" id="f-541">436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in prior periods</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionsMadeInPriorYears" scale="6" id="f-542">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in current period </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityProvisionRelatedToSales" scale="6" id="f-543">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" scale="6" id="f-544">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="f-545">509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_157"></div><ix:continuation id="f-498-2" continuedAt="f-498-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. Other Revenue</span></div><div><span><br/></span></div><ix:continuation id="f-512-2" continuedAt="f-512-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-546">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-547">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-548">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_163">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-549">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-550">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-551">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-552">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-553">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-555">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-558">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-559">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-560">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="f-561">483</ix:nonFraction>&#160;million to accelerate development of our original COVID vaccine, mRNA-1273. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of our original COVID vaccine, including a <ix:nonFraction unitRef="participant" contextRef="c-106" decimals="INF" name="mrna:NumberOfParticipants" format="ixt:num-dot-decimal" scale="0" id="f-562">30,000</ix:nonFraction> participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-8" name="mrna:RevenueFromGrantsMaximumAward" scale="9" id="f-563">1.8</ix:nonFraction>&#160;billion. All contract options have been exercised. The BARDA contract concluded on June 15, 2025, upon completion of all contractual deliverables. We accrued and recognized revenue through that date for eligible costs incurred in accordance with the agreement. As of December 31, 2025, the remaining available funding, net of revenue earned, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="f-564">62</ix:nonFraction>&#160;million. While this funding remains available, we do not expect to recognize material additional revenue, as the contract has concluded and all obligations have been fulfilled. Final billing and closeout activities are ongoing and may result in immaterial adjustments to the recognized revenue amount.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-498-3" continuedAt="f-498-4"><ix:continuation id="f-512-3" continuedAt="f-512-4"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-565">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-566">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-567">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-568">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-569">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-570">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-571">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-572">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-573">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2025, 2024 and 2023, we had collaboration agreements with Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and others. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_163">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to for further description of these collaboration agreements.</span></div><div><span><br/></span></div><ix:continuation id="f-512-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-574">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-575">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-576">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-578">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-579">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-580">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-581">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-582">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Royalty Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we entered a non-exclusive out-licensing agreement with a pharmaceutical company based in Japan for mRNA COVID-related intellectual property for the territory of Japan. Under the terms of the agreement, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-583">50</ix:nonFraction>&#160;million, which included a $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-584">20</ix:nonFraction>&#160;million prepayment creditable against future royalties. Additionally, we are entitled to receive low double-digit royalties on the net sales of the company&#8217;s COVID product. Upon execution of the agreement, we recognized $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-585">30</ix:nonFraction>&#160;million of the upfront payment as other revenue in our consolidated statements of operations. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-586">20</ix:nonFraction>&#160;million was recorded as deferred revenue in our consolidated balance sheets and recognized as royalty revenue as the underlying sales occurred. In accordance with the terms of the agreement, the $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-587">20</ix:nonFraction>&#160;million was fully recognized by the end of the first quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stand-Ready Manufacturing Revenue  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stand-ready manufacturing revenue relates to amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacities and support pandemic readiness.</span></div></ix:continuation><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_163"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="f-588" continuedAt="f-588-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. Collaboration Agreements and Research and Development Funding Arrangement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck &#8211; Personalized mRNA Cancer Vaccines (Intismeran Autogene)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a Collaboration and License Agreement, which was subsequently amended in 2018, with Merck for the development and commercialization of personalized mRNA cancer vaccines (PCV), also known as Individualized Neoantigen Therapy (INT), which has been assigned the generic name intismeran autogene. This agreement was subsequently amended in 2018. Under the PCV Agreement, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-589">200</ix:nonFraction> million from Merck and we were responsible for designing and researching intismeran, providing manufacturing capacity and manufacturing intismeran and conducting Phase 1 and Phase 2 clinical trials for intismeran, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. We concluded that the collaboration arrangement was governed by the revenue recognition standard ASC 606. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option for intismeran, including mRNA-4157, under the terms of the agreement and in October 2022 paid us an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="mrna:ProceedsFromOptionExerciseFee" scale="6" id="f-590">250</ix:nonFraction>&#160;million. Following this exercise, the Merck Participation Term commenced, under which we and Merck collaborate on development and potential commercialization of PCV, with costs and any profits or losses generally shared equally on a worldwide basis, subject to certain exceptions as outlined in the agreement. During the development phase, we are primarily responsible for process development and the manufacture of intismeran materials, while Merck generally leads clinical trials. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the years ended December 31, 2025, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses, net of Merck's reimbursements, of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-591">407</ix:nonFraction>&#160;million, </span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-588-1" continuedAt="f-588-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-592">390</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-593">184</ix:nonFraction>&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> respectively, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related to the PCV collaboration under the Merck Participation Term. Additionally, the net cost recovery for capital expenditures during the same periods were $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="mrna:RecoveryOfCostsCapitalExpenditures" scale="6" id="f-594">24</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="mrna:RecoveryOfCostsCapitalExpenditures" scale="6" id="f-595">109</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="mrna:RecoveryOfCostsCapitalExpenditures" scale="6" id="f-596">102</ix:nonFraction>&#160;million, respectively, which were applied to reduce the capitalized cost of the assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development and Commercialization Funding Arrangement with Blackstone Life Sciences (Blackstone)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we entered into a development and commercialization funding arrangement with Blackstone, under which Blackstone has committed to providing up to $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="mrna:CollaborativeArrangementFundingAmount" scale="6" id="f-597">750</ix:nonFraction>&#160;million in funding to us. This funding supports the development of our investigational mRNA-based influenza vaccine. Contingent upon regulatory approval in the U.S. and only if the approval is dependent on data from the funded activities, Blackstone will be entitled to receive low single-digit percentage royalties and up to $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-598">750</ix:nonFraction>&#160;million in sales milestone payments. These payments are based on net sales of our future influenza and combination vaccines, with sales milestone payments contingent upon achieving specified cumulative net sales targets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Given the substantive transfer of financial risk to Blackstone, we account for this arrangement as an obligation to conduct research and development activities. The funding is recognized as a reduction to the expenses of our mRNA-based influenza program. This reduction is recognized proportionally as the related costs are incurred, based on an input method. For the year ended December 31, 2025 and 2024, we recorded research and development expense reductions of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-599">340</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-600">267</ix:nonFraction>&#160;million, respectively. As of December 31, 2025 and 2024, we had a research and development funding liability of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="mrna:ResearchAndDevelopmentLiabilityCurrent" scale="6" id="f-601">43</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="mrna:ResearchAndDevelopmentLiabilityCurrent" scale="6" id="f-602">58</ix:nonFraction>&#160;million, respectively, related to the advance funding received from Blackstone.</span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vertex &#8211; Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period, leveraging our platform technology and mRNA delivery expertise along with Vertex&#8217;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. This collaboration arrangement is accounted for under ASC 606 and currently ongoing. </span></div><div style="padding-right:11.25pt"><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immatics &#8211; Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into a strategic collaboration with Immatics to jointly discover and develop T cell-redirecting cancer immunotherapies. Upon effectiveness of the agreement in October 2023, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-603">120</ix:nonFraction>&#160;million, recognized as research and development expense. Immatics is also eligible for research funding, milestone payments, tiered royalties on global net sales of TCER</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> products and certain vaccine products that are commercialized under the agreement. Additionally, Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-588-2">In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_169"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-604" continuedAt="f-604-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. Financial Instruments and Fair Value Measurements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-605" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, and available-for-sale securities by significant investment category at December 31, 2025 and 2024 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-606">2,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-609">2,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-610">2,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-613">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-616">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-618">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-619">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-620">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-623">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-625">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-627">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-628">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-629">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-630">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-632">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-633">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-634">2,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-635">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-636">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-637">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-639">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-640">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-641">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-644">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-646">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-647">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-648">8,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-649">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-650">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-651">8,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-652">2,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-653">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-654">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-655">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-658">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-659">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-662">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-665">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-667">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-669">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-672">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-674">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-676">3,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-677">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-678">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-679">3,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-681">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-682">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-683">3,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-684">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-685">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-686">3,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-688">2,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-689">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-690">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-693">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-695">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-696">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-697">9,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-698">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-699">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-700">9,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-701">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-702">5,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-703">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-604-1" continuedAt="f-604-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-704" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2025 and 2024 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-705">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-706">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-707">2,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-708">2,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-709">5,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="f-710">5,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-711">5,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-712">5,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-713">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-714">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-715">7,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="f-716">7,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-717"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-718"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-719">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t record any impairment charges related to our available-for-sale securities during the&#160;years ended December 31, 2025, 2024, and 2023. We did <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="f-720"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="f-721">not</ix:nonFraction></ix:nonFraction> recognize any credit-related allowance to available-for-sale securities as of December 31, 2025 and 2024. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-722" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2025 and 2024 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2025:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-724">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-728">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-729">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-730">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-731">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-732">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-733">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-734">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-736">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-737">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-738">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-739">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-740">648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-742">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-744">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-746">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-747">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-748">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-749">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-750">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-751">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-752">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2024:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-754">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-756">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="f-757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-758">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-759">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-760">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-761">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-762">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-763">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-764">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-765">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-766">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-767">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-768">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-769">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-770">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-774">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-776">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-777">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-778">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-779">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-780">2,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-781">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-782">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025 and 2024, we held <ix:nonFraction unitRef="security" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-783">108</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-784">252</ix:nonFraction> available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-604-2"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-785" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and 2024 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-786">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-787">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-789">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-791">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-792">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-794">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-795">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-797">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-798">3,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-800">3,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-801">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-803">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-804">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-805">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-807">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-809">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-810">7,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-811">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-812">6,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-813">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-814">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-816">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-817">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-818">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-820">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-822">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-823">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-825">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-826">3,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-828">3,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-829">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-831">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-832">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-834">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-835">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-836">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-838">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-840">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-841">9,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-842">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-843">8,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-844">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-845">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-847">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and 2024, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2025, 2024 and 2023, we recognized net losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-848">8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-849">52</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-850">35</ix:nonFraction>&#160;million, respectively, on equity investments from changes in fair value of the securities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our term loan using Level 2 inputs. The fair value of the term loan approximates its carrying value as of December 31, 2025, because the instrument bears interest at a variable rate that reflects current market rates. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_2066">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_175"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-851" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. Inventory</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-852" continuedAt="f-852-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, as of December 31, 2025 and 2024 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-853">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-854">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-855">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-856">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-857">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-858">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="f-859">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="f-860">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="f-861">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="f-862">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-852-1" continuedAt="f-852-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-852-2">Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets.</ix:continuation> </span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the years ended December 31, 2025, 2024, and 2023, inventory write-downs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InventoryWriteDown" scale="6" id="f-863">291</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InventoryWriteDown" scale="6" id="f-864">495</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:InventoryWriteDown" scale="9" id="f-865">2.2</ix:nonFraction>&#160;billion, respectively. For the years ended December 31, 2025, 2024, and 2023, losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" scale="6" id="f-866">24</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" scale="6" id="f-867">60</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" scale="6" id="f-868">141</ix:nonFraction>&#160;million, respectively. Inventory write-downs were mainly related to inventory in excess of expected demand and shelf-life expiration. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These charges in 2025 and 2024 were primarily driven by the continued operation of the COVID vaccine market as a seasonal market, along with a decline in overall customer demand and excess inventory. Forecasting demand for COVID vaccines requires advance production planning ahead of each season, including production of multiple COVID vaccine products, which resulted in excess inventory and capacity as actual demand differed from forecasted demand. The higher charges in 2023 primarily reflect our strategic initiative to resize its manufacturing cost structure in response to the transition to an endemic seasonal COVID vaccine market. In the third quarter of 2023, we completed our long-range financial planning process, incorporating revised forecasts of vaccination rates. This resulted in the reassessment of future demand for our COVID vaccine, leading to a strategic initiative to resize our manufacturing cost structure. This initiative, launched in the same quarter, involved reassessing our inventory levels and renegotiating with our suppliers to reduce our purchase commitments related to raw materials which were not expected to be consumed before expiration. This initiative resulted in a raw materials write-down of $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:InventoryWriteDown" scale="6" id="f-869">903</ix:nonFraction>&#160;million, included in the total inventory write-down amount for the quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and December 31, 2024, the accrued liability for losses on firm future purchase commitments in our consolidated balance sheets was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:LegalContingencyFutureFirmPurchaseCommitments" scale="6" id="f-870">5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:LegalContingencyFutureFirmPurchaseCommitments" scale="6" id="f-871">60</ix:nonFraction>&#160;million, respectively. As of December 31, 2025 and December 31, 2024, we had inventory on hand of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryGross" scale="6" id="f-872">267</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryGross" scale="6" id="f-873">267</ix:nonFraction>&#160;million, respectively, inclusive of inventory for our COVID and RSV vaccines. Our raw materials and work-in-progress inventory have variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of Spikevax, our original COVID vaccine, is <span style="-sec-ix-hidden:f-874">nine</span> to <ix:nonNumeric contextRef="c-251" name="mrna:InventoryShelfLife" format="ixt-sec:durwordsen" id="f-875">twelve months</ix:nonNumeric>. mNEXSPIKE has a shelf life of <ix:nonNumeric contextRef="c-252" name="mrna:InventoryShelfLife" format="ixt-sec:durwordsen" id="f-876">twelve months</ix:nonNumeric>. The shelf life of mRESVIA, our RSV vaccine, is <ix:nonNumeric contextRef="c-253" name="mrna:InventoryShelfLife" format="ixt-sec:durwordsen" id="f-877">eighteen months</ix:nonNumeric>.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_181"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-878" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. Property, Plant and Equipment, Net</span></div><div><span><br/></span></div><ix:continuation id="f-449-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-879">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-880">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-881">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-882">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-883">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-884">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-885">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-886">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-887">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-888">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-889">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-890">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-891">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-892">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-893">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-894">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-895">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-896">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="f-897">737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="f-898">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-899">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-900">2,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the&#160;years ended December 31, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-901">211</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-902">185</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-903">617</ix:nonFraction>&#160;million, respectively.</span></div></ix:nonNumeric><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_184"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-904" continuedAt="f-904-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. Other Balance Sheet Components</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-905" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsReceivableGross" scale="6" id="f-906">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsReceivableGross" scale="6" id="f-907">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Wholesalers chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccountsReceivableChargebacksDiscountsAndFees" scale="6" id="f-908">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccountsReceivableChargebacksDiscountsAndFees" scale="6" id="f-909">340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for doubtful accounts </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-910">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="f-911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsReceivableNet" scale="6" id="f-912">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsReceivableNet" scale="6" id="f-913">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-914" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="f-915">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="f-916">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments related to manufacturing and materials</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:OtherPrepaidExpenseMaterialsAndSupplies" scale="6" id="f-917">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:OtherPrepaidExpenseMaterialsAndSupplies" scale="6" id="f-918">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-919">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-920">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="6" id="f-921">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="6" id="f-922">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income tax</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="f-923">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="f-924">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:CollaborationReceivableCurrent" scale="6" id="f-925">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:CollaborationReceivableCurrent" scale="6" id="f-926">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-927">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-928">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-929">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-930">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-931">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-932">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-904-1" continuedAt="f-904-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="f-933" continuedAt="f-933-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IncomeTaxesReceivableNoncurrent" scale="6" id="f-934">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IncomeTaxesReceivableNoncurrent" scale="6" id="f-935">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="f-936">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="f-937">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:DownpaymentsAndPrepaymentsNoncurrent" scale="6" id="f-938">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:DownpaymentsAndPrepaymentsNoncurrent" scale="6" id="f-939">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-940">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-941">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Goodwill" scale="6" id="f-942">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Goodwill" scale="6" id="f-943">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-944">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-945">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-946">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-947">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="f-948">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="f-949">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-950">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-951">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div></ix:nonNumeric><div><ix:continuation id="f-933-1" continuedAt="f-933-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-933-2">Consisted of raw materials with an anticipated consumption beyond one year.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-952" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.119%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provisions related to product sales (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_154">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="f-953">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="f-954">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-955">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-956">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="f-957">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="f-958">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="f-959">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="f-960">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="f-961">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="f-962">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccruedPropertyAndEquipmentCurrent" scale="6" id="f-963">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccruedPropertyAndEquipmentCurrent" scale="6" id="f-964">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-965">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-966">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="f-967">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="f-968">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccruedCommercial" scale="6" id="f-969">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccruedCommercial" scale="6" id="f-970">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="f-971">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="f-972">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on future firm purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:LegalContingencyFutureFirmPurchaseCommitments" scale="6" id="f-973">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:LegalContingencyFutureFirmPurchaseCommitments" scale="6" id="f-974">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-975">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-976">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_175">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-977" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.119%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Estimated reimbursements to wholesalers and distributors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:EstimatedReimbursementLiability" scale="6" id="f-978">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:EstimatedReimbursementLiability" scale="6" id="f-979">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development funding liability (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_163">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:ResearchAndDevelopmentLiabilityCurrent" scale="6" id="f-980">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:ResearchAndDevelopmentLiabilityCurrent" scale="6" id="f-981">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-982">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-983">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i151f4968467f44d985f22077f4372877_190">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-984">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-985">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-986">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-987">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-988">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-989">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-904-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-990" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-991">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-992">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="f-993">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="f-994">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-995">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-996">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span><br/></span></div><ix:continuation id="f-539-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-997">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-998">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="f-999">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1000">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1001">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-1002">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="f-1003">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1004">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1005">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-1006">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="f-1007">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1008">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_190"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1010" continuedAt="f-1010-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-1009" continuedAt="f-1009-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2039. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We have <ix:nonFraction unitRef="campus" contextRef="c-4" decimals="INF" name="mrna:OperatingLeaseNumberOfProperties" format="ixt-sec:numwordsen" scale="0" id="f-1011">two</ix:nonFraction> main campuses in Massachusetts, our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters, and our Moderna Technology Center (MTC), located in Norwood. In addition, we own and lease facilities, including office, laboratory, and manufacturing sites, in various locations globally to support our research, development, manufacturing, and business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Science Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Cambridge campus previously included multiple leased properties at Technology Square and the MSC, a facility comprising approximately <ix:nonFraction unitRef="sqft" contextRef="c-271" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-1012">462,000</ix:nonFraction> square feet, that serves as our principal executive office, along with additional office and laboratory spaces. The MSC lease commenced during the third quarter of 2023 and has a term of <ix:nonNumeric contextRef="c-272" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1013">15</ix:nonNumeric> years, with options for <ix:nonFraction unitRef="numberofextensionperiod" contextRef="c-272" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtensions" format="ixt-sec:numwordsen" scale="0" id="f-1014">two</ix:nonFraction> additional <ix:nonNumeric contextRef="c-272" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1015">seven-year</ix:nonNumeric> extensions. During the fourth quarter of 2023, we amended the expiration dates of our Technology Square leases to conclude in January 2025, as we transitioned operations to the MSC. As of December 31, 2024, we substantially exited our leased spaces at Technology Square, completing the consolidation of our Cambridge operations into the MSC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The MTC is a multiple-building campus spanning approximately <ix:nonFraction unitRef="sqft" contextRef="c-273" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-1016">722,000</ix:nonFraction> square feet. that previously operated under long-term finance leases expiring in 2042, with options for <ix:nonFraction unitRef="numberofextensionperiod" contextRef="c-273" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtensions" format="ixt-sec:numwordsen" scale="0" id="f-1017">three</ix:nonFraction> <ix:nonNumeric contextRef="c-273" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1018">five-year</ix:nonNumeric> extensions. The MTC has been a critical facility for our manufacturing, laboratory, and office operations. In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings, for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="f-1019">385</ix:nonFraction>&#160;million. Upon acquisition, we derecognized the right-of-use assets and lease liabilities associated with the Norwood leases. The purchase price, after adjustments related to lease terminations, was allocated to land and buildings, with approximately $<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="f-1020">231</ix:nonFraction>&#160;million recorded as property, plant, and equipment on our consolidated balance sheets as of December 31, 2024.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1010-1" continuedAt="f-1010-2"><ix:continuation id="f-1009-1" continuedAt="f-1009-2"><ix:nonNumeric contextRef="c-1" name="mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock" id="f-1021" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1022">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1023">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1024"><span style="-sec-ix-hidden:f-1025"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="f-1026">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="f-1027">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="f-1028">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="f-1029">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1030"><span style="-sec-ix-hidden:f-1031"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1032">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1033">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1034"><span style="-sec-ix-hidden:f-1035"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1036">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1037">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="f-1038">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="f-1039">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1040">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1041">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1042">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1043">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="f-1044">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="f-1045">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="f-1046">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="f-1047">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1048" continuedAt="f-1048-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:59.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1049">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1050">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1051">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1052">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1053">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1054">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1055">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1056">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1057">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mrna:FinanceLeaseCost" scale="6" id="f-1058">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="mrna:FinanceLeaseCost" scale="6" id="f-1059">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="mrna:FinanceLeaseCost" scale="6" id="f-1060">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="6" id="f-1061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-1062">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-1063">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="f-1064">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="f-1065">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="f-1066">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1010-2"><ix:continuation id="f-1009-2"><ix:continuation id="f-1048-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:63.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1067">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1068">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1069">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-1070">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-1071">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-1072">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-1073">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-1074">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-1075">292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" scale="6" id="f-1076">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" scale="6" id="f-1077">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" scale="6" id="f-1078">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-1080">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-1081">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" format="ixt:fixed-zero" scale="6" id="f-1082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" scale="6" id="f-1083">425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" scale="6" id="f-1084">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-1086">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mrna:LesseeFinanceLeaseExpense" scale="6" id="f-1088">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="mrna:LesseeFinanceLeaseExpense" scale="6" id="f-1089">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="mrna:LesseeFinanceLeaseExpense" scale="6" id="f-1090">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability derecognized upon purchase of underlying leased asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" format="ixt:fixed-zero" scale="6" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" scale="6" id="f-1092">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" format="ixt:fixed-zero" scale="6" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1094">12</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1095">13</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1096">2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1097">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1098">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1099">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1100">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1101">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-1103" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1102" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="6" id="f-1104">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" scale="6" id="f-1105">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="6" id="f-1106">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" scale="6" id="f-1107">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="6" id="f-1108">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree" format="ixt:fixed-zero" scale="6" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="6" id="f-1110">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour" format="ixt:fixed-zero" scale="6" id="f-1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="6" id="f-1112">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive" format="ixt:fixed-zero" scale="6" id="f-1113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="6" id="f-1114">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" format="ixt:fixed-zero" scale="6" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="f-1116">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="f-1117">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1118">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1119">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1120">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="f-1121">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i151f4968467f44d985f22077f4372877_2066"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1122" continuedAt="f-1122-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. Credit Agreement </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we entered into a Credit and Guaranty Agreement (the Credit Agreement) with lenders led by Ares Capital Corporation, as administrative agent. The Credit Agreement provides for a senior secured term loan facility with aggregate term loan commitments of $<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-1123">1.5</ix:nonFraction> billion, consisting of a $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1124">600</ix:nonFraction> million initial term loan, which was funded at closing, and $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1125">900</ix:nonFraction> million of delayed draw term loan commitments. The initial term loan matures on November 24, 2030. The delayed draw term loan commitments consist of (1) a $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1126">400</ix:nonFraction> million delayed draw term loan facility (DDTL-1), which is available, subject to customary conditions, through November 24, 2027, and (2) a $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1127">500</ix:nonFraction> million delayed draw term loan facility (DDTL-2), which is available, subject to customary conditions and the achievement of specified regulatory approval milestones for certain product candidates, through November 24, 2028. </span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1122-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest at a variable rate equal to, at our option, (i) Term SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-281" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1128">5.50</ix:nonFraction>% or (ii) a base rate plus a margin of <ix:nonFraction unitRef="number" contextRef="c-282" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1129">4.50</ix:nonFraction>%. The base rate is calculated as the highest of (a) the Wall Street Journal prime rate, (b) the federal funds rate plus one half of <ix:nonFraction unitRef="number" contextRef="c-283" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt-sec:numwordsen" scale="-2" id="f-1130">one</ix:nonFraction> percent and (c) Term SOFR plus <ix:nonFraction unitRef="number" contextRef="c-284" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt-sec:numwordsen" scale="-2" id="f-1131">one</ix:nonFraction> percent. We are also required to pay commitment fees on the undrawn portions of DDTL-1 and DDTL-2. The interest rate applicable to the initial term loan was approximately <ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1132">9.38</ix:nonFraction>% as of December 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the Credit Agreement are guaranteed by certain of our subsidiaries and are secured by a first-priority lien on substantially all of our assets, in each case subject to customary exceptions and limitations. The Credit Agreement is subject to compliance with customary representations and warranties, affirmative covenants, restrictive covenants and events of default. The restrictive covenants, subject to specified limitations and exceptions, limit, among other things, our ability to incur additional indebtedness and liens, make certain investments, engage in certain fundamental changes, dispose of assets and make restricted payments. Events of default under the Credit Agreement include, among others, nonpayment of principal, interest or other amounts when due, failure to comply with covenants (subject to applicable notice and cure periods), breaches of certain representations and warranties, the occurrence of certain significant adverse events and certain insolvency-related events. The Credit Agreement also includes a financial covenant requiring us to maintain minimum cash and cash equivalents (as defined in the Credit Agreement, which primarily consist of our cash, cash equivalents, and available-for-sale securities) as of the last business day of each week of at least $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="INF" name="mrna:DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" scale="6" id="f-1133">500</ix:nonFraction>&#160;million, increasing to $<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="INF" name="mrna:DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" scale="6" id="f-1134">750</ix:nonFraction>&#160;million if more than $<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="INF" name="us-gaap:LineOfCredit" scale="9" id="f-1135">1.0</ix:nonFraction>&#160;billion is drawn under the Credit Agreement. The financial covenant is not required to be tested at any time that the trailing <ix:nonNumeric contextRef="c-287" name="mrna:DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" format="ixt-sec:durday" id="f-1136">30</ix:nonNumeric>-day average market capitalization of the Company exceeds $<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="INF" name="mrna:DebtInstrumentCovenantComplianceAverageMarketCapitalization" scale="9" id="f-1137">5.0</ix:nonFraction>&#160;billion and is subject to a customary equity cure. As of December 31, 2025, we were in compliance with the applicable terms and covenants under the Credit Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, the initial term loan had an outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1138">600</ix:nonFraction> million and a carrying amount of $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1139">590</ix:nonFraction> million, net of unamortized original issue discount and debt issuance costs, which was classified as long-term debt in our consolidated balance sheet. No amounts had been drawn under DDTL-1 or DDTL-2. The principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1140">600</ix:nonFraction> million is due in full at maturity, and no principal payments are required prior to that date.</span></div></ix:continuation><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_193"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1141" continuedAt="f-1141-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. Commitments and Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal proceedings and claims. Accruals are recognized for legal matters when a loss is both probable and reasonably estimable. As of December 31, 2025, no material contingent liabilities have been recognized. If a material loss is reasonably possible and we can estimate the amount or range of the loss, we disclose such information. Unless otherwise noted, either the outcome of these matters is not expected to be material, or the potential loss cannot be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be a party to litigation, arbitration, or other legal proceedings in the course of our business. The outcome of such matters is inherently uncertain and often involves significant judgment in assessing risk and estimating potential exposure. While we do not currently expect any pending proceedings to have a material adverse effect on our financial position, results of operations, or cash flows, there can be no assurance that future developments will not have a material impact.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our significant legal proceedings and matters outstanding as of December 31, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have brought patent-infringement actions against Pfizer Inc. (Pfizer), BioNTech SE (BioNTech) and related entities in the U.S. District Court for the District of Massachusetts, Germany, the Netherlands, the UK, Ireland and Belgium concerning our mRNA platform technology and disease-specific vaccine designs. Pfizer and BioNTech have commenced actions or asserted defenses seeking to revoke our patents in these jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) have brought patent-infringement actions against us in the U.S. District Court for the District of Delaware, as well as in Canada, Japan, Switzerland and the Unified Patent Court (UPC) asserting patents concerning lipid nanoparticles. Arbutus and Genevant are seeking judgment of infringement of the asserted patents and monetary damages. The U.S. case has set trial to begin March 9, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GlaxoSmithKline Biologicals SA (GSK) has filed <ix:nonFraction unitRef="lawsuit" contextRef="c-289" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1142">two</ix:nonFraction> complaints against us in the U.S. District Court for the District of Delaware asserting certain patents owned by GSK. GSK has filed <ix:nonFraction unitRef="lawsuit" contextRef="c-290" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1143">two</ix:nonFraction> patent-infringement lawsuits against us in the UPC and <ix:nonFraction unitRef="lawsuit" contextRef="c-291" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1144">two</ix:nonFraction> complaints in Spain concerning liposomes and modified liposomes for RNA delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Northwestern University has filed a complaint against us in the U.S. District Court for the District of Delaware asserting U.S. patents concerning lipid nanoparticle technology.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1141-1" continuedAt="f-1141-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Bayer CropSciences LLC, Monsanto Company, and Monsanto Technology, LLC have filed a complaint in U.S. District Court for the District of Delaware asserting a U.S. patent directed to methods of modifying gene sequences.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mNG Bio, LLC has filed a complaint against us in U.S District Court for the District of Massachusetts asserting a U.S. patent directed to a yellow-green fluorescent protein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE has filed a complaint against us in the U.S. District Court for the District of Delaware asserting a U.S. patent directed to modified mRNA compositions encoding a spike protein fragment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachusetts related to statements about our RSV vaccine (mRNA-1345).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business collaborators, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2025 and 2024, we had <ix:nonFraction unitRef="usd" contextRef="c-292" decimals="INF" name="us-gaap:LossContingencyLossInPeriod" format="ixt:fixed-zero" scale="0" id="f-1145"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="INF" name="us-gaap:LossContingencyLossInPeriod" format="ixt:fixed-zero" scale="0" id="f-1146">no</ix:nonFraction></ix:nonFraction>t experienced any significant losses related to these indemnification obligations, and <ix:nonFraction unitRef="claim" contextRef="c-294" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:fixed-zero" scale="6" id="f-1147"><ix:nonFraction unitRef="claim" contextRef="c-295" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:fixed-zero" scale="6" id="f-1148">no</ix:nonFraction></ix:nonFraction> material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and <ix:nonFraction unitRef="usd" contextRef="c-294" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-1149"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-1150">no</ix:nonFraction></ix:nonFraction> related reserves were established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2025, we had $<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="f-1151">411</ix:nonFraction>&#160;million of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. This amount includes $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:LegalContingencyFutureFirmPurchaseCommitments" scale="6" id="f-1152">5</ix:nonFraction>&#160;million of the purchase commitments related to raw materials that was recorded as an accrued liability for loss on future firm purchase commitments. As of December 31, 2025, we had $<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-8" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="9" id="f-1153">1.0</ix:nonFraction>&#160;billion of non-cancelable purchase commitments related to research and development and other goods and services which are expected to be paid through 2032. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind-down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2025, we had cancelable open purchase orders of approximately $<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-8" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="9" id="f-1154">1.8</ix:nonFraction> billion, reflecting amounts associated with our significant vendor arrangements, under such agreements for our clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2025, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related net product sales in the period in which the corresponding sales occur. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-1141-2" continuedAt="f-1141-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, we entered into a non-exclusive patent license agreement with NIAID to license certain patent rights related to the development of mRNA-based vaccines for the prevention or treatment of RSV infection. Upon execution of the agreement, we made a total payment of $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-1155">10</ix:nonFraction>&#160;million, which was capitalized as an intangible asset and is amortized to cost of sales on a straight-line basis over the estimated useful life of the licensed patents. In addition, we are obligated to pay low single-digit royalties on future net sales of licensed products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2025, 2024, and 2023 we recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="f-1156">88</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="f-1157">155</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="f-1158">301</ix:nonFraction>&#160;million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1141-3">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of December 31, 2025.</ix:continuation> </span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_199"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1159" continuedAt="f-1159-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13. Stock-Based Compensation and Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Incentive Plan (the 2016 Equity Plan). The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Equity Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant to employees, non-employee directors, consultants and independent advisors equity-based awards during their period of service, generally in the form of stock options, restricted stock units, and performance stock units. The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a <ix:nonNumeric contextRef="c-300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1160">four-year</ix:nonNumeric> period, with the first <ix:nonFraction unitRef="number" contextRef="c-301" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1161">25</ix:nonFraction>% of such awards vesting following <ix:nonNumeric contextRef="c-301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1162">twelve months</ix:nonNumeric> of continued employment or service. The remaining awards vest in <ix:nonFraction unitRef="installment" contextRef="c-302" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1163">twelve</ix:nonFraction> quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire <ix:nonNumeric contextRef="c-303" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1164">ten years</ix:nonNumeric> from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December 31, 2025, we had a total of&#160;<ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-1165">62</ix:nonFraction> million shares reserved for future issuance under our Equity Plans, of which <ix:nonFraction unitRef="shares" contextRef="c-304" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-1166">38</ix:nonFraction> million shares were reserved for equity awards previously granted, and&#160;<ix:nonFraction unitRef="shares" contextRef="c-305" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1167">24</ix:nonFraction> million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Exchange Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2025, we commenced an offer to exchange certain eligible stock options held by eligible employees of the Company for new stock options (the &#8220;Exchange Offer&#8221;). Executive officers and members of our Board of Directors were not eligible to participate. The Exchange Offer expired on December 12, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Exchange Offer, <ix:nonFraction unitRef="employee" contextRef="c-306" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" format="ixt:num-dot-decimal" scale="0" id="f-1168">2,864</ix:nonFraction> eligible employees elected to exchange, and we accepted for cancellation, eligible stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-306" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1169">4,289,694</ix:nonFraction> shares of our common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="c-306" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" scale="-2" id="f-1170">80</ix:nonFraction>% of the total shares of common stock underlying eligible options. Immediately following the expiration of the Exchange Offer, we granted replacement stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1171">1,653,121</ix:nonFraction> shares of our common stock. The exercise price of the replacement stock options was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-307" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1172">29.46</ix:nonFraction> per share, which was the closing price of our common stock on December 12, 2025. The replacement stock options are subject to new vesting schedules based on continued service.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1159-1" continuedAt="f-1159-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of stock options resulted in an immaterial incremental stock-based compensation expense, calculated using a lattice option pricing model, which will be recognized together with any unrecognized compensation cost remaining on the exchanged options over the remaining requisite service period of the modified awards.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="f-1173" continuedAt="f-1173-1" escape="true">The following table summarizes our option activity during the year ended December 31, 2025:</ix:nonNumeric></span><ix:continuation id="f-1173-1" continuedAt="f-1173-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-1174">26.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1175">59.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1176">5.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-1177">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="f-1178">8.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1179">30.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-1180">1.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1181">14.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="f-1182">6.71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1183">114.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-1184">27.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1185">38.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1186">4.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-1187">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="f-1188">19.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1189">38.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1190">3.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-1191">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="f-1192">7.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1193">39.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1194">8.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-1195">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></ix:continuation></div><ix:continuation id="f-1173-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2025.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1196">19</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1197">122</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1198">413</ix:nonFraction> million for the&#160;years ended December 31, 2025, 2024, and 2023, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1199">2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1200">24</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1201">84</ix:nonFraction>&#160;million&#160;during the years ended December 31, 2025, 2024, and 2023, respectively. The total consideration recorded as a result of stock option exercises&#160;was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1202">17</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1203">42</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1204">25</ix:nonFraction>&#160;million, respectively,&#160;for&#160;the years ended December 31, 2025, 2024, and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs and PSUs generally through the 2018 Equity Plan. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-1205" continuedAt="f-1205-1" escape="true">The following table summarizes our RSU and PSU activity during the year ended December 31, 2025:</ix:nonNumeric></span><ix:continuation id="f-1205-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:72.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.836%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-308" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-1206">7.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1207">91.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-1208">12.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-309" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1209">30.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-309" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-1210">6.81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-309" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1211">63.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-309" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-1212">2.52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-309" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1213">60.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-310" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-1214">11.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-310" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1215">46.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of RSUs and PSUs vested during the years ended December 31, 2025, 2024, and 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestrictedStockExpense" scale="6" id="f-1216">434</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RestrictedStockExpense" scale="6" id="f-1217">228</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RestrictedStockExpense" scale="6" id="f-1218">99</ix:nonFraction> million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2025, 2024, and 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="f-1219">186</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="f-1220">161</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="f-1221">120</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During 2025, 2024 and 2023, we granted an immaterial amount of PSUs, respectively, primarily to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally <ix:nonNumeric contextRef="c-313" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-1222"><ix:nonNumeric contextRef="c-314" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-1223"><ix:nonNumeric contextRef="c-315" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-1224">three years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="c-316" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="f-1225"><ix:nonFraction unitRef="number" contextRef="c-317" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="f-1226"><ix:nonFraction unitRef="number" contextRef="c-318" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="f-1227">0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-319" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="f-1228"><ix:nonFraction unitRef="number" contextRef="c-320" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="f-1229"><ix:nonFraction unitRef="number" contextRef="c-321" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="f-1230">200</ix:nonFraction></ix:nonFraction></ix:nonFraction>%. The estimated fair value of PSUs is based on the grant date fair value.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1159-2" continuedAt="f-1159-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for options granted under our Equity Plans (excluding options issued in connection with the Exchange Offer) is determined using the Black-Scholes option pricing model. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1231" continuedAt="f-1231-1" escape="true">The weighted-average assumptions used to estimate the fair value of options granted for the&#160;years ended December 31, 2025, 2024, and 2023 were as follows:</ix:nonNumeric></span><ix:continuation id="f-1231-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1232">4.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1233">4.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1234">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-322" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1235">5.54</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1236">6.10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-324" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1237">6.07</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1238">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1239">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1240">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-325" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-1244">18.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-326" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-1245">49.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-327" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-1246">57.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1247" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2025, 2024, and 2023 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1248">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1249">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1250">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1251">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1252">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1253">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1254">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1255">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1256">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1257">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1258">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1259">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1260">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1261">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1262">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1263">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1264">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1265">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1266">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1267">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1268">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1269">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1270">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1271">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1272">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1273">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1274">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2025, 2024, and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, there were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1275">633</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1276">2.1</ix:nonNumeric> years at December 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2022, our Board of Directors authorized a share repurchase program of our common stock for up to $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-1277">3.0</ix:nonFraction>&#160;billion, with no expiration date. On August 1, 2022, our Board of Directors authorized an additional $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="INF" name="mrna:StockRepurchaseProgramAdditionalAuthorizedAmount" scale="9" id="f-1278">3.0</ix:nonFraction>&#160;billion under the repurchase program, with no expiration date (collectively with the February 22, 2022 authorization, the 2022 Repurchase Programs). As of December 31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-1279">1.7</ix:nonFraction>&#160;billion of our Board of Directors&#8217; authorization for repurchases of our common stock remains outstanding under the 2022 Repurchase Programs, with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="f-1280" escape="true"><ix:continuation id="f-1159-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to our share repurchase programs (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.327%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" id="f-1281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" id="f-1282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1283">8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:fixed-zero" id="f-1284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:fixed-zero" id="f-1285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" id="f-1286">143.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="6" id="f-1287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="6" id="f-1288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="f-1289">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining authorization at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1290">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1291">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1292">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_205"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1293" continuedAt="f-1293-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">14. Income Taxes</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1294" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1295">2,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1296">3,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1297">4,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1298">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1299">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1300">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1301">2,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1302">3,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1303">3,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1304" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1305">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1306">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1307">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1308">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1309">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1310">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1311">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1312">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1313">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1314">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1315">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1316">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1319">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1322">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1323">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1324">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1325">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1326">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1327">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1328">901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1329">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1330">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1331">772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-1293-1" continuedAt="f-1293-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1332" continuedAt="f-1332-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax amount and rate to our effective tax rate for the year ended December 31, 2025 was as follows (in millions, except percentages):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1333">581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1334">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax, net of federal income tax effect</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1335">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1336">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax effects</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1337">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1338">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="6" id="f-1339">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="f-1340">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1341">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1342">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="6" id="f-1343">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1344">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall/shortfall</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1345">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1346">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in unrecognized tax benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="f-1347">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1348">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1349">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1350">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1351">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1352">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate reconciliation for the year ended December 31, 2025 is presented in accordance with ASU 2023-09, while the effective tax rate reconciliations for the years ended December 31, 2024 and 2023 have not been recast and continue to be presented under the prior guidance. As a result of the adoption of ASU 2023-09, certain items in the effective tax rate reconciliation may have been reclassified between categories compared to prior periods; however, such reclassifications did not have a material impact on any individual line items or the overall effective tax rate.</span></div><div><span><br/></span></div><ix:continuation id="f-1332-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2024 and 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1353">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1354">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1355">23.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1356">52.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" format="ixt:fixed-zero" scale="-2" id="f-1357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1358">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall/shortfall</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1359">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1360">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1361">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1362">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1363">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1364">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1365">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1366">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1367">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1368">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1369">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1370">19.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the year ended December 31, 2025 was (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1371">2.0</ix:nonFraction>)% and was higher than the federal statutory tax rate, primarily due to our global valuation allowance, which limits our ability to recognize tax benefits from the loss. The higher effective tax rate was also impacted by certain of our foreign subsidiaries that have taxable income, while we incurred a net loss before income taxes in other jurisdictions. For the year ended December 31, 2024, the effective tax rate was lower than the federal statutory tax rate as a result of an increase in valuation allowance against deferred tax assets, which limited the recognition of tax benefits on our pre-tax loss. The tax benefits from research and development credits provided a partial offset. For the year ended December 31, 2023, despite being in a pre-tax loss position, our effective tax rate exceeded the federal statutory tax rate, primarily due to the establishment of a valuation allowance against the majority of the deferred tax assets, which resulted in a net tax expense rather than a benefit. This was partially offset by tax benefits from research and development credits and stock-based compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2025, income taxes paid, net of refunds, by jurisdiction were immaterial both individually and in the aggregate and, accordingly, have not been separately disclosed.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1293-2" continuedAt="f-1293-3"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1372" continuedAt="f-1372-1" escape="true">Significant components of our deferred tax assets and tax liabilities as of December 31, 2025 and 2024 were as follows </ix:nonNumeric></span></div><ix:continuation id="f-1372-1"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:77.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1373">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-1374">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1375">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1376">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" format="ixt:num-dot-decimal" scale="6" id="f-1377">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" format="ixt:num-dot-decimal" scale="6" id="f-1378">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-1379">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-1380">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="f-1381">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="f-1382">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsOtherComprehensiveLoss" scale="6" id="f-1383">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsOtherComprehensiveLoss" scale="6" id="f-1384">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve and capitalization </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1385">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1386">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" scale="6" id="f-1387">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" scale="6" id="f-1388">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" scale="6" id="f-1389">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" scale="6" id="f-1390">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:DeferredTaxAssetsOutsideBasisDifference" scale="6" id="f-1391">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:DeferredTaxAssetsOutsideBasisDifference" scale="6" id="f-1392">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1393">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1394">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1395">4,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1396">3,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1397">3,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1398">3,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1399">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1400">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="f-1401">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="f-1402">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1403">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1404">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1405">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1406">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1407">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1408">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-1409">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-1410">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-1411" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1412">3,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1413">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1414">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-1415">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-1416">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1417">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1418">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1419">3,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1420">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. During 2023, following the completion of our long-range financial planning process, we reassessed the evidence and concluded that a valuation allowance was necessary due to the preponderance of negative evidence, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pre-tax loss for the full year 2023, serving as a significant source of objectively verifiable negative evidence in accordance with ASC 740 (Income Taxes).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A projected three-year cumulative loss resulting from our long-range financial planning process. This projection was due to a significant decrease in expected sales of our COVID vaccine as we transitioned to a seasonal market. Additionally, we anticipated substantial research and development expenses for our on-going Phase 3 clinical trials and to advance our product candidates into later-stage development. These factors contributed additional negative evidence with respect to the realizability of our deferred tax assets. The projections were based upon revenue from our approved drug product, which we believe can be reasonably estimated. In contrast, future taxable income projections from our investigational medicines are deemed inherently subjective and not objectively verifiable; they are insufficient to override negative evidence, and therefore, they were not assigned any weight in our valuation allowance analysis assessment.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="f-1293-3"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our evaluation also included whether there were other sources of taxable income that would allow us to realize our deferred tax assets, such as taxable income in carryback years, available tax planning strategies and the future reversals of taxable temporary differences. After assessing these strategies and all evidence, we determined it was more likely than not that we will not realize all of our deferred tax assets and therefore increased the valuation allowance by $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="9" id="f-1421">2.1</ix:nonFraction>&#160;billion during 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025 and 2024, we continued to maintain a global valuation allowan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ce against the majority of our de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ferred tax assets, consistent with the assessment established in 2023. The valuation allowance reflects the ongoing preponderance of negative evidence, including continued and projected losses. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025, we had $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-8" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1422">4.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-8" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1423">3.3</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1424">89</ix:nonFraction> million of federal, state and foreign net operating loss carryforwards, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-8" name="mrna:OperatingLossCarryforwardsNotSubjectToExpiration" scale="9" id="f-1425">4.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-8" name="mrna:OperatingLossCarryforwardsNotSubjectToExpiration" scale="9" id="f-1426">1.6</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" name="mrna:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-1427">89</ix:nonFraction> million respectively, will not expire and $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-8" name="mrna:OperatingLossCarryforwardsSubjectToExpiration" scale="9" id="f-1428">1.7</ix:nonFraction> billion of state net operating loss carryforwards will begin to expire in 2032. At December 31, 2025, we also had federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1429">111</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1430">208</ix:nonFraction> million, respectively, the majority of which will begin to expire in 2030.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1431" continuedAt="f-1431-1" escape="true">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2025, 2024, and 2023 were as follows (in&#160;millions):</ix:nonNumeric></span></div><ix:continuation id="f-1431-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1432">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1433">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1434">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1435">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1436">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="f-1437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with tax authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-1438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-1439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1440">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1441">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1442">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1443">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="f-1444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="f-1445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1446">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1447">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1448">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1449">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1450">241</ix:nonFraction> million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We file</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> income tax returns in U.S. and various state, local and foreign jurisdictions. The income tax returns of all material taxing jurisdictions remain open to tax examination for all tax years since our date of incorporation for those jurisdictions. We have federal, state, and foreign carryforward attributes generated in past years which may be adjusted upon examination. As of December 31, 2025, we are under audit in various U.S., and foreign jurisdictions; however, no adjustments to our tax positions have been proposed at this time.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_211"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1451" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">15. Loss per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1452" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2025, 2024 and 2023 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:61.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1453">2,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1454">3,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1455">4,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1456"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1457">389</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1458"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1459">384</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1460"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1461">382</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted EPS</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1462"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1463">7.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1464"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1465">9.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1466"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1467">12.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1468" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2025, 2024 and 2023, were excluded from the calculation of diluted EPS attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1469">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1470">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1471">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1472">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-359" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1473">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-360" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1474">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1475">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1476">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1477">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_214"></div><ix:continuation id="f-498-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16. Geographic Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1478">one</ix:nonFraction> reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><ix:continuation id="f-499-1"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaborators was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1479">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1480">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1481">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1482">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1483">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1484">1,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1485">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1486">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1487">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1488">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1489">3,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1490">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1491">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1492">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="f-1493">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="f-1494">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="f-1495">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="f-1496">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1497">2,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1498">2,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_238"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_241"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of&#160;December 31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of&#160;December 31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f)) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of&#160;December 31, 2025. Management based its assessment on criteria established in&#160;Internal Control - Integrated Framework&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).&#160;Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of&#160;December 31, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of&#160;December 31, 2025&#160;has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report included in this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Controls over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2025, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inherent Limitations on the Effectiveness of Controls</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, believe that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Moderna, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Moderna, Inc.&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Moderna, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and our report dated February&#160;20, 2026 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;20, 2026</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_244"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-376" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1499"><ix:nonNumeric contextRef="c-376" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1500">10b5-1 Plans</ix:nonNumeric></ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-377" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1501" escape="true">On <ix:nonNumeric contextRef="c-377" name="ecd:TrdArrTerminationDate" id="f-1502">November 23, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-377" name="ecd:TrdArrIndName" id="f-1503">St&#233;phane Bancel</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-377" name="ecd:TrdArrIndTitle" id="f-1504">Chief Executive Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-377" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-1505">terminated</ix:nonNumeric> a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c), which had been entered into on September 3, 2025, and was scheduled to commence as early as December 17, 2025, with a termination date of August 10, 2026. The plan provided for the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1506">1,439,788</ix:nonFraction> shares of common stock. No shares of common stock were sold under the plan prior to its termination.</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-379" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1507" escape="true">Mr. Bancel has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase <ix:nonFraction unitRef="shares" contextRef="c-380" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1508">558,394</ix:nonFraction> shares and another option to purchase <ix:nonFraction unitRef="shares" contextRef="c-381" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1509">193,321</ix:nonFraction> shares (the Bancel Expiring Options). Mr. Bancel intends to contribute all of the after-tax proceeds from the exercise and sale of the Bancel Expiring Options to charitable causes. On <ix:nonNumeric contextRef="c-379" name="ecd:TrdArrAdoptionDate" id="f-1510">November 28, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-379" name="ecd:TrdArrIndName" id="f-1511">Mr. Bancel</ix:nonNumeric> <ix:nonNumeric contextRef="c-379" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1512">adopted</ix:nonNumeric> a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between May 13,2026 and <ix:nonNumeric contextRef="c-379" name="ecd:TrdArrExpirationDate" id="f-1513">August 10, 2026</ix:nonNumeric>, the Bancel 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Bancel Expiring Options, which represent up to <ix:nonFraction unitRef="shares" contextRef="c-382" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1514">751,715</ix:nonFraction> shares of the Company&#8217;s common stock in the aggregate. The Bancel 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.</ix:nonNumeric> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-383" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1516" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-383" name="ecd:TrdArrIndName" id="f-1515">Stephen Hoge</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-383" name="ecd:TrdArrIndTitle" id="f-1517">President</ix:nonNumeric>, has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase <ix:nonFraction unitRef="shares" contextRef="c-384" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1518">223,357</ix:nonFraction> shares and another option to purchase <ix:nonFraction unitRef="shares" contextRef="c-385" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1519">96,660</ix:nonFraction> shares (the Hoge Expiring Options). On <ix:nonNumeric contextRef="c-383" name="ecd:TrdArrAdoptionDate" id="f-1520">November 13, 2025</ix:nonNumeric>, Dr. Hoge <ix:nonNumeric contextRef="c-383" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1521">adopted</ix:nonNumeric> a trading arrangement that is intended to satisfy the affirmative defense of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Rule 10b5-1(c) (the Hoge 10b5-1 Plan). Between February 23, 2026 and <ix:nonNumeric contextRef="c-383" name="ecd:TrdArrExpirationDate" id="f-1522">August 10, 2026</ix:nonNumeric>, the Hoge 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Hoge Expiring Options, which represent up to <ix:nonFraction unitRef="shares" contextRef="c-386" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1523">320,017</ix:nonFraction> shares of the Company&#8217;s common stock in the aggregate. The Hoge 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_247"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None Applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_250"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_253"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_256"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_259"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_262"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_265"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our independent public accounting firm is Ernst &amp; Young LLP, Boston, Massachusetts, PCAOB Auditor ID 000<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-1526">42</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_268"></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_271"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a) Documents filed as part of this report.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Financial statements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For a list of the consolidated financial statements included herein, see &#8220;Index to Consolidated Financial Statements&#8221; under Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2) Schedules.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the consolidated financial statements or the notes thereto.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3) Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Index</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285224000031/exhibit3158248-k.htm">Restated Certificate of Incorporation of the Registrant. (2)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285224000031/exhibit325820248-k.htm">Second Amended and Restated&#160;By-laws of the Registrant. (2)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex41.htm">Specimen Common Stock Certificate. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit4212312025.htm">Description of Capital Stoc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit4212312025.htm">k. (9)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex101.htm">2016 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex102.htm">2018 Stock Option and Incentive Plan. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex103.htm">Form of Indemnification Agreement between the Registrant and each of its directors. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex104.htm">Master Collaboration and License Agreement, by and between Moderna Therapeutics, Inc. and Merck Sharp &amp; Dohme Corp., dated as of January&#160;12, 2015, as amended by Amendment No.&#160;1 dated as of January 8, 2016, Amendment No.&#160;2 dated as of June&#160;28, 2016, Amendment No.&#160;3 dated as of June&#160;28, 2016 and Amendment No.&#160;4 dated as of June&#160;28, 2016. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex105.htm">Amended and Restated mRNA Cancer Vaccine Collaboration and License Agreement, by and between ModernaTX, Inc. and Merck Sharp &amp; Dohme Corp., dated as of April&#160;17, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex108.htm">Patent Sublicense Agreement, by and among ModernaTX, Inc. and Cellscript, LLC and mRNA RiboTherapeutics, Inc. (solely with respect to certain provisions), dated as of June&#160;26, 2017. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/moderna-creditandguarantya.htm">Credit and Guaranty Agreement, dated as of No</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/moderna-creditandguarantya.htm">vember 19, 2025, by and among Moderna, certain subsidiary guarantors, Ares Capital Corporation and the lenders</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/moderna-creditandguarantya.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/moderna-creditandguarantya.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/moderna-creditandguarantya.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/moderna-creditandguarantya.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285223000011/exhibit1011-amendedandrest.htm">Amended and Restated Executive Severance Plan and Form of Participation Letter, as amended on February 23, 2023. (7)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1015.htm">Letter Agreement by and between the Company and St&#233;phane Bancel, dated as of June 13, 2018, as amended by Amendment No. 1 dated as of November&#160;4, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1016.htm">Letter Agreement by and between the Company and Stephen Hoge, dated as of October&#160;17, 2017. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285222000012/exhibit1019-offerlettersha.htm">Employment Letter Agreement between ModernaTX, Inc. and Shannon Klinger, dated as of March 4, 2021. (5)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.12#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285222000051/exhibit102-mockofferletter.htm">Offer Letter by and between ModernaTX, Inc. and James Mock, dated as of August 15, 2022. (6)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1017.htm">Senior Executive Cash Incentive Bonus Plan. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285222000051/exhibit101-directorcompens.htm">Amended and Restated Non-Employee Director Compensation Policy, effective October 1, 2022. (6)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1019.htm">Form of Indemnification Agreement between the Registrant and each of its officers. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.16#*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016esppplan.htm">2018 Employee Stock Purchase Plan.</a></span><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/exhibit1022formofemployeer.htm">Form of Employee Restricted Stock Unit Award Agreement. (8)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/exhibit1023formofemployeen.htm">Form of Employee Non-Qualified Stock Option Agreement. (8)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285222000012/exhibit1026-modernarsuagre.htm">Form of Non-Employee Director Restricted Stock Unit Award Agreement. (5)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285222000012/exhibit1027-nqsoagreementf.htm">Form of Non-Employee Director Non-Qualified Stock Option Agreement. (5)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">10.21#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit103formofpsuagreeme.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Stock Option and Incentive Plan. (3)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">19</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1527"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit19insidertradingpol.htm">Moderna, Inc. Insider Trading </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit19insidertradingpol.htm">Policy. (9)</a></ix:nonNumeric></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211subsidiaries1231.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23112312025.htm">Consent of Ernst&#160;&amp; Young LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31112312025.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31212312025.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32112312025.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32212312025.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/exhibit97modernaincpolicyf.htm">Moderna, Inc. Policy for Recoupment of Executive Incentive Compensation. (8)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Link Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to 17 C.F.R. &#167;&#167;230.406 and 230.83, the confidential portions of this exhibit have been omitted and are marked accordingly.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registration Statement on Form S-1 (File No. 333-228300) filed with the Securities and Exchange Commission on November 9, 2018.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Current Report on Form 8-K (File No. 001-38753) filed with the Securities and Exchange Commission on May 9, 2024.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on May 6, 2021.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on November 7, 2024.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 25, 2022.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on November 3, 2022.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 24, 2023.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 23, 2024.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 21, 2025.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Current Report on Form 8-K (File No. 001-38753) filed with the Securities and Exchange Commission on November 24, 2025.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><div id="i151f4968467f44d985f22077f4372877_274"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i151f4968467f44d985f22077f4372877_277"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">MODERNA, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY AND SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each individual whose signature appears below hereby constitutes and appoints each of St&#233;phane Bancel and James M. Mock as such person&#8217;s true and lawful&#160;attorney-in-fact&#160;and agent with full power of substitution and resubstitution, for such person in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said&#160;attorney-in-fact&#160;and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said&#160;attorney-in-fact&#160;and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:36.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.242%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.331%"/><td style="width:0.1%"/></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ St&#233;phane Bancel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James M. Mock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">James M. Mock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Noubar B. Afeyan, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Noubar B. Afeyan, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Horning, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Horning, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Abbas Hussain</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Abbas Hussain</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elizabeth Nabel, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Nabel, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Francois Nader, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Francois Nader M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David M. Rubenstein</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">David M. Rubenstein</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul Sagan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Paul Sagan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elizabeth Tallett</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">February 20, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Tallett</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit4212312025.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i73fd9ddf2f834816978073fdc9425516_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.2</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following description of the capital stock of Moderna, Inc. (&#8220;us,&#8221; &#8220;our,&#8221; &#8220;we&#8221; or the &#8220;Company&#8221;) is a summary of the rights of our common stock and certain provisions of our restated certificate of incorporation (our &#8220;charter&#8221;) and our second amended and restated by-laws (our &#8220;by-laws&#8221;). This summary does not purport to be complete and is qualified in its entirety by the provisions of our charter and by-laws, each previously filed with the Securities and Exchange Commission and incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part, as well as to the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). We encourage you to read our charter, by-laws and the applicable portions of the DGCL carefully.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 1,600,000,000 shares of common stock, par value $0.0001 per share, and 162,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has the authority, without further action by our stockholders, to issue up to 162,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Our Charter and By-laws and Delaware Law</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our charter and by-laws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board composition and filling vacancies</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our charter provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our charter also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two thirds (2&#47;3) or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">No written consent of stockholders</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our charter provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our by-laws or removal of directors by our stockholders without holding a meeting of stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Meetings of stockholders</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our charter and by-laws limit stockholders&#8217; ability to call a special meeting of stockholders to stockholders representing at least 20% of our outstanding shares and provide advance notice requirements, including that  only those matters set forth in the written notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our by-laws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advance notice requirements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our by-laws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our by-laws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to charter and by-laws</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any amendment of our charter must first be approved by a majority of our board of directors, and if required by law or our charter, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Except as otherwise required by law, our by-laws may be amended by our board of directors and may also be amended by the affirmative vote of the holders of a majority of the voting power of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds of the voting power of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the voting power of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undesignated preferred stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our charter provides for 162,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our charter grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Section 203 of the Delaware General Corporation Law</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions&#58;</font></div><div><font><br></font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder&#59; or</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section 203 defines a business combination to include&#58;</font></div><div><font><br></font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial benefits provided by or through the corporation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nasdaq Global Select Market Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#8220;MRNA.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is Fidelity Stock Transfer</font><font style="background-color:#f8fdff;color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:120%">&#8480;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>exhibit1016esppplan.htm
<DESCRIPTION>EX-10.16
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ifab61a6d9f54466195fdf82a353f5bef_37"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ifab61a6d9f54466195fdf82a353f5bef_42"></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2018 EMPLOYEE STOCK PURCHASE PLAN </font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the Moderna, Inc. 2018 Employee Stock Purchase Plan (&#8220;the Plan&#8221;) is to provide eligible employees of Moderna, Inc. (the &#8220;Company&#8221;) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;). An aggregate of 810,000 shares of Common Stock have been approved and reserved for this purpose, plus on January 1, 2020 and each January 1 thereafter, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i) 3,240,000 shares of Common Stock, (ii) one percent of the number of shares of Common Stock of the Company issued and outstanding on the immediately preceding December 31 or (iii) such lesser number of shares of Common Stock as determined by the Administrator. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Plan includes two components&#58; a Code Section 423 Component (the &#8220;423 Component&#8221;) and a non-Code Section 423 Component (the &#8220;Non-423 Component&#8221;). It is intended for the 423 Component to constitute an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the 423 Component shall be interpreted in accordance with that intent (although the Company makes no undertaking or representation to maintain such qualification). In addition, this Plan authorizes the grant of options under the Non-423 Component that does not qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code. Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan will be administered by the person or persons (the &#8220;Administrator&#8221;) appointed by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) for such purpose. The Administrator has authority at any time to&#58; (i) adopt, alter and repeal such rules, subplans, guidelines and practices for the administration and operation of the Plan and for its own acts and proceedings as it shall deem advisable, including to accommodate the specific requirements of local laws, regulations and procedures for jurisdictions outside of the United States&#59; (ii) interpret the terms and provisions of the Plan&#59; (iii) make all determinations it deems advisable for the administration of the Plan&#59; (iv) decide all disputes arising in connection with the Plan&#59; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Offerings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will make one or more offerings to eligible employees to purchase Common Stock under the Plan (&#8220;Offerings&#8221;). Unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each January 1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and July 1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and will end on the last business day occurring on or before the following May 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and November 30</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%">th</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed 27 months in duration or overlap any other Offering. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. All individuals classified as employees on the payroll records of the Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the &#8220;Offering Date&#8221;) they are customarily employed by the Company or a Designated Company for 20 hours or more a week, unless the exclusion of employees who do not meet this requirement is not permissible under applicable law, and have completed at least 30 days of employment. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Company for purposes of the Company&#8217;s or applicable Designated Company&#8217;s payroll system are not considered to be eligible employees of the Company or any Designated Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">contemporaneously classified as employees of the Company or a Designated Company on the Company&#8217;s or Designated Company&#8217;s payroll system to become eligible to participate in a plan which is equivalent to this Plan is through the adoption of a subplan, which specifically renders such individuals eligible to participate therein. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Participation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Participants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting (either in electronic or written form, according to procedures established by the Company) an enrollment form to his or her appropriate payroll location at least 5 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enrollment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The enrollment form will (a) state a whole percentage to be contributed from an eligible employee&#8217;s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued or transferred pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant submits (either in electronic or written form, according to procedures established by the Company) a new enrollment form or withdraws from the Plan, such Participant&#8217;s contributions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code and any applicable law. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Contributions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each eligible employee may authorize payroll deductions at a minimum of 1 percent up to a maximum of 15 percent of such employee&#8217;s Compensation for each pay period&#59; provided, however, that if payroll deductions are not permitted or problematic under applicable law or for administrative reasons, the Company, in its discretion, may allow eligible employees to contribute to the Plan by other means. The Company will maintain book accounts showing the amount of payroll deductions or other contributions made by each Participant for each Offering. No interest will accrue or be paid on payroll deductions or other contributions, unless required under applicable law. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contribution Changes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase his or her contributions during any Offering and may only decrease his or her contributions once during any Offering. However, during an Offering, a Participant may increase or decrease his or her contributions with respect to the next Offering (subject to the limitations of Section 5) by submitting (either in electronic or written form, according to procedures established by the Company) a new enrollment form at least 5 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her contributions during an Offering. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Withdrawal</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. A Participant may withdraw from participation in the Plan by submitting a notice of withdrawal to his or her appropriate payroll location (either in electronic or written form, according to procedures established by the Company). The Participant&#8217;s withdrawal will be effective if submitted at least 10 business days prior to the end of the Offering period. Following a Participant&#8217;s withdrawal, the Company will promptly refund such individual&#8217;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (&#8220;Option&#8221;) to purchase on the last day of such Offering (the &#8220;Exercise Date&#8221;), at the Option Price hereinafter provided for, the lowest of (a) a number of shares of Common Stock determined by dividing such Participant&#8217;s accumulated contributions on such Exercise Date by the lower of (i) 85 percent of the Fair Market Value of the Common Stock on the Offering Date, or (ii) 85 percent of the Fair Market Value of the Common Stock on the Exercise Date, (b) 3,000 shares&#59; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering&#59; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant&#8217;s Option shall be exercisable only to the extent of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Participant&#8217;s accumulated payroll deductions and&#47;or other contributions on the Exercise Date. The purchase price for each share purchased under each Option (the &#8220;Option Price&#8221;) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was granted, would be treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section 11). For purposes of the preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the Option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Option and Purchase of Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated contributions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a Participant&#8217;s account at the end of an Offering will be refunded to the Participant promptly. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If a Participant has more than one Option outstanding under the Plan, unless he or she otherwise indicates in agreements or notices delivered hereunder&#58; (i) each agreement or notice delivered by that Participant shall be deemed to apply to all of his or her Options under the Plan&#59; and (ii) an Option with a lower Option Price (or an earlier granted Option, if different Options have identical Option Prices) shall be exercised to the fullest possible extent before an Option with a higher Option Price (or a later granted Option if different Options have identical Option Prices) shall be exercised. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance of Certificates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Certificates, or book entries for uncertificated shares, representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee or, if permitted by the Administrator, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Affiliate&#8221; means any entity that is directly or indirectly controlled by the Company which does not meet the definition of a Subsidiary below, as determined by the Administrator, whether new or hereafter existing. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Compensation&#8221; means the amount of base pay, prior to salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code or comparable reductions under laws outside the United States, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise, vesting or settlement of Company equity incentive awards, and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside of the United States. </font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Designated Company&#8221; means any present or future Affiliate or Subsidiary (as defined below) that has been designated by the Administrator to participate in the Plan. The Administrator may so designate any Affiliate or Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders and may further designate such companies as participating in the 423 Component or the Non-423 Component. For purposes of the 423 Component, only Subsidiaries may be Designated Companies. The current list of Designated Companies is attached hereto as Appendix A. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Fair Market Value of the Common Stock&#8221; on any given date means the fair market value of the Common Stock determined in good faith by the Administrator&#59; provided, however, that if the Common Stock is admitted to quotation on the Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. </font></div><div style="margin-top:12pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Initial Public Offering&#8221; means the first day when trading prices for the Common Stock are reported on Nasdaq Global Market or another national securities exchange, pursuant to an effective registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Parent&#8221; means a &#8220;parent corporation&#8221; with respect to the Company, as defined in Section 424(e) of the Code. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Participant&#8221; means an individual who is eligible as determined in Section 3 and who has complied with the provisions of Section 4. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;Subsidiary&#8221; means a &#8220;subsidiary corporation&#8221; with respect to the Company, as defined in Section 424(f) of the Code. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights on Termination of Employment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Unless otherwise required by applicable law, if a Participant&#8217;s employment terminates for any reason before the Exercise Date for any Offering, no contributions will be taken from any pay due and owing to the Participant and the balance in the Participant&#8217;s account will be paid to such Participant or, in the case of such Participant&#8217;s death, if permitted by the Administrator, to his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section 7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be an Affiliate or a Subsidiary, as applicable, or if the employee is transferred to any corporation other than the Company or a Designated Company. An employee will not be deemed to have terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee&#8217;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Special Rules</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees&#59; provided that if such rules are inconsistent with the requirements of Section 423(b) of the Code, these employees will participate in the Non-423 Component. Any special rules established pursuant to this Section 13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Optionees Not Stockholders</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Neither the granting of an Option to a Participant nor the deductions from his or her pay or other contributions shall deem such Participant to be a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued or transferred to him or her. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights Not Transferable</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant&#8217;s lifetime only by the Participant. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Funds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose&#59; unless otherwise required under applicable law. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment in Case of Changes Affecting Common Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section 8 shall be equitably or proportionately adjusted to give proper effect to such event. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of the Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Board may at any time and from time to time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order for the 423 Component of the Plan, as amended, to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423(b) of the Code. </font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insufficient Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of the Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. The Plan shall automatically terminate on the ten year anniversary of the date of the Company&#8217;s Initial Public Offering. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company&#8217;s obligation to sell and deliver Common Stock under the Plan is subject to completion of any registration or qualification of the Common Stock under any U.S. or non-U.S. local, state or federal securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S. or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, applied without regard to conflict of law principles. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance of Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by participating in the Plan, that the Company and its Affiliates and Subsidiaries shall have the right to deduct any Tax Liability from any payment of any kind otherwise due to the Participant, including shares of Common Stock issuable under the Plan. Where a Tax Liability arises in connection with the Plan, the Company and&#47;or a Designated Company may require that, as a condition of exercise of an Option and purchase of shares of Common Stock, a Participant must either&#58; </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) make a payment to the Company, or otherwise as the Company directs, of an amount equal to the Company&#8217;s estimate of the amount of the Tax Liability&#59; or </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) enter into arrangements acceptable to the Company to secure that such payment is made (whether by surrender of shares of Common Stock, net share issuance, the sale of shares of Common Stock or otherwise). </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For these purposes, &#8220;Tax Liability&#8221; shall mean any amount of U.S. or non-U.S. federal, state or local income tax, social security (or similar) contributions, payroll tax, fringe benefits tax, payment on account and&#47;or other tax-related items related to the participation in the Plan and legally applicable to the Participant, which the Company and&#47;or an Affiliate or Subsidiary become liable to pay on the Participant&#8217;s behalf to the relevant authorities in any jurisdiction. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notification Upon Sale of Shares</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each Participant who is subject to tax in the United States with respect to his or her participation in the Plan agrees, by entering the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date and Approval of Shareholders</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan shall take effect on the date immediately preceding the date of the Company&#8217;s Initial Public Offering, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders. </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br>Last updated December 16, 2025</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>exhibit19insidertradingpol.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ifad610abbfed4c36b52e21016d896bae_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 19</font></div><div><font><br></font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"></div></div><div style="text-align:center"><font style="color:#00b0f0;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</font></div><div style="text-align:center"><font style="color:#00b0f0;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSIDER TRADING POLICY</font></div><div id="ifad610abbfed4c36b52e21016d896bae_4"></div><div><font><br></font></div><div id="ifad610abbfed4c36b52e21016d896bae_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities laws prohibit anyone who is aware of material nonpublic information about a company from trading (i.e., buying, selling or otherwise transacting) in securities (such as stock) of that company, commonly known as &#8220;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">insider trading</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; These laws also prohibit anyone who is aware of material nonpublic information from disclosing that information to others who may trade, commonly known as &#8220;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">tipping</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Moderna has adopted this Insider Trading Policy for all of our directors, officers, employees and consultants, to prevent insider trading, or even the appearance of it.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This policy is divided into two parts&#58; the first part prohibits trading in certain circumstances and applies to all employees (including temporary employees) and directors of Moderna and its subsidiaries, as well as consultants. The second part imposes special additional trading restrictions applicable to all of Moderna&#8217;s directors and officers, as well as other employees who, because of their position, responsibilities or their actual or potential access to material information, are designated by Moderna as restricted (&#8220;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Perpetual Insiders</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Every provision of this policy that applies to you also applies to your family members who reside with you (including, a spouse&#47;partner, child, parent, grandparent, in-law or other family member), anyone else living with you and any family member who does not live in your household but whose transactions in covered securities are subject to your influence or control,  as well as any trusts, partnerships, corporations and other entities controlled by you. You are responsible for ensuring that these people and entities comply with this policy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insider trading is illegal, and a violation of this policy could result in severe consequences, including termination of employment. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">What is material nonpublic information&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information is &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">material</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; if</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a reasonable investor would likely consider it important in making a decision to buy, hold or sell securities. Any information that could reasonably be expected to affect the price of the security is material. The information may be positive or negative. Common examples of information that may be material include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">earnings results, estimates and guidance on earnings, and changes in previously released earnings results, estimates or guidance, or other performance-related measures or metrics&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and results of clinical trials for Moderna&#8217;s development candidates&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decisions by the U.S. FDA or foreign regulators regarding regulatory submissions for Moderna&#8217;s development candidates&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain or loss of substantial customers, vendors, suppliers, partnerships or properties, including execution or termination of significant contracts&#59;</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While the provisions of this policy do not apply to transactions by Moderna itself, transactions by Moderna will only be made in accordance with applicable U.S. federal securities laws, including those relating to insider trading. It is the policy of Moderna that the company will not engage in transactions in its securities while aware of material nonpublic information relating to the company or its securities.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in Moderna&#8217;s management or the Board of Directors&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant proposed mergers, acquisitions, investments or divestitures&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a significant cybersecurity incident&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in significant litigation or government investigations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This is not a full list of potentially material information, and what is material depends on all facts and circumstances at the time of assessing materiality (and is often evaluated by enforcement authorities with the benefit of hindsight). If you are unsure whether information you possess is material and you wish to trade, you should send your inquiry to </font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Note that you are responsible for your own trading.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information is &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">nonpublic</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; if it has not been disseminated in a manner making it available to investors generally. Information may still be nonpublic even though it is widely known within Moderna. For information to be considered public, three criteria must be met&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the information has been widely circulated (such as by press release or an SEC filing)&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the information was an &#8220;official&#8221; announcement (rumors and speculation in the public are insufficient, even if the information is accurate)&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public has had time to absorb and evaluate the information. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">What is a trade&#63; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;trade&#8221; or &#8220;trading&#8221; means any purchase, sale or other transaction to acquire, transfer or dispose of securities, including gifts or other contributions, exercises of stock options granted under Moderna&#8217;s stock plans and sales of stock (including stock acquired upon the exercise of stock options, vesting of restricted stock units or through Moderna&#8217;s employee stock purchase plan (&#8220;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESPP</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">What are securities&#63; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;securities&#8221; includes common stock (and options to purchase stock), as well as debt securities (such as bonds, notes, debentures), warrants and other convertible securities, as well as derivative instruments (such as put and call options).</font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART I</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:125%;padding-left:9.61pt">GENERAL POLICY&#58; PROHIBITION ON TRADING WHILE AWARE OF MATERIAL NONPUBLIC INFORMATION&#59; PROHIBITION ON TIPPING OTHERS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may not trade Moderna&#8217;s securities at any time when you have material nonpublic information about the company. You also may not trade the securities of another company (1) with which Moderna does business, such as Moderna&#8217;s partners, collaborators, distributors, vendors, customers and suppliers, or (2) that is involved in a potential transaction or business relationship with Moderna, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in either case, about which you have material nonpublic information if you learned that information as a result of your employment with Moderna.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tipping</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may not disclose to any other person any material nonpublic information (except in accordance with Moderna&#8217;s policies for revealing information to necessary parties and subject </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to appropriate confidentiality procedures), and you may not make trade recommendations based on material nonpublic information. You should also be careful before trading on the recommendation of others to make sure that the recommendation is not the result of an illegal &#8220;tip.&#8221;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Application After Departure</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If you leave Moderna at a time when you are aware of material nonpublic information, you will be subject to this policy until the information has become public or is no longer material.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">LIMITED EXCEPTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no exceptions to this policy, except as specifically noted below. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not excepted from this policy. The securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve Moderna&#8217;s reputation for adhering to the highest standards of conduct.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are generally allowed under this policy&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exercises of stock options awarded under Moderna&#8217;s stock plans when the exercise price is paid in cash and none of the underlying shares received upon the exercise of such option are sold (whether to pay for the exercise of the option, pay taxes, etc.)&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">surrender of shares to Moderna in satisfaction of tax withholding obligations relating to awards under the company&#8217;s stock plans&#59; </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases under Moderna&#8217;s ESPP, or elections to participate in or withdraw from the ESPP&#59; however, this exception does not apply to any </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Moderna stock purchased pursuant to the ESPP&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investments in exchange-traded funds and mutual funds that hold Moderna&#8217;s stock, so long as the company&#8217;s stock is not a substantial portion of the underlying investments&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the execution of transactions under an Approved 10b5-1 Plan (see Part II, Section 3 for more information).</font></div><div style="margin-bottom:8pt;padding-left:36pt"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">OTHER PROHIBITIONS ON TRADING ACTIVITIES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna has determined that there is a heightened legal risk and&#47;or the appearance of improper or inappropriate conduct if persons subject to this policy engage in certain types of transactions. You are therefore prohibited from engaging in any of the following types of transactions&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short sales of Moderna securities&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases or sales of puts or calls on Moderna securities&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transactions involving financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds) that are designed to hedge or offset any decrease in the market value of Moderna&#8217;s securities&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:46.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">borrowing against Moderna securities held in a margin account or pledging Moderna securities as collateral for a loan. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">POST-TERMINATION TRANSACTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This policy continues to apply to transactions in Moderna securities even after termination of service to the company. If you are in possession of material nonpublic information when your service terminates, you may not engage in transactions in Moderna securities until that information has become public or is no longer material.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">PENALTIES FOR VIOLATION </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this policy is a requirement of our work here at Moderna. A violation of this policy may be considered a violation of our Code of Ethics and Business Conduct, potentially resulting in termination of employment. Violations of insider trading laws can also result in severe civil and criminal penalties. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you violate this policy or any federal or state laws governing insider trading, or know of any such violation by any director, officer or employee of Moderna, you must report the violation immediately to the Chief Legal Officer, Chief Compliance Officer or another designated member of Moderna&#8217;s legal department.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">INQUIRIES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you have any questions regarding any of the provisions of this policy, please contact </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART II</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">BLACKOUT PERIODS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Perpetual Insiders are prohibited from trading in Moderna securities during blackout periods, as described below. In the event a Perpetual Insider leaves the company during a blackout period, such individual will remain prohibited from trading in the Moderna securities until the blackout period ends, as described below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings Blackout Periods</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The earnings blackout period begins at the close of business on the 15</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of the last month of each fiscal quarter (or the last trading day prior to the 15</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if such day is not a trading day) and ends one full trading day after the date the company&#8217;s earnings results for the quarter are publicly disclosed via press release. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Blackout Periods</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. From time to time, other types of material nonpublic information about Moderna may be pending and not publicly disclosed. While such material nonpublic information is pending, Moderna may impose special blackout periods during which Perpetual Insiders or other individuals in possession of that information are prohibited from trading in Moderna&#8217;s securities. If Moderna imposes a special blackout period, it will notify those affected. The existence of a special blackout period is itself material nonpublic information, and those subject to such a blackout period should not tell anyone within or outside of Moderna about the existence of the blackout period (except to instruct a financial advisor regarding the trading restrictions).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">PRE-CLEARANCE OF TRANSACTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Perpetual Insiders must submit a request for pre-clearance in advance of a proposed transaction in Moderna securities. Pre-clearance requests must also be submitted for transactions by entities or persons that are controlled by a Perpetual Insider, including family trusts or family members who share their household. Requests must be in accordance with our pre-clearance procedures, and approval for the transaction will be granted only during open windows. Transactions must occur during the open window period in which the approval is granted and in any event within five business days from the date of approval. Pre-clearance is not legal advice and receiving pre-clearance in no way relieves a Perpetual Insider of his or her own legal obligation to refrain from trading while in the possession of material nonpublic information. Additionally, if pre-clearance is denied, you must keep such determination confidential. Pre-clearance is not required for transactions under Approved 10b5-1 Plans. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16 Reporting</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Moderna directors and executive officers who are subject to Section 16 reporting must instruct any third party that is trading on their behalf to send same-day confirmations of all transactions to the Chief Legal Officer, Vice President, Associate General Counsel, Securities or another designated member of Moderna&#8217;s legal department. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.61pt">APPROVED 10B5-1 PLANS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, offers a way for you to transact in Moderna stock over a period of time, even if you become aware of material, nonpublic information during such period. The trading restrictions outlined in this policy do not apply to transactions under Rule 10b5-1 plans that have been reviewed and approved by the company (an &#8220;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved 10b5-1 Plan</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company directors and members of Moderna&#8217;s Executive Committee are required to make any sales of Moderna securities pursuant to an Approved 10b5-1 Plan&#59; purchases or gifts of Moderna securities by these individuals are subject to the pre-clearance procedures mentioned above under Part II, Section 2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amendment or early termination of an Approved 10b5-1 Plan, which are only permitted in limited circumstances, must also be approved by the legal department. All Approved 10b5-1 Plans must be adopted during an open window and when the individual is not in possession of material, nonpublic information. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EFFECTIVE&#58; November 6, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>exhibit211subsidiaries1231.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="idf7c99db9d904c75967d0edce3b2b2c0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;21.1</font></div><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SUBSIDIARIES</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc.&#8217;s principal affiliates as of December 31, 2025, are listed below.  All other affiliates, if considered in the aggregate as a single affiliate, would not constitute a significant subsidiary. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction&#160;of&#160;Incorporation</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Australia Pty Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biopharma Canada Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Distributor UK Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Manufacturing UK Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Securities, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Singapore Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Spain, S.L.U.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Charitable Foundation, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Clinical Supply Distributor, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Enzymatics Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna France</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Hong Kong Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Italy S.r.l.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Japan Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Korea Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Manufacturing Australia Pty Ltd.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Manufacturing Canada Corp.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Norway AS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Norwood Real Estate LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Poland sp. z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Switzerland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ModernaTX, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Taiwan Co., Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moderna US, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit23112312025.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i4ce60763ec244ab493b7f9e3a6ff5a18_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit 23.1</font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:174%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-228718) pertaining to the Moderna Therapeutics, Inc. 2016 Stock Option and Grant Plan and the Moderna, Inc. 2018 Employee Stock Purchase Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-230245) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-236713) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan and the Moderna, Inc. 2018 Employee Stock Purchase Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-271667) of Moderna, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-277318) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan, and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(6)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-285106) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;20, 2026, with respect to the consolidated financial statements of Moderna, Inc. and the effectiveness of internal control over financial reporting of Moderna, Inc. included in this Annual Report (Form 10-K) of Moderna Inc. for the year ended December 31, 2025.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">Boston, Massachusetts</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:174%">February&#160;20, 2026 </font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exhibit31112312025.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic8dc53e5657e4dd5bd0bdfb8b7b97d61_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EX-31.1 Section 302 Certification of CEO</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, St&#233;phane Bancel, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form&#160;10-K of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;20, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exhibit31212312025.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic1ae0d8485ff40988ec54dfa65ddb0e7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EX-31.2 Section 302 Certification of CFO</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, James M. Mock, certify that&#58;</font></div><div style="margin-bottom:9pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form&#160;10-K of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;20, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#47;s&#47; James M. Mock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">James M. Mock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exhibit32112312025.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="iea8d52a1058444e09c81179b33aa598b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, St&#233;phane Bancel, Chief Executive Officer of Moderna,&#160;Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:0.1%"></td><td style="width:1.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the Annual Report on Form&#160;10-K of the Company for the year ended&#160;December 31, 2025&#160;(Annual Report) fully complies with the requirements of Section&#160;13(a)&#160;or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.279%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;20, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>exhibit32212312025.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ibbacf5970fc548f996e526f0222fc4b1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, James M. Mock, Chief Financial Officer of Moderna,&#160;Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:0.1%"></td><td style="width:1.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the Annual Report on Form&#160;10-K of the Company for the year ended&#160;December 31, 2025&#160;(Annual Report) fully complies with the requirements of Section&#160;13(a)&#160;or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.557%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;20, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; James M. Mock</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">James M. Mock</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>mrna-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:2100a978-c810-4eca-85d9-7a3f37c08d9d,g:e414d930-d10b-4c86-a1cd-8d87f72aa21b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.modernatx.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.modernatx.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.modernatx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952156 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness">
        <link:definition>9952157 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetProductSales" roleURI="http://www.modernatx.com/role/NetProductSales">
        <link:definition>9952159 - Disclosure - Net Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenue" roleURI="http://www.modernatx.com/role/OtherRevenue">
        <link:definition>9952160 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsandResearchandDevelopmentFundingArrangements" roleURI="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements">
        <link:definition>9952161 - Disclosure - Collaboration Agreements and Research and Development Funding Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurements" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements">
        <link:definition>9952162 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.modernatx.com/role/Inventory">
        <link:definition>9952163 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNet">
        <link:definition>9952164 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponents" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents">
        <link:definition>9952165 - Disclosure - Other Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.modernatx.com/role/Leases">
        <link:definition>9952166 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditAgreement" roleURI="http://www.modernatx.com/role/CreditAgreement">
        <link:definition>9952167 - Disclosure - Credit Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.modernatx.com/role/CommitmentsandContingencies">
        <link:definition>9952168 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchasePrograms" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms">
        <link:definition>9952169 - Disclosure - Stock-Based Compensation and Share Repurchase Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.modernatx.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShare" roleURI="http://www.modernatx.com/role/LossperShare">
        <link:definition>9952171 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformation" roleURI="http://www.modernatx.com/role/GeographicInformation">
        <link:definition>9952172 - Disclosure - Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetProductSalesTables" roleURI="http://www.modernatx.com/role/NetProductSalesTables">
        <link:definition>9955513 - Disclosure - Net Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenueTables" roleURI="http://www.modernatx.com/role/OtherRevenueTables">
        <link:definition>9955514 - Disclosure - Other Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables">
        <link:definition>9955515 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.modernatx.com/role/InventoryTables">
        <link:definition>9955516 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>9955517 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsTables" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables">
        <link:definition>9955518 - Disclosure - Other Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.modernatx.com/role/LeasesTables">
        <link:definition>9955519 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsTables" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables">
        <link:definition>9955520 - Disclosure - Stock-Based Compensation and Share Repurchase Programs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.modernatx.com/role/IncomeTaxesTables">
        <link:definition>9955521 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareTables" roleURI="http://www.modernatx.com/role/LossperShareTables">
        <link:definition>9955522 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationTables" roleURI="http://www.modernatx.com/role/GeographicInformationTables">
        <link:definition>9955523 - Disclosure - Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessDetails" roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessDetails">
        <link:definition>9955524 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails">
        <link:definition>9955527 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails">
        <link:definition>9955528 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>9955529 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" roleURI="http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails">
        <link:definition>9955530 - Disclosure - Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetProductSalesNarrativeDetails" roleURI="http://www.modernatx.com/role/NetProductSalesNarrativeDetails">
        <link:definition>9955531 - Disclosure - Net Product Sales - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetProductSalesProductSalesDetails" roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesDetails">
        <link:definition>9955532 - Disclosure - Net Product Sales - Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails">
        <link:definition>9955533 - Disclosure - Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenueScheduleofDisaggregationofRevenueDetails" roleURI="http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails">
        <link:definition>9955534 - Disclosure - Other Revenue - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenueNarrativeDetails" roleURI="http://www.modernatx.com/role/OtherRevenueNarrativeDetails">
        <link:definition>9955535 - Disclosure - Other Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails">
        <link:definition>9955536 - Disclosure - Collaboration Agreements and Research and Development Funding Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
        <link:definition>9955537 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails">
        <link:definition>9955538 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>9955539 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails">
        <link:definition>9955540 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails">
        <link:definition>9955541 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryCurrentDetails" roleURI="http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails">
        <link:definition>9955542 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.modernatx.com/role/InventoryNarrativeDetails">
        <link:definition>9955543 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetDetails" roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails">
        <link:definition>9955544 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails">
        <link:definition>9955545 - Disclosure - Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955546 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails">
        <link:definition>9955547 - Disclosure - Other Balance Sheet Components - Other Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>9955548 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails">
        <link:definition>9955549 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails">
        <link:definition>9955550 - Disclosure - Other Balance Sheet Components - Schedule of Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsDeferredRevenueDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails">
        <link:definition>9955551 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails">
        <link:definition>9955552 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetInformationDetails" roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails">
        <link:definition>9955553 - Disclosure - Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails">
        <link:definition>9955554 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails">
        <link:definition>9955555 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails_1" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1">
        <link:definition>9955555 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditAgreementDetails" roleURI="http://www.modernatx.com/role/CreditAgreementDetails">
        <link:definition>9955556 - Disclosure - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLegalProceedingsDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails">
        <link:definition>9955557 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesIndemnificationObligationsDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails">
        <link:definition>9955558 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
        <link:definition>9955559 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails">
        <link:definition>9955560 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails">
        <link:definition>9955561 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails">
        <link:definition>9955562 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails">
        <link:definition>9955563 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails">
        <link:definition>9955564 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails">
        <link:definition>9955565 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails">
        <link:definition>9955566 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>9955567 - Disclosure - Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>9955568 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveTaxRateReconciliationDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails">
        <link:definition>9955569 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails">
        <link:definition>9955570 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955571 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails">
        <link:definition>9955572 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationAllowanceDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails">
        <link:definition>9955573 - Disclosure - Income Taxes - Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>9955574 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" roleURI="http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>9955575 - Disclosure - Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" roleURI="http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails">
        <link:definition>9955576 - Disclosure - Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationDetails" roleURI="http://www.modernatx.com/role/GeographicInformationDetails">
        <link:definition>9955577 - Disclosure - Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrna_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ProductSalesMember" abstract="true" name="ProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" abstract="false" name="IncreaseDecreaseInRightOfUseAssetOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" abstract="false" name="FinanceLeasePrincipalPaymentsNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="CurrentAssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrna_NumberOfCommercialProducts" abstract="false" name="NumberOfCommercialProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_NumberOfDevelopmentCandidates" abstract="false" name="NumberOfDevelopmentCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_NumberOfDevelopmentPrograms" abstract="false" name="NumberOfDevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_FFFEnterprisesMember" abstract="true" name="FFFEnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_PublicWorksAndGovernmentServicesCanadaMember" abstract="true" name="PublicWorksAndGovernmentServicesCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_UKHealthSecurityAgencyMember" abstract="true" name="UKHealthSecurityAgencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MexicoMedistikMember" abstract="true" name="MexicoMedistikMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_BoryungBiopharmaKoreaMember" abstract="true" name="BoryungBiopharmaKoreaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_TaiwanFoodAndDrugAdministrationMember" abstract="true" name="TaiwanFoodAndDrugAdministrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" abstract="true" name="MinistryOfHealthLaborAndWelfareOfJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RestOfTheWorldMember" abstract="true" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RSVMember" abstract="true" name="RSVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" abstract="false" name="ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" abstract="false" name="ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityProvision" abstract="false" name="ContractWithCustomerLiabilityProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" abstract="false" name="ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRefundRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" abstract="false" name="ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" abstract="false" name="ContractWithCustomerLiabilityProvisionsMadeInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" abstract="false" name="ContractWithCustomerLiabilityProvisionRelatedToSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" abstract="false" name="ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" abstract="true" name="CollaborationArrangementIncludingArrangementsWithAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_LicenseAndRoyaltyMember" abstract="true" name="LicenseAndRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StandReadyManufacturingRevenueMember" abstract="true" name="StandReadyManufacturingRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" abstract="true" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OtherGrantRevenueMember" abstract="true" name="OtherGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OtherCollaborativePartiesMember" abstract="true" name="OtherCollaborativePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_NumberOfParticipants" abstract="false" name="NumberOfParticipants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_RevenueFromGrantsCurrentFundingCapacity" abstract="false" name="RevenueFromGrantsCurrentFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_BlackstoneLifeSciencesBlackstoneMember" abstract="true" name="BlackstoneLifeSciencesBlackstoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ImmaticsMember" abstract="true" name="ImmaticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" abstract="true" name="PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ProceedsFromOptionExerciseFee" abstract="false" name="ProceedsFromOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RecoveryOfCostsCapitalExpenditures" abstract="false" name="RecoveryOfCostsCapitalExpenditures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CollaborativeArrangementFundingAmount" abstract="false" name="CollaborativeArrangementFundingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentLiabilityCurrent" abstract="false" name="ResearchAndDevelopmentLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CurrentMarketableSecuritiesMember" abstract="true" name="CurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_NoncurrentMarketableSecuritiesMember" abstract="true" name="NoncurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_COVIDVaccineMember" abstract="true" name="COVIDVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MNEXSPIKEMember" abstract="true" name="MNEXSPIKEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RSVVaccineMember" abstract="true" name="RSVVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_LegalContingencyFutureFirmPurchaseCommitments" abstract="false" name="LegalContingencyFutureFirmPurchaseCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_InventoryShelfLife" abstract="false" name="InventoryShelfLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrna_FinancingRightOfUseAssetMember" abstract="true" name="FinancingRightOfUseAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AccountsReceivableChargebacksDiscountsAndFees" abstract="false" name="AccountsReceivableChargebacksDiscountsAndFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OtherPrepaidExpenseMaterialsAndSupplies" abstract="false" name="OtherPrepaidExpenseMaterialsAndSupplies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CollaborationReceivableCurrent" abstract="false" name="CollaborationReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DownpaymentsAndPrepaymentsNoncurrent" abstract="false" name="DownpaymentsAndPrepaymentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedManufacturing" abstract="false" name="AccruedManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedDevelopmentOperation" abstract="false" name="AccruedDevelopmentOperation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedOtherExternalGoodsAndServicesCurrent" abstract="false" name="AccruedOtherExternalGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedPropertyAndEquipmentCurrent" abstract="false" name="AccruedPropertyAndEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RawMaterialsAccountsPayable" abstract="false" name="RawMaterialsAccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedCommercial" abstract="false" name="AccruedCommercial" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedClinicalTrials" abstract="false" name="AccruedClinicalTrials" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_EstimatedReimbursementLiability" abstract="false" name="EstimatedReimbursementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityTable" abstract="true" name="ChangeInContractWithCustomerLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityLineItems" abstract="true" name="ChangeInContractWithCustomerLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerLiabilityDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CambridgeMassachusettsMember" abstract="true" name="CambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MTCSouthMTCNorthAndMTCEastMember" abstract="true" name="MTCSouthMTCNorthAndMTCEastMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ModernaTechnologyCenterMember" abstract="true" name="ModernaTechnologyCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OperatingLeaseNumberOfProperties" abstract="false" name="OperatingLeaseNumberOfProperties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseNumberOfExtensions" abstract="false" name="LesseeOperatingLeaseNumberOfExtensions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseRightOfUseAsset" abstract="false" name="OperatingAndFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiability" abstract="false" name="OperatingAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" abstract="false" name="RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" abstract="false" name="RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_LesseeFinanceLeaseExpense" abstract="false" name="LesseeFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" abstract="false" name="LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_InitialTermLoanMember" abstract="true" name="InitialTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DelayedDrawTermLoanFacility1Member" abstract="true" name="DelayedDrawTermLoanFacility1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DelayedDrawTermLoanFacility2Member" abstract="true" name="DelayedDrawTermLoanFacility2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_TermSecuredOvernightFinancingRatePlusMember" abstract="true" name="TermSecuredOvernightFinancingRatePlusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DebtInstrumentCovenantComplianceScenarioAxis" abstract="true" name="DebtInstrumentCovenantComplianceScenarioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mrna_DebtInstrumentCovenantComplianceScenarioDomain" abstract="true" name="DebtInstrumentCovenantComplianceScenarioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_CovenantComplianceScenario1Member" abstract="true" name="CovenantComplianceScenario1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_CovenantComplianceScenario2Member" abstract="true" name="CovenantComplianceScenario2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" abstract="false" name="DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" abstract="false" name="DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" abstract="false" name="DebtInstrumentCovenantComplianceAverageMarketCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" abstract="true" name="GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" abstract="true" name="GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" abstract="true" name="GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_SupplyAndManufacturingAgreementsMember" abstract="true" name="SupplyAndManufacturingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ClinicalOperationsAndSupportCommitmentMember" abstract="true" name="ClinicalOperationsAndSupportCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ServiceBasedAwardsMember" abstract="true" name="ServiceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" abstract="true" name="RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StockOptionAndGrantPlan2016Member" abstract="true" name="StockOptionAndGrantPlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StockOptionAndIncentivePlan2018Member" abstract="true" name="StockOptionAndIncentivePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StockOptionExchangeProgramMember" abstract="true" name="StockOptionExchangeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_A2022RepurchaseProgramMember" abstract="true" name="A2022RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" abstract="false" name="StockRepurchaseProgramAdditionalAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_PerformanceStockUnitMember" abstract="true" name="PerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" abstract="true" name="MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" abstract="false" name="DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" abstract="false" name="DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsOutsideBasisDifference" abstract="false" name="DeferredTaxAssetsOutsideBasisDifference" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxValuationAllowanceRollForward" abstract="true" name="DeferredTaxValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StephaneBancelMember" abstract="true" name="StephaneBancelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_TerminationOfTradingArrangementMember" abstract="true" name="TerminationOfTradingArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AdoptionOfTradingArrangementMember" abstract="true" name="AdoptionOfTradingArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AdoptionOfTradingArrangementOptions1Member" abstract="true" name="AdoptionOfTradingArrangementOptions1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AdoptionOfTradingArrangementOptions2Member" abstract="true" name="AdoptionOfTradingArrangementOptions2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StephenHogeMember" abstract="true" name="StephenHogeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>mrna-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:2100a978-c810-4eca-85d9-7a3f37c08d9d,g:e414d930-d10b-4c86-a1cd-8d87f72aa21b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c7f0f6c7-a3a4-4323-bd84-4684afd1909c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_759d2a19-1e0e-43cf-9f9b-b20d5687b39a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c7f0f6c7-a3a4-4323-bd84-4684afd1909c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_759d2a19-1e0e-43cf-9f9b-b20d5687b39a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_25813e63-b245-4096-8eb0-badf1edf135b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c7f0f6c7-a3a4-4323-bd84-4684afd1909c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_25813e63-b245-4096-8eb0-badf1edf135b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a08e4069-c676-4c1c-a2d3-488b05f487d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c7f0f6c7-a3a4-4323-bd84-4684afd1909c" xlink:to="loc_us-gaap_InventoryNet_a08e4069-c676-4c1c-a2d3-488b05f487d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea89fbce-46dd-4cb1-95cb-9181ba0ded3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c7f0f6c7-a3a4-4323-bd84-4684afd1909c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea89fbce-46dd-4cb1-95cb-9181ba0ded3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46452f7c-c8a5-4b39-bc27-a3e6b6aeaa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c7f0f6c7-a3a4-4323-bd84-4684afd1909c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46452f7c-c8a5-4b39-bc27-a3e6b6aeaa0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b61a4073-ed56-4e90-bfca-1a2f6667c843" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c07a681b-f4ef-48c5-b17e-b9b51242ea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b61a4073-ed56-4e90-bfca-1a2f6667c843" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c07a681b-f4ef-48c5-b17e-b9b51242ea98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a3cf814b-3cee-4180-99d3-7acdad5b649c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b61a4073-ed56-4e90-bfca-1a2f6667c843" xlink:to="loc_us-gaap_AccountsPayableCurrent_a3cf814b-3cee-4180-99d3-7acdad5b649c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fd839e33-bce2-4981-bfc2-548c1d0e5c54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b61a4073-ed56-4e90-bfca-1a2f6667c843" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fd839e33-bce2-4981-bfc2-548c1d0e5c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0efa7ba5-b800-4620-905b-f0bdb3f81227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b61a4073-ed56-4e90-bfca-1a2f6667c843" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0efa7ba5-b800-4620-905b-f0bdb3f81227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_81c1e506-3dcc-4d53-9f01-8f142fcdfaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:to="loc_us-gaap_LiabilitiesCurrent_81c1e506-3dcc-4d53-9f01-8f142fcdfaf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15fd3749-53c0-4f29-a468-f52dfc9cca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15fd3749-53c0-4f29-a468-f52dfc9cca5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019b9299-b427-7577-b40a-d8d85e6256e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019b9299-b427-7577-b40a-d8d85e6256e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a0332a6a-e179-4253-99f6-df02749358b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a0332a6a-e179-4253-99f6-df02749358b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f1783290-ab60-4315-856a-9192b68986a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f1783290-ab60-4315-856a-9192b68986a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6b3e5585-be04-4cd0-9b23-fe2780e4d641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1d8c1218-c1d9-4c86-aa19-8fc823b36923" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6b3e5585-be04-4cd0-9b23-fe2780e4d641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dfe744a5-0b02-4c14-964b-910c754d4770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4ba9273-78a5-4862-8e21-051f885d93e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dfe744a5-0b02-4c14-964b-910c754d4770" xlink:to="loc_us-gaap_AssetsCurrent_c4ba9273-78a5-4862-8e21-051f885d93e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_501278ff-e327-4219-8cbb-a696f841e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dfe744a5-0b02-4c14-964b-910c754d4770" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_501278ff-e327-4219-8cbb-a696f841e2d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3d69d8cc-a3ca-4e1b-95d7-992fe1b17f83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dfe744a5-0b02-4c14-964b-910c754d4770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3d69d8cc-a3ca-4e1b-95d7-992fe1b17f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_53323116-5bea-4bea-b1d9-87ad8d26fb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dfe744a5-0b02-4c14-964b-910c754d4770" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_53323116-5bea-4bea-b1d9-87ad8d26fb3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_22fe73cf-3b5a-4363-9354-8e4cabeca808" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dfe744a5-0b02-4c14-964b-910c754d4770" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_22fe73cf-3b5a-4363-9354-8e4cabeca808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6263bd73-b2a6-4083-99ae-1cc0a504b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_09069fb1-2c3e-4d51-893c-2c95bd351a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6263bd73-b2a6-4083-99ae-1cc0a504b7a5" xlink:to="loc_us-gaap_PreferredStockValue_09069fb1-2c3e-4d51-893c-2c95bd351a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9a87c177-47be-419d-9841-8e73ea61cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6263bd73-b2a6-4083-99ae-1cc0a504b7a5" xlink:to="loc_us-gaap_CommonStockValue_9a87c177-47be-419d-9841-8e73ea61cac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_907bcf10-fbba-42ba-a25e-547b71c60d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6263bd73-b2a6-4083-99ae-1cc0a504b7a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_907bcf10-fbba-42ba-a25e-547b71c60d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c5c3b2e-aa8e-42f9-a1ec-9c4c060acab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6263bd73-b2a6-4083-99ae-1cc0a504b7a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c5c3b2e-aa8e-42f9-a1ec-9c4c060acab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d0ceb988-8984-41e7-8d16-75699c52b2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6263bd73-b2a6-4083-99ae-1cc0a504b7a5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d0ceb988-8984-41e7-8d16-75699c52b2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68317941-0ec1-4fa2-a45e-48e42dd79b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33cafa18-5506-4589-b5ab-6ad601343713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_68317941-0ec1-4fa2-a45e-48e42dd79b5a" xlink:to="loc_us-gaap_StockholdersEquity_33cafa18-5506-4589-b5ab-6ad601343713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a284e0d8-d759-4ee9-a02f-833ed726a461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_68317941-0ec1-4fa2-a45e-48e42dd79b5a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a284e0d8-d759-4ee9-a02f-833ed726a461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e1f12b42-6745-4ddb-8f3d-aff4862c553d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_68317941-0ec1-4fa2-a45e-48e42dd79b5a" xlink:to="loc_us-gaap_Liabilities_e1f12b42-6745-4ddb-8f3d-aff4862c553d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4aa8d88f-08a8-47a3-9a49-7a2ff8351bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fcfaa3aa-8393-40b9-9bfd-8b4b498c0796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4aa8d88f-08a8-47a3-9a49-7a2ff8351bdc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fcfaa3aa-8393-40b9-9bfd-8b4b498c0796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_50fdf273-5e75-448f-9f6b-7dc70a6d26c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4aa8d88f-08a8-47a3-9a49-7a2ff8351bdc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_50fdf273-5e75-448f-9f6b-7dc70a6d26c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_eac22170-cd15-42c9-bd34-b95091083e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4aa8d88f-08a8-47a3-9a49-7a2ff8351bdc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_eac22170-cd15-42c9-bd34-b95091083e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2eb6295-e1c8-48c8-ba69-a931fe9bf1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a1aa21d7-ecee-4cd7-8ac6-7396e7cc7156" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2eb6295-e1c8-48c8-ba69-a931fe9bf1f9" xlink:to="loc_us-gaap_OperatingIncomeLoss_a1aa21d7-ecee-4cd7-8ac6-7396e7cc7156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_260dc013-7cc5-4e62-b951-0c955ae5367d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2eb6295-e1c8-48c8-ba69-a931fe9bf1f9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_260dc013-7cc5-4e62-b951-0c955ae5367d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_65d1445b-02c6-4c06-803b-e5718e563e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2eb6295-e1c8-48c8-ba69-a931fe9bf1f9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_65d1445b-02c6-4c06-803b-e5718e563e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_011d797e-e5ae-4cef-aa1f-6bca9d2ac3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03817008-d5e0-4d6d-9f35-a94bd7cc52e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_011d797e-e5ae-4cef-aa1f-6bca9d2ac3cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03817008-d5e0-4d6d-9f35-a94bd7cc52e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6b0e9860-fd5e-4984-b20d-1e8bcf993a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_011d797e-e5ae-4cef-aa1f-6bca9d2ac3cb" xlink:to="loc_us-gaap_CostsAndExpenses_6b0e9860-fd5e-4984-b20d-1e8bcf993a3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad3b0e97-6fd6-44dc-a980-a808da4f661b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b5f7ed76-33da-42b8-95da-51de4b4fb485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad3b0e97-6fd6-44dc-a980-a808da4f661b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b5f7ed76-33da-42b8-95da-51de4b4fb485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_65509518-3928-48dd-aa4c-93083ed97da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad3b0e97-6fd6-44dc-a980-a808da4f661b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_65509518-3928-48dd-aa4c-93083ed97da7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6c7b34c7-1c5f-44c7-b41d-949d572d8b11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_65c4d26d-d331-406d-8e15-13b0133ca25a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6c7b34c7-1c5f-44c7-b41d-949d572d8b11" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_65c4d26d-d331-406d-8e15-13b0133ca25a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ed20d63-4f32-4bd3-86d3-8685818fb504" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8c03c82a-1ca4-4936-9ac7-2916e99219a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ed20d63-4f32-4bd3-86d3-8685818fb504" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8c03c82a-1ca4-4936-9ac7-2916e99219a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_8209f516-d629-4a61-b8fd-ee4088c28cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ed20d63-4f32-4bd3-86d3-8685818fb504" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_8209f516-d629-4a61-b8fd-ee4088c28cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e4b7a721-0fd5-4394-ae33-85dc0db7bf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ed20d63-4f32-4bd3-86d3-8685818fb504" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e4b7a721-0fd5-4394-ae33-85dc0db7bf3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_ba3b1b36-b1c5-4e48-a2f6-017c68543b59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ed20d63-4f32-4bd3-86d3-8685818fb504" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_ba3b1b36-b1c5-4e48-a2f6-017c68543b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4291571-d7ab-4302-a25c-1aab0260b4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84123faf-f5d3-40f5-9459-5336d09b1f27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4291571-d7ab-4302-a25c-1aab0260b4a6" xlink:to="loc_us-gaap_NetIncomeLoss_84123faf-f5d3-40f5-9459-5336d09b1f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a4666d8-2ff3-4563-b643-dcbf9c7ba081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4291571-d7ab-4302-a25c-1aab0260b4a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a4666d8-2ff3-4563-b643-dcbf9c7ba081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7e202fb0-2a9c-4f8f-ae7f-2fa6a462cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c18b0227-f494-49af-ab6d-e64b1d370fab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7e202fb0-2a9c-4f8f-ae7f-2fa6a462cc54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c18b0227-f494-49af-ab6d-e64b1d370fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8c9e36d1-a2bd-4660-98e8-eaeff2647bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7e202fb0-2a9c-4f8f-ae7f-2fa6a462cc54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8c9e36d1-a2bd-4660-98e8-eaeff2647bd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c9984520-6eab-405c-8b33-fab32a9ccf92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6c36560-f7c2-4ecb-bdec-f9b30a7cd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c9984520-6eab-405c-8b33-fab32a9ccf92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6c36560-f7c2-4ecb-bdec-f9b30a7cd6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e6f1dde-82e2-4b3e-bb63-9915c66f6a13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c9984520-6eab-405c-8b33-fab32a9ccf92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e6f1dde-82e2-4b3e-bb63-9915c66f6a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_264dfa61-68a6-4778-9828-dba8c14b6359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c9984520-6eab-405c-8b33-fab32a9ccf92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_264dfa61-68a6-4778-9828-dba8c14b6359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c52ba-98e1-727a-a885-f16f6ff8b935" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c9984520-6eab-405c-8b33-fab32a9ccf92" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c52ba-98e1-727a-a885-f16f6ff8b935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0630a660-f0b6-42e0-b774-e8b745c9e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_77e187c8-5f6f-4817-8658-ac3ddf54fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0630a660-f0b6-42e0-b774-e8b745c9e1bf" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_77e187c8-5f6f-4817-8658-ac3ddf54fcb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0ae85912-9b68-4a70-ae7a-4a718beccb84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0630a660-f0b6-42e0-b774-e8b745c9e1bf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0ae85912-9b68-4a70-ae7a-4a718beccb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_6821efb4-e69a-4999-9e9a-1e07ef942916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0630a660-f0b6-42e0-b774-e8b745c9e1bf" xlink:to="loc_us-gaap_ProceedsFromStockPlans_6821efb4-e69a-4999-9e9a-1e07ef942916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019b92a0-3127-7332-9ee9-87d2d64850ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0630a660-f0b6-42e0-b774-e8b745c9e1bf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019b92a0-3127-7332-9ee9-87d2d64850ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_019bee5c-3180-7b49-a557-f3440b1db764" xlink:href="mrna-20251231.xsd#mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0630a660-f0b6-42e0-b774-e8b745c9e1bf" xlink:to="loc_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_019bee5c-3180-7b49-a557-f3440b1db764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b539918c-5454-4906-807e-0ef51c8cfcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b539918c-5454-4906-807e-0ef51c8cfcd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_75905e83-78e8-45fa-b213-74ffb473c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_75905e83-78e8-45fa-b213-74ffb473c7ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_01adab90-aff8-441b-8218-f4613fdf858f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_01adab90-aff8-441b-8218-f4613fdf858f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e7483ea-2253-4cc4-b83a-e48a3b3ebd62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e7483ea-2253-4cc4-b83a-e48a3b3ebd62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e434bc9-7f26-430f-984c-63b9899f5c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e434bc9-7f26-430f-984c-63b9899f5c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b30fdce6-5871-4c2a-8cbf-8477b44aaffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b30fdce6-5871-4c2a-8cbf-8477b44aaffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_019c2995-fb8d-757e-a9e5-fa2edc365eff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5e26bb3-253f-45f2-9a95-4b45d7c6d144" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_019c2995-fb8d-757e-a9e5-fa2edc365eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c9995ef3-0a98-4384-9c45-b5d38dadf32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c9995ef3-0a98-4384-9c45-b5d38dadf32e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ea9a739f-4270-4482-b87b-a097dffb3007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ea9a739f-4270-4482-b87b-a097dffb3007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a5d9cffb-78d1-437c-b08a-d8fe345f4a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a5d9cffb-78d1-437c-b08a-d8fe345f4a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_090512d7-145b-4b32-980a-cef16dea3629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_090512d7-145b-4b32-980a-cef16dea3629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af09fd21-0219-4876-aac5-cd73b43f4afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af09fd21-0219-4876-aac5-cd73b43f4afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ecfe67c0-d82e-44e4-941a-abedddf874f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_ShareBasedCompensation_ecfe67c0-d82e-44e4-941a-abedddf874f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_aaf8c07d-17e8-44ef-81a8-20222766f790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_aaf8c07d-17e8-44ef-81a8-20222766f790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84c7a104-456a-4122-8561-a72e8c734c53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84c7a104-456a-4122-8561-a72e8c734c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_efd99ab5-d5fc-4338-87a4-c505614e0d58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_efd99ab5-d5fc-4338-87a4-c505614e0d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7bdf345c-82a3-48dd-b806-71701eccd67a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_NetIncomeLoss_7bdf345c-82a3-48dd-b806-71701eccd67a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fac9716e-4014-45cf-9075-62fd38ce1e60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fac9716e-4014-45cf-9075-62fd38ce1e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f824f88-8354-4344-8d7e-16e85e4b9ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f824f88-8354-4344-8d7e-16e85e4b9ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3bc9de78-2563-4e85-a84a-fc44646bbfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3bc9de78-2563-4e85-a84a-fc44646bbfaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_8fe3b33e-ae70-4923-85f0-e7e3e3dae887" xlink:href="mrna-20251231.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_8fe3b33e-ae70-4923-85f0-e7e3e3dae887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c426d0f4-c491-4aa3-b092-7e75440f0555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a069106f-6fd7-4874-a4ef-49ac5921e08c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c426d0f4-c491-4aa3-b092-7e75440f0555" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ab6072d-28de-4ec8-a580-46c2dbf865e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0f815df-1946-4935-b907-eff0c6b9eadc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ab6072d-28de-4ec8-a580-46c2dbf865e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0f815df-1946-4935-b907-eff0c6b9eadc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e88ac725-f001-472f-a89b-d3f792b34a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ab6072d-28de-4ec8-a580-46c2dbf865e9" xlink:to="loc_us-gaap_RestrictedCashCurrent_e88ac725-f001-472f-a89b-d3f792b34a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5bdd55b3-a5cb-4b69-bb54-5a7d31568b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ab6072d-28de-4ec8-a580-46c2dbf865e9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5bdd55b3-a5cb-4b69-bb54-5a7d31568b4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesProductSalesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/NetProductSalesProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvision_57d060c5-fafb-44d5-a3d2-35d925ecba36" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvision"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_69185811-a71f-4a88-ace4-0d4ae03371a6" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvision_57d060c5-fafb-44d5-a3d2-35d925ecba36" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_69185811-a71f-4a88-ace4-0d4ae03371a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_5f484560-772e-406b-9d71-8c71ed1c288b" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvision_57d060c5-fafb-44d5-a3d2-35d925ecba36" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_5f484560-772e-406b-9d71-8c71ed1c288b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ecf4f56d-0c57-4eea-8bfb-2216c71e0a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_c958f437-eb92-4210-9e76-cdf2117e6ecc" xlink:href="mrna-20251231.xsd#mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ecf4f56d-0c57-4eea-8bfb-2216c71e0a78" xlink:to="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_c958f437-eb92-4210-9e76-cdf2117e6ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvision_1c1b07e2-18a2-4926-9931-ff58f43ae1b1" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvision"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ecf4f56d-0c57-4eea-8bfb-2216c71e0a78" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvision_1c1b07e2-18a2-4926-9931-ff58f43ae1b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7c6d7f15-99b2-4081-8960-b3a1ccae3447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10237708-848d-41f7-847d-d0b8d859df8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7c6d7f15-99b2-4081-8960-b3a1ccae3447" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10237708-848d-41f7-847d-d0b8d859df8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27e05c3f-96cb-4581-a8b7-e0e985f595a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7c6d7f15-99b2-4081-8960-b3a1ccae3447" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27e05c3f-96cb-4581-a8b7-e0e985f595a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ae3d328-c05c-4e94-993a-36cc70c9e336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7c6d7f15-99b2-4081-8960-b3a1ccae3447" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ae3d328-c05c-4e94-993a-36cc70c9e336" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6897bab7-1298-430d-8983-b70f76c6077f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_edf1ab02-59c6-4aa9-ba1e-abf3871fc09d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6897bab7-1298-430d-8983-b70f76c6077f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_edf1ab02-59c6-4aa9-ba1e-abf3871fc09d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8cb66b38-32bc-47ea-b8c2-5377fcf2bc43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6897bab7-1298-430d-8983-b70f76c6077f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8cb66b38-32bc-47ea-b8c2-5377fcf2bc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_04256270-ca2e-4ead-b296-97c7ccb1756c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3b41c1aa-03a2-446a-af08-81a2ae7bbb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_04256270-ca2e-4ead-b296-97c7ccb1756c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3b41c1aa-03a2-446a-af08-81a2ae7bbb8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0e94c808-f9d8-4e1f-a11d-86562fbeff19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_04256270-ca2e-4ead-b296-97c7ccb1756c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0e94c808-f9d8-4e1f-a11d-86562fbeff19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_85dca87b-4062-4bde-8a14-29e71be52614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e0a138f4-3661-431f-b9bf-3d4a7af6f710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_85dca87b-4062-4bde-8a14-29e71be52614" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e0a138f4-3661-431f-b9bf-3d4a7af6f710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b00ca2a9-2de6-404f-8cc0-f843d9abc834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_85dca87b-4062-4bde-8a14-29e71be52614" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b00ca2a9-2de6-404f-8cc0-f843d9abc834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b34eb93a-6be3-4f30-ac4b-07eca680f776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2540df7-4800-477b-860a-0b6ccba4b72f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b34eb93a-6be3-4f30-ac4b-07eca680f776" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2540df7-4800-477b-860a-0b6ccba4b72f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5adc83e9-bad4-4747-b6e8-ec0f26ca83b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b34eb93a-6be3-4f30-ac4b-07eca680f776" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5adc83e9-bad4-4747-b6e8-ec0f26ca83b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_885a2ef3-2e19-4f9f-bb34-21e27fff5214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0ab2487e-26ff-49bb-8d6b-f664eb17b5df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_885a2ef3-2e19-4f9f-bb34-21e27fff5214" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0ab2487e-26ff-49bb-8d6b-f664eb17b5df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_0407f829-375a-4402-8470-f45e3c70ed95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_885a2ef3-2e19-4f9f-bb34-21e27fff5214" xlink:to="loc_us-gaap_DerivativeAssets_0407f829-375a-4402-8470-f45e3c70ed95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b52f00c4-8e5f-4755-a5b5-94254cd30dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f74c947d-2253-4674-8cf4-46177a412ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b52f00c4-8e5f-4755-a5b5-94254cd30dec" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f74c947d-2253-4674-8cf4-46177a412ad3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d3c292ee-ed1d-4ef7-b67e-55fbd7f4fe63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b52f00c4-8e5f-4755-a5b5-94254cd30dec" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d3c292ee-ed1d-4ef7-b67e-55fbd7f4fe63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_74de4e6a-ad0d-44a5-afa7-4a11c38a8ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b52f00c4-8e5f-4755-a5b5-94254cd30dec" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_74de4e6a-ad0d-44a5-afa7-4a11c38a8ed5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#PropertyPlantandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_411a3675-5f83-4e26-8ce8-6e64f2833f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_e6f93b9f-f589-4447-9260-8f6101f3e8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_411a3675-5f83-4e26-8ce8-6e64f2833f20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_e6f93b9f-f589-4447-9260-8f6101f3e8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ea944ce7-fd63-40f4-81bb-9bfba042fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_411a3675-5f83-4e26-8ce8-6e64f2833f20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ea944ce7-fd63-40f4-81bb-9bfba042fd76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_019c434a-acb3-7760-aba1-cbe92214303e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_019c434a-acb3-7670-8466-2b6c4eae2066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_019c434a-acb3-7760-aba1-cbe92214303e" xlink:to="loc_us-gaap_AccountsReceivableGross_019c434a-acb3-7670-8466-2b6c4eae2066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccountsReceivableChargebacksDiscountsAndFees_019c434a-acb3-777f-91f8-40095bd8da3f" xlink:href="mrna-20251231.xsd#mrna_AccountsReceivableChargebacksDiscountsAndFees"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_019c434a-acb3-7760-aba1-cbe92214303e" xlink:to="loc_mrna_AccountsReceivableChargebacksDiscountsAndFees_019c434a-acb3-777f-91f8-40095bd8da3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_019c434a-acb3-7880-9596-f069d865e5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_019c434a-acb3-7760-aba1-cbe92214303e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_019c434a-acb3-7880-9596-f069d865e5ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_fb065247-3d0d-4278-8e71-a2d6abe87a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_fb065247-3d0d-4278-8e71-a2d6abe87a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_bf100ef6-b56e-497c-91ac-937e4e2caa23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_us-gaap_OtherAssetsCurrent_bf100ef6-b56e-497c-91ac-937e4e2caa23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationReceivableCurrent_0e1567a5-176c-4f01-8d9c-50bfd8f9c785" xlink:href="mrna-20251231.xsd#mrna_CollaborationReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_mrna_CollaborationReceivableCurrent_0e1567a5-176c-4f01-8d9c-50bfd8f9c785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_fe7471de-1f88-4fab-8cb1-53f20d5d4651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_fe7471de-1f88-4fab-8cb1-53f20d5d4651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseMaterialsAndSupplies_32e042cb-d9c7-45ec-90b4-91c8fd82eace" xlink:href="mrna-20251231.xsd#mrna_OtherPrepaidExpenseMaterialsAndSupplies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_mrna_OtherPrepaidExpenseMaterialsAndSupplies_32e042cb-d9c7-45ec-90b4-91c8fd82eace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_68a94406-1fd0-4d48-8333-b869507a2ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_us-gaap_PrepaidTaxes_68a94406-1fd0-4d48-8333-b869507a2ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_6241ce40-dd8e-4c26-9014-04627b96c491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_us-gaap_InterestReceivableCurrent_6241ce40-dd8e-4c26-9014-04627b96c491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_1ff96ecc-e5cb-4d40-a923-91cb2b38b449" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b2421e3-0b5a-4fdb-a8bf-f91713f5c7d2" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_1ff96ecc-e5cb-4d40-a923-91cb2b38b449" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_19c2b6fe-ed38-4dd8-835b-c077599a9029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_19c2b6fe-ed38-4dd8-835b-c077599a9029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a279c39f-b6e1-437f-9469-10a147cc6fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_EquityMethodInvestments_a279c39f-b6e1-437f-9469-10a147cc6fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_1e8dbff6-bd69-4014-9b0b-72344450ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_1e8dbff6-bd69-4014-9b0b-72344450ab5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6836249e-13ad-46f2-954c-c662ebf46052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_Goodwill_6836249e-13ad-46f2-954c-c662ebf46052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DownpaymentsAndPrepaymentsNoncurrent_8e4c3673-1912-4429-af2a-e2275eb30f2a" xlink:href="mrna-20251231.xsd#mrna_DownpaymentsAndPrepaymentsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_mrna_DownpaymentsAndPrepaymentsNoncurrent_8e4c3673-1912-4429-af2a-e2275eb30f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c018c2da-b0f8-4db3-bb19-351627350f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_InventoryNoncurrent_c018c2da-b0f8-4db3-bb19-351627350f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3e8d99c-a7d4-48e9-b6c1-b30ec2e3e6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c3e8d99c-a7d4-48e9-b6c1-b30ec2e3e6b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cec4b8f3-5776-464f-bcb2-81329f39d458" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e2aaeb39-4423-4e91-ab68-35c8c69c44c7" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cec4b8f3-5776-464f-bcb2-81329f39d458" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_7386c429-c3ed-474d-8671-9d80390407b0" xlink:href="mrna-20251231.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_RawMaterialsAccountsPayable_7386c429-c3ed-474d-8671-9d80390407b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_346bb49c-bd67-4583-987e-7ed4c8c60c1d" xlink:href="mrna-20251231.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_346bb49c-bd67-4583-987e-7ed4c8c60c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_2b65ebee-da4c-40a8-845a-0e780e0b1ebe" xlink:href="mrna-20251231.xsd#mrna_AccruedManufacturing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_AccruedManufacturing_2b65ebee-da4c-40a8-845a-0e780e0b1ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_8929e296-02dd-4f86-be20-1f9b21dd23a6" xlink:href="mrna-20251231.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_AccruedDevelopmentOperation_8929e296-02dd-4f86-be20-1f9b21dd23a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_15af496c-1850-4292-8dea-32e94bd5f3d9" xlink:href="mrna-20251231.xsd#mrna_AccruedPropertyAndEquipmentCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_AccruedPropertyAndEquipmentCurrent_15af496c-1850-4292-8dea-32e94bd5f3d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_46c469ae-555c-4d15-9eec-b8ca2a65f561" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_46c469ae-555c-4d15-9eec-b8ca2a65f561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_d4f4e37d-7f90-43f9-a6e7-0b80458b7bf1" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_d4f4e37d-7f90-43f9-a6e7-0b80458b7bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_156398e2-539e-4a17-92df-900fd73bd423" xlink:href="mrna-20251231.xsd#mrna_AccruedClinicalTrials"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_AccruedClinicalTrials_156398e2-539e-4a17-92df-900fd73bd423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedCommercial_afe8b840-8fcb-481e-a72d-c6555425d5e7" xlink:href="mrna-20251231.xsd#mrna_AccruedCommercial"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_mrna_AccruedCommercial_afe8b840-8fcb-481e-a72d-c6555425d5e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_423f3b50-3501-4c96-9287-6e85aceb2214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_423f3b50-3501-4c96-9287-6e85aceb2214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ff7700d-d9da-4446-8e4f-563838c5155c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_660497a5-a0de-4703-925f-7f229076a1d1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ff7700d-d9da-4446-8e4f-563838c5155c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1ba3d757-a533-46b1-8a74-95a324dbb9df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_d7be50dc-8502-4127-a020-07747a5b4a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1ba3d757-a533-46b1-8a74-95a324dbb9df" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_d7be50dc-8502-4127-a020-07747a5b4a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4395a120-8fb3-4382-b716-3d5e33cfff1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1ba3d757-a533-46b1-8a74-95a324dbb9df" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4395a120-8fb3-4382-b716-3d5e33cfff1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_352ea8cc-5fa9-423f-a8b3-1f0fae094fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1ba3d757-a533-46b1-8a74-95a324dbb9df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_352ea8cc-5fa9-423f-a8b3-1f0fae094fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_f71a0626-c4dc-46ef-94d7-7adbe59866ce" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1ba3d757-a533-46b1-8a74-95a324dbb9df" xlink:to="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_f71a0626-c4dc-46ef-94d7-7adbe59866ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EstimatedReimbursementLiability_1c74e679-cdfd-44c7-99d3-3f3bb11bf015" xlink:href="mrna-20251231.xsd#mrna_EstimatedReimbursementLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1ba3d757-a533-46b1-8a74-95a324dbb9df" xlink:to="loc_mrna_EstimatedReimbursementLiability_1c74e679-cdfd-44c7-99d3-3f3bb11bf015" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3f8e5bbb-e294-4378-bf05-38a9d3f3d357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3426cd4b-2630-4330-8448-22685682c077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3f8e5bbb-e294-4378-bf05-38a9d3f3d357" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3426cd4b-2630-4330-8448-22685682c077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_3ef3ee6f-7376-4d9b-b2ea-618c920bb4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3f8e5bbb-e294-4378-bf05-38a9d3f3d357" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_3ef3ee6f-7376-4d9b-b2ea-618c920bb4ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_782206cb-3841-4b93-8e12-e6479c3e1362" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_b73f5c31-ae2e-4b76-a365-168f3823f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_782206cb-3841-4b93-8e12-e6479c3e1362" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_b73f5c31-ae2e-4b76-a365-168f3823f75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_757379fd-8be0-4467-8d4e-1d050dc78ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_782206cb-3841-4b93-8e12-e6479c3e1362" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_757379fd-8be0-4467-8d4e-1d050dc78ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_f4cfb4e5-1c8b-4318-8386-bcbd63fed451" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e46d96f7-acd5-47a1-b351-986298df623e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_f4cfb4e5-1c8b-4318-8386-bcbd63fed451" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e46d96f7-acd5-47a1-b351-986298df623e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3d64063e-e46e-4cfc-9175-c7ac33f2422d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_f4cfb4e5-1c8b-4318-8386-bcbd63fed451" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3d64063e-e46e-4cfc-9175-c7ac33f2422d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_dba48092-bb7c-4bc3-b1af-e655d894f13c" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_b675feec-6dd3-4d70-b9a5-98d35eb587cc" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_dba48092-bb7c-4bc3-b1af-e655d894f13c" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_b675feec-6dd3-4d70-b9a5-98d35eb587cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_0608d965-86cf-414e-be02-0bbf32612e9c" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_dba48092-bb7c-4bc3-b1af-e655d894f13c" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_0608d965-86cf-414e-be02-0bbf32612e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_3a11ec2d-d5fc-4c70-a6ab-41cb0978315c" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ee6d423-b020-4c55-ae32-a00bb44f251c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_3a11ec2d-d5fc-4c70-a6ab-41cb0978315c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ee6d423-b020-4c55-ae32-a00bb44f251c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d916e1db-926c-455e-9781-0682ab8d248b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_3a11ec2d-d5fc-4c70-a6ab-41cb0978315c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d916e1db-926c-455e-9781-0682ab8d248b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseCost_7a7be110-ab3b-49bd-afb6-d927b274d5ac" xlink:href="mrna-20251231.xsd#mrna_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e1f5704a-e19c-4451-af7c-a74655fd85cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_FinanceLeaseCost_7a7be110-ab3b-49bd-afb6-d927b274d5ac" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e1f5704a-e19c-4451-af7c-a74655fd85cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3806cd50-1c8b-4f3a-a0e2-dc750a862ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_FinanceLeaseCost_7a7be110-ab3b-49bd-afb6-d927b274d5ac" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3806cd50-1c8b-4f3a-a0e2-dc750a862ace" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_b2a85023-f38b-41c4-8f93-fe2ba0241248" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_b2a85023-f38b-41c4-8f93-fe2ba0241248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_9a083595-0546-4e5b-859f-ca8173c6e19c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_9a083595-0546-4e5b-859f-ca8173c6e19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_bdeeb814-7d0a-4852-9b61-b353b11130c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_bdeeb814-7d0a-4852-9b61-b353b11130c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_9697cd99-1083-4db6-9e8f-5073b8fd0d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_9697cd99-1083-4db6-9e8f-5073b8fd0d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_b469c7e3-70f1-40b6-b5c0-4d26d1695bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_b469c7e3-70f1-40b6-b5c0-4d26d1695bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_a1a8d1cc-bcc7-484f-a4b6-2af520847af5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_87c0e04c-4968-4813-89d6-dccdeb8106b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_a1a8d1cc-bcc7-484f-a4b6-2af520847af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_043288e3-1953-4f69-baed-87c46b334aab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ca15b245-06bb-4730-b24b-f3a943104b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_043288e3-1953-4f69-baed-87c46b334aab" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ca15b245-06bb-4730-b24b-f3a943104b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_387274e2-bdbf-4047-9622-64fce6aced25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_043288e3-1953-4f69-baed-87c46b334aab" xlink:to="loc_us-gaap_FinanceLeaseLiability_387274e2-bdbf-4047-9622-64fce6aced25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_20d3447b-6418-4255-bb53-8aa69704e9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_20d3447b-6418-4255-bb53-8aa69704e9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_7a0a292d-e4fe-4e5b-a811-a1ff0e3f61d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_7a0a292d-e4fe-4e5b-a811-a1ff0e3f61d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_14c816f2-0b07-4479-aee2-b57771602287" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_14c816f2-0b07-4479-aee2-b57771602287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_46ff3590-6966-4fda-bd8a-a5e326d28162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_46ff3590-6966-4fda-bd8a-a5e326d28162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_c1c91f1c-53cc-4e68-820d-2bbe29e70088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_c1c91f1c-53cc-4e68-820d-2bbe29e70088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_1dc8503f-dc05-4504-883e-ccdae105b026" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_32f4f175-b99b-4e39-8da4-e3cf36bc9e7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_1dc8503f-dc05-4504-883e-ccdae105b026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_104c8b7e-03fb-40a9-8588-6cc1b87f9734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ce974f8b-3371-4a49-9e92-1c6f736a2c50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_104c8b7e-03fb-40a9-8588-6cc1b87f9734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ce974f8b-3371-4a49-9e92-1c6f736a2c50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_50cc355e-a1af-4186-988e-582fe7c09e07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_104c8b7e-03fb-40a9-8588-6cc1b87f9734" xlink:to="loc_us-gaap_OperatingLeaseLiability_50cc355e-a1af-4186-988e-582fe7c09e07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_970b94f5-0fb0-4075-8bfd-2cc6e51fd91a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_81c0e013-c169-4c6b-a481-9088665a75ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_970b94f5-0fb0-4075-8bfd-2cc6e51fd91a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_81c0e013-c169-4c6b-a481-9088665a75ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c5307fe8-60b5-429f-b375-4ff759725137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_970b94f5-0fb0-4075-8bfd-2cc6e51fd91a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c5307fe8-60b5-429f-b375-4ff759725137" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73bd4e8c-4078-4cf9-95f6-8ad9b8e62456" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6f56e001-1fcd-4449-a15b-5a1379786fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73bd4e8c-4078-4cf9-95f6-8ad9b8e62456" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6f56e001-1fcd-4449-a15b-5a1379786fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_90af0d6e-5543-4917-9f1c-26f378e20da9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73bd4e8c-4078-4cf9-95f6-8ad9b8e62456" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_90af0d6e-5543-4917-9f1c-26f378e20da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a4c36265-57d5-446f-ba03-b4abd14d42c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_73bd4e8c-4078-4cf9-95f6-8ad9b8e62456" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a4c36265-57d5-446f-ba03-b4abd14d42c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f0166867-c5b9-4ca3-90c0-02183d64958c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b7a8c4e-2299-4c80-bb7f-b968a21d9a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f0166867-c5b9-4ca3-90c0-02183d64958c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b7a8c4e-2299-4c80-bb7f-b968a21d9a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8146b4f7-077e-4c7b-a9bc-a8c7b5a4671e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f0166867-c5b9-4ca3-90c0-02183d64958c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8146b4f7-077e-4c7b-a9bc-a8c7b5a4671e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27afd309-82ab-4e2e-ba6e-589185986447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_57308664-19c6-4aa6-af3c-94ddd9e1b55f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27afd309-82ab-4e2e-ba6e-589185986447" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_57308664-19c6-4aa6-af3c-94ddd9e1b55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_eca19e78-73cd-44ff-b512-733dbbe6bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27afd309-82ab-4e2e-ba6e-589185986447" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_eca19e78-73cd-44ff-b512-733dbbe6bfc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_42e33fe6-db6e-4b5b-ad78-ebe4cb699bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27afd309-82ab-4e2e-ba6e-589185986447" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_42e33fe6-db6e-4b5b-ad78-ebe4cb699bcd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-7cc2-be3f-2cbf8e6fdc72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-7cc2-be3f-2cbf8e6fdc72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-709e-92cf-f106c4075c80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-709e-92cf-f106c4075c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-75e1-856c-4b98230a3962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-75e1-856c-4b98230a3962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_019c1dd0-2715-716f-8028-de9715f94980" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_019c1dd0-2715-716f-8028-de9715f94980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1dd0-2715-7308-ae03-babbcbc5cdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1dd0-2715-7308-ae03-babbcbc5cdaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c1dd0-2715-7990-b6af-30a789d9be9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c1dd0-2715-7990-b6af-30a789d9be9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1dd0-2715-7f31-aa96-9baf5cda6ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1dd0-2715-7f31-aa96-9baf5cda6ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c1dd0-2715-71ae-97cb-e3cc88993989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c1dd0-2715-71ae-97cb-e3cc88993989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c1dd0-2715-768c-8896-f3d28becc0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-7e80-aa67-5d6e0bb0b619" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c1dd0-2715-768c-8896-f3d28becc0c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-710e-9a98-bdd79546a82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-710e-9a98-bdd79546a82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-719e-9365-48feb77a0bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-719e-9365-48feb77a0bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-7797-b5f1-059a423ae42e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-7797-b5f1-059a423ae42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_019c1dd0-2715-72c1-b8b4-71ad0137799f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_019c1dd0-2715-72c1-b8b4-71ad0137799f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1dd0-2715-70ec-a47c-73b415042382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1dd0-2715-70ec-a47c-73b415042382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c1dd0-2715-7b19-aec3-689769479d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c1dd0-2715-7b19-aec3-689769479d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1dd0-2715-7118-87ff-5be565639217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1dd0-2715-7118-87ff-5be565639217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c1dd0-2715-704e-8b65-1f138f94db98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c1dd0-2715-704e-8b65-1f138f94db98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c1dd0-2715-716a-98a4-96a2564c5816" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-76ff-a5e9-51198f46d733" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c1dd0-2715-716a-98a4-96a2564c5816" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c8a4601c-8e47-4987-8acc-0ad7da36292b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c8a4601c-8e47-4987-8acc-0ad7da36292b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_6541b741-505f-4001-8d5d-2665b97b2731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_6541b741-505f-4001-8d5d-2665b97b2731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_581803b5-7c51-4ff9-90a3-072855ebc46f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_581803b5-7c51-4ff9-90a3-072855ebc46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f8ec63d4-6a5c-4ebc-a905-97d8edbce14a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f8ec63d4-6a5c-4ebc-a905-97d8edbce14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_3570cd6c-22f6-4ee2-9a3b-765a6dc66b46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_3570cd6c-22f6-4ee2-9a3b-765a6dc66b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bc08e35d-5865-43bd-9baa-978d413604d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bc08e35d-5865-43bd-9baa-978d413604d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_25672e6d-983a-44fc-991e-04866c402ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_25672e6d-983a-44fc-991e-04866c402ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_3a4ca387-6d31-4e33-87bb-bf18a04c3537" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e0439be5-8048-4787-88a7-dc66375ee1d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_3a4ca387-6d31-4e33-87bb-bf18a04c3537" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_70be44d5-8a7b-47b7-9732-b9087b45d8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_c060b104-7188-4ba1-a18b-314d5174276f" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_70be44d5-8a7b-47b7-9732-b9087b45d8a2" xlink:to="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_c060b104-7188-4ba1-a18b-314d5174276f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_97f9cbf9-e990-414a-9c43-309c99e2d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_70be44d5-8a7b-47b7-9732-b9087b45d8a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_97f9cbf9-e990-414a-9c43-309c99e2d4f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_f1da051f-b47b-4d00-a11e-f44c9b8dbc80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_70be44d5-8a7b-47b7-9732-b9087b45d8a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_f1da051f-b47b-4d00-a11e-f44c9b8dbc80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8374f34b-b97b-4153-865b-37a2a287aea6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8374f34b-b97b-4153-865b-37a2a287aea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_979993aa-62b2-4f3d-abcd-baaf835eea8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_979993aa-62b2-4f3d-abcd-baaf835eea8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_cc70202d-eeb4-4722-981d-d1e3018af8c5" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_cc70202d-eeb4-4722-981d-d1e3018af8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b6f718ee-3865-4ccd-9bb2-27606a00daef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b6f718ee-3865-4ccd-9bb2-27606a00daef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_171865a0-b826-4bce-bfe8-38beffe3ca48" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_171865a0-b826-4bce-bfe8-38beffe3ca48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss_3b6f18ee-eb4f-4d81-b19e-c2e18880094c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOtherComprehensiveLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss_3b6f18ee-eb4f-4d81-b19e-c2e18880094c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_d695d83f-2718-4ec7-9a08-f684ae184b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_d695d83f-2718-4ec7-9a08-f684ae184b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_5dbe37ab-5af0-4d9c-8fdb-9f9914b93628" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_5dbe37ab-5af0-4d9c-8fdb-9f9914b93628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_0c36df58-da65-4bfb-89fe-97c21214c270" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_0c36df58-da65-4bfb-89fe-97c21214c270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOutsideBasisDifference_3c366123-cc11-42cb-9b06-d18d2f9011ed" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsOutsideBasisDifference"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_mrna_DeferredTaxAssetsOutsideBasisDifference_3c366123-cc11-42cb-9b06-d18d2f9011ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_178e2d07-98c3-4360-80d0-72895bf6c227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4f83073f-57be-4852-ba81-c15fef91ee05" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_178e2d07-98c3-4360-80d0-72895bf6c227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d9449b81-9930-4a65-86ac-11b1ebd465cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b719beb9-a219-4447-aa55-414bc46ad52a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d9449b81-9930-4a65-86ac-11b1ebd465cf" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b719beb9-a219-4447-aa55-414bc46ad52a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5ec006b3-5a06-45a6-b72c-02962f0c3dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d9449b81-9930-4a65-86ac-11b1ebd465cf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5ec006b3-5a06-45a6-b72c-02962f0c3dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b11990d-be3e-45cc-8f58-e1805f659916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0feb9ab0-7545-42ee-bbe4-7e60f4e8fadd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b11990d-be3e-45cc-8f58-e1805f659916" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_0feb9ab0-7545-42ee-bbe4-7e60f4e8fadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c7527004-479a-463e-9c5d-8b8111bc4614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6b11990d-be3e-45cc-8f58-e1805f659916" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c7527004-479a-463e-9c5d-8b8111bc4614" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>mrna-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:2100a978-c810-4eca-85d9-7a3f37c08d9d,g:e414d930-d10b-4c86-a1cd-8d87f72aa21b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:to="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14cc229b-a13f-42a7-bfd9-ab030639cb7b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:to="loc_srt_ProductsAndServicesDomain_14cc229b-a13f-42a7-bfd9-ab030639cb7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:to="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_4f81f8de-ba43-4259-910d-bf0797e770d1" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:to="loc_mrna_ProductSalesMember_4f81f8de-ba43-4259-910d-bf0797e770d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_5d04de63-9d2e-4c72-a50d-79560bbf78ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_5d04de63-9d2e-4c72-a50d-79560bbf78ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e841fd57-5b14-4f0d-a753-db807542f636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_RevenuesAbstract_e841fd57-5b14-4f0d-a753-db807542f636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3d6b28a-cd0a-4c60-8f25-eee645665b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e841fd57-5b14-4f0d-a753-db807542f636" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3d6b28a-cd0a-4c60-8f25-eee645665b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5f4f02ca-4202-499a-b4ea-596f7796795d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5f4f02ca-4202-499a-b4ea-596f7796795d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cfd83fa9-4bdb-48bf-ae68-88bed5ca2522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cfd83fa9-4bdb-48bf-ae68-88bed5ca2522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_53144bae-27dd-41c1-bc8f-5f6fd6a0b08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_53144bae-27dd-41c1-bc8f-5f6fd6a0b08b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7e132724-05ac-4566-aeba-9c339d19c5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_CostsAndExpenses_7e132724-05ac-4566-aeba-9c339d19c5e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aba3e326-4801-4385-8d57-9bee2550193d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_OperatingIncomeLoss_aba3e326-4801-4385-8d57-9bee2550193d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c8e2531a-050a-4918-ab10-4a24498e967d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c8e2531a-050a-4918-ab10-4a24498e967d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bdbba59e-aaab-49ff-9b0f-dbfb22e5757d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bdbba59e-aaab-49ff-9b0f-dbfb22e5757d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cacc1aaf-9d26-4d1a-bca2-3206c6bd44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cacc1aaf-9d26-4d1a-bca2-3206c6bd44b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1985dddd-4529-4812-a2ec-b085ff3e8713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1985dddd-4529-4812-a2ec-b085ff3e8713" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2eb9a063-ffc4-4d05-aa54-8bb4c7fe4859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_NetIncomeLoss_2eb9a063-ffc4-4d05-aa54-8bb4c7fe4859" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_482d7b6f-8625-4e04-87e3-8c99350b6108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:to="loc_us-gaap_EarningsPerShareBasic_482d7b6f-8625-4e04-87e3-8c99350b6108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e1950712-c4da-4938-b78e-3e36b31cd798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e1950712-c4da-4938-b78e-3e36b31cd798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_276d7a29-695b-4b00-990d-380f30f07a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_276d7a29-695b-4b00-990d-380f30f07a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01daa26f-c44d-434f-b28d-f52647409839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01daa26f-c44d-434f-b28d-f52647409839" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60cdce0f-58c4-4b6f-b9fa-0b594bc2cd66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_60cdce0f-58c4-4b6f-b9fa-0b594bc2cd66" xlink:to="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:to="loc_us-gaap_EquityComponentDomain_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:to="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_772a8b3c-9a12-42b4-a42b-4600348da4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_CommonStockMember_772a8b3c-9a12-42b4-a42b-4600348da4bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12ab9719-afc2-4201-9e70-e629496ae78c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12ab9719-afc2-4201-9e70-e629496ae78c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181796-77ee-402b-bb53-a740d5c562f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181796-77ee-402b-bb53-a740d5c562f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c08cf460-7db3-4610-bcbe-659e3ef7a9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_RetainedEarningsMember_c08cf460-7db3-4610-bcbe-659e3ef7a9fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60cdce0f-58c4-4b6f-b9fa-0b594bc2cd66" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3e186b1f-a739-40c8-9c85-97ec7325cc69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3e186b1f-a739-40c8-9c85-97ec7325cc69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f8deb380-3050-46b8-b1fc-92b5218e8291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockholdersEquity_f8deb380-3050-46b8-b1fc-92b5218e8291" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73ca336c-f303-4b29-9aab-9c936af56da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73ca336c-f303-4b29-9aab-9c936af56da6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_632f7e7d-7a54-4f48-b82e-d4e18553a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_632f7e7d-7a54-4f48-b82e-d4e18553a4e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e51aef21-4b08-44e2-8c28-d6d151bfeaee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e51aef21-4b08-44e2-8c28-d6d151bfeaee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019c05b4-f8b8-7604-acdc-df13dbb8747d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019c05b4-f8b8-7604-acdc-df13dbb8747d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6df0f69-187e-4018-97f0-8d32a77bce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6df0f69-187e-4018-97f0-8d32a77bce6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_00c60209-77e1-4e5b-876f-759f4262d0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_00c60209-77e1-4e5b-876f-759f4262d0fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9060eef-238a-4875-9cb6-ff2353879b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9060eef-238a-4875-9cb6-ff2353879b4a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_62261013-0a47-4e5c-99aa-0430f1468006" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_62261013-0a47-4e5c-99aa-0430f1468006" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_942d4e8d-2b62-4394-916b-e47a049afe07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_942d4e8d-2b62-4394-916b-e47a049afe07" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_fd6590e5-06b6-47be-a168-a69cae4e1e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_fd6590e5-06b6-47be-a168-a69cae4e1e72" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac9c7c75-324b-4053-bf60-10fffb736611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_NetIncomeLoss_ac9c7c75-324b-4053-bf60-10fffb736611" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9d7c027d-83d8-45ee-9c9a-c8cfbdcd5f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ebf8928-11af-4de4-9ece-f6014de30fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_cad6b8b7-667c-40f1-a70c-6cc32b0c63af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_cad6b8b7-667c-40f1-a70c-6cc32b0c63af" xlink:to="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a1579771-d575-41fd-9df4-07a9577a8bb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a1579771-d575-41fd-9df4-07a9577a8bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_92e9e2fe-e03c-4885-9f63-f46db99da02e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_92e9e2fe-e03c-4885-9f63-f46db99da02e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a05b46c1-cc26-4fd1-b692-b69ef7cf51e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:to="loc_us-gaap_AccountsReceivableMember_a05b46c1-cc26-4fd1-b692-b69ef7cf51e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2b18898b-7345-44b5-87c7-1db6cd1b11df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2b18898b-7345-44b5-87c7-1db6cd1b11df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d305439d-1d36-4f4b-8e8d-f8884788b775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d305439d-1d36-4f4b-8e8d-f8884788b775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1bdd8f24-ac0e-4a17-a08b-41f95134b424" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d305439d-1d36-4f4b-8e8d-f8884788b775" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1bdd8f24-ac0e-4a17-a08b-41f95134b424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:to="loc_srt_NameOfMajorCustomerDomain_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:to="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FFFEnterprisesMember_7ff5dd24-59de-4dc5-9245-307706460aec" xlink:href="mrna-20251231.xsd#mrna_FFFEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_FFFEnterprisesMember_7ff5dd24-59de-4dc5-9245-307706460aec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PublicWorksAndGovernmentServicesCanadaMember_019c05b6-6bc0-7189-b2be-25f0fb5a6eb6" xlink:href="mrna-20251231.xsd#mrna_PublicWorksAndGovernmentServicesCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_PublicWorksAndGovernmentServicesCanadaMember_019c05b6-6bc0-7189-b2be-25f0fb5a6eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CardinalHealthMember_019c05b6-6bc0-72d8-9b8b-e7b10efdd675" xlink:href="mrna-20251231.xsd#mrna_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_CardinalHealthMember_019c05b6-6bc0-72d8-9b8b-e7b10efdd675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UKHealthSecurityAgencyMember_d0e5499d-40c2-4a8a-b39a-2967e7f44767" xlink:href="mrna-20251231.xsd#mrna_UKHealthSecurityAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_UKHealthSecurityAgencyMember_d0e5499d-40c2-4a8a-b39a-2967e7f44767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MexicoMedistikMember_019c05b6-6bc0-7b6a-ae98-40da4fc339dd" xlink:href="mrna-20251231.xsd#mrna_MexicoMedistikMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_MexicoMedistikMember_019c05b6-6bc0-7b6a-ae98-40da4fc339dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BoryungBiopharmaKoreaMember_019c05b6-6bc0-7804-8d5d-728e65d1157d" xlink:href="mrna-20251231.xsd#mrna_BoryungBiopharmaKoreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_BoryungBiopharmaKoreaMember_019c05b6-6bc0-7804-8d5d-728e65d1157d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TaiwanFoodAndDrugAdministrationMember_a4f9cc7b-a963-4c26-851a-a56dd9c6cb7b" xlink:href="mrna-20251231.xsd#mrna_TaiwanFoodAndDrugAdministrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_TaiwanFoodAndDrugAdministrationMember_a4f9cc7b-a963-4c26-851a-a56dd9c6cb7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_566a5e2f-1bba-400e-acc2-ebaaa5b59a63" xlink:href="mrna-20251231.xsd#mrna_MinistryOfHealthLaborAndWelfareOfJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_566a5e2f-1bba-400e-acc2-ebaaa5b59a63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2867d909-3f80-4bca-a618-010ba2b959db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_cad6b8b7-667c-40f1-a70c-6cc32b0c63af" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2867d909-3f80-4bca-a618-010ba2b959db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdc60015-644e-43ec-9ce3-6bc106c262c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdc60015-644e-43ec-9ce3-6bc106c262c9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_de410452-87cf-4639-8709-d1fb014ddbd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_de410452-87cf-4639-8709-d1fb014ddbd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_5d812fe7-cee3-4136-95f5-c171df63bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_5d812fe7-cee3-4136-95f5-c171df63bd77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8a47f516-a710-4e74-85ee-881a801ef710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_EquipmentMember_8a47f516-a710-4e74-85ee-881a801ef710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_c061fc6c-0d2b-4adb-810f-c085489cad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_ComputerEquipmentMember_c061fc6c-0d2b-4adb-810f-c085489cad1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_78776f58-414a-4b93-adf9-fbd289e4a3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_78776f58-414a-4b93-adf9-fbd289e4a3d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:to="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bf587fd-7d92-4b68-aa6a-33151d975492_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:to="loc_srt_RangeMember_3bf587fd-7d92-4b68-aa6a-33151d975492_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:to="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3c86be70-b72a-48b9-8da4-67815d5a543f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:to="loc_srt_MinimumMember_3c86be70-b72a-48b9-8da4-67815d5a543f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9063cd6-e410-4302-9912-43259d92af11" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:to="loc_srt_MaximumMember_d9063cd6-e410-4302-9912-43259d92af11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5b5aaa50-b4ec-464b-854d-38a4de84d545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdc60015-644e-43ec-9ce3-6bc106c262c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5b5aaa50-b4ec-464b-854d-38a4de84d545" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2ced014-8612-41e5-9ed7-caa1b15232d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2ced014-8612-41e5-9ed7-caa1b15232d5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a45b5e69-538b-45b9-a76a-fdcbe6473b32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:to="loc_us-gaap_EquityComponentDomain_a45b5e69-538b-45b9-a76a-fdcbe6473b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bf299e8a-dab6-4c21-81fe-cbcc04539b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:to="loc_us-gaap_EquityComponentDomain_bf299e8a-dab6-4c21-81fe-cbcc04539b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bf299e8a-dab6-4c21-81fe-cbcc04539b3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8dcbe935-f785-406d-9aa6-c55fffcbf23c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8dcbe935-f785-406d-9aa6-c55fffcbf23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6aa3edd9-302a-4273-be87-5ee5615cb135" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6aa3edd9-302a-4273-be87-5ee5615cb135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3e2f19a3-78fc-47bc-b08c-dd194f8dac83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3e2f19a3-78fc-47bc-b08c-dd194f8dac83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2ced014-8612-41e5-9ed7-caa1b15232d5" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704a818e-62ec-4eeb-a503-ff78f8419c86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:to="loc_us-gaap_StockholdersEquity_704a818e-62ec-4eeb-a503-ff78f8419c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f90428b0-7fa3-4688-beec-ec4904fcf4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f90428b0-7fa3-4688-beec-ec4904fcf4ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f7c9123e-8c24-4b4f-b93d-d491acd31796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c4679ad1-e370-400a-a523-6ac9dbc1b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c4679ad1-e370-400a-a523-6ac9dbc1b8df" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:to="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_554a697c-f574-4a6f-9772-6db99e17e699_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:to="loc_srt_SegmentGeographicalDomain_554a697c-f574-4a6f-9772-6db99e17e699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:to="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_be7edb6d-3535-4cfd-9366-5638146be518" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:to="loc_country_US_be7edb6d-3535-4cfd-9366-5638146be518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6869b4d8-0f21-4070-b835-53b4d209913b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:to="loc_srt_EuropeMember_6869b4d8-0f21-4070-b835-53b4d209913b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfTheWorldMember_8358e3d7-e600-4a5a-bd06-3f25d93ca9ac" xlink:href="mrna-20251231.xsd#mrna_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:to="loc_mrna_RestOfTheWorldMember_8358e3d7-e600-4a5a-bd06-3f25d93ca9ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:to="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c7d3a34-ba18-4373-9caf-d939fd25ebc8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:to="loc_srt_ProductsAndServicesDomain_8c7d3a34-ba18-4373-9caf-d939fd25ebc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:to="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_32cec844-b8ec-430d-9e78-ab5daa5921cc" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:to="loc_mrna_ProductSalesMember_32cec844-b8ec-430d-9e78-ab5daa5921cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_COVID19Member_89d74309-9293-401b-9c6c-3f9b1bd05b15" xlink:href="mrna-20251231.xsd#mrna_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:to="loc_mrna_COVID19Member_89d74309-9293-401b-9c6c-3f9b1bd05b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RSVMember_4c012f3d-9faa-46da-b715-cc1c692a4662" xlink:href="mrna-20251231.xsd#mrna_RSVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:to="loc_mrna_RSVMember_4c012f3d-9faa-46da-b715-cc1c692a4662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6467d355-91c0-4955-b40f-89dda65d742c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c4679ad1-e370-400a-a523-6ac9dbc1b8df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6467d355-91c0-4955-b40f-89dda65d742c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetProductSalesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8e12715f-9cf2-4c99-a09c-cf17ab422617" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8e12715f-9cf2-4c99-a09c-cf17ab422617" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:to="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6d0dd51-f679-4278-ad11-3613697599ee_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:to="loc_srt_ProductsAndServicesDomain_f6d0dd51-f679-4278-ad11-3613697599ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_304514f0-bce8-4cbf-b73e-b7ee9ef0b94b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:to="loc_srt_ProductsAndServicesDomain_304514f0-bce8-4cbf-b73e-b7ee9ef0b94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_f95eb81e-fb75-4893-9815-6255d12980f1" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_304514f0-bce8-4cbf-b73e-b7ee9ef0b94b" xlink:to="loc_mrna_ProductSalesMember_f95eb81e-fb75-4893-9815-6255d12980f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfCommercialProducts_1cad84dc-63f5-482d-953d-0581776965cb" xlink:href="mrna-20251231.xsd#mrna_NumberOfCommercialProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8e12715f-9cf2-4c99-a09c-cf17ab422617" xlink:to="loc_mrna_NumberOfCommercialProducts_1cad84dc-63f5-482d-953d-0581776965cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetProductSalesProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:to="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7f6cff1-1505-4c96-a907-5f991c26b1eb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:to="loc_srt_ProductsAndServicesDomain_d7f6cff1-1505-4c96-a907-5f991c26b1eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5cc556b-8352-40ad-8010-0ebaab672056" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:to="loc_srt_ProductsAndServicesDomain_c5cc556b-8352-40ad-8010-0ebaab672056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_cdeb8a51-e0cc-4011-84ed-eee1a0dadcca" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5cc556b-8352-40ad-8010-0ebaab672056" xlink:to="loc_mrna_ProductSalesMember_cdeb8a51-e0cc-4011-84ed-eee1a0dadcca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_60b62f43-3e32-4028-8e9f-1aa645381ee9" xlink:href="mrna-20251231.xsd#mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_60b62f43-3e32-4028-8e9f-1aa645381ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_f0ed070f-c48a-4f59-92e0-74c937e629e7" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_f0ed070f-c48a-4f59-92e0-74c937e629e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_0d5bf38a-c76a-4def-9414-4e3194804463" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_0d5bf38a-c76a-4def-9414-4e3194804463" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvision_ee30b449-6e16-498c-af67-d9f273246ad0" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvision_ee30b449-6e16-498c-af67-d9f273246ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9879224-32a2-45a0-b777-16e4ef26da16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9879224-32a2-45a0-b777-16e4ef26da16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_019bb39e-c1e0-7330-b76c-f19760a8d8a1" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_019bb39e-c1e0-7330-b76c-f19760a8d8a1" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fb8b9200-476b-4d85-9f8d-dec5726d9538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fb8b9200-476b-4d85-9f8d-dec5726d9538" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:to="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b85a04c3-66c7-403b-8019-71e8c3bf2d07_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:to="loc_srt_ProductsAndServicesDomain_b85a04c3-66c7-403b-8019-71e8c3bf2d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7b63b8d-4cd1-4cfc-9000-d05c4a380dfb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:to="loc_srt_ProductsAndServicesDomain_e7b63b8d-4cd1-4cfc-9000-d05c4a380dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_b1d529a8-b81f-4673-b6f2-6f38a159d6ff" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e7b63b8d-4cd1-4cfc-9000-d05c4a380dfb" xlink:to="loc_mrna_ProductSalesMember_b1d529a8-b81f-4673-b6f2-6f38a159d6ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityRefundRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fb8b9200-476b-4d85-9f8d-dec5726d9538" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_81a0354c-5b1c-4660-9e0c-a96a0d080b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_81a0354c-5b1c-4660-9e0c-a96a0d080b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_e20840be-0e7a-4bed-a8d0-005d2d337853" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_e20840be-0e7a-4bed-a8d0-005d2d337853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_3426040f-b23d-4737-b91c-a2569b923a83" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_3426040f-b23d-4737-b91c-a2569b923a83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_38de99b9-1101-4030-be8f-b40617c546d3" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionRelatedToSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_38de99b9-1101-4030-be8f-b40617c546d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_7a35dd80-77b2-450c-a4ef-1df6078db3c4" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_7a35dd80-77b2-450c-a4ef-1df6078db3c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_b7ce871f-9164-46bd-9eb7-2e97d2aaf850" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherRevenueScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5e542c62-0645-48e1-8969-a4479cfa9ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5e542c62-0645-48e1-8969-a4479cfa9ed8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_39252819-b223-48c5-a509-651bb91a75ca_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:to="loc_srt_ProductsAndServicesDomain_39252819-b223-48c5-a509-651bb91a75ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:to="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_acb37a76-5d54-46a4-8299-bf1bae44f706" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_us-gaap_GrantMember_acb37a76-5d54-46a4-8299-bf1bae44f706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_acb5f0b1-ec51-4729-917b-3a8f31fcd077" xlink:href="mrna-20251231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_acb5f0b1-ec51-4729-917b-3a8f31fcd077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LicenseAndRoyaltyMember_b17a549b-6e2c-4631-b7de-b77c160baa34" xlink:href="mrna-20251231.xsd#mrna_LicenseAndRoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_mrna_LicenseAndRoyaltyMember_b17a549b-6e2c-4631-b7de-b77c160baa34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StandReadyManufacturingRevenueMember_019b92bf-3d1b-76a5-acf4-f047e699b25a" xlink:href="mrna-20251231.xsd#mrna_StandReadyManufacturingRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_mrna_StandReadyManufacturingRevenueMember_019b92bf-3d1b-76a5-acf4-f047e699b25a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_7c970dfa-1577-4ab2-b014-f503695d3c96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_7c970dfa-1577-4ab2-b014-f503695d3c96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:to="loc_srt_NameOfMajorCustomerDomain_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:to="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6cd42b26-85e1-4784-a29a-c5f18ea53c30" xlink:href="mrna-20251231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6cd42b26-85e1-4784-a29a-c5f18ea53c30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_ff0b6d3f-f737-4343-97e2-11d4d1858c1e" xlink:href="mrna-20251231.xsd#mrna_OtherGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:to="loc_mrna_OtherGrantRevenueMember_ff0b6d3f-f737-4343-97e2-11d4d1858c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a053065a-96e7-4cbf-909c-5ef5e0e1619f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a053065a-96e7-4cbf-909c-5ef5e0e1619f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_398d657f-1226-4a67-b39f-9dffc6af920a" xlink:href="mrna-20251231.xsd#mrna_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:to="loc_mrna_VertexMember_398d657f-1226-4a67-b39f-9dffc6af920a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember_1816393a-f000-4cb9-a0b1-986c4b9d6a8a" xlink:href="mrna-20251231.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:to="loc_mrna_OtherCollaborativePartiesMember_1816393a-f000-4cb9-a0b1-986c4b9d6a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60ba31cf-c2ed-4984-8984-255ea0edca58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5e542c62-0645-48e1-8969-a4479cfa9ed8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60ba31cf-c2ed-4984-8984-255ea0edca58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherRevenueNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherRevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherRevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_206d6ff7-d746-4d62-818f-6f0af56fc8e3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:to="loc_srt_NameOfMajorCustomerDomain_206d6ff7-d746-4d62-818f-6f0af56fc8e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_80df2b4b-872d-4d7e-b986-fd8afdf07105" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:to="loc_srt_NameOfMajorCustomerDomain_80df2b4b-872d-4d7e-b986-fd8afdf07105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_86e3e985-282e-4894-951c-42021c2d779b" xlink:href="mrna-20251231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80df2b4b-872d-4d7e-b986-fd8afdf07105" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_86e3e985-282e-4894-951c-42021c2d779b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31d3ff99-adaf-453a-8ebc-8a585acbda22_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:to="loc_srt_ProductsAndServicesDomain_31d3ff99-adaf-453a-8ebc-8a585acbda22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:to="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LicenseAndRoyaltyMember_df36cc82-63c0-47b6-a0dd-80cfd6136f49" xlink:href="mrna-20251231.xsd#mrna_LicenseAndRoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:to="loc_mrna_LicenseAndRoyaltyMember_df36cc82-63c0-47b6-a0dd-80cfd6136f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b2bcaf83-4411-4784-9a12-bce857c887f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b2bcaf83-4411-4784-9a12-bce857c887f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d84e3f4-ee1a-4fe5-9b89-06cff2253223" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d84e3f4-ee1a-4fe5-9b89-06cff2253223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b585081b-3cae-4158-8361-57ea5ead1106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d84e3f4-ee1a-4fe5-9b89-06cff2253223" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b585081b-3cae-4158-8361-57ea5ead1106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_f9f6f1bf-6c0d-4649-bfca-7b5aa94703ee" xlink:href="mrna-20251231.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_f9f6f1bf-6c0d-4649-bfca-7b5aa94703ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipants_60b5f96a-d26f-42df-bcb5-f2f0a41eed7c" xlink:href="mrna-20251231.xsd#mrna_NumberOfParticipants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_mrna_NumberOfParticipants_60b5f96a-d26f-42df-bcb5-f2f0a41eed7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_45e0aef7-b1a1-4cf5-a173-37f91579c938" xlink:href="mrna-20251231.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_45e0aef7-b1a1-4cf5-a173-37f91579c938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_979c04c4-6add-40e7-a3c3-b417035f9c26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_979c04c4-6add-40e7-a3c3-b417035f9c26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5d2a2e56-796a-42e4-91e0-cde309ddf457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5d2a2e56-796a-42e4-91e0-cde309ddf457" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37532998-57b0-40b5-92cc-06fdb217bb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37532998-57b0-40b5-92cc-06fdb217bb8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4df2d868-5ca7-4854-b210-acff6af9bc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4df2d868-5ca7-4854-b210-acff6af9bc2a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_140e6b46-fc3c-4f56-88ef-e24552fa5b09" xlink:href="mrna-20251231.xsd#mrna_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:to="loc_mrna_MerckMember_140e6b46-fc3c-4f56-88ef-e24552fa5b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BlackstoneLifeSciencesBlackstoneMember_5dc48857-eb56-449e-9e0a-cfc1067352ff" xlink:href="mrna-20251231.xsd#mrna_BlackstoneLifeSciencesBlackstoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:to="loc_mrna_BlackstoneLifeSciencesBlackstoneMember_5dc48857-eb56-449e-9e0a-cfc1067352ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ImmaticsMember_1c5b76b4-839f-4ec6-be3c-18158d6ee814" xlink:href="mrna-20251231.xsd#mrna_ImmaticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:to="loc_mrna_ImmaticsMember_1c5b76b4-839f-4ec6-be3c-18158d6ee814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04600176-a827-4180-a4e0-a588b42f2ed9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04600176-a827-4180-a4e0-a588b42f2ed9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_553c68c2-4203-4603-adbf-f18cebdf708b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_553c68c2-4203-4603-adbf-f18cebdf708b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5e075786-e61d-45b2-ba60-31e2797d497e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_553c68c2-4203-4603-adbf-f18cebdf708b" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5e075786-e61d-45b2-ba60-31e2797d497e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4048e4fc-3c43-46c2-8b57-710e4785d96f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4048e4fc-3c43-46c2-8b57-710e4785d96f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6be2f339-5189-4a9c-a90f-74b7d43b91a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6be2f339-5189-4a9c-a90f-74b7d43b91a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_141f5d3f-fd0e-463f-b229-7c08110d1c69" xlink:href="mrna-20251231.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6be2f339-5189-4a9c-a90f-74b7d43b91a2" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_141f5d3f-fd0e-463f-b229-7c08110d1c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProceedsFromOptionExerciseFee_55c3cf98-052e-4d7c-8682-d3607720fc61" xlink:href="mrna-20251231.xsd#mrna_ProceedsFromOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_ProceedsFromOptionExerciseFee_55c3cf98-052e-4d7c-8682-d3607720fc61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d11209af-48ef-42e6-95b9-f9796df1ff5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d11209af-48ef-42e6-95b9-f9796df1ff5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RecoveryOfCostsCapitalExpenditures_1ff3cebc-9048-47e8-b364-17338f2c128b" xlink:href="mrna-20251231.xsd#mrna_RecoveryOfCostsCapitalExpenditures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_RecoveryOfCostsCapitalExpenditures_1ff3cebc-9048-47e8-b364-17338f2c128b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborativeArrangementFundingAmount_6dcaeb91-73ea-4efb-a6a2-2557219e14d9" xlink:href="mrna-20251231.xsd#mrna_CollaborativeArrangementFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_CollaborativeArrangementFundingAmount_6dcaeb91-73ea-4efb-a6a2-2557219e14d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_53e65070-e91a-4c36-a9ef-d0d3a72dff2c" xlink:href="mrna-20251231.xsd#mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_53e65070-e91a-4c36-a9ef-d0d3a72dff2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_62008a2b-951d-4b25-a03c-7b26b50c8a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_62008a2b-951d-4b25-a03c-7b26b50c8a9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_8e05a4cf-4c22-48b0-849c-18faed49db20" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_8e05a4cf-4c22-48b0-849c-18faed49db20" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16240f6b-1214-4800-abe1-1ddd14686ba1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16240f6b-1214-4800-abe1-1ddd14686ba1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_d033c061-f9f1-4d1c-a6bb-47aeac294c50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_d033c061-f9f1-4d1c-a6bb-47aeac294c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_904523d0-154e-4c68-82ce-9ff7d4d76dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_CertificatesOfDepositMember_904523d0-154e-4c68-82ce-9ff7d4d76dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_d39df0a5-a859-47b7-8680-0a32094c8c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_d39df0a5-a859-47b7-8680-0a32094c8c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_12a68391-8809-4853-9458-5798c368bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_12a68391-8809-4853-9458-5798c368bd8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_922b78ba-28b6-459c-952e-9a9ec2a76c89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_922b78ba-28b6-459c-952e-9a9ec2a76c89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_850ec9a6-0da8-4d34-91db-a0042ddc723d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_850ec9a6-0da8-4d34-91db-a0042ddc723d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_b4c65164-2f85-4581-bb22-5f83dab4e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_b4c65164-2f85-4581-bb22-5f83dab4e1b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_ccc78364-91fa-4866-9ab1-99d22518103f" xlink:href="mrna-20251231.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_ccc78364-91fa-4866-9ab1-99d22518103f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_df988342-97f1-4deb-adc3-1c1a8ccf79c8" xlink:href="mrna-20251231.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_df988342-97f1-4deb-adc3-1c1a8ccf79c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58b72739-deae-4767-bd20-c2a196dd6ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58b72739-deae-4767-bd20-c2a196dd6ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eb794466-ff45-442d-97ca-4207884be74f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eb794466-ff45-442d-97ca-4207884be74f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0db0836e-5288-414b-9652-d1c18c35bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0db0836e-5288-414b-9652-d1c18c35bd0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c828967-24d5-4005-b4ca-6e934773f4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c828967-24d5-4005-b4ca-6e934773f4cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f030971-5dab-458d-b14f-c0dbfe65c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f030971-5dab-458d-b14f-c0dbfe65c7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3182772b-8915-4f2f-b8fb-1c2f52ef328d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3182772b-8915-4f2f-b8fb-1c2f52ef328d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aba86f61-d743-4fe3-9163-477f221be16d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aba86f61-d743-4fe3-9163-477f221be16d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:to="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_68028106-101b-47d0-a113-1b219ecaa3f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_68028106-101b-47d0-a113-1b219ecaa3f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019c3014-e91b-76e4-8928-baca9a0cf606" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019c3014-e91b-76e4-8928-baca9a0cf606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_963d8596-c11e-43e5-8852-b6d08aafea04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_963d8596-c11e-43e5-8852-b6d08aafea04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2e941844-ea92-480a-89b3-00188dbad8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2e941844-ea92-480a-89b3-00188dbad8df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_019c3014-e91b-7167-9022-2baba6591983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_019c3014-e91b-7167-9022-2baba6591983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2dfe3cc5-f319-420e-9f45-c073ada16c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2dfe3cc5-f319-420e-9f45-c073ada16c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a1716c0b-b6bf-44c8-938a-f1e109f16c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a1716c0b-b6bf-44c8-938a-f1e109f16c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_49a2290c-10db-43fc-af22-854880f76d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_49a2290c-10db-43fc-af22-854880f76d0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ab62d71b-2f1c-47ff-8388-d2336dc18512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ab62d71b-2f1c-47ff-8388-d2336dc18512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0a10f259-f911-4909-957e-461c91853e70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0a10f259-f911-4909-957e-461c91853e70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0f3952aa-2146-4612-a9c5-4902d2c299eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0f3952aa-2146-4612-a9c5-4902d2c299eb" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_14bf8c06-36a6-493f-960d-9f5ab9ba33b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_14bf8c06-36a6-493f-960d-9f5ab9ba33b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_561fc0ed-7d95-477c-845c-539e7232c320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_561fc0ed-7d95-477c-845c-539e7232c320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9b347dd7-520a-4b53-b7ec-399f14b153f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_561fc0ed-7d95-477c-845c-539e7232c320" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9b347dd7-520a-4b53-b7ec-399f14b153f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b02bd7a5-f9a3-41cc-91d7-65c7885f679c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b02bd7a5-f9a3-41cc-91d7-65c7885f679c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f7f501e5-58d2-49b0-a8dc-5405c584a2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f7f501e5-58d2-49b0-a8dc-5405c584a2ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_50582a3f-9fff-4e65-97c1-14556cfd276f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_CertificatesOfDepositMember_50582a3f-9fff-4e65-97c1-14556cfd276f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_3573e670-64c7-43ef-a30c-5a48e82bf80d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_3573e670-64c7-43ef-a30c-5a48e82bf80d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_88b836b0-e429-4e38-9648-e038129a95fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_88b836b0-e429-4e38-9648-e038129a95fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7c6bb036-b7d5-4a50-a9e8-e588fefe7929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7c6bb036-b7d5-4a50-a9e8-e588fefe7929" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_136a56b5-b047-4d50-a162-45375918b748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_136a56b5-b047-4d50-a162-45375918b748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_1d4339b8-23f7-44b3-8741-f8d8c0c67aad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_EquitySecuritiesMember_1d4339b8-23f7-44b3-8741-f8d8c0c67aad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f6eeeda-72d7-41bf-84e7-ceab8e421304_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f6eeeda-72d7-41bf-84e7-ceab8e421304_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bbb20a19-60f9-4a89-8258-f37dc3465f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bbb20a19-60f9-4a89-8258-f37dc3465f23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ff855304-e16b-4c9e-b4d2-bca4cce2dade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ff855304-e16b-4c9e-b4d2-bca4cce2dade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c863bd54-e273-4bf8-9a49-8ca0dbfb2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c863bd54-e273-4bf8-9a49-8ca0dbfb2be0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6b4f8603-6778-4467-9eb7-a6ec573a9328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DerivativeAssets_6b4f8603-6778-4467-9eb7-a6ec573a9328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_99905a05-e02e-46d9-896a-1975f98e8f08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_99905a05-e02e-46d9-896a-1975f98e8f08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_7a5b6f7c-123b-4d5b-9ac2-fc791e1bee44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_7a5b6f7c-123b-4d5b-9ac2-fc791e1bee44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bcc72349-c7c3-47a5-a9eb-37acb0cd2492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DerivativeLiabilities_bcc72349-c7c3-47a5-a9eb-37acb0cd2492" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3e1dd06c-0bee-4554-9fe1-823d0de91c3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3e1dd06c-0bee-4554-9fe1-823d0de91c3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_efcc9fd2-e999-4159-9b8d-b01dad2e0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_efcc9fd2-e999-4159-9b8d-b01dad2e0d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_COVIDVaccineMember_df42e68c-4af3-4480-9ea5-17430e7bd6cb" xlink:href="mrna-20251231.xsd#mrna_COVIDVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_mrna_COVIDVaccineMember_df42e68c-4af3-4480-9ea5-17430e7bd6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MNEXSPIKEMember_019b92ca-f2b1-771a-a33f-15169bb08b6b" xlink:href="mrna-20251231.xsd#mrna_MNEXSPIKEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_mrna_MNEXSPIKEMember_019b92ca-f2b1-771a-a33f-15169bb08b6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RSVVaccineMember_3a6b5afd-9bfe-48a3-b335-4ca641a88e5d" xlink:href="mrna-20251231.xsd#mrna_RSVVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_mrna_RSVVaccineMember_3a6b5afd-9bfe-48a3-b335-4ca641a88e5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:to="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae692e45-b177-47ef-8cbc-d8aecb074207_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:to="loc_srt_RangeMember_ae692e45-b177-47ef-8cbc-d8aecb074207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:to="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_579de9de-2227-4891-b80c-39fe5246eb89" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:to="loc_srt_MinimumMember_579de9de-2227-4891-b80c-39fe5246eb89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_004ddce2-ad2a-47f6-85c5-9d7a21c0975e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:to="loc_srt_MaximumMember_004ddce2-ad2a-47f6-85c5-9d7a21c0975e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_6b5598e3-3136-4e03-bd5e-0726277da08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryWriteDown_6b5598e3-3136-4e03-bd5e-0726277da08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_2cd98792-270c-4abe-af8a-ac0f6fcac63e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_2cd98792-270c-4abe-af8a-ac0f6fcac63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_988a1eb7-14f3-4291-aeb9-993f917ce4d5" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_988a1eb7-14f3-4291-aeb9-993f917ce4d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_95c6bf20-b4f8-48f1-92c9-acf05a7ba37f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryGross_95c6bf20-b4f8-48f1-92c9-acf05a7ba37f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InventoryShelfLife_b519fdbd-0dfc-4df7-9b62-b9bf9cf4ca23" xlink:href="mrna-20251231.xsd#mrna_InventoryShelfLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_mrna_InventoryShelfLife_b519fdbd-0dfc-4df7-9b62-b9bf9cf4ca23" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#PropertyPlantandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_44e6fa9a-339d-4230-a69f-93ed3b489170_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_44e6fa9a-339d-4230-a69f-93ed3b489170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_158297e8-89f7-4bc5-95eb-22afd0dd12b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_158297e8-89f7-4bc5-95eb-22afd0dd12b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_92d78b77-9baa-4409-99b4-e8ccd5f8dfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_92d78b77-9baa-4409-99b4-e8ccd5f8dfeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fbb1f7ee-eb0a-4a77-bfea-1e0ba282d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_EquipmentMember_fbb1f7ee-eb0a-4a77-bfea-1e0ba282d2ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_21c7fbe3-25fb-46e3-8f6a-4f6cf5d42b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_21c7fbe3-25fb-46e3-8f6a-4f6cf5d42b99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_901abbe1-1ffb-4b45-8b32-6c1d4a8b64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_901abbe1-1ffb-4b45-8b32-6c1d4a8b64ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_38015d90-24ff-4f28-b448-48c12508ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_ComputerEquipmentMember_38015d90-24ff-4f28-b448-48c12508ae1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_94a1d826-1e5a-4bb2-8381-7592ee00ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_ConstructionInProgressMember_94a1d826-1e5a-4bb2-8381-7592ee00ada7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_ab055175-b679-49d2-a94a-de223e86825f" xlink:href="mrna-20251231.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_ab055175-b679-49d2-a94a-de223e86825f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_4ec87b4a-18e8-4a79-9ccb-fe4797507dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_4ec87b4a-18e8-4a79-9ccb-fe4797507dd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_52a15f95-6740-4e33-b560-69730c961b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_52a15f95-6740-4e33-b560-69730c961b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d8428b03-db65-44b5-9a8a-968e0823fc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d8428b03-db65-44b5-9a8a-968e0823fc2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_18f9f61e-4a25-446c-acdd-d1c4f505e3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_18f9f61e-4a25-446c-acdd-d1c4f505e3d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_980bc306-d62a-465a-bfed-596cc120d8c4" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_980bc306-d62a-465a-bfed-596cc120d8c4" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:to="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d609cf69-794b-446c-8f52-15cd2aea3579_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:to="loc_srt_ProductsAndServicesDomain_d609cf69-794b-446c-8f52-15cd2aea3579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:to="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_4e8a4de3-0afe-46b1-a5d8-5def204aa3c5" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:to="loc_mrna_ProductSalesMember_4e8a4de3-0afe-46b1-a5d8-5def204aa3c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_181285a8-7b37-411a-be12-9bac49ff85a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_181285a8-7b37-411a-be12-9bac49ff85a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_980bc306-d62a-465a-bfed-596cc120d8c4" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c0111636-b05d-4abf-8fe2-c1314c521097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c0111636-b05d-4abf-8fe2-c1314c521097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_4f86ece9-7241-4703-b982-6e7e298c63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_4f86ece9-7241-4703-b982-6e7e298c63b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_956b50b0-173a-49b4-983a-288427efd8d2" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_956b50b0-173a-49b4-983a-288427efd8d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_aabb7fe6-d38c-4e31-a8f7-253f75377dde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d02bb470-d351-4e74-84f4-7d042ebaf5b8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:to="loc_srt_SegmentGeographicalDomain_d02bb470-d351-4e74-84f4-7d042ebaf5b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5a1ac13-1370-4f1f-8082-78c929cbaada" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:to="loc_srt_SegmentGeographicalDomain_f5a1ac13-1370-4f1f-8082-78c929cbaada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_0d747cec-6211-4c35-b13d-685a4f3f6220" xlink:href="mrna-20251231.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f5a1ac13-1370-4f1f-8082-78c929cbaada" xlink:to="loc_mrna_CambridgeMassachusettsMember_0d747cec-6211-4c35-b13d-685a4f3f6220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d0427bb2-b88f-412b-8d59-5b7ce713204f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d0427bb2-b88f-412b-8d59-5b7ce713204f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_074d5717-cc1b-47ca-a626-75426fa1ef0d" xlink:href="mrna-20251231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d0427bb2-b88f-412b-8d59-5b7ce713204f" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_074d5717-cc1b-47ca-a626-75426fa1ef0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7ea3-98fc-06c3884fc515_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7ea3-98fc-06c3884fc515_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7002-b8ce-d7b0696b4ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7002-b8ce-d7b0696b4ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ModernaTechnologyCenterMember_019bdc35-bd01-7054-98bd-c2af8e934073" xlink:href="mrna-20251231.xsd#mrna_ModernaTechnologyCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7002-b8ce-d7b0696b4ccd" xlink:to="loc_mrna_ModernaTechnologyCenterMember_019bdc35-bd01-7054-98bd-c2af8e934073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_1af7a032-94fe-452d-96ce-752152f25fdf" xlink:href="mrna-20251231.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_1af7a032-94fe-452d-96ce-752152f25fdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9a131b41-2a3a-4074-8af7-34e41e55322c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9a131b41-2a3a-4074-8af7-34e41e55322c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ca89b9fe-072b-465a-80da-8450c261aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ca89b9fe-072b-465a-80da-8450c261aad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensions_b0d7a13f-8fa7-49ef-97d1-3dba13978cca" xlink:href="mrna-20251231.xsd#mrna_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensions_b0d7a13f-8fa7-49ef-97d1-3dba13978cca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b30c805a-fe22-4a86-9087-525374f7a151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b30c805a-fe22-4a86-9087-525374f7a151" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019bdc35-bd01-72c2-924a-b73e55dcb6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019bdc35-bd01-72c2-924a-b73e55dcb6d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_019bdc35-bd01-748a-80b4-52bf7ca21de1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_019bdc35-bd01-748a-80b4-52bf7ca21de1" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_234960de-35c1-49cd-b9d8-6c7366496af3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_234960de-35c1-49cd-b9d8-6c7366496af3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_17f905f2-820e-442d-a284-1ce298a061f0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_17f905f2-820e-442d-a284-1ce298a061f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_87ac0210-997c-42b8-b0ec-146a906986e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_87ac0210-997c-42b8-b0ec-146a906986e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_274db07f-842a-4a3c-b3e7-c369a82fad37" xlink:href="mrna-20251231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_87ac0210-997c-42b8-b0ec-146a906986e3" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_274db07f-842a-4a3c-b3e7-c369a82fad37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d4c1d0f-f466-48f7-9a9f-ccdf435a042d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_234960de-35c1-49cd-b9d8-6c7366496af3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d4c1d0f-f466-48f7-9a9f-ccdf435a042d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CreditAgreementDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7d38-ad2d-56c386fe19ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:to="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7d38-ad2d-56c386fe19ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7a73-ba2b-a2aab6e2f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:to="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7a73-ba2b-a2aab6e2f7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b930b-6c16-757b-acb4-111cbb5fa148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7a73-ba2b-a2aab6e2f7f4" xlink:to="loc_us-gaap_SecuredDebtMember_019b930b-6c16-757b-acb4-111cbb5fa148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-7200-a3bc-d60dd223652c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-7200-a3bc-d60dd223652c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialTermLoanMember_019bb3b2-d3c9-7811-8063-3cc79629694c" xlink:href="mrna-20251231.xsd#mrna_InitialTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:to="loc_mrna_InitialTermLoanMember_019bb3b2-d3c9-7811-8063-3cc79629694c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:to="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacility1Member_019bb3b3-7323-740c-9dd0-1883b5a1d523" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacility1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:to="loc_mrna_DelayedDrawTermLoanFacility1Member_019bb3b3-7323-740c-9dd0-1883b5a1d523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacility2Member_019bb3b3-a227-7606-8f79-7c2fd0d7785c" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacility2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:to="loc_mrna_DelayedDrawTermLoanFacility2Member_019bb3b3-a227-7606-8f79-7c2fd0d7785c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-719c-b094-faf3a2c2c5e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-719c-b094-faf3a2c2c5e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-7b53-be89-1a4c658d6feb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-7b53-be89-1a4c658d6feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b930b-6c16-7713-be1b-92dfadc76aad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-7b53-be89-1a4c658d6feb" xlink:to="loc_us-gaap_LineOfCreditMember_019b930b-6c16-7713-be1b-92dfadc76aad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_019b930b-ea71-78fb-ae8e-d117c6e56df6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:to="loc_us-gaap_VariableRateDomain_019b930b-ea71-78fb-ae8e-d117c6e56df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:to="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019bb3b4-c0fb-7e5e-ad0a-4c9b22641bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019bb3b4-c0fb-7e5e-ad0a-4c9b22641bd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_019bb3b4-d87b-7edf-9efc-be200841bb37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_us-gaap_BaseRateMember_019bb3b4-d87b-7edf-9efc-be200841bb37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_019bfd0c-5647-7320-8bd0-f6e54c589652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_019bfd0c-5647-7320-8bd0-f6e54c589652" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TermSecuredOvernightFinancingRatePlusMember_019beed4-b404-7e53-aa00-705a958cb3b1" xlink:href="mrna-20251231.xsd#mrna_TermSecuredOvernightFinancingRatePlusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_mrna_TermSecuredOvernightFinancingRatePlusMember_019beed4-b404-7e53-aa00-705a958cb3b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-7818-84f4-990eb1e4e742_default" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-7818-84f4-990eb1e4e742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CovenantComplianceScenario1Member_019c05bc-f6f2-709e-b077-007a8f5a4e5a" xlink:href="mrna-20251231.xsd#mrna_CovenantComplianceScenario1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:to="loc_mrna_CovenantComplianceScenario1Member_019c05bc-f6f2-709e-b077-007a8f5a4e5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CovenantComplianceScenario2Member_019c05bd-4c22-738b-b8ca-c8ba6217e4d3" xlink:href="mrna-20251231.xsd#mrna_CovenantComplianceScenario2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:to="loc_mrna_CovenantComplianceScenario2Member_019c05bd-4c22-738b-b8ca-c8ba6217e4d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019b930b-6c16-7454-93fc-2ce40697c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019b930b-6c16-7454-93fc-2ce40697c8bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b930b-ea71-7fb7-b59e-2119f15708a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b930b-ea71-7fb7-b59e-2119f15708a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b930b-ea71-751f-9bcd-2c3f345f29e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b930b-ea71-751f-9bcd-2c3f345f29e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_019c05bb-107a-7636-8050-26e795f9be57" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_019c05bb-107a-7636-8050-26e795f9be57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_019bee81-97a5-7201-83b3-db4154ab4fab" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_019bee81-97a5-7201-83b3-db4154ab4fab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_019c05bc-6853-73af-a933-cae46b8a2cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_LineOfCredit_019c05bc-6853-73af-a933-cae46b8a2cb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_019c05be-4a54-7eb5-b4ff-0d9fb9604461" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_019c05be-4a54-7eb5-b4ff-0d9fb9604461" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019c1fce-6b4a-7b50-8456-88a0a50be669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_LongTermDebt_019c1fce-6b4a-7b50-8456-88a0a50be669" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesLegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_827937fd-7c22-452b-92ed-4ce4487e5116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_827937fd-7c22-452b-92ed-4ce4487e5116" xlink:to="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:to="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:to="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:to="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_019c713c-628a-718f-b0ea-12eacc6e6f43" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:to="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_019c713c-628a-718f-b0ea-12eacc6e6f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_019c713c-be57-7144-b6f4-3d01da925b16" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:to="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_019c713c-be57-7144-b6f4-3d01da925b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_019c713d-352a-774b-8266-73c5b8222b87" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:to="loc_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_019c713d-352a-774b-8266-73c5b8222b87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_019c6f03-bee3-7030-a644-6d23326021d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_827937fd-7c22-452b-92ed-4ce4487e5116" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_019c6f03-bee3-7030-a644-6d23326021d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesIndemnificationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7104-97ad-540ddbc6cde8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7104-97ad-540ddbc6cde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7aad-a56f-79f1aeb274d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7aad-a56f-79f1aeb274d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_019c6f02-335c-76ea-bd5b-3fbed76f19fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7aad-a56f-79f1aeb274d9" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_019c6f02-335c-76ea-bd5b-3fbed76f19fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_019c6f02-335c-718f-949c-8273ec2cb4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_019c6f02-335c-718f-949c-8273ec2cb4b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_019c6f02-335c-79c6-8529-8e96078be866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_019c6f02-335c-79c6-8529-8e96078be866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c6f02-335c-7058-8537-7dc04a9b53df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c6f02-335c-7058-8537-7dc04a9b53df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_a1a96d71-ba27-4a16-a67a-8ae599ad5bec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_a1a96d71-ba27-4a16-a67a-8ae599ad5bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_2a499cd7-9dbf-474c-b5f6-051e5504719b" xlink:href="mrna-20251231.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_2a499cd7-9dbf-474c-b5f6-051e5504719b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_19f29b37-1fe1-47f4-84b9-277fe499e781" xlink:href="mrna-20251231.xsd#mrna_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:to="loc_mrna_ClinicalServicesMember_19f29b37-1fe1-47f4-84b9-277fe499e781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_049bbdc7-ee81-4b08-bf4c-c44e259aab15" xlink:href="mrna-20251231.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_049bbdc7-ee81-4b08-bf4c-c44e259aab15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7ae6a653-f40b-444a-8110-debad89c7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7ae6a653-f40b-444a-8110-debad89c7a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_137c4546-1ed2-4b20-90b4-6a12539b88f8" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:to="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_137c4546-1ed2-4b20-90b4-6a12539b88f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:to="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d1704254-168e-4774-8602-deccc9fe3a77_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d1704254-168e-4774-8602-deccc9fe3a77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69c113dd-8e95-4abe-a5f5-679b94dffebc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69c113dd-8e95-4abe-a5f5-679b94dffebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_02d81a35-5b61-4d95-94ea-59e11f53b89b" xlink:href="mrna-20251231.xsd#mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69c113dd-8e95-4abe-a5f5-679b94dffebc" xlink:to="loc_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_02d81a35-5b61-4d95-94ea-59e11f53b89b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_019c2999-9156-7763-b7db-731d1c8acea7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_019c2999-9156-7763-b7db-731d1c8acea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_588aa2ac-6a17-49e7-a2a2-efeeeadde2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_588aa2ac-6a17-49e7-a2a2-efeeeadde2eb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7562-921f-97437e10fd22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7562-921f-97437e10fd22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ServiceBasedAwardsMember_019b933c-3bc3-7dc3-93ce-ef01a76f7e66" xlink:href="mrna-20251231.xsd#mrna_ServiceBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_mrna_ServiceBasedAwardsMember_019b933c-3bc3-7dc3-93ce-ef01a76f7e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b933c-3bc3-7b93-9bc3-54db8240ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b933c-3bc3-7b93-9bc3-54db8240ab35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019b933c-663b-7d6d-b623-5d62432330fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_us-gaap_EmployeeStockMember_019b933c-663b-7d6d-b623-5d62432330fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_019b933c-a408-72dd-a836-4651b505ee50" xlink:href="mrna-20251231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_019b933c-a408-72dd-a836-4651b505ee50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019b933c-a408-7570-b23f-fc7a2285fe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_us-gaap_PerformanceSharesMember_019b933c-a408-7570-b23f-fc7a2285fe3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019b933c-3bc3-7e70-8814-a6bf4491cffe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:to="loc_us-gaap_VestingDomain_019b933c-3bc3-7e70-8814-a6bf4491cffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:to="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019b933c-3bc3-73d6-bd3a-9fdb7cfff8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019b933c-3bc3-73d6-bd3a-9fdb7cfff8bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019b933c-3bc3-7588-822f-522ea5b3dea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019b933c-3bc3-7588-822f-522ea5b3dea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7c67-9b7e-711b68e26cf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:to="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7c67-9b7e-711b68e26cf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:to="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_019b933c-3bc3-7905-aff0-30d63005301f" xlink:href="mrna-20251231.xsd#mrna_StockOptionAndGrantPlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:to="loc_mrna_StockOptionAndGrantPlan2016Member_019b933c-3bc3-7905-aff0-30d63005301f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_019b933c-3bc3-7409-857b-a98405567572" xlink:href="mrna-20251231.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_019b933c-3bc3-7409-857b-a98405567572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionExchangeProgramMember_019c05c3-bc7d-7afe-b290-73965c308897" xlink:href="mrna-20251231.xsd#mrna_StockOptionExchangeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:to="loc_mrna_StockOptionExchangeProgramMember_019c05c3-bc7d-7afe-b290-73965c308897" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019b933c-a408-7bd3-8f23-0bd922654c1a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:to="loc_srt_RangeMember_019b933c-a408-7bd3-8f23-0bd922654c1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:to="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019b933c-a408-79c1-abe1-6a80886afeba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:to="loc_srt_MinimumMember_019b933c-a408-79c1-abe1-6a80886afeba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019b933c-a408-7bfe-8771-9750309a6eb8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:to="loc_srt_MaximumMember_019b933c-a408-7bfe-8771-9750309a6eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7fed-9c27-5a0ad4c9a15c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7fed-9c27-5a0ad4c9a15c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7999-b151-04a480c67927" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7999-b151-04a480c67927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2022RepurchaseProgramMember_019b933c-c865-7058-a603-39220eda075c" xlink:href="mrna-20251231.xsd#mrna_A2022RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7999-b151-04a480c67927" xlink:to="loc_mrna_A2022RepurchaseProgramMember_019b933c-c865-7058-a603-39220eda075c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b933c-3bc3-7000-bead-ee530a7b3f83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b933c-3bc3-7000-bead-ee530a7b3f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019b933c-3bc3-774e-8d79-6d8fbcb14623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019b933c-3bc3-774e-8d79-6d8fbcb14623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_019b933c-3bc3-7307-b92f-1959cfa17526" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_019b933c-3bc3-7307-b92f-1959cfa17526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b933c-3bc3-73ca-ae23-102914b837de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b933c-3bc3-73ca-ae23-102914b837de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019b933c-3bc3-7a28-b383-7c86c9d1a7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019b933c-3bc3-7a28-b383-7c86c9d1a7ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b933c-3bc3-7ccf-98cf-251d61910679" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b933c-3bc3-7ccf-98cf-251d61910679" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_019b933c-663b-78bb-bdbd-09f24489fdc3" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_019b933c-663b-78bb-bdbd-09f24489fdc3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019c05c3-08f8-7553-ba32-3d40e0bf5d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019c05c3-08f8-7553-ba32-3d40e0bf5d7d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_019c05c6-0e94-775b-9b33-b83f48f2d872" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_019c05c6-0e94-775b-9b33-b83f48f2d872" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c05c6-7db5-7bab-84e6-2ed28b9d58b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c05c6-7db5-7bab-84e6-2ed28b9d58b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_019c05c8-b0c1-7053-9819-f8f6342fd558" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharePrice_019c05c8-b0c1-7053-9819-f8f6342fd558" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b933c-83a6-7427-bff9-5c3fb1e53469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b933c-83a6-7427-bff9-5c3fb1e53469" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_019b933c-83a6-726b-ac1c-d0435dbdc55e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_019b933c-83a6-726b-ac1c-d0435dbdc55e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019b933c-83a6-746f-a365-ed2519335e41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019b933c-83a6-746f-a365-ed2519335e41" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_019b933c-a408-7d96-92e8-eaef91220587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_RestrictedStockExpense_019b933c-a408-7d96-92e8-eaef91220587" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_019b933c-a408-7dd2-9baa-b03ad35e3b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_019b933c-a408-7dd2-9baa-b03ad35e3b4e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019b933c-a408-7631-a6f8-29151934a513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019b933c-a408-7631-a6f8-29151934a513" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_019b933c-a408-761d-b055-d96251bfb32d" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_019b933c-a408-761d-b055-d96251bfb32d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019b933c-c865-77a8-8806-ab6bc7fff79c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019b933c-c865-77a8-8806-ab6bc7fff79c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b933c-c865-71c8-b358-265c9d792076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b933c-c865-71c8-b358-265c9d792076" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019b933c-c865-7d1d-a3e2-dd04e847e207" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019b933c-c865-7d1d-a3e2-dd04e847e207" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_019b933c-c865-7db8-87f3-2214d233af44" xlink:href="mrna-20251231.xsd#mrna_StockRepurchaseProgramAdditionalAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_019b933c-c865-7db8-87f3-2214d233af44" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:to="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0b47f72-56a3-46fb-a609-7e47a77e2f84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0b47f72-56a3-46fb-a609-7e47a77e2f84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d142b198-72bc-4187-ad4f-12217514756b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d142b198-72bc-4187-ad4f-12217514756b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_80eed304-035e-48b3-8264-819a00fe6005" xlink:href="mrna-20251231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d142b198-72bc-4187-ad4f-12217514756b" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_80eed304-035e-48b3-8264-819a00fe6005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5206ecd4-2ee9-4346-96fa-3802ef5e5f61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5206ecd4-2ee9-4346-96fa-3802ef5e5f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ca6bdbe-05de-498f-aa08-9aab078c2e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ca6bdbe-05de-498f-aa08-9aab078c2e49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37f0bfa3-a5da-44b9-b8d5-fd96b37537a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37f0bfa3-a5da-44b9-b8d5-fd96b37537a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cb35a0c-93fc-4317-8115-d28529b7460a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cb35a0c-93fc-4317-8115-d28529b7460a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e20ac36f-55b2-45a8-87fa-680f20dc2284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_453de62b-e776-43d6-abf6-a6decbb651a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_453de62b-e776-43d6-abf6-a6decbb651a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48c37918-756b-4f56-98b3-f7c060427a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48c37918-756b-4f56-98b3-f7c060427a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_25b56cc4-0ebb-4a64-b7ec-1e21db26f5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_25b56cc4-0ebb-4a64-b7ec-1e21db26f5c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_be0e6e83-432b-46c3-811b-e84f18fa283f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_be0e6e83-432b-46c3-811b-e84f18fa283f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8635733e-8967-46a2-b03d-f5741b1fdef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:to="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b967afe-ceb4-48ae-b3c6-55813f40adae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b967afe-ceb4-48ae-b3c6-55813f40adae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698edc3d-45ed-48f0-8cfe-9fd87c919fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698edc3d-45ed-48f0-8cfe-9fd87c919fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1aa42c85-5a3f-4237-bf16-38f58d9e086a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698edc3d-45ed-48f0-8cfe-9fd87c919fdc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1aa42c85-5a3f-4237-bf16-38f58d9e086a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:to="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6da55b46-cc8d-4e98-96bc-12bb6a81e823_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:to="loc_srt_RangeMember_6da55b46-cc8d-4e98-96bc-12bb6a81e823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b60debd-6145-44b3-b813-858b980857ae" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:to="loc_srt_RangeMember_7b60debd-6145-44b3-b813-858b980857ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_ea8bd210-fda8-4e52-aee7-15afc2dc1770" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b60debd-6145-44b3-b813-858b980857ae" xlink:to="loc_srt_WeightedAverageMember_ea8bd210-fda8-4e52-aee7-15afc2dc1770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0c02dca0-dce9-4c09-b280-99cd323278d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0c02dca0-dce9-4c09-b280-99cd323278d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3d3fc734-9251-43d4-99c2-25b813188ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3d3fc734-9251-43d4-99c2-25b813188ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_666ae08e-77e3-4a55-bcc0-e8b57d8171cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_666ae08e-77e3-4a55-bcc0-e8b57d8171cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d7f791ce-4758-4a30-9941-06a9c6735269" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d7f791ce-4758-4a30-9941-06a9c6735269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_95d261b4-60eb-42ab-8602-e9e9456098ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_SharePrice_95d261b4-60eb-42ab-8602-e9e9456098ea" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ab82cc-925e-49d8-a59a-b70e6b46edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ab82cc-925e-49d8-a59a-b70e6b46edb2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:to="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3914c395-8285-4ce2-b3cd-3078c8d723da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3914c395-8285-4ce2-b3cd-3078c8d723da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c800485c-2b5c-4e87-b700-39016052e48b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c800485c-2b5c-4e87-b700-39016052e48b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cf18723c-b7b6-4e29-84e3-27921f9aec6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cf18723c-b7b6-4e29-84e3-27921f9aec6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PerformanceStockUnitMember_610bebee-3e31-4307-b946-51f400b0fa22" xlink:href="mrna-20251231.xsd#mrna_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_mrna_PerformanceStockUnitMember_610bebee-3e31-4307-b946-51f400b0fa22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7a5628b6-6d75-456f-bbde-7c85dfba6c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_us-gaap_EmployeeStockMember_7a5628b6-6d75-456f-bbde-7c85dfba6c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bf2090d6-80e7-4466-9e0a-6878bd2a2301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bf2090d6-80e7-4466-9e0a-6878bd2a2301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6eb12546-a678-461c-84cd-1b449df2e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:to="loc_us-gaap_CostOfSalesMember_6eb12546-a678-461c-84cd-1b449df2e39b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b7d29810-9175-46d5-9262-d3eadb29403c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b7d29810-9175-46d5-9262-d3eadb29403c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e5723481-01cc-4e78-b11f-1ee52d16cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e5723481-01cc-4e78-b11f-1ee52d16cc39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3fffa-4738-49b5-a83a-c287a67af8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ab82cc-925e-49d8-a59a-b70e6b46edb2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3fffa-4738-49b5-a83a-c287a67af8b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_355801e8-94f6-4bb7-a968-708095f42027_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_355801e8-94f6-4bb7-a968-708095f42027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_20dc19a8-5c6b-48c4-91fb-2fe6e4fbe8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:to="loc_us-gaap_DomesticCountryMember_20dc19a8-5c6b-48c4-91fb-2fe6e4fbe8f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_777e4421-0fb5-4100-9497-31e8891e281b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_777e4421-0fb5-4100-9497-31e8891e281b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019c6f52-789c-77ae-bfba-86868d9fd033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:to="loc_us-gaap_ForeignCountryMember_019c6f52-789c-77ae-bfba-86868d9fd033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_292c58f6-c0d8-4ed7-8f4b-55857d221945_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_292c58f6-c0d8-4ed7-8f4b-55857d221945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_857da0b9-9fa0-42b3-a279-b1da0d451562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_857da0b9-9fa0-42b3-a279-b1da0d451562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_9267fa42-6721-48d4-8e45-77adfa6b0c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_857da0b9-9fa0-42b3-a279-b1da0d451562" xlink:to="loc_us-gaap_ResearchMember_9267fa42-6721-48d4-8e45-77adfa6b0c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_fb48156f-e324-4763-a883-76e7591c7082_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_fb48156f-e324-4763-a883-76e7591c7082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_7d83c35d-f02f-4efe-ae36-ccda2a6e9952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_7d83c35d-f02f-4efe-ae36-ccda2a6e9952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_7806cccc-ffd0-420e-8d36-4940818504b8" xlink:href="mrna-20251231.xsd#mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7d83c35d-f02f-4efe-ae36-ccda2a6e9952" xlink:to="loc_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_7806cccc-ffd0-420e-8d36-4940818504b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34d2a00a-fd17-48de-b41c-74de8b7bb88a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34d2a00a-fd17-48de-b41c-74de8b7bb88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3dfa40e2-b554-4060-89cd-4a24893982bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3dfa40e2-b554-4060-89cd-4a24893982bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d1ca0e53-df6a-435d-b81e-1da73bec78ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d1ca0e53-df6a-435d-b81e-1da73bec78ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_6e4e1ab4-40c6-426b-997a-a8ebbe14161d" xlink:href="mrna-20251231.xsd#mrna_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_6e4e1ab4-40c6-426b-997a-a8ebbe14161d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLossCarryforwardsSubjectToExpiration_5cb283e5-6261-4570-b147-ef94a5ff006c" xlink:href="mrna-20251231.xsd#mrna_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_mrna_OperatingLossCarryforwardsSubjectToExpiration_5cb283e5-6261-4570-b147-ef94a5ff006c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_21d0d0dd-06c7-4ce9-b10c-1919b269e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_21d0d0dd-06c7-4ce9-b10c-1919b269e93e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_577605b7-37ba-475d-ba9c-29da4b98b1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_577605b7-37ba-475d-ba9c-29da4b98b1ee" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7f9a830a-7c94-4f86-a796-982eb0c330cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7f9a830a-7c94-4f86-a796-982eb0c330cb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_edfcdb45-e68e-44ec-a367-77889de07fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_edfcdb45-e68e-44ec-a367-77889de07fe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_687a62c9-e64a-47fb-89d3-73a6673e7ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_687a62c9-e64a-47fb-89d3-73a6673e7ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0a8bdbf-2a8f-4bdf-aed9-d0d6d9d34c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7f9a830a-7c94-4f86-a796-982eb0c330cb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0a8bdbf-2a8f-4bdf-aed9-d0d6d9d34c9a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#GeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:to="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2df7ab5a-97cc-4876-bf35-c0ad68186fee_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:to="loc_srt_SegmentGeographicalDomain_2df7ab5a-97cc-4876-bf35-c0ad68186fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:to="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_06167185-5d4f-452c-a1f5-3c13c032d8ff" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:to="loc_country_US_06167185-5d4f-452c-a1f5-3c13c032d8ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8b820076-2862-4ff4-ab88-994071692afd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:to="loc_srt_EuropeMember_8b820076-2862-4ff4-ab88-994071692afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember_dc51962c-8caa-4bc1-acd1-f2ad01267ed7" xlink:href="mrna-20251231.xsd#mrna_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:to="loc_mrna_RestOfWorldMember_dc51962c-8caa-4bc1-acd1-f2ad01267ed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8aeb815-9da8-4f3a-9aba-62b4ad8606dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8aeb815-9da8-4f3a-9aba-62b4ad8606dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b1cfb824-179b-4d8f-89d7-480060a6ad33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b1cfb824-179b-4d8f-89d7-480060a6ad33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="101"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StephaneBancelMember_b1596b2a-f883-4076-a81d-cf6258e0bfec" xlink:href="mrna-20251231.xsd#mrna_StephaneBancelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mrna_StephaneBancelMember_b1596b2a-f883-4076-a81d-cf6258e0bfec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StephenHogeMember_019beea8-3119-7d6e-b489-3b102d54a4d8" xlink:href="mrna-20251231.xsd#mrna_StephenHogeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mrna_StephenHogeMember_019beea8-3119-7d6e-b489-3b102d54a4d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TerminationOfTradingArrangementMember_019c3fff-d7da-7d6e-9a77-605d2ef44e8f" xlink:href="mrna-20251231.xsd#mrna_TerminationOfTradingArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_TerminationOfTradingArrangementMember_019c3fff-d7da-7d6e-9a77-605d2ef44e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementMember_019beeaf-bcc2-731a-ba1b-ab28c3a7277c" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_AdoptionOfTradingArrangementMember_019beeaf-bcc2-731a-ba1b-ab28c3a7277c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementOptions1Member_019c4342-41c4-7be6-b245-e6bc7d19cdfb" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementOptions1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_AdoptionOfTradingArrangementOptions1Member_019c4342-41c4-7be6-b245-e6bc7d19cdfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementOptions2Member_019c4342-1179-702a-878d-ef2f141a5b42" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementOptions2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_AdoptionOfTradingArrangementOptions2Member_019c4342-1179-702a-878d-ef2f141a5b42" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>mrna-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:2100a978-c810-4eca-85d9-7a3f37c08d9d,g:e414d930-d10b-4c86-a1cd-8d87f72aa21b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mrna_ClinicalServicesMember_a27c3c43-a388-4347-a41e-a9bef186aa66_terseLabel_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_label_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_documentation_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember" xlink:href="mrna-20251231.xsd#mrna_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalServicesMember" xlink:to="lab_mrna_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_VertexMember_fe2c1be7-366c-4589-83f6-7fc916210d03_terseLabel_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_mrna_VertexMember_label_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_mrna_VertexMember_documentation_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vertex [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember" xlink:href="mrna-20251231.xsd#mrna_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VertexMember" xlink:to="lab_mrna_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_f29c60eb-1128-4a72-9d65-b4da67c5033f_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Equity Plan</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_label_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_documentation_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:href="mrna-20251231.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:to="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestOfWorldMember_5eb3685b-4702-47bf-b937-59900a1004a5_terseLabel_en-US" xlink:label="lab_mrna_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_mrna_RestOfWorldMember_label_en-US" xlink:label="lab_mrna_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_mrna_RestOfWorldMember_documentation_en-US" xlink:label="lab_mrna_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest Of World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember" xlink:href="mrna-20251231.xsd#mrna_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestOfWorldMember" xlink:to="lab_mrna_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_66cfeae5-a01f-417c-9499-c9b1be618f19_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation windfall/shortfall</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_91341446-b9ba-4494-9ebb-c01aa4f494ec_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e7396349-f2ad-49dc-8758-618b3a187440_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0ed07602-521e-463d-8558-c4502845ebbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: net realized (gains) losses on available-for-sale securities reclassified in net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_029acaf7-d502-4001-a934-596b7bef434f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockExpense_56fabfa0-e00d-48ef-847c-81dd0a7d0f78_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_019bb3b4-c0fb-74fe-9e63-df769e0bbab7_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_c81c0c6b-f9c4-4336-9218-f735b2621cad_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b94d8d68-436a-4e1b-8eb8-5c9b41b9b064_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_263367d7-4df9-4f36-a4bd-6f3df4e97a16_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_47e0792d-c1d2-44aa-b9e7-14eb0cec735c_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Geographic Information</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b914648f-52e5-41ba-95f8-5768d233188f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6d962f61-b903-4256-b230-765a4715b803_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_e69fee64-00d8-42d7-ac7d-f90d66b2fb24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_a66e3599-285f-40c3-bcfc-f3e26ba5eaee_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_5986f4c5-4f1d-4990-8f37-447d8f153fc9_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_efdbc4aa-fe1e-44ba-9a60-5713fce06311_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Returns, rebates and other fees</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision For Refunds and Other Fees</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision For Refunds and Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" xlink:to="lab_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_56c6cd51-41a3-4097-ba22-db66c4dbafdc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_299e5f74-51bb-4a11-90d6-5f751239efe9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_95f34dbe-1792-4993-b895-460f83a72ed8_terseLabel_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- Current Marketable Securities</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:href="mrna-20251231.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:to="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_InitialTermLoanMember_019b92eb-148d-7ebb-a6b6-c58e05b4ca58_terseLabel_en-US" xlink:label="lab_mrna_InitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Term Loan</link:label>
    <link:label id="lab_mrna_InitialTermLoanMember_label_en-US" xlink:label="lab_mrna_InitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Term Loan [Member]</link:label>
    <link:label id="lab_mrna_InitialTermLoanMember_documentation_en-US" xlink:label="lab_mrna_InitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialTermLoanMember" xlink:href="mrna-20251231.xsd#mrna_InitialTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InitialTermLoanMember" xlink:to="lab_mrna_InitialTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_31b306ef-5080-4706-b494-c65f068b8309_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_63438b4b-311b-4d41-9510-2cdcf55d7e32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a4d954d6-218d-4c9a-84cc-5e17653954f1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fe26568f-90e6-41f2-ae92-72bbfbc1052d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_a064e787-88fe-411a-b942-b5a2f4aded19_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid income tax</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7951447f-4676-4dc4-bb94-5fdeea740529_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7c5e-9598-5084e0b42a62_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a668edf8-6ede-4ec0-b54e-b32fbf6c7ef5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_830c550d-6075-4b6a-bdcc-2c9eab078441_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of RSUs and PSUs vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_d638349d-a891-4425-9d3d-be2e241c8e6b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment expenses</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ffef8fce-abc8-4159-8fa6-b999dc2d5069_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ab8f530c-25aa-4cbe-996b-5c4dae30a779_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_243267f3-5115-4800-9641-46d6ab8cac6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0d4eb0fb-afc7-42c4-aaad-7c5428a7be0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_f039a5fd-46c1-434d-8367-0fe1d5f0a291_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_70d6d24a-5baa-427b-8908-b85e8e287d47_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3f9e93cd-76a9-465d-8055-0df3ead1446a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_39c4aca3-d8ee-40bc-b7a0-0eee8f10cf7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_fda6ebe5-4e3e-4ec2-85a9-d8bc119044cd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements and Research and Development Funding Arrangements</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_384cde2e-4c32-42b9-90f3-d41caf75c177_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_94f8c561-03a8-43cf-9be2-c10e1699127a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8390da31-d104-46c0-b1f3-d9143f7a72f3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3ceb288a-df2a-4704-bbad-c300ead62eec_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_311a98ba-c8e8-4816-922f-318ee90e1b0f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6bff30c2-2c15-4eaf-a59e-bec962381b82_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_371e0123-90f0-4964-a872-c94819fee6f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average exercise price per share, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_767d08b1-8ac1-488a-bee7-875fdfe1a711_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_35a8af7a-b2e2-4061-adf0-ebef2859fdc9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses, Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70bf-9f05-dc9dcf5da8ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30aa2288-4a02-476b-95fb-b2f17c3fa000_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9bbab1fe-1e65-40a9-bde2-daadab0e7f09_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_dad6e1a8-7ce9-427f-b282-8bbd81daf46f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019b92d1-7e82-7774-98b6-9c4ecff86c64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_b39bf038-6a00-4bbf-a056-f475670c7fb7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9e8a1101-a7f3-4be9-b479-aabf7b8574c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2f47b874-abc4-409c-9878-9d06d832f0ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_577c9f1a-8d17-49e8-9fe4-49680a47d848_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_bb1daab3-bfab-4097-be34-15baa7ca413a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization/accretion of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4bebb0e7-4edf-4bf3-a35e-ef73c4b49729_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities - operating (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_965423d4-a4dc-4d0e-9460-aba4acc9ac02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_7bc99fb0-debf-4e4f-8766-93dd9fc5bbec_terseLabel_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cambridge Leases</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_label_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember" xlink:href="mrna-20251231.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CambridgeMassachusettsMember" xlink:to="lab_mrna_CambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_741ba833-d4bc-4986-b75a-fc3ed4546cda_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5aafd165-1b78-4f95-a9ad-fde87f373d48_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_0c45f63c-7f44-4342-8a98-a68a39944829_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationReceivableCurrent_024b1a46-057c-411e-9586-1d2e80131472_terseLabel_en-US" xlink:label="lab_mrna_CollaborationReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration receivable</link:label>
    <link:label id="lab_mrna_CollaborationReceivableCurrent_label_en-US" xlink:label="lab_mrna_CollaborationReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Receivable, Current</link:label>
    <link:label id="lab_mrna_CollaborationReceivableCurrent_documentation_en-US" xlink:label="lab_mrna_CollaborationReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationReceivableCurrent" xlink:href="mrna-20251231.xsd#mrna_CollaborationReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationReceivableCurrent" xlink:to="lab_mrna_CollaborationReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_019c6f10-34eb-726f-b40e-d5ce3cf17bf5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ca679240-4875-44f0-8e41-a861ccc68bf0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_9dd93278-21fe-4d33-8737-bd6fd443f8ca_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_b46bf9eb-fa55-4fdc-8483-791a02aeff5c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Losses (gains) on Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9dd31cc1-3844-4545-a4d7-a6e7594f3e17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b955e98e-c228-4c49-a5fd-5ae65b8841b1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_107fb561-1aa1-4b81-826c-7aaf2c8fc760_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4753356f-b4aa-4ed4-b5ac-815c4922aa68_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_COVIDVaccineMember_1380bc89-ff8f-4987-895a-a0eb4ad4cb04_terseLabel_en-US" xlink:label="lab_mrna_COVIDVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COVID Vaccine</link:label>
    <link:label id="lab_mrna_COVIDVaccineMember_label_en-US" xlink:label="lab_mrna_COVIDVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID Vaccine [Member]</link:label>
    <link:label id="lab_mrna_COVIDVaccineMember_documentation_en-US" xlink:label="lab_mrna_COVIDVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_COVIDVaccineMember" xlink:href="mrna-20251231.xsd#mrna_COVIDVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_COVIDVaccineMember" xlink:to="lab_mrna_COVIDVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_83e024c5-6545-40cd-b73d-3b391a745a91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_025bd9bc-f173-468b-aea4-ade674580e68_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f13fa690-adb2-4ff9-9d3e-28f299442251_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases, discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_aa680081-f971-41e5-a4a8-4a5c9e9f7f78_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AuditInformationAbstract_label_en-US" xlink:label="lab_mrna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mrna_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mrna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AuditInformationAbstract" xlink:href="mrna-20251231.xsd#mrna_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AuditInformationAbstract" xlink:to="lab_mrna_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bfeee2dd-e9ee-4f26-bdcc-2e9a2c528f48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ef4eee68-5f14-4d47-a0a1-6f3631d7d05b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_85ef24b2-afb9-42b9-989a-eb7b97f66b65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements with tax authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_35571027-7b36-4eec-98f7-609680bd77d7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_701b4bfb-ef68-4ff8-8008-23f03697d2d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_019c2999-9156-75a3-88ee-251338011215_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_019c05c6-0e94-7718-b916-6325e6884382_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of common stock underlying eligible options</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Common Stock Underlying Options, Percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Common Stock Underlying Options, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_21473ea3-7139-4a36-bfa1-44fa68a93c1f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases, remaining lease term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_53292b88-2532-4796-bf6f-e6da07131f18_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6840313e-8e7b-4833-8f4b-7491ce9160a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss_cc7ce8ee-39d3-4a53-a7e0-f2fdaebd7333_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOtherComprehensiveLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9d880ad8-64bd-449a-b64c-65afffdea294_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less amounts representing interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_803402ce-00c3-4ff1-8720-0fbe9bbbc9ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f193cc9c-fe1a-42a6-9a6f-9c276aba0722_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7c7129cd-b994-4e6c-ba6c-973dbed14895_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_a64b20ea-e28b-4ae3-93ea-8a0bc7709d7a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_46efb29c-d82b-4d97-9278-7b4de96a827e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_99f29e07-2ba6-4ab2-8b5b-46b1b338d6e0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7c9b90d5-15cb-462d-9f67-cc8f1e2a8404_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases to valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_49ac562d-80fb-4fb6-b2f4-d5a73dbb53d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fbd6c14-6053-40d6-8a19-e8550bc920f9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9849655f-42a4-41c5-9a66-74d478ee6648_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44e84ef2-460e-4d85-8a3e-9098bd8b59c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares/Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_902bad73-84ad-4852-b931-efbf1ad64e5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_33a64bde-e4d6-47e2-b0bf-0927efeff426_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for (benefit from) tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2081ff8b-5b54-48e7-8058-01c66dedaccc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b92cf-fcca-7f6c-952c-b4a4d8833c6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ce086534-14f1-4183-9f66-43d808d328d7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5504e1d-932f-4271-83fb-42f316ebe9d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_7e0fe272-5f01-4321-b07c-da275c4bfb09_terseLabel_en-US" xlink:label="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ministry of Health, Labor, and Welfare of Japan</link:label>
    <link:label id="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_label_en-US" xlink:label="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ministry Of Health, Labor, And Welfare Of Japan [Member]</link:label>
    <link:label id="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_documentation_en-US" xlink:label="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ministry Of Health, Labor, And Welfare Of Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" xlink:href="mrna-20251231.xsd#mrna_MinistryOfHealthLaborAndWelfareOfJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" xlink:to="lab_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StandReadyManufacturingRevenueMember_019b92bf-3d1b-73fa-83c6-97a03eaa5581_terseLabel_en-US" xlink:label="lab_mrna_StandReadyManufacturingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stand-ready manufacturing revenue</link:label>
    <link:label id="lab_mrna_StandReadyManufacturingRevenueMember_label_en-US" xlink:label="lab_mrna_StandReadyManufacturingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stand-Ready Manufacturing Revenue [Member]</link:label>
    <link:label id="lab_mrna_StandReadyManufacturingRevenueMember_documentation_en-US" xlink:label="lab_mrna_StandReadyManufacturingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stand-Ready Manufacturing Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StandReadyManufacturingRevenueMember" xlink:href="mrna-20251231.xsd#mrna_StandReadyManufacturingRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StandReadyManufacturingRevenueMember" xlink:to="lab_mrna_StandReadyManufacturingRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_d74ca669-5d84-454b-9c8d-fe7442ef9e9e_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnifications</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_0161dd1b-7a2a-4ee3-a3cb-681f806ba5cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchases</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3a000fc6-ecdb-4413-b51e-cf42b8b89690_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_103d129b-6ea7-4df7-b049-fa6c871c7198_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1bbfb961-ca3d-4b6d-8e78-dc8ff2554aa2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_132dc630-c7dc-4471-87ed-a10f75452a6a_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building and building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_19e18e33-c26c-4080-ada8-580aa9eb49b6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78de8fb1-c794-4c64-8b58-3e4fd8184aa5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average remaining contractual term expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_db09ea8c-fac6-4749-93e0-41586d4b3703_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4c58bc91-f5a9-44fc-8e78-489326c57091_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c1dd0-2715-71eb-9f7f-af143fec89d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_550f01bf-6260-4651-aa3a-2cd7cd69d663_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51a1745f-034f-4985-93e2-3a0988b4cfea_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33a9e17f-cef6-4916-9ebd-1c433a777cac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_41b0fb84-5135-4801-80a6-1f5e44872e77_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecd1eeda-418a-4530-b539-6bc98a388b70_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_c2f1adca-d172-4b2e-8fe7-d3428a2241eb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6271659c-4cdc-4c33-9898-feb137496230_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_e67272a6-8865-43f0-b626-931649b8c6e4_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated&#160;Useful&#160;Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e0f3f390-ada2-42ac-9a35-649fd9f1a381_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_38ec17c8-043f-4fd8-ac24-87c72a15a940_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_d70b667e-c135-4c8f-af2c-d36003ec44c2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_019b92cf-fcca-7102-8a38-fce43df83c10_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3507fd0a-e37a-4245-99c4-ae6ffacab8d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_343c73d8-6276-4f33-ae88-61f873829eaf_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset_d678760e-257c-48ac-8871-f8ad94d7e975_terseLabel_en-US" xlink:label="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability derecognized upon purchase of underlying leased asset</link:label>
    <link:label id="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset_label_en-US" xlink:label="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liability Derecognized Upon Purchase Of Underlying Asset</link:label>
    <link:label id="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset_documentation_en-US" xlink:label="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liability Derecognized Upon Purchase Of Underlying Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" xlink:href="mrna-20251231.xsd#mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" xlink:to="lab_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_3458776c-8158-4c97-9326-3cf0c797aaee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_cdbdddff-1c16-47d8-b519-370fffc8386a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_379090b8-d4a5-49d9-bbcd-03b8eed9d5fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a181a934-5a96-4427-9c99-e6cf85442d55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_1e6d75fc-701b-4896-96fb-99370f5815e8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_ffdfe85d-dd4c-46fd-b4e9-ee2cc083b4bc_terseLabel_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, financing</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_label_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_documentation_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember" xlink:href="mrna-20251231.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinancingRightOfUseAssetMember" xlink:to="lab_mrna_FinancingRightOfUseAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_609317a5-9c4b-4118-8ec1-94fb85be709f_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_InventoryShelfLife_2a2281f8-6cc1-4d02-93be-675ef2c5eed7_terseLabel_en-US" xlink:label="lab_mrna_InventoryShelfLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf life (in months)</link:label>
    <link:label id="lab_mrna_InventoryShelfLife_label_en-US" xlink:label="lab_mrna_InventoryShelfLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Shelf Life</link:label>
    <link:label id="lab_mrna_InventoryShelfLife_documentation_en-US" xlink:label="lab_mrna_InventoryShelfLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Shelf Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InventoryShelfLife" xlink:href="mrna-20251231.xsd#mrna_InventoryShelfLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InventoryShelfLife" xlink:to="lab_mrna_InventoryShelfLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_e60469a2-a611-4042-bc39-d7bcc4147cc5_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c3cb91d0-f210-4fdb-9dbe-bdf828a0a2d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_3a1e86ed-2004-4b28-885d-b4e88047295b_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Financing cash flows used in financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3c0a84-3c0b-4d93-bc3c-2bb04fb7ea9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3e8aab57-551e-4d76-af8d-00e6d4bb997c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_8ef7b32f-ea3e-4cc7-8fba-86602991b643_terseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in right-of-use assets related to lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_label_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:href="mrna-20251231.xsd#mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:to="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_dfd6bd8c-1cc4-40a0-8991-c4db9e17087a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve and capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_b9ca6a48-cd2a-4ffe-8f58-3c939dd820a9_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9710cc11-ff12-4f05-abe5-049bd3dc7999_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_d1a43479-1031-4b79-a5ec-73a45e815756_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2bc49465-6875-4abf-9887-df9383334b6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1cb84e49-c27d-4f33-95d2-146c09f4b177_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a1793ad0-0c79-4622-9793-130a77cd5b01_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5fd92fa7-d072-4db8-b3a4-d62d330f92e8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c634bd36-28d2-496b-8441-1e3831445fe3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_f7d0263a-ba80-40a4-90c2-46237c5503bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_026143c0-392b-43a8-8492-8fc61978e4ce_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Wholesaler chargebacks, discounts and fees</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" xlink:to="lab_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2af9b249-ab88-41ec-a6e3-237d8b7c4aef_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock_22afcb5e-2849-4f36-b6db-2381d93dfa87_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Funding Arrangements</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Funding Arrangements, Policy [Policy Text Block]</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Funding Arrangements, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" xlink:to="lab_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_cfaabd44-3979-4daf-aada-a814214e54c9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e367b0d4-f6f4-4fb8-a270-718a63f35153_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1f90ac84-3c1a-4fab-b8ce-6288ef55e37b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1ddc-e782-7837-b68c-1ba11081e3a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation windfall/shortfall</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e2ce938d-398c-4adf-81ac-3aa405204a85_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_fbe048a6-65c2-4f89-b696-56456c798460_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e075c762-0f7c-4035-9515-11ae3b36f1e2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a78a9e54-7366-4564-8c5d-68f47ff413a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_48026675-0aef-4358-939c-4cb9ab08507f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RecoveryOfCostsCapitalExpenditures_9faa3148-45e4-43f0-a3c0-a510a7534095_terseLabel_en-US" xlink:label="lab_mrna_RecoveryOfCostsCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost recovery</link:label>
    <link:label id="lab_mrna_RecoveryOfCostsCapitalExpenditures_label_en-US" xlink:label="lab_mrna_RecoveryOfCostsCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery Of Costs, Capital Expenditures</link:label>
    <link:label id="lab_mrna_RecoveryOfCostsCapitalExpenditures_documentation_en-US" xlink:label="lab_mrna_RecoveryOfCostsCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recovery Of Costs, Capital Expenditures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RecoveryOfCostsCapitalExpenditures" xlink:href="mrna-20251231.xsd#mrna_RecoveryOfCostsCapitalExpenditures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RecoveryOfCostsCapitalExpenditures" xlink:to="lab_mrna_RecoveryOfCostsCapitalExpenditures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1a515790-a8dc-4781-87a2-b1987561057d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e91796c4-5517-4da6-abcc-4a117c7653fa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4e94e7d3-bdb6-485d-9b28-83ce77f7ebb5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_112b90a7-070f-4c08-b576-470e1add581b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_c14ca39d-cf67-4d61-9fc9-ab481dfa174c_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacility1Member_019b92f1-3390-75f3-806e-f64f8dd760fe_terseLabel_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacility1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(DDTL)-1</link:label>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacility1Member_label_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacility1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan Facility 1 [Member]</link:label>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacility1Member_documentation_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacility1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan Facility 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacility1Member" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacility1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DelayedDrawTermLoanFacility1Member" xlink:to="lab_mrna_DelayedDrawTermLoanFacility1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4044bce9-04dd-4519-a382-6899968b4146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twelve Months of Continued Employment or Service</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacilityMember_019b92ef-a981-72ff-be85-31a5255d4ddd_terseLabel_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan</link:label>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacilityMember" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DelayedDrawTermLoanFacilityMember" xlink:to="lab_mrna_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8dbfabea-9270-4fe6-ba7e-ace2397470b0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent_57266346-5905-4f32-9931-d169d9e79ca0_terseLabel_en-US" xlink:label="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Down payments and prepayments, non-current</link:label>
    <link:label id="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent_label_en-US" xlink:label="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Downpayments And Prepayments, Noncurrent</link:label>
    <link:label id="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent_documentation_en-US" xlink:label="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Downpayments And Prepayments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DownpaymentsAndPrepaymentsNoncurrent" xlink:href="mrna-20251231.xsd#mrna_DownpaymentsAndPrepaymentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DownpaymentsAndPrepaymentsNoncurrent" xlink:to="lab_mrna_DownpaymentsAndPrepaymentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef3f3d49-18da-4f77-a6b4-9f3843207d34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_4a8fdf37-5297-4ec3-99fa-2cb1b9bf1c2e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_216e5c05-93b6-4559-aa26-b86d85616fe2_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Equity Plan</link:label>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_label_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option And Grant Plan 2016 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_documentation_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option And Grant Plan 2016 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member" xlink:href="mrna-20251231.xsd#mrna_StockOptionAndGrantPlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndGrantPlan2016Member" xlink:to="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6176ba51-5dae-4712-aee2-468b85222b48_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_808b074a-b55f-45fe-bb09-97d75334f8f4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-77c3-b459-c1bd1c156377_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f4b22db2-1fe4-48c9-bdfb-2fd184b678fc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_2dee7ae5-0045-44b1-949c-a9e4e22822b8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborativeArrangementFundingAmount_a5f09350-e5d1-498b-8e49-ea59cb25124e_terseLabel_en-US" xlink:label="lab_mrna_CollaborativeArrangementFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funding amount</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementFundingAmount_label_en-US" xlink:label="lab_mrna_CollaborativeArrangementFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Funding Amount</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementFundingAmount_documentation_en-US" xlink:label="lab_mrna_CollaborativeArrangementFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Funding Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborativeArrangementFundingAmount" xlink:href="mrna-20251231.xsd#mrna_CollaborativeArrangementFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborativeArrangementFundingAmount" xlink:to="lab_mrna_CollaborativeArrangementFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsOutsideBasisDifference_ea2a9b50-b1cd-492f-9f8c-458601e31848_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOutsideBasisDifference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside basis difference</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsOutsideBasisDifference_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOutsideBasisDifference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Outside Basis Difference</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsOutsideBasisDifference_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOutsideBasisDifference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Outside Basis Difference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOutsideBasisDifference" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsOutsideBasisDifference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsOutsideBasisDifference" xlink:to="lab_mrna_DeferredTaxAssetsOutsideBasisDifference" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacility2Member_019b92f1-6ff8-7c7a-b188-b2e31e0a164c_terseLabel_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacility2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(DDTL)-2</link:label>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacility2Member_label_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacility2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan Facility 2 [Member]</link:label>
    <link:label id="lab_mrna_DelayedDrawTermLoanFacility2Member_documentation_en-US" xlink:label="lab_mrna_DelayedDrawTermLoanFacility2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Delayed Draw Term Loan Facility 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacility2Member" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacility2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DelayedDrawTermLoanFacility2Member" xlink:to="lab_mrna_DelayedDrawTermLoanFacility2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_019b9299-228a-7c47-93fb-cb2d8abf69dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_2abd2410-768f-4183-a5cc-582745e19c3b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_529a773b-b7db-49cb-8ec4-e889deeacac7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_10884b97-dfb6-47d2-9e8b-ee2324d5452b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_56395832-6386-445e-8e3e-1f710e126638_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5ed5c4cc-ad88-4304-903f-61813a677e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4503c0c2-6f64-4109-b522-cf48dcd463fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a56b43fb-7980-4d0e-9076-57143f79dbda_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_45401b35-826b-4722-8b7c-7f392eb1ad15_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_41da7082-74e8-476c-94d2-344ddf36a7a9_terseLabel_en-US" xlink:label="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Common Stock Units And Performance Stock Units</link:label>
    <link:label id="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_label_en-US" xlink:label="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Common Stock Units And Performance Stock Units [Member]</link:label>
    <link:label id="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_documentation_en-US" xlink:label="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Common Stock Units And Performance Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:href="mrna-20251231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:to="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_28db4a06-a430-4d49-b6db-e9b0c8942011_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_2ef54ce4-3d65-490c-bc74-87eb87c10952_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount committed for funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:href="mrna-20251231.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_ce2a982f-0fd1-403a-99ad-ad09c9f72540_terseLabel_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_label_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_documentation_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:href="mrna-20251231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CardinalHealthMember_019c05b6-6bc0-7a9b-9165-0b8e393684fb_terseLabel_en-US" xlink:label="lab_mrna_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_mrna_CardinalHealthMember_label_en-US" xlink:label="lab_mrna_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_mrna_CardinalHealthMember_documentation_en-US" xlink:label="lab_mrna_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CardinalHealthMember" xlink:href="mrna-20251231.xsd#mrna_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CardinalHealthMember" xlink:to="lab_mrna_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_17a45c79-1598-4875-ade2-597a930f0123_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Customers</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_9f8795aa-cc51-47fe-98a1-258309fbf0f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_019c1dd0-2715-7c2e-91e9-bee43da306b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_269dfd97-4022-48cb-a386-fbbe0d2b787d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5ad474f4-ab5a-41ef-9b55-cb7e841beaab_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1cf352c4-71ee-4018-834d-0d424702fab2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2a746ff6-189a-474d-a5ea-943bc6882ea4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost related to non-vested stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_68a60dbb-b005-4da7-9f46-0454806b1fc6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_1f317c5c-0b7e-4d13-9373-bf2b2c4d9da2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5a406a68-1085-454d-9af3-a94b5d9c2c44_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_82ea80f7-268e-44b6-b961-daff3cbcc04d_terseLabel_en-US" xlink:label="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases member</link:label>
    <link:label id="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_label_en-US" xlink:label="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases member [Member]</link:label>
    <link:label id="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_documentation_en-US" xlink:label="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" xlink:href="mrna-20251231.xsd#mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" xlink:to="lab_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_13017102-2867-4bf3-8f6f-e74675af5327_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average remaining contractual term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_e8c85cc2-151d-484c-9045-d5f107369738_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_4a9c33bd-951a-437f-8800-fbd7a5dbaad0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_778b4cc8-1870-467f-9635-4087bd12cd47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_b81dff13-9863-4875-b11d-61c20205df2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit losses related allowance</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_36184e8a-b97b-430f-b12f-cf7feafba939_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_db7d836b-d5c7-4992-bc5c-acfe070a9ea5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_ee3e5e6f-6487-45be-8fff-e15d4dc390ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_e23fa187-b01f-474b-954f-fa0f7eb12ad5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_03c1748c-b0a6-4533-9f98-5182209bd0be_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79b1ea87-20ca-4bcc-9893-3ca626997154_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_efd086db-faea-4ce6-8aa9-a015b2ba0fe6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_aa73681a-e4a2-4f5d-849b-0b2457a99092_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_404e8b6f-4fa8-41fe-93f6-b7bee1083df2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_43d550fc-45dd-4295-9298-d2cb8b9b6756_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dcd4e3a8-c555-49d3-af14-5171b00914b0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019b92cf-fcca-7e36-9d96-6623684879f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e9b4bb9d-6730-45d2-b3f6-32898399e4af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_4b24b281-10c3-4602-a228-64ca190621ec_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c9ee033b-0659-42bf-933d-8c699486d2dd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_019c672a-c4a3-740a-9faf-810b985a8e50_verboseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Decrease in right-of-use assets related to lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_label_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained through finance lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained through finance lease modifications and reassessments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:href="mrna-20251231.xsd#mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:to="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0f3abf50-213b-4ec3-85c5-5ed7e24cd7b0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-7776-b6c5-62e7ca05d120_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax effects</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_3416d8b0-d9db-4414-8b85-d89d0d894755_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_406cbab4-39a3-468a-b5af-6204ee7ebbef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_b103f144-550f-451e-be72-76c67a713b9a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3a1d47e1-d0d9-41d7-847f-3cfed82bf413_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_104152c5-9039-4550-858b-3a6a4aaa6565_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_7de89b5f-7b78-424e-b9be-5ced71bc6df5_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, right-of-use asset, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_15a65e54-dcd2-48c4-a68b-cc5782f85dd1_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a85552f1-0282-41ff-9530-07e58722ccd2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0faa5b7-8a2d-4ef8-9ab9-b69e207c8403_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherGrantRevenueMember_329ffce7-c887-448f-8ece-b0a1349595bc_terseLabel_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other grant revenue</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_label_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Grant Revenue [Member]</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_documentation_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember" xlink:href="mrna-20251231.xsd#mrna_OtherGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherGrantRevenueMember" xlink:to="lab_mrna_OtherGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_1e1ff78e-4cbd-45d4-90b8-163333d094ad_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e6100f6e-0c0e-4de7-9436-08f56238d909_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-based Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_365059e7-cf54-4b37-826f-76fbe2ac5e1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net realized losses on derivative instruments reclassified in net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f31efd56-1e98-40ad-a794-644f48f3b60e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_59e9206f-57d5-4a98-a11a-b310fe1db7ff_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cfb1dd70-699c-4b1d-80fe-40821391e32a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_f35ce26d-198f-4575-872b-ab3fa88a60a1_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_019c713c-be57-7793-bc54-fabc69c8ba0f_terseLabel_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Patents Infringements in UPC</link:label>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_label_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Patents Infringements in UPC [Member]</link:label>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_documentation_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Patents Infringements in UPC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" xlink:to="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_019b92d1-7e82-756a-861c-988f1e859568_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d0943f85-6fee-4db2-a256-3c941b490063_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e3f5b629-33b8-4b81-82fb-1503fa67ff37_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_bb6d58bd-efec-49ed-983e-4c204c162977_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f6213058-283f-4bb2-9ac6-b6311da3c4ca_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3f0d37c8-2763-42cb-90e6-0c88a1acbb7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_80484eda-7842-49ea-954a-8145d9eebef5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Following Twelve Quarters</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_572386c5-b481-4f54-8e82-b1a6c5375572_terseLabel_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_label_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_documentation_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable" xlink:href="mrna-20251231.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RawMaterialsAccountsPayable" xlink:to="lab_mrna_RawMaterialsAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69ff80d3-e8d4-496d-ae88-b95c78c6157e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_29b3725e-44a3-4f93-baa4-e28bd42ff71a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3791828d-d22f-49ed-a331-623d73157cc1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_82538d7b-8039-47f2-9b19-d30590813c38_verboseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract with Customer Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract with Customer Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_36b078f5-d1e5-488a-afc1-78c7dceba358_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid services</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fc570f72-c152-4df4-afc4-41ef3cdfd025_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_6eef5469-3fe2-4473-9a04-a2fbeb085be3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_bc8f0c70-49dc-4a0d-a646-c99439d9c82c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Losses related to indemnification obligations</link:label>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_label_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Loss in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod" xlink:to="lab_us-gaap_LossContingencyLossInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_bc92c4f5-1f9e-44b3-bb9d-527aa2ca1d41_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e128085f-5a7f-4c90-b1f9-3263b5679394_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d3197687-25e2-4033-b0d8-2bd0aecaf303_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MNEXSPIKEMember_019b92ca-f2b1-77ec-9417-f5a636d1fd42_terseLabel_en-US" xlink:label="lab_mrna_MNEXSPIKEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">mNEXSPIKE</link:label>
    <link:label id="lab_mrna_MNEXSPIKEMember_label_en-US" xlink:label="lab_mrna_MNEXSPIKEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mNEXSPIKE [Member]</link:label>
    <link:label id="lab_mrna_MNEXSPIKEMember_documentation_en-US" xlink:label="lab_mrna_MNEXSPIKEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">mNEXSPIKE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MNEXSPIKEMember" xlink:href="mrna-20251231.xsd#mrna_MNEXSPIKEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MNEXSPIKEMember" xlink:to="lab_mrna_MNEXSPIKEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_93c4cfc2-8094-44a1-a463-4dde626de0f2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1f5284b1-1bf5-4cad-908f-24b34b779f3b_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_a2c341dc-1309-4e22-9ad1-18625b510387_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ca339da3-f0ff-496c-9965-98d7ae1c5afb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_6164571d-83c3-4436-a629-03baed7c414e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_60797298-e927-4f45-8508-e260c9af860c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_6acf62b8-3cfd-4f4e-94eb-a7a1a040165d_terseLabel_en-US" xlink:label="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More Likely That Not To Realize All Deferred Tax Assets</link:label>
    <link:label id="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_label_en-US" xlink:label="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More Likely That Not To Realize All Deferred Tax Assets [Member]</link:label>
    <link:label id="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_documentation_en-US" xlink:label="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">More Likely That Not To Realize All Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" xlink:href="mrna-20251231.xsd#mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" xlink:to="lab_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_93a86e37-fa9f-4f6d-b1a6-eddabf0e0e2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_019c1dae-2c51-7fc3-b786-f053930d2b72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_019bee5b-43b3-7d63-85df-3b344e176e33_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5562d5ab-9e92-4d94-aabe-258caa5d55da_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_82f5ab26-3290-4889-9f38-00cece1cc902_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d9975f30-8a28-483d-835b-f052daa5e08d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average remaining contractual term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_92a36357-b6e3-4911-91e3-3dc9ac7cb028_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_6f0b4918-cab6-4467-9dbe-6d4557501b57_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7359d15b-07a2-401e-b3c4-cd762327b2dc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4609af4e-e96b-4b53-9707-1d14576a492b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e21637a0-54cb-4965-b24c-360418ce4c35_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_fb16beb4-5c46-46a7-bcc3-0a721496ff45_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3f93ade4-3f41-46b8-96cf-765668c7c290_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_831c6881-fca3-45b4-bdeb-db8df2c366bf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_018d0900-49bb-43ee-b940-4d9a6b37f591_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_af7cb9a5-fb88-4319-8c79-2448ac974204_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85482b71-8f4f-46e2-9b82-1a8d1b485ed3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d97775c4-2446-4b60-b971-e605bce3e916_totalLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfParticipants_e2ef91b3-a2b6-45e0-b604-0e13b0b4e17a_terseLabel_en-US" xlink:label="lab_mrna_NumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of participants</link:label>
    <link:label id="lab_mrna_NumberOfParticipants_label_en-US" xlink:label="lab_mrna_NumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Participants</link:label>
    <link:label id="lab_mrna_NumberOfParticipants_documentation_en-US" xlink:label="lab_mrna_NumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Participants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipants" xlink:href="mrna-20251231.xsd#mrna_NumberOfParticipants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfParticipants" xlink:to="lab_mrna_NumberOfParticipants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c34fb117-b203-49b4-a4f4-c7179ddf88b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_3ca926bc-f16f-4a8d-b371-20dc4bbcc88c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2dd9f13c-2fd0-4eac-a6a5-2121f637091d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_525579c4-044a-4242-a4e6-45e84f82f396_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_e7eaaef1-eb5e-40d5-9acd-bb71334199c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in convertible notes and equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_72d2ce92-512e-43cf-a954-82206610cc60_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_f8e6ce50-efbe-4784-bdd7-e21dcdfd613b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves established</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_019c6f03-bee3-769e-9123-1ae977e8cf40_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, new claims filed, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_062dee4b-609e-40d0-8d1e-271d096933dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_70a69568-1b2f-4bd2-a8a6-6ae50c9b2368_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d3f4bcfb-2304-428d-a1f9-2fea7de3bf79_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_2d855c6b-2dde-4d25-8163-271ce95947f2_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e70b02a2-205a-4ed5-90d2-3724d007e563_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c3037711-cf02-4a8f-8002-1930782cfd22_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_71098464-ea65-4e82-b334-87b7de2359c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6a4bdd77-2369-4aad-bbbe-a0628d7bca11_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f7996187-69ec-43ed-ba96-d2e4a3794755_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedManufacturing_0cefef7b-5abe-4e1c-b404-91689fc65378_terseLabel_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_label_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_documentation_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing" xlink:href="mrna-20251231.xsd#mrna_AccruedManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedManufacturing" xlink:to="lab_mrna_AccruedManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_019c713d-352a-7899-8083-3f71205b54a5_terseLabel_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain</link:label>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_label_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain [Member]</link:label>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_documentation_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" xlink:to="lab_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_019b930b-ea71-7c97-84d9-5de047f954e7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, outstanding principal balance</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8870456f-ab5a-4034-8036-2e1e18cdf796_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4ffd402d-a5e7-450d-ab6b-7e9885852064_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5526a376-0197-4932-a049-27663507c571_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7fa18e20-2990-494e-bd68-81079dfc8975_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_96996647-9e4a-47cd-b51e-cadcc7c00040_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_06a5adf6-70dc-4a94-8cf6-12e22baaec5c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_019c434c-a52a-7069-baf1-fcf9b9f42d63_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_044ccc3d-71c9-48cc-8d4d-987b9564d065_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dc90580d-3d14-4bce-94bd-700e684f01f1_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_03919e14-49bb-492d-91d3-32f41d8540f4_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_5d34bc4c-4556-4402-8dc8-f43f70a404db_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fcee420-3092-4d0e-b333-04db20781f80_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c44ca2fc-d3aa-41e2-bff5-c40fd111dc1e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_84a58b12-4c7b-4d7e-b456-1aebdab2f5eb_negatedLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in current period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provisions Made in Current Year</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provisions Made in Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" xlink:to="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TaiwanFoodAndDrugAdministrationMember_d0a83dbd-af85-40b8-be92-5c4f7449eabb_terseLabel_en-US" xlink:label="lab_mrna_TaiwanFoodAndDrugAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taiwan Food and Drug Administration</link:label>
    <link:label id="lab_mrna_TaiwanFoodAndDrugAdministrationMember_label_en-US" xlink:label="lab_mrna_TaiwanFoodAndDrugAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taiwan Food and Drug Administration [Member]</link:label>
    <link:label id="lab_mrna_TaiwanFoodAndDrugAdministrationMember_documentation_en-US" xlink:label="lab_mrna_TaiwanFoodAndDrugAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taiwan Food and Drug Administration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TaiwanFoodAndDrugAdministrationMember" xlink:href="mrna-20251231.xsd#mrna_TaiwanFoodAndDrugAdministrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TaiwanFoodAndDrugAdministrationMember" xlink:to="lab_mrna_TaiwanFoodAndDrugAdministrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_1b9f4c9f-10b3-4f4e-beab-31cdf46fd35c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_947d200f-38b5-4291-8376-dea90cbf4669_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_51d2539f-93f4-4253-bb1b-41f442f5f958_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_ec218b8a-2ad8-4338-abff-0790d8941240_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c3ec78e7-0fb4-4835-8b52-1c10397ed088_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8f938e80-8eb2-4de8-8492-1cf8d2078d02_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6df0012-dad3-424c-8b92-fb4ffbac3ab5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f185d9ba-d8f8-4096-a37c-f983eda0801b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undiscounted future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2a21de58-8c09-4b06-ba8b-ba13adf8f9f0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_a884ef06-8aae-4d4a-82ac-e6fd1e1725e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid (received) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_5f674803-4d25-449a-b0b3-21004274d7c5_terseLabel_en-US" xlink:label="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional authorized amount for share repurchase program</link:label>
    <link:label id="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_label_en-US" xlink:label="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Additional Authorized Amount</link:label>
    <link:label id="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_documentation_en-US" xlink:label="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Additional Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:href="mrna-20251231.xsd#mrna_StockRepurchaseProgramAdditionalAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:to="lab_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c82e8677-4168-4d80-b236-57c59170f40a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_309387b2-aa94-449e-b95e-6bc1fd6b8d23_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6265bd54-58ef-4777-8996-192719a7f947_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6d595839-38f6-470f-b05a-c974cb53e65e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_291b816c-4c81-45ae-8c7d-6df62e454d31_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7250fd0b-11e4-4b6b-9e2d-0c43031790bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2da92e60-0fbe-4fad-9e78-2f066a8099e3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a70cc94c-a573-4853-aad5-96f0b7dda134_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1d00ffd4-ed7e-48b2-90ee-1936a63bddad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_fab188db-6567-4367-bbeb-2c74d7285f5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RSVMember_89f3cc04-15a3-429e-b79e-3f735c7a958d_terseLabel_en-US" xlink:label="lab_mrna_RSVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSV</link:label>
    <link:label id="lab_mrna_RSVMember_label_en-US" xlink:label="lab_mrna_RSVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSV [Member]</link:label>
    <link:label id="lab_mrna_RSVMember_documentation_en-US" xlink:label="lab_mrna_RSVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RSV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RSVMember" xlink:href="mrna-20251231.xsd#mrna_RSVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RSVMember" xlink:to="lab_mrna_RSVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_003acead-102c-497a-8e1f-0fefb8d12c14_terseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments and returns related to sales made in current period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision Related To Sales</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision Related To Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionRelatedToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" xlink:to="lab_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_85250eb7-3fde-45d2-9b01-58fe28e5330e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2671de24-9e0c-43ce-9186-37edb30106f1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase from available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f3e4f430-67a7-4484-abca-8ab12881b580_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ea433d2c-45c6-4545-a090-1ee5c9621f76_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_df7f3f72-34e6-4508-ae03-a0ce69669143_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_UKHealthSecurityAgencyMember_05d68c7e-272c-4db0-bfff-aa0025b1847a_terseLabel_en-US" xlink:label="lab_mrna_UKHealthSecurityAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom Health Security Agency</link:label>
    <link:label id="lab_mrna_UKHealthSecurityAgencyMember_label_en-US" xlink:label="lab_mrna_UKHealthSecurityAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UK Health Security Agency [Member]</link:label>
    <link:label id="lab_mrna_UKHealthSecurityAgencyMember_documentation_en-US" xlink:label="lab_mrna_UKHealthSecurityAgencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UK Health Security Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UKHealthSecurityAgencyMember" xlink:href="mrna-20251231.xsd#mrna_UKHealthSecurityAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_UKHealthSecurityAgencyMember" xlink:to="lab_mrna_UKHealthSecurityAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_ead0b026-e403-4b66-9583-a2a12f3d2d2a_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in prior periods</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provisions Made in Prior Years</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provisions Made in Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" xlink:to="lab_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_24a49e26-c5b4-4055-bf9d-e388211603ff_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCV Agreement</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:href="mrna-20251231.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2b66060c-a291-4b60-adec-2a6ad0521ae1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-70ad-954b-c0c687abfd71_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_08c7ce8a-fa8c-4f4a-8c24-49fa14ffbe26_negatedTerseLabel_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_label_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_documentation_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:href="mrna-20251231.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:to="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7556f570-98be-4a55-a612-fb8fa14749ed_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9542cfbc-7204-466f-9092-bfbf55f21e37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4c551f4d-67ba-4516-89b8-613bdb48c50a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value, 12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1dd0-2715-7121-864c-06ebe252bba2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation windfall/shortfall</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-716e-a388-abb31cea0ddb_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a73ec629-63b6-4ff2-ba9e-3df58872bc9d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ProductSalesMember_541ab3c5-4188-4c50-8756-139cc46ca0b9_terseLabel_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_mrna_ProductSalesMember_ae8076e2-ebd8-47c3-bbc8-4f2660373489_verboseLabel_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_mrna_ProductSalesMember_label_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales [Member]</link:label>
    <link:label id="lab_mrna_ProductSalesMember_documentation_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ProductSalesMember" xlink:to="lab_mrna_ProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_56ea273c-96d2-4cc6-b61f-b4a435b5a821_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities - financing (Note 10)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_194cbdd3-9cdf-49e7-a1d4-74949f555793_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f49abad1-94ce-4c06-a7fd-7bb3ccc64a3e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e11fd1bc-4d51-4613-a906-106b3035986d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_6e434331-fb4f-47b0-8139-82bf44a7ae5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_019c05be-4a54-7f37-89e4-8189f4e3dd10_terseLabel_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average market capitalization</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_label_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Average Market Capitalization</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_documentation_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Average Market Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" xlink:to="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4ff0ad88-2340-481f-bb1b-b822fcd549a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_68c65ffb-4f46-4e6b-bbe7-0f426ef0a61e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date per Share/Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d0e57f39-cbe1-4859-821a-c5b892e745b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MerckMember_8488eecd-3cbf-4c20-bdab-739b22bebacd_terseLabel_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_mrna_MerckMember_label_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_mrna_MerckMember_documentation_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember" xlink:href="mrna-20251231.xsd#mrna_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MerckMember" xlink:to="lab_mrna_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_fe85e9ab-8504-42bc-9ffa-84fa10e31e36_terseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments and returns related to sales made in prior periods</link:label>
    <link:label id="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_label_en-US" xlink:label="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability, Payments And Returns Related To Prior Period Sales</link:label>
    <link:label id="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability, Payments And Returns Related To Prior Period Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" xlink:to="lab_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_c1eb84d1-190b-4de6-a223-ef6875b41f17_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments, liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_709fe66b-20fd-4851-9c99-045737f9b2a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3b4f4f61-9423-4322-9537-1e66c3344a24_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_67e02bde-239b-4f1a-81fd-084887e81ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_566c7f91-365d-459a-a72f-e8a0333de556_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0ceb6dec-fe51-492b-9c9c-eb2fc887013b_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits at beginning of the period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_922697c3-d316-4ff5-a013-c5e4a2926d34_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits at end of the period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8305be48-7fde-4cc2-a76f-8c1aeb2e6ff1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d886617a-c8b0-4179-8dd4-ee5c8453f08f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares used in calculation of loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_02de03da-0de5-4998-a3fe-0f344467a797_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3de2cdf-d8da-4cae-a09f-426f9aed9f39_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0573e506-6660-48c1-8c01-b1fa42ce55e1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_980010a6-c395-4f79-ba5f-93d30677740c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns and other fees</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c0c057d2-4257-4180-8721-3bb17274cc0b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_827fb4fe-9b75-4e6a-9b35-aee224a88415_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized at end of period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1c812df0-aa85-42d9-8fb8-804e2fb26055_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a40df7ea-75b2-44fb-8b5e-e475f514410c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6f8f8a12-87c5-45ab-9033-ecd54fc3037b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_019b933c-663b-73d0-8470-950bf6ba8fd4_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of eligible employees elected to exchange</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Eligible Employees</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Eligible Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_398bd1f0-ee6d-4eed-93ab-23204e900d4e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6a37ffd-06fb-4802-b41b-20d71f42e486_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9f6bffd6-d12d-4af5-8fcc-832c6ef90a3e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a7dbe344-3aee-41a2-9c5c-131f1d56452f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3baad7d6-459e-4bcc-b6bf-3a59bdb47658_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDevelopmentPrograms_a228812c-2643-4c7f-81ff-a0b7d885a8c8_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of development programs</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentPrograms_label_en-US" xlink:label="lab_mrna_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_mrna_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentPrograms" xlink:href="mrna-20251231.xsd#mrna_NumberOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDevelopmentPrograms" xlink:to="lab_mrna_NumberOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c349eaf9-4194-48cd-a944-6d40979c78e9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_10341934-27c9-464b-8a57-9e6592e319c0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_eb235510-5f98-4b28-860d-e383eb1f11aa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c1ddc-e782-772c-9496-19f432838569_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nontaxable or nondeductible items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfCommercialProducts_337ad83d-1c29-43c1-9492-aae135be6681_terseLabel_en-US" xlink:label="lab_mrna_NumberOfCommercialProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of commercial products</link:label>
    <link:label id="lab_mrna_NumberOfCommercialProducts_label_en-US" xlink:label="lab_mrna_NumberOfCommercialProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Commercial Products</link:label>
    <link:label id="lab_mrna_NumberOfCommercialProducts_documentation_en-US" xlink:label="lab_mrna_NumberOfCommercialProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Commercial Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfCommercialProducts" xlink:href="mrna-20251231.xsd#mrna_NumberOfCommercialProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfCommercialProducts" xlink:to="lab_mrna_NumberOfCommercialProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_247e0b1f-652c-4ce9-8c4b-419afa2e5a71_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019b92d1-7e83-7e19-900b-887ef2564c92_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_20044979-25b1-4423-babc-5d30894b6b75_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionExchangeProgramMember_019c05c3-bc7d-75da-9027-2a7cab1cb504_terseLabel_en-US" xlink:label="lab_mrna_StockOptionExchangeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Exchange Program</link:label>
    <link:label id="lab_mrna_StockOptionExchangeProgramMember_label_en-US" xlink:label="lab_mrna_StockOptionExchangeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Exchange Program [Member]</link:label>
    <link:label id="lab_mrna_StockOptionExchangeProgramMember_documentation_en-US" xlink:label="lab_mrna_StockOptionExchangeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option Exchange Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionExchangeProgramMember" xlink:href="mrna-20251231.xsd#mrna_StockOptionExchangeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionExchangeProgramMember" xlink:to="lab_mrna_StockOptionExchangeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_bbb1ff9c-11c8-4b5f-89f3-333ec602009b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, including excise tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90a14165-e28e-45fa-9b85-584a322c36cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_cfb40933-2fd6-4f4f-b9bb-45b0f9d2fa85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8d1d0b5a-f1d4-4498-961d-b48d754393ab_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_6ce2c6ea-9cfe-442a-b56c-4ba0c215ede4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MexicoMedistikMember_019c05b6-6bc0-7c74-8b18-90deb265aa03_terseLabel_en-US" xlink:label="lab_mrna_MexicoMedistikMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mexico Medistik</link:label>
    <link:label id="lab_mrna_MexicoMedistikMember_label_en-US" xlink:label="lab_mrna_MexicoMedistikMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mexico Medistik [Member]</link:label>
    <link:label id="lab_mrna_MexicoMedistikMember_documentation_en-US" xlink:label="lab_mrna_MexicoMedistikMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mexico Medistik</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MexicoMedistikMember" xlink:href="mrna-20251231.xsd#mrna_MexicoMedistikMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MexicoMedistikMember" xlink:to="lab_mrna_MexicoMedistikMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8cbb2b04-0ae0-4f6b-9cb1-7a63c1d295af_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_11652051-eaa5-4bef-8cd1-7e170195ef36_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c70a3b8f-dd89-448e-95bd-3916cbfcf1ba_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_d94ee428-330f-43db-8298-cdb462c736ed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fdabb0f0-d441-47a3-9fa6-ca513e2a966c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PerformanceStockUnitMember_6c6887d8-d991-46cd-95f4-165aee4a0f25_terseLabel_en-US" xlink:label="lab_mrna_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_mrna_PerformanceStockUnitMember_label_en-US" xlink:label="lab_mrna_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Unit [Member]</link:label>
    <link:label id="lab_mrna_PerformanceStockUnitMember_documentation_en-US" xlink:label="lab_mrna_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PerformanceStockUnitMember" xlink:href="mrna-20251231.xsd#mrna_PerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PerformanceStockUnitMember" xlink:to="lab_mrna_PerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a6ea8f0-de7b-461d-99d8-2f4534f7c29f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_acf6912c-6e5e-456a-a3dd-6043c3a22d06_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_408632d7-7f8d-4ff1-b653-e691139f520b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9e896211-30ff-40a9-83b6-87e788932867_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_eaec0a08-7b6b-4c71-815c-fd58cca49a52_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_e7fbb1ed-72fd-47da-8866-990aef886ccb_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_236d3955-1a4c-4ff2-9de7-7a30e4f4f63c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability, current, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDevelopmentCandidates_b1c78a43-4b0d-45d7-a389-6c09640e6dfd_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDevelopmentCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of development candidates</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentCandidates_label_en-US" xlink:label="lab_mrna_NumberOfDevelopmentCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Development Candidates</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentCandidates_documentation_en-US" xlink:label="lab_mrna_NumberOfDevelopmentCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Development Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentCandidates" xlink:href="mrna-20251231.xsd#mrna_NumberOfDevelopmentCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDevelopmentCandidates" xlink:to="lab_mrna_NumberOfDevelopmentCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_5be4a8f5-04d8-480c-a89d-442bd3a6766b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_9e407187-fd9c-40a6-9a29-7295de32a264_terseLabel_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember" xlink:href="mrna-20251231.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentMarketableSecuritiesMember" xlink:to="lab_mrna_CurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_0161a660-c995-41d9-a007-aa25464f99c9_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholesaler chargebacks, discounts and fees</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" xlink:to="lab_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestOfTheWorldMember_f2026039-a691-4cbc-9eb3-41221397eb0e_terseLabel_en-US" xlink:label="lab_mrna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_mrna_RestOfTheWorldMember_label_en-US" xlink:label="lab_mrna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of The World [Member]</link:label>
    <link:label id="lab_mrna_RestOfTheWorldMember_documentation_en-US" xlink:label="lab_mrna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest Of The World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfTheWorldMember" xlink:href="mrna-20251231.xsd#mrna_RestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestOfTheWorldMember" xlink:to="lab_mrna_RestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d9529915-beb5-4c4b-88ed-429d16693b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_773e13df-6f44-4552-be81-e1b6bd3aaa81_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_05c5c17d-0c4d-42e6-86f4-43132c6f3180_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_f1b88f8c-cff5-404b-a92c-7f2a11354a12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3db7fe08-acf2-46b7-a292-8ceedd5bf8fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019c05b4-fdb1-71e0-a827-dafc0bce51e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax payments related to net share settlements on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_119aa1ce-bc11-459c-850a-7f723b8ebdd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_019beed2-8a58-7136-9303-d11b681f75a6_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal funds rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a4748c16-ccd3-4fe5-8410-1a30c9f7e232_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d33bc23d-059b-48f8-a0ad-9aa2620e4767_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_6f76cef7-c9eb-43f0-bc20-b22ba82abe58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51927f76-934d-4675-8083-0e930892d859_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_7d32952c-2ba6-4164-b078-cc79399a9711_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LicenseAndRoyaltyMember_e1b2e8ff-c8be-4fc5-a2f7-b4da47e1cd7b_terseLabel_en-US" xlink:label="lab_mrna_LicenseAndRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing and royalty revenue</link:label>
    <link:label id="lab_mrna_LicenseAndRoyaltyMember_label_en-US" xlink:label="lab_mrna_LicenseAndRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Royalty [Member]</link:label>
    <link:label id="lab_mrna_LicenseAndRoyaltyMember_documentation_en-US" xlink:label="lab_mrna_LicenseAndRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LicenseAndRoyaltyMember" xlink:href="mrna-20251231.xsd#mrna_LicenseAndRoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LicenseAndRoyaltyMember" xlink:to="lab_mrna_LicenseAndRoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c1dd0-2715-757a-aa41-c181ee207acf_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_bd9b94eb-3c78-40a8-923d-e581d804c502_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_fda74f37-cd4a-4f83-b192-cd77fe61ce67_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0dd185e9-19bd-49f4-aae0-ada7619beefd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit realized from option exercised</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_714722ca-1b2f-4f78-873f-de4bbb654cdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_210800be-3588-41ff-ac60-18418d538121_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_1ba74ee2-ea8e-4b1a-b825-b7b3405f069e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_bbc37a8b-5c74-4766-ab55-a7a5fd0b92df_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_76257454-d69a-4b5d-b690-db12d17fd491_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation costs</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ff1dc666-074c-4103-956c-495783e4df70_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, liability, current, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-75f8-993a-97c644ccfec9_terseLabel_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Scenario [Domain]</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain_label_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Scenario [Domain]</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain_documentation_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain" xlink:to="lab_mrna_DebtInstrumentCovenantComplianceScenarioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e5489485-9c0f-41c2-b046-b88614e7ea99_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_273e4fd2-6c96-4745-b106-1fd8d81b2546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9cb8499d-ce6a-462c-b186-a5bf7a8d3fa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f678aa04-8a07-461f-aace-6ac4f00d9341_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_875ac101-e557-4e90-995c-6066afdb8740_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_d5abde53-5faf-4416-8d61-5752838faaeb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and Postretirement Obligation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa14c59f-3091-4643-8a83-f3b853fafbae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Options (in millions)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_dacadc1f-4d6a-47a0-84e0-c3ba71dfc613_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b0386ddb-bd3f-4aa3-8c99-9015f0666434_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ad812c7f-7f6f-4586-a106-b385aaf61a8a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_27af42a6-1d74-481f-8497-69529254b61f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a0d3050d-c8f8-4866-8de8-8f99ef8dd871_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1b8ab6c7-8e45-406b-92db-b153c82a17ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AdoptionOfTradingArrangementMember_label_en-US" xlink:label="lab_mrna_AdoptionOfTradingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adoption of Trading Arrangement [Member]</link:label>
    <link:label id="lab_mrna_AdoptionOfTradingArrangementMember_documentation_en-US" xlink:label="lab_mrna_AdoptionOfTradingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adoption of Trading Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementMember" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AdoptionOfTradingArrangementMember" xlink:to="lab_mrna_AdoptionOfTradingArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensions_cc6ec612-879d-4750-bd7e-d7bc39e1da4d_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of extension</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensions_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Extensions</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensions_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensions" xlink:href="mrna-20251231.xsd#mrna_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseNumberOfExtensions" xlink:to="lab_mrna_LesseeOperatingLeaseNumberOfExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_a3a71d24-e18c-4060-b8fa-5ec9e3b9fa2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Options Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e5f51fe1-fec5-49d1-ab3a-16cf1546efb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_350a6c60-8c3b-40d7-8d34-c8a0aaa4f2bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_6cd4c867-355e-4370-aedf-a074c6a96d07_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_46ee5598-4659-42b5-8d2a-e4a929754d9d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets, financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d79f9c26-caf9-402c-b6ac-9ea77aaf0025_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8ac6e42b-fbcd-4eb6-97af-2bcaffa8f0a6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_f3f34325-1f4f-4007-9c4b-309c5a214004_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized licenses, research and development and start-up costs</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:to="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_BlackstoneLifeSciencesBlackstoneMember_74085b57-b949-4bac-84cc-95e1ebf02d93_terseLabel_en-US" xlink:label="lab_mrna_BlackstoneLifeSciencesBlackstoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blackstone Life Sciences (Blackstone)</link:label>
    <link:label id="lab_mrna_BlackstoneLifeSciencesBlackstoneMember_label_en-US" xlink:label="lab_mrna_BlackstoneLifeSciencesBlackstoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blackstone Life Sciences (Blackstone) [Member]</link:label>
    <link:label id="lab_mrna_BlackstoneLifeSciencesBlackstoneMember_documentation_en-US" xlink:label="lab_mrna_BlackstoneLifeSciencesBlackstoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blackstone Life Sciences (Blackstone)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BlackstoneLifeSciencesBlackstoneMember" xlink:href="mrna-20251231.xsd#mrna_BlackstoneLifeSciencesBlackstoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BlackstoneLifeSciencesBlackstoneMember" xlink:to="lab_mrna_BlackstoneLifeSciencesBlackstoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_aa3f4d07-22e1-4a4f-996e-c5af645f6e63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_859049eb-b077-4703-90ef-d92c01355dde_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_68112a91-010b-4844-b406-e83b50a4957f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss Before Provision For (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4977fa3a-5068-4033-b04c-c0d7a4dbee28_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_019b92d1-7e82-7b65-b485-30476f939b45_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_263556b4-405c-4b8c-9e66-a3aa1974199d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_a1698f82-0300-411f-b0c2-16be45896ecc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_03db2a93-cbce-40a5-bc10-acd4917f3314_negatedLabel_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating</link:label>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_b570ed7a-37d1-4454-abfd-6eb91e323b72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_019b92d1-7e82-7398-a750-a02affb919f2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1ef21f0b-7e1e-41ad-83f4-9cf2e3a73ad3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ad371e41-20c4-468b-9e00-64629c64396f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Common Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90d8f44b-5170-4f20-a403-d304372ba772_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinanceLeaseCost_2c94bb4d-a6b1-4159-a73d-5aa83d5f6748_totalLabel_en-US" xlink:label="lab_mrna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financing lease costs</link:label>
    <link:label id="lab_mrna_FinanceLeaseCost_label_en-US" xlink:label="lab_mrna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_mrna_FinanceLeaseCost_documentation_en-US" xlink:label="lab_mrna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseCost" xlink:href="mrna-20251231.xsd#mrna_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeaseCost" xlink:to="lab_mrna_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d1872fdf-dfb3-4940-98aa-c3ed9d14a0d3_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_a531b2d4-7222-4eb5-b59f-647f4d4adc2c_terseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior period revisions, adjustment</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Prior Period Revisions, Adjustment</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Prior Period Revisions, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" xlink:to="lab_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0e06b076-c2af-40ac-b8a4-875d225ab667_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd2af400-507e-41d6-86e4-ac44c2f4e525_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c9de801f-ccea-4610-8d15-5339f6666490_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_11682d82-ece7-4ae8-aba7-16fa171d2f3f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0e005d2b-bb1b-498b-9b60-51c481843999_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_9f685892-a42a-4cc3-83e1-1add5feb0db8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property additions</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_14da6bbf-2348-4a5c-b347-01b15827ab1d_terseLabel_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_label_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment, Current</link:label>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_documentation_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent" xlink:href="mrna-20251231.xsd#mrna_AccruedPropertyAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedPropertyAndEquipmentCurrent" xlink:to="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CovenantComplianceScenario1Member_019c05bc-f6f2-7176-bc3e-1104b341a926_terseLabel_en-US" xlink:label="lab_mrna_CovenantComplianceScenario1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Covenant Compliance, Scenario 1</link:label>
    <link:label id="lab_mrna_CovenantComplianceScenario1Member_label_en-US" xlink:label="lab_mrna_CovenantComplianceScenario1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Covenant Compliance, Scenario 1 [Member]</link:label>
    <link:label id="lab_mrna_CovenantComplianceScenario1Member_documentation_en-US" xlink:label="lab_mrna_CovenantComplianceScenario1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Covenant Compliance, Scenario 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CovenantComplianceScenario1Member" xlink:href="mrna-20251231.xsd#mrna_CovenantComplianceScenario1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CovenantComplianceScenario1Member" xlink:to="lab_mrna_CovenantComplianceScenario1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8c081afe-fb85-4427-a3f0-45d986e20752_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dae48d30-0488-49a9-b0f2-048948d1e27d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44a96c9e-5c11-4bc9-b714-75ee5c0326d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5cd19037-4a90-42b3-87e7-2dd33030301f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_363ad48d-a8f4-49a4-baff-ac3b7aec7fab_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-7649-8526-c4cbc5dd95c3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_248ad07f-acfb-4e06-b4fb-7363dbfc6ec2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f2c06e86-b846-49dc-b3fd-4d6c95c19464_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Provision For (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1cfc5f28-8e13-49e4-99af-fccf0107e50e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ba3e2ef4-cce5-4164-b78f-6bba8e3caeac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_96481f42-a24e-415a-974c-ca825f99c3a8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claims outstanding</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_62ac31d5-6bcf-40ac-94c8-0b6070593b89_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_eeba7bcb-bda5-4877-96a9-5c34a550a004_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product sales</link:label>
    <link:label id="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_label_en-US" xlink:label="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Excluding Assessed Tax , Gross</link:label>
    <link:label id="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_documentation_en-US" xlink:label="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Excluding Assessed Tax , Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" xlink:href="mrna-20251231.xsd#mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" xlink:to="lab_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_33985dcc-3f43-4663-9212-a7389e924412_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0da49a83-15ea-4197-a885-3d715ea37127_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b35ae562-47f2-4add-a69b-8724dddfc3f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1ddc-e782-72a8-85ef-36eb43e94c0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1dc8777a-0c68-484c-9c7b-22259744cb65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_405720bd-68ed-46ad-b6b1-9d727e4d7e87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4a466290-5f17-4200-b6df-342cf560b4e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1e8fb29f-3b9b-4f11-8dd4-99880019fbf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_653bd161-26e8-4ac3-920a-a0aa542c3efe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59d585e1-7dcb-4a6f-a8c0-a9b776e4c353_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3becbd50-a90b-4e06-9301-c1fa7d6a5040_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afbc7d08-652c-4ee5-a36e-415420bdde9e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_445c797a-98a8-437b-a501-4a11ecb068b4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ab1bca0f-74f6-4eb9-892a-b3d295e22ba0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_d8909960-2baa-4793-bd0e-9cd6efb4cf63_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d17fbd7f-47a1-42d1-84d0-320768841376_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses, 12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedCommercial_d4c3f0a1-3fc5-4b13-9b48-88d6e3afa703_terseLabel_en-US" xlink:label="lab_mrna_AccruedCommercial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_mrna_AccruedCommercial_label_en-US" xlink:label="lab_mrna_AccruedCommercial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Commercial</link:label>
    <link:label id="lab_mrna_AccruedCommercial_documentation_en-US" xlink:label="lab_mrna_AccruedCommercial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedCommercial" xlink:href="mrna-20251231.xsd#mrna_AccruedCommercial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedCommercial" xlink:to="lab_mrna_AccruedCommercial" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b8855a9d-2a88-471e-a63a-bf15ac61e00b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b95480b9-3704-4596-8083-43b4027ce5c8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0afdfc0a-bdd7-4b0c-8ceb-f0522ed877a2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_019c713c-628a-7565-afdf-2a0218b97938_terseLabel_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Patents Owned By GSK</link:label>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_label_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Patents Owned By GSK [Member]</link:label>
    <link:label id="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_documentation_en-US" xlink:label="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Biologicals SA , Patents Owned By GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" xlink:to="lab_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9e94ea7f-5c0d-4df3-b266-5f365917fa5e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees_019c1fc9-3171-7284-a65d-7f8c07b23bbb_negatedTerseLabel_en-US" xlink:label="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Wholesalers chargebacks, discounts and fees</link:label>
    <link:label id="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees_label_en-US" xlink:label="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Chargebacks, Discounts And Fees</link:label>
    <link:label id="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees_documentation_en-US" xlink:label="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Chargebacks, Discounts And Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccountsReceivableChargebacksDiscountsAndFees" xlink:href="mrna-20251231.xsd#mrna_AccountsReceivableChargebacksDiscountsAndFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccountsReceivableChargebacksDiscountsAndFees" xlink:to="lab_mrna_AccountsReceivableChargebacksDiscountsAndFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0d8a35f3-f5e6-430f-a020-f2037c02f454_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Balances of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bf742986-ce04-45ec-91c6-d200a3f71edb_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_733d4e4d-d767-4f5c-8619-fbab21f94e4e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b4657ee3-4b55-43d2-bbf5-72ac309ce929_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_a82a9a30-779c-43ac-84fd-089d2331963f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_513202af-0ba1-4e21-8027-bf1842a763cf_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_1b0c08b0-c30d-4dcc-b72d-eaa6db5eb9c7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_fe417218-c6c3-4e06-bf8c-b2010c11d0d3_terseLabel_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Operations and Support Commitments</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_label_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_documentation_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:href="mrna-20251231.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:to="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6ce31df8-48c4-49ef-8687-f6ab59443e33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1f90f72-588b-426f-ac3b-f373be2acded_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_81c6bcec-2bfc-4c43-a70d-145c29a340c7_negatedTerseLabel_en-US" xlink:label="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in financing lease liabilities</link:label>
    <link:label id="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_label_en-US" xlink:label="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments, Net Of Adjustments</link:label>
    <link:label id="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_documentation_en-US" xlink:label="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" xlink:href="mrna-20251231.xsd#mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" xlink:to="lab_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_079abeae-739e-4c16-a3b3-7cd2fd761fb1_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EstimatedReimbursementLiability_56ff0687-0e28-4785-97bb-1ba9cccc90d4_terseLabel_en-US" xlink:label="lab_mrna_EstimatedReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated reimbursements to wholesalers and distributors</link:label>
    <link:label id="lab_mrna_EstimatedReimbursementLiability_label_en-US" xlink:label="lab_mrna_EstimatedReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement Liability</link:label>
    <link:label id="lab_mrna_EstimatedReimbursementLiability_documentation_en-US" xlink:label="lab_mrna_EstimatedReimbursementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EstimatedReimbursementLiability" xlink:href="mrna-20251231.xsd#mrna_EstimatedReimbursementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EstimatedReimbursementLiability" xlink:to="lab_mrna_EstimatedReimbursementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_8df3b0a5-49a3-41d3-a76f-9560c25ad446_verboseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue (Note 5)</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement Including Arrangements With Affiliate [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement Including Arrangements With Affiliate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:href="mrna-20251231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:to="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_225e5e9f-6b5a-493f-abf6-fbff85c11b33_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5180aabe-d6ea-4ad2-bea7-c5d534363adb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_e97dae36-9776-49f6-8ed7-b02142d7bc35_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_58bf91c3-26d7-4d39-9db7-b0920c49a425_verboseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_COVID19Member_205ac1af-cbb1-49be-ab97-91dd654b166b_terseLabel_en-US" xlink:label="lab_mrna_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COVID</link:label>
    <link:label id="lab_mrna_COVID19Member_label_en-US" xlink:label="lab_mrna_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_mrna_COVID19Member_documentation_en-US" xlink:label="lab_mrna_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_COVID19Member" xlink:href="mrna-20251231.xsd#mrna_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_COVID19Member" xlink:to="lab_mrna_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f3df9d04-a7ed-4bcd-aa29-feafbb2ed09f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7f7869e8-69b3-4dfb-8e16-2907655778a1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_63b4e281-73c8-44ca-aeb8-204d70250963_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_998f5bd5-08ee-48be-a27d-a1fe1be7fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e38073ef-f556-4734-a987-77611f09a921_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_019bee5c-4d61-7408-aa94-c18aedcc46e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of credit facility issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1bee70cc-cba6-42ad-9e66-f1191e733c75_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4a7ff56c-c512-458a-ae19-0ac485ba1840_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_01d55299-9071-4dc8-9402-a0423bca7e61_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-769b-b03c-7305e05358ec_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember_019c05b6-6bc0-77c9-bf21-4d972ad79db1_terseLabel_en-US" xlink:label="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Works and Government Services Canada</link:label>
    <link:label id="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember_label_en-US" xlink:label="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Works and Government Services Canada [Member]</link:label>
    <link:label id="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember_documentation_en-US" xlink:label="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Works and Government Services Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PublicWorksAndGovernmentServicesCanadaMember" xlink:href="mrna-20251231.xsd#mrna_PublicWorksAndGovernmentServicesCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PublicWorksAndGovernmentServicesCanadaMember" xlink:to="lab_mrna_PublicWorksAndGovernmentServicesCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_45c3392d-d542-4d78-a0b9-ee910994297a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_c6049384-e49e-4a74-bb2e-6db40a033bca_terseLabel_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_label_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaborative Parties [Member]</link:label>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_documentation_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaborative Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember" xlink:href="mrna-20251231.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherCollaborativePartiesMember" xlink:to="lab_mrna_OtherCollaborativePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_265db4d8-516e-416c-ac85-5dd3a149cbf8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_27e38d39-e859-4765-b3bf-56af46a6f514_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_019bee81-97a5-7f24-9b6d-4f573075246d_terseLabel_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, average market capitalization, trailing period</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_label_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Average Market Capitalization, Trailing Period</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_documentation_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Average Market Capitalization, Trailing Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" xlink:to="lab_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_90afbd01-8614-4e6a-a0bc-115920ec3e0d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f16ca03f-de46-4587-b42d-3bcf25bfefdf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e9145403-d9f0-4d61-a594-6bd2d9a9f50a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0586c9bc-b5ad-45ca-b229-344264f809ab_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2a6a525d-ebf8-4639-8868-daf5a240f0c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9217b631-2d8a-412c-ba71-5698967d14d4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e29d6fc5-f31b-451b-81e5-947a82c6da62_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_942b17de-058a-4515-91b7-1ec42c1db8cb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3015fe91-f377-4c5b-8eea-db3e6c62c903_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax positions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6a29f948-0399-49ae-be97-f5ea6af1129e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1272d71b-2039-4043-8372-208a3425646a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_37b1c03d-0079-4c7f-95e6-713857cacd1b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period of cost expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c44b395d-dde6-42ad-9ef9-0e2bb63584bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8ab7ef1-3af8-415f-b1da-3627148ccf0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b756ee5c-f5e5-4a57-9a40-30c7b098dd0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_804fe948-c247-4d15-97f6-780766c84200_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at beginning of the period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c56e493e-e437-419b-9ec9-622706f2d8a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at December 31</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_28dfc4d7-76ea-40ea-9543-95004d945e8d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_76257bdf-2465-434c-a389-a877ee85461a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bf239c8-c3ce-4a3f-9fc7-0870dd7ce4e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_a36a59dc-d86e-46a5-8b7b-4aeab016d7bb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase from derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_8e4c8d7e-7059-4a3e-9e56-1576236ab8f1_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e514e3e4-af66-42b5-b786-63110f82a877_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_2f11aa7c-e0ae-4ee0-905b-91345ff34713_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_8da09892-b04b-46b3-ab3e-72e300a8c3cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, including excise tax</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5029360f-5fea-42d4-9f57-bd71099f68e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b9050e7b-e75f-427c-b375-87d354700c0b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_89896016-2afe-43b1-898d-b4a852da4af2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments_933c22ce-4725-4450-9fce-ca195f23f5d2_terseLabel_en-US" xlink:label="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on future firm purchase commitments</link:label>
    <link:label id="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments_label_en-US" xlink:label="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Contingency, Future Firm Purchase Commitments</link:label>
    <link:label id="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments_documentation_en-US" xlink:label="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal Contingency, Future Firm Purchase Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments" xlink:to="lab_mrna_LegalContingencyFutureFirmPurchaseCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TermSecuredOvernightFinancingRatePlusMember_019beed4-b404-7d4e-950b-4eaaadf2c3a8_terseLabel_en-US" xlink:label="lab_mrna_TermSecuredOvernightFinancingRatePlusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term SOFR plus</link:label>
    <link:label id="lab_mrna_TermSecuredOvernightFinancingRatePlusMember_label_en-US" xlink:label="lab_mrna_TermSecuredOvernightFinancingRatePlusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Secured Overnight Financing Rate Plus [Member]</link:label>
    <link:label id="lab_mrna_TermSecuredOvernightFinancingRatePlusMember_documentation_en-US" xlink:label="lab_mrna_TermSecuredOvernightFinancingRatePlusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Secured Overnight Financing Rate Plus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TermSecuredOvernightFinancingRatePlusMember" xlink:href="mrna-20251231.xsd#mrna_TermSecuredOvernightFinancingRatePlusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TermSecuredOvernightFinancingRatePlusMember" xlink:to="lab_mrna_TermSecuredOvernightFinancingRatePlusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_0dc49a63-a7e7-4373-a992-7c4a0876fade_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-73bd-9093-4a7f16c14fc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax effects</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_460d81dc-c5c3-4703-8a90-a8b47220ca6a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_b1796627-5ca0-4a98-8eaf-5654f9abf37e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_2d635971-e378-4c3b-8479-4240b08ab94b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, firm purchase commitment, loss</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_5c9051c5-20cf-4ca3-86d0-5d407e779d27_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_abd47c3f-8cab-4587-ac85-a02c6f17c459_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_de93a833-c7fa-4155-b8e8-9218bd352862_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f31638f8-0e5b-485e-87d2-f406554cacbb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25ee70ea-1fb2-4e4f-ac8a-83cfb26d4be7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_aadbe194-2fbd-48de-abc7-6ae5b5126a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_383d2333-b2a1-436b-b35b-1fd6ee259987_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_245f124f-dbfb-4b76-89aa-e2d0edf09745_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_be310b13-b135-4d51-a238-3db8ae3721f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation and Share Repurchase Programs</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_4c643035-95ce-45d6-9bf1-cd6b5fd98767_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0ab69ede-a9ef-43aa-8ebf-ce53746b87a8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_019b92d1-7e82-76cf-99d6-f7f02546f984_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019b92cf-fcca-700b-a537-3878ce3b5776_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c8bdf185-9422-4c27-a723-c49d60d3b527_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_787135b0-6663-49f8-b889-f871690151db_terseLabel_en-US" xlink:label="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets And Liabilities, Lessee</link:label>
    <link:label id="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="mrna-20251231.xsd#mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StephenHogeMember_label_en-US" xlink:label="lab_mrna_StephenHogeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stephen Hoge [Member]</link:label>
    <link:label id="lab_mrna_StephenHogeMember_documentation_en-US" xlink:label="lab_mrna_StephenHogeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stephen Hoge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StephenHogeMember" xlink:href="mrna-20251231.xsd#mrna_StephenHogeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StephenHogeMember" xlink:to="lab_mrna_StephenHogeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_019b92d1-7e82-7441-8e40-023f1825cbd9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7797af26-b78b-41b4-bc28-4bc2a6f42cf0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_2c5da8b7-aca2-4ee9-bfd2-635a713aa9e2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_468a5a3d-e464-40a4-8709-62813f79d393_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_e2280fff-a67e-41fc-a902-9cd7d87ac740_terseLabel_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other external goods and services</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_label_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:href="mrna-20251231.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:to="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b92cf-fcca-73fd-b9c0-ba6c9bc04c30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1b6ac1f0-9f2b-4145-acbb-764f76db7dc3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9efd4bd6-1101-42ad-bdb2-58244954221f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_c1dcd5dc-d00c-479b-ba49-92509f6cdad2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_efdfacf6-5ad8-4ce6-9b0e-1ac4e0c29fd2_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_7519b70e-e084-450b-be8a-709e7804a90e_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability Refund [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability Refund [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability Refund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityRefundRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ea8169a6-b684-43a9-a18f-aec8eb6acfe2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d5021df4-21be-4f95-8da4-0ac93776374d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_9e4c3dea-f703-4ce5-beba-219f42092097_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_2363b20b-13d7-4d14-aef3-44bf9104b4b5_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ce5fb4d5-0627-449c-a771-ad5f4605c884_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a55f0efb-b4a4-43e3-87fd-23b9f650998f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of AFS securities in loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4099c68d-09fc-487c-94b0-16cf0249d0d4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1bf331c0-9bd8-433c-88a8-fa1856e98828_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e1180fbf-12a7-46ed-8cb2-5a5c8a2cafc1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a09dee8a-11bd-4b02-b4e0-78aaca66e9f4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_696c8cf9-ce25-40e5-8838-b485b0b17c99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_34869b8c-8c02-4088-b791-a1660c3ba766_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentLiabilityCurrent_3d638642-ae28-47ac-94cb-341d96ed9792_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development funding liability (Note 5)</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentLiabilityCurrent_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Liability, Current</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentLiabilityCurrent_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentLiabilityCurrent" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentLiabilityCurrent" xlink:to="lab_mrna_ResearchAndDevelopmentLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_bfd036db-765d-4445-b5a4-6932a6b2ce75_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AdoptionOfTradingArrangementOptions1Member_label_en-US" xlink:label="lab_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adoption of Trading Arrangement, Options 1 [Member]</link:label>
    <link:label id="lab_mrna_AdoptionOfTradingArrangementOptions1Member_documentation_en-US" xlink:label="lab_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adoption of Trading Arrangement, Options 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementOptions1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:to="lab_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_db6dcd12-34e0-45fe-a12a-9956e02b8122_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_faf52ca0-c457-46b7-89d3-f86d71bf4471_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_14f32097-3dc5-4f0e-acc8-e758141dd81e_terseLabel_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-based Awards</link:label>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_label_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_documentation_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ServiceBasedAwardsMember" xlink:href="mrna-20251231.xsd#mrna_ServiceBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ServiceBasedAwardsMember" xlink:to="lab_mrna_ServiceBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_97d0958a-7d0e-4d4b-be85-57f4f0bcc3e5_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e97a2d85-dd5d-4515-b2e7-c23c4115611b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1e9d9e96-24cb-4024-a2c8-2436d433d62c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_c8287407-489b-41b2-a8bc-190ba0d692e8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_9acc6895-95fc-4fde-a86e-9de4fd5e2658_terseLabel_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development operations</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_label_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_documentation_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation" xlink:href="mrna-20251231.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedDevelopmentOperation" xlink:to="lab_mrna_AccruedDevelopmentOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_17f13b7d-b121-44e3-a1e1-acb79b0315b9_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e18f532-bd2b-4524-b2a1-dd7486dd093e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_1c7adfe3-29fa-47de-8f9a-e8ebaef745d9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finance Lease Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3e9647c8-64cd-4980-9e2c-8a9644394bab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_019c6f10-34eb-7ed7-be91-a492580cb8c2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_e41366df-2d85-4bbf-bdc5-59749dc77029_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_019c1dd0-2715-7552-8804-73a8b5d3605a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_bf623ee7-a51f-417b-bf91-7443d3bd00cb_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f04cd629-ef9c-48e9-b631-1e44aea6235b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StephaneBancelMember_label_en-US" xlink:label="lab_mrna_StephaneBancelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stephane Bancel [Member]</link:label>
    <link:label id="lab_mrna_StephaneBancelMember_documentation_en-US" xlink:label="lab_mrna_StephaneBancelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stephane Bancel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StephaneBancelMember" xlink:href="mrna-20251231.xsd#mrna_StephaneBancelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StephaneBancelMember" xlink:to="lab_mrna_StephaneBancelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2cda82a4-6efc-4bc5-837d-41fec605e0d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_593ab987-87e9-47c2-b1bb-087eef92b44a_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value added tax receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b2631f2b-88b0-44db-a195-af5253e0b641_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a0a3532d-cc21-4513-a2a7-fa8b08a1ec54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ImmaticsMember_208722ae-540f-4331-9c5c-c0e830a345b7_terseLabel_en-US" xlink:label="lab_mrna_ImmaticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immatics</link:label>
    <link:label id="lab_mrna_ImmaticsMember_label_en-US" xlink:label="lab_mrna_ImmaticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immatics [Member]</link:label>
    <link:label id="lab_mrna_ImmaticsMember_documentation_en-US" xlink:label="lab_mrna_ImmaticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immatics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ImmaticsMember" xlink:href="mrna-20251231.xsd#mrna_ImmaticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ImmaticsMember" xlink:to="lab_mrna_ImmaticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6893bd48-893c-4c72-aab7-09dffe1472af_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3ce327c6-cd9b-4229-938a-7844fab29236_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_019c1dd0-2715-7bd6-b90d-80091484d9cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ProceedsFromOptionExerciseFee_028ae153-55ad-4a68-aaff-6af836d16a07_terseLabel_en-US" xlink:label="lab_mrna_ProceedsFromOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from option exercise fee</link:label>
    <link:label id="lab_mrna_ProceedsFromOptionExerciseFee_label_en-US" xlink:label="lab_mrna_ProceedsFromOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Option Exercise Fee</link:label>
    <link:label id="lab_mrna_ProceedsFromOptionExerciseFee_documentation_en-US" xlink:label="lab_mrna_ProceedsFromOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProceedsFromOptionExerciseFee" xlink:href="mrna-20251231.xsd#mrna_ProceedsFromOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ProceedsFromOptionExerciseFee" xlink:to="lab_mrna_ProceedsFromOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4fced608-ab83-4135-b9b4-b0d791a7d8bd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains on Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_999cb0cf-ab30-4c52-8e31-5c34305560ea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9dbe2427-ec7a-4fa7-b7ff-a34db83f0434_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_75f004f9-e575-4b6f-b3cc-3c45f0ad1b2d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001; 162&#160;shares authorized as of December 31, 2025 and 2024; no shares issued or outstanding at December 31, 2025 and 2024</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_47aa94bc-befe-46bd-bd7e-c6eb47ba4283_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock through equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b20f18eb-d1ee-465b-b5ab-7698e924c12e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Components of Deferred Tax Assets and Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_61a01645-f48a-467f-a6a9-8dda09fb62da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable, non-current</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:to="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_11daf8eb-3394-4b0f-b647-6bdea9910d8e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ee59c8f9-9508-474d-a01e-2f3922fa5f53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2025 and 2024; 394 and 386 shares issued and outstanding as of December 31, 2025 and 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_cfec69fa-31f1-4657-b286-3dede3715330_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, financing, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_762abb44-fc49-4905-8126-a1f2905726bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on equity investments, net</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2b6d086f-fb5d-4a65-b849-15773ecd8824_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_2783d05e-7ac0-4d4c-8d64-a8d0cf0ad848_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeFinanceLeaseExpense_f09d8f8d-bc7f-4416-8a30-40ec8a61f65b_terseLabel_en-US" xlink:label="lab_mrna_LesseeFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in financing lease liabilities</link:label>
    <link:label id="lab_mrna_LesseeFinanceLeaseExpense_label_en-US" xlink:label="lab_mrna_LesseeFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Expense</link:label>
    <link:label id="lab_mrna_LesseeFinanceLeaseExpense_documentation_en-US" xlink:label="lab_mrna_LesseeFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeFinanceLeaseExpense" xlink:href="mrna-20251231.xsd#mrna_LesseeFinanceLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeFinanceLeaseExpense" xlink:to="lab_mrna_LesseeFinanceLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_f1e5238e-0c06-464e-8bf9-6e7fe7616afb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxValuationAllowanceRollForward_1f57ddc0-8cc3-4689-84e6-9fa82ee14dea_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mrna_DeferredTaxValuationAllowanceRollForward_label_en-US" xlink:label="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mrna_DeferredTaxValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxValuationAllowanceRollForward" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward" xlink:to="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b19cf07e-707e-4c13-9b6e-2e70d3933627_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_29586f36-42bf-420b-961f-fcbfaf42fa9d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_d1b5347a-b74e-4393-9e90-8d2857270d6d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_bcbec2e0-20f8-4c10-88c7-fda94f211719_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ada2d2b3-4977-4bc1-a1b8-45ed88ec9667_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d1d9bc49-ef0d-4023-8661-3a04936f22b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f31ef20e-1883-4cff-919b-b3838df778e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0936bc21-0c8f-426d-935f-b67e884c49ab_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_019b92cf-fcca-7084-b788-7294a9dfb0f2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d01b8332-e532-4e43-9f58-fed8a1096e9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2f88184a-5cd6-42eb-aa8f-0fbf0a88ad32_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CovenantComplianceScenario2Member_019c05bd-4c22-7500-b6b1-6632aa5df1d6_terseLabel_en-US" xlink:label="lab_mrna_CovenantComplianceScenario2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Covenant Compliance, Scenario 2</link:label>
    <link:label id="lab_mrna_CovenantComplianceScenario2Member_label_en-US" xlink:label="lab_mrna_CovenantComplianceScenario2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Covenant Compliance, Scenario 2 [Member]</link:label>
    <link:label id="lab_mrna_CovenantComplianceScenario2Member_documentation_en-US" xlink:label="lab_mrna_CovenantComplianceScenario2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Covenant Compliance, Scenario 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CovenantComplianceScenario2Member" xlink:href="mrna-20251231.xsd#mrna_CovenantComplianceScenario2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CovenantComplianceScenario2Member" xlink:to="lab_mrna_CovenantComplianceScenario2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ModernaTechnologyCenterMember_5825854c-7322-4f50-9775-a298e8bc3468_terseLabel_en-US" xlink:label="lab_mrna_ModernaTechnologyCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna Technology Center</link:label>
    <link:label id="lab_mrna_ModernaTechnologyCenterMember_label_en-US" xlink:label="lab_mrna_ModernaTechnologyCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moderna Technology Center [Member]</link:label>
    <link:label id="lab_mrna_ModernaTechnologyCenterMember_documentation_en-US" xlink:label="lab_mrna_ModernaTechnologyCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Moderna Technology Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ModernaTechnologyCenterMember" xlink:href="mrna-20251231.xsd#mrna_ModernaTechnologyCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ModernaTechnologyCenterMember" xlink:to="lab_mrna_ModernaTechnologyCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_6b252e91-f3ad-4384-a101-ba42dedf93da_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2024</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_aefef116-8e39-4298-bd5f-885989400c24_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2025</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_019c11af-f335-7875-b7ab-a3a453bd4cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to product sales (Note 3)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_207ae141-c31d-445f-a30e-c515264d6533_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_bf72c6c6-44e9-4096-8b55-ee1584eb02c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_414739c4-3b90-4a1c-b76b-641a736b5036_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a843258d-18a7-47aa-9eba-9802f1f8bf94_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_731a489c-2f5f-4911-b675-304084efdb5d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_753ea4f8-1d64-436e-9e10-48a744e09ae3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0f8455a1-478d-41c7-85f3-88b113454f31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1479d340-4af1-4548-b4e4-67c167a4b7c2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RSVVaccineMember_61251c76-353e-4ec4-8f9e-04f528735af1_terseLabel_en-US" xlink:label="lab_mrna_RSVVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSV Vaccine</link:label>
    <link:label id="lab_mrna_RSVVaccineMember_label_en-US" xlink:label="lab_mrna_RSVVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSV Vaccine [Member]</link:label>
    <link:label id="lab_mrna_RSVVaccineMember_documentation_en-US" xlink:label="lab_mrna_RSVVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RSV Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RSVVaccineMember" xlink:href="mrna-20251231.xsd#mrna_RSVVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RSVVaccineMember" xlink:to="lab_mrna_RSVVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_53a3da59-e755-4126-936b-13ca5fe8cbd6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0f844b1a-992b-4486-ae1b-6c77ac68cbb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_319de011-28e8-422d-8cff-30e8e7acd14f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carry-forwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_6722bc05-c7d9-4e94-ba4e-38b4eedf6e40_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e3abb431-bc39-4efe-83ce-ed7c17b93ad1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FFFEnterprisesMember_4ae39c3f-a5ee-40b4-8a4d-4b4f9c9f40d6_terseLabel_en-US" xlink:label="lab_mrna_FFFEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FFF Enterprises</link:label>
    <link:label id="lab_mrna_FFFEnterprisesMember_label_en-US" xlink:label="lab_mrna_FFFEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FFF Enterprises [Member]</link:label>
    <link:label id="lab_mrna_FFFEnterprisesMember_documentation_en-US" xlink:label="lab_mrna_FFFEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FFF Enterprises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FFFEnterprisesMember" xlink:href="mrna-20251231.xsd#mrna_FFFEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FFFEnterprisesMember" xlink:to="lab_mrna_FFFEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_893d2cae-68d5-4d41-a358-8990a1e9a248_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3695e0be-7be4-46bf-9703-0a9bf8c5b8ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_7a124aff-36df-45e2-9de0-88434bb22878_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2cb0c3d3-f0c7-478a-85a4-60b4870a973a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_18bcd928-512a-439c-a458-e4156d24b356_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a6f371c5-8953-4462-83ba-35089351de7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5886f6d1-05d5-41fa-a4b4-9f0d1765ce3f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c83eb0d-c5c0-496f-8834-917da08fec2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_123114a7-2e90-4b67-b128-1d0890e218d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dac8028c-2000-4ba3-bdde-47a0d375e75a_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_32bf1f12-13ca-4d87-bbef-c17005f5a30b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration_6b9b6ffe-94c4-482b-a300-5436ac1a21c8_terseLabel_en-US" xlink:label="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses that begin to expire in 2030</link:label>
    <link:label id="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="mrna-20251231.xsd#mrna_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_mrna_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_cbe125bb-e792-46ae-8e52-be74aa10aca2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3db3861f-6f91-4aab-a667-e4f3ad413d88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d802bf6-ff7f-480c-8186-1ca8830592c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d3579755-f019-48ec-9f79-5c4c3bd8f6a4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_BoryungBiopharmaKoreaMember_019c05b6-6bc0-788b-8f68-2500b02bbcf4_terseLabel_en-US" xlink:label="lab_mrna_BoryungBiopharmaKoreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Boryung Biopharma Korea</link:label>
    <link:label id="lab_mrna_BoryungBiopharmaKoreaMember_label_en-US" xlink:label="lab_mrna_BoryungBiopharmaKoreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Boryung Biopharma Korea [Member]</link:label>
    <link:label id="lab_mrna_BoryungBiopharmaKoreaMember_documentation_en-US" xlink:label="lab_mrna_BoryungBiopharmaKoreaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Boryung Biopharma Korea</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BoryungBiopharmaKoreaMember" xlink:href="mrna-20251231.xsd#mrna_BoryungBiopharmaKoreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BoryungBiopharmaKoreaMember" xlink:to="lab_mrna_BoryungBiopharmaKoreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_0b07feaf-6389-4a56-9654-72a9ef5bce52_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8b62d003-7e08-43da-94b0-4274b80eaab2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f3f77702-ecf4-4f35-8ee6-bdc2a91079ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax payments related to net share settlements on equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_019bb3b4-d87b-7e34-be7b-f9e8c8dfbadf_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_14304efb-95eb-44cd-8d4f-a08f550b24aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_ed4b8c7d-b312-47e3-8352-3bd1e7925857_terseLabel_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MTC South, MTC North and MTC East</link:label>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_label_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MTC South, MTC North and MTC East [Member]</link:label>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_documentation_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MTC South, MTC North and MTC East</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:href="mrna-20251231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:to="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9f022b49-fbec-4204-a020-768fd34020da_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_440e6c87-df7f-4828-bc11-c876ad36517c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_019b92d1-7e82-7573-b863-236892c7731e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ffbd741b-eb0e-4ae1-b15f-8f9fb8e6f7ae_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_919bcce1-d302-4223-b1ee-dfecf6b3b40b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dfac4713-2d07-42d4-9b79-336aead133da_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_382e51d7-fd93-41cd-aeaa-89da3925ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw Materials</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:to="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_c3b592bb-73b0-4382-ae4e-2629f08d332a_terseLabel_en-US" xlink:label="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="mrna-20251231.xsd#mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TerminationOfTradingArrangementMember_label_en-US" xlink:label="lab_mrna_TerminationOfTradingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Termination of Trading Arrangement [Member]</link:label>
    <link:label id="lab_mrna_TerminationOfTradingArrangementMember_documentation_en-US" xlink:label="lab_mrna_TerminationOfTradingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Termination of Trading Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TerminationOfTradingArrangementMember" xlink:href="mrna-20251231.xsd#mrna_TerminationOfTradingArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TerminationOfTradingArrangementMember" xlink:to="lab_mrna_TerminationOfTradingArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_a8eb8505-b588-4898-9b09-4798060043bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4598fa53-ce10-469d-a207-8edab4e46226_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_eb2a0c2b-fec4-484c-a28f-6db8217c4f51_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3d994cf8-86a1-44ed-9d05-f5c022f4cf7e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7ee7-afd1-60da1ffa4a6e_terseLabel_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Scenario [Axis]</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis_label_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Scenario [Axis]</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis_documentation_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis" xlink:to="lab_mrna_DebtInstrumentCovenantComplianceScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c52ba-76db-74f5-8fb7-3d93b7693200_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_29a34ee5-496f-4b61-84b3-ab75774b7576_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_590e1af8-088a-4c28-85f4-cb8d18187171_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c1de1-b95b-7708-988e-07246a37c8d0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Nontaxable or nondeductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_981a62ff-da60-41ef-ae93-aa1c29bcf176_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_019b92d1-7e83-7b86-9306-a5943dbfa0fd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_b3e18a15-bb48-47d9-a92e-07a784bbf901_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_47343718-76ea-4a63-93e6-ed7acc52d858_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_978bfa9a-f622-49e1-9ec0-217d6d2b42ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_bb9db64b-8ecb-4a61-b0fc-0818f47ba250_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvision_75d41ee7-8cb9-4279-9f69-1ae0f69379a2_negatedTotalLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvision" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total product sales provision</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvision_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityProvision_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvision" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityProvision" xlink:to="lab_mrna_ContractWithCustomerLiabilityProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_26cf2633-922a-4a6c-aff8-d8ff98ce3ca0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7189eed2-b41c-4c38-8baa-8f66decf5182_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5a739d80-b83d-42a7-ab08-ed2a4e4f2256_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7cc4e118-020b-40e3-b89b-e47c1794ca93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1c0f4be4-8133-4265-8372-20191b9d5309_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_c98d431b-a1d1-4408-bc68-a32b72078577_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of campuses</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_label_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties" xlink:href="mrna-20251231.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseNumberOfProperties" xlink:to="lab_mrna_OperatingLeaseNumberOfProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ad7cc538-738d-4e78-a130-6633f8dbb0ec_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6b5a49a5-fa78-4b20-80a0-5ad47fca5b48_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e8399ae5-a426-45d7-b16f-2c71d118d860_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_28b1473b-8b72-4c01-a3c5-0e0e2aa7d88d_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward" xlink:href="mrna-20251231.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsMaximumAward" xlink:to="lab_mrna_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability_0356f7d8-9bfb-494e-bf6d-de913895abc9_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5995d2b3-9071-4033-8253-54e5bac4fd56_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_78dab824-4151-4b95-8034-2a40023b44a6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ed855242-a04c-4576-9e97-bee5dc82f6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_64bd8177-09d0-4788-9650-bd1d42557210_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dc58f1dc-a128-43c4-9ebf-18cfcb90943e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_90756d41-53d2-4c8a-91cd-7c2b95012fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_6bac44f6-460e-4cd4-929f-71259e1e18a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_153a3033-b6e9-4fa3-acb0-a3e6295ffa44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dbe3b44b-38fa-4399-b7a5-808e6eca9004_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_3d4add9f-3b5f-4da4-bd31-e6337c862f85_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_3ac1cb09-6ee7-4ae8-86a3-4bf4e64e1bf0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d35f8381-b480-41d6-a273-fe2c36913386_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net losses</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6a8c8b8c-5c82-4188-99cf-6fb8d5dd480e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_eef70964-f4f4-4c8a-8f9b-08de8ea3da5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and postretirement obligation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_A2022RepurchaseProgramMember_c831ff74-037f-4af4-873e-04a99affc9fd_terseLabel_en-US" xlink:label="lab_mrna_A2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Repurchase Program</link:label>
    <link:label id="lab_mrna_A2022RepurchaseProgramMember_label_en-US" xlink:label="lab_mrna_A2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Repurchase Program [Member]</link:label>
    <link:label id="lab_mrna_A2022RepurchaseProgramMember_documentation_en-US" xlink:label="lab_mrna_A2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2022RepurchaseProgramMember" xlink:href="mrna-20251231.xsd#mrna_A2022RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2022RepurchaseProgramMember" xlink:to="lab_mrna_A2022RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_102b54e5-923e-46c9-9b9d-e44f47d855a8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedClinicalTrials_940cb77d-4998-4743-8915-933d4e95b982_terseLabel_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_label_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_documentation_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials" xlink:href="mrna-20251231.xsd#mrna_AccruedClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedClinicalTrials" xlink:to="lab_mrna_AccruedClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_5478af6e-9e72-4ae2-b6df-8894b73b3eaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows used in financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_fa6acd34-5060-4a6b-ac02-896571418862_terseLabel_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Manufacturing Agreements</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_label_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply And Manufacturing Agreements [Member]</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_documentation_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supply And Manufacturing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:href="mrna-20251231.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:to="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_85978ded-dbdc-4054-8635-d0345a5f62da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5bb5dc23-1cf9-4bbd-9aa3-437627aa0e23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe5616fd-e3ed-4e8f-9ff5-99bbe24bf915_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_39f9581b-c760-43df-9eb3-beb7ea05e1c0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_0b45a07c-c44e-42aa-bdb4-11c576634842_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_92808cb9-534b-4f58-8f9e-52f3d40fb947_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_902106ef-6cab-44b1-8d40-cb083f34ab90_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1ad082c5-9fbb-4c1e-b456-316bb7873837_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_019c05bb-107a-73af-9001-b7d34120dc05_terseLabel_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum cash and cash equivalents</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_label_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Cash And Cash Equivalents</link:label>
    <link:label id="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_documentation_en-US" xlink:label="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" xlink:to="lab_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a7c329e0-78f2-4bcc-8396-af393d43cb2a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions for current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_e6a18595-9732-4c10-a108-0f711a690796_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_243f71e8-30e9-44b5-8215-fb7dd175bc92_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_019b92d1-7e83-7040-ae12-d45bb536e030_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8f096138-5e0f-4bd7-be5b-2317a0e3c9da_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1516315c-a95b-4288-b1f5-c8cb3d36796c_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AdoptionOfTradingArrangementOptions2Member_label_en-US" xlink:label="lab_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adoption of Trading Arrangement, Options 2 [Member]</link:label>
    <link:label id="lab_mrna_AdoptionOfTradingArrangementOptions2Member_documentation_en-US" xlink:label="lab_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adoption of Trading Arrangement, Options 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementOptions2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:to="lab_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_59ab53bb-e544-45a9-a2e3-eea55489935f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_9bc2ee5e-157d-42d2-a170-33b44ab5cc6a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b8fed061-bf69-43ce-8bca-80d53b549f46_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies_29642bbf-74d2-40fe-b59d-3cfbc03e2332_terseLabel_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Down payments and prepayments related to manufacturing and materials</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies_label_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Materials And Supplies</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies_documentation_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Materials And Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseMaterialsAndSupplies" xlink:href="mrna-20251231.xsd#mrna_OtherPrepaidExpenseMaterialsAndSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherPrepaidExpenseMaterialsAndSupplies" xlink:to="lab_mrna_OtherPrepaidExpenseMaterialsAndSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5f4c306f-17a1-4bdb-b8ac-02ee22cc1c71_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_5d43c10c-0170-4477-9d7a-2a45ee61c433_terseLabel_en-US" xlink:label="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses that will carry-forward indefinitely</link:label>
    <link:label id="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="mrna-20251231.xsd#mrna_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_mrna_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>mrna-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:2100a978-c810-4eca-85d9-7a3f37c08d9d,g:e414d930-d10b-4c86-a1cd-8d87f72aa21b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:type="simple" xlink:href="mrna-20251231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1bd5fdce-cc89-4079-90f9-dcc4f973f45b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentType_1bd5fdce-cc89-4079-90f9-dcc4f973f45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_28aefbf0-9cec-4efb-9497-8f35fef47eb8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentAnnualReport_28aefbf0-9cec-4efb-9497-8f35fef47eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ff546e36-eef1-4faf-9e43-467860dda8a0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentPeriodEndDate_ff546e36-eef1-4faf-9e43-467860dda8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b7d04a41-f711-443d-84a7-92ce0260a4ca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_CurrentFiscalYearEndDate_b7d04a41-f711-443d-84a7-92ce0260a4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7c81c778-8502-410e-b4dd-c1752ad25f49" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentTransitionReport_7c81c778-8502-410e-b4dd-c1752ad25f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fb457428-7f5c-48e6-bfff-0dcde347225f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityFileNumber_fb457428-7f5c-48e6-bfff-0dcde347225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5c62b6ed-19d1-4f8f-ad83-43eca10aead6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityRegistrantName_5c62b6ed-19d1-4f8f-ad83-43eca10aead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_82dc8aa9-783d-4e07-b6fb-59b46a68f985" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityIncorporationStateCountryCode_82dc8aa9-783d-4e07-b6fb-59b46a68f985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0e8f2618-af72-42a3-a76b-7cfb2eb901e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityTaxIdentificationNumber_0e8f2618-af72-42a3-a76b-7cfb2eb901e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c54ec7ef-1521-4cbd-a5bd-87e25e193adb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityAddressAddressLine1_c54ec7ef-1521-4cbd-a5bd-87e25e193adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e1e0d120-d2c8-4b36-9ede-4706a46d7aba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityAddressCityOrTown_e1e0d120-d2c8-4b36-9ede-4706a46d7aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c82f5d19-a87d-49f5-93d9-b8a7fe2c839f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityAddressStateOrProvince_c82f5d19-a87d-49f5-93d9-b8a7fe2c839f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a0bfc9f7-14c3-4d43-a376-2b51dadcc71f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityAddressPostalZipCode_a0bfc9f7-14c3-4d43-a376-2b51dadcc71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_408fcc25-6104-4a2e-acf8-9bef3033e3f5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_CityAreaCode_408fcc25-6104-4a2e-acf8-9bef3033e3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8ad36029-534c-410f-a810-64ba380c37e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_LocalPhoneNumber_8ad36029-534c-410f-a810-64ba380c37e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dd9dd22f-d851-4e05-b866-45cde408d39c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_Security12bTitle_dd9dd22f-d851-4e05-b866-45cde408d39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d8d24edc-2c24-4c82-8c2d-d49239949eea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_TradingSymbol_d8d24edc-2c24-4c82-8c2d-d49239949eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0903634a-c075-4d99-91b8-a2d6bfa31a77" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_SecurityExchangeName_0903634a-c075-4d99-91b8-a2d6bfa31a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d762939e-276b-4661-8618-fbf7c63ad037" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d762939e-276b-4661-8618-fbf7c63ad037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b05ea2d4-a501-403c-832f-13b7735c3dfa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityVoluntaryFilers_b05ea2d4-a501-403c-832f-13b7735c3dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_da053d83-89a8-49f6-80ed-c9cc225b0506" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityCurrentReportingStatus_da053d83-89a8-49f6-80ed-c9cc225b0506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_730e4cb6-8369-4e4a-a625-fb73b6e27fb7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityInteractiveDataCurrent_730e4cb6-8369-4e4a-a625-fb73b6e27fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9d19b205-41b7-4a02-be73-48298e9cfca9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityFilerCategory_9d19b205-41b7-4a02-be73-48298e9cfca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_448c4a00-c61d-43bb-a838-49fc78f34fcc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntitySmallBusiness_448c4a00-c61d-43bb-a838-49fc78f34fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1f321956-0c26-467a-aea4-9a64772a3ca9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityEmergingGrowthCompany_1f321956-0c26-467a-aea4-9a64772a3ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_453a9f6e-1d0e-47b3-85d2-486ae517dd36" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_IcfrAuditorAttestationFlag_453a9f6e-1d0e-47b3-85d2-486ae517dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_818103ce-b842-4bf7-8758-36bbe997507a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_818103ce-b842-4bf7-8758-36bbe997507a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_078b4aef-4be7-439f-934d-c6ec86f38be5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityShellCompany_078b4aef-4be7-439f-934d-c6ec86f38be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_9e2ebd8f-1670-46b3-8d48-359c92e451bb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityPublicFloat_9e2ebd8f-1670-46b3-8d48-359c92e451bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d9160339-59bd-44b0-a688-4fcda17afccd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d9160339-59bd-44b0-a688-4fcda17afccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_21adbb7b-c8bd-40ae-99e4-d4de914a15a2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_21adbb7b-c8bd-40ae-99e4-d4de914a15a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aa450447-0bd9-4ef6-b221-bfdc79141db0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_AmendmentFlag_aa450447-0bd9-4ef6-b221-bfdc79141db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0bc1a14a-7375-4d3a-8cf7-3b6026d80aab" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentFiscalYearFocus_0bc1a14a-7375-4d3a-8cf7-3b6026d80aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_17fe7352-8e60-4f60-aef2-4cd1edbb6118" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_DocumentFiscalPeriodFocus_17fe7352-8e60-4f60-aef2-4cd1edbb6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5805c918-6168-42c0-9639-470493be1d54" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01b14dda-ba44-4ae4-a565-61f931b73757" xlink:to="loc_dei_EntityCentralIndexKey_5805c918-6168-42c0-9639-470493be1d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/AuditInformation" xlink:type="simple" xlink:href="mrna-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AuditInformationAbstract_794b3708-c7e0-4c1c-9087-2204d2f68ef5" xlink:href="mrna-20251231.xsd#mrna_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_f1864b07-217c-44d2-97ee-adff89cf3fdb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_AuditInformationAbstract_794b3708-c7e0-4c1c-9087-2204d2f68ef5" xlink:to="loc_dei_AuditorName_f1864b07-217c-44d2-97ee-adff89cf3fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e69b9886-0471-41a3-a05b-c3e45f4d5be7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_AuditInformationAbstract_794b3708-c7e0-4c1c-9087-2204d2f68ef5" xlink:to="loc_dei_AuditorLocation_e69b9886-0471-41a3-a05b-c3e45f4d5be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_11238e00-e982-470e-a8ba-64a362d4f589" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_AuditInformationAbstract_794b3708-c7e0-4c1c-9087-2204d2f68ef5" xlink:to="loc_dei_AuditorFirmId_11238e00-e982-470e-a8ba-64a362d4f589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7a0bae81-2149-4246-bfd2-15d6fb83565a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a0bae81-2149-4246-bfd2-15d6fb83565a" xlink:to="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49b605dc-6e90-4ec8-8145-04790e9e2e82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49b605dc-6e90-4ec8-8145-04790e9e2e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cd12d645-48aa-4deb-9837-3a29c1a3f0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cd12d645-48aa-4deb-9837-3a29c1a3f0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_71f4364b-52f6-4aad-be27-434126d739ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_71f4364b-52f6-4aad-be27-434126d739ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2b448ed9-50e8-47ad-b9f1-450c656755a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:to="loc_us-gaap_InventoryNet_2b448ed9-50e8-47ad-b9f1-450c656755a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e641ece9-dcec-41f6-8558-a1c0f3867f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e641ece9-dcec-41f6-8558-a1c0f3867f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d2c6e888-9b4f-405e-9051-e9c394a4360e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_94917b9a-d86b-45e4-8d4a-0c80eadc5776" xlink:to="loc_us-gaap_AssetsCurrent_d2c6e888-9b4f-405e-9051-e9c394a4360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0f2f3c2a-35e5-4a3b-91dc-752716b0375b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0f2f3c2a-35e5-4a3b-91dc-752716b0375b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d925d65f-aaf5-4a85-8ab0-12362a3dbf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d925d65f-aaf5-4a85-8ab0-12362a3dbf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe2c21bb-ff90-4dd6-ab68-c690225dfc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe2c21bb-ff90-4dd6-ab68-c690225dfc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b38f3d4-d9a9-48da-93a8-d25d73ea0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b38f3d4-d9a9-48da-93a8-d25d73ea0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b562aa01-3637-4765-a221-274b27eca6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b2c1b4a7-ba73-46a1-a2d9-1ce2aae8a00f" xlink:to="loc_us-gaap_Assets_b562aa01-3637-4765-a221-274b27eca6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a0bae81-2149-4246-bfd2-15d6fb83565a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c8aa9b79-2d20-41d0-bb93-f3a5b8899a12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:to="loc_us-gaap_AccountsPayableCurrent_c8aa9b79-2d20-41d0-bb93-f3a5b8899a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eaca5424-f2de-4fc3-8868-c12bd752c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eaca5424-f2de-4fc3-8868-c12bd752c57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cba62b37-284d-4e20-9b00-0e35fc50384a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cba62b37-284d-4e20-9b00-0e35fc50384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_83c74087-e21b-466b-90d4-c2f727b05eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_83c74087-e21b-466b-90d4-c2f727b05eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0aced105-db93-4237-b033-69e905940817" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eea00aa8-6c61-41e3-9982-4cf43264f3fc" xlink:to="loc_us-gaap_LiabilitiesCurrent_0aced105-db93-4237-b033-69e905940817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_82fbb8b0-0254-4e48-a0d4-6318eb3487b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_82fbb8b0-0254-4e48-a0d4-6318eb3487b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d3e9d5a-63c0-4f33-b7e3-862e485795ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d3e9d5a-63c0-4f33-b7e3-862e485795ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_395da134-dbcc-442c-a4a1-c68e80dadf30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_395da134-dbcc-442c-a4a1-c68e80dadf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019b9299-228a-7c60-85c7-7df298f0e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019b9299-228a-7c60-85c7-7df298f0e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e6bd3c7e-2fff-4698-8aa2-596d8144fc56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e6bd3c7e-2fff-4698-8aa2-596d8144fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_22d86c2a-a262-4305-ae1f-72b5fdb3b848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_Liabilities_22d86c2a-a262-4305-ae1f-72b5fdb3b848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b127afa3-edb2-4400-aeab-0f9dd90c0dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b127afa3-edb2-4400-aeab-0f9dd90c0dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3908f08b-9b82-4d47-8c2c-3dc6d6b039c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:to="loc_us-gaap_PreferredStockValue_3908f08b-9b82-4d47-8c2c-3dc6d6b039c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1bca6c05-75c4-4c70-8652-1b66b6843896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:to="loc_us-gaap_CommonStockValue_1bca6c05-75c4-4c70-8652-1b66b6843896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8acf53c9-9525-4eb4-a879-3057b40253ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8acf53c9-9525-4eb4-a879-3057b40253ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2a42b3a2-5f78-4893-b997-8d7e1c4e2d41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2a42b3a2-5f78-4893-b997-8d7e1c4e2d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_efb38752-addf-417a-8ae1-dc3e5a207c95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_efb38752-addf-417a-8ae1-dc3e5a207c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77267025-f767-4684-ad56-fefc435a59db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f4006aec-8991-4d02-bb24-5c96f35d5af0" xlink:to="loc_us-gaap_StockholdersEquity_77267025-f767-4684-ad56-fefc435a59db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c574926d-a198-4911-bd94-e83c58320574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e3c8670-4cc4-4aeb-ae1c-b713a808e4fa" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c574926d-a198-4911-bd94-e83c58320574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1133221e-9565-41d6-b90f-f3b84c7f595f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1133221e-9565-41d6-b90f-f3b84c7f595f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fb3dbce8-9ec0-484b-b6ef-39ff0c180852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fb3dbce8-9ec0-484b-b6ef-39ff0c180852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6cf6c250-8b07-4cb2-8478-007f4d90d840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6cf6c250-8b07-4cb2-8478-007f4d90d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0e0da95e-86ba-433b-a836-16ab0719d1de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0e0da95e-86ba-433b-a836-16ab0719d1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_13b5118e-0dc3-4bbb-81ff-47452f4437e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_13b5118e-0dc3-4bbb-81ff-47452f4437e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c27b2f5e-d54c-4075-831c-7f9e61429409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c27b2f5e-d54c-4075-831c-7f9e61429409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e056d88a-8942-45d6-a8ce-d266332bfc17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_CommonStockSharesIssued_e056d88a-8942-45d6-a8ce-d266332bfc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_071cbc67-eee8-4743-a5cc-88d80edbaa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1e38d0ce-652c-4bd7-8e5f-ae62b7196b16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_071cbc67-eee8-4743-a5cc-88d80edbaa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1ce03014-b0f4-4a23-ac61-0f575aae247a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1ce03014-b0f4-4a23-ac61-0f575aae247a" xlink:to="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:to="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_14cc229b-a13f-42a7-bfd9-ab030639cb7b" xlink:to="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_4f81f8de-ba43-4259-910d-bf0797e770d1" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:to="loc_mrna_ProductSalesMember_4f81f8de-ba43-4259-910d-bf0797e770d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_5d04de63-9d2e-4c72-a50d-79560bbf78ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2700adc0-f7dc-45bb-827d-1214253ce352" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_5d04de63-9d2e-4c72-a50d-79560bbf78ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7e459259-5729-48fe-8ad1-19fcf32415b1" xlink:to="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e841fd57-5b14-4f0d-a753-db807542f636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_RevenuesAbstract_e841fd57-5b14-4f0d-a753-db807542f636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3d6b28a-cd0a-4c60-8f25-eee645665b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e841fd57-5b14-4f0d-a753-db807542f636" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3d6b28a-cd0a-4c60-8f25-eee645665b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5f4f02ca-4202-499a-b4ea-596f7796795d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5f4f02ca-4202-499a-b4ea-596f7796795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cfd83fa9-4bdb-48bf-ae68-88bed5ca2522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cfd83fa9-4bdb-48bf-ae68-88bed5ca2522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_53144bae-27dd-41c1-bc8f-5f6fd6a0b08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_53144bae-27dd-41c1-bc8f-5f6fd6a0b08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7e132724-05ac-4566-aeba-9c339d19c5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fdeb530a-a32e-4422-b832-1fae584146df" xlink:to="loc_us-gaap_CostsAndExpenses_7e132724-05ac-4566-aeba-9c339d19c5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aba3e326-4801-4385-8d57-9bee2550193d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_OperatingIncomeLoss_aba3e326-4801-4385-8d57-9bee2550193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c8e2531a-050a-4918-ab10-4a24498e967d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c8e2531a-050a-4918-ab10-4a24498e967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bdbba59e-aaab-49ff-9b0f-dbfb22e5757d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bdbba59e-aaab-49ff-9b0f-dbfb22e5757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cacc1aaf-9d26-4d1a-bca2-3206c6bd44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cacc1aaf-9d26-4d1a-bca2-3206c6bd44b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1985dddd-4529-4812-a2ec-b085ff3e8713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1985dddd-4529-4812-a2ec-b085ff3e8713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2eb9a063-ffc4-4d05-aa54-8bb4c7fe4859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_NetIncomeLoss_2eb9a063-ffc4-4d05-aa54-8bb4c7fe4859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_482d7b6f-8625-4e04-87e3-8c99350b6108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:to="loc_us-gaap_EarningsPerShareBasic_482d7b6f-8625-4e04-87e3-8c99350b6108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e1950712-c4da-4938-b78e-3e36b31cd798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f4b5031-64bf-48a4-9e5c-78c41cbdceb4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e1950712-c4da-4938-b78e-3e36b31cd798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd5c4f7b-f05b-43ea-8d39-90f99a3a7d5e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_276d7a29-695b-4b00-990d-380f30f07a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_276d7a29-695b-4b00-990d-380f30f07a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01daa26f-c44d-434f-b28d-f52647409839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c05a37e1-1681-4048-b83b-ffabcc3e3950" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01daa26f-c44d-434f-b28d-f52647409839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9675b423-29a6-4e72-9f40-895757868b92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_NetIncomeLoss_9675b423-29a6-4e72-9f40-895757868b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8af23c68-6326-4a60-b9a6-949cbda51b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8af23c68-6326-4a60-b9a6-949cbda51b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_79d74cc5-61ba-44b8-b6c2-70e1a720af4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8af23c68-6326-4a60-b9a6-949cbda51b71" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_79d74cc5-61ba-44b8-b6c2-70e1a720af4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88c43cf5-4b6b-4ad4-9d60-d15c2a2118af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_79d74cc5-61ba-44b8-b6c2-70e1a720af4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88c43cf5-4b6b-4ad4-9d60-d15c2a2118af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_555661e1-69c2-4598-9c74-59a05bd994f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_79d74cc5-61ba-44b8-b6c2-70e1a720af4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_555661e1-69c2-4598-9c74-59a05bd994f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6ff94fb0-355d-489c-ad2c-f5dd5b3d9590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_79d74cc5-61ba-44b8-b6c2-70e1a720af4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6ff94fb0-355d-489c-ad2c-f5dd5b3d9590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_2acce238-b32e-4caa-b0b3-420d32ef0a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_2acce238-b32e-4caa-b0b3-420d32ef0a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c94e30eb-e15f-4105-b47c-d582df490492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_2acce238-b32e-4caa-b0b3-420d32ef0a70" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c94e30eb-e15f-4105-b47c-d582df490492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_ca4bb3aa-9eca-4116-ae32-4f2377489f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_2acce238-b32e-4caa-b0b3-420d32ef0a70" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_ca4bb3aa-9eca-4116-ae32-4f2377489f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8be73019-da1d-4e12-b6a7-784437347810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8be73019-da1d-4e12-b6a7-784437347810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_dbbd897a-191a-4953-b2ca-3203376cddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_dbbd897a-191a-4953-b2ca-3203376cddd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_afda6142-15cf-4fa0-838f-43926af1e9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_afda6142-15cf-4fa0-838f-43926af1e9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_59a35dba-89b5-4370-9c7b-f24ebbe4be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0dbd794b-77a5-4944-a720-da9ab570c4e5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_59a35dba-89b5-4370-9c7b-f24ebbe4be2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2627dff6-15a3-49fe-b6d4-3c2456e707eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2627dff6-15a3-49fe-b6d4-3c2456e707eb" xlink:to="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a5afe7b6-dc98-47b1-a292-c9e17e8beb2d" xlink:to="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_772a8b3c-9a12-42b4-a42b-4600348da4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_CommonStockMember_772a8b3c-9a12-42b4-a42b-4600348da4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12ab9719-afc2-4201-9e70-e629496ae78c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12ab9719-afc2-4201-9e70-e629496ae78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181796-77ee-402b-bb53-a740d5c562f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181796-77ee-402b-bb53-a740d5c562f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c08cf460-7db3-4610-bcbe-659e3ef7a9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef50c340-9508-4e49-acde-9184143e80ef" xlink:to="loc_us-gaap_RetainedEarningsMember_c08cf460-7db3-4610-bcbe-659e3ef7a9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60cdce0f-58c4-4b6f-b9fa-0b594bc2cd66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_064783ce-9b70-4e84-8e95-e346acc26ddf" xlink:to="loc_us-gaap_StatementLineItems_60cdce0f-58c4-4b6f-b9fa-0b594bc2cd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60cdce0f-58c4-4b6f-b9fa-0b594bc2cd66" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3e186b1f-a739-40c8-9c85-97ec7325cc69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3e186b1f-a739-40c8-9c85-97ec7325cc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f8deb380-3050-46b8-b1fc-92b5218e8291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockholdersEquity_f8deb380-3050-46b8-b1fc-92b5218e8291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73ca336c-f303-4b29-9aab-9c936af56da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73ca336c-f303-4b29-9aab-9c936af56da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_632f7e7d-7a54-4f48-b82e-d4e18553a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_632f7e7d-7a54-4f48-b82e-d4e18553a4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e51aef21-4b08-44e2-8c28-d6d151bfeaee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e51aef21-4b08-44e2-8c28-d6d151bfeaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019c05b4-f8b8-7604-acdc-df13dbb8747d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019c05b4-f8b8-7604-acdc-df13dbb8747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6df0f69-187e-4018-97f0-8d32a77bce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6df0f69-187e-4018-97f0-8d32a77bce6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_00c60209-77e1-4e5b-876f-759f4262d0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_00c60209-77e1-4e5b-876f-759f4262d0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9060eef-238a-4875-9cb6-ff2353879b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9060eef-238a-4875-9cb6-ff2353879b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_62261013-0a47-4e5c-99aa-0430f1468006" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_62261013-0a47-4e5c-99aa-0430f1468006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_942d4e8d-2b62-4394-916b-e47a049afe07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_942d4e8d-2b62-4394-916b-e47a049afe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_fd6590e5-06b6-47be-a168-a69cae4e1e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_fd6590e5-06b6-47be-a168-a69cae4e1e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac9c7c75-324b-4053-bf60-10fffb736611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_NetIncomeLoss_ac9c7c75-324b-4053-bf60-10fffb736611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9d7c027d-83d8-45ee-9c9a-c8cfbdcd5f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9d7c027d-83d8-45ee-9c9a-c8cfbdcd5f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ebf8928-11af-4de4-9ece-f6014de30fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45bb91f2-eb42-46ed-a36e-55188e72fbf9" xlink:to="loc_us-gaap_StockholdersEquity_9ebf8928-11af-4de4-9ece-f6014de30fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c49cdb23-3773-41c2-8191-f6fcba5e9eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c49cdb23-3773-41c2-8191-f6fcba5e9eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f66d14f9-32f0-4ef3-824e-512f4c8aa295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c49cdb23-3773-41c2-8191-f6fcba5e9eaf" xlink:to="loc_us-gaap_NetIncomeLoss_f66d14f9-32f0-4ef3-824e-512f4c8aa295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c49cdb23-3773-41c2-8191-f6fcba5e9eaf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b223c1-f987-4481-ac6e-002614db36a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b223c1-f987-4481-ac6e-002614db36a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_24d4cb81-49d6-431c-b79f-31b5a880b8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_24d4cb81-49d6-431c-b79f-31b5a880b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_843446f7-0e31-4946-8c0f-77b25ce61582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_843446f7-0e31-4946-8c0f-77b25ce61582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_5d70d163-9da7-45d1-bea5-b89d9911a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_5d70d163-9da7-45d1-bea5-b89d9911a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dba9185f-4cda-4bc9-ad1d-07ab7fdaec6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dba9185f-4cda-4bc9-ad1d-07ab7fdaec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50397e78-5903-4bca-b712-b2cb1f16592d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_892eeff6-2184-442f-8e3c-c8126e841419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_892eeff6-2184-442f-8e3c-c8126e841419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4959db01-0ed1-489d-9e8d-d48be931990a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4959db01-0ed1-489d-9e8d-d48be931990a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ca10f962-b00e-4888-b86a-d975fa0f582f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ca10f962-b00e-4888-b86a-d975fa0f582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_b795e2ae-4636-4ee3-8c6a-1b53f8eff39f" xlink:href="mrna-20251231.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_b795e2ae-4636-4ee3-8c6a-1b53f8eff39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_392e0a45-e8e5-4770-9378-0e230b9aecce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_392e0a45-e8e5-4770-9378-0e230b9aecce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_dfc85dfb-6e6d-40b5-b662-eec6ac72c1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_dfc85dfb-6e6d-40b5-b662-eec6ac72c1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fa0ef021-3ca7-4268-9d67-e8d360a35266" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fa0ef021-3ca7-4268-9d67-e8d360a35266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7526b640-7303-46cb-b709-36eb17110aae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7526b640-7303-46cb-b709-36eb17110aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ef102b8b-4451-4fee-b867-658930722d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f2543fb-234f-49e4-b6c5-0325516cdb7f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ef102b8b-4451-4fee-b867-658930722d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18eae28a-e5a1-4067-9988-025dd4728423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c49cdb23-3773-41c2-8191-f6fcba5e9eaf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18eae28a-e5a1-4067-9988-025dd4728423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_931fff7b-5412-402b-b48d-1e32cd8792da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_931fff7b-5412-402b-b48d-1e32cd8792da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_40c30718-a2f3-4746-9aaf-e43a076a6720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_40c30718-a2f3-4746-9aaf-e43a076a6720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9c498d02-f714-49aa-a7de-685334d98bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9c498d02-f714-49aa-a7de-685334d98bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d91e7b9-a0a8-40f4-9b12-e09409fe91c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d91e7b9-a0a8-40f4-9b12-e09409fe91c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c2995-bb92-7fbb-aae7-34375bd194d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_019c2995-bb92-7fbb-aae7-34375bd194d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_da654ff6-79d4-4871-8eef-aba08cb187ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_da654ff6-79d4-4871-8eef-aba08cb187ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_32a78c0f-a60f-415f-923a-29dee85e3eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_32a78c0f-a60f-415f-923a-29dee85e3eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6d59f5b-b2cb-4643-b919-9e1944ab2a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6052be5f-f618-4d09-9576-8c35d996c84d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6d59f5b-b2cb-4643-b919-9e1944ab2a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_019b929f-d922-7c4b-94d2-bd8612f06c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_019b929f-d922-7c4b-94d2-bd8612f06c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_019bee5b-d0e0-734d-b479-e57d033d18a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_019bee5b-d0e0-734d-b479-e57d033d18a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a4b6317b-d6a9-4c17-b533-8d27e23eb91a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a4b6317b-d6a9-4c17-b533-8d27e23eb91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6c3426c6-4c85-4d90-a09c-3619a5742dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6c3426c6-4c85-4d90-a09c-3619a5742dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_53763e8b-c9c3-4971-891d-491fa0b05b63" xlink:href="mrna-20251231.xsd#mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:to="loc_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments_53763e8b-c9c3-4971-891d-491fa0b05b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23c0f58e-e967-4759-a922-98397d9e62c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_563ca003-f1cc-4f7e-af57-aea10421ad0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23c0f58e-e967-4759-a922-98397d9e62c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c52b9-f4aa-7894-b06f-5c890a71298b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c52b9-f4aa-7894-b06f-5c890a71298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39cf4596-6751-49b7-9028-929ae541d8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39cf4596-6751-49b7-9028-929ae541d8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bcceca0-8205-44d7-98d3-3758597c4c88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bcceca0-8205-44d7-98d3-3758597c4c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a618faa-daad-4119-b15b-108ea61eca67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a618faa-daad-4119-b15b-108ea61eca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_aed3d448-6cfa-41ea-973a-ce85c6ced064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_aed3d448-6cfa-41ea-973a-ce85c6ced064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_77e43a6c-4502-4884-8718-bcbede9e452c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_aed3d448-6cfa-41ea-973a-ce85c6ced064" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_77e43a6c-4502-4884-8718-bcbede9e452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4fb56928-0597-4079-8145-d24a92b707d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_aed3d448-6cfa-41ea-973a-ce85c6ced064" xlink:to="loc_us-gaap_InterestPaidNet_4fb56928-0597-4079-8145-d24a92b707d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43c38f70-5198-4683-ac31-2e7a283acc38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04522e53-a3e6-40ef-a9bd-0eab21d00f59" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43c38f70-5198-4683-ac31-2e7a283acc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d51b9cd4-59a7-493c-a4ef-42f11052b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_43c38f70-5198-4683-ac31-2e7a283acc38" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d51b9cd4-59a7-493c-a4ef-42f11052b0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="mrna-20251231.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86696e5f-a6b9-431e-98bc-2185f24e6c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_69628276-00a2-4e03-8ab9-b1389ac90363" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86696e5f-a6b9-431e-98bc-2185f24e6c8a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_69628276-00a2-4e03-8ab9-b1389ac90363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_931d89ac-1d45-445f-b1d2-91e8ee0f1091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1735dbeb-0eb7-47c3-9d18-87a4d5c0dfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_931d89ac-1d45-445f-b1d2-91e8ee0f1091" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1735dbeb-0eb7-47c3-9d18-87a4d5c0dfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSales" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSales"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dd67a395-4534-4700-ab46-14c367fe1cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d535ce91-77df-4bfe-b87e-b729e496fcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dd67a395-4534-4700-ab46-14c367fe1cb3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d535ce91-77df-4bfe-b87e-b729e496fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherRevenue" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherRevenue"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2da94dcd-2568-4da9-ad01-a58ecdff321a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b6d59247-fe31-4c25-a0bb-38e84478b19e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2da94dcd-2568-4da9-ad01-a58ecdff321a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b6d59247-fe31-4c25-a0bb-38e84478b19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements" xlink:type="simple" xlink:href="mrna-20251231.xsd#CollaborationAgreementsandResearchandDevelopmentFundingArrangements"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_ce4fd68b-4d71-4a37-8999-88ce6b129a06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6aa9461e-d8e4-4305-bbfa-b63df8cd027b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_ce4fd68b-4d71-4a37-8999-88ce6b129a06" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6aa9461e-d8e4-4305-bbfa-b63df8cd027b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0e6147be-ceb9-4dfe-a15c-aac9f5f9d61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d4471ac3-d01e-4aab-bba7-2860f47f61e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0e6147be-ceb9-4dfe-a15c-aac9f5f9d61a" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d4471ac3-d01e-4aab-bba7-2860f47f61e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Inventory" xlink:type="simple" xlink:href="mrna-20251231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e6134467-664a-4a0a-90d1-83d02a18d706" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c39d6ecc-2f46-41b7-b206-5af134fca3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6134467-664a-4a0a-90d1-83d02a18d706" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c39d6ecc-2f46-41b7-b206-5af134fca3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="mrna-20251231.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_07bf3eb5-f03d-4fef-a7b6-44367dac9d02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e5d624dd-b763-43ee-bf75-1ff65d42871a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_07bf3eb5-f03d-4fef-a7b6-44367dac9d02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e5d624dd-b763-43ee-bf75-1ff65d42871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_046d6b66-1075-47b0-9e79-ca99b82a0a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8828676e-e409-454d-b178-47bd78f1f761" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_046d6b66-1075-47b0-9e79-ca99b82a0a3f" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8828676e-e409-454d-b178-47bd78f1f761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:type="simple" xlink:href="mrna-20251231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f7270415-4a1c-41d0-8892-c0c0421678a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_85286f5f-782c-43d4-8b56-9d92224fac21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7270415-4a1c-41d0-8892-c0c0421678a3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_85286f5f-782c-43d4-8b56-9d92224fac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_444e0b58-5696-4a85-a5f6-931f3a799813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7270415-4a1c-41d0-8892-c0c0421678a3" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_444e0b58-5696-4a85-a5f6-931f3a799813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CreditAgreement" xlink:type="simple" xlink:href="mrna-20251231.xsd#CreditAgreement"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CreditAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019b92d1-7e82-7138-8389-49bc7bba3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_019b92d1-7e82-7a08-bb64-d0d5e599554d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019b92d1-7e82-7138-8389-49bc7bba3bb7" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_019b92d1-7e82-7a08-bb64-d0d5e599554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b926665-2547-4344-8c18-69515d380ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b279480d-bb74-4ac9-8e18-2aa13e80a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b926665-2547-4344-8c18-69515d380ef9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b279480d-bb74-4ac9-8e18-2aa13e80a0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchasePrograms"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a32543c-8d17-4fb8-a910-f543955a3471" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb0903c7-ea51-4a3c-9be4-46b89842ec79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a32543c-8d17-4fb8-a910-f543955a3471" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb0903c7-ea51-4a3c-9be4-46b89842ec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2c827d0e-bb38-4d70-b202-8b8a3722ce7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0aa28de7-44fc-4222-ae6a-a10a93c2bb53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c827d0e-bb38-4d70-b202-8b8a3722ce7e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0aa28de7-44fc-4222-ae6a-a10a93c2bb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LossperShare" xlink:type="simple" xlink:href="mrna-20251231.xsd#LossperShare"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_29538059-db6f-47ca-9368-413bd29aefe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e79bdf9a-d75f-44fb-bd1b-2899e3838ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29538059-db6f-47ca-9368-413bd29aefe7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e79bdf9a-d75f-44fb-bd1b-2899e3838ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformation" xlink:type="simple" xlink:href="mrna-20251231.xsd#GeographicInformation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85b1c881-c5a1-4a4d-afa3-246f3e3a7377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d0f101e0-ed9a-45f7-b64d-c7df7ae7641a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85b1c881-c5a1-4a4d-afa3-246f3e3a7377" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d0f101e0-ed9a-45f7-b64d-c7df7ae7641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_57f7f32e-19f1-47ba-b0b1-fe5bf070bdab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_57f7f32e-19f1-47ba-b0b1-fe5bf070bdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_5863f60e-6719-42dd-bcab-a1316ad34890" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_5863f60e-6719-42dd-bcab-a1316ad34890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b404b43e-db60-4131-888d-a26f69c7ce59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_UseOfEstimates_b404b43e-db60-4131-888d-a26f69c7ce59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9d8ef1f7-6378-4a16-ae23-0e8fa5ca92ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9d8ef1f7-6378-4a16-ae23-0e8fa5ca92ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d99b614f-e538-47b4-ace7-6b69e6fefad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d99b614f-e538-47b4-ace7-6b69e6fefad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_3f2a4bad-838a-4d1c-a530-863d51d01a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_3f2a4bad-838a-4d1c-a530-863d51d01a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_63b9ff6f-3ffd-4cd9-b270-8410f7707ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_63b9ff6f-3ffd-4cd9-b270-8410f7707ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9bddf957-a6a7-49eb-9e8e-342aa475d39e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9bddf957-a6a7-49eb-9e8e-342aa475d39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4c4e23ea-b844-4b6a-a93b-469842582486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4c4e23ea-b844-4b6a-a93b-469842582486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_28705f9d-18e2-4894-a826-ac244c1ff212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_28705f9d-18e2-4894-a826-ac244c1ff212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_cdc0b90c-634e-4b90-bf8a-3adb74876c48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_cdc0b90c-634e-4b90-bf8a-3adb74876c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_73fb3c3c-4417-4e6a-ad39-0b160f72b2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_73fb3c3c-4417-4e6a-ad39-0b160f72b2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_43bf65a3-fdef-417e-af64-06c58d063749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_43bf65a3-fdef-417e-af64-06c58d063749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_205f18a7-4f7c-4643-b31b-1a8ed0a34b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_205f18a7-4f7c-4643-b31b-1a8ed0a34b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ac514d67-4fa9-4a1b-be12-5130b2764800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ac514d67-4fa9-4a1b-be12-5130b2764800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a533550b-7743-4530-b961-c794afdeeff2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a533550b-7743-4530-b961-c794afdeeff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_784bf2bf-8af5-4c9b-a815-95b4ba7498af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_784bf2bf-8af5-4c9b-a815-95b4ba7498af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock_2ea70a44-0ddb-4bbf-8dc3-d9a7b82e4934" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock_2ea70a44-0ddb-4bbf-8dc3-d9a7b82e4934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5271cb12-9c3b-4e67-a468-a4166652c121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5271cb12-9c3b-4e67-a468-a4166652c121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_50b23d00-dac9-4a3c-a332-ee691daf02f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_50b23d00-dac9-4a3c-a332-ee691daf02f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0745b4a0-8279-49b2-88d0-2199f501a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0745b4a0-8279-49b2-88d0-2199f501a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ae46a927-59a8-4216-9c9a-d5d34c81dcec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ae46a927-59a8-4216-9c9a-d5d34c81dcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3d7cb1f7-fd6e-444b-bd82-5aa5ff427247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3d7cb1f7-fd6e-444b-bd82-5aa5ff427247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2719aab4-dbb3-4217-a71a-8e995ea9e687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2719aab4-dbb3-4217-a71a-8e995ea9e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_32abdc92-d905-447b-8b2d-06ec6278cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_32abdc92-d905-447b-8b2d-06ec6278cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c4c6645-e70b-4577-ada1-083071aaf9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5a497b7-c9bf-4c6a-8bb3-a85d3be0e85b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c4c6645-e70b-4577-ada1-083071aaf9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ec2b6def-5658-4c08-8d50-4521bf7014c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_48a664fd-3d71-45c8-9093-46fa277bb6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec2b6def-5658-4c08-8d50-4521bf7014c6" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_48a664fd-3d71-45c8-9093-46fa277bb6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4dfbc1c5-556d-409d-8996-9db95a311e62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec2b6def-5658-4c08-8d50-4521bf7014c6" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4dfbc1c5-556d-409d-8996-9db95a311e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_90a2e26a-bece-4ef9-85c4-f03ef78fcc81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec2b6def-5658-4c08-8d50-4521bf7014c6" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_90a2e26a-bece-4ef9-85c4-f03ef78fcc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fac65b66-5675-4fa2-b828-a3a6c45c8e17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec2b6def-5658-4c08-8d50-4521bf7014c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fac65b66-5675-4fa2-b828-a3a6c45c8e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_226f52ca-3d10-4d4c-a70e-8c89a7c8d825" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec2b6def-5658-4c08-8d50-4521bf7014c6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_226f52ca-3d10-4d4c-a70e-8c89a7c8d825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e7a4b18b-2810-4186-ad1e-94939745db9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_783ce09b-c339-4802-a830-ed94150ac6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e7a4b18b-2810-4186-ad1e-94939745db9a" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_783ce09b-c339-4802-a830-ed94150ac6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0f95a1dc-e1c5-4572-b7ed-fc622eee0e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e7a4b18b-2810-4186-ad1e-94939745db9a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0f95a1dc-e1c5-4572-b7ed-fc622eee0e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_72a7cc47-8852-4aaf-bbc4-8e22a086176f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e7a4b18b-2810-4186-ad1e-94939745db9a" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_72a7cc47-8852-4aaf-bbc4-8e22a086176f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherRevenueTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherRevenueTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e7405ea-4792-4d31-9696-b7686b45c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2c8cce83-1025-476c-9e24-a79e16e2340d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e7405ea-4792-4d31-9696-b7686b45c69d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2c8cce83-1025-476c-9e24-a79e16e2340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3ab52b37-bd13-4cdb-8586-60adc75756c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_eb6be3c7-25e3-4568-aaa4-96151a4fe1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3ab52b37-bd13-4cdb-8586-60adc75756c2" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_eb6be3c7-25e3-4568-aaa4-96151a4fe1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_64234250-cd3e-46d9-a8ae-f7810b6065d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3ab52b37-bd13-4cdb-8586-60adc75756c2" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_64234250-cd3e-46d9-a8ae-f7810b6065d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_baba523a-bda4-4528-b8ca-6076b7c52b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3ab52b37-bd13-4cdb-8586-60adc75756c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_baba523a-bda4-4528-b8ca-6076b7c52b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_15894c3e-4ae0-432e-81bb-eb79b4d3f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3ab52b37-bd13-4cdb-8586-60adc75756c2" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_15894c3e-4ae0-432e-81bb-eb79b4d3f89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_866984ac-62de-4763-9cb2-66a533820789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8debaa4c-7105-47bd-b99f-92c5fea39672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_866984ac-62de-4763-9cb2-66a533820789" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8debaa4c-7105-47bd-b99f-92c5fea39672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_07e1a2c4-e217-498d-8a40-a82b828748a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d3a6c577-b430-4454-931a-91c34d42b066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_07e1a2c4-e217-498d-8a40-a82b828748a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d3a6c577-b430-4454-931a-91c34d42b066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_56fd7562-96de-479f-b166-567a5c2234bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_56fd7562-96de-479f-b166-567a5c2234bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0ee357aa-b10a-4bd2-9737-a0286d49f3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0ee357aa-b10a-4bd2-9737-a0286d49f3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_653770eb-d015-4cd4-8332-ae25b1b5750d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_653770eb-d015-4cd4-8332-ae25b1b5750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_236247e6-fd8d-4888-925e-60712394ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_236247e6-fd8d-4888-925e-60712394ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_c89b86a5-3109-4c8d-8486-f02dc37a956a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_c89b86a5-3109-4c8d-8486-f02dc37a956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_4beb0224-f7df-4df9-a98d-b3d9fb704000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_4beb0224-f7df-4df9-a98d-b3d9fb704000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_85f3a415-585a-4306-bbb0-eece870cc0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e5da160-7950-4799-aeda-e9f2fe7edbba" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_85f3a415-585a-4306-bbb0-eece870cc0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ccf1c7a1-477a-463c-a5c0-293338a8f5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_7e5ad025-d651-4bcc-b2c0-16f849352e05" xlink:href="mrna-20251231.xsd#mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccf1c7a1-477a-463c-a5c0-293338a8f5ad" xlink:to="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_7e5ad025-d651-4bcc-b2c0-16f849352e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1d755c21-ab4b-4b49-ae67-51dd369c4cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccf1c7a1-477a-463c-a5c0-293338a8f5ad" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1d755c21-ab4b-4b49-ae67-51dd369c4cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_8426d6fa-eaa5-4555-aa5c-7c0c59e134f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccf1c7a1-477a-463c-a5c0-293338a8f5ad" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_8426d6fa-eaa5-4555-aa5c-7c0c59e134f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d8ddaed9-348f-4a2b-8953-e2ecc7c7c642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccf1c7a1-477a-463c-a5c0-293338a8f5ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d8ddaed9-348f-4a2b-8953-e2ecc7c7c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92a06317-54e6-4a90-9c48-e778ed77d993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_f44c6621-5157-4613-a868-ba8fdaac6638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92a06317-54e6-4a90-9c48-e778ed77d993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_f44c6621-5157-4613-a868-ba8fdaac6638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8f41f1ed-e85c-433a-8dcf-3e9155d164d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92a06317-54e6-4a90-9c48-e778ed77d993" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8f41f1ed-e85c-433a-8dcf-3e9155d164d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6d558048-3ba2-433d-a0d3-65cd2ba3ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92a06317-54e6-4a90-9c48-e778ed77d993" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6d558048-3ba2-433d-a0d3-65cd2ba3ef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5af4ff5c-aa79-4acf-ba43-c710452ee516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92a06317-54e6-4a90-9c48-e778ed77d993" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5af4ff5c-aa79-4acf-ba43-c710452ee516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_e27fe52c-e17c-4a83-8d61-0499796dd025" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92a06317-54e6-4a90-9c48-e778ed77d993" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_e27fe52c-e17c-4a83-8d61-0499796dd025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9310f1bb-ec1c-4839-8014-4719b0a62fac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9310f1bb-ec1c-4839-8014-4719b0a62fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9e1a255a-1ae3-41d7-aa72-c9eacf9cd30a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9e1a255a-1ae3-41d7-aa72-c9eacf9cd30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d38de7b7-7808-4bd4-bbb4-dcaf186ed646" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d38de7b7-7808-4bd4-bbb4-dcaf186ed646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_288ffd96-5577-4198-bb49-437861b3ff01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_288ffd96-5577-4198-bb49-437861b3ff01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_bd6fd4e2-5f5d-4cb6-a1e7-d370f9c3e9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_bd6fd4e2-5f5d-4cb6-a1e7-d370f9c3e9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d40b87c1-a7ad-4347-a837-e7d6859bec14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f40418c9-201a-48a6-bcc0-ebc10cb88313" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d40b87c1-a7ad-4347-a837-e7d6859bec14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LossperShareTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#LossperShareTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_de0f3c51-7eb4-44ab-b9ee-9e32a73616f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5ce0d5ce-b16f-45da-b36d-142b646456e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de0f3c51-7eb4-44ab-b9ee-9e32a73616f0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5ce0d5ce-b16f-45da-b36d-142b646456e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5692b537-0021-4730-9320-4a710fef08f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de0f3c51-7eb4-44ab-b9ee-9e32a73616f0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5692b537-0021-4730-9320-4a710fef08f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformationTables" xlink:type="simple" xlink:href="mrna-20251231.xsd#GeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3c12d457-c08d-430d-a284-4c3bef967f52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_da8a336b-152a-48b7-8e90-468dae1387b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3c12d457-c08d-430d-a284-4c3bef967f52" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_da8a336b-152a-48b7-8e90-468dae1387b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#DescriptionoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f138acfa-ab37-47c1-94f9-776bbcf69369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfCommercialProducts_019c4348-25c2-7ff6-bde3-d14727e25bbe" xlink:href="mrna-20251231.xsd#mrna_NumberOfCommercialProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f138acfa-ab37-47c1-94f9-776bbcf69369" xlink:to="loc_mrna_NumberOfCommercialProducts_019c4348-25c2-7ff6-bde3-d14727e25bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentCandidates_dcfa39ec-c1ed-4269-82c3-1d15557c3917" xlink:href="mrna-20251231.xsd#mrna_NumberOfDevelopmentCandidates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f138acfa-ab37-47c1-94f9-776bbcf69369" xlink:to="loc_mrna_NumberOfDevelopmentCandidates_dcfa39ec-c1ed-4269-82c3-1d15557c3917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentPrograms_f77e8211-7b1d-4a04-9880-cbf04a90099d" xlink:href="mrna-20251231.xsd#mrna_NumberOfDevelopmentPrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f138acfa-ab37-47c1-94f9-776bbcf69369" xlink:to="loc_mrna_NumberOfDevelopmentPrograms_f77e8211-7b1d-4a04-9880-cbf04a90099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_91361bdb-c765-4793-94e6-48aa8bb63078" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_91361bdb-c765-4793-94e6-48aa8bb63078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f6bc96ea-10a8-41e4-a26c-da9b13572379" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_NumberOfReportableSegments_f6bc96ea-10a8-41e4-a26c-da9b13572379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_00577884-8d7e-4287-996c-b1b6539b30cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_00577884-8d7e-4287-996c-b1b6539b30cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5a6ee0ed-56cf-4ebd-9e92-106b8360b795" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5a6ee0ed-56cf-4ebd-9e92-106b8360b795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1c9d1286-fe71-429d-b063-ee4646f49cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1c9d1286-fe71-429d-b063-ee4646f49cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0fb1d223-a3f3-469d-b2ca-c98d68d114af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_AssetImpairmentCharges_0fb1d223-a3f3-469d-b2ca-c98d68d114af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_f6098158-d79d-4957-a80c-7acf3859a62c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0feccea0-be55-4f4f-85d2-81fda74be1b0" xlink:to="loc_us-gaap_AdvertisingExpense_f6098158-d79d-4957-a80c-7acf3859a62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_26152cd1-0a3e-42d6-9832-df41c710ac68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d4f39b8-1f43-497e-88d6-396ff690e30c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26152cd1-0a3e-42d6-9832-df41c710ac68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d4f39b8-1f43-497e-88d6-396ff690e30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_9076500b-6ff3-4402-88eb-40e9cd24a896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26152cd1-0a3e-42d6-9832-df41c710ac68" xlink:to="loc_us-gaap_RestrictedCashCurrent_9076500b-6ff3-4402-88eb-40e9cd24a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3730761c-af21-4531-967a-13df4215f466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26152cd1-0a3e-42d6-9832-df41c710ac68" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3730761c-af21-4531-967a-13df4215f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1800d03c-8b8d-404b-914a-adeafb443000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26152cd1-0a3e-42d6-9832-df41c710ac68" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1800d03c-8b8d-404b-914a-adeafb443000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fae97417-7993-4e33-b6fb-a7ddddea9929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fae97417-7993-4e33-b6fb-a7ddddea9929" xlink:to="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1579771-d575-41fd-9df4-07a9577a8bb3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_92e9e2fe-e03c-4885-9f63-f46db99da02e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_92e9e2fe-e03c-4885-9f63-f46db99da02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a05b46c1-cc26-4fd1-b692-b69ef7cf51e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_81d8de20-a0d8-4604-a9e3-83268aa0cd70" xlink:to="loc_us-gaap_AccountsReceivableMember_a05b46c1-cc26-4fd1-b692-b69ef7cf51e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d305439d-1d36-4f4b-8e8d-f8884788b775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2b18898b-7345-44b5-87c7-1db6cd1b11df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d305439d-1d36-4f4b-8e8d-f8884788b775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1bdd8f24-ac0e-4a17-a08b-41f95134b424" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d305439d-1d36-4f4b-8e8d-f8884788b775" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1bdd8f24-ac0e-4a17-a08b-41f95134b424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c32737e2-4c2c-4fd4-ac49-a97d216b6c9a" xlink:to="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FFFEnterprisesMember_7ff5dd24-59de-4dc5-9245-307706460aec" xlink:href="mrna-20251231.xsd#mrna_FFFEnterprisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_FFFEnterprisesMember_7ff5dd24-59de-4dc5-9245-307706460aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PublicWorksAndGovernmentServicesCanadaMember_019c05b6-6bc0-7189-b2be-25f0fb5a6eb6" xlink:href="mrna-20251231.xsd#mrna_PublicWorksAndGovernmentServicesCanadaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_PublicWorksAndGovernmentServicesCanadaMember_019c05b6-6bc0-7189-b2be-25f0fb5a6eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CardinalHealthMember_019c05b6-6bc0-72d8-9b8b-e7b10efdd675" xlink:href="mrna-20251231.xsd#mrna_CardinalHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_CardinalHealthMember_019c05b6-6bc0-72d8-9b8b-e7b10efdd675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UKHealthSecurityAgencyMember_d0e5499d-40c2-4a8a-b39a-2967e7f44767" xlink:href="mrna-20251231.xsd#mrna_UKHealthSecurityAgencyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_UKHealthSecurityAgencyMember_d0e5499d-40c2-4a8a-b39a-2967e7f44767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MexicoMedistikMember_019c05b6-6bc0-7b6a-ae98-40da4fc339dd" xlink:href="mrna-20251231.xsd#mrna_MexicoMedistikMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_MexicoMedistikMember_019c05b6-6bc0-7b6a-ae98-40da4fc339dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BoryungBiopharmaKoreaMember_019c05b6-6bc0-7804-8d5d-728e65d1157d" xlink:href="mrna-20251231.xsd#mrna_BoryungBiopharmaKoreaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_BoryungBiopharmaKoreaMember_019c05b6-6bc0-7804-8d5d-728e65d1157d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TaiwanFoodAndDrugAdministrationMember_a4f9cc7b-a963-4c26-851a-a56dd9c6cb7b" xlink:href="mrna-20251231.xsd#mrna_TaiwanFoodAndDrugAdministrationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_TaiwanFoodAndDrugAdministrationMember_a4f9cc7b-a963-4c26-851a-a56dd9c6cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_566a5e2f-1bba-400e-acc2-ebaaa5b59a63" xlink:href="mrna-20251231.xsd#mrna_MinistryOfHealthLaborAndWelfareOfJapanMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9105bcd0-07a3-4b87-a080-89c5e8860194" xlink:to="loc_mrna_MinistryOfHealthLaborAndWelfareOfJapanMember_566a5e2f-1bba-400e-acc2-ebaaa5b59a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_cad6b8b7-667c-40f1-a70c-6cc32b0c63af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c5d83da0-ccef-43c7-b752-32934b348200" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_cad6b8b7-667c-40f1-a70c-6cc32b0c63af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2867d909-3f80-4bca-a618-010ba2b959db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_cad6b8b7-667c-40f1-a70c-6cc32b0c63af" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2867d909-3f80-4bca-a618-010ba2b959db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4461ef60-665b-41da-8427-5514249db63c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4461ef60-665b-41da-8427-5514249db63c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de410452-87cf-4639-8709-d1fb014ddbd7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_5d812fe7-cee3-4136-95f5-c171df63bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_5d812fe7-cee3-4136-95f5-c171df63bd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8a47f516-a710-4e74-85ee-881a801ef710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_EquipmentMember_8a47f516-a710-4e74-85ee-881a801ef710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_c061fc6c-0d2b-4adb-810f-c085489cad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_ComputerEquipmentMember_c061fc6c-0d2b-4adb-810f-c085489cad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_78776f58-414a-4b93-adf9-fbd289e4a3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1abedfa9-89f6-4a95-809e-5b3bf285786e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_78776f58-414a-4b93-adf9-fbd289e4a3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:to="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3bf587fd-7d92-4b68-aa6a-33151d975492" xlink:to="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3c86be70-b72a-48b9-8da4-67815d5a543f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:to="loc_srt_MinimumMember_3c86be70-b72a-48b9-8da4-67815d5a543f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9063cd6-e410-4302-9912-43259d92af11" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76b3b650-5e99-4a8c-ae96-af4ceb1b0da5" xlink:to="loc_srt_MaximumMember_d9063cd6-e410-4302-9912-43259d92af11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdc60015-644e-43ec-9ce3-6bc106c262c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5ddb8e68-f4ea-4411-a5e2-57b5dd95039f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdc60015-644e-43ec-9ce3-6bc106c262c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5b5aaa50-b4ec-464b-854d-38a4de84d545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fdc60015-644e-43ec-9ce3-6bc106c262c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5b5aaa50-b4ec-464b-854d-38a4de84d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ab0a2d8c-24a9-4629-a33c-21e1ed0fe7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab0a2d8c-24a9-4629-a33c-21e1ed0fe7cc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bf299e8a-dab6-4c21-81fe-cbcc04539b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a45b5e69-538b-45b9-a76a-fdcbe6473b32" xlink:to="loc_us-gaap_EquityComponentDomain_bf299e8a-dab6-4c21-81fe-cbcc04539b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bf299e8a-dab6-4c21-81fe-cbcc04539b3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8dcbe935-f785-406d-9aa6-c55fffcbf23c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8dcbe935-f785-406d-9aa6-c55fffcbf23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6aa3edd9-302a-4273-be87-5ee5615cb135" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6aa3edd9-302a-4273-be87-5ee5615cb135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3e2f19a3-78fc-47bc-b08c-dd194f8dac83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_918314c4-bc6a-4ef3-8d4c-0a2b07b6f5b7" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3e2f19a3-78fc-47bc-b08c-dd194f8dac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2ced014-8612-41e5-9ed7-caa1b15232d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74df4712-2b70-428c-bbed-3c630cde0679" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2ced014-8612-41e5-9ed7-caa1b15232d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2ced014-8612-41e5-9ed7-caa1b15232d5" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704a818e-62ec-4eeb-a503-ff78f8419c86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:to="loc_us-gaap_StockholdersEquity_704a818e-62ec-4eeb-a503-ff78f8419c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f90428b0-7fa3-4688-beec-ec4904fcf4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f90428b0-7fa3-4688-beec-ec4904fcf4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f7c9123e-8c24-4b4f-b93d-d491acd31796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36cd2689-b534-419b-a96e-fa9a92b6ca63" xlink:to="loc_us-gaap_StockholdersEquity_f7c9123e-8c24-4b4f-b93d-d491acd31796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fce3e5d-9d49-4f0f-a6d0-2b1fe120ec63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fce3e5d-9d49-4f0f-a6d0-2b1fe120ec63" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:to="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_554a697c-f574-4a6f-9772-6db99e17e699" xlink:to="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_be7edb6d-3535-4cfd-9366-5638146be518" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:to="loc_country_US_be7edb6d-3535-4cfd-9366-5638146be518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6869b4d8-0f21-4070-b835-53b4d209913b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:to="loc_srt_EuropeMember_6869b4d8-0f21-4070-b835-53b4d209913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfTheWorldMember_8358e3d7-e600-4a5a-bd06-3f25d93ca9ac" xlink:href="mrna-20251231.xsd#mrna_RestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_caf14b8e-72c8-4be3-add3-034e9462a85e" xlink:to="loc_mrna_RestOfTheWorldMember_8358e3d7-e600-4a5a-bd06-3f25d93ca9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:to="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c7d3a34-ba18-4373-9caf-d939fd25ebc8" xlink:to="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_32cec844-b8ec-430d-9e78-ab5daa5921cc" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:to="loc_mrna_ProductSalesMember_32cec844-b8ec-430d-9e78-ab5daa5921cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_COVID19Member_89d74309-9293-401b-9c6c-3f9b1bd05b15" xlink:href="mrna-20251231.xsd#mrna_COVID19Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:to="loc_mrna_COVID19Member_89d74309-9293-401b-9c6c-3f9b1bd05b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RSVMember_4c012f3d-9faa-46da-b715-cc1c692a4662" xlink:href="mrna-20251231.xsd#mrna_RSVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f0b9d2c-bbb6-4f73-9f9e-f4611ff25411" xlink:to="loc_mrna_RSVMember_4c012f3d-9faa-46da-b715-cc1c692a4662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c4679ad1-e370-400a-a523-6ac9dbc1b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58eb1b68-3642-4f21-8b76-5e036306073c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c4679ad1-e370-400a-a523-6ac9dbc1b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6467d355-91c0-4955-b40f-89dda65d742c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c4679ad1-e370-400a-a523-6ac9dbc1b8df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6467d355-91c0-4955-b40f-89dda65d742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetProductSalesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aeb3ab5e-0dd9-4842-8315-517238a7c973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aeb3ab5e-0dd9-4842-8315-517238a7c973" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:to="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_304514f0-bce8-4cbf-b73e-b7ee9ef0b94b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f6d0dd51-f679-4278-ad11-3613697599ee" xlink:to="loc_srt_ProductsAndServicesDomain_304514f0-bce8-4cbf-b73e-b7ee9ef0b94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_f95eb81e-fb75-4893-9815-6255d12980f1" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_304514f0-bce8-4cbf-b73e-b7ee9ef0b94b" xlink:to="loc_mrna_ProductSalesMember_f95eb81e-fb75-4893-9815-6255d12980f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8e12715f-9cf2-4c99-a09c-cf17ab422617" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_587d820c-f049-409d-85cc-8e8903cf465f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8e12715f-9cf2-4c99-a09c-cf17ab422617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfCommercialProducts_1cad84dc-63f5-482d-953d-0581776965cb" xlink:href="mrna-20251231.xsd#mrna_NumberOfCommercialProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8e12715f-9cf2-4c99-a09c-cf17ab422617" xlink:to="loc_mrna_NumberOfCommercialProducts_1cad84dc-63f5-482d-953d-0581776965cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetProductSalesProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9da2c809-8d9c-41f4-84b6-cf39951c1420" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9da2c809-8d9c-41f4-84b6-cf39951c1420" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:to="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5cc556b-8352-40ad-8010-0ebaab672056" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7f6cff1-1505-4c96-a907-5f991c26b1eb" xlink:to="loc_srt_ProductsAndServicesDomain_c5cc556b-8352-40ad-8010-0ebaab672056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_cdeb8a51-e0cc-4011-84ed-eee1a0dadcca" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5cc556b-8352-40ad-8010-0ebaab672056" xlink:to="loc_mrna_ProductSalesMember_cdeb8a51-e0cc-4011-84ed-eee1a0dadcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4a9ef6b5-ed24-4d7f-90b3-eb4fac40c9c2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_60b62f43-3e32-4028-8e9f-1aa645381ee9" xlink:href="mrna-20251231.xsd#mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross_60b62f43-3e32-4028-8e9f-1aa645381ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_f0ed070f-c48a-4f59-92e0-74c937e629e7" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees_f0ed070f-c48a-4f59-92e0-74c937e629e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_0d5bf38a-c76a-4def-9414-4e3194804463" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees_0d5bf38a-c76a-4def-9414-4e3194804463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvision_ee30b449-6e16-498c-af67-d9f273246ad0" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvision"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvision_ee30b449-6e16-498c-af67-d9f273246ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9879224-32a2-45a0-b777-16e4ef26da16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9879224-32a2-45a0-b777-16e4ef26da16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_019bb39e-c1e0-7330-b76c-f19760a8d8a1" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_899ad4dc-21af-4f94-a6be-a6ecc9efe46b" xlink:to="loc_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment_019bb39e-c1e0-7330-b76c-f19760a8d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2836d297-8ecb-420c-9f5e-fa4a16009e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2836d297-8ecb-420c-9f5e-fa4a16009e76" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:to="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7b63b8d-4cd1-4cfc-9000-d05c4a380dfb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b85a04c3-66c7-403b-8019-71e8c3bf2d07" xlink:to="loc_srt_ProductsAndServicesDomain_e7b63b8d-4cd1-4cfc-9000-d05c4a380dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_b1d529a8-b81f-4673-b6f2-6f38a159d6ff" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e7b63b8d-4cd1-4cfc-9000-d05c4a380dfb" xlink:to="loc_mrna_ProductSalesMember_b1d529a8-b81f-4673-b6f2-6f38a159d6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fb8b9200-476b-4d85-9f8d-dec5726d9538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_165ccba3-5152-48bb-a5fb-b9f9204903f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fb8b9200-476b-4d85-9f8d-dec5726d9538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityRefundRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fb8b9200-476b-4d85-9f8d-dec5726d9538" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_81a0354c-5b1c-4660-9e0c-a96a0d080b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_81a0354c-5b1c-4660-9e0c-a96a0d080b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_e20840be-0e7a-4bed-a8d0-005d2d337853" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear_e20840be-0e7a-4bed-a8d0-005d2d337853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_3426040f-b23d-4737-b91c-a2569b923a83" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears_3426040f-b23d-4737-b91c-a2569b923a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_38de99b9-1101-4030-be8f-b40617c546d3" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityProvisionRelatedToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales_38de99b9-1101-4030-be8f-b40617c546d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_7a35dd80-77b2-450c-a4ef-1df6078db3c4" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales_7a35dd80-77b2-450c-a4ef-1df6078db3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_b7ce871f-9164-46bd-9eb7-2e97d2aaf850" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward_870ca3dd-d720-4b94-aba1-62eee906f115" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_b7ce871f-9164-46bd-9eb7-2e97d2aaf850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherRevenueScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0219b572-4d2c-475b-beea-c30cb71de49f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0219b572-4d2c-475b-beea-c30cb71de49f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_39252819-b223-48c5-a509-651bb91a75ca" xlink:to="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_acb37a76-5d54-46a4-8299-bf1bae44f706" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_us-gaap_GrantMember_acb37a76-5d54-46a4-8299-bf1bae44f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_acb5f0b1-ec51-4729-917b-3a8f31fcd077" xlink:href="mrna-20251231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_acb5f0b1-ec51-4729-917b-3a8f31fcd077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LicenseAndRoyaltyMember_b17a549b-6e2c-4631-b7de-b77c160baa34" xlink:href="mrna-20251231.xsd#mrna_LicenseAndRoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_mrna_LicenseAndRoyaltyMember_b17a549b-6e2c-4631-b7de-b77c160baa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StandReadyManufacturingRevenueMember_019b92bf-3d1b-76a5-acf4-f047e699b25a" xlink:href="mrna-20251231.xsd#mrna_StandReadyManufacturingRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_mrna_StandReadyManufacturingRevenueMember_019b92bf-3d1b-76a5-acf4-f047e699b25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_7c970dfa-1577-4ab2-b014-f503695d3c96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_092c75cf-e26b-4273-a59a-21b5468ac8b2" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_7c970dfa-1577-4ab2-b014-f503695d3c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3aa5e6ff-fd2c-44f8-a10b-7d6b91aa1e24" xlink:to="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6cd42b26-85e1-4784-a29a-c5f18ea53c30" xlink:href="mrna-20251231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6cd42b26-85e1-4784-a29a-c5f18ea53c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_ff0b6d3f-f737-4343-97e2-11d4d1858c1e" xlink:href="mrna-20251231.xsd#mrna_OtherGrantRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8f9dbc97-f403-4f63-9f3f-8ff4f29c1270" xlink:to="loc_mrna_OtherGrantRevenueMember_ff0b6d3f-f737-4343-97e2-11d4d1858c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a053065a-96e7-4cbf-909c-5ef5e0e1619f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_398d657f-1226-4a67-b39f-9dffc6af920a" xlink:href="mrna-20251231.xsd#mrna_VertexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:to="loc_mrna_VertexMember_398d657f-1226-4a67-b39f-9dffc6af920a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember_1816393a-f000-4cb9-a0b1-986c4b9d6a8a" xlink:href="mrna-20251231.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc79c69e-224e-42d0-8427-a8b2eb0cf51b" xlink:to="loc_mrna_OtherCollaborativePartiesMember_1816393a-f000-4cb9-a0b1-986c4b9d6a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5e542c62-0645-48e1-8969-a4479cfa9ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_eeba2a69-714c-4bbb-b116-ec0dbe511ed9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5e542c62-0645-48e1-8969-a4479cfa9ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60ba31cf-c2ed-4984-8984-255ea0edca58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5e542c62-0645-48e1-8969-a4479cfa9ed8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60ba31cf-c2ed-4984-8984-255ea0edca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherRevenueNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherRevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherRevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7ec4b3ae-7d5c-49bb-9bec-62b5d06ea576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7ec4b3ae-7d5c-49bb-9bec-62b5d06ea576" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_80df2b4b-872d-4d7e-b986-fd8afdf07105" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_206d6ff7-d746-4d62-818f-6f0af56fc8e3" xlink:to="loc_srt_NameOfMajorCustomerDomain_80df2b4b-872d-4d7e-b986-fd8afdf07105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_86e3e985-282e-4894-951c-42021c2d779b" xlink:href="mrna-20251231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80df2b4b-872d-4d7e-b986-fd8afdf07105" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_86e3e985-282e-4894-951c-42021c2d779b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_31d3ff99-adaf-453a-8ebc-8a585acbda22" xlink:to="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LicenseAndRoyaltyMember_df36cc82-63c0-47b6-a0dd-80cfd6136f49" xlink:href="mrna-20251231.xsd#mrna_LicenseAndRoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:to="loc_mrna_LicenseAndRoyaltyMember_df36cc82-63c0-47b6-a0dd-80cfd6136f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b2bcaf83-4411-4784-9a12-bce857c887f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfe75ed7-dd07-420d-be4d-677de619a1cf" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b2bcaf83-4411-4784-9a12-bce857c887f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d84e3f4-ee1a-4fe5-9b89-06cff2253223" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ccee8df2-7e1a-4ece-8e2d-57f57cbc0038" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d84e3f4-ee1a-4fe5-9b89-06cff2253223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b585081b-3cae-4158-8361-57ea5ead1106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d84e3f4-ee1a-4fe5-9b89-06cff2253223" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b585081b-3cae-4158-8361-57ea5ead1106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d73dd7c8-b3ab-4008-87a5-bcd3d8c82c57" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_f9f6f1bf-6c0d-4649-bfca-7b5aa94703ee" xlink:href="mrna-20251231.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_f9f6f1bf-6c0d-4649-bfca-7b5aa94703ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipants_60b5f96a-d26f-42df-bcb5-f2f0a41eed7c" xlink:href="mrna-20251231.xsd#mrna_NumberOfParticipants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_mrna_NumberOfParticipants_60b5f96a-d26f-42df-bcb5-f2f0a41eed7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_45e0aef7-b1a1-4cf5-a173-37f91579c938" xlink:href="mrna-20251231.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_45e0aef7-b1a1-4cf5-a173-37f91579c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_979c04c4-6add-40e7-a3c3-b417035f9c26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_979c04c4-6add-40e7-a3c3-b417035f9c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5d2a2e56-796a-42e4-91e0-cde309ddf457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5d2a2e56-796a-42e4-91e0-cde309ddf457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37532998-57b0-40b5-92cc-06fdb217bb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37532998-57b0-40b5-92cc-06fdb217bb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4df2d868-5ca7-4854-b210-acff6af9bc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9b35561-baed-402d-9694-4c1eaf85917d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4df2d868-5ca7-4854-b210-acff6af9bc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_5d8a982c-0046-4f91-a8bf-7ec0d9cf14b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_5d8a982c-0046-4f91-a8bf-7ec0d9cf14b3" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9c679aa1-6f9a-4da5-938e-4372b6bc5b4d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_140e6b46-fc3c-4f56-88ef-e24552fa5b09" xlink:href="mrna-20251231.xsd#mrna_MerckMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:to="loc_mrna_MerckMember_140e6b46-fc3c-4f56-88ef-e24552fa5b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BlackstoneLifeSciencesBlackstoneMember_5dc48857-eb56-449e-9e0a-cfc1067352ff" xlink:href="mrna-20251231.xsd#mrna_BlackstoneLifeSciencesBlackstoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:to="loc_mrna_BlackstoneLifeSciencesBlackstoneMember_5dc48857-eb56-449e-9e0a-cfc1067352ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ImmaticsMember_1c5b76b4-839f-4ec6-be3c-18158d6ee814" xlink:href="mrna-20251231.xsd#mrna_ImmaticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4bdf5c9-4f89-4b2f-adb0-972abb7e4d31" xlink:to="loc_mrna_ImmaticsMember_1c5b76b4-839f-4ec6-be3c-18158d6ee814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_553c68c2-4203-4603-adbf-f18cebdf708b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_04600176-a827-4180-a4e0-a588b42f2ed9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_553c68c2-4203-4603-adbf-f18cebdf708b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5e075786-e61d-45b2-ba60-31e2797d497e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_553c68c2-4203-4603-adbf-f18cebdf708b" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5e075786-e61d-45b2-ba60-31e2797d497e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6be2f339-5189-4a9c-a90f-74b7d43b91a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4048e4fc-3c43-46c2-8b57-710e4785d96f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6be2f339-5189-4a9c-a90f-74b7d43b91a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_141f5d3f-fd0e-463f-b229-7c08110d1c69" xlink:href="mrna-20251231.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6be2f339-5189-4a9c-a90f-74b7d43b91a2" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_141f5d3f-fd0e-463f-b229-7c08110d1c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_39846f37-fd7f-4fda-b4b2-0a9b9959b686" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProceedsFromOptionExerciseFee_55c3cf98-052e-4d7c-8682-d3607720fc61" xlink:href="mrna-20251231.xsd#mrna_ProceedsFromOptionExerciseFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_ProceedsFromOptionExerciseFee_55c3cf98-052e-4d7c-8682-d3607720fc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d11209af-48ef-42e6-95b9-f9796df1ff5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d11209af-48ef-42e6-95b9-f9796df1ff5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RecoveryOfCostsCapitalExpenditures_1ff3cebc-9048-47e8-b364-17338f2c128b" xlink:href="mrna-20251231.xsd#mrna_RecoveryOfCostsCapitalExpenditures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_RecoveryOfCostsCapitalExpenditures_1ff3cebc-9048-47e8-b364-17338f2c128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborativeArrangementFundingAmount_6dcaeb91-73ea-4efb-a6a2-2557219e14d9" xlink:href="mrna-20251231.xsd#mrna_CollaborativeArrangementFundingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_CollaborativeArrangementFundingAmount_6dcaeb91-73ea-4efb-a6a2-2557219e14d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_53e65070-e91a-4c36-a9ef-d0d3a72dff2c" xlink:href="mrna-20251231.xsd#mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_53e65070-e91a-4c36-a9ef-d0d3a72dff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_62008a2b-951d-4b25-a03c-7b26b50c8a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_62008a2b-951d-4b25-a03c-7b26b50c8a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_8e05a4cf-4c22-48b0-849c-18faed49db20" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b84785d-d350-4a11-a0ca-a93c50a01d88" xlink:to="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_8e05a4cf-4c22-48b0-849c-18faed49db20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fe6397b1-bf74-46c6-8383-a772c0e77182" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fe6397b1-bf74-46c6-8383-a772c0e77182" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_16240f6b-1214-4800-abe1-1ddd14686ba1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_d033c061-f9f1-4d1c-a6bb-47aeac294c50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_d033c061-f9f1-4d1c-a6bb-47aeac294c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_904523d0-154e-4c68-82ce-9ff7d4d76dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_CertificatesOfDepositMember_904523d0-154e-4c68-82ce-9ff7d4d76dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_d39df0a5-a859-47b7-8680-0a32094c8c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_d39df0a5-a859-47b7-8680-0a32094c8c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_12a68391-8809-4853-9458-5798c368bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_12a68391-8809-4853-9458-5798c368bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_922b78ba-28b6-459c-952e-9a9ec2a76c89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_922b78ba-28b6-459c-952e-9a9ec2a76c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_850ec9a6-0da8-4d34-91db-a0042ddc723d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ebea105-981e-4e79-9cc2-38ee154d4e11" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_850ec9a6-0da8-4d34-91db-a0042ddc723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d614dc8f-28f5-42f7-a85e-ca9fc71b39c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_b4c65164-2f85-4581-bb22-5f83dab4e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_b4c65164-2f85-4581-bb22-5f83dab4e1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_ccc78364-91fa-4866-9ab1-99d22518103f" xlink:href="mrna-20251231.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_ccc78364-91fa-4866-9ab1-99d22518103f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_df988342-97f1-4deb-adc3-1c1a8ccf79c8" xlink:href="mrna-20251231.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_464209a9-2bf1-4df9-a23a-587348d45cd8" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_df988342-97f1-4deb-adc3-1c1a8ccf79c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b72739-deae-4767-bd20-c2a196dd6ceb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eb794466-ff45-442d-97ca-4207884be74f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eb794466-ff45-442d-97ca-4207884be74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0db0836e-5288-414b-9652-d1c18c35bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1f2cd9-b34c-4fdc-8675-4a221e2a84b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0db0836e-5288-414b-9652-d1c18c35bd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bbbabc9-5750-4a00-ae39-d7a3e6d18934" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c828967-24d5-4005-b4ca-6e934773f4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c828967-24d5-4005-b4ca-6e934773f4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f030971-5dab-458d-b14f-c0dbfe65c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f030971-5dab-458d-b14f-c0dbfe65c7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3182772b-8915-4f2f-b8fb-1c2f52ef328d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3182772b-8915-4f2f-b8fb-1c2f52ef328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aba86f61-d743-4fe3-9163-477f221be16d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14c4d311-4148-4025-b09b-1b7209145cdd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aba86f61-d743-4fe3-9163-477f221be16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_791eddb5-4e8c-428e-8496-7029f2004628" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1a6402cf-914c-4467-b867-7e76e9689afe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_791eddb5-4e8c-428e-8496-7029f2004628" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1a6402cf-914c-4467-b867-7e76e9689afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_70e933fd-e0c0-4c7b-9de5-27e4b5324f54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1a6402cf-914c-4467-b867-7e76e9689afe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_70e933fd-e0c0-4c7b-9de5-27e4b5324f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_586b9785-139f-4b1b-96a0-66409d77cf36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1a6402cf-914c-4467-b867-7e76e9689afe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_586b9785-139f-4b1b-96a0-66409d77cf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d91d0987-ba89-4942-a9c9-b6f56045c1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1a6402cf-914c-4467-b867-7e76e9689afe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d91d0987-ba89-4942-a9c9-b6f56045c1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7ee0368e-f85a-4a46-b86d-f0ca2988466a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_791eddb5-4e8c-428e-8496-7029f2004628" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7ee0368e-f85a-4a46-b86d-f0ca2988466a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_206327e8-55f9-4f48-93b3-44c1aa734c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7ee0368e-f85a-4a46-b86d-f0ca2988466a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_206327e8-55f9-4f48-93b3-44c1aa734c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aaf85e3b-7ab7-40ff-a8ad-8792fdafd46e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7ee0368e-f85a-4a46-b86d-f0ca2988466a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aaf85e3b-7ab7-40ff-a8ad-8792fdafd46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_744b8913-ac67-49a7-9270-5e29f95e4e17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7ee0368e-f85a-4a46-b86d-f0ca2988466a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_744b8913-ac67-49a7-9270-5e29f95e4e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b72824a2-0bf4-4b7b-96e5-b44b4b11b74f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_16ea4193-98d3-4a26-ab1e-5e77016fee64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b72824a2-0bf4-4b7b-96e5-b44b4b11b74f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_16ea4193-98d3-4a26-ab1e-5e77016fee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f20e0e95-3b9f-4f32-bb91-1c28bd8fd4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b72824a2-0bf4-4b7b-96e5-b44b4b11b74f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f20e0e95-3b9f-4f32-bb91-1c28bd8fd4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_3d857449-be7d-45e9-8bb0-ac644a758dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b72824a2-0bf4-4b7b-96e5-b44b4b11b74f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_3d857449-be7d-45e9-8bb0-ac644a758dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_394dc80e-4e72-4f2b-93c4-0ea1ed7112c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b72824a2-0bf4-4b7b-96e5-b44b4b11b74f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_394dc80e-4e72-4f2b-93c4-0ea1ed7112c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_50569fde-29a0-4c5d-b817-5d17d470f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_50569fde-29a0-4c5d-b817-5d17d470f8c3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:to="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_68028106-101b-47d0-a113-1b219ecaa3f9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019c3014-e91b-76e4-8928-baca9a0cf606" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019c3014-e91b-76e4-8928-baca9a0cf606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_963d8596-c11e-43e5-8852-b6d08aafea04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_963d8596-c11e-43e5-8852-b6d08aafea04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2e941844-ea92-480a-89b3-00188dbad8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2e941844-ea92-480a-89b3-00188dbad8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_019c3014-e91b-7167-9022-2baba6591983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ddbb2dc-d5be-49ab-9f66-3e94b5b50eed" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_019c3014-e91b-7167-9022-2baba6591983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b7cdb9c-e6e9-4605-999e-c136a3446c47" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2dfe3cc5-f319-420e-9f45-c073ada16c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2dfe3cc5-f319-420e-9f45-c073ada16c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a1716c0b-b6bf-44c8-938a-f1e109f16c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a1716c0b-b6bf-44c8-938a-f1e109f16c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_49a2290c-10db-43fc-af22-854880f76d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_49a2290c-10db-43fc-af22-854880f76d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ab62d71b-2f1c-47ff-8388-d2336dc18512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ab62d71b-2f1c-47ff-8388-d2336dc18512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0a10f259-f911-4909-957e-461c91853e70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0a10f259-f911-4909-957e-461c91853e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0f3952aa-2146-4612-a9c5-4902d2c299eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe5cba6a-c789-425d-8043-0c1668d252aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0f3952aa-2146-4612-a9c5-4902d2c299eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_92dfcf3e-7c84-4cd0-b808-df39274ae483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_92dfcf3e-7c84-4cd0-b808-df39274ae483" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_561fc0ed-7d95-477c-845c-539e7232c320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_14bf8c06-36a6-493f-960d-9f5ab9ba33b6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_561fc0ed-7d95-477c-845c-539e7232c320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9b347dd7-520a-4b53-b7ec-399f14b153f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_561fc0ed-7d95-477c-845c-539e7232c320" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9b347dd7-520a-4b53-b7ec-399f14b153f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b02bd7a5-f9a3-41cc-91d7-65c7885f679c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f7f501e5-58d2-49b0-a8dc-5405c584a2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f7f501e5-58d2-49b0-a8dc-5405c584a2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_50582a3f-9fff-4e65-97c1-14556cfd276f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_CertificatesOfDepositMember_50582a3f-9fff-4e65-97c1-14556cfd276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_3573e670-64c7-43ef-a30c-5a48e82bf80d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_3573e670-64c7-43ef-a30c-5a48e82bf80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_88b836b0-e429-4e38-9648-e038129a95fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_88b836b0-e429-4e38-9648-e038129a95fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7c6bb036-b7d5-4a50-a9e8-e588fefe7929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7c6bb036-b7d5-4a50-a9e8-e588fefe7929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_136a56b5-b047-4d50-a162-45375918b748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_136a56b5-b047-4d50-a162-45375918b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_1d4339b8-23f7-44b3-8741-f8d8c0c67aad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cbb327-37a2-4e96-858d-f09a3d085fec" xlink:to="loc_us-gaap_EquitySecuritiesMember_1d4339b8-23f7-44b3-8741-f8d8c0c67aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6eeeda-72d7-41bf-84e7-ceab8e421304" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bbb20a19-60f9-4a89-8258-f37dc3465f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bbb20a19-60f9-4a89-8258-f37dc3465f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ff855304-e16b-4c9e-b4d2-bca4cce2dade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_552406e3-5567-42e2-b28c-351f4f615e03" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ff855304-e16b-4c9e-b4d2-bca4cce2dade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e0b1b511-321f-4f09-b91d-6c6dc160f13c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c863bd54-e273-4bf8-9a49-8ca0dbfb2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c863bd54-e273-4bf8-9a49-8ca0dbfb2be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6b4f8603-6778-4467-9eb7-a6ec573a9328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DerivativeAssets_6b4f8603-6778-4467-9eb7-a6ec573a9328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_99905a05-e02e-46d9-896a-1975f98e8f08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_99905a05-e02e-46d9-896a-1975f98e8f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_7a5b6f7c-123b-4d5b-9ac2-fc791e1bee44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_7a5b6f7c-123b-4d5b-9ac2-fc791e1bee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bcc72349-c7c3-47a5-a9eb-37acb0cd2492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9d02fb4-84db-44e4-9cf6-c88192e3db21" xlink:to="loc_us-gaap_DerivativeLiabilities_bcc72349-c7c3-47a5-a9eb-37acb0cd2492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_dd1a30e4-3627-4067-8b75-dc9842d5a92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e51b9ee9-0856-4234-aecd-8b466d952d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dd1a30e4-3627-4067-8b75-dc9842d5a92a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e51b9ee9-0856-4234-aecd-8b466d952d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_972804e6-5194-4b5c-8cf0-c27dd8c49dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dd1a30e4-3627-4067-8b75-dc9842d5a92a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_972804e6-5194-4b5c-8cf0-c27dd8c49dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_887d49d2-f5cb-4b0c-b488-34835908e1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dd1a30e4-3627-4067-8b75-dc9842d5a92a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_887d49d2-f5cb-4b0c-b488-34835908e1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b6deb589-0739-46c8-87c5-77cca007e095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dd1a30e4-3627-4067-8b75-dc9842d5a92a" xlink:to="loc_us-gaap_InventoryNet_b6deb589-0739-46c8-87c5-77cca007e095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_7eb6ae67-7922-4f12-8129-9789a54da9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dd1a30e4-3627-4067-8b75-dc9842d5a92a" xlink:to="loc_us-gaap_InventoryNoncurrent_7eb6ae67-7922-4f12-8129-9789a54da9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4625100d-c238-4a6d-b6f1-c827a6b8c496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4625100d-c238-4a6d-b6f1-c827a6b8c496" xlink:to="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3e1dd06c-0bee-4554-9fe1-823d0de91c3d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_efcc9fd2-e999-4159-9b8d-b01dad2e0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_efcc9fd2-e999-4159-9b8d-b01dad2e0d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_COVIDVaccineMember_df42e68c-4af3-4480-9ea5-17430e7bd6cb" xlink:href="mrna-20251231.xsd#mrna_COVIDVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_mrna_COVIDVaccineMember_df42e68c-4af3-4480-9ea5-17430e7bd6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MNEXSPIKEMember_019b92ca-f2b1-771a-a33f-15169bb08b6b" xlink:href="mrna-20251231.xsd#mrna_MNEXSPIKEMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_mrna_MNEXSPIKEMember_019b92ca-f2b1-771a-a33f-15169bb08b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RSVVaccineMember_3a6b5afd-9bfe-48a3-b335-4ca641a88e5d" xlink:href="mrna-20251231.xsd#mrna_RSVVaccineMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_916d2299-72a4-4e67-8928-6c408366348f" xlink:to="loc_mrna_RSVVaccineMember_3a6b5afd-9bfe-48a3-b335-4ca641a88e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:to="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ae692e45-b177-47ef-8cbc-d8aecb074207" xlink:to="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_579de9de-2227-4891-b80c-39fe5246eb89" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:to="loc_srt_MinimumMember_579de9de-2227-4891-b80c-39fe5246eb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_004ddce2-ad2a-47f6-85c5-9d7a21c0975e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_badee32b-830c-4551-a278-28e3c9c7ee8a" xlink:to="loc_srt_MaximumMember_004ddce2-ad2a-47f6-85c5-9d7a21c0975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_991258e9-56f8-4d22-aa7f-b829c00f7cb9" xlink:to="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_6b5598e3-3136-4e03-bd5e-0726277da08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryWriteDown_6b5598e3-3136-4e03-bd5e-0726277da08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_2cd98792-270c-4abe-af8a-ac0f6fcac63e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_2cd98792-270c-4abe-af8a-ac0f6fcac63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_988a1eb7-14f3-4291-aeb9-993f917ce4d5" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_988a1eb7-14f3-4291-aeb9-993f917ce4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_95c6bf20-b4f8-48f1-92c9-acf05a7ba37f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_us-gaap_InventoryGross_95c6bf20-b4f8-48f1-92c9-acf05a7ba37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InventoryShelfLife_b519fdbd-0dfc-4df7-9b62-b9bf9cf4ca23" xlink:href="mrna-20251231.xsd#mrna_InventoryShelfLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_454d56c6-3aa7-4865-9d33-4c7554a19d50" xlink:to="loc_mrna_InventoryShelfLife_b519fdbd-0dfc-4df7-9b62-b9bf9cf4ca23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#PropertyPlantandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1357e6cd-9d24-4499-9262-6ad16d7ed704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1357e6cd-9d24-4499-9262-6ad16d7ed704" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44e6fa9a-339d-4230-a69f-93ed3b489170" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_158297e8-89f7-4bc5-95eb-22afd0dd12b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_158297e8-89f7-4bc5-95eb-22afd0dd12b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_92d78b77-9baa-4409-99b4-e8ccd5f8dfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_92d78b77-9baa-4409-99b4-e8ccd5f8dfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fbb1f7ee-eb0a-4a77-bfea-1e0ba282d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_EquipmentMember_fbb1f7ee-eb0a-4a77-bfea-1e0ba282d2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_21c7fbe3-25fb-46e3-8f6a-4f6cf5d42b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_21c7fbe3-25fb-46e3-8f6a-4f6cf5d42b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_901abbe1-1ffb-4b45-8b32-6c1d4a8b64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_901abbe1-1ffb-4b45-8b32-6c1d4a8b64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_38015d90-24ff-4f28-b448-48c12508ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_ComputerEquipmentMember_38015d90-24ff-4f28-b448-48c12508ae1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_94a1d826-1e5a-4bb2-8381-7592ee00ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_us-gaap_ConstructionInProgressMember_94a1d826-1e5a-4bb2-8381-7592ee00ada7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_ab055175-b679-49d2-a94a-de223e86825f" xlink:href="mrna-20251231.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84416419-057f-4301-9ce7-bbfa649ec1ac" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_ab055175-b679-49d2-a94a-de223e86825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbfbae6b-b062-4b4f-a2ec-08b5f0af0357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_4ec87b4a-18e8-4a79-9ccb-fe4797507dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_4ec87b4a-18e8-4a79-9ccb-fe4797507dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_52a15f95-6740-4e33-b560-69730c961b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_52a15f95-6740-4e33-b560-69730c961b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d8428b03-db65-44b5-9a8a-968e0823fc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d8428b03-db65-44b5-9a8a-968e0823fc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_18f9f61e-4a25-446c-acdd-d1c4f505e3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_da36ef8f-1694-4151-a04f-6175a4eb7781" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_18f9f61e-4a25-446c-acdd-d1c4f505e3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50b99e31-dfba-4d27-b6b1-628fbbf8d74a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_abf0a278-6839-4317-a45c-13c66a829e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50b99e31-dfba-4d27-b6b1-628fbbf8d74a" xlink:to="loc_us-gaap_AccountsReceivableGross_abf0a278-6839-4317-a45c-13c66a829e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccountsReceivableChargebacksDiscountsAndFees_e61744e8-f006-4daf-bc65-f156ff9b9617" xlink:href="mrna-20251231.xsd#mrna_AccountsReceivableChargebacksDiscountsAndFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50b99e31-dfba-4d27-b6b1-628fbbf8d74a" xlink:to="loc_mrna_AccountsReceivableChargebacksDiscountsAndFees_e61744e8-f006-4daf-bc65-f156ff9b9617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_019c1dad-8685-748e-a964-451dbfe169ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50b99e31-dfba-4d27-b6b1-628fbbf8d74a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_019c1dad-8685-748e-a964-451dbfe169ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_f8e8b252-710c-42a4-9bf1-9538a542cea6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50b99e31-dfba-4d27-b6b1-628fbbf8d74a" xlink:to="loc_us-gaap_AccountsReceivableNet_f8e8b252-710c-42a4-9bf1-9538a542cea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a7647882-3bb3-4722-8c8e-f8d27b738048" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a7647882-3bb3-4722-8c8e-f8d27b738048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseMaterialsAndSupplies_60870c77-0ebe-44e9-9db2-be0a5ba87e24" xlink:href="mrna-20251231.xsd#mrna_OtherPrepaidExpenseMaterialsAndSupplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_mrna_OtherPrepaidExpenseMaterialsAndSupplies_60870c77-0ebe-44e9-9db2-be0a5ba87e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_7959f660-b385-49c9-a43b-c7cba5896481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_InterestReceivableCurrent_7959f660-b385-49c9-a43b-c7cba5896481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_02621af7-fa6c-4d94-8062-9a099e28b648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_02621af7-fa6c-4d94-8062-9a099e28b648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_f0a8d8ac-1b03-42f6-b138-ba7d9fd5daa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_PrepaidTaxes_f0a8d8ac-1b03-42f6-b138-ba7d9fd5daa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationReceivableCurrent_2c1fa5e0-a3b4-4d3d-bf8b-36ab207c0906" xlink:href="mrna-20251231.xsd#mrna_CollaborationReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_mrna_CollaborationReceivableCurrent_2c1fa5e0-a3b4-4d3d-bf8b-36ab207c0906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_4a8fa951-88f3-408b-bebb-1e47b0896b35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_IncomeTaxesReceivable_4a8fa951-88f3-408b-bebb-1e47b0896b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e50ca596-2931-41a0-972c-41102ccc6fac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_OtherAssetsCurrent_e50ca596-2931-41a0-972c-41102ccc6fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1892844c-cd3a-4a9f-8b78-54a13fc3cb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ec4b426-ff77-4521-a93f-bc72a4deebe9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1892844c-cd3a-4a9f-8b78-54a13fc3cb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_0e3130da-c717-4492-960d-36494662cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_0e3130da-c717-4492-960d-36494662cd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c84d70e0-04dc-4438-828d-22a246df08bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_InventoryNoncurrent_c84d70e0-04dc-4438-828d-22a246df08bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DownpaymentsAndPrepaymentsNoncurrent_800132ac-495b-4735-b181-42f5c6d8598d" xlink:href="mrna-20251231.xsd#mrna_DownpaymentsAndPrepaymentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_mrna_DownpaymentsAndPrepaymentsNoncurrent_800132ac-495b-4735-b181-42f5c6d8598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a07c410e-cad0-4214-b0a7-c1695a0b3e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a07c410e-cad0-4214-b0a7-c1695a0b3e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46439be8-8642-4fd2-83ab-6fe1a846f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_Goodwill_46439be8-8642-4fd2-83ab-6fe1a846f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64e30f37-e0dc-4820-8bd2-fc4480516212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64e30f37-e0dc-4820-8bd2-fc4480516212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b23138e1-bd80-46ad-bf8a-ec2fa678e34b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_EquityMethodInvestments_b23138e1-bd80-46ad-bf8a-ec2fa678e34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_a8777426-542f-4195-9a41-c2ada074cb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_a8777426-542f-4195-9a41-c2ada074cb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1ae84e8d-3479-4c94-ac69-3d5a8b1c38fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49a9139f-0e92-43b2-b229-f65fe12938a1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1ae84e8d-3479-4c94-ac69-3d5a8b1c38fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_019c11af-f335-733d-be0b-ed942ae48c70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_019c11af-f335-733d-be0b-ed942ae48c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c11af-f335-745c-92ae-b2da8a1314ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c11af-f335-745c-92ae-b2da8a1314ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_019c11af-f335-76b7-a60a-af5d520cb773" xlink:href="mrna-20251231.xsd#mrna_AccruedManufacturing"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_AccruedManufacturing_019c11af-f335-76b7-a60a-af5d520cb773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_019c11af-f335-7fcb-aa3b-18c0ef70e1d0" xlink:href="mrna-20251231.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_AccruedDevelopmentOperation_019c11af-f335-7fcb-aa3b-18c0ef70e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_019c11af-f335-7024-801c-3e1ae6014431" xlink:href="mrna-20251231.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_019c11af-f335-7024-801c-3e1ae6014431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_019c11af-f335-755e-bd0d-58f4d966dbce" xlink:href="mrna-20251231.xsd#mrna_AccruedPropertyAndEquipmentCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_AccruedPropertyAndEquipmentCurrent_019c11af-f335-755e-bd0d-58f4d966dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_019c11af-f335-7c03-b120-c8b806e5d8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_019c11af-f335-7c03-b120-c8b806e5d8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_019c11af-f335-7793-93cb-85a8db67dea8" xlink:href="mrna-20251231.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_RawMaterialsAccountsPayable_019c11af-f335-7793-93cb-85a8db67dea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedCommercial_019c11af-f335-7e99-91b8-f6dd58d6ca71" xlink:href="mrna-20251231.xsd#mrna_AccruedCommercial"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_AccruedCommercial_019c11af-f335-7e99-91b8-f6dd58d6ca71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_019c11af-f335-7fc3-8c9a-1b03b804961b" xlink:href="mrna-20251231.xsd#mrna_AccruedClinicalTrials"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_AccruedClinicalTrials_019c11af-f335-7fc3-8c9a-1b03b804961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_019c11af-f335-75f4-b923-c1a154a7f94a" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_019c11af-f335-75f4-b923-c1a154a7f94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019c11af-f335-7e7c-a920-9f11f1f94247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94358d1a-c310-4717-a26d-638a01374e50" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019c11af-f335-7e7c-a920-9f11f1f94247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EstimatedReimbursementLiability_a81f42f2-3267-4c20-b208-74f90c0ecb8d" xlink:href="mrna-20251231.xsd#mrna_EstimatedReimbursementLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:to="loc_mrna_EstimatedReimbursementLiability_a81f42f2-3267-4c20-b208-74f90c0ecb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_c4f3208e-7d20-4d61-a4ad-e3c30c2bf94f" xlink:href="mrna-20251231.xsd#mrna_ResearchAndDevelopmentLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:to="loc_mrna_ResearchAndDevelopmentLiabilityCurrent_c4f3208e-7d20-4d61-a4ad-e3c30c2bf94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6d70808e-0e32-486b-b9b1-afc86cd9572d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6d70808e-0e32-486b-b9b1-afc86cd9572d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_829f1fc4-3626-4835-b402-2fa09070f800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_829f1fc4-3626-4835-b402-2fa09070f800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_3a922cbb-7d68-43ab-9511-7ecb6b628cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_3a922cbb-7d68-43ab-9511-7ecb6b628cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dd9b7c87-30c5-4af9-a5b2-259b0f869311" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f430c7cf-449d-4561-a1a0-c59b17d601fd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dd9b7c87-30c5-4af9-a5b2-259b0f869311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb2080ba-c840-4ffa-9a9f-930c81c8f8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_061372ae-7999-4363-af2f-1dfbc50a6e16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb2080ba-c840-4ffa-9a9f-930c81c8f8da" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_061372ae-7999-4363-af2f-1dfbc50a6e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_bb54f187-4bcd-4cd2-a283-624402dff17d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb2080ba-c840-4ffa-9a9f-930c81c8f8da" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_bb54f187-4bcd-4cd2-a283-624402dff17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_54e9830b-335a-4107-93b6-152d0ea8e338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb2080ba-c840-4ffa-9a9f-930c81c8f8da" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_54e9830b-335a-4107-93b6-152d0ea8e338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8e8687e-3290-4358-8cdb-a56fff526fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8e8687e-3290-4358-8cdb-a56fff526fb5" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:to="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d609cf69-794b-446c-8f52-15cd2aea3579" xlink:to="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_4e8a4de3-0afe-46b1-a5d8-5def204aa3c5" xlink:href="mrna-20251231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:to="loc_mrna_ProductSalesMember_4e8a4de3-0afe-46b1-a5d8-5def204aa3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_181285a8-7b37-411a-be12-9bac49ff85a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c20564eb-750d-4a1e-b71d-81d3d301e37f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_181285a8-7b37-411a-be12-9bac49ff85a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_980bc306-d62a-465a-bfed-596cc120d8c4" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_560ecc77-d032-49dd-8cd2-5c48759264f7" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_980bc306-d62a-465a-bfed-596cc120d8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:href="mrna-20251231.xsd#mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_980bc306-d62a-465a-bfed-596cc120d8c4" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c0111636-b05d-4abf-8fe2-c1314c521097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c0111636-b05d-4abf-8fe2-c1314c521097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_4f86ece9-7241-4703-b982-6e7e298c63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_4f86ece9-7241-4703-b982-6e7e298c63b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_956b50b0-173a-49b4-983a-288427efd8d2" xlink:href="mrna-20251231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_956b50b0-173a-49b4-983a-288427efd8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_aabb7fe6-d38c-4e31-a8f7-253f75377dde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_8a67bb4f-4640-4a1b-a412-a53b5584a651" xlink:to="loc_us-gaap_ContractWithCustomerLiability_aabb7fe6-d38c-4e31-a8f7-253f75377dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_46fe532d-bb1b-4fb0-ad42-1f02010843b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_46fe532d-bb1b-4fb0-ad42-1f02010843b9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5a1ac13-1370-4f1f-8082-78c929cbaada" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d02bb470-d351-4e74-84f4-7d042ebaf5b8" xlink:to="loc_srt_SegmentGeographicalDomain_f5a1ac13-1370-4f1f-8082-78c929cbaada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_0d747cec-6211-4c35-b13d-685a4f3f6220" xlink:href="mrna-20251231.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f5a1ac13-1370-4f1f-8082-78c929cbaada" xlink:to="loc_mrna_CambridgeMassachusettsMember_0d747cec-6211-4c35-b13d-685a4f3f6220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d0427bb2-b88f-412b-8d59-5b7ce713204f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fe94e38c-5a43-4d2a-9a03-c9f5ffa63593" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d0427bb2-b88f-412b-8d59-5b7ce713204f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_074d5717-cc1b-47ca-a626-75426fa1ef0d" xlink:href="mrna-20251231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d0427bb2-b88f-412b-8d59-5b7ce713204f" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_074d5717-cc1b-47ca-a626-75426fa1ef0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7002-b8ce-d7b0696b4ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019bdc35-bd01-7ea3-98fc-06c3884fc515" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7002-b8ce-d7b0696b4ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ModernaTechnologyCenterMember_019bdc35-bd01-7054-98bd-c2af8e934073" xlink:href="mrna-20251231.xsd#mrna_ModernaTechnologyCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019bdc35-bd01-7002-b8ce-d7b0696b4ccd" xlink:to="loc_mrna_ModernaTechnologyCenterMember_019bdc35-bd01-7054-98bd-c2af8e934073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44d0d778-c41c-41af-8600-74e0c9de9ee8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_1af7a032-94fe-452d-96ce-752152f25fdf" xlink:href="mrna-20251231.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_1af7a032-94fe-452d-96ce-752152f25fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9a131b41-2a3a-4074-8af7-34e41e55322c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9a131b41-2a3a-4074-8af7-34e41e55322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ca89b9fe-072b-465a-80da-8450c261aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ca89b9fe-072b-465a-80da-8450c261aad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensions_b0d7a13f-8fa7-49ef-97d1-3dba13978cca" xlink:href="mrna-20251231.xsd#mrna_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensions_b0d7a13f-8fa7-49ef-97d1-3dba13978cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b30c805a-fe22-4a86-9087-525374f7a151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b30c805a-fe22-4a86-9087-525374f7a151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019bdc35-bd01-72c2-924a-b73e55dcb6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019bdc35-bd01-72c2-924a-b73e55dcb6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_019bdc35-bd01-748a-80b4-52bf7ca21de1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1852c202-446b-4a4c-95e4-56f442c87a76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_019bdc35-bd01-748a-80b4-52bf7ca21de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd226aa4-a6d0-4e3f-ac23-c54e5a151695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd226aa4-a6d0-4e3f-ac23-c54e5a151695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_634ef1f0-426b-4878-8680-6019fccefade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_634ef1f0-426b-4878-8680-6019fccefade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_b4a8b464-9963-4890-8dad-db5fccb335cd" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_b4a8b464-9963-4890-8dad-db5fccb335cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c9a18fb9-f49c-4cab-9619-15318736bbad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c9a18fb9-f49c-4cab-9619-15318736bbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b6c353f4-8b41-42ce-84fc-e01d20977872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b6c353f4-8b41-42ce-84fc-e01d20977872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_666342b9-e825-41e5-8c48-ea78c3d9951e" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_666342b9-e825-41e5-8c48-ea78c3d9951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6e1d9b8-3362-4911-9e2d-ef6cc0534289" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6e1d9b8-3362-4911-9e2d-ef6cc0534289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d6e85c36-e8c3-42ec-9503-d4df46e35082" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d6e85c36-e8c3-42ec-9503-d4df46e35082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_70afdd82-f471-4ebc-a437-dcedc85d949c" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_70afdd82-f471-4ebc-a437-dcedc85d949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_962bc46d-0ebf-4390-adfa-89fe4734ff1b" xlink:href="mrna-20251231.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiability_962bc46d-0ebf-4390-adfa-89fe4734ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_28d45049-06bc-4a90-ba44-d7c204a77443" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_28d45049-06bc-4a90-ba44-d7c204a77443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d65c4fa8-1c81-4faf-89d7-93a68011143b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d65c4fa8-1c81-4faf-89d7-93a68011143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c73275f5-df03-4f0a-a693-91096d29ce95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3c8b99b3-26af-4f1e-965e-1b2c1cacc82f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c73275f5-df03-4f0a-a693-91096d29ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ae75f7f1-57c8-4a3c-9ac8-ae9716fb9c78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_OperatingLeaseCost_ae75f7f1-57c8-4a3c-9ac8-ae9716fb9c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_48cd0f76-ed94-4b53-a4ac-527394f0eb94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_48cd0f76-ed94-4b53-a4ac-527394f0eb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_6f127cf9-d10f-4d59-922a-e188aa74c6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_6f127cf9-d10f-4d59-922a-e188aa74c6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseCost_1232b724-d674-428b-871a-3390517cc576" xlink:href="mrna-20251231.xsd#mrna_FinanceLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_mrna_FinanceLeaseCost_1232b724-d674-428b-871a-3390517cc576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9b53cc9b-12de-482b-9b72-bff3ae4f7e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_ShortTermLeaseCost_9b53cc9b-12de-482b-9b72-bff3ae4f7e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e336dec6-a527-4ac5-9186-ba95ca254245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_VariableLeaseCost_e336dec6-a527-4ac5-9186-ba95ca254245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5358cbf1-dd8f-419a-ac8e-edd34095918b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_OperatingLeasePayments_5358cbf1-dd8f-419a-ac8e-edd34095918b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_38040a19-57b1-4a04-8bb3-1289f0fb58dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_38040a19-57b1-4a04-8bb3-1289f0fb58dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_83335e66-129f-4380-8a7e-65bb648445ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_83335e66-129f-4380-8a7e-65bb648445ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_98c8c74a-6417-4ff4-97ce-d3154b1d07f4" xlink:href="mrna-20251231.xsd#mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_98c8c74a-6417-4ff4-97ce-d3154b1d07f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_268bdcb8-8f2c-49e1-bca5-b73f383e81b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_268bdcb8-8f2c-49e1-bca5-b73f383e81b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_e3840838-60e9-4738-9a27-681febe9119b" xlink:href="mrna-20251231.xsd#mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_e3840838-60e9-4738-9a27-681febe9119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e7edefe1-5669-4763-be1e-5a9de1de1f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e7edefe1-5669-4763-be1e-5a9de1de1f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeFinanceLeaseExpense_d7896871-37ca-4105-8e22-b51ae52ac23a" xlink:href="mrna-20251231.xsd#mrna_LesseeFinanceLeaseExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_mrna_LesseeFinanceLeaseExpense_d7896871-37ca-4105-8e22-b51ae52ac23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset_4e48783a-5e0b-4e08-b3de-f8050e2e390d" xlink:href="mrna-20251231.xsd#mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset_4e48783a-5e0b-4e08-b3de-f8050e2e390d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d418577f-07d9-44bc-ac24-6351d613f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d418577f-07d9-44bc-ac24-6351d613f6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_5f75c585-57e5-435f-abf3-b84098ef68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_5f75c585-57e5-435f-abf3-b84098ef68fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_09b26412-9fef-479a-ad38-51820f142717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_09b26412-9fef-479a-ad38-51820f142717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_9ca5293c-3531-4627-9f7a-57d3e0ea2923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d43736-0cd3-4f00-a6c2-e74c1cf02900" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_9ca5293c-3531-4627-9f7a-57d3e0ea2923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a7717c4e-fcd0-4d62-947b-b8150f7cdc40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a7717c4e-fcd0-4d62-947b-b8150f7cdc40" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_650ecf79-fba8-4edb-8110-510949c0e651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_650ecf79-fba8-4edb-8110-510949c0e651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_16de8047-925f-4690-ad89-3b837ea76ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_16de8047-925f-4690-ad89-3b837ea76ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_f4d21611-fe8c-4b38-a7f2-96a31637cb81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_f4d21611-fe8c-4b38-a7f2-96a31637cb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_7b86068b-9fa6-4d9d-b410-56ef191d01c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_7b86068b-9fa6-4d9d-b410-56ef191d01c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_a4e58f55-b44f-4d7e-b182-6ebca75f7d94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_a4e58f55-b44f-4d7e-b182-6ebca75f7d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_f4535e9e-2c8a-4060-87b8-b2d0e3b9efcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_f4535e9e-2c8a-4060-87b8-b2d0e3b9efcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8cadc1eb-b3e8-4d5d-aef3-bcb3d86d9bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8cadc1eb-b3e8-4d5d-aef3-bcb3d86d9bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_596f544a-3bc9-45de-9507-2e357e9c1848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_596f544a-3bc9-45de-9507-2e357e9c1848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9837dbd0-bd8a-4cad-a8d3-ba0dda05bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_99c34cf4-afb0-4a46-b0d3-08c2d2c0a9a6" xlink:to="loc_us-gaap_OperatingLeaseLiability_9837dbd0-bd8a-4cad-a8d3-ba0dda05bf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a7717c4e-fcd0-4d62-947b-b8150f7cdc40" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_b081f8e1-dcd2-4084-b3d8-149ac729c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_b081f8e1-dcd2-4084-b3d8-149ac729c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_86ddea93-2397-479b-a8da-99288d739f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_86ddea93-2397-479b-a8da-99288d739f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_edb4011f-3dd9-4a42-8e87-4f0e6804b8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_edb4011f-3dd9-4a42-8e87-4f0e6804b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_586a210a-d77e-45c0-91fa-6c4461f1fb45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_586a210a-d77e-45c0-91fa-6c4461f1fb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_9263c481-fd00-49de-ad66-51ec95a3b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_9263c481-fd00-49de-ad66-51ec95a3b15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_94f71809-dd52-4989-a34d-26cb6a0b1be4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_94f71809-dd52-4989-a34d-26cb6a0b1be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1d39afac-18f4-47c9-80e7-34cdd43e4c62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1d39afac-18f4-47c9-80e7-34cdd43e4c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_51ba4b2c-3f59-408f-90f2-f2d9f343d25e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_51ba4b2c-3f59-408f-90f2-f2d9f343d25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1d2cb4b1-b277-4011-9b0f-6124848146c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_37884ad7-6623-431a-bc4e-9fe07fdb601e" xlink:to="loc_us-gaap_FinanceLeaseLiability_1d2cb4b1-b277-4011-9b0f-6124848146c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a7717c4e-fcd0-4d62-947b-b8150f7cdc40" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_87ac0210-997c-42b8-b0ec-146a906986e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_17f905f2-820e-442d-a284-1ce298a061f0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_87ac0210-997c-42b8-b0ec-146a906986e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_274db07f-842a-4a3c-b3e7-c369a82fad37" xlink:href="mrna-20251231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_87ac0210-997c-42b8-b0ec-146a906986e3" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_274db07f-842a-4a3c-b3e7-c369a82fad37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_234960de-35c1-49cd-b9d8-6c7366496af3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_55321daf-6a98-4ee1-8de0-639bd6c6ac04" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_234960de-35c1-49cd-b9d8-6c7366496af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d4c1d0f-f466-48f7-9a9f-ccdf435a042d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_234960de-35c1-49cd-b9d8-6c7366496af3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d4c1d0f-f466-48f7-9a9f-ccdf435a042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CreditAgreementDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019b92d1-7e82-7f5f-8f20-619beef21689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019b92d1-7e82-7f5f-8f20-619beef21689" xlink:to="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7a73-ba2b-a2aab6e2f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019b930b-6c16-7d38-ad2d-56c386fe19ef" xlink:to="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7a73-ba2b-a2aab6e2f7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b930b-6c16-757b-acb4-111cbb5fa148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019b930b-6c16-7a73-ba2b-a2aab6e2f7f4" xlink:to="loc_us-gaap_SecuredDebtMember_019b930b-6c16-757b-acb4-111cbb5fa148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019b930b-6c16-7200-a3bc-d60dd223652c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialTermLoanMember_019bb3b2-d3c9-7811-8063-3cc79629694c" xlink:href="mrna-20251231.xsd#mrna_InitialTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:to="loc_mrna_InitialTermLoanMember_019bb3b2-d3c9-7811-8063-3cc79629694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019b930b-6c16-76e3-b42d-1bc08aa09a38" xlink:to="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacility1Member_019bb3b3-7323-740c-9dd0-1883b5a1d523" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacility1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:to="loc_mrna_DelayedDrawTermLoanFacility1Member_019bb3b3-7323-740c-9dd0-1883b5a1d523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DelayedDrawTermLoanFacility2Member_019bb3b3-a227-7606-8f79-7c2fd0d7785c" xlink:href="mrna-20251231.xsd#mrna_DelayedDrawTermLoanFacility2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DelayedDrawTermLoanFacilityMember_019bb3b3-0345-783e-b6b6-64e20c39c192" xlink:to="loc_mrna_DelayedDrawTermLoanFacility2Member_019bb3b3-a227-7606-8f79-7c2fd0d7785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-7b53-be89-1a4c658d6feb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b930b-6c16-719c-b094-faf3a2c2c5e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-7b53-be89-1a4c658d6feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b930b-6c16-7713-be1b-92dfadc76aad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b930b-6c16-7b53-be89-1a4c658d6feb" xlink:to="loc_us-gaap_LineOfCreditMember_019b930b-6c16-7713-be1b-92dfadc76aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_019b930b-ea71-78fb-ae8e-d117c6e56df6" xlink:to="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019bb3b4-c0fb-7e5e-ad0a-4c9b22641bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_019bb3b4-c0fb-7e5e-ad0a-4c9b22641bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_019bb3b4-d87b-7edf-9efc-be200841bb37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_us-gaap_BaseRateMember_019bb3b4-d87b-7edf-9efc-be200841bb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_019bfd0c-5647-7320-8bd0-f6e54c589652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_019bfd0c-5647-7320-8bd0-f6e54c589652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TermSecuredOvernightFinancingRatePlusMember_019beed4-b404-7e53-aa00-705a958cb3b1" xlink:href="mrna-20251231.xsd#mrna_TermSecuredOvernightFinancingRatePlusMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_019b930b-ea71-731e-9360-5afaff8b0031" xlink:to="loc_mrna_TermSecuredOvernightFinancingRatePlusMember_019beed4-b404-7e53-aa00-705a958cb3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceScenarioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioAxis_019c05bc-c1fd-7818-84f4-990eb1e4e742" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CovenantComplianceScenario1Member_019c05bc-f6f2-709e-b077-007a8f5a4e5a" xlink:href="mrna-20251231.xsd#mrna_CovenantComplianceScenario1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:to="loc_mrna_CovenantComplianceScenario1Member_019c05bc-f6f2-709e-b077-007a8f5a4e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CovenantComplianceScenario2Member_019c05bd-4c22-738b-b8ca-c8ba6217e4d3" xlink:href="mrna-20251231.xsd#mrna_CovenantComplianceScenario2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DebtInstrumentCovenantComplianceScenarioDomain_019c05bc-c1fd-780d-acb0-d879a955787b" xlink:to="loc_mrna_CovenantComplianceScenario2Member_019c05bd-4c22-738b-b8ca-c8ba6217e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b92d1-7e82-7cf1-890f-0c135a6b588f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019b930b-6c16-7454-93fc-2ce40697c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019b930b-6c16-7454-93fc-2ce40697c8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b930b-ea71-7fb7-b59e-2119f15708a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b930b-ea71-7fb7-b59e-2119f15708a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b930b-ea71-751f-9bcd-2c3f345f29e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b930b-ea71-751f-9bcd-2c3f345f29e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_019c05bb-107a-7636-8050-26e795f9be57" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents_019c05bb-107a-7636-8050-26e795f9be57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_019bee81-97a5-7201-83b3-db4154ab4fab" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod_019bee81-97a5-7201-83b3-db4154ab4fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_019c05bc-6853-73af-a933-cae46b8a2cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_LineOfCredit_019c05bc-6853-73af-a933-cae46b8a2cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_019c05be-4a54-7eb5-b4ff-0d9fb9604461" xlink:href="mrna-20251231.xsd#mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization_019c05be-4a54-7eb5-b4ff-0d9fb9604461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019c1fce-6b4a-7b50-8456-88a0a50be669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b92d1-7e82-70a3-821f-c0a7f06f9a27" xlink:to="loc_us-gaap_LongTermDebt_019c1fce-6b4a-7b50-8456-88a0a50be669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesLegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0623a32-d8b5-4536-a941-1b0ce2f5f016" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0623a32-d8b5-4536-a941-1b0ce2f5f016" xlink:to="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:to="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_019c6f10-34eb-7b63-9cfe-8e95c5ba9fcf" xlink:to="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_019c713c-628a-718f-b0ea-12eacc6e6f43" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:to="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember_019c713c-628a-718f-b0ea-12eacc6e6f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_019c713c-be57-7144-b6f4-3d01da925b16" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:to="loc_mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember_019c713c-be57-7144-b6f4-3d01da925b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_019c713d-352a-774b-8266-73c5b8222b87" xlink:href="mrna-20251231.xsd#mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019c6f10-34eb-7484-85a8-2847109e04e3" xlink:to="loc_mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember_019c713d-352a-774b-8266-73c5b8222b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_827937fd-7c22-452b-92ed-4ce4487e5116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_71c70a9b-bfa9-4c03-b78b-45fb0a0395ab" xlink:to="loc_us-gaap_LossContingenciesLineItems_827937fd-7c22-452b-92ed-4ce4487e5116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_019c6f03-bee3-7030-a644-6d23326021d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_827937fd-7c22-452b-92ed-4ce4487e5116" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_019c6f03-bee3-7030-a644-6d23326021d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesIndemnificationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c6f02-335c-748c-b811-9e5d763f09ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c6f02-335c-748c-b811-9e5d763f09ca" xlink:to="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7aad-a56f-79f1aeb274d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c6f02-335c-7104-97ad-540ddbc6cde8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7aad-a56f-79f1aeb274d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_019c6f02-335c-76ea-bd5b-3fbed76f19fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c6f02-335c-7aad-a56f-79f1aeb274d9" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_019c6f02-335c-76ea-bd5b-3fbed76f19fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c6f02-335c-72ad-8e2e-fa097e880ac6" xlink:to="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_019c6f02-335c-718f-949c-8273ec2cb4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_019c6f02-335c-718f-949c-8273ec2cb4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_019c6f02-335c-79c6-8529-8e96078be866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_019c6f02-335c-79c6-8529-8e96078be866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c6f02-335c-7058-8537-7dc04a9b53df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c6f02-335c-75c7-82f0-93e087d20ecf" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019c6f02-335c-7058-8537-7dc04a9b53df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d20870e8-31ec-4cc7-aa72-522eb4f085e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d20870e8-31ec-4cc7-aa72-522eb4f085e0" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a1a96d71-ba27-4a16-a67a-8ae599ad5bec" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_2a499cd7-9dbf-474c-b5f6-051e5504719b" xlink:href="mrna-20251231.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_2a499cd7-9dbf-474c-b5f6-051e5504719b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_19f29b37-1fe1-47f4-84b9-277fe499e781" xlink:href="mrna-20251231.xsd#mrna_ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:to="loc_mrna_ClinicalServicesMember_19f29b37-1fe1-47f4-84b9-277fe499e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_049bbdc7-ee81-4b08-bf4c-c44e259aab15" xlink:href="mrna-20251231.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4d923b48-09d3-44f7-b7a0-bd1f410fd484" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_049bbdc7-ee81-4b08-bf4c-c44e259aab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_7a5f4240-a73e-4e26-9a75-cfd3d20fb407" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7ae6a653-f40b-444a-8110-debad89c7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7ae6a653-f40b-444a-8110-debad89c7a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_137c4546-1ed2-4b20-90b4-6a12539b88f8" xlink:href="mrna-20251231.xsd#mrna_LegalContingencyFutureFirmPurchaseCommitments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_3b3f1461-97f5-4912-9b2d-aab784c7c366" xlink:to="loc_mrna_LegalContingencyFutureFirmPurchaseCommitments_137c4546-1ed2-4b20-90b4-6a12539b88f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce409e57-6b06-4a40-a85e-1373dbaf3936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce409e57-6b06-4a40-a85e-1373dbaf3936" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:to="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69c113dd-8e95-4abe-a5f5-679b94dffebc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d1704254-168e-4774-8602-deccc9fe3a77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69c113dd-8e95-4abe-a5f5-679b94dffebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_02d81a35-5b61-4d95-94ea-59e11f53b89b" xlink:href="mrna-20251231.xsd#mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69c113dd-8e95-4abe-a5f5-679b94dffebc" xlink:to="loc_mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember_02d81a35-5b61-4d95-94ea-59e11f53b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c378648b-5aeb-442f-96ec-6cb52070098e" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_019c2999-9156-7763-b7db-731d1c8acea7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_019c2999-9156-7763-b7db-731d1c8acea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_588aa2ac-6a17-49e7-a2a2-efeeeadde2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a2d48797-68b7-4593-b4f3-981134026132" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_588aa2ac-6a17-49e7-a2a2-efeeeadde2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4562ce1-33b4-4e04-87a8-714f181ced6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4562ce1-33b4-4e04-87a8-714f181ced6f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019b933c-3bc3-7562-921f-97437e10fd22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ServiceBasedAwardsMember_019b933c-3bc3-7dc3-93ce-ef01a76f7e66" xlink:href="mrna-20251231.xsd#mrna_ServiceBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_mrna_ServiceBasedAwardsMember_019b933c-3bc3-7dc3-93ce-ef01a76f7e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b933c-3bc3-7b93-9bc3-54db8240ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b933c-3bc3-7b93-9bc3-54db8240ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019b933c-663b-7d6d-b623-5d62432330fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_us-gaap_EmployeeStockMember_019b933c-663b-7d6d-b623-5d62432330fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_019b933c-a408-72dd-a836-4651b505ee50" xlink:href="mrna-20251231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_019b933c-a408-72dd-a836-4651b505ee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019b933c-a408-7570-b23f-fc7a2285fe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b933c-3bc3-7734-8d51-f939974189fd" xlink:to="loc_us-gaap_PerformanceSharesMember_019b933c-a408-7570-b23f-fc7a2285fe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_019b933c-3bc3-7e70-8814-a6bf4491cffe" xlink:to="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019b933c-3bc3-73d6-bd3a-9fdb7cfff8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019b933c-3bc3-73d6-bd3a-9fdb7cfff8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019b933c-3bc3-7588-822f-522ea5b3dea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_019b933c-3bc3-75f1-bac3-30e884801550" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_019b933c-3bc3-7588-822f-522ea5b3dea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019b933c-3bc3-7c67-9b7e-711b68e26cf1" xlink:to="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_019b933c-3bc3-7905-aff0-30d63005301f" xlink:href="mrna-20251231.xsd#mrna_StockOptionAndGrantPlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:to="loc_mrna_StockOptionAndGrantPlan2016Member_019b933c-3bc3-7905-aff0-30d63005301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_019b933c-3bc3-7409-857b-a98405567572" xlink:href="mrna-20251231.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_019b933c-3bc3-7409-857b-a98405567572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionExchangeProgramMember_019c05c3-bc7d-7afe-b290-73965c308897" xlink:href="mrna-20251231.xsd#mrna_StockOptionExchangeProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b933c-3bc3-7574-80d9-dd40682872b4" xlink:to="loc_mrna_StockOptionExchangeProgramMember_019c05c3-bc7d-7afe-b290-73965c308897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019b933c-a408-7bd3-8f23-0bd922654c1a" xlink:to="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019b933c-a408-79c1-abe1-6a80886afeba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:to="loc_srt_MinimumMember_019b933c-a408-79c1-abe1-6a80886afeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019b933c-a408-7bfe-8771-9750309a6eb8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019b933c-a408-7828-b229-989ce5f0afbf" xlink:to="loc_srt_MaximumMember_019b933c-a408-7bfe-8771-9750309a6eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7999-b151-04a480c67927" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019b933c-c865-7fed-9c27-5a0ad4c9a15c" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7999-b151-04a480c67927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2022RepurchaseProgramMember_019b933c-c865-7058-a603-39220eda075c" xlink:href="mrna-20251231.xsd#mrna_A2022RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019b933c-c865-7999-b151-04a480c67927" xlink:to="loc_mrna_A2022RepurchaseProgramMember_019b933c-c865-7058-a603-39220eda075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2ab0e54-a818-44cb-aedc-d015eac92556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b933c-3bc3-7000-bead-ee530a7b3f83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b933c-3bc3-7000-bead-ee530a7b3f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019b933c-3bc3-774e-8d79-6d8fbcb14623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019b933c-3bc3-774e-8d79-6d8fbcb14623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_019b933c-3bc3-7307-b92f-1959cfa17526" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_019b933c-3bc3-7307-b92f-1959cfa17526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b933c-3bc3-73ca-ae23-102914b837de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b933c-3bc3-73ca-ae23-102914b837de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019b933c-3bc3-7a28-b383-7c86c9d1a7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019b933c-3bc3-7a28-b383-7c86c9d1a7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b933c-3bc3-7ccf-98cf-251d61910679" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b933c-3bc3-7ccf-98cf-251d61910679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_019b933c-663b-78bb-bdbd-09f24489fdc3" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees_019b933c-663b-78bb-bdbd-09f24489fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019c05c3-08f8-7553-ba32-3d40e0bf5d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019c05c3-08f8-7553-ba32-3d40e0bf5d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_019c05c6-0e94-775b-9b33-b83f48f2d872" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage_019c05c6-0e94-775b-9b33-b83f48f2d872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c05c6-7db5-7bab-84e6-2ed28b9d58b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c05c6-7db5-7bab-84e6-2ed28b9d58b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_019c05c8-b0c1-7053-9819-f8f6342fd558" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharePrice_019c05c8-b0c1-7053-9819-f8f6342fd558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b933c-83a6-7427-bff9-5c3fb1e53469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b933c-83a6-7427-bff9-5c3fb1e53469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_019b933c-83a6-726b-ac1c-d0435dbdc55e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_019b933c-83a6-726b-ac1c-d0435dbdc55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019b933c-83a6-746f-a365-ed2519335e41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019b933c-83a6-746f-a365-ed2519335e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_019b933c-a408-7d96-92e8-eaef91220587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_RestrictedStockExpense_019b933c-a408-7d96-92e8-eaef91220587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_019b933c-a408-7dd2-9baa-b03ad35e3b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_019b933c-a408-7dd2-9baa-b03ad35e3b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019b933c-a408-7631-a6f8-29151934a513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_019b933c-a408-7631-a6f8-29151934a513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_019b933c-a408-761d-b055-d96251bfb32d" xlink:href="mrna-20251231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_019b933c-a408-761d-b055-d96251bfb32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019b933c-c865-77a8-8806-ab6bc7fff79c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019b933c-c865-77a8-8806-ab6bc7fff79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b933c-c865-71c8-b358-265c9d792076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b933c-c865-71c8-b358-265c9d792076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019b933c-c865-7d1d-a3e2-dd04e847e207" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019b933c-c865-7d1d-a3e2-dd04e847e207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_019b933c-c865-7db8-87f3-2214d233af44" xlink:href="mrna-20251231.xsd#mrna_StockRepurchaseProgramAdditionalAuthorizedAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de77613c-f522-4796-bad4-e4c0a5c11c65" xlink:to="loc_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount_019b933c-c865-7db8-87f3-2214d233af44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699ef9d1-3477-491b-86df-7bf6bde59f25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699ef9d1-3477-491b-86df-7bf6bde59f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ae1bd56-21e1-4ad1-b869-63be77047a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ae1bd56-21e1-4ad1-b869-63be77047a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b3dc138f-06c1-491a-a0a3-6793c83d272f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b3dc138f-06c1-491a-a0a3-6793c83d272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c409abc-56c2-42f3-821e-5856ace54ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c409abc-56c2-42f3-821e-5856ace54ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_14754530-61db-44c4-907f-fe727d5f8210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_14754530-61db-44c4-907f-fe727d5f8210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75710e5a-4fb0-4750-bf7f-0e08b855a650" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af74401-6ff9-41c3-8972-6630891d3641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75710e5a-4fb0-4750-bf7f-0e08b855a650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699ef9d1-3477-491b-86df-7bf6bde59f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18519122-6cfc-47da-bde5-1d7535c0652e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18519122-6cfc-47da-bde5-1d7535c0652e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb75df8b-6736-43a4-9372-dffbe1ef7cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb75df8b-6736-43a4-9372-dffbe1ef7cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4270f124-2f75-443f-bb1d-a681ff864723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4270f124-2f75-443f-bb1d-a681ff864723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79876660-5f35-4802-8b89-5baf1b681ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79876660-5f35-4802-8b89-5baf1b681ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45baee3c-3595-4da2-94f6-9f88f10e37d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c0d5769-ec25-43ab-b7ac-5ad40e799efd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45baee3c-3595-4da2-94f6-9f88f10e37d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699ef9d1-3477-491b-86df-7bf6bde59f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62001807-74bb-4e62-99c5-e0508e0c633b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62001807-74bb-4e62-99c5-e0508e0c633b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b78aaacb-a867-4262-8e2b-294eeb44ca38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b78aaacb-a867-4262-8e2b-294eeb44ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1a531c66-29a4-40c6-a37c-734bd47acd02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1a531c66-29a4-40c6-a37c-734bd47acd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b6095ec2-25b8-43dc-9e7e-ed6ae098d32d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b6095ec2-25b8-43dc-9e7e-ed6ae098d32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5e6ff12c-6e49-4f9b-bcd1-5f681a22feb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5e6ff12c-6e49-4f9b-bcd1-5f681a22feb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c9d43b8-0351-4805-b6ec-88b21c4ad207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bf6fd5c7-91bf-4c66-9c81-563f63384434" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c9d43b8-0351-4805-b6ec-88b21c4ad207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f26c8a37-0582-4f85-a449-a0b0a6d36363" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699ef9d1-3477-491b-86df-7bf6bde59f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f26c8a37-0582-4f85-a449-a0b0a6d36363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41c5bb91-ec00-4c0e-9e07-9de966b19a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f26c8a37-0582-4f85-a449-a0b0a6d36363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41c5bb91-ec00-4c0e-9e07-9de966b19a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f853a66b-110c-47f7-94c3-e6165706a31b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f26c8a37-0582-4f85-a449-a0b0a6d36363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f853a66b-110c-47f7-94c3-e6165706a31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_aa905989-b346-469e-86f1-bd9fa0beec60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f26c8a37-0582-4f85-a449-a0b0a6d36363" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_aa905989-b346-469e-86f1-bd9fa0beec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a84c3b45-829f-4cae-b94f-ec6fc1a665d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f26c8a37-0582-4f85-a449-a0b0a6d36363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a84c3b45-829f-4cae-b94f-ec6fc1a665d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1ebd5b7-38e0-4129-a087-08e81efb00f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1ebd5b7-38e0-4129-a087-08e81efb00f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:to="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d142b198-72bc-4187-ad4f-12217514756b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e0b47f72-56a3-46fb-a609-7e47a77e2f84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d142b198-72bc-4187-ad4f-12217514756b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_80eed304-035e-48b3-8264-819a00fe6005" xlink:href="mrna-20251231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d142b198-72bc-4187-ad4f-12217514756b" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_80eed304-035e-48b3-8264-819a00fe6005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1575dad-a114-4f4d-83aa-18b444e26c04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5206ecd4-2ee9-4346-96fa-3802ef5e5f61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5206ecd4-2ee9-4346-96fa-3802ef5e5f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ca6bdbe-05de-498f-aa08-9aab078c2e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ca6bdbe-05de-498f-aa08-9aab078c2e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37f0bfa3-a5da-44b9-b8d5-fd96b37537a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37f0bfa3-a5da-44b9-b8d5-fd96b37537a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cb35a0c-93fc-4317-8115-d28529b7460a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cb35a0c-93fc-4317-8115-d28529b7460a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e20ac36f-55b2-45a8-87fa-680f20dc2284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3985f143-ca80-4000-b67d-9e1feca457a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e20ac36f-55b2-45a8-87fa-680f20dc2284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3c068f6-6ad6-42c9-8cc0-0958907299f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_453de62b-e776-43d6-abf6-a6decbb651a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_453de62b-e776-43d6-abf6-a6decbb651a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48c37918-756b-4f56-98b3-f7c060427a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48c37918-756b-4f56-98b3-f7c060427a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_25b56cc4-0ebb-4a64-b7ec-1e21db26f5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_25b56cc4-0ebb-4a64-b7ec-1e21db26f5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_be0e6e83-432b-46c3-811b-e84f18fa283f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_be0e6e83-432b-46c3-811b-e84f18fa283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8635733e-8967-46a2-b03d-f5741b1fdef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44790f72-c5bb-4612-b7bc-fcbe98482882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8635733e-8967-46a2-b03d-f5741b1fdef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18e704f1-7fce-452d-925f-c5a149d67d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18e704f1-7fce-452d-925f-c5a149d67d1b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:to="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698edc3d-45ed-48f0-8cfe-9fd87c919fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8b967afe-ceb4-48ae-b3c6-55813f40adae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698edc3d-45ed-48f0-8cfe-9fd87c919fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1aa42c85-5a3f-4237-bf16-38f58d9e086a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698edc3d-45ed-48f0-8cfe-9fd87c919fdc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1aa42c85-5a3f-4237-bf16-38f58d9e086a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:to="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b60debd-6145-44b3-b813-858b980857ae" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6da55b46-cc8d-4e98-96bc-12bb6a81e823" xlink:to="loc_srt_RangeMember_7b60debd-6145-44b3-b813-858b980857ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_ea8bd210-fda8-4e52-aee7-15afc2dc1770" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b60debd-6145-44b3-b813-858b980857ae" xlink:to="loc_srt_WeightedAverageMember_ea8bd210-fda8-4e52-aee7-15afc2dc1770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8be826c4-103c-42fa-8622-504628131de5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0c02dca0-dce9-4c09-b280-99cd323278d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0c02dca0-dce9-4c09-b280-99cd323278d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3d3fc734-9251-43d4-99c2-25b813188ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3d3fc734-9251-43d4-99c2-25b813188ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_666ae08e-77e3-4a55-bcc0-e8b57d8171cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_666ae08e-77e3-4a55-bcc0-e8b57d8171cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d7f791ce-4758-4a30-9941-06a9c6735269" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d7f791ce-4758-4a30-9941-06a9c6735269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_95d261b4-60eb-42ab-8602-e9e9456098ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e971057d-7beb-4a0b-9d8f-af9c3208dffe" xlink:to="loc_us-gaap_SharePrice_95d261b4-60eb-42ab-8602-e9e9456098ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ba76f6-f969-4363-8d22-1ed87ca07552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ba76f6-f969-4363-8d22-1ed87ca07552" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:to="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3914c395-8285-4ce2-b3cd-3078c8d723da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c800485c-2b5c-4e87-b700-39016052e48b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c800485c-2b5c-4e87-b700-39016052e48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cf18723c-b7b6-4e29-84e3-27921f9aec6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cf18723c-b7b6-4e29-84e3-27921f9aec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PerformanceStockUnitMember_610bebee-3e31-4307-b946-51f400b0fa22" xlink:href="mrna-20251231.xsd#mrna_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_mrna_PerformanceStockUnitMember_610bebee-3e31-4307-b946-51f400b0fa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7a5628b6-6d75-456f-bbde-7c85dfba6c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4a3c679-2f27-4ff6-aaf2-c04c9921e194" xlink:to="loc_us-gaap_EmployeeStockMember_7a5628b6-6d75-456f-bbde-7c85dfba6c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf2090d6-80e7-4466-9e0a-6878bd2a2301" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6eb12546-a678-461c-84cd-1b449df2e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:to="loc_us-gaap_CostOfSalesMember_6eb12546-a678-461c-84cd-1b449df2e39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b7d29810-9175-46d5-9262-d3eadb29403c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b7d29810-9175-46d5-9262-d3eadb29403c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e5723481-01cc-4e78-b11f-1ee52d16cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb5f635a-6efb-48ab-966c-bd9b2830acaf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e5723481-01cc-4e78-b11f-1ee52d16cc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ab82cc-925e-49d8-a59a-b70e6b46edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_599b49a7-574e-4b18-a827-7cf87d6dcfc1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ab82cc-925e-49d8-a59a-b70e6b46edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3fffa-4738-49b5-a83a-c287a67af8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45ab82cc-925e-49d8-a59a-b70e6b46edb2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bd3fffa-4738-49b5-a83a-c287a67af8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06454cfb-d978-43ca-b914-1e1bc8035e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8f993aad-da20-4e3c-af80-f5239152f033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06454cfb-d978-43ca-b914-1e1bc8035e5b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8f993aad-da20-4e3c-af80-f5239152f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f3647447-e1fb-4f70-83fb-dd6100abf376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06454cfb-d978-43ca-b914-1e1bc8035e5b" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f3647447-e1fb-4f70-83fb-dd6100abf376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_7249dd32-2629-4263-b1ac-cbab0017c513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06454cfb-d978-43ca-b914-1e1bc8035e5b" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_7249dd32-2629-4263-b1ac-cbab0017c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_806354d0-3852-4795-82cc-239fd48eb170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06454cfb-d978-43ca-b914-1e1bc8035e5b" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_806354d0-3852-4795-82cc-239fd48eb170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2f20446c-a6e7-4fc3-b54f-532a993cf250" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bc9cbced-7970-4699-98b7-a36cc515fef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2f20446c-a6e7-4fc3-b54f-532a993cf250" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bc9cbced-7970-4699-98b7-a36cc515fef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09750228-c077-4dc3-ab10-df662b54df03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2f20446c-a6e7-4fc3-b54f-532a993cf250" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09750228-c077-4dc3-ab10-df662b54df03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83d3abe8-d1a7-454b-9273-cd5e04422f56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2f20446c-a6e7-4fc3-b54f-532a993cf250" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83d3abe8-d1a7-454b-9273-cd5e04422f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed1c2882-fc7e-414c-acf4-7daa316cdacb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_af8bed05-21f1-4fba-bcda-1b5321ee5bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed1c2882-fc7e-414c-acf4-7daa316cdacb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_af8bed05-21f1-4fba-bcda-1b5321ee5bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e2abd8ba-f70a-4855-b69b-18775a1c554c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_af8bed05-21f1-4fba-bcda-1b5321ee5bc0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e2abd8ba-f70a-4855-b69b-18775a1c554c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fd2f4cd0-b5eb-4e7d-8c7a-39eb863ed0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_af8bed05-21f1-4fba-bcda-1b5321ee5bc0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fd2f4cd0-b5eb-4e7d-8c7a-39eb863ed0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a7d67171-7076-445f-9a1a-d75bbf45abc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_af8bed05-21f1-4fba-bcda-1b5321ee5bc0" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a7d67171-7076-445f-9a1a-d75bbf45abc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c50b860-5f79-498f-acbc-8817db91edda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_af8bed05-21f1-4fba-bcda-1b5321ee5bc0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c50b860-5f79-498f-acbc-8817db91edda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_bba00696-ee4c-4ea5-995d-3856290c562a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed1c2882-fc7e-414c-acf4-7daa316cdacb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_bba00696-ee4c-4ea5-995d-3856290c562a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_36af12ed-0154-4cc6-be37-062fcc6ef7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_bba00696-ee4c-4ea5-995d-3856290c562a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_36af12ed-0154-4cc6-be37-062fcc6ef7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_66a113df-4028-446d-95c1-8041a039f1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_bba00696-ee4c-4ea5-995d-3856290c562a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_66a113df-4028-446d-95c1-8041a039f1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2b73af72-7331-4cb7-859a-9c5a03831b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_bba00696-ee4c-4ea5-995d-3856290c562a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2b73af72-7331-4cb7-859a-9c5a03831b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_991d8680-3582-4665-8b66-f83222aae461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_bba00696-ee4c-4ea5-995d-3856290c562a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_991d8680-3582-4665-8b66-f83222aae461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2f7a5bfd-d57c-48a4-bada-066b094d6311" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed1c2882-fc7e-414c-acf4-7daa316cdacb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2f7a5bfd-d57c-48a4-bada-066b094d6311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c1dd0-2715-7196-970e-76a5c24d1a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c1dd0-2715-7196-970e-76a5c24d1a40" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-789e-b99d-f51e15fb1c03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-789e-b99d-f51e15fb1c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-7476-a8e1-ca88d037a9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-7476-a8e1-ca88d037a9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-77a0-8b7f-e611aca039f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-77a0-8b7f-e611aca039f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_019c434b-fdfc-751f-9a43-ffa8d3da78d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_019c434b-fdfc-751f-9a43-ffa8d3da78d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1ddc-e782-7785-96b5-7850421b7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1ddc-e782-7785-96b5-7850421b7fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c1ddc-e782-798c-8b78-f216913648b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019c1ddc-e782-798c-8b78-f216913648b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1ddc-e782-74c6-8066-7bc7701afc49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1ddc-e782-74c6-8066-7bc7701afc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c1ddc-e782-76d8-8710-c10422023d91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c1ddc-e782-76d8-8710-c10422023d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c1ddc-e782-7ac8-b0a6-44eaeee13d83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c1ddc-e782-7ac8-b0a6-44eaeee13d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-777c-b799-83b4cfffdaab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c1dd0-2715-7706-b1e2-88d52b203be6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c1dd0-2715-777c-b799-83b4cfffdaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c1dd0-2715-7196-970e-76a5c24d1a40" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-731b-ad4b-7cc701ddc3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c1dd0-2715-731b-ad4b-7cc701ddc3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-7c75-8780-ad1e88385b87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c1dd0-2715-7c75-8780-ad1e88385b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-7b58-ae8e-9e39b249f185" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c1dd0-2715-7b58-ae8e-9e39b249f185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_019c4350-3f41-79a2-8638-33d075c64fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_019c4350-3f41-79a2-8638-33d075c64fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1de0-a502-72bc-8abc-4d33257c7f00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c1de0-a502-72bc-8abc-4d33257c7f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c1de0-a502-7c2d-af80-513ab8d6aa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c1de0-a502-7c2d-af80-513ab8d6aa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1de0-a502-7b9b-8579-0e4e75d0583e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c1de0-a502-7b9b-8579-0e4e75d0583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c1de0-a502-7cc3-8302-e41a757c1bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c1de0-a502-7cc3-8302-e41a757c1bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c1de0-a502-7be9-b9d8-9ac1414dd121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c1de0-a502-7be9-b9d8-9ac1414dd121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-7afe-9122-8b7ccc6aa846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c1dd0-2715-7461-bce9-43e5484d2ee6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c1dd0-2715-7afe-9122-8b7ccc6aa846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_05fc4eaf-880a-4d54-a982-3ac50d8a8112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_05fc4eaf-880a-4d54-a982-3ac50d8a8112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_148c4b2d-7d71-442b-849b-55c6a8b2bd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_148c4b2d-7d71-442b-849b-55c6a8b2bd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_b100733e-2e50-4741-91d0-29bcbb0f087f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_b100733e-2e50-4741-91d0-29bcbb0f087f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_da9dc20d-5c18-49c9-9e34-09df1872dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_da9dc20d-5c18-49c9-9e34-09df1872dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_86a5a166-b47e-42d7-a450-b42508327bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_86a5a166-b47e-42d7-a450-b42508327bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0702522b-f128-4d05-8e86-0da71c0ab199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0702522b-f128-4d05-8e86-0da71c0ab199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2a7ead40-f835-437e-a173-860f8b1db187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2a7ead40-f835-437e-a173-860f8b1db187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c1783d7e-15a5-407f-b1d8-379fd691dd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c1783d7e-15a5-407f-b1d8-379fd691dd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bc73c80a-7596-45cc-b5e3-c54e35c24354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef450fec-7605-4262-abfd-9a82bf30ad1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bc73c80a-7596-45cc-b5e3-c54e35c24354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_84cbdeaf-4b16-4289-a2a3-31a843ee1479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84cbdeaf-4b16-4289-a2a3-31a843ee1479" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_355801e8-94f6-4bb7-a968-708095f42027" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_20dc19a8-5c6b-48c4-91fb-2fe6e4fbe8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:to="loc_us-gaap_DomesticCountryMember_20dc19a8-5c6b-48c4-91fb-2fe6e4fbe8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_777e4421-0fb5-4100-9497-31e8891e281b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_777e4421-0fb5-4100-9497-31e8891e281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019c6f52-789c-77ae-bfba-86868d9fd033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fee291a-9257-45ed-8aba-64f9c84b1723" xlink:to="loc_us-gaap_ForeignCountryMember_019c6f52-789c-77ae-bfba-86868d9fd033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_857da0b9-9fa0-42b3-a279-b1da0d451562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_292c58f6-c0d8-4ed7-8f4b-55857d221945" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_857da0b9-9fa0-42b3-a279-b1da0d451562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_9267fa42-6721-48d4-8e45-77adfa6b0c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_857da0b9-9fa0-42b3-a279-b1da0d451562" xlink:to="loc_us-gaap_ResearchMember_9267fa42-6721-48d4-8e45-77adfa6b0c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_7d83c35d-f02f-4efe-ae36-ccda2a6e9952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_fb48156f-e324-4763-a883-76e7591c7082" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_7d83c35d-f02f-4efe-ae36-ccda2a6e9952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_7806cccc-ffd0-420e-8d36-4940818504b8" xlink:href="mrna-20251231.xsd#mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_7d83c35d-f02f-4efe-ae36-ccda2a6e9952" xlink:to="loc_mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember_7806cccc-ffd0-420e-8d36-4940818504b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1a4e4a75-eee6-4689-9c96-c3145aa552f8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34d2a00a-fd17-48de-b41c-74de8b7bb88a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34d2a00a-fd17-48de-b41c-74de8b7bb88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3dfa40e2-b554-4060-89cd-4a24893982bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3dfa40e2-b554-4060-89cd-4a24893982bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d1ca0e53-df6a-435d-b81e-1da73bec78ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d1ca0e53-df6a-435d-b81e-1da73bec78ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_6e4e1ab4-40c6-426b-997a-a8ebbe14161d" xlink:href="mrna-20251231.xsd#mrna_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_mrna_OperatingLossCarryforwardsNotSubjectToExpiration_6e4e1ab4-40c6-426b-997a-a8ebbe14161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLossCarryforwardsSubjectToExpiration_5cb283e5-6261-4570-b147-ef94a5ff006c" xlink:href="mrna-20251231.xsd#mrna_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_mrna_OperatingLossCarryforwardsSubjectToExpiration_5cb283e5-6261-4570-b147-ef94a5ff006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_21d0d0dd-06c7-4ce9-b10c-1919b269e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_21d0d0dd-06c7-4ce9-b10c-1919b269e93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_577605b7-37ba-475d-ba9c-29da4b98b1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9af2335c-1270-48cb-8b98-47968e1219ac" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_577605b7-37ba-475d-ba9c-29da4b98b1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13366c53-9b6c-4e14-87e3-7875aa82b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13366c53-9b6c-4e14-87e3-7875aa82b5ac" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4ee1831b-683f-46d2-998e-1f79fc0f5894" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4ee1831b-683f-46d2-998e-1f79fc0f5894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_86b6a9a6-10a6-4d6c-aff0-a00a5a41d194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_86b6a9a6-10a6-4d6c-aff0-a00a5a41d194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_62e5877e-d711-4013-a113-628138921fc8" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_62e5877e-d711-4013-a113-628138921fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_26936a1d-d2ab-4920-b771-9ef15c8b09cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_26936a1d-d2ab-4920-b771-9ef15c8b09cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_d869454f-4002-47d4-a262-92682e519eb7" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_d869454f-4002-47d4-a262-92682e519eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss_129f3617-c7ad-40b1-a72f-2d5cc5a2b157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOtherComprehensiveLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss_129f3617-c7ad-40b1-a72f-2d5cc5a2b157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f98b7d52-149e-433e-abb9-175ffd80ee14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f98b7d52-149e-433e-abb9-175ffd80ee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_4d9034cf-1e7b-421d-978e-384109c09603" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees_4d9034cf-1e7b-421d-978e-384109c09603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_d3a4d76c-57bc-4117-8ac3-c1dd3418ddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_d3a4d76c-57bc-4117-8ac3-c1dd3418ddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOutsideBasisDifference_5eb2be02-8d3d-42d4-a906-d08d82895187" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxAssetsOutsideBasisDifference"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_mrna_DeferredTaxAssetsOutsideBasisDifference_5eb2be02-8d3d-42d4-a906-d08d82895187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d6bfd22c-3581-44aa-bc5a-c07631bb30ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d6bfd22c-3581-44aa-bc5a-c07631bb30ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9df90483-38cd-42f3-9fbb-c3c92566e91d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9df90483-38cd-42f3-9fbb-c3c92566e91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61713a85-4058-4802-b58c-b2758a20bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61713a85-4058-4802-b58c-b2758a20bff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cb7958a0-1cad-42fa-b758-ec21e811e7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_73c12ce7-e1c4-4ec9-8b46-48e575e97a36" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_cb7958a0-1cad-42fa-b758-ec21e811e7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bbc43fca-8cf2-45bb-920e-1ea3d319f01e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13366c53-9b6c-4e14-87e3-7875aa82b5ac" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bbc43fca-8cf2-45bb-920e-1ea3d319f01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_0ec4b6b6-ad2a-4c35-b5cb-abdd31a39b30" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bbc43fca-8cf2-45bb-920e-1ea3d319f01e" xlink:to="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_0ec4b6b6-ad2a-4c35-b5cb-abdd31a39b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_eaa01082-21ab-4716-b5f2-7e042a732ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bbc43fca-8cf2-45bb-920e-1ea3d319f01e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_eaa01082-21ab-4716-b5f2-7e042a732ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_119af3fa-5bbb-4094-bee2-8087e4770cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bbc43fca-8cf2-45bb-920e-1ea3d319f01e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_119af3fa-5bbb-4094-bee2-8087e4770cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1a47bb78-fd92-43c9-895a-e157dae628c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bbc43fca-8cf2-45bb-920e-1ea3d319f01e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1a47bb78-fd92-43c9-895a-e157dae628c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_51221c40-a4ea-42f0-9df9-77ea055a6566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13366c53-9b6c-4e14-87e3-7875aa82b5ac" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_51221c40-a4ea-42f0-9df9-77ea055a6566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85677e29-a964-4e48-a673-4e59a32bbd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxValuationAllowanceRollForward_a82a8b96-3041-49ae-882c-aaa8146b255a" xlink:href="mrna-20251231.xsd#mrna_DeferredTaxValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85677e29-a964-4e48-a673-4e59a32bbd4c" xlink:to="loc_mrna_DeferredTaxValuationAllowanceRollForward_a82a8b96-3041-49ae-882c-aaa8146b255a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_398e58e8-da80-493e-b50d-579cdbdbd8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_a82a8b96-3041-49ae-882c-aaa8146b255a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_398e58e8-da80-493e-b50d-579cdbdbd8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_88456144-a829-4029-a1d5-408f6dc58f89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_a82a8b96-3041-49ae-882c-aaa8146b255a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_88456144-a829-4029-a1d5-408f6dc58f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d7a9c639-65d6-47af-84a8-bba3adf70557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_a82a8b96-3041-49ae-882c-aaa8146b255a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d7a9c639-65d6-47af-84a8-bba3adf70557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_47641d7e-eec9-4950-a74e-ac218f05c419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47641d7e-eec9-4950-a74e-ac218f05c419" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2ce78eb3-2dcc-4b19-8a10-babd41ff7bde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2ce78eb3-2dcc-4b19-8a10-babd41ff7bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9575cff5-b171-4ae3-918b-64adfcc31b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9575cff5-b171-4ae3-918b-64adfcc31b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_d6f8f35d-cd9d-41bc-bfa9-1843aae25ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_d6f8f35d-cd9d-41bc-bfa9-1843aae25ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b07768fc-e119-4a93-9cf8-6b3f80a4355b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b07768fc-e119-4a93-9cf8-6b3f80a4355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ea1bf27c-d40e-4517-883e-f15134281f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ea1bf27c-d40e-4517-883e-f15134281f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8a088f94-23d0-471c-a423-31ed8416d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2d379c44-6dbc-4bfd-9279-5c62ef4bea78" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8a088f94-23d0-471c-a423-31ed8416d6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cc835a3d-bf92-4c0d-9a58-d26c63749bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_eafe9f3e-37e0-4eb2-ae93-030f26a56f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc835a3d-bf92-4c0d-9a58-d26c63749bb8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_eafe9f3e-37e0-4eb2-ae93-030f26a56f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd692d63-8d4d-42ec-aace-27332bab0c39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_eafe9f3e-37e0-4eb2-ae93-030f26a56f3a" xlink:to="loc_us-gaap_NetIncomeLoss_fd692d63-8d4d-42ec-aace-27332bab0c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_197d2e73-5af6-4a6b-b057-e9f6fdc0a654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc835a3d-bf92-4c0d-9a58-d26c63749bb8" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_197d2e73-5af6-4a6b-b057-e9f6fdc0a654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c19ea42-a494-42bb-8735-c7c693512eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_197d2e73-5af6-4a6b-b057-e9f6fdc0a654" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c19ea42-a494-42bb-8735-c7c693512eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6e42c8d-0b3f-42c6-8279-a1366ad335bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_197d2e73-5af6-4a6b-b057-e9f6fdc0a654" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6e42c8d-0b3f-42c6-8279-a1366ad335bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4986a43-782a-4f57-83c8-5fffa94f14b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_197d2e73-5af6-4a6b-b057-e9f6fdc0a654" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4986a43-782a-4f57-83c8-5fffa94f14b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b550b521-abea-4cb7-86c2-def26d4fbec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_197d2e73-5af6-4a6b-b057-e9f6fdc0a654" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b550b521-abea-4cb7-86c2-def26d4fbec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_66de1d58-6e7f-42e0-b778-6f2b9eeef247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_66de1d58-6e7f-42e0-b778-6f2b9eeef247" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a9dcc7a8-82d2-4ffb-9c06-c8af1bfb55f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_edfcdb45-e68e-44ec-a367-77889de07fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_edfcdb45-e68e-44ec-a367-77889de07fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_687a62c9-e64a-47fb-89d3-73a6673e7ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837b3dab-e5df-4eff-9f29-e0bd45f4ba7f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_687a62c9-e64a-47fb-89d3-73a6673e7ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7f9a830a-7c94-4f86-a796-982eb0c330cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc863c19-d560-46a2-8745-8c19936d34d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7f9a830a-7c94-4f86-a796-982eb0c330cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0a8bdbf-2a8f-4bdf-aed9-d0d6d9d34c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7f9a830a-7c94-4f86-a796-982eb0c330cb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0a8bdbf-2a8f-4bdf-aed9-d0d6d9d34c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="simple" xlink:href="mrna-20251231.xsd#GeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3dcb5d3c-88c8-4740-9301-153b037ea00b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4fba7098-ef95-41a4-bdbc-651ce7daa338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3dcb5d3c-88c8-4740-9301-153b037ea00b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4fba7098-ef95-41a4-bdbc-651ce7daa338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3dcb5d3c-88c8-4740-9301-153b037ea00b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:to="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2df7ab5a-97cc-4876-bf35-c0ad68186fee" xlink:to="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_06167185-5d4f-452c-a1f5-3c13c032d8ff" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:to="loc_country_US_06167185-5d4f-452c-a1f5-3c13c032d8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8b820076-2862-4ff4-ab88-994071692afd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:to="loc_srt_EuropeMember_8b820076-2862-4ff4-ab88-994071692afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember_dc51962c-8caa-4bc1-acd1-f2ad01267ed7" xlink:href="mrna-20251231.xsd#mrna_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8da20abe-0e2c-4a27-9409-9bf159f59ab8" xlink:to="loc_mrna_RestOfWorldMember_dc51962c-8caa-4bc1-acd1-f2ad01267ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_93e1d7f3-00e6-4923-8ebb-7a9fea9a82d0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8aeb815-9da8-4f3a-9aba-62b4ad8606dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8aeb815-9da8-4f3a-9aba-62b4ad8606dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b1cfb824-179b-4d8f-89d7-480060a6ad33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18e1b6a2-08e7-4843-8daf-63612086c7a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b1cfb824-179b-4d8f-89d7-480060a6ad33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TerminationOfTradingArrangementMember" xlink:href="mrna-20251231.xsd#mrna_TerminationOfTradingArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_TerminationOfTradingArrangementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementMember" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_AdoptionOfTradingArrangementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementOptions1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_AdoptionOfTradingArrangementOptions1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:href="mrna-20251231.xsd#mrna_AdoptionOfTradingArrangementOptions2Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_mrna_AdoptionOfTradingArrangementOptions2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StephaneBancelMember" xlink:href="mrna-20251231.xsd#mrna_StephaneBancelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mrna_StephaneBancelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StephenHogeMember" xlink:href="mrna-20251231.xsd#mrna_StephenHogeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mrna_StephenHogeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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MBK (&J2C,.DGZJZYUW/U?9JON:_QF=?$8V)S*HZA$ERUL>JX"SU[E[K'6Z&
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M,A $@CK>^-B55P(H5:Z$.+3D+BBN.V!JPY0+?9?<[K[Q(61!]<?-=!Q\C+L
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M(F2<XX_!<=VZIG_].)XSOP-8D#,OD#/7GS-'<?>N^>/NG+G=8P E'[37!"+
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrna-20251231_g1.jpg
<TEXT>
begin 644 mrna-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2764&AO=&]S:&]P(#,N,  X0DE-! 0
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              #E   #XP
M       !                          $              ^,   #E
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #E
M %)G:'1L;VYG   #XP    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    Y0    !29VAT;&]N9P   ^,
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!$       $! #A"24T$%       !     4X
M0DE-! P     &ND    !    H    "4   '@  !%8   &LT &  !_]C_X@Q8
M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "4
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M:M7+^J7U=RL8X[L&FH$0VRE@KL!_>%C!N_STN*<K,0*'?])1PX,?#'-.?N2
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M3X:@8G6.E9MGIXF91?9^Y78USM/Y#3N7'XN=T/K?4\CJ77\NH8]-AJZ=@6O
M:UC?^U%E7YSKOY?_ %'H^G=ZC5]0<VG;3DXF%D-UHR<<MJ<QX^@_]%LW[?Y:
M7NDZ@QKM(^HI/(Q@1#(,W'0XI8\?'BQF7Z/^LX?TWK;+*ZJW66N#*V N>]Q
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M)')$C#D$(@0UGA]@<&$QXOGX8?/^^OU'J6#TS&=DYMK::FCN=2?W:V_2>_\
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M_1;;)GTY+]FV=GTG?NJRC&)'%?4VMSY1D]NK]&..,W^]'B>:^J5;;:^N5/\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !#Z    $!  ,    ! X8   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HS," P-SHT,#HU,0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   /CH , !     $
M  #E          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "      !    _^$!@$U- "H    (
M  P!   #     0^@   ! 0 #     0.&   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,S @,#<Z-# Z-3$
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   #XZ #  0    !
M    Y0         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M5R"-+M9\=/8&ZG0B%;+DQ@Q%0$PLSS&LJ,%TB8"]T46;EY8P3 !ZAZJ^"@%
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M'^LGB)HXQS\^(P/LU0B_XY?$?=O&Y%O#'XV+O[EQ]#;. ]A1>>?+ NT;MMT
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M?7)"O0,>F8X&.DDTBR*)%$"G76, J&GM;9."@0++#/;DX]Z6:S.A)X]2$K/
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M>53ZCT9H OQ'Q^(U:G$Q4=!149"0[)O'1$-'LXJ+CVB946K".CVR;1BR;(D
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M2N/9<32^BL7DY.9+5;'>:LD<41J5I8BSB4KI_']\,;0O\DVY'^3F,/\ :O\
MV]WOU/\ [_\ &?\ @.1_XM3_ *5]FL\_\S@ZS?[K^F/]D]U?]D-']\,;0O\
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M/+D)8Y["6-+I#SZF/+YP'2ZS;?1F[WM2J?*6]C[Y('), 6NTC ?$]K13(/\
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M ?X[B9EUU!_*910QA_?$=2#:@XV_COZ6P?Z]N<ZK3XJG9_$/U89CR1NB5/\
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M(J+9HT:H$30;-FZ)")(((D(DDD0J:92E* !-55454151% 554!550. JJ.
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M$B:(?PW8>*S]>L3<[,&TBLIT(-D%N^5,W?Z ,F?B9O!5\Y%7BL33PBO*TJ&
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M?<6'WE'CA]__ !0Y'_YWEKK+A]B'XYFP/_S,?_0M<%MP=41^+MVI_P CF/\
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M?%.LD*M7,=2#+8B0^?(9.^QYTR1>2L9B[IT=<)&W#<5H/=MVIX_B_4),^?\
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9-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrna-20251231_g2.jpg
<TEXT>
begin 644 mrna-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]A_VE)*D=BI%=M5S@X2<);K0QA-2BI1V84445)04444 %%%% !1110 4444
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MXEO+%+ ;?=YR20NHD1UVYVLH)!4C(()_([_@DOX&UO\ :!_9*_;2_:O\22>
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MK7M=&4I-4/:=;O[HOWOG9Z=W<_I^HH!W#(HKF+"BBB@ HHHH **** "BBB@
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MP\-_$C2)O"'PS2W?Q'KEU'+::?IYGB\U$\Z555W ^5E0L5<A2-Q KFOV1_\
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M;X[-\/'^-F@#6EN/LAN_LUR=)$V[;L^W>7]G^]QNW[??%?&/PZ_9,UWXS?\
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MBJE)RUEO9?.RM=^;Z^9,8J.D>[?WN_W=@HHHJ2@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG'X#?
M\$[=-^!7_!03XT?'ZW\4:AJ.H?&2RTVRN='DM$C@TP642Q*R2!BS[MN2"!C/
M>OHZBB.DN=;ZK[]PEK%P>SM^#NOQ1\<_L^_\$@='^ /[%GQT^#-OXXU;4K/X
MX:EKNHW6J2:?%'-I+:I!Y+K'&&*OY?4%B,GKBL.'_@B3H</P@_90\(K\0-9\
MG]E77(M;T^Y_LV+=X@:-PPCE7=B('&,J6/-?<5%5&3BTUTY?_)/A^[_AR7"+
MO?KSW_[?^/[_ ,.ECXY\$_\ !(#1_A;\7OVDM:\+^.-6T7PG^TMI=Q#K'A9-
M/B:TTG4IX&BDU&W?<#O;S)F9"N&,G)PJXUO!'_!(WP'IO_!*JS_90\4W]UXP
M\(VFCRZ6-4GMD@NED::2>*ZC4%E26*1U92">4&<@D5]845C[*+CRVTLE\E>R
M^5W;_@*VG.^?GZW;^;M?[[*__!9^>:_\&_'A^[_X)Z_"/]FO4/B9KU]X ^&_
MBL^)M60Z5"K^+4^US7*V<XWD1Q S,"5W$X4]17HW[67_  0G_9K_ &F?V>?$
MW@?3?A3\.?AWJ6N6RQVGB3P[X4L;74M(E5U=)8G1%;JN"NX!E+ ]:^QJ*VJ2
M=1R<]Y.[];)?DD3'W6G'I_FW^;9ROP.\ :A\*/@UX5\+ZMK]QXJU+P[I5MIM
MQK-Q L$VIO#&L9G=%)"L^W) .,DUU5%%$Y.4G*6[)C%12BMD%%%%24%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445']JC\S;YD>[.-NX9H DHKE?C-\7M+^!G
MP_O/$FLQWDNGV3(LBVL8DE)=@HP"0.I]:Q?V>OVFO#W[2^EZI=^'X-5ACTF9
M()A?0+$Q9EW#;M9LC'TKLC@,1+#O%Q@_9IV<NB>FGXHX99EA8XE8.4U[22NH
M]6M=?P9Z)14,U_!;OMDFAC;T9P#4P.:XSOLT%%%% @HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"<"@#D
M/C7\<?#_ , ?!DFM^(;IH8-WE00QKNFNY,9"1KW/&>P Y)%?)'B'_@I=\0O'
MVI21^"/!\,5O&3UMIM0GQV+;,*/I@_6N?\;SWW[??[9W]BV]W<1^%]*D>&-D
M^[;VD1Q+*HZ!Y7X!/JOI7W=X%\!:/\,_#%KH^A:?;Z;IUHNV.&)<#W)/5F/4
MDY)K[J>'R_):-/ZW2]M7FN9Q;M&">R?=^OX=?SJGBLSS_$5'@JWL,-!N*DDG
M*;6[3Z+M;\=;?'?A#_@J!XJ\&ZW'8^/O!ZK'D"1K>*2SNHQZ^7+D-],K]:^L
MOA'\:?#?QQ\,C5O#6I17]NI"RI]V:V?&=LB'E3]>#VS5KXD_"OP_\7?#DND^
M(M+M=4LY!P)5^:(_WD8?,K#U!%?G_P#'O2M6_P""5?Q.M?&=KJV[PC>RF.-I
M#_Q^)G<;.51]Z3;DJP';/&"*S<<GS2E-TDL-5BF]9>Y)+5ZNW+IZ?/IUT8<0
M9;BJ=%\V,I5)**48MU4Y.RM&-W*[?FV]-.OZ05FZWXRT?PU(JZEJNFZ>TA"J
M+FY2(L3T W$5^17Q@_X*J_'W_@H9\0)O!/P#\/:SX;TF3 +Z> VIM'P/,N+K
M_5VJ9_ND''&X]*N^&_\ @W=^)WQ'M6U;QY\3M'M=<N_GD3RY]6E4GGYYG9<G
M/H"/0FORQYQ.JVL'2<TNM[+Y7W/Z:AX787+Z<9\4YC#"3DKJFDZE2S_F47[O
MXKSN?KM:7D-_;K-!+'-#(,J\;!E8>Q'%25^)7C/X5_M&?\$0?&VF^(M/UQ?$
M'@.ZN%@D:&2631[UCD^1/;L<V\A .UU[]&/(K]8_V./VM/#?[:7P*TOQOX;+
M0QW68+ZQE8--IETF/,@?'<9!!Z,K*>^*ZL#F2K3=&I%PFNC[=T^I\_Q9P'/*
M<-3S3 UXXG"5'95(JUI?RRC=N+^?K9Z'J5%%%>F?GX4444 %%%% !1110 44
M44 %%%% !1110 4444 %%0ZAJ$.EV<EQ<2+%#$-SNW0"LFS^).B7K!5U"%6/
M9P4_F*TC2G)7BF_D9SK4X/EE))^;-RBFPSI<1AXW613T93D&G5F:!1110 45
MF^(/%VG^&(MUY<*K$96-?F=OH*X_4/CB[RE;+3\CL97Y/X#_ !KIHX.M5U@M
M#CQ&/H47:I+7L>A45YB/C7JD#9EL[/;Z89?US6SH?QJL;QE2^ADLV/&\'>GX
M]Q^5:U,MQ$5>WW&-+-\+-V4K>IVM%1VUU'>P++#(LD;C*LIR#4E<)Z5[ZH**
M** "BJ&K>*-/T+_C[O(86_NELM^0YK%F^,6APMCSKA_=86-;0P]6:O&+?R.>
MIBJ--VG)+YG4T5S-G\7-#O&P;B2'G'[R)E_I6YINMV>L1[K6YAN!_L.#C\*5
M2A4A\<6OD53Q-*I\$D_F6J***R-@HHJ&_P!0ATNU::XECAB3JSG %"3;LA-I
M*[)J*X?6OC;9VK,MC;R71'\;GRU_Q_E60_QLU1GRMG9JOIAC^N:[H9;B)*]K
M>IYU3-L+%VYK^B/3Z*\]TSXYYD"WEB O=H7R1^!_QKLM \46/B:W\RSF63;]
MY#PR?45C6PE6EK-:&^'QU"MI3EKVZFA1117.=8445#>ZA!IL/F7$T<,?]YV"
MBA)O1 VDKLFHKG9_BMH<,ZQ_;-V3@LL;%1]3BNA1Q(BLIW*PR".XK2=*<-9I
MHRIUJ=2ZA).W9BT445F:A1110 445DR>*X;;Q:-*FQ&\L(EB8G[YR05^O'%5
M&$I?"1.I&-N;KH:U%%%26%%%% !1110 4444 %%%% !1110 4444 %?*]J[?
M\-?D;FQ_;K<9X[U]45\SQ>%+JW_:ECOY7M(8[C67FAC><+--&'*%U3N-V1Z\
M'CB@#IO^"C7_ ":;X@_Z[6W_ *.2O-?^"2'_ ")/C;_L)0?^B:]._P""AEE+
MJ7[+>L6L$;23W5U9PQ(!R[M<(JC\217%?\$S_ 6J?#"#XA:%K,,=OJ5AJ=L)
M5202(0UN&4JPX8$$<BOO,'4C_JK6IWUY[VZV3A=_BC\YQM*;XQH5+/E5.U^E
MVJEEZZ/[CQ;_ (*(RNO[4E_MDD4?8K3@,1_#7Z!:'_R!;/\ ZX)_Z"*^&?V]
MOAUJ&O?M$:AJ0FTVQL6@MK:&6^NUMUNI5BWLD>[@D*1G. "RC.37W-H?_(%L
M_P#K@G_H(K\CRF+6,Q#??]6?T7Q?5A+)\MC%W:@[_= M4445] ?G04444 %%
M%% !1110 4444 %%%% !1110 4444 (7 8+D9;H/6EKC_B]JDVBVFF75N_ES
M0W65/K\IR#[&MWPGXHA\6:0ES#\K?=ECSS&WI_A6\L/)4E5Z,YHXJ#K2H/=?
MB:=%%%8'2%%%% !1110 4444 %%%>=_%;]K;X8? VY:W\7>/O"?A^Z3[UM>:
ME$EP.,_ZO._]*F=2,%>;LO,Z,+@Z^)G[+#P<Y=HIM_<M3T2N%_:9\;R_#CX
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MQF_X+M_M'3:QJDS^'? 6ARM'YX5GT[08CSY$"G'GW3#&YOQ.U=JUY/\ '_\
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M\'KB;P];VVJ>(+.[M[BSM&7SB9%E4AM@()V?>],J,^E<+^PAXI\06?A_6_\
MA.[>+2]3WVUM!--&L,E[%&C8=]IVEANVY '  QQ7JVF_ VW4!KR]FD;^(1*%
M'YG)JU/\$M+>/$<UY&WJ7#?IBO:IX_"0P,L!OS._-;5;:+RT_K0^?J9;C:F8
M0S%:<JMR7T>^K\]?P]3Y1_;,^.FJ?#_]I61;&/3;Z&UA@N[%[E&<6\DD6R0K
MM8!E8*A*/N4E%..*^UM$.=%L\\GR$_\ 017D?Q$_9NCUO3'BN+.SURU_YYR1
M 2I[K[_0YKK? GQ1CE,6FZD@M9H\1))C"G' # _=/Z?2OF:&3U*52K7IU.>,
MG>VS6_3[ONV/O,RXHP^+PN&PE2BZ52FG%N]XRVLT]+:W;7=[ML[FBBOR1_X.
M,OBWXL^'/QR^','AWQ5XD\/P7.@74DT>F:I/:)*PN  S"-@"0.,FL<5B%0IN
MHU<^BX#X/J<3YS3R>E45-S4GS-72Y8N6R:WL?K9+((HV9NB@DUXW\(_VZO!/
MQI^(D'AC1X];74K@2E#<6@CC_=@ELMN/IQQ3?V ]9O/$/[!_POOM0N[J_OKK
MPM:2SW-S*TTT[F$$LSL26)]2<U\@_P#!/C_D\;2O]R^_]%O7V'#N4X?'8#%8
MFM>]."E&SZM2>O?9'Y3QMC\5DV=X?*Z334JLJ<FUORRC&ZUTO=]S])J*^7/^
M"IGBC5/"WPV\*R:7J6H:9)+JKH[VER\#.ODN<$J1D9[&NQ_X)V:Y?>(OV8].
MNM0O;S4+IKVY4S7,S32$"0X&YB3Q7)4R.4,JCFG/I*7+:VO76_R*I\0PGG$\
MHY'>,>;FOITTM\SW*BFRS+!$TDC*J(,LQ. !7G?B/XDWWB?4?[/T%)-K''FJ
M/GD]2/[J^_\ *O*P^&G5?N[+=]$>QBL7"@KRW>R6[.\U#6[/21_I5U;V_P#O
MN%IVF:M;:S;^=:SQW$>=NY#D UPNE_!*2Z'G:E?-YK<E8_F/XL?\*[#POX5M
M?"5@UO:^85=M[,[;F8U=:G0A&T)<S]-#/#UL3.5ZD%&/KJ:5%%%<AW!1110!
MQ?QBUR\T2WT\V=S+;F1W#;#C=@#%<+_PG>M?]!.[_P"^J[#X[?\ 'KIO^_)_
M):\YKZ;+J4'AXMI=>GF?'9M6J1Q4E&32TZ^2+NI^([_6HECN[N:X1#N4.<X/
M3-6?!OBR;PAJZW"9:%\+-'_?7_$=JR:*[I4H./(UH>;&M44U43U74]^T_4(=
M5LH[BW<20S+N5AW%35PGP2AODL+AI#C3V/[H-U+]ROM_6N[KY+$T52J."=['
MW6#KNM151JUPHHHK Z0HHHH **** ,/XF6FKZA\./$%OX?F6WUZ;3;B/3I6Z
M17)B81,<^C[37\Z/P[\'^#_#_P <]4T?]H3_ (61HM]'=-'J4^G1Q27T-QD[
MWG68%W!/.Y"3CD!N*_I*KRO]IK]BGX9_M>Z#]B\=^%['5)HT*6^H1CR;^T]X
MYUPXQZ$E?4&O%S?*Y8OEG!J\>CV?J?JWAGXA4>'/;X;%4Y.G7Y;SIM*I#EO9
MQOHUKL[:Z^3^3/V6_P#@DK^R'\:O"$.O>$]2U3XB6&!O>;Q!)NA8_P ,L40B
M9&_V74&NM_:8_P""1_P%\#?L\^*M2\/_  ZT^WUC3;,W5O.;JXE==C!F^](1
MRH8?C7RS\>/^".GQF_8?\92>//V?_%&L:Y:V>9/(M)1;ZS @YV-&/W=VG;;C
M)_N&O0OV2/\ @N_IOC.TN/ 7[0.E_P#"/WUPCZ;<:[;6S1VS%@49;NW^] W)
MR5!7U"BL,KQ6#PN)IQQ^'C%IIZI.,DGW=]_/0^HXHR?B7-LOK8_A7-ZN+I.+
M3C&I.-:G=.UX)J]NCBDWNHVU.T_X)\_L'_ /XL_!;5KSQ/\ #CPG?W^CZC(L
MUU=*V4@,:NI8[L!1\W)]#7P[\5/A7X3_ &]OV\K/X=_L^^#-%\*^$[65K3^T
M;*W8+<0HP^T:C,23^[7I&O&?E[OQTO[4_P"U)K'[.G@'QC\+?"^I6]R/'HCM
M[N]LIO-WV*.VUH70X;[0C!<CJA/K7Z&_\$?_ -@:']C3]GJ'4]:LHX_'_C**
M.[U9V4>980XS#9@]@@.6'=R?05[/&F!P=?/:F#P$8JDN64G%)+5)J*LM-^GZ
M'@^%G$6=9!P3#B7/Z]6>*J\]*A3JSG+6,G&5649-WM:RNO\ TI-:6C_\$7/V
M<M/\,Z?87'P]L[ZXL[=(9;Z2\N%N+ME4 RN5D W,<DX &3P*P_$?_!"3]G'7
M@WD^&-:TEF_BLM<N1CZ!V8?I7V)16+RW"-6=./W(^+I\>\20ESQQ]:__ %\E
M^5['Y<_MD?\ !"?X7_![X,ZGXH\+ZYXUAN-/DA+PW=U#=1['D5#_ ,LU/&X'
MKVKR_P"!/_!!.']H?X36OBK0_B6-,O))YH)+>\T42B-T;'#I*IY&#T[U^H7[
M;J*_[*'CC<H;&G$C/J'4BO.O^"5EP9/V>=2CSQ%K<^!Z9CC->]'A3*JN0SQ3
MHI5(U$N9-K1I:63MOY'GTO&[C?"<24\'#,)2I2I-\LHPDN92>MY1;VTW/@3Q
M[_P1P_:&_96\*:MXF\-?%K3(]-T6UEOKJ6SUZ^TN2.*-2[,<C;PH/&[FOG#]
MC35/CY>?%S6OBE\)=&USQ;XKTO=_:NHKIZZE+NN\EMZODL\@5LD98#)XS7Z*
M_P#!P#^V.GPR^!]G\)]'N VN^/,2ZFL9S);:<C#Y<=09I %'JJOZU[A_P2/_
M &0Y?V0OV/='L-4MUA\4>*'_ +;UD;</#)*H\N G_IG&%4CLV^OSQY52GCO8
M8>3BH*[=]GTMYG]&T_$7'X3A%YQGE*E5JXF7)3BX)<]-?&YI6O'=):*]GJF?
M/'["_P#P5*_: ^+'[4'ACX9_$3X;V.G1ZQ+,MUJ4NDWFFS6R10O(S!7)C8_*
M!@8^\*_26D*AB"0,KT..E+7U&#P]2C!QJ3<]=WV['\]<49U@LSQ,:^!PD<,N
M6SC%MIRNWS:VMHTK+30****ZSYL**** "BBB@ HHHH **** "BBB@ HHHH *
M*** /@6'Q%X03PPO@=M>TO\ M*34?^$B)\HG&J#405@\[IN^S@Q[,?>(YZU]
MQ>/-3L],\,71O562.5?+6,]9&/0#^>>V*_+SPCX$U;QU\?+@:792W26.O-<7
M$HXCA1+G<2S=!P#@=37WWJNI:A\4O$RQ0J?+!(B3^&%/[S>_J?PK],XLRZ$*
ME&T[KWI2NUHWR]MKVT]#\EX-S6<Z5>].S]V$;)V:7-WO=J^OJ<_921PW<331
M^=$K@NF<;QW&:Z3]K:'3?&G[,&K0/?6UAI5^;2*:ZE;9':Q&YB#LWIM7/Y5V
M6H_"NSG\)1V$.%N(?G2<CEG/7/L?3MQ7B?QH\+ZMXE^$_B;P=')';3:I$%"S
M_<2175P<]@=N,^^:^?P=6GB,52JQER\DT_E=:_K^!])CJ-7"82M1G'F52$E\
M^5Z?I^*,W]FKQSX9^*G[1FGZUH6H6DEQINF:AHK6B0&WD6RCFA:TDVDG< C,
MA<=2.U<?_P ' 5_<Z5_P3EU:ZLYY[6\M]?TJ2":"0QR1.+E2K*PP58'H1R*Y
MC_@F[X8U#P;^U?J.FZI:365];Z-.'BD'_32+D'H0>Q'!KI?^#@G_ )1O:Q_V
M'M*_]*5KE\0,-##UY4J4N:*@K/R=WT]=/(^\^CKBIXG/<OJUHI2>)A=:[J45
ML[]M?,\W_P""27QD7XP?MO\ B^:S\2S^(M+L?A?X8@S]L>XA@O%M;9+L ,2!
M)YR,)".2P.<FOK[]LS7M,\.>%-#N=4DAMU-[+%:74R[H[*[>UF6"9A@\*Y!S
M@[>&[5^:?_!M!_R<1\3/^Q=M_P#TIK[[_P""H?\ R1#1_P#L,Q_^BI*_/76:
MRZ57KJ_Q/WCQ&RBEA_$"&6TV^2,*4;Z)V]DE?:U^^A;_ &!XK,:=J4B^);CQ
M%JC65J+])+U+U=/823[8UF51NSDM@EBN[&:Z[XM:I::GXI86JC? OES2 _ZQ
MAV_#IG_"OG_]@"_U#P3X/\57@MI85UM[>.TG88#!!)O9?7&X 'IGZ5]*?"7P
M,;N9=6O$_=KG[.K#[Y_OGV]*^CX9BZ6 CBJJMH[+OKO\]_QVL?AOB(XUL]K8
M'#R4K-7>EE[JNM.ST[Z6;O</@KK=E:3SV<BK'>7!S'(?^6@'\/X=?>H?VD]5
MM]+TRS\R>*SO+B"ZAL;F0[5@F*+@[OX25#*&[%NU'Q%^&\FC7#:CIJM]GW;W
MC3[T!ZY'M_*O._CEJ>I?$CPEIL B6XN--F>1F4X:52H'3U&/QKT\5A_;KZQ1
MUONNJ/E\#BOJS^JXC2VSZ/\ K^M3LOV1IKF;2_$!N[^'4IQ<PAIXY?-!_<C"
M[L#<1T)YZ=37(?MG>+-)^&OQ*\/^*M1U&SL[[0]'O/[)BFA-PT]U+)#'D1 @
ML$C+D\\9%=#^Q)&T'AOQ CJR.MZ@96&"#Y8[5XC_ ,%;_P#D8_!'_7O=_P#H
M4=>APCAU7S2%&3LFI)^G*[KYK1GG\;8J6'R>I7@KN+BUZ\RL]+;/5>:/<OV(
M;71;;P3XH;P[>07VAW7B2YN[*2(_*L<J12>6?1D+%".Q4BN#_;FU^RTWQO-9
MK?1Z1KU]HMI]DO'N1:%[=+N4W$"3D$1.PVG)ZA2.>ATO^"67_)M]W_V&KC_T
M&.O,?^"GEE-J7QP\,V]M#+<7$VC[8XHD+.Y\^3H!7SG'_-1Q%>*]YJ26N[Z7
M]?U/T#P:C#%?5G/W4X.6FRM[UM>FEGY=3Z8_96&GV_PG)T_7)/$5I]NN&.IR
MLK&Y;=ER655# -N&[ R%SWKFO&NHVNJ^)[J>SC\N!VX(_C/=OQZUQ_[//]K>
M /V?-+\+W<)M+KS9IKA5;<Q$DA94X[X/(]>*]K^'7PUCT[3I+C4H5>XNT*>4
MP_U2'M]3^E=N4Q>$PL:U=6DTO=Z_C^OYGS_%%2..S2MA\))3A&4O?TL]6DU;
M37RT?30?\&]6LY] :UA18KJ$EIAGF3/1OZ>U?CI^WC\<Y_AS^T;^V9HO_"67
MFBW6K6.EKH=FE_)"T]U]KL7G\A5.!)Y"N6(P2@(.1Q7ZO>)/#U[\,_$,=S:N
MWD[LP2]01W1O\\U^+G_!:3X%^+/"_P"U=XM^(%]I,@\*^-)4GLM0AS)"CB!$
M:&0_P294D!NH(()YQY?$N'E[)8JCK%O7RNFM?Z\C]R^C+6P5;B"IE68R4)N$
M>1.WORA5IU%&-]VU%W2U<;M=;?N#^R=_R:S\-?\ L5M,_P#22*OE7XMZ_P"#
MK*Y^(O@Z]US2[?4/%.I:OJET[PD_9;R*<?8HGFZ1G$3_ "\Y\\5]5?LG?\FL
M_#7_ +%;3/\ TDBK\W?VH?\ DY/QY_V'[K_T::^^\/<&L36G%R:M&+TMNGIO
MV>OJD?S#XP8YX6JYJ*ES5*D=;[.]]FMU=>C9^J?A4Y\+Z;V_T6+CT^05\*>)
M_$/A#_A&;[P2->TO^TDU$^(\B(\ZI_:&3 )L8W?9CY>S^\!SUK[L\+_\BSIW
M_7K%_P"@"ORWTCP!JGQ$_:.U*UTRW,IM==EN;B1N(X(TN2Q+'MTP!U)K?@O#
M0JSQ$ZDW%0Y9=-TY6O?H>7Q]BJE&GAH4H*3GS1MKLU&]K=3])OC)JMI;^'5M
M9D62YN&#0C/,>.K?T]\UY_X.U.UT?Q):W%Y%YL$;<_[![-COCK6A865Y\4_%
M[R2$K&2#(PZ0QCHH]_ZY-=IXU^&5OK6E1"Q2.WNK- D799%'\)_QKYZ$Z>&@
ML/4>LM_*_P#7ZGTE2G6Q=1XJDM([>=OZ_0^>_P#@M9JDD/\ P3-^(-Y8W$D<
ML:V$UO/!(5=&%[ 596'((."".0:^9_\ @F#\:(_C#_P4OTQK'Q1-XDTW3O@M
MIL$N+QYXK>_5;%;H$,<";>,.>I(Y)KZ)_;1^$>N?M!_LG^-/AC9WEOIMYK44
M?V=KU6\N"6*9)@IQR%8IC(SC.<5\:?\ !#?]G?QK^SA_P4:\0:-XT\/WVBW7
M_"&WGE2.N^VNU%W9_-%*OR.OT.1W KY/-,%6HXR$K7@[:].O^?\ D?T]X<9M
ME&,\/\RP\ZL8XNG[5JFVE)QG&DG))ZM)P:]W;[5KH_8JBBBNP_"0HHHH *\B
M^,'_ "/,W_7&/^1KUVL?6? 6EZ_?M=75MYDS *6WL.!TZ&NS XB-&ISS['GY
MEA9XBE[.&][ZGB=%>Q?\*IT+_GS_ /(C?XUP?Q'\,0Z1XJ@LM.MV7SHE*Q@E
MBS%F'?Z"O>P^84JLN2-_G_PY\SBLKK4(<\FOE_PQC^'M N/$NK1VENOS/RS'
MI&O<FO:M T*W\.:7':6Z[8XQR>[GN3[FLWP#X,C\(:5M;:UY-\TSCU_NCV%;
MU>-F&,]M+EC\*_'S/H,KR_V$.>?Q/\/+_,****\X]8**** $=1(I5@&5A@@C
MK7G7C[P')X8N!K&C[H5A.Z1$_P"61_O#_9]1_2O1J;)&LL;*RAE88((X(KHP
M^(E2E=;=5W.7%86%>'++?H^S,7P)XPC\7Z.)/E6ZA^69!V/J/8U\/CX,:H/V
MLV\<>9;_ -GGXD-9_9\-YVS[5M\_ICR_,_=]<[O;FOJK5;2;X4>-8[F!6:PN
M#P.S)W3ZCJ/PKY)3XO>))OV[X]+_ +2O(]&N/$HLX[-D"PFT>\\]?DQC<6(;
MS/O?[6.*^ZX9P]6+Q$\*URR@V[]NJ7F?G?%F)I26&IXQ/GC425OYM+-[:'JG
M_!9KX.WG[0/[).G^#=/O;73KS7/$]C'%<W*LT,119I26"@GD1D<=R*X?_@@-
M\'[OX1?LEWS7=]9WW_"67-OXC@^SJP^SQ7%NH6)]W\8\LY(XY%=!_P %V/'F
ML?"[]A^W\1>'[Z;3-:T?Q5I=Q:748!:)P[CHP((()!!!!!(((-<E_P &^_Q2
MUSXN_LW^,M2U^\CN[FUU]+"W6*WCMH;6WBM(5CBCBC541%&<!0.23U-?E,N3
MZ\N]C^P\+3Q__$+*TXRC]7]NKK[7->-^FS3CUTY7IK<T_P!MSX2W'B7]HJ_U
M-KQ;5+Y8H+*%+.:ZDN7@MXVD)$2L44;XUW$'E_0$U]P),MM8+)(P1(XPS$]%
M '-?"?[:OQ7\0> OVIM4BTG4/LR1I:S0[H8Y&MI'MUC9XBRDQLRG!*X)P/05
M]5?$'QF^OF'1=,W3>9M65D.?-;^Z/;U-3D-"-;&8B-/3WM7\WY^O8_/N.,16
MP^49=.NTTX>ZEOM#2UNUNKUOMHBK>SW'Q;\9"&-GCT^WZ'^XG=O]YNU>E:3I
M-OHFGQVMM&(X8A@ =_<^YK.\#^$H_"&BK#\K7$GSS./XF]/H.E;-?18S$*;5
M.G\,=O\ ,_.\#A7!.K5^.6_EY!1117&>@%<O\0/AW#XIMFGMU6+4%'#=!+_L
MM_C7445I1K2IRYX;F5:C"K!PJ*Z.%^%WC>628Z/J+,MQ"2L+/]XXZH?<=J_.
M_P#X+V?LWZE\?_CEX'FT_5-/TU=)TVRTZ072.WF/J6JI9Q,-HZ(QW-GDKTYK
M]#/BUX1>*1=:L@R2Q$&?9U&.C_AWK\S/^"YW[17C3X8_%GX;^(?#-U)IJ7VB
M26EY))8Q75K)<V]Y'<PG;*C()8W594.-RG)'>L\]ITYX5XF*]UVNET9^E^ =
M7&PXPHX/#SC&MRSY'+9KE;:V>O*FEH_PN?HK^Q/X3D\ _L:> M!GN(;J;0]"
MBT^2:+/ES-"IC++GG:2I(SS@U\Q_L5_!C5/ W[0'@7Q-=R6[V?B6+462) WF
MV?[MS&)<C&9$!=<=A7T9_P $^[V;5OV"?A?=74DEQ<7?A>UFFD<Y:5WBW,Q/
MJ22?QKYI_8<^+WB3QA^UA8V&I:M<7EC<"=C;NJ^5$8('CB\M0,1X0D?)C(ZY
MK[+A)5GE>,=*W+R+FONURST7Y_)+9L_$_%'V4>*:,<3=S]O42:VO[2-V_6UK
M=FWND>W?\%'?A_=_%+2/ >A6<L-O+>:Q*7N)@?*MHTMI'>1\<[5523BNG_X)
M_P#ANZ\&?L^C1[Y=MYI>KWUK,!TW),1D>QZCV-<=_P %0O&6J>"_AMX=ETF\
MFL)KZ]FLII8?ED\IX&W*K=5S@<J0?>K7[(WQDO[O]F&QN[ZZ:\UR_N9U,S*
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MN;@KQ+([%F8GJQR>G;VKUO3/A=HNERAQ:^>R]#,Q?'X=/TK?CC6) JJJJO
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M8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVMOB)H'_  3R\4>,/C[IMC\*?%=C;WFFVEV\P@^V3[&CMYA'\QA=Y<!5R0V
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M*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1103B@ HKX?_9Y_P""V/AOX_?MUWOP?A\-"PTM[R\T_2?$1U,2+J<U
MOG \GRQM$FR3;\Y/"\<\?<%8T*\*T/:4W='O<0<,YGD=>&&S2DZ<YQ4TFT[Q
ME>ST;[--/5-6:3"BBBMCP0HHJCXHU5]"\,ZC?1JLDEG:RSJK?=8JA8 ^W%3*
M2BG)]"H1<Y**W9>HK\^?@!_P5E^+'QY_8#\;_%+1/A9IOB3QAX;U]-)M=$T4
M7,T;0&.)WN'0;I7V>8<K'SC!X )K[2_9T^(/B#XJ_ [POXB\5>&;KP;XBUBP
M2XO]%N&W2:?*>J'(!'K@@$ X/(-13K1G\/9/Y-71]/Q!P?F63<_U]13A4=-I
M3BVI**D_=3YK6:]ZUKZ7N=I1116I\L%%%>+_ /!0?]I75_V0OV1_%GQ#T/3=
M/U;4O#ZP-%;7Q<6[^9<1Q'<4(;@/D8/7%9UJT:4'4GLCNRO+J^88RE@<,KU*
MLHPBF[+FDTEJ]M7N>T45\;_%W_@H#\7/#W[$'PG^)?@;X12>/_$7CR&UN-4T
M_34N)H-+26,-PD8:4AV(57/RKU;J*^NO#&IW.M>&M/O+RQDTV\N[:.:>TD8,
MUJ[*"T9(X)4DC(]*(5(RE**^S:_S5SMS3A_%X"C&OB.6TI3@K2BWS4VE*\4V
MTKO1M*ZU6A>HHHK0\0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^%?^"A/_!/W1OVM?BC=>.O@WXRT_PU^T!\/U@E
MN#8WRJ]SA6\B.YVDF&4JI5'88*_*P*X(YC]G?]INU_X*C?\ !/[XK^%?BYX=
MM[CQ=\,X)EU>)&>"&YN8(I9+>Y C8;766%MR E=R=-K #7_:8_X(LZMXE_:!
MUSXC?!?XK:Q\)=6\7,SZY;6RR^3<,YS*Z/%(C .?F*-E=V2,9P/6OV0?^"9.
MA_L=_LR>-/!>D:U<:QXC\>6MPFK:]>Q;3/-)"\28C!.(TWDXW%B68DY/'B?5
MZTE47)92B[JZ:<NCCV\WI\F?O&(XBR2CP_AZ:QSKXBE*BZ#]G*%:A9IU8RJ+
M1TUK[-*4FG9JR1\'_L(VUO\ LZ_\$5_BE\:O".G_ &'XG72W6B/K<<LAFCMC
M<P(N$W;%,?F,P8*"" <G%>Q?\$Z/^"/WP+^//[$7ASQ9XNTVZ\7>)_'%F]_>
MZP=3G26SE=F!2,*P7<A&"9 Q+!B?2OI7]@K_ ()[1?LN?L7:A\'_ !G?:7XT
MT_5KF]:],5JT,%Q!<@ QE6).0 >0?0C!%?-^H?\ !"'QUX#O-1T#X9_M$>+?
M"/PVUJ9WNM$<3,Z(_#)^[E1)/EXW,JD]\]:?U64>5NGS>Y%6TT?7[V]6M;GT
M&,X\P&/Q.94<-FLL'.>)=6-=*H_:44N6-.\%SQ4/BC%I1=[61\Q_##QYK&F?
M\$S/VO/A8VK7'B#PC\.=4LHM"OI'WJL;ZJ(V1#T",(5D"C@%VP,&OIG]DWX.
MZ'^R'_P1\UWXX>#]-E_X6IXA\"SWEWK<D\DTYW$F,*"2JK$-I&T _NQDG%>U
M:G_P2.\.^#?^"=?BSX&> ]4&G7WBTP3WVOZG#Y\EY<)/#(TDBH5^7;%M5%.%
M!'7DGVK]F+]F:+X+_L?^&?A5XAFLO$EOI.B?V+?N(2EO?QD,KC822%96(P36
ME/!3Y9*7Q<BBI>=FGYJVB]#S^*/$C*L3@ZGU&3Y*F-52=.SBZM*-*E&4II>[
M:I4@Y.+?Q--JZN?!O_!*/_@E+\$_VF_V+M/\=^/=+N/&GBCQA/=O>74VISH^
MGNLTD>U1&X_>':'+2;B2X[5R'_!)/P[#^S5^UU^UAI?AO4&UZ'P+HEU%IEW(
M?,:[^S3S&/<1PS94*2."0:]7_P"'$7C#X9>,]2L_A7^T%XO\!?#S7IVDO='@
M\[SXXVX\M6CE5),+\H9U!QC.<9/I/_!/3_@E7=?\$[_BO\2/$R^(D\7:#XBT
M[[+I^FI:$7WEQR-(JR,S;))&!VG 4$GL*RIX>?/&4:?LTHR3:MORV3T\]NNI
MZ^>\;9;7P.;.6;2Q4<5R2I4)1J)02K1ER>\N2+C%<MHOE:5V[V1\U?\ !'+_
M ()\_"_]NKX-^*OBE\6H9OB!XLUS7;B"ZBN=0FC^QD!'\QO+=69Y"Y8%B0%"
M@#@U>_X)V? 30/V8/^"X?Q#\"^%[^;4-!T/PY,+0S3>=):K)]FD-NS]S&6*\
M\X SS7A>FQ_!P?&'Q7JWPE_:+\=?LRPWE^T6K^&_$&F7%K/"<DO' UM,0RH^
MX".7YDZ<C!KUK_@B'\.-)U?_ (*/?$;Q)X&U#7_$W@/P_H;6/_"1:LC+/JUW
M,\):1L\AI&29PIY"A<\FL,&X2K48PBDTG=IIW]UZZ??KKT[GU_%,<='!9WF&
M)Q57ZO5H>Y0J4ZD(4FY4U&*<DJ=U\,?9.7,KR;TU\,^&J^*/VP_VIOBEX\\3
M? 7Q!^T%>PZK)9M8IXA?3(/#ZB218H65!O("(%4 A1L8X))KW_\ X)[_  +^
M+_P*_P""A^D>(O#OP'\9?"3X8^)HGL/$.D3ZN-3L81Y;E9M[$.-L@0C(8C+#
M.&Q7T!^TW_P1CO/$_P =-7^)7P5^*6N_!_Q1XB=I=5AL_,^RW4CG+R*8G1TW
M'YBOS*6)(QFO2/V ?^"=&M?LC>*==\5>+OBMXQ^)'BSQ)&L=VUY=S)8)C^+R
M6D?S).  ['@9  R2=,#@:D)PYT_=W>EG^',[];L^7XF\3LFQ.25E@:L.6I1C
M26'DL2W'W8Q:4?:?5X\C7-&I&-[I:7;9]34445[Q_+(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^8_[='P5^(W_!
M/']M/6OVG_A_H=OXX\&^*(/)\8Z1+%YDUG&5C65LX)6-O*1A(H.Q@0X*&OI;
M]G7]L3X+:'^P1KOQ0^&NE6>D^#O#=K=ZGJ.BV=NEO<6EV 99()$7@2,[ !N0
M0RD<8KPS]H;]H#]KK]D/]J3QI=?\('<?&_X:>*@JZ%;:?9-Y.EQ\A8V6%7=7
M 8K)O4K)@,&7H*W_  3)_P"":OBZ/]DSXV:7\3--'@EOC<TBP:+  'T:/9(%
MD,8)"$/(-J9R%C4'&>/#HSJ)SA03VE:ZUB^BOU3>MMNI_1&<8/!XGAW#8S/Z
M]-NF\/&$Z-1-UZ6TH5*6DE4H0<DIN*?V7=M,X?X*^&OVS?\ @I5X0;XM:3\7
M;/X5^']0N9CH&B6WF1PS1(S+R$4[DW*5WRERV"=H&!4,?[6OQ7_:[_8F^/WP
MA\::U!X7^+7PB@>XU;4;53&NM:= 7%Q"XBPNY]AC)7",LJG YH^ WQJ_:T_X
M)F^ _P#A3TGP+NOB9I^DW$T?A[6].$\MMY3L7 +0JP*;F+!9/+90Q4G@$=A^
MS-^P1\2O O[-7[1_Q0^)6GM)\5OC%H5^$T6P3SIK='CDD\LI'D>:\C* BD[0
MBC)).,9+FIR5+FMR2YKW^*VF_6^Z70^HS&M@\+.IB,5'"1HPJTG@71]DYM*K
M'XN6\G#V=W4]K]O;6Q\Z_LJ_LG_%SQ%_P2:\9^,-!^+4^A>"[ZSN=1'AZ-[A
M52"U-R+R$A3L_P!(&T' P<#=3_V8?@_\;/"7_!)'Q7\4O!OQ7\2Z5INGA-1T
M30M*NYH?[.2VNI%O=PSL*NC&3 _N<U]9_L4_"/Q9X8_X(6Z]X5U+PQX@T_Q1
M-X?UV%-'N=/EBOG>0S^6HA90Y9LC QDY&*]"_P"".OP=U+0O^"9F@^$/&WA[
M5-'N+S^T;6^TS5+1[6?RI9I 0T;@, R-W'(-;?5'*;C"Z?LHV=WO?].W0GB+
MQ"J4,/F%>7LJD89C%<O)3?/2BI/MK=0BG/=W:;]YW^9_^"C7_!5KQ%JG[#7P
M2O/ASKVH:+XT^(-LNMZC/ILC+<6L=FNRXC.WG8UP&!]4B;/&:Z;]L?\ ;W\5
M?M.>!OV8_!OPG\3ZMX9\4?&:>#4M5N])N##<6-NG[J9-R\A1)YY/M;^E<;_P
M2F_X)<:]X&_;!^)?_"P]#U;_ (13P+:WOAS0)+^!TMM3CNWD5IK<L,,GV<L2
M5R-TW/.:O_\ !'K_ ()O>*O@=^W5X\UCQEI&KP:/\,4N-&\+W=[ Z6^H&>5\
M3VY889!#N)*Y :8\YS2I2KUJD7.ZC4:D_)1Z>7-IZCQU'@O*J-7ZDX3J9?&5
M:#:BU6>)4E3@UKS*BW1;WVEHM3M?VY_VHOC+\;/VV--_9B^!?B#_ (16ZTK3
M8[K7_$4TG^DX\I78F7!952-XR2@WN\F,@"O _P!OG4/VN_V#/#/@C2O$WQIU
M+Q%X<U?5P+77=)GDMKT38 :TN'.'="N77<6&0>1C%>^?MZ?LU?&']F/]O>V_
M:8^"_AK_ (3I-4L5L/$&A11F2<8B6-B$4[V1TCC.Z/+(Z<J0:^>/^"A?C7]J
M#]OGPSX%U/6O@7XD\)^$=*U@-::796=Q>W\]R5&ZXF38)$B5,JI9%&6/+'I$
MY2=^;F]IS:[VMS:>5K;=;G7P/3P<I97]3CA'@?9KVSJ>R]M[?EESWYOWG-S?
M"E[O)Y'MO[>_QN^-\O\ P5*\*_##X6^.+[06\9^$XK6.*XF9M/T]Y/.,M]Y7
M(,J1QD@X)SC'-._X*"?MM_$C]AOX>_"KX$Z/X_LG^(VL:7'/XD\?:Y)N2TC:
M1D\S<ZMMW.)#N9694C  +$$=A\6OA!XMU#_@N]\+?%=OX7\0S^%[#PN8+G6(
M]/E:PMY/(NQL>8+L5LLHP3GYAZT[_@L)^P-XR^*_Q8\$_&CX=^&M&\>:SX/A
M%EJWA74X$GAUBV61G0B-R%DQYDBLF0V"I7E:'&K[&<XW_B23WTBI.UEVUZ=/
M)'S.3XS(?KV2X#,H4O9?5E4;:@N:O:I&"JS:VT7NS]WF:<DTSY._X;V^*7[%
MNH:?XMT_]J?P7\?-/^V(NK>%VN)I)Y(F/S&+S4RH'/S(R[3@E6&17[,?##X@
MV/Q8^&^@>*-++-IWB+3X-2MMWWO+FC61<^^&YK\LOA*GCSX\_$W0]%TS]@GX
M6^$M-6Z":U?^(]!-O;)#_$4D>&,J1R1M64D@#'>OU;\+>&=/\&>&['2=+L;/
M3=-TV!+>VM+6,1P6T:C"HBC 50!@ =J]#+5/DE=W5]-].]KZV_6Y\SXQ5,!?
M#0A0C#$^\YRC*@[QTY5..']Q25G9V3<7JW96OT445Z!^(A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %?/?_!4K]IS_ (9/_8B\:>)+><0ZU>VW
M]CZ/S\QN[C,:D>Z*7D_[9U]"5\!?\%5OV8_B/^W/^U/\(_A[9>&]8C^$NDW/
M]I>)->CECC@#N2&5<OO++"C*I"\-/[5Q9ASNC[.GO+W?2^[\K*^I]IX?X' X
MG/:#S2<88>FW4J.32O&FN9Q5VKN=E%):N^A\'>+O@EX6_9O_ &"_@S\6/"7C
M+PC<?%[PWKZ:]J]C:ZQ!+J)AG=6AC:)7+YA\N,,,9'G29[U^H?[;WQRA^+/_
M  20\8_$#PQJ%S9QZ[X2CU.TN+2=HIK<N8R0'4@JRDE3@YR"*X+6?^#>?]G>
M?2;Q=/TWQ19ZA)"ZV]PVNSR"&0J0KE2<, <'!ZXKQ'X<?#[XJ? C_@B[\>/A
MQ\3O"^I:&/"<,_\ 8=Y.\;PWUI+*K$1[7;A9 [#('$J^AKS*D:E&C7IR5DX-
MJVR:C9J]EJU9_(_<,VSO)>)ZN"QV$Q,JE?#XN#:JQC"3IUZJERPBIRYXTYJR
M7V8RVL87[(O_  3N^.?[;_[(?A+Q=JW[0OBGPO8K:NWA?2;:2>51&LCA9;F5
M9D8N[@G)WL%QZ #U7_@G?^UY\1O'_P  ?V@_A5\3=1N-2\;?"'3;^W36/-S<
M3)Y-Q'AY1@LR21963[Q5USR,UY#^Q5\0_P!L[X+?L6^"[?X7>$O"_P 0/!/B
M:SDGT2ZEPU[X=W2R*T3JTL8*JX9@6#K@X]J^A/V*_P!@'Q-^R+^R;\;?%GQ&
MU"'4OB9\2-'U"]U<Q2B9;11;SN(RXX>1GD=F*_+D@#(&3I1C:5Z2:CROFO?5
MVTM?KYKH:<88JFJ>.H9K6PU1/$16%A24/:0:K>_S*,5**Y+J?M+N4]KZ-_*W
M_!-']C?XU?\ !0?]E>2[O/CUXM\&^"-/U.:*RMK:::ZNK^["QF625_-1O+7*
MJH+''S8 R<^Z_P#!/?\ : ^*7P?_ &A_BM^S)\5O$$WC*X\-Z%<ZCHVL32-+
M-Y2Q(VW>WSM&\<R, Q)0JRYQ7SU_P2L\<?M4?!?]D.37_@OX8\-_$3P;JVK3
MV\NCWI_TO2;Q$C#S(/-BW)(I7(#, 5Y SS]9_P#!/;]@#XG^'/B'\2/CE\:I
MK>;XG>.M,GL;33+>1'^PQ2*,[BAV*Q$<2*BDA%7DY)Q%*#]WV49+W7S7O9^[
MI;OK:UMD>CX@8JC2JYM1S:OAI8?FMAZ<%35:%95(ZM1BIQLN;VLINTOLMIH^
M(_V>/$^J>#_^"%7Q?O\ 1]2U#2;Z+Q[8!+FQN7MYD!-D" Z$,,@D'!KZ>_:
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MXG?#76?C;_P03\$^.K[QIKPE\#WE]<75K--+<_V\)]0$*I,[29Q'PR[@W3
MZUZ;\4+O]OO]I?\ 9]\1?#G7_ 7A_0;&#37AU/5HI(DU#Q"B+S;P[9F0M+C:
M614')Y4&NMTK]D/XF0?\$$KOX8-X-U1?B!([%=#W1?:"#J8EZ[]G^K^;[W3W
MXKCJT5)5O91?+R*UT]U*^E_R]>A]E0S[$X2E@:N:XW"SQ"QU&\J3HZ47"<6Y
M."4>6S=FU>":NT[6^9OCE\-O$G[+7_!(OX4ZSIOQ"\57,OQ"\366MHL-W/9G
M289+!E^QQLDI+1 KG'RC/\-?57_!0_\ ::^*7Q%_:!^%_P"S5\)-=?PGK'C#
M2(-1UK7U<K<0PE&.U7'S*JI$[L5^9B54$9-<O^W#^QK\4OB1_P $JOV?O!.A
M>"=6U/Q9X6DL#JVF1/")K ):NC[RSA>&('!/6O4/^"A?_!/WXC>.O'WPZ^-O
MP7O+2R^*G@&PALY=.NW6./4H4!(4,WR;AOD1E8A71\9! ST2I33J))\G-"Z5
M[N*CK;OK:]CS99]E.+Q.$Q&8U:,JKJ8[EE/E<(U&X*A*K%*W)IHVK?:UU9X'
M^T7\#_CG_P $8O#^B_%3P_\ &K7/B1X6&J0VFOZ+K8D\J;S2<81Y9 0V"N]2
MKH6!&1FM+_@KI\8_&GC_ /:3_9AOOA;XAU;0-2\<Z?'=:2JW3QP"6XF@,3S1
M ['VA\D,IX!&.U6OB-\"_P!L#_@JE=Z'X-^+/A?P_P#"?X;Z7?QW>K/;,OFW
MY3."J>=*[MM+!>50$@G. *]2_;I_9 \7^(/VZ_V6=2\$>$;^_P#!/PWF@M[^
M[@:/R=*MXIX@N_<P8XC3/ / J)4Y2A:*ER<\;+6Z7VO-+:U_4K"YQ@J&98.M
MG%;#U<="GBG4E#V;IN/LG[&%1Q2IRFY722ULTGJT?//Q\\ _&C_@E-^UI\)?
M$3?&KQ+\1;?XC:NEIJ\.I22K#<-YT*31-"TCJ5*S91UVE2O0<5U7_!8?Q'XX
ME_;<T70_&_Q*\9?"/X'WFF1-I.O:-:3S6?V\ [Q<>2Z-NWG'S$[4VD*<DU[3
M_P %F?V9O'W[0?Q"^ MUX*\+ZAXBM_#'B-[S59+9HP+&+S;4AVWLO&$<\9^Z
M:N_\%#_$'[5FB_%FY@\ _#?P'\4?A/JNFI9_V-?6Z7$@G.=\EPLDD;9!.%V$
MIM R-V:52G*,)4[.T9Z*S:MRK>VMK_<_F<N2\1T\96RK,ZKP[Q4J->%24G1I
M-6J)4VKPE3C44?@YX6E&ZV=SVO\ X)O^&O$7AC]E/0X_$GQ3L?C!<7#R36OB
M"T<2PM;%OW<0E^_(5 Y9_F!)4_=%>[U\B_\ !&G]CKQK^QM^S+J>E^.C:V>K
M>(M:EUA-(MIA-#H\;HBB,,"5W';N(4D#(&2<U]=5[M)MTXMJSLM/D?@_&<:$
M<]Q:PU6-:'M)6G&,8QE=WNHQ]U+I[ONO=:,****T/F0HHHH **** "BBB@ H
MHHH **** "BBB@ HKF_B9\6M!^$.F6-WKUS<V\>J7J:=9I;6,]Y-<W#J[+&D
M4*.[$JCGA< *:K^!?CCX8^(VM76EZ9J$BZM9Q">;3KVSGL+V.(G D\B=$DV9
MP-P7&3C.: VW.LHK%\)_$70_'?@N'Q%HNJ6>J:'/&\L=Y;/YD3*A97Y'=65@
M1U!4CJ*KCXL>'?\ A5G_  FS:M:Q^%!IO]L'4I28X5M/+\WSCN (79\W(SBA
MZ7OT!:['1457T?5[7Q!I%K?V,\=U9WT*7%O-&=R31N RL#W!!!'UJQ0TT[,$
M[ZH**R?!OCC2OB#I,E]H]XE]:0W5Q8O(JLH6:"5H94^8 _+(C+GH<<9'-:U
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M*<8J*45LE;[B\TS/$YCBZF.QLN:K4;E)V2NWN[))?<@HHHIG %%%% !1110
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M3:1YD8)/R/N7D\<FK7CSX->%_B;I]G:ZYHEE>QZ;G[&VTQ2V8( (BD0AXP0
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M=_P?]7N4]>^+7BCQA\6]<\(^"+30XW\)P6TFKZGK/FO")KA3)';111E69O+
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MV\\,KXF\0^$X-36_NDN5L-/L(H8$5I$4O)+,S2*H4,BDAVW*% -[7_VC=/\
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M-I3C)]HW]>:#?Y,<K<KBN[MZ6DE^:.7^(_[8&J?LWW7B6W^(&GZ3=MIN@?\
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M^T^VF?#OQ- VD>)/!?B;_A'=1U+1/[8M8<7CP6SR9C:.26,NF QB<A]H)VD
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M?LS:\OP+^!OAEIM,^V?#N^TN;5RLSK')';V,UO*(3MRQ+2#&0N1GITK \0_
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M5WW! 2.B^ 7[,>H_"#XJ6>LM;^%K*S_X1F33[N#1;=[6$WTM^UR[)&VXE=K
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M'_#5WAFV\,WEY?6^M:=JEAJJ:%+H<UIOU1K^1!)%;I'&S+(SQL)%9'*;,L6
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MN4[L,">"TW]C36=2\%^!M!UBXL%LM(N/$RZNUM<-YAM]32\2/R24Y<"X7.<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLAT_R[.>Y#87.[)AV\D#YB<G&*ZY?C9X/?QL?#8\4^'SX@#^6=.^WQ?:=_\
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M+:*SAB:2XEE_LX 1J@&YF)X  R3Q4-ODD^R7XW_*W_#&D$O:13ZM_@U^=_\
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M_M;:;^UEX?\ $%[9:7?:+)HNIO;107?$E[8O\]G?H/\ GC<PXD3\1VKPS2_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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>689&#AB.AJU110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mrna-20251231_g3.jpg
<TEXT>
begin 644 mrna-20251231_g3.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" *G!G,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC<* "BDWBE)
M ZT %%)N&:7.* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5H)YCPN[^!G[8'B]3)\0/V\_&NZ1<30Z'>2V<9!'*[8W52,>HQ[57/['7Q&
MX_;0^)^??7YO_CE>[44"NSQ6T^#?[:/A%O/\"_MZ^+Y&7E8_$$TE\I]L3.XQ
M^%;&G_M+?\%1_A$5EU[0?"GQ&T^'YI#:J+>Z9?H/+R?958UZE10/F,CX8?\
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MX?\ C;XL:_\ $CQ=X<\;?"^/1]!TFXMT\,ZVNH"4ZLC(3(Q3'[O:P Z\Y]J
M.V) ZT52\07DUCH-[?6S;98;21XVQG#!20?SKQ#_ ()L_'3XE?M$_LO6/Q+^
M+&MQZAK$VJW4$ES%9QP*41@%&V-57CZ4 >^4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/(Q0!XU^WO\
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M6[=DYPR_PG##Y2:_1"UN[6^MH[VRN$FAFC5XI8V#*ZD9# CJ".]!9)11FB@
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MR9KBYE:1VZLQH)N:6I^*[[5KT23-Y<*_ZN%3T]SZFN!^,7QI\!_!CPU+XO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPQ&>O%?0U?'?_!777H_"NE?"/Q1)IMU>+IOQ,L[IK.QC#S3B,J_EQJ2-SG&
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MXY^RSXQ/['G[>>I?#;6)Q;^#_BNJSZ7*[8CAOU+;4] =S.ON)(_:@(GZ'T4
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *X?]I#XR:?\ O@7XH^+M\$9M$TF6:UAD^[-<$;88S[-
M(R*?0&NX/2OBG_@MG\0[K2/@/X?^%FF.WVCQ-X@4R1(>6CA7('N"[+^E?/\
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MF]XYWX_[^?GFOR_Q?K2I<&RBOMSA'\>;_P!M/O/#FFJG$JD_LPD_PM^ITJC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Z/^'OG[*O\ T)_Q8_\ #0ZS_P#(] 'U+17RU_P]\_95_P"A/^+'_AH=9_\
MD>C_ (>^?LJ_]"?\6/\ PT.L_P#R/0!]2T5\M?\ #WS]E7_H3_BQ_P"&AUG_
M .1Z/^'OG[*O_0G_ !8_\-#K/_R/0!]2T5\M?\/?/V5?^A/^+'_AH=9_^1Z/
M^'OG[*O_ $)_Q8_\-#K/_P CT ?4M%?+7_#WS]E7_H3_ (L?^&AUG_Y'H_X>
M^?LJ_P#0G_%C_P -#K/_ ,CT ?4M%?+7_#WS]E7_ *$_XL?^&AUG_P"1Z/\
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M "/0!]2T5\M?\/?/V5?^A/\ BQ_X:'6?_D>C_A[Y^RK_ -"?\6/_  T.L_\
MR/0!]2T5\M?\/?/V5?\ H3_BQ_X:'6?_ )'H_P"'OG[*O_0G_%C_ ,-#K/\
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MZEHKY:_X>^?LJ_\ 0G_%C_PT.L__ "/1_P /?/V5?^A/^+'_ (:'6?\ Y'H
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M\-;JW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1_L8?\^'Q*_\
M#6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QBC_A]'^QA_P ^'Q*_\-;J
MW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1_L8?\^'Q*_\ #6ZM
M_P#&* /K.BODS_A])^Q?_P ^'Q*_\-;JW_QBJ$/_  7,_8*N;^XTJWU+QY)=
M6A NK5/AOJ9DASTWKY.5S[T ?85%?(O_  ^W_8>]?B'_ .&RU7_XS1_P^V_8
M>]?B'_X;+5?_ (S0!]=45\B_\/MOV'O7XA_^&RU7_P",T?\ #[;]A[U^(?\
MX;+5?_C- 'UU17R+_P /MOV'O7XA_P#ALM5_^,T?\/MOV'O7XA_^&RU7_P",
MT ?75%?(O_#[;]A[U^(?_ALM5_\ C-'_  ^V_8>]?B'_ .&RU7_XS0!]=45\
MB_\ #[?]A[U^(?\ X;+5?_C-'_#[;]A[U^(?_ALM5_\ C- 'UU17R+_P^V_8
M>]?B'_X;+5?_ (S3H_\ @MM^PNT@2>^\>6Z_\];CX;ZHB#ZDP\4 ?7%%>/\
M[/W[>W[)'[3^I-X?^#/QLTG4M75=TFAS.;>]4=?]1*%<X'7 .*]@S0 4444
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MKZ0[(+9/=G(R<'"AC@XK\:?$M[X^_:%^)<WQ]_:@UO\ MSQ5J#@PPSY>ST.
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M!_\ 0"A_[^M_\51_PKGP'_T H?\ OZW_ ,57SG_PM2X_Z"$G_?TT?\+4N/\
MH(2?]_31J&A]&?\ "N? ?_0"A_[^M_\ %4SX;_ 'X6^.O&W_  L#Q!X/L[R'
MPW>-#H,-QNDBCNMH$ESL8E3(N=BL1E/GVD$FOG0_%6Y'74'_ ._QKV?]B/6[
MD?LH^!=<NIG:;7M"CURX=WRS27Y-XQ)Y[SX]@,=J-1Z'T2NB:0HVBT7';YC_
M (TO]BZ3_P ^J_\ ?1_QKBO^$D?^^?\ OHT?\)(_]\_]]&@9VO\ 8ND_\^J_
M]]'_ !H_L72?^?5?^^C_ (UQ7_"2/_?/_?1H_P"$D?\ OG_OHT@.U_L72?\
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M\_\ ?1H [7^Q=)_Y]5_[Z/\ C1_8ND_\^J_]]'_&N*_X21_[Y_[Z-'_"2/\
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MBO\ A)'_ +Y_[Z-'_"2/_?/_ 'T: .U_L72?^?5?^^C_ (TG]C:3_P ^B_\
M?1_QKQOX\_M%^&_V?_A9JWQ4\6/(]OIL(\JUB;]Y<S,=L<2_[3,0/89)X!KP
M?PAHO_!0O]H328OB1XF_:&L?AG9WZ"?2?#NDZ&+R2.%AE!,S.F&(/]YCZ@=
M@/MS^QM)SC[(O_?1_P :7^Q=)_Y]5_[Z/^-?/7[/$G[4OA2ZU;0/VA/'&B^)
M+.)8CH>M:7;&WFE^]O6:/ P1\N,9Z]37H4WQ+\/VVI+HMSXCLX[QONVCWJ"5
MOHN<_I3U ]#_ +%TG_GU7_OH_P"-(=&TK_GT7_OH_P"-</<^+HK*VDO+V[6&
M&)2TDLLFU44=R3T%>!_%?]J+6E_:P^%/@'X=?$.SNM"UY=2&NV^GW4<ZRM&L
M9C#,I.TC)[B@#ZT.C:3MS]D7_OH_XTW^Q]+_ .?9?^^C_C7C7@KXF>.O^$@\
M7?\ "R-8\,PZ7IVI@:&^F:@QECM=G6[WG$<F>W Z]L$[\/Q8\'W&J1Z)!XOT
MU[V9 \-FFH1F613R&";LD8[@4T!Z-_8^E_\ /LO_ 'T?\:/['TO_ )]E_P"^
MC_C7!ZKX]TG0K?[7K>L6UG#NP);JY6-<^F6(J/1_B/X?\1"0Z!X@L[[RL>;]
MCO$EV9Z9VDXSBF!Z!_8^E_\ /LO_ 'T?\:/['TO_ )]E_P"^C_C7"WGCC3=.
MFAM]0U2""2X?9;QS7 5I6_NJ"?F/L*ATSXC:!K;7"Z-X@L[PVLFRZ^RWBR>2
MW]UMI.T^QH ] _L?2_\ GV7_ +Z/^-']CZ7_ ,^R_P#?1_QKSK1_BKX2\17<
MUAX?\6Z;?3V_^OAL]025X_\ >"DD?C3]7^)GASP^RIKWB.QL6?[BWEZD>[Z;
MB*8'H7]CZ7_S[+_WT?\ &C^Q]+_Y]E_[Z/\ C7C'B'XI^+;KQGX3_P"$ UWP
MO<>'[ZXNH]>EN]2)N'VHOE"UV$J[;MVX'I\OO74ZM\0-'T&);C7-;M;*-FPL
MEW=+&I/IEB*0'??V/I?_ #[+_P!]'_&C^Q]+_P"?9?\ OH_XUPI\:V L/[5.
MI0_9?+W_ &GSAY>W^]NSC'O5)?BUX.DO[?2H_&&EM=7B![6V&HQ^9,IZ,B[L
ML#ZC- 'H_P#8VE_\^R_]]'_&LWQ;\.?!/CKPS?>#_%N@0WVFZE;-!>6LV=LD
M;#!'!R#Z$8(/(((KG_\ A(F_O?\ CU'_  D3?WO_ !XU$X0J0<)I-/1IZII]
M&BHSE3DI1=FM4UNCX[\=?\$Z/VFO@'K]UK/[*/BN'7-$N)"_]@ZE<QQRJ.RG
MS"(V(_O!D:N8FN_^"@&CRBPU3]E+4)YF)3S+6S>1-PXSN1F7'OG!]:^ZO^$A
M;&-Y_P"^C1_PD+#^,_\ ?5?DV8^#7"^,KNK0G4I7UY8M.*]$TVOOMY'Z!@_$
MK/,/24*T(5+=6FG\VFD_N/A^T\(?\%*/$[>7HO[.\%BO\4FH2PP[??\ >SK_
M "-:]A^QS_P4H\7#.L>./#N@Q-C=&MU$7'T\J)O_ $*OLG_A(6_O?^/&C_A(
M6_OG_OJHP_@OPK2UJU*L_622_"*?XE5O$W/JFD*=./R;?XR:_ ^3++_@E=^T
M=KX$WC?]K&9=W^L@M7N7 ]<9<+^@K0B_X(T6-]_R,7[1^L3=VV6(;YO7YI*^
MH_\ A(6_OG_OJE_X2)O[W_CU>Y0\+>!Z/_,-?UG-_P#MQYE3C[BJI_R_MZ1C
M_D?*FH?\$3O"+#=I_P >=29O^GC28_Z/6/+_ ,$F?V@/ "--\)?VBK7U6TN(
MY8$8^^"R_FIK[#_X2)O[W_CU(?$+'^,_]]&C$>%O!&(C;ZMR^:G-?^W,*/'_
M !52E?V_-Y.,?\D?!WC;X=?\%!/@;$U[XX^%L?BK38?]9J&AQK<$#U(A =1[
MM&![US>@?M4_#S6'^P>*;2[T6ZZ.MS"6C#>F0,C\1^-?HK_PD!/5O_'C7$?$
MWX(?!#XP1./B%\-]+OY9.MV8 D_U\Q<-^M?GV?> ^!Q*<LMQ+B_Y9JZ_\"C9
MKYQ?J?7Y3XLXFC:..H)^<';_ ,E;=_O1\HVNI:%X@M_MV@ZO:WD+=)+6=9!^
MAJE?V0QPM=QX\_X)=^!FF?6/@M\3]6\.776.WNO](A)]-P*NH]R6^E>8>(OV
M</VYOA>6$%A8^*K2/_EI8SB8L/\ =8))^E?BN>>$/&F3R<EAW4CWA[R^Y:KY
MI'Z?E?B-PSF22]LH2[2]U_CH_DV)?6//W:QKZQR,[:Q]2^+WC7PI(;?XF?"#
M5M,9#B29875?P#@#_P >J&/XY?#J_3+WMQ;G^[-;'_V7(K\\Q&5YAA9N%:E*
M+[-'V-''8/$14J<TUWN3WUES]VLB]LCR-M7I_B-X"G!>/Q##_P "!']*Q=3^
M)'@N)-T>HM,>RQPGFN=8?$2=E!_<S=UJ-M9+[RG?68(.%K,T+P3XD^*GC[2O
MA5X'L&NM4U:]2"*./^')Y9CV51EF)X !)Z5O^#?!GQ>^.NI+I'PG\!7DL<C;
M6U"6,K$GNTA^50/J37W+^QQ^R#X5_9DT]O$>KWD>J^++R';>:DJD1VZGDQ0Y
MYQZL<%L= .*_6/#WPWSKB;'0J5H.GATTY3:M==H]V_*Z6[[/\^XPXURO(<+*
M%.2G6:]V*[]WV2\[7V7E] ?!CX/>&O@]\+]%^&NE1+)%I-A' TW(\V0#YW_%
MLFNG_LG3/^?=?^^C_C7(#Q"P_C/_ 'T:7_A(F_O?^/5_;6'H4\-1C1I*T8I)
M+LDK)?<?R[6K5*]652H[RDVV^[>K.N_LG3/^?=?^^C_C36TO3@>+=?\ OHUR
M?_"1-_>_\>I/^$A/=OUK8S.M_LS3O^>"_P#?1H_LS3O^>"_]]&N2_P"$A/K^
MM'_"0GU_6F!UO]F:=_SP7_OHT?V9IW_/!?\ OHUR7_"0GU_6C_A(3Z_K0!UO
M]F:=_P \%_[Z-']F:=_SP7_OHUR7_"0GU_6C_A(3Z_K2 ZW^S-._YX+_ -]&
MHWTW3SQY"_F:Y;_A(3Z_K1_PD)]?UH \Y^.WP2\ >"_%D?QPT/PY;VKZG=6U
MAXK\C*)<*["*"Y=00N]'94+XR4;DX48K?\(?X6_Z!D?_ '\;_&MC]I/3S\0?
MV?/&W@I)6CDU+PK?PV\T;8:*8P/Y<@Y&&5]K#D<@5\U^%?C+-K_A?3==DN65
MKW3X9V7<>"Z!L?K0(]\_X0_PM_T#(_\ OXW^-(?!_A?'&FQ_]_&_QKQ3_A9[
M_P#/XW_?PT?\+.8];MO^^S3$>T?\(CX9_P"@;'_W\;_&C_A$O#'_ $#8_P#O
MXW^->+?\+-/_ #]'_OLT?\+-;_G[/_?9IAU/9SX4\-9_Y!T?_?QO\:/^$5\-
M?] Z/_OXW^->,?\ "S6_Y^S_ -]FC_A9I_Y^C_WV: /9CX5\-X_Y!T?_ 'VW
M^-,/A?PX.?[.7_OXW^->.?\ "S3_ ,_1_P"^S3)_B9*T+"*\PVT[26/!I=0/
M9?\ A%_#@_YAR_\ ?QO\::?#/AW/&GI_W\;_ !KX0\=_$7]JKX 6-C\4M=^/
M%MXGL_[0ABUC0Y-+$**DC!?W+!B6.3Z*1UP>17I'BKXD>-]9^/G@Q](U:\M]
M$M=*O;S5(XY&$<KE52-'['[Y8 _W<T ?4_\ PC/AW_GP3_OX?\:1O#?AT#_C
MP3_OX?\ &O(/^%FG_GZ/_?9KRS]D;]H3QIX_^'&HZQXZU]KR[A\27=O%(V%Q
M"NS:O'IDT!YGU?\ \(YH&<?8$_[^'_&D;P[H&>+%/^^S_C7RA^TA^T)XT\':
M_P" K3PEK[6L>J^*H[74U7#>; 1RO(X_"N0^-NO?M1^!O#FO_$C2?VE5^QV0
M>YM]*715W+&7XCWECT!ZX[4 ?;O_  CV@_\ /DG_ 'T?\::^@:"!Q9+_ -]'
M_&OC+X/7_P"T[KEGX8^(?B']I1;C3KV"SU"\T<Z*H9X759&AWAN#@E=V/?%<
M[HOQ,_:I^*?C+QM<>!_CI;Z5#X?UZ2VL=.O=/5XY%Y*@O_".W0T@1]V?V#H?
M_/BO_?9_QH;P_HH/%FO_ 'V?\:^8_P!EW]J?Q!\8_A?'XA\66\4&J6MY)9WK
M6[$1RLF/G49.,@C(SC.<<8%>C?\ "RQ_S\?^/&J ]4;0=% _X\U_[Z/^--_L
M/1S_ ,N:_P#?1_QKRW_A90_Y^/\ QXT#XDJ.EQ_X\: /46T/2 .+1?\ OH_X
MTW^Q=)Q_QZK_ -]'_&O,/^%E#_GX_P#'C1_PLH?\_'_CQH$>EG1]+[6J_P#?
M1_QI&T?2P.+9?^^C_C7FO_"R5_Y[_P#CU'_"R5_Y[_\ CU ^IZ0='TPG/V=?
M^^C_ (UYU\=/A%HU_8_\+.\+Z1''XDT&%I8)HL@WMN.9;23'WU8#*YSM<*PQ
MR"S_ (62G_/?_P >J.?XAP7$+03.&5U*LN[J#VH#J4]-BT#6-*MM7L+=6ANH
M5EB;<>58 CO[U,VCZ6!D6R_]]'_&O&/AAXXDT[PA'HTMRS?V?=7%JK,W.(YG
M4?H!70_\+"_Z:_\ CU9E'HATK3 ,_9U_[Z/^--_LS3O^>"_]]&O/?^%A#_GK
M_P"/4G_"P5_YZ?\ CU '?_V?8?\ /!?^^C3/L%C_ ,\1_P!]&N#_ .%@K_ST
M_P#'J/\ A8*_\]/_ !Z@#N7LK,9Q&/\ OHTS[+:_W!^=<3_PL!?^>G_CU)_P
MGZ?W_P!: .T^SV_]P?G3#!!G[OZUQW_"?I_?_6C_ (3Z/^\* .N>.('@?K4+
M11L,$+^-<O\ \)]'_>%'_"?1_P!X4 5_B;\$/ OQ/@BN-3L7L=6L9!-I/B+2
MI#;W]A,IRLD4R892#@XR0<=*^S/^"77[:_C+XUP:]^S1^T#J23?$;P';PS?V
MEMV_\)#I+_+%?J/[ZL-DN. [*?XB!\=_\)]'_>%'P/\ B+_P@W_!0#X+_$K3
M)?*?4M:N?"VK>6?]=:WD#,H?U"21;AZ%LT ?K^&!.!2DXI!CJ!05!H  V>U+
MGU%?!/PUOOV^/VI_C=\9=.^&O[7L/A/2_ OQ$O\ 1]-TVZ\-QW0:)9YA&-X9
M2 JH%Y#'O7LW_!/;]I;XJ?&G0?&WP]^/<FFS>*OAUXFDTC5M7TM=MK?* =LH
M&  ?E8'@< $@$D  ^D* 0>E9VB^+?"WB66:#P]XDT_4&@XF6RO4E,?\ O;2<
M?C7@6@_'_P 96W_!2#QG\'?$_C*&V\&Z/\,;/5;>UNFCCB@NI+J&,R&1L=0Y
M&"<<T ?1U%5;W7=&T[2CKFH:M:P62H':\FN%6(*>C;R<8/KFIK2[MK^UCO;*
MXCFAFC5X9HF#*ZD9# C@@CH: 'EL=J-W.,5YM^UQ\>=-_9J_9Z\3_&"]=//T
MS3V&FPR'_77;_+"F.^7(X[@&O&_^"7_[1WQD^)/AWQ)\%OVGI[@?$+PI=PW-
MTMZJK-+8W42S0L0O!V[MOMD#J#0!]744$\5Q7_#1'P7'Q*U#X22?$;2H]>TJ
MTBGU"RFO$3R1(<(A+$#>>NWKC![B@#M:"0.]8VH?$/P%I6N1^&-4\;Z/:ZE-
M@0Z=<:E$D\A/3;&6W'/L*P?B=XA^)VB^-/!UIX)N/"\>DW^LM#XE_MZ\:*Y:
MW\L[1: </*7Q\ISQ^8 .WW#UHKY[_9J^,OQ%\=?MF_';X7^*/$#7.A^$9-$'
MA^R:-0+7SXKAI<$#)R47KGI7T)0 4444 %%%% !1110 4444 %%%% !1110
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MM>DC_@E=\+?^$<\)^&S\:?B T/@76$O_  @6UB,_V45?>J1#R\8# $,06&
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M^3\QR:A\*Q:5X+OK^[T.::./4)O.EM3)F-'[LH[4D,^@O^%@_P#3>C_A8/\
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M?\2?LYV^NZ1')<0^&?%5CK&J6T?)EM8Q)&_'< RJY[ (3VKVKX:?%SPM\3_
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MJ&A>9_9HUO6VN$B#KA@-PS@\=^PI#./\6:S-_9/[68%PWS3Q[?FZ?)4?Q?\
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M>D_YZ_K1_;TG_/7]:\G_ .%KW/\ SX+_ -_#1_PM>Y_Y\%_[^&@#UC^WI/\
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M7_OJF![Q_P +!_Z;T?\ "P?^F]>#_P#"UKC_ )XK_P!]4?\ "UKC_GBO_?5
M'O'_  L'_IO1_P +!_Z;UX/_ ,+6N/\ GBO_ 'U1_P +6N/^>*_]]4 >\?\
M"P?^F]'_  L$_P#/:O!_^%K7'_/%?^^JJZS\99-*TJXU*6)0L,+-G?WQQ^M
M'6>%O' ^R74JS<2:I=R*<]09W-:G_"='_GK7A.@>/+S3M'M[26)=ZQYD)?\
MB/)_4U;_ .%E77_/%?\ ONLP/:_^$Z/_ #UH_P"$Z/\ SUKQ3_A95U_SQ7_O
MNC_A95U_SQ7_ +[H ]K_ .$Z/_/6C_A.C_SUKQ3_ (65=?\ /%?^^Z/^%E77
M_/%?^^Z /:_^$Z/_ #UH_P"$Z/\ SUKQ3_A95U_SQ7_ONC_A95U_SQ7_ +[H
M ]K_ .$Z/_/6C_A.C_SUKQ3_ (65=?\ /%?^^Z/^%E77_/%?^^Z /:_^$Z/_
M #UH_P"$Z/\ SUKQ3_A95U_SQ7_ONC_A95U_SQ7_ +[H ]K_ .$Z/_/6MSX"
MZE>^-/VQ?@GX;TT>9<-\2+6?;_=CBBE9V/L!_.OGE?B5/N'F1 +_ !$/TK[A
M_P""%7[-_B+XS?M%:A^V#XCT^6/PKX'L9M+\*331D+J.IW VW$J?WDAB&TG^
M]*N#PP !^N:#':G4 ]J:P.: /S<_9O\ V3_&G[1?[1O[1&I^&_VJ/'GP_M[#
MXO:E!=:?X1U.2WCOMUS.=T@6106 &T$@\&NC_:*_9V\'_LZ:A\&_V(? 7B;6
M-)\(?$[QE=7'Q!\1S:@RWVMRQK%M@DG7;@2&3&T8SA.N#GZ^^"7[-?@/X#>*
M?''BSP;<WTESX^\2RZWK2WDP95N)&=F$> -JY<\<U:^/_P"SQ\+?VEO _P#P
MK_XJ:*UU:QW*W-C=6\QBN+&X4';-#(OS(XR>1V/- 'R/^W9^SW\(OV$O!?A?
M]IO]E?2)O"GBK1/$UE9IINGZG.T?B"WD?#VTT;NWFE@/O8W<\G@$=#K7PS\/
M?&3_ (*?_%SX6>*[82:?KWP&MK.X7T#W,(##T*G# ]00"*]/\"?\$[?A=X=\
M=:1X^^(7Q%\9^/+SP[,)?#\/C'7&N;?3Y!]V1(P I<=F;)X'I77Z_P#";X5_
M"3XN^*OVUM<U.ZM]0;P9_9^K--<*+=+. B;<!CALQCG- 'PMX0\9?%C]H6Q\
M'_\ !*3QC;7\&I>$?%L\'Q U-F8"ZT&Q*O;X?.<R!@GOL5N=W'UK\2/VJ_CQ
M\,OB?<_"[P+^POXNU[0=.FM[:Q\1:2T26<D1C0Y1<<*FXKC_ &#7+_\ !-'P
M!K/C<>,/VZOB/IK1^(OBIJS2Z5'*OS6>BQ8CMHQZ%@@;W58_>OJT!LYH ^$O
M^"C_ (W^*'QW_:9\&_LI_ ?X9+XUD\$O#XO\::*VI):PS%6 MH)9&X51NWLI
M!W>;'QQ7(^/?B_\ M5?!']L7P7^V;\?OV9;7P%X;O/+\)>+KG3_$45_'<V\[
M,8I'"<H8F&\''(3;D9K[6^$/[,?P^^#7Q&\:?%C09[Z\U[QUJ$=SK6H:A,)&
M"H&V0Q\#9&-QX^GH,:_QU^"?@;]HCX5:Q\'?B-8O-I.M6XCG\EMLD3*P=)$;
M^%U=58'U'I0!UJ21W,0DCD#1R+E61LA@>X(KX/\ @I^R?^SIXR_X*8?';PWX
ML^%MAJ%EH4>AWNDPWDDK_9[B:RMYI90Q?<6:1F8DD\FOMOP#X0M_A]X(TGP/
M8ZE=7D.DZ?':0W5](&FD1%VJ7( R< <XKR'XP_L$?#GXK_%Z[^->G?$#Q=X3
MUS5K&*SU^;PGK1M!JD,:A4$N 3D* NY2#@#TH ^2_P!NK0_V:=9\"?%C4/@A
M\!M6\2>*/#NHO=^*/BI)>>6FBW^]7\F*=W#.5!"^5$N .O7)]2_:@UK5-=3]
MCK6]5O))KJ^^(&C2W4S'F1VMXBQ/U)KT36_^"8WP<U.R\7^'+#XA>,]-\/>-
MI/M&N>';'6 MK)=;0OV@Y0L6.T$@MM8CD'%=9'^Q)\/+CP_\.-#U[QCXCU5O
MACK\6K:#>7]\K222QA51),* 8U50 H Z4 >=_L>?\I#?VFO^NWAO_P!$W=?5
ME<!\.OV=_ _PQ^,'C?XU^'[B^;5O'S69UI+B8-$OV99%C\L8XXD;/)SQ7?T
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M_B, W?GC-<QJ_P %O"%R";>RDMV_Z8RG _ YK=>/G%$O^7=./_;C?_MZ,_\
MB$.01^W-_P#;R7_MK+S_ +:7Q@3K^RM9_P#A:?\ VJH'_;B^*\?WOV6+7_PL
MO_M5<Y=?"/5].YT#Q3-'C[L<P)7]/\*R[O2_B)I1(N=-AO$ _P!9">3_ "/Z
M4UXY\83^!T'ZPDG^,[?B'_$*.&X_%[5>DHO\HG92?MV_$^+EOV6+7_PL?_M5
M0R?M^_$>/A_V6[?_ ,+#_P"U5P4VO%#MU'1[F!N_[OI^>*JW&J:/.N$N,>Q0
MUK'QNXXO[U*E\H2?Y3,Y>%?"_2I4^<E_\B>@2?\ !0KQ]'][]ERW_P#"O_\
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M .,T?\*'_P""BO\ T9AX>_\ #EI_\9K]***+L#\U_P#A0_\ P45_Z,P\/?\
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MO_A:1_\ Q%'_  YV_P""DO\ T0SP[_X6D?\ \17[C447 _#G_ASM_P %)?\
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M<+LGM[B,.DB^A4\$58HH AL+"RTNRCT[3;2.WMX4"0PPQA511T  X J:BB@
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M55TK6=-URS74-(OH[B!^5DB;(_\ K5:H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $9ZBC
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MKXI?<G;[Y+T/@\X\6LIPL7# Q=27?:/WO7[D_4_/WX"?\$J/VA_CU>6WB?\
M:)U@^#_#S,';2X,-?3)_="<K%_O/DC^Z:_0;X$_LW_!S]F[PROA3X1^#+?38
M< 7%T?GN+DC^*20_,Q_0=@*[P=.E&/:OZ(X8X&X=X3IKZG2O/K.5G+Y:62\D
ME?K<_&,^XLSKB*;^LSM#I%:1^?5_._E8  .@HHHK[ ^:"BBB@ HHHH ****
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MPSX.\/66EZ?:QA+:QT^U6&*)1V"J !6@!B@ ' Q1110 4444 %%%% !1110
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M%_\ A,9-3A33!8_;6O7D C6#9O\ ,+= NWG/3% %\G'%*#ZU\3:)\7?VU_\
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M?AC\>OA;YD6@Z[>6_FV.J6,@.^TN5"ME2&<<JZLLCHRX(*@'QC^P)\(_B?\
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MG:PE3/W54';7ZE_#O3/&.C?#_0]'^(FOQ:MK]KH]M#KFJV\(CCO+Q8E$TRH
M H=PS!0  #C H _/S_@KY^R]_P $S/'GQITOXH?\%1/VDO$UWIE[HJZ;\/\
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M]K::IO)\M8D1"("GEJ<+G=$C$,1@\K\-OV>O^#DWQ_XA\/\ @;]H/]MGX/\
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M_$1\OQ=I'C:X_P"$DAE/[TR'Y=S9Y(W*XSZBOLZOF+]HG]@;Q=KWQ;;]I/\
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M7/\ $JZU#S-%\1+:IY<%OYJ%H_\ 5@!F02 '8=NX=, @ ^C,UPG[3'QLT/\
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MF^(!$>DWWAFXL]%NI_\ 5QW31W"*.> ?,=1[&137U#\>M?\ C/X9^&=]K'P
M\"V/B/Q/')']BTG4;Q8(95+#>2[21@87)^\/QKG_ -J_]DSX=_M:_#Y?!_C*
M6XL=0L9OM.@Z]8G%SIMP.CK_ 'E/1E/!'3#!6'AND?!/_@K?\/--7P5X6_:7
M\'Z[IL/[NRU;6])5KJ&,=,DQ$N?]\N??% '8_L0?M<_';X]_$[X@?"?X]?#/
M1?#.K^!OL:3VNCW#3?O)C+N5G\R1&P$7!4]S7TH#D9KYX_8H_8\^)?[/7BWQ
MI\5_C+\6K?Q5XH\=/;/JTMGIXABC:'S,," N<^9C 10-O%?0X&!B@ /2OBWX
MJW-KX/\ ^"R?@GQ#X_\ DT_5_ 9L_#MU<?ZL7&;@>6">-V]CQU'FJ>XK[2KR
MG]K7]DGP'^UKX!B\+^*+VXTS5--N/M/A_P 06('VC3KCCYE]5.!N7(S@8((!
M !ZL,]Z:Q_BS7Q[I'P<_X*Z^ ].7P;H'[2'@W7;&,".UUC6=+#74<>, L3'E
MR!S\^\D]S7<?"O\ 9O\ VMO WPQ^(-WX\_:-3Q;X[\9:;#;:9<74+0V.D&-9
MQF(*!MSYY)VHH!1>#0!\R^)_VM)/%_\ P4-U;X]V/P2\5>.O#?@&&;0?"J^'
M;7S8X[H96:Y+$;?F)DVXYVE#VK6_8V_:/E\$?M]Z[HVH_"[7_!/A7XO,T]CI
MGB2U\IH]6C&XNAP 0Y9U..=TB9Z5]<?L7?LU6W[*GP TGX627<5WJFZ2[U_4
M(0<75Y*VYV&>2JC:BDXRJ D9)K)_;D_9;UG]I?X?:1_P@.JVFE^+_"NO0:KX
M;U:[#;8F4XDC8J"VQEP2!U:-,]* /)_@LPLO^"QWQAANCY;7GA/2WM5;CS56
MQL@2OJ 01^!KZL^),\-M\/->N+B58XTT>Z9W8X 'E-S7@?[3/[$7C_XM>+?#
MW[1'P>^**^"?BEHFEQVUQJ4,?F6E\H'*2#:<@$L 2K J<,IP,</XI_9A_P""
MG7Q]TD_#7XV_M)^&='\+W2B/6&\-Z6JW-]%GE<A%(R.H#*I[@]* .D_X(WPS
M)^Q9:73Q,L=QXFU*2!F7AU\W;N'J,J1]0:^JJY?X,?"3PA\"?AAH_P )? =H
MT.E:):B"U$C9=SDLSL>[,Q9B?5C744 %?('P0E6U_P""NWQ:M;D^7)=>#;&2
MW1O^6BJMN"P]0#Q7U_7SE^UE^P_XH^+7Q)TK]HK]G[XJ2>"?B)H]K]F34/)W
MV][#SA)1@],D<AE(."O>@#W#XH7,%G\-/$-W=3+''%H=V\DC' 51"Q)-?&?_
M  3]^,ND?LZ?\$N==^,WB$8CTW5=4FL(W.W[5.S)'#&O^]+A<]N3VK;\5?LO
M_P#!3C]H'1V^&GQP_:4\,Z/X7N%$>KMX;TM5N;Z/NIPB]1V#*ISR#TKK/CE^
MP!<^-/AM\,_V:?AGJ=KI7PW\*ZQ#=^)K>YE<W6HHC9;E1@NY:5BW #29 P *
M /E'X#?%Z[T#]F7QE\-/B#^R'\1/$6K?$JXN;_7O$5GIH\N=Y03 R;AG:F=P
M]V;'6O4OV;/BWX\^,7_!,3XE_ .^AO(_&?@/PQ?Z3)87$92ZDL1"QC0J>=PB
M#P[<<[%'4U]\6EG;Z?:1:?86ZPPPQK'#'&N%10,  =@!7AJ?LM>,/"O[<DW[
M3/@#5M/A\/\ B3P_]A\::/-N$EQ.BXCN$ &TG"Q@Y(X#'DF@"'_@F+XD\)^(
M?V)O Z^%98F%C8M:WT<>,QW*R-O#>_(/T->_5\@^+?V /CQ\&_B7J7Q/_8-^
M.</A.WUN<W&K>#]8MA+I[RDY)C4JR@'G *AE!(#8.!#JW[-G_!3[XW1_\([\
M7_VK-#\*Z%)\E]#X.TW;<3IWPX56Y&1CS /4&@#[$HI #G.*6@#YS_X*RP3W
M/_!/[X@16\3,P72V^4?PKJEH2?P )_"O5OV;;RVOOV??!=W:3K)&_ABR*R*>
M#^Y6MKXD?#_PQ\5_ FK?#;QI8?:=*UJQDM+Z'IE'&.#V(Z@]B :^2_"?[)7_
M  4;_9IL6^'O[.'[2'A_5O!\3,-)L_%>FJT]BA.< [#T] VWN%&2* +'[9;B
M[_X*3_L\Z=:GS+B.:ZFDACY94&XEL>@"D_0&J?[.-_9>%?\ @K9\7M$\<;8=
M6US0H9/#LEQUEMP8F*(3ZH%/':,^E=]^R]^P]X^\%?&.X_:@_:B^+/\ PFWC
M^6S:VT^2" 1VFF1.NUQ$H50&*DK\JJH#-@')-;_[8'[$'A_]IJZTOQ_X6\6W
M7@_Q]X=YT/Q5IN=X4'(AE (WIDD@@Y4DXR"RD Z;]J7QK^U#X(\,:??_ ++O
MPCTGQ=J$ETXU2VU;4H[9;>$+D.I>:+)SQ@$_2OGP?M%_%K]LW_@F]\5_$VN>
M$K'2=<T\WVF-8:.SLK+"D3ORS-EOF8<'&!6E_P *G_X+"-IO_"'-^TCX%,.#
M&?$#:+']H*=,X\C&<=]F[WSS7K/[%'[)EU^RI\'K[X;^)/&<?B2ZUC5Y]1U.
MZ^Q>5&SRHBN@4D[E^7J<9ST% #/^"=WBCP;XI_8K^'<_@J6$PV?ANWLKV.$C
M,=Y$NRX##L3*';W#9[U[8,"OCW7/^"?_ .T#\!?B!JGCS]@GXZP>&M,UBY:Y
MU#P7KUN)[(2'DB+*L O89 91QO(P!/%^SG_P4T^+6L6<'QI_:IT/P_H,%U'+
M>:?X1TW9+=*K9*EPJMAAP09,?[)H ^N\T5'!$T,21 YVJ%W'OBI* /E'_@M5
M;W$__!/'QHT$+-Y<MFTFT?=7[0G)]NE>V?LDW]GJ?[*WPUU"PN5EAF\ Z.T<
MBGAE-E%6]\7?A9X-^-_PUUKX2_$+33=Z+K^GR6>H0JVUMC#[RG^%E.&![$ U
M\6>"/V*?^"IO[)6F/\+_ -E;]JCPSKG@>%G&BV7C+25:XTZ,G(4'8>GH&V9Y
M"+G%<-3VE'%>U47)-):;IIOIIW/TS)WE/$'!,<EJXRGAJ]&O*K%U>90G"I"$
M6E.,96E%P3M))-/1W5C1_;KF2]_X*N_LMZ;:/YEQ;-JL]Q"G+1Q, %<CLI*,
M,_[)KRS_ (*D_M 'XC?MS^!_@I:?"WQ%XZ\+?"NYAUWQAH'A>V\^2YO'&^&*
M0?="@"/=N_AD8#DU] ?LG?\ !/'XG_#WXT:C^U]^UA\9?^%B?%"?36M-),</
MD6&F1D'Y4 4<G.T;554#,0&+9'4_L ?L<^//V;SXZ^)7QO\ $>GZYX^^(/B:
M74M;U/3=_E+$262)-X!"@LWRXP!M Z5RRH8BO=-<O/*[V=DDK)^;:V/L\/Q-
MPIPXZ->%:.*G@,-["FHN<%4JUZM652<)-*2A2A4E%3:BW)Q<5U/BGQ-^VG>>
M'_\ @HMX+_;)A_9N\<?#G1=8MH_#7Q F\36'EV]U'(P2*8.HP&4;,Y[0J1WK
M[(_X*N_M0WW[.7[(&K3>"KEG\4>,V70?"Z6[$R^;<#:\R <EDC+%2/XV2O3/
MVQOV<-*_:N_9R\3? [4WBAEU>Q/]FW<RY6VNT.Z&3\' S[$UX#X$_8)_:1\<
M?&#X*^+OVJO&GA_6-%^#_AWRX[/3Y97;4M5C)6WNI-Z@?*BP.2>3)&>"&JG1
MQ5%3IQ=^?K:UF]'^&OJ<U+/N".(*F79KC(1H?4.:$J#G*;K4Z<74H1C*2N[S
MO2E=^[%QZ+3X]\3?$2:[_P""=NF_L::+^PE\5+/6-$:'4]/\3_V. D>L(Y=K
MK &X [G7UVM7Z0?\$[?VF[7]J_\ 9+\+?$Z68?VQ#:_V9XFMOXH-0M_W<N1V
M#X64#^[*N><U[?M.,"OF_P#9*_8V\=_LI_M'_%+7O#.OZ:_PV\=:DNK:3HB%
MUN--OF^:50N-HCW,ZK@_="9Z5I1PM;"UHM/F37*]$K6V?YKYGE9]QAD/&G#>
M*HU*"PV(IU'B*;=2=3VDJC4:T+R7NMKEJ)*R]Q[7U^DZ*!G'-%>D?CP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Y&*^>?^"?W_  3O
M\!?\$^H_BI'X$\?ZQKW_  M7XIZEXXU/^UH8D^Q75YLWV\7E@9C78,%LMSR:
M^AJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0MCM0!D>+
M/$EMX;BAEN) OG.0NXUK1-OC5QW4&O!?V\/B*/A]H/AFX,_E_:M2E3KUPJU[
MIILOFZ?;R'^*%3^@H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5'>)-);2103>7(R$))MSL..#COBI*" >HH _)
M?]OO]N7X@>.+RU^!OQ5\#+I?BKP'XGNHM4O+"0_9[Z/"JDJ*WS+N #CD@A@:
M^WOV"OVJ/'W[7MEKWQ&E\)0Z%X-TN2+3- MY#YES>W"KNFF=^@508U"J,99N
M25KY/_X+=?LX75I\5_#?QS\+:6\A\3HFE:@L4?W[R/ A/'5F0A?^  5]X?LD
M?!"T_9U_9Y\+_"F&W5;BPTY7U)E_BNI/GE/O\Y(_"@#TJBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ,XZT9K\U?^#C+_@K-\=O^"=7PK\%_#W]CIK>;XJ>-+ZZO;>*31TU
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M_@W\//!UQ:KIWC;Q5]@UQ;BU#LT.Z,80G[IPQY%>_!L#F@!U%&1ZT4 %%%%
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MUI-?W]PD,%O&TDTTC;515&2Q)Z #F@"7(Z9HS7QK>?ME_M;_ +6?C/5/#?[
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M^)VB:)#X/U8ZU9S/=RP6MHDR-#%*TL6UHG&750=N02""=3]@C]C']HWX(_\
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MM\)M$_:-_:?^/OQT^$__  TAXH\.>%]'\<3QQW6GZ@\EU$H>18[2W+M_HT(
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M:BB@ P,YQ1110 8'3%&T8QBBB@ P,8Q1CVHHH -HZXH  Z444 '6C Z8HHH
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MB@ HHHH *,8HHH ,>U&!G.*** #:/2BBB@ HHHH **** "FL !PM.HH \/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_!,_P#X*_?#_P #WEW\3+-9?!?C+P-&8E,CM(L>=N$EC+Q/&1LC=&P3N!%
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M4L_['\%>+)MOB"]T:XD4)JMT69/LP:)A,(T<O&A7<CG( !^G]?G#_P %_?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3R_8I^+%K\?9_P#A,/BAXWTYE?1=>^*&M)?C2W!X>W@CBCC#CL\@D93RI7-
M'PG_ ,'-7@SQS\.?^"%_[,?@+XFRR/XBT>]T>SUIIF+-]ICT=EDW$]]P-?O)
M:65K8V4-A86Z0P01K'##&H544# 4 = !VKY[_P""D'_!,/\ 9L_X*E_"?1_@
MU^TW=>)(M'T36O[4LV\,ZHEI,9_+:/YF>*0%=K'C Y[U]%#(% 'XC_\ !*KQ
M7X/_ &.?^#CK]KGX._M):Q:Z!X@^(L\NH>"=4UJ80+J=M+>?:U2-W."9(I%?
M&[K"R\D8%_\ X.U=9T?5/'O['":7JMM<F/XL7F_[/,K[?WFF=<&OT9_;\_X)
M._L/_P#!2O3+&/\ :B^$_P!LUG28RFA^+M$OI+'5].4G.V.XCY9,\^7('3/.
MW/-?+.@_\&GG_!,K0_&.B^.)?'GQFU"\\/ZI#?Z:NJ>/(IXTFC=77*M:]"5&
M<$9% 'L/_!6/_@G_ /L*?\%2I-&_96^.'Q3MO"_Q7T/3&USX?ZIIM]''K&GP
MS2&,S11.1]HA:6V^9 <YC!!0X:ODK_@DM^UE^WS^Q1_P5%NO^"'O[=GQ<M?B
MM:/X7FU7X?\ CVWN&FNH+>*!YXTN&?\ > /#%("DA9TD50'=7#G[2_X*3_\
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M?#OQ;_P1?AU3X7>(M%U32%^*VCQPW&@7D4UL&"7990T)*Y!/(]36I_Q!Q?\
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M'%YJWC+3(K'6IO%WB".^#1I+YH9=L,9#[NI).10!]@44#CBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$W_@N5_P6_\ ^"G7
M[&G_  5"T']AC]B#2/">J+XF\/:(="T?4_#(N[R\U2^N)H4A1S,@^=UC50<
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M@Y=R77]LZCI;7]NJVK&'R58J<OT!RIX^GJ*ZC/:@ HHR*,B@ HSVHKS]_CI
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M&O\ 98US0[.YN$B75M-NQ>11EF !=0H*KD\G)^E 'OU%-5U9%8'[PS3L\9H
M**,BC(]: "BC-&10 44$@=31F@ HH!STHSCK0 49H)%</^T'\<O#_P"S[\/)
MO'VNV$UZWGI;V.GVW$EU.^=J ]AP23S@#H3@4 =QFBN+^"7C?XG>/?#%QJ_Q
M3^%O_"*7BW>VWL?[0%P9(=BL')"KM.25QC^'/?%9_C/X\/X1^/?A3X(_\(K]
MH'B:SN9_[3^W;/LWE*3CR]AWYQUW+CWH ]$HHR/6@$$9% !10&!Z&C(SC- !
M12;E]:7/>@ HHS02!UH **,YZ44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %&:*\<_:8_:CU[X$>+/#7@OPO\)W
M\4ZAXE9TM+>/5Q:L) P 49B?<3GU% 'L=%?/ND?ML^*-!\7:7X9^/O[/6L>!
MX-8NEMM/U2;45NH#*QP%<B--N?Q]>F:^@5((XH 6BC/.*0GWH 7-%<MX9^+'
MAWQ7\0=>^&^G6=^E]X>6%KR6>S9(7$@)&QSPW2NI&,<4 %%&1ZU7U.]%AIMQ
M?A-_DPO)MW8W;1G&>U %BBN _9I^-[?M"_"NU^)K>&?[(^U7$T7V'[9]HV[&
MQG?L3.?]WBN_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"<=J /YK/\ @XF^
M"?A7]I7_ (.5?@_^SMXZNKN#1/'=OX(\/ZO-82!9X[6\U26WE:-B" X20X)!
M ..#7V^/^#,O_@F#C_DI?Q3_ /![;?\ R/7Q[_P<7>'?VI?AK_P7T^'G[7_P
M0_9?\7^.H/A_HWA/7;1=*\,WUS9W=S87\US]F>:WB8+DHH;!W -G'2O3A_P=
M+?\ !7,#'_#E;5__  2Z_P#_ "-0!^AC_P#!/GX-?\$S?^"-7QQ_9B^!&L:U
M?:!#\,_&.IK/K]RDUQYT^DS[QN1%&WY!CBODW_@RZ^'O@C3O^">/CCXF6'A.
MPC\0ZI\4+FRU#6EME^TSVT%G:M#"TF-QC1I96"YP#(QQDFO8OV8O^"@'[6/_
M  4[_P""5_[37B/]H+]CK4OACX@TWP#K^DZ#X=73;\3:KYNBW!#1QW,:N[%R
M$ 0')('6N5_X-"?A;\3_ (1?\$U/$OAGXK_#C7O#&I2?%;4)X]/\0Z//93-$
M;.R D"3*K%25(W8QD'TH ^:?^#C'1]-\ _\ !?+]B_XK>%+..SUR_P#$GAY;
MR^A4*TXM_$-OY0?'WL"5UYSE3CI6]_P=&^ E^'W_  4:_96_;/\ VAOA]J7B
M3X!>'YX=-\9106+W-K:S1Z@;F9)E (!F@=-JD?O!:N!NVD5I?\'&/P4^,WQ$
M_P""Q7[&OC#X?_"/Q/KNDZ-XCTI]8U31M!N+JWL577K1R9I(T98@$!8[B, $
M]!7LO_!VQ^T7J_PW_P""<K_"7X<?'KP?X?USQ%KUN=?\+:M=1'4]:T4),)([
M2-PW(F\EB< E8V"L""" >.?\'%O_  56_P""2/[37_!+Z\^"_P %/B[X4^(G
MC;Q!=:?-X!TWPW;M)<:)(DT;//( @-IB#S(O+?:Q,F-IP<?17BWPM\<?!?\
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MV>+SX._#GXAK<Q^$_ -Q#)#&OVB_^U1I$DBHS16T?[M9"BAO,.U5'  /.?\
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M+Q!\/_%^L:MX#^*7[.?BRZO+",?\(KXG\/6)F:8F-6!61<&,B0D$-E?ES[4
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MTGN25[ _*?6J7PN^-GCGX#_">'X%?%/X#^+IM2T6TFL+34M"TX7-K>0_,(Y
M=P*\$ CG.,]\  Z;_@FP,?LK:7_V$+K_ -&5[W7S+^S'XF\:?L^_L.KXDNOA
M;JVJ:II]]*5\/QQM#<2!YU7/*,0 #N)"G@=*^B?".N7/B;PMI_B*[T>;3Y;Z
MSCGDL;G_ %ENS*"4;W'2@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *"!110 4$9HHH 0**-H]*6B@
MHZT44 ! -)M'4TM% "!0*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\>^,]&^'
M?@S4O'/B!W6STNS>XN/+7+%5'0#U/2M>L#XI:AX*TOX>:Q>_$9%;0EL7&JAX
MV<>2>&R%Y/7MS0!YC\+_ -J[QO\ $#4]$NM4_9YU_3?#WB215TGQ!YT<T05A
M\CRJG,:MQ@M@'(QG-6OBI^UD/"?Q%?X1?##X::KXS\1VUL)]1M=,*K'9H<8\
MQVX!Y'L,@9R<5XSX,\:V7[.'Q<\'^%_@+\9HO&?@OQ=JRVA\+?:1<3:8LC@&
M6-AT5=Q;!Q]TY[D164>A_#3]KKX@>'_BS\5-:\%KXDN8;_1=6L[I8;>]B&_Y
M'=E(R-_R\@ A@><"@#WGX5?M1Z%\2O#_ (DFO/">H:'X@\)V\DFM^'-34+-%
MM0L"/56QP?<>HKBO#7[=?BO7?",?Q*/[,?BA_#+*SR:M8S13!(U)W/L!W8&#
MGBJ_@[1_@$-<\>>)/AY\9K_Q;XDN/!MPFK7$MTLZ"%8BJ;G10NX8  R3@5F_
MLE?M"_!;X<?L?:>OC'QSI:3:?;7 NM,>X5IG)9B(_+ZDMG&,=Z /6/$7[3/A
MB+X7:/\ $SX<>']2\6+XAG$&CZ?I,6999/FW!L_<V%6#9Z;36;\)/VHKOQI\
M39_@S\2/AGJ'A'Q,MC]KM;*\N(YH[J$=2CH2"0.?H#Z5X?\ "+XA_$']F;]D
M'3=:@T6&UU#QEXVE_L276%*PZ;;3^6JS2CJ%^1F [AL\]#I:&9?#_P#P4%\*
MMXJ^+T/B:Z/A6Y^U:BWDQ11.T<N(D5#A%[@$D\]: /3-6_;,@@^)?BGX1>&_
MA=JVM:]H,RQ6=C82*S7N5W,_/$:*",LQ[@=32I^UMXPNO#6EM8?LX>*I/$VJ
M75Q"GAV2,1M$L.T/,\CX"1Y=0&; )/7IGG?V:;>W;]M3XS79B7S%FM463'(4
M@9'Z"NI_:B^.7BKX=^*?!_PS\$7.GZ7?>,+YH)/$>J1[H;")<9(7(#.2> 2
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MM0 97TXKH/CQ*MG\$/@G\5C!_:6@^%+VTD\00VJ^;Y:M#'B1@/[I4CURX]:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%&:,]Z "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQK-!(KHPRK*V0?QIU=F^J.8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M,:TH-0E=1;3L[6O9[.UU>VUU<=14-_?VFF6<VHZA<+#!!&TDTLAPJ(HR6)]
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M@ KY_P#^"K?_ "C/^/7_ &2?7/\ TBEKZ KY_P#^"K?_ "C/^/7_ &2?7/\
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M)/\ MX_!Y?[)GL/#_B>^M=4$0DOK#1C+!9/)C;'*X;[_ ",JFXC/->/_  ^
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MPE>_LJZIX]^&HU/5[?Q!I=U8V=]I-KN^P2-"RF2?<RF(+W."0<<5!_P3\OO
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M\"B,Y$XLY/-E8#T"_/Z$RGKBONC]GOXO:/\ '?X.^'_BMHI55U;3TDNH5/\
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M%DQ*[;6VG!(QD!<]!7M%%% !1110 4444 <YXH^%/@+QMXJT?QKXET!+G4]
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M*,2JD DJ ISU'%?J,.E=T8QIQ48JR6R6R.64I3DY2=VPHHHJB0HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /RS_ .#I-@OP)^%!8_\ ,Y7?_I**^[O!_P"V7^R5!X2T
MN";]I3P0KIIT"LK>)K;((C7(^_63^W/_ ,$]?@/_ ,%"?"FA>#OCQ?\ B""T
M\/:A)>V#>']0CMW,CQ["'+Q29&.P YKYI_XAH?\ @G=G/_"1?$K_ ,*6V_\
MD2@#Z^_X;0_9&_Z.7\#_ /A36W_Q='_#:'[(W_1R_@?_ ,*:V_\ BZ^0O^(:
M'_@G=_T,/Q*_\*6V_P#D2C_B&A_X)W?]##\2O_"EMO\ Y$H ^O?^&T/V1O\
MHY?P/_X4UM_\71_PVA^R-_T<OX'_ /"FMO\ XNOD+_B&A_X)W?\ 0P_$K_PI
M;;_Y$H_XAH?^"=W_ $,/Q*_\*6V_^1* /KW_ (;0_9&_Z.7\#_\ A36W_P 7
M1_PVA^R-_P!'+^!__"FMO_BZ^0O^(:'_ ()W?]##\2O_  I;;_Y$H_XAH?\
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M\$^/ASX>EUZXMM/UKQ,NF:QJ"R'<EF)IL1D_W<*/PC Z<5[U\9?V6OV<K+X
M:M9V_@G3--BTG199]/U:&-5FADCC+))Y@Y8E@,Y/.: /< <]*R?&7COP;\/-
M&;Q#XY\36>DV*L%-U?7"QIN/09/4^U>?_L1^+O%/CC]F#PKK_C":2:]:UEA^
MT39W3QQ3/'&YSR245>3UQGO6?^V3\#/%_P 8- T'6_ 1LKG5O"VJ&_MM'U1=
MUKJ P 8W&1SP,?4CC.: /1?!7Q9^&GQ&TN?6O OCC3=4M;49N9K.Z5Q%QGYL
M'Y>!WK&T[]IS]G;5KV/3M,^-OAB>>5ML<4>LPEF/H/FKS?\ 9\^(?P^\86_C
M+2$^$$?@?QM8:64\3:.D(02*(VV2+C 9>>#C.".2,$\[^Q/\#_A!\1_V2-/E
M\=>!=+NVNFNUN+V>U7S5 D8;@^,@@=#GB@#Z2\1^,_"7A#0F\3^*?$ECI^G(
MH+7UY<K'$ >GS$XK-\ ?&#X7_%2.:3X=>.]-UC[/C[0MC=*[1YZ;AU'XBOEG
MX >-_AF/V89I_P!H".X\0:/X7\=SV/A2UDC:9[U@J&*(1_\ +4@R-@'(&0.P
MK0\!3WMK_P %!/#]Y;?"L^"X=6\*71FTL31[[F-4D*O*D?RHV5'RY/W0<T ?
M2WCWXO?##X711R_$/QWIFC^=_J5OKI4:3_=4\G\!5WPEX^\$^/-#_P"$E\&>
M*K'4]/Y'VRSN5DC&.H)!X(]Z^;/V??!?@_XW_M1?%;Q1\7=,@U;4M"UI;'1]
M/U)1(EI:AI%!5&XZ(HSCC)/5JZ3]LSP]I7P2_92\3Q?"'P_#HL.J7ULFIG3E
M\I8XY9421P!PFX80D#^/UH ]2TS]HWX$ZSXF_P"$-TKXLZ#<:HTGEK9QZBA=
MG_NCG!/L.:TO'WQ9^&GPMM8KSXB>.--T>.X;$'VZZ5#(?]D'D_A7S+JW[-OB
M[QW\#[/PCX*_9G\'Z6[V,$NE>);3Q8&N(Y,*PGS]G#,3W^;O[5O?&7X%?'![
MGP+\<K+0-)\7^(/#7AV.R\1^&]2Q)%>/Y>))8CP-Y)8CWP>1D$ ^B_"7C/PG
MX\T:/Q%X+\16>J6,C$1W5C<+)&2.HR.X]*TZ\K_9)\<?"SQWX!OM1^&7@K_A
M&WCU>0:]H)CV-:7VQ ^5X'("\@ '!X!S7JE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?E7_P<@7EKI_Q3_9OO[ZX2&&'Q5=R332-M5%$]B2Q
M/8 <U^A'_#:'[(W_ $<OX'_\*:V_^+KB/V[/^":G[//_  4-B\.1?'G4?$EN
M/"[7)TW_ (1_4HK?/G^7OW[XI-W^K7&,8YZU\\_\0T/_  3N'_,P_$K_ ,*6
MV_\ D2@#Z]_X;0_9&_Z.7\#_ /A36W_Q='_#:'[(W_1R_@?_ ,*:V_\ BZ^0
MO^(:'_@G=_T,/Q*_\*6V_P#D2C_B&A_X)W?]##\2O_"EMO\ Y$H ^O?^&T/V
M1O\ HY?P/_X4UM_\71_PVA^R-_T<OX'_ /"FMO\ XNOD+_B&A_X)W?\ 0P_$
MK_PI;;_Y$H_XAH?^"=W_ $,/Q*_\*6V_^1* /KW_ (;0_9&_Z.7\#_\ A36W
M_P 71_PVA^R-_P!'+^!__"FMO_BZ^0O^(:'_ ()W?]##\2O_  I;;_Y$H_XA
MH?\ @G=_T,/Q*_\ "EMO_D2@#Z]_X;0_9&_Z.7\#_P#A36W_ ,71_P -H?LC
M?]'+^!__  IK;_XNOD+_ (AH?^"=W_0P_$K_ ,*6V_\ D2C_ (AH?^"=W_0P
M_$K_ ,*6V_\ D2@#Z]_X;0_9&_Z.7\#_ /A36W_Q='_#:'[(W_1R_@?_ ,*:
MV_\ BZ^0O^(:'_@G=_T,/Q*_\*6V_P#D2C_B&A_X)W?]##\2O_"EMO\ Y$H
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MBJXM9M2_X2'4H[@JT"R*FS9%'M&)6SG.>.E>^T %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_86_8)^"_P"W?\9_VE/B3^V1X>B\::Y;_$N;P_;Z[:SW%@L$EM'LE:W2&15
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mrna-20251231_g4.jpg
<TEXT>
begin 644 mrna-20251231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1@ Y$# 2(  A$! Q$!_\0
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MH?\ OW_]>C_A,]3_ +T/_?O_ .O6%11[&G_*'UFM_.S=_P"$SU/^]#_W[_\
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MU/\ O0_]^_\ Z]'_  F>I_WH?^_?_P!>L*BCV-/^4/K-;^=F[_PF>I_WH?\
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M_P )GJ?]Z'_OW_\ 7H_X3/4_[T/_ '[_ /KUA44>QI_RA]9K?SLW?^$SU/\
MO0_]^_\ Z]'_  F>I_WH?^_?_P!>L*BCV-/^4/K-;^=F[_PF>I_WH?\ OW_]
M>C_A,]3_ +T/_?O_ .O6%11[&G_*'UFM_.S=_P"$SU/^]#_W[_\ KT?\)GJ?
M]Z'_ +]__7K"HH]C3_E#ZS6_G9N_\)GJ?]Z'_OW_ /7H_P"$SU/^]#_W[_\
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MZ'_OW_\ 7H_X3/4_[T/_ '[_ /KUA44>QI_RA]9K?SLW?^$SU/\ O0_]^_\
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M?6:W\[-W_A,]3_O0_P#?O_Z]'_"9ZG_>A_[]_P#UZPJ*/8T_Y0^LUOYV;O\
MPF>I_P!Z'_OW_P#7H_X3/4_[T/\ W[_^O6%11[&G_*'UFM_.S=_X3/4_[T/_
M '[_ /KT?\)GJ?\ >A_[]_\ UZPJ*/8T_P"4/K-;^=F[_P )GJ?]Z'_OW_\
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MQQO/?'&<UTE2<KT=@HHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-_MBW6W5V62U\PQ&3=C PX*E2=P(.16OXH\6:-X)T6?5]?U.UT?3(,"2ZO)
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M/2RS>?R_4=1117F'NGD$*K):QJRAE:, JPR",=#7/^&?$S_".S?0-=L9M7\
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M@?Q-:ZY::1>7]U9N);6'4[U[B"W8'(*H>#@\C=GGFMOXL?LJ?#SXS>)(=?\
M$.G7::Q'&L3W>GW;6[S(.BOCK@<9X..,UZ[11=C]I.][GD?@G]E;X<_#^/Q3
M;:7HTCZ;XE@2VO\ 3;N<RVYC7.%12,KR2<Y)SSFN>T7]ASX4Z+K%I?#3]4U"
M"SE\ZWTS4-3DFLXF!R,1GJ >Q)'KFO?:*+L/:3[C9(TFC>.1%DC=2K(P!5@1
M@@CN,5X"W["?P?;7+K41H5VB7!9CIZWT@M$9@1N6/L1G(!) ..*^@**"8RE'
MX6>+VG[(_@&RTOP-I\:ZK]G\&WDM]I6Z]RWFR2K*WF';\XW(...*;X^_8_\
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M51V   J>BBD9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYB8!((Z$4:A9'JGDQ_\ /-?^^11Y,?\ SS7_ +Y%?,6L_MWZ1X;\/Z?KFK>
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M=A9#/)C_ .>:_P#?(H\F/_GFO_?(I]%%V%D,\F/_ )YK_P!\BCR8_P#GFO\
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M50Q%6_!OQMT?QAJEK81PM:S3?:8FD,\4T*7$ B=X?,C8JQ,<RR*0<%0V<%2
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M_P"U/T3_ .$UT+_GO'^2_P"-'_":Z%_SWC_)?\:_.SRT_NK^5'EI_=7\J/\
M52'_ #^?W?\ !#_7VI_T#+_P+_[4_1/_ (370O\ GO'^2_XT?\)KH7_/>/\
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M8MDC"CHN.21D]%_PKSQ%_P!%.\2_^ NF?_(E'_"O/$7_ $4[Q+_X"Z9_\B4
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M^&?^GG_P-;_XBC_ADOPS_P!//_@:W_Q%=[_PKOQ%C'_"S?$O_@)IO_R)2?\
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M (":9_\ (E']K8__ )_2^\/[ RK_ *!H_<<'_P ,E^&?^GG_ ,#6_P#B*/\
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M/B[3-+O+_P /WFF2P6XMDM;N8I.D*M\L<ABD8.,J& +-_.NSCC2&-(XU5(U
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M_B:TO^&;?&/]VR_[^2?_ !%'_#-OC'^[9?\ ?R3_ .(H]IDG_3O[D'LN)_\
MI[]\O\S-_P"%]>,O^?ZU_P# *+_XFC_A?7C+_G^M?_ *+_XFM+_AFWQC_=LO
M^_DG_P 11_PS;XQ_NV7_ '\D_P#B*/:9)_T[^Y![+B?_ *>_?+_,S?\ A?7C
M+_G^M?\ P"B_^)H_X7UXR_Y_K7_P"B_^)K2_X9M\8_W;+_OY)_\ $4?\,V^,
M?[ME_P!_)/\ XBCVF2?]._N0>RXG_P"GOWR_S,W_ (7UXR_Y_K7_ , HO_B:
M/^%]>,O^?ZU_\ HO_B:TO^&;?&/]VR_[^2?_ !%'_#-OC'^[9?\ ?R3_ .(H
M]IDG_3O[D'LN)_\ I[]\O\S-_P"%]>,O^?ZU_P# *+_XFC_A?7C+_G^M?_ *
M+_XFM+_AFWQC_=LO^_DG_P 11_PS;XQ_NV7_ '\D_P#B*/:9)_T[^Y![+B?_
M *>_?+_,S?\ A?7C+_G^M?\ P"B_^)H_X7UXR_Y_K7_P"B_^)K2_X9M\8_W;
M+_OY)_\ $4?\,V^,?[ME_P!_)/\ XBCVF2?]._N0>RXG_P"GOWR_S,W_ (7U
MXR_Y_K7_ , HO_B:/^%]>,O^?ZU_\ HO_B:TO^&;?&/]VR_[^2?_ !%'_#-O
MC'^[9?\ ?R3_ .(H]IDG_3O[D'LN)_\ I[]\O\S-_P"%]>,O^?ZU_P# *+_X
MFC_A?7C+_G^M?_ *+_XFM+_AFWQC_=LO^_DG_P 11_PS;XQ_NV7_ '\D_P#B
M*/:9)_T[^Y![+B?_ *>_?+_,S?\ A?7C+_G^M?\ P"B_^)H_X7UXR_Y_K7_P
M"B_^)K2_X9M\8_W;+_OY)_\ $4?\,V^,?[ME_P!_)/\ XBCVF2?]._N0>RXG
M_P"GOWR_S,W_ (7UXR_Y_K7_ , HO_B:/^%]>,O^?ZU_\ HO_B:TO^&;?&/]
MVR_[^2?_ !%'_#-OC'^[9?\ ?R3_ .(H]IDG_3O[D'LN)_\ I[]\O\S-_P"%
M]>,O^?ZU_P# *+_XFC_A?7C+_G^M?_ *+_XFM+_AFWQC_=LO^_DG_P 11_PS
M;XQ_NV7_ '\D_P#B*/:9)_T[^Y![+B?_ *>_?+_,S?\ A?7C+_G^M?\ P"B_
M^)H_X7UXR_Y_K7_P"B_^)K2_X9M\8_W;+_OY)_\ $4?\,V^,?[ME_P!_)/\
MXBCVF2?]._N0>RXG_P"GOWR_S,W_ (7UXR_Y_K7_ , HO_B:/^%]>,O^?ZU_
M\ HO_B:TO^&;?&/]VR_[^2?_ !%'_#-OC'^[9?\ ?R3_ .(H]IDG_3O[D'LN
M)_\ I[]\O\S-_P"%]>,O^?ZU_P# *+_XFC_A?7C+_G^M?_ *+_XFM+_AFWQC
M_=LO^_DG_P 11_PS;XQ_NV7_ '\D_P#B*/:9)_T[^Y![+B?_ *>_?+_,S?\
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M_#^O^(-.O[3Q/#::!J+Z7JFM)H<TNG6<R,%;S)T!"CD<GL0: /0/^$V^(O\
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MZ/10!YQ_PFWQ%_Z)G%_X44'_ ,;H_P"$V^(O_1,XO_"B@_\ C=>CT4 ><?\
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M7_A10?\ QNC_ (3;XB_]$SB_\**#_P"-UZ/10!YQ_P )M\1?^B9Q?^%%!_\
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M!_\ &Z]'HH \X_X3;XB_]$SB_P#"B@_^-T?\)M\1?^B9Q?\ A10?_&Z]'HH
M\X_X3;XB_P#1,XO_  HH/_C='_";?$7_ *)G%_X44'_QNO1Z* /./^$V^(O;
MX9Q?^%%!_P#&Z/\ A-_B+_T3.+_PHH/_ (W5#XG?'S2OA[=I:,'GN7R5BA0.
MY )!;D@*N00,Y)P>,<UPG_#7]C_T#;W_ +]1_P#Q=>M1RO&XB"J4J3:9X6(S
MS+<)5=&M62DMUJ[?<>E?\)O\1?\ HF<7_A10?_&Z/^$W^(O_ $3.+_PHH/\
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M/_0-O?\ OU'_ /%T?V)F'_/I_A_F'^LN4?\ 00ON?^1Z5_PF_P 1?^B9Q?\
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M?V)F'_/I_A_F'^LN4?\ 00ON?^1Z5_PFWQ%Q_P DSBS_ -C%!_\ $4?\)O\
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M[W_GRN?^_+?X5]S7?QE^&-ZP,_C#07=> WVY P]@0<U7_P"%L?"O_H<-$_\
M!D/_ (JOM,)Q+/#4(T94N;E5KWM^C/S;,."Z6-Q4\3"NX\[O:U]7OK='Q#_9
M=[_SY7/_ 'Y;_"C^R[W_ )\KG_ORW^%?;W_"V/A7_P!#AHG_ (,A_P#%4?\
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MA7V]_P +8^%?_0X:)_X,A_\ %4?\+8^%?_0X:)_X,A_\51_K9+_GQ_Y-_P
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M&B?^#(?_ !5'_"V/A7_T.&B?^#(?_%4?ZV2_Y\?^3?\  #_4&/\ T$_^2_\
MVQ\0_P!EWO\ SY7/_?EO\*/[+O?^?*Y_[\M_A7V]_P +8^%?_0X:)_X,A_\
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MI:3QZ?J]G'>0QW49CE174':ZGHPZ$>HK?H 38O\ =7\J-B_W5_*EHH 38O\
M=7\J-B_W5_*EHH 38O\ =7\J-B_W5_*EHH 38O\ =7\J-B_W5_*EHH 38O\
M=7\J-B_W5_*EHH 38O\ =7\J-B_W5_*EHH 38O\ =7\J-B_W5_*EHH 38O\
M=7\J-B_W5_*EHH 38O\ =7\J-B_W5_*EHH 38O\ =7\J-B_W5_*EHH 38O\
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M+_H*V'_@=;?_ !RO@.BC_52A_P _7]R#_7S$_P#/B/WL^_/^%P>$O^@K8?\
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M='_"G])_Z'7QA_X4]Q_\71_:>-_Y_2^]A_8N6?\ 0-#_ ,!7^1C?\,L^$/\
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MTG_H=?&'_A3W'_Q=']IXW_G]+[V']BY9_P! T/\ P%?Y&-_PRSX0_P"?1?\
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M\8?^%/<?_%T?VGC?^?TOO8?V+EG_ $#0_P# 5_D8W_#+/A#_ )]%_P"_L_\
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MX4]Q_P#%T =[Y.J?\_5I_P" S?\ Q='DZI_S]6G_ (#-_P#%UP7_  I_2?\
MH=?&'_A3W'_Q='_"G])_Z'7QA_X4]Q_\70!WODZI_P _5I_X#-_\71Y.J?\
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M&&Z_)/\ XFO1/^&3?$'_ $%(/_ 62C_ADWQ!_P!!2#_P%DH^OY+WA_X#_P
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MX6[XR_Z&&Z_)/_B:]$_X9-\0?]!2#_P%DH_X9-\0?]!2#_P%DH^OY+WA_P"
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M+_GSM_\ OTO^%']EV7_/G;_]^E_PJ'^U_P#IQO?^_7_UZ/[7_P"G&]_[]?\
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M,H8,WW003U/;UK%\<>.(_"/A'7]9L[&7Q'=Z1 TSZ3ILL?VB1@,A!N8!6/\
MM$4 9'VKXH_] SP?_P"#&Z_^,4?:OBC_ - SP?\ ^#&Z_P#C%=79:]:W-GIL
ML[I87%]$DL=I<2H)<LH.W )#$9P=N17&?'CXW:7\ ? \?B;5M,U'6();^WTZ
M.STM$:=Y9FVH '91UXZ]Z +'VKXH_P#0,\'_ /@QNO\ XQ1]J^*/_0,\'_\
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M\R_Y]_C'_,/];<F_Y_?^2R_R/<OM7Q1_Z!G@_P#\&-U_\8H^U?%'_H&>#_\
MP8W7_P 8KPW_ (:]U+_H#R?^!:?_ !FG1_M>W_F+YFCS>7GYMEW'G'MF&E_J
M_F7_ #[_ !C_ )A_K;DW_/[_ ,EE_D>X?:OBC_T#?"'_ (,;K_XQ1]J^*/\
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MP?\ ^#&Z_P#C%==_9MQ_T%+K_OB+_P"(H_LVX_Z"EU_WQ%_\10!R/VKXH_\
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M?_X,;K_XQ77?V;<?]!2Z_P"^(O\ XBC^S;C_ *"EU_WQ%_\ $4 <C]J^*/\
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M21+E;7$*L B#,(^[@ _-QFN__P"%^>$?37__  F=2_\ D>C_ (7YX1]-?_\
M"9U+_P"1Z .+UCPSXST32=(M](O-:GCN=-M9=:EN[B>ZE\U)8_-V 2*ZNRL^
MY8F7(4[1D#-0>'?B!=Z?J,T%]K FM].<Z8KF:!?FNB&!C:8L\@AW;/-?<-RY
MP0"._P#^%^>$?37_ /PF=2_^1Z/^%^>$?37_ /PF=2_^1Z .1TFS\1PQVYU4
M^(+OPJ;Z0M#917<%TO[E APTSW)A\SS,C<#N*G&RKFBV/B;PO\'--O;#3M5E
MUK2]4N[W^R+AP;F\ADNYQY<F#AF,<HD&3]Y5/6NB_P"%^>$?37__  F=2_\
MD>C_ (7YX1]-?_\ "9U+_P"1Z .*L_#/CII;;1-5NM7O;32KNWMVU!+AT.I1
MW$HEGD+*0=L2 1 \8R<5D>"_AWJVE^#]3N[&W\1Z=JNF^&M.@L+>2ZN$+WT"
MS[UVLW[T;RJX;<FUAM&#7IG_  OSPCZ:_P#^$SJ7_P CT?\ "_/"/IK_ /X3
M.I?_ "/0!-XJCET?X@Z?XAN]*N]7TM=-DLX_L5N;F2RF,@9F\M<MB10%W*#C
MRP#@&N&^SWFB^,[;4K?2==\*:5/IBXL=,T@:@&/VRXD*2;8W\IBL@?:I&/,(
MR=M=G_POSPCZ:_\ ^$SJ7_R/1_POSPCZ:_\ ^$SJ7_R/0!Q6K?"[7=?\"^)F
MNYV,<=WKE]IFCPV CN'DE>Z6'=*6)8,LV0H5<[@"<9!Z7QQX%T?POX3\2ZOI
MMI]GU[5I;6;S 26>]65!;E1V._8..N.>YK0_X7YX1]-?_P#"9U+_ .1ZAN/C
MAX)O&A,]OK<YAD$L1D\+ZBVQP" PS;\'!//O0!Z517G?_"_/"/IK_P#X3.I?
M_(]'_"_/"/IK_P#X3.I?_(] 'HE>7>*-%F\6?&*/2+C6-7LM)C\/-<_9=-OI
M;4-.;C:LI:,@Y49P,X.>0<"KO_"_/"/IK_\ X3.I?_(])_POOPAG.-?STS_P
MC.I?_(] 'ER_VK;?"OP3XDNM>U;4M6\264\&K?:;IVMYUDTRZF^6#/EQ%7B3
M:453C(.<FI=)A\47-C\+;#Q9=Z8OAW^SX[W3YM+LY8Y'OXK0F*WF=Y&"@HTC
M@J!N,17C.&]+_P"%]>#\ ;=>P.@_X1C4O_D>E_X7UX/( *Z]@=/^*8U+_P"1
MZ /$;C2[SX=_!GPH;&WEG\+>*+;0C/!"A;^SM2,MJ?- 'W8I\?-V60!O^6C$
M:OB"Z\5ZI=:W\3M.\.VU[8Z?J\=[I]^-2*W#:79B2&9$@\D[A*CWKJ-XW>:A
M["O6?^%]>#]NW;KVWT_X1G4L?^D] ^/7A!5P%UX#T_X1G4L?^D] &MY&I^,)
M)+?4].T#4O!MZF]&\^266:(@-&6C:/8<G:3\WYUX_P#!'7-%^'<=E=:_=6VA
MZ;=^'[>#3KJ[(B@Q!=7AF@5C@!@)(FV=2#P#M./2A\?/""@ #7P!T_XIG4O_
M )'I&^/'@YE"E->*@Y /AC4L#_R7H \YT_PS;:7I?PRUX^'LZL^L:H]M$T(C
MNC9R6VIS6]MDC* HT8VGH2!CBJ'@&=FNOAA9CQA;^++>WN%V>%[>!(Y=( MY
M%5Y&'[S%N#Y1$P&XL"?FP*]6_P"%]^$#C(U\XZ?\4SJ7_P CTB_'CP<K,RIK
MP9OO,/#&I9/U_P!'H ]&HKSO_A?GA'TU_P#\)G4O_D>C_A?GA'TU_P#\)G4O
M_D>@#T2BO._^%^>$?37_ /PF=2_^1Z/^%^>$?37_ /PF=2_^1Z /1**\[_X7
MYX1]-?\ _"9U+_Y'H_X7YX1]-?\ _"9U+_Y'I >"?'[X4:])XN?4]/LIM1BD
MB2.2*!=TBE!M#!>K*5 .1G!R#[^6?\*\\5?]"SK'_@#+_P#$U]DW'QR\%W2[
M)X=<F4'I)X7U%A_Z3U7_ .%Q> /^?#5O_"4U#_Y'K[#"\25\-1C1<$^56OY'
MY[C^#<+C<3/$JJX\SNUH]7N?'W_"N_%7_0LZQ_X R_\ Q-'_  KOQ5_T+.L?
M^ ,O_P 37V#_ ,+B\ ?\^&K?^$IJ'_R/1_PN+P!_SX:M_P"$IJ'_ ,CUU_ZU
M5O\ GTOO9P?ZAX?_ )_R^Y'Q]_PKOQ5_T+.L?^ ,O_Q-'_"N_%7_ $+.L?\
M@#+_ /$U]@_\+B\ ?\^&K?\ A*:A_P#(]'_"XO '_/AJW_A*:A_\CT?ZU5O^
M?2^]A_J'A_\ G_+[D?'W_"N_%7_0LZQ_X R__$T?\*[\5?\ 0LZQ_P" ,O\
M\37V#_PN+P!_SX:M_P"$IJ'_ ,CT?\+B\ ?\^&K?^$IJ'_R/1_K56_Y]+[V'
M^H>'_P"?\ON1\??\*[\5?]"SK'_@#+_\31_PKOQ5_P!"SK'_ ( R_P#Q-?8/
M_"XO '_/AJW_ (2FH?\ R/1_PN+P!_SX:M_X2FH?_(]'^M5;_GTOO8?ZAX?_
M )_R^Y'Q]_PKOQ5_T+.L?^ ,O_Q-'_"N_%7_ $+.L?\ @#+_ /$U]@_\+B\
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M>H?_ "/1_P +@^'_ /T#]6_\)/4/_D>@#U'<O]X?G1N7^\/SKR[_ (7!\/\
M_H'ZM_X2>H?_ "/2?\+@^'__ $#]6_\ "3U#_P"1Z /4MR_WA^=&Y?[P_.O+
MO^%P?#__ *!^K?\ A)ZA_P#(]'_"X/A__P! _5O_  D]0_\ D>@#U'<O]X?G
M1N7^\/SKR[_A<'P__P"@?JW_ (2>H?\ R/1_PN#X?_\ 0/U;_P )/4/_ )'H
M ]1W+_>'YT;E_O#\Z\N_X7!\/_\ H'ZM_P"$GJ'_ ,CT?\+@^'__ $#]6_\
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M^N@[[5J7_/A#_P"!/_V-'VK4O^?"'_P)_P#L:OT5\L?<%#[5J7_/A#_X$_\
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M;37@O_##?P9_Z%O4/_"AU+_Y(H_X8;^#/_0MZA_X4.I?_)% 'O6TT;37@O\
MPPW\&?\ H6]0_P#"AU+_ .2*/^&&_@S_ -"WJ'_A0ZE_\D4 >];31M->"_\
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M)KCY/@WX8,5DMO;7NG/:0&UCGTW4KBUE,)=G\MWCD5G7<S$!B<%CC&37G?\
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MLYJF%P]67-4IIOS29Z3_ ,*-\(?] >S_ / .#_XBC_A1OA#_ * ]G_X!P?\
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M3_T"9_\ PI]0_P#DFC_AC?X$_P#0)G_\*?4/_DF@#WC^S+G_ *"EU_WQ%_\
M$4?V9<_]!2Z_[XB_^(KP?_AC?X$_] F?_P *?4/_ ))H_P"&-_@3_P! F?\
M\*?4/_DF@#WC^S+G_H*77_?$7_Q%']F7/_04NO\ OB+_ .(KP?\ X8W^!/\
MT"9__"GU#_Y)H_X8W^!/_0)G_P#"GU#_ .2: />/[,N?^@I=?]\1?_$4?V9<
M_P#04NO^^(O_ (BO!_\ AC?X$_\ 0)G_ /"GU#_Y)H_X8V^!/_0)G_\ "GU#
M_P"2* />/[,N?^@I=?\ ?$7_ ,11_9ES_P!!2Z_[XB_^(KP?_AC?X$_] F?_
M ,*?4/\ Y)H_X8W^!/\ T"9__"GU#_Y)H ]X_LRY_P"@I=?]\1?_ !%']F7/
M_04NO^^(O_B*\'_X8W^!/_0)G_\ "GU#_P"2:/\ AC?X$_\ 0)G_ /"GU#_Y
M)H ]X_LRY_Z"EU_WQ%_\11_9ES_T%+K_ +XB_P#B*\'_ .&-_@3_ - F?_PI
M]0_^2:/^&-_@3_T"9_\ PI]0_P#DF@#WC^S+G_H*77_?$7_Q%']F7/\ T%+K
M_OB+_P"(KP?_ (8W^!/_ $"9_P#PI]0_^2:/^&-_@3_T"9__  I]0_\ DF@#
MWC^S+G_H*77_ 'Q%_P#$4?V9<_\ 04NO^^(O_B*\'_X8W^!/_0)G_P#"GU#_
M .2:/^&-_@3_ - F?_PI]0_^2: />$T<&9)+BXFO#&=R+,5"J?7:H )]S5ZO
MG^W_ &*?@C>;O(T*\FQU\OQ)J+8_*XKWV&%+>&.*,82-0BC)/ &!S0 ^BBB@
M"*U_X]8?]Q?Y5+45K_QZP_[B_P JEH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KY(TGQ!\8OVBO$?Q,U/P7\0;?P#I'A/6KC0-'TD:5#="_N
M+=1ODNWD!94=B  F,#GG'/UO7SQXS_9!&K^*/%6I^$_B+XD^']AXN?S?$.DZ
M.(7AO)"NUY8S(I:%W7AF4\T <SJGCSXN_$OXK:#\)[/Q!I_PZUG3_"\6O^*=
M8TNU2^9YGD,2PV@F&T(2-Q8@D9QVY\[\8?M"_%?X<VOC#3M7\0QZQ?\ PK\2
MZ3/K.I6=E%"NM:%>#D2Q[2(Y4W*24(_0U[MXD_9#T5AX1OO _B76?AYXD\,:
M9_8UEK.FLEP\UGG)AN$E!64;LMD\[B36CX1_95\-^'/ASXY\-7^I:CXEU'QN
MDO\ PD'B#5F5[J\D>,QJV  JA ?D4# H \"_: _:)\>-<_'G7O _BA]-\+^
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M @E>I;:Y(Y.+&N?L]ZGX@@U:6ZUR!=2UBWN!?36T;PA9I;FTD'DX)*JD5HJ
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MH_X6)XJ_Z&;6/_ Z7_XJO9_^&0;S_H-3_P#@%'_\?H_X9!O/^@U/_P" 4?\
M\?H_M?)_YE_X"_\ (/\ 5[B'^27_ (&O_DCQC_A8GBK_ *&;6/\ P.E_^*H_
MX6)XJ_Z&;6/_  .E_P#BJ]G_ .&0;S_H-3_^ 4?_ ,?H_P"&0;S_ *#4_P#X
M!1__ !^C^U\G_F7_ ("_\@_U>XA_DE_X&O\ Y(\8_P"%B>*O^AFUC_P.E_\
MBJ/^%B>*O^AFUC_P.E_^*KV?_AD&\_Z#4_\ X!1__'Z/^&0;S_H-3_\ @%'_
M /'Z/[7R?^9?^ O_ "#_ %>XA_DE_P"!K_Y(\8_X6)XJ_P"AFUC_ ,#I?_BJ
M/^%B>*O^AFUC_P #I?\ XJO9_P#AD&\_Z#4__@%'_P#'Z/\ AD&\_P"@U/\
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M_P"*H_X6)XJ_Z&;6/_ Z7_XJO9_^&0;S_H-3_P#@%'_\?H_X9!O/^@U/_P"
M4?\ \?H_M?)_YE_X"_\ (/\ 5[B'^27_ (&O_DCQC_A8GBK_ *&;6/\ P.E_
M^*H_X6)XJ_Z&;6/_  .E_P#BJ]G_ .&0;S_H-3_^ 4?_ ,?H_P"&0;S_ *#4
M_P#X!1__ !^C^U\G_F7_ ("_\@_U>XA_DE_X&O\ Y(\8_P"%B>*O^AFUC_P.
ME_\ BJ/^%B>*O^AFUC_P.E_^*KV?_AD&\_Z#4_\ X!1__'Z/^&0;S_H-3_\
M@%'_ /'Z/[7R?^9?^ O_ "#_ %>XA_DE_P"!K_Y(\8_X6)XJ_P"AFUC_ ,#I
M?_BJ/^%B>*O^AFUC_P #I?\ XJO9_P#AD&\_Z#4__@%'_P#'Z/\ AD&\_P"@
MU/\ ^ 4?_P ?H_M?)_YE_P" O_(/]7N(?Y)?^!K_ .2/&/\ A8GBK_H9M8_\
M#I?_ (JC_A8GBK_H9M8_\#I?_BJ]G_X9!O/^@U/_ . 4?_Q^C_AD&\_Z#4__
M (!1_P#Q^C^U\G_F7_@+_P @_P!7N(?Y)?\ @:_^2/&/^%B>*O\ H9M8_P#
MZ7_XJC_A8GBK_H9M8_\  Z7_ .*KV?\ X9!O/^@U/_X!1_\ Q^C_ (9!O/\
MH-3_ /@%'_\ 'Z/[7R?^9?\ @+_R#_5[B'^27_@:_P#DCQC_ (6)XJ_Z&;6/
M_ Z7_P"*H_X6)XJ_Z&;6/_ Z7_XJO9_^&0;S_H-3_P#@%'_\?H_X9!O/^@U/
M_P" 4?\ \?H_M?)_YE_X"_\ (/\ 5[B'^27_ (&O_DCQC_A8GBK_ *&;6/\
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M]A?%C_H=/"/_ (2US_\ )]>BT4 >=?V%\6/^AT\(_P#A+7/_ ,GT?V%\6/\
MH=/"/_A+7/\ \GUWNH:A;:7;_:+N=+>'S$B\R0X&YW"(OU+,H'N11?ZA;:7
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MH']E>'];UJ;6=)36HH;..!7AMVV;?,\V9 &S(!@$]#Z4 0_V%\6/^AT\(_\
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MG_X]1_PU%XM_Y]['_ONY_P#CU'^K6/[+[P_UTRKO+_P$^C?["^+'_0Z>$?\
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M1_87Q8_Z'3PC_P"$M<__ "?7;?V+!_SUN_\ P+E_^*H_L6#_ )ZW?_@7+_\
M%4 <3_87Q8_Z'3PC_P"$M<__ "?1_87Q8_Z'3PC_ .$M<_\ R?7;?V+!_P ]
M;O\ \"Y?_BJ/[%@_YZW?_@7+_P#%4 <3_87Q8_Z'3PC_ .$M<_\ R?1_87Q8
M_P"AT\(_^$M<_P#R?7;?V+!_SUN__ N7_P"*H_L6#_GK=_\ @7+_ /%4 <3_
M &%\6/\ H=/"/_A+7/\ \GT?V%\6/^AT\(_^$M<__)]=M_8L'_/6[_\  N7_
M .*H_L6#_GK=_P#@7+_\50!Q/]A?%C_H=/"/_A+7/_R?1_87Q8_Z'3PC_P"$
MM<__ "?7;?V+!_SUN_\ P+E_^*H_L6#_ )ZW?_@7)_\ %4 <3_87Q8_Z'3PC
M_P"$M<__ "?7H<>X1J'(9\#<5& 3WP*SH_.TR\AA>9[BUG)1&E.7C< D#/<$
M ]>01[UIT %%%% $5K_QZP_[B_RJ6O!K?]JIUMXA_P *<^*QP@&1X;&.G_76
MG_\ #5;_ /1&_BO_ .$V/_CM 'NU%>$_\-5O_P!$;^*__A-C_P".T?\ #5;_
M /1&_BO_ .$V/_CM 'NU%>$_\-5O_P!$;^*__A-C_P".T?\ #5;_ /1&_BO_
M .$V/_CM 'NU%>$_\-5O_P!$;^*__A-C_P".T?\ #5;_ /1&_BO_ .$V/_CM
M 'NU%>$_\-5O_P!$;^*__A-C_P".T?\ #5;_ /1&_BO_ .$V/_CM 'NU%>$_
M\-5O_P!$;^*__A-C_P".T?\ #5;_ /1&_BO_ .$V/_CM 'NU%>$_\-5O_P!$
M;^*__A-C_P".T?\ #5;_ /1&_BO_ .$V/_CM 'NU%>$_\-5O_P!$;^*__A-C
M_P".T?\ #5;_ /1&_BO_ .$V/_CM 'NU%>$_\-5O_P!$;^*__A-C_P".T?\
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M_P -5O\ ]$;^*_\ X38_^.T?\-5O_P!$;^*__A-C_P".T >[45X3_P -5O\
M]$;^*_\ X38_^.T?\-5O_P!$;^*__A-C_P".T >[45X3_P -5O\ ]$;^*_\
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M_P!1<N_Y^3^^/_R)\^_\*0\9_P#0+A_\#[?_ .+H_P"%(>,_^@7#_P"!]O\
M_%U]!?\ #53_ /1&_BM_X38_^.T?\-5/_P!$;^*W_A-C_P".T?ZTXS^2/W/_
M ##_ %%R[_GY/[X__(GS[_PI#QG_ - N'_P/M_\ XNC_ (4AXS_Z!</_ ('V
M_P#\77T%_P -5/\ ]$;^*W_A-C_X[1_PU4__ $1OXK?^$V/_ ([1_K3C/Y(_
M<_\ ,/\ 47+O^?D_OC_\B?/O_"D/&?\ T"X?_ ^W_P#BZ/\ A2'C/_H%P_\
M@?;_ /Q=?07_  U4_P#T1OXK?^$V/_CM'_#53_\ 1&_BM_X38_\ CM'^M.,_
MDC]S_P P_P!1<N_Y^3^^/_R)\^_\*0\9_P#0+A_\#[?_ .+H_P"%(>,_^@7#
M_P"!]O\ _%U]!?\ #53_ /1&_BM_X38_^.T?\-5/_P!$:^*W_A-C_P".T?ZT
MXS^2/W/_ ##_ %%R[_GY/[X__(GS[_PI#QG_ - N'_P/M_\ XNC_ (4AXS_Z
M!</_ ('V_P#\77T%_P -5/\ ]$;^*W_A-C_X[1_PU4__ $1OXK?^$V/_ ([1
M_K3C/Y(_<_\ ,/\ 47+O^?D_OC_\B?/O_"D/&?\ T"X?_ ^W_P#BZ/\ A2'C
M/_H%P_\ @?;_ /Q=?07_  U4_P#T1OXK?^$V/_CM'_#53_\ 1&_BM_X38_\
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MT44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
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M7WK_ "#_ %XS/^6'W/\ ^2/L[_AJ;PA_S]K_ -^I_P#XW1_PU-X0_P"?M?\
MOU/_ /&Z^,=P]:-P]:/]5\%_-+[U_D'^O&9_RP^Y_P#R1]G?\-3>$/\ G[7_
M +]3_P#QNC_AJ;PA_P _:_\ ?J?_ .-U\8[AZT;AZT?ZKX+^:7WK_(/]>,S_
M )8?<_\ Y(^SO^&IO"'_ #]K_P!^I_\ XW1_PU-X0_Y^U_[]3_\ QNOC'</6
MC</6C_5?!?S2^]?Y!_KQF?\ +#[G_P#)'V=_PU-X0_Y^U_[]3_\ QNC_ (:F
M\(?\_:_]^I__ (W7QCN'K1N'K1_JO@OYI?>O\@_UXS/^6'W/_P"2/L[_ (:F
M\(?\_:_]^I__ (W1_P -3>$/^?M?^_4__P ;KXQW#UHW#UH_U7P7\TOO7^0?
MZ\9G_+#[G_\ )'V=_P -3>$/^?M?^_4__P :KT#PQXR7QEI,>I:-)87]FY*^
M9'<OD,.JL#'D'V-?GAN'K7U!^QKINHPVOB*_=)$TF<Q1Q%AA9)5W;BOK@$ F
MO'S;(<-@L+*O2D[JV]M?P1]%D/%6-S+'1PM>G'EE?6*:M97ON].GS/H7SM4_
MY];3_P "6_\ B*/.U3_GUM/_  );_P"(J_17P9^J%#SM4_Y];3_P);_XBCSM
M4_Y];3_P);_XBK]% %#SM4_Y];3_ ,"6_P#B*/.U3_GUM/\ P);_ .(J_10!
M0\[5/^?6T_\  EO_ (BCSM4_Y];3_P "6_\ B*OT4 4/.U3_ )];3_P);_XB
MCSM4_P"?6T_\"6_^(J_10!2M=1:2X-M<0FVN=NX+NW*Z]RI[X].#S5VL[4F#
MZAIL:_ZX2F3CJ$",&/TY _&M&@ HHHH YSQKX9?QI\/=:T".X6T?5--ELEG9
M=PC,D97<1D9QGIFO+_A?\(?BC\.X?#VD-\1-+O/"^E>7$VGKH8222!3R@E+D
M@D?Q5[;#(L5G$SLJ*$7+,<#H*;?7JV5I)-M,S*C,D,9&Z4@9"KD\D]OK64J<
M92YGNCU\-F6)P^'EA*:BX2=[2C&6MK73DG9VZJQX"/V6+P?L]ZW\-O\ A(K?
M[1J&J-J U#[(VQ 9TEV%-^2?EQG/>M+6_P!F^]U3XD:_K<7B2.+P]XGTZ+3M
M=TA[,-)-''"8E\J7=\AZ-T/(KU#P#XPD\:>$]/UB[TFZ\.W-TKLVFZB5$\05
MBOS 'OC/T-="MQ%(K,LB,J_>(8$#ZUDJ-*25O+^OQ/4JY[FU&K5A.:YFY\VD
M7K)QYGLUO"+36S5XG@7@#]F/5/"6N: U]XHL+S1-"</;06F@P6]W<[?]6+B?
MDMMP.@!..M;?A_X W.B>"?BEH+:U#*_C.^OKR.9;<@6HN$VA6&[Y]O7(QFO8
M?M$017,B!&^ZVX8/TITDBQJ6=@BCJS' JHT*<=D<];/\QKR<IS5W;:,5K&7,
MMDM;ZOOL]#Y[T_\ 9C\0>#VT74O!OCA- U^'1+?1-3FDTX7$%XD2@+*J,V4<
M #')Z#WS['\/?",_@?PC8Z/=:WJ'B*[A!,VIZG*9)IW8DD\DX'. O8 "NBWJ
M%W%@%QG=GC%"NLBAE8,IZ,IR#50I0IN\3EQN;XS,(<F)DGK>_+%/K:[2NTKN
MR;LN@M%%%;'C!1110 4444 %%%% !1110 5\R^%_VVM+UWQQ\8O!UUHZ:?X@
M\#)?SV$+71*:O#:HQ<@[1L<$+E1NP&!YP:^FJ^(_&'[%'B3QKX9^+UR'M]%\
M:7GC&^\0^$]3@N 6:":!(G@E8#Y4E4,K*>GRGMB@#W?PW^U-X('PI\"^+_&W
MB#1O!-QXJTR#4(;"^OU!&] Q520"RJ3C=@#Z5U/B/X\?#KPC<:=!K/C71=.E
MU&U2]LA->(/M,+.$5XSG#@LP QG.:^8/"_[-OQ.^%\WA+7M,\*^&?&]]_P (
M%9^$=0T;6]0$2Z;-#G,D4GENKQ-N^=1@G'O6Q\&?V/\ 7_AU\1_A/<ZVFFZ[
MH_A;PA?:;<WFX,(;^>[,RK!&XSL17=5;L!VS0,^B;;X[?#J\\=/X+@\;:'-X
MK1S$VD)?1FX\P=4VY^^.Z]?:E7XX> Y/"]EXBB\5Z7)H]]?_ -E6MYY_[N:\
MW,GD XSOW*PQC/!KY1T3]DGXDVOA_P -?#6?2?#-OX>T3Q8OB+_A8$-V3J5Q
M&MRTX'D^7N6=LA"Y?;@=ZZ;1_P!E/Q=8_M+7=[+]A;X1V>LWOC#2[83#S?[6
MN;98BAC[(CF20'ID^] CU7P3^U)X1F\!^'=7\<>*?"OAW5=8@FN8;>SU83VT
MT27!A#12D+OYV@@#AB1VKMO^%V> _P"P1K7_  E>F_V2=5_L,7GG?N_MV_R_
ML^?[^_Y<>M?,/P!_9-\7>#?%'P.N_%FCZ7/9>$/#FK6-^K3I/Y-W/=M)"47'
MS?(Q^8=,UC:M^R_\8+/1Y? NG:5H%YX3@^(L?C*'6VU,I=36[70E,/D%,*Z
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M=R72P1NMN%&%B8MSSVKZ<H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"&ZO+>R4-<3QP*QP&E<*"?3FJW]N:7NW?VA9[L8SYZ9_G4'B+PCH7C"
MUBMM>T73];MXG\R.'4;5)T1L8W ." <$C/O7/_\ "C_AS_T('AC_ ,$]O_\
M$4 =+_;.D[0OVZRVKT'G)@?K2_VUI14 W]D0O0><G'ZUS/\ PH_X<_\ 0@>&
M/_!/;_\ Q%+_ ,*/^'/_ $('AC_P3V__ ,10!TO]M:5M"_;[/:/X?.3'\Z%U
MO2E7:-0LPN,;1,F/YUS/_"C_ (<_]"!X8_\ !/;_ /Q%'_"C_AS_ -"!X8_\
M$]O_ /$4 =.NN:6J@#4+, < "=./UI!K>E*NT:A9A>FWSDQ_.N9_X4?\.?\
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MA_\ GVON1+_P@/@7^YI/_?NU_P#B*/\ A ? O]S2?^_=K_\ $5%_PJGX8_\
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MQ+#X[B\,>'-*TVZE.E-J;W6I7+Q(N)1&(L(K'+9X;H,'.> >^K+_ .$;L_\
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MA3,\9CJN(IR4HR=U=ZI=OEL?)E%?6?\ PR/H/_/>[_\  P?_ !JC_AD?0?\
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M^>]W_P"!@_\ C5'^LF [O[@_U+S7M'_P+_@'R917UG_PR/H/_/>[_P# P?\
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M&S_[^O\ _$U^8XNK"OB)U::LFVTC]LR^A4PN$I4*TN:44DWW-"BL_P S5?\
MGC9_]_7_ /B:/,U7_GC9_P#?U_\ XFN0] T**S_,U7_GC9_]_7_^)H\S5?\
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M;3/_ (BC_A2/Q@_Z.)U;_P );3/_ (BO>:* /!O^%(_&#_HXG5O_  EM,_\
MB*/^%(_&#_HXG5O_  EM,_\ B*]YHH \&_X4C\8/^CB=6_\ "6TS_P"(H_X4
MC\8/^CB=6_\ "6TS_P"(KWFB@#P;_A2/Q@_Z.)U;_P );3/_ (BC_A2/Q@_Z
M.)U;_P );3/_ (BO>:* /!O^%(_&#_HXG5O_  EM,_\ B*/^%(_&#_HXG5O_
M  EM,_\ B*]YKYCU3]HKXH^-O$WCE/A/X$T77O#O@N]?3;RXUK4)(+C5+N)0
M9H;144@%<X#.<$XH Z/_ (4C\8/^CB=6_P#"6TS_ .(H_P"%(_&#_HXG5O\
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M6)K'[2.A^'_B%J(OO$^@+X%L?",7B66>!+F:\"27'EI.&1#$T!! &TE\]L4
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M \TMKXCTV[^S*+R&*XN(!<I;2RJLOED9W;<YQCOTH \8_P"%(_&#_HXG5O\
MPEM,_P#B*/\ A2/Q@_Z.)U;_ ,);3/\ XBO5]6^(GAC0[47-[K^GPP?:HK(R
M?:4(6:1@$0X/!.>_;)Z"M>UU:QOKJXMK:]M[BYM\>=#%*K/'GIN .1^- 'B/
M_"D?C!_T<3JW_A+:9_\ $4?\*1^,'_1Q.K?^$MIG_P 17O-% '@W_"D?C!_T
M<3JW_A+:9_\ $4?\*1^,'_1Q.K?^$MIG_P 17O-% '@W_"D?C!_T<3JW_A+:
M9_\ $4?\*1^,'_1Q.K?^$MIG_P 17O-% '@W_"D?C!_T<3JW_A+:9_\ $4?\
M*1^,'_1Q.K?^$MIG_P 17O-% '@__"D?C!M(_P"&B-6)]?\ A%]-X_\ '*3_
M (4C\8/^CB=6_P#"6TS_ .(KWFN6\4?$SP[X.U./3M4O)DU"2W:[6UMK.:YE
M,*MM:3;$C':IZGH,C/44 >7_ /"D?C!_T<3JW_A+:9_\11_PI'XP?]'$ZM_X
M2VF?_$5W-Q\;/#%U8WC:1J*W]R+.XN;*3R)1:WABC9V6&<J(Y2 .0C$@ ^AQ
MSVF_$?QEI&F^#=5\0_V!?6'B0PPK#IEO-;SV\DMNTRD!Y7$BC:0V-I ^;L10
M!C_\*1^,'_1Q.K?^$MIG_P 11_PI'XP?]'$ZM_X2VF?_ !%:/A7X^7GB'X/I
MXBN=+@T_Q1;?V>NH:2SLT<?VIX@DL;<%HWCEW(WJ"IY5A6_K/Q6N=,^+EAX;
M2R@?P^?+L[W4F<^9!?SH\EM"!TVE(CNSSNFA ZF@#C_^%(_&#_HXG5O_  EM
M,_\ B*/^%(_&#_HXG5O_  EM,_\ B*]NU:^DTO3I[J*QN=2DC (M;/9YLG(&
M%WLJ^_+#I7BEO^T!?ZIH.C3F?0?#-U<6*WMW+K;.T:L\DJ1P1HC@EL0NSON(
M0 <-G@ 9_P *1^,'_1Q.K?\ A+:9_P#$4?\ "D?C!_T<3JW_ (2VF?\ Q%=[
MJ/Q(N;/P'I.I)IT,OB35X0+#28;I9HY9BA8D3)D&%0"YD'\ SC)"US]UX\\8
M-\,=+\;I?>'[&RN-&M;^2SETVXN)6GEB1O*C*SIG<[A$&,Y(&30!A?\ "D?C
M!_T<3JW_ (2VF?\ Q%'_  I'XP?]'$ZM_P"$MIG_ ,17M'AN359?#^FOKD=O
M#K+6T;7L=GGR4F*C>J9).T-D#)K1H \&_P"%(_&#_HXG5O\ PEM,_P#B*/\
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M[D_^+H_X:2\8_P!ZR_[]R?\ Q='^K.._N_?_ , /]=LJ_O?=_P $]F_X4?\
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MW_@1)_\ %4?V#9_W9O\ P(D_^*K(W/%O^%'_ !A_Z.)U?_PEM-_^(H_X4?\
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MVG^P;/\ NS?^!$G_ ,51_8-G_=F_\")/_BJ /%O^%'_&'_HXG5__  EM-_\
MB*/^%'_&'_HXG5__  EM-_\ B*]I_L&S_NS?^!$G_P 51_8-G_=F_P# B3_X
MJ@#Q;_A1_P 8?^CB=7_\);3?_B*/^%'_ !A_Z.)U?_PEM-_^(KVG^P;/^[-_
MX$2?_%4?V#9_W9O_  (D_P#BJ /%O^%(?&'_ *.)U;_PEM,_^(KW:%'CAC21
M_-=5 :0@#<<<G ]:SU632KR"+S9)K.X8H!*VYHWP2,,>2" >O0XK3I %%%%
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M5$\174<CF:\U2]N1.\J H R#[N25.%'%>S_\+ \<_P#1*]0_\'-C_P#'*/\
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MWD7,+!,DLA'F1,H4G(SBOH;_ (6!XY_Z)7J'_@YL?_CE'_"P/'/_ $2O4/\
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M:[OKB.036RGY8UMXD$62,A$9&"C^Z%Z'BH_^%@>.?^B5ZA_X.;'_ ..4?\+
M\<_]$KU#_P '-C_\<H Y:'X*:LBZIMM-$CE6SU"SLI7 D#K<7OVC+*8\)E#L
M/#@%0<,.*E\%?!G5+3Q^^L^(+?3[O31Y\T$,UP+J2*22"VA((\F->D#\@='
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M_A8'CG_HE>H?^#FQ_P#CE 'HU%><_P#"P/'/_1*]0_\ !S8__'*/^%@>.?\
MHE>H?^#FQ_\ CE 'HU<M_P (M<_\+1_X20M";,:-_9P7)\T/Y_F'C&-N,=^H
MZ5A?\+ \<?\ 1+-0_P#!S8__ !RC_A8'CG_HE>H?^#FQ_P#CE &/)\(=6_X5
M7X#\-126,=[H,12X9681$G3[FV^0A<GYYE/(' /?@U?#?[/MGX)O/"6IZ%I^
MF6NHV>EMI.K+@[9$:$ S1,02LBR*!G W([@]%KHO^%@>.?\ HE>H?^#FQ_\
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M (%I1_PH#QE_SZ6O_@6E?4__  L'QS_T2S4?_!S8_P#QRC_A8/CG_HEFH_\
M@YL?_CE'^M&-_EC]S_S#_4?+/YI_>O\ Y$^6/^% >,O^?2U_\"TH_P"% >,O
M^?2U_P# M*^I_P#A8/CG_HEFH_\ @YL?_CE'_"P?'/\ T2S4?_!S8_\ QRC_
M %HQO\L?N?\ F'^H^6?S3^]?_(GRQ_PH#QE_SZ6O_@6E+'^S[XQDD53;6<8)
MP6:[7 ]SBOJ;_A8/CG_HEFH_^#FQ_P#CE'_"P?'/_1+-1_\ !S8__'*7^M&-
M_EC]S_S'_J/EG\T_O7_R(WX.^&-.^%_@N'27U&.ZNY)&N+F5%;:9& &%R.@
M ]\9KN/^$@T[_GZ7\C_A7%?\+ \<_P#1+-1_\'-C_P#'*3_A8/CG_HEFH_\
M@YL?_CE?+5JLZ]256H[MZL^YP^'IX6C&A15HQ5D=M_PD&G?\_2_D?\*/^$@T
M[_GZ7\C_ (5Q/_"P?'/_ $2S4?\ P<V/_P <H_X6#XY_Z)9J/_@YL?\ XY61
MT';?\)!IW_/TOY'_  H_X2#3O^?I?R/^%<3_ ,+!\<_]$LU'_P '-C_\<H_X
M6#XY_P"B6:C_ .#FQ_\ CE ';?\ "0:=_P _2_D?\*/^$@T[_GZ7\C_A7$_\
M+!\<_P#1+-1_\'-C_P#'*/\ A8/CG_HEFH_^#FQ_^.4 =M_PD&G?\_2_D?\
M"C_A(-._Y^E_(_X5Q/\ PL'QS_T2S4?_  <V/_QRC_A8/CG_ *)9J/\ X.;'
M_P".4 =M_P )!IW_ #]+^1_PH_X2#3O^?I?R/^%<3_PL'QS_ -$LU'_P<V/_
M ,<H_P"%@^.?^B6:C_X.K'_XY0!VW_"0:=_S]+^1_P */^$@T[_GZ7\C_A7$
M_P#"P?'/_1+-1_\ !S8__'*/^%@^.?\ HEFH_P#@YL?_ (Y0!VW_  D&G?\
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M!XZK0II1C%V5UNN^O?<^J?\ AK[1_P#GROO_  $C_P#C]'_#7VC_ //E??\
M@)'_ /'Z^5O*?^XW_?)H\I_[C?\ ?)KTO]7,O_E?WL\;_7+-_P"9?^ H^J?^
M&OM'_P"?*^_\!(__ (_1_P -?:/_ ,^5]_X"1_\ Q^OE;RG_ +C?]\FCRG_N
M-_WR:/\ 5S+_ .5_>P_URS?^9?\ @*/JG_AK[1_^?*^_\!(__C]'_#7VC_\
M/E??^ D?_P ?KY6\I_[C?]\FCRG_ +C?]\FC_5S+_P"5_>P_URS?^9?^ H^J
M?^&OM'_Y\K[_ ,!(_P#X_1_PU]H__/E??^ D?_Q^OE;RG_N-_P!\FCRG_N-_
MWR:/]7,O_E?WL/\ 7+-_YE_X"CZI_P"&OM'_ .?*^_\  2/_ ./T?\-?:/\
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M3J?_ #]VO_@,W_Q=7Z* *'DZG_S]VO\ X#-_\71Y.I_\_=K_ . S?_%U?HH
MH6U[/'=+:WJ(LC@F*6+.R3'48/(/MS5^LV^D6XU*QMHSNEBD\^3'\"A6'/U)
MQ^=:5 !1110!@>+?#*^-/ FK>'WN&M$U33Y+)KA5W&,21E=P'?&<XKR?P?\
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MOK9ONS6TJR(?HRDBM(QC#2)YF+Q&)QDE5Q&KBE&]DME9)V2NTNKU+5%%%:'
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M5?V79_\ /I;_ /?I?\*/[+L_^?2W_P"_2_X4 <M_PNGX??\ 0\^'/_!K!_\
M%4?\+I^'W_0\^'/_  :P?_%5U/\ 9=G_ ,^<'_?I?\*/[+L_^?.#_OTO^% '
M*_\ "Z?A]_T//AS_ ,&L'_Q5'_"Z?A]_T//AS_P:P?\ Q5=5_9=G_P ^EO\
M]^E_PH_LNS_Y]+?_ +]+_A0!RO\ PNGX??\ 0\^'/_!K!_\ %4?\+I^'W_0\
M^'/_  :P?_%5U7]EV?\ SZ6__?I?\*/[+L_^?2W_ ._2_P"% '*_\+I^'W_0
M\^'/_!K!_P#%4?\ "Z/A]_T//AS_ ,&L'_Q5=5_9=G_SZ6__ 'Z7_"C^R[+_
M )]+?_OTO^% '%WGQ4^&E\X:?QIX;:11@.-6A5@/3(<'%5_^%D?##_H=M!_\
M'J?_ !RNGUC4M!T)2;Q+6+;C=F- %STR3@#/N:Q_^$_\'?\ /?3_ /OY!_\
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M^#]?_CE'_"S/AG_T/.B?^#Y?_CE=3OM/^@)+_P" R?XT;[3_ * DO_@,G^-
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M&:=X?>_\CXZVCT%&T>@K[%_X91\*?\\9/_ J7_&C_AE'PI_SQD_\"I?\:/\
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M7&I^%(-<NQ8:#-J4LTSF,'9%&2R1C+GG/4#/J =M_P *7?\ Z'_QM_X-E_\
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M_P"0?Z]X'_GU/\/\SZW_ .%20_\ 11O&7_@Y3_XW1_PJ2'_HHWC+_P '*?\
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MC_A4D/\ T4;QE_X.4_\ C=>A_P!EV7_/G;_]^E_PH_LNR_Y\[?\ []+_ (4
M>>?\*EA_Z*-XQ_\ !RG_ ,;H_P"%20_]%&\9?^#E/_C=>A_V79?\^=O_ -^E
M_P */[+LO^?.W_[]+_A2 \\_X5)#_P!%&\9?^#E/_C='_"I(?^BC>,O_  <I
M_P#&Z]#_ ++LO^?.W_[]+_A1_9=E_P ^=O\ ]^E_PI@>>?\ "I(?^BC>,O\
MP<I_\;H_X5)#_P!%&\9?^#E/_C=>A_V79?\ /G;_ /?I?\*/[+LO^?.W_P"_
M2_X4 >>?\*DA_P"BC>,O_!RG_P ;H_X5)#_T4;QE_P"#E/\ XW7H?]EV7_/G
M;_\ ?I?\*/[+LO\ GSM_^_2_X4 >>?\ "I(?^BC>,O\ P<I_\;H_X5)#_P!%
M&\9?^#E/_C=>A_V79?\ /G;_ /?I?\*/[+LO^?.W_P"_2_X4 >>?\*DA_P"B
MC>,O_!RG_P ;H_X5'#_T4;QE_P"#E/\ XW7H?]EV7_/G;_\ ?I?\*/[+LO\
MGSM_^_2_X4 >>?\ "I(?^BC>,O\ P<I_\;H_X5)#_P!%&\9?^#E/_C=>A_V7
M9?\ /G;_ /?I?\*/[+LO^?.W_P"_2_X4 >>?\*DA_P"BC>,O_!RG_P ;H_X5
M)#_T4;QE_P"#E/\ XW7H?]EV7_/G;_\ ?I?\*/[+LO\ GSM_^_2_X4 >>?\
M"I(?^BC>,O\ P<I_\;H_X5)#_P!%&\9?^#E/_C=>A_V79?\ /G;_ /?I?\*/
M[+LO^?.W_P"_2_X4 >>?\*DA_P"BC>,O_!RG_P ;H_X5)#_T4;QE_P"#E/\
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M^%7/_P#(M'_":?M(?]$Q\#?^%7/_ /(M 'OE%>!_\)I^TA_T3'P-_P"%7/\
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M<\.66E6L:VYDDM[JVNQ<I*X)"O&2 I7J03S70?\ ":?M(?\ 1,? W_A5S_\
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M7/\ _(M 'OE%>!_\)I^TA_T3'P-_X5<__P BT?\ ":?M(?\ 1,? W_A5S_\
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M+M4N9M2?5K>\N4BBO3)O@D6'S-A$16%5!7D1+FLK_A-/VD/^B8^!O_"KG_\
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M?^?"]_[]#_&O$_\ A-/VD/\ HF/@;_PJY_\ Y%H_X33]I#_HF/@;_P *N?\
M^1: /;/[6/\ SX7O_?H?XT?VL?\ GPO?^_0_QKQ/_A-/VD/^B8^!O_"KG_\
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MFG[2'_1,? W_ (5<_P#\BT >V?VL?^?"]_[]#_&C^UC_ ,^%[_WZ'^->)_\
M":?M(?\ 1,? W_A5S_\ R+1_PFG[2'_1,? W_A5S_P#R+0![9_:Q_P"?"]_[
M]#_&C^UC_P ^%[_WZ'^->)_\)I^TA_T3+P-_X5<__P BT?\ ":?M(?\ 1,?
MW_A5S_\ R+0![9_:Q_Y\+W_OT/\ &C^UC_SX7O\ WZ'^->)_\)I^TA_T3'P-
M_P"%7/\ _(M'_":?M(?]$Q\#?^%7/_\ (M 'MG]K'_GPO?\ OT/\:/[6/_/A
M>_\ ?H?XUXG_ ,)I^TA_T3'P-_X5<_\ \BT?\)I^TA_T3'P-_P"%7/\ _(M
M'MG]K'_GPO?^_0_QH_M8_P#/A>_]^A_C7B?_  FG[2'_ $3'P-_X5<__ ,BT
M?\)I^TA_T3'P-_X5<_\ \BT >V?VL?\ GPO?^_0_QH_M8_\ /A>_]^A_C7B?
M_":?M(?]$Q\#?^%7/_\ (M'_  FG[2'_ $3'P-_X5<__ ,BT >SW,UUJD;6T
M5M-:Q2#;)/-A2%/4*,DDD?@*TT18T5%&%48 ]!7@O_":?M(?]$Q\#?\ A5S_
M /R+7O,+2-#&955)2H+JIR V.0#WYH ?1110!%:_\>L/^XO\JEJ*U_X]8?\
M<7^52T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !2,ZK]Y@OU.*6O+_ !-\/;#QI\9(Y==T;^U=&C\.
MM"HNHB]MYS7'H?E\P+T/WE!.,9H ]%U75(-'TV]OIR3#9P/<2JG+;54L<#Z
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MO_B*^?O^$5UO_H"ZE_X!R?\ Q-'_  BNM_\ 0%U+_P  Y/\ XFC^P\J_E_\
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M!_X; 7_H#WG_ ']B_P#B*/\ AL!?^@/>?]_8O_B*^?O^$5UO_H"ZE_X!R?\
MQ-'_  BNM_\ 0%U+_P  Y/\ XFC^P\J_E_\ )G_F'^M&>_S_ /DD?\CZ!_X;
M 7_H#WG_ ']B_P#B*/\ AL!?^@/>?]_8O_B*^?O^$5UO_H"ZE_X!R?\ Q-'_
M  BNM_\ 0%U+_P  Y/\ XFC^P\J_E_\ )G_F'^M&>_S_ /DD?\CZ!_X; 7_H
M#WG_ ']B_P#B*='^V!&9%#Z3?*F>662$D#Z;1G\Z^?/^$5UO_H"ZE_X!R?\
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M";?]^$H^PWW_ $$V_P"_"5H44 9_V&^_Z";?]^$H^PWW_03;_OPE:%% &?\
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M?%5QJ-_:+BY(5E^S11JP$$0#< ;L<]<UF>'/V.O^$?\ AS\)O"O_  E?V@>
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M !1110 4444 8'C#QUHO@.Q@N];N9;:WFD\I&AM9K@EL$XQ&C$< \D8KD_\
MAHWP!_T%KS_P37O_ ,9KTNC- 'FG_#1O@#_H+7G_ ()K[_XS1_PT;X _Z"UY
M_P"":]_^,UZ4S!5+,=J@9))X%4['7-.U1G6SU"UNV0998)U<J/4X/% ' _\
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M -_7_P#B*/\ AHSP9_T&+/\ [^O_ /$4?4,7_P ^9?\ @+_R#^U<!_T$0_\
M X_YE;_A>'PQ_P"?NY_\$U]_\9H_X7A\,?\ G[N?_!-??_&:L_\ #1G@S_H,
M6?\ W]?_ .(H_P"&C/!G_08L_P#OZ_\ \11]0Q?_ #YE_P" O_(/[5P'_01#
M_P #C_F5O^%X?#'_ )^[G_P37W_QFC_A>'PQ_P"?NY_\$U]_\9JS_P -&>#/
M^@Q9_P#?U_\ XBC_ (:,\&?]!BS_ ._K_P#Q%'U#%_\ /F7_ ("_\@_M7 ?]
M!$/_  ./^96_X7A\,?\ G[N?_!-??_&:/^%X?##_ )^[G_P37W_QFK/_  T9
MX,_Z#%G_ -_7_P#B*='^T1X.ED5%UBQ#,<#=.RC\24P*/J.+_P"?4O\ P%_Y
M!_:F _Z"(?\ @4?\RG_PNSX7[<_:;C'3_D"WW_QFD_X7;\+O^?JX_P#!+??_
M !FO1[;5KJ\MXY[>RCG@D4.DD=TK*RGH00.14GVW4/\ H'#_ ,"%_P *XM3T
MDTU='FG_  NWX7?\_5Q_X);[_P",T?\ "[?A=_S]7'_@EOO_ (S7I?VW4/\
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M]7'_ ();[_XS1_PNWX7?\_5Q_P""6^_^,UZ7]MU#_H'#_P "%_PH^VZA_P!
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M %8T:1I" 23]YB2>2>IJ[2 **** "BBB@#X<_:*6_7XA9O-_D&V3[/NZ=_,
M]_,WY_"O+Z_0_P 4?#W1?%ZXU*RBN!NW%98E=2<8S@C@X[C'O7-_\,_^#?\
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M_P" J4?ZU87_ )]R_#_,/]1,;_S]A^/^1\*45]U_\,_^#?\ H"V/_@*E.C^
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M,?\ A1_9][_T$Y/^_,?^% %^BJ']GWO_ $$Y/^_,?^%']GWO_03D_P"_,?\
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M=:--VD>Y@<FQF8TG6PZ32?+K**;=KV2;3;MT1T7_  Q/\-/[_BK_ ,*S4O\
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MS10!X-_PQ/\ #3^_XJ_\*S4O_C]'_#$_PT_O^*O_  K-2_\ C]>\T4 >#?\
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M_P"!#5U?ZJXC_GZOQ.+_ %\PG_/F7X'T1_PQ[\)_^@AXB_\ "QU#_P"/T?\
M#'OPG_Z"'B+_ ,+'4/\ X_7SO_PL[Q=_T,NI_P#@0U'_  L[Q=_T,NI_^!#4
M?ZJXC_GZOQ#_ %\PG_/F7X'T1_PQ[\)_^@AXB_\ "QU#_P"/T?\ #'OPG_Z"
M'B+_ ,+'4/\ X_7SO_PL[Q=_T,NI_P#@0U'_  L[Q=_T,NI_^!#4?ZJXC_GZ
MOQ#_ %\PG_/F7X'T1_PQ[\)O^@AXB_\ "QU#_P"/T?\ #'OPF_Z"'B+_ ,+'
M4/\ X_7@VA_&CQAH.I0WBZU<WJQL"]O>-YL4B]U(/KZCD5]UZ'<VVMZ+I^HI
M;1QI=V\=P$*C*AE#8_6O"S+*:V6<KJ--2['T^2Y_A\ZYU2BXN-KI^?H>&_\
M#'OPG_Z"'B+_ ,+'4/\ X_1_PQ[\)O\ H(>(O_"QU#_X_7O_ -E@_P">,?\
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MQU#_ ./T?\,>_"?_ *"'B+_PL=0_^/U[_P#98/\ GC'_ -\"C[+!_P \8_\
MO@4 > ?\,>_"?_H(>(O_  L=0_\ C]'_  Q[\)_^@AXB_P#"QU#_ ./U[_\
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M?-B5]HWJC#=[5W7V/XM?]!GP7_X*+O\ ^2:/L?Q:_P"@SX+_ /!1=_\ R33
MX"Z_8[T>Z\376LGQ'J"RW'CVW\>F(0Q[1/%'L%OG^X1SGK3O%'[&_AWQ9K'C
MG5;K7=2M]2\1:Y8^(K6ZMDB#Z5>6D/E1M%N4AP1G<K@@Y(KO?L?Q:_Z#/@O_
M ,%%W_\ )-'V/XM?]!GP7_X*+O\ ^2:0"_!_X1O\+;;6)+SQ/JGBS5]6N%N+
MJ_U%8XE&U=JI%#$JQQ(!GA1R22:]#KSO['\6O^@SX+_\%%W_ /)-'V/XM?\
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MT&?!?_@HN_\ Y)I/L7Q:_P"@SX+_ /!1=_\ R37GGKG;?VI-_P! R\_\A_\
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M&7_0(7_P+A_^+KT_JN2?W/\ P)?YGC?7>)_^GO\ X"_\CK_^&IO%/_/K:?\
M?V?_ ..4?\-3>*?^?6T_[^S_ /QRN0_X4MXR_P"@0O\ X%P__%T?\*6\9?\
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M%<?_ ,*6\9?] A?_  +A_P#BZ='\$_&4CJO]DHNXXW-=P@#Z_/2^JY)_<_\
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M-,_Y_8_UH_X233/^?V/]:\VHH^IP[L/[2J=D>D_\))IG_/['^M'_  DFF?\
M/['^M>;44?4X=V']I5.R/1+K6-%OH3%<S6UQ%D'9*NY<@Y!P14O_  DFF?\
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M_P _4/Y?_6H_X2#2?^?J'\O_ *U><44?4X=V']I5.R/1_P#A(-)_Y^H?R_\
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M&>237T_175<X'6D[^9\S?LT_!GQ=\/?V6_$O@_7M+6R\0WG]H>1:"XCD#>;
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M%I8V4LFHM&2$M(C%%C8J\[< _05ZQX;_ .0Y9_[_ /0UF5I^&_\ D.6?^_\
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M?Q9R/_"!'_G]_P#(?_UZ/^$"/_/[_P"0_P#Z]==11]9J]P^HX?\ E_%G(_\
M"!'_ )_?_(?_ ->C_A C_P _O_D/_P"O7744?6:O</J.'_E_%G(_\($?^?W_
M ,A__7H_X0(_\_O_ )#_ /KUUU%'UFKW#ZCA_P"7\6<C_P ($?\ G]_\A_\
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M_P#/[_Y#_P#KT?\ "!'_ )_?_(?_ ->NNHH^LU>X?4</_+^+.1_X0(_\_O\
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MD?\ A C_ ,_O_D/_ .O1_P ($?\ G]_\A_\ UZZZBCZS5[A]1P_\OXLY'_A
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MA_Y?Q9R/_"!'_G]_\A__ %Z/^$"/_/[_ .0__KUUU%'UFKW#ZCA_Y?Q9R/\
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M&0_^!4G^%']BYMV7WQ#_ %BR#^9_=(^D?^$"/_/[_P"0_P#Z]'_"!'_G]_\
M(?\ ]>OF[_AK+7_^@9#_ .!4G^%'_#66O_\ 0,A_\"I/\*/[%S;LOOB'^L60
M?S/[I'TC_P ($?\ G]_\A_\ UZ/^$"/_ #^_^0__ *]?-W_#66O_ /0,A_\
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M&0_^!4G^%']BYMV7WQ#_ %BR#^9_=(^D?^$"/_/[_P"0_P#Z]'_"!'_G]_\
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M&+:VT^>:TN-6U"6Y:*2[A?:2X6UB4[E#-\S;>2#7Z!?\)]9?] W7?_!-=?\
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M_M6R_P"?RW_[^K_C1_:ME_S^6_\ W]7_ !KGO^$QTK_H#:Q_X([C_P"-T?\
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M_P!\G_&C_A6/A7_H!VO_ 'R?\: .GHKF/^%8^%?^@':_]\G_ !H_X5CX5_Z
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M:7DSFJ8:C5?-4IIOS29#_P *1\)?] BS_P# .#_XBC_A2/A+_H$6?_@'!_\
M$5-_PAW@?_H%6G_?MZ/^$.\#_P#0*M/^_;U?UJO_ ,_'][,_J.&_Y]1_\!7^
M1#_PI'PE_P! BS_\ X/_ (BC_A2/A+_H$6?_ (!P?_$5-_PAW@?_ *!5I_W[
M>C_A#O __0*M/^_;T?6J_P#S\?WL/J.&_P"?4?\ P%?Y$/\ PI'PE_T"+/\
M\ X/_B*/^%(^$O\ H$6?_@'!_P#$5-_PAW@?_H%6G_?MZ/\ A#O _P#T"K3_
M +]O1]:K_P#/Q_>P^HX;_GU'_P !7^1#_P *1\)?] BS_P# .#_XBC_A2/A+
M_H$6?_@'!_\ $5-_PAW@?_H%6G_?MZ/^$.\#_P#0*M/^_;T?6J__ #\?WL/J
M.&_Y]1_\!7^1#_PI'PE_T"+/_P  X/\ XBC_ (4CX2_Z!%G_ . <'_Q%3?\
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M%6G_ '[>C_A#O __ $"K3_OV]'UJO_S\?WL/J.&_Y]1_\!7^1#_PI'PE_P!
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M*77_ 'S'_P#$5RW_  B/@7_H&6?_ '[>C_A$? O_ $#+/_OV] '4_P!F7/\
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M^\9F!9G*<MGC=T[4"*5K^V!\/'T'Q%J-])K.BW&A75M976D:II,T&H-+<?\
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M0&4E2HP>N;.B_"K2-%O-)N5GO+N73IKF\#74H<SW<XP]S+P,R!2ZKC"JKL
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MV5_S_P#DK_R#_57//Y/_ "9?YGSM_;VI_P#02O/_  (?_&C^WM3_ .@E>?\
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M - W_P F%_PH^V7_ /T#?_)A?\* -#-&:S_ME_\ ] W_ ,F%_P */ME__P!
MW_R87_"@#0S1FL_[9?\ _0-_\F%_PH^V:A_T#1_X$+_A0 R\B6SU.SN8AL>>
M3R)0O\8*D@GW!'7T)K3K/@M+BXNTNKS8AC!\J",E@A(P6)P,G''3C)K0H **
M** (K7_CUA_W%_E4M16O_'K#_N+_ "J6@ HHHH **** "BBB@ HHHH ****
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M^*O^AEL?_!3_ /;J/['\5?\ 0RV/_@I_^W57TWXM>$-:U"VL-/U^SO;NZ3=
ML+%DE;9OV!\;=^WYMF=V.<5Q7AGXL>+YO#/A#Q1KFCZ(F@^(GL8PFGWDINK8
MW;(L1*N@5\-(@8 @@9(SC% '>_V/XJ_Z&6Q_\%/_ -NH_L?Q5_T,MC_X*?\
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M/_@I_P#MU=-10!S/]C^*O^AEL?\ P4__ &ZC^Q_%7_0RV/\ X*?_ +=7344
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MC^*_^AELO_!3_P#;J^4/^&G_ !;_ ,\;'_OJ?_X[1_PT_P"+?^>-C_WU/_\
M':/]6L?V7WA_KIE/>7_@)]7_ -C^*_\ H9++_P %/_VZC^Q_%?\ T,EE_P""
MG_[=7RA_PT_XM_YXV/\ WU/_ /':/^&G_%O_ #QL?^^I_P#X[1_JUC^R^\/]
M=,I[R_\  3ZO_L?Q7_T,EE_X*?\ [=1_8_BO_H9++_P4_P#VZOE#_AI_Q;_S
MQL?^^I__ ([1_P -/^+?^>-C_P!]3_\ QVC_ %:Q_9?>'^NF4]Y?^ GU?_8_
MBO\ Z&2R_P#!3_\ ;J/['\5_]#)9?^"G_P"W5\H?\-/^+?\ GC8_]]3_ /QV
MC_AI_P 6_P#/&Q_[ZG_^.T?ZM8_LOO#_ %TRGO+_ ,!/J_\ L?Q7_P!#)9?^
M"G_[=1_8_BO_ *&2R_\ !3_]NKY0_P"&G_%O_/&Q_P"^I_\ X[1_PT_XM_YX
MV/\ WU/_ /':/]6L?V7WA_KIE/>7_@)]7_V/XK_Z&2R_\%/_ -NH_L?Q7_T,
MEE_X*?\ [=7RA_PT_P"+?^>-C_WU/_\ ':='^U!XK5U+6]DZ@\KOG&?;/FT?
MZM8_LOO#_7/*>\O_  $^K?['\5_]#)9?^"G_ .W4?V/XK_Z&2R_\%/\ ]NK'
M^%?BG3OB=X1@UF!+NUEWM#<6YNY&\N1<9 .>1@@CV-=?_8EO_P ]+K_P*D_^
M*KYJK3G1FZ=16:T9]G0K4\32C6I.\9*Z?D9']C^*_P#H9++_ ,%/_P!NH_L?
MQ7_T,EE_X*?_ +=6O_8EO_STNO\ P*D_^*H_L2W_ .>EU_X%2?\ Q59&YD?V
M/XK_ .ADLO\ P4__ &ZC^Q_%?_0R67_@I_\ MU:_]B6__/2Z_P# J3_XJC^Q
M+?\ YZ77_@5)_P#%4 9']C^*_P#H9++_ ,%/_P!NH_L?Q7_T,EE_X*?_ +=6
MO_8EO_STNO\ P*D_^*H_L2W_ .>EU_X%2?\ Q5 &1_8_BO\ Z&2R_P#!3_\
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M ,50!D?V/XK_ .ADLO\ P4__ &ZC^Q_%?_0R67_@I_\ MU:_]B6__/2Z_P#
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M(!^E?H-_PF5Y_P!"GKO_ 'S;?_'JC7Q1,MP\Z^#M:$[@*T@BMMQ Z GSLXH
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M9?\ "3:SJ7B*WM9@5:*WNKEY(01VRA5L?[5?0%<POB^ZC4*OA+7%51@*$M@
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M212N(PP485E8_+G;@%20<C(SFO+O^%'>,O\ H'0?^!T'_P 77VC_ ,)E>?\
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M_P#WV*/^$@TW_G_M_P#OL5D?\)E>?]"GKW_?-M_\>I?^$RO/^A3U[_OFW_\
MCU &M_PD&F_\_P#;_P#?8H_X2#3?^?\ M_\ OL5D_P#"97G_ $*>O?\ ?-O_
M /'J/^$RO/\ H4]>_P"^;?\ ^/4 :W_"0:;_ ,_]O_WV*/\ A(--_P"?^W_[
M[%9/_"97G_0IZ]_WS;__ !ZC_A,KS_H4]>_[YM__ (]0!K?\)!IO_/\ V_\
MWV*/^$@TW_G_ +?_ +[%9/\ PF5Y_P!"GKW_ 'S;_P#QZC_A,KS_ *%/7O\
MOFW_ /CU &M_PD&F_P#/_;_]]BC_ (2#3?\ G_M_^^Q63_PF5Y_T*>O?]\V_
M_P >H_X3*\_Z%/7O^^;?_P"/4 :"S?VQ>V[0JWV.W;S#,P($C8( 7/4#))/3
MI6K7,_\ "97G_0IZ[_WS;?\ QZK%AXHN;V\B@?PYK%HKG!GN%@V)[G;*3CZ
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M6DF2=ZKC ;)/(YYKP2U_:MUN+1])\8:MX ET[X<ZI=);0:P-022YC5W*)+)
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MG.UDS6%JS6(Q:L85)M^ /W?'R\ #C'2KM%%=1\NY2ENPHHHH)"BBB@ HHHH
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MB-LJ&0RJ5SN78,_+G(Z4[P_XLTGQ5X5L/$FE7BWFB7UJM[;7:HRB2%EW*^"
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M17TC\"[K4;[X*> +G5]W]JS:!8R71?[QE-NA;/OG- CN**** "BBB@ HHHH
M***\T^(VER^(?B5X&TF34=2M-)GM]2EN[?3[N6V%SL6#8KO&RL "Q(P0>/0D
M$ ]*9@JDG@#DUPWA_P"-O@_Q--IL=E?W:+J946-Q>:7=6L%T67<HCEEB5&+
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M_P" 1_\ CM'_  UMX<_NW7_@$?\ X[7R+YB_WA^='F+_ 'A^='^K. _O??\
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MID@G\:]<K\SQ=*&'Q$Z4'=)M7/VS+\14Q6$I5ZL>64DFUV,_;JO]^R_[X?\
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MV>824^;A?NC/3FF/\6O",<T<9UR#=)9_VAE5<JEOEU\QR%P@W1NOS8^9=O7
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M_P"$DT?_ *"MC_X$I_C1_P )-H__ $%K'_P)3_&F?\(EH?\ T!=/_P# 2/\
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MQD@;E&,XQFNNC\1:+#&L<>IZ>B* JJMQ&  .@ S2?\(GH?\ T!=/_P# 6/\
MPH_X1/0_^@+I_P#X"Q_X4 /_ .$FT?\ Z"UC_P"!*?XT?\)-H_\ T%K'_P "
M4_QIG_")Z'_T!=/_ / 6/_"C_A$]#_Z NG_^ L?^% #_ /A)M'_Z"UC_ .!*
M?XT?\)-H_P#T%K'_ ,"4_P :9_PB>A_] 73_ /P%C_PH_P"$3T/_ * NG_\
M@+'_ (4 /_X2;1_^@M8_^!*?XT?\)-H__06L?_ E/\:9_P (GH?_ $!=/_\
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MH?\ T!=/_P# 2/\ PH ?_P )-H__ $%K'_P)3_&C_A)M'_Z"UC_X$I_C3/\
MA$M#_P"@+I__ ("1_P"%'_")Z'_T!=/_ / 6/_"@!_\ PDVC_P#06L?_  )3
M_&C_ (2;1_\ H+6/_@2G^-,_X1/0_P#H"Z?_ . L?^%'_")Z'_T!=/\ _ 6/
M_"@!_P#PDVC_ /06L?\ P)3_ !H_X2;1_P#H+6/_ ($I_C3/^$3T/_H"Z?\
M^ L?^%'_  B>A_\ 0%T__P !8_\ "@"GJ5QX:U;)N;^P9B-I872 D>AYY_&L
MW^Q_!G_/SI__ ($1UH7^F^%]-;;/I>GJ^,[5LT8@>I 7@?6JF[P?_P! NQ_\
M %_^)K2+FOAN925-OW[$7]C^#/\ GYT__P "(Z/['\&?\_.G_P#@1'4N[PA_
MT"['_P  %_\ B:-WA#_H%V/_ ( +_P#$U?-5[LCEH]E^!%_8_@S_ )^=/_\
M B.C^Q_!G_/SI_\ X$1U+N\(?] NQ_\  !?_ (FC=X0_Z!=C_P" "_\ Q-'-
M5[L.6CV7X$7]C^#/^?G3_P#P(CH_L?P9_P _.G_^!$=2[O"'_0+L?_ !?_B:
M-WA#_H%V/_@ O_Q-'-5[L.6CV7X$7]C^#/\ GYT__P "(Z/['\&?\_.G_P#@
M1'4N[PA_T"['_P  %_\ B:-WA#_H%V/_ ( +_P#$T<U7NPY:/9?@1?V/X,_Y
M^=/_ / B.C^Q_!G_ #\Z?_X$1U+N\(?] NQ_\ %_^)HSX/\ ^@78_P#@ O\
M\31S5>[#EH]E^!%_8_@S_GYT_P#\"(Z/['\&?\_.G_\ @1'4N[PA_P! NQ_\
M %_^)HW>$/\ H%V/_@ O_P 31S5>[#EH]E^!%_8_@S_GYT__ ,"(Z/['\&?\
M_.G_ /@1'4N[PA_T"['_ , %_P#B:-WA#_H%V/\ X +_ /$T<U7NPY:/9?@1
M?V/X,_Y^=/\ _ B.C^Q_!G_/SI__ ($1U+N\(?\ 0+L?_ !?_B:-WA#_ *!=
MC_X +_\ $T<U7NPY:/9?@1?V/X,_Y^=/_P# B.C^Q_!G_/SI_P#X$1U+N\(?
M] NQ_P# !?\ XFC=X0_Z!=C_ . "_P#Q-'-5[L.6CV7X$7]C^#/^?G3_ /P(
MCIT>E^#X9%>.\L(W4Y#+<Q@C\<T_=X0_Z!=C_P" "_\ Q-*O_"(LP5=*LV8\
M #3U)/\ X[2YJG=ART>R_ M_;-$_Z& ?^#(?_%4?;-$_Z& ?^#(?_%4W^S/#
MO_0O1_\ @J_^PH_LSP[_ -"]'_X*O_L*R.@=]LT3_H8!_P"#(?\ Q5'VS1/^
MA@'_ (,A_P#%4W^R_#O_ $+T?_@J_P#L*/[+\._]"]'_ ."K_P"PH =]LT3_
M *& ?^#(?_%4?;-$_P"A@'_@R'_Q5-_LOP[_ -"]'_X*O_L*/[+\._\ 0O1_
M^"K_ .PH =]LT3_H8!_X,A_\51]LT3_H8!_X,A_\53?[+\._]"]'_P""K_["
MC^R_#O\ T+T?_@J_^PH =]LT3_H8!_X,A_\ %4?;-$_Z& ?^#(?_ !5-_LOP
M[_T+T?\ X*O_ +"C^R_#O_0O1_\ @J_^PH =]LT3_H8!_P"#(?\ Q5'VS1/^
MA@'_ (,A_P#%4W^R_#O_ $+T?_@J_P#L*/[+\._]"]'_ ."K_P"PH =]LT3_
M *& ?^#(?_%4?;-$_P"A@'_@R'_Q5-_LOP[_ -"]'_X*O_L*/[+\._\ 0O1_
M^"K_ .PH =]LT3_H8!_X,A_\51]LT3_H8!_X,A_\53?[+\._]"]'_P""K_["
MC^R_#O\ T+T?_@J_^PH =]LT3_H8!_X,A_\ %4?;-$_Z& ?^#(?_ !5-_LOP
M[_T+T?\ X*O_ +"C^R_#O_0O1_\ @J_^PH =]LT3_H8!_P"#(?\ Q5'VS1/^
MA@'_ (,A_P#%4W^R_#O_ $+T?_@J_P#L*/[+\._]"]'_ ."K_P"PH =]LT3_
M *& ?^#(?_%4?;-$_P"A@'_@R'_Q5-_LOP[_ -"]'_X*O_L*/[+\._\ 0O1_
M^"K_ .PH M6>K:!8A_)U.Q#.<N[72LS'W);)JY!KVF74RQ0ZC:32L<*D<Z,Q
M^@!JA9Z#X<OE8PZ3IS%3AE-FBLI]""N15RW\-Z19S)-!I=E!,ARLD=NBLI]B
M!Q2 T:*** ,K6M('B#PI?:6TGE"^L9+8R#^'?&5S^&:\^\(_"?3/$%P_B#Q7
MH%G=:E<6EG:M:7UJ'-N]NK(X!.0R,V64XP1@]Z]1M?\ CUA_W%_E4M 'ANO_
M  #UW7KRXDFUZVE##48A+/\ :9'DCNH)H@#&9?*C\L2J $4;@O\ #FNL\6?#
M._U_5KF2"]M(["]M-/M[B.:)BZM:733J5P<$,'92#TP#SR*]&HH \K\=?!F;
MQ1XRD\2V][$MTBPK#;2O/$A 25)-SPNK D.I!'3:00<\5(?@"G]@ZOITE_%&
M=0LK:,O!'( MQ%>SW>\DR%RA>8 _/N(4G=DY'K]% 'D6C_!O5="U1/$5G>:=
M%XBBDVK')]IGMW@V,I1GED:3=EBP8$!>1M.23TF@_#>2'P=XDT36[R&_;7;J
M\N+B2U@,2(+C^%5)/W<\$G)P#UKN:* /'--^ ][#<:5=7NNQ7=W]FF?6&%L5
M6_OV\WR9\;OE6,W$^%Y/$?/R5HZ!\)-2T?4-,674+.?3K*_M-3 \EA*98M.%
MFR]<;3M5P>HR1[UZE10!PFH?#>>\\.^*]-2^CC?6M3^WI)Y9Q$,PG:1GD_NC
MS_M5BP?!.6WUG4;K^U8Y+3^T[6ZTNU: C[!;K>)>7$((/)DE4X.!M58QCY>?
M5:* /"8?V:Y(=-32QJ%L;*RA>&RFD:YEE.[@%U>4QJ0FX'8HW$Y^4?*>]C\%
MZWIVN:E_9VI6$>AZGJ"ZE<)<6IDN4?$8>-#NVD-Y8PQ&5R<9PN.YHH \/A^#
M-_X#\!W>@:/=2ZF-=TZ'2K]9 \F+DJL)NPY)V1K#NRG3]W&%P2=WMZKM4 =!
MQ2T4 %%%% !7YF?&Z[U[4?C1^T=+8:?\0M7U'1#9R:1J/AK6I;>RT-_L2NTD
M\0E&Y,C>0L;DA6X!.:_3.O#/&'[&OP[\<>,O$7B34'\0PWOB)HVU6WT_7;FU
MMKP)&(U62*-P&7:,8]SZT >!>&/CSJ?A?XF>*O%PU^W\7VUK\*]"OXY+O4C9
M:==W4DQ1Y\R<1EF))^7>?N@9P*Z33?V_+S3O#/Q"EUOPYI^HZUX;ATZ6R_L6
M6YBM;Y[V4PQ1M]JACDCVOC<VTJ1R*]FU?]D'X6ZTNI17'AYDM+[1K/06M(+F
M2.**UM9/,MQ&%(V.CX.\')QSFHH?V//AGYVORWVGZGK<NOZ4FD:K)K&K7-V]
MY$D@DC=VD<GS$95VN""H  Q0,^=O''Q^\?\ PA_:)N?$GQ*TBUM#HOPYNKY=
M%\.ZM+/97LC7T21$AU78X=]A8J< $@D<5:\5_&KXB>$_VAOAWK_Q(TFST33K
M'PCKVMOIWAK5I;F"[C2W639)&RJ/-3: &.Y3OR",&O>-#_8O^%NBW]W>2:7J
M&LW%[I$VA7;ZUJMQ>FXLY&4F-S(Y/R[%VD8VXX]:D\(_L<?#+P;X@T_6[6PU
M/4-0L;.XTZ)]7U6XO5^R31^6]N5E=AY84D!>@W'UH \H\#_MO>+_ !!;27.J
M_#MK2ROO#U]K>G7EO;WZP6[P6S3I#<R36\:.'5<"2%F7.!W!KV3]GOXM>+/B
M7\)X?'OC+0-,\.Z??6,6I6%OIMV]S(UN8M[O("H"DG)51G@C)S5?PU^R#\-?
M"K7IL[#4YEGTRXT>WCOM6N;E-/LYE*RPVJR.1""IQ\O..*],\$^"]*^'W@O1
MO"NCQ/'HVDV<=A:Q3.9&$2*%4,QY8X'4]:!'A'P=_:.^(OQ,7PUXKN/ .DVG
MPU\3>>UE>0:VO]H6<:;MDEQ'(%1@Y7I&25SD]*Y;X:_MP:MXN^)OA[P[J.BZ
M";'Q&E_]ADT6]N+EK1[:)Y0)9FA6"8.J$;H'8 ]:]3\,_L=_"OPGXHCUNQT&
M=F@-PUGIUS?SS6%BTX*S-;V[.8XRP9@=H[\8JOX>_8S^&GA>_P##=W86VM+)
MX;N))M'2;6[J6.Q1T97@B1W*K$0QR@&#WH \P^%O[:'C7Q%#\*]<\6>"]'TK
MP?X^N+C3K2[TW49)KJ&YB60[WB9,"-O*8 !BPQD]A74?"G]ICX@_$:WT#QE)
MX!TN#X6Z]+<K;7D&L ZG:0Q%PL\T+A5<,8S\D9+#T->A:/\ LQ^ ]#\/?#W1
M+2RO%L/ =\^HZ(K7CLT<S>9DN2?W@_>OP?4>E4?"_P"R)\,/!_C:U\3Z9HEQ
M'<V5Q+>6-A+J$\EA8SR9\R6"V9S'&S9/('&>,4 >2?";]N+Q)\2/$GAB5_AY
M<Q>$?$UU);6=Y:V]ZTMDHW"*:>5K=;=T8K@^5(=F><X->E_LG?&OQO\ '[P6
MOB_Q#X:TCP_H%TK1Z>UC>R33W$D<TD<K,C* B?( O))(8G Q6IX7_9-^&_@[
MQ9:Z_IFEWL<EC+-<:?ITVI7$MAI\LN?,DM[9G,<3'<W*CC/&*[;X6_#+0O@[
MX'T[PEX:AFM]%L#*8([B9I7'F2-(V6;D_,[4 ?"'Q\\0^)O&WP_^,WC:R\2Z
MGI6HCX@6'@O1OLUY+#'I]O;7$2,RJK ;I)9"SG&2 !TXI9OCUXJ\;?%W1/#W
MB&YO=$\;^%O!GB?3O$FG6\[QP27<5LI@NT"G:PD4>8C=B3C'%?1T'[+*:CXN
M^(ND:^L5_P##;Q+K5KXMLX[>[>&[M-41D,J$!<&)FC1P=WJ".<UZ#XK_ &=_
M WC+XB'QQJ.EN/$K:1<:))=V\[1>;:S(R.K@<,P5F 8\C- SX-^"/QX\9^'_
M -EW5_AG=ZQ>7WQ#\1C3?^$4O+BY>2XEMM57!D5V);]P4N"3GY3BF_"7QAXD
M.@_ R.?Q'JUR\WA+QLUQ))?2L9WB:X$;OEOF9<#:3DK@8Q7W'H?[*_PZ\/:]
MX#UFTTB4ZEX)TQM(T:>:Y=S%;LI7#Y/SL S88\C<:IZ'^R+\./#UOX;AL["^
M1/#UCJ6G6&Z^D;;#?ES<ALGYB3(V"?N]J8'Q3^S7XDUO0]:_9ZUHS>./#%MK
MTQM-:U[Q)JLUYI'B!Y(V$4$$7F2;'=A\K.(P,=Z].^&OA#4/VAOAKXT^*_B;
MXL^(_!/BFUUO4(;.YMM6>WT[P[%;2E$CDMMRQL-H!??RP8<]S[QX%_8I^&/@
M#5?#]]:6VM:G_P (_()M(M-8UJYN[6PD'W7BA=]BL.QQQ4WBW]BWX3^-?%5_
MKNI:#=+)J5P+O4M/M=2N(+'4)@<^9/;HXC=L]<CGOFD!S%OK>H^#?VHOAE+'
MXA;7=+^(WAFX@OO(D;['->64,<T=[!'N*QB2-V!"\$%>I&:^F*\='PCU?5OV
MD-,\:ZB+&S\*>%=#?3/#MA:.3(9YRHN)I%VA45418U4$\9/'2O8J!!1110 4
M444 %%%% !1110 4444 %%%% !7#>//%GB#2_%GAGP_X>L]/EN-8CO))+O46
M?R[985C(;:G+Y,F,9'4'/%=S69>>';*^U[3-9F1C?:='-%;L'(4++LWY'?\
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MZEYKVC_X%_P#Y)VK_='Y4;5_NC\J^MO^&1_#W_/6\_\  _\ ^TT?\,C^'O\
MGK>?^!__ -IH_P!9<!W?W!_J7FO:/_@7_ /DG:O]T?E1M7^Z/RKZV_X9'\/?
M\];S_P #_P#[31_PR/X>_P">MY_X'_\ VFC_ %EP'=_<'^I>:]H_^!?\ ^2=
MJ_W1^5&U?[H_*OK;_AD?P]_SUO/_  /_ /M-'_#(_A[_ )ZWG_@?_P#::/\
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MJ_\ /&R_[^O_ /$T;]5_YXV7_?U__B: -"BL_?JO_/&R_P"_K_\ Q-&_5?\
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M&,)&#UQGDD^I_2KU !1110!%:_\ 'K#_ +B_RJ6HK7_CUA_W%_E4M !1110
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M+8O[_P")EMH^E:;'?>'3::@#=J<3W=Y;&'='!E@FQ3(4+,<%P0" A)0'4_\
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M?^ ,/_Q-=7^J^-_FC][_ ,CA_P!>,M_DG]R_^2/L_P#X135?^APUC_OS:?\
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M7QA_PO;QE_T$+;_P!A_^)H_X7MXR_P"@A;?^ ,/_ ,31_JOC?YH_>_\ (/\
M7C+?Y)_<O_DC[/\ ^$4U7_H<-8_[\VG_ ,9H_P"$4U7_ *'#6/\ OS:?_&:^
M,/\ A>WC+_H(6W_@##_\33XOCSXRBD5S>VD@4YVO8Q8/L<+1_JOC?YH_>_\
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M=#AOK8 $3/?B(D]QMV'I]:I_VUXH_P"A8M__  :K_P#&Z /A9?V+?'VD:/\
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M,?VUXH_Z%BW_ /!JO_QNC^VO%'_0L6__ (-5_P#C= '3T5S']M>*/^A8M_\
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M_C='^LV/_N_=_P $/]2<J_O??_P#Y)_X9I\8^MA_WW+_ /&Z/^&:?&/K8?\
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MT^,?6P_[[E_^-T?\,T^,?6P_[[E_^-U];?VWXI_Z%BW_ /!JO_QNC^V_%/\
MT+%O_P"#5?\ XW1_K-C_ .[]W_!#_4G*O[WW_P# /DG_ (9I\8^MA_WW+_\
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M?_P:K_\ &Z/[;\4_]"Q;_P#@U7_XW0!K_P!N6GK-_P" TG_Q-']N6GK-_P"
MTG_Q-9']M^*?^A8M_P#P:K_\;H_MOQ3_ -"Q;_\ @U7_ .-T :_]N6GK-_X#
M2?\ Q-']N6GK-_X#2?\ Q-9']M^*?^A8M_\ P:K_ /&Z/[;\4_\ 0L6__@U7
M_P"-T :_]N6GK-_X#2?_ !-']N6GK-_X#2?_ !-9']M^*?\ H6+?_P &J_\
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M_9]^$NL?$[Q!\*=$\;Q>+H-$'PXNVOD^U7ED'NAJL_EI,ZE27"L&"L<G"G!
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M^_#_ .%']CW_ /SX77_?A_\ "O2_U?RS^7_R9_YGB_ZV9U_/_P"2K_(^E?\
MAL"S_P"@7>?]^X__ (NC_AL"S_Z!=Y_W[C_^+KYJ_L>__P"?"Z_[\/\ X4?V
M/?\ _/A=?]^'_P */]7\L_E_\F?^8?ZV9U_/_P"2K_(^E?\ AL"S_P"@7>?]
M^X__ (NC_AL"S_Z!=Y_W[C_^+KYJ_L>__P"?"Z_[\/\ X4?V/?\ _/A=?]^'
M_P */]7\L_E_\F?^8?ZV9U_/_P"2K_(^E?\ AL"S_P"@7>?]^X__ (NC_AL"
MS_Z!=Y_W[C_^+KYJ_L>__P"?"Z_[\/\ X4?V/?\ _/A=?]^'_P */]7\L_E_
M\F?^8?ZV9U_/_P"2K_(^E?\ AL"S_P"@7>?]^X__ (NC_AL"S_Z!=Y_W[C_^
M+KYJ_L>__P"?"Z_[\/\ X4?V/?\ _/A=?]^'_P */]7\L_E_\F?^8?ZV9U_/
M_P"2K_(^E?\ AL"S_P"@7>?]^X__ (NC_AL"S_Z!=Y_W[C_^+KYJ_L>__P"?
M"Z_[\/\ X4?V/?\ _/A=?]^'_P */]7\L_E_\F?^8?ZV9U_/_P"2K_(^E?\
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M . O_P!G1]EU+_G_ (?_  %_^SJ_10!0^RZE_P _\/\ X"__ &='V74O^?\
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MX$K_ (TO_"S?"?\ T,FF_P#@2O\ C72\T9H YK_A9OA/_H9--_\  E?\:/\
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MO_@2O^-'_"S?"?\ T,FF_P#@2O\ C72YHS0!S/\ PLWPE_T,FF?^!*_XTO\
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M/_Z#-C_X'0__ !5'U3$_\^Y?<P_M#!_\_H_^!+_,N?\ "7>!/^@]IW_@=_\
M94?\)=X$_P"@]IW_ ('?_953_P"%[^#_ /H,V/\ X'0__%4?\+W\'_\ 09L?
M_ Z'_P"*H^J8G_GW+[F']H8/_G]'_P "7^9<_P"$N\"?]![3O_ [_P"RH_X2
M[P)_T'M._P# [_[*G:/\6_#WB"]2STV_M;V[?[L,-[ 7;Z#?S^%=)_:%W_T"
M[C_O[%_\56$Z<Z;M.+3\]#JIUJ=:/-2DI+R=_P CF?\ A+O G_0>T[_P._\
MLJ/^$O\  G_0>T[_ ,#O_LJZ;^T+O_H%W'_?V+_XJC^T+O\ Z!=Q_P!_8O\
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MM"[_ .@7<?\ ?V+_ .*H YC_ (2WP'_T'=-_\#O_ +*C_A+? ?\ T'=-_P#
M[_[*NG_M"[_Z!=Q_W]B_^*H_M"[_ .@7<?\ ?V+_ .*H YC_ (2WP'_T'=-_
M\#O_ +*C_A+? ?\ T'=-_P# [_[*NG_M"[_Z!=Q_W]B_^*H_M"[_ .@7<?\
M?V+_ .*H YC_ (2WP'_T'=-_\#O_ +*C_A+? ?\ T'=-_P# [_[*NG_M"[_Z
M!=Q_W]B_^*H_M"[_ .@7<?\ ?V+_ .*H YC_ (2WP'_T'=-_\#O_ +*C_A+?
M ?\ T'=-_P# [_[*NG_M"[_Z!=Q_W]B_^*H_M"[_ .@7<?\ ?V+_ .*H YC_
M (2WP'_T'=-_\#O_ +*C_A+? ?\ T'=-_P# [_[*NG_M"[_Z!=Q_W]B_^*H_
MM"[_ .@7<?\ ?V+_ .*H YC_ (2[P'_T'=-_\#O_ +*C_A+? ?\ T'=-_P#
M[_[*NG_M"[_Z!=Q_W]B_^*H_M"[_ .@7<?\ ?V+_ .*H YC_ (2WP'_T'=-_
M\#O_ +*C_A+? ?\ T'=-_P# [_[*NG_M"[_Z!=Q_W]B_^*H_M"[_ .@7<?\
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M +]%4/LNI?\ /_#_ . O_P!G1]EU+_G_ (?_  %_^SH OT50^RZE_P _\/\
MX"__ &='V74O^?\ A_\  7_[.@"_15#[+J7_ #_P_P#@+_\ 9T?9=2_Y_P"'
M_P !?_LZ +]%4/LNI?\ /_#_ . O_P!G1]EU+_G_ (?_  %_^SH OT50^RZE
M_P _\/\ X"__ &='V74O^?\ A_\  7_[.@"_15#[+J7_ #_P_P#@+_\ 9T?9
M=2_Y_P"'_P !?_LZ +]%4/LNI?\ /_#_ . O_P!G1]EU+_G_ (?_  %_^SH
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M9Z.N>L\;_$W5M!^).FVEDENWA;3FMXO$$KH3(CWCF*UV-G"A&56?(/RRJ>*
M.;_X8_T+_HH/Q-_\+"Z_QH_X8_T+_HH/Q-_\+"Z_QKW?<-V,C/IFO+=/^)>J
MZ_\ %;2;+3DM_P#A#KFUU!(YF0F6]N(&@!EC;.!"#(R X.\AC]T*6 .:_P"&
M/]"_Z*#\3?\ PL+K_&C_ (8_T+_HH/Q-_P#"PNO\:U;+QQXETGQYX>T/4_$.
MD:KKFI29U#PQ8VNUM.@,3.94FW;B$(127'S[N I(%8WPO^*FI^(H/#VJ:QXH
MOMFJ!FCL_P#A'3!9SRD.5MX[HK@OQ@?-\Q4@9Z4P)/\ AC_0O^B@_$W_ ,+"
MZ_QH_P"&/]"_Z*#\3?\ PL+K_&M'0?B7K5KHO@OQ5K.NZ;<Z;XLN[6TCT>WM
M@AMGN>(TCEWEG>-L!]PYPY 7&*]GI >#_P##'^A?]%!^)O\ X6%U_C1_PQ_H
M7_10?B;_ .%A=?XU[Q10!X/_ ,,?Z%_T4'XF_P#A877^-'_#'^A?]%!^)O\
MX6%U_C7O%% '@[_LA:#RS?$'XF*,_P#0X70'\ZC_ .&1_#W_ $47XE?^%E=?
MXUQGQZ^-6M6/B<Z5I4RVGEQK*\S1JY&X;E50P('RD$G&22><"O+O^%R>,O\
MH./_ . \/_Q%?5X7AW%8JC&LI12EJKWV^X^$QW&& P.(GAG"4G%V;25K]=VM
MCZ$_X9'\/?\ 11?B5_X65U_C1_PR/X>_Z*+\2O\ PLKK_&OGO_A<GC+_ *#C
M_P#@/#_\11_PN3QE_P!!Q_\ P'A_^(KJ_P!5<5_S\C^/^1P_Z]X#_GU/_P E
M_P#DCZ$_X9'\/?\ 11?B5_X65U_C1_PR/X>_Z*+\2O\ PLKK_&OGO_A<GC+_
M *#C_P#@/#_\11_PN3QE_P!!Q_\ P'A_^(H_U5Q7_/R/X_Y!_KW@/^?4_P#R
M7_Y(^A/^&1_#W_11?B5_X65U_C1_PR/X>_Z*+\2O_"RNO\:^>_\ A<GC+_H.
M/_X#P_\ Q%'_  N3QE_T''_\!X?_ (BC_57%?\_(_C_D'^O> _Y]3_\ )?\
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M&1_#W_11?B5_X65U_C1_PR/X>_Z*+\2O_"RNO\:^>_\ A<GC+_H./_X#P_\
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M@DCVQ7T3)\!? 4W@VZ\*R>'89- N;UM1DLWED/\ I#')D#;MRGZ$5F:E\ =
MTOPUX@M_!UE::'K.IZ9'I@NKQ&O(3#& (XY(I&8,N!M/&><\FH^KU5JGKZ^3
M1Z2XDRFM:C.C^[YG:+A%12E4ISU:NUI&2:2>C5NQXWJGB#QO\._&/PF@E^)E
MSXPLO$5RUS>6ABA5G BW;4*#)B8G ![@<]17&^'?C=\5M7\/Z?X^@N=7G^TZ
MGY;6-Q_9\.B-#YA4VZEI!,),#@GDG\Z] ^&_[*NL:1X\\+:SJ>E>%?#=GH$[
M7;?\(_)<33ZA-LVKN,W^KC!YV+P,G\/9(_V>?AQ%XJ'B-/"5BNK+/]J$@W>6
M)LY\P19\O=GG.W-9QHUIZIV^;\C?$9QDN#:IRIQK2<=9*G"WQ3?*U%I*Z<?>
MBVU9:7T7@6J>)/B+X@U3XYW^G_$&^T6S\%WDD]C8QVT4BOMC9_+9F7.S"8P.
M[9/I7TK\)?%5SXY^&/A;Q#>*J7>I:=!=3*@PN]D!; [#.:2'X4>%;=/%:1Z2
MJKXJ+'61YTG^EEE*G/S?+\K$?+CK6YX=\/:?X3T&PT;2;<6FF6,*V]O &9A'
M&HP%RQ)/'J:[J5*4)7;_ *O_ )'Q>;9I@\=AXTJ-+E<7&SY8K102E=K5WFKJ
M]_EL:-%%%=1\F%?)OB[]CWQ'\8OBU\3/%7BKQC?>&=/UJTCT#3+/P_+%)YVE
MJGSI<>;$<;Y,MM0]^O3'T=KD_C"/4'&CV6AS6.T;7OKN:.7..<JL3#&?>J'V
MKXA_] WPQ_X,+G_XQ0!\M_#/]F_XV?#/5/#?B*)?!OB/7(/#(\'7]OK5U,8H
MK6&=VM[F)UC).8V57B(&=OWN<C,;]C'XF>'_ -G_ ,!Z9X9U+1+'XF^%[_5D
M2[$[I:/8W_G+*H8)D':\;!<<%>M?6_VKXA_] WPQ_P"#"Y_^,4?:OB'_ - W
MPQ_X,+G_ .,4P/EOQY^QIX^DAM/"_A35=/A\&#PA!X:C U.?3I+650PFGG2&
M,F]5RQ;RW=5!)X]>I^#?[-WC3P_XZM->\66FA;8/AK;>#0EI<M<?Z1#*Z[AN
MC'R/%L)/J2,$#)][^U?$/_H&^&/_  87/_QBC[5\0_\ H&^&/_!A<_\ QB@#
MY-^&?[)GQ:^#.F^'=3T*'P=XAUU_"3>%=5T[Q!<3-;6P%U-*DL+B,[T*R /&
M57..M:WC_P#8]\8R>)M(\2:-#X<UR];PM%X=U#2X]0O?#]E;2H[,)K=;,\P_
M.P,#8!QG.3Q].?:OB'_T#?#'_@PN?_C%'VKXA_\ 0-\,?^#"Y_\ C% 'SCX>
M_98\?_!WQ3H^K^!8?!VM)<>$X/#&IV.M-<Q063([N9;;(E9HB9#F)FR<#D9X
M]&^ /P'USX<_LI)\,M>.DW.KFTU&TDX>:Q<3RS%=RC8Q0K(-R@@]0#WKTC[5
M\0_^@;X8_P#!A<__ !BC[5\0_P#H&^&/_!A<_P#QBD!\G:/^Q5\1=<\$^,O"
MVLZY8^'=%U#P[#I%AI\.JW.KPK<Q7"3)*C3QK)!;$1A/LX9QACR<"MKQ1^S-
M\4_BK-XBUOQ1!X1\/ZM'X%OO".D:?X?N)FANI+A0/-N)&C79&NT;4 ;;GKQS
M]+_:OB'_ - WPQ_X,+G_ .,4?:OB'_T#?#'_ (,+G_XQ3 ^3_$O[$OCGQ))K
M$JWVBVTX\/>%K>P6XE>6">^TOF6*= @_<N> 1D]#BO4OA/\ "/XD1_M+:E\4
MO&]CX7TJ*_\ "Z:+]A\/W,LICE2X5P79XUWY4'YN,#:N#C->O?:OB'_T#?#'
M_@PN?_C%'VKXA_\ 0-\,?^#"Y_\ C% '@7Q>_9=\9^._BG\5;C3Y]'7PI\1/
M#$.C7%Y<3R+=Z=/!&_ELL00K(C.4S\P(&>N.>0\1?LS?&KXA7UM=^)(_"%DU
MC\/M5\'VL6F7T[[YIH5CBF<O$,*Q ) ^Z!_%GCZL^U?$/_H&^&/_  87/_QB
MC[5\0_\ H&^&/_!A<_\ QB@#QCP?^S7KNA_%;X2^(;FWT@Z;X7\ R>&[Y8WR
M_P!L81C,:[,,G$GS$@_,>.37GGPM_91^*OP5M_ OB/0X_"NO>)M(T;4-!O='
MUB[F6U2&:_EN8IK>98R0P$@5E*C(X!KZJ^U?$/\ Z!OAC_P87/\ \8H^U?$/
M_H&^&/\ P87/_P 8I ?.OPG_ &._$7P\\;?!O4M0NM)U6T\,C7KS5_+W+'%=
M7[!XTM8V4_NT.0"2".N.<5+8_LQ?$'2?CRFOZ3<Z/H/AEO%#^(+R6PU*Z:*]
MA;.Z)]-E5XDN&.,W"2+ZA1TKZ%^U?$/_ *!OAC_P87/_ ,8H^U?$/_H&^&/_
M  87/_QB@#LZ*XS[5\0_^@;X8_\ !A<__&*/M7Q#_P"@;X8_\&%S_P#&* .S
MHKC/M7Q#_P"@;X8_\&%S_P#&*/M7Q#_Z!OAC_P &%S_\8H [.BN,^U?$/_H&
M^&/_  87/_QBC[5\0_\ H&^&/_!A<_\ QB@#LZ*XS[5\0_\ H&^&/_!A<_\
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M 'F7QD_9XF\8ZPNIZ7.+>YVB-BT9='49VA@OS!ESC(!! &<8Y\X_X93\3?\
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M"Y_^,4?:OB'_ - WPQ_X,+G_ .,4 =#&L^I7D,\L+6UM 2T<<F-[N01N('0
M$X'7GMBM*N,^U?$/_H&^&/\ P87/_P 8JUI=QXV;4(!J-AX?BL=W[U[6]G>4
M#_9#0@$_4BD!U-%%% &%XF\0_P#")^#[W5_L-YJ1L[7S?LEA#YL\F .$3(R?
MQKY+O_VJ?%_B+]FQ_$Z+=:#X@M-6M89]4AL0EG<0O/(I6 N7W%53#\<$U]DI
M%YVGK'G;OBVY],KBOD:/]G7XF+\"9_AM-::')#I^KP7NGWT5ZP-Q']H>27S
M5^4@%<#ODUPXCVE_<OL_O/O^&997R/Z]&/,JM)WD_L>\I:/1K:Z\[_9/:?#?
M[2WA#7K[6[.ZCU7PW/I-B=4E37;%K4R6@_Y;Q@Y)7D>AY'%.\'?M(>'/%^O:
M7I1TS7M"DUB-I-)N-9T\V\.HJHW'R7R<G;R <$BN3^,O[/NK_%3XK7>H+/!9
M:!=^$9M$:Z\S,L=R9C(A\O'*_=SSZBN<^%_[-?B#1?&'AB[UGP[X9TRVT#]X
M^H6E_=W=Q>S*N$>-'8+#R,G@^@'I+GB%-1M=&RP/#T\)*O[1QFXWY>9/E?*]
M-;7O)*ZLVD^FZ[GPO^UIX.\5:1?ZK;:?X@ATRP@DEN;R336:)'5U00AD+!I6
M+ A5SP><5H6?[3'AR;^V8K_1_$&A:AINDRZW_9^K6 @FN;2,$L\0+8;IT)!_
M(UQ'A/X$^/-!_9<U#P-9:G;:'XLFNYIUN+:X;8T;3[RGFJ-RED^7('&:\Z\3
M? 3Q7X-BU[Q@^BZ+HND_\(EJEA?65KJMQ>2Q$P.1+OE'SLS8X& !ZGFLW4Q$
M;-KUT_K8[J65\/8BM6IPJ6M.48>^G=*UGT^/5*REM:Z=N;W+PK^U9X/\5:QH
M-DMGKFF6^ND1Z=J6I:>T-G<S8YA67)!8'Y>.,]":Q?#/QYTSPBWQ!D\0:_K&
MOO8^*&TFSL?[-03>:P^2UMEC8F4<'YFV_05P7PQ^&7C[XI> _A!::LVB6?@C
M0S::U#>6DDAO;D(N8HBA&%(S@L#@]?:IO$G[*'B;Q)>>,-1<Z;]JE\8/X@TR
MTN+F00WENRE6BE:,!HV(Q@CI^-+VE>45)*__  QL\NR##UZF&JU>5;-<RD]*
MEE:32LW'XDK<O7LO7K;]ICP@N@^(]1U5-4\.W'A](Y-0TK5K(PWD:R$",K&"
M=P8D $'J><5L^ _C/IGCK79=%.C:]X>U5;<7D=KKE@8#-"3C>C LIZCC.?:O
M'O#_ .S5KW_"/^-)I/#_ (1T34M6M8K.STR22ZU&$QJZNPN)I'!.XJ-I0 H<
M'VK;^!?P5\5^!?B!-K-S#;>%?#OV VS>'['6+C48KF<L")OWH C  X Y_6M(
MU*_-&ZT/(Q6 R*.'KRH5??CM>2WY8NRLW?WN9:<R[R5KOZ&HHHKT3\]"BBB@
M HHHH **** "O+/B%^U!\+_A7XF_X1_Q/XLM]-U9(TEGA$$TPM4?[C3O&C+"
M#V+E>M>IU^>_[2,S>"?C%\4K_1=3\3>"O$.M65OC2+KPZNNZ+XR*P[$CC41M
MY;8_=LK'C)/2@#] [6ZAOK6&YMI4N+>9%DCEB8,CJ1D,".""#G-<!XV^/W@K
MX?:OK>E:QJ5PNJ:-HZZ]>6=M933R+9F40B1=B$,=Y V@D]\8YKXS\<>)->M]
M<N(/BK>>-/AU##X.TV3P?H_@9;J&S&HFW/VB("W4AI4FVJL<GRA>/>N/^*6J
M?$BUMO$NN:__ &IIGCX_!C3#>75B)(;A+DZO%N&Z/!60H?F4="6% 'Z3Z]XO
MTKPSX0OO$^IW+6NB6-FVH7%PT3DQPJF]F* ;LA1G&,^U5&^)'AJ/P!!XWN-8
MMK+PI-91ZBNJ7C&&);>159)&+XV@AEZX/-?G_P#''5]1U2_^,UAX[U[Q]9>(
M1I2Q^"M'T,73:?>V+68W%DC4QREGW^:93E1G&"./8?C7X)NO&'_!-/3[*WMM
M1FU*R\'Z;>0V=BTBR221V\>4=%Y=0"Q*$$':..* /K^WN([RWBG@=9895#I(
MIR&4C((/H14E?G7X=^)D'PQU;77T_5O&>I>#_$7PV6V\+2,NH7IEU1&F6:--
MP+1RJYZG;A5&#M K)T"S\7>/+'2(-0\6>-+!+#X(QZZ#I^J7,#3ZE%+(4:5@
M<N^2"0>6P,Y% S]*J*_.O3-2^*GA:+X5Z]X6\1^*/$'C#Q]X$U>]U"SUBZDN
M+8ZA%:)+;&.%ALA=7;"@ 9P <Y.=;X&^)M3N/B1X"C\$^)?B!X@DN-%O7^(D
M'BHW;6]G.+;,9'G*%BF\_("Q<;<=LF@1]_45^;/A_1_%5A^R/\/_ !A>^/\
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M^Q1]J@_Y[1_]]B@"K_9<G_01O/\ OI/_ (FC^RY/^@C>?]])_P#$U:^U0?\
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M_B:/[+D_Z"-Y_P!])_\ $U:^U0?\]H_^^Q1]J@_Y[1_]]B@"K_9<G_01O/\
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M/J*S=2U*-H7MK5TN+R52B1H0<9XW-CH!UYJ_;0BVMXH5.1&@0'Z#% $E%%%
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M#P/_ (;:^&__ #[>,/\ PC]3_P#C%'_#;7PW_P"?;QA_X1^I_P#QBO?,T9H
M\#_X;:^&_P#S[>,/_"/U/_XQ1_PVU\-_^?;QA_X1^I__ !BO?,T9H \#_P"&
MVOAO_P ^WC#_ ,(_4_\ XQ1_PVU\-_\ GV\8?^$?J?\ \8KWS-&: / _^&VO
MAO\ \^WC#_PC]3_^,4?\-M?#?_GV\8?^$?J?_P 8KWS-&: / _\ AMKX;_\
M/MXP_P#"/U/_ .,4?\-M?#?_ )]O&'_A'ZG_ /&*]\S1F@#P/_AMKX;_ //M
MXP_\(_4__C%'_#;7PW_Y]O&'_A'ZG_\ &*]\S1F@#P/_ (;:^&__ #[>,/\
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M?"C_ *!/BC_PBM1_^1Z]_P#[2M/^?N'_ +^+_C1_:5I_S]P_]_%_QI@> ?\
M#8GPH_Z!/BC_ ,(K4?\ Y'H_X;$^%'_0)\4?^$5J/_R/7O\ _:5I_P _</\
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M/^&Q/A1_T"?%'_A%:C_\CU[_ /VE:?\ /W#_ -_%_P :/[2M/^?N'_OXO^-
M'@'_  V)\*/^@3XH_P#"*U'_ .1Z/^&Q/A1_T"?%'_A%:C_\CU[_ /VE:?\
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M.1D#FH/#:>(/AO\ $?P!K,OAI-<UP>#8M(N/"[W\$>H6)B<KYZ*[8*,%Y(/
M9L^Y]9JW=U9>C_IG-#AS+9TH3C6YI<K;BJD-7R<RU:]S6Z;DFKJU[VO]&P_M
M ?#V?PYJ>OIXHLSHVFW*V=Q>8?9YQ4,J)\O[PD$8V9_2BS_: \ :AX0U7Q/;
M^(H9-&TED6^E\F426Q9@JAXBN\9)&/E_E7R#X7^&WB3XD>'?$>K:'IQCN=%^
M($VI3:/H]['&2IC4,MM,1L+QG[IZ<G%=;KGP4\7>(/A_\5-4A\,^(DU?6K&T
ML;.#7M6BNM0O?+N(G+.B (FT*<$L3C-*.)K25U'\'YG55X9R:C45*IB&GSQ3
MO.&B<H)IJVNC<N9:+L[-GT1)^TE\-DTE]2'BFVEM%NC9*T,4LC2S! Y6-54M
M)A6!)4$#/6NM\%^.] ^(>CC5?#FJ0:K8;VB,L)(*..J,I *L.." >:\2^+GP
MQU&;1?AS<Z3X6U.:30K;RGN/#.HI9:EIY:)%/E*X\N121A@2",<=375_LU^'
M?&&@>&];/BZ&2![K4I)[%;U8/M[0$##730C:TA.>>3^E=$*E7VG)):>C/F<9
MEV6QR[ZWAJCY[VY93BW\36D4K[).[MOLU9OV"BBBNT^-"OF/PE^UOJ&I_ME^
M*/@SJ^E65GH]JGEZ3JD6\2SW(MXIVBD).W.QY", 'Y!7TY7QU\4_V-_&?B_Q
M)\4_$^@:YI>C>)M5U_2]<\+:@9)-UHT%J;:=9B(SMWJSXV[LX7.* +/PS_;V
ML/$WQ*^*D'B2&QT+X>^%&A73]:CBGDFNQ)=FU5V"[LJT@(!5>_/0UZ3^TE^T
MWIWP9\&^,AHTMKJ/CG0=%AUU='O(I1$UK)=1VXD9U &-SD8#9R.F*\:U;]@3
M59-,\9:'I&KZ;I^DW_A+1=%TR=_,:07MC<"X:69 N-DCC)(8GYCQ3/B1^R;\
M8OB_>^/M8\2ZGX-M]6\1>#K?PY;6^F27*P6\D5_#<;G9XRS*51SN X+!<8&Z
M@9UNO_MV:+#XA^(_A6V^RZ/K/AK1%OK75M4M[N2QEN?*9YDE2.$LD<97[V3O
MS\N:[^^_; ^%_@Z*WL/%GC&RLM?AL;.ZOH;:SNFC03PK(LJ_NR1$0V=Q^Z"
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MW2KZ/6XF_M+5+;3Y4O[F;'R.7>9DVJ0,1[=@7Y0 #3 PM!^.7V5M:N[#Q/\
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MR_%G_0PZA_W^-'_"R_%G_0PZA_W^->J_\,DZU_T%5_\  0__ !='_#).M?\
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MVA_[]C_"C^S[7_GVA_[]C_"JW]K2?] Z\_[Y7_XJC^UI/^@=>?\ ?*__ !5
M%G^S[7_GVA_[]C_"C^S[7_GVA_[]C_"JW]K2?] Z\_[Y7_XJC^UI/^@=>?\
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MQC_[X%'V6'_GC'_WP* /"/\ AN_X&?\ 0])_X++S_P",T?\ #=_P,_Z'I/\
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M@4?98?\ GC'_ -\"F9GA'_#=_P #/^AZ3_P67G_QFC_AN_X&?]#TG_@LO/\
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M_98?^>,?_? H^RP_\\8_^^!0!X1_PW?\#/\ H>D_\%EY_P#&:/\ AN_X&?\
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MD_\ !9>?_&:]W^RP_P#/&/\ [X%'V6'_ )XQ_P#? I@>$?\ #=_P,_Z'I/\
MP67G_P 9H_X;O^!G_0])_P""R\_^,U[O]EA_YXQ_]\"C[+#_ ,\8_P#O@4 >
M$?\ #=_P,_Z'I/\ P67G_P 9H_X;O^!G_0])_P""R\_^,U[O]EA_YXQ_]\"C
M[+#_ ,\8_P#O@4 >$?\ #=_P,_Z'I/\ P67G_P 9H_X;O^!G_0])_P""R\_^
M,U[O]EA_YXQ_]\"C[+#_ ,\8_P#O@4 >$?\ #=_P,_Z'I/\ P67G_P 9H_X;
MO^!G_0])_P""R\_^,U[O]EA_YXQ_]\"C[+#_ ,\8_P#O@4 >$?\ #=_P,_Z'
MI/\ P67G_P 9H_X;O^!?_0])_P""R\_^,U[O]EA_YXQ_]\"C[+#_ ,\8_P#O
M@4 >$?\ #=_P,_Z'I/\ P67G_P 9H_X;O^!G_0])_P""R\_^,U[O]EA_YXQ_
M]\"C[+#_ ,\8_P#O@4 >$?\ #=_P,_Z'I/\ P67G_P 9H_X;O^!G_0])_P""
MR\_^,U[O]EA_YXQ_]\"C[+#_ ,\8_P#O@4 >$?\ #=_P,_Z'I/\ P67G_P 9
MH_X;O^!G_0])_P""R\_^,U[O]EA_YXQ_]\"C[+#_ ,\8_P#O@4 >$?\ #=_P
M,_Z'I/\ P67G_P 9H_X;O^!G_0])_P""R\_^,U[O]EA_YXQ_]\"C[+#_ ,\8
M_P#O@4 >$?\ #=_P,_Z'I/\ P67G_P 9H_X;O^!G_0])_P""R\_^,U[O]EA_
MYXQ_]\"C[+#_ ,\8_P#O@4 >$K^W=\#&8 >.4R>!_P 2V\_^,TG_  W=\#!Q
M_P )TG_@MO/_ (S7N_V6'_GC'_WP*/LL/_/&/_O@4 >$?\-W_ S_ *'I/_!9
M>?\ QFC_ (;O^!G_ $/2?^"R\_\ C->[_98?^>,?_? H^RP_\\8_^^!0!X1_
MPW?\#/\ H>D_\%EY_P#&:/\ AN_X&?\ 0])_X++S_P",U[O]EA_YXQ_]\"C[
M+#_SQC_[X% 'A'_#=_P,_P"AZ3_P67G_ ,9H_P"&[_@9_P!#TG_@LO/_ (S7
MN_V6'_GC'_WP*/LL/_/&/_O@4 >$?\-W_ S_ *'I/_!9>?\ QFC_ (;O^!G_
M $/2?^"R\_\ C->[_98?^>,?_? H^RP_\\8_^^!0!X1_PW?\#/\ H>D_\%EY
M_P#&:/\ AN_X&?\ 0])_X++S_P",U[O]EA_YXQ_]\"C[+#_SQC_[X% 'A'_#
M=_P+_P"AZ3_P67G_ ,9H_P"&[_@9_P!#TG_@LO/_ (S7N_V6'_GC'_WP*/LL
M/_/&/_O@4@/"/^&[_@9_T/2?^"R\_P#C-'_#=_P,_P"AZ3_P67G_ ,9KW?[+
M#_SQC_[X%'V6'_GC'_WP*8'A'_#=_P #/^AZ3_P67G_QFC_AN_X&?]#TG_@L
MO/\ XS7N_P!EA_YXQ_\ ? H^RP_\\8_^^!0!X1_PW?\  S_H>D_\%EY_\9H_
MX;O^!G_0])_X++S_ .,U[O\ 98?^>,?_ 'P*/LL/_/&/_O@4 >$?\-W_  ,_
MZ'I/_!9>?_&:/^&[_@9_T/2?^"R\_P#C->[_ &6'_GC'_P!\"C[+#_SQC_[X
M% 'A'_#=_P #/^AZ3_P67G_QFMGP?^U_\(_'WB;3_#V@^+EO]8OY/*MK86%T
MGF-@G&YH@HX!ZFO7OLL/_/&/_O@4JV\2L"L2 CN%%("2BBB@"*U_X]8?]Q?Y
M5+6'XG\11^$/!.J:Y-&98M-T^2\:,'&X1QEL?CBOG/P?X?\ C#\2_AM:_$2P
M^(T]GXCU!#?6'AU((ETP1[OEA?(R<J/O'IG\:PJ5>1\J5V>Y@<K^N4I8BI6C
M2@I*-Y7UD[M+1.RLKMO1'U117D7B+X\3>#[K0O#EUX9OM=\=W>G+?7FCZ*\;
M):J.'8R2,J[=V0HZFN$\7?'5O&WB#X+W_A/4[_3=.U3Q'-I^J6$G[J3=&JAX
M)EYZ$]CCFDZ\%IU.C#\/XW$--QM%J3YMUI&4NFMI<KY7L^A],45X/^RYXZUW
M7?V?'\0ZM-?^)]6AN+]EC+A[BX\N1MD2DX&3@*,^M>&ZI^TMX_\ $7P%\1:I
M<KJFD7]CK\446N6L<<,9B,ZJ;0;.3(JD[N.<]:B6)A&*D^JN>A0X4QF(Q=;"
MPG']W45-N_63:32W:T]?Q/NJBO(_"G[2&CZYXBU71=9T36/!][8Z<VKJ-:A5
M!/9K]Z5=K'&/[IYZ]P:H>%_VIM&\0ZMH,5UX<UO0]'\03_9M'UJ^CC$%W(?N
MJ0KEDW8^7<.:T]O3TU/(>19DN;]R_=2?39IO37WM$W97>C['M=%>)>%?VI-/
M\676M+:^$?$;66BS7<%]?PVHFBC>'.U%VDEWD(X4#C(SBK&B_M+65YK2:5J_
MA37/#=[=:=<:GI\>H"+_ $N*%"[K\CML?:/NMBE]8IOJ5/(<RIN494M8J[5U
M>V^U^BU?9:O34]EHKP#P[^V'H>M6OA[4[OPKXAT?PYK,RVD>O74"?9([AB0(
MRP;)&1C<!C(/H:W+C]IO0]/\%^.-=OM+O;.X\):B=-N]+=D,TLI95CV$'!#E
MN,^AH6(I-7YBJG#^:4Y\DJ#O=+H]6^6VCWYM'V;5[71['1531[Z34M)LKN:U
MDLI;B%)7MI2"\1902C$<9&<''I5NNC<\"47%N+Z!11102%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<[XK^(&A>"KG3[;5KN2*[U#S/L=K;VTMQ-<&,
MN$2-69B P. .F3V-=%7+:WX5N-2^(7A;74,/V72K>^BE#D^9NF$(4KQ_TS;/
M(ZCK0!3TKXR>$->O+6VT[5OM3W;&*"9;:80/-L+^3YQ38)0 <QEMXP01D8KC
M/#7Q.\:?\(GX)\5ZX/#]QI'B233XFLK"&>"Y@-V45"K/(ZR[&<%AM7Y0S \8
MK9A^%^HP^#[#2D>S2X@\5R:ZQ5B%,+:E)=8'R_?V.!CIG(SCFN>\#_LZVW@&
MV^'.I:9I^EQ>(]"MX[/56^9HKE'B5)Y(R1D2JRAE; )&]3@.< #_  O^T%>Z
MY\(?$'B"\TNWT[Q3H]@U^VF,[-#-"VXP3H>IC<*0>ZNCJ>F3TOC#XJ7/AOXD
MZ)H<-C#/HI\E-9OV8[[-[IVBL@H'!WRHP;/0,A[UR/BCX ZOJWP=T71M.O[/
M3_&&FZ<VFF[)8V]Q;R8$]O(0,E" &4XRKHI]0;^J?L]+XPLO%]SKNM:I;:SX
M@NI9?^);J<T=M B82S_=@A6,:1Q,<CE]W44P/9Z\RG^+EU-\2(M&TW2Q?Z M
MGJ!DOHR3-<7EMY1:&!>C*OF%2QZO\H^ZU;.G_#V*^M8-1UA[JV\336@2\N--
MU.Y$*3M%LD:)"P0 $DK\G'!QFN1M?@7?>&?%'A*_T7Q)JUSIN@65W!'I][<P
MJK%Q#Y<>5@SL;RSO/WNA&3FD!-J'Q4\2^!5TG4?&5CID6FZG;7,[6>F^9]KT
M\PVTER5<L<2@+&4+ )AV3@@\:MGXU\6:/J&@-XGTW38[+7I#;PPZ<[F:RN#$
M\J12,YVR!A&R[P$PV!@@Y'.:/\/_ !;XD764\;Z-IDE_KUC/IUWJUGJ[R_8;
M>1"/)M8&MUVH#M));<Q&YB< #;;PEXU\53Z#!XAFTK3H=$=KE;_3I7GEO;H0
MO%%+Y3QJL2KYC2%2SY8*,X!)8#-*^(7BBU\5>']-UZ'0O.UAV271M-F=[[2Q
MY32AY26*R(-H1F"H SKC=D9]'U35K31;47-].MM 98H!(^<;Y)%C1?J7=1^-
M>9V7@?Q5K/BSPUJNMZ?H&EWND3>;>:WI4SO=:H!"\7E%3$GEQL6#LK.^-B@9
MP&'2?$SX8:?\3--M;:\FN+>2WNK>=)(;F:,;8[B.5E*QNH)81[0QR5SD=*0'
M9T57T[3X=*L8+.W#B"% B>9(TC8'JS$L3[DDU8H **** "BD)"C).![TGFI_
M?7_OH4 .HIOFI_?7_OH4>:G]]?\ OH4 .HIOFI_?7_OH4>:G]]?^^A0 ZBF^
M:G]]?^^A1YJ?WU_[Z% #J*;YJ?WU_P"^A1YJ?WU_[Z% #J*;YJ?WU_[Z%'FI
M_?7_ +Z% #J*;YJ?WU_[Z%'FI_?7_OH4 .HIOFI_?7_OH4>:G]]?^^A0 ZBF
M^:G]]?\ OH4>:G]]?^^A0 ZBF^:G]]?^^A1YJ?WU_P"^A0 ZBF^:G]]?^^A1
MYJ?WU_[Z% #J*;YJ?WU_[Z%'FI_?7_OH4 .HIOFI_?7_ +Z%'FI_?7_OH4 .
MHIOFI_?7_OH4>:G]]?\ OH4 .HIOFI_?7_OH4>:G]]?^^A0 ZBF^:G]]?^^A
M1YJ?WU_[Z% #J*;YJ?WU_P"^A1YJ?WU_[Z% #J*;YJ?WU_[Z%'FI_?7_ +Z%
M #J*;YJ?WU_[Z%'FI_?7_OH4 .HIOFI_?7_OH4>:G]]?^^A0 ZBF^:G]]?\
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M6W@G^S-#N$G;5+/3';4M0\LYC$GF92-L@$LISQ7U#;W<%XK-!-'.JMM8QN&
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MXF^&_P"Q7I'Q/@T[^W_%$V@Z?>2N;<&W2::%&>:959-L0).=G0LN!BJOBO\
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MM:^;(H>./SPOE[F5E(&[^)1U(%><>%/ 7C-KV^B-Y'H$7]@6&ASR36BW*SM
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M48U?[1;Y7;E4G=WZ]7IL6?[%T[_GPM?^_*_X4?V+IW_/A:_]^5_PIG]LQ_\
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M?^_*_P"%']BZ=_SX6O\ WY7_  IG]LQ_\^M[_P" S_X4?VS'_P ^M[_X#/\
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M_*_X4?V+IW_/A:_]^5_PIG]LQ_\ /K>_^ S_ .%']LQ_\^M[_P" S_X4 /\
M[%T[_GPM?^_*_P"%']BZ=_SX6O\ WY7_  IG]LQ_\^M[_P" S_X4?VS'_P ^
MM[_X#/\ X4 /_L73O^?"U_[\K_A1_8NG?\^%K_WY7_"F?VS'_P ^M[_X#/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7$^,+Z[OO'7A3P];W,MI;RK<ZO>-"Y1I8K8Q*L61SM:2>-F]0A4\,:
M[:N3\6>'[ZX\3^&=?TQ$EN-/EEM+J%W">99SA1(5)_B1XXI .X1AU(H \/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4K$.$EK;0[^BO#9/VV?@W'X@;23XM&Y9?(-\+28V8?T\[;MQ[].^<5V'Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV&!VKJ:**"&[N["BBBD(*K:IIMOK.F7FGWD?FVEW"]O-'G&Y'4JP_$$U9HH
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MG_SYR?I_C63_ ,-/>#O^@A#^4W_QJC_AI[P=_P!!"'\IO_C5'L<P_P"?$O\
MP%A[;*?^@J/_ (%$UO\ A&]3_P"?.3]/\:/^$;U/_GSD_3_&LG_AI[P=_P!!
M"'\IO_C5'_#3W@[_ *"$/Y3?_&J/8YA_SXE_X"P]ME/_ $%1_P# HFM_PC>I
M_P#/G)^G^-'_  C>I_\ /G)^G^-9/_#3W@[_ *"$/Y3?_&J/^&GO!W_00A_*
M;_XU1[',/^?$O_ 6'MLI_P"@J/\ X%$UO^$;U/\ Y\Y/T_QH_P"$;U/_ )\Y
M/T_QK)_X:>\'?]!"'\IO_C5'_#3W@[_H(0_E-_\ &J/8YA_SXE_X"P]ME/\
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M+)_SQ.WD>Q8.1]:]AK/72IXU55U*X55& JQQ  >GW:7^S;G_ *"=S_WQ'_\
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M_LVY_P"@G<_]\1__ !-']FW/_03N?^^(_P#XF@"_15#^S;G_ *"=S_WQ'_\
M$T?V;<_]!.Y_[XC_ /B: +]%4/[-N?\ H)W/_?$?_P 31_9MS_T$[G_OB/\
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M9W\#_P#/IK'_ (46H_\ R163<?M>?!RSUZXT:Z^(&DVFI6]Q<6LT-RSQ>5+
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MMSZ[_P"%'_#?_GI??^%1?_\ R31_PH_X;_\ /2^_\*B__P#DFOD3_A9'BO\
MZ&75?_ M_P#&C_A9'BO_ *&75?\ P+?_ !KK_P!5*W_/U?<S@_U\PW_/B7WH
M^N_^%'_#?_GI??\ A47_ /\ )-'_  H_X;_\]+[_ ,*B_P#_ ))KY$_X61XK
M_P"AEU7_ ,"W_P :/^%D>*_^AEU7_P "W_QH_P!5*W_/U?<P_P!?,-_SXE]Z
M/KO_ (4?\-_^>E]_X5%__P#)-'_"C_AO_P ]+[_PJ+__ .2:^1/^%D>*_P#H
M9=5_\"W_ ,:/^%D>*_\ H9=5_P# M_\ &C_52M_S]7W,/]?,-_SXE]Z/KO\
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M .AEU7_P+?\ QH_U4K?\_5]S#_7S#?\ /B7WH^N_^%'_  W_ .>E]_X5%_\
M_)-'_"C_ (;_ //2^_\ "HO_ /Y)KY$_X61XK_Z&75?_  +?_&C_ (61XK_Z
M&75?_ M_\:/]5*W_ #]7W,/]?,-_SXE]Z/KO_A1_PW_YZ7W_ (5%_P#_ "31
M_P */^&__/2^_P#"HO\ _P"2:^1/^%D>*_\ H9=5_P# M_\ &G1_$SQ;#(KK
MXEU0,IR,W3G]":7^JE;_ )^K[F'^OF&_Y\R^]'UR/@C\-P01)?9_[&B__P#D
MFC_A2/PW_P">E]_X5%__ /)-6/V?_'5U\1? *7VIQQMJ%K.]I-,J "7:%(?
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M]\BCR8_^>:?]\B@#RS_A2/PW_P">E]_X5%__ /)-'_"D?AO_ ,]+[_PJ+_\
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M\0/&VL>._$=Y=>']-UW4M7\-^(M-LVFEN;*2ZT^V\N:WN!L4^4SE@K $X )
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M&TPF,/V&-U@>4-PLQ/H2#TKZ7W_%[_GCX)_[^WG_ ,31O^+W_/'P3_W]O/\
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MY7_A%KD_%3_A(SY)LQHO]G#G]X)#/YAXQ]W '?J.E86_XN_\\?!.?^NMY_\
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M "47_P".T?\ #(>K_P#08_\ )1?_ ([7MF_XO?\ /'P3_P!_;S_XFC?\7O\
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M_P E%_\ CM>V;_B]_P \?!/_ ']O/_B:-_Q>_P">/@G_ +^WG_Q-'^L.9?\
M/S\(_P"0?ZHY-_SY_P#)I?YGB?\ PR'J_P#T&/\ R47_ ..T?\,AZO\ ]!C_
M ,E%_P#CM>V;_B]_SQ\$_P#?V\_^)HW_ !>_YX^"?^_MY_\ $T?ZPYE_S\_"
M/^0?ZHY-_P ^?_)I?YGB?_#(>K_]!C_R47_X[1_PR'J__08_\E%_^.U[9O\
MB]_SQ\$_]_;S_P")HW_%[_GCX)_[^WG_ ,31_K#F7_/S\(_Y!_JCDW_/G_R:
M7^9XG_PR'J__ $&/_)1?_CM/B_9#U/S%\W5W\O/S>7:)NQ[9FKVG?\7O^>/@
MG_O[>?\ Q-&_XO?\\?!/_?V\_P#B:/\ 6#,O^?GX1_R'_JCDW_/G_P FE_F:
M_@/PS;_#SPS;:+IFE7A@BRSRR-%OE<_>=OFZG], 5T']I7/_ $"[K_OJ/_XN
MN(W_ !=_YX^"?^_MY_\ $T;_ (O?\\?!/_?V\_\ B:\"I.563G-W;W/JZ5*%
M&$:5-6BE9+R.W_M*Y_Z!=U_WU'_\71_:5S_T"[K_ +ZC_P#BZXC?\7O^>/@G
M_O[>?_$T;_B]_P \?!/_ ']O/_B:@U.W_M*Y_P"@7=?]]1__ !=']I7/_0+N
MO^^H_P#XNN(W_%[_ )X^"?\ O[>?_$T;_B]_SQ\$_P#?V\_^)H [?^TKG_H%
MW7_?4?\ \71_:5S_ - NZ_[ZC_\ BZXC?\7O^>/@G_O[>?\ Q-&_XO?\\?!/
M_?V\_P#B: .W_M*Y_P"@7=?]]1__ !=']I7/_0+NO^^H_P#XNN(W_%[_ )X^
M"?\ O[>?_$T;_B]_SQ\$_P#?V\_^)H [?^TKG_H%W7_?4?\ \71_:5S_ - N
MZ_[ZC_\ BZXC?\7O^>/@G_O[>?\ Q-&_XO?\\?!/_?V\_P#B: .W_M*Y_P"@
M7=?]]1__ !=']I7/_0+NO^^H_P#XNN(W_%[_ )X^"?\ O[>?_$T;_B]_SQ\$
M_P#?V\_^)H [?^TKG_H%W7_?4?\ \71_:5S_ - NZ_[ZC_\ BZXC?\7O^>/@
MG_O[>?\ Q-&_XO?\\?!/_?V\_P#B: .W_M*Y_P"@7=?]]1__ !=']I7/_0+N
MO^^H_P#XNN(W_%[_ )X^"?\ O[>?_$T;_B]_SQ\$_P#?V\_^)H [?^TKG_H%
MW7_?4?\ \71_:5S_ - NZ_[ZC_\ BZXC?\7O^>/@G_O[>?\ Q-&_XO?\\?!/
M_?V\_P#B: .W_M*Y_P"@7=?]]1__ !=']I7/_0+NO^^H_P#XNN(W_%[_ )X^
M"?\ O[>?_$T;_B]_SQ\$_P#?V\_^)H [:&"XO;R*YNHQ;QPY,4&X,VXC&YB.
M,XR !ZFM&O.-_P 7O^>/@G_O[>?_ !-7M#;XEG5K;^V8O"8TS=^_-C)=&;;C
M^#<NW.<=:0'<T444 16O_'K#_N+_ "J6HK7_ (]8?]Q?Y5+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7D?Q$_:R^%/PI\3R>'O$OBV&RU:!
M5>Y@AMIK@6BM]UIVC1EB!X^^1U%>N5\.^%_B!I/[-GB3XY^'OB+X1UK5]3\4
M:_=ZMIC6>D2WD?B*TG0"*V61$905Y0JY &X^] 'VSI>IVFM:;:ZAI]S%>V-U
M$LT%S X>.6-@"K*PX((((-6:^ OC!XB\7_ 6V\+ZIX6\-ZAX4M?B%X3/A2Q\
M(17;31:%K!8&T90,*C>7*X.T#F/VKF_CA8^*OA#XP_L>+Q-XKUV;1M%TVWTC
M3Q>:M9W5S.D8\Z2QG@66"ZDEDR7^TK\I.WH,T ?>?B#XK^%O#;>)8KG58YK_
M ,.Z>-3U/3K-3/=P6Y4LK^4@+'<%.,#G%=#H>L6_B+1=/U6S\S[)?6\=U#YT
M;1OL=0R[E8 J<$9!&17YX?$CPZOA']H+XQZQ<MXMT;Q!K/@'^T=!87-V?.O3
M9SFXC+Q_N\QX^5#A48?( <56E\0ZL_V;_A9OB+XGZ1CPAH,G@G_A$!=.UU<-
M:1FY8A!MENO.R"LYQ@G/:@#]#?&'B[1_ /A?4_$7B"_CTS1=-@:XN[N;.V*,
M=3@ D_0#)KS3_AK;X:KH5]K<NI:E;:/9Z0NN37UQHUW%&+5K@VX8;HP2WF?P
M@9P=V,<UQ/[;7AVX\4?L3^)_M8U674[32K>\$>3%<2SKL!6:.([6^\VZ,97(
M]A7RW\;O .H>!=/^(OAO1KKQ1J6BWGPHL]0%EJ6H75_']L;4K96V"1F"L%7&
MT=!GM0!^G%G=17UI!<P-OAF19(VP1E2,@X^AJ6OS,\2:[K>GZ3XOC^&FN_$2
M_P!,A^'U\_BK_A(6O5^Q:FJ)]G$!E"F.?=N!6'Y=O3BNY\6>'[WP'#\)X?&7
MBOXA?\*MUC1GU37M8L;^\FNFUAX8?+CGDA!EBAV@[$4!=V<]Z /OJN<U+Q]I
M.D^.=$\)7'VK^V-8M[BZM?+M)'AV0[=^^4#8A^88#$$]J^"]8UCXB7'P%\$W
M'B+Q%XGTW0E\2ZH+276HM0@DO]* _P!!_M&YLQ]I@;[Q0[2'PN[H,Z>D^+/B
M!K&H?"ITG\;:%=7'P]\2%DN'EOKL3H^VVG*$1B:3: T8D57(*CKR09^@E1?:
MH1="V,T8N&0R"'<-Y4$ MCKC) S[BOB3]B7Q+KLGQ1N=)DNM;U_36T$37VJ_
MVAJ<MFEV)%&+B#4(PT-TV6.V%R@ (QW'M'CS7Y=(\8ZQ<OJUSHTDGB#3=*FN
M[:,/)'IQLVEPN5.U3*TQ+XXVD_PT"/>*0L%&2<#U-?/VI^-=22T2T@\07TNA
MOJ4Z:?K=Q=+9K=0I!"=C7(@D+D2R2JFU,R",Y)VG=B2WWB/XE_"WQ7J&IZUJ
MT9A\,V;_ &&Q'DJ+DQ.;DD! Q;<F"O&W!^49IV ^G:*\/_M+65B\2:]IOBG4
MM0T_2]5T^#3( 4D@N+9X;,RESLS+O,LIW9^4],8-<S'XZ\<XU65]32+6%M=4
MDO=-CN7G>S$<,QA*V_V51$5=8@K&1A(">7W @ ^EJCN+F&U56FE2%6=8PTC!
M068@*O/<D@ =R:^=O$FO^-?#FK2V*Z[*9H+.VDTI[^\:-]0F==TI,,=K)Y_S
MG9Y:LNU0,!<AJM^(M9N-6OM/BU#7M17Q$OBRTCF\.I$&@BM4OT\MMFS(3RU2
M3SMW).,\[0 ?05-:1$8!G52>@)QG'6O*/BIJGBRU\2+H'A^^GM9_$MHL>G7B
MQ!TT^>!F>=R2, /$R@;NZ<5YQXZU[6_B1X5GU:5]2TS3M0L[^6"UAC\N6W2W
M%JC\[=PS*+@G^\H7L* /IR*YAFDF2.5)'A;9*JL"4; ;##L<$'![$4GVJ$W1
MMA-&;D()##N&\*20&QUQD$9]J\+\O4--_P"$X\3Z)X@U">&UU.PDM(XRDD%[
M']DLE=I#M)EWJ2-P(QC(P<UUWQ@U*7P)<Z3XZM;.:^;3Q+IUW;6\9=YH9P!$
M,#GBX2 9[!W- 'HUO=0W2NT$T<P1VC8QL&"LIPRG'0@\$=JDW 8R<9Z5\TW5
MSXR\!WAT.+48;2\LXK:2PC>[D0:E=3?O+J7R5MI#<;IWD4J'4JH!^7.X[-U9
MWEVW@[7]?\3:Q#&/%U_&[>>((+>)?MT4"8"C"G;$F6^]OZ\B@#WZHS=0K<+;
MF6,7#(9%B+#>5! + =< D#/N*^;-*\=>,;C+:CK;V&HRPW#:C9VDSW4UE,/]
M0B6QM56,^;Y<8#2$2*YY8D,.JTO6-9U*/PEJ.N@VWC1/$IM+O3D'[NS5[=_,
M@B/\<7E*LN_)W%0W&-J@'MM%%%( HHHH **** "BBO,O&WAE/%WQ=\.Z??W&
MHC1ET+4)I;6TNY;>*647%F$+F-E)*AGV\]R>U 'HNH7T.EZ?<WMR_EVUM$TT
MKX)VJH))P/8&N-T'XT>&O$$VGQQ_VK8C44WV,NIZ1=6D=U\ADQ&\D:JS% 6"
M@Y(!P.#7CL>CZAI_PQ\,:[)?ZU?Z[J<M]8:E-=W4TGVBW-K>;4>(G8-IBAP0
MH.1G)+-F_I6D^*/L?POM?%6I6MWX<_LZ.XLETS3'MG348K3,,5PS2R?(4,C
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M5*[E=L[AE@GA_4M0\<ZU\/K&36+.]MO#L[7-W#:Z?+;300K9S0/]N#DB)R)
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M"XO_ (S1_P -@3_] 6Y_\"XO_C->'_\ "!^)O^A<U?\ \ )?_B:/^$#\3?\
M0N:O_P" $O\ \31_8V4?RK_P)_YA_K'Q!_.__ (__(GN'_#8$_\ T!;G_P "
MXO\ XS1_PV!/_P! 6Y_\"XO_ (S7A_\ P@?B;_H7-7_\ )?_ (FC_A _$W_0
MN:O_ . $O_Q-']C91_*O_ G_ )A_K'Q!_.__  "/_P B>X?\-@3_ /0%N?\
MP+B_^,T?\-@3_P#0%N?_  +B_P#C->'_ /"!^)O^A<U?_P  )?\ XFC_ (0/
MQ-_T+FK_ /@!+_\ $T?V-E'\J_\  G_F'^L?$'\[_P# (_\ R)[A_P -@3_]
M 6Y_\"XO_C-'_#8$_P#T!;G_ ,"XO_C->'_\('XF_P"A<U?_ , )?_B:/^$#
M\3?]"YJ__@!+_P#$T?V-E'\J_P# G_F'^L?$'\[_ / (_P#R)[A_PV!/_P!
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MNS\C]PR^I7K82E4Q,>6;2;7G_73H4/[/N_\ H*3_ /?J+_XFC^S[O_H*3_\
M?J+_ .)J_FC-<AZ!0_L^[_Z"D_\ WZB_^)H_L^[_ .@I/_WZB_\ B:OYHS0!
M0_L^[_Z"D_\ WZB_^)H_L^[_ .@I/_WZB_\ B:OYHS0!0_L^[_Z"D_\ WZB_
M^)H_L^[_ .@I/_WZB_\ B:OYHS0!0_L^[_Z"D_\ WZB_^)H_L^[_ .@I/_WZ
MB_\ B:OYHS0!0_L^[_Z"D_\ WZB_^)H_L^[_ .@I/_WZB_\ B:OYHS0!0_L^
M[_Z"D_\ WZB_^)H_L^[_ .@I/_WZB_\ B:OYHS0!0_L^[_Z"D_\ WZB_^)H_
ML^[_ .@I/_WZB_\ B:OYHS0!0_L^[_Z"D_\ WZB_^)H_L^[_ .@I/_WZB_\
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MZ$YO44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!^A1_8&F?] ^V_[]"K]% %#^P-,_Z!]M_WZ%']@:9_T#[;_OT*OT4 4/[
MTS_H'VW_ 'Z%']@:9_T#[;_OT*OT4 4/[ TS_H'VW_?H4?V!IG_0/MO^_0J_
M10!0_L#3/^@?;?\ ?H4?V!IG_0/MO^_0J_10 R&".VC$<4:Q1CHJ* /RI]%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mrna-20251231_g5.jpg
<TEXT>
begin 644 mrna-20251231_g5.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
MRH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&
MN?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_
M ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'
MJ/\ B$V_X*F?])=O_*AKG_QZOW^HH _D]_X+"_\ !+O_ (*!_P#!'OX;>#OB
M1\2/^"BFN>,8/&.N3Z;;6VAZ_JL#V[Q0B4NQEFP00<8%%?H)_P 'O/\ R:S\
M#_\ LH&H_P#I"** //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW
M_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJAXH\4^&?!'AV^\
M8>-/$5AI&DZ9:O<ZEJFJ7B6]M:0H,O)+)(0L:* 268@ #FOF?PM_P6J_X)K>
M/+W4(OA]^T!?^([#29VBU3Q+X;^'FOZAH=FR_>,NJV]@]DB@<EC,%QSG'- '
MU/17!? O]J3]G/\ :=MM4U#]G3XV>&_'-GHLT$.IZCX5U6.^M89)H5FC3SX2
MT;,8V5BJL2H89QD5WM !1110 4444 %%%% !1110 45XW>?\%!/V-M/_ &Q[
M7_@G[>?'G28_C#>:2=2MO!)AG\]X!"T^/-\OR1+Y*M-Y)D$IC&_9MYKV2@ H
MHHH **** "BBB@ HKE?C9\<?A!^S?\,-6^-/QX^(VD^$_"NA0";5==UN[6&W
MMU+!5!8]69BJJ@RS,P5020*\W_9K_P""DG[%O[7'Q6U[X%_ CXR-J/C3PSI-
MMJNM^%-7\-ZEI&H06-Q'#)#="#4+:!Y(62XMV$B!EQ/$21O7(![E1537M>T+
MPKHEWXE\3ZU::;INGVSW%_J%_<K#!;0HI9Y))'(5$4 DL2  ,FOF3PY_P6H_
MX)K>-]9U+2?AU^T%?>*H-'G,.K:]X0^'VOZOHUFPP29=3L[&6R10"#N,P7!!
MSB@#ZFHKS[X%?M8?LT?M/MJ9_9R^.?ACQU#H\%I+J=YX4U:._MK<7*R-"C30
MEH_,*Q.3'NWJ-I95#KGT&@ HHHH **** "BBO#_$W_!2+]B;P7^U!IW[%_C'
MX[V>E?%#5[F*#2?!VI:5>P7-ZTH8QM$SPB.1&VMMD5BAVD!N#0![A1110 45
M##J%A<7<VGV]]"\]L%-Q DH+Q;@2NX#E<@'&>N*\A_9?_P""@G[&W[:'C#QO
MX!_9@^/6D^+]7^'.J+I_C&ST^&=#8SLTB*5:6-%GC+12*)82\9*$!J /9***
M* "BBN<^+OQ;^''P%^&.N?&7XO>*[?0O#'AO3I+_ %S6+M6,5G;H,O(P0%L
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MN:<]I=^,++3KJROGN(+.0">))O+N8[>.9$DE,,<@0)+&3^8W[5?Q/\)_'O\
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M&]!U[3I]6T[QYK$FNV%M=(UQ:M+*IB:9 =R;XT&TL!N"\9Q0!C#]JC]G<_\
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M_L\Z3\:M7_:U^'O@G4VTR-_%7A'QEXNM-+U'0KT*!/;2P74B2$)+N19%!63
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M#&]B\07]BL5K.MR[?8C*8RR,(_*)#N7!"D(Q7R7_ (/?OB5\//%'C/\ 9W\
M^&O'&DZAK?AZ'Q;)KVDV6H1RW&G+.=&$)GC5BT6\P3;=P&?+;'0UU/\ P<!?
ML,76A1^"/^#@/_@EOXYL9]:\*G3KOX@:CX+O(KJ)FA2-;?65\HLK[5V072'(
M:-D9UVB9B ?H=^S1\:];_P""17_!"[P)\4?^"B>I7Z:O\-/AU:Q^(-.25;B^
M:=Y?+L=*3+;7G59;:U^]L4H26"*6',>'?^"T_P 4/AQXS_9FOOVQ?V>_#_A+
MP9^UA:J? FH^'O%$U[=^&;N=;62QM=366WB203QWMMF6(J(G+JR%5WU\L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _$'_ (/>?^36?@?_ -E U'_TA%%'_![S_P FL_ __LH&H_\ I"** //_
M /@TV_Y2F?M=_P#;Q_Z?)Z_?ZOP!_P"#3;_E*9^UW_V\?^GR>OW^H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HJOJVIVVBZ5<ZS>1W#PVEN\TJ6EI)<2LJJ6
M(2*)6>1L#A$4LQP "2!7S?X+_P""Q7_!-/Q_\>[7]ESPY^U?HG_"P[S6FT>'
MPAJ&G7ME?#4%)4VKQW$">7*&4KL?#;OEQD@4 ?3%%5=;UK2/#>C7?B+7]2AL
M["PM9+F]O+F0)'!"BEGD9CPJJH))/0"OG3]GG_@L!_P3C_:T^(*?"K]F;]I>
MS\<^(7A\Y]+\,^']3NI((=ZH9Y2EL1#"&= 99"J*6&6&: /I6BBB@ HKS;]I
M_P#:\_9X_8Q\!+\4_P!IKX@GPKX:,ZPRZ_<Z1>3V=O(S*J+-+!$Z0;V=57S"
MN]CA<D$5O? _XX_"C]I/X4Z+\<?@;XUM?$?A/Q%;-<:+K=DKB*[C5VC+*'56
MP&1AR!TH ZNBBB@ HHHH **** "BBL#XF?$SPE\(?!MYX_\ ',NH1:5I\;27
ML^G:+=W[PQJI9I&CM8I) BJI+/MVJ!DD4 ;]%?._[-'_  5>_P""?O[9/C27
MX>_LL?M#VWCS5[>-);VV\.>']2N%LXV;:LD\@MMEO&6XWR,JY[U]$4 %%%%
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M=MQ9WMNLL4HSG#(P(89 /([5)I]_9ZK80:II\XEM[F%98)5Z.C %2/J"*FH
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M.2\CU%[2)KB*)XXIS&"Z(Y4LH;J 2B$CH2BYZ"I'1)$,<B!E8896&01Z4M%
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MW=HVM>(/V1OCII/CBR\/7,5OK5QI44RBTEE5FC5O-C0Y8*QXSTKUZ@ HHHH
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MK,D;?M-0Q6_C*SLY2?[*T.R7S/%$+'.0N8GTH/U$FI0MC%?F+_P:.6MM:?\
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MVM[\;)=!U/X=^'YK9TNM8M-"OSJ,TL$9&YQ<!W@BQS*T7RY!4D ]\_X*>?\
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M2_M7P!JWA7Q'/>II6IA5=M&OUG@BWR8DB1;F+Y6ED">6 =X\L\9_\'"GQ2\
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M'A^+1M2\,^)(=/U:76(5M;F2*ZTN254E+;&*QV\[G!X6%ST4X /T"_X(G?\
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M^SQ^S7::&_A+PWXPUB*]\4?&NP\)QZGK>A:>U[';7<&AL\4IM[P0;G>2)'F
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M^$WAO-+FT%=*5;RS>^LENH1)<1V\^8X]Z NH=E9I-OH'_!'/_@I/^PO\$_\
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MH[>Z5Q9RL88W0J'CP[%B!Z[_ ,%"/^"UOA']EWXU_ []DW]G#P!8_$7XD_M
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MH8-5V12ZA;RVD,313^2X62"0LI>+=%M=FC\\_8Z^"/C+]L'_ (-"OB-\%?@
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M%?"<,GQ*\-6VL>!/'7P]\0W5U;#STN&BANH;J"-_G>UF02(>#Y9*8=C'C_\
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M'^#_ !3\+O$EOX*OO':+I,^OQ2:3.()X;><K*HG<N(8W422JJNJ[9$)^ O\
M@R;^)7P\M/V5_BQ\*KOQSI$7B:X^),=];>'Y=1C6]FMCIL*^<D);>Z9BD!8
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M+>,=;NTM=._M0VUK)=V,ES(1''/YEG-($8@E)8\9)H ^;?\ @DS^V_\ $/\
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MT219%6:,, ZG*L >X/(/:B2QLI;N._ELXFGB5EBG:,%T5L9 /4 X&?7%2T4
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M3W.*O44 9U_X1\)ZIKEKXGU/PQIUSJ5BI6RU">RC>>W!ZA)"-R#GL16C110
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M#2H9H8"O"E$=2JXP,8'%:UI9VFGVL=C86L<$$,82&&% J(H& H X  ["I**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX'_\ 90-1_P#2$44
M>?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C
M_P"D(HH_X/>?^36?@?\ ]E U'_TA%% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7
MX _\&FW_ "E,_:[_ .WC_P!/D]?O]0 5\N?\%"/VX_%_[.?Q@^!7[*7PGDT+
M3_&?Q^\97FC:1XH\5VLEQIVAVMG;+/<SM!'+$US</YD,,$/F1JTDH+-A=C?4
M=?.W_!2O_@FI\"_^"G7P+@^$GQ;O]3T/6-"U)=6\#>./#T_E:EX;U1!\ES W
M&Y>@>,D!@ 04=4D0 \R_8R^)?[?^AWOPHE^)WQ+\._$GP%X^\1^)-'U[4[GP
MU+8ZYX>NK3^U)[6831W#P7-K+]A,)5HHWB9X@'<-A>B_;$L_^"P_Q!U'Q!J?
M["WBWX5^ M)\-QNGA_3_ !YH4^IZAXQND0,Y>2.58M-M6?,4?RR2OM,C&-65
M1\?_ /!(S]OO]K7]C3XC?#O_ ()L_P#!13PFFL^'?B%J>M6?P)^.>EYV:]<V
MU[<>?9:E&68I<M('(?.[=+&&\P/YP_0;]O\ ^#G[7_QX_9RU[X8_L8_M'Z#\
M,?$^K:9<6Q\0:QX6DU"0ATVA()4N$^Q,1N4S^5<,NX,B!E!(!YY_P3N_X*96
M?[4?_!*70_\ @I)^T/X5A\$00>%]7U3QI#;JYM8%TN:YBNKBW#DN8G%J\B(2
MS#=LW.1N;R*U_;X_;VO_ /@G1+_P6#BL/#*>$TTU_%T/P-.A,;AO!B2DM(VJ
M^=N&I&R!O XC^SCB$Q'_ %U?-]S^T9\;OVB/^#8[]I/X0>/?A!I'@OQY\!/[
M5^&7BO1O"5D+?3R-'>R:>2")/EC3[+*RN%.TM&[J%5U4?5UI?>&;#_@V42^A
M:(Z7'^PSGMM9/^$/P0?<],=<GUH [3]K_P#X*BZ#\/\ X'_!'6_V4X=+\3^,
M_P!IK7M)TGX.Q:RL@LHX;V..:35;Q(V61K>U@D622)&5V9DCRNXLJ3_M=_&K
M]D3]N?X8?L=?M9>/=)\8:!\<=*U%?A]X[LO#RZ5/9:_IZ1RW&F74*2O$T,T,
MJ-;R#:X=6B82Y$@_+S]E'1/&>F?%7_@CG=?$E)QI;^$O&']FFY!V"9X3);XS
MT)B>RV^H QTK[&_X+\+J=]^VK_P3VT;PT&.JO^U%8W*"/[WV.&>Q:[/'.T1'
M+>U 'Z=4444 %%<9\9M$^.6MZ991? [QOHNAW:3L;Z76M,:Y66/;PJ@$;3GG
M->-?%Z]_;O\ @Y\--9^)^N?'#P;=6FBV9N)[>T\*-YCJ"!A=S@9Y[F@#Z8HK
ME?!]SX\U_P ):7KL^MV6^]TZ"=_]$QR\:L>,\=:TOL7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8
MHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :
M/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :T--CU&*U":I<1RR[CEXD
MVC';B@"Q1110!^(/_![S_P FL_ __LH&H_\ I"**/^#WG_DUGX'_ /90-1_]
M(110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7
M[_4 %>&?M0_!G]JGQ%\:OAW^T%^RO\3?"MC>>#=,UO2O$/@WQI87)L/$ECJ+
MZ?)C[5;L7LIH9-.C9)!#-D2.I4 D-[G10!\$?LS?\$]OV@OC'XL^#/Q?_;77
MP]X<TOX(>(?$&N>#/AUX;EGO)KO6KR\N0FH7][/%#^[ACD+06\4(W%Q))(<>
M4/7D\-_\%>M(^./C!;'XF_ /5_AQJFIR2^"IM6T#5H-8T&V;[D4\,$GDWVSC
M/[V%I""=T88*GTS10!XQ^S]^P_\ ";X)_L\>)?V?]?#^+HOB#J.LZK\4-5UB
MW1'\4ZEJ[.VHSS1QX6-) YB6)>(X4CC!.W<?G.#_ ();?M,Q_L2-_P $I6^.
MOA\?!'<VE#QP%N#XM/A0W/G#1/LY3[*)O*/V/[?YA'D<_9=_-?>=% 'S9^V'
M_P $X_ 7[0/P4^&W@CX/:C:> _$WP-\0Z3KOP8UN*P-Q;Z)<Z<JQPVDL(=6F
MLI8%\B6(.I*[6SN1:HZ'^Q1\4?C7^V?X*_;>_;+O_"HU+X5:#J&G_"_P/X.N
M+F[L=+O+]4COM6GNKF*%Y[B2*-(HXA"B0*&.Z5R'7ZAHH **** "O*/VY_\
MDT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I
M6[6%\+O^29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME"<*L%.#NGJFM4UY&/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q14%&/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+6AIMY/?6HGN+"2V8L1Y4I&?K
MQ5BB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\
MZ0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_
M?Z@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC
M]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_
MZ)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J?B'Q#H7A+0;WQ3XGU>WT_
M3=.M9+F_OKN41Q6\**6>1V/"J%!))Z 5<K\<O^"T?_!3X_''Q!=?LG? +Q 7
M\'Z5=[/%&L6<ORZW=QM_J$8?>MHV'7I(XR,JBEOJ>$>%<=Q;FT<)0T@M9SZ1
MCW]7M%=7Y)M?-<5<38+A;*Y8JMK)Z0CUE+MZ+=OHO-I/RO\ X*6?MU^./^"C
MW[0>F_#GX0Z7J%QX2TO4C8^"=#MX6,^JW4C",W;QCDR2'"HA^XG& S29R_\
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M45\(?;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-1_\
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M=6WT26K9YN;9K@LDR^>,Q<N6$%\WV2[MO1(\=_X+6_\ !4#_ (5CI-]^Q[\
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MG+]J/[9XX^%L4/P_\:3;I&O=,M1_9]_)U_TBV7 5B>LL>ULDLPD/%?F/XF\
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\/\ _@AK\7OV"OV95DO+_P /?"J?4XM/DNQ/JNJ2I.]_->3@?/)/>3VUTQ?
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M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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MB\;_ /0;LO\ P&/^-?MQ^?FQ16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
M]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XUH:;'J,5J$U2XCEEW'+Q)M&.W
M% %BBBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\ [*!J/_I"** /
M/_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ KR/\
M:5_8Q^&/[3?B_P &_$[7?%GB_P +^,?A\]\?!WB[P3XDDL+RP2\6%;N)D(>W
MN8I1;P;H[B*5?W8P!SGURB@#YB_9'_X)E^ /@!KWA[XK_%OQ_K_Q+^('A2'5
MK;PMXA\47D;0>'[>_NI9KC[!:6\,-O;RS(ZK-.(S*X!0.(\)7G/Q9_X( ?L8
M_&KXQ^)_CUXY^+'QO;Q-XOU#[9KE[I_Q;OK59F Q'&$BVJD<:82.,#:B *H
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M]E:+JWV<%<(T^&,"YUGSXFIK4GOKORI]D]W]IZOHD4445\(?;!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUN6/\V]^@4445^W'Y^%%%% !1110 4444 %%%% !1110 4444 ?B#_P>\_\
M)K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>
M/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
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M)W^*E^+G@G4M0U30=*G,VG^/O![2PS6 '1KA$/F6IQP6RT?.-Y)Q7T5^P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH ****
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MA+)<=Q5FO^LV<QT_Y<TWLDMI6[+[/\SO/M=:***_%#]B"BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEH.OWP8Y6YURX:- /53.PX_W:[KPG_P3Y\:7NV;QGXWT_3T/)BL87N'^A)V
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPRPVI"0M)$0#"\J2- 5!B*$9H ^1/^"AGA?XE^#_ /@J%_P38_:B^-%J$/\
M:.I>$/&%R% AM?$.HZ7&L$61\H:6=K@*!U\@XKH_^"X7A/5_C)_P42_X)\_
M_P (1//JJ?'B;QA<Q0C+0Z=HOV*[N96Q]U=@8 GJ1@<U]Z_M'?LV_!_]J_X5
MW?P<^-WA@ZEH]S<P7<#V]U);75A>02++;WEK<1,LEO<12*KI*C!E(]"0>:^#
MW[%OPU^%?Q;NOVA?$/BSQ-X\^(5QH2Z'#XU\<W\-Q>6.EK)YGV*VCMX8;>VC
M:0!Y#'$LDS*IE>0JN #U^BBB@#C/C-HGQRUO3+*+X'>-]%T.[2=C?2ZUIC7*
MRQ[>%4 C:<\YKY\_:M\&_MIV'[.OBZ\^('QG\'ZAHL>DL=1LK'PX\4TT>Y<J
MCEOE.<<U];5Y1^W/_P FC^/?^P"__H:T =!\*['QR/AAX<#ZY9%O[!L\D6IZ
M^0GO6_\ 8O&__0;LO_ 8_P"-1?"[_DF?AW_L!6G_ *)2MV@#'^Q>-_\ H-V7
M_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#
M'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7
M_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#
M'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7
M_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#
M'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7
M_@,?\:_)G_@LW_P4XUKQWJ6I?L<_!?QC%/H5E/Y/C76]-&U=0G0\V4; \PHP
M_>$??<;?NJ=_NW_!:#_@I^/@)X=NOV5_@-XAV^-M7M-OB35[27YM"LY%_P!6
MC#[MS*IX/6-#NX9D(\!_X(L_\$P#\9=<L_VM_C]X>W>$],NM_A+1KR+Y=9NH
MV_X^9%/WK>-AP.DCKS\J$/\ L_!/#^7\.97_ *UYXO<C_!@]YRZ2MY_8^<WH
MDS\AXQSW'<09E_JQDK]Z7\::VC'K&_\ Z5\H+5M'KO\ P1J_X)=:]\+-(T_]
MKOXS:3;V_B?4;;S/".C:C;%GTJVD7BZ=3]V>13\HZQHW/S,0GZ(_8O&__0;L
MO_ 8_P"-;%%?FG$7$&8<39K/'8MZRV72,>D5Y+\7=O5GZ)D&18'AS+(8+"K1
M;OK*763\W^"LEHC'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**\,]H
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M_P"-'V+QO_T&[+_P&/\ C7A7C#_@H3H%MO@\!^!+JZ;HMQJDZPJ/?8FXL/\
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M_P!(111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_
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MY9M0O@SX]=L0?GV.*]&\+_\ !/3PY!ME\9_$&\NCU:'3;980/;<^_/Y"N/\
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M2DG%QY%).+W34^9-?(_&']NK_@A5\8/@3#<_$C]EZ[OO'/AF%3+<Z.8@=7L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!$GQ)_:"^+GA[P;H4<JQ#4_$6JQ6L<DK?=B3>09)&Z!%RS'H#0!V-%%>6/\
MMN_LC)\6C\#&_:&\+?\ "4C61H[:7_:B?+JA7<-.,O\ JQ>%>1:EO.(YV4 >
MIT5E>-_'/@KX9^$=1^('Q&\7:9H&A:1:/=:KK6LWT=M:V<"C+22RR$)&@'5F
M( KEO@G^U)^SW^T;)J-M\$_BSI.OW.D+"^J6%K,4NK6.4$PRR02!9%CD"L8Y
M"NR0*2I;!H [ZBBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\
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M@D/T3.X_@*\V\5?MT_!/0MT6B-J6LR#A3:6GEQY]VE*G'N :\5\+?L-_&_Q
M5FUJ#3]'C;EC?7@=\>RQ!N?8D5Z3X5_X)[^$;3;+XR\=W]ZPY:+3X$MU^F6W
MDC\OPKA_UO\ '#B33*\HAA(/[59^\OE-P_\ 33.C^Q/#[*O][QLJTETAL_\
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M445[)P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>%?">FZ< ,9LK)(R?J5 )_&M6FO!'.L[?-Q)GE:NGO"%U%>G.Y+[J:%_Q$#
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
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MJ7_R/7SS_P 0[6C?]':77_A$K_\ )E'_ !#M:-_T=I=?^$2O_P F4OK/$_\
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M8^;^V[&]?'U^T(?UJ?\ 6/D_B4)+^O.QK_KFJ?\ &PM2/]>:1^Z]%?A3I_\
MP51_;\\,7'V34?C-/.8S\UOJ6A6FX>Q(A5_UKK-#_P""U?[8NE8%_9>$M3P.
M?MNF7*Y_[\W"5<>*,NENI+Y+]&:0XYR:7Q1FO5+]&S]JJ*_(C0?^"[?Q=M]O
M_"3_  +\/WG][[!K%Y;9^F]I<5VF@_\ !>OPI(%3Q/\ LN:I%@?-+8>//,S]
M%>U7'_?1KHAQ#E,MYV]4_P#([*?&&03WJV]8R_R/U#HK\\=!_P""Z/[)ET0/
M$OPF^(]F2>39S6MP!_WU<1G]*[30?^"R'_!/G5P#J'B/QKI61S]OT>1L?]^7
MDKICG&63VJK\OS.R'$61U-L1'YNWYV/MJBOEK0?^"F7_  3?\0D+:?M+>0Q.
M"M_8:C;8/UE@4?K7::#^UQ^PMXD _LO]K+P<"P^5+KQG!;L?PE=3GVKIAC<'
M/X:D7\U_F=M/,\NJ_!6@_22_S/<:*X/0?%?P+\4E1X8^+ND:CN.%^P>)X9LG
MVV.:Z-?!6C.H=+R\*D9!%XV"*WC*,E=.YUQG":O%W-FBL?\ X0?2/^?F]_\
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M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO
M_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4
M ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1
M_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;5H:;IT&E6HM+=Y&4,3F5RQ
MY]S0!8HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\
MZ0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_
M?Z@ K%\??#?X=_%;P[)X0^*/@+1?$FDS,&ETO7]*AO+=R.A,<RLI/)[5M44
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M%XOL]_/JOF;A^(K\]=>_X-YOBE;AO^$8_:1\/WG'R_;]#GML_78\N*XK7O\
M@@;^V7IA+Z1XR\ :DF?E6'6+J-S]1):@#_OHT?VCG]/X\,GZ?\.P_MCBRE_$
MP2?H_P#)R/U ^,G[6?[/GP*^%.I?&;Q[\3]+&AZ8@+R:?>)<R7$C'"0Q)&Q,
MDC'@ >Y)"@D?"?\ Q$I_"W_A,OL/_#+6O_\ "/>=C^U/^$C@^V>7G[WV7RMF
M['\/GX]Z^&/VVOV _P!IS]C_ ,.Z/XE^,_A.TM])U2_>TMK_ $_4H[B,SA-X
M1MIRI*AR,@9VMCH:^=*IYIC9Q3E#D?9[_BCX'B3Q XDPN/5"E#V'*E=-)MWU
M^TM%;LK^?;^G#]GW]H+X5?M/_"K3?C)\&_$BZGHNIJ0CE-DMO*O#PRH>8Y%/
M!4^Q!*D$]I7\['[(G[+7[8/Q_P#">JZQ^SYX!UW5M'L=06&[FL-02WA6Y*!B
MO[R1 S["A.,D KGJ*]<_X=5?\%*=7YG^ ^J2>?PWVGQ1IXW9_O;[H8_&B6=X
MR,K1PTI>:O9_^2L^PRSC3-,;@*=;ZC*3:U<;V;V;7NO2_F_4_<:YO;.SV_:[
MN*+=G;YD@7/TS5"Y\;^"[/?]L\7:7%Y?W_,U"-=OURW%?B;;?\$;_P#@HM/N
M\WX!10XZ>9XMTHY_[YNC5ZV_X(L?\%!IRGF_"O3(=W7S?%-D=OUVRG],U/\
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MQS+[5-?=_D<!<_\ !PM\'5#_ &3]G?Q,Y!^3S-5MTR/? ./UJA<_\'#W@)6
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M_:I_X)'?MG?LGR7'B*?P2WBOPY;DN/$GA%7N4C0<[IH<":' ^\2I0?WS7/\
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MB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH ****
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M)&/)8^P "@ =I116R2BK(]>E2I4*4:=.*C&*LDM$DMD@HHHIF@4444 %%%%
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M3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HHHH ****
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M_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^(/\
MP>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M KN*ZQWB_6+T^>_9G@YWPQD?$-/EQU%2?26TEZ26ORV[H_GOU;PW_P %$_\
M@ESXU,ES!XG\$I-<8%Q;R?:-'U,CI\R[[>8X'0_.H/137V%^RE_P7I^'6MFV
M\+?M?^ [[1K@D(WBKPM-+-:G_:EM68RQCN3&TF2>$ K]0?$/ASP]XNT6Y\->
M*]!LM4TZ\B,=WI^HVJ3P3H>JNC@JP]B*^&_VKO\ @@?^S'\8_M/B;X!:G/\
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M\WO_ (%M1_P@^D?\_-[_ .!;5D>'/V@O@+XQQ_PB/QN\(:KNZ?V;XEM9\_\
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M(_Y^;W_P+:M#3=.@TJU%I;O(RAB<RN6//N:L44 %%%% 'X@_\'O/_)K/P/\
M^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;?\I3/VN_^WC_ -/D
M]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110 4444 %%%% !1110
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX
M=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?M5NQ_K7[[4CHDBE'4,K#!!&016O_$5\OQ'^^Y/0J?<O_2H2,_\ B&&.P_\
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M+_AX^M3?9IV_&D__ $H/[6\7,+_$P-*HNZ:O^%1?D?HUX;_;8_8Z\7X'AO\
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MT:NKK\'<Y\+BL-C:"K4)J4'LUL[.S_%!1117.= 4444 %%%% !1110 4444
M%%%% !1110!^(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\
MTA%% 'G_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]
M?O\ 4 %%%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY
M1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T
M_P#1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P
M>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
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M/^'MW_!.C_HZ31?_   O/_C-'_#V[_@G1_T=)HO_ ( 7G_QFO4_^&7_V:?\
MHWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\ \:H \L_X>W?\$Z/^CI-%_P#
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M-X\"_P#A)6?_ ,:H \L_X>W?\$Z/^CI-%_\  "\_^,T?\/;O^"='_1TFB_\
M@!>?_&:]3_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-X\"_^$E9_P#QJ@#R
MS_A[=_P3H_Z.DT7_ , +S_XS1_P]N_X)T?\ 1TFB_P#@!>?_ !FO4_\ AE_]
MFG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J /+/^'MW_  3H_P"C
MI-%_\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_ ,9KU/\ X9?_ &:?^C>/ O\
MX25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !J@#RS_ (>W?\$Z/^CI-%_\ +S_
M .,T?\/;O^"='_1TFB_^ %Y_\9KU/_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\
M9I_Z-X\"_P#A)6?_ ,:H \L_X>W?\$Z/^CI-%_\  "\_^,T?\/;O^"='_1TF
MB_\ @!>?_&:]3_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-X\"_^$E9_P#Q
MJ@#RS_A[=_P3H_Z.DT7_ , +S_XS1_P]N_X)T?\ 1TFB_P#@!>?_ !FO4_\
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MX\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:H \L_X>W?\$Z/^CI-%_\
M "\_^,T?\/;O^"='_1TFB_\ @!>?_&:]3_X9?_9I_P"C>/ O_A)6?_QJC_AE
M_P#9I_Z-X\"_^$E9_P#QJ@#RS_A[=_P3H_Z.DT7_ , +S_XS1_P]N_X)T?\
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M\/;O^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C->I_\ #+_[-/\
MT;QX%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU0!Y9_P]N_X)T?\ 1TFB
M_P#@!>?_ !FC_A[=_P $Z/\ HZ31?_ "\_\ C->I_P##+_[-/_1O'@7_ ,)*
MS_\ C5'_  R_^S3_ -&\>!?_  DK/_XU0!Y9_P /;O\ @G1_T=)HO_@!>?\
MQFC_ (>W?\$Z/^CI-%_\ +S_ .,UZG_PR_\ LT_]&\>!?_"2L_\ XU1_PR_^
MS3_T;QX%_P#"2L__ (U0!Y9_P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7
M_P  +S_XS7J?_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\
MXU0!Y9_P]N_X)T?]'2:+_P" %Y_\9IK_ /!7+_@G,C*I_:CT?YC@8TZ]/YX@
MXKU7_AE_]FG_ *-X\"_^$E9__&J\5_:?_9_^ VC_ !A^#5CI/P2\(VL%_P"-
M98KZ&V\-VJ)<1_9V.R0+& ZYYP<B@#7_ .'MW_!.C_HZ31?_   O/_C-'_#V
M[_@G1_T=)HO_ ( 7G_QFO4_^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/
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MC>/ O_A)6?\ \:H \L_X>W?\$Z/^CI-%_P# "\_^,T?\/;O^"='_ $=)HO\
MX 7G_P 9KU/_ (9?_9I_Z-X\"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJ
M@#RS_A[=_P $Z/\ HZ31?_ "\_\ C-'_  ]N_P""='_1TFB_^ %Y_P#&:]3_
M .&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :H \L_P"'
MMW_!.C_HZ31?_ "\_P#C-'_#V[_@G1_T=)HO_@!>?_&:]3_X9?\ V:?^C>/
MO_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J /+/^'MW_!.C_HZ31?_   O
M/_C-'_#V[_@G1_T=)HO_ ( 7G_QFO4_^&7_V:?\ HWCP+_X25G_\:H_X9?\
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MS_XS7J?_  R_^S3_ -&\>!?_  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-4
M>6?\/;O^"='_ $=)HO\ X 7G_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S7J?\
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M_P#XU0!Y9_P]N_X)T?\ 1TFB_P#@!>?_ !FC_A[=_P $Z/\ HZ31?_ "\_\
MC->I_P##+_[-/_1O'@7_ ,)*S_\ C5'_  R_^S3_ -&\>!?_  DK/_XU0!Y9
M_P /;O\ @G1_T=)HO_@!>?\ QFC_ (>W?\$Z/^CI-%_\ +S_ .,UZG_PR_\
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M\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\ XU0!Y9_P]N_X)T?]'2:+_P"
M%Y_\9H_X>W?\$Z/^CI-%_P# "\_^,UZG_P ,O_LT_P#1O'@7_P )*S_^-4?\
M,O\ [-/_ $;QX%_\)*S_ /C5 'EG_#V[_@G1_P!'2:+_ . %Y_\ &:/^'MW_
M  3H_P"CI-%_\ +S_P",UZG_ ,,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\
MT;QX%_\ "2L__C5 'EG_  ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT
M7_P O/\ XS7J?_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\
MC5 'EG_#V[_@G1_T=)HO_@!>?_&:/^'MW_!.C_HZ31?_   O/_C->I_\,O\
M[-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S_P#C5 'EG_#V[_@G1_T=
M)HO_ ( 7G_QFO7O@G\>?A%^T;X*_X6)\$_'%MX@T7[7):_;[2.15$R %DQ(J
MMD!E[=ZJ?\,O_LT_]&\>!?\ PDK/_P"-5TWA3P7X.\!Z2- \#>$],T6Q$C2"
MRTFPCMH0YZMLC &3@9..<4 :=%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/
M>?\ DUGX'_\ 90-1_P#2$44 >?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\
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MC;]K/]C7XK_ #Q5X^WCX<W/Q'TZ 6'B"13C[.D\,C*EP<J!'\R[F5"X9XU<
M^ZZ*XK]I#XVZ'^S;\ _&'QZ\1:;+?6OA+P]=:G_9MLV)K^2*,M%:Q<'][-)L
MB08.7D48.<5XK^TW_P %#?B3\"EC\)_"O]A3XC?&'QGINBV^H>.-#^'+V\MG
MX;:2(2?99+VY:(7-R0=R6\,;S-&4D9(UEBW@'T)\2/A]X<^*O@74_AWXNBE?
M3=6MC!>+!*4<H2#PPZ'BM+1M*M-!T>TT/3U8065M'! ';)"(H5<GN< 5XS_P
M3V_;\^!__!2?]FRQ_:6^!$6JVEA+J%QIFL:'K]H(+_1]1@*^=:7"*S*'4.C
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M:+H'C$Z@VEZ=KOE"[CCMM0N;/=*(F=%9C;E]JLP 8#)QFO8Z "BBB@ HHHH
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M]KYBS2))O;YD!"B)NK%5(!\:?\$_?VL_"_Q$_P""WOQE\/\ [6W[*/B[X/\
MQZ\0^!;.P^'>F^([NVNK2^\&V#F1A!<6K-%-<RW)EGD9'EBV0+&C[K>0R=5_
MP=+ '_@D#XH)'3QSX7Q_X-[>O5?#?P%\3_M9_P#!1OP'_P % O%?PAUGP/X=
M^$_@'5]%\'P>*;>.VUC7[_5&B6:>6V1W:VM+>"-T19MDSRW,C>6B(K2\!_P<
M<_#3XR_M#?\ !._4?V=/V>/@EXL\<^+]:\4:)?6VG>'=%DECCM[2_CN)7DG;
M;"AVQD!"^\EAA<9( /OJ::&WA>XN)5CCC4L[NV H')))Z"OF_P#8(\(:%\9O
M@MK/[3OCO08KZ3XS_$!O'VG1WL6X)IL,D$7AQP#T*:=8:9< =%F=V')W'7_;
M#U[Q[\:/V-=2\(_!;PKXIM-7^)DEIX35I]!N;2]T&UU&Z2RO]0FCD0-!]EM)
M+FX#L-I:)-I;>I/1?M-_%#Q1^R1^S!>^(_V?OV:-?^(NK:#ID5AX0^'GA")%
MDN'5/+@C9W(6"W0*-\AR51?E5V*J0#YQ_P""U_P6LOVZ=&^$_P#P3F\.62WF
MN^,/B5IOB?7[J--Q\-^&=*D,E]J;M_RS9R\=G"#CS)+LJ#A)"OV1\5P&^%OB
M56&0= O,C_M@]?FA\"O^"@'_  4#^$&D:WXRU;_@AC\=/%GQ/\7&.X\5>*M1
MU;3+*&^N$5A!:1 /*;+3[<.R0P#?L5GD<RS2S2R?H5\5?$_BSPK^S7J&I>-/
M#%YK/B27PJT%[I7@O1[B\-SJ+VQ5H[>)0[K&9<A6D("@C>XY- 'RA_P;&?\
M*#3X$_\ 7GKW_J0ZG7WG7Q!_P;Q_#SXK? /_ ()7_#C]F3X]?"'Q1X+\:^"$
MU2+7-)\1:-) N+G5[ZZA>&;!BF!BE0D(Q9"<,!D9^WZ "BBB@ HHHH ****
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MK&M_#71UN9;[&^.WUB=;EKN2!C_"&O;J)&QDHW0$\?(%M^W_ /M[:Y^T;?\
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M8;>!(8]BHN/TYC$@C43.K.%&YE7 )[D#)Q^9H =1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH _$'_ (/>?^36?@?_ -E U'_TA%%'_![S_P FL_ __LH&H_\ I"**
M //_ /@TV_Y2F?M=_P#;Q_Z?)Z_?ZOP!_P"#3;_E*9^UW_V\?^GR>OW^H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(
M111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@T
MV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFAIJEMI]I;1SPLCQ2WE]<@J5;YH=.NU(()K'_P""ML-S_P $SO\ @H/\ ?\
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M^#_$6H61T^'4KJ\CM[]IC/=QK/<R2/(5FE9&P[!'5X^&C90 >PT444 %%%%
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MI4I<DZ<FUVV/K\LX^I8G 4ZE:A+G:UY4K7VNKO9G[E45^&O_  V)_P %5O\
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M\6^ O E[X@T7Q:GQN\0WUN+BUM6G2&[M-1OI[:[AE>-49)(V8[OE(8\^9?\
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M% 'SI^W;_P $KOV./^"A_P (/#GP;^.W@.YL;7P5.DW@75_"%Y_9M_X;=41
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MUU)"7=I999G,S[I@TK$2 A2O7?L@?LG>!?V*?@EI?[/7PL\9>*M4\+Z#$(-
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MY/%VE>,? ^GW.FV&L>#/&5YHTM[IMP<S6%R]JZ/);L2^55E)$CC=AB*^@**
M/D3]M[_@B3^P_P#MU_%+P_\ 'CQK8>*_!'CWPW8QV-AXV^%WB1M%U%[.,$);
MR.B,C*JDJK;0ZJ=H<* !Z?X4_P""=W[(?A;]D74OV''^$L.K?#K7;6>/Q)IF
MO7LUY<:U-.P>:[NKJ1S-+=-(%D\\OO1D0H4\M OME% 'Q]^Q7_P1#_8R_89\
M=:=X]^'6N?$;Q/+X=:4^"-*^('CJXU33?"9E1HW;3K0A88'*.Z>:5>0*[ .
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^'_ !_P1M_Z2$_#_P#\"YO_ (W0!]?T5\@?\/\ C_@C;_TD)^'_ /X%S?\
MQNC_ (?\?\$;?^DA/P__ / N;_XW0!]?T5\@?\/^/^"-O_20GX?_ /@7-_\
M&Z/^'_'_  1M_P"DA/P__P# N;_XW0!]?T5\@?\ #_C_ ((V_P#20GX?_P#@
M7-_\;H_X?\?\$;?^DA/P_P#_  +F_P#C= 'U_17R!_P_X_X(V_\ 20GX?_\
M@7-_\;H_X?\ '_!&W_I(3\/_ /P+F_\ C= 'U_17R!_P_P"/^"-O_20GX?\
M_@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO_C= 'U_17R!_P_X_X(V_])"?A_\
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M"-O_ $D)^'__ (%S?_&Z/^'_ !_P1M_Z2$_#_P#\"YO_ (W0!]?T5\@?\/\
MC_@C;_TD)^'_ /X%S?\ QNC_ (?\?\$;?^DA/P__ / N;_XW0!]?T5\@?\/^
M/^"-O_20GX?_ /@7-_\ &Z/^'_'_  1M_P"DA/P__P# N;_XW0!]?T5\@?\
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M/^'_ !_P1M_Z2$_#_P#\"YO_ (W0!]?T5\@?\/\ C_@C;_TD)^'_ /X%S?\
MQNC_ (?\?\$;?^DA/P__ / N;_XW0!]?T5\@?\/^/^"-O_20GX?_ /@7-_\
M&Z/^'_'_  1M_P"DA/P__P# N;_XW0!]?T5\@?\ #_C_ ((V_P#20GX?_P#@
M7-_\;H_X?\?\$;?^DA/P_P#_  +F_P#C= 'U_17R!_P_X_X(V_\ 20GX?_\
M@7-_\;H_X?\ '_!&W_I(3\/_ /P+F_\ C= 'U_17R!_P_P"/^"-O_20GX?\
M_@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO_C= 'U_17R!_P_X_X(V_])"?A_\
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M"-O_ $D)^'__ (%S?_&Z/^'_ !_P1M_Z2$_#_P#\"YO_ (W0!]?T5\@?\/\
MC_@C;_TD)^'_ /X%S?\ QNC_ (?\?\$;?^DA/P__ / N;_XW0!]?T5\@?\/^
M/^"-O_20GX?_ /@7-_\ &Z/^'_'_  1M_P"DA/P__P# N;_XW0!]?T5\@?\
M#_C_ ((V_P#20GX?_P#@7-_\;H_X?\?\$;?^DA/P_P#_  +F_P#C= 'U_17R
M!_P_X_X(V_\ 20GX?_\ @7-_\;H_X?\ '_!&W_I(3\/_ /P+F_\ C= 'U_17
MR!_P_P"/^"-O_20GX?\ _@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO_C= 'U_1
M7R!_P_X_X(V_])"?A_\ ^!<W_P ;H_X?\?\ !&W_ *2$_#__ ,"YO_C= 'U_
M17R!_P /^/\ @C;_ -)"?A__ .!<W_QNC_A_Q_P1M_Z2$_#_ /\  N;_ .-T
M ?7]%?('_#_C_@C;_P!)"?A__P"!<W_QNC_A_P ?\$;?^DA/P_\ _ N;_P"-
MT ?7]%?('_#_ (_X(V_])"?A_P#^!<W_ ,;H_P"'_'_!&W_I(3\/_P#P+F_^
M-T ?7]%?('_#_C_@C;_TD)^'_P#X%S?_ !NC_A_Q_P $;?\ I(3\/_\ P+F_
M^-T ?7]%?('_  _X_P""-O\ TD)^'_\ X%S?_&Z/^'_'_!&W_I(3\/\ _P "
MYO\ XW0!]?T5\@?\/^/^"-O_ $D)^'__ (%S?_&Z/^'_ !_P1M_Z2$_#_P#\
M"YO_ (W0!]?T5\@?\/\ C_@C;_TD)^'_ /X%S?\ QNC_ (?\?\$;?^DA/P__
M / N;_XW0!]?T5\@?\/^/^"-O_20GX?_ /@7-_\ &Z/^'_'_  1M_P"DA/P_
M_P# N;_XW0!]?T5\@?\ #_C_ ((V_P#20GX?_P#@7-_\;H_X?\?\$;?^DA/P
M_P#_  +F_P#C= 'U_17R!_P_X_X(V_\ 20GX?_\ @7-_\;H_X?\ '_!&W_I(
M3\/_ /P+F_\ C= 'U_17R!_P_P"/^"-O_20GX?\ _@7-_P#&Z/\ A_Q_P1M_
MZ2$_#_\ \"YO_C= 'U_17R!_P_X_X(V_])"?A_\ ^!<W_P ;H_X?\?\ !&W_
M *2$_#__ ,"YO_C= 'U_17R!_P /^/\ @C;_ -)"?A__ .!<W_QNC_A_Q_P1
MM_Z2$_#_ /\  N;_ .-T ?7]%?('_#_C_@C;_P!)"?A__P"!<W_QNC_A_P ?
M\$;?^DA/P_\ _ N;_P"-T ?7]%?('_#_ (_X(V_])"?A_P#^!<W_ ,;H_P"'
M_'_!&W_I(3\/_P#P+F_^-T ?7]%?('_#_C_@C;_TD)^'_P#X%S?_ !NC_A_Q
M_P $;?\ I(3\/_\ P+F_^-T ?7]%?('_  _X_P""-O\ TD)^'_\ X%S?_&Z/
M^'_'_!&W_I(3\/\ _P "YO\ XW0!]?T5\@?\/^/^"-O_ $D)^'__ (%S?_&Z
M/^'_ !_P1M_Z2$_#_P#\"YO_ (W0!]?T5\@?\/\ C_@C;_TD)^'_ /X%S?\
MQNC_ (?\?\$;?^DA/P__ / N;_XW0!]?T5\@?\/^/^"-O_20GX?_ /@7-_\
M&Z/^'_'_  1M_P"DA/P__P# N;_XW0!]?T5\@?\ #_C_ ((V_P#20GX?_P#@
M7-_\;H_X?\?\$;?^DA/P_P#_  +F_P#C= 'U_17R!_P_X_X(V_\ 20GX?_\
M@7-_\;H_X?\ '_!&W_I(3\/_ /P+F_\ C= 'U_17R!_P_P"/^"-O_20GX?\
M_@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO_C= 'P!_P>\_\FL_ _\ [*!J/_I"
M**\3_P"#M+_@HY^P[^VY^SQ\)/"W[*'[2OAOQUJ&A^-+ZZU:TT.9W>UA>T"*
M[;E'!;BB@#\;/VL/^3IOB7_V4#6?_2Z:N HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 13, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moderna, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">325 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,939,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,595<span></span>
</td>
<td class="nump">$ 1,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">5,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,544<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, non-current</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,338<span></span>
</td>
<td class="nump">14,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,688<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001; 162&#160;shares authorized as of December 31, 2025 and 2024; no shares issued or outstanding at December 31, 2025 and 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2025 and 2024; 394 and 386 shares issued and outstanding as of December 31, 2025 and 2024, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">7,223<span></span>
</td>
<td class="nump">10,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">8,650<span></span>
</td>
<td class="nump">10,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 12,338<span></span>
</td>
<td class="nump">$ 14,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">394,000,000<span></span>
</td>
<td class="nump">386,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">394,000,000<span></span>
</td>
<td class="nump">386,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,944,000<span></span>
</td>
<td class="nump">$ 3,236,000<span></span>
</td>
<td class="nump">$ 6,848,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="nump">1,464,000<span></span>
</td>
<td class="nump">4,693,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,132,000<span></span>
</td>
<td class="nump">4,543,000<span></span>
</td>
<td class="nump">4,845,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,018,000<span></span>
</td>
<td class="nump">1,174,000<span></span>
</td>
<td class="nump">1,549,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,018,000<span></span>
</td>
<td class="nump">7,181,000<span></span>
</td>
<td class="nump">11,087,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,074,000)<span></span>
</td>
<td class="num">(3,945,000)<span></span>
</td>
<td class="num">(4,239,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">314,000<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="nump">421,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(87,000)<span></span>
</td>
<td class="num">(124,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(2,768,000)<span></span>
</td>
<td class="num">(3,607,000)<span></span>
</td>
<td class="num">(3,942,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) tax provision</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="nump">772,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,822,000)<span></span>
</td>
<td class="num">$ (3,561,000)<span></span>
</td>
<td class="num">$ (4,714,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="num">$ (7.26)<span></span>
</td>
<td class="num">$ (9.28)<span></span>
</td>
<td class="num">$ (12.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="num">$ (7.26)<span></span>
</td>
<td class="num">$ (9.28)<span></span>
</td>
<td class="num">$ (12.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares used in calculation of loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="nump">382,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="nump">382,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,818,000<span></span>
</td>
<td class="nump">$ 3,109,000<span></span>
</td>
<td class="nump">$ 6,671,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,822)<span></span>
</td>
<td class="num">$ (3,561)<span></span>
</td>
<td class="num">$ (4,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Available-for-sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: net realized (gains) losses on available-for-sale securities reclassified in net loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net increase from available-for-sale securities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Net realized losses on derivative instruments reclassified in net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net increase from derivatives designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gains (losses) on foreign currency translation</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax', window );">Pension and postretirement obligation adjustments</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (2,767)<span></span>
</td>
<td class="num">$ (3,448)<span></span>
</td>
<td class="num">$ (4,467)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 19,123<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="num">$ (370)<span></span>
</td>
<td class="nump">$ 18,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, including excise tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock, including excise tax</a></td>
<td class="num">(1,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">13,854<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="nump">13,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,561)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">386,000<span></span>
</td>
<td class="nump">386,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2024</a></td>
<td class="nump">$ 10,901<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">10,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock (in shares)</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax payments related to net share settlements on equity awards</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2025</a></td>
<td class="nump">394,000<span></span>
</td>
<td class="nump">394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2025</a></td>
<td class="nump">$ 8,650<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 7,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,822)<span></span>
</td>
<td class="num">$ (3,561)<span></span>
</td>
<td class="num">$ (4,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/accretion of investments</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss on equity investments, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(439)<span></span>
</td>
<td class="num">(2,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,873)<span></span>
</td>
<td class="num">(3,004)<span></span>
</td>
<td class="num">(3,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(5,768)<span></span>
</td>
<td class="num">(6,529)<span></span>
</td>
<td class="num">(3,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">5,563<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">5,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="nump">3,967<span></span>
</td>
<td class="nump">3,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible asset</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Investment in convertible notes and equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from credit facility</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of credit facility issuance costs</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock through equity plans</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Tax payments related to net share settlements on equity awards</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments', window );">Changes in financing lease liabilities</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(1,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of changes in exchange rates on cash and cash equivalents</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">668<span></span>
</td>
<td class="num">(999)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">3,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid (received) for income taxes</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Principal Payments, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Right Of Use Asset, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.</span></div>Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We currently have three commercial products&#8212;Spikevax&#174; and mNEXSPIKE&#174;, our COVID vaccines, and mRESVIA&#174;, our vaccine against respiratory syncytial virus (RSV). Additionally, we also have a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating and reportable segment, reflecting the integrated nature of our business focused on the research, development, and commercialization of mRNA-based medicines. Our Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), responsible for assessing the Company's performance and making resource allocation decisions. The CODM evaluates financial information on a consolidated basis, focusing on key metrics such as total revenue, operating expenses, and net income or loss, which is our reported measure of segment profit or loss. The CODM allocates resources based on the Company's available cash resources, forecasted cash flow, and expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities. Resource allocation decisions are informed by budgeted and forecasted expense information, along with actual expenses incurred to date. Disaggregated profit or loss information at the program or functional level is not regularly provided to or relied upon by the CODM, as our integrated operating model emphasizes shared resources and centralized decision-making. The interdependent nature of our research, development, and commercialization activities, supported by common infrastructure such as our mRNA platform, makes further disaggregation of expenses less meaningful for assessing performance. Additionally, there are no segment managers accountable for operations, operating results, and planning for levels or components below the consolidated unit level. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net <span id="ice4d497822074fb680bb6adb64870e63_40370"></span>Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations.  In the U.S., our COVID vaccine and RSV vaccine are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, government rebates, and other related deductions. These provisions are recorded based on contractual terms, our estimate of returns for product sold during the period, and other relevant considerations, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wholesaler chargebacks, discounts and fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our vaccines are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, projected market demand, and our historical experience with returns. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates and other fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets. In 2024, we began recognizing Medicare rebates associated with our RSV product. The estimation of Medicare rebates requires judgment and is based on historical utilization trends, and the mix of customers and payers. The estimated liability for unpaid or unbilled rebates is presented as accrued liabilities on our consolidated balance sheets. For 2024 and 2025, the product sales subject to Medicare rebates were immaterial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control, such as the limited historical data, constrained third-party information, and evolving market dynamics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now have two years of data on our product returns, this remains limited and subject to significant variability given current market conditions. We will continue to refine our projections as additional information becomes available. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue consists primarily of grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing and Royalty Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License revenue is recognized when the license is granted to the licensee, provided no significant performance obligations remain. Royalty revenue is recognized based on sales by licensees when the underlying sales occur, in accordance with the terms of the licensing agreement and when collectibility is reasonably assured.</span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stand-Ready Manufacturing Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into long-term strategic agreements with government entities to establish domestic mRNA manufacturing capabilities and support pandemic readiness. Under these agreements, we are required to build and maintain manufacturing facilities and to supply vaccines in accordance with minimum spend commitments or annual demand forecasts established by the respective governments. A portion of the total consideration under each agreement is allocated to a stand-ready obligation to maintain manufacturing readiness and is recognized as other revenue on a straight-line basis over the contractual period. The remaining consideration is related to our obligation to supply vaccines and will be recognized as product sales when control of the vaccines transfers upon delivery.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in other non-current assets in the consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific-identification method, and are included in other income (expense), net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument&#8217;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Available-for-sale securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other income (expense), net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other income (expense), net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (see our &#8220;Revenue Recognition&#8221; policy within </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors. The allowance for doubtful accounts was immaterial at December 31, 2025 and 2024. Additionally, bad debt expenses were immaterial for the years ended December 31, 2025, 2024 and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable, net related to our net product sales and other revenue. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, stand-ready manufacturing revenue from international government entities, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:50.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;<br/>Accounts&#160;Receivable<br/>December&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">FFF Enterprises</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Public Works and Government Services Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom Health Security Agency</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mexico Medistik</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Boryung Biopharma Korea</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan Food and Drug Administration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ministry of Health, Labor, and Welfare of Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable debt securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value, with cost determined principally using first-in, first-out method. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-launch Inventory </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2025 and 2024, we did not have any capitalized pre-launch inventory on our consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and permanent land improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Limited-life land improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Determined on a project-by-project basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5-12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress includes direct costs related to the construction of various property, plant and equipment, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets primarily consist of acquired intellectual property and regulatory approval and commercial sales milestone payments. These assets are recorded at cost, net of accumulated amortization, and amortized on a straight-line basis over their estimated useful lives. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long-lived assets, which consist of property, plant and equipment, finite-lived intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2025, 2024 and 2023 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are initially measured as the lease liability plus direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaborator are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). See our "Revenue Recognition" policy within </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaborator, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Funding Arrangements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into research and development funding arrangements to support a targeted programs, under which a third party has committed to fund us up to a specified amount. Contingent upon the regulatory approval of the program, we are obligated to pay certain milestones and royalties as outlined in the respective agreements. We account for funding received under research and development arrangements as a reduction to expenses when substantive financial risk is transferred to the funding party. These arrangements are accounted for as an obligation to conduct research and development activities. The funding is recognized proportionally as the related costs are incurred, using an input method. Contingent payments, such as milestones or royalties, will be recognized separately upon achievement of the related conditions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations. Advertising expenses were </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$133&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in 2025, $146&#160;million in 2024, and $204 million in 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation&#8212;Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2025, we estimated the expected term of our stock options using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. During 2025, we used historical exercise data in estimating the expected term of stock options, utilizing a methodology that combines historical settlement data with a hypothetical settlement pattern for outstanding options, based on estimated time to arrival at-the-money and adjusted for employee departure rates. The change in methodology used during 2025 did not have a material impact on stock-based compensation and our financial statements. However, during the fourth quarter of 2025, in connection with our stock option exchange program (see </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_199" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), which resulted in changes to our stock option population, we determined that we no longer have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, as such data is no longer indicative of future exercise patterns. Accordingly, beginning in 2026, we will estimate the expected term of stock options using the simplified method. We will continue to apply this process until a sufficient amount of historical information regarding the expected term becomes available and we believe that historical experience is relevant to our expectations for current grants. The expected volatility is based on our stock price volatility and incorporates both historical volatility of our stock price and implied volatility derived from the price of exchange traded options on our stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted stock units, performance stock units, stock options, and shares under the employee stock purchase plan that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments, derivatives designated as hedging instruments, and foreign currency translation, as well as, pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive loss for the years ended December 31, 2025 and 2024 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gains on Available-for-Sale Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Postretirement Obligation Adjustments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses (gains) on Foreign Currency Translation </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early adoption is permitted. We adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_205" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 14</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Income Taxes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires entities to disclose, on an annual and interim basis, disaggregated information in the footnotes related to certain expense categories included in income statement line items. Specifically, entities are expected to provide tabular disclosures for prescribed categories such as inventory purchases, employee compensation, depreciation, and intangible asset amortization for each relevant expense caption. The standard also requires disclosure of total selling expenses and a definition of those expenses in annual filings. Any remaining amounts not quantitatively disclosed are expected to be described qualitatively. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption permitted, and the standard may be applied on a prospective or retrospective basis. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU No. 2025-06, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU makes targeted amendments to the accounting for and disclosure of software costs under ASC 350-40. The amendments modernize the guidance to reflect current software development practices, including nonlinear development approaches, and remove references to &#8220;development stages.&#8221; Under the ASU, the following two criteria must be met for entities to begin capitalizing software costs: (1) management, with the relevant authority, implicitly or explicitly authorizes and commits to funding a computer software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition threshold&#8221;). The ASU clarifies that this threshold would not be met when there is &#8220;significant uncertainty associated with the development activities of the software (referred to as &#8216;significant development uncertainty&#8217;).&#8221; The ASU is effective for all entities for annual reporting periods beginning after December 15, 2027, and for interim reporting periods within those fiscal years. Early adoption is permitted, and entities may apply the amendments prospectively, retrospectively, or using a modified prospective transition approach. We are currently evaluating the impact that this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU No. 2025-07,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration From a Customer in a Revenue Contract</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU expands the scope exceptions in the derivatives guidance to exclude certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties to the contract, including the occurrence or nonoccurrence of an event specific to those operations or activities. The ASU also clarifies that share-based noncash consideration received from a customer in exchange for goods or services should be accounted for as noncash consideration under ASC 606 unless and until the entity&#8217;s right to receive or retain such consideration becomes unconditional. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact that adoption of this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU No. 2025-10,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU establishes guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The guidance defines a government grant as a transfer of a monetary asset or a tangible nonmonetary asset from a government to a business entity other than in an exchange transaction and excludes transactions within the scope of other U.S. GAAP. Under the ASU, government grants are classified as either grants related to an asset or grants related to income, and recognition is permitted only when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The ASU permits alternative presentation approaches depending on the nature of the grant and requires disclosures regarding the nature of the grant, affected financial statement line items, and significant terms and conditions. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, including interim periods within those annual reporting periods. Early adoption is permitted, and the standard may be applied on a modified prospective, modified retrospective, or full retrospective basis. We are currently evaluating the impact of this new accounting standard and do not expect its adoption to have a material impact on our consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Product Sales<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Net Product Sales</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Net Product Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">_______</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Returns, rebates and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in prior periods</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in current period </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. Other Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of our original COVID vaccine, mRNA-1273. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of our original COVID vaccine, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8&#160;billion. All contract options have been exercised. The BARDA contract concluded on June 15, 2025, upon completion of all contractual deliverables. We accrued and recognized revenue through that date for eligible costs incurred in accordance with the agreement. As of December 31, 2025, the remaining available funding, net of revenue earned, was approximately $62&#160;million. While this funding remains available, we do not expect to recognize material additional revenue, as the contract has concluded and all obligations have been fulfilled. Final billing and closeout activities are ongoing and may result in immaterial adjustments to the recognized revenue amount.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2025, 2024 and 2023, we had collaboration agreements with Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and others. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to for further description of these collaboration agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Royalty Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we entered a non-exclusive out-licensing agreement with a pharmaceutical company based in Japan for mRNA COVID-related intellectual property for the territory of Japan. Under the terms of the agreement, we received an upfront payment of $50&#160;million, which included a $20&#160;million prepayment creditable against future royalties. Additionally, we are entitled to receive low double-digit royalties on the net sales of the company&#8217;s COVID product. Upon execution of the agreement, we recognized $30&#160;million of the upfront payment as other revenue in our consolidated statements of operations. The remaining $20&#160;million was recorded as deferred revenue in our consolidated balance sheets and recognized as royalty revenue as the underlying sales occurred. In accordance with the terms of the agreement, the $20&#160;million was fully recognized by the end of the first quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stand-Ready Manufacturing Revenue  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stand-ready manufacturing revenue relates to amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacities and support pandemic readiness.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16. Geographic Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaborators was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Other Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Net Product Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">_______</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Returns, rebates and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in prior periods</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in current period </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. Other Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of our original COVID vaccine, mRNA-1273. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of our original COVID vaccine, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8&#160;billion. All contract options have been exercised. The BARDA contract concluded on June 15, 2025, upon completion of all contractual deliverables. We accrued and recognized revenue through that date for eligible costs incurred in accordance with the agreement. As of December 31, 2025, the remaining available funding, net of revenue earned, was approximately $62&#160;million. While this funding remains available, we do not expect to recognize material additional revenue, as the contract has concluded and all obligations have been fulfilled. Final billing and closeout activities are ongoing and may result in immaterial adjustments to the recognized revenue amount.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2025, 2024 and 2023, we had collaboration agreements with Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and others. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to for further description of these collaboration agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Royalty Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we entered a non-exclusive out-licensing agreement with a pharmaceutical company based in Japan for mRNA COVID-related intellectual property for the territory of Japan. Under the terms of the agreement, we received an upfront payment of $50&#160;million, which included a $20&#160;million prepayment creditable against future royalties. Additionally, we are entitled to receive low double-digit royalties on the net sales of the company&#8217;s COVID product. Upon execution of the agreement, we recognized $30&#160;million of the upfront payment as other revenue in our consolidated statements of operations. The remaining $20&#160;million was recorded as deferred revenue in our consolidated balance sheets and recognized as royalty revenue as the underlying sales occurred. In accordance with the terms of the agreement, the $20&#160;million was fully recognized by the end of the first quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stand-Ready Manufacturing Revenue  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stand-ready manufacturing revenue relates to amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacities and support pandemic readiness.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16. Geographic Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaborators was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Research and Development Funding Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration Agreements and Research and Development Funding Arrangements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. Collaboration Agreements and Research and Development Funding Arrangement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck &#8211; Personalized mRNA Cancer Vaccines (Intismeran Autogene)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a Collaboration and License Agreement, which was subsequently amended in 2018, with Merck for the development and commercialization of personalized mRNA cancer vaccines (PCV), also known as Individualized Neoantigen Therapy (INT), which has been assigned the generic name intismeran autogene. This agreement was subsequently amended in 2018. Under the PCV Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching intismeran, providing manufacturing capacity and manufacturing intismeran and conducting Phase 1 and Phase 2 clinical trials for intismeran, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. We concluded that the collaboration arrangement was governed by the revenue recognition standard ASC 606. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option for intismeran, including mRNA-4157, under the terms of the agreement and in October 2022 paid us an option exercise fee of $250&#160;million. Following this exercise, the Merck Participation Term commenced, under which we and Merck collaborate on development and potential commercialization of PCV, with costs and any profits or losses generally shared equally on a worldwide basis, subject to certain exceptions as outlined in the agreement. During the development phase, we are primarily responsible for process development and the manufacture of intismeran materials, while Merck generally leads clinical trials. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the years ended December 31, 2025, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses, net of Merck's reimbursements, of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$407&#160;million, </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$390&#160;million, and $184&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> respectively, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related to the PCV collaboration under the Merck Participation Term. Additionally, the net cost recovery for capital expenditures during the same periods were $24&#160;million, $109&#160;million, and $102&#160;million, respectively, which were applied to reduce the capitalized cost of the assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development and Commercialization Funding Arrangement with Blackstone Life Sciences (Blackstone)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we entered into a development and commercialization funding arrangement with Blackstone, under which Blackstone has committed to providing up to $750&#160;million in funding to us. This funding supports the development of our investigational mRNA-based influenza vaccine. Contingent upon regulatory approval in the U.S. and only if the approval is dependent on data from the funded activities, Blackstone will be entitled to receive low single-digit percentage royalties and up to $750&#160;million in sales milestone payments. These payments are based on net sales of our future influenza and combination vaccines, with sales milestone payments contingent upon achieving specified cumulative net sales targets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Given the substantive transfer of financial risk to Blackstone, we account for this arrangement as an obligation to conduct research and development activities. The funding is recognized as a reduction to the expenses of our mRNA-based influenza program. This reduction is recognized proportionally as the related costs are incurred, based on an input method. For the year ended December 31, 2025 and 2024, we recorded research and development expense reductions of $340&#160;million and $267&#160;million, respectively. As of December 31, 2025 and 2024, we had a research and development funding liability of $43&#160;million and $58&#160;million, respectively, related to the advance funding received from Blackstone.</span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vertex &#8211; Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period, leveraging our platform technology and mRNA delivery expertise along with Vertex&#8217;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. This collaboration arrangement is accounted for under ASC 606 and currently ongoing. </span></div><div style="padding-right:11.25pt"><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immatics &#8211; Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into a strategic collaboration with Immatics to jointly discover and develop T cell-redirecting cancer immunotherapies. Upon effectiveness of the agreement in October 2023, we made an upfront payment of $120&#160;million, recognized as research and development expense. Immatics is also eligible for research funding, milestone payments, tiered royalties on global net sales of TCER</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> products and certain vaccine products that are commercialized under the agreement. Additionally, Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. Financial Instruments and Fair Value Measurements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, and available-for-sale securities by significant investment category at December 31, 2025 and 2024 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2025 and 2024 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the&#160;years ended December 31, 2025, 2024, and 2023. We did not recognize any credit-related allowance to available-for-sale securities as of December 31, 2025 and 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2025 and 2024 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2025:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2024:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025 and 2024, we held 108 and 252 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and 2024 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,925&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-813">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,015&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-844">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and 2024, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2025, 2024 and 2023, we recognized net losses of $8&#160;million, $52&#160;million and $35&#160;million, respectively, on equity investments from changes in fair value of the securities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our term loan using Level 2 inputs. The fair value of the term loan approximates its carrying value as of December 31, 2025, because the instrument bears interest at a variable rate that reflects current market rates. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_2066" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, as of December 31, 2025 and 2024 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the years ended December 31, 2025, 2024, and 2023, inventory write-downs were $291&#160;million, $495&#160;million, and $2.2&#160;billion, respectively. For the years ended December 31, 2025, 2024, and 2023, losses on firm purchase commitments were $24&#160;million, $60&#160;million, and $141&#160;million, respectively. Inventory write-downs were mainly related to inventory in excess of expected demand and shelf-life expiration. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These charges in 2025 and 2024 were primarily driven by the continued operation of the COVID vaccine market as a seasonal market, along with a decline in overall customer demand and excess inventory. Forecasting demand for COVID vaccines requires advance production planning ahead of each season, including production of multiple COVID vaccine products, which resulted in excess inventory and capacity as actual demand differed from forecasted demand. The higher charges in 2023 primarily reflect our strategic initiative to resize its manufacturing cost structure in response to the transition to an endemic seasonal COVID vaccine market. In the third quarter of 2023, we completed our long-range financial planning process, incorporating revised forecasts of vaccination rates. This resulted in the reassessment of future demand for our COVID vaccine, leading to a strategic initiative to resize our manufacturing cost structure. This initiative, launched in the same quarter, involved reassessing our inventory levels and renegotiating with our suppliers to reduce our purchase commitments related to raw materials which were not expected to be consumed before expiration. This initiative resulted in a raw materials write-down of $903&#160;million, included in the total inventory write-down amount for the quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and December 31, 2024, the accrued liability for losses on firm future purchase commitments in our consolidated balance sheets was $5&#160;million and $60&#160;million, respectively. As of December 31, 2025 and December 31, 2024, we had inventory on hand of $267&#160;million and $267&#160;million, respectively, inclusive of inventory for our COVID and RSV vaccines. Our raw materials and work-in-progress inventory have variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of Spikevax, our original COVID vaccine, is <span style="-sec-ix-hidden:f-874">nine</span> to twelve months. mNEXSPIKE has a shelf life of twelve months. The shelf life of mRESVIA, our RSV vaccine, is eighteen months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. Property, Plant and Equipment, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the&#160;years ended December 31, 2025, 2024, and 2023 was $211&#160;million, $185&#160;million, and $617&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Components</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. Other Balance Sheet Components</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Wholesalers chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for doubtful accounts </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments related to manufacturing and materials</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income tax</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consisted of raw materials with an anticipated consumption beyond one year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provisions related to product sales (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on future firm purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_175" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Estimated reimbursements to wholesalers and distributors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development funding liability (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Non-Current Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2039. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We have two main campuses in Massachusetts, our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters, and our Moderna Technology Center (MTC), located in Norwood. In addition, we own and lease facilities, including office, laboratory, and manufacturing sites, in various locations globally to support our research, development, manufacturing, and business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Science Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Cambridge campus previously included multiple leased properties at Technology Square and the MSC, a facility comprising approximately 462,000 square feet, that serves as our principal executive office, along with additional office and laboratory spaces. The MSC lease commenced during the third quarter of 2023 and has a term of 15 years, with options for two additional seven-year extensions. During the fourth quarter of 2023, we amended the expiration dates of our Technology Square leases to conclude in January 2025, as we transitioned operations to the MSC. As of December 31, 2024, we substantially exited our leased spaces at Technology Square, completing the consolidation of our Cambridge operations into the MSC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The MTC is a multiple-building campus spanning approximately 722,000 square feet. that previously operated under long-term finance leases expiring in 2042, with options for three five-year extensions. The MTC has been a critical facility for our manufacturing, laboratory, and office operations. In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings, for a total purchase price of $385&#160;million. Upon acquisition, we derecognized the right-of-use assets and lease liabilities associated with the Norwood leases. The purchase price, after adjustments related to lease terminations, was allocated to land and buildings, with approximately $231&#160;million recorded as property, plant, and equipment on our consolidated balance sheets as of December 31, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1024"><span style="-sec-ix-hidden:f-1025"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1030"><span style="-sec-ix-hidden:f-1031"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1034"><span style="-sec-ix-hidden:f-1035"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:59.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:63.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability derecognized upon purchase of underlying leased asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2039. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We have two main campuses in Massachusetts, our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters, and our Moderna Technology Center (MTC), located in Norwood. In addition, we own and lease facilities, including office, laboratory, and manufacturing sites, in various locations globally to support our research, development, manufacturing, and business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Science Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Cambridge campus previously included multiple leased properties at Technology Square and the MSC, a facility comprising approximately 462,000 square feet, that serves as our principal executive office, along with additional office and laboratory spaces. The MSC lease commenced during the third quarter of 2023 and has a term of 15 years, with options for two additional seven-year extensions. During the fourth quarter of 2023, we amended the expiration dates of our Technology Square leases to conclude in January 2025, as we transitioned operations to the MSC. As of December 31, 2024, we substantially exited our leased spaces at Technology Square, completing the consolidation of our Cambridge operations into the MSC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The MTC is a multiple-building campus spanning approximately 722,000 square feet. that previously operated under long-term finance leases expiring in 2042, with options for three five-year extensions. The MTC has been a critical facility for our manufacturing, laboratory, and office operations. In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings, for a total purchase price of $385&#160;million. Upon acquisition, we derecognized the right-of-use assets and lease liabilities associated with the Norwood leases. The purchase price, after adjustments related to lease terminations, was allocated to land and buildings, with approximately $231&#160;million recorded as property, plant, and equipment on our consolidated balance sheets as of December 31, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1024"><span style="-sec-ix-hidden:f-1025"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1030"><span style="-sec-ix-hidden:f-1031"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1034"><span style="-sec-ix-hidden:f-1035"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:59.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:63.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability derecognized upon purchase of underlying leased asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Agreement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. Credit Agreement </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we entered into a Credit and Guaranty Agreement (the Credit Agreement) with lenders led by Ares Capital Corporation, as administrative agent. The Credit Agreement provides for a senior secured term loan facility with aggregate term loan commitments of $1.5 billion, consisting of a $600 million initial term loan, which was funded at closing, and $900 million of delayed draw term loan commitments. The initial term loan matures on November 24, 2030. The delayed draw term loan commitments consist of (1) a $400 million delayed draw term loan facility (DDTL-1), which is available, subject to customary conditions, through November 24, 2027, and (2) a $500 million delayed draw term loan facility (DDTL-2), which is available, subject to customary conditions and the achievement of specified regulatory approval milestones for certain product candidates, through November 24, 2028. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest at a variable rate equal to, at our option, (i) Term SOFR plus a margin of 5.50% or (ii) a base rate plus a margin of 4.50%. The base rate is calculated as the highest of (a) the Wall Street Journal prime rate, (b) the federal funds rate plus one half of one percent and (c) Term SOFR plus one percent. We are also required to pay commitment fees on the undrawn portions of DDTL-1 and DDTL-2. The interest rate applicable to the initial term loan was approximately 9.38% as of December 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the Credit Agreement are guaranteed by certain of our subsidiaries and are secured by a first-priority lien on substantially all of our assets, in each case subject to customary exceptions and limitations. The Credit Agreement is subject to compliance with customary representations and warranties, affirmative covenants, restrictive covenants and events of default. The restrictive covenants, subject to specified limitations and exceptions, limit, among other things, our ability to incur additional indebtedness and liens, make certain investments, engage in certain fundamental changes, dispose of assets and make restricted payments. Events of default under the Credit Agreement include, among others, nonpayment of principal, interest or other amounts when due, failure to comply with covenants (subject to applicable notice and cure periods), breaches of certain representations and warranties, the occurrence of certain significant adverse events and certain insolvency-related events. The Credit Agreement also includes a financial covenant requiring us to maintain minimum cash and cash equivalents (as defined in the Credit Agreement, which primarily consist of our cash, cash equivalents, and available-for-sale securities) as of the last business day of each week of at least $500&#160;million, increasing to $750&#160;million if more than $1.0&#160;billion is drawn under the Credit Agreement. The financial covenant is not required to be tested at any time that the trailing 30-day average market capitalization of the Company exceeds $5.0&#160;billion and is subject to a customary equity cure. As of December 31, 2025, we were in compliance with the applicable terms and covenants under the Credit Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, the initial term loan had an outstanding principal balance of $600 million and a carrying amount of $590 million, net of unamortized original issue discount and debt issuance costs, which was classified as long-term debt in our consolidated balance sheet. No amounts had been drawn under DDTL-1 or DDTL-2. The principal amount of $600 million is due in full at maturity, and no principal payments are required prior to that date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. Commitments and Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal proceedings and claims. Accruals are recognized for legal matters when a loss is both probable and reasonably estimable. As of December 31, 2025, no material contingent liabilities have been recognized. If a material loss is reasonably possible and we can estimate the amount or range of the loss, we disclose such information. Unless otherwise noted, either the outcome of these matters is not expected to be material, or the potential loss cannot be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be a party to litigation, arbitration, or other legal proceedings in the course of our business. The outcome of such matters is inherently uncertain and often involves significant judgment in assessing risk and estimating potential exposure. While we do not currently expect any pending proceedings to have a material adverse effect on our financial position, results of operations, or cash flows, there can be no assurance that future developments will not have a material impact.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our significant legal proceedings and matters outstanding as of December 31, 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have brought patent-infringement actions against Pfizer Inc. (Pfizer), BioNTech SE (BioNTech) and related entities in the U.S. District Court for the District of Massachusetts, Germany, the Netherlands, the UK, Ireland and Belgium concerning our mRNA platform technology and disease-specific vaccine designs. Pfizer and BioNTech have commenced actions or asserted defenses seeking to revoke our patents in these jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) have brought patent-infringement actions against us in the U.S. District Court for the District of Delaware, as well as in Canada, Japan, Switzerland and the Unified Patent Court (UPC) asserting patents concerning lipid nanoparticles. Arbutus and Genevant are seeking judgment of infringement of the asserted patents and monetary damages. The U.S. case has set trial to begin March 9, 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GlaxoSmithKline Biologicals SA (GSK) has filed two complaints against us in the U.S. District Court for the District of Delaware asserting certain patents owned by GSK. GSK has filed two patent-infringement lawsuits against us in the UPC and two complaints in Spain concerning liposomes and modified liposomes for RNA delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Northwestern University has filed a complaint against us in the U.S. District Court for the District of Delaware asserting U.S. patents concerning lipid nanoparticle technology.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Bayer CropSciences LLC, Monsanto Company, and Monsanto Technology, LLC have filed a complaint in U.S. District Court for the District of Delaware asserting a U.S. patent directed to methods of modifying gene sequences.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mNG Bio, LLC has filed a complaint against us in U.S District Court for the District of Massachusetts asserting a U.S. patent directed to a yellow-green fluorescent protein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE has filed a complaint against us in the U.S. District Court for the District of Delaware asserting a U.S. patent directed to modified mRNA compositions encoding a spike protein fragment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachusetts related to statements about our RSV vaccine (mRNA-1345).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business collaborators, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2025 and 2024, we had not experienced any significant losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2025, we had $411&#160;million of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. This amount includes $5&#160;million of the purchase commitments related to raw materials that was recorded as an accrued liability for loss on future firm purchase commitments. As of December 31, 2025, we had $1.0&#160;billion of non-cancelable purchase commitments related to research and development and other goods and services which are expected to be paid through 2032. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind-down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2025, we had cancelable open purchase orders of approximately $1.8 billion, reflecting amounts associated with our significant vendor arrangements, under such agreements for our clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2025, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related net product sales in the period in which the corresponding sales occur. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, we entered into a non-exclusive patent license agreement with NIAID to license certain patent rights related to the development of mRNA-based vaccines for the prevention or treatment of RSV infection. Upon execution of the agreement, we made a total payment of $10&#160;million, which was capitalized as an intangible asset and is amortized to cost of sales on a straight-line basis over the estimated useful life of the licensed patents. In addition, we are obligated to pay low single-digit royalties on future net sales of licensed products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2025, 2024, and 2023 we recognized $88&#160;million, $155&#160;million, and $301&#160;million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.</span></div>Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of December 31, 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation and Share Repurchase Programs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13. Stock-Based Compensation and Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Incentive Plan (the 2016 Equity Plan). The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Equity Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may grant to employees, non-employee directors, consultants and independent advisors equity-based awards during their period of service, generally in the form of stock options, restricted stock units, and performance stock units. The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vest in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December 31, 2025, we had a total of&#160;62 million shares reserved for future issuance under our Equity Plans, of which 38 million shares were reserved for equity awards previously granted, and&#160;24 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Exchange Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2025, we commenced an offer to exchange certain eligible stock options held by eligible employees of the Company for new stock options (the &#8220;Exchange Offer&#8221;). Executive officers and members of our Board of Directors were not eligible to participate. The Exchange Offer expired on December 12, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Exchange Offer, 2,864 eligible employees elected to exchange, and we accepted for cancellation, eligible stock options to purchase an aggregate of 4,289,694 shares of our common stock, representing approximately 80% of the total shares of common stock underlying eligible options. Immediately following the expiration of the Exchange Offer, we granted replacement stock options to purchase an aggregate of 1,653,121 shares of our common stock. The exercise price of the replacement stock options was $29.46 per share, which was the closing price of our common stock on December 12, 2025. The replacement stock options are subject to new vesting schedules based on continued service.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of stock options resulted in an immaterial incremental stock-based compensation expense, calculated using a lattice option pricing model, which will be recognized together with any unrecognized compensation cost remaining on the exchanged options over the remaining requisite service period of the modified awards.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during the year ended December 31, 2025:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6.71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $19 million, $122 million, and $413 million for the&#160;years ended December 31, 2025, 2024, and 2023, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $2&#160;million, $24&#160;million, and $84&#160;million&#160;during the years ended December 31, 2025, 2024, and 2023, respectively. The total consideration recorded as a result of stock option exercises&#160;was approximately $17 million, $42 million, and $25&#160;million, respectively,&#160;for&#160;the years ended December 31, 2025, 2024, and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2025:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:72.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.836%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6.81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">63.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of RSUs and PSUs vested during the years ended December 31, 2025, 2024, and 2023, was $434 million, $228 million, and $99 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2025, 2024, and 2023, was $186&#160;million, $161&#160;million and $120&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During 2025, 2024 and 2023, we granted an immaterial amount of PSUs, respectively, primarily to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for options granted under our Equity Plans (excluding options issued in connection with the Exchange Offer) is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for the&#160;years ended December 31, 2025, 2024, and 2023 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.54 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">49.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">57.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2025, 2024, and 2023 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2025, 2024, and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, there were $633 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.1 years at December 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2022, our Board of Directors authorized a share repurchase program of our common stock for up to $3.0&#160;billion, with no expiration date. On August 1, 2022, our Board of Directors authorized an additional $3.0&#160;billion under the repurchase program, with no expiration date (collectively with the February 22, 2022 authorization, the 2022 Repurchase Programs). As of December 31, 2025, $1.7&#160;billion of our Board of Directors&#8217; authorization for repurchases of our common stock remains outstanding under the 2022 Repurchase Programs, with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to our share repurchase programs (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">143.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining authorization at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">14. Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,655)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,768)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,607)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax amount and rate to our effective tax rate for the year ended December 31, 2025 was as follows (in millions, except percentages):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax, net of federal income tax effect</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax effects</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall/shortfall</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in unrecognized tax benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate reconciliation for the year ended December 31, 2025 is presented in accordance with ASU 2023-09, while the effective tax rate reconciliations for the years ended December 31, 2024 and 2023 have not been recast and continue to be presented under the prior guidance. As a result of the adoption of ASU 2023-09, certain items in the effective tax rate reconciliation may have been reclassified between categories compared to prior periods; however, such reclassifications did not have a material impact on any individual line items or the overall effective tax rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2024 and 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall/shortfall</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the year ended December 31, 2025 was (2.0)% and was higher than the federal statutory tax rate, primarily due to our global valuation allowance, which limits our ability to recognize tax benefits from the loss. The higher effective tax rate was also impacted by certain of our foreign subsidiaries that have taxable income, while we incurred a net loss before income taxes in other jurisdictions. For the year ended December 31, 2024, the effective tax rate was lower than the federal statutory tax rate as a result of an increase in valuation allowance against deferred tax assets, which limited the recognition of tax benefits on our pre-tax loss. The tax benefits from research and development credits provided a partial offset. For the year ended December 31, 2023, despite being in a pre-tax loss position, our effective tax rate exceeded the federal statutory tax rate, primarily due to the establishment of a valuation allowance against the majority of the deferred tax assets, which resulted in a net tax expense rather than a benefit. This was partially offset by tax benefits from research and development credits and stock-based compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2025, income taxes paid, net of refunds, by jurisdiction were immaterial both individually and in the aggregate and, accordingly, have not been separately disclosed.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2025 and 2024 were as follows </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:77.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve and capitalization </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. During 2023, following the completion of our long-range financial planning process, we reassessed the evidence and concluded that a valuation allowance was necessary due to the preponderance of negative evidence, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pre-tax loss for the full year 2023, serving as a significant source of objectively verifiable negative evidence in accordance with ASC 740 (Income Taxes).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A projected three-year cumulative loss resulting from our long-range financial planning process. This projection was due to a significant decrease in expected sales of our COVID vaccine as we transitioned to a seasonal market. Additionally, we anticipated substantial research and development expenses for our on-going Phase 3 clinical trials and to advance our product candidates into later-stage development. These factors contributed additional negative evidence with respect to the realizability of our deferred tax assets. The projections were based upon revenue from our approved drug product, which we believe can be reasonably estimated. In contrast, future taxable income projections from our investigational medicines are deemed inherently subjective and not objectively verifiable; they are insufficient to override negative evidence, and therefore, they were not assigned any weight in our valuation allowance analysis assessment.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our evaluation also included whether there were other sources of taxable income that would allow us to realize our deferred tax assets, such as taxable income in carryback years, available tax planning strategies and the future reversals of taxable temporary differences. After assessing these strategies and all evidence, we determined it was more likely than not that we will not realize all of our deferred tax assets and therefore increased the valuation allowance by $2.1&#160;billion during 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025 and 2024, we continued to maintain a global valuation allowan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ce against the majority of our de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ferred tax assets, consistent with the assessment established in 2023. The valuation allowance reflects the ongoing preponderance of negative evidence, including continued and projected losses. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2025, we had $4.1 billion, $3.3 billion, and $89 million of federal, state and foreign net operating loss carryforwards, respectively, of which $4.1 billion, $1.6 billion, and $89 million respectively, will not expire and $1.7 billion of state net operating loss carryforwards will begin to expire in 2032. At December 31, 2025, we also had federal and state research and development tax credit carryforwards of $111 million and $208 million, respectively, the majority of which will begin to expire in 2030.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2025, 2024, and 2023 were as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with tax authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we had $241 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We file</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> income tax returns in U.S. and various state, local and foreign jurisdictions. The income tax returns of all material taxing jurisdictions remain open to tax examination for all tax years since our date of incorporation for those jurisdictions. We have federal, state, and foreign carryforward attributes generated in past years which may be adjusted upon examination. As of December 31, 2025, we are under audit in various U.S., and foreign jurisdictions; however, no adjustments to our tax positions have been proposed at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">15. Loss per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2025, 2024 and 2023 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:61.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted EPS</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12.33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2025, 2024 and 2023, were excluded from the calculation of diluted EPS attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Geographic Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. Net Product Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">_______</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Returns, rebates and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in prior periods</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in current period </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. Other Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of our original COVID vaccine, mRNA-1273. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of our original COVID vaccine, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8&#160;billion. All contract options have been exercised. The BARDA contract concluded on June 15, 2025, upon completion of all contractual deliverables. We accrued and recognized revenue through that date for eligible costs incurred in accordance with the agreement. As of December 31, 2025, the remaining available funding, net of revenue earned, was approximately $62&#160;million. While this funding remains available, we do not expect to recognize material additional revenue, as the contract has concluded and all obligations have been fulfilled. Final billing and closeout activities are ongoing and may result in immaterial adjustments to the recognized revenue amount.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2025, 2024 and 2023, we had collaboration agreements with Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and others. See </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to for further description of these collaboration agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Royalty Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we entered a non-exclusive out-licensing agreement with a pharmaceutical company based in Japan for mRNA COVID-related intellectual property for the territory of Japan. Under the terms of the agreement, we received an upfront payment of $50&#160;million, which included a $20&#160;million prepayment creditable against future royalties. Additionally, we are entitled to receive low double-digit royalties on the net sales of the company&#8217;s COVID product. Upon execution of the agreement, we recognized $30&#160;million of the upfront payment as other revenue in our consolidated statements of operations. The remaining $20&#160;million was recorded as deferred revenue in our consolidated balance sheets and recognized as royalty revenue as the underlying sales occurred. In accordance with the terms of the agreement, the $20&#160;million was fully recognized by the end of the first quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stand-Ready Manufacturing Revenue  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stand-ready manufacturing revenue relates to amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacities and support pandemic readiness.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16. Geographic Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaborators was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mrna_StephenHogeMember', window );">Stephen Hoge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Stephen Hoge, our President, has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 223,357 shares and another option to purchase 96,660 shares (the Hoge Expiring Options). On November 13, 2025, Dr. Hoge adopted a trading arrangement that is intended to satisfy the affirmative defense of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Rule 10b5-1(c) (the Hoge 10b5-1 Plan). Between February 23, 2026 and August 10, 2026, the Hoge 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Hoge Expiring Options, which represent up to 320,017 shares of the Company&#8217;s common stock in the aggregate. The Hoge 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Stephen Hoge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 13, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">August 10, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">270 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">320,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=mrna_TerminationOfTradingArrangementMember', window );">Termination of Trading Arrangement [Member] | Stephane Bancel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">On November 23, 2025, St&#233;phane Bancel, our Chief Executive Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c), which had been entered into on September 3, 2025, and was scheduled to commence as early as December 17, 2025, with a termination date of August 10, 2026. The plan provided for the potential sale of up to 1,439,788 shares of common stock. No shares of common stock were sold under the plan prior to its termination.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">St&#233;phane Bancel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">November 23, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,439,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementMember', window );">Adoption of Trading Arrangement [Member] | Stephane Bancel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">Mr. Bancel has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 558,394 shares and another option to purchase 193,321 shares (the Bancel Expiring Options). Mr. Bancel intends to contribute all of the after-tax proceeds from the exercise and sale of the Bancel Expiring Options to charitable causes. On November 28, 2025, Mr. Bancel adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between May 13,2026 and August 10, 2026, the Bancel 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Bancel Expiring Options, which represent up to 751,715 shares of the Company&#8217;s common stock in the aggregate. The Bancel 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mr. Bancel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 28, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">August 10, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">255 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">751,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions1Member', window );">Adoption of Trading Arrangement, Options 1 [Member] | Stephane Bancel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">558,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions1Member', window );">Adoption of Trading Arrangement, Options 1 [Member] | Stephen Hoge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">223,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions2Member', window );">Adoption of Trading Arrangement, Options 2 [Member] | Stephane Bancel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">193,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions2Member', window );">Adoption of Trading Arrangement, Options 2 [Member] | Stephen Hoge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">96,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mrna_StephenHogeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mrna_StephenHogeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=mrna_TerminationOfTradingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=mrna_TerminationOfTradingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mrna_StephaneBancelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mrna_StephaneBancelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=mrna_AdoptionOfTradingArrangementOptions2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity organization&#8217;s mission is to provide a targeted set of services, support and capabilities to reduce the risk of cyberattacks, rapidly detect and contain threats, and mitigate risks to critical data.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Recognizing the threat of security breaches and cyberattacks globally, we have developed a cybersecurity program, overseen by our Chief Technology and Information Security Officer (CISO), that is designed to protect patient trust, defend the Moderna brand, and reduce the risk and impact of cyber-attacks. Our cybersecurity program is informed by industry standards and includes periodic risk assessments and security testing supported by cybersecurity technologies, including third-party security solutions, vulnerability management, and monitoring tools, designed to monitor, identify, and manage risks from cyber threats. In addition, we have implemented employee security and awareness training. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management has established a cyber incident response plan (CIRP) designed to assess, identify and manage risks from cybersecurity threats and enable prompt response in the event that a cybersecurity incident is detected. We have a process in place for notification to our leadership response team in the event of a significant cyber incident, and for escalation of these events to our Audit Committee and Board, as appropriate. To date, we have not experienced a cybersecurity incident that has had a material impact on our business strategy, results of operations, or financial condition.</span></div>We undergo several annual internal compliance audits and external reviews to evaluate our controls, including cybersecurity controls. In an effort to minimize third-party risk, we have established a process to assess the security practices of third-party suppliers and related risks, including through review of relevant supplier certifications and security and responses to standardized information gathering (SIG) questionnaires, as applicable and appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Recognizing the threat of security breaches and cyberattacks globally, we have developed a cybersecurity program, overseen by our Chief Technology and Information Security Officer (CISO), that is designed to protect patient trust, defend the Moderna brand, and reduce the risk and impact of cyber-attacks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors oversees Moderna&#8217;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee receives cyber-related updates from management, including our CISO at committee meetings. During meetings, our CISO updates the committee on Moderna&#8217;s cybersecurity posture, potential threats and risk mitigation strategies, and the progress of the Company&#8217;s cybersecurity initiatives, as appropriate. The Chair of the Audit Committee and management provide regular briefings on such matters to the full Board of Directors, as appropriate. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board of Directors oversees Moderna&#8217;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors oversees Moderna&#8217;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff. </span></div>The Audit Committee receives cyber-related updates from management, including our CISO at committee meetings. During meetings, our CISO updates the committee on Moderna&#8217;s cybersecurity posture, potential threats and risk mitigation strategies, and the progress of the Company&#8217;s cybersecurity initiatives, as appropriate. The Chair of the Audit Committee and management provide regular briefings on such matters to the full Board of Directors, as appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">The Company operates as a single operating and reportable segment, reflecting the integrated nature of our business focused on the research, development, and commercialization of mRNA-based medicines. Our Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), responsible for assessing the Company's performance and making resource allocation decisions. The CODM evaluates financial information on a consolidated basis, focusing on key metrics such as total revenue, operating expenses, and net income or loss, which is our reported measure of segment profit or loss. The CODM allocates resources based on the Company's available cash resources, forecasted cash flow, and expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities. Resource allocation decisions are informed by budgeted and forecasted expense information, along with actual expenses incurred to date. Disaggregated profit or loss information at the program or functional level is not regularly provided to or relied upon by the CODM, as our integrated operating model emphasizes shared resources and centralized decision-making. The interdependent nature of our research, development, and commercialization activities, supported by common infrastructure such as our mRNA platform, makes further disaggregation of expenses less meaningful for assessing performance. Additionally, there are no segment managers accountable for operations, operating results, and planning for levels or components below the consolidated unit level.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net <span id="ice4d497822074fb680bb6adb64870e63_40370"></span>Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations.  In the U.S., our COVID vaccine and RSV vaccine are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, government rebates, and other related deductions. These provisions are recorded based on contractual terms, our estimate of returns for product sold during the period, and other relevant considerations, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wholesaler chargebacks, discounts and fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our vaccines are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, projected market demand, and our historical experience with returns. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates and other fees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets. In 2024, we began recognizing Medicare rebates associated with our RSV product. The estimation of Medicare rebates requires judgment and is based on historical utilization trends, and the mix of customers and payers. The estimated liability for unpaid or unbilled rebates is presented as accrued liabilities on our consolidated balance sheets. For 2024 and 2025, the product sales subject to Medicare rebates were immaterial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control, such as the limited historical data, constrained third-party information, and evolving market dynamics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now have two years of data on our product returns, this remains limited and subject to significant variability given current market conditions. We will continue to refine our projections as additional information becomes available. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue consists primarily of grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing and Royalty Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License revenue is recognized when the license is granted to the licensee, provided no significant performance obligations remain. Royalty revenue is recognized based on sales by licensees when the underlying sales occur, in accordance with the terms of the licensing agreement and when collectibility is reasonably assured.</span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stand-Ready Manufacturing Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into long-term strategic agreements with government entities to establish domestic mRNA manufacturing capabilities and support pandemic readiness. Under these agreements, we are required to build and maintain manufacturing facilities and to supply vaccines in accordance with minimum spend commitments or annual demand forecasts established by the respective governments. A portion of the total consideration under each agreement is allocated to a stand-ready obligation to maintain manufacturing readiness and is recognized as other revenue on a straight-line basis over the contractual period. The remaining consideration is related to our obligation to supply vaccines and will be recognized as product sales when control of the vaccines transfers upon delivery.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific-identification method, and are included in other income (expense), net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument&#8217;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Available-for-sale securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other income (expense), net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other income (expense), net, in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (see our &#8220;Revenue Recognition&#8221; policy within </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span> for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable, net related to our net product sales and other revenue. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Significant Customers</a></td>
<td class="text">Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, stand-ready manufacturing revenue from international government entities, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable debt securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;6</a></span>). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value, with cost determined principally using first-in, first-out method. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-launch Inventory </span></div>Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2025 and 2024, we did not have any capitalized pre-launch inventory on our consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and permanent land improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Limited-life land improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Determined on a project-by-project basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5-12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div>Construction in progress includes direct costs related to the construction of various property, plant and equipment, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. </span></div>Finite-lived intangible assets primarily consist of acquired intellectual property and regulatory approval and commercial sales milestone payments. These assets are recorded at cost, net of accumulated amortization, and amortized on a straight-line basis over their estimated useful lives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets</a></td>
<td class="text">We evaluate our long-lived assets, which consist of property, plant and equipment, finite-lived intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are initially measured as the lease liability plus direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaborator are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). See our "Revenue Recognition" policy within </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaborator, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock', window );">Research and Development Funding Arrangements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into research and development funding arrangements to support a targeted programs, under which a third party has committed to fund us up to a specified amount. Contingent upon the regulatory approval of the program, we are obligated to pay certain milestones and royalties as outlined in the respective agreements. We account for funding received under research and development arrangements as a reduction to expenses when substantive financial risk is transferred to the funding party. These arrangements are accounted for as an obligation to conduct research and development activities. The funding is recognized proportionally as the related costs are incurred, using an input method. Contingent payments, such as milestones or royalties, will be recognized separately upon achievement of the related conditions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. </span></div>Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation&#8212;Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2025, we estimated the expected term of our stock options using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. During 2025, we used historical exercise data in estimating the expected term of stock options, utilizing a methodology that combines historical settlement data with a hypothetical settlement pattern for outstanding options, based on estimated time to arrival at-the-money and adjusted for employee departure rates. The change in methodology used during 2025 did not have a material impact on stock-based compensation and our financial statements. However, during the fourth quarter of 2025, in connection with our stock option exchange program (see </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_199" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), which resulted in changes to our stock option population, we determined that we no longer have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, as such data is no longer indicative of future exercise patterns. Accordingly, beginning in 2026, we will estimate the expected term of stock options using the simplified method. We will continue to apply this process until a sufficient amount of historical information regarding the expected term becomes available and we believe that historical experience is relevant to our expectations for current grants. The expected volatility is based on our stock price volatility and incorporates both historical volatility of our stock price and implied volatility derived from the price of exchange traded options on our stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted stock units, performance stock units, stock options, and shares under the employee stock purchase plan that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments, derivatives designated as hedging instruments, and foreign currency translation, as well as, pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Share Repurchases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early adoption is permitted. We adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_205" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 14</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Income Taxes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires entities to disclose, on an annual and interim basis, disaggregated information in the footnotes related to certain expense categories included in income statement line items. Specifically, entities are expected to provide tabular disclosures for prescribed categories such as inventory purchases, employee compensation, depreciation, and intangible asset amortization for each relevant expense caption. The standard also requires disclosure of total selling expenses and a definition of those expenses in annual filings. Any remaining amounts not quantitatively disclosed are expected to be described qualitatively. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption permitted, and the standard may be applied on a prospective or retrospective basis. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU No. 2025-06, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU makes targeted amendments to the accounting for and disclosure of software costs under ASC 350-40. The amendments modernize the guidance to reflect current software development practices, including nonlinear development approaches, and remove references to &#8220;development stages.&#8221; Under the ASU, the following two criteria must be met for entities to begin capitalizing software costs: (1) management, with the relevant authority, implicitly or explicitly authorizes and commits to funding a computer software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition threshold&#8221;). The ASU clarifies that this threshold would not be met when there is &#8220;significant uncertainty associated with the development activities of the software (referred to as &#8216;significant development uncertainty&#8217;).&#8221; The ASU is effective for all entities for annual reporting periods beginning after December 15, 2027, and for interim reporting periods within those fiscal years. Early adoption is permitted, and entities may apply the amendments prospectively, retrospectively, or using a modified prospective transition approach. We are currently evaluating the impact that this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU No. 2025-07,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration From a Customer in a Revenue Contract</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU expands the scope exceptions in the derivatives guidance to exclude certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties to the contract, including the occurrence or nonoccurrence of an event specific to those operations or activities. The ASU also clarifies that share-based noncash consideration received from a customer in exchange for goods or services should be accounted for as noncash consideration under ASC 606 unless and until the entity&#8217;s right to receive or retain such consideration becomes unconditional. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact that adoption of this new accounting standard will have on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the FASB issued ASU No. 2025-10,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU establishes guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The guidance defines a government grant as a transfer of a monetary asset or a tangible nonmonetary asset from a government to a business entity other than in an exchange transaction and excludes transactions within the scope of other U.S. GAAP. Under the ASU, government grants are classified as either grants related to an asset or grants related to income, and recognition is permitted only when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The ASU permits alternative presentation approaches depending on the nature of the grant and requires disclosures regarding the nature of the grant, affected financial statement line items, and significant terms and conditions. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, including interim periods within those annual reporting periods. Early adoption is permitted, and the standard may be applied on a modified prospective, modified retrospective, or full retrospective basis. We are currently evaluating the impact of this new accounting standard and do not expect its adoption to have a material impact on our consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Funding Arrangements, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span>Included in other non-current assets in the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span>Included in other non-current assets in the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:50.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;<br/>Accounts&#160;Receivable<br/>December&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">FFF Enterprises</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Public Works and Government Services Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom Health Security Agency</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mexico Medistik</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Boryung Biopharma Korea</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan Food and Drug Administration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ministry of Health, Labor, and Welfare of Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text">The estimated useful lives of property, plant and equipment are described below:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and permanent land improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Limited-life land improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Determined on a project-by-project basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5-12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Components of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive loss for the years ended December 31, 2025 and 2024 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gains on Available-for-Sale Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Postretirement Obligation Adjustments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses (gains) on Foreign Currency Translation </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaborators was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">_______</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Returns, rebates and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in prior periods</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in current period </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by product were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Includes sales of Spikevax and mNEXSPIKE.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes product sales provision for the periods presented (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales provision:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns, rebates and other fees </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales provision</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">_______</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licensing and royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stand-ready manufacturing revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, and available-for-sale securities by significant investment category at December 31, 2025 and 2024 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2025 and 2024 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2025 and 2024 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2025:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2024:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and 2024 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,925&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-813">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,015&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-844">Derivative instruments</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, as of December 31, 2025 and 2024 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text">The estimated useful lives of property, plant and equipment are described below:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and permanent land improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Limited-life land improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Determined on a project-by-project basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5-12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Wholesalers chargebacks, discounts and fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for doubtful accounts </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments related to manufacturing and materials</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income tax</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Assets, Noncurrent</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Down payments and prepayments, non-current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>Consisted of raw materials with an anticipated consumption beyond one year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provisions related to product sales (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on future firm purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_175" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Estimated reimbursements to wholesalers and distributors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development funding liability (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Noncurrent Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Deferred Revenue</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> December 31, 2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Returns, rebates and other fees</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in prior periods</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in current period </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments and returns related to sales made in prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Assets And Liabilities, Lessee</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1024"><span style="-sec-ix-hidden:f-1025"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1030"><span style="-sec-ix-hidden:f-1031"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:f-1034"><span style="-sec-ix-hidden:f-1035"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs were as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:59.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:63.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows used in financing leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in right-of-use assets related to lease modifications and reassessments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability derecognized upon purchase of underlying leased asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Finance Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text">The following table summarizes our option activity during the year ended December 31, 2025:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6.71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Common Stock Units Activity</a></td>
<td class="text">The following table summarizes our RSU and PSU activity during the year ended December 31, 2025:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:72.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.836%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(6.81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">63.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted</a></td>
<td class="text">The weighted-average assumptions used to estimate the fair value of options granted for the&#160;years ended December 31, 2025, 2024, and 2023 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.54 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">49.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">57.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2025, 2024, and 2023 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Summary of Share Repurchase Program</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to our share repurchase programs (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">143.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remaining authorization at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Provision For (Benefit From) Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,655)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,768)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,607)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision For (Benefit From) Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax amount and rate to our effective tax rate for the year ended December 31, 2025 was as follows (in millions, except percentages):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax, net of federal income tax effect</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax effects</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall/shortfall</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in unrecognized tax benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2024 and 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation windfall/shortfall</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Deferred Tax Assets and Tax Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and tax liabilities as of December 31, 2025 and 2024 were as follows <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:77.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve and capitalization </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Wholesaler chargebacks, discounts and fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Returns and other fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Summary of Valuation Allowance</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2025, 2024, and 2023 were as follows (in&#160;millions):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior positions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with tax authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2025, 2024 and 2023 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:61.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted EPS</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12.33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2025, 2024 and 2023, were excluded from the calculation of diluted EPS attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales by customer geographic location were as follows for the periods presented (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Total revenue by geographic area of our customers and collaborators was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>candidate </div>
<div>developmentProgram </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_NumberOfCommercialProducts', window );">Number of commercial products | product</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_NumberOfDevelopmentCandidates', window );">Number of development candidates | candidate</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_NumberOfDevelopmentPrograms', window );">Number of development programs | developmentProgram</a></td>
<td class="nump">35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfCommercialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Commercial Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfCommercialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDevelopmentCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDevelopmentCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of payment terms</a></td>
<td class="text">Payment terms generally range from 30 to 60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 133,000,000<span></span>
</td>
<td class="nump">$ 146,000,000<span></span>
</td>
<td class="nump">$ 204,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,595<span></span>
</td>
<td class="nump">$ 1,927<span></span>
</td>
<td class="nump">$ 2,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 2,597<span></span>
</td>
<td class="nump">$ 1,929<span></span>
</td>
<td class="nump">$ 2,928<span></span>
</td>
<td class="nump">$ 3,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Percentage of Revenue | FFF Enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Percentage of Revenue | Public Works and Government Services Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Percentage of Revenue | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Percentage of Revenue | United Kingdom Health Security Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Percentage of Revenue | Ministry of Health, Labor, and Welfare of Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Percentage of Accounts Receivable | Public Works and Government Services Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Percentage of Accounts Receivable | United Kingdom Health Security Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Percentage of Accounts Receivable | Mexico Medistik</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Percentage of Accounts Receivable | Boryung Biopharma Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Percentage of Accounts Receivable | Taiwan Food and Drug Administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_FFFEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_FFFEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_PublicWorksAndGovernmentServicesCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_PublicWorksAndGovernmentServicesCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_UKHealthSecurityAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_UKHealthSecurityAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_MinistryOfHealthLaborAndWelfareOfJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_MinistryOfHealthLaborAndWelfareOfJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_MexicoMedistikMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_MexicoMedistikMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BoryungBiopharmaKoreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BoryungBiopharmaKoreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_TaiwanFoodAndDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_TaiwanFoodAndDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing and laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing and laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">$ 10,901<span></span>
</td>
<td class="nump">$ 13,854<span></span>
</td>
<td class="nump">$ 19,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">8,650<span></span>
</td>
<td class="nump">10,901<span></span>
</td>
<td class="nump">13,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains on Available-for-Sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension and Postretirement Obligation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Losses (gains) on Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Product Sales - Net Product Sales by Customer Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="nump">$ 6,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">3,109<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_COVID19Member', window );">COVID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">3,084<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_RSVMember', window );">RSV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_RestOfTheWorldMember', window );">Rest of world | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 3,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_RSVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_RSVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Product Sales - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_NumberOfCommercialProducts', window );">Number of commercial products</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_NumberOfCommercialProducts', window );">Number of commercial products</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfCommercialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Commercial Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfCommercialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Product Sales - Product Sales (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="nump">$ 6,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross', window );">Gross product sales</a></td>
<td class="nump">3,304<span></span>
</td>
<td class="nump">4,517<span></span>
</td>
<td class="nump">8,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees', window );">Wholesaler chargebacks, discounts and fees</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees', window );">Returns, rebates and other fees</a></td>
<td class="num">(449)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityProvision', window );">Total product sales provision</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="num">(1,408)<span></span>
</td>
<td class="num">(1,532)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 1,818<span></span>
</td>
<td class="nump">3,109<span></span>
</td>
<td class="nump">$ 6,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment', window );">Prior period revisions, adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Prior Period Revisions, Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Provision For Refunds and Other Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Excluding Assessed Tax , Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward', window );"><strong>Change in Contract with Customer, Liability Refund [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Balance at December 31, 2024</a></td>
<td class="num">$ (370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Balance at December 31, 2025</a></td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward', window );"><strong>Change in Contract with Customer, Liability Refund [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Balance at December 31, 2024</a></td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear', window );">Provision related to sales made in current period</a></td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears', window );">Provision related to sales made in prior periods</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales', window );">Payments and returns related to sales made in current period</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales', window );">Payments and returns related to sales made in prior periods</a></td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Balance at December 31, 2025</a></td>
<td class="num">$ (509)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractWithCustomerLiabilityRefundRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability Refund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractWithCustomerLiabilityRefundRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityProvisionRelatedToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Provision Related To Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityProvisionRelatedToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Provisions Made in Current Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Provisions Made in Prior Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Refund Liability, Payments And Returns Related To Prior Period Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="nump">$ 6,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Other grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Collaboration revenue (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Collaboration revenue (Note 5) | Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Collaboration revenue (Note 5) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember', window );">Licensing and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_StandReadyManufacturingRevenueMember', window );">Stand-ready manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Total other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_OtherCollaborativePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_OtherCollaborativePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_StandReadyManufacturingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_StandReadyManufacturingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">63 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>participant</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_NumberOfParticipants', window );">Number of participants | participant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">$ 6,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember', window );">Licensing and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember', window );">Licensing and royalty revenue | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Upfront payment</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Participants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsCurrentFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Current Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsCurrentFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_LicenseAndRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Research and Development Funding Arrangement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,132<span></span>
</td>
<td class="nump">$ 4,543<span></span>
</td>
<td class="nump">$ 4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentLiabilityCurrent', window );">Research and development funding liability (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrna_MerckMember', window );">Merck | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ProceedsFromOptionExerciseFee', window );">Proceeds from option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RecoveryOfCostsCapitalExpenditures', window );">Cost recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrna_BlackstoneLifeSciencesBlackstoneMember', window );">Blackstone Life Sciences (Blackstone) | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_CollaborativeArrangementFundingAmount', window );">Funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentLiabilityCurrent', window );">Research and development funding liability (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrna_ImmaticsMember', window );">Immatics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_CollaborativeArrangementFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Funding Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_CollaborativeArrangementFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ProceedsFromOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ProceedsFromOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RecoveryOfCostsCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery Of Costs, Capital Expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RecoveryOfCostsCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_BlackstoneLifeSciencesBlackstoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_BlackstoneLifeSciencesBlackstoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_ImmaticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_ImmaticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="nump">$ 7,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,128<span></span>
</td>
<td class="nump">9,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">8,135<span></span>
</td>
<td class="nump">9,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,595<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember', window );">Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">5,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember', window );">Non- Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,595<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,595<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Cash and Cash Equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,595<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Current Marketable Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Non- Current Marketable Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Cash and Cash Equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Non- Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Cash and Cash Equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Non- Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Cash and Cash Equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Non- Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">3,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Cash and Cash Equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">2,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Non- Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Cash and Cash Equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Non- Current Marketable Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 3,199<span></span>
</td>
<td class="nump">$ 5,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,533<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">5,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 5,540<span></span>
</td>
<td class="nump">$ 7,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit losses related allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of AFS securities in loss positions | security</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net losses</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 52,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">$ 8,135<span></span>
</td>
<td class="nump">$ 9,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">3,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 7,925<span></span>
</td>
<td class="nump">$ 9,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments, liabilities</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,956<span></span>
</td>
<td class="nump">8,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments, liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Certificates of deposit | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury bills | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury notes | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="nump">3,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="nump">3,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Government debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Equity investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Equity investments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory, Current (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Inventory, firm purchase commitment, loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LegalContingencyFutureFirmPurchaseCommitments', window );">Loss on future firm purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember', window );">Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_COVIDVaccineMember', window );">COVID Vaccine | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_InventoryShelfLife', window );">Shelf life (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_COVIDVaccineMember', window );">COVID Vaccine | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_InventoryShelfLife', window );">Shelf life (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_MNEXSPIKEMember', window );">mNEXSPIKE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_InventoryShelfLife', window );">Shelf life (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_RSVVaccineMember', window );">RSV Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_InventoryShelfLife', window );">Shelf life (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_InventoryShelfLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Shelf Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_InventoryShelfLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LegalContingencyFutureFirmPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Contingency, Future Firm Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LegalContingencyFutureFirmPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 330<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_COVIDVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrna_COVIDVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_MNEXSPIKEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrna_MNEXSPIKEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrna_RSVVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrna_RSVVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 2,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(737)<span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember', window );">Right-of-use assets, financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccountsReceivableChargebacksDiscountsAndFees', window );">Less: Wholesalers chargebacks, discounts and fees</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: Allowance for doubtful accounts</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccountsReceivableChargebacksDiscountsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Discounts And Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccountsReceivableChargebacksDiscountsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid services</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OtherPrepaidExpenseMaterialsAndSupplies', window );">Down payments and prepayments related to manufacturing and materials</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value added tax receivable</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income tax</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_CollaborationReceivableCurrent', window );">Collaboration receivable</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_CollaborationReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_CollaborationReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OtherPrepaidExpenseMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expense, Materials And Supplies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OtherPrepaidExpenseMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Other Non-Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivableNoncurrent', window );">Income tax receivable, non-current</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DownpaymentsAndPrepaymentsNoncurrent', window );">Down payments and prepayments, non-current</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible asset</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DownpaymentsAndPrepaymentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Downpayments And Prepayments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DownpaymentsAndPrepaymentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Provisions related to product sales (Note 3)</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccruedManufacturing', window );">Manufacturing</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccruedDevelopmentOperation', window );">Development operations</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent', window );">Other external goods and services</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccruedPropertyAndEquipmentCurrent', window );">Property, plant and equipment</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RawMaterialsAccountsPayable', window );">Raw materials</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccruedCommercial', window );">Commercial</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_AccruedClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LegalContingencyFutureFirmPurchaseCommitments', window );">Loss on future firm purchase commitments</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Commercial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedDevelopmentOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Operation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedDevelopmentOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Other External Goods And Services Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedOtherExternalGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LegalContingencyFutureFirmPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Contingency, Future Firm Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LegalContingencyFutureFirmPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RawMaterialsAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Raw Materials, Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RawMaterialsAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_EstimatedReimbursementLiability', window );">Estimated reimbursements to wholesalers and distributors</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentLiabilityCurrent', window );">Research and development funding liability (Note 5)</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease liabilities - financing (Note 10)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities - operating (Note 10)</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_EstimatedReimbursementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Reimbursement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_EstimatedReimbursementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Schedule of Other Non-Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Tax liabilities</a></td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components - Deferred Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>ft&#178; </div>
<div>numberOfExtensionPeriod </div>
<div>campus</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>numberOfExtensionPeriod</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingLeaseNumberOfProperties', window );">Number of campuses | campus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember', window );">MTC South, MTC North and MTC East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensions', window );">Number of extension | numberOfExtensionPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember', window );">MTC South, MTC North and MTC East | Moderna Technology Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred | $</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property additions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensions', window );">Number of extension | numberOfExtensionPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseNumberOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Number Of Properties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseNumberOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrna_ModernaTechnologyCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrna_ModernaTechnologyCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating, net</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets, financing, net</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent', window );">Total current liabilities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance lease, right-of-use asset, statement of financial position [Extensible List]</a></td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position [Extensible List]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, current, statement of financial position [Extensible List]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets, financing leases</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense for financing lease liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_FinanceLeaseCost', window );">Total financing lease costs</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows used in financing leases</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows used in financing leases</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments', window );">Decrease in right-of-use assets related to lease modifications and reassessments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments', window );">Decrease in right-of-use assets related to lease modifications and reassessments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for financing lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LesseeFinanceLeaseExpense', window );">Changes in financing lease liabilities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset', window );">Lease liability derecognized upon purchase of underlying leased asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, remaining lease term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, remaining lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, discount rate</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, discount rate</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Derecognized Upon Purchase Of Underlying Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained through finance lease modifications and reassessments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum Lease Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2026</a></td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2027</a></td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2028</a></td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2029</a></td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2030</a></td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Thereafter</a></td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths', window );">2026</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2027</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive', window );">2030</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted future lease payments</a></td>
<td class="nump">$ 396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Agreement (Details) - Secured Debt - Line of Credit - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod', window );">Debt instrument, average market capitalization, trailing period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization', window );">Average market capitalization</a></td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Covenant Compliance, Scenario 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents', window );">Minimum cash and cash equivalents</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Covenant Compliance, Scenario 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents', window );">Minimum cash and cash equivalents</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Debt, outstanding principal balance</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Federal funds rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Term SOFR plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Initial Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">9.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Delayed Draw Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">(DDTL)-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">(DDTL)-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Average Market Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Average Market Capitalization, Trailing Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DebtInstrumentCovenantComplianceScenarioAxis=mrna_CovenantComplianceScenario1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DebtInstrumentCovenantComplianceScenarioAxis=mrna_CovenantComplianceScenario1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DebtInstrumentCovenantComplianceScenarioAxis=mrna_CovenantComplianceScenario2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DebtInstrumentCovenantComplianceScenarioAxis=mrna_CovenantComplianceScenario2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=mrna_TermSecuredOvernightFinancingRatePlusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=mrna_TermSecuredOvernightFinancingRatePlusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrna_InitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrna_InitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrna_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrna_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrna_DelayedDrawTermLoanFacility1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrna_DelayedDrawTermLoanFacility1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrna_DelayedDrawTermLoanFacility2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrna_DelayedDrawTermLoanFacility2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Legal Proceedings (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>lawsuit</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember', window );">GlaxoSmithKline Biologicals SA , Patents Owned By GSK</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember', window );">GlaxoSmithKline Biologicals SA , Patents Infringements in UPC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember', window );">GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Indemnification Obligations (Details) - Indemnifications<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Losses related to indemnification obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims outstanding | claim</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Reserves established</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_LegalContingencyFutureFirmPurchaseCommitments', window );">Loss on future firm purchase commitments</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember', window );">Supply and Manufacturing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember', window );">Clinical Operations and Support Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LegalContingencyFutureFirmPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Contingency, Future Firm Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LegalContingencyFutureFirmPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember', window );">National Institute of Allergy and Infectious Diseases member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible asset</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 13, 2025 </div>
<div>employee </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 122,000,000<span></span>
</td>
<td class="nump">$ 413,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit realized from option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">84,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Consideration for options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000,000<span></span>
</td>
<td class="nump">228,000,000<span></span>
</td>
<td class="nump">99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to non-vested stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=mrna_A2022RepurchaseProgramMember', window );">2022 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount', window );">Additional authorized amount for share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member', window );">2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-based Awards | Twelve Months of Continued Employment or Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-based Awards | Following Twelve Quarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | 2016 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Stock Option Exchange Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees', window );">Number of eligible employees elected to exchange | employee</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares) | shares</a></td>
<td class="nump">4,289,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage', window );">Percentage of common stock underlying eligible options</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share available for future issuance (in shares) | shares</a></td>
<td class="nump">1,653,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (usd per share) | $ / shares</a></td>
<td class="nump">$ 29.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember', window );">Restricted Common Stock Units And Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value of RSUs and PSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,000,000<span></span>
</td>
<td class="nump">$ 161,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Common Stock Underlying Options, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Eligible Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_StockRepurchaseProgramAdditionalAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program, Additional Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_StockRepurchaseProgramAdditionalAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=mrna_A2022RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=mrna_A2022RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionExchangeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionExchangeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">26,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">8,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(6,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">27,180<span></span>
</td>
<td class="nump">26,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share)</a></td>
<td class="nump">$ 59.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">30.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">14.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in usd per share)</a></td>
<td class="nump">114.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share)</a></td>
<td class="nump">$ 38.63<span></span>
</td>
<td class="nump">$ 59.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number&#160;of options, exercisable (in shares)</a></td>
<td class="nump">19,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, exercisable (in usd per share)</a></td>
<td class="nump">$ 38.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- average remaining contractual term, outstanding</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- average remaining contractual term, exercisable</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest (in shares)</a></td>
<td class="nump">7,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- average expected to vest (in usd per share)</a></td>
<td class="nump">$ 39.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- average remaining contractual term expected to vest</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value expected to vest</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details) - Restricted Common Stock Units And Performance Stock Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares/Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at beginning of period (in shares) | shares</a></td>
<td class="nump">7,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares) | shares</a></td>
<td class="nump">12,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(6,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled/forfeited (in shares) | shares</a></td>
<td class="num">(2,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at end of period (in shares) | shares</a></td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date per Share/Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 91.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (in usd per share) | $ / shares</a></td>
<td class="nump">30.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">63.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">60.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 46.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) - Options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.04%<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months 14 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average fair value per share (in usd per share)</a></td>
<td class="nump">$ 18.64<span></span>
</td>
<td class="nump">$ 49.76<span></span>
</td>
<td class="nump">$ 57.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_PerformanceStockUnitMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 143.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Aggregate purchase price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized at end of period</a></td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (2,655)<span></span>
</td>
<td class="num">$ (3,697)<span></span>
</td>
<td class="num">$ (4,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (2,768)<span></span>
</td>
<td class="num">$ (3,607)<span></span>
</td>
<td class="num">$ (3,942)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision For (Benefit From) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="num">$ (57,000)<span></span>
</td>
<td class="num">$ (225,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="num">(45,000)<span></span>
</td>
<td class="num">(129,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">888,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">901,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for (benefit from) income taxes</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="num">$ (46,000)<span></span>
</td>
<td class="nump">$ 772,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="num">$ (581,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal income tax effect</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Tax credits</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="nump">509,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation windfall/shortfall</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for (benefit from) income taxes</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="num">$ (46,000)<span></span>
</td>
<td class="nump">$ 772,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal income tax effect</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Tax credits</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(18.40%)<span></span>
</td>
<td class="num">(23.50%)<span></span>
</td>
<td class="num">(52.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation windfall/shortfall</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(19.60%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(18.40%)<span></span>
</td>
<td class="num">(23.50%)<span></span>
</td>
<td class="num">(52.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">Foreign-derived intangible income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation windfall/shortfall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefits</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(19.60%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation, percent</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(19.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases to valuation allowance</a></td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember', window );">More Likely That Not To Realize All Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases to valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating losses that will carry-forward indefinitely</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating losses that will carry-forward indefinitely</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating losses that begin to expire in 2030</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating losses that will carry-forward indefinitely</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts', window );">Capitalized licenses, research and development and start-up costs</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss', window );">Other comprehensive income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserve and capitalization</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees', window );">Wholesaler chargebacks, discounts and fees</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances', window );">Returns and other fees</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DeferredTaxAssetsOutsideBasisDifference', window );">Outside basis difference</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,014<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(3,738)<span></span>
</td>
<td class="num">(3,084)<span></span>
</td>
<td class="num">$ (2,224)<span></span>
</td>
<td class="num">$ (155)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsOutsideBasisDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Outside Basis Difference</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsOutsideBasisDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Valuation Allowance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrna_DeferredTaxValuationAllowanceRollForward', window );"><strong>Deferred Tax, Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at beginning of the period</a></td>
<td class="nump">$ 3,084<span></span>
</td>
<td class="nump">$ 2,224<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases to valuation allowance</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at December 31</a></td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="nump">$ 3,084<span></span>
</td>
<td class="nump">$ 2,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at beginning of the period</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions for prior years</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements with tax authorities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions for current year</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions for prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at end of the period</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,822)<span></span>
</td>
<td class="num">$ (3,561)<span></span>
</td>
<td class="num">$ (4,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="nump">382,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="nump">382,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (in usd per share)</a></td>
<td class="num">$ (7.26)<span></span>
</td>
<td class="num">$ (9.28)<span></span>
</td>
<td class="num">$ (12.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (in usd per share)</a></td>
<td class="num">$ (7.26)<span></span>
</td>
<td class="num">$ (9.28)<span></span>
</td>
<td class="num">$ (12.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="nump">$ 6,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="nump">$ 3,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 363<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>386</ContextCount>
  <ElementCount>537</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>120</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>17</UnitCount>
  <MyReports>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Net Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetProductSales</Role>
      <ShortName>Net Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Collaboration Agreements and Research and Development Funding Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements</Role>
      <ShortName>Collaboration Agreements and Research and Development Funding Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Other Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponents</Role>
      <ShortName>Other Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Credit Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CreditAgreement</Role>
      <ShortName>Credit Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Stock-Based Compensation and Share Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GeographicInformation</Role>
      <ShortName>Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Net Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetProductSalesTables</Role>
      <ShortName>Net Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/NetProductSales</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Other Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherRevenueTables</Role>
      <ShortName>Other Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/OtherRevenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Inventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Other Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsTables</Role>
      <ShortName>Other Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/OtherBalanceSheetComponents</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Stock-Based Compensation and Share Repurchase Programs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/LossperShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GeographicInformationTables</Role>
      <ShortName>Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GeographicInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionoftheBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/DescriptionoftheBusiness</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Significant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails</Role>
      <ShortName>Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Net Product Sales - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetProductSalesNarrativeDetails</Role>
      <ShortName>Net Product Sales - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Net Product Sales - Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetProductSalesProductSalesDetails</Role>
      <ShortName>Net Product Sales - Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails</Role>
      <ShortName>Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Other Revenue - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Other Revenue - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Other Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherRevenueNarrativeDetails</Role>
      <ShortName>Other Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Collaboration Agreements and Research and Development Funding Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails</Role>
      <ShortName>Collaboration Agreements and Research and Development Funding Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails</Role>
      <ShortName>Inventory - Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails</Role>
      <ShortName>Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Other Balance Sheet Components - Other Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails</Role>
      <ShortName>Other Balance Sheet Components - Other Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Other Balance Sheet Components - Schedule of Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Schedule of Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails</Role>
      <ShortName>Other Balance Sheet Components - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Leases - Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CreditAgreementDetails</Role>
      <ShortName>Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/CreditAgreement</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails</Role>
      <ShortName>Commitments and Contingencies - Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Indemnification Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails</Role>
      <ShortName>Commitments and Contingencies - Licenses to Patented Technology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails</Role>
      <ShortName>Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision For (Benefit From) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Income Taxes - Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mrna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GeographicInformationDetails</Role>
      <ShortName>Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GeographicInformationTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mrna-20251231.htm">mrna-20251231.htm</File>
    <File>mrna-20251231.xsd</File>
    <File>mrna-20251231_cal.xml</File>
    <File>mrna-20251231_def.xml</File>
    <File>mrna-20251231_lab.xml</File>
    <File>mrna-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrna-20251231_g1.jpg</File>
    <File>mrna-20251231_g2.jpg</File>
    <File>mrna-20251231_g3.jpg</File>
    <File>mrna-20251231_g4.jpg</File>
    <File>mrna-20251231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="1310">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mrna-20251231.htm": {
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "mrna-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "mrna-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mrna-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrna-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 472,
   "keyCustom": 65,
   "axisStandard": 36,
   "axisCustom": 1,
   "memberStandard": 56,
   "memberCustom": 61,
   "hidden": {
    "total": 17,
    "http://xbrl.sec.gov/ecd/2025": 2,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 10,
    "http://www.modernatx.com/20251231": 1
   },
   "contextCount": 386,
   "entityCount": 1,
   "segmentCount": 120,
   "elementCount": 916,
   "unitCount": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1310,
    "http://xbrl.sec.gov/dei/2025": 38,
    "http://xbrl.sec.gov/ecd/2025": 28,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://fasb.org/srt/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://www.modernatx.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.modernatx.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.modernatx.com/role/DescriptionoftheBusiness",
     "longName": "9952157 - Disclosure - Description of the Business",
     "shortName": "Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.modernatx.com/role/NetProductSales",
     "longName": "9952159 - Disclosure - Net Product Sales",
     "shortName": "Net Product Sales",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://www.modernatx.com/role/OtherRevenue",
     "longName": "9952160 - Disclosure - Other Revenue",
     "shortName": "Other Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements",
     "longName": "9952161 - Disclosure - Collaboration Agreements and Research and Development Funding Arrangements",
     "shortName": "Collaboration Agreements and Research and Development Funding Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements",
     "longName": "9952162 - Disclosure - Financial Instruments and Fair Value Measurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.modernatx.com/role/Inventory",
     "longName": "9952163 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.modernatx.com/role/PropertyPlantandEquipmentNet",
     "longName": "9952164 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponents",
     "longName": "9952165 - Disclosure - Other Balance Sheet Components",
     "shortName": "Other Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.modernatx.com/role/Leases",
     "longName": "9952166 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.modernatx.com/role/CreditAgreement",
     "longName": "9952167 - Disclosure - Credit Agreement",
     "shortName": "Credit Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.modernatx.com/role/CommitmentsandContingencies",
     "longName": "9952168 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms",
     "longName": "9952169 - Disclosure - Stock-Based Compensation and Share Repurchase Programs",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.modernatx.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.modernatx.com/role/LossperShare",
     "longName": "9952171 - Disclosure - Loss per Share",
     "shortName": "Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.modernatx.com/role/GeographicInformation",
     "longName": "9952172 - Disclosure - Geographic Information",
     "shortName": "Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-376",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-376",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.modernatx.com/role/NetProductSalesTables",
     "longName": "9955513 - Disclosure - Net Product Sales (Tables)",
     "shortName": "Net Product Sales (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.modernatx.com/role/OtherRevenueTables",
     "longName": "9955514 - Disclosure - Other Revenue (Tables)",
     "shortName": "Other Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables",
     "longName": "9955515 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.modernatx.com/role/InventoryTables",
     "longName": "9955516 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables",
     "longName": "9955517 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables",
     "longName": "9955518 - Disclosure - Other Balance Sheet Components (Tables)",
     "shortName": "Other Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.modernatx.com/role/LeasesTables",
     "longName": "9955519 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables",
     "longName": "9955520 - Disclosure - Stock-Based Compensation and Share Repurchase Programs (Tables)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.modernatx.com/role/IncomeTaxesTables",
     "longName": "9955521 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.modernatx.com/role/LossperShareTables",
     "longName": "9955522 - Disclosure - Loss per Share (Tables)",
     "shortName": "Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.modernatx.com/role/GeographicInformationTables",
     "longName": "9955523 - Disclosure - Geographic Information (Tables)",
     "shortName": "Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.modernatx.com/role/DescriptionoftheBusinessDetails",
     "longName": "9955524 - Disclosure - Description of the Business (Details)",
     "shortName": "Description of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mrna:NumberOfCommercialProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "mrna:NumberOfDevelopmentCandidates",
      "unitRef": "candidate",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails",
     "longName": "9955527 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)",
     "shortName": "Summary of Significant Accounting Policies - Significant Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails",
     "longName": "9955528 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails",
     "longName": "9955529 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)",
     "shortName": "Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
     "longName": "9955530 - Disclosure - Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)",
     "shortName": "Net Product Sales - Net Product Sales by Customer Geographic Areas (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.modernatx.com/role/NetProductSalesNarrativeDetails",
     "longName": "9955531 - Disclosure - Net Product Sales - Narrative (Details)",
     "shortName": "Net Product Sales - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mrna:NumberOfCommercialProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "mrna:NumberOfCommercialProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
     "longName": "9955532 - Disclosure - Net Product Sales - Product Sales (Details)",
     "shortName": "Net Product Sales - Product Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
     "longName": "9955533 - Disclosure - Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)",
     "shortName": "Net Product Sales - Product Sales Provision Recorded as Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerRefundLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:ContractWithCustomerRefundLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails",
     "longName": "9955534 - Disclosure - Other Revenue - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Other Revenue - Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
     "longName": "9955535 - Disclosure - Other Revenue - Narrative (Details)",
     "shortName": "Other Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-106",
      "name": "mrna:NumberOfParticipants",
      "unitRef": "participant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "mrna:NumberOfParticipants",
      "unitRef": "participant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
     "longName": "9955536 - Disclosure - Collaboration Agreements and Research and Development Funding Arrangement (Details)",
     "shortName": "Collaboration Agreements and Research and Development Funding Arrangement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
     "longName": "9955537 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
     "longName": "9955538 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails",
     "longName": "9955539 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails",
     "longName": "9955540 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
     "longName": "9955541 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis (Details)",
     "shortName": "Financial Instruments and Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-161",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-222",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails",
     "longName": "9955542 - Disclosure - Inventory - Schedule of Inventory, Current (Details)",
     "shortName": "Inventory - Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.modernatx.com/role/InventoryNarrativeDetails",
     "longName": "9955543 - Disclosure - Inventory - Narrative (Details)",
     "shortName": "Inventory - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
     "longName": "9955544 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails",
     "longName": "9955545 - Disclosure - Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)",
     "shortName": "Other Balance Sheet Components - Accounts, Notes, Loans and Financing Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955546 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails",
     "longName": "9955547 - Disclosure - Other Balance Sheet Components - Other Non-Current Assets (Details)",
     "shortName": "Other Balance Sheet Components - Other Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IncomeTaxesReceivableNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IncomeTaxesReceivableNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails",
     "longName": "9955548 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)",
     "shortName": "Other Balance Sheet Components - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerRefundLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails",
     "longName": "9955549 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)",
     "shortName": "Other Balance Sheet Components - Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "mrna:EstimatedReimbursementLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "mrna:EstimatedReimbursementLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails",
     "longName": "9955550 - Disclosure - Other Balance Sheet Components - Schedule of Other Non-Current Liabilities (Details)",
     "shortName": "Other Balance Sheet Components - Schedule of Other Non-Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
     "longName": "9955551 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)",
     "shortName": "Other Balance Sheet Components - Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.modernatx.com/role/LeasesNarrativeDetails",
     "longName": "9955552 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "unitRef": "campus",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "unitRef": "campus",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
     "longName": "9955553 - Disclosure - Leases - Balance Sheet Information (Details)",
     "shortName": "Leases - Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.modernatx.com/role/LeasesLeaseCostsDetails",
     "longName": "9955554 - Disclosure - Leases - Lease Costs (Details)",
     "shortName": "Leases - Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
     "longName": "9955555 - Disclosure - Leases - Minimum Lease Payments (Details)",
     "shortName": "Leases - Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.modernatx.com/role/CreditAgreementDetails",
     "longName": "9955556 - Disclosure - Credit Agreement (Details)",
     "shortName": "Credit Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-276",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-276",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails",
     "longName": "9955557 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)",
     "shortName": "Commitments and Contingencies - Legal Proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-289",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-289",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails",
     "longName": "9955558 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)",
     "shortName": "Commitments and Contingencies - Indemnification Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-292",
      "name": "us-gaap:LossContingencyLossInPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-292",
      "name": "us-gaap:LossContingencyLossInPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails",
     "longName": "9955559 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "shortName": "Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "mrna:LegalContingencyFutureFirmPurchaseCommitments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-296",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
     "longName": "9955560 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "shortName": "Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
     "longName": "9955561 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails",
     "longName": "9955562 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs - Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails",
     "longName": "9955563 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs - Restricted Common Stock and Common Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-308",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-308",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
     "longName": "9955564 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-322",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-322",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails",
     "longName": "9955565 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails",
     "longName": "9955566 - Disclosure - Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)",
     "shortName": "Stock-Based Compensation and Share Repurchase Programs - Share Repurchase Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
     "longName": "9955567 - Disclosure - Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)",
     "shortName": "Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails",
     "longName": "9955568 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)",
     "shortName": "Income Taxes - Provision For (Benefit From) Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
     "longName": "9955569 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Effective Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails",
     "longName": "9955570 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955571 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-349",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails",
     "longName": "9955572 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails",
     "longName": "9955573 - Disclosure - Income Taxes - Valuation Allowance (Details)",
     "shortName": "Income Taxes - Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "9955574 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
     "longName": "9955575 - Disclosure - Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails",
     "longName": "9955576 - Disclosure - Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)",
     "shortName": "Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.modernatx.com/role/GeographicInformationDetails",
     "longName": "9955577 - Disclosure - Geographic Information (Details)",
     "shortName": "Geographic Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-370",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrna-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "mrna_A2022RepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "A2022RepurchaseProgramMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Repurchase Program",
        "label": "2022 Repurchase Program [Member]",
        "documentation": "2022 Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r1030"
     ]
    },
    "mrna_AccountsReceivableChargebacksDiscountsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccountsReceivableChargebacksDiscountsAndFees",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Wholesalers chargebacks, discounts and fees",
        "label": "Accounts Receivable, Chargebacks, Discounts And Fees",
        "documentation": "Accounts Receivable, Chargebacks, Discounts And Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r314",
      "r315",
      "r655",
      "r1444"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1292"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r918",
      "r1056",
      "r1443",
      "r1444"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "mrna_AccruedClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccruedClinicalTrials",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trials",
        "label": "Accrued Clinical Trials",
        "documentation": "Accrued Clinical Trials"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AccruedCommercial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccruedCommercial",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial",
        "label": "Accrued Commercial",
        "documentation": "Accrued Commercial"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AccruedDevelopmentOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccruedDevelopmentOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development operations",
        "label": "Accrued Development Operation",
        "documentation": "Accrued Development Operation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "mrna_AccruedManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccruedManufacturing",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing",
        "label": "Accrued Manufacturing",
        "documentation": "Accrued Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AccruedOtherExternalGoodsAndServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccruedOtherExternalGoodsAndServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other external goods and services",
        "label": "Accrued Other External Goods And Services Current",
        "documentation": "Accrued Other External Goods And Services Current"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AccruedPropertyAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Accrued Property And Equipment, Current",
        "documentation": "Accrued Property And Equipment, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r942"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension and Postretirement Obligation Adjustments",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r15",
      "r22",
      "r83",
      "r1228",
      "r1229",
      "r1230"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains on Available-for-Sale Securities",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r215",
      "r225",
      "r226",
      "r1228"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r632",
      "r633",
      "r634",
      "r635",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r84",
      "r204",
      "r789",
      "r817",
      "r818",
      "r1407"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r632",
      "r633",
      "r634",
      "r635",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "verboseLabel": "Total",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r15",
      "r22",
      "r627",
      "r630",
      "r696",
      "r813",
      "r814",
      "r1228",
      "r1229",
      "r1230",
      "r1285",
      "r1286",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses (gains) on Foreign Currency Translation",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15",
      "r22",
      "r81",
      "r82",
      "r225",
      "r226",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r1228"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1030",
      "r1479"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1408",
      "r1481"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax payments related to net share settlements on equity awards",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1381"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AdoptionOfTradingArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AdoptionOfTradingArrangementMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption of Trading Arrangement [Member]",
        "documentation": "Adoption of Trading Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AdoptionOfTradingArrangementOptions1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AdoptionOfTradingArrangementOptions1Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption of Trading Arrangement, Options 1 [Member]",
        "documentation": "Adoption of Trading Arrangement, Options 1"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_AdoptionOfTradingArrangementOptions2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AdoptionOfTradingArrangementOptions2Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption of Trading Arrangement, Options 2 [Member]",
        "documentation": "Adoption of Trading Arrangement, Options 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expenses",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r1001"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1099",
      "r1109",
      "r1142"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1102",
      "r1112",
      "r1145"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1137",
      "r1146",
      "r1150",
      "r1158"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation costs",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r535",
      "r544"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccountsNotesLoansandFinancingReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r316",
      "r357",
      "r360",
      "r362",
      "r1444"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r316",
      "r357"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space (in sqft)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r821",
      "r1397"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1398",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r821",
      "r1397"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment expenses",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r39",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r131",
      "r201",
      "r244",
      "r247",
      "r248",
      "r284",
      "r292",
      "r307",
      "r308",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r604",
      "r606",
      "r662",
      "r773",
      "r774",
      "r784",
      "r866",
      "r967",
      "r968",
      "r981",
      "r1030",
      "r1049",
      "r1050",
      "r1066",
      "r1343",
      "r1344",
      "r1428"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r209",
      "r244",
      "r247",
      "r248",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r604",
      "r606",
      "r662",
      "r1030",
      "r1343",
      "r1344",
      "r1428"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r1016"
     ]
    },
    "mrna_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.modernatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1095"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.modernatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1095"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.modernatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1095"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r366",
      "r783"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r779"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1308",
      "r1309",
      "r1440"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r778"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair\u00a0Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r366",
      "r641",
      "r655",
      "r656",
      "r657",
      "r658",
      "r770",
      "r936",
      "r1016",
      "r1020",
      "r1027",
      "r1306",
      "r1412",
      "r1413",
      "r1414"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r366"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, non-current",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r319",
      "r366"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r661",
      "r1012",
      "r1013",
      "r1184",
      "r1446"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r661",
      "r1012",
      "r1013",
      "r1184",
      "r1446"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1342"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BARDA",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "documentation": "Biomedical Advanced Research And Development Authority [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_BlackstoneLifeSciencesBlackstoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "BlackstoneLifeSciencesBlackstoneMember",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blackstone Life Sciences (Blackstone)",
        "label": "Blackstone Life Sciences (Blackstone) [Member]",
        "documentation": "Blackstone Life Sciences (Blackstone)"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_BoryungBiopharmaKoreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "BoryungBiopharmaKoreaMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Boryung Biopharma Korea",
        "label": "Boryung Biopharma Korea [Member]",
        "documentation": "Boryung Biopharma Korea"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building and building improvements",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "mrna_COVID19Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "COVID19Member",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID",
        "label": "COVID-19 [Member]",
        "documentation": "COVID-19"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_COVIDVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "COVIDVaccineMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID Vaccine",
        "label": "COVID Vaccine [Member]",
        "documentation": "COVID Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_CambridgeMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CambridgeMassachusettsMember",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cambridge Leases",
        "label": "Cambridge, Massachusetts [Member]",
        "documentation": "Cambridge, Massachusetts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "mrna_CardinalHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CardinalHealthMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "documentation": "Cardinal Health"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r197",
      "r939"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r96",
      "r241"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r96"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollForward",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract with Customer Liability, Current [Roll Forward]",
        "documentation": "Change In Contract with Customer Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ChangeInContractWithCustomerLiabilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ChangeInContractWithCustomerLiabilityLineItems",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change In Contract With Customer, Liability [Line Items]",
        "label": "Change in Contract With Customer Liability [Line Items]",
        "documentation": "Change in Contract With Customer Liability"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ChangeInContractWithCustomerLiabilityRefundRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ChangeInContractWithCustomerLiabilityRefundRollForward",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Contract with Customer, Liability Refund [Roll Forward]",
        "label": "Change in Contract with Customer, Liability Refund [Roll Forward]",
        "documentation": "Change in Contract with Customer, Liability Refund"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ChangeInContractWithCustomerLiabilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ChangeInContractWithCustomerLiabilityTable",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Contract With Customer Liability [Table]",
        "label": "Change In Contract With Customer, Liability [Table]",
        "documentation": "Change In Contract With Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ClinicalOperationsAndSupportCommitmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ClinicalOperationsAndSupportCommitmentMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Operations and Support Commitments",
        "label": "Clinical Operations And Support Commitment [Member]",
        "documentation": "Clinical Operations And Support Commitment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ClinicalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ClinicalServicesMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Services",
        "label": "Clinical Services [Member]",
        "documentation": "Clinical Services"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CollaborationArrangementIncludingArrangementsWithAffiliateMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration revenue (Note 5)",
        "label": "Collaboration Arrangement Including Arrangements With Affiliate [Member]",
        "documentation": "Collaboration Arrangement Including Arrangements With Affiliate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_CollaborationReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CollaborationReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration receivable",
        "label": "Collaboration Receivable, Current",
        "documentation": "Collaboration Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "mrna_CollaborativeArrangementFundingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CollaborativeArrangementFundingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding amount",
        "label": "Collaborative Arrangement, Funding Amount",
        "documentation": "Collaborative Arrangement, Funding Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r123",
      "r786",
      "r852"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r397",
      "r398",
      "r920",
      "r1329",
      "r1334"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share available for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1054",
      "r1055",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1285",
      "r1286",
      "r1288",
      "r1408",
      "r1477",
      "r1481"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r853"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r853",
      "r872",
      "r1481",
      "r1482"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2025 and 2024; 394 and 386 shares issued and outstanding as of December 31, 2025 and 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r447",
      "r453",
      "r788",
      "r1030"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r220",
      "r222",
      "r227",
      "r771",
      "r797",
      "r798"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "verboseLabel": "Computer equipment and software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r313",
      "r822",
      "r823",
      "r919",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r313",
      "r822",
      "r823",
      "r919",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r313",
      "r822",
      "r823",
      "r919",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r919",
      "r960",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r313",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r919",
      "r960",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r313",
      "r822",
      "r823",
      "r919",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r957"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesTables",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Balances of Receivables and Contract Liabilities",
        "verboseLabel": "Schedule of Deferred Revenue",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r462",
      "r481"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Upfront payment",
        "terseLabel": "Additions",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r462",
      "r481"
     ]
    },
    "mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityDeductionsDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Contract With Customer, Liability, Deductions During Period",
        "documentation": "Contract With Customer, Liability, Deductions During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r462",
      "r481"
     ]
    },
    "mrna_ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior period revisions, adjustment",
        "label": "Contract with Customer, Liability, Prior Period Revisions, Adjustment",
        "documentation": "Contract with Customer, Liability, Prior Period Revisions, Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ContractWithCustomerLiabilityProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityProvision",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total product sales provision",
        "label": "Contract with Customer, Liability, Provision",
        "documentation": "Contract with Customer, Liability, Provision"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": {
       "parentTag": "mrna_ContractWithCustomerLiabilityProvision",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Wholesaler chargebacks, discounts and fees",
        "label": "Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees",
        "documentation": "Contract with Customer, Liability, Provision For Chargebacks, Discounts and Fees"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": {
       "parentTag": "mrna_ContractWithCustomerLiabilityProvision",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Returns, rebates and other fees",
        "label": "Contract with Customer, Liability, Provision For Refunds and Other Fees",
        "documentation": "Contract with Customer, Liability, Provision For Refunds and Other Fees"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ContractWithCustomerLiabilityProvisionRelatedToSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityProvisionRelatedToSales",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments and returns related to sales made in current period",
        "label": "Contract with Customer, Liability, Provision Related To Sales",
        "documentation": "Contract with Customer, Liability, Provision Related To Sales"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ContractWithCustomerLiabilityProvisionsMadeInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityProvisionsMadeInCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision related to sales made in current period",
        "label": "Contract with Customer, Liability, Provisions Made in Current Year",
        "documentation": "Contract with Customer, Liability, Provisions Made in Current Year"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ContractWithCustomerLiabilityProvisionsMadeInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerLiabilityProvisionsMadeInPriorYears",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provision related to sales made in prior periods",
        "label": "Contract with Customer, Liability, Provisions Made in Prior Years",
        "documentation": "Contract with Customer, Liability, Provisions Made in Prior Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerRefundLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Balance at December 31, 2024",
        "negatedPeriodEndLabel": "Balance at December 31, 2025",
        "terseLabel": "Provisions related to product sales (Note 3)",
        "label": "Contract with Customer, Refund Liability",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer."
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "mrna_ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments and returns related to sales made in prior periods",
        "label": "Contract with Customer, Refund Liability, Payments And Returns Related To Prior Period Sales",
        "documentation": "Contract with Customer, Refund Liability, Payments And Returns Related To Prior Period Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r994",
      "r996",
      "r1016",
      "r1031",
      "r1051",
      "r1474"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r733",
      "r952",
      "r956",
      "r1011",
      "r1269"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r244",
      "r252",
      "r253",
      "r420",
      "r456",
      "r697",
      "r714",
      "r782",
      "r947",
      "r949",
      "r950",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1402",
      "r1403",
      "r1404",
      "r1405"
     ]
    },
    "mrna_CovenantComplianceScenario1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CovenantComplianceScenario1Member",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Covenant Compliance, Scenario 1",
        "label": "Covenant Compliance, Scenario 1 [Member]",
        "documentation": "Covenant Compliance, Scenario 1"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_CovenantComplianceScenario2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CovenantComplianceScenario2Member",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Covenant Compliance, Scenario 2",
        "label": "Covenant Compliance, Scenario 2 [Member]",
        "documentation": "Covenant Compliance, Scenario 2"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r1341"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r1341"
     ]
    },
    "mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets And Liabilities, Lessee",
        "label": "Current Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Current Assets And Liabilities, Lessee [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1277",
      "r1282",
      "r1393"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1277",
      "r1282"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r1277",
      "r1282"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_CurrentMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "CurrentMarketableSecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Marketable Securities",
        "label": "Current Marketable Securities [Member]",
        "documentation": "Current Marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1277",
      "r1282",
      "r1393"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r1292"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1169"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1169"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1171"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1171"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1173"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1171"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1164"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1165"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1165"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1163"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1163"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1163"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1166"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1168"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1168"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1169"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1172"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1170"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1167"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Agreement",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r244",
      "r246",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r405",
      "r406",
      "r416",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r432",
      "r439",
      "r440",
      "r442",
      "r625",
      "r672"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r57",
      "r58",
      "r119",
      "r122",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r1028",
      "r1277",
      "r1278",
      "r1279",
      "r1284",
      "r1330",
      "r1331",
      "r1332",
      "r1423",
      "r1424",
      "r1438"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DebtInstrumentCovenantComplianceAverageMarketCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average market capitalization",
        "label": "Debt Instrument, Covenant Compliance, Average Market Capitalization",
        "documentation": "Debt Instrument, Covenant Compliance, Average Market Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, average market capitalization, trailing period",
        "label": "Debt Instrument, Covenant Compliance, Average Market Capitalization, Trailing Period",
        "documentation": "Debt Instrument, Covenant Compliance, Average Market Capitalization, Trailing Period"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum cash and cash equivalents",
        "label": "Debt Instrument, Covenant Compliance, Minimum Cash And Cash Equivalents",
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DebtInstrumentCovenantComplianceScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DebtInstrumentCovenantComplianceScenarioAxis",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Covenant Compliance, Scenario [Axis]",
        "label": "Debt Instrument, Covenant Compliance, Scenario [Axis]",
        "documentation": "Debt Instrument, Covenant Compliance, Scenario"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DebtInstrumentCovenantComplianceScenarioDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DebtInstrumentCovenantComplianceScenarioDomain",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Covenant Compliance, Scenario [Domain]",
        "label": "Debt Instrument, Covenant Compliance, Scenario [Domain]",
        "documentation": "Debt Instrument, Covenant Compliance, Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r418"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r625",
      "r777",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r1028",
      "r1277",
      "r1278",
      "r1279",
      "r1284",
      "r1423",
      "r1424"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r1028",
      "r1277",
      "r1278",
      "r1279",
      "r1284",
      "r1330",
      "r1331",
      "r1332",
      "r1423",
      "r1424",
      "r1438"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r43",
      "r44",
      "r54",
      "r107",
      "r108",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r625",
      "r777",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r1028",
      "r1277",
      "r1278",
      "r1279",
      "r1284",
      "r1423",
      "r1424"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit losses related allowance",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r366",
      "r374",
      "r376"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded",
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r375"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses, 12 months or more",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r371",
      "r972"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated fair value, 12 months or more",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r371"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized losses, less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r371",
      "r972"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value, less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r371"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross Unrealized Losses, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r368",
      "r972"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Estimated Fair Value, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r369"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r972",
      "r1319"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of AFS securities in loss positions",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r370"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1282",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1282",
      "r1392"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r555"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r149",
      "r1277",
      "r1282"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r120",
      "r578"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r555",
      "r785"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1282",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetDomain",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Asset [Domain]",
        "label": "Deferred Tax Asset [Domain]",
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists."
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized licenses, research and development and start-up costs",
        "label": "Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs",
        "documentation": "Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve and capitalization",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "mrna_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "documentation": "Deferred Tax Assets, Operating Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherComprehensiveLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOtherComprehensiveLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Deferred Tax Assets, Other Comprehensive Loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "mrna_DeferredTaxAssetsOutsideBasisDifference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DeferredTaxAssetsOutsideBasisDifference",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside basis difference",
        "label": "Deferred Tax Assets, Outside Basis Difference",
        "documentation": "Deferred Tax Assets, Outside Basis Difference"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns and other fees",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails",
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: valuation allowance",
        "periodStartLabel": "Valuation allowance at beginning of the period",
        "periodEndLabel": "Valuation allowance at December 31",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "mrna_DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesaler chargebacks, discounts and fees",
        "label": "Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees",
        "documentation": "Deferred Tax Assets, Wholesaler Chargebacks, Discounts And Fees"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets, operating",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Asset",
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Property, plant and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "mrna_DeferredTaxValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DeferredTaxValuationAllowanceRollForward",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax, Valuation Allowance [Roll Forward]",
        "label": "Deferred Tax, Valuation Allowance [Roll Forward]",
        "documentation": "Deferred Tax, Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DelayedDrawTermLoanFacility1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DelayedDrawTermLoanFacility1Member",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(DDTL)-1",
        "label": "Delayed Draw Term Loan Facility 1 [Member]",
        "documentation": "Delayed Draw Term Loan Facility 1"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DelayedDrawTermLoanFacility2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DelayedDrawTermLoanFacility2Member",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(DDTL)-2",
        "label": "Delayed Draw Term Loan Facility 2 [Member]",
        "documentation": "Delayed Draw Term Loan Facility 2"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_DelayedDrawTermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DelayedDrawTermLoanFacilityMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Delayed Draw Term Loan",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "documentation": "Delayed Draw Term Loan Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r233",
      "r284",
      "r296",
      "r308",
      "r951",
      "r967",
      "r968"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r624",
      "r641",
      "r642",
      "r649",
      "r656",
      "r657",
      "r658",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r859",
      "r860",
      "r902",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r936",
      "r946",
      "r948",
      "r949",
      "r950",
      "r1016",
      "r1020",
      "r1027",
      "r1055",
      "r1412",
      "r1413",
      "r1414",
      "r1478"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments, liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r624",
      "r641",
      "r642",
      "r649",
      "r656",
      "r657",
      "r658",
      "r834",
      "r835",
      "r836",
      "r837",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r867",
      "r869",
      "r870",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r946",
      "r948",
      "r949",
      "r950",
      "r1412",
      "r1413",
      "r1414",
      "r1478"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/NetProductSalesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/NetProductSalesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesTables",
      "http://www.modernatx.com/role/OtherRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchasePrograms"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation and Share Repurchase Programs",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r499",
      "r530",
      "r531",
      "r533",
      "r998"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1095"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1095",
      "r1138"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "mrna_DownpaymentsAndPrepaymentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "DownpaymentsAndPrepaymentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Down payments and prepayments, non-current",
        "label": "Downpayments And Prepayments, Noncurrent",
        "documentation": "Downpayments And Prepayments, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in usd per share)",
        "verboseLabel": "Basic EPS (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r228",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r274",
      "r276",
      "r277",
      "r278",
      "r283",
      "r445",
      "r534",
      "r599",
      "r602",
      "r638",
      "r639",
      "r772",
      "r799",
      "r959"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in usd per share)",
        "verboseLabel": "Diluted EPS (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r228",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r276",
      "r277",
      "r278",
      "r283",
      "r445",
      "r534",
      "r599",
      "r602",
      "r638",
      "r639",
      "r772",
      "r799",
      "r959"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (Loss) per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r280"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r279",
      "r281",
      "r282"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of changes in exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "terseLabel": "Effective income tax rate reconciliation, percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1003"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal statutory tax rate",
        "terseLabel": "Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r250",
      "r558",
      "r590",
      "r1003"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1003",
      "r1277",
      "r1283",
      "r1384"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign-derived intangible income",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign tax effects",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r562",
      "r1003",
      "r1277",
      "r1283",
      "r1384"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nontaxable or nondeductible items",
        "terseLabel": "Non-deductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r1277",
      "r1283",
      "r1384"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation windfall/shortfall",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1277",
      "r1283",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1277",
      "r1283",
      "r1384",
      "r1385"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation windfall/shortfall",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1382",
      "r1384",
      "r1385"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State and local income tax, net of federal income tax effect",
        "terseLabel": "State taxes, net of federal benefits",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r1003",
      "r1277",
      "r1283",
      "r1384"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in unrecognized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r1003",
      "r1277",
      "r1283",
      "r1384"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1277",
      "r1283",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1277",
      "r1283",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation-related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1379"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost related to non-vested stock-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period of cost expected to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit realized from option exercised",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "verboseLabel": "Employee stock purchase plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "verboseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and laboratory equipment",
        "verboseLabel": "Manufacturing and laboratory equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r187",
      "r188",
      "r189",
      "r224",
      "r225",
      "r226",
      "r255",
      "r256",
      "r257",
      "r259",
      "r266",
      "r268",
      "r270",
      "r285",
      "r355",
      "r356",
      "r388",
      "r444",
      "r458",
      "r534",
      "r588",
      "r589",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r675",
      "r696",
      "r795",
      "r813",
      "r814",
      "r815",
      "r831",
      "r891"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r298",
      "r308",
      "r353",
      "r1210",
      "r1317"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net losses",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r1316"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r1031",
      "r1061",
      "r1062",
      "r1063",
      "r1484"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1099",
      "r1109",
      "r1142"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1096",
      "r1106",
      "r1139"
     ]
    },
    "mrna_EstimatedReimbursementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "EstimatedReimbursementLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated reimbursements to wholesalers and distributors",
        "label": "Estimated Reimbursement Liability",
        "documentation": "Estimated Reimbursement Liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1483",
      "r1485",
      "r1486",
      "r1487"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "mrna_FFFEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "FFFEnterprisesMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FFF Enterprises",
        "label": "FFF Enterprises [Member]",
        "documentation": "FFF Enterprises"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r651",
      "r656",
      "r701",
      "r702",
      "r703",
      "r936",
      "r977",
      "r978",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1016",
      "r1020",
      "r1027"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643",
      "r645",
      "r1016",
      "r1413",
      "r1416"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level 1",
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r485",
      "r490",
      "r491",
      "r642",
      "r649",
      "r656",
      "r701",
      "r936",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1016",
      "r1027"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r485",
      "r490",
      "r491",
      "r493",
      "r642",
      "r643",
      "r649",
      "r656",
      "r702",
      "r936",
      "r977",
      "r978",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1016",
      "r1027"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643",
      "r645",
      "r1016",
      "r1413",
      "r1416"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r651",
      "r656",
      "r701",
      "r702",
      "r703",
      "r936",
      "r977",
      "r978",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1016",
      "r1020",
      "r1027"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1416"
     ]
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalFundsEffectiveSwapRateMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal funds rate",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "mrna_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financing lease costs",
        "label": "Finance Lease, Cost",
        "documentation": "Finance Lease, Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "parentTag": "mrna_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense for financing lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r685",
      "r1029"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating cash flows used in financing leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r689"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Leases",
        "label": "Finance Lease, Liability, to be Paid, Rolling Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r693"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities - financing (Note 10)",
        "terseLabel": "Financing lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease, liability, current, statement of financial position [Extensible List]",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Lease Maturity",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease liabilities, non-current",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r1278",
      "r1284",
      "r1438"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Next Rolling 12 Months",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Rolling Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finance Lease, Liability, to be Paid, Rolling Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Rolling Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Rolling Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Rolling Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less amounts representing interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing cash flows used in financing leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r689"
     ]
    },
    "mrna_FinanceLeasePrincipalPaymentsNetOfAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "FinanceLeasePrincipalPaymentsNetOfAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Changes in financing lease liabilities",
        "label": "Finance Lease, Principal Payments, Net Of Adjustments",
        "documentation": "Finance Lease, Principal Payments, Net Of Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, financing, net",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "parentTag": "mrna_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets, financing leases",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r685",
      "r1029"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease, right-of-use asset, statement of financial position [Extensible List]",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases, discount rate",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1029"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases, remaining lease term",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r1029"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r358",
      "r359",
      "r363",
      "r364",
      "r365",
      "r367",
      "r372",
      "r373",
      "r441",
      "r457",
      "r625",
      "r636",
      "r652",
      "r661",
      "r664",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r781",
      "r796",
      "r972",
      "r1016",
      "r1018",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1031",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1409",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418"
     ]
    },
    "mrna_FinancingRightOfUseAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "FinancingRightOfUseAssetMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, financing",
        "label": "Financing, Right-Of-Use Asset [Member]",
        "documentation": "Financing, Right-Of-Use Asset [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible asset",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r1325"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1146"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1146"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1146"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1146"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1146"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r875"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "mrna_GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain",
        "label": "GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain [Member]",
        "documentation": "GlaxoSmithKline Biologicals SA , Liposomes And Modified Liposomes In Spain"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GlaxoSmithKline Biologicals SA , Patents Infringements in UPC",
        "label": "GlaxoSmithKline Biologicals SA , Patents Infringements in UPC [Member]",
        "documentation": "GlaxoSmithKline Biologicals SA , Patents Infringements in UPC"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GlaxoSmithKline Biologicals SA , Patents Owned By GSK",
        "label": "GlaxoSmithKline Biologicals SA , Patents Owned By GSK [Member]",
        "documentation": "GlaxoSmithKline Biologicals SA , Patents Owned By GSK"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r381",
      "r769",
      "r968",
      "r974",
      "r1004",
      "r1005",
      "r1006",
      "r1010",
      "r1017",
      "r1030",
      "r1322",
      "r1323",
      "r1396"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1324"
     ]
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant revenue",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r1348",
      "r1350"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1095"
     ]
    },
    "mrna_ImmaticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ImmaticsMember",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immatics",
        "label": "Immatics [Member]",
        "documentation": "Immatics"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r104"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r249",
      "r557"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r125",
      "r130",
      "r773",
      "r775",
      "r793",
      "r953",
      "r955",
      "r956",
      "r963",
      "r967",
      "r1290",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r249",
      "r557"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on equity investments, net",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r395",
      "r396",
      "r609",
      "r614",
      "r615",
      "r623",
      "r646",
      "r647",
      "r650",
      "r663",
      "r664",
      "r665",
      "r810",
      "r812",
      "r876",
      "r934",
      "r936",
      "r1004",
      "r1006",
      "r1013",
      "r1014",
      "r1019",
      "r1027",
      "r1394",
      "r1395",
      "r1447"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r609",
      "r614",
      "r615",
      "r623",
      "r646",
      "r647",
      "r650",
      "r663",
      "r664",
      "r665",
      "r810",
      "r812",
      "r876",
      "r934",
      "r936",
      "r1004",
      "r1006",
      "r1013",
      "r1014",
      "r1019",
      "r1027",
      "r1394",
      "r1395",
      "r1447"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r558",
      "r559",
      "r570",
      "r584",
      "r1003",
      "r1389"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r558",
      "r559",
      "r570",
      "r584",
      "r1003",
      "r1389"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r250",
      "r550",
      "r558",
      "r567",
      "r568",
      "r569",
      "r575",
      "r582",
      "r591",
      "r593",
      "r594",
      "r595",
      "r780",
      "r820",
      "r830",
      "r1003"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for (benefit from) tax provision",
        "totalLabel": "Total provision for (benefit from) income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r150",
      "r244",
      "r269",
      "r270",
      "r284",
      "r297",
      "r308",
      "r556",
      "r558",
      "r592",
      "r801",
      "r953",
      "r955",
      "r956",
      "r1003"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r552",
      "r553",
      "r575",
      "r576",
      "r581",
      "r586",
      "r827"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1003",
      "r1384"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax effects",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r562",
      "r1003",
      "r1384"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1003"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nontaxable or nondeductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566",
      "r1384"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation windfall/shortfall",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1384",
      "r1385"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State and local income tax, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r1003",
      "r1384"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in unrecognized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r1003",
      "r1384"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid (received) for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r240",
      "r583",
      "r584"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r1213"
     ]
    },
    "us-gaap_IncomeTaxesReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesReceivableNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable, non-current",
        "label": "Income Taxes Receivable, Noncurrent",
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r1274"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1186",
      "r1274"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "IncreaseDecreaseInRightOfUseAssetOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets, operating leases",
        "label": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "documentation": "Increase (Decrease) In Right Of Use Asset, Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnifications",
        "label": "Indemnification Agreement [Member]",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1137",
      "r1146",
      "r1150",
      "r1158"
     ]
    },
    "mrna_InitialTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "InitialTermLoanMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Term Loan",
        "label": "Initial Term Loan [Member]",
        "documentation": "Initial Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1162"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1162"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1162"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r238",
      "r239"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r943"
     ]
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, firm purchase commitment, loss",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r231"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryGross",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, gross",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r940",
      "r1030"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, non-current",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r196",
      "r206",
      "r377",
      "r378",
      "r380",
      "r732",
      "r958"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r945"
     ]
    },
    "mrna_InventoryShelfLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "InventoryShelfLife",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf life (in months)",
        "label": "Inventory, Shelf Life",
        "documentation": "Inventory, Shelf Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r944"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r295",
      "r308",
      "r967",
      "r1231"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization/accretion of investments",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments and Fair Value Measurements",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r152",
      "r317",
      "r320",
      "r653",
      "r654",
      "r1437"
     ]
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and land improvements",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease, Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1426"
     ]
    },
    "mrna_LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability derecognized upon purchase of underlying leased asset",
        "label": "Lease Liability Derecognized Upon Purchase Of Underlying Asset",
        "documentation": "Lease Liability Derecognized Upon Purchase Of Underlying Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r694"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_LegalContingencyFutureFirmPurchaseCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "LegalContingencyFutureFirmPurchaseCommitments",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails",
      "http://www.modernatx.com/role/InventoryNarrativeDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on future firm purchase commitments",
        "label": "Legal Contingency, Future Firm Purchase Commitments",
        "documentation": "Legal Contingency, Future Firm Purchase Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_LesseeFinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "LesseeFinanceLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in financing lease liabilities",
        "label": "Lessee, Finance Lease, Expense",
        "documentation": "Lessee, Finance Lease, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r695"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r695"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r1278",
      "r1284",
      "r1438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less amounts representing interest",
        "terseLabel": "Undiscounted future lease payments",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "mrna_LesseeOperatingLeaseNumberOfExtensions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "LesseeOperatingLeaseNumberOfExtensions",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of extension",
        "label": "Lessee, Operating Lease, Number Of Extensions",
        "documentation": "Lessee, Operating Lease, Number Of Extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1425"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r57",
      "r58",
      "r59",
      "r62",
      "r63",
      "r64",
      "r67",
      "r244",
      "r247",
      "r248",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r605",
      "r606",
      "r607",
      "r662",
      "r851",
      "r962",
      "r981",
      "r1066",
      "r1343",
      "r1428",
      "r1429"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r124",
      "r791",
      "r1030",
      "r1049",
      "r1050",
      "r1277",
      "r1281",
      "r1318",
      "r1419"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r195",
      "r244",
      "r247",
      "r248",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r605",
      "r606",
      "r607",
      "r662",
      "r1030",
      "r1343",
      "r1428",
      "r1429"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_LicenseAndRoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "LicenseAndRoyaltyMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing and royalty revenue",
        "label": "License and Royalty [Member]",
        "documentation": "License and Royalty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, outstanding principal balance",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r122",
      "r1441"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r122",
      "r245",
      "r254",
      "r429",
      "r443",
      "r777",
      "r977",
      "r978",
      "r1028",
      "r1441"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r42",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature [Axis]",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r399",
      "r400",
      "r401",
      "r404",
      "r545",
      "r819",
      "r975",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r399",
      "r400",
      "r401",
      "r404",
      "r545",
      "r975",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r399",
      "r400",
      "r401",
      "r404",
      "r545",
      "r975",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves established",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r1180"
     ]
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyLossInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses related to indemnification obligations",
        "label": "Loss Contingency, Loss in Period",
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r1335"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature [Domain]",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r399",
      "r400",
      "r401",
      "r404",
      "r545",
      "r819",
      "r975",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, new claims filed, number",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claims outstanding",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1336",
      "r1337"
     ]
    },
    "mrna_MNEXSPIKEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "MNEXSPIKEMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "mNEXSPIKE",
        "label": "mNEXSPIKE [Member]",
        "documentation": "mNEXSPIKE"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_MTCSouthMTCNorthAndMTCEastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "MTCSouthMTCNorthAndMTCEastMember",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MTC South, MTC North and MTC East",
        "label": "MTC South, MTC North and MTC East [Member]",
        "documentation": "MTC South, MTC North and MTC East"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r984",
      "r987",
      "r1043",
      "r1047",
      "r1445",
      "r1448",
      "r1449",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1475",
      "r1476"
     ]
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Customers",
        "label": "Major Customers, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r291",
      "r400",
      "r401",
      "r402",
      "r403",
      "r494",
      "r525",
      "r526",
      "r527",
      "r545",
      "r645",
      "r730",
      "r809",
      "r811",
      "r819",
      "r843",
      "r844",
      "r895",
      "r897",
      "r899",
      "r900",
      "r910",
      "r913",
      "r914",
      "r916",
      "r917",
      "r931",
      "r932",
      "r971",
      "r982",
      "r997",
      "r1004",
      "r1007",
      "r1008",
      "r1020",
      "r1021",
      "r1025",
      "r1026",
      "r1044",
      "r1345",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "mrna_MerckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "MerckMember",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merck",
        "label": "Merck [Member]",
        "documentation": "Merck [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_MexicoMedistikMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "MexicoMedistikMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mexico Medistik",
        "label": "Mexico Medistik [Member]",
        "documentation": "Mexico Medistik"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r291",
      "r400",
      "r401",
      "r402",
      "r403",
      "r494",
      "r525",
      "r526",
      "r527",
      "r545",
      "r645",
      "r730",
      "r809",
      "r811",
      "r819",
      "r843",
      "r844",
      "r895",
      "r897",
      "r899",
      "r900",
      "r910",
      "r913",
      "r914",
      "r916",
      "r917",
      "r931",
      "r932",
      "r971",
      "r982",
      "r997",
      "r1004",
      "r1007",
      "r1008",
      "r1020",
      "r1021",
      "r1025",
      "r1044",
      "r1345",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435"
     ]
    },
    "mrna_MinistryOfHealthLaborAndWelfareOfJapanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "MinistryOfHealthLaborAndWelfareOfJapanMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ministry of Health, Labor, and Welfare of Japan",
        "label": "Ministry Of Health, Labor, And Welfare Of Japan [Member]",
        "documentation": "Ministry Of Health, Labor, And Welfare Of Japan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "mrna_ModernaTechnologyCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ModernaTechnologyCenterMember",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna Technology Center",
        "label": "Moderna Technology Center [Member]",
        "documentation": "Moderna Technology Center"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1352"
     ]
    },
    "mrna_MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More Likely That Not To Realize All Deferred Tax Assets",
        "label": "More Likely That Not To Realize All Deferred Tax Assets [Member]",
        "documentation": "More Likely That Not To Realize All Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r984",
      "r987",
      "r1043",
      "r1047",
      "r1445",
      "r1448",
      "r1449",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1475",
      "r1476"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "National Institute of Allergy and Infectious Diseases member",
        "label": "National Institute of Allergy and Infectious Diseases member [Member]",
        "documentation": "National Institute of Allergy and Infectious Diseases member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "netLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r98",
      "r126",
      "r189",
      "r193",
      "r218",
      "r221",
      "r226",
      "r244",
      "r247",
      "r248",
      "r251",
      "r258",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r275",
      "r354",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r445",
      "r448",
      "r450",
      "r454",
      "r534",
      "r599",
      "r602",
      "r639",
      "r662",
      "r794",
      "r873",
      "r889",
      "r890",
      "r953",
      "r955",
      "r956",
      "r1064",
      "r1343"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1103",
      "r1113",
      "r1137",
      "r1146"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "mrna_NoncurrentMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "NoncurrentMarketableSecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- Current Marketable Securities",
        "label": "Noncurrent Marketable Securities [Member]",
        "documentation": "Noncurrent Marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_NumberOfCommercialProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "NumberOfCommercialProducts",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusinessDetails",
      "http://www.modernatx.com/role/NetProductSalesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of commercial products",
        "label": "Number Of Commercial Products",
        "documentation": "Number Of Commercial Products"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_NumberOfDevelopmentCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "NumberOfDevelopmentCandidates",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of development candidates",
        "label": "Number Of Development Candidates",
        "documentation": "Number Of Development Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_NumberOfDevelopmentPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "NumberOfDevelopmentPrograms",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of development programs",
        "label": "Number Of Development Programs",
        "documentation": "Number Of Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1297"
     ]
    },
    "mrna_NumberOfParticipants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "NumberOfParticipants",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of participants",
        "label": "Number Of Participants",
        "documentation": "Number Of Participants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r970",
      "r1297"
     ]
    },
    "mrna_OperatingAndFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingAndFinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Operating And Finance Lease, Liability",
        "documentation": "Operating And Finance Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Operating And Finance Lease, Liability, Current",
        "documentation": "Operating And Finance Lease, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current lease liabilities",
        "label": "Operating And Finance Lease, Liability, Noncurrent",
        "documentation": "Operating And Finance Lease, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_OperatingAndFinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Operating And Finance Lease, Right-Of-Use Asset",
        "documentation": "Operating And Finance Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r953",
      "r956",
      "r963",
      "r1290",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r1029"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities - operating (Note 10)",
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease, liability, current, statement of financial position [Extensible List]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "mrna_OperatingLeaseNumberOfProperties": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingLeaseNumberOfProperties",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of campuses",
        "label": "Operating Lease, Number Of Properties",
        "documentation": "Operating Lease, Number Of Properties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating cash flows used in operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r689"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, operating leases",
        "verboseLabel": "Right-of-use assets, operating, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1029"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r1029"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "mrna_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses that will carry-forward indefinitely",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses that begin to expire in 2030",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r190",
      "r191",
      "r192",
      "r824",
      "r825"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r1030"
     ]
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "mrna_OtherCollaborativePartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OtherCollaborativePartiesMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Collaborative Parties [Member]",
        "documentation": "Other Collaborative Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase from available-for-sale securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r15",
      "r115"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities:",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase from derivatives designated as hedging instruments",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net realized losses on derivative instruments reclassified in net loss",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges:",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r795"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income",
        "verboseLabel": "Other comprehensive income, net of tax",
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r15",
      "r115",
      "r219",
      "r222",
      "r266"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: net realized (gains) losses on available-for-sale securities reclassified in net loss",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r84",
      "r217",
      "r352"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension and postretirement obligation adjustments",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax",
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r84",
      "r110",
      "r217"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214",
      "r352"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r40",
      "r89"
     ]
    },
    "mrna_OtherGrantRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OtherGrantRevenueMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other grant revenue",
        "label": "Other Grant Revenue [Member]",
        "documentation": "Other Grant Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r1030"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "totalLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Noncurrent Liabilities",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r1011"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid services",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1320"
     ]
    },
    "mrna_OtherPrepaidExpenseMaterialsAndSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "OtherPrepaidExpenseMaterialsAndSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Down payments and prepayments related to manufacturing and materials",
        "label": "Other Prepaid Expense, Materials And Supplies",
        "documentation": "Other Prepaid Expense, Materials And Supplies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r58"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsScheduleofOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Noncurrent",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r121"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1101",
      "r1111",
      "r1144"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1104",
      "r1114",
      "r1147"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1104",
      "r1114",
      "r1147"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax payments related to net share settlements on equity awards",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of credit facility issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r234",
      "r318"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of business, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of intangible asset",
        "terseLabel": "Purchase of intangible asset",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in convertible notes and equity securities",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-based Awards",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "mrna_PerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "PerformanceStockUnitMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Stock Unit [Member]",
        "documentation": "Performance Stock Unit"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PCV Agreement",
        "label": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "documentation": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r455"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r853"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r455"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r853",
      "r872",
      "r1481",
      "r1482"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001; 162\u00a0shares authorized as of December 31, 2025 and 2024; no shares issued or outstanding at December 31, 2025 and 2024",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r447",
      "r452",
      "r787",
      "r1030"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income tax",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r973",
      "r1320"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from credit facility",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r1277",
      "r1279"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r1307"
     ]
    },
    "mrna_ProceedsFromOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ProceedsFromOptionExerciseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercise fee",
        "label": "Proceeds From Option Exercise Fee",
        "documentation": "Proceeds From Option Exercise Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of marketable securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r234",
      "r318",
      "r351"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration for options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock through equity plans",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "verboseLabel": "Total other revenue",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1348",
      "r1350"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/NetProductSalesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r184",
      "r310",
      "r733",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r937",
      "r952",
      "r955",
      "r956",
      "r984",
      "r985",
      "r1042",
      "r1044",
      "r1045",
      "r1048",
      "r1052",
      "r1183",
      "r1207",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1338",
      "r1339",
      "r1445",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1475",
      "r1476"
     ]
    },
    "mrna_ProductSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ProductSalesMember",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/NetProductSalesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product sales",
        "verboseLabel": "Net product sales",
        "label": "Product Sales [Member]",
        "documentation": "Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/NetProductSalesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesProvisionRecordedasAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r184",
      "r310",
      "r733",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r937",
      "r952",
      "r955",
      "r956",
      "r984",
      "r985",
      "r1042",
      "r1044",
      "r1045",
      "r1048",
      "r1052",
      "r1183",
      "r1207",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1338",
      "r1339",
      "r1445",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1475",
      "r1476"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property additions",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Accumulated depreciation",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1185",
      "r1328"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1185",
      "r1326"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1212",
      "r1327"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r694"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r144",
      "r147",
      "r148"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures and other",
        "verboseLabel": "Furniture, fixtures and other",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r144",
      "r147",
      "r792"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetTables",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment",
        "verboseLabel": "Schedule of Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r694"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated\u00a0Useful\u00a0Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r361"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Axis]",
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryRawMaterialsMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw Materials",
        "label": "Raw Materials [Member]",
        "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Domain]",
        "label": "Inventory [Domain]",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "mrna_PublicWorksAndGovernmentServicesCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "PublicWorksAndGovernmentServicesCanadaMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Works and Government Services Canada",
        "label": "Public Works and Government Services Canada [Member]",
        "documentation": "Public Works and Government Services Canada"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r123"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r123"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]",
        "label": "Purchase Commitment, Excluding Long-Term Purchase Commitment [Table]",
        "documentation": "Disclosure of information about purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes long-term purchase arrangement and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r123"
     ]
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitments",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r123"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "mrna_RSVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RSVMember",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSV",
        "label": "RSV [Member]",
        "documentation": "RSV"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_RSVVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RSVVaccineMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSV Vaccine",
        "label": "RSV Vaccine [Member]",
        "documentation": "RSV Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r291",
      "r400",
      "r401",
      "r402",
      "r403",
      "r484",
      "r494",
      "r525",
      "r526",
      "r527",
      "r533",
      "r545",
      "r645",
      "r704",
      "r713",
      "r730",
      "r809",
      "r811",
      "r819",
      "r843",
      "r844",
      "r895",
      "r897",
      "r899",
      "r900",
      "r910",
      "r913",
      "r914",
      "r916",
      "r917",
      "r931",
      "r932",
      "r971",
      "r982",
      "r997",
      "r1004",
      "r1007",
      "r1008",
      "r1020",
      "r1021",
      "r1025",
      "r1026",
      "r1044",
      "r1055",
      "r1333",
      "r1345",
      "r1413",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.modernatx.com/role/InventoryNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r291",
      "r400",
      "r401",
      "r402",
      "r403",
      "r484",
      "r494",
      "r525",
      "r526",
      "r527",
      "r533",
      "r545",
      "r645",
      "r704",
      "r713",
      "r730",
      "r809",
      "r811",
      "r819",
      "r843",
      "r844",
      "r895",
      "r897",
      "r899",
      "r900",
      "r910",
      "r913",
      "r914",
      "r916",
      "r917",
      "r931",
      "r932",
      "r971",
      "r982",
      "r997",
      "r1004",
      "r1007",
      "r1008",
      "r1020",
      "r1021",
      "r1025",
      "r1026",
      "r1044",
      "r1055",
      "r1333",
      "r1345",
      "r1413",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435"
     ]
    },
    "mrna_RawMaterialsAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RawMaterialsAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Raw Materials, Accounts Payable",
        "documentation": "Raw Materials, Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]",
        "documentation": "Information by name of property."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r172",
      "r921",
      "r925",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]",
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r172",
      "r921",
      "r925",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "mrna_RecoveryOfCostsCapitalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RecoveryOfCostsCapitalExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost recovery",
        "label": "Recovery Of Costs, Capital Expenditures",
        "documentation": "Recovery Of Costs, Capital Expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1096",
      "r1106",
      "r1139"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r244",
      "r252",
      "r253",
      "r420",
      "r456",
      "r697",
      "r714",
      "r782",
      "r947",
      "r949",
      "r950",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1402",
      "r1403",
      "r1404",
      "r1405"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Abstract]",
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r1383"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r1383"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r1383"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r934",
      "r953",
      "r954",
      "r967",
      "r1436"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "mrna_ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Funding Arrangements",
        "label": "Research and Development Funding Arrangements, Policy [Policy Text Block]",
        "documentation": "Research and Development Funding Arrangements, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ResearchAndDevelopmentLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ResearchAndDevelopmentLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development funding liability (Note 5)",
        "label": "Research And Development Liability, Current",
        "documentation": "Research And Development Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements and Research and Development Funding Arrangements",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r933"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "mrna_RestOfTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RestOfTheWorldMember",
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of world",
        "label": "Rest Of The World [Member]",
        "documentation": "Rest Of The World"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_RestOfWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RestOfWorldMember",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of world",
        "label": "Rest Of World [Member]",
        "documentation": "Rest Of World"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1097",
      "r1107",
      "r1140"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1087",
      "r1098",
      "r1108",
      "r1141"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1105",
      "r1115",
      "r1148"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1209",
      "r1275"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash, non-current",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r1211",
      "r1275"
     ]
    },
    "mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RestrictedCommonStockUnitsAndPerformanceStockUnitsMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Common Stock Units And Performance Stock Units",
        "label": "Restricted Common Stock Units And Performance Stock Units [Member]",
        "documentation": "Restricted Common Stock Units And Performance Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock unit",
        "label": "Restricted Stock or Unit Expense",
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r109",
      "r790",
      "r816",
      "r818",
      "r829",
      "r854",
      "r1030"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r255",
      "r256",
      "r257",
      "r259",
      "r266",
      "r268",
      "r270",
      "r355",
      "r356",
      "r388",
      "r444",
      "r534",
      "r588",
      "r589",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r626",
      "r628",
      "r629",
      "r631",
      "r637",
      "r673",
      "r675",
      "r813",
      "r815",
      "r831",
      "r1481"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails",
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails",
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "totalLabel": "Net product sales",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r284",
      "r293",
      "r294",
      "r306",
      "r308",
      "r310",
      "r311",
      "r313",
      "r478",
      "r479",
      "r480",
      "r733",
      "r953",
      "r956"
     ]
    },
    "mrna_RevenueFromContractWithCustomerExcludingAssessedTaxGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxGross",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/NetProductSalesProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross product sales",
        "label": "Revenue From Contract With Customer, Excluding Assessed Tax , Gross",
        "documentation": "Revenue From Contract With Customer, Excluding Assessed Tax , Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of Revenue",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r935"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformation",
      "http://www.modernatx.com/role/NetProductSales",
      "http://www.modernatx.com/role/OtherRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Product Sales",
        "terseLabel": "Other Revenue",
        "netLabel": "Geographic Information",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r480",
      "r483"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationTables",
      "http://www.modernatx.com/role/NetProductSalesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from External Customers by Geographic Areas",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "mrna_RevenueFromGrantsCurrentFundingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RevenueFromGrantsCurrentFundingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount committed for funding",
        "label": "Revenue From Grants, Current Funding Capacity",
        "documentation": "Revenue From Grants, Current Funding Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_RevenueFromGrantsMaximumAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RevenueFromGrantsMaximumAward",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award amount",
        "label": "Revenue From Grants, Maximum Award",
        "documentation": "Revenue From Grants, Maximum Award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of payment terms",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for financing lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r1029"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r1029"
     ]
    },
    "mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Decrease in right-of-use assets related to lease modifications and reassessments",
        "label": "Right-of-use assets obtained through finance lease modifications and reassessments",
        "documentation": "Right-of-use assets obtained through finance lease modifications and reassessments"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in right-of-use assets related to lease modifications and reassessments",
        "label": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments",
        "documentation": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Income (Loss)",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r1421",
      "r1422"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Income (Loss) Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Available-for-Sale Securities by Significant Investment Category",
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision For (Benefit From) Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Components of Deferred Tax Assets and Tax Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/LossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r1003",
      "r1384"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1410",
      "r1411"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Provision For (Benefit From) Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1282"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Common Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets, Noncurrent",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.modernatx.com/role/PropertyPlantandEquipmentNetDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r694"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r1383"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r116",
      "r1442"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r533"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Repurchase Program",
        "label": "Class of Treasury Stock [Table Text Block]",
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r1002"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1296"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1406"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r288",
      "r311",
      "r312",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r774",
      "r775",
      "r776",
      "r836",
      "r839",
      "r841",
      "r896",
      "r898",
      "r901",
      "r911",
      "r913",
      "r915",
      "r916",
      "r917",
      "r921",
      "r922",
      "r923",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r938",
      "r960",
      "r984",
      "r986",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1046",
      "r1055",
      "r1445",
      "r1448",
      "r1449",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1475",
      "r1476"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r309",
      "r311",
      "r965",
      "r966",
      "r969"
     ]
    },
    "mrna_ServiceBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ServiceBasedAwardsMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service-based Awards",
        "label": "Service-Based Awards [Member]",
        "documentation": "Service-Based Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award requisite service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock underlying eligible options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Common Stock Underlying Options, Percentage",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Common Stock Underlying Options, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of eligible employees elected to exchange",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Eligible Employees",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Eligible Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, non-vested at beginning of period (in shares)",
        "periodEndLabel": "Outstanding, non-vested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares/Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, non-vested at beginning of period (in usd per share)",
        "periodEndLabel": "Outstanding, non-vested at end of period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date per Share/Unit",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of options, exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average exercise price per share, exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/forfeited (in shares)",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Options (in millions)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options Activity",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payout percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Twelve Months of Continued Employment or Service",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Following Twelve Quarters",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r503",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price (usd per share)",
        "terseLabel": "Weighted average fair value per share (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1346"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1346"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of RSUs and PSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average remaining contractual term, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average remaining contractual term, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average remaining contractual term expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term lease costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r1029"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243"
     ]
    },
    "mrna_StandReadyManufacturingRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StandReadyManufacturingRevenueMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stand-ready manufacturing revenue",
        "label": "Stand-Ready Manufacturing Revenue [Member]",
        "documentation": "Stand-Ready Manufacturing Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r73",
      "r74",
      "r187",
      "r188",
      "r189",
      "r224",
      "r225",
      "r226",
      "r255",
      "r256",
      "r257",
      "r259",
      "r266",
      "r268",
      "r270",
      "r285",
      "r355",
      "r356",
      "r388",
      "r444",
      "r458",
      "r534",
      "r588",
      "r589",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r675",
      "r696",
      "r795",
      "r813",
      "r814",
      "r815",
      "r831",
      "r891"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r288",
      "r311",
      "r312",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r773",
      "r774",
      "r775",
      "r776",
      "r836",
      "r839",
      "r841",
      "r896",
      "r898",
      "r901",
      "r911",
      "r913",
      "r915",
      "r916",
      "r917",
      "r921",
      "r922",
      "r923",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r938",
      "r960",
      "r984",
      "r986",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1046",
      "r1055",
      "r1445",
      "r1448",
      "r1449",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1475",
      "r1476"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r285",
      "r446",
      "r447",
      "r449",
      "r451",
      "r675",
      "r733",
      "r826",
      "r832",
      "r833",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r853",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r862",
      "r863",
      "r864",
      "r865",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r874",
      "r875",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r891",
      "r955",
      "r956",
      "r1056",
      "r1480"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r285",
      "r314",
      "r446",
      "r447",
      "r449",
      "r451",
      "r675",
      "r733",
      "r826",
      "r832",
      "r833",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r853",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r862",
      "r863",
      "r864",
      "r865",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r874",
      "r875",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r891",
      "r955",
      "r956",
      "r1056",
      "r1480"
     ]
    },
    "mrna_StephaneBancelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StephaneBancelMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stephane Bancel [Member]",
        "documentation": "Stephane Bancel"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_StephenHogeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StephenHogeMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stephen Hoge [Member]",
        "documentation": "Stephen Hoge"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1143"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options to purchase common stock (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r109",
      "r509"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options to purchase common stock",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r73",
      "r74",
      "r109"
     ]
    },
    "mrna_StockOptionAndGrantPlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StockOptionAndGrantPlan2016Member",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Equity Plan",
        "label": "Stock Option And Grant Plan 2016 [Member]",
        "documentation": "Stock Option And Grant Plan 2016 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_StockOptionAndIncentivePlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StockOptionAndIncentivePlan2018Member",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Equity Plan",
        "label": "Stock Option And Incentive Plan 2018 [Member]",
        "documentation": "Stock Option And Incentive Plan 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_StockOptionExchangeProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StockOptionExchangeProgramMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Exchange Program",
        "label": "Stock Option Exchange Program [Member]",
        "documentation": "Stock Option Exchange Program"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_StockRepurchaseProgramAdditionalAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "StockRepurchaseProgramAdditionalAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional authorized amount for share repurchase program",
        "label": "Stock Repurchase Program, Additional Authorized Amount",
        "documentation": "Stock Repurchase Program, Additional Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1346"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized at end of period",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock, including excise tax (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r109",
      "r828",
      "r891",
      "r912"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock, including excise tax",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r109",
      "r831",
      "r891",
      "r912",
      "r1065"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r73",
      "r74",
      "r100",
      "r855",
      "r872",
      "r892",
      "r893",
      "r1030",
      "r1066",
      "r1277",
      "r1280",
      "r1281",
      "r1318",
      "r1419",
      "r1481"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchases",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r894"
     ]
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summary of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_SupplyAndManufacturingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "SupplyAndManufacturingAgreementsMember",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply and Manufacturing Agreements",
        "label": "Supply And Manufacturing Agreements [Member]",
        "documentation": "Supply And Manufacturing Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "mrna_TaiwanFoodAndDrugAdministrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "TaiwanFoodAndDrugAdministrationMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiwan Food and Drug Administration",
        "label": "Taiwan Food and Drug Administration [Member]",
        "documentation": "Taiwan Food and Drug Administration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carry-forwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "mrna_TermSecuredOvernightFinancingRatePlusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "TermSecuredOvernightFinancingRatePlusMember",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term SOFR plus",
        "label": "Term Secured Overnight Financing Rate Plus [Member]",
        "documentation": "Term Secured Overnight Financing Rate Plus"
       }
      }
     },
     "auth_ref": []
    },
    "mrna_TerminationOfTradingArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "TerminationOfTradingArrangementMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination of Trading Arrangement [Member]",
        "documentation": "Termination of Trading Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r441",
      "r457",
      "r625",
      "r636",
      "r652",
      "r661",
      "r664",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r781",
      "r796",
      "r1016",
      "r1018",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1031",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1409",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average price per share (in usd per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r45",
      "r69"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r109"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsandResearchandDevelopmentFundingArrangementDetails",
      "http://www.modernatx.com/role/OtherRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "mrna_UKHealthSecurityAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "UKHealthSecurityAgencyMember",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom Health Security Agency",
        "label": "UK Health Security Agency [Member]",
        "documentation": "UK Health Security Agency"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/NetProductSalesNetProductSalesbyCustomerGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government debt securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury bills",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury notes",
        "label": "US Treasury Notes Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails",
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Unrecognized tax benefits at beginning of the period",
        "periodEndLabel": "Unrecognized tax benefits at end of the period",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r571",
      "r1002"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax positions for prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r1002"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlements with tax authorities",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r1002"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions for current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r1002"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions for prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r1002"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r286",
      "r289",
      "r290",
      "r291",
      "r773",
      "r775",
      "r961"
     ]
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences."
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails",
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases to valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value added tax receivable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r1029"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1342",
      "r1406"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.modernatx.com/role/CreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1342",
      "r1406"
     ]
    },
    "mrna_VertexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modernatx.com/20251231",
     "localname": "VertexMember",
     "presentation": [
      "http://www.modernatx.com/role/OtherRevenueScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vertex",
        "label": "Vertex [Member]",
        "documentation": "Vertex [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationandShareRepurchaseProgramsWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r645",
      "r713",
      "r931",
      "r932",
      "r1020",
      "r1430",
      "r1432",
      "r1435"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r278"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares used in calculation of loss per share:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/LossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r278"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "330",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0001682852-26-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001682852-26-000033-xbrl.zip
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M9*O$ 407X8%'/8,^TUC*;X%B@;J T[2P4L!'6&R@_-<9< '@@D6+=$'ZSMH
MLZ36ZP[$; )_SY"6X:]%!Q2)Z];0L^M: T&G\,GR>1WM+PM[HDW\)"3//*ED
MX9"W0/.WR#1;VV:5&I+^#=)I;OEL9LP*FM_D#2I"B0A$9)3 %I'E@M#/D <0
ML:]-BHP19O-3!^N)EBOI!D65PN0*?0N3 <V0U"3<0-=SUM4RG1^[.F^R/.4'
M4&7),Z>Q?P^*+>SE-7!F@T+XBQ>L)SE10$^AWN':AI%S2WX5W(OP)LH Q1-E
M=45&!@N 4V_\W'<M]DC#FT-X.<5Q4\MYLP:!"TW!S'#E@#6"'"Z%*XNP"EO
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M2WD?0QKS,);9YY\]?OIBAW-MC/A9,?6)Z,1VG;.-ZX=XQ8MU.)9"(AQ"6&[
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MN^5[=W(X:+97#^.AYXN'R'94$UK9-*9>+:.19,G$!0697=U5'F,L<0%[Y2/
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MTB8TX7(R6FWH,Q]Q"B/Z+-ZG,)$H9#[$CQW&^]Q6!HYS="RH)['5B*5G/[8
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M;$F.)[/@+"%WJ,ER].PWK6OU$?0AMJW-HJF-#E$]!$Z$U(/.%!D5GR">06:
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M_UO_LO=&]/[WI'>.9N(76(7?PPXG!QCN!(,X ,$*C/=I!>3=<K>HB!]69D(
M'"*XT'<5 XDGV:R-9<WJ3(8P";E69(#\>;A:>D@-DA]BNU CYFSJP&.%&RI5
MG%!M)#JF)UFJ7,DTT. )3YO"_L/,ZS0FR.PNV5)V@DZN,+FBY899N,% JUSE
M,*RC<MDT%ZG8GDM20;DQ2F%N61ETV#\00PT(&LE$,B_P*2K+UEI7@PVES(33
MHAIVG4=(R&E&9;^XPANL\'39FC8J+PM7T \G)88%#1) QK#6RB)50;>DB3F_
M,TOC,BKNJ<W!7MTA6./9C));8=4K( RB![-9%4$)UOX36)2'\/!=:Q^K<^+7
MQ\90G,<WBHV1%M (=W&%!J0%J<GE$DD[)NTVQ:I5KG0#ZS]S"J"-)::^ T]0
M>KHV@H9<C+O'\1$L,+'CD:&XJR6SLL47\6]^KT7/%/(C<A951.W=STB>O7$P
M^X$FORK3HS1&$='AFC-AP.)6N8NIL,"@[=![[8:XGN08P(HC9,B ;NC XHT4
M/B)I6_&JRMNYBJH_!S?U0!AW0A@^*FC7\"2,.G.-UD1%E=Y%SIY(YVA\<_(U
MDDILY,SK*XK>Y 4?@S2;8G$^$F65!E=7SJMR:U$?N=T)6ALW7KUH!$_89(9R
MD*G;Q"4@=M78$G,\G!Y53_B#AK#=FR[,I4,G_T=.P]PCKQ2H_"6FD:!DGY14
MQI0OD+E"!:!6*@XMD-UDLGNC9#4CKE)>PC()6'NJJD+84"*"KFX>G[@Y6GJV
M<5I:#$.'F,.@0,6PF:S/3!V,N"ZZ2U$+[.P/GNUUQ#FAFJQ2XAQK&O?[+?&>
M&;QX0OK>)#,-1]$*$,9G  L^?]6?'K:?;[5'Z,FV>80(&Q "!]Z'&(3NR67_
M#[C<N[=^HK"F?:RX3HL/>1;D0R)@*;^C\!9[SXVV5\C6J)"PLW06"M%[#PCY
M@A8B#^BFP# K1^'L.N]K74W#5SHOYCG;B.&.K>OO4I<IEN#KI7MO$#7ERJ93
M%)"Y=NU.6-GR[9?5NY4M>[\U 3L&R5N#8"M5+\#X;4"A>UC(K["CT+'KUS,O
M&7.,GFA*#%ZSP _KN^WKNU ""8%/R&F'( [2B//# S1KC6+/C2)_W52:*IZ
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M7T^:<32])R\^*:#\6[+_)()")5BFUT4V_"^_?"^><]#,GZ_P%U!+ P04
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MAZ@/;V-DFVL2 ^R]\R(A5^HM%Q^]35KRQQ<?_.B-MZDYHZ>!(SR3X*VZ1)T
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MY/Q@N*Y8!KK\7"PHRTT&(%E?^:)(&^$=\+W'K4Q1T!+@"2,R(Z"2"/JJ@!D
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MCN7*FQ\+]/K^H+I0X0- .'>K*D^\+%)\AE=7=OTK,_\'4$L#!!0    ( #N
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MN@IC9N*MG<[?LT7^F6+?FS"?*&.AUTU>.-!?7HN_%T[ROS7^!E!+ P04
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MI595-?D,7*)3'<,'_$X7L;&EL9*HO8-+'3KQ0EH05(L.PL>O*Q4;^%&"!TD
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M^8\;.^@#^?MZS:6OUUR3[N!;627RD_@I,S/\-2(TUR;>2'NF:O%:5ZA3UX6
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MSK5EY\$%44N,5?W4%9Z,^.9?WLU]9KK]]-7E8'R'%4 6 63O^0#96QY CBJ
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M+T]!:)7=Z-V$ ;;,\R^] ;QA VR9L"B[,;Q6 VR9![]RRW=S6S,NI&F23#/
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M.SV^BB8/C<8 9"O(XRE>A]#CY_ T.[Q@' 9.8L?1,V>(5O!:!*\_)<%!/N#
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MKM\/112'"7$12S#4"LQB%MX8M%!4CE9<B.^-.*,3R?X.%/*PHOME2&&,.45
MB; 8D<0!>C7G65&(#V!Y_96@/9R3"DS94H EK/PE%D83!L!%_ "X1(TXB"<?
MIB ^QBXW*N2@S*_%DD6M!]"O OER2%N7*L3H/$%X>;(> ;794G/CD"WL*!@1
M)<;L;1L'?MKC#QB^1"LX HB3853+!9#FP!KV%,J_$C>D.*$6(E/"@,VNI\WZ
M"A&6Y=]&BB/PH=.# TVN;0G/<]$I&FGNGI? B!@:)'E=8!J4)#%VK0M"'^#H
MV4.9G60^EEHQ$&FG<>_4!R<H4B*="O#+B4%&4GY',@1%7/0\-QKF@Q;S\ "
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MKOY\K2'#D-S%8 ]H3TJ44T;?5XZNE4(NT_^=.P"?&+ 5-KJY[* <H"035>R
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MW9"[@",0N"1MX=UQHFF8-_OR_:>"!78C&_NN?Q=XL'C.[^<J /Z;Z@)JQ:*
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MYQRYHF!;\?;:QZW#MV2><>=>1W42FJI118(:I 2LD7&^)E*8-"06E@D0)=P
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MDTA'0%&!QS99NK6/,G+[S]"*%CF[UGC8?\[I03F:UO&>/V@')<!6#?UN[IK
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MPW.64"EKF:X/W;=: =HX=6XT7[O9Q$<-X/]4]SOFH3O>@NT%>9MN*DV+D\U
M=W5P;(P'IYZ$%?8><BT=RSE5"Q8BH29L!VIGN]P*/_%8 U0/V[S.\H/:8.1U
MC-SL6!Y->*-X8Y.SE]=6"]M>L2"-UTF:<?S!6P*=_)9?E';"QZ<R_(4<W+;!
M%2/5W^P^DCMZ56>S:ZXY]^.7A%/J\D?.O'"0K)__L9$<N;)!O=(ZUIRF6*T
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M[[E<0@[V#1,[UTQP 850WI'QC U5@TDS$&8C!783>7>5=$=M"JBZ(9?3,M@
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MIVT>@H0F\4$N0&['JQ8U4XG(PUW)16"JKOCI,E?.P[,^UU9+V;\8@-#2(WM
M^.'0+N94Q8P2TL:(6W)MJMT867UYB,U:8NIE].Q9V]TD#:>\D!7(%**/2-V)
M+'&Q&F.5$=LH-[P^U(ZI3:!3%O75J*K!C-]-#4V%K@!^%NL1ARCGVS(YF"#_
MEUG?*J^#[2U<FLGD>PQI=R]E6=*.)470%[S]Y$#MK+JLO:EL-SGO71OI$-N7
M0<!*#6LV^9V[&CJQ4EP*1I-B^FL 0G&K^P,V<B-Y*4%?I+_23_B!P54#9W@
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M:V[SR'!TV54AD\LG1[( VN!@70JJ$YH4:7G':G5I:\E\/ 9078J618>S"^+
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M+V"06YG@W#*TA&*$I6,1F!8/K[,IHW-/701V[>3UX>EC%K(HU[7U<"BAY3E
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M&7D]8Q9%U6@@@I9R*%YT;?F40W'H(C_. W**U55Q"I5\M%)KQ5C%?9VK!R
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MWU^,S7NAN'O&>%LL!R31+0)0IU!BGF?9M%&174TK=K<[V;=[A$LHNZ8#IXE
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MBP_CO-SV!_NJN7V)$D @$DP8K.SS9H$(TN@UP*_!XVNS:\..*X$4:JY9P5O
M!<)7<$@R3)F5JZID!2-<J-"K^HM&<=1F X3QKH9)"4;QSP<'][:)$G_R53VN
M/?QLO2F2PM&_>#C^3/]D4S9(",02EI_B+3D/X<$DQL\:A&5A?1EODX6R4FX1
M*66-0H5W 9_Q-9&HDKM%QP2BWR/GT-TJ^JA5]".W]F=;1;]&]63@<]IRP5:?
MM(XJ;9%T%@@)F1G;RY%L@CLI&=Y[H-8H@YLI>1H/3)SM:0R?A\EG0]*]X+]+
M7]1]&K&JOD*AS[6KKZ+;,](D)0OQ!D'&N[7W06OO5W!;D0_C<ZX_(;\H-YQR
MK(-$*J<$3K+J5JN:BZX?5#&(TS4\*^L0R&Q-KKD+WYR7V@ 'D4APAHG88CAZ
M8>FVM)!3_,<E<2&UW1Q'= .N3DF*WJVUW[?6'I>0RO[,2RUSEMR!=QD\5DB;
M:[//9 8G3@@Q!-@:/"N*P$,@5;A&6P,CR%I+.1T%@<V-JP/8:)?88.=3%B+2
MBPQ'\HQ6\VZA_<Z%!BZ@8"N$>^2Z:!?=9UMQ;\835$A#43%7\UO7Z0SVZ3!]
M>EFLE^5J0Y>NQ4>RTABUXCWIY#&7 %H@9QH!_;HLVIC]0G<2"SF"8F&/4USC
M.4)7-@(MK>1!C._@;H'^7H^ONK)H^*I9@?B4);L_?Z[,[ <$$A=8=#!Q6I7/
MST9%PJ(=!9DP/6;)$=_%B'<O9#$%J3JP[(H9FN9LH<61D-R7KF!4O^:7+)\U
MN3[!T0,NPM[GG@W/NV[PNLB%\028E=OKLJQ'O!@6.;%?D2=FT0_HO_0=2817
M&TVBD[NG:3?,(O>W:1Q9 ?C,2T(/ES&K2=N2V$/#@88\'7C:W9>Z3(8;GA?;
MF20_NJ[>2<Q T)-0LI=UU;3AIXF*2DQ2_JXP2U)*!A\5%\=U46^=B9+R:EAF
M?$ZM?7:;596&K]N"&;W9I/Y=0^U#,9X?8GV&8./5ZU^Z^\-D294S'(=70=;Y
M2O!3&N_PBTB8)ULJ<R//.56O(%SVHE+4J15B^_-AQ!!(5*,#*7SE#WPD;KH5
M@%G-=1UF_0] H2!.XDMA$75Q%<6-$<X2Z6+6[ARDPN6X2%0TC*D8HQ7,?I\P
M]RU2Y\>^?5Z@>#^LGQ17 ]A2ZED*%JJ]T.QB#Z\$4MRS2;?&VJUW+!5@F?LB
MX@]:DG\6CF7)S+_>D'F82;[8+X2T_X[@GO?<.,P$?L4_&F0H"T]P:@L=4"VK
M,#SC4_]$#)F+<.++=R>22.<#M24*,B4[Y\)#L9WJK;#CSZO5Z<0/GZ([DJ49
M^SWA%-@P"J7O7] #(OR<*'<<MJ!LTHOF^!=7WQ+T+'$8'ZOUU1?!(FJI3\SM
M>@-R&N&M*]:R(F>P1\(YS+ZY>7-1$T-IMB"5W*;]/!O&RUGQ>5@)OX50)'SU
M4Y9J/[*GZ/6<1=3/Y* $+^"B^ WER;!%WX9AW75R-&V;C<U;FU'AQ]:/$M7*
MFD4_6(#8O;7:3X4-"17"HQGFQU43GN'SC;,;7H[M"L1=:80KP>6'0?MJ\AAG
MR_FJF,MQ_BOL4_@\O('4TV%AX 7&ZFNUI.Q(W97S'6TFYH1V91T<".#+HDF1
M72=X?G5BBG"8U8NF/8%WN0)&WWVI:Y;;</:5)C/$EA V%H!6"M \&-[Y)2EA
MZ,&V<&7'[J=4P;? @&D+ @_Z=1,<G<89Y>VNK7GPMZ+&4(B_H>Q.DT4)W* V
MB*2*',5YQ/"%$6)CMZ3)ZG(U=)\4%A?#5?YWW8EE0XX8&0YXL, =1$2]EQK3
MC6KTS*N*J3^B"L+O!*_ LTN_H0A)>$3HX0 0H]3 @<09^M*N]H\W&GZ!HQ(\
MSJX'4'CX\'\<S\1_6'65\U3U82%'\Q('0R-SAC7QK\X.3M0NX;R]ZD(!].>.
M;"Z+]-8@2@(R"(V,3=L[Q]&FAH4*<.T^[0UI .PLY2S$>862Z6I(54YZ(*$,
M0BO<+>P6BTZ]0#(%@&GG^Y#?B 7>9K[3KM"8(PSOAM6N;D(*BI4\-0RV&2@\
MC /PV$BX5C9&7;-=M=H2W%)C_,/>FK6%*%8AS]0PC5[P!J5TRG4XXK>47+ F
MPS'G"(3)A5B1Y:I\5\U6>U6_F L0(>D=J8>IWF'P,J,U[C9E\59KWP!6-, $
MNP?H2G2&8<.[/P97M-5NV'BAG=%O6!9B4U+-^ 3_*V\ZP2(5?]KTF/2&!(=M
MNYA[*VI2A!)M#__^J@HK/8R,B8:1H[F3<'4;#I"5L"G$:@%7[_$8D -Q57E]
M<T+!8 ,O7SP-BV?6*'Q9P]@H:M7I<)4$=R" M3*@P]P)][5 (RH J+O2U>]B
M"F.W(KZ<C?E6(20>>U'L05H! E9D$6CGXB--^RNS21R)?!A/W748<B$%S7 B
MALN$'<&>D;"RXNNXO2=J+\F!$,XPM(P L)>L4@KYS26UIQPI61[7\N@UT3VD
MU5H5(0B$$<: GSV;G,W!Q;:77OWT;RR*2%\),(P )2VAUUR7?0N=L5G6PDIV
MP<,Y7%4XO)#]<XN+J#-E?L,M:-IM+G5^M!Y(&X68E("<'N>7*%I5T@0<W04N
M!, :6IXXPEM;+M+M$T6?L^(;;@&@!L-3=V^KU:K+5CYL\6*RV+4\(BZ+F24
MEKMZ49#VBXQCEP5ZFB^S!#ZB\#NHW_NA?H_NH'Z?QQE5XWWD9HWT5Y.FO2AJ
M[9B/[MBL@<QU:B@B;TSP*^EX258953IH@9G\ U._DB=B-]4FN'R61Z/SJ$7B
M:VOD1]:1=:@'WX$19%ZL-_SGP^_T6L14/?I.#6"UW4\G?P^A'?]#V][[V0L7
M4<FY!R[N3;6PS+4I-$C"2E]78/0$*X+N6>VF';IVN"L6');HVA+44WJ=:I3?
MPD[.C3;"!889R(<UQEEI5GUES(;:3A:IAO4(3L8_/-O:VW?HLW) ]8GLS)B:
M-R  26-]9 UC9^T#1]$Q^:'AD.>OU&IQX]L0C R:#:&2R ^>L2)IVQ(>J^E[
MV[GZEMYJ;(G00K#?"IQ!Z<J#G%ZQ+:0<0HFVJ,.6P; &\##<Q:1G>?[VQ?<T
M9M&"4Q.KA.(.ZHOHDF"9;U74DD^'>YG?J&U69=R,X<C?= FG001NF5J%PY=G
MNTY9+0 N6ZA:;#:NXLK9.&VJ3<FHB>V-86&-O8-%#?TJ7K]TJMLS6)-PQL=E
MJOSYTHAP76ACZ+H4MFX6OCJCMM'60C[;#=7W0Y#HW]?P]]7#XVSX>_+RU?G+
M5V=OGDY>OWSR[.SGR:NGK\]?OGC][/&SGY^]^3^_:\]_SOZL,[8WJ8@$Y18J
MV1# ?HAOR@U\0>Q&MTWT[(K3A6<KX95E$7+7-Z574K-RX0H07<,N5Y6GMJ+F
MO2>O7]V/,C!B*!+4L[.C9EUMC8;%W.NI[U8BVX\#0S&;T:B.183:$=H<;AB"
MP. >2^E+E)Z9MJ#X%.P ?7 <PT7W9^?;4P RWMTN'$X+J<=QWVF##0DM\QJ\
M>[S3R?F*'#R1"1&O^9F2\R%"^?+8F@DG H&'1?V)HN[*7?)*<O^)'$>=GU?9
MHE*GYTE<>IL06<UAZ/]G<)"^TPI"N+CY2IW*#ICU+F<A1"G-:Z%:.MN\8%_#
M:7=]?;H6#V?[[C0L@S_F:_J/<<V?V(TS 3">3&WS3DJ^D@$P,:O/OA2^.KJE
M<":,&<_+TO387P.#H4B62'Q IW!9:>Z,B^/UTR=*J:FB&1N;90K':I5 JT1=
M-%_;X(;6JM]WT1(9/#!"[S%KGZ9'_JLOC_7(?'[^],VS-\]>OO@T35>?<_V]
M^9#>7N5&( W&EC1'$C,![T&'C-#'/EL[ 2#A0J*4_)M$>DQT=:X"!C_Z#;&]
ME6H"%I;6#P?,)<A;D"P*L15_A\::,0Y^\RVC^F0B6?I\6WY\/1WRL8YA.?2+
ME?2!B!DP/P'UA$WLM!,QPXTP!W+BI2NW1_\_G2S:W045B>!+[*<#:KZ!S"&#
MA)WBXXJL8LHU!\C=Z>0GXX A'^0\6U>.HZ7S:N=]O\Z?78R%7+H38R"7))O*
MG%I ]H<X FFM_7KH,:PDI9T5'C,L:($1?;(0:>*;^?9T'Q3,'X?XKU(B-"$M
M%7=-1A;,*;'&(^+>LE&J*UCWR)?JKR#YZ90>28D1GB<8/;*!8\,BM%,!3(,T
M+K*YHLC<KBW]"W- Y*TY]4C]^)KEH:%(X,C!&%]?EK4 W$2T!)%R9+TI5JNJ
MJ!5Q81&D<*@KQ-(BUV-*>HP;C]?"8[.*JNRW-6#[M90E$+DLP$\&R9[MY'P9
MKB. YL=5\^)-6/ST<S("LHQ2CRFXABE&H=BSLR02"?<,4EI*_9N+"4C73<OV
M=5$WRXJ/]:*Y*JZ*=];2V<\QTO^RY0F(1B]NE&>/0H/97>3E8[-H06@M%7R#
M!V@^.YB;%,<!=1\1OHL/'5X.EDD3H.9T9XQMU^5-H_[CJGC7O [^X.5?5O+U
MRR;"1TFI -X)U?,6QE825"6\'VXFTY6 ?N2(DW0F4$:< N$N'=W22R/PG73]
M-4]*K7?V<E)FRTFWOLO%'Z^M6RX> D6ZZG*U\PK".L3;Z)/P=#A)LR?O_3M-
MQ>?<>D]ZHXQAPV3%-E$CPD5ADI&J^&YK(#@CIB@NV0QSQ&.)GIG "EIECK4!
M+I<@^YACDQ3+4OVV;;,J6V4?GLJ/%)X.F<^^*]&!_D7/CLOP_U8Y&-BQ<TK-
M;L)<1+C2 EI>U6P7,:16A&ZUM$%ZW6IM72:QE=LS$P)$=$5>_K:LUC-@*X3<
MCA!_?2P=0;M/=N-YTWFO]+8MGF>U;H 4FRJ\&J7!H=4K5L',+?81(J)I,WY+
M/#V,%+<HK)I8R@JK9 ?N.12RRRL!%-#<L)= G#;5UY@70K(Z!^!.!CW&R&H;
MAJ25IY/79<JO5-W;R0^RL#6[\N8R'29RY^E89*0/11<F-A!,8T6_*W.JIEBT
M4>J]G<"?S!2'S1%51(RS7FX@U@RT.=AH+5F3D])EDJR-4I)M%H^=:BKHR)V;
ME_6<>_QH'O.@Z\+3:B26M6EK]$TFQ"4?<'Y[:XGML..^?GYR2>],2]@#5K;=
M*TDT8*&J#AK2PO8%V[CE%<CA4PROP;HGOG>T3/,P O$!G2G<U=J>L=U_E^U[
M+&[9#$@@[5BF:ED@FT;WFSOF[[MJ_A;[A0EDBP"XN%ER8E\.D&0%1 ]1C%;*
MY6DVYA*5J3_48YWT524M( %.A;?F9LL"43#DK<2#NH.' ![RQ1T\Y/C.Y0-9
MRH3$@!-T6]V+7\O4T7F MG8\7!##&T7L6=T*1^R^@2,W""!$UFNNL:!4Q+T)
M4S NV+UCU]M'F&OAI]/LC+98#A,M-UKU[&44N5[V3'M2PQRDI Q4T$3<2&P
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ML>Z=K"G\=7O76CK5^LN,4Z9E#A83TXQ,N4Q >E7$-N7\#, IA8G0UKQ5*=P
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MYL9OF@A&71#BAFXPX,/(,F9)]2?ENTW5.BH!+CR=/]SM30L!HG ,3UZBZ9L
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M?8OWT2Q<K64L( 836+$V_4/V.B(5&&S\0D2:WS_:L9SI?,)[Q"5)\8378A>
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MIRNG,)1)LC"Q /P2H\F."E82K:!  CP0J8-+#TA(7#F[+AE^AI10,2A-#W7
M&:SJNKE*A"C+ O7"YHK]"\(-$9T6E-D*">FPDK0C,?PYZT"*U6)7\=.(ZDJT
MB#5TRW1Y-=W+F$AY,"0[P$!&5I9SP&)0HL&YCZ9B:F[D$(Z5U_SZVB$JOH'L
M JO5,R7,ZF+B9K7:&&(H!%R40-/6E)6<V'+LYJG\WCSIC+N7+E)98KG:F9T2
MFFKQA+:FVEN([ZD_+JVV_UF([/[P7UE,P8IA;D"23([:#_50LN3[/7G%L<AD
MT=SW-9.ZO"@L/DGUZ9Z^4^[:'EMN+B\AZEJ,A5*XT_&OUV7*Z,-KP29@Y%W[
MBZCLEQAEEO8L8<N,?I>M1NNG](E:\^Y=F;6.=H0J#?4B'(F\S#P)%PL?F1!L
M,<E1+R+ 8[%KK94F2W>TV8UC ^6XPJJF$90[1]S%F'0*GE]YA2-MJA1$<W*S
M] CC2IS%B9LC>QC153<)0XD<&E6]\TD2]DW2IV!^9RGMXV*$:$.ZRX;!<(A=
MB ^AO;;2T6T]]O)-E-7'F=,,T<C%19X]L*!U6)=+OQ4Y,M2X2B&1E@Z$G@>F
M- -=:D?.I-(@Y7ZAS1?8,'2 Y!OHV[\L5\N35;6$Y&&AFLV+X 97K.D8'$\V
MR%894U2?0I@).K7[\4E6>R8\PE1L93?EUYOZ(BX[A4AKPK=+,)B$:QG5E&(N
MDF5)ESV?PE<(:WEFV(R,A%7R /-B$_F%IA.5]LP9"3*!8Y3RA5Y7>\63]G<V
MS>&\#Q/#,AB"O%(R@_LTXZ,S/(UPD>@MAQ<MV[Q0B<$H*>4E6TB9YI5:3--,
M)M?AL4L:P/8.=O'4^89A;->2N'#A)_^]Z\POB"@8TP4).[V,PA_;_#MBA%80
MRCN4TC#3)<Q%DLH^" A<!&= $NJR$-:O7IPY8?AE50(2U<4B1K2O?//$,I2?
M(RJ/RA=E8"YI!CR*SU(=RDI)"QI6G4@9<D0J>$&6W'=2L)9X5CW=GIC9!Y0$
MXSGS.JFT/59DJ"JT)9:/R:M(6J^?/3DHU_V/::(=<R;XUS'TSVA5Q=)*+AWD
MU&"'B*%;'I;]6DI.[D"7@:])'MR+HXZ/ 6BF-U6OE):.L?T)8N*3R$B69'*C
M;K2D!XC<R%'0!C) 1_N5@HX@733M>]0+QAW;5,1)*4"MB[F'C6 ;C=43@BOW
MUINMJ\&DN@O[+GPU;9 JCEZZ*_X@Z^A)W?66CK9+,'T\%'FK/KK/^_GC1D5$
M5.ACA1-B_;LU+8^FJ*ICVI7E6S+](NN(L#TL&O@Y[N13PQL^D42J^<6Y8^"=
MAIY_ %#1(,H:OR&:IO/PC7@NT/2M5E9D;:D#7KL'.VSPIUK!U528/H8#KU9+
M 7#YX])4Y2(<!<8^!!ZR6U/"3\=0MF>UW:XT5C+F)L&QL'F5<GRF4V<.C.Q;
MW3NI'AJ^5$M)$SX(58FU7KS--^%-KZV[+H0VTI0M*']I$;<(3PKBP+,[T'8V
M=6/QL3'83-QCF3NB RTFL),$E+,^Q[QU_H%ZJ3. T6<9>+327*&RKBF(&+1'
M(-_CM4DL,)B.2#DFW',\6P=IHF,>Z_?V(=\T3OTA)DXVJ>?6" 2 O1D"S_]#
M)!D_W^2-JTP0[6)2!XF*WU4,:2>+E?)G(_-OU?UNZ%C?3<L_9UIHCW9M8N=+
M3&ZJ*\L<=+;71$_><'=-Y[LJ+3S^]YFQSS0QN:UCL!XG( FP6T(IR^H@72HS
M@9:LIC[IA?JQP#%C! ^QTO=4&AB;L+#R[S.OQ[837=*1PQV\*-#I:7\9X<\Z
MN</4HP/PA,^82;8^-4\*.KF7MYF@A)PWQ0L:(RX5$KJ$P+ F_XXR>P@U66'+
M,6:C8@$K+$3DM2_NULJGM-H?L4"T*! SDO/+<OYVTU1$KU(8&>XDPF).?PIY
MN/.1""PU#)1(>="U-F].+#,-]-/=Q'^JB8\EBK 70Y!5Q>D?+SC<3<2GW(&(
M.<('M89\K,5H6[8R3:?N-?I*[=[@M!;A22.6]IU,6>R).^YN\C[EY(4M4M87
MV\L47HXFL8 R! ,,C^78+6D8%Y5E,>=YK,3^[S.+GVFRKB_%/\&A<UR+ZP__
M91FOSP2"4<"6&!CTA7018JM]F,<V8/\^N^'8;)J$9U;45\*+8A?B\U:9CQ'.
MS17[%MR'>4FW/G?FFM:%CEF_G$O&\-]W>&G@I;^\'7CINTWV3]IDAA5KE.C
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M+^*2..]1=A9L4I)@7450F5;:P^YNE;J*B#/]9R;0(D!E >IP7>H-IG>D./)
MRX&F;P:0EP$/E@H,^,;]//6R**(D(M#- ;U =R"R']WTPJX99HB$CK+QP&(_
M685X U##62GA)]*^H@DZP.;<VNUDO3=FB<#$VGD*K,2]H27<Z+1GA->^YID9
MG(PF-49./ S+$R7WI#:/&#9N,,\_"TQX)]Q<"68LP@%"U7W5;"5<Z>4=7/I=
M\.4)>S43F8-@5[NMULMVM9;I1)_:8?NW;1$#I)BYC79X1"<(=[B@1%%PR]J*
M>2"9@P3.'EZ(WR;3;;6&?V ?3(4Q5]JC;/S<J*SV&?PZ=D1:(3%>1JZP:#@1
M"\A0&(]SAR3E@C<=>;\WAM%&KP+?0_3_M)K>*3NU;K;B(D1V(;+$!XG2 4-"
MJ=$,[N) 4@+TJ.%2>M;A3ANZ))5&B0;5?@K>05EWM+2OTIF)12&K(.PF:G7P
MULS.&O; N(8''3!B!]*;_YXM_5E\(=-#$4AL.@Q)+!V""-EIN<YG)9A?#\3'
M?S]]?B8S;QTS.2A,G%(.8.]:_=SI*)9BM@N6EMA54< 04I"-X\7-[H/$^2!3
MZ-O2;(__&Q&1-S7\C@F.R>C,9$B8.#JZ>WZIV;KY>AMQ)+(3,C3[5 E6?+M&
MAN;I-T@I/[&3$(.SG0YJ:UMRN[ G?B[!J=+*).RTGO8E>Q4SM;O8=J:Z:IE?
ME:03JG7,?LFY/K+JE5J_US5F:QUZ,^'%@L&ONLM2KOH2MHD&YDTB<>T  T]+
M'JLZ_.<39H=XZ\=*B=M-GH83<9>ZF%Z9S/R])X^?OKJO[29=(Z>FZ2^'NV53
M*RU[ H!*^$]U>,B;RF=]4JY60(Y,)V^8=.,W?L2%WL11.%M<P:_93YZ8QK,"
MU*%N@&=B0PYW_"_3V'+1&\HTW6%*4*0.B_NW@2796^29) %CUXRHF42\N^?5
M'U\V&=MLSZ0GK-A_%V'?3D<?%^?&GNIS>.QH_4XG+YHM)I$J,";J8MU#8*4Q
M5N%>+(VQS4W=5 ']<NEY-%T^[I3.M1&8U\ &]_MFG95SB5,O8G2SRE5% *GO
M*_"EFSZL+IGT4M1*5E494[<'7N+6&MFS/H!1.R_[_L 'SM#A^E0(7E;0:[BX
MO'DQM!;4A(? NJ6\E-:3-V4(<(D!<^3&<]2\O@?>VQ=,K,4MB8$9-'BE3G>Q
M'4#(<]O#]T1HS'1CA0Z=\+26R0AWE#;C%CFGMJMF*U6_M(V$;[!@RB<TQ4CV
MN"** R#."&,Y&GU">+>YV"2>8C\OGS<<\9&*?)@> $E]2>;_9^]->R,YKJSA
MOU(8/, K 4D^4GL9>P0,T.Z6[)ZQW VU;3U?LZJRR%1G999S(57^]6_<<Y>X
M$9G%7FR*18DP8#7)JEQBN7&7<\^14XR>@$*["P*\)UT28<*$(RPYPK#WIWJ+
MFC&4U_93<Z4Z/TM3@'@GNBQ+3?!KJH^T5^&-]7!,;2%.!FE4*N1Y0(7-.9ZJ
MA^/C7J^3ZG;OVQ?%_0+28>J39BI0$"^69:T@+"LN;<[74LH@&K+2H*EZ>;/6
M2*D*[B70,N9@TSR5M.22[Y?W'>N3>0\F/,]X85>5=R^8RT+< ]< B)Z^%8L&
M9?7*V0UO15-I[?CMY02G%:D.TE MK@'A7>;C=Z/'[Z#O32@^%J'U%?63JPXM
MW>&!M#$, 9S%UMD3VAR@\T\\JJSO;UF%\.=BXU^'U[GM^G>B+T@(',6,4S+7
M^R*-BOODOF]J%R_)M:(QT\LDZ7C60&ATPY,)B?E\KP< L3K4>GFW OL'_SZX
MJ6]F11KO"I(S0DTA),-PQ=@5:Q^3@_Q"/[O04J+598>9J((S"^VKCMHXVPCF
M5]$5I!?X*'2O7DC>TTY"8X<A*T9;)GR(V?UW.M1LM8SJJ%JHR&>]X=SD"#,8
M5;'71Y;'"I9\G,3PK>M.7M%V6:;".;-)X;YC[0KLB3.4/M:3+/%[-]MOOG@<
M]>KS,4\I!1/YZF&Q(ZKQMJ*.A8S"T885(K@5[#0+^%&UA^6#ZGY[09N,FE&.
M76]JA=R7HJ!^!YD1>I?J,,I)UG8DZ2IL)0,](4*]2)4:K%0D,),K3JUL>A/9
MO.H<JF?LN4^KX!Q@*F6G,2\9",7N_(B]ZN1;R$"+4$%WX).WFT8>G4-/-MMN
MPN?K==<-E3K3VOLF-32YI<O<:J"9C)1022U5#Z*7>D<[MHHLZ60%&U:;.T(&
M1]1F6(DM,7U13278NUVUA>X.Z[?3JZJ+0=U/K4I+L>B#=S*6X %W0@**^8'0
M]8[%0RN1XE6E-C8#,5AHHF^,4!H.6DFYYFT*080ZS*E@-Q>O]@U1B8/(L"),
MB1"XG1##CAJ\FE''1(RF=?,'I"R11*^&RJ73#'BVN =EOQT[4V+>4'AA"I\^
M9R[[C9/B$GM)=CX\(1Q/_'L:84H,&S"<=_'V(W/6KWVBM^R=3&T4*-74&USQ
MPCMO"_UYYSPV'U2)@VKAR<6+Z-KG="T&"'$#@^IL=+*ZD,4_LJY!K,7:TEP,
M[X5D0OH;?$C JI]7'0.-,U2CM]12(ST1E.5-GA*RL*H&J<:%HXB:)5!1U&\O
MD:-9(ZDHH>J'"SXYPLV%+V.8^ILJK!P*]+(\,.,J*346+KB?AM$X>-GKAB!X
MGA_7Q:F 5E_[HKQ-58T^HC-'6M/OT?D.$T5&S^GKH #CA77T7"(C08X\]7YA
MW.DX.+C\MR<"0+>WE@SDT4(X7%(:B!L>%LE0<A5;A5;<U%=UPV%R."ZNY(8\
M8[.DQ17V@C27)Y4'1PWIMWM44D.%*.5E:AH(VUH2!,#9?[(UUJD2S_^!8!7&
ML$<<F02$JW?'<T-:B.HJZA+5O.= L[PZ*P\%4(%5J%CX/#ILRIQ#YN+<!E;7
M]P.-V%F2=U&:ZJ%6$-/'2CX32SJ$&2V\LH&0'I(]I?I694(70VK7PEG)F#O+
MSYW;").MKV[X2#<'VR<"O0,0[+;\/=;A67I.CC@IN5.)J"1Z5P/+/- DYAU%
M_RS-2,63 H]H*MI2'[9A\<?.V4V>)6MONG?"4#S1&=]0:3*+ 3,B1$WD0RZ<
M8&CMLI?%V>XYX2LB*N;XJ4R%'J4FCI6(QW4;SB\H5O]X@*>C;H1XBAK+.=DG
MI]*44KBD4H=:%UA(^/=.&W38=-Z?8\\TQX.< 3#G;NI?3BM0?:K@\W9D"CFA
M3-YWRAAAO</P/GU1@%S!?FHJW:@QE,:\I.5T?!B9TH+U7'D-.6&<Z)#.LPE-
M>9NG7D^6M+I19P;394[EIBGKO>-]B;D?='P-=<\WEP2*5S7^\ K0HXWLOJ]2
MC607T#C^41>UL-PQ[V:%MEQ\^>P_?^732Y38(@Y#!H,PV<A[&(S%4S5GT#.2
M',*DMV0_;\-O6JGM[= 'AR=S;,1@@<ZKS.K^(L=.[:VH; !_D]18<<;,?QUI
MK(1:&M5?1O[-^*6%6AJD# LL]&3 RKZIJSX?5!J-;JO%M$*XYELP+[BPB-XJ
M DH3ZAY-FB85O#8/>$^@6I(N/#;K#-Q9W9:,D6JJD=*4-+&]N"@1D!Y>-8QL
M8]N$M^ M27-7[[@N\L/$)[ZK@&_JFYK;^7H2F"5T3A7^7P5M0R#%#2D[Y6$:
MB.N%<U#<('DJB\:GV*H4,&85OPPG3-(%,T!N7^TF[DY26U+2(V%12Z=CC'0'
M!@33[SE@EBK01(]:@;.!'H0J51]"7*TAYJZN $VH>JE,N>RZ1+ZUNDDA^#A0
M/DM.5GMXXNF66)6A8% V%X(6754#-DN*A,B*R3G[L._"=&?Z,L:!1\F7ZGVD
MKPB>9?;3(DM/<%%@0X>YJ+\G5;(PIS&5G$(W&'QP.TQU(ML-<-0%!YKZ=_)5
M!2/JHWUJI\F@B6BAY>-/V*.3[C;ZRZUDC]^10\1*]6.UP'7(6-9NPRT=#/"C
M]Y'6J5ZV!"5LA[!-UF1]UK0RV?6Z#A[.+#V=YJ0?R%^F9TH(X<_-XRTT)I-T
M;IZ9$J2/S1T*M-,C/NS3+-I=#5Z;A6W ]:WOZ##/H*3?UK;9W@HM<WC>S[[[
M^MNWG\]IXL@D#5-_JO00VU]<=4%@$#L<G\&/]TI&J(MY<C#>Y%7:E4_8V"N<
M<ESMP=,"PT(W:NJ(=,*=5$Q621T9L,)!GOBO6I$KF YS/[5Z61)%]^4UKL.0
MK:$_HQY:_1A>8( A$!5"R1J*=4QNYMFB(S^T>;3"=RVLU0U59"VE?J,IR=@C
MQ!ST].7@=HW' PRWNK\AF@K^?A\KD!PJ1 4<]JL:4(Z87T4I5W6D4\_) 'M+
M3(%212O8::+)=-EZ;VXCTPB9UW],#(?U>/[$^X0;3Z?](/;?T2FXA+Q0&K*#
M()A9"U (=Z:.#YU:5-&,*$> 20AH8N]$+JQ+#182^)N#Y0_4'0_MW/W0<\C!
MXRIZ0C7M-$OD ?CEYYMSK^MFVU?M<@8%!7#!$5J-3VH'*;6I*@9P =(R\QR+
MP^OE @97YTMW:#FPKL[N$TCE_2"5+Y] *O_J24;\ ZNWTX%VV^I%\#U&4?D=
M5O\SM=7JV1?/?FWT_>2L/0#SX/*[_+D+H=_J#YB%U=>,6:W)P-]<KKXKZW N
M;+MS<YW0$1B<IE9Z4PBS;&T+9S.R+ZZKF_X,,ZW;;A,L?AO.5:Y56FZRUS8'
M'X:A7W-;21=(!BW0')A*6C/6!P=Q!G^&B=ZOZZN)^+TTUT9YMHD26(A"SF;F
ML"?.;][4?,Q8V&*$W 17I2%7H2$(?36X^;(<*;F=W"A,*99M@J0R_%3JSP1'
MO:"T.B^56]04CGE=?'R:P@^>PA0AMM@*:@(R5#](FK)_F*CW"I"7=(]%,!:W
MX)BSB'D](F]^L2_?)>"&[RNM[2D=,TPJ90[JZZX+OF0+%2&N?HP"DG?YCKB^
M(O<*1,[8C9/P-J/Q\:S[%"58;LYWME W<[:@0^Q2\QLN-7?2]]=]5VZU*0#U
M $%U3JUV>)7;DH607'*H^E$*H0F(1^(2!)_BE\^:8%#VH6Q*E("[51X.8L;F
M>RX![Y JK5D1)VF!L92O%D*:(YSHGQ5!S1NG")/(= [2_\/]GK8/PM0C*X?1
ML+Y6:T0\YY&YTRI\2] OK>TH_V:MI8>E(;)>7^X:9CI!6S,JK 165>LRVG(2
M=C2II<O5'RH"PAKD?YZ1YNS)/&/,176KS(%1,&84W#,;O"T>)Z_^\O*BHIU(
M/UP10[?5$(Z2IB!Z[C_^^<WGK,L#\2IM44MQ8BY&#\[6GLQ)L)7?IC3%-%0O
M.#DQK#Y[\>V+SV%M;I#*Q1OBX=0Q#VLB/"*GU $?OER%[^1?F2FDH5O;0-JG
M1+48)%<VQW$^I;$?.)4.D[T 0RVB1K$K/&D!YS]3RRY!R*FQ13(D*+$Z1/@:
MDI.#E#H[-,TX%#9R9)Q-<?3JUU5#Y!([1-OK<MQ<5\,=)4DQP%@E_&>&],HW
M"_G>;*W,UK$_H0AUKJW/G"(3@DU9ATF5-%[:=^G;DK1"_QV)2"!K8Q= Y!#I
ME1E&"H5WW+6P-\-*3-<2;N!DUH3*PW(T66M:UD/K"8 BS"6><P*D#.L9CZS0
MT 0@J5VG_LDC16D;!QD+_;82KG?NS1BIUE,X,4E_9:V+1S_GKJ$N5=QU@;=K
M'7R']@S #1]^P'WYC-($VN-\*UN3T:SDYK$$S#;LQK[>* >6]#JSCV35[5_]
M_ME_)E1!88H96])(. 81%R;(8:IA:0Z[Z<*<1%<I"@?1'!CB!9/:=L+IQ#A=
MG!+*;K03I((\62'5S<%Q3IE;EP!UMUW%-#4H+U&<\39LI&J_#K?YU1<%)45^
M?P:S>NIPQAQ27(JR&JW9'9#8<8W+^7AJ-DE_7"VC[$V;./ZFSA W?(2+KZ'!
MB;-[(&:"2 D[GUZ^!&F92_W?/UDL"7.0/U3L8?_FB]]\MO[\LR\_5P/ZC81^
MW\#5?QF>68_,88]&G.<;01;P!7[UFR_UJ]*4^2>N,[RM^ALZNL/G8;)E77[8
M8@>?L!)M^96ONMK%C.T$Q63Z[*=</VVA\*U,%L+\8PK;?'?,E__EZN\\:<.=
M-P_CR##N\K;LMZ(&+)>4XSA:RG 4\<MAR<C #;:1+D.40W.HNB9 -B )N["A
M4K8M.(#T!"LCW)L_[ F[0:4EM6!RS?]O<(3FVFL=3VPX@5M.*;R0!JR,_>_\
MG?3E8.4[U.6<^-8(Y5'OYBGC@E6_4Y+2^5H[X['XR%!.4$]3GW1:IK A6HY5
M"ZX:<FS42ZTY_,ZT172P"+M: C]C[F?A'2OXKH5!2ZY+OE3XI;(J#-?UX:#D
M%AX"_>_ 3#XP(];).".A$G%4/;UO8Y5@!196I8932!<341F=ZS(9U0/.Z8*$
M>ZD4C>[+C-F5Y&??W0Y:D([OC\49>6N3-S$JR^;(SZ&A1/5CM9D4+J^78[\>
MW4]".H)!HVM=Z C(TU&A/LVT=B:0BA5+IU9^V8,1SV@,5HY&;Q+<YC!RE)SB
MD$&:L0I655M5?=]14^]U5S,Y+Y](HMI1WCK<+;_?ICXHR"!&K1I-16GIQ+X1
M!8%UBUHC<;82PRB7AV%B:QJFB&19.59<6^G6UIM9$75F* %P$0$'+G;E+C?/
M?4M9;8ZWCNIAY4Q%YYU5N],(O$+"@M6_$[TF@XY4+ %?6!"BXH_E,)Y((X!B
MR<$-3O!$FRQ\:H4$/QTQ Z:(H,2TM7#-_/6:Y-++X0,>*<:0]##A/03G2[_'
M7M+-L.O24-;# WW<+1Y7+YDVE^BP36KOL.47TTP) X!GRG.$"O2_M*_#8/GD
MR8GQ9#?*97R%G",'UXGI74 ]IH@I1,W!#+4S0F$!Y])?FCA%82/YD*70-GV:
MAK9BK\=M1E]V.C7B.C*/=7NE!2XL/8*$ 8\7)K)NPVG*:SLMZ)3\N4C6ZVRE
MD#>Z'O\YA:>M#K#M9NL0241X_TNY8912"8>;WU&YM\A%J-'?$+=XH84.P$G9
MF2VP<#()DW;7ATW:3QNM"*5\-T+GY9U !LV$_1[.[(]UMGZ1:)QG3VB<CSX#
M030B^@*:*1.+!5JI?U;L@05/RJ>N8>XH@<(H,MI82=)&V]89TH=SQF/JX.2A
M\6Q>]3C.@>G!&Y+>>#G&G%6'Y[::#OQTJT'@^[OX!7I#_+&(5?B9?^X.TE3D
MOM37!&K5E*9.,00J[?1"!Q(]1PY57J"15=NB6I(HVZQRRC7E3WQ?'/.^B8+#
MP*8S >YGSHCDK=)33AT.'2I'8&"UBNB3P[@OCB71T04[R JTLQP <[48*?_"
MP%^N7M]!A<F")F@OZU36.+Z8RF7B4*$7D>:0IKM5B59 9(G +'%%X&*A]<7F
M5)UT\<^H4X8)RR'D,=L%M./"<JM02=J\X[Z0^HK[@P;!"J"S2,(L]'JX6"OY
M-LO7>SX98\:X07]/4SD!\"IL>:[&S(2T>$-MJ9EJUSEF!8P0QH]0 7RI1^O]
M?Z_2+B9O#7]O0D(P#'P,!",/S^UUQWE)F@9KD\%&1&8@^@TN>E-;$R,S&G :
MW$V(V<*4I1O8!:".JT.9?ZU@+R7"F$!P2I!"XQEQ2D*JCM5@UR_8J) 3Y=(0
MG F '0L_]]/!RIHQ%$@H-LU/?>D\7AM%Y4 >G;RB'#(8E$W? ;+1CN6^;LU0
M+D9,@*?+0/ "1RWRQ7>O!\EXU-)BIS883RQH>_6N*B>-]_-K"F4*4M[ "UG6
M:3Q,LK!F5E9-OJ-12^9,6R/D'.)>S+ )8%B/U/E6K Y3KW+$.$LYF0#>.;[1
M@1H09[7O4TE>F+0G;1MQU3SX0\OBXW6/&H.;SJ:<6O)TG%PL'5L7.+;LV)/"
M<W#IXS'H)B?Q$,QE,"^"\"^LD(4#6Q>$+@<5QSS9(2@F8 AFB5J"$I^E7%B!
M&KXEL=J?P@%]0Q:6 [K24?L;N0^2E6CYFW'N[F*V*UN@#C&C!^AOR:Q\^8Q:
M?<B0FO,@'Z3S7DI?FD?0[$I2EC?A7$1_P!*Z3 "DO]7%#COM754=R*^%\<ZR
M$'*0KQF&A,=\S\M0LD8A1X_ZV-:HQ)_6=R5@8UE2?3\..[C]D]ED::8*(1FX
MU6,L&U!ML#*R!.XCK\*0=D<.($IQ!,(;ME5_N7HK\!;A<[[K(4U? -H"L. 2
M?305?(O. "ZSPU>.9!SET3ET'D%V#$3M#7'8!VN/#IORF@2?K\C'>$O+RGL0
M=[X!/P";A4_V(Y9D6GY&Y[/BT+Q"B+;0N3)!.0PHR$AXA:]0N4B_9=]A^Y9P
M-KBRQ%TZ"QI26"?@57D8++J>5RP&;@\]RFY"RXMVG4E5RGMN<#%\)ZK^P3?T
M:8]]%@/+Z0":<9*OHBT93A;R+4RDDK=R&_428NX9W&U%2E8=JRH(S)+PODVC
M'WV94]%D<)3K9LFYBKM*CA^RN#V5OZ 1<L9+]B,KUNQD4C60$>=N$R/IVAZM
M)@JWP0/Q#*2[U]H*N^0*XH\!ZMV&HA;O4*,!H1<0U[/NQ8^5Z']9]X3.QS"E
MYSPS=S=)S8";8S3,[Z/ &23T59QB>1.. I?L<6.Z*0] 1;*N91)/.,:L<O20
M5P0$ MI-3RPZV6!]^'1*ZC*J4>+1R4P)83K$<^:)MAI!RE\JQ#(6Y#.G6(I]
MP^5#$2M0EFHA9]>4\G+/R<$(,U:&L#;8X&UIH93T:OQO^/R6^GM3KJ9EJ0%>
MWY&2+DXI>_]B9T^#$*0BJE-]U71K.+$+HW]NT=*CW=1_[1Q/C>3FPMRTLX%/
MZTF.L)=9W%(CZ/)X,VA)>%G@,AR0Y#:LK^L.:L-%2F@0VZ0((: 2F@Q?'**.
M6E+KA,KTH 3 B0]9X,3H6DZ&TM.J]6J':4]6)UVK6IFHVBN4DYT.3_*^:05<
M:Q%DR(BX!9>Q')K@XQW;CNN9EPBP[RFTE)ZE-NRDFXXY$P@(S,@)!70O\XT7
MLR')F ?-+!LB,"\-$IS?LHIBR5*O$"&]YGZ(I(D,MUIQA31B)-CV&L_O%7%Y
MD9,70L_MU'#H2Q>ZF Z4P1?@C*8.DFQ/@5QUP0P0[&Z)"^H;R2*P7F4V/)_;
M1GM,'$A0EVO2Z#&'2\B]BO=8LPC]2:.+'*3/  5UI-N1Q\XW]6+\Q$V)49.C
M^WRTIN?[.<HEEG@R"#'(P1A$@GK;[%3.RMWXZ(ZHEU<TJBS7DKA[";"0W71<
MG%DKCAF,)7B,4X\;"?-H=O8!]242]?4HQ1;-YD@V7#/&C$7.(]L%!C=V\Z_*
MUAA$/WOQ[>OA\[R;-^_#1"7IQ*L62\7($\/N/C+G7LV%YOP;N9=E+TFGCX:)
M^=J8I),>;.HWUTRQ:4.W4,Z N;SC2>G/!9O3MFLO(*],^,@&Q5E2PK[H^HL#
ME>86;K@P)PC[-)HLT7(A,1RE]]A@;+ V,WFR>%D:OV[X>"CU+Q)+\:LG+,7'
MC=C+N,&7D=PX5M-%G:3B-OZH1GB]*T5?AGIG.$!K*G-C4FK<X$]0FFV&CJAH
M4_C0S)UKB.B\T5-/CDDE),$OO\P$2:))L<PC07 9/X> Q-4@_NO3-MR!'+SV
MZJ*I=K)TL$1J5&S_Z^++WQW&GWYG$&''L]]^=5X1SU?)4'WYZ\O?T-!PFYIU
MF)$A[JL0@#*;EDL>ZQ27!+JS6+N41+:ZMV)JA8!,2,FHQ:?<,[(;/%5?/4WG
M/4VG;''-I*.']F#*259G<(>]F]JX>R.UFVM<GEKG>R>$"N2PV%UR=I-UV;ZC
M9]H80DCOSHUOZ;V_HB=Z6A[WM#Q"9'6H-FXQQ$/('2Y>7#:1RY+JF#'V:7NV
MD*5ZU4.&MO>KQ+[L!-+N#Q\)CJ8^@3T]V@CI-5Z$:4<LR7*R8PLPH3AR4TNU
MVH'*>[$\9CN+*[;A>-\30?6QLQPF(N-9P9TBDPF<T$Z!2;,OH+XGV6>KCZ8/
MIQJS'$^,-34468B[0,LLRF]Q#65H=C87S;N8# :8*L_Z(I/0E(C"RY-C9^V^
M/QZ8%:/ L7/!*:%(L@E+>%-=KKY+-0U2(#^I!\&'RNH$<-*Z0>@/1?Y)+1>S
MT.CB1IW)*&Y./K8':V>>F0J%+@K2Z2GL80_,TICQY[^G/3 6?AV@)ZV^2E-"
MC@YTGP?L\$"]IUR<T210PB)D%6(:/.[+K2N5=FPK(C7(B@GSZ%J+.(75*V6E
M6TFZ<!0_&MPN\I\S3?0&1/7!-:8R5HA"06AWSH;FX]M$LZ2_-QW+!0 &,1 '
MN531MO45AB=+SI3C0@)G5E3KHF@&-2LC)3US+LYYQ-]KVD\. %&(]8<.O2ME
M4IUB< 89D2D$^7821A0G)H(AA_97K=[K= A+\+R?T9 KAGGIJ9IL!&9-B)6Q
MY3][_NKS ME5 >15$NZQ7Q;]-P[L<..L+NA>ET.Y04RH%X+0RG9\OWW9[$0>
M8-#^&5Z-0N;L&)_Y/5/0R?4T$M+8C)-5.SJWS-1B^995F@63GY8KH_P\UK%Y
M+-Y[<UQ3-GW#"$7Z8-_MZT$(EH""P -1,H, 6)>KOQW"E&WY,;../C=A>5,/
M=P+M1BJA&%VR884+BJE1+I@.Q@F8>-OD7M!#I2E/P:U&0RUD:NE;W4P-$9ZO
M_;[%7#SJ79D9HJ4A=Z;I?<(;\1353(L**'CY]G$,+\V<>!MF-Q_*=4>''OG/
MP3,&&%E56_6>'=]($&&5,#;'J$UF<LBA(TF=QOL,=/Q"8.R0'-):QEIN\?"8
M*=MC N?W%>#M5E64V+/DW:Y2)%PP4PECJ<7<=,VTKUA^1SHVJ$),/EFL?Q3:
MVY9Z8@HT*HP=!/@Q5[PBR@S:[X@^TA$::C"G.:=JUCCG=]&C7>_/<PR#Q\YD
M.!A9!K5O4&9('I< Q/8 ^)J0#L0AC^73.Q:D5%RD^B_U?JG0X$F-E5,A5<Y1
MBY$.GTLS.GM7#=)ZH2[!,+L5.OY)0KFAKA-3/#7N/(H*8 LB!5UEF4[.7A5:
M+?9D!#B6Z8).5@?-2IM^JI6P3"(B<VQ%YI2NA1'IN]OQVE^V$%ZG=,X.B=GV
M._/.;N:4CC JNIWQVOZ79)J76P#@]%(@"*M JT))2989^,1*@/-HH/2%M#;*
M;-+@-N'E06ZA$ 8-26#_@:+<:Q*;ZW><!4.:\_'"Q3YIM(.; ]^1B[ZNBS_L
MW2VKM+FA%Z2&R*_3J>QX'E-=#@=(@<NW![62$:V,N!DO?=R*.R;#LU"OT=O8
MB)?74T^]63!6-V6(/]=-93"5HT;.#%"MNYXSV)6K=YI^A@^_#;M!)[[(JQMB
MQ.R!7VH2Y<<5E_0A9&U>[WF7(G[ E!^9T;T(/S"EXC1>=+N++9KM>_X(T7^
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MJ#:F04 '/<EJ*TQ.?+LC7UJ ?JJN!/AI;&'#E%=CK9RERH&N JX,90=U)&(
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MJ9TVZ: ]6@\CV>(+^11-D_M==2<':TRCXW=;UDC:5OLPZ$=7[_"3[4%BG I
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M_.BB7E;*8T3SLS'Y,9(:8#5.06!@#;SH6J ;&1"RJ[90S7:R Z.J/PADA+0
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M4XNX9S5^IV-ZUT3./Q/JH?.1S8$1RO85A^]9#9440#P_9F8'4C!JO3,"<+5
M&V1$1< &'1/(UB+60?\K2[C*<QW*>LMXV$*N9,I"T)^Y]5J:T@D52S#B.+&9
MRY/:Z8.MZ,C8=6%%L J1:9R)"10X_[SH[D:9Z6;F[NZ_9!P?Y(SYYF076O@Y
M>(FET/'CY,%B<VK8N4J<&T%UF!Y^0.X^%.YHP_N  <!'&](J##YCP[[U<W)D
M7Y0'FH+5BZX_")$@8D*/\J3&@BNAZ4SIK\MV):J^Q.>Y*SD0)C. C49N.W'?
M@*?CMB06%;U&IL]4F$!3)5.3"C2=P-">Q)TH*6]\/-.OLN>D/U]WS588 GGS
M;:MUV([PH D"SIM9XBFIQF#W-U#<:H\^>Z_-\C .R%XQ_IO?N&K$)%($1-$?
M*1R$9X!R%0)LYF",3Y @^#>;?JJ<>83,=PMCQ'12#%*ER)/U2H[ BW!2S0CY
M(*JPW]=B^1#EC_0J.^ZC,#M--2"F"0]7.0-K\3X5:NGSB!WK(:XJE;U>)F9Q
MRA$',O-6G'IC/D?NQ@FKU?$+B/M&'&Y:F\,]8]_]R+!CNH8UE5#NFFF_R4(G
M6#[B4Q<6Y]E:A* JSW!8"6$I 58J[ H*GF[!R1X"RW8CV.IXV2A,$B'3<9BP
M,9(;$@/^U#2/P(G^".B:!<<NV?-S ZEQ1Z"F<$U_01@7(#B'JI4(K:GF2[AM
ML8H5$W2QJT:7)C0^/NWWBX29_NH)9OII )%8DDBU5\)SW7+7G<M-:K,,=7*P
MC .0\C3KR,7BKR'(Z/I*?DT()=P'8'SNWY(B?%B%@\-I *-11*"' '','4<>
M EW6MGE$&4GWCZ9G^ZNR%:#(0KF +N#+S.6V/ A%])[00966F\-B82_)7AXN
M4^+;:_L^G>GPH;@0,$P'2S!"+3"E@_!<R0H\ERRQ#+N =<IVX,JJ#9@&-Q[P
MHH"5^-Q"MTP0G&ZLDB8$] "EPBCE+27<P=A6'BGS'?Z3S[C(7M8;Z@G93/]R
M./.02__M F@,TF,IQH#Y-5+$4T0[;?IN&*1]K45C2U\>()Q./E%IFJ,4YJ(C
M%LX*UML6W$TR:T.RZ[;5@4+2X+8@=U+$GA%VN[LU+U^.&\33&:3]4E?=4.^A
M@EMUT^"F:_7:;0QRZ?DT\LLQ[FM#7X&]1/<81@G+X;K><>03%X;N7(8)'$V.
M"-8@:A)AQW.*/^J*!V/13S5OPW#!\,=_3&',=U1R<-*LUNA!KF$]3O(FU%05
MXBMMPSI0C:\GVR;?I$<HQ2]7>8,;@G*OEIQ8OY%Y.ZG2B'9[Q3825] E\<.V
MTAP).Y,>$)'8D=4^A'G@"D+UL1+OD,GA*=,"K2'UG#K,Z]1JY61K;)CIVSS6
M#9GDBC)4( ]:%2TB-3U>-=V:!G&V7_T0[[IN#&NR'7.^K+]T_6W7;?&%;\N^
M67>040P>_?XPR?Q]&SSX<G,=?AQ'U>3P-Y,$W)TR>9?A*N+YF0A'N@J04ZA^
M1&;.P533CC-^<]G%)Y)84F&*#^7/!6]@'+4)OY.<<IFAX5ALRY):&TE7. $M
MO]?CX$)*RJ$^HV3*3%W[ S=>MV2RTC$D\KO*LA)X!^5VQGI*BWR># IK*=8'
M3Z. M6/,BJ2QYG_.A^#'QS$+K V\WF:<5K;JE;?A9R%.^-K'JTLULGS?98/"
M=HE4[V0PH<9&F:!1(F))13,'\KX;*R\;M8#/6E<[=::9$WL!S1YEV\IIO [[
M\I].[R@FE/2OH]._TA8HTE,5S'SP,*W%=NEFI !8ANT??(M$IL][US%3VDYA
M3]%G3Y@WI_8LS LP=W0>EAO^P52)"\HID0V7O@J2%"SF\-W$4'N5(\4P2L_X
M',%X<AH*S]&H8"-5HY.!P9PSHTBPEUO6GRW1;DP7E2/+%PR"6Q7FI1ZN65HR
M/F9PU^MM7?9ZVB.HYD0E.9!]7XJ 8^+VF7@>2$3B*%3O>]'!59%*/9."!SJ\
MNZ3*N1+'%6JQ 0N5M2C>S*FS,9;^1.OFI#H6N9*T"DNG0,MX%=M=:H6SB@(G
MUCWL9['&P[-!CR%3L1"//7'C/0PL,LI#QAX>SKJWSE7*MG$*1:9=0%U.UZ5H
M"Z<+WOD1WF-Q=PXVFKK$N0>4;"F3] UB>X7NJVE$"ICB:/CJ^'!3E5O^%9H\
MPI8^'/3)7'-YV+<3N37KL(?KL(B_FKOL3VOJW[.FD#\-IU$75LT@C,L+JO1]
M5>_74S G7$$0))F7NU4Q+UYN3\CU>YTQ:KBV*6)5%F%C)19[+_5J#67A2&"\
MTBTT.H\K<.XZ5<VG&;NO&:.D3M6#38U K^@L96D.B2*Q_Y)=%+5A^?"6,FMU
M&!&2";J$]]JA*3?5T^S=6Z^55*-845EE GB"CE&7K!<WSWYSZ,BYVT@*@7)Z
M4\]M=. ](H<Q4BX*:N!I%N^MWZ>U_M*M:-Q+XEJ9<,+QMF76/ LX7"8U9LTJ
M^7JEZK=+V_9I(N]-P?':IHI@\(BAD9.7SFL$94(ZUEX)N1LF)X;618C:?BP<
MOW3A>*SHNSS#I^A/Z1&^GOJP',(P_5% A"])UNY-'YQ8=GR_,^+"U;,OOOSM
M__WM?_Y^]=D?7[[Y[O.GM7&?:P/AT(%*)QK"*P_5Q)0.JOC"^1*.BG6)0 .M
MSM%9D>\X!$N':70T=E:O07+*,K.JXZ[IW1./0)WV'9T028;H:7W<7UN[T::^
M>D,3H9MUV?-JM34NA,B5R")X1L8H-4]^] 5SMIKRY=,TWMLV[\,T7KCI4YH+
M;Z/I,UR2M<0KB>[UTOB(?W';[TQZCTGWAM77_*GG*:EH-.P#DM-3<S53'GI9
MT6+0W?^"X[%*01%(KE9MV7"*F1(AD(QC(DYR)&^D+ .CPD]QZ$G_JKH2,@_6
MO:_U0[D:0M<,\1 4.'H9)F#WM"SO]?3A$P"%(%=14-L2O(Z(P\GD$AI#T>-C
M4"[^QT1FYZG9_'X51US95V? ;1L[%YBC"1S?^"N:0!YO#4\J;SFO:Z3P%09N
M0EXJL$#'@C!2%VOJQ$29RC%TITXR;.$W\J477=]/AS'XR)K[(&;ZS[YY\>;Y
MY\+#_K^K/\A%<\$^=<Q4XLLJ'R]F5*;5BBZI_,3\+ISH%E<M8ZZI_9G/#9(;
M?E2A.2[1HAL6R3\921)V]/XRG J*K2?LGMT6H!HZ1.(]'"#&R)^)GKO<  >%
M6N%V"G;AJ#FZ0N"PQ_ADQ>JZ&X O$+ZR@[#WKG.I='9.M]TF-OABT/3[$2B$
M"RF3=16GMP/,)MPI#*^V&3-V'"\0'X2)L%LYA3D"2\N,[OZ@M8Z\:<)[S+AQ
M0 H/!)AP]W%GFCT1KH>+-/QE#+KWMIEV/CSZWZ7Z2DNG\*O4(T7 U _(O7#+
ML[_ %-6#E02'*I+;GH*QX" 'Y#),;HQ(90!)U #;02LU]/F=ETT)0U<. V.Y
M*,%N)1WI!C^J@L&0$"-8([@G& -5";.+45CJ&[&YZ\"(VPCX>5LI9(B3^K2"
MP0AV\DUO:;>%^[>5L'\CKYGR146DS*(X%T^+^-CR,TJ7X?[<\QWFCM&6)Z&'
MY#F%8? *@LDP+  %[GHI1Q' >I0H2#/2-%:GN%;KY,Q\>1;@I?F9\(O$FO\Z
M'8;SQIJ?_7F=GC=Z/B2)@_?L6)A-4.OAH*%^4'?PNYVKQ]&%RW9OF0*7,M43
M[".I-;*(N>>(\PH^PX&.EK7A_]JPHQ<I_7^*-N'S\D3O:AF%ZB(-=^*EE&RF
MT3C35DIR0D2D8D650]%1-ZN.!]S8&J".P1K&IAF=H_NHPO;#?V5E451ZF$8]
MD\A_>?"Y?&Q;^'MTPQ'6[6HJ10%^9/6&0LE9'(J;/#, U)E\R2>9HIJ\>(,]
MG\?K:K5 [T^=E7=X\]XUBC S=>]Y;:D_?+GZ-GR+'+-""'04UIY2S?"YOOS
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ML^6UE6\9>4 ,.NW 5A+%?WA&AC(H8F\V<(?4F101!E2(96FZF%]"^GES)&]
M/Q;^2'+K8U9"4L+,QM)C29^XKY-;*G].&?*X\Y)?_N:#)CD3 6)'1V;XCKI*
M$3R&=BMQ@T44LU*1^?^V0,(4VOH(']YA^A#T"8R6>5#?LW3"S].!D#Z8],2?
MZNDHH'@LW.!F:BAS+P?[MMQ3+R\O(QV+<'I/6-I3JV0,1&:)W5X0ZP]04&W)
M/5-A-87!JNA-J903/CWLBVQ-CM?D]-.*+'O)"3905I@HC#4*9S"=]MA?DG5/
M@TB['CUJ>&2HNE/X1>,1MX<C@;?/\<3Q)!<S5B,=4.:^W,ET+TP/$\'.A_]#
M1K_3%NN.KQ ?+@YJ^"^X&()3:-<-7WH7)BER,SBZN^@>>ED>\T!E'BY"T!=V
MG*4A_(,[M^R./;#6.5QIG7#'-+3'0T6$MV:0!(@U"++!2G*Q6H+AUXC?+D=2
MQS<E&/S(&P6H?]1[DJDX#)]?KOY +/9:627S$0DC@ A+_(&A.X3S;@3V*8Q1
M%29U.T-!3KRMR6(SB@VVH6GJ*QI*D.-6[17M$0JS&VE.BXV[P8<0:CS4,J^K
M'0=A/*%H2H!SC0N[W>KW>3(?3_ D@B?]9@D/=*[PI',XU90!'T4DZ60**P_\
M<#ZOY-:\E'#I0'G^:K7OME7C:-_D@,RP#6HB8%R1R '@A>U+L(Y]<!78)LM^
M0^S)"8"RKW,DG^0#IJAU(T=H"*-;I\ZAR'VA].)#BRMEBGOQ>!J?EM"HW@9$
MS9O;BR@^L50JGR*^/\" "PF66O*$IRNZV;C/N?8H(S9QJYF8Y9ES*?AA>.[.
M^":7%ERX !><DY"\(G?-R"E@BJZBWD.$9Q32:RZ&LMF[B1AQPGX"4JELAV[/
M_][65PQ4_G&DTA!=W$ZZ:D^NJS^<F2&G#4;NHMM=2%9('R0\5@>36U$O:,7T
M0.XL(?,-7B'Y_.=>#J$J6TR8Q"6(8'J<M9ID9[\-B[25'$6TN:"KHU5^U>MG
MRYOP]/KE%/Y;V,+O<DI$T, 91[P_;D&0I5-JL^TP7C%T^*D=064%=X3\MF'@
M3V&#2;J ;G+' !22WJUZ"RH\093V:T7*?E>>5X]Z,?J0I-6I  3WE0Q4F6<A
M);0)#D<UDD!VUY\\<0M*+-\N:0LL2 M,0T8GY4U-"J]7)P\6B^H&8K#F;&1*
MX#,#+W.%DU/=*,DPTD\2Z=BXX1Z9I?%4(E.[(AK5^D"\/QGX'XT#/34_@!%8
MXTL>JN@V1Q;O)$Z:+8-DM9L!2V%;<9ITX<8[;?EW;DLR.ZT]OZT+A=<&'_.*
M@:]N^00O^;IN*D]6.P)H,5:'P5/7I@$*F/$8->=9B2E%%[8E!<U&K80%+?(R
MW[#X ;[XTV>(</!;K!F?F'Y30B@\/'2$FYEE%#I.0I4YP-VV>Z\JP*D+KBR!
MJ8_"L9+7"Q +9HT#^F78(S8X6%6;IJSW,U '-5@JEQ[6B<V<0X*X^2B=/KNE
M C'ER5/+VQ6<&8LE!!U)H/"V%%$9X)%*"%>567%'C!5?R#\]K53/3[Z<K &L
M$/OO\3+@DL?F(O%BM?B6J6VYXY1;CIN<L EU8*46EZL)]8&*+?9U/KY0AY(N
M(K%&88)1F6%*6M]C;,61J-R8((XTYE:$/KN.#$1%"S'G"F,7<5,K\#(IQ&>0
MS*Q46V[B.2>[8F>'\\!D]#@$B+@"=_S;_\9_6_\[%PL%6AR<6760O_Y;(6_I
M"18B>X* DE=_JF@SA3-&-\>;8!Z]C_6<4:OZ*^H.##/[Y>]__]O59W]Z]>8Y
M=1!&Q\V>RV&=Y4ZZR3W10XI!3F/W%U3L[?K@7:Y>4(YM'R[_1J[QG* KY':0
M>&?LQ'-?T4]^!T( [G?$1ZCG,29;&.!+A/-TE-!_&9U7)4$$VT>#/B#Y#G>%
MB$8W&]+9/<D:J920OBMQUVTFGFYI"5-@*<R'^<]Q/,+[):D7]FB# 6Z80I)M
MG\8/?^T$[2M9%@HM$MPDNYFS;-N"O;K+ERP29[*8>Y-Y)@YY( Z]XMJOVY@2
MD^ UW9FI&1%>6G/]3I@//WG.7',]U<U4YG[.2$>K&$Y-O3]CO9JKMKDF;1I&
M$6 "MA1X5=NX T5:R2^6G- _$0)::*FS:\,%K;;GG+;_-,T:!8ZFK.#74[B9
ML7Z3_S'UPY3M,IMH\2UEZ:1CR"9*.AKD@B#7;J-+:IJYZXH!,^$ONWI$_J"#
M@95HC!TL]"TK#J:IWX6H[)K(W EQ?_Y%M?>A5G2D:=@T19LQJ@_(]%?;V0P,
MBU,03]Q-&*>A4BCU5<<='11<X:XU8TFP:U+! ;'/**5CV%DF19LG=#(\+$X]
MNV4"8:8<(&9'V&H%.&OT0-O:NEY5#6:;K9A;E7;'"]4"IHJ4V#=RP+?!4!NS
M,#1JF%5X@2N>0";<-V)=2Y[?*--P4_\V:0>^L\05I779Z5G>&(8$M,'4SM_.
ME"R3^9G!9M"&P@?HR8/3!E/=]6-=-=X\$HBGUN2?M%2+U6!J!8D0N7,/(+2E
M%U?G3"P,^9Z>OAHKK^0H)V$DIVQ+&]S*X3IF(9E^2,9^QM"=^C?QLR4TA,32
M&P(H!' 3,\ZP]D/IGCZ\?,VA3>31,;>V[XXEL6(EK\':M]:$E29%P H RX8R
M#47>G3@HT^ 00D/75!]P7O&;Y9-^JU.#Q5S%)'2R/,L%$\URYYE\#2 1S G^
M(>^2KH.EL3QGH_Q)("3M)AM,3 @@U^!:D>D!?CCV]\^F$K^+[<71)\J0SHZ^
M(&EW$@1@9F\B]B\J#U)ZG?0SSWD"WB/""GQED\ =F7:;,83R_L!7@S68IZ!P
M7.+IX$>3%@;HV,GXRJ'D%,?(I47I0/4.C,Y4\XUAJ=/?*E-#3S6@8#%I)W);
MP#:8R(ZBC801'XY]/UW9@Q_U("QH^L/XID)A\[VEP<[,5:#R4L(;4;<7T:19
M]1IGR"N$ #M03KKO>4<B*E9Y/;&(IU_R(LW\V.FAIUXM-UQQ?(0 S=%9]"QM
M,%?JNFLZ=S@B6XA6#ZQ)P8>*5<QJ(?B.NFN=4F&<\P[Y!#"6V8L\1.)N6$%(
MI>4*7Q)TV:(HH<>TD;HVJ"'OH^5*?Y$U^=\^U>0_'KSYS<OG$@&F-+>ZI'WS
M-2_%/,? 73ETG6M:Q*)_(YU=^$))\&JR@1M;U6%_U!#*VDJH$3Y3CI24;;HQ
M.H+_(+^U-LL_OXXQ9I7<9-)*[L=;S^ORGV5OR1-N U]=(VN8E:9T%&)7.DF8
M=-M<["L=#+*%7LP@X7^-1<4JRL]Q5,B0 73M#&#.\K7$"L)F^D,_",3>VBS0
M%R^CZP:U7+CAD0]1^Q29\+#>@G?K7O0BW'I;2FJ; +TMDE-RC_51RL%WT3;P
M@NDVE&?2(A_W.KH$%1!X5%&Q=PY7J,#"I",2L]M^R'"T$JD!0^YPF]Y)L^FC
MUD29_.Q+9-TDP,7*JJP=Y<7KO[]Z:6E/R(AP;NU_2MJ8$OGV%0\3]]QQ@4;7
MAZ5HQC!-W^&^"\5=7A"W7N7-:<$)G:<ULGKR@L4.[P6=^#NZ\L/DZOIP350K
MU:@/+EUZ%N%2RW!J](!K0&^?MQ-/LX",,>%4MFPR>%LD_.&H069N]H'839-J
MN_U9O<Z?D=?P1G9AK/)1-6&J1T^NDS2=<^C'Z5MOUGP]#[3C8!U[7^[U46?N
MT/;U(_%&;7V&(HXEE;WS;+GSUPOM]5^2H8U21_D6/L$&1PF)%+-PN9I/KU3&
MI.3%M0X"#ERX/[CJ&9GX?1OK?I*T72.#,OHU0MLL?(:1]'R<;4I.[5+.K(^&
M5$@E"IR6F[Y>XP<EO]-/W=8@C]J;!AJLWF:,% <^2;:D-YFG(>79@\V&0^S.
MR1.);(*O5J3JAI5/(_S#Q. 8/;2$\C$^\-32YD'J:LMS>;=67;A8@8=!$I,
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M)",A-'%2K>+VZZ9A[QI6X0PD;P,?&< /XN)\:Y)(KXPQ)WU; 6MN RV /G4
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M-4UFAG6B92X>!+3Q314%B5-\"\_QMLTASRRUPK^N;;EKP2+\EYM+U@[#^1I
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M. 7:QJ=G"76XPGLQWOU'5]7==+7-=[7-G/&51M8RCOKG#>K'*5Z4W-/:3;'
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M*&Y/Q#9CI<73VT6L>"*O1-.JMB\@S3\ZJW#C<95K):Q30?/$66&\\D J7B7
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M69<>/,3OH1X)P?3X6P:V$6RF.KI</.[?>"BN1IF\^PQ*9]P@9$NJY&>_PFM
MG\8'P1<?H)-!I81H4)1\"J,;=C^]Y55SQ>E8?"3BBB\/IM)S=7$-O^J^8@P5
M^E(\D9W]_D_F"TMGPKS3MR9C2TN'\A,VC31G&P240!/'6'Y>LZS+(D0!57S=
M6S7IY H[EB#OVMN_':\G#9>"%O)SWGTQW83>#H.\\L F+"25=-#UQR<O,C=,
M#B$OK>NOU%1D C^ 0TF3IUL+73T:.F(C86YE!LN 3>/$M(P=$>)=TS?!X>:
MCZ: 6F%K"E:*KV?]<C#@FX5@7VP_^3ZK>$5\<W<S^0T,N"*AU+0CO_T![#Y5
M,9US/S (LFZ]H)&R3)PJU!+/B@\V'"3AL2(^4L)6@S]G!+S0U5SIOH@XAR"K
M*?'A$)>J"+%0@]X+RG!4YR?H4KNBNMB$>Z-IU01E>%AFSAE+ 55 4<5I(?JX
M!*<0RX:J60/>C5S"5. 24!U(:?Y,T5E^NT>,Y 1O1$' J'<>,&I^G2X87P 1
M;UV"S0[)49IP[^A!2L;=SM9+ZLW\62#(Z#,P^.*5DOHN'$FG"'H4%:6WH%'=
M(G:M>6#CKP5)( XNMKX-Y[#HQ[%%HW!@/?J7JX$]-O4]2WX<\(*JNI8 B"K#
M+&FV-!50Y,*4-V&"K66@,H,^YF7J)>,6(\=,:LH(*(B,K0GY&1J;J&(K 9K"
M%Z,C-Z4]&&?3C!"KF@"8V1=F/81D'"J9..4O]0SQ$1($-I94K81";<UVC6E,
MH,' *X5%;BU?#^2C)UTK<*[5"=/%PW#^4N&WX&OX%X]JJA.A2F^\K#'8CQP'
M*TSX:Y.3SQ\B)OR]U-N_G\#/Z[_\E%=OT8< 5=MR/$FODJ56/"]IU<=N5+&-
M]".G N!;3_Y*F&A?;% ,;"N&4//)Y?<7Y\C[WJ$ Y"0O."?*F./J/-"<7^6,
MIX/ ['7KHT+^8]"7O:24 ".Q+("C!Q['&O]CG?O05#J.7Z?A'[&3_\OTY&_Q
MEW\_ED<A49T3@+CP^W56Z;5@-TWP*4YA'I7RAR8T(YE$K&*\&$J?-4%?0O.9
MUJF@! J[$AL(!$W)5A]&(#>1W"V9KQUTP HPD0BZ,3 <Q;=6+J\^?/?WHU?>
ML6(GC2PFM(:([:RAP#M?*0*='<V2'"1: TPRR2RE#=>U: [*#28/U[PK >*!
M"7:)/Q.JS#:^@3&I>D39232>0 P_</.2M;'6CMY_:-;A:7C!!OD1%4!A!611
M040GJ9KRRR/?^5AKHN]@-@,'4MH8UMY_//AIW9 @X+//X12-%5031B?SYYQG
M?Q4HY/2&7,D0<<*G@CAW6BLM"P8V.#Y:H:LS&DFPP&A.?!3@E3S.)J \,ZYB
M<HB(Y7"0UGH?K"]YAN(J#?BZ0V,5!O,HM. !.MOYO"J4(G@O._$IL_*N2O)7
M9 _C.!<\/\C&?^'4&-/L=7E*J>3_R*:SE\D_0)Z:=1;"MPZM.OQCXQ_3T[CP
M^X\41#OM'"O07UP]1=/4_P!;3HIQ54\2[*6EX ?]%I5BI(V-OK41*W)<B-BK
MAW>OBM/OO9X2(==H*E6C7Z]#H][.JH99G.=UUS@]O9<AZWNK33K"6<+[YW=)
MKB-7G.;=U/_]IYJ6LTE^TJ")?OFKEI)2+9CY[*_E9G+01#=N-O+0!JCVOYG6
MO_UY? #G&$3CO[KB4I*IMSV%!) [9FE^_7YW_\76B[T7R1H^ABZGIR_QW[RJ
MZQITYJUF:)TSC*AB:'9C6H%3F#M.G"#E3I.$BT0WC>(C X:"7O=D8<'_04\O
M'MJS[>?[3_>CH>&_KQA:.$)1X+KAL<DU-YR, 9W6N^*2;G;FF G/++"_P.'&
MR"DJ0L,=7#[T86^S(/-I41G9<3>K0?IEA&-7YF2WU(K'-&%$<!STHF<_UI-@
M%VPWO>XRL1(VO&61H/QCWACJ"XE]NHHDB4V&03*.647Y&;AS>6\EZX+M#".)
M=U%<D3I/O715:L7M;M,/GSY:G=8W5A=>\7ASJ#U@]G- [,V9&]SMS<$?,=))
M;]__QG22O9%@<YP?IJ] R8LB07AN(P-OJW/9_Z>/>1NM ]SS>X4+@MQNI*O6
MEALEM:[=N2G"[6V7!HFC*\ 3* 0SG<\PNUK6AI)[\IU_+RB)<SY@:^]>K=],
M+9!2X',[)#9]B:&,,I5NQJ[=QY\.UJ\2E4A=/-_8WA*!P>D$,?+:[MVK!:,/
M"V65VB(G#T85X-[+24YX7)PI"7XG&![@U:.!M?-LD1@O.S[&07W2M5WSM7&Z
M93IU(!@_NY.:-X:\.IWD3PI0#OJ**]I)Y.7/ZEJ5#,4BM0H-1Z+6]/-U'RL+
ML1E#U'C+P-DK,->P9M*$KDAPXRK>.&1$36@V5D3G!HME+KV&;ZZ->!7Y#,2_
MS,H*L6OR$=K")\0O!?^!B0/R/*@>P#/%-6TUDRP4@G+G3,#=9-+V-S>P[Q'$
MXK7%*!:B;3(J.HSZ!&XFO41?/.8[IF<JJ*A'HLP2.S$\>%(@$:A&;RY^6N^H
MF28M,9P7O9M)79 1;BGEP?J1R8'R-8@^GH;[SCK_8_7ILNJ?MARU,VZ%5KX>
M7X ]Z7\N^HZ_*RD\ZOD<4S#1OUZ#?B6[=M'/UGY_KWTZ\%\>#9T.#OAAV"::
M$R0__5F:3:ED6U$<D]9%!2O]J_NP*I7TD(JQ\154%\Y8]:^S*"6J^'BXBG:7
M_!9E1'Y*!!,^3^P^$_?57*UG>*POM4*2Q(%7] ZY+( _K;(2/.%_$A7;N?.?
M8J(,^W[HW'HSGSHN.(Q,&"<29&56"L1Q V_D;VP@A-"KW0-BU'$\+31ZMMEH
MVO'6PT<[5Y_U@+&#0S\F X(>2\,B75)*HW146_;LMM'</V7V],4J>WI3M++C
M7Q^9)?9NU%:AU>&7(OM<'8.>/?L5OXT&&2+.CO!P'Q^ D77\J]I7J(5]_[A1
M+O=E:^&G'X[_'@H?YXVN89N+&]_8M:#K;R.J(L5 N7!OF'BYZ/9O9#EUI83<
M0PU+ND AFW(CG*WHYT4Z^%H#K)+@[#;;8,_F@N+S-B./K I!R=TK?FIVY-&:
M=QK=!NL.]<,UA@I>@M]$OKU4<T9U+@%D) 7$ND(*=,EY!&$;(:WY".N8, ;/
M5S4*_QB$#;N$KS$=KK092!Z-&6"O_.B2?OJEE_22['\O"$XRX&HL$NUDP1?I
M2LUG4>TP&)C,+\.%@L'RI3: ;%R#83[W=\HV'*-EWDC$']WD;RU?DA?S*DMU
MF"KX8-A]C<"4FA10,_/A16NH8?O"->C#F?ZA1VTS+)KS]PK#7">^"G1\\T!+
M=,]_PP#)P#6_#-4FMXU(%N5ED4T?F4S[&,T.;97>Z1B<U/E&U(E@!G&QF_S9
MFL5+8 VK]1HR2M?%&SF9D8_X/"# :[#P]E,3P><ADZ]*Y_OG'",C_V4.!#+4
M]@\%1EGF#@4O"599BY5$60-J-LSKIJ4"N+ !/@>@EV*_EDO,7NU#<MRXCHLR
MR<X)W1:&"8N"]_3CM$8%0INIQ$U%CBZAZF0&X+DSS4P5?B%J=F.1Z^E:A"5H
MO:IMOC(8/9R/ZDW1BS720XX9RH*N!>Y6PPH&^*^YRJ%0WFAR?90>WTR.NY/&
M_=%1JP-M2WQ]7C4((BXHHLMF[FQ%$CY4TL1[+:FU,*Q'*?\_5T5176@%JC_L
M@YJ"J<',ZC%<"=:VRFG1?:#F1C1/3T&P=='C'E9JDW)MB[T;!8G*K,,P\HEK
M+[!XET5#(&5"%1V<1T;\@/6:=>RO!3'#L@T>2L #YIXMVN=9[4 R<@5NX-?3
M\,9HT%2MXI# FR_]"<)8P:>\I+*>;AF:+F]I?OR47<*:'X*SZQ. C\L2\3GK
M+2R^F)MN\MMOARE"%#09BJ4 1C-(E'X8NL-3_/I<13X^<PGSI,9HS^RE$87H
MIJX]J\8DRE301S!0!#'#6G;TS;*:"VWV!W=FIF]_P5#NHSXH,D<1>/C7MQ7P
M7@=-+.5J6R.-VX),^U X>K&09\FEPYML V^<,ID4706W^DAJIUN7EW<MXP_/
M+WV@+6US]3!/TZ@.[;ZU]/3MZ__W^/W1KZ\'JUBNT-.VVII&[VOH$.Y#D,X:
MS%&K3">3.I-VW&52X'_&G/#SK55.^(9Z1XA5L>+BL  )3 X80>R1W+*A]6 /
MP87 K2%Y3YHS@A(LT$D>T;PY!6".+=9QBOH**HM00N6^9(R4^NLN8U86\G)\
MY:RKF42U0-9=#B+ GT[<659,&)"#!XSHO&$6#>'.PX]'9X0&JLA+!.Z+BUZ-
M/GE_3FV/[><<&I.@(?J;'"S;Z^LPUDW>@PO@%$9^7G^&=Z-E<,#SW'ZQNV>Z
M*JFL2-AC3ZJN[6=8P>P!7;NQO;NWS[62K#<'K_>YZ![\7QYI/IGHKH'+.V7<
M(3\/*38"48!%.14X#T1-0\"',JOKZD(C<*J,>;&9"1=O!G_9;<M2X8<8JY*>
M@3T:G8^2[.GP./C([H[>BM-*23S%;0Y]-HA'W6B[[,.SV5_!@\[YJ#T&3?*3
M')P0-D$!M0$YV&=_<B/M,@XK82+K%Z[6^OQOT@P?=!)3DZEJXL9(97TCS!&C
MS- J*:LIA>F8'3N;,U\:# DY.-6> KS"$S;N1CD%*#O!#OZ6FL$K J\',.95
M9((.MB /.VPN8?B(4$G@E'6F-5WVH->7GD7-0'Y-&@EAS9]8CHWY:R7,.;I5
M L 13/#\UJ H-\3&VGLR<'R6A14 ].(;U/+'V<2!R(!(CXJJ 7M]J2D"WE:M
M@6-<G';Y4UG7V]^"3./%LZ4DT_CNA^/]P8>/R='1#0_![NRJ6=Q\]6&QEEE9
M[&]B2ON3U%L% N__U5 1$6C4UW]TA-.IM+O':.#*E?M&\*X(!Q3S177R7@QC
MNKWXM^:"NF<-M-"V&EXALS+$7,4+0@NPS*KTG4#)>6^D1;@6XFLDI(JL&6=_
M)+\4U0E8(\<.(_XJ!,&H:"ZG)U6A&'9OP$X0R+GOQ+MQRZVB34G>NYH([3#_
M\4N=S<Z6(#QY+3[>Q"<C9V;XIS1\L&^+@G)T)UBNZZ8!DQ"NKWR4MY8R3T$!
MT9C%REW]*IF_^D</^7S\^I!$FZSIQGGPO=B&K-EWN\@;9^'Q\(M%'C@^5' R
MC,()[ 69E ,3X+'EI:>CH21C[8B<;N0TCWJI:4^TQ=G)EF*:0=-71MN?P1)X
M=+>0 -[UO"@ZIDH4HJ!95N>-(")PV0N8P$PDR'ZWKRT5WWA?-W/4<54ZDB]5
M2*17N[:K2X\G:_5$:M7#3WEE8%^.X"V? _O L2!D"P+'^ZJJ?>IY?VN+523_
M2$I/Z8OO\8_KS!H'XQ.$1+@WIM1))6@P6(US[II6([8_((PR([/$?^ ,.I+3
MEE@5<MR1/X_3XRKB$XK/P.S.X%*K:FI:!BNX*Z3V [_#Z6_+3W$*K@QB=U"$
MVYS(94AU7"M)058:.'H(02Q.+PL6(U:&M>EF\>J,LS8C?(A1UK41"@A?)+,:
M$5BLFEKXDIR[3TN'G++,:82<UZ-,V*I2^'-- )_Q!F"S&'B-TA(8&)/G-\2B
MIJH(?X,2<6_LYU-PF.L17.F@>3;P4&WO[&[_S^G^YC]GIT] ^MK_?+*]L__T
M2<\UV=O:GGU^&=L!^["#YYA*@566]] K^<]B5\/--OO,K*+YQCZ:XC<:YPVF
MMY36E3$D%\&/?5_@YK-LW$-C?[K#8J617P0M1D@U9GZ;^!#E?_S;]M.ME]N[
MVI7X$XAPUQ#*[Z6/%'4M$0M0' ;#5@*IC*@JV%XZ&E4=!:SP?CZIJT]J6'/L
M%$-)>4NGLN&S47;*>GKB2L?P^41,51/,+$)Q(3I71MBY2DH%![KL_5IF)',4
M0J3PYX&Y(UJ8[R_7XJ%HH2X(%%>F.<V0B,7/M*TQG PW/D],<;96V;;KXP$[
MJVS;#97+*[$+P#:!'UPN^=6M_)@E]B!(!);0WY-9EH\QBGH6+!VT:/KW'H>?
M*SJ0#+U$D ]P\*[^F3<HL6[$.0K?\DV[F1R@!<ZW[M@A5YT2/<P]F?!>3E#=
MC9VBUR# .AACAO[JA(!BX!]QF)Q^/'88%\8A*EK^1.#;+>%98&O!0G#F2E>#
M#E_B*1%2JH@M22,B)U+.#HG:$'5%E:^L1TO[7.W.[]A4I%P -Z(+B#CK+!F<
M.C2@;AB@ 97:X$RIK%A+G7G@A[##8/L<^&)1YCY&0PB>7+!3=(#Z\S";$0>V
M!3OQU'%(TUEFBN281A#FDJI@: !>%YT4#2$SC(24BI-_RX8AGG\^SC/DBQL0
MIQKW&!YVTDE+UQ%9Y[@N8!5V!=>6:J)T7O:\(\H"ZT&2F#>("[^MW"^!)W=;
M"\=XI\)H)( $&"PC&_9W<F4E3H992U<VO!+OBZQ<=K:+HY*,<:8;\JEFQ[,9
MV=G,<#8$XDE<#3NXT4S?<'3$OBH8'0?$CI-\<$P16")M!'QY:^-79@(P 0/$
M_X>GV;C!,CAHMQ20#XYJ]8X5>>?WLJ8(+)637Q$U72XI>%L-=6TO^]K?*%Z]
M!")U=:C7EV=PW&>'[Y:?] )Z%:[:H( R-LR10%"5LW W#8:%\#E,5?7#[N96
M<L+L5,(=5R*%,[%)4?85SF:/P1M[?.!1[=G"4!7=PC <RA+#\\1K"*,;$[ N
MU27._?2'[<UG['W)N/3RFE\"S2SK2F2>P#&\JAD**DB1"!IDP8=;//\E%YEC
MV! =Q8)73R9W\>JK(,G_GVP9AI& M$[^\\F_W2"K]^(%I:QQ*;.'.?KM71KZ
MU9)P5T*H##O@G(WI/@_VNJE1F5 S9C Q0B$+F:<+E-@=$:)M;SU=YD3NT\WD
M__O@&%#B_[]U(' 59 E!EMUO472QO?5B577AA?/99O+FX.W!+Z_?O'[[4>[A
MX^35T?'A[\?'1^_>)@=O7\'_'OSVW\='Q\F[GY.?C]X>O#T\.O@M.7SW]M71
M1_W.A]?'O__VD;[R[OWK#P?XA^/[OW!O6;/YWU6G+C+(@A!Z^QR@H:;CJ$-6
M7#:YMTP&(AM*WCH?"$F05IU"%F2ML&5SG=JU+ C@PCL;A@X_L(J9NNC)Z'-%
MXR[(G*.<T)5.W69RK*PTA,@;GH=A&+:X]"D+%Z56L""8WFU>;@-+]M5#Z%3L
MO%(ZF[*RIY=S?)QIB,C GR[@FMHHJNI3K^B2TFG"#2GTAUQ,&9$E'F#6E[=3
MF)\OA\)A3#RGH:BP"C!WR?OW^!&3C<0R(VI!@.3K;^"%LW,1PF,D;R.28^31
M<[6O1"@NF7(>-U:_&$HSL7P6;G;D8O9$DU<M6T\<;G!8EL<(']:*[\Z13Q<>
MLS3CO)+.- .OSY8#C+2;>'R.VH#*>4MXF>^7F+IQSOV,%!.F3YK&E:>.@<.H
M V%]4XC<_9<9E"[P-7/\E+;\I!H'?O61*XK&DASG%+:%3[LBJU/":*VSTK%Z
MP#@T0Z5B]YB<0H;#)]<SFQ%8"X7;&2094]2<5&M#F#+DHK$\93RND5$FPU0=
MJ'#2%W4WY:@O\>-@]P0K#V;1.>GR@L/P*,]YV6&8FU>06IHQ)P^C(#&>\=&@
MY6FXH3OU:&M]/IX>ISO,\SPG#=$%@FJ)[+;4N4)T#(@ 5V/%>8':ICK!(,(L
MGSD"=$0$"=C/,:Q&4<TH/&W(1Q,1"_DSE2"%/63J8M"II%>ZQM,W!V3 JASQ
M\,WRR[U#SY4?V+\NSXE>X%;G5)* %S0RD0G*[,X6 MU?2'H'*RL;E 6\>5$]
M9IX9&TR([-0-'"S/JJVJ+\<TJJ?,KKA 2-'>R&:>U5BLQ03W&#YW-;'XY@S;
MCUH=]&=.4"2^[5A2 &8S>!L5%6M:C3,N]4J]S ^S#8?G<_< 7)<<LHTI;[U0
M4G*!2:BP;H3B,1E";?D14]/#'#4NJ?P63D=6.*Y9Z6HABN7%IM#3 *4N:9&=
MEPI[_!__MOULCPE[?0\K?Y8N1+44(&;[->VMTJX/2[+>7):C2](<S.*S]N'X
M[^M\BC"5+JI(=\H>.GL@=_87G$?=*QS&;OPE+SUA<4"._,HV+9@22X%4<.5M
M205MGL0+.4L*_&MS=\&+6\:2E^ :OZ4+0DU0,5/GH3V1KS_#")L'T11OF\/V
M!9RGK-"F'FMZD:>B'A3-_4IM1-V@]&-PEC!8S%6HX[H[]63<\0/$4W"?$2$5
M_JU=H0%B)3DDY8SG[RV8NE4U3OL-JK_/M"_6<9Z8[/$P?DJ5NY(RU:X<;[35
MABO%2HB'HZUN9<XE^Z@F,#<\0^V,7S@!=\XJ1VXL4[4 WP--43HWUGJ@,(B\
M(82B$"@G6X9L<U^<*?AQ&UQEV!_:I,[ C^H80X!J+F?L:BCQH->E\:7DM2'R
M=I;\" WA4TD36BR+M\B808AR3)-'(9%(?ECWI,WJ4V> 2QEE3MN""2_^_H_%
M+0_\#]N;H$,E1_(S7#4;_PV&AU8A@$M(*W/_T[K]:8_AMZ@V>@-KHQ.L64F*
M"D8XD>D9VQB%1K):N#(F>S22<@OXDRO/,C7K3K)"*EZ=8\@(?AA5LB,[>Q1.
MF12@"EC:N!/2#\''";+DAZ=;6\E4WJS%SV;4'27,$#BFJ!JR[>$W>^8WX!%0
M4^6XSBZ&IIN=9WG!/9FBT^SR/4O%9[8@?#_L?[/G/T_['0.@ZW*P3K2 .[20
MUNX4R]316()W8Q5)^2#!93Y2C?T'="([UE^_H67V'A;D&-,5]S^A:W#Q6)/2
M\5F8KKUP5 EZ6E(V6=L*>,I4K[_Y(D[)<E4ZN_0_[&[NQ'_%5?KAZ>;S^-.)
M&<JBU/&>D($@2*.$[ BZ;)-7?>8T281P#S^L/=O<>;H>/7CQ'.V0B_AA.,6U
M%YL[SQD\X8>U[9W-W=WUKQOQT@C&@MY)J0]X%7R+):A*N6W%1PA)O)((P]_%
MK?NRVN,9ZLWR=*-P$TG54$HF+Y%<Y\>-[>??N]!^^%13H/?IRWOPE@8SV-&J
M;>]M[N,JQ5[VC]=5*-QU(2[7(#KI!SAGA."]K81J]*D>4A, J"ZP.>2I,H P
M<8'G5-(GDJ?O'TLNR,_@ Y ^>(5&Z\%X"B8 )1B(S>[G5P?KX?5B;0^_S<<M
M.!31.,P,Q8&+5"FLLC'W/R'6\U.&?:":_11;&BX<P2]3IPZ8-AT1A> WMW=0
M$3[=$^7&L:4V*> 088K <4M>02"+F->0M,2F@07+&UX#GA(;UTQ&D3*#4\:@
MJM3Y5N294CH:@DUMVF+['-]%2Z&+U,1D81^S_"*[+3G GS+CO?<PV@I6:O>;
MJUT)9-Z3MOV1$B06F0H=\Q/'-?FL)8@$W.JL+=%!7G/U5?-F<M0.:IO=;<YQ
M8MHT5N16WVT_1U6W_T)>@WVFIXXPOR@3UAIWCS4=%\+C)U^H:^Y+GA^\]![#
MHI/3.BDZ%:$?[ZNB[9U$KS:VM[:WK$/+7>R<W.3.=7"6,/<['*2[ZDZD-I(>
M"&A>DB=1E8WC=-"LS@G*8](U68$QPI]S[)AQ"-4A 9-3.DH^LPFF!ID'R<?+
MF4LP(<NW:\RG:6#>3H3OK4E@\QR^67IHV'3YZ3<P7:JNQ7@BY89QPDWLYL^R
M]NP"&P.U21N&E'K:;,0/#<:/T0'[6Y$A(J>3#(/1R!6.4TU#O^P9.P7"TDF.
M#&[K=B-PX=;8P%!SE(+K%"F:&,=),'5"R1360?P2M.DLLOS<0C:-K[1P?C7-
MVJ5^/W ZLY9JCNL$%E0*E4EP:+J-I,FSY'U-E14S9@!'6_)W$&*0$X9P6'O_
MZO>?84-.*^[P)@]6JL;WOXCO^KX5UR.\B"-5]K]CVWT95-KSW7F5AI=L7Z&Q
M]B()907FBP6RBXS12B9=3:5DIUT^IHBJKQ1"N:<R7W[^ES;SK^[3+Q3"MQ5&
MM#%#K9)WCWYX3;U1Q:4F9D#5N;(&]>KA/]31)68Q9!7[FP,-.Z,"P(;.4[+F
M'>9U>,Y957LB%%#_%4KC>RH=WQ5]KEY]V5^)D&Y7]-2]K=WU)0C;W3(&]DXK
M;S[:8H_5.?NNY^RH;/-F"NM?8C-2A:P4]Z;C53O[@J,\#(XE?6][_]EZZK.S
MDM0-+A-E 4I79?##4^:P <EB#B,D%,E.M&F9S*TWKD:H(?IO&HED$/@@,JV:
M'DJ?D28Z6KEMT&J4BI<I&%WY#--/W12C[V"^-J9"=NJ*K(3E28D.J9EB_ N+
M!).BHWPPEMTF:V^/#W\[A F>%+!7B%+-GW,5-%[)])-15L/RP,/(!H\Y)80/
MB&9FB@]")A)Q=<(U)S,]$9U#(/5^S6G1IB?::T_+].OK__[XX?=7!PI:/'93
MRG^3K=N '2?%L5/R=34#7SLN^AFYC0F60C5=?9Y+*!.L[]QYM)$SV(8-<F9U
MQ9(UKD<[.CKZR]'?UTW!K6ICJERC_/L#,QX?O/;@0[F[_^+>;F>T"UF(M_^R
M$Z38#RQE,"\L!Q% :B1#.P,9NMQ @)IQ.&-]E='HQ<Q9<U4*5+82/"=UOCP&
M M[L%/ZE4HT-*IF;NC;#(O)\9!0!FPSTA?\]] TZR,,/(3V1:EA:4#8R4Q:L
M@Z73CHT=V!!/1:"W]K"6P%+X@->"YLFLM; Z[M_UN+\'AXKI#S.DK9SFH)S?
M@SMO"J/NS7B@$[_[8N<9XS-0I.?4Y[!\E(3JN"AG8TUX'^MEN//Q\,7:J^Z1
M!AQ8C0'3X@/A4\$'HH"0:EA',HMH69/3NNIF*5?R4P6^F8NM_V-F1;H,*=KD
M+1);90OS ]4U\<'F-#EE<-508"?MY@_LKGR$@98WKCV[+*88_XN.U)LW2W6F
MGFWMAP/2$$9O:)7".(E6FQQ+\23^^U"%\R.;RP?>J%^HS).UXX\''SZN)[.\
MJ'R]>*J1T<'CS%>? KF>YN4277)7.[\4=_*%Y+_/J'Q^:0:]@.##HFD@1>L?
MH"!;QN;C6B5?-QO7NTJ57L[-17%>W>0=?H7OCL$S(?@-">=SJOW$C3+LS]1N
MTJP@HZQQ]M'T,S#TLI,B;\X04Y0B@AA>WZ"*P:"Q/2]J$U(/H0@J.07569?2
M*!FJ@F%L:$>.AJ9(59CP?^ (C[!WBTJV<&^CFDL:IBF=+BI3Y"R%%;;NN(FJ
M.[D9Q:=8HDIQR>!0SQBQ=0C 6 >+,4K.7%:@DPM7 !BYHZ5JM%A87QOSU=(5
M+'UG4D[/Q=#Q>C'=FZ&&HWRK9+#([V7V7%\"F_R6@2>:)O^G<R!E:8+)%V%Z
M"["5H114@W8#=SX.Z1<O.;@)&G<FLEL0\4#U(\4W.0@8I4E>J]A.F0B04UDT
MWK_QWLD46+_M81SA0GL.N;>.ZLT1**WE4+;$#[L9]U=K'9 I6<%?_?9^\_GF
M-F'=$0_,SR"=&R!T&Q,L 3I3-\?4[H2F7ZYSQW+@PFUT!'L!#CX\ &,!E\RW
M1XY4B)O"M?&V.J]@]82=GG=G>E+G8\RZO2M;1-V34O^PZB;.T$@KA1MU%M//
M=B%$)],W2E/.S6#-<=,FG:P6I+:XI$Q7TW"AY2B;$Z18TM0V&Y"$H#^D\VR,
M*F^)2BL7GCE?);J@IMU22GNA/ZRH(4]*95_/<M:"[XT6!(.ZK,X%"6#M\/7[
MHW51SWPB\!/6C+HE4A&_OV?*TJD.77I<5"F#VYN?F[!=/U3G#T(_"F BB'_;
M#[H[+R=%Y\I_9?/Q]M1GU9_K2>9^E'D;Q&5U<2D0O$<3N<Q0(<,/3I'50BZV
MOMHF9T$'H&-*?0\/GR7)@L/[+BI65D:49Z[",&168^\G/1R^5$B*G6Z0E&'Q
MZ (*$A_ZX_&!L"+S1YX*\[3CAAJ"O#"DU#.)F6,JA?MW"B6"<K,KJ^LYWPLS
MPN-(9B2?0[D0Z1Q>;'"?8SX>@Y9!Y+VIK9G!;LW)!'TMG ZB@M^>.^U/66FW
M_TVP9;9W5M@RU*[@VVW>!<03A598&K6_"/J1&B;N?Y2W# N^=:WOKVL(M_+^
MIW U.N7<@,$<&H%I "JM3DY=1:P%H"E9DZ(UX8CZ6)(>C7>UF9JR08.K<729
MK,%-(A=EL_[CP%Q9WWN=5<.%LD&FRZQQ/^I_O!SGS:S(+G_,2QH^_>A+" 3@
M&&]N\5%N:_C?L;Y9_KP)?_K+_.?[VYLO]O<'_[2UN7W+SY\]V[GN%S!O7*C_
M?++KJ1-T!4HP.^_M6S=:K.W=S6=/;[LHBS[?>[%WJU\\O$'M7OFHOY"8UHOV
M2 )X/VXEV[-V\5;>\&M?+SW;^W/OW)E]QK>^-/<EAAO[9Y6/Z?>S1YY?=P>1
MEOAOJJ%\/=>IUKO?V_&#VZF[^98H\+::_0CC3PA&+<$->GF%./#>+A2([[OC
MZ&#ZW<5]_=*)7K.#CV*E]E8K=<.5VHU6ZAI=<9*-/IV2H[PA@P-WV$TF5TWX
M2IWZ_0Q*FF]4KW\3$;ENO@]!&UXWEX5BW)?DK63)M_>'_I9^NZF_['O5RS+G
M[73[Z3[WW]_9[/&OMUJ%Q2KS-@=J);B/6W"?[3Q=">Y*<!^BX&XMH>#>VG:;
MT/\\%-N-VY.^R&CK3?0A&&W^6SNWV\!!C;%4QV?_MF=G6$SO3*_?1%@>WZ8\
MVUWMRM+MRG:ZNW]/^_*] P'?.;VTQ7F\AC+SE.\?")P^XIC C<[,P)8N_YEY
MNG7;$S,LN??A-SS>77F^_846\VI7[G!7=M/]%\_O9U\>N;/"8*)_%F?ENKF(
MVROU$+LSK SOL+J"DB4W2Z,\HE#(MUR5I=4MV^GS[=OJEF^X,/?DBZQ.PNHD
MS-^RVULO5B=A=1+^]"?A:?KTV?;#.@EDI_Z%RCH?5IFL?M"OB%VRNM<7+S:?
M[>S<NNQU9W-G[]IBU1M^_NS9-RN:?'I-T>1M*CF?/O)!7?VH[U"T>+.2T*6J
MUQJJ^F1]:DL_OWO1YZ,HA%L55ZZ**Q]7<>5]Y%08_?1; W \10"0:]\^T(.(
MXK.QNSE@BF C*S[@R5_7MM?O)OFS*@-ZW&5 7YS46-6O+<LF_AD%=S?=>KZW
M$MR5X#XTP?V2\-&J\/+KRV2._WYGB<Q'5[+UA2FO)0C8/]X]V;EM?\QJ4^Y^
M4Q!P<GOGY5)6-RY%4<5W_M8C[_S\BH*<K[<W5TG.;[\J2ZO8OJ3PY1LNS')[
M7JN3\"<Z"5]2^+(Z":N3\/A.PM='+I:J\.4[UK;\#__/'1;9W""WM/,M<DO?
M>>&.E&&%*X*J20 T)GA0)?=>=HS= QJ[A;@*4+O$+]Z>(4-2H&O0RJ>&T=5C
M=OITP2JD'NS84!HC?"UQ+&_J?R0761-XB0VD?UXF;S+"K]V[ >UQJE"V_]65
M3J9#K*+Z9,2&QE>YS[.,BCW:2BESHD<CX;&@*GO6XZOICHOJ@D@?FUE>,R%D
M6V>C5FF0D[7?/GQ\M9Z,LJ[A&<)Z$ ]DD74E4GW8E?:BI<LCZ+Q#8/=[Q!$B
MBP3S#>SRT9KB&''VR$@2T]W/K^$UI/>R,)YPEGD1;L)\?^UT_=BOF/#^LI^L
M?R#5(JQ?."6XN$;^/<RQ60.FVK5K#]^!38,'EQ$- $NXI7&IZM.L%#*5AJ2!
MJ PVCS?3J\: L@SW&J+ZY_#VG'&.D9+*X8:(3(R1ZR(_Z6#_&CY>Q#D#WT$^
M7;CU"'-YG-=NU/(3:M=FN?\] _Z/\&4"#%W#&.<K*_$+\(SJM!3N/.H@19SL
M*:'&AW$EHS,$CL>+'4'=R_,J'SD<)V$Q,S0I/'L*=_,LNPR+AICP=*O#KV@H
M#6'CXM=Y"##PKB[YRP8XO897$0LU'1&BRZ"K"@8%&J0;\;(ON4P2]4/@8>92
MU&Z*^_XOU_3VPJ_.C6%>AP!O5SBO*YS7%<[K?1;B?G^<UZ6J$[P6RG4%XGI=
M3>B P[NTV[TJ-?[&I<9_IO7X4Z&U_D)$T0L8"QXY0,NJDNTQ5[+MIKM;JQ+,
ME> ^.,'=2_>WGZT$=R6X#TUPGZ<[7PH,]JAJA^^C)^S]<-2NUWS^V$&2[F!>
M?Y[?WT/K9,^]9"KRIW?$UG[E^?G'@IQ"R"5@R'_B^GS8C]U'NE%Q](,$YEO;
M3K=VGZW?]J9: BOJ4>_)]M[V:D^6:D]>/'OZW7?D'DRVY;F+/G#R.=5TL\DV
M?^4%])!-ND?7G;.VM_?BY@=KU2_U'79DY^DM#(+5CGR''=G?O\7E\WTZUQX%
MA@SW:BVH]5E!RRSSC?C%L;0_:P3U@81/P?G9>WY[4_LQ-.JL9/4!RNK6\Y6L
MKF3U0<CJ_N[.$LGJ(\>RF2_H7W%TK/#8_ZQX["N.CM5)6)V$%4?'ZB2L3L*C
MX^C0X<9->KO?.6EV)8C!8%KOA1Z5O!R[LOUQX\4W'?)CASO(L''\GUW34E-L
M->'6\L_4GEM<)C_L;#]EZ9:N4&SAQD83S&A."C=JL?$T@W](RRS^?5;G54U=
MY*;G5'M^J4U7.Y.UXY;[BWV;KBG;";VJM3O/JZZ)$0H2;,.ORLWDP$^BH8;C
M&MO#>*S[]C57CXWI7\JJ3?"?=9X5R]X!? BRE6'W_VGM'$]_FEUZ](-N-JGA
M&:%E&I<3N\?]^G6S67&)#=<@OUE!>R*KES7)V$U<72,@@CMW9>=@G:_$EQC/
M_0*__</VUK-8B*(-,>YE2OS"9_GH+/EA;R?Q,D?0#B!L_),3["F'L_0OWF)L
M6@<1@65'D +<VLVAQN4K=DWW2U9V[^DF=AC-GVG?D_SO<9V!*,NM\)/L!!1V
MUR[^R5S3U/=7L\^?]I(MYO^>U4'9GKJ-$UCO3QO9!,;Y8U9<9)<-7B3VUH K
M0QZ^^Q3>?H-ITRWU9/&^W.F9HH?]F+<PE-'5K62T5.\$'X!%>LE50CS8434%
MG=? DT_KC' /Z/,4K>$B RN# ";"Q[ @KFQ(JX,FKJO+K&@O_=/PLZ:%_[L!
M$C&^!%U3=@@#TM6$"J):XA=Z%:GRH;<T#$5SXEQI+@,P=W+"-*FKJ4%JV&AF
M5=E4J%,8[R$_!]T1PV.(OB,0!+@K?LJKJ1OCE0OWPGE6CN"W'QQ<%34H%GS(
M*QA'4<WHSCOHVK.JSF&2:S\=?'AUL,[@,J] D96-&WC ^[KZ)^BB)CDX=>4(
M?O;JX,/[@W5&T8!?_D(WR<]H\?&LJ=P4)]6TL [N-!\EH&ES?*S K+QQ]>A3
M\A_9=/8R.:PVTP3NYV2-/H7A_!UTO/N<O(=;<9J-7$?&1(/?J>H9+JTLS8+O
MK;WNZFKFUI/?\FE.( ]M=>I02/31ZZ$LB0!*J%+V'/\^YH5*92\5UP2D,9E5
M"!)"("<?WAXDM."(0+()[[E*A/+&JG^\BZJNW3!BIS<9W57T;+[R]5<(DU*@
MZ=%QVGL&<[@D>* ,#EH*5X4;=:V__O<VD^/K)%:>39,O*C M0=%%VQ5N5]JO
MD=RZ!D\$UZ+-^1%3^!O]O?^R;(PK!-<<W'&%(VFI'7X;_SP"048@%18: MO!
M;X ,FM?'JQ==GK>]]98-K:2*]-9-,4I6$"4KB)(51(E;090L$?+ "J)D!5&R
M@BA9093<9#W^9! EQ@5=89.L.N4??J?\SLX2MLFO\!U64GMU G^%2K*2V@<G
MM2^6$03JD9> '@X%\/\L5:#^6X^N&V_[MN@^JQ;)[P 7MJ+#7+Y->7Y/)^61
MAP*N3!+^64(#-SHU#Q)J9/L+^9N6P(=XO)NR]X6QBM6FW.&F?!FS[P,%Y_G.
M:WMMX<?*D7GPYMG6@[69OWHCENFHW;HOY&&$G.Z5=WTE8RL9>R!N)HO.[O6R
M,\W'X\+=%Z-]5&/X9_$R;Q@>7_4M?OM565J=L[WS]&$1+'^_Y.#J'/RISL'7
M9<)7YV!U#A[%.7CVP,[!<!?[?36\#+<-'E8-]513>\Z2-^=$8]7^X2:ILPO?
M"XVMVZYNJK)T18KLWWF!;7,!TAIYQ9$Q.L&VJ#.7H:IJD&^A::I1SH3/V#X5
MA^*P!6R CWXS^4C-3_P(;6B6OV(M@AU6^%3>V-)CXQ?)B'/L,R8*\HU9AJUC
M\;?H =SP-LF1B'M2U=.N"*U\,S@*V:G_ZF82+QT,J KKUYSELYEYK'TO)[VP
M9PR>C-38GC$=QZ[KD)J6>.[?SDMP7XB,_CPK.AH8=KV-L ^:-@.;CUWKS!?Q
MXZ)J&G[7)*^GR:RKX:$-TY7GW#J_1"UDPR<JZN(<FRY.[ \OFZ4_9=@"5V8@
M:4ZW^:1KJ"=0FUNG&6S7I!IU7A! ,O-S[BT\=27V![HD2QI0A_D$5",VVDZ1
MUP2_7R]:'Q;5)5^=:W<7YB=]@$$M= 0W<'*9= $LPG<9#K4'7C'C7@,"(XSL
M[_4A1G:_-Y? CH:)=I[Z"_J[OOUEM"*[.XAK\N2ON ?4+\Q;Q6H+-"5JS)>K
MQ?VZQ=4F[,L$S*RJ!F$OJ'_XU*PX'VTX+?D8VY=7:_Z5:P[*903?1(,S3<JJ
M#/^@.UC^-:]8/:P*7-JG=39=[<1=J);83FO=Z*R$P9VR=9.7DSIKVKK#O[N7
M^-EJ#[Y6 YTB0DIO:47B>Q@.X[H[3>955G1L6K+6YXV0P6W9?M[?%OSD"KR8
M^S+GQ.$X@8E[L)78" $-W;K3J@8+;F6/W*GZ5N]T0Z53#<?4(,2 EY75Y 2>
M@#D]R=7%:MIJ]&D#T=D(Z@1_R$Z?/&2ET[]R>[P5[ZUV!CGIHZN0CYR@CTR[
MU'3H$32$C](5+3@\M)WGB-IV2L!<X P1L!Q\HZWA@@AN4(P2M';XX5U#^#X9
M7MPE8:?PM>WO?5@C$!,WJ+I2N6DL6DU=9^4ICWXE(-]*0/H!([$"<,$C(R!-
MIM68O& ZJ.  VV -V&1CAWXRX1IZL)R*S+01X?!DA.ZDN%'R;43P<1B.F;D1
M/CR9="4%ET 04  <B$XUA<]K]T>7URX@ZX7!.8G$M +NXX-5]+T!>4O[PB8!
M ;=19/#Z,Q/,(2PI1$&J=40VJN0/02_*UCL);^ DK 3VFVNT %=9P2=.435-
MK%*ZJ7 C"7R1]AXW$?R-C5$V(Y,+!8O]BZYA)"O&BEH0'Q%Y?CD?OEMMZ*TV
M5/$RD9R15AE>"?=,52*G5I:3N1L.6RX!6;X.Y!?>+R$P,+QI$!<3,45KEXW.
MG/T&GO:)RYK\)(32P9>G;Q-$'L*S%G30Z9Z;=*1:0"96#LXWV&V;$!AC9!'O
M'(JFXT9DT__+WK<_IXUDC?XK*G^S]R9U,8-XD^RZRI-X=ET[$^?&V=F[/VT)
M:(PF(#%ZV/'\]?><T]U2"PF00(" WOJ^# 8]NL_[U>> "R,D9DW)<H@<!UT"
M%OXH86C&D@ L%NR+BR;+VLAL'-[=HV<D'W1A'4Y[E]OA="U@_DTRA$Q?-E_,
MW%?&,H(H2+-PR8C%@75N+T5J30WXBI09&ETB#" /=RG6FXR/U8V/(>/"E!E.
M2 VR\'G.DZM>QKD.<R!"0,(=N/!X8=;(<WW?\.$5'D\>4F_.FI*+!$1/+>1(
M[!1I!5$R+JFT\2WK]*M8#T"%)V&P53(7ZJ)=,IE_O.\C_N5PBQ-ONS8X]#QK
M04TY\2G6=61=@L=I5SXUD]6[470 ]]?#+LL%%Z@1\(D-[4B*1FTA*;.S##M!
MJQL1K#R%>YJR_'-3FFDL0HQ3WD_:-UBJEYMH>\U[H>.#L)?3BMZ4AVU(.1C4
M^]B7L%@_RFZCWAATR^E!:-:;O7YIC1&+-<D\R*)ZO?4M%HLLJI_]4QG=&L^D
M=2(O3-I/_T3=@'!IKQ<"KSQM"#6\MFQ36/!T:'0DY, 51;2WS\)&2]L@&8;'
M4OIFS[13)HD=XU4'ZF"ADD^FPUSN1*"<!;7WS@2GX^#$&C#L&!;:B9DK?C81
M%8%*[NKJ8YVV*EQ=7:Q*^EC;ZG8.VD%!;/,P5?^:OHZ_+;/6'&Q9AZ\I3%-8
M+@H;-(HVM"J)PDKJ-<()IU%=RGEP1E26MM+#.+L>',W&EB,P*] @X7RQ8G:*
MMDO56#F "5G4@JQ6GX?3=,:^8-Y&NF&*4[_"%<M%?3LU&SN6;FH?2?>?1 >X
M8R&E?[I.Y?DBI7LD/^Q '?DVRNGFH-[L+!>:'%IX-^/./8LB<=JR:XPZ]?YN
M8\#-O'/ <\8$!=)+[L50?5^[V+XK*USZ@Z+==PIM?)_*8(=><YI:3Y-:S5JG
MM643=$VOQT??Q=%KL]9H;>EE[X]>SZ:=?W8:_2%?9=V[/&47._9<O)S[J^(K
M'"6F\S$Z;$P'I405<D2"VQG49]K"[*3:X;8Z6QK'%8A;:_JJ/GUUFKIE?"40
M<:;TU>L<*1MZT2F>KWBH,M6=AXYP)LY!9S>*.USFYVA4.=##?ZJ'%;/6Z.M)
M657$BVENV2#]X%)\C?:H<IG4(S^S-TZX<6M;>IY]'56O</%G=2S3\\4*R()V
M1^.E<GCI]0<G;6=77T*O:(BVE4 ^23.@.=#&606QTBU:V*JQ<HARXX-63.46
MQY48P57:555)^52B/$P9[+8Q\[A3@94>A5,^5"HKR%HU<\?R@<H.A=J]&$9S
MP@5Q0KO6*7Q@0'."YH1SY(3^MC&@*@Y(.V#U_G^C_Y70W?* ZU9J\@_ZYF2G
MTFZ]U<;=W\MY8I81\$'&$Z/963$&!J>?9;2J:[4+7"^:VK6;!>YIU8W5W70L
M+VH8R)NCP@ZPO]Z0/=D.M<@67RP :BZU/'Z9VJ.I[*9,C0)?+#]J?#U[E=TH
MQTL3<4ZAEV*AXRQJ(T/1"IJW%.13)^1L/& :WA(\-9\F;J)/C8UE)V,W#'Q[
MS)*=];'S%+;2C/I4VVQ5OWVD$&RICXL:X> %/H*/6K87:*M?-_ZM=M4<N]18
M4_;6-=)3'<2>E)$.*R*5M14#"'%QXH7IRL$:;]"\7$N@M@ 6_2;YPQ.M/I>Z
M>B9F&+XPCY\^9? ^1!>A;<S[N2-2.9I?D1,*T4>%QO9E4_R&6LU$]V0BY6RT
MP<6SUVL_L)[47NCQ>+SEUOJ)-K*\P7_,&"AN(CP+24*4//_RZ=;P1S:#+[ O
M],RFE4??I&M*1/MU,3\@>W!EQ)S ,'P<HS4T )S/]HBI@S67B7QIS)&8R5-+
M#+-<[DV-HC$ WAJ&LE&K@!4VG'>]$YD&^#7>>;Z2'M(Q?(0B+$2=4+0*7>N>
MFA(RT6N0S*P1CGZP18?CY>>GAS;4!%EAQ__753,@\HU+JA:6<J?QA06P;CYE
MI*56<(-"Z$MJC8P$.="4Q*<-B@MGK+)G&_;X[,*%\%#)FXE%H;:AI[[@Z";!
ML*1ILWI UY;VFE]_9%-MC1H8KU!@E9?L_[!]-!%&J+EKH.'XV(*Y-49M-O31
MIK!IA!B:#WQ0"L U1S/\1+OHI-A.=ATGOE*'+F1):/5W,C<$]#<1I*4V]$?F
MM!PQR0'H$V3KJX%6$4[WX)W,:;0K$( ]MW$Z#4V+$1=(&A9#8T@N(:II4F^6
M<EKZ2K6]J?UU9)#18)HY&]O471"1@%1-JW90%RC]UZE)>?2--";Y6(G*T]J'
M*8Y:(@)"](T",<R&NK<' $M&7H7EO$KX?7/<%YH#%#K\HV?[WSC\0#R#YXP-
MVU'P(E#DC!: F#U?6&(T%'\3H&M]AF%L(PAI&#0\T0G7W6#[D9$M.N#+OO>*
M+;,T'KANW*]$., #A21*$>N)WYHUJC*6EOA@W+@_!SL2K-<P<-$:QI&7GOML
M>Z&<?ST+_\^'A]_N/R*A#FV'CU42;2P5@JREMBC0X #.^0-D[TO#>@*8^P%\
M ;!&<0"7/MY^>;S^X/YVW:PI?@!)DBG@'^V:%&<&0 SPCTL2FRQ#.P<$8NM@
M',\?  Y'A@:4(37RO81>-%**8'NM1VKPD1I]/5(C$S#<*TEYMO? 7N.QS9W1
M%T:"AC3*)LVC6*] ( %0[3<F1AM$X]IQDIT;/O$8"=<Y?)+AR%V0&40,K]P
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M5.O 585PGU<-VQ9FF#+9GF!04ZH=X.9/**C%,SNU&/%9V>J9ZSQ=DX,]9L/
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M211Y']EH?\>8N\/3B#+L]A1])PIAO2?+$6D98:S%\29A8_+(EP5?C?G7LL(
M=2Q(*-+AJ:,7LF:=:K2&,Q&1'@LK-:XCHT+8D P9CPVY#80U)$'H\;#=!D!0
M=HD.\!!VJ11L87\#??T] 0TE:\6CFC4R;D49""^DI*H[BKW1H^"[7'"3J:*A
M#^*-ETNN2I@EL87Z "2^[<9%&Z+F&PV 3W?_[_'S_3_OHN,Z&3#HD!UIS7PW
M"Q#X\B^/OT7O6_.@=@1JA%9-(2W<F_(0KCV)_.+P*4#J9>K"6^'-GB^2Q3X_
M/0"&J,@5N89EP#4^1:X#HLOHK '\Z)'^E?=/F34+IB->CN\^(^54WP)!2VSD
M@D;[DU%,/B%X $3,B0I(Y$DU<06%P2>X>>G.A^ %S+%,)7A=\-IH(URX3G28
MI&ZD1)NP!<4*QK0$>$]</1PC"0T\[XGAB5-^,LO%6'/$C.)T@0M6LK&P7F/"
MQW,)=-R4%Q1(TQ0OYTL0G%M36$8RMAK#EV(%>"0<Q=+'9^I3Y78\Y*3(IY7Q
M<K2I,)KMUQ(^%.Y8+$+N@D,(2'9I!2 DG" IF+ T7Y1[1^<(:P:6$O!OHE)>
MGO.8LV#JHCB(+9H9"!_T7\CO%!?4C;O(2<!-H2/DXW:8!<PN3BOR3/'O@'=^
MN%$M\B8G !D8?3!A]N$!$@*"ZD4\,J:#DCO'ECNFB$DVCQS8R^=\()E/0D^<
MWEH92B)B4PUN/!KYY$:'!15!HC*AB(2D')*J2V,R9A8+6&K"3QJMBS(Z#$LF
M[8 X5:U1C8-VD9NB>BEDTH!'!D\.9U2E2,)>5CA*Z2&$ JPDVRSBK"[D-S?'
M8!&_,UF904J#$I?\]!E\Y%MF5$2)K^2BA>HU111(GM#%S7-]&RDA]>C3S)[;
M2&%*^ E(SJK1"D'@4ITFF0[7N-%751B):,:S.Z,R$5$D,'YU *4CC-?,771I
M9[-HW[P@AT!'-3Q<7B^P,HN7D*SQ#]62T*'G6F"D4K "J=A%NP(1%IWFD/0K
MSK* A37Z)K0BKP>B8Q;X?A%< Y.*(@DO& 1XX5'1X,6E6ASB(P2+#*Y*MHG4
M'N&'ETC[$4R%?8B(3.R(0X,*Z8PG*G22JQ0@5$-3_V:\ZE38J8P3RP0-.[&2
MW_GA:3IRI!0XJUICR 14GL'60D0(HS\94 /&F(T3(;5$E%(:O$ \,J@V8O(N
M@I<5QZ]$D:P09MFQT,I(DFP?\@L;<;/>]OUP.=3M.BZ6PM-.*K./526QVC@X
M%^/@VGB,3_H_*C+E-B;.ST*MU7+G"&MJ2L"B$+F!6:IFXWW$!/><"93W/(*6
M'%O>V*=+S?=IR^ R@W*#QBD%Y:HC;;.RFA47K;>JX>VQ)^ &*AKFYZ$R]C,1
M/B-5^#**%:7Z[="1 DNX@!BDX45K9".A1\QF[@L85WMX=7OYU2T\MX/9PPFV
MIQ)2XC/8@<;]O7%]#^+#Z$D+>W6^(]>K93H:&_5,P!!3CC0]1I6$9('<?1=I
MJ@]X/(T#X,WCW8>W]%(V]$*4CTT!S5/P5^+\CZBZE$U[_+0KJ#B V?CE<065
M8MY@KHL7C?MOHSF*XE52TE(S,=COS%KX[)W\\%YVD;4=6CK=]!X6]P2"28CG
MC '5)([XS['(JC>XV!(]:,6;Q<]U^.G']/<=4!EF-_.G1MW,_'[5H_KU02/[
MEU5/6OU]>]#6:SKPFIIKG[2AN_':AMJ#U&49+1:Y-;'WKH+]7#-3_T-.Z5U"
MDO(>@R!.<PQ*W1T<:SM.'L@>RP<KWON!:]9G\#I1V62T=-Z%@)1VH7F;,E:6
MM!!.>4;MKMJHNM=+ %9[5W8K"-.J@X2SV[$IZ)0@]I<$L XTBA% =OA>N%]X
MU>5.H[PW"XUC#=D^P96=WN+*G''7:BB3*!1669Y,40G>65W1I >4G\R 7[/6
M-_LG.Q!.4UCU*:Q5,QM'&FZG*>PB*.R-66L.XA;W)T1=T?UG-]#R3;MY6(0<
M?(=[<9).SPI\$$6,Y$==SC1-LWFDD=IZ;N-:K!QI;J/&REK]G%\5:'R<'SZJ
MK9J//P>UJE=IP&G :<"=Q%4'&J5\% ]##D7>WL-(3B_<9IQEI=2;61NTBTZ-
M+P2"$XB&G LN6[5FJZ@GJ7%935Q2'+)XV.ML\'ABV&HW=(1RRP@E+:!H>')N
MC\<S=H0():](5L:4[53N<>SJ!'U_!0LPCD7;'_!L*@['R:J_.%_9W>^>;LW"
M^6+%K+6[6_HE&B_[M'0Z@Z[.CE<*(^T#ERN<D>UY:BKZRXHA/Y>3*V_5S%93
MYV4KAY=VK=-N:;Q4#B]OP) R=<Z\6CAIZ:3YI3C5.28V7HZK;=8:)WQ X)SQ
M8O:TLUT]O+PQ.]K9KAA&6MK9+O^\[K&T,R\'<5-)G5W\Z=RGMJM/[9TM]'51
M*)R =W%&&.W5S+ZI,7I&&'W3K)G= DKI#+%Y8@AK%:@5T=[_Z=:*_.+ZOF@T
M'/6QVTO)Z?9"ZUB@>=.J-7KM\JK;MA=: @(5*E0\26P.VAV-S?/ 9K]7U$ \
M0WR>F$G1U ?D+Z+\]!X;NS&?)I&Y\R,<D3_6QEMFT?CT3I9S<;ES5%?F6%AI
M-SL:*Y7#RAOS8 G_$\/(\?1S@32.=OE/5S_S!C8BBU##686'3^X?3>ST#V2#
MGIA3<#Q\]#1"JH20WD$[%YX84HZFF@_=[._45/.YN,X4C1\R''XMO&<CL+Y7
M+M5_-&W1K/6Z!33X_M*(1_,IS@F;K5JW44#]:VQ6&9O]5E'+X0SQ>6)F1;-X
M2<9%F179IE15ZP0_R]'A-(?NS9 Y;&('E-Q_BV9$/%O\<OS]SD$KQD_,G3F:
MXF\?JF!<(R3?T8I&0[-)Y937FZ9YJ.#8B>KGLMW^HTT5FH'?OZ7=+"; MF#?
M8S?$>;)RM;LY%Z<YQJ-\V%26=]XT:_TB)36E@^9(1=>:+S1?; @K=;K%:PLT
M7VB^.&N^Z.T8H#M=SCCG"-X%-NGX,;" ^N3D</J'7S+TL#FFN#SYXUY6G)HE
MW%0F[*Y8R.%7F8)K,]5CWABSD<<LGXV-X:OQ@UEO&4-[-K-=IV:XGM%N_*5F
MV [-;Z\9"\^>6QXLQAA[-MR.MUCX!'P)7N8LCTFM&ZG)J9O>V%3?.+.\)X;O
M@Y4&+CA++\P3CWEV9R$"Q)T8;N@9'QY^N_]H/%NC$:[%&GF83[5FN-$G/-E4
M-^X=(Y@RXU_UQWHMO5*Y#909\X7EP0=X(8X8K\$C)C,VHA/8EO'*+._:!1ZY
MQD_J[O%+?&-R*6,&R!K7C:]3.]Z[\6+Y!KPEL.&&5]C#Q(<% 3QL1P('(/T-
MOO.G%F6$:>T>"RQ[9HRFEN.P6<WPP\7"]0(.2KS #X'5?7\2S@!TH2,ZL2V8
M-W$]6,:((;CFG^[^W^/G^W_> 5@]W!3>B?#^$?[IPDO\A>U9@>N]BDW0V3##
MAW6Y#L'Q+O3<!:-G\V7QSJSX^<7U9N."\!74))$M]H+7S1B]&IYMC9]I_8O0
M@^T#!*TGCS%L+N?#^V=6P!^8@+UOO-C!U'A"Q#AXJ3$*?9!ES//A#1;\"<SB
MV<-0W"QY0D ;R!T($K%<,P!=+PQP"__E1"B1S=$K;H%E<;3YB&_\TX:]C@*\
M&;"8A? DD'@7'EP.2&]XR\QUGJX#YLT-ZL8#I#RBI\!5_M1>I#<(_V\'-L/]
M@09XFA)OV XH@A"V^@K+<\()K(@CWO(\G!=/4*P;B?%V1*$$6, -K!A Y=M^
M0$!,(3""RA,\+Y"/J*'ZG5E@(W "BKY&@,WL$8,GXB+@+\]]M6;!:_QR!)>D
MAQA84Q!C*  "N.<:^&2\O"%Q?[WB(OAS NG(X%B3.8K($';CX"?0XB^ 7RX.
MNQG\#HP^XW*($QIRRM8TDZ!R9 T;0 F4N BL;TN"PXYE:65 G:V3TQW1C[]@
M>M@[&]2P/<I!+=F-KX\-[NRU/H"X&:GK)3GR0]3$>JZJ^OY?I/9.J0O%!@"5
M. O'7$_9WO@::?E52 R;&P _])<?;SL@"$B%O7AVP*['[HO#+VT.3".Z++9H
M,''J62\@3X!U0$C[))=P;1/LA38%1L O?#:WKZ-ODIH^>B>7<*$3!O8,8#=>
M$E(C"UC5ACW@52\VB#)<'8&-+W'0DBL$H9P-4+,NCK8D;*?>9H"V\P'4['1R
M0[0]Z,00S;]K8VG7K6X_?@RI"##A<#D.H "D6:3Y0?_,[8"K?KQNA(;!;,:5
MS(2)'70;B0U(A0R/ *WB(S3 L9D2C=%3.&Q<TH%@'#@Q0&I)=13;OM*:D$8
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M/>73J&\*C.(YD6EPFF#/FV"+M\?7%%L5[%TBQ7;T#-6SFJ%:I GXWE%9A48
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M "!'KS6EP8 83?ULPZIQH&OF"1HZ+N(]\\.DQD-RIFQ-GB+$<%O\8'=B/+F
M!F<N9R/#RA9X?(K107]E^&R-MD&GC\8XB7EBV1Z=>&1UXT-../CX0K5(GY^^
M7!H)7F\;0W4D>.<ON/KYPO+XH<+E![3KQL]B0.<KLSR#X:R^]&MHE/+4PB.
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M,!M:N>>V'+&5X=H>3 >RR39"DW3V+^"^\ /_:-KR3^9*<_6HZR7L8R5'_HZ
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MS1 RV;'0C3T,FXT>]M[M==-"9ML>AKOBLMK=0S4+:Q8N)296)@_C8?M:.^-
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M+$IM\7@=&Z7ZJ)'V#LIS*4-0!S8 = & EF],/'<.\CV0QYFOM+]ZS_$6,I)
MQE$JOT4@IMY;3%^WCG5GSF;^_60]@>U-7!CBK72Z12FL*J,4IPELG079VG5&
MMH-[OI7(5BQDVZ8@G 79&H1LO8/[6);!M!QU!Q].J702'$MM0(K91$,O4;_;
M34PS;Y5]A:\-K?;0$(Z"5UA@6!EDC$8O\>JB\6H/9> H>$41U6;]X $EI<\@
MOY# PL,4FF!9,18STPEH@ !.C5Z@^O=JG 5'#0U\E2#^B@ &A?JC F\6C71N
MAHVR/=,U8<N^;O\-Z+(GO\5Q4)5Z1IE B4T7BTW[>OSW8CZ]FV&OGE;[BE:U
MNJM&L',*B64_J6?+1U3Q^G?-WB(MQ<_0V@G.S+<)-T!BCT(?+O%]&K.''U!"
MK,G';45'!7LJS?6#Y/;/$M""!Z5C6I?\QDJRXHG]0UC5OX7G9A%5_P;TVWZS
MT7Q?$+VWM*=.9*<?":$&)4)=#D(=5[IOQ*@4YG3J-\,BM!I[[88W"FW;"4SG
MT48O.PTD*$WM/$3VYPBJ:V>H=7"\50$ZLY0FT9FD<!I'=A:]G69NHK?$HF)A
MT;Z2]Q L:A4-BUYK!)R+.?!@L984,(*6A3+9<0,Y31>=X<&R#(7G*ZB_('SU
M =.[4T^[-'^N%(?VE>0'(%&G1*++0:+CVM I+$IC"_9S+,"8J==J-T=='Q:R
MJM88+4%@[U&(N8-J>SV%S3G*[375S%$1[,NKF3L]#$X.V@<G@^Q[?!=@9;U2
M5-PB_H^(BWW&Q71I7(F+KQ07MR@11\3%P<VPG4>2W"EP\=1Q^M.V>OAD.Z8S
MSJ'5PSY=-_;NAK"+0?"Z%E?V/"_2 LO-GJJ;_09KKS$H )?=I0II[ G+#HR)
M.:;6QZ\F*GJDLJ-?,3O@?G)'4,W0-KK8-+>>CH:6P:R+1I ]"HA6,&1G#VJW
M4;0@5HD]IR\3>C'V%"Z0GF<(M,C2EKW?E#:<%+6&[?LAV#L"MN\'KR?*>8Q\
MI/L)UL=]E@"]0WAF$4'K9M@L9\46&CN.$;_,Q([=66<9_[Y6_-DQ<GD@_A0N
M]/TJ#=U(VJ(D=N=S%U?BCO\R@BGL]7&J\HZP*K=LVG5H]PV$+%; 98KA[LVP
M591>-*41<X8>&ANQ ]MFYA6,*;&C(-BQ3R>,C=C1OQGFEL)P9#EZ?H_V6;WC
MEVFO?S=_&*H7F^&)F1D(RPA<*OWUIZ:'/;J"8";X D![J3:8SZ9GE4;\(4;\
M)]?[)A:R9.M^<D=*&G&#+$8P %N^-.6+C"/',.4WX<C.%EFO7C2+K$2C$R<C
M[XI'V_.'>EC>6&ED- 6\Z'3E HOHNZGI/,*#;,>81!E#^0QBOT0]/ ]1//<<
M\QVG7PF:A?S5LP&N"W.F"(;*W6^M/T,NW\K2S7M-H(1#!FB41EO!D&6-4,X'
M6UIE6?AU8<L:T9L/MK1!W>\5 %U*F[]("RRJ@^/BB[W>R'F_;S45JQSX>^JR
MKR@A7B]O2//&SLVP,\BK*7DA:FG*V:FGK^O:$=EP4%Y>#:5+7"LBKIUT3F\F
MUNWI@:'*5OBGG--[1JSY.)F(,><YQOX9\8/_,#P3V[L +G'O5,?B7S!X\@3'
MZ;PP__%UUTQN9O-\(/>3C_(,OL$1W#M(@_C_QQCRWX0?>/8X$!:U,W2LY ?:
ME9^=\2Q$8'X W=GUS=DO<!H+N /^QK793B@L.7G;S8S?]OI989L"5EJ65;\%
MT%2*@,*[1Y7R:Q-;(OBU(/B6<-1%(7@_O[#I*1#\6FKEUWMM;&?L4=CK#> 8
M_?:6VNH!0E12^A4I75Z$-?1]Z<?)6><ZB'*_PNI=,(GX*#_((XWH6><1S#>R
M:+2!V9/I(%QIGU\/OAX8PUMCGY\?=9LWP\$@W1*H6$9\B;6%\BJ='VNQIK!?
M=*R];M?3W<X*3\48B4?;<3"<Y4Z,I3"]TN^TKP[4.:(.M*_OM]^F3G+-LI-<
MB9V,G<U>D="S@Q.C!\V#%?(2/:\$/1O](J%GEP8$-PX>/'U!_AQ&IOI5*#,"
M/ERCQAS7L"@0O/['\79^#?RF721VTT-IV!GD->>^$-)P@Z%?TF!)@X4SF/HY
M&4PE#98T>$$T6"RS<)"367A!OL/BZ-W9S<<?PL6"R_K-&:O?DYG[;-@.'RT<
MSHM:D:<MHQ; PG)#''IV<+OO74SQU[:ZH]N)!:WCN*,:#A,H_XU'PY6$]1;Y
M$J8)N'-A!.:/=.7&P97BERP!KT[(;<E.^$R(\!WQX"O@R1>1%= :U$$VY97@
M?P$*8(GAY]Y5GAFCNZ$XMFS(S0M1XGB)XV?*?M@-VYO8;C&'XIC"&Q*%5\Q8
M&PL$.O(/*5R_'AK.VEQ1:3A738R18 /59K?'N-@VF"5Z7Q5Z;U7#MN(W-O1H
ME_A=XG<A\7M+W<X.^-T!K2NOK+0R=6(G%^X7UZF2YU8;5>U8^W4P.<%PQ:N[
MOVP3] JLF*^R6::/&4<+SUW JI85&I<0$)EAMM*"9AW9E$%/_8. Y,8 C,#'
MILHF^NWQ4OC0"^'[#>T:2WEZ5?)T6_!U80?F[../A7 L.PA!M'YVQJ'G">OG
M,/CB!O\M2-1FR=GNS;!_<.^C4H\L\?X<=M(AB-^[&1[NPRX1OT3\<QA0AR ^
M9K"UBN(:*W7?(BVPW&RYV1TW^U. Y@C\:]E/PW_ #W7UW/0>;:<Z<H/ G;];
M:8,_%NCYR9'UD@FXD?<VB?>.O)^&WZ>"[*DYO'N)_@S'Q:YJ.)0&%H.!I4?/
MG(&EY5$?MF J?!PNZU ^( VRD:X0N,@/X /JMER+6.8J).0*VLU:KP.K7+B^
MC9SV'8W%L9_$^V?;"J9*.F@W2MC5XUO,$2PB#-;?4@ 8-^J])"CTG[A4%$!V
MH].8M ?=?KO;F[3;UJ#?F32;]1[\T>HU^[W>OQKMSHVZ:^JI]2_,1U$=><+\
MJVI.8'OOS-FSN?01'77< \23:VIU8=$[0(ODDP06HTG6)M;B=^O4^)URW1'L
M?[O_\/';E]N*\?G+W7J$+.32O]Q___A@?+\W[NZ_/-S_^OG#[?>/'XQ/G[_<
M?KG[?/NK\? =/OCMXY?O#SGL*^N$]T'-?H2:K#U]">>PZW':7$^J:_?>H^G8
M?U,:[%W$4."/6\?Z"KH;9LWBG_>33XK#/$0,!AM/S5P?=+SO\(J?9S1D12ES
M ]8<J2O5;2 _PP4(4/P6B.I>*!CY3WZRC9KQ 9;AV0O2=YFE&C^'/@YA]U.'
ML/&$3L[-?G,MX3DF4)0SKAEOX(TS@>YO,5M6C&<[F!IVX">E@Q^.?-NR3<\6
M?@5$RA*W'#WG652,$#YW0\]P/0+%'8NBMX8-4L@8V2".QE,']O:X-*28,DSK
M27G?#0=V-9Z9/OD0Y\*RQPA)8VY:@C_Q 9,>A6< *S#>S.'GVYJ!_V@7H[2S
M!";$\& VR_:P[R@N9^1:2VI0UGL/.Q.SF8\7+#S7"L<"Y2.8"O!I.#.]"CQQ
M/O),1^!>?&S]@1" :P-A.W#?U R,J?D$DA4?[0$JAF  X,4+3SP!6@,DC9%P
MQ,0.&)RX@@7<#E^!?(47@V4!I$&0\5P3P+N A7KA'+<**@GV&O%KQCV $[23
M -/,C5%HSRSND\I$X8:^A" W5!V9/JR"?*B+Q<R&)1-X_+$MX)(*0&8&"_.6
MAG82>#5@4C@!0RGTX"0JLM4['DKHT\*!UM@5NR20A9X?(L10ES !<6:P"<\=
MA7Y@+.R%0&S#7>!Y6@"-F<N.WS&\BG )]O6'D$=%7^.KM#,<>ZZ/^\&F*C;N
M4<+#> +]!B\!-'/&O'P-_+(,EIXK;]"_71$</R587 %)%'FP/&?BGC%3! 8X
M?+!I6C&@QP3M5H0@'$BSWJ@C+3)R D8[/F(.ZG8XY=C$(F%A>N-I%32\1Y%!
MAG#VH";."9WPZ">VF%$9,6$2XBW>!# C/9&$S\(#:#.6FP!Y0#!4+&%#:!(#
MTGN O3/;Q8>H Z232AX='[H/"(%:ZMRU3';]5R(*0166V%2(CY4Q!NWY^$RI
MYB*U)I Z1F%X)-,O8*[[3$E7L K;BE=,_8?C/3*'H!. N\CA0/A+_@@GF"T9
MV&O]'_+^C4[OSU\^)0:B %:.A,>3QW@97_DIR6*B*K F+"AZ=CT+>&/D#JDK
M"0J8=3,,IIX0*8=(QA9]V;_Q86'_)9[,'__K/QJ]]GOF$%\^_M^'KY__ZR-_
MQGS^[OZ?GS]H1$D7?OOX\,_/M_IE\@+#?#2!>0:(@PL;SL@%1N0OG?&26.*3
M[0&EO_GV\$_@ZK>6198!G-&2\!F@Y"J.JU!,YRTZWUE[$A$#VE@&O>XL/L2O
MNXLX61;(@3J;Z0'6:UBA0GP$U-J%:[=*^CQT!U\EF6>MOYDY@#L);L4E8B+
MUI**@OP@M(#.:O00G8<-C?WTHETUUT[C99KK R@*]@36[ 2W'(H$7O$5N E(
M3#^EC[;KK90^"I\51!]MUHR'< [& BEFVLZ,>&N&VMOYU5-ZV#MT\]KC'7;W
M,Z@VI!CJ!@5Q'#DP:L:QYX3]L<<N]T(;6LS]9 5EEOPS VW:)T:0;(4"=<FM
M_AY2RT")!=4N#M%[%JJ8+.)_KSW4C$=0;5'U6^+78H$/,V,D6\0G\N:7V]NO
MR-!!R?#$1'BHB$K= E@XNZA0JT!]=4PI (^AS:^#\YX+Q%_XGN[%7U G,<-@
MZGIV0&ZF-2_.6*'4:'X'K@I_D04*V_59@5+?:K0"5S@6SFT&I+*(E@CGWMP^
MW+TES,N\]O<%\W6X[/>WTBKDX$-D_&;?^+,+_QAO/MT^_/SV$%UU+TQ.D,M:
M_.T4 G_1P;D=?V5ZB6Z!LF8(W^DF+.#D;,;Y]DH+)GV9Q1UKJ"-SQK85:1XC
M(1P#M(PYO%;BTU@'7P$-C#V9[.\^*5 ?_0 TB6 O*;$7UOV.4W6CM\1XUBT$
MGOTAS2=R/ BU2D*(/T/K4;)):OF)%$P<:<YI3, WP1QAW'!W8[=L"&5X[LG(
M&*$5BT^*UP$L:&K[H#V3JB5^@!E$YCT]Z@EP&RUF3\Q @\?<*]\/YPM&:3)[
MGA&19[9 ^]"%7PUL:PJ:-K)>X(."?3=CVQN'<U@GHG^%/@*Y&\X"$K+/4WL\
M)4.$/2LDF]&2FIM_X?HU,(W<,) ^!,^CS3V9LY!E-:Q-2!!HN5YH9>$-"#3E
M5=L(N@CHZA3@)O+"A P3!)&#J6D6FX+Q/20SJ,VKL@D]DDD($\M&V;% .0A@
M)//918O5\.$XQG@\VJ3AY GA4SR!8C.6.O$.-#B24XC>CY<Q5/$S])QHK07@
ME+"2"Q[\9-HS/*F:P=$>,H75 ]7Q:B@Q-Y=@+DU0=N+2/)LD(F]&7_+ELZX'
M01AG?,[HR%!,%^R>E@KO[YO"VRT:9V^5DW[7Q*%+\QU8^3$-'YX&M,\?JJQH
MI@]B"CZ_N8(ZV$SC>9JK!>1AZ!&Q(E:-I L<.,*8!D6ZCF(@Y'NJZ*9D9<7=
M(L,(RN-4109HQ<Y!]HC>36T!8NJ'&(>D MY/0#M#TA3>$V^+I#]==1_MZP,8
MR#X^^S?S+[CXS=W]A]_>5L@= =S1QKTB#T.NY/MJEQ)F_X^/A$JHI5BMY'5P
M.S$$\B=)%=&2;_*93O%%AD"^1U"/68%.XVC-).4%L=4*0Y%:$CO&7V()L, V
M,ZC, +? K;H!,0%B>!7M'!7?8Q [/!(">SW )F>N#Y\SQ['9^Q"Q45"Z?7F<
M\NS1WD=/MKQ1VY7<M/ C./@&'YD\]!A^$?/B_BG1];A#X):FKSH74FN52LRZ
M90;0>@@!$)X%*'.(SHX\/UJV8K&>.U+^:]Q4"!8!1QELDMF,EO1"W<D1UP/4
MC&^;3ID8/I\EST<=@?RCB $5&,2[DR>BGSNL?N;"8;'[E!EZ)+!LF?1$D0S8
M<<WX8/OFXZ,G'DT9D-".)8%.4HA*1PU>,@F=,?O4C!GN$L^=9=TCQCQ +D0C
M7N%UZ!85%$((%RB!EGR:<.8$;T08C0'$2#=W+7BTF"^F)C)#0-,I69(Q>A"]
M"PRW +$+*P)CE0F*D8OT<DO@Z>-1)!G,7HPD/L4*G/Q"XOB(0E!S]*H[$P].
MQPO'] I%5?@><GFKZ$L%"1ZI-_1(#;#BDY#\*CJV&6(7FJZPG4DX6^$J&A]9
M=73B@X540B+:@RO-1^'YRM U%:-RHS$].M5+;8#!@?GWU,X<KZ=3]_%D4=5T
M'5*B0!=TGUE!TRD+78]\0VU5&S .TQ56TD<HD>'Z<T?ZZW-'"I,%DAUOD@[.
M#+=G\WCVV9[*WS>I[7\#/?G1L8_I^I.O^@0J])U+,>/@#V#==R%89/" M0I9
M/P.$_9-[CM<X5D"Z@+CRYAA (6-T@>$UL!8"9=KJ-I4R&PG6R,&)OWD>6D-L
MF2E+)'XJ\C04<=(:\L? L/"9MP]W1K?>I1B/9(QL+KD8G2/.A0H>2,^%;[QA
M0^I)5/%O%C5OWQEO[+< 9HRL3Y:*D]'!O/'?LEPE4UR>T'NX?O4&7;5S1T R
MS%:5[::>1[?"O4E@:5XC=$".!5[V]#92C;(O4K[,G5^-[/P-/#:">W0>SU/A
M&"1B#&&"],I^)(I['W[S)R#4:_O&82(.1?G056(HF/UX%%ZZEOJST)>3H2PT
MMVF?[\B)@5?Q&#1>'\61QJ)MM0>]/@:/VI-1MU\?C;JF->JV^[VZZ+;^!5RM
M5[]1VY<A5^/!1(?RWC I!"BW.;I\U)OC6"XBV;>'?\9Q>HFE6JQX;GI_B4#7
MN>$:U'%!T!B/[I/PG-@]0VJ<8TJUT]7RQ$"G!EN='?*UAUI&0'EU,<1#0-:C
MVFO#*M _ Z]^GKIP/'!$'K\2]#*PCT9AX'I2":*D!=3)0&L#7"%=D?."^ F>
M", R4?=/A3D+IF,.@Y ^[/G[DLLY3C+F"VCIR8B^X1/N$H<@5N+.-*.(KN D
M$=R].FO)*$$=72[0QPA0(AM 90_5C!>)S*\Q6[J/N)*607<_^6HN$76^ W/5
MG,*#FZ'\PD"VJX=V2.2P.ZM5Q_5WZV G+?U5I;2"[)32 T@<\ XQ4+J@Z+;,
MGB+F22HV[O%+"HK*K2>E'H(9M7[I0[,T3,0AU]ZCP+(2']_]Y"+'MW#$)CDH
M)Y0H!DIX@(6O,;DL/%&E=I:^3,)B\Q(OYR4 JH8>ZOLQH<%G(S3 &=?914EJ
M-)E6,G.%379?Z$]->"DCFUT)'+1#"=R5A*>0]0!:A-H%0PCI4O.OLE=S94WL
MD48[ ZE*F2YAY&M! XKF%Y"+&!T=4]=2V81SUP>+Q/Y+H%N6=1*^@/SDX8+=
MQ0D_[+]#$XP]M&S9I85[A6-#XQ\/W[3^!$1042/=&4OT AI)0DG0+J\97W7,
MJ"A<B*%;28+7=9C5\"X#\BY0VRX5HD=9[OGD$M(""C0O/9R';!1% E]#0FG#
MLX=C)G4!?  8^\(#ON8$2[0]W;'-.!KE(L:(8'-@3/P[Y$P.--5G3Z@D/$SM
MQ4*Y!*?P8Y;LDT";5.>)BF XF]BSV8KWA-U/+FT9X\IX4-DZ"F I=BN3QC*;
MZ3&F8VJ6C/S&25SH>0%C5F(ONP H24SEO"%*I.E8_)!%Z'1-BF.FD\R+X_]>
M(P'6,)^8Z9 O2A0A]6.;*%,\B+$U$L^53-G,/ :K]Q:8F8I=",A9JNL:QIM?
MOMZ_)<,%,PF%D[ (,-HCW7\NA4IT'AC!C_U2,6S17\JI*.QMYC +15U&(G@6
MD@X5\V>E?P34P?XU_$X3&"J6Y8A'-["E<P_OX!=&MVP!!CT']DKYRZ2X?'*]
M6"52*3-*/J"_W!ZS9XS=7@"1\5^*XL?(U&$!-IX_J->/@NTT?AMYD83CLW6!
M+D. Z29MC!AUK%,PK/6#\#-$)=E+.O5NEYU\4E(,Q*GYOL@@!F1^ZV4?XP3*
M%)),$IG0Y^=1QNTD))]AA$AR08  4_/)YBW'9TSO8ZUX=9><"XV[U-G6(V4&
MKC OQXJ[9G G9VZ<P?Y>V+/T86[272Z/O2EY*W6/\Z]_&P];Q7,=QR.KATD:
M;Y1V".PM2L8%S6@A$ZY9DAN8>A(PE=J+<&8F$PT(=0'C/D8*J:ZH:8FX"MVD
M$\.*)#C1?12ED<OA2"&IH/#ZF>EI"XQU7^5;GE!W)8=R>^5&$]P'9Z8Z8D;J
M[9\LI:5!:0F N-(88;'9.0Y*(N"^$G0>A?\3:JF"@(UD1,Q:ZD"<V+;:9@:9
M0"IM0R8!&?Y4J&P%>-QNU)I4*YF!SU3HYHK(\Y>4.:)I_A>@='Q"UJQZ$)&H
MM<%4P%+9)7Z\R3>0". 1BY>B4)8>Q80?*:R^" )4 YYLDP.>2I!59/8:%2Q(
MHE^ U!&<R&-S/DZ4?;UB9)C^"W&ZAIZ89KW9KG!V$&A.$3;B4G[#Z#N_2I[M
MBD&!ST=/C43J+ &<>H:'':$PK*N2A11E1>)8XP# /** 7@!*EJ5<.V@8VC_8
M3E)P)FV #FV50RBP+(E)A ZUW:7?I&*F%I?@%P? %;4O!"RM"7[I5!*^%R9^
M,+[^I"(U-PVE9T$&CDK>*;PCZH.4*LG$."[]@0U0]%^W_UGNQ9XKM,UMSLQ%
MFQ3PG8I#%(Z@R %-C-.8R-:-XZI8ZP,J%QQ*@,]/T""[OF(U%Y=&TA3.3$,S
M.$2S0@L$84JBD1A!E1E!,FJ/V0E/8"=3T%N*L*4#X!QC:ND<60*L,MIV+"TY
M2,MR286$9"DB85SL[= =!!&56&$4.^"R*':"H?<A*B\$$,B$,4DC,S18V%D%
MB[$!/95V(,D)%54;_0<8>GZ6Y6//+@V/)+&.H%$HOR)=$:=M).@YUO=$<,5W
M:ZBM;X:!PI3X:#^A<Y+K2!0D 2X<%V>CX1FH,X*53 >G8A]>S)]"Y>QB.:0*
MJ+\@@P[4:G1C<<)<.DNN(O<$.!1;>^HN69RD*!6]$B;OG(KTMK=66 VDIVIG
M<@@ZO*Z@^^"B@^[-S*![:VUA*,>3BZ$1;@K*W9-2*(,"5QA5NY?N;O;5DK3S
ML<-E%+0";@KJFW3Z4LX>NBS-D815_#% 6CA^E)+I+D'[7,9?$S/"\I$JIBLO
M5PI>Y649&L-%@'A? T0':%X[/EOE063-LWH=N\"KE*KJ>E*\ DX]4=@CX>RD
MDN9U28W*_M3<\V27**<>6<_*K\9/LN>CT//)3^ '4=8HII:K6AM<']A&O"@9
MGF-/E86Z(&I3%,"@!R32-75[&%,9N=<)"?U8+4Q0"\OEJ'N1A!,],\H@47[-
MN*#!%\D,E2A.,E'%\SX%N>T@P,#';6S@1%E]*^$_>D*4H&ENR".53Z@9"21-
M.&(3+XDMCT?9""&=GZ>506!29)0)* %!6*1Y>)XY>LZVA\TUHAAU(=M'U7PD
M *24@MCQO&9W$:PU^)N8 PGH0&TF8A=.L+YWSS7QHKL$-[]>0:>X%>EWY(I$
M-1]I73Q25H &!MT?I/R(28+DP*1RN]@B@X_Q[2P541M/)&NOJR*(_"C2:RD9
M)ULP>DN2![(-]37I/%$55@7+A6QRK9@D;#I,>&["!; H=$0*2FZ7#(8"Y]MH
M2 8RDJTHU!_*M*C$=+62 <VIW.A\7<V&-@#D8,>X8#3%SJ98O^"ENMS)2/S
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ML"9[LES##Y-KR8 =7)Z!!]'C%3J*-<]_ES>Q=7>BM97TN9U&JJO5R:2G*N8
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MT_!1J@_OB&^R+HLA$W<%I_#X-<19E6D+L#5-B?TH3Q2)2* !I;DD\CSQB(8
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M)$<^+O)CBA]HPOMI7TCA3(0$%<9THC"!6E-JGT=:21;YD9]9]JZ=J)NH"H[
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MB >8JZ?B*_V$CYVT .,1'D]> E;)HL(-5EQA'Y0"Q$R-"A"S@L^5=1'GRFI
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M4&<S*WFJI,Z2.DOJ/(@ZVUM</;M19PMDY\%F=R'(<XO1GF=/@_*J=5>5AU"
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MV8D1:C7IYQRRT@$X*#8O.H $OP$YBN G3<4B5%N$ P,-;I$Y!P"<:G4; T#
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M)G4XM.@ =#"?A#YAT*YJ4\-B>*9"\'_?_\_3]]_?W2MOUF0U=<!'_;>_TJ>
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M^F?X&'XB&#8:8UAC4$A> L/\@7-]E&%^F^?M$-T+/SUC"%D$"%'>/'QXB]?
MQ-+!V..E.C%ASH%O;?K6L\NR-NRU&=Q./WP(SC'TR QR. M<^L-W4W=DA7?B
MND5"]X%"=>O.X_<_?7^+;_.(@?FKWWS'];'W62#O":M*Z.569%7(8D&/'D'X
MAUIQ@R[)5I^S2% 3GH0G]&?\&+H9:Q@%\F@H'IDM+8#\<Y!-@$LY)Z;!WO\3
M,^?Q!A<S 9ZCL-K>[KMX-O; M9RQC].3,I7)#\K4V+TY.':$:T:/C?2NG0YI
MH>!ZM,-94\=F_[HPDLJ0?G+=>61!S R^9DZ3!>EE*W/\778/J#OTBCH\&D7R
M! ,%$[TD9Y>&U)-R71N^$C4T\\E]M)X13_ Q<K5*\U)T6%%<-JWS"\9,6_Z:
M_@N4&IXA\8:4'F18"SRF^-ER,!T15DZ8F[WKT3<P/]KC(?+#^5NVD>R:E827
MH<W=M6CRLJU]4 PN"8^XQV]'45"9&XT&"+Z%10&"E GV=F8,Z<WSLPUKEW"V
MR&)\KM5N?5RM8-UF;H+E^NR;F!$3BN"^DH==#WP+Y:LU8_+SM&N6<06V;2\;
MI9MDX)+8_[=I1=N%@X_^"X"#$ I57M0.*$]49[>PJL,A3#,$*77&:N5;-LLV
MHK+(2BL6"^9=85)N/*=E/Y^%C7NESPF7++;ND2RV<@,;@TXWN%Y,<T3W2@I2
M#G3MW9:A7L#T13 @SUO-O7T^<%V;"9$+\"T,BI"]*IIGTYZ"LMJ+ESP]O/_.
M^YYGT.YG:6(2OWC&ZLE6MYW0%P*/UJS-"JSML/=+15=3.UM'=7*0XA.$DV*&
MD.S9A&T2_4'>S_Y-U7;OEWHT]PN$EPI]*/+!5K*$)3H83%AB24I[IB7TWE9X
M!1$<>N9RUW/M>N&*@])'?"*=0*-&10] %[K'LZC.C +(5?!/^"0JKRD8C2#*
M@26GM+SLX$E$XJX,-?H>*A3P[-Q6P)C0.BR#BH.-P7%CFYB-N7:8S0LN<."_
MHX<]!6>-&AIZEL%3 2Q5S,UW(Y+E!B9G@Z]WR%^^X3 O<*7_B)7+!9YL^(](
MM'?;@NL%/%O;WTNP:^Y=*.SY@#NE[.XJ/0/1#VP-?-HWYSBZR'S;R@<6O4Y2
MZL8"TQ2;VQL%ARRP+)<="&/%;;O0;:3,[W49!'SAU,K.!-01Q\Q=#W/=8094
MD4VQL)-5LP50.;:<,+R]#=LS.4$HGID;&/Y61>Z'8]P#S,5U9SLN=CF#Z[>9
M^Z0>SWW*4PHUWI9"B90QE;TFZR.]-J3@^FB](U.LR/JL.S\(+6!^#VCV-H\$
M#EGTM(GE6LRV/SEZ6*;KN2=*M@:=7BQ-"WZ67+*U79J];ECC"QVT3AZK!J!O
MMFKBHP4G"7^G#C_H!I8RF3XFVM!J#OH[P;(36#M)W64.-?T+[N<+J)QP(I'=
MS]<Q+CO 'F=+,O=-\G6!(\#_1P8!>'I<VHZ'J4F1L3PA]A*@U"^YSB]S>SIW
MUY^.F1N89I/^B7GQX6Q9%%1_T0T3'VJ!"]I" Z"X6P'#4&'49AC;18&WP5&6
MVE/OQ%U+6O^Z*^E2I_'L4M<;][CT7ANUM4Y?CDF.28ZI[#&IE;<\[(ZOKN5A
MS$J<T^NPT)JE=W'KQ(G ,G/;E72D2%ULZA7<KS G!@YDN5K&ECM&S/T].#&<
MT;DONF4WO^V_6W#.,P7?]]^0A4IN_.UM_"=:K'L5.R^4Y<0#/KNKHJ?\(GU.
MI= D1",$%AD<HL##BP1/KD*LKPB;+)%$X+W?Q64%'N0N6'RU^%P9\[E)1,/G
M%]MJ";SO4GPN+SXE-0[?XI_7U,>9F-*W5Q6'<7-A6HD?ZI+JZ/BSK2B_%JVQ
MF9?/MY]MROFRY5(::-R'5S4?;.<1L(CWHY'+T##B@V&57Y'G:+]GH.6O6G/;
M:P7?D)0FA_R]S?ZX<.>WO-MW;9V1I>!)P8L(WBRH+27SWQS;=7>A& QT_4I
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MY-IVO 5 WU:\I>[!/CL$?JWH= &8"P[+$XY?,6$"\ P;<5OYDR@6,;PE@,:
M]8*E]6P8B&G"VXA+(E_D*I;MX$MGIC\GX9<I.GS=RG9(RS1^P%A;\'.K9=G>
M]@.O!KQLJ;^0Z)M7RI3 O G,<X;)GQN<'OS<@&_0'6<#PJN\Z*9/7#I$V#4;
MGC -\D+V7SR%7Z)"@'>#C)FP9 J(\5)9.X8U,]:P5 @7G!JLJ*?H*] R,)6Y
M3Q^!I8%W@8*CF&D?=$2 +0O64*=[AF(="G0@>MT!R&:XFG<. <T)6_;+JS'W
MEJ%&CSP5*++.[A%]"FK+]XX_$E%:,X+3*-4F4<VB:MV#E8G\N=SVSEGKSZ0U
M!:#]:.D+&.B=;K[J&Q?U:60^*\-J11<OP[RILFX<U[;LSX/="@1PT.FUM/TW
MKW3G&0:Q,RKEK^C>)/A_-WW9G0&*PICMC6:8;#E<EX!,H*!\,O2I85(=I'RF
M;%^@,D!$/N@@F7^@0"HVZI;OJ*H<E-)?===PCUB_I,W:,Z.'I0"'6OEQMB1S
MWR1?%S@ ^OULL/?6/#+4<*1?K>VXZ+">4#4\P?M_->W9CYU.!F- 0%.O$6:.
M3\KORT*7_6E)P+TR3?L5UY$Z&Z[B^BO )[R%*ON%8>F@QE"+[?;(C.S1*K)'
M"]RCE]T>.=L]FN)BP"N2^L#L? 3E#9@-F**)INSMMCT,'=A.@5&7"U6MOG;)
M7?B77^:&NS;US9UAT8G2AW[9E[3^.N9Q42%GO]XI@G:'*8,@V2+XYN#7;?C5
MW^,_[X_;PVXW\5>=MIKSY\.AENN)8X-2.^WQ2 XJZZ#Z)U]U1J.VC.UATC[F
MV*^'.6 GDGJ8D;[X<7)TH&)BFIW*T(>=2M 3C@<9\GU.+L[X.A>$V;' :% ?
M^G<7!K^W&M7!+=_',I^!A=V23^#3FXJ:)?<L=:XWLEA:$E3KFIG('+X[WKF)
M>9XO#CPYLA,CXU3=RB+='7'+7#_;%MDHX!3_(."MPWRXE[<63E$72?!S]WRN
M7X1?ZZBG8_R'@<I="',_H)D4JQ\@DV7A"W-Q:C4D^.L&?NURX!]*\$OP"PW^
M+B_P9Z[@&XU$J^#C=+01WC-\P&$L8" >H4':.:$71)(_]#*BU;N<71F#71&E
M)XU$##?$I*3:7$ 9CSLU;/TEX<3@-+B8 AJK BF@6PGL['?'FAJF*8G++B0Y
M*:WFSE/$Z8F-8PU+ WN]>.>&JSTQ2D0Q1*6T;[B$:9=<3_6%4PJ9Z<445$\L
M!74K)W=>C3&ETYPF66H*!]'%)*N/I87JN'#/+WD,$PU1W"[7LIO^.G:]EW!B
M<.)V795300W%4E"W<NKGV_9+NM:I\G61&[$,\C5J3+I-M4ZWQ1)1#%'<+H*R
M.P!C>?:O+9PN<DN4JJ!&G8Y8"NI6SOZ<VY9(#SM5P"YV;S;JJ(W)0'8EJQUB
M+G)?=,K"CSK\VH=(.(D&)VZ717'8= 520&7W&XM4YP>O:.'G[\8E%^=31+S_
MRS>\393Y@G>E_J#=SS"2!%X)K*9I==L)E=13W27X@L;DC;KCT&+T"#(,P54'
M<+OAB^N 7A+=N#P67C=@-&X75W' ]"5@:@B8TN^E1AU^]U(RB) +&>_@L1=J
MW<'C<#W'W_,X9 "!KV2E7-'M-H-5G2=)RK Q$26_5@*#&S!2[I;BP,BN6OE5
M54G8B :;E ND+/ID+(X^*>G8?WT]SD[XK&G/W!Q-<[YYUT0/I*7^4.G?<AB^
M,]R9:2/[5-ZK/K73F R;8XU7FF_U_.A2M*1H%?',3HA67'JP.&XPEK(C9><V
M9"<MOXF;6=(:DT%SW.<5B[PPLW]]R?(BI,BB,.8==FT0B)CNFH=VTU>T>]_7
M<LFL9?QL+6&HQ+I#==1-C:M>XH(THU8[TLWD)NQNEKG7Q/9F#C5'=':2:>TU
M)CV^9C7#)HCMM4H)N@D)RAR3WY.@S(%YM<_[SE/*EY2O*Y*OS)<7*19J<"T6
M*L5G#GN8P#3(<8&KUZ<2.MVE=;8+7[7?W86= V2SF/KU91%R4+)93,G-8GJR
M68QL%E/YELAF,;)9C&P6<\LCNQ5V$=DL1K8,R'N@KXA_0,64Z*8Z%H5[4,J&
ME(V8;'"C#L@I&R,I&U(V!)>-\DD25.%HD&ZEWDRVFBE5M"Y'&*%U&I.^)DCE
MB$0,-\1<A$#\I#+65%FA5E<X=2]'/J!I BF@6PD+R58SI4G.15@8TD^,6A=/
MC!U5\GK4#E$7(0@_;=I[HIVS))RXP:D:/NR1UA=+0=W*R5VVFBE-LB[""YY!
ML@9(Y-SIBD(#*1'%#5&E-Y =:4-YJJ\MG"JZS=)&8BFH6SGURU8S)<M7-6UF
M1]H8Y6LH3"<'B2ANB"J]S>RHRZ^#O(23:'"JILWLJ*N*I:!NY>PO6\V4+&"]
MR]V;=;&7?'<DB LM(<,-,N73=G?Y=9*7<!(-3MQNB^*PZ8FD@6Z:R4@VFY%^
M_BDEP.V.+ZX$\!J/%V^#/!D*@QAN=U=QQ PD8NJ(F/+OIKK\[J;$"B1<IQ.2
MPI68W[!+[SY5Z%)N\#)TCNAB:5E'$"=>(H,;,E+NG@JTHNGRJ[J2L!$--BD7
M3!D42J\CD$*1O6CX5^9*TO\;(/U/\RRXD?[WL)M&4],X<S_*?AI2M$05K;2T
M(&ZBA5>$3:TC6]5(T;H1T4K+C^(F6MW&9-3LJ.)W4*LY59]L57,K0[OI"]Z4
M5C6]GFQ5(Z;=O9U& -ECT:<; ?3ZC4EA/HC<FR"VURHEZ"8D*'/,_KQ6-2"A
MLE6-E*_;E:_,EQLI%FIX+19*MJK)U:JF'.!J"-Q_LO_%VN*4FK&I\<C8+'GA
M/NYR7.&<HZQ!6(R9N5$\1Y^3N4)8)NRNLD5Y-;REXA!]#L, \?>(LS(LVF!H
ML6U5XBJZ0^!#,Y3&.38N^<NW/?A;P)R^=HP9? @L+>@ ^&I<D\AW--F7S):Z
M]4SHL':OWKT5?FQ[2^(HY.>:6"Y1+.(UZ4]]!U45#?KH^*VN!_]A4[07BKTF
MCHY;Y+8/CG%, WV!DQZ,+[WE4NE[=4_'?]@#IJ_HUIPV@X%U(\K<F",-B;+4
MX>0*TVDM8'NLF0$KK--PG0*K;NX4LK)B753H-D76&;2_CHOM.PZH3 6P:APN
MF' +] &F!I!0-D1W7(58")/8<K'&.>&B=>FB(:B>+?BF.:)(,6U8*;K8_YG'
M(L9*35R0<OC;H6%DZ>6['+T/+U^,[P1T GS_;[IA?8*O3[*3H\;D6'D K*,)
M_VKF''"LFH'SB,<GR B#(=.-R#?J6/HUWU'W.XU)]U@D>KO0#G'79(8:WMPT
M45I(K&A 63CVZH@: VPA4G=*KZU4+UST97>&!TLTVQ.W6"L;[: 5$TSG*U7&
M'[;:YN,N:B; U$[JC3^) GL&@/((W97]?4)[@F8.U *,RL=&4TK0Q0<V=>U[
ML'=/L:?P/;NG]/7:L7_2;P DP(K,=,?9X)N"WE[)JKVI3,E,]UTVK%T<$GZ,
M&L[ OD8P<E3=.KS),:@A=M@\X(<.69@ 4O@Z4./X7&" \1,PZD="E!2_8[&X
MQ)(SGWN.IIR:XCOPY(G#?*%_Z"(,0UDZJ&W^PU#[ZJ(W'L!I?[CH]>;C47^A
M:9TA_*,[U$;#X3^USF#0F'P!_T91U7_\79]4Y,E1=PH/.#@3D#_#8I$,^%>"
MHX,JU;!\^NOLW26#+^P.8$1Q3W?;__%O^_'^X#36V3VB3\$[\[WCC\2Z=Y5Z
M%J;KJ4:ZZ[%EB_R)0T5SD0X/==AOA$\MM]WHUOHS:4W!C?[1TA<PO3O=?-4W
M+IZHHLT\#:L57?(,JT5/L(WCF\G^W/-TXU[,OAG%(X+EV<YF=[_[!!__U;1G
M/W9&$QXC8$K7.!S'#VY\+KAIR29IV%:VP\UA='*MQ^-L2>:^2;XNME_UP-3K
M$ZK?A+71F L#\D;F]U[PLU;9*W;\ $CGT#QFA+;G"WJJ,EP\4@4&;F&;IOV*
M9NP-N#>!;^2^O4M8^JMH0CO4VL/12,36JE?8[Y5[F.EXY"WCQ?G)CUU?*]2H
MI&9(UA!VY>O4WA,5IFR$FG&ELK0OO@AJ>:5IP?*7?TGS77]5\" )I[TS^PR<
M2#?*D6*TC[L:7_#EGGHM[O=22M:W?B/ \7.(QB_$^[KX3F!T+XE7??UN8S)6
M.14S9=Z/BFK@I"A)46*BE%++?YXH]1J3XHQ_U8E227;]O*S52NSZG[;S@][!
M.O:S0]Q(U%S2]U1@UW [/EK?''L&>Y$JC9AER:LP2(!$+PF5/'H['U0& !51
MVK3(,U<VU'PP+,-=DKGR;-MS2>]:J6(.]^(WW(I4:1LV)EU>;I( APH)E3R*
M.1]41J"81>'?%-!ISLS'78F&IMP=-/MF__)/LGC(>NB2#10HFB3U,FY,U#XO
MCGY)'E ]=J2P<##1R<(R0-8K=7BEPE+(3!_D6JE]6B!=<B6Y+)(_\>HK"%V6
MG$G4.<@DPKJ#(.54,J?GC>/4S^[5S[IE=@5M*Y"#)".GHI&K$7>W1'F]4)[9
MASN)<J1-ZQ=F,!4UX"UH[6M",>-!+AZCWU%'H00:%I9BWK7P)PPFT1J!72XS
MYBTG9#-K'*%<5JUMO!"BY*T[L<H:-IB-I%L[T:PO5B"+=458/&NL:9DK9F?[
MJS5]SY1L; N>LU@Q9"0K?L\Y4PPL(IJ9_EY!;?0#0<TH_ [SO??*:J>ZJ5LS
MHKA+ A]IQU<S7O:5"$%:VK '0?S)B1J&2M/DE5?'\$AK;K]:+F;,8Y&LZYL>
M[A'YB1> 3<7&\A;BS@@L3Q,THJ.OL>J6K:Y#=!>6L4G3ZL-*4TM9&,Y*6?O.
M; E(A85>K8R@BG"_EAJ_$7Z[AJVUZ)?.;)?^UP6]Z^:K?U9R%,PV(Q6S1N)B
MO!(8:+&"V6/WJ_@M[^!+DLQ+%V_>C^64\:J+/6=@O<:D-TZM(RU:_CK*,;CQ
M;G"8K] ^5IH[32IR/1LM63!^.>Q\@._\%GSEP_8;CY3^8B7?4>KD"V,IWT"'
MC<G@F$_%#5N\!HL],7JI(KH/MF2%2W&RT@W+W"C4Z@,$/3NBD$#_,2W,]#&^
M$#XR)RM<"_P_6"MST3*-!<%?&TP5MI5/64&Z=F!U'&/_^X.OC-KHY%?0JMQ7
MF#'[<@*&>F$[K+SWF"VGM5:V2_9= !'JQ4]:S*<EP<DO=2>H?M^O)3M8S+D#
M^PY^RR;T,YA_N;-68<G9P]<_/KY37O39#+XQK&>F5M&EAA56GOT0X&_:UG/@
M*B&L<8S40()OJ,,6S'P73@6@NR+P"'9R"RBJ]<A,=SVL<@L^B)6V>^. K<?R
M?P>93^8OU"M:._;<9Q('AP;+PL?U)=&I,T?TV3(8;S-PP/#WD6?@0ROP*HRU
M>3CEX$/(DK(T9LO _6#^V^'HZ91F^EJ?(34!KM+,\V&%@GG,C<6"(/4')2I8
M!!/=R@LK:U_"GL(:[6]D=T\.:)$Y]3M<#TO+GXT9? Y\<\:?"0("@P3HT,IW
M>+._P'%07A'JO6!9._Z [@ZJ 1OY7. Q6D3OZ!;S\_$G &$T/"OXANU^)T$"
M%0A[?&DX<^4O7W= <'!9MZ0?Z$69A+K7,'+$2LM!J@9EQYBRW;DUR^VBFV4[
M:UHO#C]VR(OADOEVZ:C680-AH T*[9^6AKNW43@R= 1!Y[BKP)%;^'0)(AC#
M<>U-#HPI,N_ -^-2I*TV/GYJM8-Q[9Z%U^N^A>6MX1A=4/_AXE&_SS9?X+?A
MT/&=^"T[P)E(C.!2W,'Y@3S;]-6A&%*(^.NU:1#P(.A( <MLI(GZ,J)C#PY
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M/4@#K/*Z>.>W716=9*2L2ED5PF-(E-4AR&JO\%V9$+*:T+FK"DK1?[+_Q3N
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MT;.X/0GZHZW\89GHI)&C_F*XY&(SO:DP0X0V&&[M8 #)I[HLH*"PI-G/%:,
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M8/EZ(RSP[._=KJWFF*IQS,$R]D8J<(RZMWU_7J[PI>9@Q4^*!$9=RF'1-9Z
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M@%16OK&@:/RK8P,C+-W3SV2CHGBPE,]LZOB:\ZITNT1]^-?V'>6##8Q!6L0
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M\?;:9:%KE[>,YZ9N3E/Z=A7R<MS]-K?DC#H@.9,R  :O5VHR8)"B*"ZQG56
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M#=X@%P!7I)E-^??*PGY!R.DF* OQ>IY?*U1#7*1H]E,&A%XY-GR-.+&(;67
M]<!9-4[\3CCQDVR<>!PJ[F"&.E#G_<EPW!^.YOV^/AD/YMUN9P0?>J/N>#3Z
MOZZ*>%750Y?/CV'V27,0=\/]RIS'!;!T"D39((%%=F 3)QW+2!VT%01BQ'BA
M0F.M.!3>=]'4R?<"P+:IYL*2,$%SY0T"/;ZE";DX(>7-IZ^/;Q'S+H9NQ]_"
M]!8H @<[AU@^J2,!B@SO .. /P'TE>]ACQ.T@;F&7QN";IC45@3>5-J+N-E@
M(Z V;ACT"@2[SKXA8H&)\"]VB@E!\J>OBA] 07L8\_?!Z'(]8$QER6"?T(L
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M/0>52!7,&%1B-,0VJ4,:@9N0TA"R(I7<-3) B?S=/3R#C_<=U0$X?((<GG0
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M6],@.8 USWDD&4*XYY6&^X>Q"J:*@,AW!(']*8# ?A 0V!)NFO\>"IGXO1D
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M+1763B0^(6^L@8.)CNBX.'QH+!/;CH[,N#A\V"(3>1X-!#T\B9ZM5L2;4?F
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M)$;I'86X<BZU?I3I74K-)/GA<JV?(\D6B/YE(R5_NQWB2=U@C^ 70LL;X!\
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MWV:36D5UD?1X-UW;]?EX07_U@KZ='K_'^7B6+U?CDD<RZ9ST><Q FI:!=^@
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M28J"HA>@!&?@T1I(N0C.+1I,::/W;U<$0]#NAR+7E7?P("([I*8?\<0CLRB
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MACQB7H>;606N%JH[QX-C' M]N[%ZW(#P_!1A$QGW,]'IY'2.TYNP$C.\)).
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M]8&TA)U7U'5([2/9EBQN6D;]WYO_/AU]I>.C-H@\[[7/I$S,<"B^D&62>8)
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M6X7EN5Z)-I%]#T;/7;C.7X4NR'JZX5R-:COWE6W8ZZ 2&XB^!]?J'H3*J)K
MZT'$Q:5!\1"$#*"=E<KE&G :8LO8XM7@T#JQCL2'ONF+Y/5K;A2(XFC)VG&(
M40C0Q<D<(AV:L76IVV[=]+7B;9U[NW6$WKH>YSQ5Y]<P_1WG]7"\9>NDE*RK
M6=N>ET .F#%D-4<.WF<A-'><R6X=P!Y\U)-GNP>)MJZ9^# 9IP<!TF*=DTJ
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M849[JTA..$\[JE"95L^8!G+Q Q@D(]!:651JWM!R38S#J])P:?"]\M7#!O0
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M;C5$8STHG^M(;14@HQ 2G7%T,'8*\=W_G.=#>&NAWN;;]F95T-=GR'%A$]T
M_Q++9(I79JZ_QI,IIM&B$P?]TQ?'D^E\]#]GC3D4)F<CK8D[<K[)GB87*J4(
M!97U5C.;;Z9Z]&>/M%O6#JEIFT#2KJE"#U<PCUQBQ\5I$;@N7H.QBM7A"Q*B
M-@R,MY(E;WC[.>R]+NA/#>^-_B&C%0\LKI!YVG&%V2GA(I.0H]&U+[L&'UP
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MZNG:;ITG]WR!]V@A-+K*N_W\-]_2T6G=AI;],R]_=*G+,LK"E:D)\T6#\ER
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MM.)WG"1CA$$,KYL?KT'!.P(IO>CW15'V%ZZ;'U1XEN%Y]VF4-GM6/"KPD3O
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M>J%Q;5K\6 OW(!R&ACL&-^8[303:V,D;8:E]R!(+V@-H Z: !6 "& -@P 9
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MRJUJN-JV^L7=@W<?UNROJ:B5J+U9M[<NO9ZI/O8>Q;TS][8:CC4LWO>Y/_7
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MKJ>G<\#SV!D#$L9SP27&#J=9,_P(HWM[1N>UMYY/A>:%&7]\L^938O)Q>5/
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MDUTFNTQVF>PRV66RRV27R=_,A.+[BZ@02+@*;R"OFNK6 * )@/[#@B/RG](
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M]^LQX#SUS$U1#U(1S7-RI(4S-I:3H>U.3^C#];.WCTL\O"M8$'?EO+/@1%.
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MWE>I9G^P3*D8R*<L)$V.&Q-Y)TO>>,K48MQ25G=5C]2N0?\D&7FRO.[JNA6
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M(@J)1RTG\N\^7IY%Z;RH"SYJ(HRPWG/B8\BJ$1W4B1$Q?(^^7L*U-;PETP\
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M]AH[>^_,N=9<<W[?VFN3I\E+@*LZFMJ: "HJ*L!GR@= 7@98:@0ZOP$ ]/0
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M:8BS WZM/K4"6.=:,2W9=;MSC^=35S*^?HL'DYO>@ADEC9,!];>J\4J!-#U
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M/E"B)H7WK-JCM8@A"V3 IN'4]PX%/]#]2&[E6_FY1>+-9Q7<&Y@&,?/0G()
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MG6U0\X,&)<*Y/7!G8K2:=&!RCV!]9%Q409FUK?G\E>FY9E@J2SA-O+3DPZ[
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MA$TUJOG%](I\>?@WS#]0)"G<CFED2.]X,CIEOVJ:-_O4UQGIO[()(PC/$9G
MO98E>[)8G6/T6'NI4X<,(?1]RW*!:A:?>%^E#[@6\Z@Q)^X#*\^KJ+I^</%%
MS24  F,*GLJ]=?&5R('-ZSUK#(<:XC+]9,5-#[6;'BZ:+Y0<%.N-#!H*Y1H@
MD$7N5_X)0A#H;U^%+)!C0$0Q%5K32\!GX\Z&Q@[.7_S(D,D%X_C]==/,Q1\]
M0O,C]&9\7HO'F<@KPP^X^GJ(7\6J[_[,VJA=OZ4F_%8"MD]"!D*YM-RY#2EE
MVX :N)F_251O2FZ^5JR\)5.FT^Z2Y-D2IUE(_!+@[^F\H^S-33E<.G.6\GG'
M 9?J))<_XQAE]&IUMFTXQLMJQ=D)H01:R,/G$T9P=?A_IF#O)$."[UW-S717
M9\JN98ZH(9.WK7"4^D_&!PL3/K\A8?G6H=B/_U&T/D<=WWH1JOQH-4ZT=X7=
M6Y+.S]-LIA,QYY6QWM#.\/I6?9-GA)=HNDU?^--U.Z;#O,:2O1E<!-[NHGT?
MZ9SPB<1^-<JVK"[3#]RM,,9WVOV\YO]\-FY/FE08^WTTN#V<"-Y*( B#XF N
MM M;/:HWIT_@(<'\V+S/7E6O98O3'1S= V$J0X8M&/M_^)^G2I=;,#HDB 4\
MVQ *=H,XCU;C&^5R31N6W+RQ*LJ<1:D7^@I:(7CP@F+NR$)@L(7G2M9I]N+*
M'=M#H:1]9".R_S#NZ!+09=0FBNU!0^(EZYEQ>9\QB'C1J(SZ"Y7UX]C&9;-[
MPTG]SQ6$% 9D#@G"0ON-.#X\!R$06[&JG[!V+D2(JW1V'\<8\("3W72?HS0-
M'GE6N"YBU)M3,XP> L2><D7TP3]SBT\#5UM7**%F$#3L[C@ZD);RJX1WY)^_
MEMW+!KQ[[_T_[9F."'<]_AM1I42BI#@G\QO!(/L2;A"="+[H*HZ!S/%0-+-E
M8YBW KV?=XQ#4L[MN$$+J<WGE1G4GXK\+3E=SMG&Y$G\*2O/RY0L?.9*#/BA
M8P:Q@\'MR:N/A(WP(%,3#A?*S/9RS3N5J 6-@_&E3><AF?$4)+J]XT%P7TMX
M'F8)B"_!@@9&@?N1+8UA*(RS4+(@4"IF]$4I)W%PI'XU]4T2J(Z'2O7>/T1S
M N2;7X&N&,HWLIX@*^JZ$CB2*9OD>1B^B13KH"])4%4FZOWZ8_,(3T&P0HO+
MNGT"FY'X?NFUUZH3-?C][$2T^%TMM.]1^<)GD)1^C@98Q_ ]KQR)_G&]*:]_
MZ)=1D[-2G,P3I=WYPITF@-?74.U4"(-D,U^SJ2 EU-G"2?.QJM2K3A#U[9>Q
M4JK'V04B-+BI5'T%F+NVQ?R\/$N%CRE2@]'L6S#O_\[S,1VO$)E$\=F7@'"#
MB\@V9XRN?Z_BS'XC7C5A_*?;P2/VI(-H6X-S1Y":62<(:P*93\  ]\?/C8E\
MA$ '=/M;X.<6O7%\>I3L[XUX!;+F^ZD>YR-BPL.%DM1 A/L[SH.$NI*V]A7=
M V(EO R?R[/Z02$;'SHJQ/IFN]&H($4'5]R<;8)JS?EB9-GZ&\J%.?QDRWR1
M=0EXC0P%,BL+K$G>7H3:8I<[,O%P.W#E4XG\-SDSW^/RS22_0IMZJ.S])QW;
M@[^3%E8XOQ/JKO@B$9?02TOEPB+GOMM!GV!<WU2?DY^YV!R;R/5<9%C;.#3[
MD^BG6=CJ,FQ^.4@0YW4AW\<<\#FQ96%1KE7Y$]N=Q.I7V0_)R<FK17N#.:&J
MA#(L'^EV*VX-/=![2+ECR8K-?G052"WKX]KD9Y.'*Y\%VC19D/T8Y-3I"&\;
M3BK3C OP,-6GKGB?&9?9GE9E04Q8?/3^4  3T"3FP\ @DHHE-,F5]S],*;$M
M3Q?C+9'PF\JL!;V31O6S[,5<3?Z L'4.(0T&T^-\JL[5""7=>%&7?720($I[
MPY!]$.W0G/I.4^* 8FBYR_TWX 1$$(+M^^,X!BX! )@3, S$X,T1I]N_<MMK
MX=QK5GEQ\46N7J^?OR:EM#:SJ4&;R9QR[%PBJ0]T]Q+P_O#32@WDTSZ)Q4^W
M^Q)P5YD! WXL-"%1U&-+\/6J%7VV,]E_IR+\M;GBZAJJX_-%]-5^\# $#R)K
M(?TKS%#-Z?O3'8+0YQ,GE$O6?<(9KHQ68QCIM8BD7*UWHD?K'Z5OZ7^Q<[9-
M=E&&9Y[.+.B"X)F_G?M9RUUR%</!5M2&RL],F1F_J!2R5QT>"_?IB";O!$\>
M&*/.Y(\:B0Q:>'G"E:2_27Z1NM[:1CC!K-PB\!E,;T8/HU#.U=7P@^Y^AV2S
M8\,VQ'#YIP$>.<#0>,M_;_% &PTBOWK!HE?JA/H@=_761!.H?YLIQL=5ZO'I
MRG^IX7-=7E'2Q/V,):-_62'A#E*!=8DJNY^_@K)<)*[/D2@)=CTP.F6."I>I
MA9&"Y;P_[8(X^H?']X[?+B8_L/[X\YKMDW&@Q;]C(5_31I$X"1$XOK7T_K*J
M34+.6I5T((>>]/(SV(\^WM@#81]1.L[GI86?3=;7LS6$@;[SFKI+T+GVO-:B
MUEVPE7V ZKVWI9,568:C%>BBB,T&[FPF64NFU.<[TV]+."0@X >MNGL-F:I\
M%[G*!N5^0-)M$USP)4!K&D$M>";)_<^-YIKF0/]$!OO;-)\?#O)SLI\%XC]>
M-)/N07DO/B/?)40@:> ;EX"P#%RH1@TBP:PE92QW5CJQWUHYXV)W2"1!JO;5
M+94/6AE0\8L0U4=.*U@M@V@>V@,2]VX:Z=$LU,&AU'Q;#.M_*O?;5?YYH78C
MF=W)/6)Q^^G:.)&!KQ]63[['A!74NVZ(!L8B;WO%/!9[VY:HE6&J$)MVR'MP
M>Y??:7BQU.$>UD/D9<7008F;I6\#7G=9]^><ZFB36[53N=W.9 X0;I:Z$+M6
MS7TGNSC%=1*?UDJPR<L(@5S!P/GBFS('%S(:"CPW]LL@W:L;$!]LE]<R\!E<
MEF>S;CE!Y_=XW7O7>@D@B(*N ""$?WXEPGC\M-1F]]U4'T"?M>@QZ_E,3EN6
MUXJ(3:ES,-.U#HFY%*;4N?,E2G4N0+VO)$44 >W:)D3; [Q)<'P9MJ9-U%.(
M&/Y0Z&:7L2S-T?3\.'8?@&EO)-VQ.;_F!\>C+]+;)*D4&Y+ .+O.H^(R1T\W
M[N7NG=W7#+UA,<HN/\L'!Y0L6)3MXP1X\/Z5TLEFEF#$R49'*V21X+]6PGD)
MD,AC??L!L?U@A*#SI=E,LGF?2UA@[TNS90Q$0[1@8R4.B7T!1Y'AS2^^*MNL
MC4KBPW' 2-FBB<V\WA;^R7%\X-<[/,"AC V[3=Z-U(;O?_WN8=I.,;X]-HYK
M$.)=@RY5Q0Y<<9L 5F7CI&^F<DK7\Z)-:/J&2(J2=K96C\3JTD/ KFT63NT0
M?WY1= EP7*&#/IXCWD1?W.JGED5/GS@51LG2WLV7E,/N9R36-Z$LF,B%4F^U
M+(GBU0D9Y,2[.H?H4#_Y5Z!(>B6F7Z<:^$\TQ0*[2,<S9-:AURFF:6?"R*3]
M"TB2%S&UI',&.CKY'91*=<[PN2BD(G/M0UVOF#?'<$I!$0M%7[." +>5_+N9
MU<Q6_=F_66OI/1#ZX!$0]CDR3'$L"T?99R9-5,/)IC7$4"_B';7#=6^!:OJ'
M'HC?%<V&%@![0":P+O5+@#,\&D0'<^()NP34F77K>1.%*OUZGH<:SB)./!KO
M=AO&S[@?BY0_.^@+?B?PBB[%&KG?<\Y.-"+\FW5=?I'7QO#=3\AT^DJ!.XO1
M5!4_PT957K=L43T:8PF_]\' \H3V2G01&4XQ\O%M0=C=-4A7X(BN9'3NM1_A
M8S:*^[,*)\(OZ1D?0;/"_]*E1III]3\E4Z$ODMGASQ.2D4@]P!1470'\GV.'
M/ >%-GT&NJ\S!2+5Q4IIQAL?XC172W4JC1H%,^6J\(B97/)S#2(M8>MJ5F^Q
MI!B<<<\E@!TQ'L7-S%XHETF*J8I2+FN;=/_L;W]#[LZA4758"!M;E21!M*0?
MR.YW"<"G7'R%=# 3(DQ_R4IR;N.6G$4:#3BO6T5]DU*>(*O!1PQ1E7S45#*!
M1ZY<OR)\6H)(ZG+$ZDJ,*LN_S9I@X6<V1-^ N@7IOXT;CSZ5;>D<+.C>W'A)
M3S$&@!M=M,#L:5D(H?C=BS1OR1M^FJ1_FU91;WY:)AW<2AB:K,+DWFL]?6@7
M.:5,UEF:^EB'.3I=2/D]H@4$'A6O@AG]:.Z_$^X06I5MVC,SH);[8/J+2E;Q
MVEY>39@68]FPFYFV^/O)@'KH,>ZX$\@.7/VR@BCI!M')]\/IB1J-A+B*HF(X
M31%_!76/_Z_""1EQOC*C.@<NGU317^XV9D1FGMY@A73\XH07D(.H@TOO!H:<
M9MKK%>ZB9 N/+2[:R-JL_27B6OT'?NI/H]2R4VRGKIQ)QD5&6]#Y4Z(:@=)[
M%4ZYP\W;B!V(7#XV29XON-XO*3<=X;K7]H83E]?B<DAD!/;R(-[%X-YMT@*(
M\EB>/I[/9]69:;!_YF:WW>]E;T'3*?F3&IXJV'PN_B4M_RY5QR-60']L(C=Z
MM,*C:K\*?@K,&$G&<2D[O*]X5(X]9!*111L9>3G+ND09NV!3%:8-"8_1SIJ[
MCI[_WO+-(K'C6,*!#BHT0'JH<0VAR_W#D1X80ZE%WSW;A_2]FWXX^(K&@O1:
MV_A4([ =&O,?_!C?!C[G"/[9DIN^5@!VK/"+L4PWU^-%O9%15':+S'_8F;KH
M<W!?F^R>??;<G,G!I.M4C,O8B$$2 <C6_]EST;+'),XI4-O2/=:.S69Y1^K4
M:/O@'.Y=<$<XOU[5_G]9Y;(:@G'LJR)'TV38^<*M%Q<&RFV+<]ZES3Y:UO/\
ML+-74_BRH)6^="NL\XX+,B18@6"'D4-X%VUG?HZIL.@5RM)OK\OMQBM$=:8,
MYM#K970NLK IC#E1-RH.B[)TP^B\@%P$"1XZIY:BW++OXQPC7!MU?Y.DOSL$
M:WD[O-9Z^2H^OR(AAIOKRJE=>6"*.I?9&L)+9^0"N=&7KV@K \G1X_C5VS9Y
M\GP*W[<#_]RL'M#0,)LX"03==69NQ#\:\';\M]'**-MBBN:J] ^5KAMT)Q6,
M,E-U-P[+[X@*=74H3';<VY8&.9U&!3E3S_3%#)8/,SL).#D8?"4[&HQM_NW>
MKR5;]=^/!$-Q2ABW4"RXTS(O6EFOM*_PMZ*R;=#&>O3/'X)JZV$W6Q(5R*O<
M-$3&Z5MRAE<?JG[[15::7PL57:L2ZI_<J=GVC?)#"9QOIW>9I.^="I>/L@VR
MW5/,CHT/^$7^E>CT[Q_J4(:+[VU&J*W8#@X_1\M9SE"!W86OCMGQX5JQ93 "
M,_A7,#/Q/A;914NA_HT [#DS"/_C1V%?/[6?=ON4NU(M(2/!Y['0;(NBJ,+4
M9QM,<O/VVT>Q05#E#ZF[8Z_6L'W#^J*3XO/01$,+54G<6.JJDJY2G"U.[/NT
MY+<IU_G4K)]-N4\Y#8G?CL8Z[;&/AIC,KJ)=)F4@3N@E[F9U1)EZJ;4?R,B5
MS^29J;&C3VFRC%X356+M_<'!ORVS,3;(*N1HT&[SYC[R!/D7V)SS?QVEF@&+
MB,:_3I"1EB5A[P_YFV;KS0LR2<+[#DY5-SY*BXXV#M-+)W;)0U!/^Q]_H_GT
M7SKNT?16D^YT+#:PM/RO=SOYU@!D_Y]UX7K*6W>7E5XQ]L^WF__C1SCPHHQT
MO>O\)6G<5I0 \RXS*%@@E _.J^Q)4=@WWDQMO/GVVGD[!?Q)?GZ1PG3H9[S+
M^$0.J[*-M;C?VQ^':1]<#(,R?0UL9,!E6SRU\GO[D'/!X#%;)H(ON-P:;$IB
M:0#;MV?24:4#!@^3RY_SP+@"S6QP'%V[.%KT03OZKP3WK(JG?M,4RNOEZ.TT
MN=@?Y)\T]U;/3(<4\O-X-]:W:XKY'O::]HUPF9I5/'C<Z%"9M>FV *F>598G
M41R>TYF3.GD 69T!L$A)93TWU)>S] 4)5].EKJ27C*C"6.H<S^7VX>@'_2(/
M--ZG=F".7XPS?,7LV-74;E88-FO/BS:VUFH'#5XMF>/_^[;(4P7&=Q_O" M=
M_\_7^H@']8,!8Q!*N 1\/YLKN?"WG3% >3QW((Q@WXG+]"Z+&M /B;VA/4QY
M<<Z)(33"^!/X.7'(X</H/[ H$ 51"1>JV3A%U"[J*;><7Q+8;VF5EF$H?5W+
M]X"JDNSAH KKV0PH DD&%<*6'V%VG_[:VX-(WM50F5^2_5E*H\9F79=*GMC<
MJ8R)_%VU!>MR)H#7Z>?<9HDG1(-$F..2ZNZ5:$S[L\+C[+YD#7V,D\MR!\9Z
MM7HY9VDTO_O"]799*J6FB44*_E[GEDF/\RY[^V$?:#YK%=@=1*NA*AK:J\HY
M=24C&<W[O!DI)2)<&86&'1/#%CP_O$EP"_:;_:#(?D[;8WMG$LJ%M@JBU9VJ
M>N\5:/Y3RJ*/]6X^9_+W@-?KN,-7Q ?8BI[@FS/V'1-_;)3T6M/Z%UXXNZ)O
MKS@T+M[[:%?H?AA4KL 1QSQG4W^>NM<N,3>\"[886C'I0,8A3FIA2BJ'L'L7
MH2<7!MT!\I'!S(10O3R-:>(U+P[M^MQM"7M7FHV</8.O>:+^3^T;%;;Q[KGU
MHXZ]JO>Q\ON0=<+P:6\-P;&?!5SBIWFJVV%8U+OY,[VFM;'_3W:;YPCGVH?W
M(@=ZK58+>5V*NH19(%V.ZMRYCY+@5-JYXV''SS%^*;>#UFDY6O43V20(UJ#;
M':J9TA>3/R\?^349PB$VN'&=Q43(I?D)XX]KT;AL=GGGD:TKH7.SNOVPY9>5
M8/K(V5Z>_NS\#A2)-7+5[;0EPXZ'RR#I_4)?U.%.>T%WMS/#Z_RA;IMU\1SM
M:AJ?EHJ&!V1[-%F"*?B;R?R-9"X!+@DLA$8\S%6WF\2(ZT?(X_O#,[_(LX?&
MJ1WW>!:7V+G5_HT[5GY4U1NS,6PP2NEZCYEL6S?O,S=S,]9A*V+SEU>SC-)N
ME-N!V#+@UY!,;?VX!*V6=$U03^+ O5 +%'!O=S6(I4<>I8<,_[,Y=:+-F[;O
M<,NQU2E;65.;,STH]MI+;<H%1BU-^(4S9!QTM.BQA%BZ!&SKD2QAG;^PXRQ+
M! Q/@B?T\=0FKKHYWTF1NJ..'^L730TTFI5P<\RQU<S (Y-8OI3S1;A4Z)"Y
MU[A4EU1!;6<[6/5X.[Y7; <SX&1^[?@$2$:* ]'\;5/T<ZJ&N?=XSTW:>QP*
M%N/$G+[]>*L>Q(9C63T,#Q8;<.FX-['OS2:FR^$<Y;35N!37Q:_&I?[:_OJU
MSK$/HO*6%]E0BBH"4 ][,1#NA9BH+WE75Q_V@J[WYVWH>SZE(U]'I5K/[.E=
M\)5%A\+$TW)S7CJ/!N=AQ?_N[DYD&PP8Q,# %Y^]>=C\U"TZO%I^B1_^&=5_
M1NG)"TPSU31]29:J_*D@V8]IF #2Q)GU@2*!G([MN$M M,PY[9W=_+F>V0"O
M$;=,9QN)R7>.2MH9+Y*9Z3I>>B;ZFOU2W/KH!:+WDS:@67'VD6>G^B%>9RYS
MS^JO;ES9CP^,KU_3W+K)[AA2#Z(=JM(#E\RC&B.%Y"VS\EW/[3LL-3H,C#?Z
M8_(T&%_%>*0DO)H\\M4#IGZBF8A.U_+=K)Q)^-HFB:OHFSLKZ;X$1-H^;)DK
MP$K&RKC2*PC].DCF<!4U;?YKKWO^GCF-,DH@C%YC:8/N$XO/V:87C&8WF*H=
M1UT2WN:,J>+>ZLUC#X_S]19'=S@@Y#YI,S%;E[=>BR/PNZJ/_1+=H5;"NV)I
MTJM_G\XNLTWFMV+WV^10'TR4Q-;"='H:E/>&J<+>2K='5KEC8WIXUT9)/5/$
M\7W8_L6R&1 R7[<//)F"L/VIDFC^VP+";L96G0IV./NZR:YO[#J<'@V!#ITO
M#@>/$SYFD@KR_<[7;D64[6;&G21\/MR;TU=,G<L11U0XIQVQ2*Q(44MF]WW-
M3ES$#>0&CZK*X+0&LFAO$4"]RV)S,N.2G9:0R,WDL;6]EHC(DI9D$_\7G;?H
MNOD21+DG+=&^G*[D*U 8EKP+R8B(]*:]ZQ=H, V_'ZN^.5ADZ=0U&*]7Z)_T
MR6#P/#UE0+#*[WAU+HPDN(WW:=F,<@CDSLJK:9AB;'C]\7;TL_MK-P"WC:X!
MR(Q:D9)=LK"<J;],;LNP&(,_X$T_LWT#;)M\CP'EMJ??6I]E]SQ1?>*MMK'Q
MW26+RO2TM<'DYVH9=QP#ZC/<FSBSR2QF\QB)!I705TU8);_D2X#V) (>J1@?
MCRI]@,\"@UTE9OWVOB>%,VOG%"H-2GY.<5Y\RO/4&436=O\[X=V<5CWV(/U6
MEB.,NXR1$M#9&C<SN9I;)>Q@NMQ;<\]^.K.D*X%B-T .7K+L!]-MJIN# ^LA
MF&1 ]^:6BV1N8!0@[N':#5?6>]%\16<KEX#Z2\ ZJ.JDH^BQC=79.6BSXU!]
M,P]5,= A?I$'E<<Q] 2SX-)J_,PZIW;Q++Y'%]7G/;Y1WHQT*5(<N8\_QYO8
M#]U:UBMQ[C[E%D?@#+J0T;EDD_4K[.  Q&GO;82*ZOY)N%6,^0'F1_(F1RD&
M<%MMB.V6 K8(=(/^&ES_*GIQ3"#;YJ:<)BKQA/\9WXOSNS%]+^-%R<N!IZ+-
MDH)2_9@/BF\;E0VQA^JXJLT\]PIGGX#/9V8Y>/E,E5'(UK-?(XU37FZ#0>KL
M:7GB*7,DR@NN#FW\38% Q(6%%<[L;[T_<,\&LV^DJ^+9W2$!8U3'D?54. NV
MNE: JBY:ZTL7W"J+7UYKS"A(_'Q?ATG$4&K\RZ[EV'<L!-.X?PU#S6$Q(RXI
M"37^YBSI&^0U)Z?(;Y8V2S<2\-JS[E1DO0PH?.WIWZ=,)T(]L,^V' 2--^ZN
MZ';>.=UX7&_*UU.9E!\<9IXU8@MF'RFZXV_=M$Q ]X<RS;;+XU5S)_V^E<V<
M=E?+BM?<ULJD44\05WN-"XDNP7GZ6S6^(IGIK"11.$-VX2L7UMCQN.1=4)W-
M2L2"!BX]2A9.T+$\-6B=.@'7^#^8?^/^0?+;VV_=;_S2/U@_,WWA2NY<?8H'
M3L@&PCXNL\U"GV)<[?HLMZ)D8L0U\3LGG_IK55KH[T<%FZ?G/ME(X$_6KH)3
M7"DW<JRHK5PZNEUU"4'YKB[CJTS5NCSUG73^0L<609:0@>LMHY3J==C^*,?B
M;3S.XA]GK "BGHZZC.KY=T-&GVM/R+:?>2%S.JRV+X*UJ?\<(<==8?"9M-+_
M3$#EH836S*(Z. G'Z)5PHFC!MF71:8(L1P5Y)LDW6OSQ_?KDM?'[FM:TDC=O
M40P"X@M2(O QA)B #N 4>D)96!84%D]3Y2Y65Y5;7^72Z)3VS0$->=#Y+L7/
M[#>GAXK9 ,_M?:@GCJ<KF#_S:(<RX:;UDO5"#RM(8GW\/7Z/AT_ASGJL7=+V
M%1 ![UUE):-81$MMZZ Z]F#$?2G'AB%QH.\ 4.36W[JA/V7069_EL>46JY.+
M "8.3]'].1SR-[1N;3R6FV,6Z#1R":#?Y:%R);H6$*;4L/7,\HU'%I7L5.EE
M 5BQ<:FE.\-]##]CZ389R9-%P398\CY(V"6 KH-A^XPEBL,4!PDE<E6 ;+>-
MEI3,";GW_=]1APX)_63C2WG_J/$GMZR$7%TT'DD5W*_*.@E]4.44\&7.$I^$
MH:7<SF5J:VAY]1*/E]*E?W[GX[.XS33^H%D3T4^BD,X\@%5WL""V&E'JEV*.
MNU6!AM&.HP\1MI5O]=0>.X00MZ-+?Q;L[5"P4J?QV\\H/3AOM4%L.UL9F!TC
M4YHV@D#V'0=6)(,#I E$A:"%*] D#)V;:&%<!7><_C1#KY&2J'\]'"DQX"[B
M':7"Y9UX/NNL*%MG4OD!'H YCJ.&O&&HEO&!=%61W-V>/#;(!G:I.(QWN.:W
MH14+::CYVI>;X*K&FV,?]&::N$17.GA)/=P,.'BLLC^&6G77&#M6@Q-ZEO!D
MKF0JYY5-9ZU#X9W.L R,.,/SQR)F+:$VC7V0D$S)/M"GQHY;B=I%VYZ66A!G
M@31Z/2FTR.Q1S[RE4+R\[?Q35.3VNS.0@87<)8#<86<HN17<COBC+3E@]CL>
M@J]WE7%6O6YCH,->Z>&WI?6<<7D4C+>(O03P_XT*"8K($S^*FPAA,L-;7>1[
M&R0HYD5.&=F0:S=/N!4BFGXQ_LP<B]X5S:<LA-ZRH'L6PPN(Y=A8O+6S1^(E
M\L5@W!+0K3;J+ULLE)4JS7?5G":8JHL;7#L?]E]OWFUDW3<GD1&N248$2UC[
M+5CAF.:B9 _W^B=<!0(57&^V9[T0%.Z^I]R_7'$L#R#[*"_%[]42M++!$2QZ
ML%N4(2J3N3QR[$OD.0G\<G(88RN,B^AK]^Q6O5W_:PU&T>4J""_;505W"S89
M\_M,:+"9OCOJ]/'HE#@!2 F!D0Z'<:A+0'\,#UM)E P'D&8GF!XG.Q"!6D;]
M7M*2[F.4$*116P=F-5%=9V$#;%;[C:S*]AWVBB*9"%:]<\MT<[)63I4GFO&S
MHJTV.@J-_B]PSQ\*//E9P9OHD_WP-0OM12[,L14TO_L")]#>@:@"'_L5V.2!
M6EMF^+6%'OU,JOAH\LKU8OD)X"8Y&>#:,]^YNO.#*@*(Q/,R#>4+\LZY!'#
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M8SG7"QXRAJHC9Q!Z@FNO<H_[,K?"N4D*$D8S]>>N<L<_G=$IX31,\S7)VD\
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M[TPWW%.6CCD_MH%8C+/2TIBW51!M.[H>E.XJ%R2C^J^>801D:> NMQ\^0;7
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M-I$YN*NF#;$MU<O42/4NMM2(-::/*H9F]R;F.GQB*1#>&PN^\UH<J4>2]EU
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M4.Z,CC)A]4_!*R-^1A>E+I07VKBTSN@;N?EL\;F%>HTIEH<TT+D#Q C$N>5
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M4#Y.(WP1'9P8!@*M\74EL!NTTV!X1^$?OU95JA:LM%*1:J+]$\/A#(VDP,?
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MA!AWJ5#RX4%)1U)AYT3DB.5>ZJ]PR)]2HT5*?>K0RX0F'%?B]O-_\>TC9]9
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M[WG90(O%3R2E_!1T_I@BDZF.;.RKY 3<"]361O<7YQ")_W U#!C**"X.^!.
MT'<F&6;P.38@>'>:%780.=EKP% U2MS9;<A9>V/)R*ANU/^V66^"GA1^HF="
MK3MG.NYF&>'2VJ@F__A]X4*M"\<3EIP/WE]^=.][U5"!ONG<R&4%K ]4U,/
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M-C]^26%$]J[;:MQ+^JZ+XL!D+@NJ"V+P0I&2.+ OB4D&_-.9VDVJ06T!63>
MDK2O796!NZN4,&&?NZ'A$S'!Z-2!U1^_J+^X<<]1<)N&/5!S/4__BO^\T=?;
MIS'T)D&?T*!.&LCR$8WQO[5OA&C.R$7!5Y0BA 9.1,:A8.9+I(4[\KA0F.$O
ML-0&>,,+J/Y/;O$9\[?E*,:[8 X'#/A[\K&W_=0*?J]PDS%N_3#P&RH/4QCO
MK'F@(NCM4-4G[.(T@$"GT6G)<JB3RAC7WVCO;F>]^0,[32Z1LV=:=&Q#_8#9
M*LG8-:\_:A?2G[DKUE.MA%1>3%W/VO]Q#Q\1^)@T2Q7,B!$X>&7-WA5?I!Q.
MO/LYCKPBE&%N%G:H0R/3W;&JUTXFW<KF^8TAF^5Z[/:FI+$+E^Q_H;4R)UIP
MI&);V3;YB+V-VBR_;[5O\K0/1KI:+"US0'+VJ"T!'Q.MG.5#;F?O6\M-^--7
M?_6Z9HAV$;DX 9:<@:HJL8MC EN$(2[IXI_MK/FM#:BO#8+^V\]'T"Z0.7/
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M#LFY!I9=1W_RW-U4$Y_R(_16N]2/CC2.LC'/I_/!J+Q^65N^KZ_)'PX3\I=
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M>;+?KS;>R$4Q^A.YD"-$$X6"^U:WXI%.&0Z.1Y/'F-U'/?VVNB4?<WASWO_
M=>&#Y&UP-7L%7@<F,WVFZ8X)3*':/O%.3=R6K/G%,N5LF<-OCDH''E9=IB.R
M_.<9,<3<2R28]=>RD2RW#OP:IM-I>!M#QHJI'*JOEUY.#47O-KD[E!H&E6,_
MA7I=_W)V?<594W_=^4_S:MT!=M\TV[F1!>56,R8YY(JMEUM[3]8_D\L>V&/>
M'C]GYL%;$\&X9?F."07O06_S;C9C+$0DLXW>TWKD+NS-BK,_PGTY)"JI=WAK
M88?"HQL.EZ!<Y>I&(I)S\.O\]!:8>,XC2)=C5QAP%\)G*SZND[!0K/)W.G=Z
MN3\810F\>M+,(VHWCE?J[<%''.OM_!;S :_+3> @&?5TX0B>)DP86"SP0&D^
MZW@\<*%%K2O6D-BXA?Y01O\%TX'[O_276PJNLB(I[K3RY6UVI)K"$KEDGXAV
MG%S3W)WQ'3%&^[+@3T)"]WW/C>]$2-5K@.5KM557D[]@>F9YJX7ZS8F.ZNUH
M#4*CO$81PSS$4T?:S[ZZ,[9V+G.,N.-LUZR]GNQ/Q(%<G:I94DO#3B'&46N0
M,JNA2M/;I74%A0SK!]-)/)DP[*:M5E)SEU;X[7Y!8AR>AG<]R<BMD/+V(IE+
M&-93>LG4$G H_1@X]"A4:9&57YRMB0W@R93$*W6[8C<?2ZG_PZBZ.=N>CP@V
M%OP!#QH-@6^!L;B3 H=RRU[[8]:#O@_F),,2N[0=+0O:1X,:;SL1O@UQ-G7R
M0HC!&,8[4&,AY)Z&73^0-9A_^R"))P<:R$I-/N*U JV9L^<U'S&@PIH)514>
M0'%T,3P1' BA<34)MC7D(VK E!8#W?5^/!_1LH$QPI.T@)@2[+N&FX68HCPY
M*2!('0C:]I<@P:\AC:#*DX!LA'C_3>WRUV'W!#=Z$0L'D@"M:EG_IZ1-4'42
MIC\5FCNFKP.FX1,LQY#0UV+X@7/D/Y*#H;60&):8I>WR?YE-\;C\NI^P[=^E
M; ,; ?4K3Q*Q]_]A=3I8O96/J'X-]:=B_EH.<0Q1C%$2O(O(W8 4@VC.P#T;
ML$7M%M<QZR%:"X9AB?IK2\PO3YMS-M7S0H(%#B7^\O3XSF)4".;?9!AS=)5Y
M(D[ G4<%[@3AK+&>FC<V^*S56.$J"JP$&@8?$V@)_64E'P&'CJ+70Y5:4'\F
M925Z>P^\4$D5QJL7T&<T([3H=1OR=0,II[,#5SJ8[Z8_NKEZ:Q3VG2F^4ZUP
MI7N!R\$&+OU$/^$65)4*['\RPCM)K:; -P0W"=>@,#(H_2FH.9<^8$EU%-!/
MBMQ2LJOWWF(]'R%"Y(D PFB$ W'4V<!',.,Q-!#Y2D"G1IOPP$O!VS$\=6S2
M$XL[PB,HSFX,O O#E2(##PP"J^H$!!\\KP0,,DD3A%8V!-C11(BT,/R.>@$Q
MTOF(?D#(YEPJ_K;U2X[@'I/1&XBP$Q:XZR/P8WCGZ- FAWN+@I\_!?-$ ,LQ
M<OL'=4X+U(%&F_3_KDV^0)LU, ;LK&0  4&@,GY) N4AXLL3,?DE@OJG"*[\
MZ["WF(,0S1RJ-,$ 07I_"C+F[ )5JLR52@N&?MN#F_,)5?W $?P8S  (5P1F
M:3"F_S0+Q4BC]">3YEP2Y?[NR/%=L_O^E'U<X+._"3<#,K2!C.W_)(/PR.+$
M)+()O+2$&&?4EM3-_TEW#YZ(X3_KOE6@NW9S)1G>M6:"+04#FBYV$N*X$&%+
M+.,,ZD\!#;_<.+92X$8*D(/CB1S]2X[%;S>"BJH\;H[]W@P2XR9(3;KFTF'#
MS1<(H&]7@<J\_PAJ>?:/TC&,,\@E=8Q ^J>_I"\^13T'#2@5ZD\&^400N"%:
MX(94TGTJPV*VDZ4N,/3I+T.C+$R?!1*;J/ 9\-'TDKK:WR0)#+7GB0 '&SD+
M%-S_R]#MOPPUK\3"@F\\/_\E*?VWVU,P_4G4/_>+^>7VUMT[2X5FO7B;TCB;
M?'GAOVQ*$B0[5/4$V$+\RY:SP!;*\?37P.5 $8AAT?:GCK\D*W-V8>"=TURI
M.!#_H=_QCQ3$_P>('4CIE6##I /_H C(Y?XDRIR+XS]HHBO0!&/-?4[Q:%Z_
M.Z>4+0J?8*CULJUK5E^J;]MWP](6#P#X_>"QP@FWBVQQV&5+W,]Z9,WE;]:C
M*S27SAG*?D8V4> S*(8%94D=]2N8YK]2$PGOI'*EB +5E'_M=$*PDP=O4S!G
MDP<OO%Y@<S1P9\>U)/8^7I]N^<"X=-JD7#_[8?N0"ZG^:QZRIC*>JR5PJY8"
M#*C#2LD("05N6)GNFR213*82 K6X*@&$0ILG CJYT45!*$Q^^2!6X / ,@)E
MP$&@TR?M$_@@^;=_(X QH)NW//WEX#,0")W2KSTH-".08D;0Z.=?-0!<VW0!
M;\F@3-$9OC16)E.[CI);^% ^)LF.^WK)U",$IY!U%_'HM>P+UQER^XE*.*E?
M#C605NWN2R.'"/F%.;:J[E&5,K*5M&FX)D_7D1]X6VNZ8=Z-+7JK:X9Z#><&
MJ?S$!;/0@&%SBJP+616%L[DP[2+;C>-8888>]NCR-<\K_"81$3$_':%?+)M1
MZ3 LNTH^6.)[-1-BO2HNLL_$=ND9Q^[:O/\3BA@3$YR^7=6-DD>(+5DY$HIQ
MYB/"[#3+XH.",TY(5\WL:]RZKJ#AOD[UQ7MSUPU]-(LF-1F@I7<T95Y.%"LI
M#'SZPF[<;&.NO'^1)J<')7FP+\75:)/;^\S>FR8%[C_?EZ"*&JO[) (USW@J
M-TRY-LOH39%W#4DO3&UCTJM52!L(302Y=WR$R\C GLOF_7\,%W/-63SF\'.U
MQQB7*:W^!:T*]3W"],%0UG<^XE)S0,FFIDT5(AM-9=R=2^*-MK+#.PI(U1AA
M;PCU/7%3V]2)N<M[6NQGA32'OS'3PB]3?!) %[H&AGZ1>@DI2%;=4G">^@-(
MG![S96W@$V)X_+OI5C["Z5G.V3D<M!'$;B?NL.#^#=UKXKPX^\T L_*MJ8$.
M9O:0-7+6U#KWNAFS"X;:F1/A+_F( !.H!^@^&#GJ;5R]$5N3L0"&2I1^$-2C
M0.\M[E6;=-#F"-=,0D_./?=C^^*MVP[S6KA19A6ZBWW*SO4CZWRF^N)>< J>
M>:4\WF=X#$^@BTZ<B.,)J?&.I]&$U\UE6$YC.0^',D >KF5.%%)A%QGG!8_-
M))ZFG22IR+PFC!K;QL*U_F!AX5,(3%28YM<)^>6,X=<V?:-W'N_G*2!Z%^F:
MGZ^ P\NVW5Q3].YQ+V4L/$V(H9/=27QAH;;H=0K#HD-L'U  (4<?&4^!QMSS
M"9K**N,C"N/J5DRP56Q!0;H!7[P1YA97J-0O4)S#L)P]%/:Y6W'8U?-^>@E"
MM>K&Q%+9#S%<3-6[GW.4D'B+[2-F04P$'V&[9I"/4%BR=-1A/N )'UZJ,N&I
M%PV@F"('KV$V%S@^#N.\OG.&T$L1'QCZ+19BGSNJ/,5FRJ-1+/LBT)BK!9QI
MI5;9Z:GVV[Y/92@_EPC>;XJD4XFZ--7]DZ<[<IFED6K39U)F'I"&U'6\K:NX
MN\\N?H)FE%^"2EXIPIR#?%GG!8+ 4"@X*[CU@S0S'X)8#@&@\*=YWQQOZ'4U
MW)#YN;3KS1DW]5Y2KSVE/=OS:-T75?;M,37V33"+K^D,T3S$N,_:(=8,"+2Y
MN>!&?F%)4AY=!!1'!6BLBX1W(<-S-N.A=X,'OZS"VQE!,Q)W73G;*T^Q8U _
M.XKN5<AYQPU@(F]3$+#:\<?LL]_4% IS"P+ONCK=FT2,FWQ ;/3."46K,QVW
MOTXYD:!C4JJ8I$P^5CYE&VB^UIL0+CM^RFVOPV"%X&NJI2P\2-^KS=T>E9;X
M0[ U6\[-TNT1U2 MX2Y]Z$%^Z)M37R\.KOO@VKZANY0,6X"NZK&DCORKJV(]
M"9\AH=L>78W]00&,,". NKKN7' \O[W?_#I5XQU!U9SF, ^9.K^K-U5+9L:R
M<E3BNY54KL0N*:>.T+Z/TB0/O*ZB=O7.4'UO>[@O8$!1T<"8K304]#PPSH+W
M8@13XA68$J_!E)"7!U,BE@0FT(F=.3UY3SB=H*4*8B#QJZ4N\&3S?[?48,$%
ML@4MU=L7M%0[04O=*6BI_Q/R!1,.@D^#48L%]B(A6B,P]SAA.51I*$.>Q IZ
MN]NOWIXJZ.W?@"(K@2(;@2*J@M[^2Q&4/QB0JB1&;=_?!0M&9QTI$F*8-<.[
MC>NQ4N003_(]M/2[MBRG_:-+Q]!:1C;J"X-W=L5%E;@B$ BA#'UO8(T^0$/-
MYB#P(/5: 7:FW CY6'M4X^;.OJ!'*& N8\0#WJ7&7=\LB(S;;\BLT_,+^QU3
M!X/-[C=D_N&3?*+O7&4W5&X5$[ V(^TZ1HQ"^T)EG,$N;4O\2S81OE7$V13'
M"W$%HS+_%R[_<07@<H!1_U_M\E-STWDD@.G_*B6))SLE )B Y4@!_^U5$-"E
M!6E EP3@]%_%".C2'6 YX/ M:X%+):, JI%@1P"^),#%_R9)P)?T( &P#?(&
M@U3TN(  <.L$?.G6?R0*$*8$@#XI<T<%TS4P&7 7 MT"4 F=_T@0YM^\1+DA
MH$ "&/ZO8E#_[B9LL8 # 7C^W]/75E:@G:TX!UP4AUM8GPQ8DF[LVT(^(H\<
MKL =#'CE5/1R7)AL$$B8:CF.K$+!-[&_=JL'NPEXVT.P6]R?N^T'N^T!R'$
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MD5--+#Y;2AR-X I$T#TNDGP47SGOF%+#\]Z[*IO/U^K^NIE&$FK_P3VA?6.
MS<C2_L2Z(GMQZ>XBS *$J#]4RBA$ZS3ZW72R@C[K[[#6P8P3>R#?-]D6XU@G
MBNV3_5P):&-..KC[#9O,,-0@ JM6OP D?EH^R;\H$+&8B1/.D=+7S'@H_B@%
M1'>,T#_R?OX^-AS@I331J( Q5<OJ!_8X/'08<0PF\9N-.N/%'HNKX;)WGG5]
MP2O<7[GL-Y,Z?U917)B<2X?"Z N#&=J0*30M@#*&;:&J=Q^6KB*U_B)<;?@F
M7&\U ]R.@7$\?,ASD/,W\8ITMZI1* 9%QGG8 JJ(2F'&"??]K+&G?A*MB_'?
M_67E3YJE&+#D8]3N>.Z!OADYMB*^G8>2M=["9/9 EYGE[;;OUYS'JC]25UI[
MGC_X6#6+RA:Q>"Y^B]<(KZI_XS.T'/3W>YXZ"0VH>9.EJ?F=>B:R@#!=VV\Z
M 9<:IAK84'7)^EB-4;C$Q_:TEG59C]=(B<_<KN"W$*^@# =PO?=G6T&X2ZW7
M'QUK8P1!)C1CQ<3)<49(>.&"0H+9D>L@RP$N\3\0LA<5283&00(T8_9/RU A
M\5?*2W9-Y*7X3X<:PMO&TN]-@A6- HUYUJ#7KH.LE8F/';^A:QU[@E(4])E-
M" .X(34B;5.SWE8(>CE/(5^7<+K_6AK/-8&_\GW5+D[,=T@_W$P0$=%"^4,[
M3=5(? (77O@V7C>&/>;J\F$+>DU?_8'T;:X-OIBN.QN@V O@^W&V-R[J8YYY
M,;/VI4X09"OID]0%-'E*)0GC(?M^&&Y?_"%G![SNM4/F'@U0''4<FY/.=<W"
MGX?/J6=(;2O7)#2(QS.=!S]&QD9"5!^0"EYP1(6LGQS;I2+IT7 GVYF^]H!#
M5=%[(+[ B6[>^98+07^U8$,U?Z(%8CL>T-R*BA'QBMP7OC[D65MCNS/V-EF#
M?K5OTJJ!V5+$ *%N,YEU&OJU4CFW5&_2OH;^K=3PV,7M<.?=G?VN)58,#^JG
MWA23 XCAZ>*_<V>&\P3O]UC?9#Z:=#.5BS.).KU]]_>)7K-"X9JR4QS=, OR
M)_K=6<3W?[JI"\*)<VR*]B2^=^Y,*UTEH?Z::$(?_Z^^-/G"9P?B^!7F#UCD
M^>Z!:FT91_Q[<Y))FDG@INBYV ^N''JTTPDE976-*FC5A.D/W)Q%WJ/;1\%W
M Y</I&RAIA+-F!^,3OI6P*"T FIX O&L'YNVWX,E6C9L*;>9ONF$?;87T.^P
ME][,ZH<EHB"^F.E'M'I@"@,'L<'-$"+D8R+QT@4H)<J3RUX]F;IS-_:V.#@L
M1O]4>%8V2)2#=MKW$?3X#.(KF'(#^71+,QD+9LT&$-6_L"+KD1*^QZU<V$(T
MVHIXP3T6_GQ5?17)-4C,1_/ZU@%S7^<(M_U5!\H%\\7X7 -D.T4M9]KT^U8N
MR(3^7Q)RKW3%=H-.'@U[_U/]SQZ(UL1L-SD+,Z5]=\$]S4NGPPT!J$YV$ZJH
M?@^$BBQNS?7?;5ZUX(NO2?^RZD]&)YDH>@%ZU;!>_/F,<:C K+OOSK,F4UHX
M["?BR75N&Y?A7)UY),4:G(PU!CKHQW^;& *YQ*ATC]NMK:TNJ?0/0<%UY\KT
M0<'Z*ZZ##/$BDF;7'B@67>=5FF8B"@S\,1U]3SURV'@I9[9'U^($X@YL_CKW
MZ+':R**(!AB$W$*_,\?J;W5(G4<ENDLJ' -B2?R86@!J-GTU\,LAW[/Q]:(@
M4%QO,^CYKVGD.NH_.14-[P!\+Z$I>R[AP_>#N,E_"GGO!J90)DZ\#;>%T&%U
MJX^?"7^,[1=?@M1)H.B.,'>\'05'-B3V\W=9^RHA)PN.#0? DX,4CV[\*0*I
MW@GY6C;8\NN3,SO"-R"[<],?L":F)];I$O&4D06]! ^J9)>MC*NV@NS0%/;*
MZ&'!KL+#X0=@TJ!G/Q>L05'CI"R;@\^SH J3B"]0R@VT] PF%7&41=#+,ZG1
MVX34ALKK. S\I*%X:VX+O9I^1-!9Q]6B$Y'^2)X9_P(9-KQ%%@%O A:;3.0F
MM&>TXZR2OF3U.ST7OZ!V&;;[\.%#VSO"KDKQ5M!S^RG*)A#X9<";,F@*V%*T
M[%H2>PM,)HZ-U.M^C*[KRA]M>\N2>U/>5BC0JRA=7<?BW:9?]$/60]:GW@/Q
MW5I?YHX/+4:K=%7J=\5M")STEG^5ZP]^=$%A)D<EQ4%)(!9ZAG$"Z*4:NNUG
MY\/M ;U*X.L&4L"G0&'$>SC4>V9QQO+$F_PV3>D^7[DM9-+$4(%V6\L(0[X2
M.G5MJ/]0OM&S+Y_LGSRXR! $^1ZP=59?A@(GEKN#DM#22*]FAB_5M#O">;QL
M[C@N9F[.(S)=CLL=-,_W3RV&3RO+##Y(01+W0%V?HEA\UE3#!04,&V!1@K]9
MLK7-PW\C=7<=MLY?<LI-6\P)+/T$BC[;#_I5RPB)"BN%J=\>/77?YU?3\(;2
M4[/5M)J:@]&",!6&Z 1QH@N9QL:"3F""B$H]W5!U'<CXQQD=V83,2=#%@ 0$
M\D#_C)Z='X*B"0T$,H&:V@ENO#K+.#<:=@B(H&#]U9'@WOVVLG\LPTZ/_PD9
MC4VX.-FS&*:SDT35?5*PCT(]UC9'1KA0,\[;BP=TXN_O@<XT76B+'+QVG6LK
MI%O5I(&JFTR-H$VPMS/>W_DIAFX &Q9^BA1X$.0^/M)USBE9<SO\9MQ*B^7%
MD8T7O9>Z%@4!Y'T<<!+2*5L61D@$-UXVT4XQL-_4MI7TK3#K] RT?]YTCCKR
M'WIP:Y\>@#)5,8+[:0MP"VIOI^UD4P_R,$L6R"1=&6=;^?IFC9]$\Y_C?W1D
M;Z.E#S[,^#;R%G,54/RPBC@&&"Y$1SFW1Z5^ZS\P[%^9;/(W4_NJ$ZI%.>9\
M=*]^]TE]Z6XXCF[/\ 3>S*-GLN91>!0?6QEZ3:GBHVO5OA_)6YL@%8Y:K5V1
MFX@)9,-.M[PP<> 578GUU5FPNI@J[-@H*=F:\#>JJM[JWKD3P3#OF3]W:PO%
MOP1\OLX]<I2:>?+B(-MYW6&RY3/_-N0=D,52.%:&#(RF-02<<.[2LS.JU0T8
M#-*4(KM3*:E=$"FX-,5OV959J6,LJ!,@218N\\M3>]%4,'[&R7L:L28NK79&
MZX?0"X[?;2T]JC\C/,2I*@E89=9/=JRYUK9YA,%/[4+RL:3P$1J-^97,;*]1
MG8 T^_<.BFH<4KM\,1>E[PF=3P?30O9S<N'@B0\Z2"[6Y#/8C+7+;UR#-E)\
MQ;_U=@1*RS--^D7"P)FU 57.M:NJ[V)$\KF/%$X,0"CV@ZE@$2POH@NK J13
M2KMSG15:O(S+&D8_T':?/WUE7],L\D5_Q?T3W<A_NC<% 8*!NQ6.X3+7KH^V
M@TO<H&Z6.R5Y5K=G?Y):[MF2;E<,A;TY7:ZR4[#DFBAFD>CK+60U-5IYWM+_
M>S%/I_4GC?LE554;!8FN@T\_EXK%OG;L@S1J]H)33?Z3\XH8P/&U@TGY_1 \
M]E3S:&Z7\S59>!M5IN3S[D%JUH^4OQA 59-L++F>13\)RR?VUW]C?@SH02^\
M#.:W+K=]\82#X8+PY6&M6]_<SO.?UBM5W@,]1);_;(9HE]\\56Q6/JB L5:?
M=?^PXNSLNWFQK;)8WN4GK?B>C:#Z67EUDB:@N$RVH/H3T7'M-^@FK!'GDK>0
MKB".55Z-]3S\KU^KG4L17>O(I*) T]\E)K^PWPHNIVB=2A._)?H]BJ]"O"CI
M784%9F$QA*HG[*'O8E25<\_Y17F#K\7M@7-7;[R&WOZJH;/8/7=Q\6;LEP'U
M/XH+O8PCI23S_5Q%&:C\FO-X(8$3;DU,Q7#^KB"S8N473_*Z)*S+ORZ?95S=
MX+[$O5(+SBD23"E-L0O^3=X#<0_]-1;2F/\Y$^]W]VUZ'6UTS.SKYE?:BQ/3
MP8\M0\,E4E2KLQ8O_2^^X2+\%0<8*>V!>DK_HNFG\L"L)&PE@6)/ )1SN[\Y
MM2NRUQ[*%GR@=IY%[^#3?X(?IL=3O:6WVOW?OU=3;LB6E"T1\13"WDM/%!#)
MG<7-MT$H-K:I4,HM\&3)("T .$O\)&8Q5M4>6;(6$(:Q//[Y;E/&@A,D_$.$
MV#E26K#_NK# RLW]QWI_74H<,@=ZI)2\?E\MM$.\OLZ] "4W[!<B )KL5R/J
M,D.LE)2+/XFKVZZ$3F/P-!-]2O3('J@80-ZR-N^R"CI.N2JJ9Z%\YK>%N4#E
MMF3J=KH3<GYMD\>GLL(U.AWG;;CL;VO0_FX&U=^D/XA5EZ2Q*41\X%^,/++#
M'GL$V6&V!_)$B?Q&B'X<-E'YC5!G0Q.](5-?\_2I,*G3[]OJ;H]66)\S[_BQ
M8,7 <Z%-6MBSV@\RO%D3<X;,EOW$N X;Y/P;Z!$&^!W<A@)-W- 6A.*Q)C5Y
M;IK.(TM_#LEUFBZ+?E1\R!SU\O):Y$QCEH1%.V@"Y_7FA5 2I<&-#UD#C_/[
M_.K.I,^0V:!^UG4>#7<<A'YT7#\[#P7T/;K1XKA )*":V*4IY9\GF-L58('?
M PDBY%:PQW,&>O&-NN2$@*3(E^6NC8=N2QA\Z1V&LFUV/A="N=&V":@MQR+G
M2\"-$63U>:BXJR]$>%/;VA2/$!NZ_['^!Z/W1:_OO6JW7TG2 NG:&YZ:ZIIJ
MR:YSF#W0P?VCOMXA.B'U@RCL&63'48@OF&,:$"8^Q>DV8> :P*OW?3HE^67?
MG=[G315U\+<D7Z]^*6L?GW"$8QE'"6Y:KUP(FD2S!&>:F7EP85*0""S>@K*)
MJA]<_V3:[9SO[OY!S"_+YIEVU3>E2S=$'ROY&=X"4UP)&0A=8(>]Q6< ;_8<
M1JCRB3U6FT^H@$*0..Q/)XXS=+QEO/UZQ'F+P [/-.8KOGAE2Y!HL,TPEDI_
MQ):$-G+^'8YR'0PHZ?2NQ]+-X(\IIVNHJ3>IV5A,&2QET#9*X[CZ[>KIV^2B
M*T3!+;,&/?$324HU*BIU^XT D1TGL9J(,<(1K )K&ET#[FU&2#$> RZ_S K7
MFG)8 1GE'D<-R:=OJ7M=\9:KK#R5D=9\M(R[!_)1I1.2O >JR64<(2PT)#+$
M\+3+S(IV68I83V.3LW<WAH_A3LGN.F^3_5 R#%O,^>K]+:4EMXQA78X<H0LM
M]%.(,80V,ZM]O_[&F?E>VT!Y5$?S /S2&,;(T#],T?*(XX79*NPM]+:_NN*Y
M-*];$Q/@VL$.**#IF&IB!//H03:!R2X4C!D%_'3CVK_2)P@9V/V+(41S'GN'
MR%]]R><B#J<5/C.Y=-Z2KHSL4&H@)!+$]D /$IE%.L:2[A1'L@&1?&F#8#7B
MF360:-WF\@3VZU3AJ7SO^7)]Q:.+?*#=>-IAMLD@<-Z#,UDT*PJ*C*'[PD.!
M5\3!-(+(7QCCHDK&AW9OG?;64UE>Q(P?IR\E==Q8Z0&!.* 8A.@/<"=";,3H
M]'1Q]PXM$"U8_JD]*W1"P?G@'[F=\![+#4O,U\$X-GJ@ 'T]&@_E)NLKI 9-
MKJ,4=4'X'RQF:G+[@T6,#)3R,(EDIV21,GO5I4=O/IRXQAR['CZQ"L5_TNHY
MKX=G"EL R9CN2G]:JW']^5^503P9AM^ZDR^/J($.) 9_/P("Z7\N%!X<W#\]
M<__!\7?J<L\;36(B0UR,EDG5F7L5]:XZG\(VFKFL\MGLO 5^Z>KYC[7"QK-X
M+=4Y,1[Q1R,Z6SL,$1R-"M30==EZ=@X28!UE.6%DA?'9 ]4-)ND$ ;?^05$Y
MYMB1 $9R?T/QUR\1%4K/>P9%(,J>-S) _W9HE6P-"V--[1=!.<&UV*(^S\S6
ML4UDJ6S!.502PB \C*O-+4\U5+4\W9WZ#A@X?#DX'VCP#*G@N%\'$[A_\@#$
MCQ"#.,<L,9%E3:Y01KJA@DB?JJ ;HPQ+E<3 S7LMV1A1S\PY54_HK%DCT?;5
M^]/%CKXJ>2"J)J#2RSCL,@]A'-&BF5)*R01Z&",$>$[23-T#B6D3R'^I8>@T
MY:8 _O[P,]T^E=G6\7("(,1UD/C*'HAR*UK1'O!BSU>?/8]0N$$--;P\4A"5
MHA,EFUK9UN,;-*ZN[BE\=G!3BJ14L#@._KP)* \R) DLWI4%==24!TV66<\2
M!U +ER5%4=P$^%7*WTR_ OFF"(V:RQX>AV^_%CDN]O5=G ,V@5F*FW^-K"\E
MB]"M65\@]> DA"H,P:+/FVW/+G>I][V#06\W%XQ+S5GY#)^I?*48/GTIAN<S
M^0)88P59]PG-D-1D\>'IIG (L[8]C&C)$F(-ME;E)C+4*3BK\?=U=5ALJ+++
M6G%ZXLN'Z?7;QSY_F;[X?;_(D/4-RHN[MP<"#+1H!<S7V$-3JQ)S$C\0?+_)
MQ<ZKCU_D/NRL*TD/'MK-%.VV7[I3B,Z^P!D+O8H81E.N@6<\%G+)343DS Z+
MUYYN#K/H5#@*))?,3#-L*)I=UA)6_6"7'(Y&V?HSQ"N_^">X;+E_X<^]9OM9
M-$,L@L7'28EG\05075A\>O1P^$4@H&(-+ KG\"WL]Z;0YE:E[N5,?;#3$_GI
M6;&KZP$Q.)$1S/$9Q.2C"C:61A5"G7[G^@=%ZKQ.]C4,S;![H@Y^VX%91M*T
M !&Z!D..6>TX+\D07YTA+G<2IC-MDU!E@"-IAW'"4=&2"M/+)Y-)S=P/0EIC
M"EPX9<N/MI[EA0X=PGDARWT<\Q#993IOQKH_/)^955O$*Y[D8\?=1UGBN^KT
M_6I'5>1\([(I"(\39/4@&P?)&A1'-R#H+9 W<:,5>/L>N/=+4]*M@_,I3VGP
MTY-2 I)7AI+!6LU?[@A)LOC6J/XWF6P',X\YR_XG$\0YP)14FF+"SX  80'5
M_@4<@/C[AK&=I&W^UP$YFYXUZ-IWYZLC=SND=NL<</.OYA0 $EU@OSXIOY-0
M&[%>2K>&>=/LJ>"8H&JX]0(AK4"B@!\IO.8P9*W]R-FP[WA/;63(6P.[GOL'
M=4=UMO481U)9O&;T*PQ;9C%CO_B5O;*X8,2/'+ 02Q<&N2@C5#C-1*-+8%E7
M^X[/+84W7OD69B=TD<M)/-&,+@\7V3\ $Y9*BQU&J+(G88KT@SX-9QT:>K!!
MREI XR$"K195MAIMG9ENKM:O#O1 O_/(O_BX=(@3))R^[Y/W0!^]\6A 4Z]S
M4P+98<I^J]1=G<J-T@PC@/T>>\<SQ(*(O.10E( O+4/QRKNF]+AD7I53D6I'
M,JW$W%WH@C!#4T"'#6"7]E.FX49 V)'6\/P%:*J)SDBH/NE-TXS+C-.,&5_B
MP'K%\;1E(\>Q.1#[FR[(CEN0^5<XJ?80,$/T)BFQDVFZ .X2/FQ;!4Y$2_YM
M:W'$.V:)_-*ISZDUWZ@ V7_;*HL=FXI LR\5QX48R.LEF]&%$#.$.FXR;_5T
M7P7PC?:$>C^92+YIUJ0>&.15WV2Y'*>[:+$<Z'5SX"=G"F@GP-1^C)LA4R14
MJR.+:D3BI6:^T7 &[8-:+)&_ACO>AG4#C_* 7%H"L];D//P<^S(JB$YH;6XG
M00PV89M/^EE5 JMTHVBTN:X-^^:,])RHJY4=RR.&MZ6=EA(]KOY,:N*'<Q!#
MM([%7U6&Z#C?RQ!=AC*K68*3#,UAAN*C0@#9+1/QM)K@/LYFL1HY!.LWLXS\
M*'A \N+M]@6IS]Y]*N/88\@._@;;=#3E"B&>[;PU4UGJI@NX5#"71_P-"J3+
MF#/*K'1UR"C1*"$\SBQ82N!PGVS:"U ,_#3$6]Z%I@IT4"9(!(:H(HV?V="N
M14S7ZQ[WI:I;49?C-ERLJ YI&UP3TR&&*$/I.S/!O ,701,-<ZQ>A##S$W*>
MB)S6FR_M&4PJT&JBF* IO9?;QXS4%PBBUG>#JL06W^%#[QTK.'R[)NWPATF-
MUWPT0B*NKHDA5T.2[1=>0/5LSCR:WWS*4"^9<TF/Z%$0I>3W5Z])U'SA+YL[
M&-)WO'KX=XU(\[.+F < +UM7_@&5% R+;X>:S^+CJH*AS=B&(P+G+_F=9Y,;
MN!5=RULU?9Q\5$W2=S(DSAH$CV#_9/8CA'(M"#B%([,MY. .8$K$'8;"Q=@>
MLM,0*>>C(#@6IM<J8TW("CA5&3A@\V/.LS(VYN*UQ6I;3O;WL?OT&,;/XN^G
MN#CO5S'OWV'"JL#PW:V;J>U.93. +=X9DJQ<-]*N[GVPS<[0Y\>;-*&0$8Z+
MAJEB4!C S>+MH%KAT11G0A*!<F,VJ"M/OC>.X45I',1+M![UE=F^GZR1/6VF
M7O?-Q HIHJ^8LMO[&4VQQ 'J2(88A"B9VF[(G@:*66HBWT]!=D^3>RI+&<9
M>7$_A*%X\]J45U/F.>DQ<W&;/= K^XC*,Z<N&" !#7025A&!QX%P7FC@!+0#
MF@R1T*P')V.51D-Q(D!JY_IT8JIFJ)N^<]UME\:_OLJYY(K"#>G;5U:>P=4O
M IQ$U&0$+0.X2>UE\7+2#R&F"B1:$WLD&G&21A"J<$>$QGL@Z_+SL4"EW)TM
M8:,#WZ5BXR(.Z/[YQT5WVT=4B"]D9H(F#B#G-Z?!M)<CZWL@-K5X^F^!*IG
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M'!N=*?W0ND.?2/+G+C);RGJT<4*=)G_<!E\(<2,U(BPSZ&?GVBOM@/V.(/>
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M34!=L@,C#^O<.&D$*0<"B8+<U[T%0<V9L@EI\2.YS\^R_N7]RR=5XZA9>*3
MYC8J!LM30Y5,)OET9V25S7XX_)5?<"K\.:ASD;G@KNY-/SC+L&>BX,9T8\2P
M\^(Y6&IG91V>=>J'IX=.#IZ>:S<?V'E7FJ?#7@H/PN<.F_ @.UQ,Y'QQE">
M%>TE!?&II/-@^/F2EO>5;J92*YD>)P;I2X-85<YB)@KG;SO-3]KL$DZ&'D+H
MP\\-P;6J@=,]LS(3%JV^J#?G^K;J=C./?;8_6K[A7\ 6B/[:>2,PEY''/'^Y
MJ*:8+^2PYGLJ5R7UK*_$F<R/:_7K7MSC6FZ]Z_9T>88-$\T(^,]=2AF3TRY
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M2L0Y[RRC6(Y((8;'/3VCIWK]?E9T9J5R)=GW]/BA%[E3E>_OJN>:I$G\^O)
M)J.F6]'DTQ:([@Z;A3*W0( [*P*(Y J_X8EZZX2E%654T98LR]9C0,BXU/#Q
M<3WQH.^1BH/:V?)"DE2S'(6-H$;LX7@^IBG $R;^>DX%RG0V>UZ/>12(I(>3
M16LPL9"46T3@9,&Y::-!=6RNZ?.4X[_4(ZHJ?+$I@V['](K=!(>@=;!NXCR8
M*[;S4[LG*Y0=QNG@N0VJP,TE@XXQE!S;!#"C[*A0EX[.V+O@^V%'T)=KZN*D
MIUW-JRXO3>&S!50]F@)]@[M[6\IWY\((<12-)@HX$2K.]GX.F/1[$=/#*J=6
M5>L:L5DR6=]00/%>^,;58]<N@X9O%ZS^89GP-NX*E)3F9\# =()G<<P+]#4:
MF&?WE0^WSB"EF-D*WM\)V<D:[]3B&WG.R47A#-V3]S*QJ,_:'TQK =5OG7!%
M+H%(=R7.8YFQP-.0$'*X)/($\)M"L_!IQK;\IJV_/TD9(0ZG7CF-'* ^?K1P
M])%/QB?!*1.B@K6^)EL!*D/;R9.2$Y;1Z"LI1K7 J?XF*+.2F?,I_TPLLWHI
MO.3*)GMX'AM9/#. ;@2SI6J9V9RG:%(JKEXO^18DNS#_$4.3>2^UD0:G;*2<
M_W;^_5B5RL-XGB/V<TA[0[;E[EE:M+#/RP7)S&$]$IZMJ%J+[CH250NH?YE9
MM:%OG&JF;_1H90MYLT^U HFA^U?^7H_N5XCSMK@:GDNY<,_NVZFQ_N*&^Y?2
MUF$\Q[)+9@L41$SCL8LC9 Y+'DV*TH+L1(W#&U+3O>B1<+BMU6MX545%72Y"
M_H20R@59Q\0[B#S+L$[!@58'6I,@6V*""NN!\QB]GF=_6%09FEI %:)^XA30
MQ+.B>DE1,TE?NV-$C#AE?O/WDQP'M8_,_Q7]:*#U(UL6X<T<X32A26U$"-0?
M+8SNLD5IL/6!D.=LR[$_2L[.]*RW7-3,OD-IG1^&E8M_KK4Z4=S5^.>?5G7^
M#>^!$6*X8E[ FZKO&.'V,]M'*X '_7/%Y[U )<6^CIH25GV:/^*;<WA(N&7-
MR(!"H,C^GY>>EN7\@#9XK%YBV;,M>?+]A7V;TX#T)9G24(K /+DCKP(1XN?K
M-VW?UG:7;&!_T6G/&$D+.9)6J2AQ3)E'IEU#P S+CML+IY\-SX;2G3%9Q,:-
MM YMI 4=VM.&5D3 >I?,6DT*^S$*=N'JS32SH8&B:Y<:<W>DGMRUU+F9O>I.
MAS(YO!_F(&Q[(70W<!J.?AJ<2N1'RKU$%/[M(:-[<(FW&^9Z*KV]!YNNM00N
M6F[N(#7L7.U*N>+[VOHE7695BG5\6R@W@296 #!$+A:E9_?#^:O:3?RK.VH#
MB2&M%VBG T7?/APIVS=@8GC)U=0R;7.%B>04HTE8WA:?6%F30'W< M7!5X?)
M4((,*>L91:L:UADC7Y"N.F&D(QIPG5/RV5D[ME^ \BPG94'.1!*DQ&/0#68?
MIY*GRYY@ZDU66:R].%IF/*07G':[[VLZ!9+=FI1N-$7+RO/_K/#FRSW)?-M;
M0S%AI2\#(&:"T;+(!E+M_&->],+C,W2BGSDG%T>J0LO@@C"BB#=]S:TF?:,@
M]DGZ4@O%PCGY;+SKM//\C;?MU_LZSR\XGKN\[-6QRFF#7L0 !R%L24'F<<"$
M=6)I#G&&/$J[1 _O/8,HZKGMFU^J.3[NZ7F"$%1LF)ZJED34>_>P$:%^2-T#
M\&2Y\)A\$"?7[E'*-F:@V1*C9'AWF^%D]4P_9*]1MJ)#G#"A/)V9$!0:;CAR
MY9:8Q)><F"-#!S?O"([!!;9 E]<( >0UMF0Z19.62-D"S7OTHE2 &,J:*+[R
M.WSWST);_W+76I'8@8J/P6X.*N=/B"W%_;2*7/^#[*&']&]/2*YVX K;,22Z
M,++6XL!I//-F WWA)B#8)QTSUOPL"N4%R7G@>,7L3$2[^>&:7@+^ANCZGW\[
M!G+LO5L(VASJ*1&FK_7""%C*MP3DN<KJX4QF@;_BV-L?K)2W0]\[?X'=[!SH
M.*8[D,2U:IKHT$=DN<"Z46(Y.+)40^ZQH9L7?NY9MM#C^\K]SI?VTUJ);<!H
MOLN" 2L4Z^IR[=O632&!A:&?6C+;IQUSO+^(OKMALRP0,O5^Y1>[X-XO]@<]
MB<>G'P;LL=_O9-%W-J'6K,LEO@6>7WYF_(=160QK82*5\?C085/SG(A'\H?_
MF@@==L\HAL\]K14RJJXI>>7]%7>G1!M+!Z>@+! C",N!=<R^8!F_DUL@Y4'-
MB[A4679(V@0R-I**%G5B:/9N@9K0*88XR5/95EG9E4$;ES_,9M"21>3L!>_
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M0'*,4G^3^0*!Z(N7A34VRHB?.*!R0^Z19/,1DRMW!/GFMSM;:L3T$#,A M
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MB(*]DT?&]*'G^,XVMC!BNCD"5G*&M,LV\B'16C+Y Q\=W3Z'D1Y!C&T/N3\
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MDQE-3R\X360&D8N_FX<I#IXK"C:2(J]Y'M!2SR590U#=\.9L/#&1@*:!J:/
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M:9LO/Y=,ZM_:733QV(\FM>#H9Z" 9@ >(OQ/XB"!B^^0_H24H(:0KU8@W8&
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MH]@0+'J'-S5"_S@X08] ;NC:ZZE2FKFCV>0BB2\3T*Y%,%!#N@?D$=FZ:)<
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M0]^W]W_H13J]L*0GR1>=/,UTB>581Z7>7>OM!=8?]-H?<(XC_T-TQ=]9G6Q
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M]6N;%$"UKQ%:%]\[Q ) EY3Z/-K<ES""7H,>"$52NK_&RT]:S+930??G'%C
M06N?N>U,BBEJU.H.23@*-]1K[MWIC3-["=MSLO_Y^V%3>P+LG_CTC8'%/W]
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MY(S3"2IX4G8[M;Y#'-7%"GNO'@//!O,:*K8U)16GUCL(U8\QG6UK[M:_TJ>
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M G+5,60]X* ?*:NO_,NW6ATMT5 3M>.6YO"/\$YQZ='U-+XDR; SKW:\UV"
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M#[CQ/7>3L)T>C=?P_U&Z;ERJ.ONSOSYKWA3CK<[K@V_ 4V]_0(-IDT7T%8@
M6M-?<>P*075M3/UST=92IDA^M-[!RH<<N82S_,:AZI'#P?;(I/GX1 ,E3<^<
M+0V/K[^/Z=^:,UAZ=B9P(L;V"7L0]A%/%:I@0;'D[1*J625*YS;]'7MBHG97
MX_N[X("OL=.ZBE3?QW,A8L4T1$>^^FX<S+<%PHO:(8OU)9S'/!7_65GA;+14
ML];1?Y.%>]D_]VHI.49K\*KUO3LVS^U_S,\' 9'4-H^IY1?HW+.?UQ;M#*Q4
MS ^)J=Q,=B\>M# C&RZ+286;#P0_Q?#X!4[ B(5XL2#$ 33X*:DRQG6>C(2L
M'7JSPJ#70WS2ELWZ=/DN9TQ_KONQ!ZI&/JG8 ]U'SE:L,^Y-:)FY?T-[%<RM
M02'-C2L[(U?V=X8=.*VHRUZYUDO'=1'D(Q?P]3H)07ANM&DS;2B1UJR[-:_D
M6!,?'M'8I!&*QN8>VSFKQ^4BUV.Y6P)SP<VJDT)B7N\6R3!R)EE>[UFP)JQU
M5=V$VO0+%Q.;M/%L Y".QI:*S'FK3#/K((KXN#/6(FL/%(D/4%7I6-(UR,H6
MO.__,/;Z=9EWO%)-X?:OJE]O*C?VI2D[Z:FGALQ#0@4S8^BW<7'RBI!M+HXB
MC8 ="5%X+UA<_GE:2 SKQBS+IAK5.WABS,_A-/HK:,544@:QU-]K$>Q\>B2W
M.U)\O-6@)M1]#P3/F?O:-[\0&PBX?S+_?7G]'5#F-=[^@R\O:("D:@9-/3.(
M+D/O[H%XWD#H<7_UN-GW0W!_-:KPQ(\*L.HD#L_O\>$P8EL89P1QMX"CKA
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M)-EZ[L3WLS]?9H^%"[>'<R?]+"UE//K3U&3-G/[)GA[,!Z]AA6!NK%>_EO9
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MPJ)C/$D*?NEGSDJ%$BFZ"NEGX?I,$188N$2',$S'ENA3CQ^UU#?[U#5^RI]
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MN<F@4 /JLZJ$#E7]A^03Z3>;!EA)%P[;?IR.[,30;A%F;)TYNEK"D*3CN^J
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M<$GF:_V?QB5@;NZ!MM3P0# >.-H+4P?9ZAUJ'_6Y+3_<PO('9!UDXP$8Y"0
M]$?+8PST@:R0'BZS$NS&["DE W^C1/./8UK?)9R"J:W+PMZ\AOW$XM^'F!H9
M;#CB <&@AS4[%;XX.F6]XT$\ (?A&KG^,&;]7+1R'&B)JG@,Y^.*!UKM"_%
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M^VU/4K_0P-PCE#WMM0[:J:^I9&8 0XFN@R^0MG&0=ER)E0OF:AA]G\GLM=]
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M@V+&D901,5Y!PFUU),^\RAR/HM=HRM*E-FK3EA7]SGE<FZ^>L3.)<H97;+7
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M'6AN__$]);^!BAUED0I_+,Q@Q$#=/Z+.GUBHW+RS.#LE!RBB")$<' <ALNA
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M0P,;PN66KJ(I6B7MO4TG0^;4VBJM.K$=+=EW81"."=8&/>+8!6'/)V =B!9
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MPT54F T]9<IQC)/EX#,'NX?P?MAQ99V0U YDE'@3*!QZ,_2KTK,7;#:'7L4
MO/,&YS WB^O<$[82MEBC7D3<LMGAQZDK>.!E6P8IP.N %0IP60&AA/7 ,JVP
MD*1[ X0<^4-3"=[Z;?;)UR-.W8G0LGSUZM43,QY![Z@[H->X@B>;QE<PZAA1
M;'\RUOZ)US&8C-5).,JK+<GEE7NSA:E=P--NB"B\9+,)(TR0C= .<7F#M'-0
M0MU/@BTJN5O/P_B:0I7"K[JMI="1H#=:*4"9=ET6=.#9;8LY=>X>&?E(V+6A
MK6;%BJL5G:?ISN0U*;:8JN@KN3KLC$I['7>-<1KA"++\NKLM7KXT7XZV[A@W
MZE-2>FJV;>>+"_[FQN\;P^,A%"'7EWYEN[M>A:1),&Q2XVFHY^RME9N9#^"+
M-8=&UKP2KZCP."GY3$1G*[<A$*"7CH.?J#+D1]C'MZ*/(,XB442;J_%-RDJQ
M2Z4JPX[6ID$"(=*O7I^>][.A"1=T9V'E$% WRFP@?KG&]KX_%667;%J7;&JN
MF#2^9KJS&K&=24T5H("34$=<NYDGFJD5V\DXGSC ;OC0>Q-U-NK9T9&F]R&B
M3$6[@PU1_1 :<D^:-"$Q"HUEJTAN&"K,RW64&W/$#)RQUH+!7(-/G'J<P<<!
M:GE.+KLV!\U-J82<B7+2'W5B7"U%P616AMJL_& ^GOZ:6@@]O"'.-$:5%G]E
M;!,K5:NG6(82!%V*F)^T 0^-F; +A/,^^\',\MIW$=HG6Z\"7_GHU_JD]BQ.
M3>D2+ #$,@K=,=B,L54L\3W=U'KBPLB9FZN'.]3F=+@81(8<QKD:7HZH^3UW
M_'KN!TS:V/UZA9S^0^T=TM)#N=EJR1_#R%@*P%$Z'C;&20PIG+,6K, G9/G8
M<O4I!ME718P9WYH1*>_;+G^*5J2]@\DA*1&3\Q 7B:FX8=Z[I4)L^/5NQX$M
MB2B[RIHA?I=D[YZ\7L#G6'\K&X-\PN):D1F=',,U+[M)'--HMI>71',KR32N
MMSP[IUN+JP?Q_;H6)[!_F3+@:R:6G^'3=EM,S6_U+WU+.S4PC4$=&LX[///L
MEIG-4";#8UYZ\;%\8CPVI"*\S-&+ 7%Q$J8V=>L&77*!(0SXV'+9X>.!ASL#
M$-(I =D= 02UZPD1Q5 ;-8UC@JV+-[!T'T(>E*VPS_'7H9ZLD QL"^8PSYI]
M'=U\8]7E7:1RGP32#1C#%ZQF/E+CFI_X1RL.BYYUR:4;U\-,^]\-R(CU+Q]<
M\^UY+TG:O7ARBEXZ/LXWD\P9G;C'4J]  1KB%BA Q!\F,HZ<--P+)PO=AH=-
M6K^_EGN>\*.@.74C<^1TLR/GLK5M^5!&:QV^563UT/4>Y%TTW>"\26)2[!.$
MX22KI$YZ8^_PO*G1MI+Y@_!2\VH==N")AI=D606@?\QT_W^CSXJIKE_1@B8:
M6R$)-Y$_C6E:B/:;Y_$QL=!<<ZCY2@0">M<KL_X12_J3,DU5$V_IJ&;V]X6L
MM$<&[SX*OK4(M@&Q?,J AUWI0UCA9(_JO)\UACOS>?D;7?5<X.$]=6"148!W
M>]2LLL4/LW\TDW8;.72<GP)@];S^_"3VIQDC>G!6P%<R3X\8X<'3>>42I7"$
M-!2K4K>JLUMS6WKH8!PX/IRQ2B0E"O>HI\@9;0-B%BV,2U**4#7#0FL,&,<;
M$WV&A#*>ZN<.7JJQH09H;^T)!H$N2>84_F4T5G<0V36,HVI9!DU\#_[]$%BJ
M5<L8@D,N]JX_//3L0;ZPOL/E8OG8(DZ:JN\)-H^^B,2;<\V \6\?H&=A!!29
M,Q%";=Q_/P3\%/ZYY/_P$ANJ><M2ZP2&,))(P/WQ![OTF\C$9S^V ^Q?I=BH
ME*ST5,D2C14AZXI$JG\SZJ/(I^/_X'I,JZ23/>_P+F&JBLXNAQ(>)TM/,=?;
MQ!:WP=92*\$BW^"T3U7<3-*Q:4GW\)4Q#W/L\7M5)165T<]5RY<.AT_&1YTK
M[[MW1MVA*^I>T2^,K@B%X,!3@'!5'FPLRYA )FN8=8<^T^<I)M=WXW>,;C,?
MG4^V<@MBF'"+I)V@ &%O\=J9V.1D#U^ZC JP4]TKHY$VD>45D9H&_&[*!V&W
M1S$OTO\!'[M!V_6@8&R@X["0HXRU1#^_HUO])4 @&6!.RZ:M<S5!T\'D(ZW4
M/ T>FG:AI*7-FU$P9FG1)CKMIR*1(@]>F?B<_J0I,ST3?_V7D21P) S[+A::
M3;1N&16-Z&Q<*VLNM:C8SN\R8/+->B1;>6W1T'@D'G,A2?;3KK30@BYKOE-U
MZ+,W7Z;GS-6&6P8V'W"^O_.87:_H]F-V.1BN\J )-2Z?M*4 FB[12/S;:FKU
ME/.'F=Q'LWVF*;\F;=U)L@/Y]Y7S#RSI)K0V6#&U)E_+A![+TKM;9_C5T#@_
MZ[9])3U]KP*UNFF4(FJ2_7G(Y,[]TM7/,*B<+=>>@(QF\[=HJA!&SM[B(9W:
M$R>'07B16$,WJFXP7E+.IZ-\3]V*LXJW3[:0_G3/?DGR>E36:+.B#?)WT/;/
M<C##AY%V9/?VJ%J/,>G\"50W5?%(:@A\C6D!$6^,( E>J,TTI?US)^S!FS)F
MU.*UBP)\--WF'<>WJ1^E .G4PA5=0@$(7\'8!,1Q"J!.K4&1]A0 ]Z+D9U">
MR(;T'N2L%R&,S+D%VJ]:X>/;>[)U8?\C :?]"V NGO]7*/XGX'\"_A\&6$%]
M[ $%('G7T3=:LPJQ]F3VECJL[ZFW'UF1D33]$6LB4J^WI=!&31R_AXG/7D_?
M$43<I28:-6I Y[EMTG+O+%-"@8[H]+#RA^T 5@89A!IO\Y:>.%%P)?X]LK,_
MFTRKM-_D_W9@^7.<_V-P_NQ'_W!J/GUMPY$"!+;O+_G="'/H5^P#/O77<BD
MV"2=R#Q.LA+Z[< 5\C,?.C\1U/5?@AU-//(/8L\PGRO@^E15^:K0V7N)V=3I
MS19C7<DVP52R0^>3"K>13F2MT\59G7 9)/']NFYO6_0-T?+ <ZTB>P;"@EJ<
M1G2@<)(":U0M1^ZL$H>>BTON=SU[D2(;/ZEG+T3LHP(?8M+F027.T3[4(NJ
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MRV! %R^B9SK&R7NRQ.M[B=3\HNY- ;;FD VO?[LN<Y?:#75&K^Q19;?0==#
M.4EKH\2"]?08EI1['%+-&Z0IL0C_U&HY4&#7*MCRVI>K"9\,A9_K;IKBL3LI
MD'P,H#DOM)'UIXS''.W1N)DFA4]=CD0D+VXP*9:]<"/))!NNH5X$ (CSA+J9
M*"FJ[<AUHZ062;1O1N;X+V/./JTH_G(R)T%U;^($C3MX$(621N(&0%L\VS=?
M%OH]MS&^8OAZ94(N:3" NYR;S>#F_%9,M HR0KIY&\1&8B>""U%/ZNG%GY".
M^TG)U[#8++7EF(%DADR23,*^,9]A^/JB,Z<P%";;DLZR4B]/M.[$DE&%S9.[
MR7EULL:]_>J?P^6EWJK<AYUF'3T6=X;^RLX:IXD^XYL"GCWSUAI(9-XD]&N!
MTUFW.**+)&1(.7>V=W2X'<0R1P%82/K8.M9/6W/83KXY?A3I1-=<"<0AX2G$
M-RJ_=1'#[2%Q%@=^Z'VX]9K39@&^9)(K-;T!Q3YO+KJ7N'DMU</QX5TLDXI]
MU8=G4]YZQH.?HA*,:S9C#I]O]B_0TNG#C0Q8VCYY_CR5UWIYJP:F( JM@SFJ
M+VC=?]%++ <%*S=!6&S[[N-1D5%KQ"RO)YDQR_U>*E>/0\H*WC>=$ V?%JJE
M3=IP&4S4)5BEE>%4EAX:5$4:U";0VN9"^>]S\V=A&7U>X2*#>(0/C*Q"Q\]J
M69XI>OP\_OL:H=8 (AB:%Y9[17UWW"++<[%PM)ZSM'O!R_]2A$1A+R[HI[<$
MCA@V<<"7%/3HPFRQ@Z4C,JU]LN(Q]]S6;(W%>#NO0566()S(6;X)"D#B'442
M(E:@T]$VFXOXL>!\>($,B14GAE\)\7*4][=I&A@P:K_K>/J,<8>)%5;=]L)P
MRIG)0#7H3P#4^PDZY$=IU/CX*9IJP;R%]>/6O<Y)_??0Y3[5408'&$P]J8V3
M1(=NL\JNC>&N1O#2P)A;_!>V[;::;RW>-A=&@U.\,H[\3-;/4/.0W.JGJ?'[
M,()^DI73:7CY;G>^2)]H4=E]I7--J=Z29SHG-;8*"CB:S0,JWC@,Q7TKS\VS
MT/)P86E\_UDSP[6R4^2 7%07O<(F*@*\SHQ'DIF=T<1FD!,QDP)H=-)3@(F6
M!6I+:&JC6'3714Y38:/4..^TO,NY4.9QSZ.&-X8'BA!NN">DDUA!I%E)46*3
MC]]E%KDYY0=%>V^T:8_33=/<I@"E6L!]_[S)V#U:51 %"!9 D<_J#-53$T&7
MW"<*0#Q;30%P7/V#T($*1;\')=6W+2&7XUH=W4XSN'\],G) DRU%L(JK!0$G
MCF:1:/"J 6+]I>TZMX,L=OV55=2DV;)][6 Y@/=U3$S=[('6G^%R_H384I:D
MX&D.2XAWFP2'"9W#)VZBGD@A5!R%BF N OH*G^,?!#]HWRU;[<!AIGGIZE"[
M4$/%.5?9)8.:+U/Y]>Z+]AV*P2G<G;P+&L=\?H7+JF9LN-5+,*^3?>1S5ARW
MJV#@_*4-X5L^F-+/N'.*F0Y%X5</#7G1?A.\<6%W;-2!]NFN:3-HAPX.I@!T
M2A#2O=@RQ'4*D&%/S6YX&R\*T")95MLG+3\[H%^3 [.Q8T3)/Z(1SSB85FKM
MI)B$<!0=[5/,6>0R=SQ MS]K +A!?E;C]=^KV0$"IZ9(\*1( %^R;K6^6 _D
M9KRUXPF+\^5?.;X\*)]H$AQL.3M6#85=&EC5,QZ;YAL[<3"2\U'$_?OV]#$2
MM.&_I+>\#%U>?XX)^M*9&59&RJ6%N6C&A*9N5JKWP1"SY!Z.;V>6!3;M!8HP
M?#AYFL:]7]G(6"___>ANOG[K2Y<DCW$+WW^T\%&>IN'7MW5K'./YI;*6M&!>
M+%/6MK7=G4+3!H0/=ZMNYS''3 2QOCYH1,_Z*__P4/NF^#Y:/O>P_>V^SY_<
MFR8D.MWA!UZY(&$^)T5XSGR;CSPIY<P;\F#))J:5GKZ>!7 #_T(Y7D.8)_+H
M(^:1J1;&I3U+K\H94.*WC2K>W7Z4]#J7JK>&G5/E_&%/UI,YO'B3:#S\.0,>
MV&>^LYB&N#4#=W[I;EV:N''F$8B5F=:DM)A^F]&2FW-B-]]QAM0?&&]3YR,>
MO<<&,IT2'(6C"R?,F(..OM/Z\K1PXF7GF&2',BX)F"3_%(8R?XZ>#AE'F/XT
M)X!E_3?BX68$,%'_"SA+*ZCCO0\*99;OLUE8M/2TG?2\9:0'#J2KI "L)#M\
M;'AA_M)B&5^/Q>=OY6A8[S*,^\<E%_4;!OQA*N>^&U^C49,XP/JS54K\9+;E
MBP''X1XW\;#$2*F-AP]11\9$C"WFC\9U?RX^?[F%SM>.*<K5#T>7/T)LU"HA
MV":&VO7=C;6N+8O;'&N:03QM^5J(B[K#+;CJVZH9>,3E5UE@LTI@)=*:HW=]
M@6G.Z\[FUA>1<@I@7Y%@#^_"3GV/N'TBC>DH\/G+=*#$+W78E\[IJ&X=>V*\
M4<2O\<GZ]DG8G/M50XFA1N%8&:4'ZQ_S_7DF*T(06GF:[^9VBCL]7"TMS@;=
M#)UZIW_8UI9!!A"?LIO@Z+I!^ZL<0]64ANNO8HE/J1']H;_I)>-_]9*'6H K
MQ/'/LX>1?Q...X@;[>"@2I\CENY(:S5:O+**L[64T67^IFES_KR17(P>']<,
M$H^I3MRCF:*6YZ5402@L=7TI^I[D5* <L#!\$ZV(&)!\LEHKZ&A48-)CD:?D
M4G5["_PK(ZA5(O-O&5.7J*83N=-)=K%$Z*@^.7 5.6&.)"11ZWS3-=GM+6(K
MJ<-PHT*,6D./;TNA/V_)_L?@@OM);61_\ED*<(8"6+B[;.]1@+@V4JS[+R-K
M(Q*+\I+=H?U" 1XY4B>H)4!H71]ZEE6<?"B; O!E[D&^H6?&<: UUO\#],93
M+0K]&XO"K_P>S!]H_XMT&_=@7] S6V1]V56UME^8)8KE9YY_(GT#2>T;TY%1
MR&_@@9%D,A(Y16U^3H[\*N;@Q_])[$_$9NOL6H]O1TX[K/GZ;I=;M:8\M..'
MS)/WNS3J<@KP$EE0I40B4X OMF2=RC\'KOT]-/]&X/+Y&"!63@S!UL"@5_M=
M#M4.FL1<CD1<.W_?)3Z'_*8:M#@<N\-HA1QG0Q*X)CK8L\49\A2J-CS?7RH]
M:9)<:UX=H'/R5_G8:B_9C0)<U$?M3LJ23\3^%B)=]G_@;DZ:S[^L-S!(NQ%D
ME_$">?]8S">9NXHX<E B9*L)0M("W'^9]L<'*T#KG%1 ^P=_3DJ0VZFY+B,+
MLT?@H0!L&L=B?UG(^&S"6O<.R:!7GNQ_):O$&3Q[BNKI^Z>&-AG1_Y/U_QS6
MK48>ELO@:7'3P[UJA)O'*ZM*:F.&YIH([<\XL=ZI'^VA-"UN<8?754VBA?<W
M(9SXZ]>U^_YZDAL@\2;B[UZ26 I 0_Y<O=*$8D/8EQ-BGZC>PKK00:T5JJM<
MC@P^N5LQ4&"8T';VZ>MX*%O%#^&C+S:0X>K2\(<-2:75SAD*+F7:7,F+2:)+
MW^ G3[)K,9W"=1'&2L#8 +A.+X1:0MI3(]"4WQV$ F%A M5DH-\RIM(GSQIJ
MFK 3DUXP:.V &;J6*O@M_OMPZ461"+)%L)1AF>ZNO"X/[;.^@9DFU&#Z;8)B
M[*X^/$N5(<<2/H!D,Q\GJB]>;EAP.,H=-TP?O-7(AG$^XBJYF$Z$I+&M4V,+
M_E4?>ELH]O?#1^FLB#M$ULFZ>ZVX6X55^#!S B86H24'@?NTF!1K=YL/\<;#
MZG'"#D.JRMM7LK^)"U[(1ICOI9 \\N E1C7]M=*32+;A^0#^G@>EH$4+?;Z.
M5"F3G/B+(A47H&+L0>0'-BDI4U&FPU1\:-63<ZC]QSJYR%4UT.^' ,('1P$&
M7:P(V@6$CEU+? C5AC=R2%R9%D2?FY5[ZQ7\SQ4M[L,M8:QGGG'R $*&&KKO
MP6Q@.Q3;K+)'\\0*[?Q90226JS^M;O/V8/3RAZM7<R^(SZ24DPW5?%&EZ)_$
M_K,: &*O,5&@<&AA:(8D!J%3Z Q/W&EY]:85&ZW]=0]FJGT;=D\/-@3#Y@^*
MF-R;S_9Z.+Y4A)]I@ARMIR4^O-CM.:IIW!??Q'\YD2%;M\>064]XS9;]&.CI
M_946>(=DW\_8?AX?A&^UC#_RJP_'IH<,0<(*:V_AW&P()_4'7)R]\K;ZG&$%
M7>>?M55(LN/=OA=MH)@H0 B4(*M#M,&.AXAC8VK<9$((,H+>_@%L3+?U[[L,
MV2:< ST\II<@$&#T-GZHOI^Z?AL+,D!2 (94?0KP;/8/$[0=8.C*8>*;T5H6
M@LI'94[R<4)ZT(:XY+LAB7-C9I8M]]*.S\O]* </BM7;$Y06VW#2/(WUM%VB
MQ("Q$VDSC3ZF2CL-<T7SS@IM7Y+,,A,N9.L6!(Z@YXZ;M731X+@VJ<E.MO/P
M#I0:/*[.0TBQ.K\?:H"X'=%,"(A7%DFI+T <<9*@U!3-I(=_D,:/9)4[V6GS
MOE6.M8QW2(-/-$K8[).H!GT4XZSJ7;RI6?$ 23"'V#HQ78';/SEJ KT8"6(8
MFF^\D7RICSE_O#9.VV"JY;HJ(2[957U6? '\=UTA4/TB\15>LU4I[)8%B';^
M0QZ"*_E2:.\2+%?>-!1?;>:?]<'VJ1B8IN]14I77KAP<U5!_HJ<@@-]!*8 ]
MW8IXRR?;:>BY:&9TF7O1R^;&^*;FBN@];4-5TP'(+TR_:E>(Q$I@#0Z0<A@J
M@=LW6W.5]9;R% T(W"S[\*&LIE)%(TJZ4MHG]%#3\D5<G$?$EBR?M1Y]$\/=
M5V7&SJHZ+BS?E"_'Q+=E1XO91P=<.M8ZD__MDL>+!Z8V%(!IK4$]B0*0.903
MJ25-_X7Z<T1&G%$HV4+ZGOZL]HDJ%T8GL<N\=P/'[3]CA\D[ZN\"S[MP:^)0
M1)VW!HKC$-,8IL%2.^_*A(F*EP&=QUZ+&A1R'N#'OH3=R6>B^S:4'5P6V2;-
MVJ3D2HR;,>%O*3CW?M1RI5R/_0?,C?'#X> SL36!K.TM4/0_8(&1 ZIR.#4.
MO1[I]<AV)_BRY["95Z[SLGAU8KN>S9HWS8GJ&DGU'^&)QZ]U/Y4S@OM,'AI+
MSVD_M/E!K*(W92YBVH%GNOKXH^AW4JN'?1ZL05Q'JCX!,53.>68>^RM0#5#,
M2Y:LD_G[8<81';T2PK&SPZDWB4$K#>]V+G4-:OD<ZB'_.'!,OM/][IKJM^B/
MRZ?=B@L=RM7%\.A/[8J;C=?Z;0=*ZXR7MW9/8#]5U8;J5[4FBAWABW(/IS,<
MNZ4&??,/,!M1@N^,2;* <=RJ[E^!R>?5//3N8\=VS5\?N2*:=NGKQ6%VFJ.J
M-N)<SR;087[EB1-[UY9;QIO\O//>$:'7@AK&]/,>R_H?Z*SS+@E8=SE="?M2
M%MH=;/WJ9WUW_SS1=7#L=(P5:/)(^J1 W>D5TQZ,05P'N,@B^974NW-T=JL8
MZ7#.0R,9N#9@@A];W^G[AM@Q;%S1XS7.Z'AC+C)24$Z7/]!FLRV<4:]<:?5E
M_J/-7-ZUPU^&K=+_OG\?,RG UUAA2$R3=C6I46ZC"XE#=K$L@3'8J1?+"8(]
M":+!4H.,7!Z5!]R>^D&.P7ET\.C')/V\N?)T>TR9(\QNC48T;</VHO--;Y7-
M(\JXM.G2GT-H* X7%N3"SZ%67W$A]**4MB'3O'311^$S[6CZ@VLK&D(OM'S'
M_SZ-0N'65I/1W"[<B'NQNI4#"@^EQ<"L"IV#GL-S,,UKSHKY69G"/[1=Y8+3
M+G[,0__>A<5)LNC#]N<Q:[U@?-2?H5FBA\K'&4D<D_H%#TWZRES8S0SI"C:3
MLZ&^ P;GYET2F+?=N.#QCEHWHH)3DA+UPIIY%,%,#U3-?-[)AB%+<'6]TSV+
M/V)TT!%=+PNF?9X%!46?#,IP/LN%.^^BO__MDPD2387UQUDPEG<_="62>3#!
MGX'"ND>]Y%/1?[:Q)F?YFLXP)!U"X@'L1WK#F$1Y5Q3^4@BZI.RD=.Z:!LC[
M%&'-VPQPV79H<B(&+33[90U4$%2NX9?*EF+2\UH?9H]'ZQ8T.GK?T[6['/Q%
MY7'.5F$F?'3Z]:+D !+K#P<[CU9OCAL2M;VDD'-JM#C,8RY7'FO:7C);JCYH
MQU"#?TP[&\<@4M&WOD1KC(?-NVBO3268O1&6M\UTV#R6^I8TG@JG-CV"'EI$
M'\$7 V@OV.NYB@!01?"UZIH3$F</]6.3#MD$\C*<@*7JJM*6XGK"6CL/2P L
M"!HJBW]RHSD!7&OPJTO/,1'!3UE#%:1828D9K!=Z27*PK#DD<QD.NSC?F>\4
M"^.X=+):T=W"R<-B^'Y4AD1W=/9K89N(UQ-\@X7UO&:QO!;$XK$QK#?<>NQ@
MC)4PDR^7M3:HMKE2_3H'3>4'\>F/J/U7T+:PM%'1"%PVZ<:?'*E'MC667E+N
M-/13\LH9?$M6_ 8%T,E@U7Y3N_+W(P[KY?^$)6_I@Q !Q.LHO<F9OO7=4V6\
M;\-/QDGP>$88P9AY\DX9'=%V=6=%)R ;:@FF>TS*K62@C5J&8P:50,=J>3QK
MQ,,L7UV<$P_9X*8JZA;5B-W@M&2$@@M)5(&5K(/ZT$ 012CP=KL:OC GZ\Q4
MDED:<&YR3>\+53N6'#8>IH/VOQ?\&[C[KS6L-$/6I19 1%I9"L !N4/URTD\
M/8GH-$Z\X@3:=S8960#9&5I  1Z_>TT!/F]@R&54L:;KK]C3[X2%4?]:W7U&
MV"))HKF0727YR EF-,E@_S/"5/(N=111@/TO1! 4-EE_!K2._ G33K\%V5^V
M+NQ_#M1T?&4M#050YZ\@LR>%[1LG!3#/0W9F;7V@ $9X"K!&AKBK@ZE&[#.)
MVN'VBB71)/YIJP#7> 1ZUFP C*>#D,7JJ:U=2/,$ZS:^'XU_W@?>+X\LK0$J
M72P6U,1EH+GO<12@X!9ZIF?W.S('CMRF +)5H/\,:UA'_G\&MO<UT65R<.IV
M;R-_E?=Y8% 7;'P6 OD9\O[!RF$?06O8/"3V5 XUC\ANO*\@[4 >LFZPL@S4
MUD\9[H*)C%O8\<;UHK[!&T95E0^K[IK0?QWA/-CI?B *5X6Z,H(> Z7Z^I"D
M*0!5\^NLO]$=B)4"S(*HH,7W02.<3Y02%&S-WZWZ@+4;[CI.S&JRZF,CBM5T
MW"D /,#3&;+"VE%;0^:A;Z0 ._3SXT2]^3\SS_H7P/'[@#\H=U[_$U*!Q-W&
M-=3^]R$_44V,_&B':GU^8?]2= 13F^<]V@T7DL@&ZWY$^[_BEAYDPP216H1I
M[.T;M)KFG[)D7X7L5MB,]@\RGK30AL:Z(JA^DA&PK^NT?W'9OW&/S__U]VP(
MFB&55U=^M@(0OE(=1 &ZP-38VV!H]*?6=\6NTD#_>EGH2+A-17Q[DM:%6\=U
MF=*-#2<..6%2= BX3UTM[/*83*W9/&RT+@W1/ZV.^\+!9WF%WA\.WC_JN_F6
M-N=-!/";@_&OFU. UGSPLNQJK@/P)D+B[UY9TW%H4?433N9:"=2^?P?&U&(,
MGZOU=<N&NS0/P4@#0\[)KLM!O%F)';>[EJ6:.,&21W3NL YT.%Y =8Q'IPD2
M;,=C239YQ 3)E? $?NY'V:WN9%:"_6; :RS3VW(6-U=II4/>WJP2(L=R6LLL
MT<0E&)ZV&0,^.C&@(&W10 '8 H[IY,Y5*&<,2^TTIUP)KZ/_6JQ;&!(4Q2W.
MR;Q'-QV%B0CHJ.>K(@KLRA)]%9Z4"5J8E/4*W.H_61Z][#Q3E2AWY<FKMDK9
M4@GR+%?J[IF WD00J%#U.O0A-MI4*UV_7U8X=!*F>%LZ:>S")1V!SU./W&FV
M<2 ?ND="V^W',)],QSGJ11"RQ(I=8V)V@[<?=^X;N/>689^"I+_W)/+LI#Z7
MF.2=]--GK;Z957;0L;B;^[1(H@X'#%L+$W/=_-6R&W<_KULIF00YWFYU%'K]
MCF'B1:BK8MN!(#>2]3K-C@X5Q91VUB2($RK$MY=%NEY@/68Q2DQN5(8\*8#5
MSMQP=/'(I3T@T?D5\2+VG3*F#*%*Y,M#7!K8*)#]5,].0#5VAE57!"U+>=D2
M;O7E5"1E'E+L'=9>K3F03\O#RWO0+>UB^NN4[B0BTT1Z4[O.9A)AYJ,LLV7G
M^>2/?E8M99.5 ]HW-G=]%+T);9TBU7QG_$)1;P,4$'ZU1'&"RB<CJ-'W9ORN
M51DZ8L;XZ9FT@9W#5PF%2\/>NA'S-);+@@^-3@[+:4.QD2O#-I.VJ&#/NEOK
M*,9A)P^X5^UUMW?2,5D/E2U4JBIB+E<P2P=??C_FB2I-V,U@QCQ(+]-I H4G
M]9F[-%K1-BK&?2=J&A*<WXU)U;S@ON@%>IG0]?RC)> A1\K8.!"H7M0N1J@L
M7'GIKNV+>BZ^]ZY> M[;E";V :\4AA"$@1[+US M.:I>S(N3L:L,:S]K8:E]
M69^_4">E*?=D1B%H<F5)(!<A1LPEB#?S@T)*?16^UXICV\KC)I<=FRB 0RT;
MK[Y(_?5;[(J8:.UK#%+G,UBKJ5Q-@3@#O@<H$2^IGYH+4,4/A/E/@I@<3?CK
MTU35Y!N&/&O2/^O^.'?@X]O'MH&?@(DCDE5[:0%J\)5)^I@R0R;X< /+VU)E
M)R?OZGQEK_;'AHF'NTJ5#M9K7SQR9 # '\Y@?>VA[? FD+D[22*#5MZ.ZFGM
M?%0WE?LW)E'J!)UPA*E2DV[M66Q+C[0-N15V3;_]&H/8=M.8>0N;X'EG]\%M
MM^Z2C_09TXE)>&AL>)I4?SUH=F<YERX1^I98WC!-;3.X#4N_7RA.FQ23XQZ6
M.,%]\.!5;EYQ>E7[P*7U1O'&83 +47'WT]#\7'CN^+S/*:Y2GP%]6+$GC8B-
MBMP7GH.V/O3GSW^F[T=TMR->9T*3$H/5Z8D^#4G-2\WMY5EW,\=G^5-6$^*T
MY"SD-]TO7#BG4UD\D_!D:_7[0'8D6?SV$,DFO;EES4@?>63^.MRS(<%'NW]Q
M_$?]J[<W5XOCO[")5'R5^NX6KP$RH'+PPT55;Z\BQ\J!V[%P=JOJOM4MS_)5
M(Y1(?MS)R^YT=!?I54UCB$H-BFG"1(LW8^U9H"?F&VDIQZVX=Z_KL@OW=I*?
M!9V)TS45(*3HA+0<T5"/FHZ!_EABG]YMQ=2SX_,3\,3<)55%YR'P40,I[S8W
MP=YARU<:S+WZ MK/"CVB.[:_\!6])6JOM0ZUQ'.::\>^;\Z<,_5#E(^=JE=Z
MUX.5'5-DY/+YFEXE$9>">"^7\/D=?>^Q[J2I>J[YA)WLH*6$\2O!EW<YM_@]
MJ_WSZ$+Y[KR:?*K]G<_@L^[Y8VQ/6;D&>GZC[O,K_(C;7:HL)UISK9N9HUQI
MZR\L T!1*^*()+4,#'V)=]D[N$0!+J")_8A.PO08>7Q2:PU"SSA??]$Y1*.1
M6EG2CJ9[K%@_3-KC.-0(=R+";^4J^8JLEY5MRZTRMT4555K:6JJ=OGZ%I<#%
M7WFY8F072N:W^81>YZ@@35, W$UDXU6X$CG(FP*DC).<ZD7;^0K'-RSH2:N[
MF&TAEYV-EQ2@L]*?6K1.Q9:CL>]4!2C 115DAPM908<DWQJ,G!5WV6ZG "UY
MDY;=2>#^!Z"UMA7(%&AAP(9:]&*WJ*U@G/K03YR \+U"+-1LF8J>4:( _*AP
MJCM0@%L?D)VR=<BG2)19+&DW;%26K+N;K4G<QL:R.5V_?7O>Q-#G[/ Q]PZ"
MB_-'[J@#_GDUNR995"1'*<"$(06P@207Z4@W=3<?J(VO.11M<[#H'APXLHWJ
M865I]6$-\ZS<.&"P,]14<2C&\.51YTY<TC9BX516PJJRL4O2CMJZ^DQHR<XV
MIBP:+H*#W5HJ6!_8F559,D\D$:FI^Q%X+QKDU(>>:0"1&"C HM,>UVKK"*=Z
M?RZR\S&8R$$!OG=O%NB3]_^U]S&=W(+JUOCGC__/_<A' 8:*AS\';?8-G_QP
M_=QG01HU&E6V[7NEI],^=,N\\+:;ECWU2*B*MQ6CH)#TN=R5P?>Y-K74&VL%
M%P &6IQ&!_]]GR)B:O<MF%G$X;>,\.@HDIH']D>Z+B%D=SZIOS;Q7'JI99'Q
M?9::LREOV#X4'I[,(5* 30LBC !NYA$Z3A"*]'V89WE")%XSWWHX]_!KTZD(
MV^L?%R\4^I!Y728Z]YC\PLB<^\]$1(SHMJ+0]\=#TH\J"%AI0O#OQ\<O0KDB
M+?>*)R_(9$0=TEUFU%7% Z %)1-TD^'@ G:KV4"\,0D27JO@XI\-][Z?KE\>
M/7:P_/3K6S>UVU;OT)22:H^<+Y3\&<]U"L"LA+<GA]11_891<-__)6C'RG=-
M(&$DR;=P$X'/I?Z*PU<C5I<M%AZ710DG3&I6ZUD(FL6*;*&H"@@5(,I16^HQ
MJEQ#CE"]^PLGLI&%1/WAM0NU(&X(VW^>& $LKP30$L6-8EN_J$=9(3S?IPF#
MG)[[?Y"R-EYW&26E()+]_084MA8+\*W&722#MU9P6_M>DA[LKF-NPY8'2%E%
MA,&)9ORYQ'LZTX-;8E7CQ+OH8/"Z]#R(:#0/(3W3(9T9_Y2^P[W!2I+PHD:A
MC".939 24".2B_4HBWYCT$U,:9N!@)'N\KMHV]+R.UV7#U0>YGST=2+%W<#/
M-C7%6_&#A4;R\1#N\Y@+#3D?^=0;:F7_(2G5XUD_H@\BSA),(Q!ZV%1&-3DS
M@CP%<.QW-C$#=?I_&V3\=HFEHY41^)('XJYG(6KB$D-TPE1AF85EF04-5E)T
MCB<D3T])TFF;'#LKZ'L0DT(!_B@[,#:4S$QM,BIRD%C-7.2J%N!)/KV72.8C
M]II'WNJOE3V&B;R39+&M=./3L<V<P[IV,4JW7MP4H@V..=M37(;Z/H[E>2+O
M3W\5C8]HA[VY'7VN/6'GA\BNL$BDKX@9K;Z0WK;EA_Q?2I1EA2_@"Y*AUM_?
MQB>?*--A)K5TXH-6>8*%PU1Y[)XE^]MK>5+01R&N&LT6!)_%5OQX*\]0V5@1
MMCG-ROAKY[5J-BL#1H6Z_#<6\/[K'XUB:+8U.LZXGR^T^(?DW*6 >C1VF" >
MKJI9.%]]D#_A]22+C)K #:5K*X+M;\[:1K5<ZP[2&P'423=!3&2 R#,Q.O#:
M!VO NJB$F7UF:6UI9>"ETI+N+GO.WNYP%98&\#-E^1MX_I8QTZQ8& @8P&5_
MDD?F'[R5O@XF#U.80.,;D73(68L^,/YU'WK[1.Q/@M40VBCM+L4$_6.:?CC0
MJ]UKS?3_*:W[[Y2";:G--OWF^#,*P $NWHOL&$/VNXQ7\+6.S9QOAU>0SJQ\
MRGB+;%#*N;-& 4X>R=R_-_TGN@/5C U#R:#XQFKUT &^7OD7P_:L5%>J%KK\
MU']QBKQL:JVWD);!G^9RP*%DV,%((?'+ZT#Y33->><D?O%>6Z45XO^?2"^,-
MA4WC_D;H^B.C?FG9^,Y&O\X0S_0CUG-N(W/\^D-M-@=CFCYN-E]E+D@=M I.
M63UWY**"T_C''6GT8WM\P_<\A\2C[0<'BE647A8GG%N^Y\/>_#T^Y4<XZL0_
M&D&W]"7E>Q<GRB-]7AR$\OO&6)7G +;A7\X+&HI5;JNS$.\TWR_?Q%1[#&G
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MB;I< ,NZ0SM(K<B/@4A:OA4_ Y+_(ZY_@<R:@P7/]"'Q7&2=_Q22Y?U=V"@
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M_RG,_TRK<OD=61+_<P7Q7V 1!L?XXO0CPU',]NY2S9=R-X8R#OBW6Z/2ERC
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M?/(FDFL=P@$/L-(VN.A)A'6\RKE,6\O8?3JHAN&KHMF1D33?+21O0+<?3V#
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MVXVQL@EKVBHB4L=HI$\P/7TZ,)NTL8XU\!,B NG)!D3@TQ(,F[N?@>SYNNF
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MY82LD:SY*0,,<P=VE]2_NSOAJ4BK$Y8&8OESOCX&>_^0"%1+$<C52$9]^R#
MYF 4CN;1) @]^7=! /["X+\# U4?BS]6UKNVMU%!XC'X8=TCF:=I6[A>@8QZ
M=.-NU/B+2JKEK[&E,93-1Z)5&[A53W/7T@G?>G[XP"G]?]Q>RWGPS\U_@7]<
M^/V_^V7>6&WY!(\PI_%10\UB-8JP1J*TV!ZM1#T+)-L"JY'$;$=H9D#',6OR
M)Y_-V4Z[+<@CD)JLT&RUP;FR/CRE9^%H;H[QHINP@6X;.Z]5%-M=3&L^'&O
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M95COV75_RE;*LJDUBNTYR+;S59CA,-4='[_N$'OE;E+17A=)3^2H H1,532
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M&WJ\:)+&7#D]/0*DBY9ZV,T$Q4P:2KPE+K7(SQ:Z4ES@N>L1S],SO,HIF,-
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M-ATNC;"@F6_Q4)'9H[P0H+0BW(7)O9UB]^W-J'[0IK%3#^*AI8&NZ7@_/N7
M8/D9/GKZ%9&AU\N\@<DB/CN#NC+6KI%?9#@2]#R)]EO&$?H+NMY^NZN&.0O[
MX:6\R+#*;HA>K_?;ZCS3R/JZD[0AB^&/^MGFO?O:&/1Q(Q\F3RTK2J(+1T'L
M7YU5I;'IWU+*(,[/RBY[;QR)CPPW- :.+ [.O6?PV-$<L<%1H?QSVZ<:+GOM
M$4=EA^MR.U3:TI1BNG=@TYYB)GD!ULH'^<HWS*NW<_?2[SABQ_T\LPS;E MT
MM$11$P[?5CD.N^^OU+DOO/&3*#[06TPFRE=@/S^=;K!NE??!V#86.TH\C^P0
MNXBH]V%^)[*AO</KG(9WP;US"&(?B3%JE,"U99(S?L.UE_2WQ=RO%85I\]T]
M<_:)?<@W+V4_+U5J_)G *50LS0RTY$':E8CF7@?FR[2^!GOQ'XL@78;'\ZYD
M')E5$?VT!K99YZAZM2"KPD@$XZ\C*T?Z7#$>]_SIEX(Y7%[+;6&@32!YLWQ_
M6'1)KBK?*=49+*%#(T]NU*5ZW=*S^NK*\'Y%L3.,&^5@#F<.H,'9DH (<T,L
M_&F%N%%_\_Z$EF'&>*KA1\88PZ3G&9>WD7DN'0[\ M^2*!'-C=HUA\_J33(8
M\*'3!^0(RS ZBH_::"8.*YGD5(=_G0[LUV1E>$(1MG3SHEOJ_@2[,*WP4L$1
M0J$37U_5DD3T)@S+Q*-*_)0;D:,ED9!P.VVS(O/Z2&.5P;RVW*K]TJ0&F_$]
MW#URQ7+DKQ\(.( ./S #8KV,ZSQHX;,KIPXE&.:9..YX<^"RVX:/ZP^? YWW
M47C H2 0Y[S O8=$P\I[X$$L^)$V52'L;DL.N=IW-1_)Q4ED3><1I'E;6S^O
M<%;'V:4IO3QQ^C3C33<U7GI$%2AX4A.;G&/K4NCD!DU4:\")26&:3OJ;*YE4
M=PZ$GJ;]^NGN4?=9ONW/CK#JW-#*]P]<BI1Y9KN*M6X/I!CV/^#OW93(?Z#5
M(P"J;[K3-/;ICMM&\L>>C*!/X'++G9Q<@O50I;B\"38\?>;:>CUXV@4,J:+Q
MRG%,K$B\=D.I\=; S6N68Y'[FU;H*?!7'^()!'> Y(]CEP0.[ EG5)EAM(>(
M%7_5KW5=A\35>?NQ@QH5OUY*3A)0-8_."Y"?.C36LS0V1[3*E5N9.'K+X8K[
MT:S/DW)8/D:F65R<JM*FE'!NP$ZV(X]!LZ8("-:B;9>,$^'#SH71^5GGL<=U
M:/0'\KQL;4?'XJ3CK1C(M2$Y%H5J8*M#3P\03&TFSF''Y(>M;PT%J# <IH\W
M='?IE:[:NE/P@SNGRT=*6_WY7AXH.?02>T90M%XZB]NZ2K?*,H9W;YF<K4HP
M?I[LR,Y_*U+]5!X%A<-G7P&*-B_8*+4A#M:*#*L%1WBB6*#@RR/%7LYUY3.\
MS&?]1Z$KGZH&1I.MGW%QC"8)B=;<C?J"Y5Q-?^V(8B""2G[,'# \0+MH0;>H
M2Q"1A68?,,ON9K70/MI5Z;ZD=JVKM,W-J +QE;/5 (K\4-OSE"BJ.V.##<R9
M0^2:53UE+]MCQ:0%E&IU7:-J-L%Z'PE.<*:^<Q@\>0L/F>KY\<61HZVR(E6\
M1+Q ;4IX\1J:.NG;@6[C/(OY9_FI"_$IWZD?.IQ<!#&C'DA2!,@/%V^E1;O8
M&PV:WX";OJ\>6+VCDI054_BIK-Y&"B"NV.(/*D'1X <0*JBK3ME0406<!8]0
MK^GG'\D>JK"4#RRN3/SVE$_[Y)&[1\ZQ>L2<"K;(C47=.W"Q-QW8AC'A"\3!
MMW6/CJ!'1A2)$:[%LI^,EJN4PC8C-]: SQ8V?!<O%:WS!7U(MKHXR#C)"5]Y
MKZS"^-BETI*#;E$\H.*N4,5]0Y?TK]4*5[_-\T _\#?@0*M/IQIX6I@7N1^F
MS(#8.VMM2TH])$+OEA<7%W>NA6L:>?F(H>2^#'UA?).)#SMP"E#!>\Q8:FG5
MPTU0+H(3/,5F2VU]-\P\W?,\-]5KW[MD2]TQLJ5^IFA,,ROYY<IR6P9O;T7:
M),\7B^*X4,=,;0__:7_?M=,G!)M4GH\.Z]B?9BP^3?U,5+T-\JZAJG0F5L>P
M-\"<[WEM=TYZ20&F*M2YT%+)O.4,ZVB/_(7.A2PW]-&@!W:/51 SKFW=%-,^
MZ".XHSM*W<9H\$*_[.?DZ#,F0K9W7H7;'GZ9R([_S/C(.1EGO&HZ#:/'E[>H
M\D9HX#@C7;<NWT_D9?Q@D9UHF0^]9\1X892M3GI5@]*V3*UDLQ7$X EG)T@.
M!E![IU4X=PM7)-._3HII_Q[^ ;!YI"GU$?FJ@@1\X=,!/QDF<B':-Y;,=@D"
MS,N[M97$Y')S)[M+5Z7,Q\U>NHE=CZHQ.-1TH.A-V>G"2A+.>#C#;9&".7SD
M%/3X)('_;(MJP7YR[\SX?2.1EOSQ&M4QG[QOA^4!/$P1JR40=9P!-&K6,) #
M=%PN0;-DURGM*Z5&51*M#^=D->]R6"\)N)N$G4#DQ4JW"]T<2FQYAT=>;2SM
MNQ>N<A%W=\-6[[1<>]@(11>/]V,%Y<1!)U19[M/*+A<F<Q2^O, JX%J?K&.E
M);CEMB-.MOA=\AFVY'S[.H?'>:=</_MV T*1,,=H)N;+V/8[?5Z\L&:<4]!%
M".,2M\9:),+1M[YZW/E24E.81V7]Q]V=-B=8! FH9@IN/+,TP5%1W:>LGV,*
M35[35=(=EE61T;(6G^'HKGFNT$6(X#KFT>9^G$.6Z6N$*8XJ;4IJ!A2)B8C<
MAC-"2P,,W?(F,1(2UXP@Y1K<[TY<I7A$M>(Q(OMRNN?+,I&9O J!:>I%?VS#
MAJ%^3+@5H+V#?.=R\- V0T_(]>4!:AL_GGS0H/":09QS9PKO7 )M[KD:KGM=
M2715O\)9Q<^!^8&$!)I]8W!]$Q"CC;"AU5,W0]&3 &<FN@ 3'/M;1.9"AH"B
MUU8YVAJIDQMZS[V/Y92KEEV,[4WZ@N Z8X:IR2]V74U\%P;FW^%DRZ!Z>D,(
MX^I^<ACFJR#VCGWN%V/*.V'C8)AVVH7A,=6:"(R"V&K=C.*4@7"/0ZLF5BNB
MZZ)KTO1Z[PX@UV,*T+:KGP1H^GRV-D8$Z'NI!RK^P6/_=Z'H=C/)QRMWZX;7
M;*NJ4_6$N7E,2V@>L,9HQF@!&YJBB>22)Q9+?7@,"<;J^I. -N?^A6[ -Y<@
MX_H8O"!.+F%"G->)TEH_MR>)TE;//['K2&%>VR1 V6^V6PQ4:GJ5#XH__$I.
M9],M\K8O*=^BIB"OX#Q33/MT5K"IU ,2$-/W<\<NN6,DZ_"MY#F[S=L==X\G
M/L)<7NQIU)J_*7WV4^E)MNN=)H)!]ZDNNBU^)"Q0=*.FLP*.D+-UYQX"JQ4)
MP*5"\ [K *S7C,R'<F228-<@FEHL1\[03QGH^%!JBSZ(S3 \,MK+XBMS9!Z%
M[6L$?NR#/T^D0:+PW2!LW\3/;;]S<YDNN6T"M>^C,'(NF6^?G1;8.JFR4#<H
M7L1O*E%RORKVA4A%/R5EQF,6OU[J=!* UL13$$-&$'C!!A(P*P/[;5MVT3=+
MYL@<XF>IL%^D_J;M9^7P>YPG_P[.*:G2:GR6/KB#Z=:O1V>(<P81L1CQ1?Z%
M@%0D":!#3\,)AV,DX-\ 'K&>F7S*+13*QGM]0]0MO2[GV=FUY>"Q5][ K/+,
M>QC>H8<*UGN_ATA$D0!FRSO8FJC2N5S=RF]IEPIFW[WP=3<LY&K\K UN34)-
M0P.D2 "B#D%@A<!PJ>#?M<O)GCPYU;-/;TH")D?^4CC'8.T/J<1(P/KRCW.G
M<P>E8)MS$#P=">"77+6@/J14)P$4\+W_ MYL@>KD!$7UQX[.J VF?_'^%^__
M[;PO_"/>PGW$/C[&9 V-83%UJ0_C2N<)VC=H5;.BR30&). #9(]ZYRTYO)PA
M <%:A$X8MDZ5<[4'\U!J@*A630Y\B41.U^;UO?T:$M D3HZ&)Y%:54,E2/'9
MC(E.A:EX]>SX<5%1X87+%/$&@=6WR 'H$9EI& F@G1G<2M2UY',DAY'J:1_"
MH05L*ODO8?JW'2,YA[\A5!W-@_5>@DU=^>6AX5R"Q&38Y.:V&SEBF?^R4ORV
M;96R,ZY.#$:3@*.<A/,'#\F)MMHTV18Z(MN/(%D7Q GK&6HGTKC^$IE_T_2#
MC'HQ[5,S$8Y#L%FKM1&'%!%$RA]/.:?"FE?QEB0 ; S"GVO\)0;_KD-V$>8R
M"%XX!<:>@37#JY9 6XP@_(D?CY_^R][_$GLW_QE[/Y@3>Q&,13/,37GCZESS
M#_S$%T#[@@UR"APF0X/?3:A.68<:%FV?\9"^+.!N;I$W=B_QI.C2\2EXCGGV
MD=_^M!CWMY\6M?][?EKT;8^J!+,[P5C/8H<CBLP6DJTU7#36!,HX+YY\<L"L
M)D;5+%V'HN#ZK)4U!%[Q!Z_"5R'E0COP^!U(A?7\1O7#KUOCW0#T*O$2+B@3
M.Z^&HRJ%W3N7$KTB<29%N[)"I$IC14*"W^&[D$?\MU47=/H>5[OR_),'L_5@
M^JT#UZ.C>#XB@[@79/6M7.<N5LN)Q1Q*"-$IW\LSM>&GV[R;-+M0A=4,$X3G
M.HKGC*;+W^1Q$:\B/(,+SS23@%$%WJ 8)]-ZH6P]YQQS[=PKO8L:NE$N) #N
MSN\0/JD7_S+H212PYW^S!C'=\P%%B[?:T4Q$8\8SHCU>C]]HK7_ZJ:I'-IH<
MPH*U.6 1?K NV<_5T?5NW 3]!GR(S+B328!\@5:6AC]CNNA7$F G++7$:$OA
M<-3Q9 <)R!5 9JX16#,A^* N]??]+O;]8KIUYJ8=?-^>?.CL3:+.O!)U>37X
MMCD>HEV!W730=\0*QO4I,]B62U6XIB]I!8ZF*2PGWJ O[#9:;^%,,>/JEST\
M2R,OLIR\_J#T<7VX^IPTX<N'3X%[K5!YM"7WP(&\EJ5>\WS[\.HTOGBUV,-%
MIDIWIS"3O^/4YSHCU\3=PL'FRVW' I7L[3D0CL>*ZX/NG#C;RDT_;:@)$,+<
M]^'-D.-.P]YR(U:@R@0> 8?7AL>N:W:_S_IX^KE00N[I_5O4(5"1'@CN"EY5
M<B60M<VO.#?\NVDQ05M)_-4%GGSKZHR3RN]-)S0B17E?O1$6DPY?J!?-P4/T
ML*H1L)+%?FBN6;A2.E47VKV)MUE\T,=@#V?.__!6E!J\6[SR?MA%X]0=2X_I
M^0AE;=X$)VZ->M1]=?9R37I=>AM W_3XF6L4WZE/,5XJ:E"?0H5L*ZP(IJB%
M"XN)!Z&=ALNT7;^KF;O%!E19T;D'Z@(6>,ATVCH5GD*CK_+DL'^7B7=CNT3\
M]^CC\?!S_)1G$SN.B^87F,G%.DX?2C"H-@N&]P-&,H[<5XX(',X)9&@O.:V>
M_NL9<:JG#M\D'P:=L=N$/7-)7#FH]=D$=C?EY[%(222Y9F0+4.D+L*H9+'I3
MPU/-GGS.2XCK\_&IV9KV!@\8MH?(0 XCXG#BT9R@X."9ZUP!RN<'WZZSNX@%
MZ:8^>BAT,B;_:8ZIV</]B:5#&;UO <(:@>0%D%Q&34WN'_U"_B.B_]NFL<_^
M$#DB(=P)X$\;)&#PABOA,&*6J-7\W'C\-^) OVDL&W$2 [NP_W;TJ11J<P<$
MWP/1ZD.\R*D[&"]/?%P%QM,^A_W\?[$)9&]7$DU 'UYM(P$]7X+ _X1Z^L3*
M>[#Y,133)M,V*P\Y&M_#DX!X; [[+H0@30)"80MTUN0$(5_KMZU?;0+_7[)(
M$?S8BC%.PZNOR$?X8_<;4&_?[X5E_A 6<2!<\AI%>__ ]<5I>?<TL#012FA0
MJ79M]6>W4\\>PS3'JP?U:7"'7=6!-N?Q L C$;V5@\E]&G+T"2)K0TO8Y(0L
M&\Z;#<_YE.[O4-!MBXDKR\O+G[U.#-L7B=@)7#^D_$8"4%*_;(N]B]IB3202
MVHGL'WU2%@I^ZF"#V4^0@-Z;>@>;(/RM8_^ E.U(4%3F(8)<.U]6 *]_@DUK
M_>9. /(F[V=>^C_?JL;YOTTHA9=8(.H&';'N\WT5[P=***8Z_$R%4TY&:E69
M<K= "B>]W,L<_DM;P"/J=X6>OQPT,F5$ DKUT$;53Z/QA>?(17H\4G^+!)1L
M"Q&DP&B]=7PAV2L_3O& CQ3@1UOZH=+3$]5(]-%QG9S%1*OLBU*&S]J9[V;'
M/9ZIY]<^S*^W?8OW0?.)X5R#Q8H"V)%Z],Q+9@]SYW6H4Z]I0E]>;J=&.;5Y
M9>EBM-X'=Y2^C!4R9TS4WE@^_W8<:9.F6^>II4$>TGK8@0.B" EH+C?XMP-V
M6 DR1!(0A<(6#:+PAW[?47$$!:^<I=I7BM^?8+R3!)Y-CI]K?K%J)95BRG/)
MH*%IT<H-M'HFZS+.^0YV+LL_>Y%XLKI/?-L_T,]YZ$Z-],6P6WJ=EQF>79XK
M,.3GL5SSN+<Q9B>4;O!V\FS=P,"Z7['\1=3T4R(W#-8*P1LY00A!</Q]6#AB
M$F=,9$_]<0IB2=J,4%LX%O&T\=0B1J4RH])^9KG#)1EK08@LB.I<N'/B0Z)Q
M$(A@5CW4R/D5CVQ-V6>,Y-/F3S77O:E0-%@4\YJF/.21PLE+"CFK6=U=L.5]
MNX3.4C<TFF5ZK>.KCU^'2R/6V;7[E/WO?=#W!W2V5[F9(BN0[(ZE2XIR6<X%
M7ZY=TTE32#;IX-7\+F!7X7QGO4#YO>:=;[.R=G J<ATDA'<\) 'LL&G3?!AN
M'_Q;,QOFHFSX&/[< _[=Y($SB6TA%T-@U R2("HK^>,\IM\/F/H^M?]B;G1_
MY(;Z':'5)N2H"7%D0AH+;X''[G-&(;_Q<0?JF/03A)#*;F$#E3S^'@+>,5=F
M&8O"Z.;%LCT2'S.]_A-W(SFP]JOW?*<"J;5P6E';H!/XY#FF)SM\0JB!++D^
MC)[H>+;D14+FDV\=/5<QBO;L*XT\AR7BLB#6="9++&=4@+B/;U9/R4*^+^5M
M[<+1*\'C]Z^E1W6',"5_N:0\\UC@S]Q27S?#N5HS<18/P0FB-09<":RSEN#F
M%+[3_?,)&YV[S%DB+!,W$H[G&'E],J"/&<DF,!WF0MHR3F-'0@@ZTRX^:+^=
M_&G\=J B"3 ZL>=7X1 I&'_UX0V7Y/'*QY<4/BRJ<8#_L?V%JLJ'A9Z2X?N[
M+0VBEOVN+O98NVBJVMB&XT,NW\^Q75YHMKCJ V.EG0O0.7!US* 9?E <H#&5
M[JQ9YE,6OK&Q-#?$1_/P"OO&*D9?!I?Y3%2;FYWRE-UC>=@_%INWC<1,8$;:
M4M<2W^ I6H-$>PE*^8+QQ=!0K2KM>Q6UE\:B&=?E;J6%;T1Y'PQX,6&6^@*L
MBQ9K)1\'&,_ F1S,WBQ@4$]ETFR2><S?J-F:^/B6%3SD^<JVNON:YL\F.#O,
M:1D6874:MY7BW2B"\W6-E,+?'+A!]27-,>/+Q9P\'H^3HGV?W<?]4B?J#VL#
MQ%_C)2%#REK3J^;HB3-]7C4!*A[3A1WB!!)0V9EA8Y+V:>.)+874LW> \,Y'
MJOE_8EZCL!0[S["[J\=<D>W93>?B\E_WG.(.2[-H\HR>$W:84)CRB;MZER?I
M(>TS-:39:Z9_9FX#6-??F9E%Y$),Y^X2#,FKCEW.CX/8)AS^Q>L_RHN:S$L8
M[UP12Q1I(@'Y/X[9GAU$_"$N66A%-9Z=6&@4CT:GZH675!YJ;,T-]B2YG9(J
MTCD=DV\/#DB0BR-L (*/E7=_+V?A#^IB4F9C,.WA9P97/1G4K_=7=O%$],DZ
MI\ ]/E7UW\BP41#G^_[TJ_9G[PTJ32B",N#J@0%4#.\SPY$U*^ZT/R%<F2[A
M$SYS21PSGFH>+LSRPOL:IZ-XN) =(Q08^S-HRI6E<,XM?02>BO*12GIHOY*X
MT*WHVW'G+N>;CND]?&MKX<+8:*UQ-AA]+YRBV)/O+#X+9HV+$KX_-!W=K&B[
MBHJHI#O:-V=>ET,OU+$7D;SNR$<-:DP!>]X]FO)/3(RE:J+TN]J:VGX9%6?U
M6IRR[YV!$LF41[;?0]^PS%* T:V^L+#U>HT9I@@Y/D&<<>R:LD+VJ&.(]L,*
M-$O'N9'T\_'9FV<?Y!T]=U5_D^4KY=0M2LB?K3W#KI'U7CC% ?2^9TI>LO&N
M%?W@NL&H;G#&-C)+QS*F-^F,Y8V8*Q*^]X_/U,$C]I^G0J*M!V1-ZR''QK<+
M.VPYGPI6)?.$7<GI]!58C5<_:HA]=/-(TP=JZ?^1E=8'5!J!/G[9-Q>GK):!
MG!G7T"+""T@ MAU%0P(6SLQ($L2\F,CCU1?7-4L="6I+,0M"!$JD'ROI-6.-
MN*_V@&H)H*1GS!4X\!TAB*USPGJ[\LG%A[KQR+T:5^;(+.[/CAZBH[<W5URY
M[UV /IT>4M!)^MH@;XZX"D/S$83(]41$) I;.@C^<?KB[V1"E,BJ?\;Y'-+7
M(HB4LB!L>;TE"5"7R"4!P0R6D*42?F(0LF6&!$ N(#;G(,%;9"36FV'[QZ'1
M)(".5_TO \8?BR"&\)W]\:;@K1\C9A/ULZ(_CLU0:IW<NK@$PY\8A!74P/?V
M42?^&WBZ_I%GVF]X3F% ;7 N!\7G\M'%%A-%#^A&)^33V*+'KZDV9L5#O!9\
MY# 3T;E+PBZG''U<>3]<R1(YJ6Z]C:2[V.EL^ZHD2U>G=&M/ A;Q^?W0^9J:
M'UMP\/'\4?.M'VX0_-D-Y-KBZUT2\&,/D<FC\#)R"%,FEV*-QZ 1 QE'_AT&
M0O\, P!*_4]AN4X";$.)/S:N"*!5[:(FX.!$/'F@_F%X_-$S(ZC#9*:]6= A
M]OR!&&BS#7PP=8OZ\9\/-"L2L&,"GH^![7[(6GD'^[&?S'JP&M]_TEHF KFO
M.;"&V(OCD$;LG9+\<<2HT/]RI?\WN0CU?\G8_^]=*P,NA3<OYPCR(%@[J2&2
MK9AHZXV,AC4NHPFNF1LKL5=B6Q(?2XTTW!K<^D*(J*G6"-E@ESR5!RQ^'EC*
MS:1"FM^0*'[S@I[FQ"60?JJ:M@;;+6HF7- P65X(\4)E98A.VLL*T;R9<#:)
MM3:J(X9: HE?C",#N Y?SN/DT>M'QO$]+<0S=0-%UN'[8)KQ@B975Q&;@HNK
MC%?V^7QWD;G]T-4B%E/+^T_/TO<K'+ESI$-@B_U<0XOQ,X'>CXGJI\<2-)N2
M(O+X\XJ$-&4%<_@7'OD.BQX)2>9A6)NP&,-8^A>;6CHV+GW"5\WHL4"9FA#<
M02#M*1BSDU\&*M^)$Q.X&AN?\/F:D/[F2T7Z\Y_[$O2XNNWPQEI\[/C8;&<K
M$;Q;$3Y+LQHK^-+.2/Q,25"/V_?SI]O0R=//9I/&/XNN18DBENK\1WU!ZGP2
M3JSPH9%U5<$<@5$GX<K1:T1)KTSL#QAX\$@TEG#"_)#I5F68\NU\)SK;[TKI
M%_LUU%FNJRDI2LWS!CI+-P51C'C"(F#'O1H\FO;?UDUW4]\9 AGU:B0J+]G$
MU[_LK@,L&!O Z8%?=PY<JP+AJ\R!2/N7WUSY[,9FO2=J>OPDD,5%&/::FBBJ
MEX2:)R5L=3 OC\$#6LB=V&IB!0G@-W6+$_2['E7G4B=7$32\LY1>4*<TL:CB
MI9RUXU]9[H4SRL_!'YW_8&:5&70N1*F#6T'R$:.=7,O],4\N7ACM]M+YDDZW
M;W!A[)>QVVWWSUD--]2^?Y PH5M=O2=007O^3<6E*W]Y=>5OGWHFH\.X>N$9
MR6,!^MC/Y?X>>5_QRQ9I+4RB;=&"Z>Y+P=RL\*GSQX5*KBES;Z%8S B7$XV2
M*AATT'(8*\XNN,' FN"K4P%?;=+OQ&SM.4NOP#A0"])3* (;>;G?T 4"<+CR
M'<F:@2!ZY_QIG@;UEL:S57B8ZU0TKU3">>)@O&4K^)7),XKTB)C@J)4MU)?:
M'JO*A/FV"3F<UE.D ':LD>^=3L>]IQ7^OK-T%V*S+C?>8*B;% @.3=W6*R68
MD2=/3P@YX='W(0$=,H'PF9%#J@!.LCNC443MUTR,,+Q0"5SV%4Y[-OUV=PUV
M:"3,SD&F2]336=M[1>GL4\VM\XR;R?<59%<X2$ Y$>&*$YI>C]%$>HZH,O:^
M[7U=*?6VZWD\\XTXOW ^DRFW;H?#WTK(^KVU[@A>L"V(D0#%S3]1UBM8,JX-
MJ&45L<!@PC:V=;PR%(8G C;?:7,]5-%U@YT WT4PX0]:^"X.\K3N-R*HGR)'
MC%,GE'2T;4*VO5<\:Z QC69)E.HUDGROC)%_)MEWA024T2(C*T57Y6?THF7$
M)2WJ(VZ/;*6+.!3/#B)/G/=]$I5AP^>H9FE]E_'F!2DC6=!7OJ_UUD5+9D)P
M@N$TC,D9\V99$14AD_8\BJ?P]9URL=& +TD[L4LQ\O[&7CO@:,C622R$2"M!
M O8$X7_ _L.4!,JZ@6^Y9<2L \?WNFP,NC/9_O8,O?]5G-8[\_F#)QX9%>ML
M06U$7IQ=Z6RZT;+E8/&V)+-SLNK9RMJJ:Z&+QLG/]O0KS)]'4-J[UYS^%K4>
MU(YS)H:JTI& )HU)$B#0]SL=GM%A8=,\!/&J88%ZG&K^3#?$J,8\NO!0P_JI
MYA FGTU*I)WE2 :;N[9@ V/]^N_P EGC*TG 9<0Q<LKWAKQ()#A0])U'*AV
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M]K@6FQ,S\U6H(07 A.BO6?\SKR/E.>$MLZG0IU:CG@2XLV3G(U^SA&;UE+1
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M!)@'"3@*F0-9SL#V_7]Y?TN1K*"3*SEZ_PT<?1+ H#N#V-NN( &H<K+=G=_
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M24#M#\VS_8H\Z-?^05CS93)&/8/@%#*$]3._(I=%1NZG2_#_-^K_ZDKX;ZZ
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MYP(V&3A+^0GJF]HS\6G1UU?&WT0)L_QJA)7YP4W\K@G>&JO5HBK0*Y%5-O0
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MS$PD4WA;XJ?UOQ_5OH!:FAV[!NR2)3RO ^D:(<))P#<%>R()V)*=@=$&G8=
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M#(C (-4 T]>HJ+BA]Q\_EMS +#9NAL-/*E^R S,VL!C8IO%I/>EVJ-"BT_U
M+S>31RW"0':TK?#DDY.>/*-#.[J?]2OC)[&?1O=<1MU\A5"++1)1XSFOD=V:
M+<EWC+ZY7^L^F4CU:LSR277''485((V<X8GG-D<O&_1.!?[%K@0-1PG%I.?)
MGM9U/LREAKR22\,UB"Y'1N,J1XM@CCAULX:* S$W>]K=PI'1\^W.CE*L\R'W
M:&*RS/,I X^OFYU#O%=KM!H!EX<&K..^$JR?/;:6^];C/.\X$?OHP>O#1/:N
M]33%/$^(!H8%=SKQZN!NRJJI^-ZTVL6<-$<!@['L"'VWXR<Z)XNJ8K\MB621
M6GL85NW6!_1#!$8($K=1,<ULZF <KO9Y!(WS)P(?X1XSD6;]&.D]'S1+VW%7
M&^B=],@E&5?/M0>!*$W78 /A<T<?9;)>9UV/$:GL<^4"-QV(Q<1EC:O=SS%H
M>F=L?/5\7$84<!9RU>J>@D)QX19X@AS)784IF"G:#,5=/!.O'[-!W?$F^0KK
MJS-GGDG.<$KR*3F;R<_2A8#9_,[!FE+K,)1!CUQK>ZGLO6IC>@B"N@_A5A.2
MGT-%H=7*]WJ_+G>4E"UES*D61)2J]8+*A9H<&;&KLXN-)0Q+R793-@0NQ/:N
M2)"2[5SN:PYK^_-B3? :NAM;M#I[]S".S:1X>>M+ATQ\ZB>"A1E5V]>RC%JI
M%\N,/'QP:Y/OG+PKY>LW:!>(B^[U=O:!B/<8H5BP%83;A/"9K]D]63G8999C
MW8]6>Z7]2N!4T]3QVQ?HQ3?C+*TFI73 <A27N[T=UVW1.FT@Y@8FK+XF>C3>
MS3EK4L79-V/2Q$MR^EP;RWUHP%8J6OVP)>B9R-**\ <?6U/E]L8J4%E)*S4L
MK($20P1"_9BP.DT2F69O'&F7]=]OG#LNZ)4U21[_'+BM/K%I,%TVE8\QOH(-
MQB0?(HO#LSP3*$870O:UAS:40O6W<R4_11E> 1X?TUCD1:B0-5)\F 9PO.B2
M9BX52#UZ(75$_N+NZ(0LI7VXP+95%]='::ZZ6J?S%W(_0ZIJ[-2_I31#WCN&
MX530'B@!1)2;HC&,&_N)<.E6G1"4N;1MG5?D_&IU%G2]AXRU1^35(.PA(NR@
MM3@26>UW"GH!76M4[CR-K4\/Q!0_T UL(H<GA5ZBT-GW*JFSR?ZL4Q6WE=A"
M\CLB< I'=WC9%GZZ@<76R#J,?EER6=](:V?U$=-M25:^EQPWWIXJ1^OGG(,W
MT@4@3C]JD(9J8^1C1=<<Z"+*;<5:UX.;.H]TB_=^?;OH=TIU,JZG)U=VMYO1
MQ&Q<KR+VJ1((K3+K&$H$K#<YH'QUZ) 4P21GFK(O=K?L)-G$Q6E;Q,H2@;-W
MW;O(!IF&5N%ED!8QB6881=U]I'!A)C9HYK6X(D<]]X';5J[NAY<,Y.7PUT-;
M9+2-'27O\S)?^8V;QKYNX%J"<>.L9KN( #UVXDX%6C L0<IXS-/C9H)BN?PQ
MJJP!WYFK"5\#)U_J1NF'>';M66/AJ&[0K3Y9\%/"\8;1#6M%):]<T_;[%9H;
M4PZS$_%1L=73Z4JCTR]TG<_UB"]S3C=#J+]Z@I";(;A+OG[CV0N)]VFS1J-3
M/W>\85Y,];9.)3,58+S[JLK#*2-"F%[W.B/P/WR1M:T0 :IR7Q?4XZ19GX%]
ME@._)+F73*EYL8\MGE\Y\X1-8XIJAMXYT%86'NS]L&*V%WMCOJ8FXO"0 D87
MQG>.E_[&X1@F:I,R5Z'=;FTI1U]:05,BZ.!>;*,NNEM"@D.57<5FVNX!W&8K
MB8JYYVOM.U_)=5-(J*L!5!Z)EU"O\DB@51X149^Z^=@J^L@1YS8G1;U@QA.=
M]4T1PED\)!6![Z]B'51NLR\8-1W@!J):26212Y#O/JTAEJ[+LS5O2"%_Y((P
MV6RZ[(CN3=ORC1C%=@2U# SDZ=VE"O=+M+7/'U\IP*>&<R^;/U-_$YUE_HQL
M5F'CG ,+LCLA:-:1%9LQOK5ZJ-*"^F*2R31&%LC'SHKM<7KR1$=VN/_RM]>%
MGNU-1& LF2[8["S<>!#G@8J^JMD54C,DMDM9Z89XEL^6U')5M>T)Q0S9D?JT
M".$3&IU?@QEUU9_]0W;I1A*^KHX4V-Q6/YZJ:8\\STA=TQL>-=<L''FB+29.
M45$5LR@]?Z+E[GJ':USI[?:>6Y^CDG3A4FS>BJ;#6\]4S[>&3)E35;QW$[L@
MB=QF%N1QJ:>['^&N8=4<9[M];HX6U:D4D;JB053"N)C:M=>GDMG.F\GKZ^FQ
ML5&R4:87;T50+2;L7T"$@NEV2H*G: =QLAGAB+*U( >?<*5.2X\'&QM?QY+"
MP4;+PAF!Q@Y_"'_EGIN#^*#)P*;,UZM?Q=<<S_AXS3RSLHP.T+NS=D76+@+
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MQRO!3^TB )<!S?HCIRO S*'>2\V6>W;=,0H73]GFK2^T+$08B:2N\Y)<+=8
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MNTZ(F];ME3W4B+[>X<F$8G;%TQ5AM")Q6V?/\-FR*%'M_)HS?C'PV8 !?T:
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M[F;+_ ?EE;\(_R+\7TQ84$.:$B+5(G8Z=KEX#%>8;SN5J;BK=ZP<'WNFEKZ
M4"P56=[\,C*HJPEC,"FM69:2.<OF6#-(.Q&!)[L%H]J2-@FE"VSZ5'^VML#1
MX?'Z&.C*,XR9A%2[&K51JH/(*L>RE>_CJ==TZ7[]^;#>*!"6-$E\T=V+UB1
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M_MVW1& ;@U]3S@PA-0"Z)%'TO]&3LFP<.A%_1)0(H$_2??\?Y[8R XGZ.IQ
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MC6C4!!<O1Y%]Z[ARR$%5HF.NEIN5=;7QVL*&.II/@]7\B<(BCXO!U!%\D9@
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M#&RM-BPJB"FO":A#DV-/"%Q\T/8@M#MI-C7@S.2GTN )4B_%I\"E0YHO'_K
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MI%/1&RX1[?>*=*8BO7TZ#5WU'!Y!U_'U^42@[\8V$3@"PMG\O.J.S@\<;8A
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M1461U2\'")(4L!TI0]@_LB_B@$T4\;?L.T^'M24"S$2@EP-TN (C**KA9(A
M)&PQ.A:_"R8"7,6QN_:@,=]%T,'RB_U$PA%?R$\,OH, P=,D0/X&PE;H+^29
M!'98*V*[K9UP\/VLZGY"D<6A1!UX]&9N'0)]>H4(_*S_]ZQ&FADL2_^>UEZ
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M*4G$ ZHO=,K539PY5\2?"]R]<_M6%G"T2CE%TXL)F>UJFCJ-(6UJK2H(*>F
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M\2?[CAVM_8LCZ*7?+/7,\^\%+AC%'A3[X/8(NTZ L"<;,ABJ\=[ < U!_SQ
M$2M2'@BI=L8#/HIX('RHO<Z8L!7R=G+[S0PN=QI2NT=HLD [0R(;X&K<Z9VA
M'P<<?S3.9J9K?0(^38D'9DLW^=_43X(36/_%"CSG!FC#"P^@B(^<.SW:UO&
MKY?SCR-*?@#C&?);Y(J_&0$O?R,^G()C 3Q@Z&B$/JR?3OKW0E?\)W+(_^+^
M\]/W$+O%J/[(:X450<H-+H76(,>@TT?<WR$"\!J(A!CWLU-<O;$_V#BL=\52
M;^O+#6:@.:-LLBQCJ[SFPAHW@BT&4$U;TPN%2]IER_5317B@#HRU^HH'3/$
MZ*DW*P;*N&RO;#ND_<"@X6QR@-*;*PQD&4I<Z *#@J]HIY3 YGNO67IM#(Z*
M^9L?MCR^JIW#JJO,.60"L<TY.N0_),SUK6%5!7NK]1N!>("Q^WU%EVS76#8>
M\.[ 8>#HU#^>.CX ^>B/)T7_B.7X=./_<4/.B)9O'N6LEMOS"+W296!R4"(S
M8'ZFF)(S$/_A8ZQZ7_(],]VSG8@9V=S3D >R>==^6U#;AIRN8-5G)(]8+=/+
M ^\7>2C&40?*P[[$:"P+&1&G>;=+)$8F4IR>U7_F>15.,Q 8D2)_#M,_Y_>5
MR2E<@13Y3'PZ*NY ;$U=9RG)LB+"V)?>\S.';7"*@_(!D=%C.[1=<U5"78Z7
MR4R"N+7PV"EGAIA#31B7@!+BFH]4S/U)O2S)-T!SZ+1980+]0]=(Z7?G[,,Z
MLK[$,+J$EKK+;UMEN_249BH\8VQ;?9'314!)C=&_@PEQSH#QZU9&[C@Y9BI>
M##9_-"RX?M:$!/3:Y ;SD#)D=<05'%YRY-W4 C$KC;I=WBV2)Z-R,L*97*>?
M^UJA=4O%N50.]R&/#*P9*B#=>,@JAQSVX)O*@M7+)[=U9E4W?>9<BA5D#K(N
M/W.XD7T?ZX8*C<M(M^.=Z$Q/#WM-U_M46TNHQ=HD1C%,R456(KGA&].SUF?V
M8*V,*F^>]5BJ^2BM:/E!W*I(E7+Y^O+10,[@DN3X5CQD1.R^C= =5'XF^L2>
M!L8U?2)]H,QW4" ME[*#XX$!<8RLVEU04Z@;HIF)Q:JA3A 3G;[8UNK-\A%-
M4O35J5/REN$ME@?:M\@;'.J7B:,"2)Z<\#KII5-_H>;Z(,A%A/:B[<F4\D.>
M*<NM8+M3;"/S5!KS,]Z+7?<L$6BK1H%.9G.#%TXQ\%$&38<LNUBH0+L!VP13
M02?BK<O.IP\QM+QZ$BP51E=;^CXL!-]Y[\5[H>!KVIRMUKOX.YN6'<5J&DTU
M3(>\R_4H?PRU5N##P"96X;X2^3X[XYJ^]_V\WT,K7[&W?@<6]3>(UPP=<)V"
MV5@9<_3=H5@9AL$DW<J*BI+[=H:^OL$?'MY.OD(<\(EF<189&  O'EU=YLLN
MSBLLM]+U[XKKJ+TOJ_&5XP//]1H?-5G5FS,%00=J+X4IU/3<3$I[5W<8A-$.
M.D65NK37VWRT>8;9CGK/N3-6S&2UI;3I!SE>ZW-T5-&%!$@X.AH:YHSVNJA6
M.XTP@X/@9I(@!E@44G,W+T=R&-,Z^>VB'8GDDR*/9Z)*S)'TZ\ L<6\^5@S#
MD(-1:=$:G:Q$#N_4?QPKK<U+#X^B\#-G9WTR)OC$\XGY\T[7N,!F"&BX+<]<
MH]RR) A94A-B_U7CRX<>A6&R&"JNNT<;)@:>\!+1Y\(?J)C2@YQUG#YGQDR:
M(@3UO%*,+ID<K=\[?VW3X10]N\CJU2U'?>C2NZ(NH=,],+>'-7HJ,^%!\G**
M5@4N5T5S)THKEU]KTR +@G;CU)JD]5L.>(MA_M:I)BROK1]'ZFKNTM^;^R*S
M?KV);2>[[@JF]O'[I<FSU7UK\=JL5^I+RLH>OKH8?CJ!^-LX*_77N^&K7VK,
MRJ6HZ]]7DB-"$BE+PG'*.Q7)OBT<D59![!&/QYA.ODKS=VF_\(KI\8V-X$A(
ML!%]W.YDC_.E<NK7\KHVZ:'<%5_MV[_Z**Q%E#('2 80M;>3:<N['7@:%!\?
MO-!3#A5%M@X]K"O259%.2$N7NW-O_'QZ4,.HKGK[846![&_=SAEMO<$$$X'@
M>=S@Y'U!DQA3+6S0!\4@X<=]FH7@W<VDV0=&,+A*/Y>0H669J]!YHD@+RN'9
M3(Z'$%20!7S[9!]A):2"H)+)X(W*J>?B\GPV\ #X-$YD80LKBA)9:+6"!I6[
MKY8G7BPJ\F"BYQK0S%V-Z.<)NR#>6/Q\B_G=$&$E/15#F$5E#2%X@(C]M_O+
MJ;OQP")Y)AZ8YH'/R(+P@%\L85U.SD/@2+B.;P<[S1<N\;0,@J%*FKU+^*.*
M'.&/?$F$U3L"#_B#_Y6XG'#]']N./+DPO7B \'('-U#8=>29B>G[R9<B]I([
M^(C("0]@3R*P5XBF4)$64]LT'PG=@A]AHH=BE)W@!V>.O[QR!QXFA*.4!N%\
MJN"X$VVX"_!&KA0\T$VG1GA6A^#%!TR(DS-4($RK&3[6>'Q/6*0%'MBF*?S=
MEOF/K@@PU/X)@_",/P#!4:F"<;X$F.>39A6Q''&0HY/6<-1E2.M; F6)_Z3,
MY-^@+.H?E&7^1IDH @_<M )C3ZNA,^"-E_\9Z_%%[@C,[1+(P8DE/( Y#<;<
M)\8#,Y=[T(@U?69WKW1(*P*C+&S2M9L7 %^9^1?O/R>,ZI_>.?[A76$!Q_G/
MV$=_B/WO1Y_[;?0L833KU!)!2-'(Q1JNV0+RY3K6P?7MPS7VAV61O<L3ZQH@
MIBPM%M@-:0_&OG]-!(N_BX"6((*S4.(Q#/R3-ZA72M(*2=//ZU3]I"1@5KTN
M7#\@C/2"9*@MVR-SELJ\+@)2NX,S.O#I6_ PL;_/+PN!5-8P JDJ(.PI-70Z
M(8;X8\I+?Z/\%\HBCL3DS(#)L,:HMZBAER+IC#RQU[L<K<SAS+>63)XA&=0X
M6I68""MFJU4^HEF/1R#7?MG=_9)/=HX]/7#.YVSOS]$0,KC]>P;)?\\@)R'K
MB[P$=3R_>GS:O&HJX7F]-CQP0@-KF?0#/:D_ "5TIACE$O@!N<Z_R!R,BCH6
M+NVQ<%__.X5K0Q#NX&_U^7OR<_\#POT3B[_5^K%P]?\AW-]@,_T-[,O'L+G_
M"5LE=9M0[&W_1K'K_0Z$Y+C8"61$+AY!2JWM\0#T]\$$9UI_</:G>87 &>_O
MG"G^SMF?I@9"L2_^H]C_79S=P$0I/'Z1/4RYM/NO3C1_\@5O9/^A>'^;:/Y4
MW:E_IO]?G1[_7!ED! M_EH;%?TC&QYS]J [(C[KK^B%!ZG_)/Y"990"STOI<
M6?_1C-WRL9-/Q*+; CIW:A5."N_Z1HCY.>6@/RY^QDNDK"M]:1GS;:!8@<W]
M%=WSG>SX&@)PV6HP%H#B.$M"XC"VII=5Z[V;H<.XLW@@*8'@X@1[ZB&X(6EK
MZSCZV\Y\&Z?@W7P$G  ='@A*=?6#+-(1@O AQP/- UN:Z^USJ2/>)/^Y\3V=
MVM7G]*1CI^6/$--=^_O'_%Z2@!1B&?  1 *.(U%\L(X*/#JQ"D<1P3%Q8C Y
MW',7" :HQZHR#WA\_+_G66@:#QR</%;6"3R %G;47&^*09AB*.$F&"&<]W%B
M3X4C_D1_?W7-Q3]X#IL\3]"&(0('\!/:?441HU5QBUWH<[I=R O(PL*Q)%\N
MXMI0YECL<<HI652J&\';Y,?B.(D'D!83,Z#_SKX36&.G,4^TPS<;Q31>=3C2
MLZ,[(3]PW5N O<33H'VGV$P*$-[A.-[J5V:[/NY0+,*2PZU[((N/P!A!,%83
M_*??Q0Z%FNJW^0DUY5N :T2L=A$6N.Y:,.Y,_>&9]D66W4YJ7 "ACEX0D+:H
M__!* UZ$E<0#M[;AF&MX8/4*K@.U<41.**_I'#SP,9G,J_@V'DCQ@4^WP]$/
M?W@QM5K_)R^0'\T03?V;D?+_$.F?;0"N8\)J!_1DN+.$^J51_/,+U1_C2OW!
MBL__ OP_#_#$0&)>LD[@IK/D^6\.ZT-WOK:-QWS.>64U:MK?<4$B+*VWL#'-
M,57@ 'CJG_ABIF/.Y%Q4IH!&@(99\!>O4]P1VKQ8L33=KU$WTT=N"C+G1HR]
M+THR)KO@T_,^^ HQMUXOV4NIJU[I)8GWZPHCA]LA@9ZFCABSFL-&R.GMKO,&
MD)=2VLFZ$T^U:6-<\BR]GC*/U585W2#Y+BAD^GJ6Y-%>@7HI'D#HP,>A<P^Z
MR0)6")/6SH3[)E*Y=,52CD+A(@\>L(SX'KY\^CW0:KJ9NMF<#<@S^>*!<U:Y
M:/,FR2.X5F4D^9C2*K^-\*''R_F@D!P]0^%E;3*2ZRX/0'>)NR[5,@8#F_4L
MG@SQ+:R"4<UE>X6\O3S<%"4%4DJRR@]4N\AS3LAED3B-WB23>A@X?0;^:/G
M*1:MX$S.;='1P.S#VZQ=/+'!T6Z0XN8#D4%>2!@19ZV7!]QH$2@[S>[2VVB:
MA/D$NI?OHYZV<8V:E\-$!5^;QRA$N>A\?"1KI- 7J::<C!6+!)/!HFX/;ERL
MMW%9WD0B573.*OG.8C25(:Y25 [/0'KK%LD@YCYOXLDF^W1#HY5"PXFC./-!
M>GT:_</=+<^WZ.HYG<YFC)$:Y=:F5OAS5-2#GAT* =-^GH6^W((UD>M2,51O
MC?O\X_D-;"0U&Y8%%6O=HR\0-3X%4RS4H#:"M_OKPL4&2R'E:8FZS7+7$]+,
MHPY3NPXU0\@:Q&UV$A16#K7$>2$E:[8EU5H^B(_Z>4@C@UNGI-Y>UGCQO%1+
M !&;I/G>1XH3/)*OY-3?VYIB;9V; K/.B,@W?;T^3:?]NC6-<]KERO@];_7-
MQ%W(R15WE\HLN/E3+<I%]\3DJNA& [VW?.IH>ECW^JB<F\E9!6TNAL;92H))
M&? +,1PQBF7R>>J$2E:8Z[W ._6ZQ)]#(G-.5Y]3'F%LJK[:MV?OW\#E6IZ]
M=I_L9@OO[P?<SYNWKM1ZJ&-Z#A55'F=B;PWLL)P?^9SV5(9Q,+V\J'MJ]<X:
M!_JTPO?VR5NMW_UMB<0+^B107?3>K?7GL/:S_)2PJ/OP\TT>2,ZP4GTOB&%E
M:5G-:?HP+:749PPNH2;C!]UDSV$FL]\R9^!!B=?0SX;6L% ;*U3!K?IPE5JE
M$<LAUP=WU1>^OE/0#>*:F_1>9/B4'Z5Z5,\OO'$6>RM6'S6?]&'%B"GP7DS'
M(:W^FSR[Q%V-L^KEHRGA2KMU8J*]:0[<(Z7P$;(9VY*JU]JLK$]*ZGIRMVE+
M?.>5D,&#@VJ"XPH7PL(1+VJ8WSG&!8.'MV:2$@HZO#*7W<>K<*_C%'(X"W,,
M)FJ_*[-%BKE$?-ZBC':I8/L G+TOM&#'[.F-/K[(891SH3F)JB1$7^X]5KRJ
MSI"NJ:JD>,2H?:B'XW:@YO#,U&/C3(#J-+-F 0WV*29H!C+*-#-9CV97+NX1
M7@&?6AD=6YID'$BO]%T7+M<556:ZAA 1]:%?UZAG"V7<"P/M\F/TWT]-3"JG
M+S-VMJQ'B/J[' SFV+O;\GPWY103%(?PM8PJB,XB]*(:(85M3?RDF!=J@VO6
M(M)R]PN+*_K>>T$U*VJA1:K@F-TY4Q=6G0>R1B_L=Y)!5U"0M5HD'CBOK^R8
MC96T4N'> $&MW)WG:FL/&FQ1^L)+%%^C]%O#6;1/*.G&WF!I*'ARE(CCA14C
MH8TP3X]97N*[J/4D+Q/:],=V&1.U7\-LC2<WV*Z=B'305("Q<XE FZ!%H";H
MF=*EXH_]\[K;'6&LDY)K>O-SPH?BKW,_CN:&WV;+:NOX=J/@+DK-=[L@<)*\
MIX8[M1F].*KZSH6V\.Z\ N4E__M?W4R>]^\D*_IYLAREUEW"WH52P/)G/TFH
M9C9!J=W63-U(R^I':>TSUB(-%-D>/IIS5U V^+Z=KS]3L-:0 ZM&V@762'Y8
MK#I=B&:$'@6HTNXBY_)81[E>GS:ST#K](INRBNP12&\'<A;7!C^#Y4*^W*EF
M(76QH&C271H2V^I\;-SG6RQ26RT>+MCPAB6UGCX;QWH4BF.$&>&!)E<7VM'>
MSS/509P]O3:VRSJKZCW1TT$L7W)O"WPA>C'I(]4T8[>6,@NEE$,5&*#-?;>]
MN!MP,A45?7E\VQ,*RODIE4%/)"<Y[YX:^_((,&YBD/9W!I^!6R)>0BCSMD$,
MRM,L?"#_JNUR;ALWTH_G,BW/RC=V"?/1& B$8B,BF[J'4@@-?C'89QL"\I3N
MX>4IH&WZY-KU83%X*+R3N7/^2277WHN]@H8=UFC%1CQ0Q-4$(L.,#C4?F 79
MLW1&-Y?'B%(M4W]^;"+U=NNR[\B[-B91-3;[1 %95F54_"X2S=6,H((9:V/<
M'.G\/%6=+Y<FS.75KJ@\27T6;#EGY5SN9%PA\S#0S.T;A3MT-0%=T(H'P#6T
M=?QH4$ ) K1(=Z=G:<W$@Z-O7)FY5Y%;4- G:!.HB50R?B:@ETAW%.7-A)%L
MB:G"O4V?;+L<6FQ@>> T&MU<QNA9M/ U<I(0#C5+YY=PH5;N,HP^JN,61G+:
M2[+1B#' RHOVTY='X4BSZ+:W[$HC9M^QW_J)4(%M7><Q\:U3()P0;+2CN2HQ
M^@/B)2TK>4]=IQN/P-+N[A ENV#V1Z:TF%O?[",!EAOI\;-#P34V:-?;J+V7
MMG9.:DP8_89$KKX:Y4S];^B&R^-:7QY5RV9:G;[@]G(BZ$8;S;83N.C+4QD^
M3$B:U0H-(?MV5"M:=;S%X9-K,]4E Y2OOOB=; B*$W[FZNXKWND."C[^)BPQ
MK -Y$=V:FEZ!YK:D8^2(==DJ,;+);6]?GG[VE>8-J51HM]#TE"^$5<I\!@^,
MN&ICS%USC:"><FCZ/OC,A9J*2C>^RV4#VJ3R+I?KGSV8CDIZC8Q'Q;:R<DB
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MEF[)VV_;<[/2=VS!FUU<CLBVE@X*,+*F*@M-/7)S^JV-S5P?Y51'#1V]6/J
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MH<+@<T=1A_H&?4[UI0EE4S;5X> ;!YQ(,7 ZH(X'_+0)"4]ITB;D7S0):X;
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MKAXTNF_ )?[IY(=8.L;96,!41J1'SU'PC\8'^O%6YB.R?+!X>ZK4';.JUZP
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M#T=(7R$GG=.CKB 69>04_- )^#L$WPTC1K7%S(: LEK^?G.]$&$VK,QQ[KV
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M=YU1XZ%_N9$)SZP83"3!S$;]E"XPV6BT N$TAR28@YDI$-VF9-I4%+DPE\F
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MF]6Q'>6B^TC'%*=!F+3"J!O!"<J2GIW6I*6U'7I/'1<_,<..V8X7*X21-Z$
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M $T1ID!4X[.\4K.WOBF#%A^-GH(V0L\$IH)AYP@!C4_.,HS @E];N+/"?ZZ
M\R$;>.',LDWB78D I=E;OYIVZO_:-H"V@R'21$"6*R,4Q5'TAXWEOJ%4 !:$
M!Y>'$0&[F 7@"?<^B'!;UR)PDN.R:&D^O.X+#MS16*RGD8]UR?NVKD;.V1I,
MCK%27HX>E)CT5A^H@=9XMYTJC0LZ6X ZDL<'"S50X:WU"5P"JP ::^ 3_?]X
MR',U,Q/S4.R4%141L#+5R8%77X>>/(W[>S$L#U/%E>/^M:FHGT@AVZ&'![AP
M NU1UJ^=.$@_T[^JGW^.5.7/I"=_)"4"_IZU^8^L'']AG?L#:]P_L$[_D?7V
M?\#Z#Z(._)F41_)_33KU5U+0?U74__U:_9WT?S?IG>/G)](W=28:GW2=WF?^
M19+W'\#IMS_D2IS[9]]J=K)_M& "_V>Q7G [=H2(OV=<JL1Y% /5L%YY9XGQ
M/0-7_'.=4(Z]2SAU JUI'!' C1RL['M;ML9CC!Q[?^[16;)L"AV8!OW$03M?
M*5P@L%Q!J9^>A^B>"69XYKN^[4';GT+.I,O6B01A(T>AA^Q-1,#Q_1%"((H(
M:(XB2$#_)^-+_EO'?\]^[FQE(["YA""E,TB;X!G+HA\(5:%T%3K(W\&!5W4"
MG<19$@&G^6?Q.>C%F8/O^'50OKH4M++%<8QO7E#^G>%/#.>;:SC:DJU!E1#=
M@?)@& =!/9OP(XOB#O?Q7PE._\WG\#O#[PR_90 ",?G8SIG[[3;H'RG#(-+U
M^R -0>_6.1@T".*)!H/NC'#BY*SF-)?N(A%,S36O6:_L:O)<?^PV&F_92O75
M&_ ^7Q.P41%$>'STA\T56^=+Q9JHM*0AGIIP(V<]89Y&0P=#B^8;+QJ3!LR-
MOENRX2-PO9;X"C3P/)5*JZ;_QZE63_<7SUT@=73:!9=V5V04.P+D_UH$O5&Z
MG0/H67.:CQ#8N%8C[65*6I4[.3'EI*M!TT!B !4.^F:[DOY"]>5X='INS^S*
M^+.D5?W<2 ,4Z:AL;E\B9'K0U KJ"7?-4IEVV?HX@N&KJTL2QGQ42]"TM2Z.
M)-6B\P%0H!2NX<Y"P9]?A7VKK8 ^J4C=T;8JX5HCE9OEL[>3'[$"#S3+^+_.
M55% VRZ@9T3OX>PCMCV%S;02>GB1GA$BV9=-C"%Y+S2U&YH8QT6#/)J9\6$K
MK:GL^5CX0VQ'<_AST^$%JU&>2$>N)PPMSR$UWX1\>6L7">(W88\3EDZAJ!@'
MVP_@!Y*FQ<WB1AN,)B]GE$PLOF_/5)M"_11%I@[>X#U]T1]1WR &=D<E.@<&
MRAP]CE5Q0EKP7N',6RR2"X%\IY\:K?(V,F]4![,)=7S"H]O;O[C"GVI_[KWQ
M<@XDNG.9/<.GC/+.:28$#,Y>0YP;/0&AM;YA]J\+SO$U7385B-8P-N<B$;MT
MRQW.]-T78TH0Q4LOF&W3X'O\H=06O50K7RVD#>&>-R*$N4U"^I1<ZZ5%FQ4%
MD\9*)8OAW0=* U3OGLG<'XZ#Q=P;QN>35J<;B<%*^])^6A8)S^F4-CY9T+[2
MPLPZ.?#&4T"B5(J+OB =:[SWB$RHZPL@=47"*A9!B@.&26;1.!Z=2#/;Q3"E
M/'*]J9H\H<PO2OMHX97;SFZL8.QI<2#C!A% "Y%'-60!>9#><@RE[+F\H;">
MJ7XW1A*.FVH7#56_&RGM+QMRD$-T2WR\T64U!#8</2*_!.^[5\*#HRZE'SO=
ML.%^R17ZB+PM8:)5<D0/9CRZI#MX^*#Y1@^.D?RI(!*F+BC93^_J=W.ZW,BG
MYC YJJI*<:$-6LW1/L?F$RE,J8)3+"642 0^-UPO0UAWHND_*#\E,R#C)N..
M[!\%.5F%IEH<Y#JZ+;#<5LJ*EXGA\9RFIBBY^783:,N#3-F8NP11GI3>W*?_
M%"69ETKW?)SO-1<L&%8I6)5.!/B[R0S(EE]%[H.U5$\374^8B #R\33HIQ]S
M$(1(U:AU\NP28IC<X1W'[4^R4]'/1#3W/O-'E&C[=P<,5!+*_'\H,?=4C'&N
MCB;JO;-Q\>$KE^WHV9+R4Y4DJ<N2BLD+2$&[3EY#K83 K#9GK+Z.'\!+F+5X
M[LKR[!BT"-C>S%-_>^?PS?K-[1B$%)X#-2WW',&)HR]-6-=<-KU():[-0>;W
M^4GLK'K_R"S"%;?=#HT(Y!D]<2WX%/<9EEEBS^PHFC,S.?%#BS'DLNA+A6XK
M!>M]6:8+J2'MCFC@64A(>W+N<R\J#RG9.O^C.BJ.LNF$=IV!CU]P):?!.O?B
M8DB+W4#=?BK<V] R[LA>0L9=.$/@H61=?L]49!&5%;_86+F[V:?%U'K8MO,I
M"Q!S#GL I7;R._+)Z5N=!/=,3%L^.?#M4+G)WWO<=H=Q(FLX"C1YH84Y_+6D
MU94I?"23!)@WWC5_QY;.C,&ZF)VKH5.3\1":! E!0<-F>?#QJ#G:]4GV=)NZ
MH4!.[2+MW-6?%9WWWX^*33U0:\-EU?N]=+-PJ</J=\QRXJ$X_<?A[4I<VE:F
M%=4552&68SGUHZ*0AC?I53F B.H;K4(/Q>_+I X;Z9YP?!@S"GOI)$E_\WU8
MEH)^(RKG9;!CB7/NRV53D>_]6?<TCS4A4MJ\^]?1:8Y@AM4)096KE1)5)-2&
MD@;"?/1!O'<N*#J78JUB]X!O_&3&(++%=XI_N#I$?TF@D%F/SCO_66;^E6\Y
M';X.VZ6;IHIW=\_#F^FG:E-,]?C'75Z_85ODN)2CJJ17N[.HI\9(1][%INT)
MK;(*ASS)]G$U4Q()TV#?T$OPIV\R5IH=I+F%U":?'+Z2Z0O*][B;;^78S5N0
MJV3/E&);T8N AQ4>;KN8/!0^T7:\6E[Y<&MJ<RSM@$(@IT$GAN(PKLT*AOA8
M1)@(%,"+EZP9&OHI%OOZ/2QBP G]Y)J],7GCDKQ[Q2(W@..MT4@2#MD!^C'7
M&2B*X^\ 75EE7D[)]4DS0.XUN;=-!B5HC\=<+*K)L.,2A_M5+;ALHMPC 578
M@8.#+SCIK^61;WT26-@H4=NAS/0C^X7H3,VRKREV8Q;!6SW5KUX9^.\.(O,(
MPU;5LQE8^U:$&+-$37U<K <; YNGA_^W?%K)SRFZ4Q%,H^=BOJM=L.?^)-@)
M<_UQQ2#Q 2XY/,_IR"4K;PZOI3KDT3W7YW@1$]-2ZVBG7#O!'9W F/4>]P ?
M?\QW\A3?[+^ L?E:GQ4"WG>E]9&;:T\>/WJ6(GBQ,=ZJW:UN8D&HQX!UZT)P
MJUM0?5"&2_.QE\,7?#@:% I&].9N*#$/,1PA#<>$MQ8KDE=Z[#_P:J"$XCN-
MMI]M#_2F;F\W/P>&$J@C9]L[,F]75B)1%57UB+#)[VNY=Q0$N7J:&WCNJ=B[
M'6>_^L%/O\S! +(%O;'DQ?%_/80H0E%=PPJ^*!8+TI5C-<>%S&'T+(/&A%1G
MS[>^Z<1O;!=?F-JWNT88@=@18GBSUI5V004$S:"$\/V%K[0/GTZ.\_$ES,0'
M/LVW6GP2UK/"V HX8H(Z1@F"8MGYL5L%WGDF^"L:V(""R&M?J6X?)CM^$#.3
M?V![-ZFEFQ_AW(1WQU6U6C'P-\&QB!KX3R^-!'-3;5?A:ESGX<3UR,>&/W[(
M6-\*<%YF<SX C$EJ43DKQWWU*LKIG5?D;V<PJCR,D6VLK+MRF- )8->G(;U
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M&W;';0NF2"&1O;,,N3G-ECWK4YJCK1MEVR=#L2\ [AH#^CLRJZ23>Z9_.1(
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MN*Q3TN8=/2"!JZEW ;@YYXEVI=$L<=C]+/8 X!G/E%31\GU0@]-M,!BPZCP
M0B5#3(@ $$/6SRTH0=KJDRT^.E7&^$9AD9E9J2OR([[,-00MNU#<DY@6XIJ2
M;&BXEA,0JT*X)AU-!*Q*$@$);Z&XJW\S:#T1@+?-8H .=!2<'F<1 3&_NJ15
MH0<.\=5$0+,[$8"KWPN$)1 !9Q_/62WZ<NBB78_\B8 @T*XL$&\^*TX$9",)
M]^_\J>];6B=TCYD(Z-8 X2,WB("_%5?]1&P@"K2"'B&<#A !G:M'XUJG R<7
MH6\#U".:U[8))$1 WR((Y>XS0 BQ.KQ!1@30JI^(N#(1 8/.1  OYZ^2QN5$
M0)@)SO[DQ!0Z5W<F^PP'ME=)B C(BM(Y_@DB EAR-TQ$?X*P](0[^^Q\1$!!
M,_X*$2">-4A0]"E7'\VIJZ^%CY4F!26,KP\+ES5U&MPAFT4@AS![I<Z:E:/7
M1S#C+(5T'E3G%P4%GF0J;BQED!T8C.6-?B1,(6@=UUMZ:KQ&%,J:1FV5F?9/
M!=>CY#? 2M\IS?P%O\T'2T9*, R$&C!>*,@NCQLHGK\I$Z MN.$O*,J]IT3_
M,4TWQ@K#<&A1]SACYFC?[[D)H6.D^4^=O'1/HPJ@?VH-]PGZO(L(4((WXR^?
MZ4_]H ^ZN_&K_NT @7['?@[XGT9=!1 !FQ;R?^EAQ_&CWOL$;TH$S"41 13V
MOWWR;SB4?Q_J]Z'^CQF*UM+QMNG=GU*TI:5]3N;D86.)K!AK&4["TVKPLEF4
M3[Y5 U<XQUUQ$Z31E?5X25A3XR!/R/.4*WS]D7X8L@0WO&&ZVV?=8LZV0@JR
M[*NO/*_J*K/^C#8R2$01*NMIN4W!8D^>WFG=/<E=6ICS$D1QO/93T42+AK]=
M0QX<L,N$Z*N/<E4.B4)ARM.0?<2')=KWW[Z;,:X%C1JM&ORECUZB4YC055+%
MA[)E]W] G7D%-P/L=+)Z;[0;MA=[KVQXU$O:^_2FRLU.^F5EI7!05RNJS*=T
M$@&,VD\Q:&W^#NFL"60)=\DD)E/\?8L,2<KS=/>N['+E00A9+N3I:5[Y BX@
M[J"1:AZLA,F-GS#X9!M]38:;Q^6I^."NE?6A9G591^OZ[?&47N675R]$V].G
MMJF:'2&(@&5_>I_.)HW1I2@]2(]HQBS%_=3*$=ON &%< !&00># ,5N=2./-
M/OE$#@\'*#'!9-!CC?=3C.0\SO'=?%M->VN7I_/\EL+YVX_4,$60JT3 :SOL
M ,</!)_I5V'#&V!"OZN8TA!=G3!S5GHHO^!<ZNFUG;<B@U'1*XR,>;<^+N8D
MIN]])N2?;K=_VX* J>T%4*D_#Y'-.9#AY,RM5,T">Y<:TSDT\ V!:E2)XT0-
M7X2R"F-(83:_%D@=?'RLU#J=[/8R2E!-[.$N;6!Z>I;I'/YI,] .1_4*KY[O
M$SS7<0-U_*ZAM@9(]4[_D(=K-B+P)-/N-AP!O'],UFLQ51,S(VV3RB!ICE(>
MX+]0ZKAOT.]!!% UR;-;/!3,,)>N*-*N,^$[G$,</G;5-9LSM> ;R]CW!LDI
M,:_N=A?Y\,U.$JCDT3RF]=T^R9.\&\[7&SMW5:<'!&)RN&5E.F]WF>X-A(.H
M]L!^H#A+KMJ:42A<R//4<+)M5YN*M[^X_I97L' /T[>7P)<  '(B[9K7)M6,
MM'>>\9@[[.Y*8E#D>^M1;^]#7S;C[^*E$2LO/J&77*MKEI>=-<H]-Q.;$OUG
MLH"!WQ.,UZ#7%)CL<XW7F&>??XK<T!L$NPJ)@!^K(Q_%=,?\R)3MGOFF*/Z3
MC5-53^/1I8V@\>1Z =V#VVYUN[++X-.J-S&!ZBR"SB)V^R['/'!8@M;R6>SC
MD27WSY:-_:=*RW[%MQUM'7=97L7N-_75).^4?B_W&:Q32Q:TH?MLPHIQY(])
M&[VNW\Z,*4G$V8=OERGHH#*@#^XE+^@DFVD56K3Y)KN'TM'SX^,7(I7E7S\9
MC03\JB0=*(>[6!ZMP.9;['PMY8BA"*5-W;DN6&0R+K@VO(2N6\'G.?0]@+YI
MM$QJ1FU'7F-HIE'BPC<;C9T%%:_E1NYH-2E]ZWZC1^F[9>,[ZC$CKK;(OLY5
M-@TAPT[BU8[;<RR4368<I4Q!Z?!S=I'RVLN7;%[D/B_^;N9=7-328=&$ET1-
MS55VZJ$%S?S-6.BK8UHBLJO?]]/=NOE2>L%;X159F3&[%3:\8S(K8A.B@Z*T
M8C=U0O V582;A^@'8T2U@VKE7:RU\UY=?\LAQ Y(DFGI,$;"_ ?(YGPB($RE
M3BFFVJ7I?N#]Y5Q_X3W#HW3D"Q66>[OB=AH+"7;QCS?)>D@NQ%N6++B&'2A)
M)DS.SZW+\>6Z7NRH-@V+N]DNIRYW,5Z%_LF)0'MTF"IWOKT#E&S3(PO8CSK.
ML-<?5Y 73C.!/IOE+58N]"]/)'G.4M[?4,1?+G$NM'#U[.W V8:'[T'IG)(/
MC@B)?N7N11:*NY/F*DO/ZU7$65GOMY3=O?)EWGJ%CDIJ6?1-HL_][S\[ CDJ
M&H?+T-?JO^?R=DV5)>7>'G# <"?YM'A9>Y$:<EP'8+90>%">-GMV_1BA"&W?
M6 &^U5MB+JA@V'?'8>%V,5C(0#/0_)V>,8;>U#5<VH\94>58M)XIA*,/S?NR
M=JG,0GW)K.%5/D)CA"?:Q6OZ6 40:/.6:CL,P9?5J71^$):69[PM4FI0Q@"J
MY^,02@N DW;!/&!1\\V7.^8'R->86<6JUYX\?\OTWKJG!?)=O80UJ[.FZ+_E
MK, _>9UC^XL?2&@LGM-O/%:P6M,/Z" "DL.'\P@CC6<1<%WS-HH(8-X+_$0$
MO,<U5^>>%!0.65J=YI]YO%\EM>8Z\PC#C6PN!1P'@T/[LMY C P1<&-=PB@%
MZC@+'9B>^WGV6L1P3'IG[?Z4/CT!+:B/SNV2';R#OMMG%NQMKMX&K6RY'N.A
MG7$8^8'#XS3"F7G/77<]##F^#^KQBZ%?FOL-]"!CY>2TGPB  O%#^](GK:?Y
M'$N*:I$[V[_!'C_<)00NGZ49X2<.1VD$:\)PW$YFKJJO]V_!IP6^9^*[0^?:
M"1(!VD3 +:BC^J&.;DYCPV_A?Z,!I5\* /UI_A:_)?B;B>I#^S@F=0GZHP[E
M(G^#!_UFJD7-RT",P.]Z^EU/O^OI=SW]KJ??]?0_2$^2'U''QQ\\2^[Y1UA0
M[GQ>#.EX\"7V1D/2Y3:QA#B1E>PA5?H6OY6W4T1 5Z/5ENA.F6O[ ?-*)\M&
MUF;,71V@C]2D(3S@Z<SC&2>Q&^VE%=9WU?+HQ=YJ<F+64LMQ8H0-';PG].#&
M96FX;KL-2<D8N[>&"M!MV1Y;[HO="K%'!9#I#%6O)E.RD---DH]Z&#PB6^CP
M7KC9^T$OJA(VM]I\(4O@X\-8IH4"^AMG"<_ZF@G_#9/5N<9WKAXPKWIM'YWP
MDW-8I,GPTX:T5M/E J'H=:312+_[#=NG>=MBV)? !T]3M/%0R*3V%@R[OO$(
M;B9?5SK7KL19YXC9@E2%T6IT9)(J+"P+Q@?+(V\O.#S!&59]=F;G^/*ENJK>
MAN.=JS#]]@?SL/BOE8)F6ZU,.N]#$BV) &RYX8BGU<4)*I$VQ9N4>N/E-E<B
M&)AH4*_<VJ-W&Q#N%L9]])<5E?QN%#D2 2Z'TLBCILQP*:LL.^.>2,;ZR'QY
M19[#=QCP8\L*B\PX*[<&\]T!"GPJLJ->P2^T6(NL;T@;_*+!%OZ!>H(KWE_L
M"R<A@,K9D*_).I,%OU8R-4657'^0Q%Z,*Z<0>9K8'5^Q_NWI0)%I-[Z[W IO
MAN*(D<P0@5:NFP;&>7J"91[-FD=<$:LAYYP/:F4L;AOS+"H0/K"G=@X)NT;?
MK3Z?H!=S=$-P:B!IQJJTS$O"J)5P$<>/X5_0"7X)T1U!\#HF_##K<'\Y:3";
M1?%MS:6/U84&LWB=\YG?,R/XB?AI&42V"')N",&)7]^9:Q\VUQ%^77$OFA#P
MU9ZL.]KV#3=5[(0"TC9.ZK$M&TPI**>Q!#6  6%7T'FIZ4H<XXO)NP]K_'NC
M!$M,A%=HLGOE<H-JSZVM"X):.6 K;=MO4@]"<ASD]I!^-=4[O*5I)M]B*4AY
MNN-?D]S@YD\UM O\'A!GF].H;GY:'4CCX_\U<14>>'/&S54T7K&_*6_$[-YA
M*]7-(DN@6WR'OU1:D:DS<P#L-+3/*-GH]N=!<V74\+TG;WO4'ZF>=WOGK1HI
MV(W@)8R!+B-H\1$>HG0^X=UC7TIY2TL;4Z@ W)S=7]@:W4.^RW9 9ER/U7RR
MNAA U9?'B0!:%BWL033XV2 LRODV)RQ,*^%5>7+FD^D&([=NIGYY9K5W>>6#
MQ\61.!:=2>XV$"6"!G]-#U<>-:6/&*O^\2QL75Z6ZGN.5\SPFZLN@ 19F979
M>B(@=(Y= 8A+^'X I=AP]!GGEO8:Z1S4=I%MEY,A$27+3->KH*8SG5)ISFF4
MTIFRGY\.Y 3SX*M=3" A$&$^J2>G"I@&M^T1A)M%^%<B(&Z6!*]H7S" #G@I
M;S=Z+2"CZ3/83;+-;3>'DZ><>WFMG^')Y@HL[FY.XS$JI6ON_(GE\+X@$4#E
M'#^M^BD&.33#;=;[O);?O>3576R@2SHS&@,%SX6D^*'72M"?E'<.!0.$H[L=
M^M/=;EO4_E30M0/9*W[V+Z5O@>CA<?/0$"DO?7R)F18?8GE\DGS2=X5C]IZR
MIJ6ZHFP1@@'B@K7OC&))R[KD?*,P38]A>6+!P3Y$MA,_??Y<ZTK!U2N]@NYF
M*G4Y")O3RF8GY^:@%X[,H#"7)SKTT]]2]#I\[>S"-^W]$E@X769S8V$]D(>G
M7W)3.N?():$4^$QM^18YV-A7OY&9B<]/QIF>FH@W:16>2TOJ='_8-RYASY/E
MONDGV(.X1ACEH"+<=AYQ0%Q#QGPO89:(<G8'\S;TA)3P8:5MRED7T@V K 1D
M,P6!#9^ZH#RNH-:E#P/#-6T=A=O,I-VXN=Z2;\E[Y]NI5V5@P#K/<AKG.N:J
M=5Y!KLSW4W:DAM54^7B;UIHY"QX+I'IX7X^35^\!&'[WLR&MP! !SJZA1NR,
MXY![B!O1#I,&\U^2U[+?7BJX:<PC"/?X $@O[+IJ$I6@8\;>JNKKVC8WZ8Q:
MZ=1VL6!I-QWI+ND,L_HR.]D-%LQ>[V&E:GGFL<**%/8^=H>P5E0DH%UII[G5
M/7ES3:,N/4 ELJ19<[BGNZP^=!N.NGTL.SNNN!6YL >-9K^,1'!T+_B#:"::
M0VUB\E+T[ 3BP:BD5B9#L@N.3-VL+P4CL#J8(&P!FBQ">$]8\.OGU)B10Z^2
M $?A>O.:%PS2GH $O\O10X5U/-N?NJITS1_&X1+;CGY^/75&[6>,M>.SU%^9
M6YK!&H0<7E\GT?"Q.?XZ[W=LE'[RZ+3\A'[^E*/+*]DT]!N./YS2A'%Q9-$A
M>3_DC9$BD];'[K5((0JZQ$IUA*X5C7$@4OP,\L%S/*LS!@5\(^?4I?2QR,3Q
MY>&CMI]/9=J>DRPEO:6KX^9#A-3B=U&BH:!+)QRE/E,=40JIL1DN.(O3#Z^/
M0AA'JTO.![?+=B]$[S[LZ'F7^W'CG5$ZY-9ICA+'B775J(B".)J\C#J+*76+
M,L_9USK:,SZIY1 TR4J]_VV*,#5'NN4)&S'J>!"4OV-XI,64W%?C1J@MF_;?
MR[?3.5M]FQF'O%C5!$D/6P]K)I.'=\@^D@TGQ[__ES-[2Q N#ET0><*+HVRU
MI,/F%X0OUN,N-NUMNZ.9\B,9$=\+?\PP+5R/TT72KR"NG,*R$:,2W&BJJVM'
MGK-Q_MX>D^;B<]_@4DCPA<.[M]Q)1^UGU0&>^UZ2CY=X/0)457W+.X#1%7B5
M^7YDG(+LIVF?XIE-[:4/E7$0L\O:7/W2??E/&5G>+-KG>P52C>?C1$/VA"T=
MAF_ *"G]X;$*&,,$R9>DOBU\P;*F1I*K.9'W0J_J*E_\PV5T!0?O@EM1!M+A
M"SIJ#+_,SJP>@#WIFUJ?L+Z^Q?B<QFW R>;^UC=,87EBH_JQI4\YZA0[HJ"=
MZ^/BW!FN/7IQ-L)3 :ONZ/:"*_Z9_N[G8NJE"YP+'\NS%2AQ]NU9=,*P" E9
M5YXTC93NIHK&RN3)=0;!.A553JI=4>[QJ&LW7T8VJ-NH^L"# A5]0LSQ0=EX
MUZ\(<E?*.%KC&2?FI["?:=Y77]"0-X0_/>0-(K&.SY1#5@\^R%G(I1#(B;^N
M>O71N3]<]+LZ7\LG]3N5J'#>7]_OG7*W2RNQ8<4FM#WJ0Q>_6%GDX81>JT1_
M?+(+(-_;>%#;T3_!H:5K>0Z[<E _J*!>N,[ SA5KP;!"H+LDX<Q$U^,%G_0Z
M/._[19?WI3'XV]J@D1FN 2T=&<C>ZNJ>^P,?.*4>>\F^&=FH&PC&<-H2 4;G
MBR$8GG"9!59O">/ [YH[5:.%958H:+1(("=$'OLS0E2BSL.L5.^[?)$0'T\U
M;_B#MV) W?C!R/4;-&,9OWY]Y (Y11NF,$10[MQZ2K3><.>L5M$'-8U[>GW*
M1Q>4KPF44V"!G< (A$A<VRQW6@L#?RL[=Q(D:_,8F:CW!0YY7R9"_^KN:^NW
M!9RTX_46H(-D/+38N7+-\*BT7>/3TO5Z9Z;D80QFM'JH5=8BH3[4Y>K!@L2F
MPUHW^T=5GXQF3 RV9V?,/NS8."6@$!'),R02G6@VOY4J.;'+!99__^+V>)G3
M'"RE79MA#5T[+I(I@"EU?=8 'RE(GA7T#Z6Z6LY51/[Z%M-SZW1=._8SCV^=
MT_@).!F"6CQR*?+RE/]&G27<*&KO]FF ;;1?"1+'QZ"\<^F65Q(K.BW@6!<"
M&MEK4CHPPRC#,'N3_Q=[[QW65)OUC091D*[T'A04D28"(C4B B)"%*27J("T
M!Y#> A$0D"X@H"!$Z4@3(83>JS3I$GKH/:$&",F)\\X[\^C,\\R<]_J^<YUS
MOOEC7Q<[>]_W^JURK_5;)/O>3XW4L[5';3T9*;T$7HCM05D:^-]'/GPF;JW4
M7O#0_(GU\5TO4G&^C?,?U:F0V395C#1@-.PN=_+(JQCW7O#P_N!NNJ3@7F3=
M5(^(">X+V.4Q:1G58EG8>%M3DW)WL"C[2VE4MDWL_.ML"QT#W.':.+/A#X;B
M7@BB(P(Z7/I.B(!E^RXE+OS=*BPRDG!Q><?$I-E^ME";B\OH@XBQ6]SDI8G#
MF[TFW,[A>[\?(@<GWQ6+LRO0W8RYFQXNO 0N4?+!A65,VL,9$#2^9Z9SU6D]
M]?-.5M*M$BC1'91SYF,STRR&N+DFU+/:[+IC>1RKVYZ.^A4_#NU'T2V<._DP
MW$'$22M!KV<%@PN:32OUSO.Z=\5=\?*1KK/?;/4[:-8.>"H9I1U;#6.\AFI_
MG[=82VO%(7OUL\$R$: 2+]0RD!?JQ3GPT$[[H9.J1]P;DQ5_P[%:EM0-WP(0
MLUT\SM-T>%U!*-=T<N6<)'!/H[Q79[[CM14#ZIHF3R4[/U?,O0/QX/TJO?H@
M!^#=FOB'@;-IWHZ+9G&:DA([-$44(Y.Q2&X+GOQ.-S"/EXK* /I+1;\2WTJI
MFN%)ZL=J?TU6/BE:"X7X;X.B4%6TJ(I637\-,-O._-R N)AE1<6H](%!W<GL
M87"-[%.N_@59GN=:[D^Q9252M0G,$_$;6.^ZZ>&]H84&2\,:%EB!Q:6SNK:K
M"YD^Q\EU5@LL@NF(Q)"0CWF"$772]D>I)3M2)_1?%>DNZR;$S=2G/J<\KJ_2
MW63W*/+<#R8"XNBP3(36XZT3QN%1G&?SOA)K?V%9K9SXY8')YQ_?EDH(BG2W
M)SX3B ,+Q.MO_5:X)RR[(;:!KD*DTKHTRE%J,$>R6"F<4[?0"\E<'GSHN]E[
MOX^#]IDP2D?_I4ZD4VUZH>?B@7V&]<(('./4.@HO>8L=B9KSLS,3NI2RD<8<
M;6"BBC0:$W@-P#G><J&>.Q-CM^L$A*ICZD,)#%#*H$84;W#6BDSWO%=$"RO,
M28MUUE)9MI']NO<[#P'&VY$,X%H1J$RFK8^D+:NQ7E1VW-?EW_C*[[S(M_;:
M;A@/BD^3[?ST$$?>A%TNS,@)V74?X 1+K:P].8<4/]D2=YPXGI,>ZW8^>;JE
M-X3?0N "3A&&]>7:"N>ZP!R-SNGFMF%H81[A]1L'UVO+.C[GFAZ^M5857[VE
M0+TO_MVD$0/Q_ZK$5S,@XJ#;RC:P>DXYEWVT=^?TA8MD'1V M&N^R4=U$ #N
M*7JJC8H$48,NQ+^3Z_L=_6D%N(A#D_4XB^\=#"%A-@588G-DE19O55$_MNXP
M</: -\?NQ74_F\KK!5E< O[F4.G1&<QT(Y 1!S'!?;28:5Z<4,GS4CIH6G/W
M>[Y$OA#[2J0=0!O[.3JCT&_N^"+.!TQ#Z".P?/&-6,N]H2E=:J</MWI_>[N4
MS^:@KC\H=L>-/^?>KH-*0QW7\-Z=H6*\8N;4ZA5EDZX(]LRW%MG<>0I^]H[Q
MGBSWIOJ-^&>V@@DW,:$-TRC7.4Z\@80M*C''PU%J0_<!PM;"UR-VG"KX)GTA
M[UEV>>K]5N_+,;DK<CD!,#O[2?IO*RCICL]IO<-SVY'/RS\84?3-LO,%?.<\
MN3%2P__1*\[PTO"NF;Q>XO1;\Z,!V630@29Y3%-Z2D,=9R5A8*=&,;/K)*<,
MXE3RZJ38]NMA)01^^I2,-?-AN%[B_BBX 0=JD\#!P ,$P)HD#OD(YXGV@HJ?
M,O2*<Y 5*RO\:+CN8G)EIH1R@9\^\VB("*!74$$[O3).:ML@O^] V7;44L?Q
M5GT.SK R;96XJD85X?$XOZ9B(B-R4YN*Y2!X-%A*<X-3].*2VN"FU-LW(AY,
MQFT8/FY 26P9V?I5,[;F(TC(.J$ST[;<1Z_(TYOUQ@JU]:C="TG5YG'AW_S-
MO3Q;4';^O3I>%H]PQ1898UM>FS7,=<Q&>^=E4MX7!+\IM:;T?GSKT/=I+; E
M3:0&YXH6#ZIC3EZ[B_&;1(;R)RCXH7O.:7B>MORJPQ)9^FH_CR8RCL9%U6]6
M/  JK?19VALJG]F53S$A/M7&K[0%N5:T?KQ88#_%V@_5HW6V-U8,*6%VJ&1Z
M@-!H@C_@YN:4#5G+W@?)U]'C<C2&_.6@QN58"J0[N@O&Y.6X>G9+RDQF/6X-
M<+&TMH9;S$/]@HXVEZVBMG!2%;86^=*?'H7R<D([ALV)TZNX*<!#ZZY@COR0
MSF_FKT=-!&I:WIS!N+;ZIQ2_=+NR)Z^EX68FZ\YU$Y]BWUH6J77:B_^ITO7\
M0#6R]LOYQ2]JKB6W[W_!N=XU,_ @ I T9VM.IJKW-_OJ;!:!2(/:F"""5&<!
MSG,_'L,6CO#3!H;X^"V%%#)I#Q6[U2.-;5U>G?6%B6"RC%[UZ4TP5&R K'SE
M88R$P2E!K';JG'>-O8B/J_(G.P_.4]]M1T6F#._?3$KZNG0"D3=<JCR6-/RV
M.WUN#)&6GX-:]8AT<=AZ;)0A.&I_2E(C8UG..O2WQ#Z-P4*I:E7YX-HW5+2/
MCS8>4-C4O90;C2J<_[&EUAG!4CJ,_>U:UMF:5(_S(FB%-RK,%6>J:0F(9J@;
M%AQ(N :U.TD3@X)$TTIGJU-OF]@^Y!-B^M)'YF9IQ;'$,4=1MS"TFR]JUV8B
MJM8[1>A]&":ZF6YDX3QZQO <C+,#@7.=E6<ML7>B62[?L+B0V)\^.*OK.!]H
MK"#>H4$N8/$AR_GVI_![XQ"LDAEN+!M%*EW(T$9;M^]\@YMB&V:7O/BIZGE=
MBF8H;U("M84;ZECMD--TTVBU8#0XK K6'&56G$T8&'2'TXOBJ^)>N^BH+01T
M/9'C:0PU/A&KP?3&Y*[N)Q=.)5BX?S**-(%H_1:C0 ZOF'<TS_FX]<#>G JS
M%2:67CF\2R>N5Q'Q:K'N2[@U^*.5@.[B5>DX?1O\ !89<J$?9M%'H4ZWF>&7
M8:=TPW9]7.<S*WA!NEKX-V4!^(7'+3?4O.<JC^3W>T=V^X+3>'">62M*K)B%
M5,0P+EK1^M$@J[T9_^-(RO,!@=]E.RE?]9(5Y[G'T-C4740$CNH-B$C+FW@R
MJM M?+H?>XV=]E/#BUMS%W.&R\Q YB6^HMI-HSI?H([(FF"KR+ELO0!F5YIQ
ML^Q1UYUJ55S8:4BY4W.JIR$NU&HNXDY/D%<$>,"_V='2+5:?K/3$EN+1F6HG
M<@3X^ +4' ?!( B75.;F'*S]O',[ODV8C7&T=E.;*E#?3G-Q149N\B8<#. 8
MFGG5X(Y37 -TY7#!5%N&[Q?'' \IW2P<S\W3JS&<JC'8=SQY9X6S^H KUL8B
MLH/0EX:E$X<*#3J/[ZEE.7<D2H0<^;N9&0ZBFAYZ;BO)?\8XA;G'C+&AQ8H_
MKHP^]]+>:GV]RCIR-3/^602?]</)1V5\L>V;G03.(6Q:5@Y>$W/PPNT,KIXA
MO.@E1BPA'>?9N)R4R'@&('S^H@/Y"W^+.!F/'O]W)JAF>\=$C KWC>5J1O9O
M5Z_NH@ S#':= U"&V1[*!W%$P'U2Y<F!:+P^T$^44!6V+C)ZQ*1^K:YDI+T=
MAH';$ &G0(Y;G*MU\K4.P/LC;H;ZXP\3+]O,.XE-6"^<GBG3H9<['[[@3VN?
M"&=2,#K6M9=SSS<UL4O6ZQE^K]/\CKKD;5OCW0Z!Q]'XT:GDZ6 W,),W:)Q3
M"9[O+2CA5S4BBR]=K0YHG]4>Q$MFK,@%3YY$QUM8^7D *BJ1Y7?GW]('? >8
M\.X6J9?KCYN!R'<B-'$!LV9@ M56@9=Q[_XDWB!'@Z=U[U.3_ITPQ*4KK?LS
M,:F^R:L*ZMY/9H 11$ I$1"EX/K;(.ZLU[W>*>&\"]<;'9[S.1K=4@AQ\W_7
M#FJ&.,.:2C V)JV\C-\"IP!B!L?7:<$AM#+X>IENLJ4*"H1CC7SFM"U5YL2*
MAP&GSL7T[SV.,:<^15XY'UL&D*-UUI[;[RH_P(/C"Z#.F'CT4HO3*Q><9D-R
MVF>#YE&)U3J1;Q&J2TV88)OTEPGZL55BMT1T%?.7-&.X3+Q49B9KX2%U@C9U
MXIAYF5NMF(-6)2"X?//Z^Y"'U>_CQNAO"K(K&*QL1LR>B#=[/!V\._C;;K[I
MYK:(PP!S7]$PX%EN#!GNB7O,QI/96CZ[:N1)]?IY[^-:SXU).+3_>905;S+-
MC$F8(YYI=F5ID")"*MF]NBXYX]30VS=O7^Q"JG'Z"\R/N#^2>D&^]/ K@/_A
M0=Y5=P5_NI\@"KV%\:]$GRX;*O.CIOF>W;\EBF^ILAT^5;[1[-CT;MEU0[6]
M8?P*U-NAR)81M8PR0P8[0B4IXNWM6"XR=M7<S3P' $ZV*[J:9ZC*)_6)%GE'
MIV+L-(%CW5 QN2\*&;?\F(YU.RZX]'_Q3C/??+_DN-56#:=:MFY68NEW\WAK
MRB/WE4;RFEDZ6$Q:ZWL?Q_A[WY%"9JK.VJ;P*YE_V]O  (@-;1#'ZL["PJ#\
M/-LK,07&7 ^]^KT#15Y[.G3T:;]C^?[PONW8)*]$$:%KBLWIS,H1,$1$JH\&
MS)J38R?CF5BNXCZ&B(78/P[:.><31^$:9.89JL35-SL=!CP'->+-XBY&!U@O
MF)11GK 4SDB<:O?LI9)=EGM:G7RETG3;KB>-'Q,ZXQE! .+6=+#BKQ2>9'E]
MV=&;W#\>D_*,/AP%5H?+WN\NN9-#V?6H\6C'?%*5F5K'Q?.)*K..P%\>XB8=
MPAU/3I)KQ'.A)ECK: 6-'-NZ2RD&B;TF[.*_-9>G/7ZE]OWI78<683=VE-QH
M\</[68(\,?3U)RG/:C%.K\HN%+>%ZF.3<67@_=MW[@E&0_BY#D'5;?CH6N%L
M7#&FO<7_YO"'^F]0(_I8JK*XKUL:PV7#0V['P1:QXG%FSE?W';UFPG>KKE2:
M#QA4=D%%,=P@&@+OLA(SLA;^,%2CG!6].K?5V2GP6HXV/N#[8X^B[/ K%ZJK
M/Z>'"YV]6IZ7/;XF9[4(]P:FV'K2C/?P.E?RW/N,5Y9^%@[ 3)\A\=2KF((T
MSH'+N"0_]QD8O?:ED@&']5;$4$?E]DQ%A<')O.9[!]1U0(_52OV7U+U,.;4(
MYSE^]YEIAHDI\^5DR+Y+)J9'[E[^DC;P((SC70?9H[3%NI#TU!Z_S!@&3-+Z
M-"C$$K,F\XIQ[EBPD<E+ 3U4_';@IE,9P_L96K^^D<H>X7WEBD%_7J_V9L%6
MB;M3?*2T^#$"_ODUWPW[H MF/[Z,VIRW&!H=<-.M\-4X4(+A4H^OJ&"%6Y,3
M:YV+VD\/F-C:6M,FFKLY]U@OTG[-:G_''7'AC-J HIW3&4)7/>;56MWY$3:#
MSVP^2DCW@HG6)UF%!4P<#C7!X=+T]UZRRZ>^3S[X)&066I9:Z-I:(XYA@V#\
M*_913M'F#*=YS)>,":UFTG3-FA(BWQ"-%F^1)8[,,@[#BS+PSZD;!\$.NT(U
MSF=:"WQNKWP:-3:YYV!FY:W0]63I3(SW<^"%L,9&GCID>NKW8:-"786M65!3
M=7&H#S)BCZO'6%1GKD5&'PF>'V?7OQP^=N$QV;..I\&AV<Z]DN;%L_6']$9$
M0/T)W3-]> @1,"]K32 "=J43P %']/$N^:S'&0.DJ#P<7 =?1V(6<_:]8-_F
MCR-65O;R0+-<)+:]U L>Q-OW_^U]HHCIO<Y]]?B3%/#AN\5I3-0J;&=)<.7'
M!L<R>41 WWMX#FXTLU]]5'",YO@&?$>RI_[OTY!*T4LG72( +@L"8XLUTF.*
MP%^ ^PZ@1>N4WPWO)P+.3N40 4HN_O Y\WA5H"G<$CA61@2\2W/X_25U/+\/
M''_8>02+\M%B]G/Q>PU[-DAXYHW\^^? O^&37I%Z2 *N_&_@IOP/HO\@^@^B
M_],0C;1'*5VU,3]#?GQO\XK&TXSNI]>;<Q^0/>/GO\G.T^,"P@Q.T1,!'UZ"
MWDSC[:J%3ES*O%<&'#PU2GL+OJPKG*3^=CNR6E95TH1POA9,@,Z?@-IB<&I[
MH,.=^%TB@+.3" A)PWB>G+Z SR8"YA[!FL%>\H3 <P1=&/;3Z/=%X X:@J.Y
MMC\&/CFC3F+L885_H*PE$?#[H:#9G!H>(D#Y+$RH'C?,VWZ-E%T9B8 &0]_?
M<@B!&41 P)V1WV?=C+_#^P+[:2SP)P5C+-["^L)@,R**Y:2AR@])4Z;;_Y&;
MC'XV3@S.=HL2]NTV\*L305J]I!NTU%*/8>4=%R+=D4L$S#R4_J.:4 #_:2A>
MZB"H?OD"PX(,R8(9_VTD!H<W1,"W1S#,E>0_\"3XYX$$3M_&Z=USH=LII%;B
MX;HKPR%6''\FM/PK;/DJ",>LY?0[/_V^Z G^/) (H%.<V3HZJW*H102TY>[+
MAN)Q2813S>-6H%T6()[Z\C\/O?A?QOT2"+[<S02H)A% ]F3C"_R(.H9PANE_
M$D**T4](SKA$!+SX_'\[AMP@9:-!6;&ZQ_<F9;@=83?)]I3T>+N ?YVOY/AO
MD33T!Y%4+<QCO/:H-&2SETL^W^B-@JN*9R4/^/99;3M8F1UL9\&)-%B0"'A5
MK(A>3$U6M$K2L5L%8V[^D=TKC]5^@-8G G",,%RX4O\/QR;4$T[#"1>32$F#
MX2_$(N2/P,!_DIFQP4G2VH04=AI$ /K*T?PQ'Z$G!]\]^T<Q6+3T\XA?P%0J
M=8!*;8D R?\1_!^,AV$=!>ONY?KG3M[T_^GVGU59BU\/^H_N_^MTMR,$?YQ&
MK8Y\Z;);X2S7Y'9N=1])CDF51::QEE?25'<]9;]^E$^?L<?B\J;$-<ZN55T\
MAT/H\B[UE?0*\(/P48(B:<TYPQ(T'QH3 >T%H$WQ[3R;?]EQ%W=I/>TSQAI$
M$&3$@\OJP^2*6[E@7!.-L[40Y<I*3KW ,/X+8ES=YSY%5E[]ZJ\C;[!JYN)/
MCC.9W0I!FE^J^.8@4)[48IR9W)MNF3J_(Y9)S1&"]@ADAF:<>J'DC+7>L)^;
M)L.UH_42ED+*M-2;8?12DTK'QO4F81;5%;8;GMX//IS1E)IN>?[IQ3Q3.$)F
MXR&6J^$@<5]) 5,<*KJ)V*)>-1?X9OEM*SN5/VY@O,_>]\,JPU7UWE#*UXKV
M4TPS.4%$ !+OE-^3*;K0%\47.&H:O:J6R)6;'I6NNMV)RK X]YS"U=R7"*#U
MG(%0>^FV8KWD-6P45#_A_'=42FJ'$301)=;<)=<+'KXSPN<BS[\.^K U$/">
MX27(KABX2H.IVVFK8\2<P(/]+XU+<;HNHUX.F*$FN"RN'G[]2M'>>!PJ%!MW
MMTASW_,D7<$*#2+#*V+8FAG.+E]; V*B3>U'K5LX4P>-Q\<+=[^I,SMZ=O&7
M7KCT[G/E+KH6-B.X;C\S'>PC_M*=3O.>21^G+><]HTX7Y $32EE>]8NW:'IL
M>9MI8M=5(5E%8?.U?0F<KOLLC-Y&Y79-.1*#9S)>.=#WR>JIG7BNR:\A("IW
MTS/JW?>-I^I29[=[*/>_8OM:-G1GT^)GG*AL'MI-B0PBC!PS1ITNG_L^\;W[
M8CRC6F8GQX62X,ZOV]?L8YU0JSRZK1 ZO"L:2)7)693P!#WNIRTO?#CV) G\
MBD/_-"VC:KS=3$=FD==*\E'QK1.X M6LF6^37%W4QZ)WKK.*2G.: _S(=R-7
M^-X&71%Z+_M4LO*+BT;?Y2]2D#'P;'G0)]N#_2/N."T+I3QG9D\9G2X.ASL.
M-?21+=<KYFS9>4INL4-.$T2A#[&)A;.'-4]F070K4]Q8L823_)Q)&U1[BK,-
M=>A=ZW"MP@M7&K9>L5 &K9GV;4@>ZZ\1 110 [\L&WTEWKH8S?[Z<C%T7>*F
M;UZ(R<%M>9OW)H%L8=87J/8YBN_BK(Y%\3(X%31X8YK.1F=\U7D<D56&]!R<
MI+G"OI".-#)[>05L>2H;.[W>A3E JT<X*J@7+1\PV1EX1%CX[?O=1D]QX9CC
M8B?:N3YU?])H>&Y#_M7Z)*_&%TO>8B#GU$2J;C8&D#$ESL$:C4^P)JT\Q9+7
MYBI+Z@YD#\NNW5]4OT"V9FH0!;(-4V+%/\82*MF"TI-:#,PY,:N-CD=E<?R3
MD[W]ZK211=]$G!,%.CGQW]=Z?)6RCAGQ L-EM1>;EI1K;<K&Q==;8J7M<Q<J
M2NE-37K7^"35:,ZQ= (>TP-8OMD#ORPU:_G/F<:1"JH$F+XTTWC94[_.ON#4
MP!C2)-/F[/DW-R\DG7[L>@LH@0N=\XRN.^\_P"N.!;7XR8-]X0S0ZS(9]S!3
M'Z42#2RG/[4=6SZP\.LK":,D\SREW.KF[(^"GW.K/^O5_F#4'YB5U9LRZUVC
MG@/Q"R2@.FJL7!W$4?Q1;V<#&-4\RAGN[1=3$SI@-'C^7#NV\BK: Z1<8L+E
M,-CE_%Q3\Y1J=:MGT6#I<<_)!PR/KTD\6*DOF6[:$%?%LB;Q1ODZ4]1FIW*N
MFO3HKRY:E@B"K$,T!)Z%*[SP^,A#F07PULO9D,46ZV#=D2]G,)# N1$$A"8G
M8O<P<UA,JX;5CU>HA'?Q3<F#&[-JW@+4\[M@U "/19O^-.,%S!3<*M<<*N)@
MEJ(S8H4,$-#2[+@F(=#"U-U)SW^=E]F]U>^)+4:]2=]<9!"OP?*R*]_0!HB)
M;!2J?/WINR/=0D(OU=>8MSM;IF;(=3-,XK1ZZ#TG>DW7G-:/R% =FHB5"1I)
M]_W"2M%4M--[T!0[^<T/M*"QG/WD$25QKZU6I7-8BI2<YER;_1M5;PQ0CV1>
MJTCILG+1&CAG!KPIGB*W)X^%J(XFXACV;3'BS3#V=G0MZZ N[P56!XL;'WWS
M)\TTW,_S!4@DJNU0SYP13<T("-^["OCO?^+]T2'<A]=%%[/(M)RMD9BMD"(1
MU3 5.Q=SNT ULI=3QBTL9X^GI_JZ@IJM69994DGQNY&$%X"/U^G";/WBUY6>
M[<0(^^,=5E(GC[Y11DU 'V&U"V<4A4V'1*0F0>I8L^!NC_*1+W<=URUOZ)K>
MZ1/SZ*!N:MC00]W;GACEF&'*+L51C#9-\8[4R!83 <_:\^P\1V=G C=;'?9[
MKPT %9/5(]AU'GVI%)Z>GL=9?="<+613MC<"E4JYCUD#WQ\JSVLX=5F+'E>:
MNJZEI>>D-'"*C$P!@PO?TIWQ,)3K:)R#"#0]*G?Y^F FJ+%!\984V4Y=*-H,
MT@0[[<9 8V\<-3PX;7ND]O'CZDYWF\FK9'M=Q8*8]V4E;#<WL=<4WK@:FXOA
M2G+&\#;Q+=;&%>&CS4=OE+A]SV@0^D1K*DPJOP=O;\=W4G:#OXI:<CM*;R0C
MF^KI[-,8^Z$R?CE^.??Z,\L2FV1BD0W[K?=%@/)?;KSPGF>D5Y9VF6Z0$ZT/
M<H2*[JM<CG!GQO31QDE*I3]MT^G6UI3P$%B2E?U 7944*77<*:T%[!UV"QO@
MB-W3D!I#(Y&HT.L18?S;=>8?XI3;?;9Y?%7J,>+AA1L*DD]\9YN=<R#&J+6D
M*CCJXHB3_]>M4QU9X_:!4>(I?)0'OV6$2&_!O^]_L9D>TVW=KV9%'HO$3@(E
M>V(<!X @7_XBG_E1X4P\#V8QWMU)^!(A.[%$@37QJ.BC],2-DBIFJRB!IQ0/
MWG1VHNXMG0Y_[.T1[V>;M39%5X*)AJ-%V71&(O<Y$9O%9QK.$@%/D_7BP*"%
M-*M$:8?^1/;I'8<GJ0[B#3Y24[*#NV:GS>QNC%SKH8QP6JQ*O.OD>?MVH]"S
M"YNTP9<$7#GS3D?-\!ZKXM0_VHB9H[1TU*+'UC<XEW32+"QH7G X'$AL1P.X
M0KM/!;RGU8.=A?(,U##0E7'JYZ-/ER*CYJ(''/2-+AX&G$X03.QBG?">[#,&
M+/ES>O'?CD=?+D$KTFAKR=\=9-3B[&[:*M]\/#-Y7_FFE;YJF!^UYJKPJ#VH
M^>A,3/"N/ ___:#U?=8'!>?:X^X^D.A4B/.)\Q:(L[_]^LQ??XX'I/?O]T!B
MH+=V'$? I1J.$>0RDU_G[V9,^Z-A4Y2UWO[VNR8M2E0#T =93AO\;R6Z1&+S
M\\\W7#(\#X=:3_W81N,AX3RIMU1,(I#]V,G#8/JQ5UPBD(%:6JBZU03,O_V^
M+TC80B)!0BI?('OKDZ<!H4R)JH>CN+9^5AVG3GBQ#\&=^:_=.JZ0EB2IM^3M
M(@( 'W[LUU%]8M=,HJ25_I3O"!_1]4N[_HM0IF1)B"^L*083<T*V7H^A9B!Q
MU5\0/"0@2-1P::(>0 0\P$)VCD"N_Z9$TKGQ9R)@9Q/R I;K57QX JR$GUZ,
M')V:QF3@^8F 6[[B^%-!/_@M@1GV$K;,8$5JT1[\V!:ET!!V>"#> !I2,, 3
M8B;Z EW5[+><?@5&!%"#FD"[E%](#?T5$"X<-%( PA\GS0!7>84),/5-ZT;9
M#.D#Y#_#%0R<!1Z1C\%FF(%X5>":/I#@UX5AV&-@(0) &0>2,^_[DX_'?T7U
MLYGV\AE(W<$"CO(H-)S$X/N/WV&T;7K\-OX!U2]F.AH.)=WN@B<_46F%]2V?
M=.,$I9[5[?^*Z5<3_;?SR'[G.RJ6?Z*=4#^>"9-Y721VA?7>J@O#]\<W00>M
MXO^%=OJOMFG?M)8\OCJVR@JG?BK3=5%%=.*+L0A\IV5CWI>57GVD-J1T]%Z:
MM)[9O5D]M5,%S@#*G,DL0@\I.C^D]IU@2=TT$P2.SC^QJUE#3?3N@XP;9O4I
M:<"T6?YW$DYH=O48UL?A1U031, TR5]8*=@STI_?M)<(N!A2#2E2J:E7??#S
M;.K[#GTGIS=A6Z]("R 9\'_J]?J_7G?,"AF2:H7L-3US7CW'3P'2OG44:RRM
MWZ<5W3-URS+9D]TVRZ%;/>?S/K?>I[^4ZM_U;Z8&K86WUS1P,NBU<>$P47'1
M7?EW3RJ"PVL</TOHZ\B>/O_:?IY''$U?,@LAQ\MCE8*Q$$.L>B3"I,O0"7K)
MUQ^9=['C;JQ"?2WOS?F='I?AEJO:/4"#-Y@34U10H79ZQ.*"1O9>:6*AX->R
MR66_)56OI!B0[1L,[\<"Z;Y 1)X4W46KD!U][PM!LGQL(1SL"KE4QU\E=&4V
M+O'TM?S@V[;F3$-[82*M[[=7;VSS(:-1;NJ2'29<+"SMW(F-[?>*"W1KBYS;
M+W1;,]AR^F^\+^[A,G*9.EH^65[>&[;Q5639V2O>"$LWU:)()_ ,/<98M1[L
M0\WY;6=0IG4-BW133]M,<"4X@UR\/NYC%I0? YWB&[9(6P1)BVYL.+"Y(25E
MF]2"AG9PY'J<0_/OX_LY]#M=:17MW*[J0'<\POLG]XP5.:NJ/.P+HYO"#VG:
MICD4'A9#(9C)8,([- PP#FM2S)\P6WFVPMS+.J(>;3A&I;-6-O?\ZV=N XT9
M,.K9M!8&%EBF**PV C4JG+2)R-,XR<@=;[_Y\FY_X';'(XT+5_WU.-J$6<*#
M4;"128:GQ=1S>?W!ABAM#?G+!?%+4P8+QUQ3J$)PMDTQ-Q:X(?0D?46)Y5@F
M9,^^^!PN2L!7BV+YTGNL"/3NH%0!"[.'[(5J'5M863F\P$M<9[@ +UTPN2;G
M^*'*;#' ,4S@F[;WF4RZA5>?J7:HVEER1H0V7+\2FKN]6<!6&1Z3G@MU1\+9
ME?!J/S'?2RQH?2!"*8HU8DZ^$*9:]VV/@5J9I6<CL(ME]!UWYMEN';56$X&
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M1$#$]$Y[(^A@?X<(",N M6X=SLW CX^]B8"6;Y0)-C RO&LA5&\4[X#.%V=
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MA]4=2[_C"^,2%F$FCM=L ];E@*TQM+C0!^&] _N6MN@X7Z.BPDO(P$VI1L]
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M8!,7+E2G"YA\R,E\JRN1K4Q=-\LY+]*Z)?^_Z:<#T4\"SAA^?-*#:^8I8,B
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M*L<..[5*VW'[=>N<#.)R&2)Q6VM#YID$ JG&C CL.Y+(3:_1.K$@WT'B9FQ
M:YC1Q"K#J>%US/"9H*+<T9C'Y[V4784H>9F;[G6C;$[(EU.P>S%V4,0:HR?9
M BM%["%/Z].@Q-#X%WG"W>_8/2-",YMF^/"6_=["UI^9B_;6@^-WZV43-06P
M+\%QFI4[JP5'QA.4P[IV,W5H)I;85F"MW]/PSF9$@2E5@W;6N>1M<D1HZ!Z)
MTO9WFKD2QRLFPXQ4'A/-<6N3=#2KTD8(?8,M[,-ZO@/S#67=HK+576@^$_2U
M7OJ?<S^<RS^FG^VCTN?+^!N("\/A .]U8V,UW]6K6ESTEB$XX%&GC,:Q^3)+
M<3V7K2T8)L%N"6%F\Z>FF5S1*XY[?^A_GD8T$FY$OD*MMK7;@T'WI4CO#PG_
M) R,@18.]$80QX J6TCP/"*NQVSKL8T,V-Z/^TALG;;1R&QQO+:Z:'"E.&.2
M?9 6]&WMK51:X<,CG^/R7?;0R@<,$Z!.ON>A--$/M]LDH"V[[Y6GD6?Z257=
M$.WEQV6A^YXT!(IQ:6<JQ%WL,ON)1+ _XB2[Y-=Q0.#0QB:YTVKHC\F?7J9S
M:,#$Y:FBT$?Y@N\"'._W*Z"UL@]O\%$"DIXI.<)8O*PF!'D%D;H#JU]G2K&*
M.LXSA/3@,!NC-L<B,/,\+44S*;]_:%?9KVJ5].46UX2(?*U\MV@Q[(WP=\VW
M?=F"_A#*5-)(3''!?KQ@<2,K[R8>'D20,##4W]N!DQ\N6_AXP<NT"Q@7U,XY
MZM=VN%I1L8JS.!:GA2!3,E-V8$+6T *[+K/N6)M3X$F>!B\JC@!K+EDQ2HBS
M*<%%[C=U!8.=BO;[S5DZ2O@).2H4_GYX=PO%5#:]PK9F/4,$P(E'NJO;2+$W
M"1+K/)O]^4<$G]AYO='S?X4RLW[A(3T35GX@[+4D!SV7>AOB\P5M;>,!]/LZ
MZ (]=&@&$>"LZ3[9I5>6;9.[DHJ2'Y:<<=UN:9&^XM]H=E1.W,E#9/J)4'7B
M5;6[-"@_7H3Z3-X;[.$2D2YQ@(T#_&MF<W$]SH@KI+D^>B+DX8\0OIN9)$&L
MJFT$V4K8JA<P3-M\GC7FW,'E,U50'AL3;Y?#'8PI>XR)/?;YQ*H95_W?),[T
M +W+<3U$>*,9 4>3.9(PU)<OFEB-L8TQ>"$^4':AP,$5I4$9O2PS;ZT9>O_0
M(Y=KA^"%)'$HZ=<JJ]-RF9(2R[Q,"4VZ%1A-*3BR;-Z7R6F>U%SCLJQ1'^5[
M*<+\$4KG([&TIJE&FS^*(]I[6?!UO&-DUGX$.1\.>!+$<3VGH,(;L1L7G'D/
M 3-9A"^[]*T^>P^Y73[4#/DY&\0\:O%8+D"IMD3O$I:[[#:R)&]V@EQ=_JF.
M&,H6L( /H$##W%3<)9?T+EZ:2RR3_SG:?XL1"D]X)M*>W4^2B#!LG!\-#KX=
M?4FL4][K=T/;@,)0^*C [<*T<,8!!&A,.!V_ PM $&_0K^?,T.%RCMB&5^DV
M!48FJAMGB-0<>UM%ES7Q9UXO;S2_.2.6!-LB@&;F=(B]V"3V7"1. 1?D(HT^
MTF.C=V\0(5G23G-+CB#)+WZ=M?3N_;J[IK2@(,Y5HIBXQPE]UYSOS9.,.3DL
M-IO-Y\6XR#0 ^U9$B?0UNCJTV 50E]+23Q(,D<[-__RHKG^T/14INXZZ]L)P
MKO_'W ZLOVT/_<=#]Z(?+1?\BB[F_\@$C<M7<OOP=TD\7?NQ;^%2O[S2!8<B
M26+^4Q%(T1!7\3Z#;%]46>6"]Y+,J5?W!^D31S>U3S5('OEI>0\J'GD2F4<
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M U,<K; K#:8UY39^)>HO,OKD7P0\*&Y.<>34>:''B*R04SO%PY+Z2=@8AT+
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MX'QP*VXB++[D2<?H:<[?J-=9<Q<N?LIRJ0U5H&@.X!.12FRY()R<C1A82;H
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MMH#;46"[7Y1SSJ:P!,SM:9N:O>5:=T6E!7_)*2G+7?U'>-&U[8?+=K^/U^[
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MPI8=K;<Z7_&XIR25_.M<#3:4>0"46<$3=V!LH;67 .\&6-Z/50=OK\Q3HWR
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MI5'L\3 , CA6)8@C$-%3#CILS:!&YU!XL0.Y7>>P@#N+V_5M*2Z(W=[(FLD
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MU:67*S@2.$FBCIV%XI2AQ*WN85,EX@R?5I]'[73@>.J^$UF*M\W9[6^DM5I
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MZKF'.U0@6$[LOL.]%+NB@P^UA-?.6G[5_>W,VYQXB-W!FJ,0W6Z"(SQW0C=
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M&>JZH=P\CM76.ADD_JNNFW^=F'GRLWLWYZR'C6**G,//10J>(;IJ#9!(^VN
M @J_,Q#V,NBZ+:&B(83-*='E<TC!NH7I$9M%_#42K#6I].#3X61NS-EA<[FC
M=!BJ$_0UV[A80W)*3,Q/"DLK?>% R:L5G(B^YY4Y089C1= :^<607AC1QX;M
M4:[2@M$%HW:3*.@3 @A(W%&C1UE=NT> RA"9;5#HOBB#!Z9_B!& >L!A]G?G
M:?HQ^]K4EA(:K.GW[6@99AY:_]=3D3T__,DIN\DS*.)D-HHCL2G!C#_(H)"-
M:O@>+[!LO-&>$:K.%H8H]ECNK^D,U)#_\KPV=_^FTAWCG&9WD^R@S!2Z2.QY
M8(+N#ZC3YIFU&XS#^MI);@>*RAG:%%ABM5;H6GCSP$_KC8; ]>HK24MO<E1'
M5!<$BLV+,I<]4N O OZVV07V:FD'<M^*NL&,A^] 3KG]O+F9-8-AV4%[<;0]
M:"9? -L[P','HCC4B:/MK=^!#*NY-R11FEDVF!3TVO[ '4CQA:: OTMQ\%?Y
MOUC8J!S_8A4)2HD98N0/O=^!T%6ELECWP.\-@7!Q%/'[C#\Y:@>"@&['%N+0
ME10.%I_!#N3!<]0$FD;=@93WK?[:_G/9^)_*_YZOP5]6^V&AZ-]ZNYGA)_?O
M0+;TGQU8)48Q[L,.@ ^X1W<@I\M"Q\4[-GXKHV1W(*]%RUFI9^;^%V41^>]9
M^+N@P/$EEIT_ <U\P&>U [&V$$'_XYKB,W[8/^]@8]]#_WFK^U]NGJO_(U>Q
MSEA5YML=R.(P(V8'<EE\!_)Y/-X$FX3?/,LP 1^HVS.%'C:[P'EPBX^!*-9[
M)\RVDGKDOQ:AO\K_J0(30/^C.05G-4?+#J3O%8-_!U)[Z\4.9)FS.-YT!_(O
MIB\.@OZGB?[B7ZJ/?^9LJ]<_:73(>ILXND^7 GZN@FV=<2)[QVKM0'+\B7CZ
M'C?T]P=5T_^/)S?ZKU3^,TZKJ'\= E2MR+T+X"\.D3C>8Z=LB:;Y8A@2+&M>
MIV6X/DL$63UNFV%RJJ&NT77=/T A5_GM&[2.Q.64CQEN-B?\.M8N\[_XCDU#
M_X?6C.'3<+"K"<.,&]24U ;HI+ +8$'9:&>)CFGIS?&U*0<:YKW#W-4.2<U<
MN* @YYF45XCEM4O)L5=[WM]#_<PQ7>_<AZ-8\0.J69EH0@FZ]EL5"7,7SR-/
M@7<A(,C5\Q3[+@R_:[/^*ZG!M*Z1>NG'CRR=KO[F.6IUH/F):N2F)YR6N1N\
M$34QKT<5[[8'E*WNH*\"++X99,*&%:6[MVNU-3+.[_>KLF#W]#[V)U7<IS2[
M'$W9Y//9A+-_I$&8O,5M;DP<+M1>CM7KQ0Z<IZ2WTXS%[[#T&?[49 QA@[T]
M.D3#[8+7&_NFH!\=M=&X*XT7? .<[(\V]<I1WWQX\X,U@9;"7;6?P1!3UB+H
MKLA?-M3D6]3>,V/.Q%^9:RVF[R[2W%B%V0-ASSU/YK38\7[NST <G"9^*?;6
M.AW/MCK]E]7]_T+Y7VUUU9<0@!J<(>Q(@#-$5@D>4"XS3?S*3;F:HB#;2J1T
MKYP<IG^LQ?#EP=]:ET,-M<VI.6P03M65')5A_?\82CK"L?2+(:1+HS.KT#[V
M=_"@Q! *8)3S]ES/ZXCX.VZ%#?X4%5)AWM/\GX,-Y%Z,;X6E:YI'_:T/L>MS
M&MXM[UE_,/68969FR]"ZIDZ;6*_M_9]:J_&S6D\)&YR!U<4_NMQ:7O;,]_!2
M>$3]HJ47DU6_YI^LZ5HSLV8^QA$*\?7B/3"Q6$D 1P_&IK0<*V,(4/GOZ ^Q
MQQI39NOF[:*JO+P\;H]I;_BG0><Z99*>-:4)OGF38W/ M A#S:*I@U-Y&L#1
MWDZ@ S')L,:L=EFIR9F^YTB%T^,HZ'P0C)(9>(V>;^0ZN\>4[A.<&L^GEB%^
MAY2I#_F%!U2P:T<YUO+HJGB&$I!1T5X)-"^PMU8"E0N?L&4VFBUNF;C*#[YM
M 9)G/F0_4]MWCAN7M]>0URY6>O=JWNZE3("#Q15%P>UF42L$8:U,K$UUK"(5
MV]%ZK&%#&% S/145\PS 6C8RR>2&CX87/C!.5A.C'IAP7K12.QQ706&C(<&6
MF #H?I8JNM,"-3LO/=ZFAL2<$X/SZ^/YD4I7ADU5#R78*Z-?6X>%J7N<W5 _
M%M(GHOY$:[J?4K[6 '9#F%F"$K2@"+.X;:@%1(M?25IB1K$^(11LYP1E#NCY
M(J'KYC$8=3#S$U=CTAMK><W#NL6F>S(@L>UT%-"V UE(88CYL[B*J#%>(_ZO
M/\?:/$?FL_H_+2ZZX>U+9^R^"C,I7E,W>1_2JM-9/)1W3W^1*T%L21MNT9-8
MP=+/N\P^R]J(RY1<<UNC?AH6'(AQGD W#:UIEZ&FY#@I(4M)L8[\268'8]6I
M92GI;>) Q2NS8;&"BNDCAR2)3J?TGU"_25[A?7OAU3&+ZJA3S#0S548PLXXA
M2D>@IJ)8HE)Y'54<#J,L<0#:/B%N&&GL^76[-&JZ_I?ST9,_9FU$ D7".,\?
M=.@-KS[U@F-,[[P%) PCV:8,X(BYCWW11/[$=Q-WK[Y[6I(_8Y&C'QS!<X_<
MDLE%2OO]@U;%+&%I(+&T"&I4BCYN2J5'2K9L/F=XJ!+N8>[=X#GPXXWCD[CC
MP:M!_PA:GP'."W'>;1+(L*Q$[ ECOL<':ZGTVU6@#;:)0&^+:*,WRE[\@UL$
M\=F!=-B"9/M<!+I3<9I02LX*J*!50:'!V[J+.+##&(KO<$QN<=ROD>$=")<6
M=@=R,FF#N=508_%7V_]>;7V1\(5OV20$&0J<?E5PGO7AB]]H!*S60X&9OZD1
M?<^,OW_U[763J\[2]$C46+[A6A3]")!'\F6\;BP*#J;!#TQ]1),V+CP033!%
M"W#H')%9RQ@*8CP%=<P9=/LY#=A5?+J7T@@LP!-QX1T%D[G.FGD9E"KM8>/S
M,E1QWIC_<:Z%GU#(_E27#QRAZNM(]"U=+_D/1UUS)0V6]4I$&@KF Z.[]2:B
MBL> EE\9US^F'._T!9)S7A0\*!CA"6CZJIP?EXL]12MG"7G"64D\>/IRP [D
M=I[S#J3HY"_6MANB<RA5;@_00)2&R3%TJ)E/L0$3U(WZL?KFAGPUCK"W-IT'
MDLYQF@KPA3AWC94;._Z1'U@E=5./KA?W0(7[M6/BNYO/&^RB)78@?T]@JW\G
M[GBWZ/[_HUJ1/5E_3_YZ]-]3_MIY\[_:_M7VK[9_M?VK[5]M_Y/:NDF%+/X:
M+XY)Y])\5"-WL=1_M=OEO_':WF',G=A314C;$ZU4^]2?,7$PN]&JJV]Q;<T/
MK$1;5,L*K7PZ7CC8J#P3O8Z3P1'JT11'$K6W2QQ>&_5>6T"<@GH85=<MU?T$
MI]44)8U^80F].6T@>].:I' XS7T%:944-NM>8,5UREK3WRP["^U<[^R\6 #7
M[_:P2R!>JW9Y.=VWS/GS0?--S9GO+=/V_7_&&VF"9\(()?AZN0+*$O% W@L/
MI*WM6$960K@)TF7HY9QUAVXD-?-LCLQA>7IJ#YO>XX$=2,IN6% []/=I].;F
M,/JW3ML6Z&\=!9\=L5K[2:Q$3*>0<"D)P*IK_:=;99[=/P(,KFO/^\(BOUV"
M&2(_KQ'JTIA[L&,_LH0K_GCHLL@P///DQ7F/:L<+L2,K$QHE<8AHDQ\F#678
MWX6.Q&XOM3*-F3M!G_0KS7PEWE2[;-GGZS3FUE]Z>^G^.(T5&PX5 -][ AS)
M?9BH@KAQ9!.AH'FPUJX,O_9N).(VY"I4LY#G+EO"<.-6WYX'$\M9:\=!"-G*
M+-Q-Y54#").\FX XDF1D3\+V$DLI:E,.=N,/_,JCPNR!S*)+B_H_\=W:MW&\
M+$.DSBIQJ1O'MMPF/XS@V-ABGINT?KQTX.U7&?^4"Y+V!Q/A>; F_MW,/PMP
M/F;= G3M4J5-Y63&R  ASFN1YXW5!<U0:9XCLCEVV%N_%GW2OJ8(4ISO.%R\
M,1W,DS[EE)F-*)N9BCZWK/F\P-B_D^']_GK$]3-9PDES([FUGFNY&Y_$0C;8
ML[<_O:HN&KZU[ZK S9$)(L?:?7 L]LS7Z,O:@J!770*DE,-7YV5'RNG'?R68
MNG_KC'A.>NG^8>5JHT+]-2D8;<\Q[/ANP"L6MSA=%S6]?6B04M 3S/Y6QF2#
MH5))3CS?V#M_R#1;A__WLJ2OI.1!*ERPVTQN:?;(TT"K:>+VQ>27<\=RJ;_G
MCY<.U1(+3?N,<L8<:9>V1PLSF=%>(PQZ:4R2R'DX9]SK\_]V!>:_<-D#)/XK
M997U3PMD>T ]0PEL8I3ITIIW($U93#-[..X+P+8#82] ]SO"@G%TY YD=/$G
MG?GOB>;_OD1;D8=V(,I9)#P=@F,E-ZS\_ IM@C'R85GHM;T[D&VISQP1_["-
M',SSCPNAG__C1\%%0<W+$,UC<3N6H;JA?&CB'B#BQ8DPJGI7;@8SF^. 7KK/
M0\.1"M*Q?:?+D_^PV7_^UM9F; D4XW>18F3TXUSHO$U$R)9-T-2W;U/5/(H#
M2W>[!W(%X(936N16(=,H%H\[*,SF.Y DGU(\JA<',;7($@H28\$S] >.18^0
MGT;79:38+#K^:&+46;[_C5'[AJ.<Q@-*8)^4F[;1Y#RZ.1!E?+RT [$WP#D[
M+$ZG4'O1<0>B<2]KCNW7)(+^LIF1Q>*RVX'L6Z)JDZ>H?DNDE)Z?K9CW;N=>
MC*XZY^6\S>MR_MK2TR@D_/:6YKM W2=''*+,OC([1NO),*M1PDAX@41(2(BW
M2TA5U0*7S-$7W"]>&EV"0""$/?!JJA,BGG VC^G:5W9S!(Y[V=3LUAT9$HBH
MDS53GF9@DZ^_0DC[0U?E$-+GTYF#A@WW1^S?V;LS*X(II4_&SEN@Y% ?=R]&
M((?(8?1]J$%X(R8ELX!Z__TRLX)7^;A)U[;?I+ZTMGDM8</<QLSCUN@3\I#^
M;WGZ972[X@XD&#X9[(Y(A_%$\.Q A(%@VP*R 4J#\B9'FJD>^"&:>/>QO/K=
MWS6YYNRV\D;8.3?CG]BW1(3 C76QAL/7:0^,1PMKFKR<6U!N46>!-F7"V?NI
M"*<P6L2[BYF9S&.Y([]7ITHV56ARH(IG J1VF \03?<+=$1FV7K66) T=42E
MDMYML2_()[T]W^,9V1=O(W04.[9Q&R:%$F'$4NR:NN")J..CL18EGOQS\\NC
M*=R3^TJP?-)W[Y;$=[X1W<21.T&>7&0^^1_LO7=84]&V+QI%1$!$.M*BTI2J
M=*3$AH@(B$@O4>E=I$-(5$24%J5*C4H3$"(= 8G4* A(#45(0N\DE!!(>W'?
M[]UOG_U.>>^<=^\^Y]S]Q_K(RB#)G&O-,<9OK#E^8Z"\0'5ALWB?.U00L6"R
MP'M*91CFCOV!H9T=?R3P:E4ATEZJFIU;8!\^X_^'_W$9A$L&"0W9)_E:MPV9
M*&?XEWO"28E ^T0C'7;)[K?.LCUOKL?GK%M$@P/U@3C$2=RJ2YJ@D%!3H:*D
M[%S&(E<ZP5I?Z=2F,(%_1&&!FR]FW#*IRK@7U1WYM:A_Z6P<F?,O,]ZD"I+'
M22  =%BP+H^%J)OM#+?E!:Y%8G:5.FK?ZR?SYL ^_> $0R8<)[ 3G5'.@6*_
M3(233WUX].,LS^MNPR,\W\^B9/NU(K7P/\$CVQRFO$L'QGTJ=NK+]?:JN\>S
M];L#J<KUWT8L'*TMYZ5VS3#0#*D/<?*=>D_^.1SSW^3X/RI-0SZ6]N%/?[87
ML"ILFSAXUJPSU\7.\])M;9ZBXYA "<GZ&"/1N1#<B5RC,U<D??0EZN2:/0;B
M4^<&C;PF(Z5<G;Z*J9^R*I,6[M28')"J]\'#_%&3\?B]M?.$&[,SLJ]N6T^L
MDR/]V<F1O>TKFF$K =UMF5R2I".'MB]%DU<I\G\*T0)!N$_8VKK\&3/QL!=;
M]M[QG<.ZX3/U9NG=OW,4>%BV8EW!2L*Q'&4YOM?N41_,(">\Z9SL%(]VWV);
M(=2(ZX5E.]C;KI[VK+L:QCK.SR]/YA(SI?R.+EHB)Q'C?*0[9&>*")5O"'H<
MHE+],V2V;R38R/EPU%WB$UX'XZ1% .N/8Z6E6G:TP1I"'M\C!J"R:+A:]WIP
M)$6+B:XC86II4[/\\$[/:P(S29'K7K)BC=$#ONO2='_D%MK 7:8/A;=NPQZB
M\I%#"R!R9%?\F%HYY[5J>]]+78?:3L\EFRFL&;DY)__L?"65XLC*;XT7D+M7
M;C[\<3(EU'=E,K*.4DWJ#EH>*'I_)/5NE?'UY/'3'^+D./_G"OE!1#^A"A!5
MVS!YQ\BQ>!.0_<#NL>:F*=5[-4:XS*A38B<#AB7>)21YV\5]- U:*&9SJS7Q
MRU1]+G>EZ];R1MY/:AVM 8;#-LA2W#O,QN*M>4"]"BTLHTA]"ZQOX5">7O[;
M6>2F(2=8GMX+)MPQF_2FLQ?.ANOSAV6;#;L.!BV35F#<NJ[\'S\??FS2= 'K
M<_/'\<S$ZH9\(KA%?1Y;R[;F2]&ACSGQ,@#/+6:+VU=]#3XD9IB-GJ;UTO/,
MB-<N)7:K_KB6^O#HO%_:09_A3-#* UAU6')<YX/I#$]M=!\#X#4E/IQ.G>+N
MJ4:<.&,F0'O?/N(DTCC:@X-:4317/LT.I>)1#[%_&A.T4WQLKQ6&J78@QJ *
M6_6.83J.;YR;OI]R9G'W[3[.EZKSY)3K[9F6.&0':-*8?JR,<@O:G3$$,2%S
MAD;.(CAM>D@O*W;>QGD=V%@TJ+U&]ZSC]C\O;J3+"PL,T3N !"=P I#-;@B_
MN>[H'#H+.]%E)869D5./EU[.4+@Z]90^;JLM]?VW8I!;BPBN&B+YL^%N(]*X
M7(-&WI>?9  .)=^MZ[MQROUEV,\R_BJZ[+NEX65SY<=.?AC*;-B>.<C5HT(2
M)[L.)!B3<@G782>A1ZG7AJA7BNJ.=(W>-O&:<^_)DVEO8P#6&MC$F'>S'OG=
M&[^*][Z5Z-'0=TEMR$2_5\_\H)QC)T#-V2HA-5_1PG09*5/SP(#?ZL;[_P04
MO/\*E+Z_D#LMH^2M!X,G!89W3$RGM\;'TY04W6UYXBJM#J6^OGG_RL[II)&'
M_[EL]'GQ02F5FWC+&[9O<8=6+Y^:5B'"8UHDR!;FQ/[$W4E?Y9N#/G.-P[6<
M/S0,_#G.NX7H/^&@RM)0*%]P/)!@@9HP-"%'$8JO#;L1IEJ*2=R'PNQ8:>MS
M%2&T"M<^W7$V9 ]O **E=PE%L&&J66W_^I794R W_R<30S]P>A)DF<(HEPXX
M#UCRT3TXRE^4^_4)\2[ZY00X$H9+0A%N>\!<_8]V4BY#O'X-4PTP:Z@!A0H^
MV7:2'V@$$.' M* V4_>@:\Z+4Y1B[OD&9:XMY77JJ%#GB(EYT5[BZ&9U]1YB
M'-Y$O(6>^4)R3B!R7J*W]TC[*&KD>L6[NU=M( G(6N5(?&*_-1/J>,%:]9O/
M4(Y!1!U5YGUWN457*]&:\<'?,:<;3MG;&)TZ:9C,=G4]X[2+'$W20( \ZI[I
M')@0==M-"3(BLX%=:I*J,?[PBQ:JU/,YW/2H\&V%<,]66^61/?^0@Z]7X\Y5
ML-3\LSEV<PS )(S.SLJ,1\>\0V>YE,W K&'3]YFNGUWFE5>+X^_8KU,M5WOS
M-CB,AI0N=T8],(BPM?+/G'M;^^K;2-!"8S$JQ5Y];L@0D3EO&Q(8$^;C*WV7
M.W]Y(6]YORB32J?:TK*8V,&?+ WLU()$.H>7+'FDA$>$)C:KJAH782L>GWV=
M-KGM_%;V2HZ[]Z$L2L9?4!\%HD-^X4.7@(YEN:)B@M,G^9V4AF:=BQPU+[N;
MVHW 3SUHU"]X^ZT3^C(LOCT/2 R)#<;#!9:L(O*RH]A?[)D-*R9[*$GJF0^T
M6EDLW9#?AI/PS&\]1%;N@OF08RG"*Y_)D1:^@SVXWKLA&D)<P_'A2793<"W#
M*8F;@*X/*,?W7;JR:'[GF)D(N;2H?">1*$KMTO[[ICVS[C)"!O\C5\^'#8_+
MR@S#S?-0(3\.*FQW]N #-"'[ 8A1@;TW77QDW7]-^8QMN;)/A:"->^(+RX'A
M-%?)UU=:RRS)+ 0+4C6M&81+0_')D -*QKTB')OY-H>I;#,-CFM^_'FNS]WG
MIJ)?O?/1.&K\-(YF2WN)PI7#JH'K&>+(F!NENF=F;2];$RJ^/,Y?5XFP,VO[
MS6W0]J-5YX(J6+Y30M1=FQ54CI_H>)!76J!>M2F%=%W(AF>-'?B)$CG/]<M%
M69_,/7YUH"W"D10?TK05DI'R^R ][ARR#X[Z>V<:_I?(7$3V8\E*H/7 4OI/
MJ"XMBZI.5.V:8((#_2/DU9G@OEQB69>$.*JA,FOZ2 W7 U?%^6J%T;JAOK[M
M&I^D7Q.-&QP.P%]R3,,/ESA.RX7J+UM ?X!J@#$[8#[;L,GV/<SC,$.[ZNU\
M5&5-^J#.JQ<W^#L5Y_.$!8+#>5X_^P( RL):=4 NO:!K!%0K8L*:Y$Q&S(@"
M3_0BR5D@<7+$4-=>:!;WRZ!7]E;V.H6U69YGMF<;[66,WG'TBR4+*1V>#21E
M,/7@IA>X'IF@:T+D)GV@54"5R-#0827%%G&R/QZ1!#8:TE5^P'-QTO%8_FW'
MZ=[Z=94>C?46K[9W"I?K.T&?E6(H-V&MIV&>_D^!7/J"5-L68L;:(L4H;+M#
M0BP:7]$DWQ^,<[P[L;%DJ/?\D['HXS?R6DN74[]SKJ72\^E#6)'F /=0H;5)
MBL9ONWZB=:=(H)%K<"!WKC=>3^]MU\'\UEZ2QO'33UYC M\EAGPP4SL-Y&$Z
M0140[AVLQNP;F"P5NLY*#"7](J:A.[B85X"X%T^5+PBKH]_@(S=RG=6*J3:2
MYQU4_?U]E!Z@<)/S2^;(VZ$AYC@#AV&X5W]Z UQ#S)K%F:U+*K?+DK^R)8+J
M-SK87Y[XE*5B$XYR%?&L.CRT!@6GAYXZM@T+=_I39?\D[26$YT^!_F/>Q$@2
M!RW3RKB' >"&R"$LXLV2U\Q*5Y(+-F'J<SC(EEFX7NV0T#?>6WW\ 37.UXC%
MK=%TKD= ?L7@<_H=B$K8&'^LJ,$2 3L&23B(?S\?Y<'RFE:,PGV<5J:5MG!#
M.V%'4>Z;O%X2QT<8 !\3N\'9SHBZIQ$#V*5+K 47>LOM[4Q1:D+'!]4;';@S
M!:1=VQ]D5-+>-8=R4WE1= X=BF:8!=ZTN-2>*D-[KZZSR4)N:A-Y\24XTM>Y
MXN/3FO*[F'65FP-F"BEJ?.OWJXHPKI[\ZI 'A&)2 '%S+7^6FRREV:D<)^)
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M77T] _#*@!J+F+X:K3&'F'UY__%M'U/O72I0@K GB,]_.M/-F>DI0K#R'IU
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MZ=%([%%M^]S'^/S+>O?ZVN%[WHT$!)5OL2NCR8V(2-RAZ7'+R L[X>G/<Y\
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M.M-"'KE"GJ1H]@<3#4D>#<.ZOG@==]7: IY%F\$TT\<_A($>EKC]-X#V9&>
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M$-+/^J2HH&4X0[?E+D(5+ -/^:E5]C+0^-,-&1/]5UO(1@UP6%QI' \_X"B
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M@<&5"K,JQ@C]Z[Z.137Y%I$FNMC'V+!_<Z&RZ;ESCHLG'>)+.F3:;"<^O<W
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M=6S0%YC!?+DB<R?&M%NUF>J+,^A(1G@)#E#-6 )[MLO]K** 8(P/8;:V9/>
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MHIG)1NCDZ^N2\_LO$VK*B >YD.JK"X,OL/* PRF<MZ,F2Q7[?@ZQ)KO%G]=
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MRCE@3+;X:9[3*.?;%^&U5U_\BV[SA9D#$'<5$^M[7$CA\D((00A?5<_^6J[
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M7%PGU&7=!&JI^4?H$F4NE-]M]1$_J#=L2]]2/3Y47FF&P60:.L#,C7Y?&K,
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M(I:@&@>TPM6?ROZN\G!'P[+"N8\<HWWI",H,X9<T^UB//Q>"=4( W9A'V_%
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M._RJQ$51-)2WAL8!#:HUM]%F O9*5+?##<:5F>;TEPH7&M8LC65>)>O_X7N
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M/%+!#9EA28O6V1=DYVU[ICT-PVV)]VUWM"+!?6WS?(SC('V&Y-*&'3,C!3Q
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MGQ7$&PZ%R/<HZCDO"0_V)U;.\LUR/W;OAYKBMJ'NL$,HS<!XMF 9B/#'@G\
MKGC1X77 ]>:=U2L<6)V\"A1 18&&,H0(!7K96R,H%ADH( #J7,S:A0VFW[K
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ME0+,3NIM@U+O)"R4PF7^,L(]O6*V_ 0'QC,+_?1-#T#=!!&*&*@KX8W:D7Y
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M1*V@?IT0#<7-AI)\KO<(3[PLZ#-%3'[HV$>ID7AKYG6-+5-ZL$7AN*>_H?R
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M\O7ES]WW):9OY\^+'JJY%UPK\950A*)X4:OIK:!WR%1WQ/8YZ9!O#\@R!.'
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MO,@T_ZK6?3.QO7[2SD0LLT- 9=)^Q?+:R'DNNI'$%/Y#!&6 80"] &/ F:5
M?\5*U1[+*^"^_,S,/57_S+AA\%M[H_O:69^N/U?,K31MTBPJ*BI6515KQ98A
M'NIQT[S:,)MI0@\.?JF3!>%GA_3,R*I6"7<Q8SFVMBVN63:C1F+Z79U9A;<?
MM9X:.I)36/CB-M>\11=(@(P?LPN,;DK?1Y/5*B6$E>ZMZSVK]=3B^>M35X#M
M#=]_6_]_Q/ISQ^B#(&\.YF,*BO*$&'N'T6(@1!-*<@\F^5,_OU :8)>M&ET<
M[1WLYU(8[U!0.[67WV*5=UCDX[V@+@F:2ST25'N?.(4=.V[$"@-<NR%6ZU5/
MD GL/EN)!P,GCYKMGV<:BF_M-1,/D/0UE3Y7F'DH7FW+1-8#3556]C]AZA=/
MDP^[[A05%SV5JTSE3CRQS0A-8!R%I#S+%F'W 67)S?'#V :X8(U7ECM6X/ V
M.:1=/].&M-H[56E3)*#*(T8FYAI;$12]IW5@*P7(L4MTZ@=6PK>>&A%B_,A2
M&WX'9#EQH\$%,O4((;^LBBH;77ZU\G+?TYT2+XMJ(G<F&'>VDR[8AH]R+3ZU
M^HB@GL.!JEX-W> ^Y1BF*_4(*LQ>$[2C.9#Z=M.2FX0?6?N,N1UY?)3KP V5
M9G,^M7MEX@_VB%8[QF+'# ZC SFP,(O_P=Z;1T,9AW_#4Y(08]\9V<M6V2HR
M24*25CM324A,A8R,N4OV;4*(RB1*V?<1D\%8DB0[8YE%H;+,5,9=LWC&<\YS
MGG.>]WU^Y[S+.;_W/>?WQ\WMC_O^WK[7=7VNS^>^O]?UG2<F;$+$PK$BFY"0
M8)@DVON?<V-SVR_!]!)S"PM\Y.I=ZZ\IEI<?W++HM]K[+O+A,;5X=YR4-0P5
M1J]^$ %/Q!BEN(U$!/L)TCOVVNLY6.U?0E6G$F]4@T;F6+9A1P3S^B:$)08.
MT%UB[YUYG7MOL.>]_.D&I:L)CT^$KJQ\S0\U,MAX5!Y^_M"K#P=,4X;JN44T
M9++:;F8OR<>"OO$P(JP,C';_0ALW+><>(3NF?WM<D_PR5V_H=!8R/2?GDI/*
M_6VZ,MM*BX-<"\2Q047??W2*Z@=2[UM>B[,3>7?T,Z3<['?I,H*?<77!<^Q;
MG-M@'P-.(Y*PBH%N@&"$CX4S4[ W+1RY_-UHU6C\>V).Z.+G$Y>:/OM?O/Y[
MVZ20[C@\D)A^3VB9QE#>DC?.?H:SN#BT9629XY70R=SUHN3GAB^I"X[>!H$0
MK?HWD.P4R/)2=19P PKNDT_E;0N^NPD1Q2A@.A$RU@<X-C4,[NNW\T1Q]/X&
MIU:82#Y]KFE"_E?2L%,"R?163X);FK"(1DOH\M:;4X!QGN\-6ZKC.IO>V_XS
M)MCQ_1>S9%-  ;3L=M68N,3@O7QHB+PM<5TEX]+HHUOM*^'A9Z$OEJJ?$:EO
M8(P+L <XQBG*5,$B*QT<\8\N-Z'8^;T $0[A\@6-_<V"%X"/22E.A/1?;[9%
M1=HA7QH8C?-ZE+\>?QF8>ZSTS0X![/A][?]PL7E;Z-:./:\INP"^?<GS-/OE
M +IQ0MNA]TS=[D$)QU=+]S[YJF91[/&!+SW\KQ-P5S]_K(;U0_($&=T.&N^=
M6 7<$JMM[+T<=2+8S13O]1@U7'F=,''F"\'LU5'>VPJ*BWK*7,_'*>N@5>W,
MG$L[(=^>E.GOAZPM5<=;[^3'6AA:D8XE]Y,0M?B5 +82QPW<1J^&(6'BH1C-
M[U]$H1(.I;  1UIFCI'XQ5T\_YF/\22K&YL0+\PP3#D</H6GPM*LCZ)2G7/_
M373ZJK6,;D+J0YY*(_ID_%\VICYD3Y5,2>U6(:3L#TN!K 16/X$'$4$]9!?N
M@1,LCB?+Z\1)MNT'!YV'0M:A*H& N.^<%URL(5/8NE][I?^$4:B#9=:<PMSU
MM)*TS(I:Y#*<6DC!+[9OT6[X\I0?VPF]*_520TW>V>81LW0HHD$"L?0O31#]
MTRG.U5^\:.B!JWI%$JH/(C#,D^/L96 [UL0':8 @Z8BG]PTW^6'1Y$_IBZ?9
M,U]9@S;DEE-_6WL Q@5DG+7$)B0V#A3B"7?KDA J%JE6,7YEOE.HV-^D.H]
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M9_2RL950EZ&=XZ.(_AG>=UDK7Q*XZZ@N._C?&S]RR^$WX=M^%N@N<]D',21
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M/GG7_,K(F;J %6TNG5/[L+G;SS3NRLZ85%;/)B05S\13!Y?SD.S^D(#ND'E
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M#];'EUUX GS2PAX$$Q2Q7,'S;,I?6)A;/F8(UQ# T8,M(\%B8B.QL6UH$W(
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M;+*7E?B%H\B<IF$[Q02ZK;?5,:^)F>?3%;Q(YG<]TU^UG^VVM4,E+T"Z3U1
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M4$_C:6S6,QR>KI@,;U3Y<1DKH_W73A;";]]457>Y@O]IA7(1WL$@IA:K"AW
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MX)P^6DH ">-77YQ)O(0M71"Q%IB[(1)68#\S:PM6#+$] "K]!:5?H6*2C3#
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M.G3?2XQ$!SS=2X'U+((#2M] DP-,-CV7#"BI>K^Z$XP2)A7MS\?Z)6BFN_C
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M+ 8K<\ULU^4=LJ\Z6YU6.I9@EO[JO^U[\&^#!TCD4N]>#NA- Q/, ;7&UW)
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M/43[-B>3]L1J D6>[I[4YOLW?VZ>_>Z^VGV8-B20K_67@E^JCV9>G%Y+LFH
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MFS5_OEW-.W[4K*;TZF?A#=ZX=^5;9!)3,I)LU\\!$4E#\,ZM)$L=)"M6%>"
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MIJ'I%XPP++W2%\+__UL!_T\>8,[<?P%02P,$%     @ .X!47"WD X:*E@$
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M>:5HOY4<WJOD[#A,0Y0QB-/,AP@%$<Q8R"#A 0^03U,>$Z,CRU$R4V\R:WJ
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MK4N]?<!YU>87JFN!-M>0UVU0PSM5(D[^?"L5<-652WC_CU5;:J6K>*D>E*I
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M7_+FX:T\E<E#6[6^N?Z4%_QCPQ_K!?*))TB*8.2'$42IY\/4PS'T1<012I.
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M "@4!V8JZ1Q<>KK'(0AF2N:7KV"@#%K28$-[@I1:33D=:8QSU&95#9JB[^L
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M77LZ^WVE]'OV_-JU7%HFT4IO%73Q[]H=7SUNB]UYD+ 4IXP'.*,%PT6H/>&
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MWXOB>>OJ>Y[2Q$U^+XI\W//W\BMN2MWT*M^D";Z8__RTO)/5O!0SQG,5\"S
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MKFNQ_1-@DUQK;.WLRQAX.;B*->IIWVP\.T/>A.=;)]&?58&*[,FH6).=U*9
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M)XMS\_%W9AY\D:M^5%1 ".<\%C@+>8%)SCG.!1&XR#-6)"D100HZ* T1&_^
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MEI7)_9\%<1$6TAC&@C']CTB[2Z&(<1PI$HH\(8$"7?L#:(_M0FE.SE0U[U9
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M\37QM8%G.(_O#GP3<$P=.:"\Y6F?PSZ)M""9T( J'.=,>Z51$>+<%)0+28N
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MKVG:4X [=8 !M8C-C@03T#KW3#1]8CLV4,/'WNW/EI>1  -$:T<"SBUFZQ%
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MT\6G9;VJFI_9[<]Y/<N2)%5)%N B-QW]:9)@FH815BPWICHCA03U^3U#9^2
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M7LBEL8XI;:B+EEHO=Y.L]UE6/9Z,$SI(N+8X/!,X2P351YTHPQ'-.&4A9TD
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M!<ZB(A$RCFB4VD]EN$AN9.ULZ*,= VC' > U>ADVB].$5S!@VMN+@TNIU&5
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M7,W-V!VUTJJ#'DK0C*@XPUP0JJ^&>8Q96$3ZGUFF9!IR:89>;B?07U2VTV1
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M#PGO?YKVFO*-7$A5;@ZZNJN(!ZG,]>L])RDFA3"YO4I@(E*N[R-A05+B%N$
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M+XJ4Y*$B$:81,7T%$XJ+C'#,:1XEJBAX3$&E\I=)CJP?-1%SC^,54;2$UE
MT+-[ ?K%!*9RAC;J$#=-L2KRJ*9_A6H.?$Y?M976VTS6BP0GGM1J"\#Q_%;K
M)]U;X#0^?KWJ>EVJTC0-;!L7/]'Y9[HQ>8,O9MK,@;,GC2B/0Y'HDS)O>@D7
MA.<X8&F0!4D1LQS<(L>5F0G=;M</R]6F_*]JFM:Z.3NN-^6#:0O8&6IE/OJ9
MKOZ2F\I!U$VU92^H(Q1JI8*WYW'>.CL[-=6&0(,)6Z[0CJUSH-:SQL;TTOE
MR6./(&=6)N\A-!2T4SV&!J_I4(;_53[+Q9,T?O=3'=_?_VQ:[IHJ$?U_XH[^
M_&.E+?M,2D8SQAEF@B:8Y%F&BY06..$QH4D2T""P"EL,XF)DRUG10(^KI7CB
M&V3J,2!SN)RA[3=PDP$&LVP-1U4$9VO,T#_WQT-L^4(M8U5DX@I5S$V!+: 1
MP!08N_4'&!-K6 ^!H1CUMA9P7GRZC@-#Y=]K1#!XL:'GZ#HN]'&A3:7^R2R.
MBSP1G.-8D1B3-(UQ$861F:>8%[*(" E!*6CG"(V>[%*3:1)>74^J!^! 3Z'N
M(KN>,)O8KRF'J8F.<6P\+9;W(^$!F5<Z[IT6]OQ1[LSG86K*3?[PZF7VY[=9
M("@I:![C,#&-Y\,BPS3/$QR+S/PDSL+(:@#.;LF15<\,;=?OG2IUUO+UWA&W
M7\7<A( ITY]?/MZ]?X>^W5W?O?\V7'V.6>[Q\#8?KO6D^<=.13I+3:(,QZRW
M7_L3OW$NYEB90O-WLOZS,_GA+7TL-W2^'77"XH3*)(TPR93^#Q5FW&_!<)Y%
M1 BA>*R@DZ L28^L,&^KVONUZ<O0M,6H2CEV'2_^ URD88NI[0MM#*1@6KF;
M-(8VRVTYAD1?9/O.,S^'#Y>I!$*_M:+];G9A]]%&O%&&S,!1]5?/84MXZE(.
M(" GJCB@*WBM0:LU^>/BG51RM:H.ZU6GC;5QL-:3UN?SY=^FW5A;EL:QS/((
M9Q'-<9Y(A>-4,A++@G!8>M1PEJ8S<\\M;41;XJY3\=PWP-KV30@KS";:EZO5
M[!KH6X:KS]8LHRW/:,OT9#5L#D".6]8&8>A7J'1S -"R^,UE93=SVJ'P:7?L
M.9LD,PL%S[,LHSC@:8Y)3C@N>,9P%$5)D1'"69HX#.,"LF&EV(.G<'EHG.T*
MLYV%' ,UQPY!'=/68>4*N:46@DV<(Q*>[!F4^J3&RQ&:0TOENHQCA8_I$_E&
MGR.%2:27BW5M]%8K8Q?-^F]>=A^YI2_5=("_Z4IL>Z!H>_GT\%A-"S!I]UR;
M@'\LYWH9TU/-O*EG)$BR*& "I[D4F*148):R$!<BBS))1"9ST*UV IY'/B>V
M1-'SEBJP'FB";;,SC;_89L#,:<49KEA#7?91AW]SQ>Y^KI$!54)<=9-+.H)<
MH>T6[V2ISJT>*Y&F0]Y7Q=($'$];V33=%AQ50$U(VK%EL*Q[;[ZGJT6YN%\W
M2<Z$DC2-B@ G*LPPT;#KMX%0."815TD:,")!R:RGR8QLP%NBJ*4*[-A[&AH[
MBSM<8)B1/))UA+YS_3+YZHM[FLBT+6][!3WJ9MO_Z8&.O>NGS8^E2;VJ:QEE
MKEA4:$5D!<-$A2'.A3 %C7D>!&&AF (-KS]-9O28^-9)]'^>5N5:E$U[-(<:
MQS,X 7UJSM)#P^-.@KN[N$[*Y=MMM4_D=5Q1)P4]ZUXZ_>G!':7KD46=^^!A
MVG<2,Q&F(8Y2:0:I<9/2$E!, TH3_6*-]:72L9WT!=(C*_1>DG<S,>N3:Z-\
M *"6EY]18 +>8?H1FJ@9@JW\_GM&7R+\6@VC+0'IZ19MNX*C0WH[]+5NHM!>
M(;[*N7'CFCJ*=76#8)T;Q'H;5D\*D>2)#'$FN#XNT%1AFO, TX)E62H)CY,8
M8G&&L3.V%:KN_VS__M]Q$5C$SL?8 TOG]63(NCM?'$&%NZ^]8.'+FSV,F6F=
MVUZ ._)U^UG5S0":1!KS_\:5_DSG9N6O4J]<&D^(^<7U0NS_H//)6<PD9R(Q
M!B]H^E@6<1!B'BJ:B90F 0EFCW)5+L6W#5UM[*S@()X@JGK(F7V*@Z9YA;A)
M0I([TE6X:;5EK/K]%6+ROER8BZLYF[Q(>KZ =80-HHKQ3 0Y3I.(ZPV2":9Q
M6I5/$Q.-$+*0S0:]7XA?<GM:OD;9'*E_^ K;0DC"LR*CN,BIOJG$&<-:5T)]
M@@A#K5%!FC,RVRPW=/Z+;<F.)^OMN#./-'#;; I:_UC^O3 I+)L?$FG+O%[.
M2U'5L*[;UN]5][/JPVJ^_!MX 1JV=7;'C<DV!';:J%6C2I[<T;M".TY0_0FS
M+0<_W'N@+OU^,D:M2;Q;+OR=3[R Y^EX,HR724\G7F [/)SX672(CW8[[V%[
MXJ<L9)P&"F=$I?JEQ@J<%Q'%+!91D<@H8C2 .VF/Z$SCI=V-LW"]/YV#">*C
M'22\DY,6)+>CA_:L5%Y=M,=47L%'>U;4TT[:\Q]W3>Q;::4W*:IUYN!,Y$50
M%&F M3)23+(BQDP$$A=<I%(QPE4*\XP<$!A9.7?D]$%$(_3DT-[^"!-+3\4
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M+W)C"EK;,3-O7LR,F8^+>@28&=57SY<Q*>9M&#&+8T$D$5AD:8:)2CC.T[#
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MCAU(O@$(VGZ='Q4PX.'T!%;7)[%R20X'809(T1@+.[<,#9\8PA(T7'#HS<\
M+3A=>H:+G'O9&4X+#)OV_$$*X_#:C@=J'%UOY$*J<C-+N8Q#H<Q\9TXP*:3"
M>9IG6*64)04AL8R!K2)MR(YL>1OB;G.;+P!F=XSR#P/,GFXS'1H&NK/K&Q[0
M;PT7O_N?S6PGMN>1S!>(OLHD9CL@S@U@MGS:=3AF=PS]C3+]V/CR?F$ZLFE:
M#9'U^Y]-=/3ZH4H=NY4K,Q%0_^!N^?XG?3## :NA]INGU6+]=3F??UBN3%;P
MC(:J"%06X23/&2:1F<_#8X95G,5,1I0+*6!C-L=E>&2CU&6WTL.68?3=,($:
M+H %V*/OHIV]^Y7V!F8I!V^+PZ31:;#R-K-T9'8GGGXZ#?C'<U0GHNMP6Z]+
MRF7E![A=E9K-1SIO1QU]D9L;=2W^\VE=7U5G><A3QB7'$5,<$TYB3+- X) D
M/"IH3 *>04LM0!Q8V8+!I1:=U%U5E]PO[M'<,(CFT"Q=!Y0M;N[^07,RH T;
MK<-RRTD[46U]A30SZ$:A#CNCX0:XO8^&G]OUW2^.L N\$Q2]-WC8BM-=X9TD
MW;O#NZT K]J^UN\!O65?Z(.<!5FA?T\ESN)":IL;IIC&+,89%Y$261HJ%MH6
M;7?6'?G$VU!"AI1]Q797[GXK.$ :F(FS$@14K7V";:=B[>XZD]5JGV"^6ZI]
MZM<.IY+WZTWY8%[>7V7YP)[TM\]HU#;9?):D2@7&517(R'3MS1-<9(SAD-&"
MZ_\I F%5261#;&1%V5)'JR[Y-=HLT=^=8D\3/1 F9:UD3QIAR%OT$IH6YPV/
M&,'4;P?/'N5=X8E'' #G!X]XN)T8W'&!G0XL!>T]#UQ:8[H3@*4T>^]\VV=<
M0J7Z#D?9L@X'=(8/;ZL2.C];F_*;:Z6J:Z1LXE6Y4#$+:(*)OGQA$@IS'TL5
M+I(TX%%"!2&I71F?%WX@7WNG@KX]!K7!K"KYT&]?EAN)DO.^[!&0MXFN3H@F
M,.*Z!V-WZO6N'J;+'#+<H2U[3F'8H8!#0K,3 N\8KAU[ X Q7$^ ]<=UAQ*9
M,-;K"8_]^*^O19T+]O=[>=<I_5&4R$06"J<LH?HU$BM,F4JQ8DKE"0]#!HL!
MGR8S=K;-B3;R%PH!(!C9A4&&2PXUXF"A70JM>V3R5TM]BLC4Y=(]@IZHB.[[
MM)N"'D[+VLW1,E.U/M--\Z]OVE3,9?/OEW?:/LR2, ^H7A2+5&HEIJ:H4-(,
M\T0D,8G3F H&F6KNS@I(T1U'FL-T>@"L=GH_#5@PVV U[:]E1?]V7ID"?9FL
M<A0K1K>_1H;5*_2!EBOT#SKOZ9P!-B_#H?-D@@8P,JF9&@[8H2GSL**;N3/3
MRA\[J9>RR 25<8J++$OU042?07(I,LR"*"21R!B/$\A!Y&#]D4\@G^GB25%N
MT#$=&K06-6>]Y>H%R985F.4Z1"C)F2I"'N,H-0,.1%S@0C"#4!$%G!241 FL
M9\\ C)RN[U.@9&>T!T@.]%^VA$:HNCLCA">;>+CZI(;NC&B'UNO<QUQ\<3?_
M^/@N+)IO410DE(=48<Y8J*V1/EM15F2X"(5($\+"-+4:"WB\]-A7(4,+XI?9
M$]O&J^4J#/!V8\C@L'#R->W)!'$<N<KFZ 5J9/3EQ3G%?;]+9N^)"?TKISC=
M=Y:<_(3;2</DV,\KMPJ=FV8P'^;+OS\NJNX!E2NF;7:D8J$*$1!,,RDP85Q@
M2J,"*TD58Y$400&JL;6D.[)!Z'*!N.F.I#0?J-PQ GO?VJ)I]QX> 2.8G=F#
MIVH>95A '1Y&:0$%E-O3*]V6ZJ2O>B 4AT< Z.-^G#,'@\X?EJN-R>8TE91O
MZ+I<SS*5Y6DA<YP6+#:C%IB^SH0ICHH@2Y,DRW(:#G')7&)@9$?,EJ!#D3(8
M2S<_C$^$1O"^6"(XV*=B"\-(GI2+Y%_5?V(+SB6OB?4Z\-92-YL?<F6Z'7V6
MU+0XNG[8V':9.O'HR(>-BN)>;Z:&=/5]?[*]VY^3N]\0>! 9IN?NTH+:4/7(
MY-21ZM1ZDS6GZA&FVZ>J[V..MX ?="6U,AJM?#"E=(=QV#<ONX\T*;W5A(N;
MQZI8]^9IL][0A0G4_E.6]S\V4EP_RQ6]E^]_RA4OJX1@+DU9AFK*I]*8$1GE
M(<YBGF-".,54LESO!A&9WI&@2$&QU>E%&-E<M%R@A@W4\H$J1M"C5J]*(N 5
M9?JMMKSM_-(;"+PX&49QQ2GJ2K.7S<)>4/=SC4BHDND*-5+IO^SDND*7OA2C
M7,=>;6-\W>RF%V#:2^*K;=#1??/U.'%[\9E>QPL38?E4+N3'C7Q8SXHB5PD3
M"0YR*3')C7<[R@2FH9(ADYFBA$)>3,<D1GYQ; FB[X8DJF@"DWU.X&)GQ8=)
M"[.R0$'!AN^\+)X,TPD"DQJ.\P(>*G;/)QU/G$U'MQOU59JZ#:Y5W7BHKA?5
M'R9V]:SOCHO->M>H3<9YD,52894D*2993# M\@QG61J&*BAH$5D5>PW@86Q_
M=*?/W7YA=/V3ELO*&0L\]SD ;GEP&Q=&F$UH6:B:/&G8*J]U-4K(_*7#RZ@]
M]09 XNO,X\#!M(<6=XB.3AT#EG*S7FU5ZXTRSJV/Z_63\7 8CU8U<9%)F7!,
M1*IOMR3(,:4%P3S,J12<DU1&@#8 %B2MM&EPW7][/]&&B*^D*#=(45Y5^:"R
MX09QPP[,+O5!:6=_AB+CVFF]+CZHIF>Q#6KI5AYK#^7G .D\F8P^2I.:!@N1
M#TV S2-NJOZ9KOZ2&_.JV/FP;Y?SDK_,]&U 9@'GF#.JSR,1%;B0:8I5&!:A
MS.*89Z"LO/.D)K@Q@/I/6(!CI[M^1(:I[H[F7ARJ)HN^-W^.<BZX+*XG7>XA
M-*DJ7Q;X4),MGG!39).C7:5H-UYS\W6O%Z[_NSOV$IHIE:1:KY,PPB3)C6LZ
M+'! .<D31L.<!!"]_O_<O6V3VSB2+OI7&'%NG-L3(>SE"TB"NY^J;5<?W]MM
M5]C5/3'1'Q1XK=*.2JHEI6I[?OT%2$JB5!*)A$"6=R-FW*ZRB,Q\*"02B<23
MUI)'GN:'*O6@HPEPRMO#:.<!1@$'YA#.XS*-1P";[\E!V,N=U%^ X3AU'_ !
MKF.1O:??ZG:/[]=/=+'2P;](T[@H4!'FD:';)ZC 88QHB..$<9K+#)2B."]F
M9#^QYT@UK'^UV.#/1C PBW@!)#O'<+WI,"_@8K4S#^QYHSSSOIX(>1.>U_.&
M7N)UO?!IU]S^67;8=TTCR\7JX4 VO?_H<=)M7Z^I]_0\$B)$<1ZE*,\*AEB8
M<)0G82K#-$F)Y+#;)?Z4@\P(IXLID.*4$;"W/7=X"SRAYQ67J:9GP0>E)*^[
M(78^]\40&ASKN:N?&>6LUS^,WHY*O"DV\1&+;T!?'\UXE^!P0^ANRW1X]?=U
M^4_#W/_+6GN:E8F]OLKR9<%E]8ZNJ*#MK1/C3L.492ACW#3%XP5B*C;Q4I''
M5.2%L&/M TL>.7!J5 EJ7>I#AX,VP4Z=H-$'<&,'!&V_MQP5,& "U1XKEVM.
M(-  MZ#& L_MDI2/+QSL'I6+_;W7K$ #3G<+R\7.HTM:3@.X!;I_M.VZORVJ
M.4YYDA2Q0"+%L7:H.=%[3U8@*8LH+ H<%SFH>J4S]LC.LY6DPQHM"[C1[")@
M%R\ZV@7S<98F@:.T,\I["K.Z(T\:)YTQZ330.?<1ATBEKI[N\$V]R#M:FBQS
MNQCP+,1%0C"2V% *TQPC<\$198+AD(:)2>-8!R<#PD:>4K5TP*(Y!(U%<.'1
M8-A<:^X;'$D.6M$N\<,0%("0P2,D;E%"#S2>H@)+$WL#@:$QIEO[+:TY6NYM
MGW'M[EI54G8)UCM56G&6:M<D"$JC3#NL*..(<I*B5(B$1KC@3!%8B]?+PD9V
M6(TT:%O7'FSL@@%?%L,\5B-U%ASU-S!U:>-T>1TVT5NKUQY1$_=['3;Z==-7
MBV?<9G'M(^K\=O5N6Y;:C\_C7";$D!5)DA8(YUF*6,(42C.J<$8SE4967.V7
M14P18@2\D1706C)L_IY!Q6[67F>K2W31")L%K3A_L_.R*9[FY!D!D\[$RP:>
MSK^>3SH$^W4UV*K:E'78]$[OPO6\-AU%GY<+,\';VR5-T<D[^KS8T.7B7W5X
M=5_2A1[VX4Z6B[5HRSI)A/0&.D6YBC$J6"805FF>A'D:X\RJ:9]?M48_"6:;
M8+%7=!;0]MK94ZU9P(]4FP6;5CES.5%K!XBW_;THBTW*F\ /<SA-36D'^9V6
MP4'-V?X68*-I\.[D=>R4#>[>[G4 -DIO\EK<ME23OA[87LP[BKV[-G_2IMO?
M>4?H:"?H?W2W:/.3&;UZO"O7+PLAQ<_??Z^D^+AJ:GU-'LT<-M?EE?,BI(J)
M,$(DBS#",J,F:<Q1%*5%'$J>R%! ^'CL18/6+S@3SZ=ZC:H>@^=6%7/I>K%3
M(Z![/6 A*P!:NU!V',!@*TY]0>JN@]-/1@F-UM^"O1Y!J\CW6:<7P_M%Q9O#
M9OWQ_6&SO^ 8#HZGH!D@>-)@&@[(:9#M, *<G.?FX6'S[E%[LU6U^L,TZ_ZZ
M?7HJOQM/6&U6]\QT:+UY7K+E/\HVJ6I)W0,>>.0H6>M3UM>J@J8WJFF->J<_
M;W;$35GQ6NF9H^.,[;(F$F]+- *U+@V]N%[_5Y6YXWFGAZV"+_)Y76[JJ1<8
MRVCY_9A$HKZX:$\6!'\/_4YK]%< \UMO@KY'PN*KX'3B.()+FXP!R1F(+C^2
M^R"NA:;::6C'>4<70GO6N8HR3L-$(2%Q9NZ/Y(CA6*"$<16G3$DE0%RI)^./
M[,WJ..!9BZHGR**5#2W_/$;$+@JZPDZ8R]@)"HRD6;#O+7[8H>GYO_O0;!?3
M=,(?GP679VWV5C5Y//K$I8]G37M=OWC^8_#&P._;K?RM#DCI\A^2EK?Z-]5<
M%A%.<9@@4:BPN99-TP*CC(E8%+10:6AUHM\C8^P\7"LU:,0&1FY0"[9O'WP)
MG?ZYZ<EF8/(+;BZHR?" 04X-AR^-.5GSX0&CNHV(AS[JM@S69)Z?E0ZU3'FZ
M26.<O188IB3C!>.(I53HU9%3Q.*X0 G&<885"0MJU3T )G;D"5HK80+--O)T
MX ZWA,]N*?4/"FP&[_$X:##-?4J8X9Z664NADZZ^,"!.%V7@TX[GX;NXJCYF
M_V+XWCZKWRM9G_[-8YK1-$X%DDP1A+.D0(1D! FJ4AKC4(4\ QV-]TD;V3W4
MTM!:H6TEVT/R6;#>AY5+A[*7?O"*.,I9ED0H%H0B',7:W=(\0FE6D"++180%
MAEU8\P:?TQVT?@!GP4H"=RC]\-DY66^0P'SK83M2RYT%>W"T[*9&P6-E@HV-
MOHH4>F5-6Z]@8_:KT@6KAQP[PNUN!Q[N<-&-/'?):R[C0F2*IT@E$=,!EOZ#
M1#)%!<XIB7DF:!9#3G/L18]\FG.X(;FAWP(M$TA]#,"PP#&+<B%1:-@_-(8:
MOHCE*)(<QSP2C'!0D#H2AO"5Z(#AHKEENH,R*$]NF6J->%^1T[40V_G8<8"#
M.5S[F[EW YC!N]B!S??5X,Y>\+2][\" O&J+!Q_!S67_OC)3ZF%ELHE:2GOL
M4+V7O*SCO2^RVB[-<G&KK;PK%^NR.??7G[U;5XMFEB1AE"I91-J9YSG"/#6M
M<B1%@B4RXUG,BS!Q8!/TH9O5A+N:=M#,M>>=R#HE_6S4";Y+6@)#9B\OQ,YM
M38:ODT/K:E<[LYU^LV"G8;#7,#"3,*AU; N5ZD?V:OIS=CY!\^0&O:@TJ8/T
M">*IZ_0ZMH^<@2%XG&<T+E2!"0J3HD"XH!(Q6>1(I9)F5$517$CW1($1,7),
M=MC0U8D %Q;5,["X[&&AQEZY<?7;W.NR*:/L3VL!;[@I[1K8OQ,]^J0CX;%^
MD9_HDVP9O*(XCT6N-Y:QGG,(ASA!),EC_2.A"8[3#&>@6^;'PX\\W8RPP$AS
M9#4[P<)NGKE;")MC ./@5,1G;?#%/GP\^+2$PV<->\4Q?/Y3COF<I^?E^KN4
M+1W$^<8IG]9U09X4=8^4ZMZD3+K_;B;VI_7F'W+S9;\N-RON[;IL?V4^%\V3
MG$4\3 0*PUQ/6)XK5*0R0WF4D#3GE(L(EL^85/V1'<*NU0S:W6YI;J_43.=:
MQ4!^>Y9UUX7-.F!-HJ11%I@;F?:56^97?M@7"?-[9SMI'?H.S8*]#;L&6T9I
M_=N-WDEN@H/>L]TFQVPU.[I[S.F\">2^\D+3*C]M;NE-7LRK_-3;:.'8QF>S
MYO\T=/M2O-^6^ZLKM=)5_8]M9Z]=_RXQYQBSI$@%$D+N6?-5@4(9,Y8E*<$,
MUDD>K,+8*?9=2SZ]?JP;T6;E>-8??VRV=T]/ZU50&=6"GQ;Z;[6J?P/V\X$C
M+PEEN5012J@Y48]2A5@D*$JR.(\PX5R%PB&7.-(+N#ISN!<W*<AVR^ZX7UKW
MI?/:9I4[=:NZ"M_3M<;K0?/55 FNP+0]E9P!>M52R7TD/WSJE;FZT;"3+I?K
MO\S%R3G+TZSNK*12F2),TQP5%(<H"7G.PH(($5('_V4A>AJ'9:A'_CUXV4D/
MZ$[\=:SKYZ D(5;2Y$QYC'.$A3G?SI7>#Y(PSS).L+9GWFR#OFYHN9D6R=:-
MG<JW!O*/UQ &5/LP^;!8K4S^4:_,FT<)8BF H,OU]Q07B402)QK=J& ZQ.$%
MRN(X#S-E:K+2%MT/*_&&V.ZD7XOL>\GKBS1!$OE'TVY%]8P/; E]W3M KX4'
MK&X&)_+5C01ZS!VIJ\ YB6_:8J '@J%^ WV/NJUGOZS7XJ_%<GFS$A]7&_U=
M6;!E4PA6G59TQT0HCD6.\DQ2A$/]1Y'B1/\1AE@4.)7$BED&+GKDC=!.D9J9
M^*!*.T%@C@* IYV_& <EF-OH!VB:@GDX#I[\"4#PI&X%#LBI=W$8P<W)M 19
MMU(_0I>O6@#,\RQ.<R84BG&F ^8$<T034B!*\EQ*DN(L AW3#<@;V9VT8F%^
M8P@B.V?AT7"8AV@%!ZWD\[U#_#D#2SL]>8 A:9-.>TO33^>Z[6/.+8SJRII=
MA<W'5;WW?EPO]1B5:6R\^?YEO307VDTB9AXR%2<%U]NZA!ONZD2A0O$<A20/
MA<BYQ+* W3P'R1_9 >RT"7[:Z?.WFJ6AH]+_'31*!7\:M8)6+^ !/Q1U.Q\R
M(I8PGS("C"Y]AES \-=,""1]ZHY!+M"<:0OD-,P5U+8F>5S*1T.GLJNN_G5=
M5890XE;OJOZ/% _R%[I8F5_>*.T ODB^I%6U4 O>;+Y6=:D@K4E@:9+1M! <
M"6)HK?4/B+"<::\F*0NC3.2,0:ZQ^%<1Y.[<R,L6N[E:%^'J][%XJ<G%*_WW
M:O&PJ@EM:!4\:L5-8NO U>G"PNOW!=JYQ;=]+3#/N2/2[RB[NQ+RDU'M;[.@
M9D\Q.@>UTK/ J+W_5VIT#TZ5K[=_6OU9T!C@F5=X%'!]\A+[57!Z7N-1 #[+
MBSR.)#BUF]'CAF^V=+G\;GA;_F@J$.KCH6:%^;)9'3(REKQNL%%'#C:/3T);
MK6K"H."E^K>@UBSHJ*9G]69;6G(^.&#8[TW'A0^X9W5#SG/C W=$G#C5@*(F
M(U1S@Z#+IN8X LRI5.5FOBO#W!'D-ER$1&).1"Y1'IH."321J)!IAJ(TSV(=
M(C*BK'I%7I0P47'IC@S:SD%<QJ/?#WBQ$C;=3PWT2(TX:$U?%*(?[D0@^J?#
MA+T\[B3S<M"LW?0;_N U[82:YB:GIR<RC;!,)$949:8\CZ6(Y21#61)%H2*Q
MR1W#NPF=E37RS'-O)G0>&;O]C"=[87-PUTIHUT)HS ,C"P.]-A(Z+^D-^@CU
MFGR^C5#_(]=52NVOKS<G2X9F,U911&G.D0RI1%C*$!5ARE 1)3A5*L%YE$#F
M[F51(T_=?3V%8:=P:2K4 Y+=-/9C.FP6[ZWNT$SLCH(_^23U&3;.<\W(&4%O
M4BIRV>!+%2(]3UQ1,?]%[JK!C\HK:[KJ.1$T+$@1(Q9BAG#&$D29#GOS6"9A
M2 E/.'<MT^X3/$V1XT&#YG[5H19^9K*=+1&O_%97T.OI[U"PW8NNW?3W Y9;
M.79]+Z C.VB$M^7435V9QTHR:U-]%E'WRIN^9MK&_+,ETE8/.CH*_BC%=BEK
M%L8=>7U?%K FIC^$JVD8%TD6*I0J4U86"XP*E>:(B=QT E<9D3'HGLUU^HP<
M,>RT,T[%Z+->F3.04^K_P00^T-M<^8HL?=%TP ,]50=S$,K!GTT3A5'V)Y[@
M\N7MKM1F6E_H![I7GM+3L*[[)2V"-PQM^N]+V9Z#W#RMRTW;>&O.]#XIE#E#
M,D^5=I9Z#\62/$4D%TF*\S#D(>A^O(W0T?=0!Q7J$T;:D0W=35E :+NO\@L,
M=(=UD&ZXKEKY-3PW-O X;+7L[?6VZ;(0.?'VRQZ$UQLQP+-N'D)[I7(KQ9?U
M=[HT/:]V;8B)X4H.HPS%5$F$$Q8A_2N!&*8DC07%5($BJ MR1O8#>W&P.7\)
M%+MI[L%4V,QN!09[B2-T:1XPRM/TO21ETAD[8.KI)!WZN$/GYE_E@Z$TJ,GG
MY8I_O]UNMJ6\791/=^V.2P</3XM-7>LT+Y*$Q[&I><WC%&&<AJ;P52).HR)5
M<:)28355X:+'/L30X5"@5RA5ZQ HK<0QDT"K!J"W+PS9_OD^+E[00Q"M1M#1
M8Q8TF@1&E6"G2_!N M0 78]'0\^ML[%/%&&-BYV Z&U.#!MQN@;$3I8>-1EV
M&\'!#=_+\NFKY'IP\?E%EBMS&'V[6-$5UY(-<?+=<ENUI0EA5# I!=8!4HA1
M+K T=Q@9PI)2*E3,$TJLG3! \,@NV&@2?/U\^R5X7MHVW )C9^%F1T($YF0;
M,!HM@KT:P5Z/AA?=:#)<!W(=8@ 7.Q)R;@[6'D%/?M7!^EZO"AEO.I_J8.61
M1W5YWFV[>5]2(?4.MLZ M1V6JB^2R\6+R7LUU0+S4'!<T"Q!-)>YWGSF^F]%
M$:.<8QJ2/%-Z$,CFTTKJR)YT)S8XR'5HW6.'G]T^U3LJX%WK*2#C%N^ [/6T
MH;63.>GV%@3#Z687]K#SQ<^V-\51AY';=2D7#ZNCSA7O%TI)L]M>T*4)P7@D
M1(CB/$I1GC"!BK!($*:YZ4H<8<53X 50%SU&]B.M^+HZ2-;M/(#)+5=X[9S*
M!*#!W(Q] YL=LJ>?Z^HY,ZGRK<_$VI6 ^;L5ZJ3%U+=#KX'JS"W1JX9S\VY-
M7-541_ZZH$R+W7R?XRP4)!(<\91KCY6'"2*T"!$E#.=Q''(*(Y4_*V5DS]2V
M?ZU)W.IS\::CP[(5#\["GT?*S@U=;3_,R;3B=KT=]A+]N8E>@SPY@?,R)IWB
MO6:>3N#^#\-O]MV7XJ8LWV^;%EBV-_>.GQI[%]&A)=V)M+]V=V)@_U2ZSC9@
M9D6'E6;[#S(/=!WNO"5.U]U.AIKL.MMY$[K7U2Y\X@I:@Z_;E2B__WIPX9^T
MGNUI*(OR(LOB'*6<ACK*+@@BDBJ49BE6!64JR6&]AP8$CCRU:O$.Q %]$-DM
M5CX-A\V[IEJM$1UT9-<M [CO,V1;.WW>K^\3-_UM>0OCS]Y]MWG.=;/]H@=9
ME]_/GY^8(]AY++(D+?((R20G"/.$(8)-*Y48ARPDE!485"!F(7/DN;[78';Q
M5'D6++4>T*WU,)BVVVBO$,&\0@>=2^>>.L;M0\=A%VQMK[<=[[#$B7>WUA"\
MWLG:/^K(MKA^>M[JB6:XDY[-F.U!5,J+,(UXJO'E2KL&JO>MF0A1*G"8RSPO
M1 RZ,7M!SLCN8"<UD#NQ=55DM5:;OV@)I""_!!5E N<\48AP:EJ3DQQ13E)$
MPYAG*LHY3HOYBRS9>D*PNO)^++CL_*0'"&"^<6_[7J+'._^65OFBH+P@95KJ
MR7Y37U%.#GS<D;!:[SIWWSLABX22)$$\5]0TBDD1(Y*@(HX($TD:DPQ4^-H9
M>V0O5DL*2JG7@IX[<H, V$T\1[-@DZVQR/_\.J.\+V+GSLC3,C>_-ND5-?.9
MC\#FBY"+^:\:W>7=XWHE/VWK[XM*HBPABJ!0IGI=(ZDT-T=BI'"8I:D."3BS
MVAV<&WSD&5.+"VIY02/0;MJ<Q:%_WEQK'6SB  RSGCQ]%O3DT?1CS<31?SG,
ME[.#33)A^LS8S9C>S\#SRC="U WGZ!*'\<O[1<7UUG);2C!)W.! 8V>?]_(#
MK<!/+W\+#CK89Z&'X1A.3'M% C:W^D 8@<?-VE*G7/;PZ).EMZT-[6:\[1]R
MO!YU.)"H;E;BDY9T^,V]_EM%>=T+K V>XE3*W'0QB12+$998F4T>123A^A>9
MP$R"]L- ^:/ODY=:N759T_ >'=;4EP@[/S>)Y<TC707'#[FU'8>^!KL8=D1P
MH9O*\7&%W_AR0\?733"@]&EOB+E!\^KFF.,PCIP:AK3RKEQP.:=4,!D5&,6*
M"1VR"XDHXSG*J [ATRC.:$1AJ:C#X*-GGVI1P;.1%?RTK83I9-=T.(4R6!P
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MJ]LF+L+'/@?OMA1JLJ%:IV-:AD8M *LL%-_^56ILU(#IK$:1 ; @#9>NQP_
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M7@TJ>&3_VQQ,RU:'X,$HT9!EMFH ,I00."URLR.!!'.:N];5#4X[-8):C_H
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MKP-5V<HW2?H7_>N)"+ L7YM=[/\#O0R@V[N^L']/2M5YIQ\Z[]3\>IR+C-.
M_M8$4Y;:_O=@CH)![XT2"BAVW#/M3WK%:L^>[O^2RQ?YVWJU>31E)I@G0E*D
M\C Q1T4I8I)1O6 4"L=AH?\'(E6\4I_Q3[>S<4ZW+^'K]XC; VKCGG,;!?>'
MW5$<-/I-?]8] -3$!]Z7M/DA3[T'H',]^AX:UN$X;2]4.]=NZY/ZRM5G]7LE
M:QZG>9QD"8M#AJ)$Y B+"",JE?9VF*DB"C'#++4Y#H<('?ET_-X\ CB>L87*
MXI1K! !@/NG@B\Q]G)/F1K46Z+-"6H^&=VT$E "G5B.@Y79,Y0LUV!D5T/S>
M0RG;L:8[A0):=W3L!'WVF@Y->V+10[NZN8[T%,,B16$6:Z>("XYHGD>(BE3A
M+$PY,4UF #5"ER3].)YP&!2[:,V+J3"?UXB<=:B5@X-8WXV=>BSSVN/IG)PW
M:/?48^[YSD]]#[C?-FR;9BQD=?-"%TM3;G2[+K_2I?Q]54JZ7/Q+"E/S=;>N
M%L;S?]H:YKW/:O=S-:=IJD*I&&*8FF,WF2"2*X'BA!4J2\.B(%97!KQJ-?*.
MKI%7,_S>?@VJO;:F'D._FBIXWBD"OZ]X_1NQ\R>3XPSS/?4MQX-^LV"O(5+K
M$AD=9\%!R[HP,=CII;>$^S=T-_@JG*Y!>H/.XPW)ZW6:_/*D-QC/W:OT-[B;
M@]V-MX^ZOLJ'>F<ZQ]HM\HP(%!:*(TQRC@K,0A1E7(4Q+D0H0,WV+DJ:S!&N
M]Y%^U8J&N;[+6-FY,R\(P%S4P?C#-N?KD/%@9S-HF"<'<EG.I$YAT-S3B3[\
MP(_6?ZANO5!]7-W)<K$6PRUG(J:2).(A*IBY6)$D'!%""5(T(FDF"T)B,M=/
ML_7;-R$"V@:9G%T+K>?HQZK:_M#-AZ!?AI%/:=_R!4]^GFO9@J@QV<3VC='_
MD_H0.;[.MSXI]F[7?X\SY;%>YW0-B5P5=%O#[_5CGU5'[[I/I8PB$BJF4!33
M'.%,"D2X(3F@*2<TYE3Q"!)\GY4R<N#];KW4*JQ-Q/,BCUR>*4KI_MSQ:,</
MN73]/ ^HW9IT-4RP]6%\A,!NO!<!3R[UO(Q)W5NOF:>NIO_#\/KE+[(RO$EF
M).-)ZN^G9;GRF4='GL4=B<%[J0=X6JR:(,8H8-D5X)+5_;/2@\&P^=AOJ[>Y
M-F"74V7QN?$F*R3N,:9;-]SW,=?C 27+4HK;=:F7Z=7'%5\_R7OZS524K2KY
MLUQ)M=C,:5@(:2X&1Q$3"+,P1@S+$.6$4DXSO3]5H%26G=B1)V8K')J]MP+,
M-CWO&P9H_KV1'[0*!(T&@58A:'4(?FJUN+R9=DBM0\SVECNW$CIQ<AP"Q.OL
M-^AI7S0@;<NUK,@XX:I 7,8IPJ%,$2$)T7Z!I"QD4<X+4!.M2X)&=@('ZL7Z
MI.\U4\:UK"!6'?A\@@!S 6<L'F[)YX$#Y%S7NA%H0*9L<V=K[# 9B)?6=WK8
M[=-V:?A%Z\V/V>67\E&[!KWM:9R%.1>KVT[.$TRR@A&N-\EZ;<<AT1,Y+R)$
MHRP+><)HGF7 V6PM?.09WE&EW04>*;-;\WXR^ORM[9@*W#&#H+;V!*, "/8.
M'K%S<1M@$/RY$GO14[L7,"AG7 Y\#(<ZZO.MB/9%W#M*_T1D"<EPC*@T/?]R
M:D[*.4,)CD2125'DA=6M?H#,\3?]A_Y8HM,?RY!]U&S%>^:6GSZM]=8XM3RL
M@L#:[VE& @N<,&APNCGI(]:Y!0)O)V&)#Z#8VC].;K76/O""U5G#+.\ML[8<
M:KHJ:YAM1T76P$?A.<[[4MR4Y<>5J#D^++.;1P^-719DS5SRVISAM*6S)3#_
M<U_2VAUW<M.FUX)8O"S$EBX],9=<-,@I4WD\TF0YRK,&=+.3YS_@\?;5*P?.
ME B33)CN!:E &.,4L91BE!5)3#,6<YE??_WJJLC!\=9!T'*_=]L9>+AMY!(A
MC $+;([VWB^Z*DZPQLG#M:SI8P5?N/FYE^44,5@/]O8WLZRB!O##+JW\Q+HN
MP_BLVL6ML[:U!1J155(2.-J(68A6!Y.A/;M@MXH$T7#J\BJ\(*WG1L'-L?.<
M-7Z^6LZ!C>_O.&<_W(0-Y\ V'O>;@S_N6.*\.S'^K)K$CG8]9](]!V(GE@DN
MHA@EYH 7ITHB&L44%46:R3!F)(I!_2B \D?>M.RU,7/A;"[3M9T[%&>[-/"(
MZ,%\L!?@X#6Q;N;[JEP%2I^VOM0-FE=5H([#N'#4]]$@OY=BRVNW]WY;:G?8
MU([.%55IS&F(.$Y-&2?+$2E$@A3)1!XQA7$>S5?RP62R[VUYZN%Z6,VKHIE7
MK[0!E&/L9$/HT1U0M8C[Q@+)L<RSI3__^P7Z\UEP4"EH=&KK^$=&$L(R/RZB
MCA3S(R +Y)IWAZ6?:-YAW E9YMVM/J:8OV(<!Q?>=D*NKP34=P&J=F<48948
M0C>4")XBK$(=-7).D,Q3$N%("!+9-Q*Y)&7LV+ 1BUA]C:@1#' ?%[&Q\+8^
M+ ;&<ZVQ/W>,==D]7[0:X!E]6._F_MQ0@#FX(>MZO=C%AZ=S54/Z'_FCP0_#
MG$Y5;II[2E_DLWZ%CWK8NW+]4-*GNOJ]R$58I*9?D= .!PM<MR]*49HK[8(8
MYXE,;;Q.OYBQW8X1'!PD!ZUHT-V= :#Z79 _\X$^R-%RZ_EG9UC?;E&/T-DI
MZI\.N\2!P2>9H'8&[F:HY:?A9]7-3'^W7%?R?OW;ZGEAZ(N 1]=]8_Q0)]F]
MQO9/-)]V E/HS=)6BS67G.\73]+0J_[VZ>YCA^^K&NGPV\9HI[/PWH$G.QJW
M,:][4F[U^1^-T>+3>O52$TX/\Q?((J>QT NQ$.9</HU2Q&*9(QXG'$=1FD41
MFS_7NY&O&UIN+#/)/X!ID!EZ:J#]P>UV4VUH72<X"U;K%7IIJ>@W 9,/B]7*
M;,+7*F@$_,"\%X"O3"0+4<@B0[$I_,1AC!&-]08RQDDF<)*(+.;M5^;#2OQ/
M_L+LS//Q=9$K\3_MBV)Y;O(#J#IRX#P)+<K>VO])?"CP5_C#4Z$ 3/H?PH("
M?XG3$: XZ.86[9D+X>7"M/YX1ZM'+;:M&YQS$I,<ASG"I-#+:<1B1 GC*"I"
M1D.1%;$$THE=$@7Q<D[L7@?! =>2FR6.0VK]!M&R6U-\( #S\QW3W]6F'X3Z
M\[-#9GGR?1?%3.J/AHP]]1&#GW=(ECP\;#Z4]96K3^O-/^1F1Y0AX<T7;<8:
M.7FB52CK$^] *[)>R?6V.HY)M&*!UBPXJ ;(M=A@99%S\0P3,/<"1VB$UHP0
M#-Q2,38"IDO) ,P]2LU GG.ISN6\W,KNG:&V)GB]FA>4\XP4*2I20QBLA-2+
M=B91(:3^(95QEA+K0]0>02-[A.ZUM/5.)N0DM0\CB\-43Y8#)WDC].A.WEZL
M)]LAY<=^,'"L-W;" EAB/&Q@?TUQS_,3%A$/6W%<-6SQ>7BG]8]<E3=;L=!P
MWVPV-<>4'O!V21_F4:ZBA.4"L2B.$,8R0322$:*<Y04+DRAE5BPO_6)&=D@?
MW]U^"5K)04=T8&3;-U_O@:G?*_DS'N:3W.P&]6,?-LNI*WO/L)/U9A\VK=NA
MW>+3CC0NXC^WU:9.,]RO;X2HFQ;0I6F*^''UCCXO-G19IRG8:2;CB_RO[:):
M;&1;E-&4?WV1?/VPJD=I$JJAC(A*DQ@Q$3.$TQ@C%M,("9%CD@D1%HG5(>Y4
M"H]=CF$ZI[<U8+RC') 19NRW9I>R^)'>!3">NOOX;G8^@7U\59N7Y@)=H-:&
MFZ;:!!T5/1+13(2C+_*:L=6=EO!F(O!?D>1,)==M83A[?_0WNC'=<+[7S#V'
M%$G$<RJ4#M[B0E&$<[VS)*J@2!*MO%0Y3@6(K \@>VQWS1^EV"YK]KZC*\[!
M3AV8XX:@:N>#1\(*YDXOW_[N]EC>:=4R>05>DU!7X.')+4(D3^KA'" Y=58N
M0TQ<8=3?M;Y3Q;!/F'Y<;<K%JEKP)N9)9)'AG!.482X0+DB("AES1*C^/4X*
MS+2:D*NI;V7)9"GYQ4YL\%)W]I2MHF;6FQ/*B>H_KG[S=I[VO\7[A/EM#Y4>
M^UJ./]JRH)4(/G2^!^;7^E/=(J+#%VAOYP]3W>'K7;UU2<?5=OSWJ./P];J\
M%6]X4PA^D^57'?L_U'J^TUK5%S/"J."9BD+#ML!0+D6.F#2\N[B(4Q)R1K@5
MV\+YX4=>9PX"37D"K-G,!3SZ'?WU5L*\+]! T+V4RW9<<1_ES*"3W4.Y;%#W
M_DG/I]S"T;OV)HMV T^+>K?^X1M?;LT,_G6]>C"'MX=_:AB8)8Z2+!,*U37J
MF#&%F+FVFA8Y+@3/\S &[8;A*HP\,7<*!0>QLV"O4V"40D:KSK^[$5\[@&\7
MRHT+*<P+V*!Y;] \\T'_G-CNR'B*>!P4F#14<0?H-,:X8B3'E%[3R>.=:0=0
M?F\O4IL0(1(B1'$>I2A/TQ@1$F*4)Y2P5"19F%)0[NZ,D)']D5.GG;-@6*;<
MKC01F%MKF^>8KCG_[[9<5&)1LRZ,T$>CSS!?2;)S(J;-AO48^2KMU?=9>"5$
M>X)[NRB?/HHY4UF<2)DCFD8*X2AGB"D=G.<8)R)A(M3QN6WQP]'(8^=_VB-_
M(RSX^-Z^PN'8_.&B!F>C@&>!EO: *A?.ZNY4K' \TF3U"6<-Z)8DG/^ V\K4
ML(#MR<)^-=":_;;9LZD0<Y'%!9*JX @362"6)1&*),944CV'4E!:MD?6Z&?_
M'9*[EM9N)WX6_$R7]1F*2T_5/OSLUC1/J #3CSX  :]R%J9Z6NSZ)$VZYEF8
M?+KTV3SB0O&TD<^/="5_-J]V": P.O/<F%_,1EK0B'-B+CIG*(2UZ$J#'1F+
MC@WWQ5'48TL_/]&Y!R?D)NK1^YB7J.^#URR)IDW2K5;*$+$M5EN]-=Q7Y%8_
M2Z7#TWU?1EFUT>H\YH*2V#0JD*;0G_$4D207.L14DNO]G P%J)VJNRH_XL;O
M"F A2^G8<,$<VG$G-?,U#PZ*':KGJX#5JG4ZM1K2EB&<'9?@:R#RND([*?(&
M"_@U@)U?WZ\:T<VQU<=<-T)(H0<]-*7<]<)(BX2R@N2(Y#K2QSF/$8L80Z'^
M6>\ 8J:C?HCSZA<WLH.JA0?42 \V]%M0.O9]'<#,SB_Y0P+F>QH0:L%U$NL@
MVF-S$)B1GKS'@+!)/82=X:=>P/(IUQ#&% '5%:X?5^\EV]RLQ&^T_*?<&!D-
MS<%7R4T-V4)6AAE<EANZ6.U:%E25W%0']K!#922+LR12,4.$L!!A+!BB49$B
MP^:=)C)D&8Y@ <XXBHX=_M1%>0NZ/.)9,04X!\*4X#=)C4[UOT$#I9%>GVT8
M]?8O!1ID[34V)'A&Y_IM'+3>\>(<] Y^,I]H53^T3ZF5_UN'.L_SE>VI0/86
MIHVDYL1!W+A@OP[Q1I;G> RY8Z?INJ;]+__/0L>?)7_\_G[]I'69TY F:1(+
MQ+FY(II&":(QS9&BVO<3&DF>@C:S(.EC._"#F]X+KCW&IYL_@C\;%8"98!BX
MEN>=8T$&/ B]"BWX8:B+U;Y.24&RIST^=8'EU;FJTR .Z>:/3T]Z,\MWK/&Q
MWD7&,94HQ:%".$DB5/"4(QY*DFA'@U.66U-@'(\]LJO8"0-DH$]LMTBRNUL$
M#)1:.2YY]1.K !EU=^O<<NF#KPR61#^O?F_Z_.21Z1+GYW4]2IE?^(A;2-$>
M%7Y]E')_4M4N<1DI$B8P0?J_'&&>QXA2EJ.P$$K)".<Q59#XX;*H*4^/#UN_
MNW55W_D\=W#J%$'T8&D7+OA!"'I@YQT<<, P;+>GZ*!'T*2AP+#!I^N^Q1/.
MIV7U1?WWLOGOQY79_*ST"],[FWG"91+G/$-<&+K*."Y0D9B^'@1C15E<Q$D&
M:/-F)=3JNWYU3[>=0. UY'ZXK(^YKK3>]22KH63X:2?X;R;9TI'M]9AJV$1_
M)U$]LJ8^;!HV^\QYDL5#;K/[@UZI^6;?+=*DJO5\,80'VLTO%[4;T;]\5TJQ
M:.ER3^N:F<@0*T*!B)YU$298%%PYS'D'5:;Q!.9DA3=28;[ !5P[#S$65DY^
M8Z],YVP[,/H$QPK-ZG]H=)HUI.4STY*0>SVFN@(:3_[&18-)O= 5$)WZIFN&
M<D@ZW)5K+J6H#]:;^Z ?ONDOT**2MU+.PYA0&:4)2E,J$*89T1L2I5!&%4DR
M$64TM,]!](H:>4.RD]V4D[0]X&4K/E#2\HS; C*+U(4W(&!>98^!D=O>A0]V
MDH-;CQ@ $AW>L'#+>[AC DN(6)G9FQ_I'V&Z=(F5)4?9$[LG'"D!N7[KVZ6)
M0S[)S>\K'<XM%_^2XG"<](O>L)G*H38'AQ67(@NU'V,D03A*4AUJ,8Q8*/(B
MHKD@3( H_H *C.SG#@H$1FX5&'Z,%[I8FE,TI-8E^DJ7LG.F"^3R@\)M%WR-
M"2+,1]Y\?O=Q%G3TJ6%L:Q%GS3'Y ;S9&6QU $;+^KJK]RMOKC#YHM*#BI^6
M&L\1G%=4=Z[C.&X7:6EZF%4Z:J]).N[6RP7_?J@_*8J"LY K[:^2$&%NKKS*
M)$(I3W 2IFD62E")X8"\D=W33OJNN->TWZK5 &X#!T"SW/+Y@P*XO=NA<+<S
M7SN-6GCP9_O?40IH+ WVM6D;D#;M!LW.]%>;,<O''/DZ&BX>0ZG)_VN[*.5^
M-;E=EV8M.:PT9N&9%X+)&,<YDCRG""N:(Y;KW1A-L-#1C IQ@AW21$ UIDD1
M[0@'*G-(\G0H2JL<(Q<HUG8N9 SHW/9VK2*&Q:Q5Q298\<C%X8:$+R(.H/1I
M63C<H'E%P>$XC*-OTB]&EJ44-0EX0SV8IRH,L2J03'-#%I0IQ!+.4<*Q_A<J
M(A:#]DYG9(R>!FHE!I41.0O^K_#?PC",_B.(LOA__Z\H"_^C[@9:!72[>5R7
M]4:*UC[HO>1UO!<DT2PP7\"ZG$O_!?]'L%H'[6.+JC+M/M9EL#[0IYGVHY<?
M!_JQ,^_%TE==AS8TU[0#^FL#="UO%GRL\?'H=BX;Y<NUG)$PK?NX;.(K%]'S
M45<W<,C=U(/>Z==<S7%.:8$91TP+1#AC C&12\0SR7#.*(Y) O,$Y\1,FA,V
M,[<NMM!SG:^?GM:KQD<$F\=RO7UX#&13#O]L-(/.V;,@VD[;:Z%QS!+7J-02
M@[M>FQTF;9])WN;M62$33]T^0U_/WMY/.[177"X_?--!@3E->J?C\(?Z?+O-
MS-FV5>P98^3YJ44'>]G!03B@9V(? /W3SZ?MP!3D!;,])A1MC7-K?M@W\'1-
M#RW,.VIV:/-Y1Y;XMB_#9_6^79[OZ;?FPLK-2NP8ZK6TDYX*+ Y51"1#(I)F
MD4T98BEE*,\*(HL8\R@&=2-RU&/D6=[M6O%U\;!:J 4WS=0-E_%Z5>]IZ^B[
M#2=-P4.C<QU FQ\[F@-)W!U?C-W"/0'<,,?21?H2GAVU1NU\<24XOAC+';68
MEF_\.JA>L85?.=PU##$U,\/AYG:G[7@6T3#*<(H4)E3[NEPAFM$"$2%H6"B6
MQ0)TS#$@;V2?UE9M';,H7-&M?0@].X?D$1.8X^D2M!PQ*HS1P]W22J^<+)>E
MO0'QRJ#IY]E5AA]S)U:HJ[YO%ZM%I7W/+^NUJ#[)S6?U15:R?)'5/(H$52;2
M29("(\Q"A5B&<Y0Q(6E11*$@H$C'0N;('F G.'@PDN%<!D.(V<YXKSA 9WTK
M?!;LT:CEZWDOZ[LO.QW\4@18&NSQMO^0Q,DO[EM"<.X.ONVC;L[@79U8ZZ2N
MI4P+3E2!BC0D".=8(!T(2!2KI(AC15.5@A*)IP)&GN;O.HG"6?!,R[:YU.%8
M89:%8>!RIJ ]8?U30K*3PP7SVZ/3A8&Q9CH(J9Z;HN(E\/+-JQ=FYWBN>0TP
M+].^@7%/&2Z9X\F'O!I^4H=QR;A3[W#Q<]?W[/RR>'C43N;W2M8;D3DWW(^F
M/6<2J<AD/G+$8I*A1$@ADSQ*DR1T[=%Y(FMD!U%+0VN%MI74$]7LLF:!:NY\
MFO9B*PG<"O3!9C<W/8$!FZ8G33?WL&C)3?IA%E"E\3TJO;QY6I>;Q;_Z>TY?
MU73S@OTC--D\E?1F334OF-S71//2(S[(8AMFG]^D7AD[)99-T/%^\;(0<B6J
MS^7[1;4I%VQ;DSW.\RRFC&&,%,<%PD68(A+%&:*1BO4/>9PQYG9']DK-IJF-
M,AJ:PN[V1')Q4,[!H7AX'9#TP^CH^J*<;=G/&@V#CUV,V^W+7DU3[G&DZ%CD
ML]> -@H)K9-";TA&>PV _:2T5XWLOIEJ&B[5?&@U*^Z#U(&%K.8QRT1(,H44
M2^N+>REB1/O**,WS1')!2 QB(NN1-<$6JY5<[VAX5W;PTZ?U1@91_#?XMN82
M=/8[' ^ P#<[72R.Q/K=[@S8YG'G<TG2Y)N@ 9//[8>&'G&;V%_DBUQM9>U6
MONDILZ++=]MJH[U-6?W\_1>Y?BCI\^."WQCR@I.SR3@GB0A3B7+*0X0%YHB(
M#"-*1,A-D2;!!#+QK]!EPH/C5LMVY6[U#/:*FK;0!U6#6E>8P[CFE=@YE(F
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M?9E:F^JV(K55LV!G5] :MO]44)OFN773Y*_$9W^GZ92?O@G4Y"_F;*>HZ;6
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M++3M*)<A03@1%!68A0C'.68DE)0RT)EIO[B1'>M>>% UM$XMTQ7=*^!.=#6
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M&%[%Q  -G6:L3E^*1TOOAXN&LZ)UA-J&BXILS/WD[33!]_^$ZY&R5$7'+,I
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M +.^M=$ Q,Z^^3%^>0)O9O//R-'Z =48%J\@+._^=5/1'!/C22,_TGI/9()
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M)FL6W:0*KWP&$S1)T94!5X$1SQTGT0$S@/%?J'[@/4E0(U@Z0-.[0'.TV!O
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M;=@;_MZ0V(=B&G"15^T9O_COL"@SH3$8'QE3*ODUQO&*\M* 21);ROU##)#
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M9'%VMO^].]A,R *"(IF*5&;[9.)-0%!(H4W"TPVA5GDS_I"H"@UKMB^P;2^
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MG^!R-M]M1%VR4.IZB1:ESM<S33QP05 PV:OH'<^U2]SW(FS8*7<] :J^2AK
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MV0IT[ >XG^4ZX-2*:<#J;>>VFTF^N+GW4-RP&- )<+'DJ &] R^UQ3]8Z<7
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M$;2'4G<#2+\[F&X96C7YV,@WH$S6OF#Z,/U4Y#0?3\^[Z2T/F&?*.AG+#O=
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MV["8632>(6@,:E*7=M(J4L*=$,)ZFY6O'1O>I^"H\0QK#V!;,<5JYLG#=SN
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MV9?Y@?_37_H;QI367@'/A(7@T2Q2P) >CTH(WGL5ROLJL=_Y\HQ5]P*0_4D
MU)NX6\C /TP2OAM/X>T2+A:CZ),.I56GUF7:(\UE;@"-1,<H>*!1B^IO9W=3
M,VS%\BDN! \3?(L0^@CS\@5_#FS$K3;)44=$QJTF0T2+JIDEE-'@>7#*I= W
MB#;H:>SZYD"=_PA*ARK@)W]=^W$^NX3Y\MI/4ZGL[_KEX=\_S_+R=]3/2W\Y
M7OK)NIU?[P7O!U%SRDKXX\75?XF\E)I!UA2WA2K7C<D3*[DA2C'))4)7B^H/
M\7LKD;\;)' C^H^3HID-^:_.%952P$#%DBP!?0C)T!BH,E[*!/R64U2XZA.^
M]J2MV3+ZYR!E]X2'BHIIX&3>R<U&)4H"V8V3+_4GZ,/H,AG7X'&16 Z4260X
MF<I8VX.L86'6#QX>=]^IJIR6\;91IL+PUU+VR(C+W9QZ12QU0%00(7.KC-6U
M2Z+W(&M8O%6'PKY0.U O#4#MQ15*%,\!Y.;FKV\O+N>S;ZO>RS?!>+*,9S D
M0C=+66CB5%8D,L-2U@)E5MNX[458HW [% ZSOG73 .!NA;0FWWIILF*:E)%-
M1(*1Q"HH'3:8MQ1=$?QR96@](&'8&NF^072,O!N RVH0&,P?LA&I9CGJ2&CB
MZ*;Z%(AE-)>!/$I:%WUB>]4B/BL?LI6488L3^X9/#?DW *.=8OJP_ KS(JO;
M.BMKC,ZJ]$.6Z(H&)XA/V9$<$K<.I!>IMCW:F[AAD[=]0ZT?'0U<+_O)3\]7
MCB<*0%F3$S')<20:HQWOM2=",,62,TJZO:;3_: ^]G;!88^U7D._PP7; AIN
M0*QQ3VA%B0+G2L%-+ 47>"YG&2&P0)/?ZXG//G@8NDCV0&4]5/<!DAOZ%<5X
M^O^3]YY-;N5(VN@ORGOAS4>US+R**Q>2>N;NIPJ8A,2=*E)+5JE;^^O?!,NJ
M["&)PP/61&STR&V=- ^ ]#D[.3NY(%PF9R):!M&>K^^C>S('!<8ZKK,.6LE!
M\<BG&BAN?G1BI6^CLD4+^4VM^/#W#<*S9T:F;* &'^J^2 '><\*_%-K300B%
M#VHO?K)SYN\-%3]*B7,3Q6\MOYZMS>L\9<G),,8U&*60^, $/I'_;F+BS"1A
M1&H]L^AIJJ9U9::-%F^GFI[!]N<*R]GQNUDAB45=JV;HXE3$C3*UIU&K#-(%
ME=&IK%7K=N(!9'4:O=L2"4.!MJ5:&DYWG*:JH$82%O,:N%P4^MNSD[/C<(IY
M[=S5OUOB=YRO9C_QW6*G7< C4K//JH+=Q35^54&(+(A,3[H@3Y_P*SP$*>FW
M'#EF5M"FPZDJ>%3(;^>DOK6HSY\@JW)1EBP0$<D<58)D$"/2R4U&LI21F>9[
MRS:AK]OJ@DT0<\_TF'$4U,$C?K7MM#X3I[^N#__YP#!%+P4:#UK680&:_)Y@
MR6FF]RFB459&.2ATM$D=RV,$30ZOD7!PNYREF5(Z0-@M'B[BM;$([]$%R"&:
M6JW/Z_81A!138FJ];*WU#7XO(1/7J;13]#W9M]VDW@%T!ARXRW%PW$FNDH*8
M2$ *BP2750*Z]".ST10=6]<)#"9N6H@U ,+FS^$66NEBB/P-UC[@Z9_S)=;Z
M6<QOYS]Q=5H/ZC](>O62OTQJUZ/HI89BG0;%3 8?@H&D=2DED9C'*&_=B,;N
MW\QMP/(P)-OKK:^+\!66V1SS'SBG7YQ6)W_U(O_WV3F7%]R9$"3F[$&R&JX6
M5D)$9T$C:L-UJDMVQT/E  HGW\2R7TRVUEE?B/RZ)'Z.S[5WFRN)HG ?)%A7
M$B@;R0IF9 KGS+TJ+H?D6@_^'D;9Y-M<]HO 5CKJ"WF/>6'7P=0@$GGX7($S
M-7/#48/';"&%P"/70HH\XFTXB,;N[\,V?NVHJNL!FA]?OGUQ>KJ<Q;/UPONO
MBT]K!9!-\K%\#7]_7AP?OUDL_PK+?"1-RL+4(4A:*F+-KQO7$4KPP8MHTIVN
M[MU1.9R\[HW&'7!R&Y0C*:T#/'XY7:1_?U\<D[96YW[@D64J..X0C*B9'T3B
M0#,)A0SAXHBCY%HO5+M+Q<3H&DOA=Z)X.TE_:_S\P.5LD;^<AN5I$Q0]=@0O
M9?9IL5RK[QZQ'A7/Z)F(#&RI8QN,<V39$ON8%/U-247%UA73.Y(\\7.\)WSN
M4Z]]7H;%)L^%1'!)D/2B*A"]S)"5YR%ER6WSQ:1;7H;C>2+378:;2'_'R_#U
M/(]8AD"R^K1<Y+-T^B4<X^K6;^.ORS$V_\#%MV7X\7V67BPQ[%)JL.,7VY03
MM&2[4<G $[MCKK+!Y.BB1%W7'RD/JK "P61&/@TOR 7#U-SX'DC:KK?<J]DJ
M?/NVQ&]KC7XL%Y^]J%]SM?+1.)!&D9E<-[NZ: UH9)*\-\-L\VCU8_1,:P:.
M@97;MUXS;4Q<5'R5I[P^R^%XG:/46@7C;8*B+5WBP13PU@I8;V%";M'X0?4H
M3Q08/TC M!AJI]]%:V%/C1C\=IN%B]1C"H6K2#Z0%<G1LX^UARI+8%*A5T8$
MIP?-#W@*,0\1,%U?0B/%+EI+>4*HK.NUEK^._OQR%-%BCB:#U%*#2G4YH31T
M7(QT7)F(FKM'<+'"]/]\6_S\?R]^XCDT+GYSC8SK[TT(@S9*6^PDP8FOA]=G
MM4KY,O7EC(\J.V#K7?.L]MDXXD!+^E/!O.=RT(BY)VZ$F]^<KD>EK?9WDN74
M4U#K+G=R,K_COQ;+XWR9F9?T;LIL 0UC=!7J #$S [((G;U,Y&L.V]9QWT^?
M;LI^6[6W$=_$=\"%M_AQ>;$N8OT2NF2S#%)!#)RD(:T$3Q("HMV7+#3&]-@K
M,/0NN._;TT;]1C$E=Q9Q'Q"IVT4N=XI<G!I96/19U.1C+6 KE8GBL>Y_Y;P0
MV%63QL8'"9C.?-A=IW<!LJ. IWY(;L:=+HL:1,+D% G$U4R+9&0+H740HLXA
M:"_X[0Z1AY;[W/G9DZM^5VTMVHEN:LV__/C/MZ^XOWS\?+9$KP<OO"3CAT>H
M@]_I\?-T?6:F(Q^XH>?FCYW.5AQ!W]L+;&I5?_[RSPNJ56)<%$FP+"& ,IEL
M',LUI,23\2(H8\0P$_'R1TYG%XZ@XNT$U4&&[@$3Z-WUC&UEK ^9 \I:>\18
MW>X@))B0?(Z)1]=\Q?53-$V;O6MN-(ZBB@Z@]42P__7?Z?AL/?%PM4+ZO_PU
M_'UDB,4LM0;/$['HZ5=1L0)T:>9@--V<HG6V9 LRNPR ;XF3Q7Z5UNVT_-N9
MU;"LJP%^8L.,\>T?.4Y*^%'"]YSS#1@EF; (K%;9*T=WHI/T&&INA73!)F^?
M9\[79B=8@L)J^I+Y#$ZG5%>+>R8361-Z3V_F >5\-\'*ACG?X=KH(_;R>YRA
MF$PBT1P*7>NU2X7<PLPYF1A<&F^U]]@B>;=U>&ZJ3.\&6GTJ/+>)B/N R'W.
M"U.:J\(@)G2@4BSD>4BD_R!ZK)Z-:I'2.93PW$8Z'1:>VT# 4WON]\28BM<8
M'2=O-EI-%ZPGY];5>4="Z\R%=ZSPITR:0PK/;:*M)\)SFXBN \_K20_!(1>6
MZP(^%7)3D_<0F$^0"K<A*B$,;]VZW\2IGRH3M/E3,XHJIKY4/IS5T_"QO%R<
MD.669N'X\O@=\12R4SF!D:6>$)'!:YF!:<>M-=[H-&S5ZL/?Z-(8V5*1B_92
M/13/^N:OVSG7]_W44?SK)\G?LXOM<Q#)L3H<E\"F>%'@5#0$.^F]YHDKT7J$
M?0\NM@KTAINH 7-M9,B6SAV+$C"J$I)BR:?64[(.W\7>!"L;N=B;:*,/_^EW
M7X$(-JD4#ERS6L579Q9[9D$7[WD2)G)LZ#H=BHN]D5:?<K$W$7$?$+G'ITAD
M]FEM(CBIZ8UG@2Q!QAFPNJ@Z&BN8'M2\]DQ<[(UT.LC%WD3 4UO#]_B)*9.;
M&#0'9*DN).:<+EC,@(@\L!QR2F&0%7P8+O9&VGK"Q=Y$= ?A8GL?<C7=!0\%
M5/$*@HE(_\&4Z%Y%95KO\#Y@%WN;IV8454Q]J6R1?_W'<K%:'1D6C2A*@D19
MSZ)PX- 7X"$8I:7CB'[0U;,M!5T:,EN"8+%OC4P-N_LX>S<+<78\._U%M_7/
MV8K$^F:Q?/D]++_1]9[^O2*1KQMAZL/P!G%U5!AF9NM>..4"B5C7&C=D8,DR
MD!:-\&@'0; %-5U>=@W@N'=-;0Y-?P[->>6>SL.>$?H9R]D\5U;7PS;6_+*L
M8Y'$:JJS?%5&>EX4IX<&)??*,:5N]Y[OBLQ[J.BR;&V?B-Q5,P>%Q"-$R:)2
M'@QR \K794C%6,B^""N%,N'V;LF=,#?MNLBIT;61M'?&T>(T'$]6(IF]LUZ0
ME2Q%(+-"A[HAS5K@!A4687+@K0?HC%4BJ0\*COM2VO:VX,ZX''+B9HOEI_6
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MF"T!L-BO-CJXR^[C[IRI*QZ/' ],:I5 1UZW;AL&'LE_"-X$EIEC4;6N$QU
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M62X!N+865(@"(N/$BV;2>)UE:K[4_3%ZIHF*CV?U-)/]I$]0E<_[\-^+Y64
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MK3$PS"GHUFA[?GM<-\))BSVN&RBMVR%1-RLU6RQQ??3GM2\N[6I]JT5ZZF1
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MLN\ 1U_IWWTL-WHOUO=L2HB.3#JPR ,H3$CW+%EVVA;B(28BI'5,^5Y".B[
MV,96:2?T#I!SLU^'CL*'Q3Q<_\E7^M4JI-/U@*4+DST[A;(HP#5[!37XZ#RP
MNM=4""V%&!2>V0!3&Y(X;1RG 2@6^]-0!P#\+:/\XE[.:OBTYII_?5T\]*\O
MKVTR()GC$60*Y%!R3<=9&DYRQJ Q9,Z;]XZVI']:Z(X*M#M37R;2>@>(?S*-
M&7V46A,#,=2T(J.+PANO0"6.==:-YS8W1O$!5Q[L\H0W5<74CN6-Q-.Z@'CU
M/OP].SD[>;&>T51\,87' B:1E:R,JGW?*8"-.@2O+),XK K[T<]TF4394IT/
M[+3=4;93H^3#6;TS/Y9U\5::_:C,U$(&7;P)D(4IM2BLT/&)&HHH+"B.Y&*E
M0>"X[Z=W&:IL@(F=)3DU%.Z ^F*0[YNS>:UT>1E^A%3'KRF-+&"Q$'E8;W_0
M$+B5(&WQ7%N?_&T_<NC5<?\'N_07Q[A$&LB[ WOFT6&!+\].SH[7=MO+<)J^
M__GC>L?>U\6%0"ZG#K['L#I;DOOT:;D@!:Q61YZ892HI,"%74:.%().$J#A=
MJG30DFAOSX_%39<VU&ZP[@P"DW9K#Y+%D<XB"-0&;'TDE$ %OFZ83!DE\SD7
MU;Q4ZE&".E\[.QHH-U)$!Y?L-N6ITI(/[KTC1S@R$AZ9(5ZD1 YZR5%P&Z/#
MQE@;JZ9XNNVSNR!P;*5U@,LG)@6O^:^;5;_-9_^+^4CE(K(SQ%T*%I33"H@I
M5@>YE-I4%),8-""RU?5WA\)!:+0'B<815=5M<?OO\\HN6Z-6ZVE#YQ5*X;<*
MI0M3_$:,<8=*^'8?;U,V/Y(PFM78WULR=EDNK;,+W@FZ"%DM<R1/J+:L%;"U
MP\BGPE5LG7AZG*)=;\[+J=CUE-_[G6NQ7Y[<KXM/N"R+Y<F;Q7*=K5Z=AT"E
M=\H4::%D6S>DYT#F<13 @H_>:Q^-:^TFM:-^ZFK]9JB[?=].I. >IS_X9*P/
M=2- \61LYT!&C70(2EH134PZJD$9C;&F/XP&KZDP\-2LB$T4<C"S(H**N>CD
M23B._A-%@9#)B/96A!@MJBQY Y0=ZJR(C72^U:R(310P=?#[/2[3OR];UQ5#
M$^F"+TDF(EX;< [KY$&EM2A!1S:L]/+&#SV$21$;Z6O10'A3*_V/XY#^39[/
MG%RJ@E_2#.<)5]=_>L&2SDDYIRU@)&Z4\EAW:P9()7%FK"2VAFWW'O:]0Q@;
ML3541A#YU"AZ>W)"VDE7@R_HYK1T L#5^2@*DX&(=!2XX]IE@^CXL&'0O__<
MZ69 [P$5.XBP@Z#7_45^Y"$PQJTA#T%84-RQNB"-_J.=BTH4T7Z5SO;EMJ/E
MVR>V>-NIJ .<;5J1I[5,QB51*^$E$*^R'L<"A;N$=%(M<X.&I?UG%>=N!(H=
MBW,WT5 ' &Q:IJF166V= 30\@])U[G8P#"1'8;W-RMO6Z:C_W.+<C8 V9G'N
M)EKO /$[/%I__*KWR_I*44PY5"6!3*I*G_3@(AFWEC-4UNGL3?ME@@T(G[;R
MJA/38?\0.&S<5Y8O_ $3410I/6A>_8'@$P3/"E@5Z:3+.FU]4$/\?G!_37B7
M.8@Q =<.\EMJ?VH?GMA8T1MZ7%/=[S]_>/&RCJU8_C.D-)OCZM/+?_Z>+*W;
MB,\[CB\]XOH"KL-@7[Z'Y8\JN,7W$WRY6/ZXBHOQHM<3NS/#NMZHU/5^'FQB
MCG.6>3+#@HJCDWJPZ-\6>XMN@7#8+\%UG8J,;GWG0)::D3HXA\!2()W(I%E@
M/+OVXRQWIWO:$MW#MW^V \#D;\%RD1#SJM;I??Q1M?WZ;SK0LQ6^021/*LE4
MO .FZY"B;!,XXP0Q9IBU@I5D^+![_+'/'.P=O*7*%Z/(O]OK\_7?/^JC<90Y
M%\S7J3<U1:8$&O Z>BC>>I,++T6GO=R+%P1-&RN>#';ME37U'58+-W_B\M?'
M\G*Q.EV]##]FI^%XS4F>G9Z18H^(7IGJG"5/G@(HB[5EUBC@5DI71.+B=G3X
MP3:NI[XU;1QAVMNLL2:F!M9#X;W+XM"3FAD\,CD%)",;K,0ZX*)$"":(.@G;
M"NZ1J]NYKZ>W+3_\N6G-M&GAU5X?O2+L\^S;]W6P^V,\GIU7Q%^U75\4R>/[
MV3&NRP@^A5_KV#A)_&*PTY&6:#2S#-#7^11)&I(N7>2991FLR(5.VDZ8W)'
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M2AXAJDQR2D&EA"*'W'IES2/D3!M?GA9<VVBD W!M5J<>?&:B1$77?FUI4ZC
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M7<Q2G'_[//OV_?1C^7-U/FWV@I40F=;<:HC&>EB/8PG$'F040J(SC@R 06G
MQ[\S""SNT,#26L ]6U+7V=0<I,'B"G!31T/Q6DS*5 %#7 :%Y+FZUL&IIZGJ
M96;T% 'W[533,]CHU^?'"M=.RJV3]0>6Q1)?I'1V<G8<3C&_0N(@S<[5/<\O
M3A;+T]G_G@^)59B<C73@N,,Z$H(.H4\I0D%EO=7,YMOU4B/F8YNQU6E =DLD
M#@7Z1+ XW),R4!A:!*Z+UV"L8G7IK82H#0/CK63)&]Y^Q\FH#'4:19[T=(P
MA<W/A3\_%W/\5NGX.OGQ*'1"!PHF.R5<9!)R-+JNI]3@@PO@C4/FA"Q)["WO
MVXRK3B/ETQZ4D4#1P9#"FZS0KX_Q/IZX*[X8CO0HBLJ321!2SI!Y4D4SC3*W
M#L$/H:O36'P;J#973+>5I^M@[Q_AN)Z^+]\13VOL;C&OJ0<Z<XLS^M\/BU-<
MO5N$^2I<'M3J76/"V<_J1.U0H-KPZVWJ6,<21Z-RUX_+;V%^@;\:$5L<S_+E
M1?CI!M<W5G9<K?%8794V:A:]1\DAD_-;FPLM1!,Y&.%*C,5EVWQX?!/"=]Z/
M=*'!:UV==PZ$2*Y^;;\UKHZVE=Q"4#H!E\F8X(1'VWKEQP.D3.M&[A]==W8F
M-=#0U '>NSR\_!Z6WS"&].]5G9&Y_MMJ\V!='4#/D5+D\A;&#$DK%(B);)?"
MM2G%1[+P[5.WZ.:?G=8AFPYG(RNH'P?LQ?'QXJ_ZB+U9+%\MSN)I.3N^RW<=
M$)7J/#APQFFPRB$$;\A:TCS'@F0Y8>ONV&&43>L(=7 1MM=?1^"\PT@=,%\<
MNBBT ,MKBW =?>5C;>+3T@6M1,+0>F+TO81,Z]AT +V=M=/,L]ZCLT.R_1%F
M^?7?/W"^PFK:K__QQ5".\UV.XS@ZFWQY="=G:S%TY> (3"HJ8:"4.DY+"W+]
MO:P/=YVHEQ$CM@Z9=.'@K'7UNPHO-'<4K%'6.0$RQKI03PAPB9X+N@N$C58Z
MIEHOVWF8FN?@YFR"L=M7;",]3>WIW,/&U1ABDN67LQ\_CNLR1\.<98FDQ$@H
M=3VD!Y^C@(@LZ!B<1:$&^3@#/_@<O)MMX#6:4CI(N+Z=T\_"U>D-I^URRXS7
MOAC#($JR@96O(Q^4C'5S: S:D3G<O/SE06*>@]NRR\761DL=P&V]LOM%)H/F
M:_C[+C=,&,%#L5""J4,GO )7"XA\8&1WBUH2W?HU?9RBY^"T[ *\AOKJ 'T7
MUS>Q0A=U8<%E%Q+PFMA4HAB(7#J(P69?LLXAR,98N_G]:9L@ID?6UKJ8VCI[
MN3BF/UJ<[V:_>R1$XB5H9!!D5'0D9(987 1I0A3,)N:9&624/?Z=:1L=)K;%
M&JJ@@UOI[3PM3G!]$&Z$(%5P)7C-P;DZD8T1_1%C!([*1D8/>Y3M-V_>0\BT
M[0_3WU.[:Z<#B*V=E_,HT^4A0<U2T-Z \)*#XH&!MX(><<Z92"F9TGR^QUTJ
MIFV7F!Y<.^JE V3][A&_N(AK_LX2KULVE$J0LJR=V[[4_:<.ZD@Z69),4;>N
MBQA UB#L^>>+O=::.\3LQ/JO/I &QD]'//JIT?,/PQGM*N&@?/!<$NH8>@%*
MUCB:$!Z*T04YW9 NM(Y!=9%PN-?HN+$!FJ'DDN4 R7);A^B1RVU8)@M7>66,
M2)FUC\T]2M)S2#UL@K9!9N*6&NO@6;]O[7AR*EM&;A53F>P11?ZY$R[7 5%"
MF5S("&Z]5G?;->^=)R%V ]INFIDZ?%(7(OP(O\X%LA;:Y>]N,.08XU($XL7K
M",K*NL')\1H9TLEDI[T;MJ-NR->>0W)A&T2-HXX.+J]7%Y^]NI//S9U:;A.8
M38HSA!0R(_JY@LB"A<2-UX%%B:KU%-6'J7D.R85=KK)&>NH <?]8+/)?L^/C
M(V64]+$.432*Q%$7!3L9(A@21G#*%(^MW\C+;S^'A,(N:-I*!QU@A^0Q.\5W
MLY_U()R&^;<968[7)\$HE*Q("\CJV^X$(Q><6"JI;AW6W C>NHGB<8J>0^9A
M%YPUU%<'Z*L-?J>_WN/I]T6NIN7J8B%,)#-*.N00LZ,+V(1U#B4 )E&"L0ZE
M:CT_[@%2GD,"8A>\M=!0!T"[$5U\/ULE/#X.<UR<W30S@[/6UFBF)L,2%/>U
MRUAQ2")D,@A4BJ;UX_DT5<\A1;$+_!KKK2\DWF""!W0*R6F6JLZO2EY!2,:#
MS#JXR)-TI7GSYGV$/(>T1".\;:F=0TQ$O$AI>49DSD*\6& _6O?W ]_91Y_W
M$!:[RC]X);7+/$"2G-[8&KH-PF0PA&#&I578?(]N%_F'NC>P_IQ_S4Z_OSQ;
MG9)[OB2@G\VOU/?KO$>.AP)%2@U6UBH;9!$P>R4"*I>:+Z090-9SR$-L@KI[
MYGDVU5P'[_5KNO,6OY!NVO6<FAL7R%49ZN\,U0YV3XS0HY,#/362J]2ZW?9)
MHIY#GF(7(+;5VM19BXO'ZWV8GQ62S-ER-O]VFP$323R&!0A%9RU8BM8.6RUY
MWT]_#EF);?#31MR=X.45_L3CQ?GT]Q]X7J]ZFX^2(H0@(W"7&!;+D&>V"6SN
M^\AS2"WLBIZ=A=\)B-8V]6LRB^G/CFN4>]UOALN?L_3@9<I$[<3@"222ZV08
M5TKR34 UY*//(>.P*\B:*Z<3T%T.@KLY ^X!=K2F-SNS#-H5E;TQ.=XVMQ['
MVB/?>@[)AETAUDH5'9CR%QQ]7OP*QX^8@HE)B%PP2"XZ9E!G%UOW8CU RG/(
M-NQBMK?0T-17V.?PUW5K]L74E4_AU_5DGVL^K)?@)1D!3@>7H[$9@QMT=SWR
MD>>0,MCZTFHE_*E!='$07BY.3G!9A72;>JR;JWET4$S.)"N3@MW(Q+K^T<\A
MYK_K*[>EH'N!"?WE+(7CKVO<W_4R)+CDP[J]E>Y+5>>+;P25WW[\L!@G>^9X
MV5[B4V/F'7X+QS50.YM_PWGZ]>;L]&R);V;+DT]GR_0]K+ >AME%GO^VB5<4
M1"\D)!ZX5L$6?WNJ[ -8VNBSPS#V# /I(VNH'R/\Z8@LV@3!DY'G"^>%$QM"
MM=Z\]B QPP#XC /H;=1TB,GPFZ/Q1L^(/_&Q_73F#62VJ]QX49(EFTIM9LJ@
MM.$0:K=RTCYRFPWCI7FUUI2Y\?7#\'IU.CNI^:S/.#N)9W0EG]S0VZ^CX'A1
MH@B0PEA0B4YE%,R!5<6SQ##%@8TK3WSH.:2Y-P'0;Z]S2R5,;0M^)FG1U[^3
MY&[D*ZYXN;SRDRJ26$"PF;A1N<I*A0PH$PE11+KTAZVO'/:]YY"\WAI>(ZBD
M ZOOYB:@.[R8;)FKO#"4 I2KBQM)2A!*<B9EKZUH?9<_1L]SR'UO [_FNNIB
MV?-%\G7^[7Y^G""[M20%T@A#_-3F0L4$B!*89Y85QYK7V#U*T7/(G>^"OH;Z
MZ@-_U<+^<C;/RU_W.%.27">18J1KW#A0M5',:\[)K4K11"-<*LU'3#Q&T'-(
MJN^$OF;:ZN#173-S#QLY^VB3LT!RTJ!"\1!TI#-$ J(#9+SDHX!N2[AUGF#?
M&6X[:N@08RR7F[P7Y=9HH-$#+IM\>?3HR]9BZ"H4$ZM[RV* Y.HRVU("^#JK
MRQ-X'4^NN/PL%\_=&2!P0VNU%Y<9+FTM*;;>U_5F1I*5+ KP7&+2+!CDK5??
M/$'2<XC;;(*V)T<^[*"Q7M[W.\;*C;ZU&+4JG)X1%1,]32D+",)),$*1S9Q+
MH?=I+];E\QJ@M L$F^JL%PS>SXE6Z)UD$:34 11GEB04#7 M,L/@4,I1EM-L
MC[O.@SH[XVYW/1VBL7EYZW_&GS@_&VFQ\0,?&=V$',)<5]9B=NB,LPA2> *Q
MU Y<RI'\&U-*T<*4V'JR^/2)NY??P_P;OIW?UQ]Y%>+ZNJY2U(9AJAM\,JL!
M5I]SE8\ G92SV@NCRK#5L<._^1S,PDU@]?LT_W%4,^'3O%J>'GU:+O)9.OVX
MO&@&>?'W;'64#?.I&$_FK8KGJ^T=B88N>N(B8)#:#EJ@1Q^X<>SH=]='[J%O
M3P.Q416\:"CM/M!RLWGHU>(DS.9'23!M%$:PFI$U&CA"M)S$PK/,DG&4MK2#
MS%T"IL%-&YW>!<B. IZZ6N""BR_A&%?O\23B\DBAJY/>);!0$%3=1AMT=J S
M%L%4"#+I0:_5W9\]N>IWU=:BG>BZR&1=\' ME;59>L$-=US41@JP4=JZ+B)
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MYGSH1[4L7GB"T''J%3C+Y$&00\I27JN:+$:3!*!5A+;"A&^^1WS,>H4JOJ.
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MPE]O\3R=P7:NO94NN(BP".#^&IV0M5@C8ZW#2GL:>3/.X)Z\G6ASS&O:BP>
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M]TKS1'2R5+-T,E9@'\Y??>+\%9B P9#\JO?_'M&4EDPHQB+2)D^_EA;4CEE
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M7MK1Y-RD&*DA%ADJ%)R_,>3K!A9)GHS7L/$4'6P>S!HMC1BB _2\$SH]A-X
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M>96T:,>>!^XY^IE=Q\SAF?>S*SN&@&AQ-9LL?W+7#S8_#\SRH"!(%RH_]$G
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MZ'H4KE8=%H<H:FVIND'9RS*?[A) [:TT'C_0-5]5M0[:1)L6K*:A+3*?=A-
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M";LR5G)X]6&RHG^=TG5^P-GXYZS$>=[_JVT8C=YH.5C<E>'R)S!X\7:Q$>_
M!_SU/>P+P&3_KU5S"LO H[=XV[$B9_-/:<7&I[1$\#T;A='1^Z/5KGD6MR&]
MA%V[C?F.\%MZ)^'YN7EK^-Z/PY*W-]-)F+^=P6]*(:<0"=4NEI;!45E%5$;5
MV^L0YI]FGQ;?9^^ POGG\&ERS\W'1?[Y7_,O:>PS6]\6XRR@_+!'*4B5^'ZU
MRZUE\%10!;4?Q8DV]\4=7,I\O$ZU0^>E0N8&1FLG>E?4ENF5?KY:O6Z+P]HO
M6[MV\F;Z-8ZC7\2PPM#!-TXVKUBO_M]/7R_*I79[&9 2[GNQ/J4T\K#N^TF9
MO;9[]7HFL)\N.\NKMLV,<?;K;'KUX\-\?E50HR^M6\WW[6M'=\NHMD7]GF?W
MAWM"2VGQI76K>9Q]K>MN&57?B]-OTX4=E[B^M[Y6M2DIO??<1EG4U]"97US9
M\?CFLQV%0HK:M&2U>2C]]?6"9&KW5.62.U"XC!H+F<9M:U8;<])3<3MD4]OM
MO&OH/[N^*&8;MRY:;T))7R]SAW@:TMZ2LD<6HJ02-ZU=;[Q( 5V^(*P63.D]
MJ<4-ZM:5ZPT&.<2N[A)4]3Z?J]'B)C]M<BM*"&\NET^XO1TE("8"MZ6TN^>G
MZLT)Z:GN?J*L'3:NF9D_Y\M#9/GXV_?I&*3\95$JDMSO4_5&C/3.W?4197/Z
M_Q@7'R9^>EDHA][I _4FC133]7:Q-:?A9TGFH33]PH<Z:;RIW%$/,5;6_ ;S
MDSE?);_**+WK-SKINZ7LTY[":VZ3?UI\C[.!]_?F;W12=4N)JSV%5WM76W<U
MMK/?1O-%P5+W]E4[J;.E=-9. =56X'/+<F@F9,N2G;H56DIFO2R:ZIG_.^-?
M7H&[UNZDR99261V%5?W87'/A#M7CQ@4[*:^E3,9+8JD]ZC2?S)FC0@K;M%XG
M?;64>7A!*"WDBHL\C_5XH4X*:BE=L$D,U4^SZ<$]=W=K=-)'2\'\&O-M] L?
MK(Y]&Q]I2_%V@_V.T\FOUOY8$?8VSOULM,SG%VIXW+U\)R6V%$EW%UGU<RF,
M,EUVS#&]?N"N5!USU^J=--M24-U98+6/M<E\\LLD+?)=E&*-K%O6[-1<WE)X
MO4,XU4O1#]>(RM6<-Z_9274MQ=,[A-/J&/L/D_D(A/EM9I=/&,YFN0$WC^=?
MNS!TX$S[%SY39,!]5S8*3+M_]JEGL.@Y-7;KLH>D,N^7^R4_B7+XG/N-"U8<
MJ;I+%T^2ER\(HW;*^9ZT@R\EKBU533<O2GNC5AJZIG@V'F^P)67FKFY?N %=
MO3""=:= *NKL<C:QY]\>GJ#_E)Y3NTE[^;];*HA01I9*VF.EFM-5=RMCVE<R
MO=4X/EB#9V'ZHX#Z.BQ3<ZCJ?KKK+I-&%?=I^3=S4DB!:\O5'!-93I&;9=2V
M0FE9A=+:TWN&4"AM0:&WGO*K>]^BJX/YW[<N_OO6Q7[&[^LB_OAN)_&7G/_9
M.#UUBYG;^!_6=!.WBWC:D=^*9]"2K#CYG^E%W%<'3_ZKFK[>'@K8Q&F] ^/W
MQ6R<PX9Y/MT"&-DR^=X7EJVFIOVR2+L%4SV7E*DJ\4CTTY6J>=K[9ODVL-^*
M2KZ-%@<G8)\L5<U;[JF4)P*HK)4O5^-(L!,DY[VR+Q_#^[&].$@]V]:L-D]G
M/SWM$$G]AH\A=/;"LM4&Z.RGMMV":<( W@7,;^VBA!%\LERUX3E]#.$F031D
M#+_-+B>+LK;PT9+5QN;T-X7/!=*6)2RDL.VK5IN8<Y =;$YM=P'#?36FD"5<
M7['>D)P^UG"+/)K0U;N?/T:SDJI:6[#>")P^FMHLC284]?;JEK "*KI?JMY
MFS[*69= $VKY&OW5;+08Q?G9Q<79M1V-#[Y*^<*Z]4;2]%'8B[(YC8;!S]/Q
MR ,#GV=3_Y3RH@V#3SXS0,/@=C:*-PP^_M0SC!3H'-R\_D&5P]7RX?'2I6+O
MW:LWTESXHMZ>EAL[RJNR?=Y,Y\?I8D5JF7Q_]Z\TDOX_4,\OR&]XB[[ZB_R+
ML_/X__Y?_S]02P$"% ,4    "  [@%1<>UT*U?D@  #6LP  %P
M    @ $     97AH:6)I=#$P,39E<W!P<&QA;BYH=&U02P$"% ,4    "  [
M@%1<]WL&-0X:  #*IP  '@              @ $N(0  97AH:6)I=#$Y:6YS
M:61E<G1R861I;F=P;VPN:'1M4$L! A0#%     @ .X!47,;)0(+T!   9D$
M !X              ( !>#L  &5X:&EB:70R,3%S=6)S:61I87)I97,Q,C,Q
M+FAT;5!+ 0(4 Q0    ( #N 5%P)A.Z]N@,  -L4   6              "
M :A   !E>&AI8FET,C,Q,3(S,3(P,C4N:'1M4$L! A0#%     @ .X!47$B(
M)U -"   >"0  !8              ( !ED0  &5X:&EB:70S,3$Q,C,Q,C R
M-2YH=&U02P$"% ,4    "  [@%1<TB^;=OT'   Y(P  %@
M@ '73   97AH:6)I=#,Q,C$R,S$R,#(U+FAT;5!+ 0(4 Q0    ( #N 5%RD
MB?U5O 0  -T8   6              "  0A5  !E>&AI8FET,S(Q,3(S,3(P
M,C4N:'1M4$L! A0#%     @ .X!47-$BVU*N!   T!@  !8
M ( !^%D  &5X:&EB:70S,C(Q,C,Q,C R-2YH=&U02P$"% ,4    "  [@%1<
M[$4D9X$1   )4   %0              @ ':7@  97AH:6)I=#0R,3(S,3(P
M,C4N:'1M4$L! A0#%     @ .X!47%<E:B4;+@0 H]HH !$
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M82TR,#(U,3(S,5]G,2YJ<&=02P$"% ,4    "  [@%1<Q<<A!'++  "$U0
M%               @ %1[P4 ;7)N82TR,#(U,3(S,5]G,BYJ<&=02P$"% ,4
M    "  [@%1<VAV08?.* 0"0U@$ %               @ 'UN@8 ;7)N82TR
M,#(U,3(S,5]G,RYJ<&=02P$"% ,4    "  [@%1<$9H(-1>A @!:! 0 %
M            @ $:1@@ ;7)N82TR,#(U,3(S,5]G-"YJ<&=02P$"% ,4
M"  [@%1<J8R3T JQ 0"X6 ( %               @ %CYPH ;7)N82TR,#(U
M,3(S,5]G-2YJ<&=02P$"% ,4    "  [@%1<+>0#AHJ6 0!UY0\ %0
M        @ &?F P ;7)N82TR,#(U,3(S,5]L86(N>&UL4$L! A0#%     @
M.X!47)YH)2BZZ0  NBH+ !4              ( !7"\. &UR;F$M,C R-3$R
@,S%?<')E+GAM;%!+!08     %  4 $@%  !)&0\    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>mrna-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrna="http://www.modernatx.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrna-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2026-02-13</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:FFFEnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:FFFEnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:PublicWorksAndGovernmentServicesCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:PublicWorksAndGovernmentServicesCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:UKHealthSecurityAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:UKHealthSecurityAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MexicoMedistikMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BoryungBiopharmaKoreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TaiwanFoodAndDrugAdministrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MinistryOfHealthLaborAndWelfareOfJapanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:RSVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:RSVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:RSVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:StandReadyManufacturingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:StandReadyManufacturingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:StandReadyManufacturingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2025-06-15</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:LicenseAndRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BlackstoneLifeSciencesBlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:ImmaticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:COVIDVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:COVIDVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:MNEXSPIKEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrna:RSVVaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrna:ModernaTechnologyCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrna:ModernaTechnologyCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:DelayedDrawTermLoanFacility1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:DelayedDrawTermLoanFacility2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">mrna:TermSecuredOvernightFinancingRatePlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:DebtInstrumentCovenantComplianceScenarioAxis">mrna:CovenantComplianceScenario1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:DebtInstrumentCovenantComplianceScenarioAxis">mrna:CovenantComplianceScenario2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrna:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrna:GlaxoSmithKlineBiologicalsSAPatentsOwnedByGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrna:GlaxoSmithKlineBiologicalsSAPatentsInfringementsInUPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrna:GlaxoSmithKlineBiologicalsSALiposomesAndModifiedLiposomesInSpainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndGrantPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-13</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-13</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">mrna:MoreLikelyThatNotToRealizeAllDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:TerminationOfTradingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:TerminationOfTradingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephaneBancelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">mrna:AdoptionOfTradingArrangementOptions2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mrna:StephenHogeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>mrna:product</measure>
    </unit>
    <unit id="candidate">
        <measure>mrna:candidate</measure>
    </unit>
    <unit id="developmentprogram">
        <measure>mrna:developmentProgram</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>mrna:segment</measure>
    </unit>
    <unit id="participant">
        <measure>mrna:participant</measure>
    </unit>
    <unit id="security">
        <measure>mrna:security</measure>
    </unit>
    <unit id="campus">
        <measure>mrna:campus</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="numberofextensionperiod">
        <measure>mrna:numberOfExtensionPeriod</measure>
    </unit>
    <unit id="lawsuit">
        <measure>mrna:lawsuit</measure>
    </unit>
    <unit id="claim">
        <measure>mrna:claim</measure>
    </unit>
    <unit id="installment">
        <measure>mrna:installment</measure>
    </unit>
    <unit id="employee">
        <measure>mrna:employee</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001682852</dei:EntityCentralIndexKey>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-496"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-497"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-222" id="f-813">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-246" id="f-844">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <mrna:InventoryShelfLife contextRef="c-250" id="f-874">P9M</mrna:InventoryShelfLife>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1024">http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1025">http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1030">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1031">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1034">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1035">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-379" id="f-1524">P255D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-383" id="f-1525">P270D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38753</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Moderna, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">325 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">714-6500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-29" unitRef="usd">9900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">394939424</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-36">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity organization&#x2019;s mission is to provide a targeted set of services, support and capabilities to reduce the risk of cyberattacks, rapidly detect and contain threats, and mitigate risks to critical data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognizing the threat of security breaches and cyberattacks globally, we have developed a cybersecurity program, overseen by our Chief Technology and Information Security Officer (CISO), that is designed to protect patient trust, defend the Moderna brand, and reduce the risk and impact of cyber-attacks. Our cybersecurity program is informed by industry standards and includes periodic risk assessments and security testing supported by cybersecurity technologies, including third-party security solutions, vulnerability management, and monitoring tools, designed to monitor, identify, and manage risks from cyber threats. In addition, we have implemented employee security and awareness training. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has established a cyber incident response plan (CIRP) designed to assess, identify and manage risks from cybersecurity threats and enable prompt response in the event that a cybersecurity incident is detected. We have a process in place for notification to our leadership response team in the event of a significant cyber incident, and for escalation of these events to our Audit Committee and Board, as appropriate. To date, we have not experienced a cybersecurity incident that has had a material impact on our business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/div&gt;We undergo several annual internal compliance audits and external reviews to evaluate our controls, including cybersecurity controls. In an effort to minimize third-party risk, we have established a process to assess the security practices of third-party suppliers and related risks, including through review of relevant supplier certifications and security and responses to standardized information gathering (SIG) questionnaires, as applicable and appropriate.</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-37">Recognizing the threat of security breaches and cyberattacks globally, we have developed a cybersecurity program, overseen by our Chief Technology and Information Security Officer (CISO), that is designed to protect patient trust, defend the Moderna brand, and reduce the risk and impact of cyber-attacks.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-41">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors oversees Moderna&#x2019;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Audit Committee receives cyber-related updates from management, including our CISO at committee meetings. During meetings, our CISO updates the committee on Moderna&#x2019;s cybersecurity posture, potential threats and risk mitigation strategies, and the progress of the Company&#x2019;s cybersecurity initiatives, as appropriate. The Chair of the Audit Committee and management provide regular briefings on such matters to the full Board of Directors, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-44">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors oversees Moderna&#x2019;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff. &lt;/span&gt;&lt;/div&gt;The Audit Committee receives cyber-related updates from management, including our CISO at committee meetings. During meetings, our CISO updates the committee on Moderna&#x2019;s cybersecurity posture, potential threats and risk mitigation strategies, and the progress of the Company&#x2019;s cybersecurity initiatives, as appropriate. The Chair of the Audit Committee and management provide regular briefings on such matters to the full Board of Directors, as appropriate.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-42">Our Board of Directors oversees Moderna&#x2019;s overall risk management strategy. The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee, which oversees our risk management processes for information security and technology risks. Our cybersecurity risk management processes are integrated into our overall risk management strategy, which is overseen by the Audit Committee. At least annually, the Audit Committee discusses our risk management program, including information security and technology risks and findings from any audits, with our internal audit staff.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-45">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-48">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-47">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats. Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies. Our CISO reports directly to our Chief People and Digital Technology Officer, who is a member of our Executive Committee and reports to our Chief Executive Officer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have built a cybersecurity leadership team designed to align with key services, with a separate lead overseeing each service offering, all reporting to the CISO. We also maintain relationships with law enforcement and industry groups to support our cybersecurity intelligence and risk management efforts.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">At the management level, our CISO is primarily responsible for leading our cybersecurity strategy for assessing and managing material risks from cybersecurity threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-50">Our current CISO has over 25 years of cybersecurity experience across a wide array of industries, most recently serving in leadership positions at two different public companies and previous roles of increasing responsibility at multinational technology companies.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-51">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-52">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-6" id="f-53" unitRef="usd">2595000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-6" id="f-54" unitRef="usd">1927000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-6" id="f-55" unitRef="usd">3204000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-5" decimals="-6" id="f-56" unitRef="usd">5098000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-6" id="f-57" unitRef="usd">184000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-6" id="f-58" unitRef="usd">358000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-6" id="f-59" unitRef="usd">153000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-6" id="f-60" unitRef="usd">117000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-6" id="f-61" unitRef="usd">408000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-6" id="f-62" unitRef="usd">599000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-6" id="f-63" unitRef="usd">6544000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-6" id="f-64" unitRef="usd">8099000000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-4" decimals="-6" id="f-65" unitRef="usd">2336000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-5" decimals="-6" id="f-66" unitRef="usd">2494000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-6" id="f-67" unitRef="usd">2134000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-6" id="f-68" unitRef="usd">2196000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-6" id="f-69" unitRef="usd">719000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-6" id="f-70" unitRef="usd">759000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-6" id="f-71" unitRef="usd">605000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-6" id="f-72" unitRef="usd">594000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-6" id="f-73" unitRef="usd">12338000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-6" id="f-74" unitRef="usd">14142000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-6" id="f-75" unitRef="usd">317000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-6" id="f-76" unitRef="usd">405000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-77" unitRef="usd">1386000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-78" unitRef="usd">1427000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-6" id="f-79" unitRef="usd">99000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-6" id="f-80" unitRef="usd">153000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-81" unitRef="usd">185000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-82" unitRef="usd">221000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-83" unitRef="usd">1987000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-84" unitRef="usd">2206000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-85" unitRef="usd">153000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-86" unitRef="usd">58000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-87" unitRef="usd">653000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-88" unitRef="usd">671000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-89" unitRef="usd">20000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-90" unitRef="usd">39000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-6" id="f-91" unitRef="usd">590000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-6" id="f-92" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-6" id="f-93" unitRef="usd">285000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-94" unitRef="usd">267000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-6" id="f-95" unitRef="usd">3688000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-6" id="f-96" unitRef="usd">3241000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-97" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-98" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-99"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-100"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-6" id="f-101" unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-6" id="f-102" unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-104" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-105" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-106" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-6" id="f-107" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-6" id="f-108" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-109"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-110"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-6" id="f-111" unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-6" id="f-112" unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-6" id="f-113" unitRef="shares">394000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-6" id="f-114" unitRef="shares">394000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-6" id="f-115" unitRef="shares">386000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-6" id="f-116" unitRef="shares">386000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-6" id="f-117" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-6" id="f-118" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-6" id="f-119" unitRef="usd">1382000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-6" id="f-120" unitRef="usd">866000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-6" id="f-121" unitRef="usd">45000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-6" id="f-122" unitRef="usd">-10000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-6" id="f-123" unitRef="usd">7223000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-6" id="f-124" unitRef="usd">10045000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-6" id="f-125" unitRef="usd">8650000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-6" id="f-126" unitRef="usd">10901000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-6" id="f-127" unitRef="usd">12338000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-6" id="f-128" unitRef="usd">14142000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-129" unitRef="usd">1818000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-130" unitRef="usd">3109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-6" id="f-131" unitRef="usd">6671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-6" id="f-132" unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-6" id="f-133" unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-6" id="f-134" unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-135" unitRef="usd">1944000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-6" id="f-136" unitRef="usd">3236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-6" id="f-137" unitRef="usd">6848000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-138" unitRef="usd">868000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-6" id="f-139" unitRef="usd">1464000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-6" id="f-140" unitRef="usd">4693000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-141" unitRef="usd">3132000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-6" id="f-142" unitRef="usd">4543000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-6" id="f-143" unitRef="usd">4845000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-144" unitRef="usd">1018000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-6" id="f-145" unitRef="usd">1174000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-6" id="f-146" unitRef="usd">1549000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-6" id="f-147" unitRef="usd">5018000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-12" decimals="-6" id="f-148" unitRef="usd">7181000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-6" id="f-149" unitRef="usd">11087000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-150" unitRef="usd">-3074000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-6" id="f-151" unitRef="usd">-3945000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-6" id="f-152" unitRef="usd">-4239000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-6" id="f-153" unitRef="usd">314000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-12" decimals="-6" id="f-154" unitRef="usd">425000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-13" decimals="-6" id="f-155" unitRef="usd">421000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-156" unitRef="usd">-8000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-6" id="f-157" unitRef="usd">-87000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-6" id="f-158" unitRef="usd">-124000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-159" unitRef="usd">-2768000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-160" unitRef="usd">-3607000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-161" unitRef="usd">-3942000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-162" unitRef="usd">54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-163" unitRef="usd">-46000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-164" unitRef="usd">772000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-165" unitRef="usd">-2822000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-166" unitRef="usd">-3561000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-167" unitRef="usd">-4714000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-7.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">-7.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">-9.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">-9.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">-12.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-12.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-6" id="f-174" unitRef="shares">389000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-6" id="f-175" unitRef="shares">389000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-6" id="f-176" unitRef="shares">384000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-6" id="f-177" unitRef="shares">384000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-6" id="f-178" unitRef="shares">382000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-6" id="f-179" unitRef="shares">382000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-180" unitRef="usd">-2822000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-181" unitRef="usd">-3561000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-182" unitRef="usd">-4714000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-183" unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="-6" id="f-184" unitRef="usd">120000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-6" id="f-185" unitRef="usd">210000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-1" decimals="-6" id="f-186" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-12" decimals="-6" id="f-187" unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-13" decimals="-6" id="f-188" unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-189" unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-6" id="f-190" unitRef="usd">124000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-6" id="f-191" unitRef="usd">248000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" decimals="-6" id="f-192" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-12" decimals="-6" id="f-193" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-13" decimals="-6" id="f-194" unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent contextRef="c-1" decimals="-6" id="f-195" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent contextRef="c-12" decimals="-6" id="f-196" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent contextRef="c-13" decimals="-6" id="f-197" unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-198" unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="-6" id="f-199" unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="-6" id="f-200" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax contextRef="c-1" decimals="-6" id="f-201" unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax contextRef="c-12" decimals="-6" id="f-202" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax contextRef="c-13" decimals="-6" id="f-203" unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-204" unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-6" id="f-205" unitRef="usd">113000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-6" id="f-206" unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-207" unitRef="usd">-2767000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-6" id="f-208" unitRef="usd">-3448000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-6" id="f-209" unitRef="usd">-4467000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-6" id="f-210" unitRef="shares">385000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-6" id="f-211" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-6" id="f-212" unitRef="usd">1173000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-6" id="f-213" unitRef="usd">-370000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-6" id="f-214" unitRef="usd">18320000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-6" id="f-215" unitRef="usd">19123000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-19" decimals="-6" id="f-216" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-19" decimals="-6" id="f-217" unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-20" decimals="-6" id="f-218" unitRef="usd">25000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-6" id="f-219" unitRef="usd">25000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-6" id="f-220" unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-6" id="f-221" unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-6" id="f-222" unitRef="usd">305000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-6" id="f-223" unitRef="usd">305000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-6" id="f-224" unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-6" id="f-225" unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-19" decimals="-6" id="f-226" unitRef="shares">8000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-20" decimals="-6" id="f-227" unitRef="usd">1153000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-13" decimals="-6" id="f-228" unitRef="usd">1153000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-6" id="f-229" unitRef="usd">-4714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-230" unitRef="usd">-4714000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-23" decimals="-6" id="f-231" unitRef="shares">382000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-6" id="f-232" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-6" id="f-233" unitRef="usd">371000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-6" id="f-234" unitRef="usd">-123000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-6" id="f-235" unitRef="usd">13606000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-6" id="f-236" unitRef="usd">13854000000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-23" decimals="-6" id="f-237" unitRef="shares">382000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-6" id="f-238" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-6" id="f-239" unitRef="usd">371000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-6" id="f-240" unitRef="usd">-123000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-6" id="f-241" unitRef="usd">13606000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-6" id="f-242" unitRef="usd">13854000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-28" decimals="-6" id="f-243" unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-28" decimals="-6" id="f-244" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-6" id="f-245" unitRef="usd">42000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-12" decimals="-6" id="f-246" unitRef="usd">42000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-28" decimals="-6" id="f-247" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-29" decimals="-6" id="f-248" unitRef="usd">24000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-6" id="f-249" unitRef="usd">24000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-6" id="f-250" unitRef="usd">429000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-6" id="f-251" unitRef="usd">429000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-30" decimals="-6" id="f-252" unitRef="usd">113000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-6" id="f-253" unitRef="usd">113000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-31" decimals="-6" id="f-254" unitRef="usd">-3561000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-255" unitRef="usd">-3561000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="-6" id="f-256" unitRef="shares">386000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-6" id="f-257" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-6" id="f-258" unitRef="usd">866000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-6" id="f-259" unitRef="usd">-10000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-6" id="f-260" unitRef="usd">10045000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-6" id="f-261" unitRef="usd">10901000000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="-6" id="f-262" unitRef="shares">386000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-6" id="f-263" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-6" id="f-264" unitRef="usd">866000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-6" id="f-265" unitRef="usd">-10000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-6" id="f-266" unitRef="usd">10045000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-6" id="f-267" unitRef="usd">10901000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-36" decimals="-6" id="f-268" unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-36" decimals="-6" id="f-269" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-6" id="f-270" unitRef="usd">17000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-6" id="f-271" unitRef="usd">17000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-37" decimals="-6" id="f-272" unitRef="usd">2000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-6" id="f-273" unitRef="usd">2000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-37" decimals="-6" id="f-274" unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-6" id="f-275" unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-6" id="f-276" unitRef="usd">483000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-277" unitRef="usd">483000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-38" decimals="-6" id="f-278" unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-279" unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-6" id="f-280" unitRef="usd">-2822000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-281" unitRef="usd">-2822000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-40" decimals="-6" id="f-282" unitRef="shares">394000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-6" id="f-283" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-6" id="f-284" unitRef="usd">1382000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-6" id="f-285" unitRef="usd">45000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-6" id="f-286" unitRef="usd">7223000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-6" id="f-287" unitRef="usd">8650000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-288" unitRef="usd">-2822000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-289" unitRef="usd">-3561000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-290" unitRef="usd">-4714000000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-291" unitRef="usd">483000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-6" id="f-292" unitRef="usd">429000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-6" id="f-293" unitRef="usd">305000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-1" decimals="-6" id="f-294" unitRef="usd">215000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-12" decimals="-6" id="f-295" unitRef="usd">189000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-13" decimals="-6" id="f-296" unitRef="usd">621000000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-6" id="f-297" unitRef="usd">67000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-12" decimals="-6" id="f-298" unitRef="usd">95000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-13" decimals="-6" id="f-299" unitRef="usd">61000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c-1" decimals="-6" id="f-300" unitRef="usd">-8000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c-12" decimals="-6" id="f-301" unitRef="usd">-52000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c-13" decimals="-6" id="f-302" unitRef="usd">-35000000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-6" id="f-303" unitRef="usd">-77000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-12" decimals="-6" id="f-304" unitRef="usd">-60000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-13" decimals="-6" id="f-305" unitRef="usd">-7000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-6" id="f-306" unitRef="usd">-156000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-6" id="f-307" unitRef="usd">-534000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-6" id="f-308" unitRef="usd">-493000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-6" id="f-309" unitRef="usd">-153000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-6" id="f-310" unitRef="usd">-145000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-6" id="f-311" unitRef="usd">-1802000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-312" unitRef="usd">34000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-6" id="f-313" unitRef="usd">-83000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-6" id="f-314" unitRef="usd">-747000000</us-gaap:IncreaseDecreaseInInventories>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases contextRef="c-1" decimals="-6" id="f-315" unitRef="usd">-38000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases contextRef="c-12" decimals="-6" id="f-316" unitRef="usd">53000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases contextRef="c-13" decimals="-6" id="f-317" unitRef="usd">605000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-6" id="f-318" unitRef="usd">-92000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-6" id="f-319" unitRef="usd">-69000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-6" id="f-320" unitRef="usd">13000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-6" id="f-321" unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-12" decimals="-6" id="f-322" unitRef="usd">-385000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-13" decimals="-6" id="f-323" unitRef="usd">-340000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-6" id="f-324" unitRef="usd">41000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-12" decimals="-6" id="f-325" unitRef="usd">-439000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-13" decimals="-6" id="f-326" unitRef="usd">-2060000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-327" unitRef="usd">-21000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-12" decimals="-6" id="f-328" unitRef="usd">28000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-13" decimals="-6" id="f-329" unitRef="usd">551000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-6" id="f-330" unitRef="usd">-6000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-12" decimals="-6" id="f-331" unitRef="usd">78000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-13" decimals="-6" id="f-332" unitRef="usd">88000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-333" unitRef="usd">-1873000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-6" id="f-334" unitRef="usd">-3004000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-6" id="f-335" unitRef="usd">-3118000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-6" id="f-336" unitRef="usd">5768000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-12" decimals="-6" id="f-337" unitRef="usd">6529000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-6" id="f-338" unitRef="usd">3760000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-6" id="f-339" unitRef="usd">5563000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-12" decimals="-6" id="f-340" unitRef="usd">5562000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-13" decimals="-6" id="f-341" unitRef="usd">5575000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-6" id="f-342" unitRef="usd">2353000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-12" decimals="-6" id="f-343" unitRef="usd">3967000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-6" id="f-344" unitRef="usd">3206000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-345" unitRef="usd">192000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-6" id="f-346" unitRef="usd">1051000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-6" id="f-347" unitRef="usd">707000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-348" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-12" decimals="-6" id="f-349" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-13" decimals="-6" id="f-350" unitRef="usd">85000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-6" id="f-351" unitRef="usd">10000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-12" decimals="-6" id="f-352" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-13" decimals="-6" id="f-353" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-1" decimals="-6" id="f-354" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-12" decimals="-6" id="f-355" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-13" decimals="-6" id="f-356" unitRef="usd">23000000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-357" unitRef="usd">1946000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-6" id="f-358" unitRef="usd">1949000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-6" id="f-359" unitRef="usd">4206000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-1" decimals="-6" id="f-360" unitRef="usd">600000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-12" decimals="-6" id="f-361" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-13" decimals="-6" id="f-362" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-6" id="f-363" unitRef="usd">22000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-12" decimals="-6" id="f-364" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-13" decimals="-6" id="f-365" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-6" id="f-366" unitRef="usd">35000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-12" decimals="-6" id="f-367" unitRef="usd">66000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-13" decimals="-6" id="f-368" unitRef="usd">46000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-369" unitRef="usd">2000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-12" decimals="-6" id="f-370" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-13" decimals="-6" id="f-371" unitRef="usd">1153000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments contextRef="c-1" decimals="-6" id="f-372" unitRef="usd">18000000</mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments>
    <mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments contextRef="c-12" decimals="-6" id="f-373" unitRef="usd">10000000</mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments>
    <mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments contextRef="c-13" decimals="-6" id="f-374" unitRef="usd">270000000</mrna:FinanceLeasePrincipalPaymentsNetOfAdjustments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-375" unitRef="usd">593000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-6" id="f-376" unitRef="usd">56000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-6" id="f-377" unitRef="usd">-1377000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-378" unitRef="usd">2000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-12" decimals="-6" id="f-379" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-13" decimals="-6" id="f-380" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-381" unitRef="usd">668000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-6" id="f-382" unitRef="usd">-999000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-6" id="f-383" unitRef="usd">-289000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-6" id="f-384" unitRef="usd">1929000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-6" id="f-385" unitRef="usd">2928000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-6" id="f-386" unitRef="usd">3217000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-6" id="f-387" unitRef="usd">2597000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-6" id="f-388" unitRef="usd">1929000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-6" id="f-389" unitRef="usd">2928000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-6" id="f-390" unitRef="usd">26000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-12" decimals="-6" id="f-391" unitRef="usd">197000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-13" decimals="-6" id="f-392" unitRef="usd">-357000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-6" id="f-393" unitRef="usd">10000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-6" id="f-394" unitRef="usd">24000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-6" id="f-395" unitRef="usd">39000000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-6" id="f-396" unitRef="usd">83000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-12" decimals="-6" id="f-397" unitRef="usd">97000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="-6" id="f-398" unitRef="usd">130000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-399">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1. Description of the Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body&#x2019;s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.&lt;/span&gt;&lt;/div&gt;Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We currently have three commercial products&#x2014;Spikevax&#xae; and mNEXSPIKE&#xae;, our COVID vaccines, and mRESVIA&#xae;, our vaccine against respiratory syncytial virus (RSV). Additionally, we also have a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <mrna:NumberOfCommercialProducts
      contextRef="c-1"
      decimals="INF"
      id="f-400"
      unitRef="product">3</mrna:NumberOfCommercialProducts>
    <mrna:NumberOfDevelopmentCandidates
      contextRef="c-4"
      decimals="INF"
      id="f-401"
      unitRef="candidate">25</mrna:NumberOfDevelopmentCandidates>
    <mrna:NumberOfDevelopmentPrograms
      contextRef="c-4"
      decimals="INF"
      id="f-402"
      unitRef="developmentprogram">35</mrna:NumberOfDevelopmentPrograms>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-403">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating and reportable segment, reflecting the integrated nature of our business focused on the research, development, and commercialization of mRNA-based medicines. Our Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), responsible for assessing the Company's performance and making resource allocation decisions. The CODM evaluates financial information on a consolidated basis, focusing on key metrics such as total revenue, operating expenses, and net income or loss, which is our reported measure of segment profit or loss. The CODM allocates resources based on the Company's available cash resources, forecasted cash flow, and expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities. Resource allocation decisions are informed by budgeted and forecasted expense information, along with actual expenses incurred to date. Disaggregated profit or loss information at the program or functional level is not regularly provided to or relied upon by the CODM, as our integrated operating model emphasizes shared resources and centralized decision-making. The interdependent nature of our research, development, and commercialization activities, supported by common infrastructure such as our mRNA platform, makes further disaggregation of expenses less meaningful for assessing performance. Additionally, there are no segment managers accountable for operations, operating results, and planning for levels or components below the consolidated unit level. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Net &lt;span id="ice4d497822074fb680bb6adb64870e63_40370"&gt;&lt;/span&gt;Product Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations.  In the U.S., our COVID vaccine and RSV vaccine are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, government rebates, and other related deductions. These provisions are recorded based on contractual terms, our estimate of returns for product sold during the period, and other relevant considerations, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wholesaler chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our vaccines are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, projected market demand, and our historical experience with returns. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government rebates and other fees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets. In 2024, we began recognizing Medicare rebates associated with our RSV product. The estimation of Medicare rebates requires judgment and is based on historical utilization trends, and the mix of customers and payers. The estimated liability for unpaid or unbilled rebates is presented as accrued liabilities on our consolidated balance sheets. For 2024 and 2025, the product sales subject to Medicare rebates were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control, such as the limited historical data, constrained third-party information, and evolving market dynamics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now have two years of data on our product returns, this remains limited and subject to significant variability given current market conditions. We will continue to refine our projections as additional information becomes available. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue consists primarily of grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licensing and Royalty Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue is recognized when the license is granted to the licensee, provided no significant performance obligations remain. Royalty revenue is recognized based on sales by licensees when the underlying sales occur, in accordance with the terms of the licensing agreement and when collectibility is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stand-Ready Manufacturing Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into long-term strategic agreements with government entities to establish domestic mRNA manufacturing capabilities and support pandemic readiness. Under these agreements, we are required to build and maintain manufacturing facilities and to supply vaccines in accordance with minimum spend commitments or annual demand forecasts established by the respective governments. A portion of the total consideration under each agreement is allocated to a stand-ready obligation to maintain manufacturing readiness and is recognized as other revenue on a straight-line basis over the contractual period. The remaining consideration is related to our obligation to supply vaccines and will be recognized as product sales when control of the vaccines transfers upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in prepaid expenses and other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other non-current assets in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific-identification method, and are included in other income (expense), net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument&#x2019;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Available-for-sale securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other income (expense), net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other income (expense), net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (see our &#x201c;Revenue Recognition&#x201d; policy within &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors. The allowance for doubtful accounts was immaterial at December 31, 2025 and 2024. Additionally, bad debt expenses were immaterial for the years ended December 31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable, net related to our net product sales and other revenue. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, stand-ready manufacturing revenue from international government entities, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;&lt;br/&gt;Accounts&#160;Receivable&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;FFF Enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public Works and Government Services Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom Health Security Agency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico Medistik&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Boryung Biopharma Korea&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taiwan Food and Drug Administration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ministry of Health, Labor, and Welfare of Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;* - Represents an amount of less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash equivalents and marketable debt securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value, with cost determined principally using first-in, first-out method. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-launch Inventory &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2025 and 2024, we did not have any capitalized pre-launch inventory on our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and permanent land improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited-life land improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Determined on a project-by-project basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-12 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement&lt;br/&gt;or&#160;remaining life of related lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress includes direct costs related to the construction of various property, plant and equipment, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets primarily consist of acquired intellectual property and regulatory approval and commercial sales milestone payments. These assets are recorded at cost, net of accumulated amortization, and amortized on a straight-line basis over their estimated useful lives. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets, including Intangibles and Lease Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our long-lived assets, which consist of property, plant and equipment, finite-lived intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2025, 2024 and 2023 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are initially measured as the lease liability plus direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaborator are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). See our "Revenue Recognition" policy within &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaborator, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Funding Arrangements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into research and development funding arrangements to support a targeted programs, under which a third party has committed to fund us up to a specified amount. Contingent upon the regulatory approval of the program, we are obligated to pay certain milestones and royalties as outlined in the respective agreements. We account for funding received under research and development arrangements as a reduction to expenses when substantive financial risk is transferred to the funding party. These arrangements are accounted for as an obligation to conduct research and development activities. The funding is recognized proportionally as the related costs are incurred, using an input method. Contingent payments, such as milestones or royalties, will be recognized separately upon achievement of the related conditions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations. Advertising expenses were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$133&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in 2025, $146&#160;million in 2024, and $204 million in 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Compensation&#x2014;Stock Compensation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2025, we estimated the expected term of our stock options using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. During 2025, we used historical exercise data in estimating the expected term of stock options, utilizing a methodology that combines historical settlement data with a hypothetical settlement pattern for outstanding options, based on estimated time to arrival at-the-money and adjusted for employee departure rates. The change in methodology used during 2025 did not have a material impact on stock-based compensation and our financial statements. However, during the fourth quarter of 2025, in connection with our stock option exchange program (see &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_199" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), which resulted in changes to our stock option population, we determined that we no longer have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, as such data is no longer indicative of future exercise patterns. Accordingly, beginning in 2026, we will estimate the expected term of stock options using the simplified method. We will continue to apply this process until a sufficient amount of historical information regarding the expected term becomes available and we believe that historical experience is relevant to our expectations for current grants. The expected volatility is based on our stock price volatility and incorporates both historical volatility of our stock price and implied volatility derived from the price of exchange traded options on our stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#x201c;more likely than not&#x201d; criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted stock units, performance stock units, stock options, and shares under the employee stock purchase plan that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments, derivatives designated as hedging instruments, and foreign currency translation, as well as, pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive loss for the years ended December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Gains on Available-for-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Pension and Postretirement Obligation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses (gains) on Foreign Currency Translation &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss, balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss, balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early adoption is permitted. We adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_205" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 14&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Income Taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU requires entities to disclose, on an annual and interim basis, disaggregated information in the footnotes related to certain expense categories included in income statement line items. Specifically, entities are expected to provide tabular disclosures for prescribed categories such as inventory purchases, employee compensation, depreciation, and intangible asset amortization for each relevant expense caption. The standard also requires disclosure of total selling expenses and a definition of those expenses in annual filings. Any remaining amounts not quantitatively disclosed are expected to be described qualitatively. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption permitted, and the standard may be applied on a prospective or retrospective basis. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU No. 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This ASU makes targeted amendments to the accounting for and disclosure of software costs under ASC 350-40. The amendments modernize the guidance to reflect current software development practices, including nonlinear development approaches, and remove references to &#x201c;development stages.&#x201d; Under the ASU, the following two criteria must be met for entities to begin capitalizing software costs: (1) management, with the relevant authority, implicitly or explicitly authorizes and commits to funding a computer software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#x201c;probable-to-complete recognition threshold&#x201d;). The ASU clarifies that this threshold would not be met when there is &#x201c;significant uncertainty associated with the development activities of the software (referred to as &#x2018;significant development uncertainty&#x2019;).&#x201d; The ASU is effective for all entities for annual reporting periods beginning after December 15, 2027, and for interim reporting periods within those fiscal years. Early adoption is permitted, and entities may apply the amendments prospectively, retrospectively, or using a modified prospective transition approach. We are currently evaluating the impact that this new accounting standard will have on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU No. 2025-07,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration From a Customer in a Revenue Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU expands the scope exceptions in the derivatives guidance to exclude certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties to the contract, including the occurrence or nonoccurrence of an event specific to those operations or activities. The ASU also clarifies that share-based noncash consideration received from a customer in exchange for goods or services should be accounted for as noncash consideration under ASC 606 unless and until the entity&#x2019;s right to receive or retain such consideration becomes unconditional. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact that adoption of this new accounting standard will have on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU No. 2025-10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU establishes guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The guidance defines a government grant as a transfer of a monetary asset or a tangible nonmonetary asset from a government to a business entity other than in an exchange transaction and excludes transactions within the scope of other U.S. GAAP. Under the ASU, government grants are classified as either grants related to an asset or grants related to income, and recognition is permitted only when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The ASU permits alternative presentation approaches depending on the nature of the grant and requires disclosures regarding the nature of the grant, affected financial statement line items, and significant terms and conditions. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, including interim periods within those annual reporting periods. Early adoption is permitted, and the standard may be applied on a modified prospective, modified retrospective, or full retrospective basis. We are currently evaluating the impact of this new accounting standard and do not expect its adoption to have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-404">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-405">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-406">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-407">The Company operates as a single operating and reportable segment, reflecting the integrated nature of our business focused on the research, development, and commercialization of mRNA-based medicines. Our Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), responsible for assessing the Company's performance and making resource allocation decisions. The CODM evaluates financial information on a consolidated basis, focusing on key metrics such as total revenue, operating expenses, and net income or loss, which is our reported measure of segment profit or loss. The CODM allocates resources based on the Company's available cash resources, forecasted cash flow, and expenditures on a consolidated basis, as well as an assessment of the probability of success of its research and development activities. Resource allocation decisions are informed by budgeted and forecasted expense information, along with actual expenses incurred to date. Disaggregated profit or loss information at the program or functional level is not regularly provided to or relied upon by the CODM, as our integrated operating model emphasizes shared resources and centralized decision-making. The interdependent nature of our research, development, and commercialization activities, supported by common infrastructure such as our mRNA platform, makes further disaggregation of expenses less meaningful for assessing performance. Additionally, there are no segment managers accountable for operations, operating results, and planning for levels or components below the consolidated unit level.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-408">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Net &lt;span id="ice4d497822074fb680bb6adb64870e63_40370"&gt;&lt;/span&gt;Product Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations.  In the U.S., our COVID vaccine and RSV vaccine are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize net product sales when control of the product transfers to the customer, typically upon delivery. Payment terms generally range from 30 to 60 days, in line with customary practices in each country. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, government rebates, and other related deductions. These provisions are recorded based on contractual terms, our estimate of returns for product sold during the period, and other relevant considerations, using the expected value method or the most likely amount method. We update our estimates quarterly and record necessary adjustments in the period when we identify the adjustments. Product sales, net of provisions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable when the uncertainty associated with the provisions is subsequently resolved. Shipping and handling activities are considered fulfillment activities and not a separate performance obligation. Taxes assessed by governmental authorities that are imposed on and collected from our product sales are excluded from net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wholesaler chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contract with retailers, healthcare providers, and group purchasing organizations (GPO) to broaden our customer reach and offer contractual discounts. The chargeback represents the difference between the invoice price billed to the wholesaler and the negotiated price charged to the retailers, healthcare providers and GPO members. For distribution and related services, such as stocking and cold chain storage, we provide compensation to our wholesalers and distributors. We typically offer our customers invoice discounts on product sales for prompt payments and pre-orders. The estimation of these discounts and fees is based on contractual terms and our expectations regarding future customer payment behaviors. Wholesaler fees and invoice discounts are deducted from our gross product sales and accounts receivable at the time such product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We typically offer customers in the U.S. the right to return products, up to a certain limit as stipulated in our contracts. Estimated returns for our vaccines are determined considering available return rates for similar products, estimated levels of inventory in the distribution channel, projected market demand, and our historical experience with returns. The estimated amount for product returns is presented within accrued liabilities on our consolidated balance sheets and is deducted from our gross product sales in the period the related product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government rebates and other fees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs, are recorded as accrued liabilities on our consolidated balance sheets. In 2024, we began recognizing Medicare rebates associated with our RSV product. The estimation of Medicare rebates requires judgment and is based on historical utilization trends, and the mix of customers and payers. The estimated liability for unpaid or unbilled rebates is presented as accrued liabilities on our consolidated balance sheets. For 2024 and 2025, the product sales subject to Medicare rebates were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining the amount of variable consideration to recognize necessitates substantial judgment, especially when assessing factors outside our direct control, such as the limited historical data, constrained third-party information, and evolving market dynamics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now have two years of data on our product returns, this remains limited and subject to significant variability given current market conditions. We will continue to refine our projections as additional information becomes available. The actual results could differ from our estimates, and such differences could have a material impact to our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue consists primarily of grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have contracts with government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize grant revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Grant revenue and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licensing and Royalty Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue is recognized when the license is granted to the licensee, provided no significant performance obligations remain. Royalty revenue is recognized based on sales by licensees when the underlying sales occur, in accordance with the terms of the licensing agreement and when collectibility is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stand-Ready Manufacturing Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into long-term strategic agreements with government entities to establish domestic mRNA manufacturing capabilities and support pandemic readiness. Under these agreements, we are required to build and maintain manufacturing facilities and to supply vaccines in accordance with minimum spend commitments or annual demand forecasts established by the respective governments. A portion of the total consideration under each agreement is allocated to a stand-ready obligation to maintain manufacturing readiness and is recognized as other revenue on a straight-line basis over the contractual period. The remaining consideration is related to our obligation to supply vaccines and will be recognized as product sales when control of the vaccines transfers upon delivery.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="c-1" id="f-409">Payment terms generally range from 30 to 60 days</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-410">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-412">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in prepaid expenses and other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;Included in other non-current assets in the consolidated balance sheets.</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-411">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in prepaid expenses and other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;Included in other non-current assets in the consolidated balance sheets.</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-6" id="f-413" unitRef="usd">2595000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-6" id="f-414" unitRef="usd">1927000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-27" decimals="-6" id="f-415" unitRef="usd">2907000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-6" id="f-416" unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-6" id="f-417" unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-27" decimals="-6" id="f-418" unitRef="usd">17000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-6" id="f-419" unitRef="usd">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-5" decimals="-6" id="f-420" unitRef="usd">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-27" decimals="-6" id="f-421" unitRef="usd">4000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-6" id="f-422" unitRef="usd">2597000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-6" id="f-423" unitRef="usd">1929000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-6" id="f-424" unitRef="usd">2928000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-425">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report our available-for-sale securities at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific-identification method, and are included in other income (expense), net in our consolidated statements of operations. We classify our available-for-sale securities as current or non-current based on each instrument&#x2019;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Available-for-sale securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Available-for-sale securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other income (expense), net, in our consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in other income (expense), net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-426">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net represent amounts due from customers less wholesalers chargebacks, discounts and fees (see our &#x201c;Revenue Recognition&#x201d; policy within &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt; for product sales provision) and allowance for expected credit losses. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for credit losses, we determine the allowance based on ongoing credit evaluation, historical experience and the aging of such receivables, among other factors.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-6" id="f-427" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-6" id="f-428" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-12" decimals="-6" id="f-429" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-13" decimals="-6" id="f-430" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-6" id="f-431" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-432">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable debt securities, and accounts receivable, net. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. We invest in a variety of financial instruments and limit the amount of credit exposure with any individual financial institution.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable, net related to our net product sales and other revenue. We sell our products primarily to wholesalers and distributors and other governments and organizations. We do not require collateral or other security to support accounts receivable. To date, we have not experienced material losses with respect to the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock contextRef="c-1" id="f-433">Our accounts receivable, net are generally unsecured and are from customers in different countries. We generated revenue from product sales to wholesalers and distributors and other governments and organizations, and to a lesser extent, stand-ready manufacturing revenue from international government entities, grants made by government-sponsored and private organizations, and collaboration revenue from our strategic alliances.</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-434">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;&lt;br/&gt;Accounts&#160;Receivable&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;FFF Enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public Works and Government Services Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom Health Security Agency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico Medistik&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Boryung Biopharma Korea&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taiwan Food and Drug Administration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ministry of Health, Labor, and Welfare of Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;* - Represents an amount of less than 10%&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-44" decimals="2" id="f-435" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-45" decimals="2" id="f-436" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-46" decimals="2" id="f-437" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-47" decimals="2" id="f-438" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-48" decimals="2" id="f-439" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-49" decimals="2" id="f-440" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-50" decimals="2" id="f-441" unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-51" decimals="2" id="f-442" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-52" decimals="2" id="f-443" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-53" decimals="2" id="f-444" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-54" decimals="2" id="f-445" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-446">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash equivalents and marketable debt securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;6&lt;/a&gt;&lt;/span&gt;). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-447">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value, with cost determined principally using first-in, first-out method. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. We also assess whether we have any excess firm, non-cancelable, purchase commitment liabilities, resulting from our supply agreements with third-party vendors. The determination of net realizable value and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments and contractual minimums, among others. We hold raw materials beyond our one year forecasted production plan, which were classified as non-current and included in other non-current assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-launch Inventory &lt;/span&gt;&lt;/div&gt;Costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when future commercialization is considered probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. For pre-launch inventory that is capitalized, we consider a number of factors based on the information available at the time, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from the related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential impediments to the approval process such as product safety or efficacy, historical experience, viability of commercialization and market trends. As of December 31, 2025 and 2024, we did not have any capitalized pre-launch inventory on our consolidated balance sheets.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-448">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and permanent land improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited-life land improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Determined on a project-by-project basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-12 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement&lt;br/&gt;or&#160;remaining life of related lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Construction in progress includes direct costs related to the construction of various property, plant and equipment, and is stated at original cost. Once the asset is placed into service, these capitalized costs will be allocated to certain property, plant and equipment categories and will be depreciated over the estimated useful life of the underlying assets.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-449">The estimated useful lives of property, plant and equipment are described below:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and permanent land improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited-life land improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Determined on a project-by-project basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-12 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement&lt;br/&gt;or&#160;remaining life of related lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-55" id="f-450">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-56" id="f-451">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-57" id="f-452">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-58" id="f-453">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-59" id="f-454">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-60" id="f-455">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-456">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired and is carried at cost. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. To date, an impairment of goodwill has not been recorded. &lt;/span&gt;&lt;/div&gt;Finite-lived intangible assets primarily consist of acquired intellectual property and regulatory approval and commercial sales milestone payments. These assets are recorded at cost, net of accumulated amortization, and amortized on a straight-line basis over their estimated useful lives.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-457">We evaluate our long-lived assets, which consist of property, plant and equipment, finite-lived intangibles and right-of-use assets to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges contextRef="c-13" decimals="0" id="f-458" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="0" id="f-459" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-12" decimals="0" id="f-460" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-461">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are initially measured as the lease liability plus direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in the statements of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-462">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaborator are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). See our "Revenue Recognition" policy within &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional discussion of revenue recognition under these types of arrangements. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Additionally, for any payments related to capital expenditures that are partially reimbursed by a collaborator, to the extent the underlying capital costs qualify for capitalization, any reimbursements received will offset the capitalized cost of the asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <mrna:ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock contextRef="c-1" id="f-463">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into research and development funding arrangements to support a targeted programs, under which a third party has committed to fund us up to a specified amount. Contingent upon the regulatory approval of the program, we are obligated to pay certain milestones and royalties as outlined in the respective agreements. We account for funding received under research and development arrangements as a reduction to expenses when substantive financial risk is transferred to the funding party. These arrangements are accounted for as an obligation to conduct research and development activities. The funding is recognized proportionally as the related costs are incurred, using an input method. Contingent payments, such as milestones or royalties, will be recognized separately upon achievement of the related conditions.&lt;/span&gt;&lt;/div&gt;</mrna:ResearchAndDevelopmentFundingArrangementsPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-464">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Research and development costs also include costs and shared cost associated with third-party collaboration arrangements, including upfront fees and milestones paid to third-parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. &lt;/span&gt;&lt;/div&gt;Assets that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, are capitalized and depreciated over their useful lives. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project, and that have no alternative future uses and therefore no separate economic values, are considered research and development costs and expensed when incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-465">Costs associated with advertising are expensed as incurred and are included in selling, general and administrative expense in the consolidated statements of operations</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-6" id="f-466" unitRef="usd">133000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-12" decimals="-6" id="f-467" unitRef="usd">146000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-13" decimals="-6" id="f-468" unitRef="usd">204000000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-469">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Compensation&#x2014;Stock Compensation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2025, we estimated the expected term of our stock options using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. During 2025, we used historical exercise data in estimating the expected term of stock options, utilizing a methodology that combines historical settlement data with a hypothetical settlement pattern for outstanding options, based on estimated time to arrival at-the-money and adjusted for employee departure rates. The change in methodology used during 2025 did not have a material impact on stock-based compensation and our financial statements. However, during the fourth quarter of 2025, in connection with our stock option exchange program (see &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_199" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), which resulted in changes to our stock option population, we determined that we no longer have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term, as such data is no longer indicative of future exercise patterns. Accordingly, beginning in 2026, we will estimate the expected term of stock options using the simplified method. We will continue to apply this process until a sufficient amount of historical information regarding the expected term becomes available and we believe that historical experience is relevant to our expectations for current grants. The expected volatility is based on our stock price volatility and incorporates both historical volatility of our stock price and implied volatility derived from the price of exchange traded options on our stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-470">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#x201c;more likely than not&#x201d; criterion. We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-471">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted stock units, performance stock units, stock options, and shares under the employee stock purchase plan that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-472">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments, derivatives designated as hedging instruments, and foreign currency translation, as well as, pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-473">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive loss for the years ended December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Gains on Available-for-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Pension and Postretirement Obligation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses (gains) on Foreign Currency Translation &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss, balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss, balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-6" id="f-474" unitRef="usd">-114000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-6" id="f-475" unitRef="usd">-9000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-6" id="f-476" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-6" id="f-477" unitRef="usd">-123000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-64" decimals="-6" id="f-478" unitRef="usd">124000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-65" decimals="-6" id="f-479" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-66" decimals="-6" id="f-480" unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-6" id="f-481" unitRef="usd">113000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-67" decimals="-6" id="f-482" unitRef="usd">10000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-6" id="f-483" unitRef="usd">-12000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-6" id="f-484" unitRef="usd">-8000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-6" id="f-485" unitRef="usd">-10000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-70" decimals="-6" id="f-486" unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-71" decimals="-6" id="f-487" unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-72" decimals="-6" id="f-488" unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-489" unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-6" id="f-490" unitRef="usd">38000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-6" id="f-491" unitRef="usd">4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-75" decimals="-6" id="f-492" unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-6" id="f-493" unitRef="usd">45000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-494">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of our common stock repurchased pursuant to our repurchase programs are retired. The purchase price of such repurchased shares of common stock is recorded as a reduction to additional paid-in-capital. If the balance in additional paid-in-capital is exhausted, the excess is recorded as a reduction to retained earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-495">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early adoption is permitted. We adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_205" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 14&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Income Taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU requires entities to disclose, on an annual and interim basis, disaggregated information in the footnotes related to certain expense categories included in income statement line items. Specifically, entities are expected to provide tabular disclosures for prescribed categories such as inventory purchases, employee compensation, depreciation, and intangible asset amortization for each relevant expense caption. The standard also requires disclosure of total selling expenses and a definition of those expenses in annual filings. Any remaining amounts not quantitatively disclosed are expected to be described qualitatively. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption permitted, and the standard may be applied on a prospective or retrospective basis. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU No. 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This ASU makes targeted amendments to the accounting for and disclosure of software costs under ASC 350-40. The amendments modernize the guidance to reflect current software development practices, including nonlinear development approaches, and remove references to &#x201c;development stages.&#x201d; Under the ASU, the following two criteria must be met for entities to begin capitalizing software costs: (1) management, with the relevant authority, implicitly or explicitly authorizes and commits to funding a computer software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the &#x201c;probable-to-complete recognition threshold&#x201d;). The ASU clarifies that this threshold would not be met when there is &#x201c;significant uncertainty associated with the development activities of the software (referred to as &#x2018;significant development uncertainty&#x2019;).&#x201d; The ASU is effective for all entities for annual reporting periods beginning after December 15, 2027, and for interim reporting periods within those fiscal years. Early adoption is permitted, and entities may apply the amendments prospectively, retrospectively, or using a modified prospective transition approach. We are currently evaluating the impact that this new accounting standard will have on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU No. 2025-07,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration From a Customer in a Revenue Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU expands the scope exceptions in the derivatives guidance to exclude certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties to the contract, including the occurrence or nonoccurrence of an event specific to those operations or activities. The ASU also clarifies that share-based noncash consideration received from a customer in exchange for goods or services should be accounted for as noncash consideration under ASC 606 unless and until the entity&#x2019;s right to receive or retain such consideration becomes unconditional. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact that adoption of this new accounting standard will have on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the FASB issued ASU No. 2025-10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU establishes guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The guidance defines a government grant as a transfer of a monetary asset or a tangible nonmonetary asset from a government to a business entity other than in an exchange transaction and excludes transactions within the scope of other U.S. GAAP. Under the ASU, government grants are classified as either grants related to an asset or grants related to income, and recognition is permitted only when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The ASU permits alternative presentation approaches depending on the nature of the grant and requires disclosures regarding the nature of the grant, affected financial statement line items, and significant terms and conditions. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, including interim periods within those annual reporting periods. Early adoption is permitted, and the standard may be applied on a modified prospective, modified retrospective, or full retrospective basis. We are currently evaluating the impact of this new accounting standard and do not expect its adoption to have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-498">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3. Net Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales by customer geographic location were as follows for the periods presented (in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales by product were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COVID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes sales of Spikevax and mNEXSPIKE.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes product sales provision for the periods presented (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wholesaler chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Returns, rebates and other fees &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; December 31, 2025 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns, rebates and other fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and returns related to sales made in current period &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and returns related to sales made in prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4. Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other revenue for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing and royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stand-ready manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of our original COVID vaccine, mRNA-1273. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of our original COVID vaccine, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately $1.8&#160;billion. All contract options have been exercised. The BARDA contract concluded on June 15, 2025, upon completion of all contractual deliverables. We accrued and recognized revenue through that date for eligible costs incurred in accordance with the agreement. As of December 31, 2025, the remaining available funding, net of revenue earned, was approximately $62&#160;million. While this funding remains available, we do not expect to recognize material additional revenue, as the contract has concluded and all obligations have been fulfilled. Final billing and closeout activities are ongoing and may result in immaterial adjustments to the recognized revenue amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes grant revenue for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of December 31, 2025, 2024 and 2023, we had collaboration agreements with Merck &amp;amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and others. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to for further description of these collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing and Royalty Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, we entered a non-exclusive out-licensing agreement with a pharmaceutical company based in Japan for mRNA COVID-related intellectual property for the territory of Japan. Under the terms of the agreement, we received an upfront payment of $50&#160;million, which included a $20&#160;million prepayment creditable against future royalties. Additionally, we are entitled to receive low double-digit royalties on the net sales of the company&#x2019;s COVID product. Upon execution of the agreement, we recognized $30&#160;million of the upfront payment as other revenue in our consolidated statements of operations. The remaining $20&#160;million was recorded as deferred revenue in our consolidated balance sheets and recognized as royalty revenue as the underlying sales occurred. In accordance with the terms of the agreement, the $20&#160;million was fully recognized by the end of the first quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stand-Ready Manufacturing Revenue  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stand-ready manufacturing revenue relates to amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacities and support pandemic readiness.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;16. Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Geographic Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total revenue by geographic area of our customers and collaborators was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-499">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales by customer geographic location were as follows for the periods presented (in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total revenue by geographic area of our customers and collaborators was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our property, plant and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-6" id="f-500" unitRef="usd">1165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-6" id="f-501" unitRef="usd">1726000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-6" id="f-502" unitRef="usd">1720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-6" id="f-503" unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-6" id="f-504" unitRef="usd">573000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-6" id="f-505" unitRef="usd">1353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-6" id="f-506" unitRef="usd">603000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-6" id="f-507" unitRef="usd">810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-6" id="f-508" unitRef="usd">3598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-509" unitRef="usd">1818000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-510" unitRef="usd">3109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-6" id="f-511" unitRef="usd">6671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-512">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales by product were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COVID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes sales of Spikevax and mNEXSPIKE.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes product sales provision for the periods presented (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wholesaler chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Returns, rebates and other fees &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Includes an adjustment of approximately $216&#160;million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other revenue for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing and royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stand-ready manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes grant revenue for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-6" id="f-513" unitRef="usd">1810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-6" id="f-514" unitRef="usd">3084000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-6" id="f-515" unitRef="usd">6671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-6" id="f-516" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-6" id="f-517" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-6" id="f-518" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-519" unitRef="usd">1818000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-520" unitRef="usd">3109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-6" id="f-521" unitRef="usd">6671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mrna:NumberOfCommercialProducts
      contextRef="c-6"
      decimals="INF"
      id="f-522"
      unitRef="product">3</mrna:NumberOfCommercialProducts>
    <mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross contextRef="c-6" decimals="-6" id="f-523" unitRef="usd">3304000000</mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross>
    <mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross contextRef="c-7" decimals="-6" id="f-524" unitRef="usd">4517000000</mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross>
    <mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross contextRef="c-8" decimals="-6" id="f-525" unitRef="usd">8203000000</mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross>
    <mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees contextRef="c-6" decimals="-6" id="f-526" unitRef="usd">1037000000</mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees>
    <mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees contextRef="c-7" decimals="-6" id="f-527" unitRef="usd">1141000000</mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees>
    <mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees contextRef="c-8" decimals="-6" id="f-528" unitRef="usd">976000000</mrna:ContractWithCustomerLiabilityProvisionForChargebacksDiscountsAndFees>
    <mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees contextRef="c-6" decimals="-6" id="f-529" unitRef="usd">449000000</mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees>
    <mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees contextRef="c-7" decimals="-6" id="f-530" unitRef="usd">267000000</mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees>
    <mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees contextRef="c-8" decimals="-6" id="f-531" unitRef="usd">556000000</mrna:ContractWithCustomerLiabilityProvisionForRefundsAndOtherFees>
    <mrna:ContractWithCustomerLiabilityProvision contextRef="c-6" decimals="-6" id="f-532" unitRef="usd">1486000000</mrna:ContractWithCustomerLiabilityProvision>
    <mrna:ContractWithCustomerLiabilityProvision contextRef="c-7" decimals="-6" id="f-533" unitRef="usd">1408000000</mrna:ContractWithCustomerLiabilityProvision>
    <mrna:ContractWithCustomerLiabilityProvision contextRef="c-8" decimals="-6" id="f-534" unitRef="usd">1532000000</mrna:ContractWithCustomerLiabilityProvision>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-535" unitRef="usd">1818000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-536" unitRef="usd">3109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-6" id="f-537" unitRef="usd">6671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mrna:ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment contextRef="c-7" decimals="-6" id="f-538" unitRef="usd">216000000</mrna:ContractWithCustomerLiabilityPriorPeriodRevisionsAdjustment>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; December 31, 2025 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns, rebates and other fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and returns related to sales made in current period &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and returns related to sales made in prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c-91" decimals="-6" id="f-540" unitRef="usd">370000000</us-gaap:ContractWithCustomerRefundLiability>
    <mrna:ContractWithCustomerLiabilityProvisionsMadeInCurrentYear contextRef="c-6" decimals="-6" id="f-541" unitRef="usd">436000000</mrna:ContractWithCustomerLiabilityProvisionsMadeInCurrentYear>
    <mrna:ContractWithCustomerLiabilityProvisionsMadeInPriorYears contextRef="c-6" decimals="-6" id="f-542" unitRef="usd">13000000</mrna:ContractWithCustomerLiabilityProvisionsMadeInPriorYears>
    <mrna:ContractWithCustomerLiabilityProvisionRelatedToSales contextRef="c-6" decimals="-6" id="f-543" unitRef="usd">28000000</mrna:ContractWithCustomerLiabilityProvisionRelatedToSales>
    <mrna:ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales contextRef="c-6" decimals="-6" id="f-544" unitRef="usd">282000000</mrna:ContractWithCustomerRefundLiabilityPaymentsAndReturnsRelatedToPriorPeriodSales>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c-92" decimals="-6" id="f-545" unitRef="usd">509000000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-6" id="f-546" unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-6" id="f-547" unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-6" id="f-548" unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-6" id="f-549" unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-6" id="f-550" unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-6" id="f-551" unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-6" id="f-552" unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-6" id="f-553" unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-6" id="f-554" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-6" id="f-555" unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-6" id="f-556" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-6" id="f-557" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-6" id="f-558" unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-6" id="f-559" unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-6" id="f-560" unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mrna:RevenueFromGrantsMaximumAward contextRef="c-105" decimals="-6" id="f-561" unitRef="usd">483000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:NumberOfParticipants
      contextRef="c-106"
      decimals="INF"
      id="f-562"
      unitRef="participant">30000</mrna:NumberOfParticipants>
    <mrna:RevenueFromGrantsMaximumAward contextRef="c-107" decimals="-8" id="f-563" unitRef="usd">1800000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity contextRef="c-108" decimals="-6" id="f-564" unitRef="usd">62000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-6" id="f-565" unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-6" id="f-566" unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-6" id="f-567" unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-6" id="f-568" unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-6" id="f-569" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-6" id="f-570" unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-6" id="f-571" unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-6" id="f-572" unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-6" id="f-573" unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-6" id="f-574" unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="-6" id="f-575" unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-6" id="f-576" unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-6" id="f-577" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="-6" id="f-578" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-6" id="f-579" unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-6" id="f-580" unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-6" id="f-581" unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-6" id="f-582" unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-121" decimals="-6" id="f-583" unitRef="usd">50000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiability contextRef="c-122" decimals="-6" id="f-584" unitRef="usd">20000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-123" decimals="-6" id="f-585" unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-124" decimals="-6" id="f-586" unitRef="usd">20000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-125" decimals="-6" id="f-587" unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c-1" id="f-588">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5. Collaboration Agreements and Research and Development Funding Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck &#x2013; Personalized mRNA Cancer Vaccines (Intismeran Autogene)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, we entered into a Collaboration and License Agreement, which was subsequently amended in 2018, with Merck for the development and commercialization of personalized mRNA cancer vaccines (PCV), also known as Individualized Neoantigen Therapy (INT), which has been assigned the generic name intismeran autogene. This agreement was subsequently amended in 2018. Under the PCV Agreement, we received an upfront payment of $200 million from Merck and we were responsible for designing and researching intismeran, providing manufacturing capacity and manufacturing intismeran and conducting Phase 1 and Phase 2 clinical trials for intismeran, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#x2019;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. We concluded that the collaboration arrangement was governed by the revenue recognition standard ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, Merck exercised its option for intismeran, including mRNA-4157, under the terms of the agreement and in October 2022 paid us an option exercise fee of $250&#160;million. Following this exercise, the Merck Participation Term commenced, under which we and Merck collaborate on development and potential commercialization of PCV, with costs and any profits or losses generally shared equally on a worldwide basis, subject to certain exceptions as outlined in the agreement. During the development phase, we are primarily responsible for process development and the manufacture of intismeran materials, while Merck generally leads clinical trials. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the years ended December 31, 2025, 2024 and 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses, net of Merck's reimbursements, of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$407&#160;million, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$390&#160;million, and $184&#160;million,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; respectively, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the PCV collaboration under the Merck Participation Term. Additionally, the net cost recovery for capital expenditures during the same periods were $24&#160;million, $109&#160;million, and $102&#160;million, respectively, which were applied to reduce the capitalized cost of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Development and Commercialization Funding Arrangement with Blackstone Life Sciences (Blackstone)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, we entered into a development and commercialization funding arrangement with Blackstone, under which Blackstone has committed to providing up to $750&#160;million in funding to us. This funding supports the development of our investigational mRNA-based influenza vaccine. Contingent upon regulatory approval in the U.S. and only if the approval is dependent on data from the funded activities, Blackstone will be entitled to receive low single-digit percentage royalties and up to $750&#160;million in sales milestone payments. These payments are based on net sales of our future influenza and combination vaccines, with sales milestone payments contingent upon achieving specified cumulative net sales targets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the substantive transfer of financial risk to Blackstone, we account for this arrangement as an obligation to conduct research and development activities. The funding is recognized as a reduction to the expenses of our mRNA-based influenza program. This reduction is recognized proportionally as the related costs are incurred, based on an input method. For the year ended December 31, 2025 and 2024, we recorded research and development expense reductions of $340&#160;million and $267&#160;million, respectively. As of December 31, 2025 and 2024, we had a research and development funding liability of $43&#160;million and $58&#160;million, respectively, related to the advance funding received from Blackstone.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vertex &#x2013; Strategic Alliance in Cystic Fibrosis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period, leveraging our platform technology and mRNA delivery expertise along with Vertex&#x2019;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#x201c;back-up&#x201d; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. This collaboration arrangement is accounted for under ASC 606 and currently ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Immatics &#x2013; Strategic Multi-Platform Collaboration to Develop Oncology Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, we entered into a strategic collaboration with Immatics to jointly discover and develop T cell-redirecting cancer immunotherapies. Upon effectiveness of the agreement in October 2023, we made an upfront payment of $120&#160;million, recognized as research and development expense. Immatics is also eligible for research funding, milestone payments, tiered royalties on global net sales of TCER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products and certain vaccine products that are commercialized under the agreement. Additionally, Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-126" decimals="-6" id="f-589" unitRef="usd">200000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ProceedsFromOptionExerciseFee contextRef="c-127" decimals="-6" id="f-590" unitRef="usd">250000000</mrna:ProceedsFromOptionExerciseFee>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-128" decimals="-6" id="f-591" unitRef="usd">407000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-129" decimals="-6" id="f-592" unitRef="usd">390000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-130" decimals="-6" id="f-593" unitRef="usd">184000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrna:RecoveryOfCostsCapitalExpenditures contextRef="c-128" decimals="-6" id="f-594" unitRef="usd">24000000</mrna:RecoveryOfCostsCapitalExpenditures>
    <mrna:RecoveryOfCostsCapitalExpenditures contextRef="c-129" decimals="-6" id="f-595" unitRef="usd">109000000</mrna:RecoveryOfCostsCapitalExpenditures>
    <mrna:RecoveryOfCostsCapitalExpenditures contextRef="c-130" decimals="-6" id="f-596" unitRef="usd">102000000</mrna:RecoveryOfCostsCapitalExpenditures>
    <mrna:CollaborativeArrangementFundingAmount contextRef="c-131" decimals="-6" id="f-597" unitRef="usd">750000000</mrna:CollaborativeArrangementFundingAmount>
    <mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-131" decimals="-6" id="f-598" unitRef="usd">750000000</mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-132" decimals="-6" id="f-599" unitRef="usd">340000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-133" decimals="-6" id="f-600" unitRef="usd">267000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrna:ResearchAndDevelopmentLiabilityCurrent contextRef="c-134" decimals="-6" id="f-601" unitRef="usd">43000000</mrna:ResearchAndDevelopmentLiabilityCurrent>
    <mrna:ResearchAndDevelopmentLiabilityCurrent contextRef="c-135" decimals="-6" id="f-602" unitRef="usd">58000000</mrna:ResearchAndDevelopmentLiabilityCurrent>
    <mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-136" decimals="-6" id="f-603" unitRef="usd">120000000</mrna:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-604">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6. Financial Instruments and Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents, and available-for-sale securities by significant investment category at December 31, 2025 and 2024 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="45" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the&#160;years ended December 31, 2025, 2024, and 2023. We did not recognize any credit-related allowance to available-for-sale securities as of December 31, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2025 and 2024 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or More&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2025 and 2024, we held 108 and 252 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and 2024 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-813"&gt;Derivative instruments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-844"&gt;Derivative instruments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025 and 2024, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2025, 2024 and 2023, we recognized net losses of $8&#160;million, $52&#160;million and $35&#160;million, respectively, on equity investments from changes in fair value of the securities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Other Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our term loan using Level 2 inputs. The fair value of the term loan approximates its carrying value as of December 31, 2025, because the instrument bears interest at a variable rate that reflects current market rates. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_2066" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-605">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents, and available-for-sale securities by significant investment category at December 31, 2025 and 2024 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="45" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-137" decimals="-6" id="f-606" unitRef="usd">2595000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-137" decimals="-6" id="f-607" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-137" decimals="-6" id="f-608" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-6" id="f-609" unitRef="usd">2595000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-138" decimals="-6" id="f-610" unitRef="usd">2595000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-6" id="f-611" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-6" id="f-612" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-141" decimals="-6" id="f-613" unitRef="usd">91000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-141" decimals="-6" id="f-614" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-141" decimals="-6" id="f-615" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-6" id="f-616" unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-6" id="f-617" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="-6" id="f-618" unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-144" decimals="-6" id="f-619" unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-145" decimals="-6" id="f-620" unitRef="usd">653000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-145" decimals="-6" id="f-621" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-145" decimals="-6" id="f-622" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-6" id="f-623" unitRef="usd">653000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-146" decimals="-6" id="f-624" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-147" decimals="-6" id="f-625" unitRef="usd">653000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-148" decimals="-6" id="f-626" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-149" decimals="-6" id="f-627" unitRef="usd">2188000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-149" decimals="-6" id="f-628" unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-149" decimals="-6" id="f-629" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-149" decimals="-6" id="f-630" unitRef="usd">2190000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-150" decimals="-6" id="f-631" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-151" decimals="-6" id="f-632" unitRef="usd">1185000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-152" decimals="-6" id="f-633" unitRef="usd">1005000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-153" decimals="-6" id="f-634" unitRef="usd">2535000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-153" decimals="-6" id="f-635" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-153" decimals="-6" id="f-636" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-153" decimals="-6" id="f-637" unitRef="usd">2540000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-154" decimals="-6" id="f-638" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-155" decimals="-6" id="f-639" unitRef="usd">1250000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-156" decimals="-6" id="f-640" unitRef="usd">1290000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-157" decimals="-6" id="f-641" unitRef="usd">66000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-157" decimals="-6" id="f-642" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-157" decimals="-6" id="f-643" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-157" decimals="-6" id="f-644" unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-158" decimals="-6" id="f-645" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-159" decimals="-6" id="f-646" unitRef="usd">30000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-160" decimals="-6" id="f-647" unitRef="usd">36000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-161" decimals="-6" id="f-648" unitRef="usd">8128000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-161" decimals="-6" id="f-649" unitRef="usd">11000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-161" decimals="-6" id="f-650" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-161" decimals="-6" id="f-651" unitRef="usd">8135000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-162" decimals="-6" id="f-652" unitRef="usd">2595000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-163" decimals="-6" id="f-653" unitRef="usd">3204000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-164" decimals="-6" id="f-654" unitRef="usd">2336000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-165" decimals="-6" id="f-655" unitRef="usd">1927000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-165" decimals="-6" id="f-656" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-165" decimals="-6" id="f-657" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-165" decimals="-6" id="f-658" unitRef="usd">1927000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-166" decimals="-6" id="f-659" unitRef="usd">1927000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-167" decimals="-6" id="f-660" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-168" decimals="-6" id="f-661" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-169" decimals="-6" id="f-662" unitRef="usd">52000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-169" decimals="-6" id="f-663" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-169" decimals="-6" id="f-664" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-169" decimals="-6" id="f-665" unitRef="usd">52000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-170" decimals="-6" id="f-666" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-171" decimals="-6" id="f-667" unitRef="usd">52000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-172" decimals="-6" id="f-668" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-173" decimals="-6" id="f-669" unitRef="usd">786000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-173" decimals="-6" id="f-670" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-173" decimals="-6" id="f-671" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-173" decimals="-6" id="f-672" unitRef="usd">786000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-174" decimals="-6" id="f-673" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-175" decimals="-6" id="f-674" unitRef="usd">786000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-176" decimals="-6" id="f-675" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-177" decimals="-6" id="f-676" unitRef="usd">3048000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-177" decimals="-6" id="f-677" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-177" decimals="-6" id="f-678" unitRef="usd">15000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-177" decimals="-6" id="f-679" unitRef="usd">3036000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-178" decimals="-6" id="f-680" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-179" decimals="-6" id="f-681" unitRef="usd">1958000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-180" decimals="-6" id="f-682" unitRef="usd">1078000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-181" decimals="-6" id="f-683" unitRef="usd">3590000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-181" decimals="-6" id="f-684" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-181" decimals="-6" id="f-685" unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-181" decimals="-6" id="f-686" unitRef="usd">3580000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-182" decimals="-6" id="f-687" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-183" decimals="-6" id="f-688" unitRef="usd">2172000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-184" decimals="-6" id="f-689" unitRef="usd">1408000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-185" decimals="-6" id="f-690" unitRef="usd">138000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-185" decimals="-6" id="f-691" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-185" decimals="-6" id="f-692" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-185" decimals="-6" id="f-693" unitRef="usd">138000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-186" decimals="-6" id="f-694" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-187" decimals="-6" id="f-695" unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-188" decimals="-6" id="f-696" unitRef="usd">8000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-189" decimals="-6" id="f-697" unitRef="usd">9541000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-189" decimals="-6" id="f-698" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-189" decimals="-6" id="f-699" unitRef="usd">28000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-189" decimals="-6" id="f-700" unitRef="usd">9519000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-190" decimals="-6" id="f-701" unitRef="usd">1927000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-191" decimals="-6" id="f-702" unitRef="usd">5098000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-192" decimals="-6" id="f-703" unitRef="usd">2494000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-704">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity at December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-4" decimals="-6" id="f-705" unitRef="usd">3199000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-6" id="f-706" unitRef="usd">3204000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-4" decimals="-6" id="f-707" unitRef="usd">2334000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="-6" id="f-708" unitRef="usd">2336000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-6" id="f-709" unitRef="usd">5533000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-4" decimals="-6" id="f-710" unitRef="usd">5540000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-5" decimals="-6" id="f-711" unitRef="usd">5106000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-5" decimals="-6" id="f-712" unitRef="usd">5098000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-5" decimals="-6" id="f-713" unitRef="usd">2508000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-5" decimals="-6" id="f-714" unitRef="usd">2494000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-6" id="f-715" unitRef="usd">7614000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-5" decimals="-6" id="f-716" unitRef="usd">7592000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-1" decimals="INF" id="f-717" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-12" decimals="INF" id="f-718" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-13" decimals="INF" id="f-719" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-5" decimals="INF" id="f-720" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-4" decimals="INF" id="f-721" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-722">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2025 and 2024 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or More&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-193" decimals="-6" id="f-723" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-193" decimals="-6" id="f-724" unitRef="usd">111000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-193" decimals="-6" id="f-725" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-193" decimals="-6" id="f-726" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-193" decimals="-6" id="f-727" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-193" decimals="-6" id="f-728" unitRef="usd">111000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-194" decimals="-6" id="f-729" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-194" decimals="-6" id="f-730" unitRef="usd">176000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-194" decimals="-6" id="f-731" unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-194" decimals="-6" id="f-732" unitRef="usd">235000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-194" decimals="-6" id="f-733" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-194" decimals="-6" id="f-734" unitRef="usd">411000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-195" decimals="-6" id="f-735" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-195" decimals="-6" id="f-736" unitRef="usd">608000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-195" decimals="-6" id="f-737" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-195" decimals="-6" id="f-738" unitRef="usd">40000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-195" decimals="-6" id="f-739" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-195" decimals="-6" id="f-740" unitRef="usd">648000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-196" decimals="-6" id="f-741" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-196" decimals="-6" id="f-742" unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-196" decimals="-6" id="f-743" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-196" decimals="-6" id="f-744" unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-196" decimals="-6" id="f-745" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-196" decimals="-6" id="f-746" unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-6" id="f-747" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-6" id="f-748" unitRef="usd">931000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-6" id="f-749" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-6" id="f-750" unitRef="usd">283000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-6" id="f-751" unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-6" id="f-752" unitRef="usd">1214000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-197" decimals="-6" id="f-753" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-197" decimals="-6" id="f-754" unitRef="usd">101000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-197" decimals="-6" id="f-755" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-197" decimals="-6" id="f-756" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-197" decimals="-6" id="f-757" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-197" decimals="-6" id="f-758" unitRef="usd">101000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-198" decimals="-6" id="f-759" unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-198" decimals="-6" id="f-760" unitRef="usd">729000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-198" decimals="-6" id="f-761" unitRef="usd">13000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-198" decimals="-6" id="f-762" unitRef="usd">960000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-198" decimals="-6" id="f-763" unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-198" decimals="-6" id="f-764" unitRef="usd">1689000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-199" decimals="-6" id="f-765" unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-199" decimals="-6" id="f-766" unitRef="usd">843000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-199" decimals="-6" id="f-767" unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-199" decimals="-6" id="f-768" unitRef="usd">1646000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-199" decimals="-6" id="f-769" unitRef="usd">13000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-199" decimals="-6" id="f-770" unitRef="usd">2489000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-200" decimals="-6" id="f-771" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-200" decimals="-6" id="f-772" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-200" decimals="-6" id="f-773" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-200" decimals="-6" id="f-774" unitRef="usd">37000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-200" decimals="-6" id="f-775" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-200" decimals="-6" id="f-776" unitRef="usd">37000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-5" decimals="-6" id="f-777" unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-5" decimals="-6" id="f-778" unitRef="usd">1673000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-5" decimals="-6" id="f-779" unitRef="usd">22000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-5" decimals="-6" id="f-780" unitRef="usd">2643000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-5" decimals="-6" id="f-781" unitRef="usd">28000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-5" decimals="-6" id="f-782" unitRef="usd">4316000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-4"
      decimals="INF"
      id="f-783"
      unitRef="security">108</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-784"
      unitRef="security">252</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-785">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and 2024 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-813"&gt;Derivative instruments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-844"&gt;Derivative instruments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-201" decimals="-6" id="f-786" unitRef="usd">963000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-202" decimals="-6" id="f-787" unitRef="usd">963000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-203" decimals="-6" id="f-788" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-204" decimals="-6" id="f-789" unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-205" decimals="-6" id="f-790" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-206" decimals="-6" id="f-791" unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-207" decimals="-6" id="f-792" unitRef="usd">1445000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-208" decimals="-6" id="f-793" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-209" decimals="-6" id="f-794" unitRef="usd">1445000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-210" decimals="-6" id="f-795" unitRef="usd">2190000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-211" decimals="-6" id="f-796" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-212" decimals="-6" id="f-797" unitRef="usd">2190000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-213" decimals="-6" id="f-798" unitRef="usd">3163000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-214" decimals="-6" id="f-799" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-215" decimals="-6" id="f-800" unitRef="usd">3163000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-216" decimals="-6" id="f-801" unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-217" decimals="-6" id="f-802" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-218" decimals="-6" id="f-803" unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-219" decimals="-6" id="f-804" unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-220" decimals="-6" id="f-805" unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-221" decimals="-6" id="f-806" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets contextRef="c-222" decimals="-6" id="f-807" unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-223" decimals="-6" id="f-808" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-224" decimals="-6" id="f-809" unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-222" decimals="-6" id="f-810" unitRef="usd">7925000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-223" decimals="-6" id="f-811" unitRef="usd">969000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-224" decimals="-6" id="f-812" unitRef="usd">6956000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-222" decimals="-6" id="f-814" unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-223" decimals="-6" id="f-815" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-224" decimals="-6" id="f-816" unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-225" decimals="-6" id="f-817" unitRef="usd">1195000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-226" decimals="-6" id="f-818" unitRef="usd">1195000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-6" id="f-819" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-228" decimals="-6" id="f-820" unitRef="usd">52000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-6" id="f-821" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-230" decimals="-6" id="f-822" unitRef="usd">52000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-6" id="f-823" unitRef="usd">1016000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-6" id="f-824" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-233" decimals="-6" id="f-825" unitRef="usd">1016000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-234" decimals="-6" id="f-826" unitRef="usd">3036000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-235" decimals="-6" id="f-827" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-236" decimals="-6" id="f-828" unitRef="usd">3036000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-237" decimals="-6" id="f-829" unitRef="usd">3763000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-238" decimals="-6" id="f-830" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-239" decimals="-6" id="f-831" unitRef="usd">3763000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-240" decimals="-6" id="f-832" unitRef="usd">138000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-241" decimals="-6" id="f-833" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-242" decimals="-6" id="f-834" unitRef="usd">138000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-243" decimals="-6" id="f-835" unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-244" decimals="-6" id="f-836" unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-245" decimals="-6" id="f-837" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets contextRef="c-246" decimals="-6" id="f-838" unitRef="usd">10000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-247" decimals="-6" id="f-839" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-248" decimals="-6" id="f-840" unitRef="usd">10000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-246" decimals="-6" id="f-841" unitRef="usd">9224000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-247" decimals="-6" id="f-842" unitRef="usd">1209000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-248" decimals="-6" id="f-843" unitRef="usd">8015000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-246" decimals="-6" id="f-845" unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-247" decimals="-6" id="f-846" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-248" decimals="-6" id="f-847" unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-6" id="f-848" unitRef="usd">-8000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-12" decimals="-6" id="f-849" unitRef="usd">-52000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-13" decimals="-6" id="f-850" unitRef="usd">-35000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-851">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7. Inventory&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, as of December 31, 2025 and 2024 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the years ended December 31, 2025, 2024, and 2023, inventory write-downs were $291&#160;million, $495&#160;million, and $2.2&#160;billion, respectively. For the years ended December 31, 2025, 2024, and 2023, losses on firm purchase commitments were $24&#160;million, $60&#160;million, and $141&#160;million, respectively. Inventory write-downs were mainly related to inventory in excess of expected demand and shelf-life expiration. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These charges in 2025 and 2024 were primarily driven by the continued operation of the COVID vaccine market as a seasonal market, along with a decline in overall customer demand and excess inventory. Forecasting demand for COVID vaccines requires advance production planning ahead of each season, including production of multiple COVID vaccine products, which resulted in excess inventory and capacity as actual demand differed from forecasted demand. The higher charges in 2023 primarily reflect our strategic initiative to resize its manufacturing cost structure in response to the transition to an endemic seasonal COVID vaccine market. In the third quarter of 2023, we completed our long-range financial planning process, incorporating revised forecasts of vaccination rates. This resulted in the reassessment of future demand for our COVID vaccine, leading to a strategic initiative to resize our manufacturing cost structure. This initiative, launched in the same quarter, involved reassessing our inventory levels and renegotiating with our suppliers to reduce our purchase commitments related to raw materials which were not expected to be consumed before expiration. This initiative resulted in a raw materials write-down of $903&#160;million, included in the total inventory write-down amount for the quarter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025 and December 31, 2024, the accrued liability for losses on firm future purchase commitments in our consolidated balance sheets was $5&#160;million and $60&#160;million, respectively. As of December 31, 2025 and December 31, 2024, we had inventory on hand of $267&#160;million and $267&#160;million, respectively, inclusive of inventory for our COVID and RSV vaccines. Our raw materials and work-in-progress inventory have variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of Spikevax, our original COVID vaccine, is &lt;span style="-sec-ix-hidden:f-874"&gt;nine&lt;/span&gt; to twelve months. mNEXSPIKE has a shelf life of twelve months. The shelf life of mRESVIA, our RSV vaccine, is eighteen months.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-852">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, as of December 31, 2025 and 2024 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the consolidated balance sheets.</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-6" id="f-853" unitRef="usd">91000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-5" decimals="-6" id="f-854" unitRef="usd">63000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-6" id="f-855" unitRef="usd">29000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-6" id="f-856" unitRef="usd">26000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-6" id="f-857" unitRef="usd">33000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-6" id="f-858" unitRef="usd">28000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-6" id="f-859" unitRef="usd">153000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-6" id="f-860" unitRef="usd">117000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent contextRef="c-4" decimals="-6" id="f-861" unitRef="usd">114000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-5" decimals="-6" id="f-862" unitRef="usd">150000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-6" id="f-863" unitRef="usd">291000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-12" decimals="-6" id="f-864" unitRef="usd">495000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-13" decimals="-8" id="f-865" unitRef="usd">2200000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-1" decimals="-6" id="f-866" unitRef="usd">24000000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-12" decimals="-6" id="f-867" unitRef="usd">60000000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-13" decimals="-6" id="f-868" unitRef="usd">141000000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown contextRef="c-249" decimals="-6" id="f-869" unitRef="usd">903000000</us-gaap:InventoryWriteDown>
    <mrna:LegalContingencyFutureFirmPurchaseCommitments contextRef="c-4" decimals="-6" id="f-870" unitRef="usd">5000000</mrna:LegalContingencyFutureFirmPurchaseCommitments>
    <mrna:LegalContingencyFutureFirmPurchaseCommitments contextRef="c-5" decimals="-6" id="f-871" unitRef="usd">60000000</mrna:LegalContingencyFutureFirmPurchaseCommitments>
    <us-gaap:InventoryGross contextRef="c-4" decimals="-6" id="f-872" unitRef="usd">267000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-5" decimals="-6" id="f-873" unitRef="usd">267000000</us-gaap:InventoryGross>
    <mrna:InventoryShelfLife contextRef="c-251" id="f-875">P12M</mrna:InventoryShelfLife>
    <mrna:InventoryShelfLife contextRef="c-252" id="f-876">P12M</mrna:InventoryShelfLife>
    <mrna:InventoryShelfLife contextRef="c-253" id="f-877">P18M</mrna:InventoryShelfLife>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-878">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8. Property, Plant and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the&#160;years ended December 31, 2025, 2024, and 2023 was $211&#160;million, $185&#160;million, and $617&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-254" decimals="-6" id="f-879" unitRef="usd">78000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-255" decimals="-6" id="f-880" unitRef="usd">59000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-256" decimals="-6" id="f-881" unitRef="usd">1183000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-257" decimals="-6" id="f-882" unitRef="usd">743000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-258" decimals="-6" id="f-883" unitRef="usd">542000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-259" decimals="-6" id="f-884" unitRef="usd">344000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-260" decimals="-6" id="f-885" unitRef="usd">403000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-261" decimals="-6" id="f-886" unitRef="usd">207000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-60" decimals="-6" id="f-887" unitRef="usd">39000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-262" decimals="-6" id="f-888" unitRef="usd">31000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-263" decimals="-6" id="f-889" unitRef="usd">196000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-264" decimals="-6" id="f-890" unitRef="usd">150000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-265" decimals="-6" id="f-891" unitRef="usd">298000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-266" decimals="-6" id="f-892" unitRef="usd">1057000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-267" decimals="-6" id="f-893" unitRef="usd">132000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-268" decimals="-6" id="f-894" unitRef="usd">132000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-6" id="f-895" unitRef="usd">2871000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-6" id="f-896" unitRef="usd">2723000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-6" id="f-897" unitRef="usd">737000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-6" id="f-898" unitRef="usd">527000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-6" id="f-899" unitRef="usd">2134000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-6" id="f-900" unitRef="usd">2196000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-901" unitRef="usd">211000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-6" id="f-902" unitRef="usd">185000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-6" id="f-903" unitRef="usd">617000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-904">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;9. Other Balance Sheet Components&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Wholesalers chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Allowance for doubtful accounts &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments and prepayments related to manufacturing and materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value added tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Non-Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivable, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments and prepayments, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consisted of raw materials with an anticipated consumption beyond one year. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions related to product sales (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on future firm purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_175" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated reimbursements to wholesalers and distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development funding liability (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - financing (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - operating (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Non-Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-905">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Wholesalers chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Allowance for doubtful accounts &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c-4" decimals="-6" id="f-906" unitRef="usd">368000000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-5" decimals="-6" id="f-907" unitRef="usd">698000000</us-gaap:AccountsReceivableGross>
    <mrna:AccountsReceivableChargebacksDiscountsAndFees contextRef="c-4" decimals="-6" id="f-908" unitRef="usd">181000000</mrna:AccountsReceivableChargebacksDiscountsAndFees>
    <mrna:AccountsReceivableChargebacksDiscountsAndFees contextRef="c-5" decimals="-6" id="f-909" unitRef="usd">340000000</mrna:AccountsReceivableChargebacksDiscountsAndFees>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="-6" id="f-910" unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-5" decimals="-6" id="f-911" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet contextRef="c-4" decimals="-6" id="f-912" unitRef="usd">184000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-5" decimals="-6" id="f-913" unitRef="usd">358000000</us-gaap:AccountsReceivableNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-914">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments and prepayments related to manufacturing and materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value added tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="-6" id="f-915" unitRef="usd">169000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="-6" id="f-916" unitRef="usd">173000000</us-gaap:OtherPrepaidExpenseCurrent>
    <mrna:OtherPrepaidExpenseMaterialsAndSupplies contextRef="c-4" decimals="-6" id="f-917" unitRef="usd">61000000</mrna:OtherPrepaidExpenseMaterialsAndSupplies>
    <mrna:OtherPrepaidExpenseMaterialsAndSupplies contextRef="c-5" decimals="-6" id="f-918" unitRef="usd">106000000</mrna:OtherPrepaidExpenseMaterialsAndSupplies>
    <us-gaap:InterestReceivableCurrent contextRef="c-4" decimals="-6" id="f-919" unitRef="usd">42000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c-5" decimals="-6" id="f-920" unitRef="usd">59000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-4" decimals="-6" id="f-921" unitRef="usd">37000000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-5" decimals="-6" id="f-922" unitRef="usd">45000000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:PrepaidTaxes contextRef="c-4" decimals="-6" id="f-923" unitRef="usd">33000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c-5" decimals="-6" id="f-924" unitRef="usd">28000000</us-gaap:PrepaidTaxes>
    <mrna:CollaborationReceivableCurrent contextRef="c-4" decimals="-6" id="f-925" unitRef="usd">13000000</mrna:CollaborationReceivableCurrent>
    <mrna:CollaborationReceivableCurrent contextRef="c-5" decimals="-6" id="f-926" unitRef="usd">58000000</mrna:CollaborationReceivableCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="-6" id="f-927" unitRef="usd">8000000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-5" decimals="-6" id="f-928" unitRef="usd">72000000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-6" id="f-929" unitRef="usd">45000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-6" id="f-930" unitRef="usd">58000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-6" id="f-931" unitRef="usd">408000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-6" id="f-932" unitRef="usd">599000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="c-1" id="f-933">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivable, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments and prepayments, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;Consisted of raw materials with an anticipated consumption beyond one year.</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:IncomeTaxesReceivableNoncurrent contextRef="c-4" decimals="-6" id="f-934" unitRef="usd">161000000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent contextRef="c-5" decimals="-6" id="f-935" unitRef="usd">97000000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-4" decimals="-6" id="f-936" unitRef="usd">114000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-5" decimals="-6" id="f-937" unitRef="usd">150000000</us-gaap:InventoryNoncurrent>
    <mrna:DownpaymentsAndPrepaymentsNoncurrent contextRef="c-4" decimals="-6" id="f-938" unitRef="usd">100000000</mrna:DownpaymentsAndPrepaymentsNoncurrent>
    <mrna:DownpaymentsAndPrepaymentsNoncurrent contextRef="c-5" decimals="-6" id="f-939" unitRef="usd">139000000</mrna:DownpaymentsAndPrepaymentsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-6" id="f-940" unitRef="usd">81000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-6" id="f-941" unitRef="usd">81000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill contextRef="c-4" decimals="-6" id="f-942" unitRef="usd">52000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-6" id="f-943" unitRef="usd">52000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-6" id="f-944" unitRef="usd">45000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-6" id="f-945" unitRef="usd">40000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-6" id="f-946" unitRef="usd">6000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-6" id="f-947" unitRef="usd">14000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c-4" decimals="-6" id="f-948" unitRef="usd">46000000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c-5" decimals="-6" id="f-949" unitRef="usd">21000000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-6" id="f-950" unitRef="usd">605000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-6" id="f-951" unitRef="usd">594000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-952">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions related to product sales (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on future firm purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_175" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c-4" decimals="-6" id="f-953" unitRef="usd">509000000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c-5" decimals="-6" id="f-954" unitRef="usd">370000000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-955" unitRef="usd">420000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-956" unitRef="usd">312000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrna:AccruedManufacturing contextRef="c-4" decimals="-6" id="f-957" unitRef="usd">140000000</mrna:AccruedManufacturing>
    <mrna:AccruedManufacturing contextRef="c-5" decimals="-6" id="f-958" unitRef="usd">109000000</mrna:AccruedManufacturing>
    <mrna:AccruedDevelopmentOperation contextRef="c-4" decimals="-6" id="f-959" unitRef="usd">106000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedDevelopmentOperation contextRef="c-5" decimals="-6" id="f-960" unitRef="usd">120000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent contextRef="c-4" decimals="-6" id="f-961" unitRef="usd">57000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent contextRef="c-5" decimals="-6" id="f-962" unitRef="usd">131000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <mrna:AccruedPropertyAndEquipmentCurrent contextRef="c-4" decimals="-6" id="f-963" unitRef="usd">45000000</mrna:AccruedPropertyAndEquipmentCurrent>
    <mrna:AccruedPropertyAndEquipmentCurrent contextRef="c-5" decimals="-6" id="f-964" unitRef="usd">99000000</mrna:AccruedPropertyAndEquipmentCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-6" id="f-965" unitRef="usd">31000000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-5" decimals="-6" id="f-966" unitRef="usd">46000000</us-gaap:AccruedRoyaltiesCurrent>
    <mrna:RawMaterialsAccountsPayable contextRef="c-4" decimals="-6" id="f-967" unitRef="usd">30000000</mrna:RawMaterialsAccountsPayable>
    <mrna:RawMaterialsAccountsPayable contextRef="c-5" decimals="-6" id="f-968" unitRef="usd">41000000</mrna:RawMaterialsAccountsPayable>
    <mrna:AccruedCommercial contextRef="c-4" decimals="-6" id="f-969" unitRef="usd">23000000</mrna:AccruedCommercial>
    <mrna:AccruedCommercial contextRef="c-5" decimals="-6" id="f-970" unitRef="usd">45000000</mrna:AccruedCommercial>
    <mrna:AccruedClinicalTrials contextRef="c-4" decimals="-6" id="f-971" unitRef="usd">20000000</mrna:AccruedClinicalTrials>
    <mrna:AccruedClinicalTrials contextRef="c-5" decimals="-6" id="f-972" unitRef="usd">94000000</mrna:AccruedClinicalTrials>
    <mrna:LegalContingencyFutureFirmPurchaseCommitments contextRef="c-4" decimals="-6" id="f-973" unitRef="usd">5000000</mrna:LegalContingencyFutureFirmPurchaseCommitments>
    <mrna:LegalContingencyFutureFirmPurchaseCommitments contextRef="c-5" decimals="-6" id="f-974" unitRef="usd">60000000</mrna:LegalContingencyFutureFirmPurchaseCommitments>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-975" unitRef="usd">1386000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-976" unitRef="usd">1427000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-977">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated reimbursements to wholesalers and distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development funding liability (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - financing (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - operating (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i151f4968467f44d985f22077f4372877_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <mrna:EstimatedReimbursementLiability contextRef="c-4" decimals="-6" id="f-978" unitRef="usd">84000000</mrna:EstimatedReimbursementLiability>
    <mrna:EstimatedReimbursementLiability contextRef="c-5" decimals="-6" id="f-979" unitRef="usd">103000000</mrna:EstimatedReimbursementLiability>
    <mrna:ResearchAndDevelopmentLiabilityCurrent contextRef="c-4" decimals="-6" id="f-980" unitRef="usd">43000000</mrna:ResearchAndDevelopmentLiabilityCurrent>
    <mrna:ResearchAndDevelopmentLiabilityCurrent contextRef="c-5" decimals="-6" id="f-981" unitRef="usd">58000000</mrna:ResearchAndDevelopmentLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-6" id="f-982" unitRef="usd">25000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-6" id="f-983" unitRef="usd">23000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-6" id="f-984" unitRef="usd">17000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-6" id="f-985" unitRef="usd">14000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-986" unitRef="usd">16000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-987" unitRef="usd">23000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-988" unitRef="usd">185000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-989" unitRef="usd">221000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-990">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-6" id="f-991" unitRef="usd">249000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-6" id="f-992" unitRef="usd">231000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-4" decimals="-6" id="f-993" unitRef="usd">36000000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-994" unitRef="usd">36000000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-6" id="f-995" unitRef="usd">285000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-996" unitRef="usd">267000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-91" decimals="-6" id="f-997" unitRef="usd">188000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-6" decimals="-6" id="f-998" unitRef="usd">108000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod contextRef="c-6" decimals="-6" id="f-999" unitRef="usd">189000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability contextRef="c-92" decimals="-6" id="f-1000" unitRef="usd">107000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-269" decimals="-6" id="f-1001" unitRef="usd">23000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-9" decimals="-6" id="f-1002" unitRef="usd">212000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod contextRef="c-9" decimals="-6" id="f-1003" unitRef="usd">90000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability contextRef="c-270" decimals="-6" id="f-1004" unitRef="usd">145000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-6" id="f-1005" unitRef="usd">211000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-1" decimals="-6" id="f-1006" unitRef="usd">320000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod contextRef="c-1" decimals="-6" id="f-1007" unitRef="usd">279000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-6" id="f-1008" unitRef="usd">252000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1010">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10. Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2039. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We have two main campuses in Massachusetts, our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters, and our Moderna Technology Center (MTC), located in Norwood. In addition, we own and lease facilities, including office, laboratory, and manufacturing sites, in various locations globally to support our research, development, manufacturing, and business operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Science Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Cambridge campus previously included multiple leased properties at Technology Square and the MSC, a facility comprising approximately 462,000 square feet, that serves as our principal executive office, along with additional office and laboratory spaces. The MSC lease commenced during the third quarter of 2023 and has a term of 15 years, with options for two additional seven-year extensions. During the fourth quarter of 2023, we amended the expiration dates of our Technology Square leases to conclude in January 2025, as we transitioned operations to the MSC. As of December 31, 2024, we substantially exited our leased spaces at Technology Square, completing the consolidation of our Cambridge operations into the MSC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MTC is a multiple-building campus spanning approximately 722,000 square feet. that previously operated under long-term finance leases expiring in 2042, with options for three five-year extensions. The MTC has been a critical facility for our manufacturing, laboratory, and office operations. In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings, for a total purchase price of $385&#160;million. Upon acquisition, we derecognized the right-of-use assets and lease liabilities associated with the Norwood leases. The purchase price, after adjustments related to lease terminations, was allocated to land and buildings, with approximately $231&#160;million recorded as property, plant, and equipment on our consolidated balance sheets as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1024"&gt;&lt;span style="-sec-ix-hidden:f-1025"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1030"&gt;&lt;span style="-sec-ix-hidden:f-1031"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1034"&gt;&lt;span style="-sec-ix-hidden:f-1035"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease costs were as follows for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows used in financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability derecognized upon purchase of underlying leased asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-1009">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10. Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2039. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We have two main campuses in Massachusetts, our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters, and our Moderna Technology Center (MTC), located in Norwood. In addition, we own and lease facilities, including office, laboratory, and manufacturing sites, in various locations globally to support our research, development, manufacturing, and business operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Science Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Cambridge campus previously included multiple leased properties at Technology Square and the MSC, a facility comprising approximately 462,000 square feet, that serves as our principal executive office, along with additional office and laboratory spaces. The MSC lease commenced during the third quarter of 2023 and has a term of 15 years, with options for two additional seven-year extensions. During the fourth quarter of 2023, we amended the expiration dates of our Technology Square leases to conclude in January 2025, as we transitioned operations to the MSC. As of December 31, 2024, we substantially exited our leased spaces at Technology Square, completing the consolidation of our Cambridge operations into the MSC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MTC is a multiple-building campus spanning approximately 722,000 square feet. that previously operated under long-term finance leases expiring in 2042, with options for three five-year extensions. The MTC has been a critical facility for our manufacturing, laboratory, and office operations. In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings, for a total purchase price of $385&#160;million. Upon acquisition, we derecognized the right-of-use assets and lease liabilities associated with the Norwood leases. The purchase price, after adjustments related to lease terminations, was allocated to land and buildings, with approximately $231&#160;million recorded as property, plant, and equipment on our consolidated balance sheets as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1024"&gt;&lt;span style="-sec-ix-hidden:f-1025"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1030"&gt;&lt;span style="-sec-ix-hidden:f-1031"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1034"&gt;&lt;span style="-sec-ix-hidden:f-1035"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease costs were as follows for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows used in financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability derecognized upon purchase of underlying leased asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <mrna:OperatingLeaseNumberOfProperties
      contextRef="c-4"
      decimals="INF"
      id="f-1011"
      unitRef="campus">2</mrna:OperatingLeaseNumberOfProperties>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-271" decimals="-3" id="f-1012" unitRef="sqft">462000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-272" id="f-1013">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrna:LesseeOperatingLeaseNumberOfExtensions
      contextRef="c-272"
      decimals="INF"
      id="f-1014"
      unitRef="numberofextensionperiod">2</mrna:LesseeOperatingLeaseNumberOfExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-272" id="f-1015">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-273" decimals="-3" id="f-1016" unitRef="sqft">722000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensions
      contextRef="c-273"
      decimals="INF"
      id="f-1017"
      unitRef="numberofextensionperiod">3</mrna:LesseeOperatingLeaseNumberOfExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-273" id="f-1018">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-274" decimals="-6" id="f-1019" unitRef="usd">385000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-275" decimals="-6" id="f-1020" unitRef="usd">231000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-1021">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2025 and 2024 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1024"&gt;&lt;span style="-sec-ix-hidden:f-1025"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1030"&gt;&lt;span style="-sec-ix-hidden:f-1031"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:f-1034"&gt;&lt;span style="-sec-ix-hidden:f-1035"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property, plant and equipment in the consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-6" id="f-1022" unitRef="usd">719000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-6" id="f-1023" unitRef="usd">759000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-6" id="f-1026" unitRef="usd">42000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-6" id="f-1027" unitRef="usd">65000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-6" id="f-1028" unitRef="usd">761000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-6" id="f-1029" unitRef="usd">824000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-6" id="f-1032" unitRef="usd">17000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-6" id="f-1033" unitRef="usd">14000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-6" id="f-1036" unitRef="usd">25000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-6" id="f-1037" unitRef="usd">23000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-6" id="f-1038" unitRef="usd">42000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-6" id="f-1039" unitRef="usd">37000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-1040" unitRef="usd">653000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-1041" unitRef="usd">671000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-1042" unitRef="usd">20000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-1043" unitRef="usd">39000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-1044" unitRef="usd">673000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-1045" unitRef="usd">710000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiability contextRef="c-4" decimals="-6" id="f-1046" unitRef="usd">715000000</mrna:OperatingAndFinanceLeaseLiability>
    <mrna:OperatingAndFinanceLeaseLiability contextRef="c-5" decimals="-6" id="f-1047" unitRef="usd">747000000</mrna:OperatingAndFinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1048">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease costs were as follows for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information relating to our leases was as follows for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows used in financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability derecognized upon purchase of underlying leased asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-6" id="f-1049" unitRef="usd">89000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-6" id="f-1050" unitRef="usd">103000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-6" id="f-1051" unitRef="usd">88000000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-6" id="f-1052" unitRef="usd">24000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-12" decimals="-6" id="f-1053" unitRef="usd">22000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-13" decimals="-6" id="f-1054" unitRef="usd">500000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-6" id="f-1055" unitRef="usd">3000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-12" decimals="-6" id="f-1056" unitRef="usd">24000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-13" decimals="-6" id="f-1057" unitRef="usd">38000000</us-gaap:FinanceLeaseInterestExpense>
    <mrna:FinanceLeaseCost contextRef="c-1" decimals="-6" id="f-1058" unitRef="usd">27000000</mrna:FinanceLeaseCost>
    <mrna:FinanceLeaseCost contextRef="c-12" decimals="-6" id="f-1059" unitRef="usd">46000000</mrna:FinanceLeaseCost>
    <mrna:FinanceLeaseCost contextRef="c-13" decimals="-6" id="f-1060" unitRef="usd">538000000</mrna:FinanceLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-6" id="f-1061" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-12" decimals="-6" id="f-1062" unitRef="usd">13000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-13" decimals="-6" id="f-1063" unitRef="usd">2000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-6" id="f-1064" unitRef="usd">22000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-12" decimals="-6" id="f-1065" unitRef="usd">42000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-13" decimals="-6" id="f-1066" unitRef="usd">113000000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-6" id="f-1067" unitRef="usd">71000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-6" id="f-1068" unitRef="usd">78000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-6" id="f-1069" unitRef="usd">93000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-6" id="f-1070" unitRef="usd">3000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-12" decimals="-6" id="f-1071" unitRef="usd">19000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-13" decimals="-6" id="f-1072" unitRef="usd">39000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-6" id="f-1073" unitRef="usd">23000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-12" decimals="-6" id="f-1074" unitRef="usd">12000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-13" decimals="-6" id="f-1075" unitRef="usd">292000000</us-gaap:FinanceLeasePrincipalPayments>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments contextRef="c-1" decimals="-6" id="f-1076" unitRef="usd">-10000000</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments contextRef="c-12" decimals="-6" id="f-1077" unitRef="usd">-4000000</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments contextRef="c-13" decimals="-6" id="f-1078" unitRef="usd">-67000000</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-1079" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-12" decimals="-6" id="f-1080" unitRef="usd">100000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-13" decimals="-6" id="f-1081" unitRef="usd">714000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments contextRef="c-1" decimals="-6" id="f-1082" unitRef="usd">0</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments contextRef="c-12" decimals="-6" id="f-1083" unitRef="usd">-425000000</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments contextRef="c-13" decimals="-6" id="f-1084" unitRef="usd">-213000000</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-6" id="f-1085" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-12" decimals="-6" id="f-1086" unitRef="usd">75000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-13" decimals="-6" id="f-1087" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <mrna:LesseeFinanceLeaseExpense contextRef="c-1" decimals="-6" id="f-1088" unitRef="usd">-5000000</mrna:LesseeFinanceLeaseExpense>
    <mrna:LesseeFinanceLeaseExpense contextRef="c-12" decimals="-6" id="f-1089" unitRef="usd">2000000</mrna:LesseeFinanceLeaseExpense>
    <mrna:LesseeFinanceLeaseExpense contextRef="c-13" decimals="-6" id="f-1090" unitRef="usd">3000000</mrna:LesseeFinanceLeaseExpense>
    <mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset contextRef="c-1" decimals="-6" id="f-1091" unitRef="usd">0</mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset>
    <mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset contextRef="c-12" decimals="-6" id="f-1092" unitRef="usd">579000000</mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset>
    <mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset contextRef="c-13" decimals="-6" id="f-1093" unitRef="usd">0</mrna:LeaseLiabilityDerecognizedUponPurchaseOfUnderlyingAsset>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1094">P12Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1095">P13Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1096">P2Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1097">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1098" unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1099" unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1100" unitRef="number">0.059</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1101" unitRef="number">0.059</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1103">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1102">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2025, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths contextRef="c-4" decimals="-6" id="f-1104" unitRef="usd">65000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths contextRef="c-4" decimals="-6" id="f-1105" unitRef="usd">27000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c-4" decimals="-6" id="f-1106" unitRef="usd">78000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c-4" decimals="-6" id="f-1107" unitRef="usd">20000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c-4" decimals="-6" id="f-1108" unitRef="usd">81000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c-4" decimals="-6" id="f-1109" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c-4" decimals="-6" id="f-1110" unitRef="usd">82000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c-4" decimals="-6" id="f-1111" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c-4" decimals="-6" id="f-1112" unitRef="usd">80000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c-4" decimals="-6" id="f-1113" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive contextRef="c-4" decimals="-6" id="f-1114" unitRef="usd">680000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive contextRef="c-4" decimals="-6" id="f-1115" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-6" id="f-1116" unitRef="usd">1066000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-6" id="f-1117" unitRef="usd">47000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-6" id="f-1118" unitRef="usd">396000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-6" id="f-1119" unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-6" id="f-1120" unitRef="usd">670000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-6" id="f-1121" unitRef="usd">45000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1122">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11. Credit Agreement &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2025, we entered into a Credit and Guaranty Agreement (the Credit Agreement) with lenders led by Ares Capital Corporation, as administrative agent. The Credit Agreement provides for a senior secured term loan facility with aggregate term loan commitments of $1.5 billion, consisting of a $600 million initial term loan, which was funded at closing, and $900 million of delayed draw term loan commitments. The initial term loan matures on November 24, 2030. The delayed draw term loan commitments consist of (1) a $400 million delayed draw term loan facility (DDTL-1), which is available, subject to customary conditions, through November 24, 2027, and (2) a $500 million delayed draw term loan facility (DDTL-2), which is available, subject to customary conditions and the achievement of specified regulatory approval milestones for certain product candidates, through November 24, 2028. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Credit Agreement bear interest at a variable rate equal to, at our option, (i) Term SOFR plus a margin of 5.50% or (ii) a base rate plus a margin of 4.50%. The base rate is calculated as the highest of (a) the Wall Street Journal prime rate, (b) the federal funds rate plus one half of one percent and (c) Term SOFR plus one percent. We are also required to pay commitment fees on the undrawn portions of DDTL-1 and DDTL-2. The interest rate applicable to the initial term loan was approximately 9.38% as of December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The obligations under the Credit Agreement are guaranteed by certain of our subsidiaries and are secured by a first-priority lien on substantially all of our assets, in each case subject to customary exceptions and limitations. The Credit Agreement is subject to compliance with customary representations and warranties, affirmative covenants, restrictive covenants and events of default. The restrictive covenants, subject to specified limitations and exceptions, limit, among other things, our ability to incur additional indebtedness and liens, make certain investments, engage in certain fundamental changes, dispose of assets and make restricted payments. Events of default under the Credit Agreement include, among others, nonpayment of principal, interest or other amounts when due, failure to comply with covenants (subject to applicable notice and cure periods), breaches of certain representations and warranties, the occurrence of certain significant adverse events and certain insolvency-related events. The Credit Agreement also includes a financial covenant requiring us to maintain minimum cash and cash equivalents (as defined in the Credit Agreement, which primarily consist of our cash, cash equivalents, and available-for-sale securities) as of the last business day of each week of at least $500&#160;million, increasing to $750&#160;million if more than $1.0&#160;billion is drawn under the Credit Agreement. The financial covenant is not required to be tested at any time that the trailing 30-day average market capitalization of the Company exceeds $5.0&#160;billion and is subject to a customary equity cure. As of December 31, 2025, we were in compliance with the applicable terms and covenants under the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025, the initial term loan had an outstanding principal balance of $600 million and a carrying amount of $590 million, net of unamortized original issue discount and debt issuance costs, which was classified as long-term debt in our consolidated balance sheet. No amounts had been drawn under DDTL-1 or DDTL-2. The principal amount of $600 million is due in full at maturity, and no principal payments are required prior to that date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-276" decimals="INF" id="f-1123" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-277" decimals="INF" id="f-1124" unitRef="usd">600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-278" decimals="INF" id="f-1125" unitRef="usd">900000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-279" decimals="INF" id="f-1126" unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-280" decimals="INF" id="f-1127" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-281"
      decimals="INF"
      id="f-1128"
      unitRef="number">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-282"
      decimals="INF"
      id="f-1129"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-283"
      decimals="INF"
      id="f-1130"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-284"
      decimals="INF"
      id="f-1131"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-277"
      decimals="INF"
      id="f-1132"
      unitRef="number">0.0938</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <mrna:DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents contextRef="c-285" decimals="INF" id="f-1133" unitRef="usd">500000000</mrna:DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents>
    <mrna:DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents contextRef="c-286" decimals="INF" id="f-1134" unitRef="usd">750000000</mrna:DebtInstrumentCovenantComplianceMinimumCashAndCashEquivalents>
    <us-gaap:LineOfCredit contextRef="c-286" decimals="INF" id="f-1135" unitRef="usd">1000000000.0</us-gaap:LineOfCredit>
    <mrna:DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod contextRef="c-287" id="f-1136">P30D</mrna:DebtInstrumentCovenantComplianceAverageMarketCapitalizationTrailingPeriod>
    <mrna:DebtInstrumentCovenantComplianceAverageMarketCapitalization contextRef="c-276" decimals="INF" id="f-1137" unitRef="usd">5000000000.0</mrna:DebtInstrumentCovenantComplianceAverageMarketCapitalization>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-288" decimals="INF" id="f-1138" unitRef="usd">600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt contextRef="c-288" decimals="-6" id="f-1139" unitRef="usd">590000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-288" decimals="INF" id="f-1140" unitRef="usd">600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1141">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12. Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal proceedings and claims. Accruals are recognized for legal matters when a loss is both probable and reasonably estimable. As of December 31, 2025, no material contingent liabilities have been recognized. If a material loss is reasonably possible and we can estimate the amount or range of the loss, we disclose such information. Unless otherwise noted, either the outcome of these matters is not expected to be material, or the potential loss cannot be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be a party to litigation, arbitration, or other legal proceedings in the course of our business. The outcome of such matters is inherently uncertain and often involves significant judgment in assessing risk and estimating potential exposure. While we do not currently expect any pending proceedings to have a material adverse effect on our financial position, results of operations, or cash flows, there can be no assurance that future developments will not have a material impact.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our significant legal proceedings and matters outstanding as of December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have brought patent-infringement actions against Pfizer Inc. (Pfizer), BioNTech SE (BioNTech) and related entities in the U.S. District Court for the District of Massachusetts, Germany, the Netherlands, the UK, Ireland and Belgium concerning our mRNA platform technology and disease-specific vaccine designs. Pfizer and BioNTech have commenced actions or asserted defenses seeking to revoke our patents in these jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) have brought patent-infringement actions against us in the U.S. District Court for the District of Delaware, as well as in Canada, Japan, Switzerland and the Unified Patent Court (UPC) asserting patents concerning lipid nanoparticles. Arbutus and Genevant are seeking judgment of infringement of the asserted patents and monetary damages. The U.S. case has set trial to begin March 9, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GlaxoSmithKline Biologicals SA (GSK) has filed two complaints against us in the U.S. District Court for the District of Delaware asserting certain patents owned by GSK. GSK has filed two patent-infringement lawsuits against us in the UPC and two complaints in Spain concerning liposomes and modified liposomes for RNA delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Northwestern University has filed a complaint against us in the U.S. District Court for the District of Delaware asserting U.S. patents concerning lipid nanoparticle technology.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bayer CropSciences LLC, Monsanto Company, and Monsanto Technology, LLC have filed a complaint in U.S. District Court for the District of Delaware asserting a U.S. patent directed to methods of modifying gene sequences.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mNG Bio, LLC has filed a complaint against us in U.S District Court for the District of Massachusetts asserting a U.S. patent directed to a yellow-green fluorescent protein. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioNTech SE has filed a complaint against us in the U.S. District Court for the District of Delaware asserting a U.S. patent directed to modified mRNA compositions encoding a spike protein fragment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachusetts related to statements about our RSV vaccine (mRNA-1345).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#x2019;s or director&#x2019;s lifetime.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business collaborators, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2025 and 2024, we had not experienced any significant losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments and Purchase Orders&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2025, we had $411&#160;million of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. This amount includes $5&#160;million of the purchase commitments related to raw materials that was recorded as an accrued liability for loss on future firm purchase commitments. As of December 31, 2025, we had $1.0&#160;billion of non-cancelable purchase commitments related to research and development and other goods and services which are expected to be paid through 2032. These amounts represent our minimum contractual obligations, including termination fees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind-down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2025, we had cancelable open purchase orders of approximately $1.8 billion, reflecting amounts associated with our significant vendor arrangements, under such agreements for our clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2025, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licenses to Patented Technology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related net product sales in the period in which the corresponding sales occur. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an Institute or Center of the National Institutes of Health (NIH) to license certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for use in COVID vaccine products. Pursuant to the agreement, we have agreed to pay low single-digit royalties on future net sales, a minimum annual royalty payment, and certain contingent development, regulatory and commercial milestone payments on a licensed product-by-licensed product basis. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2025, we entered into a non-exclusive patent license agreement with NIAID to license certain patent rights related to the development of mRNA-based vaccines for the prevention or treatment of RSV infection. Upon execution of the agreement, we made a total payment of $10&#160;million, which was capitalized as an intangible asset and is amortized to cost of sales on a straight-line basis over the estimated useful life of the licensed patents. In addition, we are obligated to pay low single-digit royalties on future net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2025, 2024, and 2023 we recognized $88&#160;million, $155&#160;million, and $301&#160;million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of December 31, 2025.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-289"
      decimals="INF"
      id="f-1142"
      unitRef="lawsuit">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-290"
      decimals="INF"
      id="f-1143"
      unitRef="lawsuit">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-291"
      decimals="INF"
      id="f-1144"
      unitRef="lawsuit">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyLossInPeriod contextRef="c-292" decimals="INF" id="f-1145" unitRef="usd">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyLossInPeriod contextRef="c-293" decimals="INF" id="f-1146" unitRef="usd">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-294"
      decimals="INF"
      id="f-1147"
      unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-295"
      decimals="INF"
      id="f-1148"
      unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-294" decimals="INF" id="f-1149" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-295" decimals="INF" id="f-1150" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="c-296" decimals="-6" id="f-1151" unitRef="usd">411000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <mrna:LegalContingencyFutureFirmPurchaseCommitments contextRef="c-4" decimals="-6" id="f-1152" unitRef="usd">5000000</mrna:LegalContingencyFutureFirmPurchaseCommitments>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="c-297" decimals="-8" id="f-1153" unitRef="usd">1000000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="c-298" decimals="-8" id="f-1154" unitRef="usd">1800000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-299" decimals="-6" id="f-1155" unitRef="usd">10000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-1" decimals="-6" id="f-1156" unitRef="usd">88000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-12" decimals="-6" id="f-1157" unitRef="usd">155000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-13" decimals="-6" id="f-1158" unitRef="usd">301000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1159">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13. Stock-Based Compensation and Share Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Incentive Plan (the 2016 Equity Plan). The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Equity Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors may grant to employees, non-employee directors, consultants and independent advisors equity-based awards during their period of service, generally in the form of stock options, restricted stock units, and performance stock units. The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vest in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;December 31, 2025, we had a total of&#160;62 million shares reserved for future issuance under our Equity Plans, of which 38 million shares were reserved for equity awards previously granted, and&#160;24 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Exchange Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 13, 2025, we commenced an offer to exchange certain eligible stock options held by eligible employees of the Company for new stock options (the &#x201c;Exchange Offer&#x201d;). Executive officers and members of our Board of Directors were not eligible to participate. The Exchange Offer expired on December 12, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Exchange Offer, 2,864 eligible employees elected to exchange, and we accepted for cancellation, eligible stock options to purchase an aggregate of 4,289,694 shares of our common stock, representing approximately 80% of the total shares of common stock underlying eligible options. Immediately following the expiration of the Exchange Offer, we granted replacement stock options to purchase an aggregate of 1,653,121 shares of our common stock. The exercise price of the replacement stock options was $29.46 per share, which was the closing price of our common stock on December 12, 2025. The replacement stock options are subject to new vesting schedules based on continued service.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange of stock options resulted in an immaterial incremental stock-based compensation expense, calculated using a lattice option pricing model, which will be recognized together with any unrecognized compensation cost remaining on the exchanged options over the remaining requisite service period of the modified awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during the year ended December 31, 2025:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $19 million, $122 million, and $413 million for the&#160;years ended December 31, 2025, 2024, and 2023, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $2&#160;million, $24&#160;million, and $84&#160;million&#160;during the years ended December 31, 2025, 2024, and 2023, respectively. The total consideration recorded as a result of stock option exercises&#160;was approximately $17 million, $42 million, and $25&#160;million, respectively,&#160;for&#160;the years ended December 31, 2025, 2024, and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2025:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.836%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value per Unit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair value of RSUs and PSUs vested during the years ended December 31, 2025, 2024, and 2023, was $434 million, $228 million, and $99 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2025, 2024, and 2023, was $186&#160;million, $161&#160;million and $120&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2025, 2024 and 2023, we granted an immaterial amount of PSUs, respectively, primarily to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation and Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for options granted under our Equity Plans (excluding options issued in connection with the Exchange Offer) is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for the&#160;years ended December 31, 2025, 2024, and 2023 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2025, 2024, and 2023 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2025, 2024, and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025, there were $633 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.1 years at December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 22, 2022, our Board of Directors authorized a share repurchase program of our common stock for up to $3.0&#160;billion, with no expiration date. On August 1, 2022, our Board of Directors authorized an additional $3.0&#160;billion under the repurchase program, with no expiration date (collectively with the February 22, 2022 authorization, the 2022 Repurchase Programs). As of December 31, 2025, $1.7&#160;billion of our Board of Directors&#x2019; authorization for repurchases of our common stock remains outstanding under the 2022 Repurchase Programs, with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to our share repurchase programs (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining authorization at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-300" id="f-1160">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-301"
      decimals="INF"
      id="f-1161"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-301" id="f-1162">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments
      contextRef="c-302"
      decimals="INF"
      id="f-1163"
      unitRef="installment">12</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-303" id="f-1164">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-4"
      decimals="INF"
      id="f-1165"
      unitRef="shares">62000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-304"
      decimals="INF"
      id="f-1166"
      unitRef="shares">38000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-305"
      decimals="-6"
      id="f-1167"
      unitRef="shares">24000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees
      contextRef="c-306"
      decimals="INF"
      id="f-1168"
      unitRef="employee">2864</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-306"
      decimals="INF"
      id="f-1169"
      unitRef="shares">4289694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage
      contextRef="c-306"
      decimals="2"
      id="f-1170"
      unitRef="number">0.80</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockUnderlyingOptionsPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-307"
      decimals="INF"
      id="f-1171"
      unitRef="shares">1653121</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharePrice
      contextRef="c-307"
      decimals="INF"
      id="f-1172"
      unitRef="usdPerShare">29.46</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="c-1" id="f-1173">The following table summarizes our option activity during the year ended December 31, 2025:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-4" id="f-1174" unitRef="shares">26200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1175"
      unitRef="usdPerShare">59.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-12" id="f-1176">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-6" id="f-1177" unitRef="usd">359000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-4" id="f-1178" unitRef="shares">8910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1179"
      unitRef="usdPerShare">30.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-4" id="f-1180" unitRef="shares">1220000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1181"
      unitRef="usdPerShare">14.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-4" id="f-1182" unitRef="shares">6710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1183"
      unitRef="usdPerShare">114.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-4" id="f-1184" unitRef="shares">27180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1185"
      unitRef="usdPerShare">38.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1186">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-6" id="f-1187" unitRef="usd">153000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="-4" id="f-1188" unitRef="shares">19540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1189"
      unitRef="usdPerShare">38.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1190">P3Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-6" id="f-1191" unitRef="usd">151000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-4" decimals="-4" id="f-1192" unitRef="shares">7640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1193"
      unitRef="usdPerShare">39.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1194">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-6" id="f-1195" unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-6" id="f-1196" unitRef="usd">19000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-6" id="f-1197" unitRef="usd">122000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-6" id="f-1198" unitRef="usd">413000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-1" decimals="-6" id="f-1199" unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-12" decimals="-6" id="f-1200" unitRef="usd">24000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-13" decimals="-6" id="f-1201" unitRef="usd">84000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-6" id="f-1202" unitRef="usd">17000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-12" decimals="-6" id="f-1203" unitRef="usd">42000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-6" id="f-1204" unitRef="usd">25000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-1205">The following table summarizes our RSU and PSU activity during the year ended December 31, 2025:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.836%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value per Unit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-308"
      decimals="-4"
      id="f-1206"
      unitRef="shares">7860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-308"
      decimals="2"
      id="f-1207"
      unitRef="usdPerShare">91.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-309"
      decimals="-4"
      id="f-1208"
      unitRef="shares">12670000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-309"
      decimals="2"
      id="f-1209"
      unitRef="usdPerShare">30.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-309"
      decimals="-4"
      id="f-1210"
      unitRef="shares">6810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-309"
      decimals="2"
      id="f-1211"
      unitRef="usdPerShare">63.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-309"
      decimals="-4"
      id="f-1212"
      unitRef="shares">2520000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-309"
      decimals="2"
      id="f-1213"
      unitRef="usdPerShare">60.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-310"
      decimals="-4"
      id="f-1214"
      unitRef="shares">11200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-310"
      decimals="2"
      id="f-1215"
      unitRef="usdPerShare">46.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense contextRef="c-1" decimals="-6" id="f-1216" unitRef="usd">434000000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="c-12" decimals="-6" id="f-1217" unitRef="usd">228000000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="c-13" decimals="-6" id="f-1218" unitRef="usd">99000000</us-gaap:RestrictedStockExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-309" decimals="-6" id="f-1219" unitRef="usd">186000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-311" decimals="-6" id="f-1220" unitRef="usd">161000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-312" decimals="-6" id="f-1221" unitRef="usd">120000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-313" id="f-1222">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-314" id="f-1223">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-315" id="f-1224">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="c-316"
      decimals="INF"
      id="f-1225"
      unitRef="number">0</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="c-317"
      decimals="INF"
      id="f-1226"
      unitRef="number">0</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="c-318"
      decimals="INF"
      id="f-1227"
      unitRef="number">0</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="c-319"
      decimals="INF"
      id="f-1228"
      unitRef="number">2</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="c-320"
      decimals="INF"
      id="f-1229"
      unitRef="number">2</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="c-321"
      decimals="INF"
      id="f-1230"
      unitRef="number">2</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1231">The weighted-average assumptions used to estimate the fair value of options granted for the&#160;years ended December 31, 2025, 2024, and 2023 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-322"
      decimals="4"
      id="f-1232"
      unitRef="number">0.0404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-323"
      decimals="4"
      id="f-1233"
      unitRef="number">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-324"
      decimals="4"
      id="f-1234"
      unitRef="number">0.0413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-322" id="f-1235">P5Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-323" id="f-1236">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-324" id="f-1237">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-322"
      decimals="2"
      id="f-1238"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-323"
      decimals="2"
      id="f-1239"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-324"
      decimals="2"
      id="f-1240"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-322"
      decimals="INF"
      id="f-1241"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-323"
      decimals="INF"
      id="f-1242"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-324"
      decimals="INF"
      id="f-1243"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="c-325"
      decimals="2"
      id="f-1244"
      unitRef="usdPerShare">18.64</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-326"
      decimals="2"
      id="f-1245"
      unitRef="usdPerShare">49.76</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-327"
      decimals="2"
      id="f-1246"
      unitRef="usdPerShare">57.87</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1247">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2025, 2024, and 2023 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-322" decimals="-6" id="f-1248" unitRef="usd">152000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-323" decimals="-6" id="f-1249" unitRef="usd">163000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-324" decimals="-6" id="f-1250" unitRef="usd">136000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-328" decimals="-6" id="f-1251" unitRef="usd">314000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-329" decimals="-6" id="f-1252" unitRef="usd">254000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-330" decimals="-6" id="f-1253" unitRef="usd">144000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-331" decimals="-6" id="f-1254" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-332" decimals="-6" id="f-1255" unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-333" decimals="-6" id="f-1256" unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-334" decimals="-6" id="f-1257" unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-335" decimals="-6" id="f-1258" unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-336" decimals="-6" id="f-1259" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1260" unitRef="usd">483000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-6" id="f-1261" unitRef="usd">429000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-6" id="f-1262" unitRef="usd">305000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-337" decimals="-6" id="f-1263" unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-338" decimals="-6" id="f-1264" unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-339" decimals="-6" id="f-1265" unitRef="usd">37000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-340" decimals="-6" id="f-1266" unitRef="usd">291000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-341" decimals="-6" id="f-1267" unitRef="usd">264000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-342" decimals="-6" id="f-1268" unitRef="usd">157000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-343" decimals="-6" id="f-1269" unitRef="usd">166000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-344" decimals="-6" id="f-1270" unitRef="usd">140000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-345" decimals="-6" id="f-1271" unitRef="usd">111000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1272" unitRef="usd">483000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-6" id="f-1273" unitRef="usd">429000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-6" id="f-1274" unitRef="usd">305000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-4" decimals="-6" id="f-1275" unitRef="usd">633000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-1276">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-346" decimals="INF" id="f-1277" unitRef="usd">3000000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <mrna:StockRepurchaseProgramAdditionalAuthorizedAmount contextRef="c-347" decimals="INF" id="f-1278" unitRef="usd">3000000000.0</mrna:StockRepurchaseProgramAdditionalAuthorizedAmount>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-348" decimals="-8" id="f-1279" unitRef="usd">1700000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock contextRef="c-1" id="f-1280">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to our share repurchase programs (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining authorization at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Average price paid per share includes related expenses and excise tax, applicable beginning January 1, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="-6" id="f-1281" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-12"
      decimals="-6"
      id="f-1282"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-13"
      decimals="-6"
      id="f-1283"
      unitRef="shares">8000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1284"
      unitRef="usdPerShare">0</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-12"
      decimals="2"
      id="f-1285"
      unitRef="usdPerShare">0</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-13"
      decimals="2"
      id="f-1286"
      unitRef="usdPerShare">143.26</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-1" decimals="-6" id="f-1287" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-12" decimals="-6" id="f-1288" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-13" decimals="-6" id="f-1289" unitRef="usd">1153000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-4" decimals="-6" id="f-1290" unitRef="usd">1667000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-5" decimals="-6" id="f-1291" unitRef="usd">1667000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-27" decimals="-6" id="f-1292" unitRef="usd">1667000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1293">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;14. Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss before income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following components (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for (benefit from) income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the federal statutory income tax amount and rate to our effective tax rate for the year ended December 31, 2025 was as follows (in millions, except percentages):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax, net of federal income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation windfall/shortfall&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate reconciliation for the year ended December 31, 2025 is presented in accordance with ASU 2023-09, while the effective tax rate reconciliations for the years ended December 31, 2024 and 2023 have not been recast and continue to be presented under the prior guidance. As a result of the adoption of ASU 2023-09, certain items in the effective tax rate reconciliation may have been reclassified between categories compared to prior periods; however, such reclassifications did not have a material impact on any individual line items or the overall effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation windfall/shortfall&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective tax rate for the year ended December 31, 2025 was (2.0)% and was higher than the federal statutory tax rate, primarily due to our global valuation allowance, which limits our ability to recognize tax benefits from the loss. The higher effective tax rate was also impacted by certain of our foreign subsidiaries that have taxable income, while we incurred a net loss before income taxes in other jurisdictions. For the year ended December 31, 2024, the effective tax rate was lower than the federal statutory tax rate as a result of an increase in valuation allowance against deferred tax assets, which limited the recognition of tax benefits on our pre-tax loss. The tax benefits from research and development credits provided a partial offset. For the year ended December 31, 2023, despite being in a pre-tax loss position, our effective tax rate exceeded the federal statutory tax rate, primarily due to the establishment of a valuation allowance against the majority of the deferred tax assets, which resulted in a net tax expense rather than a benefit. This was partially offset by tax benefits from research and development credits and stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2025, income taxes paid, net of refunds, by jurisdiction were immaterial both individually and in the aggregate and, accordingly, have not been separately disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2025 and 2024 were as follows &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized licenses, research and development and start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserve and capitalization &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wholesaler chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Returns and other fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis difference&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;millions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. During 2023, following the completion of our long-range financial planning process, we reassessed the evidence and concluded that a valuation allowance was necessary due to the preponderance of negative evidence, including: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A pre-tax loss for the full year 2023, serving as a significant source of objectively verifiable negative evidence in accordance with ASC 740 (Income Taxes).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A projected three-year cumulative loss resulting from our long-range financial planning process. This projection was due to a significant decrease in expected sales of our COVID vaccine as we transitioned to a seasonal market. Additionally, we anticipated substantial research and development expenses for our on-going Phase 3 clinical trials and to advance our product candidates into later-stage development. These factors contributed additional negative evidence with respect to the realizability of our deferred tax assets. The projections were based upon revenue from our approved drug product, which we believe can be reasonably estimated. In contrast, future taxable income projections from our investigational medicines are deemed inherently subjective and not objectively verifiable; they are insufficient to override negative evidence, and therefore, they were not assigned any weight in our valuation allowance analysis assessment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our evaluation also included whether there were other sources of taxable income that would allow us to realize our deferred tax assets, such as taxable income in carryback years, available tax planning strategies and the future reversals of taxable temporary differences. After assessing these strategies and all evidence, we determined it was more likely than not that we will not realize all of our deferred tax assets and therefore increased the valuation allowance by $2.1&#160;billion during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2025 and 2024, we continued to maintain a global valuation allowan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ce against the majority of our de&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ferred tax assets, consistent with the assessment established in 2023. The valuation allowance reflects the ongoing preponderance of negative evidence, including continued and projected losses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2025, we had $4.1 billion, $3.3 billion, and $89 million of federal, state and foreign net operating loss carryforwards, respectively, of which $4.1 billion, $1.6 billion, and $89 million respectively, will not expire and $1.7 billion of state net operating loss carryforwards will begin to expire in 2032. At December 31, 2025, we also had federal and state research and development tax credit carryforwards of $111 million and $208 million, respectively, the majority of which will begin to expire in 2030.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2025, 2024, and 2023 were as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease due to prior positions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements with tax authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to current year tax positions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025, we had $241 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; income tax returns in U.S. and various state, local and foreign jurisdictions. The income tax returns of all material taxing jurisdictions remain open to tax examination for all tax years since our date of incorporation for those jurisdictions. We have federal, state, and foreign carryforward attributes generated in past years which may be adjusted upon examination. As of December 31, 2025, we are under audit in various U.S., and foreign jurisdictions; however, no adjustments to our tax positions have been proposed at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1294">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss before income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-6" id="f-1295" unitRef="usd">-2655000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-6" id="f-1296" unitRef="usd">-3697000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-6" id="f-1297" unitRef="usd">-4056000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-6" id="f-1298" unitRef="usd">-113000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-6" id="f-1299" unitRef="usd">90000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-6" id="f-1300" unitRef="usd">114000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1301" unitRef="usd">-2768000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-1302" unitRef="usd">-3607000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-1303" unitRef="usd">-3942000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1304">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the years ended December 31, 2025, 2024, and 2023 consisted of the following components (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for (benefit from) income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1305" unitRef="usd">11000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1306" unitRef="usd">-57000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1307" unitRef="usd">-225000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1308" unitRef="usd">4000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1309" unitRef="usd">-1000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1310" unitRef="usd">72000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1311" unitRef="usd">29000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1312" unitRef="usd">13000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1313" unitRef="usd">24000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1314" unitRef="usd">44000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1315" unitRef="usd">-45000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1316" unitRef="usd">-129000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1317" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1318" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1319" unitRef="usd">888000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1320" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1321" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1322" unitRef="usd">8000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1323" unitRef="usd">10000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1324" unitRef="usd">-1000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1325" unitRef="usd">5000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1326" unitRef="usd">10000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1327" unitRef="usd">-1000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1328" unitRef="usd">901000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1329" unitRef="usd">54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1330" unitRef="usd">-46000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1331" unitRef="usd">772000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1332">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the federal statutory income tax amount and rate to our effective tax rate for the year ended December 31, 2025 was as follows (in millions, except percentages):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income tax, net of federal income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation windfall/shortfall&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation windfall/shortfall&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1333" unitRef="usd">-581000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1334" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1335" unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1336" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-1337" unitRef="usd">62000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1338" unitRef="number">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="c-1" decimals="-3" id="f-1339" unitRef="usd">11000000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="c-1" decimals="3" id="f-1340" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-1341" unitRef="usd">509000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1342" unitRef="number">-0.184</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-1" decimals="-3" id="f-1343" unitRef="usd">2000000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-1344" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1345" unitRef="usd">43000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1346" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-3" id="f-1347" unitRef="usd">10000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-1" decimals="3" id="f-1348" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-1349" unitRef="usd">17000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1350" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1351" unitRef="usd">54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1352" unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-12"
      decimals="INF"
      id="f-1353"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-13"
      decimals="INF"
      id="f-1354"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="3" id="f-1355" unitRef="number">-0.235</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="3" id="f-1356" unitRef="number">-0.526</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-12" decimals="3" id="f-1357" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-13" decimals="3" id="f-1358" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-12" decimals="3" id="f-1359" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-13" decimals="3" id="f-1360" unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-12" decimals="3" id="f-1361" unitRef="number">-0.055</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-13" decimals="3" id="f-1362" unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="3" id="f-1363" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="3" id="f-1364" unitRef="number">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-12" decimals="3" id="f-1365" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-13" decimals="3" id="f-1366" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-12" decimals="3" id="f-1367" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-13" decimals="3" id="f-1368" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-1369" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-1370" unitRef="number">-0.196</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1371" unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1372">Significant components of our deferred tax assets and tax liabilities as of December 31, 2025 and 2024 were as follows &lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized licenses, research and development and start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserve and capitalization &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Wholesaler chargebacks, discounts and fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Returns and other fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis difference&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-6" id="f-1373" unitRef="usd">1156000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-6" id="f-1374" unitRef="usd">424000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-6" id="f-1375" unitRef="usd">129000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-6" id="f-1376" unitRef="usd">131000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts contextRef="c-4" decimals="-6" id="f-1377" unitRef="usd">1693000000</mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts>
    <mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts contextRef="c-5" decimals="-6" id="f-1378" unitRef="usd">1794000000</mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-6" id="f-1379" unitRef="usd">308000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-6" id="f-1380" unitRef="usd">251000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <mrna:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-4" decimals="-6" id="f-1381" unitRef="usd">134000000</mrna:DeferredTaxAssetsOperatingLeaseLiability>
    <mrna:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-5" decimals="-6" id="f-1382" unitRef="usd">138000000</mrna:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOtherComprehensiveLoss contextRef="c-4" decimals="-6" id="f-1383" unitRef="usd">3000000</us-gaap:DeferredTaxAssetsOtherComprehensiveLoss>
    <us-gaap:DeferredTaxAssetsOtherComprehensiveLoss contextRef="c-5" decimals="-6" id="f-1384" unitRef="usd">4000000</us-gaap:DeferredTaxAssetsOtherComprehensiveLoss>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-4" decimals="-6" id="f-1385" unitRef="usd">152000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-5" decimals="-6" id="f-1386" unitRef="usd">205000000</us-gaap:DeferredTaxAssetsInventory>
    <mrna:DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees contextRef="c-4" decimals="-6" id="f-1387" unitRef="usd">26000000</mrna:DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees>
    <mrna:DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees contextRef="c-5" decimals="-6" id="f-1388" unitRef="usd">43000000</mrna:DeferredTaxAssetsWholesalerChargebacksDiscountsAndFees>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances contextRef="c-4" decimals="-6" id="f-1389" unitRef="usd">116000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances contextRef="c-5" decimals="-6" id="f-1390" unitRef="usd">86000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <mrna:DeferredTaxAssetsOutsideBasisDifference contextRef="c-4" decimals="-6" id="f-1391" unitRef="usd">84000000</mrna:DeferredTaxAssetsOutsideBasisDifference>
    <mrna:DeferredTaxAssetsOutsideBasisDifference contextRef="c-5" decimals="-6" id="f-1392" unitRef="usd">125000000</mrna:DeferredTaxAssetsOutsideBasisDifference>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-6" id="f-1393" unitRef="usd">213000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-6" id="f-1394" unitRef="usd">160000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-6" id="f-1395" unitRef="usd">4014000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-6" id="f-1396" unitRef="usd">3361000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-6" id="f-1397" unitRef="usd">3738000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-6" id="f-1398" unitRef="usd">3084000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-6" id="f-1399" unitRef="usd">276000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-6" id="f-1400" unitRef="usd">277000000</us-gaap:DeferredTaxAssetsNet>
    <mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-6" id="f-1401" unitRef="usd">135000000</mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-6" id="f-1402" unitRef="usd">139000000</mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-6" id="f-1403" unitRef="usd">58000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-6" id="f-1404" unitRef="usd">55000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-6" id="f-1405" unitRef="usd">23000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-6" id="f-1406" unitRef="usd">16000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-6" id="f-1407" unitRef="usd">216000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-6" id="f-1408" unitRef="usd">210000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-6" id="f-1409" unitRef="usd">60000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-6" id="f-1410" unitRef="usd">67000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-1411">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes changes in the valuation allowance for deferred tax assets for the periods presented (in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;millions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-6" id="f-1412" unitRef="usd">3084000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-6" id="f-1413" unitRef="usd">2224000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-18" decimals="-6" id="f-1414" unitRef="usd">155000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-6" id="f-1415" unitRef="usd">654000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-12" decimals="-6" id="f-1416" unitRef="usd">860000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-13" decimals="-6" id="f-1417" unitRef="usd">2069000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-6" id="f-1418" unitRef="usd">3738000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-6" id="f-1419" unitRef="usd">3084000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-6" id="f-1420" unitRef="usd">2224000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-349" decimals="-8" id="f-1421" unitRef="usd">2100000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-350" decimals="-8" id="f-1422" unitRef="usd">4100000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-351" decimals="-8" id="f-1423" unitRef="usd">3300000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-352" decimals="-6" id="f-1424" unitRef="usd">89000000</us-gaap:OperatingLossCarryforwards>
    <mrna:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-350" decimals="-8" id="f-1425" unitRef="usd">4100000000</mrna:OperatingLossCarryforwardsNotSubjectToExpiration>
    <mrna:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-351" decimals="-8" id="f-1426" unitRef="usd">1600000000</mrna:OperatingLossCarryforwardsNotSubjectToExpiration>
    <mrna:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-352" decimals="-6" id="f-1427" unitRef="usd">89000000</mrna:OperatingLossCarryforwardsNotSubjectToExpiration>
    <mrna:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-351" decimals="-8" id="f-1428" unitRef="usd">1700000000</mrna:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-353" decimals="-6" id="f-1429" unitRef="usd">111000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-354" decimals="-6" id="f-1430" unitRef="usd">208000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1431">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2025, 2024, and 2023 were as follows (in&#160;millions):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease due to prior positions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements with tax authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to current year tax positions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-6" id="f-1432" unitRef="usd">240000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-6" id="f-1433" unitRef="usd">231000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-6" id="f-1434" unitRef="usd">128000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1435" unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-6" id="f-1436" unitRef="usd">10000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-6" id="f-1437" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-6" id="f-1438" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-12" decimals="-6" id="f-1439" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-13" decimals="-6" id="f-1440" unitRef="usd">27000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1441" unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-6" id="f-1442" unitRef="usd">19000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-6" id="f-1443" unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1444" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-6" id="f-1445" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-6" id="f-1446" unitRef="usd">86000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-6" id="f-1447" unitRef="usd">241000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-6" id="f-1448" unitRef="usd">240000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-6" id="f-1449" unitRef="usd">231000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-6" id="f-1450" unitRef="usd">241000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1451">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;15. Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the years ended December 31, 2025, 2024 and 2023 were calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted EPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of December 31, 2025, 2024 and 2023, were excluded from the calculation of diluted EPS attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1452">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the years ended December 31, 2025, 2024 and 2023 were calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted EPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-1453" unitRef="usd">-2822000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-1454" unitRef="usd">-3561000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-1455" unitRef="usd">-4714000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1456" unitRef="shares">389000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-6" id="f-1457" unitRef="shares">389000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-12"
      decimals="-3"
      id="f-1458"
      unitRef="shares">384000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-12"
      decimals="-6"
      id="f-1459"
      unitRef="shares">384000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-13"
      decimals="-3"
      id="f-1460"
      unitRef="shares">382000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-13"
      decimals="-6"
      id="f-1461"
      unitRef="shares">382000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1462"
      unitRef="usdPerShare">-7.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1463"
      unitRef="usdPerShare">-7.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-1464"
      unitRef="usdPerShare">-9.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-1465"
      unitRef="usdPerShare">-9.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-1466"
      unitRef="usdPerShare">-12.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-1467"
      unitRef="usdPerShare">-12.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1468">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of December 31, 2025, 2024 and 2023, were excluded from the calculation of diluted EPS attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-355"
      decimals="-6"
      id="f-1469"
      unitRef="shares">27000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-356"
      decimals="-6"
      id="f-1470"
      unitRef="shares">26000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-357"
      decimals="-6"
      id="f-1471"
      unitRef="shares">26000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-358"
      decimals="-6"
      id="f-1472"
      unitRef="shares">11000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-359"
      decimals="-6"
      id="f-1473"
      unitRef="shares">8000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-360"
      decimals="-6"
      id="f-1474"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-6" id="f-1475" unitRef="shares">38000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-12"
      decimals="-6"
      id="f-1476"
      unitRef="shares">34000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-13"
      decimals="-6"
      id="f-1477"
      unitRef="shares">31000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1478"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-361" decimals="-6" id="f-1479" unitRef="usd">1199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-362" decimals="-6" id="f-1480" unitRef="usd">1785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-363" decimals="-6" id="f-1481" unitRef="usd">1895000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-364" decimals="-6" id="f-1482" unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-365" decimals="-6" id="f-1483" unitRef="usd">598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-366" decimals="-6" id="f-1484" unitRef="usd">1355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-367" decimals="-6" id="f-1485" unitRef="usd">692000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-368" decimals="-6" id="f-1486" unitRef="usd">853000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-369" decimals="-6" id="f-1487" unitRef="usd">3598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-1488" unitRef="usd">1944000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-6" id="f-1489" unitRef="usd">3236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-6" id="f-1490" unitRef="usd">6848000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-370" decimals="-6" id="f-1491" unitRef="usd">1468000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-371" decimals="-6" id="f-1492" unitRef="usd">1532000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-372" decimals="-6" id="f-1493" unitRef="usd">303000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-373" decimals="-6" id="f-1494" unitRef="usd">283000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-374" decimals="-6" id="f-1495" unitRef="usd">363000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-375" decimals="-6" id="f-1496" unitRef="usd">381000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-6" id="f-1497" unitRef="usd">2134000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-6" id="f-1498" unitRef="usd">2196000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-376" id="f-1499">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-376" id="f-1500">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-377" id="f-1501">On November 23, 2025, St&#xe9;phane Bancel, our Chief Executive Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c), which had been entered into on September 3, 2025, and was scheduled to commence as early as December 17, 2025, with a termination date of August 10, 2026. The plan provided for the potential sale of up to 1,439,788 shares of common stock. No shares of common stock were sold under the plan prior to its termination.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrTerminationDate contextRef="c-377" id="f-1502">November 23, 2025</ecd:TrdArrTerminationDate>
    <ecd:TrdArrIndName contextRef="c-377" id="f-1503">St&#xe9;phane Bancel</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-377" id="f-1504">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-377" id="f-1505">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-378"
      decimals="INF"
      id="f-1506"
      unitRef="shares">1439788</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-379" id="f-1507">Mr. Bancel has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 558,394 shares and another option to purchase 193,321 shares (the Bancel Expiring Options). Mr. Bancel intends to contribute all of the after-tax proceeds from the exercise and sale of the Bancel Expiring Options to charitable causes. On November 28, 2025, Mr. Bancel adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between May 13,2026 and August 10, 2026, the Bancel 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Bancel Expiring Options, which represent up to 751,715 shares of the Company&#x2019;s common stock in the aggregate. The Bancel 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-380"
      decimals="INF"
      id="f-1508"
      unitRef="shares">558394</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-381"
      decimals="INF"
      id="f-1509"
      unitRef="shares">193321</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrAdoptionDate contextRef="c-379" id="f-1510">November 28, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-379" id="f-1511">Mr. Bancel</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-379" id="f-1512">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-379" id="f-1513">August 10, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-382"
      decimals="INF"
      id="f-1514"
      unitRef="shares">751715</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-383" id="f-1516">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stephen Hoge, our President, has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 223,357 shares and another option to purchase 96,660 shares (the Hoge Expiring Options). On November 13, 2025, Dr. Hoge adopted a trading arrangement that is intended to satisfy the affirmative defense of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rule 10b5-1(c) (the Hoge 10b5-1 Plan). Between February 23, 2026 and August 10, 2026, the Hoge 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Hoge Expiring Options, which represent up to 320,017 shares of the Company&#x2019;s common stock in the aggregate. The Hoge 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-383" id="f-1515">Stephen Hoge</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-383" id="f-1517">President</ecd:TrdArrIndTitle>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-384"
      decimals="INF"
      id="f-1518"
      unitRef="shares">223357</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-385"
      decimals="INF"
      id="f-1519"
      unitRef="shares">96660</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrAdoptionDate contextRef="c-383" id="f-1520">November 13, 2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-383" id="f-1521">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-383" id="f-1522">August 10, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-386"
      decimals="INF"
      id="f-1523"
      unitRef="shares">320017</ecd:TrdArrSecuritiesAggAvailAmt>
    <dei:AuditorFirmId contextRef="c-1" id="f-1526">42</dei:AuditorFirmId>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1527">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
